PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Qiao, FY; Moss, A; Kupfer, GM				Qiao, FY; Moss, A; Kupfer, GM			Fanconi anemia proteins localize to chromatin and the nuclear matrix in a DNA damage- and cell cycle-regulated manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-D GENE; GROUP-C; GROUP-A; COMPLEX; COMPLEMENTATION; FAC; APOPTOSIS; INTERACT; OVEREXPRESSION; LYMPHOCYTES	Fanconi anemia (FA) is a genetic disease characterized by congenital defects, bone marrow failure, and cancer susceptibility. Cells from patients with FA exhibit genomic instability and hypersensitivity to DNA cross linking agents such as mitomycin C, Despite the identification of seven complementation groups and the cloning of six genes, the function of the encoded gene products remains elusive. The FancA (Fanconi anemia complementation group A), FancC, and FancG proteins have been detected within a nuclear complex, but no change in level, binding, or localization has been reported as a result of drug treatment or cell cycle. We show that in immunofluorescence studies, FancA ap. pears as a non-nucleolar nuclear protein that is excluded from condensed, mitotic chromosomes. Biochemical fractionation reveals that the FA proteins are found in nuclear matrix and chromatin and that treatment with mitomycin C results in increase of the FA proteins in nuclear matrix and chromatin fractions. This induction occurs in wild-type cells and mutant FA-D (Fanconi complementation group D) cells but not in mutant FA-A cells. Immunoprecipitation of FancA protein in chromatin demonstrates the coprecipitation of FancA, FancC, and FancG, showing that the FA proteins move together as a complex. Also, fractionation of mitotic cells confirms the lack of FA proteins in chromatin or the nuclear matrix. Furthermore, phosphorylation of FancG; was found to be temporally correlated with exit of the FA complex from chromosomes at mitosis, Taken together, these findings suggest a role for FA proteins in chromatin and nuclear matrix.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Kupfer, GM (corresponding author), Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA.				PHS HHS [R01 63776] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; ALTER BP, 1993, HEMATOLOGY INFANCY C, V1, P216; Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1997, GENETIC BASIS HUMAN, P317; Brois DW, 1999, CARCINOGENESIS, V20, P1845, DOI 10.1093/carcin/20.9.1845; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Christianson TA, 2000, BLOOD, V95, P725, DOI 10.1182/blood.V95.2.725; Cumming RC, 1996, BLOOD, V88, P4558, DOI 10.1182/blood.V88.12.4558.bloodjournal88124558; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; DUTRILLAUX B, 1982, HUM GENET, V62, P327, DOI 10.1007/BF00304549; Escarceller M, 1997, SOMAT CELL MOLEC GEN, V23, P401, DOI 10.1007/BF02673750; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Fanconi G., 1927, JAHRB KINDERHEILK, V117, P257; Garcia-Higuera I, 1999, MOL CELL BIOL, V19, P4866; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Heinrich MC, 2000, BLOOD, V95, P3970; Hejna JA, 2000, AM J HUM GENET, V66, P1540, DOI 10.1086/302896; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; KAISER TN, 1982, CYTOMETRY, V2, P291; Kruyt FAE, 1998, BLOOD, V92, P3050, DOI 10.1182/blood.V92.9.3050.421k56_3050_3056; Kupfer GM, 1997, BLOOD, V90, P1047, DOI 10.1182/blood.V90.3.1047.1047_1047_1054; Kupfer GM, 1997, NAT GENET, V17, P487, DOI 10.1038/ng1297-487; Kupfer GM, 1996, BLOOD, V88, P1019; Laquerbe A, 1999, MUTAT RES-FUND MOL M, V431, P341, DOI 10.1016/S0027-5107(99)00177-3; Li YL, 1997, J CLIN INVEST, V100, P2873, DOI 10.1172/JCI119836; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Marathi UK, 1996, BLOOD, V88, P2298, DOI 10.1182/blood.V88.6.2298.bloodjournal8862298; McMahon LW, 1999, J BIOL CHEM, V274, P32904, DOI 10.1074/jbc.274.46.32904; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; Naf D, 1998, MOL CELL BIOL, V18, P5952; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pemov A, 1998, P NATL ACAD SCI USA, V95, P14757, DOI 10.1073/pnas.95.25.14757; Pulsipher M, 1998, MOL MED, V4, P468, DOI 10.1007/BF03401752; Rathbun RK, 1997, BLOOD, V90, P974, DOI 10.1182/blood.V90.3.974.974_974_985; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Ridet A, 1997, CANCER RES, V57, P1722; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; Smith MM, 1991, CURR OPIN CELL BIOL, V3, P429, DOI 10.1016/0955-0674(91)90070-F; STONESIFER KJ, 1987, ACTA CYTOL, V31, P125; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Waisfisz Q, 1999, P NATL ACAD SCI USA, V96, P10320, DOI 10.1073/pnas.96.18.10320; Wang JX, 1998, CANCER RES, V58, P3538; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITNEY M, 1995, NAT GENET, V11, P341, DOI 10.1038/ng1195-341; Whitney MA, 1996, BLOOD, V88, P49; Yamashita T, 1998, P NATL ACAD SCI USA, V95, P13085, DOI 10.1073/pnas.95.22.13085	53	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23391	23396		10.1074/jbc.M101855200	http://dx.doi.org/10.1074/jbc.M101855200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11297559	hybrid			2022-12-25	WOS:000169531100024
J	Tchernov, D; Helman, Y; Keren, N; Luz, B; Ohad, I; Reinhold, L; Ogawa, T; Kaplan, A				Tchernov, D; Helman, Y; Keren, N; Luz, B; Ohad, I; Reinhold, L; Ogawa, T; Kaplan, A			Passive entry of CO2 and its energy-dependent intracellular conversion to HCO3- in cyanobacteria are driven by a photosystem I-generated Delta mu H+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN PCC-6803; STEADY-STATE PHOTOSYNTHESIS; INORGANIC CARBON TRANSPORT; CYCLIC ELECTRON-TRANSFER; SYNECHOCOCCUS UTEX-625; SYNECHOCYSTIS PCC6803; ACTIVE-TRANSPORT; CO2-CONCENTRATING MECHANISM; CONCENTRATING MECHANISM; ANABAENA-VARIABILIS	CO2 entry into Synechococcus sp PCC7942 cells was drastically inhibited by the water channel blocker p-chloromercuriphenylsulfonic acid suggesting that CO2 uptake is, for the most part, passive via aquaporins with subsequent energy-dependent conversion to HCO3-. Dependence of CO2 uptake on photosynthetic electron transport via photosystem I (PSI) was confirmed by experiments with electron transport inhibitors, electron donors and accepters, and a mutant lacking PSI activity. CO2 uptake was drastically inhibited by the uncouplers carbonyl cyanide m-chlorophenylhydrazone (CCCP) and ammonia but substantially less so by the inhibitors of ATP formation arsenate and N, N,-dicyclo-hexylcarbodiimide (DCCD). Thus a Delta muH(+) generated by photosynthetic PSI electron transport apparently serves as the direct source of energy for CO2 uptake. Under low light intensity, the rate of CO2 uptake by a high-CO2-requiring mutant of Synechococcus sp PCC7942, at a CO2 concentration below its threshold for CO2 fixation, was higher than that of the wild type. At saturating light intensity, net CO2 uptake was similar in the wild type and in the mutant IL-3 suggesting common limitation by the rate of conversion of CO2 to HCO3-. These findings are consistent with a model postulating that electron transport-dependent formation of alkaline domains on the thylakoid membrane energizes intracellular conversion of CO2 to HCO3- .	Hebrew Univ Jerusalem, Fac Sci & Math, Dept Plant Sci, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Minerva Ctr Photosynth Stress, IL-91904 Jerusalem, Israel; Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Nagoya University	Kaplan, A (corresponding author), Hebrew Univ Jerusalem, Fac Sci & Math, Dept Plant Sci, IL-91904 Jerusalem, Israel.		Kaplan, Aaron/GLN-5655-2022; Tchernov, Dan/AAE-2545-2021	Tchernov, Dan/0000-0003-1135-8270; Keren, Nir/0000-0002-7356-8831; Kaplan, Aaron/0000-0002-0815-5731				ABE T, 1987, PLANT CELL PHYSIOL, V28, P671; Allakhverdiev SI, 2000, PLANT PHYSIOL, V122, P1201, DOI 10.1104/pp.122.4.1201; BADGER MR, 1994, PHYSIOL PLANTARUM, V90, P529, DOI 10.1111/j.1399-3054.1994.tb08811.x; Bonfil DJ, 1998, FEBS LETT, V430, P236, DOI 10.1016/S0014-5793(98)00662-0; BRECHIGNAC F, 1985, PLANT PHYSIOL, V78, P551, DOI 10.1104/pp.78.3.551; Cooley JW, 2000, J BACTERIOL, V182, P714, DOI 10.1128/JB.182.3.714-722.2000; Cortes P, 2000, BBA-BIOENERGETICS, V1456, P67, DOI 10.1016/S0005-2728(99)00109-7; ESPIE GS, 1991, PLANT PHYSIOL, V97, P943, DOI 10.1104/pp.97.3.943; Fridlyand L, 1996, BIOSYSTEMS, V37, P229, DOI 10.1016/0303-2647(95)01561-2; Hagemann M, 1999, PHYSIOL PLANTARUM, V105, P670, DOI 10.1034/j.1399-3054.1999.105411.x; Huertas IE, 2000, J PHYCOL, V36, P314, DOI 10.1046/j.1529-8817.2000.99142.x; Jeanjean R, 1998, FEMS MICROBIOL LETT, V167, P131, DOI 10.1016/S0378-1097(98)00372-3; Kaplan A, 1999, ANNU REV PLANT PHYS, V50, P539, DOI 10.1146/annurev.arplant.50.1.539; KAPLAN A, 1987, PLANT PHYSIOL, V84, P210, DOI 10.1104/pp.84.2.210; Klughammer B, 1999, MOL MICROBIOL, V32, P1305, DOI 10.1046/j.1365-2958.1999.01457.x; Letellier L, 1997, J BIOL CHEM, V272, P11109; Li QL, 1998, PLANT PHYSIOL, V116, P1125, DOI 10.1104/pp.116.3.1125; MARCO E, 1993, PLANT PHYSIOL, V101, P1047, DOI 10.1104/pp.101.3.1047; McGinn PJ, 1997, CAN J BOT, V75, P1913, DOI 10.1139/b97-903; MILLER AG, 1988, PLANT PHYSIOL, V86, P677, DOI 10.1104/pp.86.3.677; MILLER AG, 1991, CAN J BOT, V69, P925, DOI 10.1139/b91-119; OGAWA T, 1992, PLANT PHYSIOL, V99, P1604, DOI 10.1104/pp.99.4.1604; OGAWA T, 1985, BIOCHIM BIOPHYS ACTA, V808, P77, DOI 10.1016/0005-2728(85)90029-5; Ohkawa H, 2000, J BIOL CHEM, V275, P31630, DOI 10.1074/jbc.M003706200; Ohkawa H, 1998, CAN J BOT, V76, P1035, DOI 10.1139/b98-076; Ohkawa H, 2000, J BACTERIOL, V182, P2591, DOI 10.1128/JB.182.9.2591-2596.2000; Omata T, 1999, P NATL ACAD SCI USA, V96, P13571, DOI 10.1073/pnas.96.23.13571; Price GD, 1998, CAN J BOT, V76, P973, DOI 10.1139/b98-081; PRICE GD, 1989, PLANT PHYSIOL, V91, P505, DOI 10.1104/pp.91.2.505; REINHOLD L, 1984, PLANT PHYSIOL, V76, P1090, DOI 10.1104/pp.76.4.1090; Ronen-Tarazi M, 1998, CAN J BOT, V76, P942, DOI 10.1139/b98-085; Salon C, 1998, CAN J BOT, V76, P1, DOI 10.1139/b97-154; Salon C, 1996, PLANT CELL ENVIRON, V19, P260, DOI 10.1111/j.1365-3040.1996.tb00249.x; SHERMAN DM, 1994, PLANT PHYSIOL, V106, P251, DOI 10.1104/pp.106.1.251; So AKC, 1998, CAN J BOT, V76, P1084, DOI 10.1139/b98-071; STANIER RY, 1971, BACTERIOL REV, V35, P171, DOI 10.1128/MMBR.35.2.171-205.1971; Sukenik A, 1997, J PHYCOL, V33, P969, DOI 10.1111/j.0022-3646.1997.00969.x; Tchernov D, 1997, CURR BIOL, V7, P723, DOI 10.1016/S0960-9822(06)00330-7; TU CK, 1987, PLANT PHYSIOL, V85, P72, DOI 10.1104/pp.85.1.72; Tyerman SD, 1999, J EXP BOT, V50, P1055, DOI 10.1093/jexbot/50.suppl_1.1055; van Thor JJ, 2000, BBA-BIOENERGETICS, V1457, P129, DOI 10.1016/S0005-2728(00)00072-4; VERMAAS WFJ, 1994, FEBS LETT, V337, P103, DOI 10.1016/0014-5793(94)80638-1; VOLOKITA M, 1984, PLANT PHYSIOL, V76, P599, DOI 10.1104/pp.76.3.599	43	64	69	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23450	23455		10.1074/jbc.M101973200	http://dx.doi.org/10.1074/jbc.M101973200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11297562	hybrid			2022-12-25	WOS:000169531100031
J	Bourette, RP; De Sepulveda, P; Arnaud, S; Dubreuil, P; Rottapel, R; Mouchiroud, G				Bourette, RP; De Sepulveda, P; Arnaud, S; Dubreuil, P; Rottapel, R; Mouchiroud, G			Suppressor of cytokine signaling 1 interacts with the macrophage colony-stimulating factor receptor and negatively regulates its proliferation signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-CSF RECEPTOR; LEUKEMIA INHIBITORY FACTOR; FACTOR-I RECEPTOR; C-FMS GENE; GROWTH-FACTOR; DIFFERENTIATION SIGNALS; TYROSINE KINASES; FDC-P1 CELLS; BINDING-SITE; PROTEIN	Macrophage colony-stimulating factor receptor (M-CSF-R) is a tyrosine kinase that regulates proliferation, differentiation, and cell survival during monocytic lineage development. Upon activation, M-CSF-R dimerizes and autophosphorylates on specific tyrosines, creating binding sites for several cytoplasmic SH2-containing signaling molecules that relay and modulate the M-CSF signal. Here we show that M-CSF-R interacts with suppressor of cytokine signaling 1 (Socs1), a negative regulator of various cytokine and growth factor signaling pathways. Using the yeast two-hybrid system, in vitro glutathione S-transferase-M-CSF-R pull-down, and in vivo coimmunoprecipitation experiments, we demonstrated a direct interaction between the SH2 domain of Socs1 and phosphorylated tyrosines 697 or 721 of the M CSF-R kinase insert region. Moreover, Socs1 is tyrosine-phosphorylated in response to M-CSF. Ectopic expression of Socs1 in FDC-P1/MAC and EML hematopoietic cell lines decreased their growth rates in the presence of limiting concentrations of M-CSF. However, Socs1 expression did not totally suppress long term cell growth in the presence of saturating M-CSF concentrations, in contrast to other cytokines such as stem cell factor and interleukin 3. Taken together, these results suggest that Socs1 is an M-CSF-R-binding partner involved in negative regulation of proliferation signaling and that it differentially affects cytokine receptor signals.	CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; INSERM, U119, F-13009 Marseille, France; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Bourette, RP (corresponding author), CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	bourette@biomserv.univ-lyon1.fr	Bourette, Roland/ABB-3343-2020; Dubreuil, Patrice/V-4816-2019; Mouchiroud, Guy/K-1153-2018; dubreuil, patrice/F-5346-2011; De sepulveda, paulo/K-6043-2015	Dubreuil, Patrice/0000-0003-1155-1150; dubreuil, patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; Rottapel, Robert/0000-0002-6024-5558				Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Aperlo C, 1998, CELL GROWTH DIFFER, V9, P929; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Cohney SJ, 1999, MOL CELL BIOL, V19, P4980; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; De Sepulveda P, 1999, EMBO J, V18, P904; Dey BR, 1998, J BIOL CHEM, V273, P24095, DOI 10.1074/jbc.273.37.24095; Dey BR, 2000, BIOCHEM BIOPH RES CO, V278, P38, DOI 10.1006/bbrc.2000.3762; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KATO JY, 1990, BLOOD, V75, P1780; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Metcalf D, 1999, LEUKEMIA, V13, P926, DOI 10.1038/sj.leu.2401440; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Metcalf D, 1999, EXP HEMATOL, V27, P1715, DOI 10.1016/S0301-472X(99)00120-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Novak U, 1999, GROWTH FACTORS, V16, P305, DOI 10.3109/08977199909069148; Novak U, 1996, ONCOGENE, V13, P2607; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Pawlak G, 2000, EXP HEMATOL, V28, P1164, DOI 10.1016/S0301-472X(00)00522-1; Pawlak G, 1999, EXP HEMATOL, V27, P797, DOI 10.1016/S0301-472X(99)00013-2; Pawson T, 2000, GENE DEV, V14, P1027; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROHRSCHNEIDER LR, 1995, GUIDEBOOK CYTOKINES, P168; ROSNET O, 1993, CRIT REV ONCOGENESIS, V4, P595; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STANDIFER KM, 1994, NEURON, V12, P805, DOI 10.1016/0896-6273(94)90333-6; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; TUSHINSKI RJ, 1982, CELL, V28, P71, DOI 10.1016/0092-8674(82)90376-2; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348	47	38	38	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22133	22139		10.1074/jbc.M101878200	http://dx.doi.org/10.1074/jbc.M101878200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297560	hybrid			2022-12-25	WOS:000169412700023
J	Ko, YG; Park, H; Kim, T; Lee, JW; Park, SG; Seol, W; Kim, JE; Lee, WH; Kim, SH; Park, JE; Kim, S				Ko, YG; Park, H; Kim, T; Lee, JW; Park, SG; Seol, W; Kim, JE; Lee, WH; Kim, SH; Park, JE; Kim, S			A cofactor of tRNA synthetase, p43, is secreted to up-regulate proinflammatory genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-POLYPEPTIDE-II; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSFER-RNA SYNTHETASE; TUMOR-DERIVED CYTOKINE; EMAP-II; MICROGLIAL CELLS; APOPTOSIS; ATHEROSCLEROSIS; INFLAMMATION; CHEMOKINES	An auxiliary factor of mammalian multi-aminoacyl-tRNA synthetases, p43, is thought to be a precursor of endothelial monocyte-activating polypeptide II (EMAP II) that triggers proinflammation in leukocytes and macrophages. In the present work, however, we have shown that p43 itself is specifically secreted from intact mammalian cells, while EMAP II is released only when the cells are disrupted. Secretion of p43 was also observed when its expression was increased. These results suggest that p43 itself should be a real cytokine secreted by an active mechanism. To determine the cytokine activity and active domain of p43, we investigated tumor necrosis factor (TNF) and interleukin-8 (IL-8) production from human monocytic THP-1 cells treated with various p43 deletion mutants. The full length of p43 showed higher cytokine activity than EMAP II, further supporting p43 as the active cytokine. p43 was also shown to activate MAPKs and NF kappaB, and to induce cytokines and chemokines such as TNF, IL-8, MCP-1, MIP-1 alpha, MIP-1 beta, MIP-2 alpha, IL-1 beta, and RANTES. Interestingly, the high level of p43 was observed in the foam cells of atherosclerotic lesions. Therefore, p43 could be a novel mediator of atherosclerosis development as well as other inflammation-related diseases.	Seoul Natl Univ, Coll Pharm, Natl Creat Res Initiat Ctr ARS Network, Kwanak Ku, Seoul 151742, South Korea; Sungkyunkwan Univ, Dept Biol Sci, Suwon 440746, South Korea; Sungkyunkwan Univ, Coll Med, Samsung Med Ctr, Cardiovasc Inst, Seoul 135710, South Korea	Seoul National University (SNU); Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, S (corresponding author), Seoul Natl Univ, Coll Pharm, Natl Creat Res Initiat Ctr ARS Network, Kwanak Ku, San 56-1 Shillim Dong, Seoul 151742, South Korea.	sungkim@snu.ac.kr	Kim, Sunghoon/AAE-8314-2020					Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barnett G, 2000, CANCER RES, V60, P2850; Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; Berger AC, 2000, J IMMUNOTHER, V23, P519, DOI 10.1097/00002371-200009000-00002; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; de Winther MPJ, 2000, J CLIN INVEST, V105, P1039, DOI 10.1172/JCI9919; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Izikson L, 2000, J EXP MED, V192, P1075, DOI 10.1084/jem.192.7.1075; JANEWAY CA, 1999, IMMUNOBIOLOGY IMMUNE, P380; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; KAO J, 1992, J BIOL CHEM, V267, P20239; KAO J, 1994, J BIOL CHEM, V269, P25106; KAO J, 1994, J BIOL CHEM, V269, P9774; Kim Y, 2000, J BIOL CHEM, V275, P27062; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Schluesener HJ, 1999, ACTA NEUROPATHOL, V97, P119, DOI 10.1007/s004010050964; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schwarz M, 1999, AM J PHYSIOL-LUNG C, V276, pL365, DOI 10.1152/ajplung.1999.276.2.L365; Scott MG, 2000, J IMMUNOL, V165, P3358, DOI 10.4049/jimmunol.165.6.3358; Steinman L, 1996, CELL, V85, P299, DOI 10.1016/S0092-8674(00)81107-1; Tas MPR, 1996, INT J BIOCHEM CELL B, V28, P837, DOI 10.1016/1357-2725(96)00038-6; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Zhang FR, 2000, DEV DYNAM, V218, P490, DOI 10.1002/1097-0177(200007)218:3<490::AID-DVDY1005>3.0.CO;2-C	32	125	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23028	23033		10.1074/jbc.M101544200	http://dx.doi.org/10.1074/jbc.M101544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292833	hybrid			2022-12-25	WOS:000169412700139
J	Petitpas, I; Bhattacharya, AA; Twine, S; East, M; Curry, S				Petitpas, I; Bhattacharya, AA; Twine, S; East, M; Curry, S			Crystal structure analysis of warfarin binding to human serum albumin - Anatomy of drug site I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; RESOLUTION; FRAGMENTS; INSIGHTS; REVEALS; CELLS	Human serum albumin (HSA) is an abundant transport protein found in plasma that binds a wide variety of drugs in two primary binding sites (I and II) and can have a significant impact on their pharmacokinetics. We have determined the crystal structures at 2.5 Angstrom -resolution of HSA-myristate complexed with the R-(+) and S-(-) enantiomers of warfarin, a widely used anticoagulant that binds to the protein with high affinity. The structures confirm that warfarin binds to drug site I (in subdomain IIA) in the presence of fatty acids and reveal the molecular details of the protein drug interaction. The two enantiomers of warfarin adopt very similar conformations when bound to the protein and make many of the same specific contacts with amino acid side chains at the binding site, thus accounting for the relative lack of stereospecificity of the HSA-warfarin interaction. The conformation of the warfarin binding pocket is significantly altered upon binding of fatty acids, and this can explain the observed enhancement of warfarin binding to HSA at low levels of fatty acid.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BW, England; Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England	Imperial College London; University of Southampton	Curry, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Biophys Sect, London SW7 2BW, England.			Curry, Stephen/0000-0002-0552-8870				Beljaars L, 2000, J BIOL CHEM, V275, P12743, DOI 10.1074/jbc.275.17.12743; Bhattacharya AA, 2000, J MOL BIOL, V303, P721, DOI 10.1006/jmbi.2000.4158; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BIRKETT DJ, 1977, MOL PHARMACOL, V13, P987; BOS OJM, 1988, BIOCHEM PHARMACOL, V37, P3905, DOI 10.1016/0006-2952(88)90072-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carter D. C., 1994, ADV PROTEIN CHEM, V45, P152; CARTER DC, 1994, EUR J BIOCHEM, V226, P1049, DOI 10.1111/j.1432-1033.1994.01049.x; Curry S, 1999, BBA-MOL CELL BIOL L, V1441, P131, DOI 10.1016/S1388-1981(99)00148-1; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DIANA FJ, 1989, J PHARM SCI-US, V78, P195, DOI 10.1002/jps.2600780304; Dockal M, 2000, PROTEIN SCI, V9, P1455, DOI 10.1110/ps.9.8.1455; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FEHSKE KJ, 1982, MOL PHARMACOL, V21, P387; FEHSKE KJ, 1979, MOL PHARMACOL, V16, P778; HE XM, 1992, NATURE, V358, P209, DOI 10.1038/358209a0; HO JX, 1993, EUR J BIOCHEM, V215, P205, DOI 10.1111/j.1432-1033.1993.tb18024.x; Holford N. H. G., 1998, BASIC CLIN PHARM, P34; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; KRAGHHANSEN U, 1988, MOL PHARMACOL, V34, P160; Lindup W. E., 1987, PROGR DRUG METABOLIS, V10, P141; LOUN B, 1994, ANAL CHEM, V66, P3814, DOI 10.1021/ac00093a043; Mao HY, 2000, PROTEIN EXPRES PURIF, V20, P492, DOI 10.1006/prep.2000.1330; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Peters Jr. T., 1995, ALL ALBUMIN BIOCH GE; Petersen CE, 2000, CHEM-BIOL INTERACT, V124, P161, DOI 10.1016/S0009-2797(99)00143-X; PETERSEN CE, 2000, PROGR DRUG METABOLIS, V124, P161; SJOHOLM I, 1979, MOL PHARMACOL, V16, P767; SUDLOW G, 1976, MOL PHARMACOL, V12, P1052; SUDLOW G, 1975, MOL PHARMACOL, V11, P824; Tsuchida E, 2000, BIOCONJUGATE CHEM, V11, P46, DOI 10.1021/bc990065v; VALENTE EJ, 1977, J MED CHEM, V20, P1489, DOI 10.1021/jm00221a025; Vorum H, 1996, J PHARM PHARMACOL, V48, P870, DOI 10.1111/j.2042-7158.1996.tb03990.x; WANWIMOLRUK S, 1982, BIOCHIM BIOPHYS ACTA, V709, P247, DOI 10.1016/0167-4838(82)90467-8; WEST BD, 1961, J AM CHEM SOC, V83, P2676, DOI 10.1021/ja01473a020; WILDING G, 1977, SCIENCE, V195, P991, DOI 10.1126/science.841323; WILTING J, 1980, J BIOL CHEM, V255, P3032; Yamasaki K, 1996, BBA-PROTEIN STRUCT M, V1295, P147, DOI 10.1016/0167-4838(96)00013-1	39	670	695	3	101	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22804	22809		10.1074/jbc.M100575200	http://dx.doi.org/10.1074/jbc.M100575200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11285262	hybrid			2022-12-25	WOS:000169412700110
J	Yuste, VJ; Bayascas, JR; Llecha, N; Sanchez-Lopez, I; Boix, J; Comella, JX				Yuste, VJ; Bayascas, JR; Llecha, N; Sanchez-Lopez, I; Boix, J; Comella, JX			The absence of oligonucleosomal DNA fragmentation during apoptosis of IMR-5 neuroblastoma cells - Disappearance of the caspase-activated DNase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED NEURONAL APOPTOSIS; CHROMATIN CONDENSATION; DEATH; CLEAVAGE; STAUROSPORINE; DEGRADATION; INHIBITOR; INVOLVEMENT; MECHANISMS; INDUCTION	Caspase-activated DNase is responsible for the oligonucleosomal DNA degradation during apoptosis, DNA degradation is thought to be important for multicellular organisms to prevent oncogenic transformation or as a mechanism of viral defense, It has been reported that certain cells, including some neuroblastoma cell lines such as IMR-5, enter apoptosis without digesting DNA in such a way, We have analyzed the causes for the absence of DNA laddering in staurosporine-treated IMR-5 cells, and we have found that most of the molecular mechanisms controlling apoptosis are well preserved in this cell line, These include degradation of substrates for caspases, blockade of cell death by antiapoptotic genes such as Bcl-2 or Bcl-X-L, or normal levels and adequate activation of caspase-3. Moreover, these cells display normal levels of caspase-activated DNase and its inhibitory protein, inhibitor of caspase-activated DNase, and their cDNA sequences are identical to those reported previously. Nevertheless, IMR-5 cells lose caspase-activated DNase during apoptosis and recover their ability to degrade DNA when human recombinant caspase-activated DNase is overexpressed, Our results lead to the conclusion that caspase-activated DNase is processed during apoptosis of IMR-5 cells, making these cells a good model to study the relevance of this endonuclease in physiological or pathological conditions.	Univ Lleida, Dept Ciencies Mediques Basiques, Grp Neurobiol Mol, Lleida 25198, Spain	Universitat de Lleida	Comella, JX (corresponding author), Univ Lleida, Dept Ciencies Mediques Basiques, Grp Neurobiol Mol, Lleida 25198, Spain.		Comella, Joan X/D-7333-2012; Comella, Joan/GQA-4279-2022; Yuste, Victor J./C-7071-2008; Bayascas, Jose R/C-9450-2011	Comella, Joan X/0000-0002-6218-0786; Yuste, Victor J./0000-0001-5322-9261; Bayascas, Jose R/0000-0002-6096-2151; Sanchez Lopez, Isabel/0000-0003-1218-3636				Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; Boix J, 1997, NEUROPHARMACOLOGY, V36, P811, DOI 10.1016/S0028-3908(97)00030-0; Boix J, 1998, EXP CELL RES, V238, P422, DOI 10.1006/excr.1997.3852; CUVILLIER O, 1996, P NATL ACAD SCI USA, V93, P8395; de la Taille A, 1999, CANCER RES, V59, P5461; Deshmukh M, 2000, CELL DEATH DIFFER, V7, P250, DOI 10.1038/sj.cdd.4400641; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P699, DOI 10.1006/bbrc.1999.1888; Ferri KF, 2000, NAT CELL BIOL, V2, pE63, DOI 10.1038/35008692; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Herrmann M, 1998, ARTHRITIS RHEUM-US, V41, P1241, DOI 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; McIlroy D, 2000, GENE DEV, V14, P549; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; Posmantur R, 1997, J NEUROCHEM, V68, P2328; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Walker PR, 1999, ANN NY ACAD SCI, V887, P48, DOI 10.1111/j.1749-6632.1999.tb07921.x; Walker PR, 1997, BIOCHEM CELL BIOL, V75, P287, DOI 10.1139/bcb-75-4-287; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu YC, 2000, GENE DEV, V14, P536; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480	43	61	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22323	22331		10.1074/jbc.M100072200	http://dx.doi.org/10.1074/jbc.M100072200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294834	hybrid			2022-12-25	WOS:000169412700049
J	Delom, F; Mallett, B; Carayon, P; Lejeune, PJ				Delom, F; Mallett, B; Carayon, P; Lejeune, PJ			Role of extracellular molecular chaperones in the folding of oxidized proteins - Refolding of colloidal thyroglobulin by protein disulfide isomerase and immunoglobulin heavy chain-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE SYNTHESIS; SALT-DEPENDENT LIPASE; ENDOPLASMIC-RETICULUM; HEN LYSOZYME; N-GLYCANS; IN-VITRO; BIP; STORAGE; SPECIFICITY; THYROCYTES	The process of thyroid hormone synthesis, which occurs in the lumen of the thyroid follicles, results from an oxidative reaction leading, as side effects, to the multimerization of thyroglobulin (TG), the prothyroid hormone, Although hormone synthesis is a continuous process; the amount of Tg multimers is relatively constant. Here, we investigated the role of two molecular chaperones, protein disulfide isomerase (PDI) and immunoglobulin heavy chain-binding protein (BiP), present in the follicular lumen, on the multimerization process due to oxidation using both native Tg and its N-terminal domain (NTD), In vitro, PDI decreased multimerization of Tg and even suppressed the formation of NTD multimers, Under the same conditions, BiP was able to bind to Tg and NTD multimers but did not affect the process of multimerization, Associating BiP with PDI did not enhance the ability of PDL to limit the formation of multimers produced by oxidation, However, when BiP and PDI were reacted together with the multimeric forms and for a longer time (48 h), BiP greatly increased the efficiency of PDI, Accordingly, these two molecular chaperones probably act sequentially on the reduction of the intermolecular disulfide bridges. In the thyroid, a similar process may also be effective and participate in limiting the amount of Tg multimers present in the colloid. These results suggest that extracellular molecular chaperones play a similar role to that occurring in the endoplasmic reticulum and, furthermore, take part in the control of multimerization and aggregation of proteins formed by oxidation.	Univ Mediterranee, Fac Med, INSERM, U555, F-13385 Marseille 5, France; Univ Mediterranee, Fac Med, Lab Biochim Endocrinienne & Metab, F-13385 Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Mallett, B (corresponding author), Univ Mediterranee, Fac Med, INSERM, U555, F-13385 Marseille 5, France.		Delom, Frederic/J-2782-2014	Delom, Frederic/0000-0002-4600-7633				Baudry N, 1996, FEBS LETT, V396, P223, DOI 10.1016/0014-5793(96)01107-6; Baudry N, 1998, BIOCHEM BIOPH RES CO, V242, P292, DOI 10.1006/bbrc.1997.7952; Berndorfer U, 1996, J CLIN ENDOCR METAB, V81, P1918, DOI 10.1210/jc.81.5.1918; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; Brix K, 1996, ENDOCRINOLOGY, V137, P1963, DOI 10.1210/en.137.5.1963; Bruneau N, 1998, J CELL SCI, V111, P2665; BRUNEAU N, 1995, J BIOL CHEM, V270, P13524, DOI 10.1074/jbc.270.22.13524; Delom F, 1999, BIOCHEM BIOPH RES CO, V255, P438, DOI 10.1006/bbrc.1999.0229; DORNER AJ, 1990, P NATL ACAD SCI USA, V87, P7429, DOI 10.1073/pnas.87.19.7429; DUNN JT, 2000, WERNER INGBARS THYRO, P91; FELDTRASMUSSEN U, 1978, J IMMUNOL METHODS, V21, P295, DOI 10.1016/0022-1759(78)90156-4; FRATI L, 1974, ARCH BIOCHEM BIOPHYS, V162, P126, DOI 10.1016/0003-9861(74)90111-8; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; KIM PS, 1995, J CELL BIOL, V128, P29, DOI 10.1083/jcb.128.1.29; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KNITTLER MR, 1992, EMBO J, V11, P1573, DOI 10.1002/j.1460-2075.1992.tb05202.x; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kuznetsov G, 1997, J BIOL CHEM, V272, P3057, DOI 10.1074/jbc.272.5.3057; LEMANSKY P, 1994, ENDOCRINOLOGY, V135, P1566, DOI 10.1210/en.135.4.1566; MALLET B, 1995, J BIOL CHEM, V270, P29881; MARRIQ C, 1986, FEBS LETT, V207, P302, DOI 10.1016/0014-5793(86)81509-5; Mayer M, 2000, J BIOL CHEM, V275, P29421, DOI 10.1074/jbc.M002655200; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; Mezghrani A, 2000, J BIOL CHEM, V275, P1920, DOI 10.1074/jbc.275.3.1920; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Muresan Z, 1997, J BIOL CHEM, V272, P26095, DOI 10.1074/jbc.272.42.26095; NOIVA R, 1992, J BIOL CHEM, V267, P3553; Primm TP, 1996, J BIOL CHEM, V271, P33664, DOI 10.1074/jbc.271.52.33664; PUIG A, 1994, J BIOL CHEM, V269, P7764; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RUF J, 1983, EMBO J, V2, P1821, DOI 10.1002/j.1460-2075.1983.tb01664.x; Saber-Lichtenberg Y, 2000, FASEB J, V14, P1005, DOI 10.1096/fasebj.14.7.1005; Tepel C, 2000, J CELL SCI, V113, P4487; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; van den Berg P, 1999, EMBO J, V18, P4794, DOI 10.1093/emboj/18.17.4794; YAMAUCHI K, 1987, BIOCHEM BIOPH RES CO, V146, P1485, DOI 10.1016/0006-291X(87)90817-5	41	40	41	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21337	21342		10.1074/jbc.M101086200	http://dx.doi.org/10.1074/jbc.M101086200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294872	hybrid			2022-12-25	WOS:000169297900073
J	McManus, DC; Scott, BR; Franklin, V; Sparks, DL; Marcel, YL				McManus, DC; Scott, BR; Franklin, V; Sparks, DL; Marcel, YL			Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL-ACYLTRANSFERASE; CORONARY-ARTERY DISEASE; BINDING CASSETTE TRANSPORTER-1; RECONSTITUTED LPA-I; APOA-I; TANGIER-DISEASE; TRANSGENIC MICE; CENTRAL DOMAIN; HEART-DISEASE	We have devised a combined in vivo, ex vivo, and in vitro approach to elucidate the mechanism(s) responsible for the hypoalphalipoproteinemia in heterozygous carriers of a naturally occurring apolipoprotein A-I (apoA-I) variant (Leu(159) to Arg) known as apoA-I Finland (apoA-I-FIN). Adenovirus-mediated expression of apoA-I-FIN decreased apoA-I and high density lipoprotein cholesterol concentrations in both wild-type C57BL/6J mice and in apoA-I-deficient mice expressing native human apoA-I (hapoA-I), Interestingly, apoA-I-FIN was degraded in the plasma, and the extent of proteolysis correlated with the most significant reductions in murine apoA-I concentrations. ApoA-I-FIN had impaired activation of lecithin:cholesterol acyltransferase in vitro compared with hapoA-I, but in a mixed lipoprotein preparation consisting of both hapoA-I and apoA-I-FIN there was only a moderate reduction in the activation of this enzyme. Importantly, secretion of apoA-I was also decreased from primary apoA-I-deficient hepatocytes when hapoA-I was co-expressed with apoA-I-FIN following infection with recombinant adenoviruses, a condition that mimics secretion in heterozygotes. Thus, this is the first demonstration of an apoA-I point mutation that decreases LCAT activation, impairs hepatocyte secretion of apoA-I, and makes apoA-I susceptible to proteolysis leading to dominantly inherited hypoalphalipoproteinemia.	Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Pathol & Lab Med, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Biochem, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Microbiol, Ottawa, ON K1Y 4W7, Canada; Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Immunol, Ottawa, ON K1Y 4W7, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa Heart Institute	Marcel, YL (corresponding author), Univ Ottawa, Inst Heart, Lipoprot & Atherosclerosis Res Grp, Dept Pathol & Lab Med, Rm H460,40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.			Scott, Brian/0000-0002-7012-4696				Albers J J, 1986, Methods Enzymol, V129, P763; ASSMANN G, 1993, CIRCULATION, V87, P28; BANKA CL, 1991, J BIOL CHEM, V266, P23886; Bergeron J, 1997, BBA-LIPID LIPID MET, V1344, P139, DOI 10.1016/S0005-2760(96)00136-1; BERGERON J, 1995, J BIOL CHEM, V270, P27429, DOI 10.1074/jbc.270.46.27429; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BRESLOW JL, 1995, METABOLIC MOL BASES, P2031; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bruckert E, 1997, ATHEROSCLEROSIS, V128, P121, DOI 10.1016/S0021-9150(96)05982-5; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; Calabresi L, 1997, CURR OPIN LIPIDOL, V8, P219, DOI 10.1097/00041433-199708000-00005; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Collet X, 1997, J LIPID RES, V38, P634; Daum U, 1999, J LIPID RES, V40, P486; Daum U, 1999, J MOL MED, V77, P614, DOI 10.1007/s001099900034; DEEB SS, 1991, J BIOL CHEM, V266, P13654; Dhoest A, 1997, J BIOL CHEM, V272, P15967, DOI 10.1074/jbc.272.25.15967; EISENBERG S, 1984, J LIPID RES, V25, P1017; Frank PG, 2000, J LIPID RES, V41, P853; Frank PG, 1998, BIOCHEMISTRY-US, V37, P13902, DOI 10.1021/bi981205b; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Holvoet P, 2000, ARTERIOSCL THROM VAS, V20, P459, DOI 10.1161/01.ATV.20.2.459; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Lee M, 2000, J LIPID RES, V41, P975; Lindholm EM, 1998, BIOCHEMISTRY-US, V37, P4863, DOI 10.1021/bi972888i; Lindstedt L, 1999, J BIOL CHEM, V274, P22627, DOI 10.1074/jbc.274.32.22627; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; McManus DC, 2000, J BIOL CHEM, V275, P5043, DOI 10.1074/jbc.275.7.5043; Mendez AJ, 1997, BBA-LIPID LIPID MET, V1346, P285, DOI 10.1016/S0005-2760(97)00031-3; MENG QH, 1993, J BIOL CHEM, V268, P16966; Miettinen HE, 1997, ARTERIOSCL THROM VAS, V17, P3021, DOI 10.1161/01.ATV.17.11.3021; Miettinen HE, 1997, ARTERIOSCL THROM VAS, V17, P83, DOI 10.1161/01.ATV.17.1.83; Miller M, 1998, ARTERIOSCL THROM VAS, V18, P1242, DOI 10.1161/01.ATV.18.8.1242; Pirillo A, 2000, BIOCHEM BIOPH RES CO, V271, P386, DOI 10.1006/bbrc.2000.2649; Qin SC, 2000, J LIPID RES, V41, P269; Roosbeek S, 2001, J LIPID RES, V42, P31; ROSSENEU M, 1995, FASEB J, V9, P768, DOI 10.1096/fasebj.9.9.7601341; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Sorci-Thomas MG, 2000, J BIOL CHEM, V275, P12156, DOI 10.1074/jbc.275.16.12156; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; Sparks DL, 1998, BBA-LIPID LIPID MET, V1390, P160, DOI 10.1016/S0005-2760(97)00172-0; SPARKS DL, 1995, J BIOL CHEM, V270, P5151, DOI 10.1074/jbc.270.10.5151; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; SUBRAHMANYAN L, 1988, SCAND J IMMUNOL, V27, P251, DOI 10.1111/j.1365-3083.1988.tb02345.x; Sviridov D, 2000, J BIOL CHEM, V275, P19707, DOI 10.1074/jbc.M000962200; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; THOMAS SS, 1995, BBA-MOL BASIS DIS, V1272, P37, DOI 10.1016/0925-4439(95)00065-C; Uboldi P, 1996, J LIPID RES, V37, P2557; Velez-Carrasco W, 2000, ARTERIOSCL THROM VAS, V20, P801, DOI 10.1161/01.ATV.20.3.801; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1722, DOI 10.1172/JCI114355; WEISGRABER KH, 1980, J CLIN INVEST, V66, P901, DOI 10.1172/JCI109957; Yamakawa-Kobayashi K, 1999, HUM MOL GENET, V8, P331, DOI 10.1093/hmg/8.2.331	60	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21292	21302		10.1074/jbc.M100463200	http://dx.doi.org/10.1074/jbc.M100463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11292828	hybrid			2022-12-25	WOS:000169297900067
J	Canicio, J; Ruiz-Lozano, P; Carrasco, M; Palacin, M; Chien, K; Zorzano, A; Kaliman, P				Canicio, J; Ruiz-Lozano, P; Carrasco, M; Palacin, M; Chien, K; Zorzano, A; Kaliman, P			Nuclear factor kappa B-inducing kinase and I kappa B kinase-alpha signal skeletal muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; NITRIC-OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL 3-KINASE; IKK-ALPHA; EXPRESSION; MYOGENESIS; ACTIVATION; PHOSPHORYLATION; MYOBLASTS; PROTEIN	Nuclear factor kappaB (NF-kappaB)-inducing kinase (NIK), I kappaB kinase (IKK)-alpha and -beta, and I kappaB alpha are common elements that signal NF-kappaB activation in response to diverse stimuli. In this study, we analyzed the role of this pathway during insulin-like growth factor II. (IGF-II)-induced myoblast differentiation. L6E9 myoblasts differentiated with IGF-II showed an induction of NF-kappaB DNA-binding activity that correlated in time with the activation of IKK alpha. IKK beta, and NIK. Moreover, the activation of IKK alpha, IKK beta, and NIK by IGF-II was dependent on phosphatidylinositol 3-kinase, a key regulator of myogenesis, Adenoviral transduction with the I kappaB alpha (S32A/S36A) mutant severely impaired both IGF-II-dependent NF-kappaB activation and myoblast differentiation, indicating that phosphorylation of I kappaB alpha at Ser-32 and Ser-36 is an essential myogenic step. Adenoviral transfer of wild-type or kinase-deficient forms of IKK alpha or IKK beta revealed that IKK alpha is required for IGF-II-dependent myoblast differentiation, whereas IKK beta is not essential for this process. Finally, overexpression of kinase-proficient wild-type NIK showed that the activation of MK is sufficient to generate signals that trigger myogenin expression and multinucleated myotube formation in the absence of IGF-II.	Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	University of Barcelona; University of California System; University of California San Diego	Kaliman, P (corresponding author), Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Avda Diagonal 645, E-08028 Barcelona, Spain.		Palacín, Manuel/G-9786-2015; Zorzano, Antonio/R-5479-2018	Palacin, Manuel/0000-0002-8670-293X				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; DENIS C, 1999, MOL CELL BIOL, V19, P5785; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; EWTON DZ, 1987, ENDOCRINOLOGY, V120, P115, DOI 10.1210/endo-120-1-115; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kaliman P, 1999, J BIOL CHEM, V274, P17437, DOI 10.1074/jbc.274.25.17437; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; KALIMAN P, 1996, J BIOL CHEM, V271, P146; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; LEE KH, 1994, J BIOL CHEM, V269, P14371; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Ozes ON, 1999, NATURE, V401, P82; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	39	31	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20228	20233		10.1074/jbc.M100718200	http://dx.doi.org/10.1074/jbc.M100718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279241	hybrid			2022-12-25	WOS:000169135100076
J	Lisby, M; Olesen, JR; Skouboe, C; Krogh, BO; Straub, T; Boege, F; Velmurugan, S; Martensen, PM; Andersen, AH; Jayaram, M; Westergaard, O; Knudsen, BR				Lisby, M; Olesen, JR; Skouboe, C; Krogh, BO; Straub, T; Boege, F; Velmurugan, S; Martensen, PM; Andersen, AH; Jayaram, M; Westergaard, O; Knudsen, BR			Residues within the N-terminal domain of human topoisomerase I play a direct role in relaxation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC DNA TOPOISOMERASES; CELL-CYCLE ARREST; CATALYTIC ACTIVITY; BINDING SEQUENCE; SPLICING FACTOR; PURIFICATION; CLEAVAGE; PHOSPHORYLATION; MECHANISM; CAMPTOTHECIN	All eukaryotic forms of DNA topoisomerase I contain an extensive and highly charged N-terminal domain. This domain contains several nuclear localization sequences and is essential for in vivo function of the enzyme. However, so far no direct function of the N-terminal. domain in the in vitro topoisomerase I reaction has been reported. In this study we have compared the in vitro activities of a truncated form of human topoisomerase I lacking amino acids 1-206 (p67) with the full-length enzyme (p91). Using these enzyme forms, we have identified for the first time a direct role of residues within the N-terminal domain in modulating topoisomerase I catalysis, as revealed by significant differences between p67 and p91 in 13NA binding, cleavage, strand rotation, and ligation. A comparison with previously published studies showing no effect of deleting the first 174 or 190 amino acids of topoisomerase I (Stewart, L., Ireton, G. C., and Champoux, J. J. (1999) J. Biol. Chem. 274 32950-32960; Bronstein, I. B., Wynne-Jones, A., Sukhanoua, A., Fleury, F., Ianoul, A., Holden, J. A., Alix, A. J., Dodson, G. G., Jardillier, J. C., Nabiev, I., and Wilkinson, A. J. (1999) Anticancer Res. 19, 317-327) suggests a pivotal role of amino acids 191-206 in catalysis. Taken together the presented data indicate that at least part(s) of the N-terminal domain regulate(s) enzyme/DNA dynamics during relaxation most probably by controlling non-covalent DNA binding downstream of the cleavage site either directly or by coordinating DNA contacts by other parts of the enzyme.	Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Univ Wurzburg, Sch Med, Med Poliklin, D-97070 Wurzburg, Germany; Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA	Aarhus University; University of Wurzburg; University of Texas System; University of Texas Austin	Knudsen, BR (corresponding author), Aarhus Univ, Dept Mol & Struct Biol, CF Mollers Alle,Bldg 130, DK-8000 Aarhus C, Denmark.		Martensen, Pia/I-3996-2012; Andersen, Anni/O-1162-2017; Murugan, Vel/AAA-3554-2019; Lisby, Michael/K-9814-2014; Straub, Tobias/B-2023-2009; Murugan, Vel/AAX-9679-2020; Boege, Fritz/H-3261-2019	Lisby, Michael/0000-0002-4830-5247; Straub, Tobias/0000-0002-0547-0453; Murugan, Vel/0000-0002-7368-7742; Olesen, Jes/0000-0002-6712-2702; Martensen, Pia Moller/0000-0002-1259-0226; Knudsen, Birgitta Ruth/0000-0002-3484-3802; Andersen, Anni/0000-0001-7194-3258				ALSNER J, 1992, J BIOL CHEM, V267, P12408; ATTARDI DG, 1981, J BIOL CHEM, V256, P3654; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Bronstein IB, 1999, ANTICANCER RES, V19, P317; CHAMPOUX JJ, 1978, J MOL BIOL, V118, P441, DOI 10.1016/0022-2836(78)90238-3; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; CHRISTIANSEN K, 1994, J BIOL CHEM, V269, P721; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; ENG WK, 1988, MOL PHARMACOL, V34, P755; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haluska P, 1998, ADV ENZYME REGUL, V38, P253, DOI 10.1016/S0065-2571(97)00008-3; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; JAVAHERIAN K, 1983, NUCLEIC ACIDS RES, V11, P461, DOI 10.1093/nar/11.2.461; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; Knudsen BR, 1996, J CHROMATOGR B, V684, P307, DOI 10.1016/0378-4347(96)00152-1; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Labourier E, 1998, NUCLEIC ACIDS RES, V26, P2955, DOI 10.1093/nar/26.12.2955; LAZARUS GM, 1987, BIOCHEMISTRY-US, V26, P6195, DOI 10.1021/bi00393a036; LEVIN NA, 1993, GENETICS, V133, P799; Lisby M, 1998, BIOCHEMISTRY-US, V37, P10815, DOI 10.1021/bi980757r; LIU LF, 1981, P NATL ACAD SCI-BIOL, V78, P3487, DOI 10.1073/pnas.78.6.3487; MCCONAUGHY BL, 1981, BIOCHIM BIOPHYS ACTA, V655, P1, DOI 10.1016/0005-2787(81)90059-9; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; RIOU JF, 1986, BIOCHEMISTRY-US, V25, P1471, DOI 10.1021/bi00355a001; ROWE TC, 1981, J BIOL CHEM, V256, P354; SAMUELS DS, 1994, BBA-MOL CELL RES, V1223, P77, DOI 10.1016/0167-4889(94)90075-2; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; Staron K, 1998, MOL BIOL REP, V25, P157, DOI 10.1023/A:1006827925817; STEVNSNER T, 1989, J BIOL CHEM, V264, P10110; Stewart L, 1999, J BIOL CHEM, V274, P32950, DOI 10.1074/jbc.274.46.32950; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; Takata M, 2000, MOL MICROBIOL, V35, P454, DOI 10.1046/j.1365-2958.2000.01722.x	44	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20220	20227		10.1074/jbc.M010991200	http://dx.doi.org/10.1074/jbc.M010991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11283003	hybrid			2022-12-25	WOS:000169135100075
J	Perez-Terzic, C; Gacy, AM; Bortolon, R; Dzeja, PP; Puceat, M; Jaconi, M; Prendergast, FG; Terzic, A				Perez-Terzic, C; Gacy, AM; Bortolon, R; Dzeja, PP; Puceat, M; Jaconi, M; Prendergast, FG; Terzic, A			Directed inhibition of nuclear import in cellular hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX; CARDIAC-HYPERTROPHY; NUCLEOCYTOPLASMIC TRANSPORT; HISTONE H1; GENE-EXPRESSION; PROTEIN EXPORT; HEART-FAILURE; MESSENGER-RNA; LEPTOMYCIN-B; SIGNAL	Each nuclear pore is responsible for both nuclear import and export with a finite capacity for bidirectional transport across the nuclear envelope, It remains poorly understood how the nuclear transport pathway responds to increased demands for nucleocytoplasmic communication. A case in point is cellular hypertrophy in which increased amounts of genetic material need to be transported from the nucleus to the cytosol, Here, we report an adaptive down-regulation of nuclear import supporting such an increased demand for nuclear export, The induction of cardiac cell hypertrophy by phenylephrine or angiotensin II inhibited the nuclear translocation of HI histones. The removal of hypertrophic stimuli reversed the hypertrophic phenotype and restored nuclear import. Moreover, the inhibition of nuclear export by leptomycin B rescued import, Hypertrophic reprogramming increased the intracellular GTP/GDP ratio and promoted the nuclear redistribution of the GTP-binding transport factor Ran, favoring export over import, Further, in hypertrophy, the reduced creatine kinase and adenylate kinase activities Limited energy delivery to the nuclear pore. The reduction of activities was associated with the closure of the cytoplasmic phase of the nuclear pore preventing import at the translocation step. Thus, to overcome the Limited capacity for nucleocytoplasmic transport, cells requiring increased nuclear export regulate the nuclear transport pathway by undergoing a metabolic and structural restriction of nuclear import.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Guggenhiem 7, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	PUCEAT, michel/R-6140-2017; Jaconi, Marisa EE/J-4392-2013	PUCEAT, michel/0000-0001-9055-7563; Jaconi, Marisa/0000-0002-2004-8226	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064822] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111, HL64822] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; BISHOPRIC NH, 1987, J CLIN INVEST, V80, P1194, DOI 10.1172/JCI113179; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Brodsky AS, 1999, NAT CELL BIOL, V1, pE66, DOI 10.1038/11036; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; DINGWALL C, 1992, SCIENCE, V258, P942, DOI 10.1126/science.1439805; Dzeja PP, 1999, CIRC RES, V84, P1137, DOI 10.1161/01.RES.84.10.1137; Dzeja PP, 1999, MOL CELL BIOCHEM, V201, P33, DOI 10.1023/A:1007016703229; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Englmeier L, 1999, CURR BIOL, V9, P30, DOI 10.1016/S0960-9822(99)80044-X; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hieda M, 1999, J CELL BIOL, V144, P645, DOI 10.1083/jcb.144.4.645; Hunter JJ, 1999, NEW ENGL J MED, V341, P1276, DOI 10.1056/NEJM199910213411706; IZUMO S, 1987, J CLIN INVEST, V79, P970, DOI 10.1172/JCI112908; Jaconi M, 2000, MOL BIOL CELL, V11, P1845, DOI 10.1091/mbc.11.5.1845; Jakel S, 1999, EMBO J, V18, P2411, DOI 10.1093/emboj/18.9.2411; Janssen E, 2000, EMBO J, V19, P6371, DOI 10.1093/emboj/19.23.6371; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; McKinsey TA, 1999, CURR OPIN GENET DEV, V9, P267, DOI 10.1016/S0959-437X(99)80040-9; Meyer N, 2000, FEBS LETT, V478, P151, DOI 10.1016/S0014-5793(00)01839-1; MICHAEL WM, 1995, CELL, V83, P415; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Nachury MV, 1999, P NATL ACAD SCI USA, V96, P9622, DOI 10.1073/pnas.96.17.9622; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Pante N, 1996, SCIENCE, V273, P1729, DOI 10.1126/science.273.5282.1729; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Pennisi E, 1998, SCIENCE, V279, P1129, DOI 10.1126/science.279.5354.1129; Perez-Terzic C, 1999, CIRC RES, V84, P1292, DOI 10.1161/01.RES.84.11.1292; PerezTerzic C, 1997, BIOESSAYS, V19, P787, DOI 10.1002/bies.950190908; PerezTerzic C, 1996, SCIENCE, V273, P1875, DOI 10.1126/science.273.5283.1875; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Pucar D, 2000, J BIOL CHEM, V275, P41424, DOI 10.1074/jbc.M007903200; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Rakowska A, 1998, J MEMBRANE BIOL, V163, P129, DOI 10.1007/s002329900377; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; SWAIN JL, 1982, P NATL ACAD SCI-BIOL, V79, P655, DOI 10.1073/pnas.79.2.655; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; TERZIC A, 1993, PHARMACOL REV, V45, P147; Terzic A, 1996, J PHYSIOL-LONDON, V492, P395, DOI 10.1113/jphysiol.1996.sp021316; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang Q, 1998, MOL CELL, V1, P223, DOI 10.1016/S1097-2765(00)80023-4	57	23	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20566	20571		10.1074/jbc.M101950200	http://dx.doi.org/10.1074/jbc.M101950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11283025	hybrid			2022-12-25	WOS:000169135100120
J	Sapkota, GP; Kieloch, A; Lizcano, JM; Lain, S; Arthur, JSC; Williams, MR; Morrice, N; Deak, M; Alessi, DR				Sapkota, GP; Kieloch, A; Lizcano, JM; Lain, S; Arthur, JSC; Williams, MR; Morrice, N; Deak, M; Alessi, DR			Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser(431) by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; GLYCOGEN-SYNTHASE KINASE-3; SERINE-THREONINE KINASE; EMBRYONIC STEM-CELLS; IN-VIVO; MAPKAP KINASE-1; MOLECULAR-BASIS; BH3 DOMAIN; ACTIVATION; BAD	Peutz-Jeghers syndrome is an inherited cancer syndrome that results in a greatly increased risk of developing tumors in those affected, The causative gene is a protein kinase termed LKB1, predicted to function as a tumor suppressor, The mechanism by which LKB1 is regulated in cells is not known. Here, we demonstrate that stimulation of Rat-a or embryonic stem cells with activators of ERK1/2 or of cAMP-dependent protein kinase induced phosphorylation of endogenously expressed LKB1 at Ser(431), We present pharmacological and genetic evidence that p90(RSK) mediated this phosphorylation in response to agonists that activate ERK1/2 and that cAMP-dependent protein kinase mediated this phosphorylation in response to agonists that activate adenylate cyclase, Ser(431) of LKB1 lies adjacent to a putative prenylation motif, and we demonstrate that full-length LKB1 expressed in 293 cells was prenylated by addition of a farnesyl group to Cys(433). Our data suggest that phosphorylation of LKB1 at Ser(431) does not affect farnesylation and that farnesylation does not affect phosphorylation at Ser(431), Phosphorylation of LKB1 at Ser(431) did not alter the activity of LKB1 to phosphorylate itself or the tumor suppressor protein p53 or alter the amount of LKB1 associated with cell membranes. The reintroduction of wild-type LKB1 into a cancer cell line that lacks LKB1 suppressed growth, but mutants of LKB1 in which Ser(431) was mutated to Ala to prevent phosphorylation of LKB1 were ineffective in inhibiting growth. In contrast, a mutant of LKB1 that cannot be prenylated was still able to suppress the growth of cells.	Univ Dundee, Sch Life Sci, Med Res Council Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; Ninewells Hosp, Canc Res Campaign Cell Transformat Grp, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Alessi, DR (corresponding author), Univ Dundee, Sch Life Sci, Med Res Council Prot Phosphorylat Unit, Dow St, Dundee DD1 5EH, Scotland.		Lizcano, Jose M/E-6080-2010; Arthur, J. Simon/B-8058-2010; lizcano, jose m/AAK-3577-2020; Lain, Sonia/B-6980-2014	Lizcano, Jose M/0000-0002-3154-5383; Arthur, J. Simon/0000-0002-8135-1958; lizcano, jose m/0000-0002-3154-5383; Lain, Sonia/0000-0001-9693-5246; Alessi, Dario/0000-0002-2140-9185				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bornfeldt KE, 1999, CELL SIGNAL, V11, P465, DOI 10.1016/S0898-6568(99)00020-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIS PD, 1992, J MED CHEM, V35, P177, DOI 10.1021/jm00079a024; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Harlow E., 1988, ANTIBODIES LAB MANUA; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki A, 1999, CELL MOL LIFE SCI, V55, P735, DOI 10.1007/s000180050329; HIDAKA H, 1990, NEUROCHEM RES, V15, P431, DOI 10.1007/BF00969929; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; MAENHAUT C, 1991, BIOCHIMIE, V73, P29, DOI 10.1016/0300-9084(91)90070-H; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Nezu J, 1999, BIOCHEM BIOPH RES CO, V261, P750, DOI 10.1006/bbrc.1999.1047; Powis G, 1995, ACTA BIOCHIM POL, V42, P395; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Watts JL, 2000, DEVELOPMENT, V127, P1467; Westerman AM, 1999, LANCET, V353, P1211, DOI 10.1016/S0140-6736(98)08018-0; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	58	206	212	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19469	19482		10.1074/jbc.M009953200	http://dx.doi.org/10.1074/jbc.M009953200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11297520	hybrid			2022-12-25	WOS:000169091000109
J	Le Naour, F; Hohenkirk, L; Grolleau, A; Misek, DE; Lescure, P; Geiger, JD; Hanash, S; Beretta, L				Le Naour, F; Hohenkirk, L; Grolleau, A; Misek, DE; Lescure, P; Geiger, JD; Hanash, S; Beretta, L			Profiling changes in gene expression during differentiation and maturation of monocyte-derived dendritic cells using both oligonucleotide microarrays and proteomics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CALCIUM-BINDING PROTEINS; CANCER-IMMUNOTHERAPY; ARACHIDONIC-ACID; TUMOR-GROWTH; IN-VITRO; CALRETICULIN; IMMUNITY; METABOLISM; GENERATION	Dendritic cells (DCs) are antigen-presenting cells that play major role in initiating primary immune responses. We have utilized two independent approaches, DNA microarrays and proteomics, to analyze the expression profile of human CD14(+) blood monocytes and their derived DCs. Analysis of gene expression changes at the RNA level using oligonucleotide microarrays complementary to 6300 human genes showed that similar to 40% of the genes were expressed in DCs, A total of 255 genes (4%) were found to be regulated during DC differentiation or maturation. Most of these genes were not previously associated with DCs and included genes encoding secreted proteins as well as genes involved in cell adhesion, signaling, and lipid metabolism. Protein analysis of the same cell populations was done using two-dimensional gel electrophoresis. A total of 900 distinct protein spots were included, and 4% of them exhibited quantitative changes during DC differentiation and maturation. Differentially expressed proteins were identified by mass spectrometry and found to represent proteins with Ca2+ binding, fatty acid binding, or chaperone activities as well as proteins involved in cell motility, In addition, proteomic analysis provided an assessment of post-translational modifications. The chaperone protein, calreticulin, was found to undergo cleavage, yielding a novel form. The combined oligonucleotide microarray and proteomic approaches have uncovered novel genes associated with DC differentiation and maturation and has allowed analysis of post-translational modifications of specific proteins as part of these processes.	Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beretta, L (corresponding author), Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.	berettal@umich.edu	Julius, Annabelle/A-7276-2010	Laura, Beretta/0000-0002-2054-684X				Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Avigan D, 1999, BLOOD REV, V13, P51, DOI 10.1016/S0268-960X(99)90023-1; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; Bagnard D, 1998, DEVELOPMENT, V125, P5043; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Borkakoti N, 1998, PROG BIOPHYS MOL BIO, V70, P73, DOI 10.1016/S0079-6107(98)00003-0; Chen BG, 1998, BLOOD, V91, P4652, DOI 10.1182/blood.V91.12.4652.412a03_4652_4661; Clarkson MR, 1998, NEPHROL DIAL TRANSPL, V13, P3043, DOI 10.1093/ndt/13.12.3043; Colaco CALS, 1998, CELL MOL BIOL, V44, P883; DWORNICZAK B, 1987, NUCLEIC ACIDS RES, V15, P5181, DOI 10.1093/nar/15.13.5181; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fearnley DB, 1997, BLOOD, V89, P3708, DOI 10.1182/blood.V89.10.3708.3708_3708_3716; Geiger J, 2000, LANCET, V356, P1163, DOI 10.1016/S0140-6736(00)02762-8; Gharahdaghi F, 1999, ELECTROPHORESIS, V20, P601, DOI 10.1002/(SICI)1522-2683(19990301)20:3<601::AID-ELPS601>3.0.CO;2-6; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Gluckman JC, 1997, CYTOKINES CELL MOL T, V3, P187; Hanash S, 1998, GEL ELECTROPHORESIS, P189; Hart DNJ, 1997, BLOOD, V90, P3245, DOI 10.1182/blood.V90.9.3245; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KUHN H, 1995, J LIPID MEDIAT CELL, V12, P157, DOI 10.1016/0929-7855(95)00016-J; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Liang XL, 1996, ANAL CHEM, V68, P1012, DOI 10.1021/ac950685z; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MANARA GC, 1993, BLOOD, V82, P2865; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; MING Z, 1993, J BIOL CHEM, V268, P35; Nair S, 1999, J IMMUNOL, V162, P6426; O'Donovan N, 1999, CYTOGENET CELL GENET, V84, P39, DOI 10.1159/000015209; Pandey A, 2000, NATURE, V405, P837, DOI 10.1038/35015709; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; PRIETO J, 1989, SCAND J IMMUNOL, V29, P391, DOI 10.1111/j.1365-3083.1989.tb01138.x; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; Sigal E, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P309; STAHLER JR, 1989, PROTEIN STRUCTURE PR, P65; STRAHLER JR, 1991, BIOCHEM BIOPH RES CO, V175, P134, DOI 10.1016/S0006-291X(05)81211-2; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; Thery C, 1999, J CELL BIOL, V147, P599, DOI 10.1083/jcb.147.3.599; Timmerman JM, 1999, ANNU REV MED, V50, P507; Todryk S, 1999, J IMMUNOL, V163, P1398; Trahey M, 1999, P NATL ACAD SCI USA, V96, P3006, DOI 10.1073/pnas.96.6.3006; ULLRICH A, 1994, J BIOL CHEM, V269, P18401; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Young J W, 1999, Curr Opin Hematol, V6, P135, DOI 10.1097/00062752-199905000-00003; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	53	193	207	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17920	17931		10.1074/jbc.M100156200	http://dx.doi.org/10.1074/jbc.M100156200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279020	hybrid			2022-12-25	WOS:000168866500043
J	Lollike, K; Johnsen, AH; Durussel, I; Borregaard, N; Cox, JA				Lollike, K; Johnsen, AH; Durussel, I; Borregaard, N; Cox, JA			Biochemical characterization of the penta-EF-hand protein grancalcin and identification of L-plastin as a binding partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	38th Annual Meeting of the American-Society-for-Cell-Biology	DEC 12-16, 1998	SAN FRANCISCO, CALIFORNIA	Amer Soc Cell Biol			CALCIUM-DEPENDENT PROTEASE; HUMAN NEUTROPHILS; POLYACRYLAMIDE GELS; CRYSTAL-STRUCTURE; SMALL-SUBUNIT; CALPAIN; MEMBER; FAMILY; ALG-2; DOMAIN	Grancalcin is a recently described Ca2+-binding protein especially abundant in human neutrophils, Grancalcin belongs to the penta-EF-hand subfamily of EF-hand proteins, which also comprises calpain, sorcin, peflin, and ALG-2. Penta-EF-hand members are typified by two novel types of EF-hands: one that binds Ca2+ although it has an unusual Ca2+ coordination loop and one that does not bind Ca2+ but is directly involved in homodimerization, We have developed a novel method for purification of native grancalcin and found that the N terminus of wild-type grancalcin is acetylated, This posttranslational modification does not affect the secondary structure or conformation of the protein. We found that both native and recombinant grancalcin always exists as a homodimer, regardless of the Ca2+ load. Flow dialysis showed that recombinant grancalcin binds two Ca2+ per subunit with positive cooperativity and moderate affinity ([Ca2+](0.5) of 25 and 83 muM in the presence and absence of octyl glycoside, respectively) and that the sites are of the Ca2+-specific type. Furthermore, we showed, by several independent methods, that grancalcin undergoes important conformational changes upon binding of Ca2+ and subsequently exposes hydrophobic amino acid residues, which direct the protein to hydrophobic surfaces. By affinity chromatography of solubilized human neutrophils on immobilized grancalcin, L-plastin, a leukocyte-specific actin-bundling protein, was found to interact with grancalcin in a negative Ca2+-dependent manner. This was substantiated by co-immunoprecipitation of grancalcin by anti-L-plastin antibodies and vice verse.	Univ Geneva, Dept Biochem, CH-1211 Geneva, Switzerland; Rigshosp, Granulocyte Res Lab, Dept Hematol, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	University of Geneva; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Lollike, K (corresponding author), Novo Nordisk AS, Krogshoehvej 53A, DK-2880 Bagsvaerd, Denmark.							ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BORREGAARD N, 1992, FEBS LETT, V304, P195, DOI 10.1016/0014-5793(92)80617-P; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOYHAN A, 1992, J BIOL CHEM, V267, P2928; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; COLOWICK SP, 1969, J BIOL CHEM, V244, P774; Cox J.A., 1996, GUIDEBOOK CALCIUM BI, P1; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P49; Dutt P, 1998, FEBS LETT, V436, P367, DOI 10.1016/S0014-5793(98)01167-3; Han Q, 2000, ACTA CRYSTALLOGR D, V56, P772, DOI 10.1107/S0907444900005096; HESSIAN PA, 1993, J LEUKOCYTE BIOL, V53, P197, DOI 10.1002/jlb.53.2.197; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Jia J, 2000, J MOL BIOL, V300, P1271, DOI 10.1006/jmbi.2000.3925; Jones SL, 1998, P NATL ACAD SCI USA, V95, P9331, DOI 10.1073/pnas.95.16.9331; Jones SL, 1996, J BIOL CHEM, V271, P14623, DOI 10.1074/jbc.271.24.14623; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; LOLLIKE K, 1995, J IMMUNOL METHODS, V185, P1, DOI 10.1016/0022-1759(95)00099-V; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Maki M, 1997, BIOCHEM J, V328, P718; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; Mosior M, 1997, MOL MEMBR BIOL, V14, P65, DOI 10.3109/09687689709068436; NAKAYAMA S, 1994, ANNU REV BIOPH BIOM, V23, P473, DOI 10.1146/annurev.bb.23.060194.002353; Pettit EJ, 1997, HISTOL HISTOPATHOL, V12, P479; TAKEYAMA Y, 1986, FEBS LETT, V194, P110, DOI 10.1016/0014-5793(86)80060-6; Tarabykina S, 2000, J BIOL CHEM, V275, P10514, DOI 10.1074/jbc.275.14.10514; TEAHAN CG, 1992, BIOCHEM J, V286, P549, DOI 10.1042/bj2860549; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang J, 1999, J BIOL CHEM, V274, P24349, DOI 10.1074/jbc.274.34.24349; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WINSKY L, 1995, J NEUROCHEM, V65, P381; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569; ZU Y, 1990, BIOCHEMISTRY-US, V29, P1055, DOI 10.1021/bi00456a030	39	42	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17762	17769		10.1074/jbc.M100965200	http://dx.doi.org/10.1074/jbc.M100965200			8	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279160	hybrid			2022-12-25	WOS:000168866500021
J	Singh, S; Pandey, K; Chattopadhayay, R; Yazdani, SS; Lynn, A; Bharadwaj, A; Ranjan, A; Chitnis, C				Singh, S; Pandey, K; Chattopadhayay, R; Yazdani, SS; Lynn, A; Bharadwaj, A; Ranjan, A; Chitnis, C			Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM-INFECTED ERYTHROCYTES; INTERCELLULAR-ADHESION MOLECULE-1; CHONDROITIN SULFATE; MALARIA; IDENTIFICATION; INVASION; KNOWLESI; ANTIGEN; GLYCOPROTEIN; ANTIBODIES	Invasion of erythrocytes by malaria parasites is mediated by specific molecular interactions. Plasmodium vivax is completely dependent on interaction with the Duffy blood group antigen to invade human erythrocytes, The P, vivax Duffy-binding protein, which binds the Duffy antigen during invasion, belongs to a family of erythrocyte-binding proteins that also includes Plasmodium falciparum sialic acid binding protein and Plasmodium knowlesi Duffy binding protein, The receptor binding domains of these proteins lie in a conserved, N-terminal, cysteine-rich region, region II, found in each of these proteins. Here, we have expressed P. vivax region II (PvRII), the P. vivax Duffy binding domain, in Escherichia coli, Recombinant PvRII is incorrectly folded and accumulates in inclusion bodies. We have developed methods to refold and purify recombinant PvRII in its functional conformation. Biochemical, biophysical, and functional characterization confirms that recombinant PvRII is pure, homogeneous, and functionally active in that it binds Huffy-positive human erythrocytes with specificity. Refolded PvRII is highly immunogenic and elicits high titer antibodies that can inhibit binding of P. vivax Huffy-binding protein to erythrocytes, providing support for its development as a vaccine candidate for P. vivax malaria. Development of methods to produce functionally active recombinant PvRII is an important step for structural studies as well as vaccine development.	Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, New Delhi 110067, India	Department of Biotechnology (DBT) India; International Center for Genetic Engineering & Biotechnology (ICGEB); International Center for Genetic Engineering & Biotechnology (ICGEB), New Delhi	Chitnis, C (corresponding author), Int Ctr Genet Engn & Biotechnol, Malaria Res Grp, POB 10504,Aruna Asaf Ali Marg, New Delhi 110067, India.	cchitnis@icgeb.res.in	Ranjan, Akash/C-1670-2009	Chitnis, Chetan/0000-0002-8773-9865; Ranjan, Akash/0000-0002-4582-1553				ADAMS JH, 1990, CELL, V63, P141, DOI 10.1016/0092-8674(90)90295-P; ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BREUER WV, 1983, BIOCHIM BIOPHYS ACTA, V755, P263, DOI 10.1016/0304-4165(83)90213-1; Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15; Chen QJ, 2000, J EXP MED, V192, P1, DOI 10.1084/jem.192.1.1; CHITNIS CE, 1994, J EXP MED, V180, P497, DOI 10.1084/jem.180.2.497; CHITNIS CE, 1999, MALARIA MOL CLIN ASP, P249; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; DOLAN SA, 1994, MOL BIOCHEM PARASIT, V64, P55, DOI 10.1016/0166-6851(94)90134-1; Dutta S, 2000, MOL BIOCHEM PARASIT, V109, P179, DOI 10.1016/S0166-6851(00)00244-9; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FANG XD, 1991, MOL BIOCHEM PARASIT, V44, P125, DOI 10.1016/0166-6851(91)90228-X; Fraser T, 1997, INFECT IMMUN, V65, P2772, DOI 10.1128/IAI.65.7.2772-2777.1997; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; FRIEDMAN MJ, 1984, J CELL BIOL, V98, P1672, DOI 10.1083/jcb.98.5.1672; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; Michon P, 2000, INFECT IMMUN, V68, P3164, DOI 10.1128/IAI.68.6.3164-3171.2000; MILLER LH, 1975, SCIENCE, V189, P561, DOI 10.1126/science.1145213; MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; MITCHELL GH, 1986, BLOOD, V67, P1519; Narum DL, 2000, INFECT IMMUN, V68, P1964, DOI 10.1128/IAI.68.4.1964-1966.2000; OCKENHOUSE CF, 1992, J EXP MED, V176, P1183, DOI 10.1084/jem.176.4.1183; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; Okoyeh JN, 1999, INFECT IMMUN, V67, P5784, DOI 10.1128/IAI.67.11.5784-5791.1999; PASVOL G, 1982, NATURE, V297, P64, DOI 10.1038/297064a0; PERKINS ME, 1988, MOL BIOCHEM PARASIT, V27, P23, DOI 10.1016/0166-6851(88)90021-7; Ranjan A, 1999, P NATL ACAD SCI USA, V96, P14067, DOI 10.1073/pnas.96.24.14067; Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198; ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15; ROWE AJ, 1997, NATURE, V398, P292; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; SIM BKL, 1994, SCIENCE, V264, P1941, DOI 10.1126/science.8009226; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897; Smith JD, 2000, MOL BIOCHEM PARASIT, V110, P293, DOI 10.1016/S0166-6851(00)00279-6; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405; TURNER GDH, 1994, AM J PATHOL, V145, P1057; WERTHEIMER SP, 1989, EXP PARASITOL, V69, P340, DOI 10.1016/0014-4894(89)90083-0	46	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17111	17116		10.1074/jbc.M101531200	http://dx.doi.org/10.1074/jbc.M101531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279211	hybrid			2022-12-25	WOS:000168730400069
J	Moor, AN; Gan, XHT; Karmazyn, M; Fliegel, L				Moor, AN; Gan, XHT; Karmazyn, M; Fliegel, L			Activation of Na+/H+ exchanger-directed protein kinases in the ischemic and ischemic-reperfused rat myocardium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASES; SODIUM-HYDROGEN EXCHANGE; RIBOSOMAL S6 KINASE; SMOOTH-MUSCLE CELLS; CARDIAC MYOCYTES; H+ EXCHANGER; INTRACELLULAR PH; STIMULATION; STRESS; HEARTS	The activity of the Na+/H+ exchanger has been implicated as an important contributing factor in damage to the myocardium that occurs during ischemia and reperfusion. We examined regulation of the protein in ischemic and reperfused isolated hearts and isolated ventricular myocytes. In isolated myocytes, extracellular signal-regulated kinases were important in regulating activity of the exchanger after recovery from ischemia. Ischemia followed by reperfusion caused a strong inhibitory effect on NHE1 activity that abated with continued reperfusion. Four major protein kinases of size 90, 55, 44, and 40 kDa phosphorylated the Na+/H+ exchanger. The Na+/H+ exchanger-directed kinases demonstrated dramatic increases in activity of 2-10-fold that was induced by 3 different models of ischemia and reperfusion in intact hearts and isolated myocytes, p90(rsk) was identified as the 90-kDa protein kinase activated by ischemia and reperfusion while ERK1/2 was identified as accounting for some of the 44-kDa protein kinase phosphorylating the Na+/H+ exchanger. The results demonstrate that MAPK-dependent pathways including p90(rsk) and ERK1/2 and are important in regulating the Na+/H+ exchanger and show their dramatic increase in activity toward the Na+/H+ exchanger during ischemia and reperfusion of the myocardium. They also show that ischemia followed by reperfusion have important inhibitory effects on Na+/H+ exchanger activity.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Western Ontario, Dept Pharmacol & Toxicol, London, ON N6A 5C1, Canada	University of Alberta; Western University (University of Western Ontario)	Fliegel, L (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.							Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Avkiran M, 1999, AM J CARDIOL, V83, p10G; Bianchini L, 1997, J BIOL CHEM, V272, P271; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; BOND JM, 1993, AM J PHYSIOL, V265, pC129, DOI 10.1152/ajpcell.1993.265.1.C129; Clerk A, 1998, J BIOL CHEM, V273, P7228, DOI 10.1074/jbc.273.13.7228; Counillon L, 2000, J BIOL CHEM, V275, P1, DOI 10.1074/jbc.275.1.1; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; FLIEGEL L, 1991, FEBS LETT, V279, P25, DOI 10.1016/0014-5793(91)80241-T; FLIEGEL L, 1992, BIOCHEM J, V282, P139, DOI 10.1042/bj2820139; Fliegel L, 1997, J MOL CELL CARDIOL, V29, P1991, DOI 10.1006/jmcc.1997.0479; Fliegel L, 1996, NAPLUS HPLUS EXCHANG, P1; Gan XHT, 1999, AM J PHYSIOL-HEART C, V277, pH993, DOI 10.1152/ajpheart.1999.277.3.H993; Haworth RS, 1999, AM J PHYSIOL-CELL PH, V277, pC1202, DOI 10.1152/ajpcell.1999.277.6.C1202; IWAKURA K, 1990, EUR J PHARMACOL, V186, P29; Karmazyn M, 1999, CIRC RES, V85, P777, DOI 10.1161/01.RES.85.9.777; Karmazyn M., 1996, NAPLUS HPLUS EXCHANG, P189; KHANDOUDI N, 1994, CIRC RES, V75, P369, DOI 10.1161/01.RES.75.2.369; Knight RJ, 1996, BIOCHEM BIOPH RES CO, V218, P83, DOI 10.1006/bbrc.1996.0016; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Meyer M, 1996, BASIC RES CARDIOL, V91, P86; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Omura T, 1999, J MOL CELL CARDIOL, V31, P1269, DOI 10.1006/jmcc.1999.0959; Phan VN, 1997, HYPERTENSION, V29, P1265, DOI 10.1161/01.HYP.29.6.1265; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; SARDET C, 1991, J BIOL CHEM, V266, P19166; Seko Y, 1996, CIRC RES, V78, P82, DOI 10.1161/01.RES.78.1.82; Shimizu N, 1998, CARDIOVASC RES, V38, P116, DOI 10.1016/S0008-6363(97)00327-1; Silva NLCL, 1997, PFLUG ARCH EUR J PHY, V433, P792, DOI 10.1007/s004240050347; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Takahashi E., 1997, HYPERTENSION, V29, P1265; TAKAICHI K, 1993, AM J PHYSIOL, V264, pC944, DOI 10.1152/ajpcell.1993.264.4.C944; Takeishi Y, 1999, CIRC RES, V85, P1164; TERZIC A, 1992, J PHYSIOL-LONDON, V447, P275, DOI 10.1113/jphysiol.1992.sp019002; WALLERT MA, 1992, AM J PHYSIOL, V263, pC1096, DOI 10.1152/ajpcell.1992.263.5.C1096; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Wang HY, 1997, J BIOL CHEM, V272, P26545, DOI 10.1074/jbc.272.42.26545; YASUTAKE M, 1995, CARDIOVASC RES, V29, P222, DOI 10.1016/S0008-6363(96)88574-9; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	44	82	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16113	16122		10.1074/jbc.M100519200	http://dx.doi.org/10.1074/jbc.M100519200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279085	hybrid			2022-12-25	WOS:000168623100075
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Defining the drug-binding site in the human multidrug resistance P-glycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; PREDICTED TRANSMEMBRANE DOMAIN; CYSTEINE-SCANNING MUTAGENESIS; HIV-1 PROTEASE INHIBITORS; DISULFIDE CROSS-LINKING; BLOOD-BRAIN-BARRIER; FUNCTIONAL CONSEQUENCES; SUBSTRATE-SPECIFICITY; LABELING SITES; TRANSPORTER	Defining the residues involved in the binding of a substrate provides insight into how the human multidrug resistance P-glycoprotein (P-gp) can transport a wide range of structurally diverse compounds out of the cell. Because verapamil is the most potent stimulator of P-gp ATPase activity, we synthesized a thiol-reactive analog of verapamil (MTS-verapamil) and used it with cysteine-scanning mutagenesis to identify the reactive residues within the drug-binding domain of P-gp. MTS-verapamil stimulated the ATPase activity of Cys-less P-gp and had a K-m value (25 muM) that was similar to that of verapamil, 252 P-gp mutants containing a single cysteine within the predicted transmembrane (TM) segments were expressed in HEK 293 cells and purified by nickel-chelate chromatography and assayed for inhibition by MTS-verapamil. The activities of 15 mutants, Y118C (TM2), V125C (TM2), S222C (TM4), L339C (TM6), A342C (TM6), A729C (TM7), A841C (TM9), N842C (TM9), I868C (TM10), A871C (TM10), F942C (TM11), T945C (TM11), V982C (TM12), G984C (TM12), and A985C (TM12), were inhibited by MTS-verapamil. Four mutants, S222C (TM4), L339C (TM6), A342C (TM6), and G984C (TM12), were significantly protected from inhibition by MTS-verapamil by pretreatment with verapamil, Less protection was observed in mutants I868C (TM10), F942C (TM11) and T945C (TM11). These results indicate that residues in TMs 4, 6, 10, 11, and 12 must contribute to the binding of verapamil.	Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University of Toronto	Clarke, DM (corresponding author), Univ Toronto, Dept Med, Canadian Inst Hlth, Res Grp Membrane Biol, Rm 7342,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188	NATIONAL CANCER INSTITUTE [R01CA080900] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA80900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen G, 1997, J BIOL CHEM, V272, P5974, DOI 10.1074/jbc.272.9.5974; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Cotten JF, 1999, J BIOL CHEM, V274, P5429, DOI 10.1074/jbc.274.9.5429; Degtiar VE, 1997, BIOPHYS J, V73, P157, DOI 10.1016/S0006-3495(97)78056-1; DEVINE SE, 1992, P NATL ACAD SCI USA, V89, P4564, DOI 10.1073/pnas.89.10.4564; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; Frillingos S, 1998, FASEB J, V12, P1281, DOI 10.1096/fasebj.12.13.1281; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GROS P, 1991, P NATL ACAD SCI USA, V88, P7289, DOI 10.1073/pnas.88.16.7289; Hargreaves AC, 1996, MOL PHARMACOL, V50, P1284; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hockerman GH, 1997, J BIOL CHEM, V272, P18759, DOI 10.1074/jbc.272.30.18759; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; KAJIJI S, 1993, BIOCHEMISTRY-US, V32, P4185, DOI 10.1021/bi00067a005; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; Kenyon G L, 1977, Methods Enzymol, V47, P407; Kim RB, 1998, J CLIN INVEST, V101, P289, DOI 10.1172/JCI1269; Lee CGL, 1998, BIOCHEMISTRY-US, V37, P3594, DOI 10.1021/bi972709x; Loo TW, 1997, J BIOL CHEM, V272, P709, DOI 10.1074/jbc.272.2.709; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 1999, J BIOL CHEM, V274, P35388, DOI 10.1074/jbc.274.50.35388; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; LOO TW, 1993, J BIOL CHEM, V268, P3143; Loo TW, 1997, J BIOL CHEM, V272, P31945, DOI 10.1074/jbc.272.51.31945; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Loo TW, 1998, J BIOL CHEM, V273, P32373, DOI 10.1074/jbc.273.49.32373; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1993, J BIOL CHEM, V268, P19965; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; Rauer H, 1999, BRIT J PHARMACOL, V127, P1065, DOI 10.1038/sj.bjp.0702599; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; Robert J, 1999, EUR J CLIN INVEST, V29, P536, DOI 10.1046/j.1365-2362.1999.00495.x; Sahin-Toth M, 2000, P NATL ACAD SCI USA, V97, P10729, DOI 10.1073/pnas.200351797; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1999, EUR J BIOCHEM, V259, P841, DOI 10.1046/j.1432-1327.1999.00098.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; Zhou Y, 1999, MOL CELL BIOL, V19, P1450	64	171	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14972	14979		10.1074/jbc.M100407200	http://dx.doi.org/10.1074/jbc.M100407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279063	hybrid			2022-12-25	WOS:000168528800061
J	Kurokawa, Y; Yanagi, H; Yura, T				Kurokawa, Y; Yanagi, H; Yura, T			Overproduction of bacterial protein disulfide isomerase (DsbC) and its modulator (DsbD) markedly enhances periplasmic production of human nerve growth factor in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLO-BETA-LACTAMASE; HIGH-LEVEL EXPRESSION; IN-VIVO; BOND FORMATION; BACTEROIDES-FRAGILIS; ALKALINE-PHOSPHATASE; CYSTEINE RESIDUES; FOLDING CATALYSTS; ELECTRONS; CELL	Production of eukaryotic proteins with multiple disulfide bonds in the Escherichia coli periplasm often encounters difficulty in obtaining soluble products with native structure. Human nerve growth factor beta (NGF) contains three disulfide bonds between nonconsecutive cysteine residues and forms insoluble aggregates when expressed in E. coli. We now report that overexpression of Dsb proteins known to catalyze formation and isomerization of disulfide bonds can substantially enhance periplasmic production of NGF. A set of pACYC184-based plasmids that permit dsb expression under the araB promoter were introduced into cells carrying a compatible plasmid that expresses NGF. The efficiency of periplasmic production of NGF fused to the OmpT signal peptide was strikingly improved by coexpression of DsbCD or DsbABCD proteins (up to 80% of total NGF produced). Coexpression of DsbAB was hardly effective, whereas that of DsbAC increased the total yield but not the periplasmic expression. These results suggest synergistic roles of DsbC and DsbD in disulfide isomerization that appear to become limiting upon NGF production. Furthermore, recombinant NGF produced with excess DsbCD (or DsbABCD) was biologically active judged by the neurite outgrowth assay using rat PC12 cells.	HSP Res Inst, Kyoto 6008813, Japan		Yura, T (corresponding author), 12 Hazamacho,Sakyo Ku, Kyoto 6068071, Japan.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; ALKSNE LE, 1995, J BACTERIOL, V177, P462, DOI 10.1128/jb.177.2.462-464.1995; Alksne LE, 1996, J BACTERIOL, V178, P4306; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BECK R, 1994, PROTEIN EXPRES PURIF, V5, P192, DOI 10.1006/prep.1994.1030; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; FUJIMORI K, 1992, BIOSCI BIOTECH BIOCH, V56, P1985, DOI 10.1271/bbb.56.1985; Georgiou G, 1996, CURR OPIN BIOTECH, V7, P190, DOI 10.1016/S0958-1669(96)80012-7; HOCKNEY RC, 1994, TRENDS BIOTECHNOL, V12, P456, DOI 10.1016/0167-7799(94)90021-3; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Joly JC, 1998, P NATL ACAD SCI USA, V95, P2773, DOI 10.1073/pnas.95.6.2773; JOLY JC, 1994, BIOCHEMISTRY-US, V33, P4231, DOI 10.1021/bi00180a017; Kishigami S, 1996, GENES CELLS, V1, P201, DOI 10.1046/j.1365-2443.1996.d01-233.x; Kurokawa Y, 2000, APPL ENVIRON MICROB, V66, P3960, DOI 10.1128/AEM.66.9.3960-3965.2000; Makrides SC, 1996, MICROBIOL REV, V60, P512, DOI 10.1128/MMBR.60.3.512-538.1996; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; Missiakas D, 1997, J BACTERIOL, V179, P2465, DOI 10.1128/jb.179.8.2465-2471.1997; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Ostermeier M, 1996, J BIOL CHEM, V271, P10616, DOI 10.1074/jbc.271.18.10616; OSTERMEIER M, 1994, J BIOL CHEM, V269, P21072; PEREZPEREZ J, 1994, BIO-TECHNOL, V12, P178, DOI 10.1038/nbt0294-178; PEREZPEREZ J, 1995, GENE, V158, P141, DOI 10.1016/0378-1119(95)00127-R; PerezPerez J, 1996, J BIOTECHNOL, V49, P245, DOI 10.1016/0168-1656(96)83990-3; Qiu J, 1998, APPL ENVIRON MICROB, V64, P4891; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; SHEVCHIK VE, 1995, MOL MICROBIOL, V16, P745, DOI 10.1111/j.1365-2958.1995.tb02435.x; Sone M, 1997, J BIOL CHEM, V272, P10349; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; Thomas JG, 1997, APPL BIOCHEM BIOTECH, V66, P197, DOI 10.1007/BF02785589; TOBE T, 1984, MOL GEN GENET, V195, P10, DOI 10.1007/BF00332716; WALKER KW, 1994, J BIOL CHEM, V269, P28487; WULFING C, 1994, J MOL BIOL, V242, P655, DOI 10.1006/jmbi.1994.1615; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; YAMAMORI T, 1982, P NATL ACAD SCI-BIOL, V79, P860, DOI 10.1073/pnas.79.3.860; YANO R, 1990, J BACTERIOL, V172, P2124, DOI 10.1128/jb.172.4.2124-2130.1990; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	41	61	73	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14393	14399		10.1074/jbc.M100132200	http://dx.doi.org/10.1074/jbc.M100132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11279016	hybrid			2022-12-25	WOS:000168356600116
J	Wartenberg, M; Donmez, F; Ling, FC; Acker, H; Hescheler, J; Sauer, H				Wartenberg, M; Donmez, F; Ling, FC; Acker, H; Hescheler, J; Sauer, H			Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells	FASEB JOURNAL			English	Article						VEGF; hypoxia; multidrug resistance; P-glycoprotein; HSP27	LASER-SCANNING MICROSCOPY; IN-VITRO; DRUG-RESISTANCE; GENE-EXPRESSION; P-GLYCOPROTEIN; ENDOTHELIAL-CELLS; PROSTATE-CANCER; HYPOXIA; DOXORUBICIN; PROTEINS	Tumor vascularization is the rate-limiting step for the progression of cancer. Differential steps of tumor-induced angiogenesis were studied by a novel in vitro confrontation culture of avascular multicellular prostate tumor spheroids and embryoid bodies grown from pluripotent embryonic stem (ES) cells. Vascularization in embryoid bodies started on day 5 of cell culture and was paralleled by down-regulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF). In parallel, a dissipation of gradients in the pericellular oxygen pressure was observed as measured by O-2-sensitive microelectrodes. After 24-48 h of confrontation culture, cells positive for platelet endothelial cell adhesion molecule (PECAM-1) became visible in the contact region between the embryoid body and the tumor spheroid and sprouted within the confrontation cultures during subsequent days. Tumor-induced angiogenesis resulted in growth stimulation of tumor spheroids, disappearance of central necrosis and a reduction of the pericellular oxygen pressure. Furthermore, tumor vascularization resulted in elevated levels of HIF-1 alpha, VEGF, heat shock protein 27 (HSP27), and P-glycoprotein. Tumor-induced angiogenesis may augment the oxygen consumption in tumors resulting in an increased expression of hypoxia-related, proangiogenic genes as well as of HSP27 and P-glycoprotein, which are involved in a multidrug resistance phenotype.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	University of Cologne; Max Planck Society	Sauer, H (corresponding author), Univ Cologne, Dept Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	hs@physiologie.uni-koeln.de	Acker, Helmut Anton Josef/AAS-6841-2020; Acker, Helmut/AAJ-8332-2020	Acker, Helmut Anton Josef/0000-0001-5589-5508; 				BJERKVIG R, 1986, CANCER RES, V46, P4071; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Browder T, 2000, CANCER RES, V60, P1878; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Folkman J, 1992, Semin Cancer Biol, V3, P89; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gassmann M, 1996, P NATL ACAD SCI USA, V93, P2867, DOI 10.1073/pnas.93.7.2867; Grunstein J, 1999, CANCER RES, V59, P1592; HEACOCK CS, 1990, BRIT J CANCER, V62, P217, DOI 10.1038/bjc.1990.264; Hockel M, 1996, SEMIN RADIAT ONCOL, V6, P3, DOI 10.1016/S1053-4296(96)80031-2; HOCKEL M, 1993, RADIOTHER ONCOL, V26, P45, DOI 10.1016/0167-8140(93)90025-4; Jouan V, 1999, BLOOD, V94, P984, DOI 10.1182/blood.V94.3.984.415k31_984_993; Kasimir-Bauer S, 1998, EXP HEMATOL, V26, P1111; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KNEUCHEL R, 1990, AM J PATHOL, V137, P725; KNUCHEL R, 1988, J UROLOGY, V139, P640, DOI 10.1016/S0022-5347(17)42550-X; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Kunz-Schughart LA, 1998, INT J EXP PATHOL, V79, P1, DOI 10.1046/j.1365-2613.1998.00051.x; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; LUK CK, 1990, J NATL CANCER I, V82, P684, DOI 10.1093/jnci/82.8.684; Nygaard SJT, 1995, INVAS METAST, V15, P179; OFFNER FA, 1993, INT J CANCER, V54, P506, DOI 10.1002/ijc.2910540325; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; RISAU W, 1988, DEVELOPMENT, V102, P471; SAKATA K, 1991, BRIT J CANCER, V64, P809, DOI 10.1038/bjc.1991.405; SANNA K, 1994, INT J CANCER, V58, P258, DOI 10.1002/ijc.2910580219; Schneider J, 1998, ANTICANCER RES, V18, P2967; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; VAUPEL P, 1990, ADV EXP MED BIOL, V277, P895; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; WALEH NS, 1995, CANCER RES, V55, P6222; Wartenberg M, 1998, LAB INVEST, V78, P1301; Wartenberg M, 1996, ANTICANCER RES, V16, P573; Wartenberg M, 1995, MICRON, V26, P395, DOI 10.1016/0968-4328(95)00009-7; Wartenberg M, 1998, INT J CANCER, V75, P855, DOI 10.1002/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.3.CO;2-2; Wartenberg M, 1998, CYTOMETRY, V31, P137, DOI 10.1002/(SICI)1097-0320(19980201)31:2<137::AID-CYTO9>3.0.CO;2-J; Wiles Michael V., 1997, Leukemia (Basingstoke), V11, P454; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	45	138	150	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					995	1005		10.1096/fj.00-0350com	http://dx.doi.org/10.1096/fj.00-0350com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292660				2022-12-25	WOS:000167959300014
J	Pallavicini, A; Negrisolo, E; Barbato, R; Dewilde, S; Ghiretti-Magaldi, A; Moens, L; Lanfranchi, G				Pallavicini, A; Negrisolo, E; Barbato, R; Dewilde, S; Ghiretti-Magaldi, A; Moens, L; Lanfranchi, G			The primary structure of globin and linker chains from the chlorocruorin of the polychaete Sabella spallanzanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WORM RIFTIA-PACHYPTILA; MULTI-HEMOGLOBIN SYSTEM; 3-DIMENSIONAL RECONSTRUCTION; CRYOELECTRON MICROSCOPY; EUDISTYLIA-VANCOUVERII; POLYPEPTIDE-CHAIN; EXTRACELLULAR HEMOGLOBIN; QUATERNARY STRUCTURE; MOLECULAR-WEIGHT; HIERARCHY	Annelid hemoglobins are organized in a very complex supramolecular network of interacting polypeptides, the structure of which is still not wholly resolved. We have separated by two-dimensional electrophoresis the 4-MDa chlorocruorin of Sabella spallanzanii and identified its components by amino-terminal sequencing. This work reveals a high rate of heterogeneity of constituent chains in a single animal as well as in the Sabella population. Using a cDNA library prepared from the hematopoietic tissue of this worm, we have isolated and fully sequenced most globin and linker cDNAs. The primary structure features of these polypeptides have been characterized by comparison with model globin and linker sequences.	Univ Padua, Dipartimento Biol, I-35131 Padua, Italy; Univ Padua, Ctr Ric Interdipartimentale Biotechnol Innovat, Ctr Biotechnol, I-35131 Padua, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy; Univ Padua, Dipartimento Biol, I-35131 Padua, Italy; Univ Padua, CNR, Ctr Study Metalloprot, I-35131 Padua, Italy; Univ Antwerp, Dept Biochem, B-2020 Antwerp, Belgium	University of Padua; University of Padua; University of Eastern Piedmont Amedeo Avogadro; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Antwerp	Lanfranchi, G (corresponding author), Univ Padua, Dipartimento Biol, Via Ugo Bassi 58-B, I-35131 Padua, Italy.		Pallavicini, Alberto/H-9281-2019; Negrisolo, Enrico/K-8124-2015; Pallavicini, Alberto/J-4158-2012	Pallavicini, Alberto/0000-0001-7174-4603; Negrisolo, Enrico/0000-0002-6244-805X; Pallavicini, Alberto/0000-0001-7174-4603				ANTONINI E, 1962, ARCH BIOCHEM BIOPHYS, V97, P343, DOI 10.1016/0003-9861(62)90087-5; ANTONINI E, 1962, ARCH BIOCHEM BIOPHYS, V97, P336, DOI 10.1016/0003-9861(62)90086-3; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBATO R, 1991, FEBS LETT, V290, P162, DOI 10.1016/0014-5793(91)81250-C; Bjerrum OJ, 1988, CRC HDB IMMUNOBLOTTI; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; deHaas F, 1996, J MOL BIOL, V255, P140, DOI 10.1006/jmbi.1996.0012; deHaas F, 1996, J MOL BIOL, V264, P111, DOI 10.1006/jmbi.1996.0627; deHaas F, 1996, BIOPHYS J, V70, P1973, DOI 10.1016/S0006-3495(96)79762-X; deHaas F, 1996, PROTEINS, V26, P241; deHaas F, 1997, BIOCHEMISTRY-US, V36, P7330, DOI 10.1021/bi970131l; Dewilde S, 1998, J BIOL CHEM, V273, P32467, DOI 10.1074/jbc.273.49.32467; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913; Green BN, 1998, BIOCHEMISTRY-US, V37, P6598, DOI 10.1021/bi972644y; Imai K, 1996, COMP BIOCHEM PHYS B, V113, P613, DOI 10.1016/0305-0491(96)83567-X; IMAI K, 1985, EUR J BIOCHEM, V147, P453; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; Mezzasalma Vincenza, 1992, Animal Biology, V1, P85; Negrisolo E, 2001, J BIOL CHEM, V276, P26391, DOI 10.1074/jbc.M100557200; QABAR AN, 1991, J MOL BIOL, V222, P1109, DOI 10.1016/0022-2836(91)90596-X; Rashid AK, 1997, J BIOL CHEM, V272, P2992, DOI 10.1074/jbc.272.5.3000; Royer WE, 2000, P NATL ACAD SCI USA, V97, P7107, DOI 10.1073/pnas.97.13.7107; Sambrook J., 2002, MOL CLONING LAB MANU; SUZUKI T, 1995, BBA-PROTEIN STRUCT M, V1252, P189, DOI 10.1016/0167-4838(95)00147-M; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SUZUKI T, 1990, J BIOL CHEM, V265, P12168; SUZUKI T, 1990, J BIOL CHEM, V265, P1551; TERWILLIGER RC, 1975, BIOCHIM BIOPHYS ACTA, V400, P302, DOI 10.1016/0005-2795(75)90185-3; TERWILLIGER RC, 1976, COMP BIOCHEM PHYS A, V55, P51, DOI 10.1016/0300-9629(76)90122-5; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vinogradov S.N., 1985, P9; Vinogradov S. N., 1982, ELECTRON MICROS, P135; VINOGRADOV SN, 1991, COMP BIOCHEM PHYS B, V98, P187, DOI 10.1016/0305-0491(91)90165-A; VINOGRADOV SN, 1985, BIOCHIM BIOPHYS ACTA, V828, P43, DOI 10.1016/0167-4838(85)90007-X; Zal F, 1996, J BIOL CHEM, V271, P8875, DOI 10.1074/jbc.271.15.8875; Zal F, 1997, PROTEINS, V29, P562, DOI 10.1002/(SICI)1097-0134(199712)29:4<562::AID-PROT15>3.0.CO;2-K	39	10	10	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26384	26390		10.1074/jbc.M006939200	http://dx.doi.org/10.1074/jbc.M006939200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11294828	hybrid			2022-12-25	WOS:000169823300098
J	Jacobsen, L; Madsen, P; Jacobsen, C; Nielsen, MS; Gliemann, J; Petersen, CM				Jacobsen, L; Madsen, P; Jacobsen, C; Nielsen, MS; Gliemann, J; Petersen, CM			Activation and functional characterization of the mosaic receptor SorLA/LR11	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LIGAND-BINDING; PROTEIN RAP; SORTILIN/NEUROTENSIN RECEPTOR-3; SORTING RECEPTOR; FAMILY MEMBER; HUMAN BRAIN; EXPRESSION; LR11; IDENTIFICATION	We previously isolated and sequenced the similar to 250-kDa type 1 receptor sorLA/LR11, a mosaic protein with elements characterizing the Vps10p domain receptor family as well as the low density lipoprotein receptor family. The N terminus of the Vps10p domain comprises a consensus sequence for cleavage by furin ((RRKR53)-R-50) that precedes a truncation found in sorLA isolated from human brain. Here we show that sorLA, like sortilin-1/neurotensin receptor-3, whose lumenal domain consists of a Vps10p domain only, is synthesized as a proreceptor that is cleaved by furin in late Gels compartments. We show that the truncation conditions the Vps10p domain for propeptide inhibitable binding of neuropeptides and the receptor-associated protein. We further demonstrate that avid binding of the receptor-associated protein, apolipoprotein E, and lipoprotein lipase not inhibited by propeptide occurs to sites located in other lumenal domains. In transfected cells, about 10% of full-length sorLA were expressed on the cell surface capable of mediating endocytosis. However, the major pool of receptors was found in late Gels compartments, suggesting possible interaction with newly synthesized ligands. The results show that sorLA, following activation by truncation, binds multiple ligands and may mediate both endocytosis and sorting.	Univ Aarhus, Dept Biochem Med, DK-8000 Aarhus C, Denmark	Aarhus University	Gliemann, J (corresponding author), Univ Aarhus, Dept Biochem Med, Ole Worms Alle,Bldg 170, DK-8000 Aarhus C, Denmark.	jg@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Madsen, Peder Sondergaard/0000-0002-8845-4802				Andersen OM, 2000, J BIOL CHEM, V275, P21017, DOI 10.1074/jbc.M000507200; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BODENMULLER H, 1986, EMBO J, V5, P1825, DOI 10.1002/j.1460-2075.1986.tb04433.x; de Chaves EIP, 2000, J BIOL CHEM, V275, P19883, DOI 10.1074/jbc.275.26.19883; Gliemann J, 1998, BIOL CHEM, V379, P951; Hampe W, 1999, DEVELOPMENT, V126, P4077; Hampe W, 2000, J CELL SCI, V113, P4475; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Hermey G, 1999, BIOCHEM BIOPH RES CO, V266, P347, DOI 10.1006/bbrc.1999.1822; Hirayama S, 2000, BIOCHEM BIOPH RES CO, V275, P365, DOI 10.1006/bbrc.2000.3312; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Kanaki T, 1999, ARTERIOSCL THROM VAS, V19, P2687, DOI 10.1161/01.ATV.19.11.2687; Kanaki T, 1998, DNA CELL BIOL, V17, P647, DOI 10.1089/dna.1998.17.647; Kikuno R, 1999, DNA Res, V6, P197, DOI 10.1093/dnares/6.3.197; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Mazella J, 1998, J BIOL CHEM, V273, P26273, DOI 10.1074/jbc.273.41.26273; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; Morwald S, 1997, ARTERIOSCL THROM VAS, V17, P996, DOI 10.1161/01.ATV.17.5.996; Motoi Y, 1999, BRAIN RES, V833, P209, DOI 10.1016/S0006-8993(99)01542-5; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nielsen MS, 1999, J BIOL CHEM, V274, P8832, DOI 10.1074/jbc.274.13.8832; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Petersen CM, 1996, EMBO J, V15, P4165, DOI 10.1002/j.1460-2075.1996.tb00791.x; Petersen CM, 1999, EMBO J, V18, P595, DOI 10.1093/emboj/18.3.595; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; Simmons T, 1997, J BIOL CHEM, V272, P25531, DOI 10.1074/jbc.272.41.25531; SUN Y, 1993, BIOTECHNIQUES, V15, P372; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Willnow TE, 1998, BIOL CHEM, V379, P1025; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761	32	129	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22788	22796		10.1074/jbc.M100857200	http://dx.doi.org/10.1074/jbc.M100857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294867	hybrid			2022-12-25	WOS:000169412700108
J	Koschak, A; Reimer, D; Huber, I; Grabner, M; Glossmann, H; Engel, J; Striessnig, J				Koschak, A; Reimer, D; Huber, I; Grabner, M; Glossmann, H; Engel, J; Striessnig, J			alpha 1D (Cav1.3) subunits can form L-type Ca2+ channels activating at negative voltages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CALCIUM-CHANNELS; BETA-SUBUNIT; ALPHA(1D) SUBUNIT; CLONING; CURRENTS; ALPHA-2-SUBUNIT; ALPHA-1-SUBUNIT; CONTRIBUTE; RECEPTOR	In cochlea inner hair cells (IHCs), L-type Ca2+ channels (LTCCs) formed by alpha 1D subunits (D-LTCCs) possess biophysical and pharmacological properties distinct from those of alpha 1C containing C-LTCCs. We investigated to which extent these differences are determined by alpha 1D itself by analyzing the biophysical and pharmacological properties of cloned human alpha 1D splice variants in tsA-201 cells. Variant alpha 1Ds(8A) containing exon 8A sequence in repeat I, yielded alpha 1D protein and L-type currents, whereas no intact protein and currents were observed after expression with exon 8B. In whole cell patch-clamp recordings (charge carrier 15-20 mM Ba2+), alpha 1D(8A) - mediated currents activated at more negative voltages (activation threshold, -45.7 versus -31.5 mV, p < 0.05) and more rapidly (tau (act) for maximal inward currents 0.8 versus 2.3 ms; p < 0.05) than currents mediated by rabbit cylC, Inactivation during depolarizing pulses was slower than for alpha 1C (current inactivation after 5-s depolarizations by 90 versus 99%, p < 0.05) but faster than for LTCCs in IHCs. The sensitivity for the dihydropyridine (DHP) L type channel blocker isradipine was 8.5-fold lower than for alpha 1C. Radioligand binding experiments revealed that this was not due to a lower affinity for the DHP binding pocket, suggesting that differences in the voltage dependence of DHP block account for decreased sensitivity of D-LTCCs, Our experiments show that alpha 1D(8A) subunits can form slowly inactivating LTCCs activating at more negative voltages than alpha 1C, These properties should allow D-LTCCs to control physiological processes, such as diastolic depolarization in sinoatrial node cells, neurotransmitter release in IHCs and neuronal excitability.	Inst Biochem Pharmakol, A-6020 Innsbruck, Austria; Univ Tubingen, HNO Klin, Inst Physiol 2, Sekt Sensor Biophys, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Striessnig, J (corresponding author), Inst Biochem Pharmakol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.	joerg.striessnig@vibk.ac.at	Striessnig, Joerg/S-9334-2017; Glossmann, Hartmut/AAL-9790-2020; Tuluc, Petronel/C-2527-2011	Striessnig, Joerg/0000-0002-9406-7120; glossmann, hartmut h./0000-0002-7392-3266				Avery RB, 1996, J NEUROSCI, V16, P5567; BEAN BP, 1984, P NATL ACAD SCI-BIOL, V81, P6388, DOI 10.1073/pnas.81.20.6388; Bell DC, 2001, J NEUROPHYSIOL, V85, P816, DOI 10.1152/jn.2001.85.2.816; Berjukow S, 2000, J BIOL CHEM, V275, P22114, DOI 10.1074/jbc.M908836199; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Cahill AL, 2000, J NEUROSCI, V20, P1685; Carlin KP, 2000, EUR J NEUROSCI, V12, P1635, DOI 10.1046/j.1460-9568.2000.00055.x; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Garcia-Palomero E, 2000, FEBS LETT, V481, P235, DOI 10.1016/S0014-5793(00)01984-0; Grabner M, 1999, J BIOL CHEM, V274, P21913, DOI 10.1074/jbc.274.31.21913; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hsiao CF, 1998, J NEUROPHYSIOL, V79, P2847, DOI 10.1152/jn.1998.79.6.2847; Huber I, 2000, BIOCHEM J, V347, P829, DOI 10.1042/0264-6021:3470829; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; IHARA Y, 1995, MOL ENDOCRINOL, V9, P121, DOI 10.1210/me.9.1.121; Kollmar R, 1997, P NATL ACAD SCI USA, V94, P14889, DOI 10.1073/pnas.94.26.14889; Kollmar R, 1997, P NATL ACAD SCI USA, V94, P14883, DOI 10.1073/pnas.94.26.14883; Lee JH, 1999, J NEUROSCI, V19, P1912; Magee JC, 1996, J NEUROPHYSIOL, V76, P3460, DOI 10.1152/jn.1996.76.5.3460; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; Moser T, 2000, P NATL ACAD SCI USA, V97, P883, DOI 10.1073/pnas.97.2.883; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; Platzer J, 2000, CELL, V102, P89, DOI 10.1016/S0092-8674(00)00013-1; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Sinnegger MJ, 2001, BIOPHYS J, V80, p450A; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; Striessnig J, 2001, LANCET, V357, P1294, DOI 10.1016/S0140-6736(00)04440-8; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; Takimoto K, 1997, J MOL CELL CARDIOL, V29, P3035, DOI 10.1006/jmcc.1997.0532; Verheijck EE, 1999, AM J PHYSIOL-HEART C, V276, pH1064, DOI 10.1152/ajpheart.1999.276.3.H1064; Welling A, 1997, CIRC RES, V81, P526, DOI 10.1161/01.RES.81.4.526; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; ZIDANIC M, 1995, BIOPHYS J, V68, P1323, DOI 10.1016/S0006-3495(95)80305-X	39	350	355	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22100	22106		10.1074/jbc.M101469200	http://dx.doi.org/10.1074/jbc.M101469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11285265	hybrid			2022-12-25	WOS:000169412700018
J	Mahoney, DJ; Blundell, CD; Day, AJ				Mahoney, DJ; Blundell, CD; Day, AJ			Mapping the hyaluronan-binding site on the link module from human tumor necrosis factor-stimulated gene-6 by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN CORE; HUMAN TSG-6; ESCHERICHIA-COLI; PROTEIN TSG-6; CDNA CLONING; DOMAIN; CD44; IDENTIFICATION; RECEPTOR; AGGRECAN	Link modules are hyaluronan-binding domains found in extracellular proteins involved in matrix assembly, development, and immune cell migration. Previously we have expressed the Link module from the inflammation-associated protein tumor necrosis factor-stimulated gene-g (TSG-6) and determined its tertiary structure in solution, Here we generated 21 Link module mutants, and these were analyzed by nuclear magnetic resonance spectroscopy and a hyaluronan-binding assay, The individual mutation of five amino acids, which form a cluster on one face of the Link module, caused large reductions in functional activity but did not affect the Link module fold. This ligand-binding site in TSG-6 is similar to that determined previously for the hyaluronan receptor, CD44, suggesting that the location of the interaction surfaces may also be conserved in other Link module-containing proteins. Analysis of the sequences of TSG-6 and CD44 indicates that the molecular details of their association with hyaluronan are likely to be significantly different. This comparison identifies key sequence positions that may be important in mediating hyaluronan binding, across the Link module superfamily, The use of multiple sequence alignment and molecular modeling allowed the prediction of functional residues in link protein, and this approach can be extended to all members of the superfamily.	Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Oxford	Day, AJ (corresponding author), Univ Oxford, Dept Biochem, MRC, Immunochem Unit, S Parks Rd, Oxford OX1 3QU, England.		Day, Anthony/O-1658-2015	Day, Anthony/0000-0002-1415-3134; Blundell, Charles/0000-0002-1439-9126				Bajorath J, 1998, J BIOL CHEM, V273, P338, DOI 10.1074/jbc.273.1.338; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; Bayliss MT, 2001, OSTEOARTHR CARTILAGE, V9, P42, DOI 10.1053/joca.2000.0348; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BLUNDELL CD, 2001, HYALURONAN; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; CHRISTNER JE, 1977, BIOCHEM J, V167, P711, DOI 10.1042/bj1670711; Day AJ, 1996, PROTEIN EXPRES PURIF, V8, P1, DOI 10.1006/prep.1996.0068; Day AJ, 1999, BIOCHEM SOC T, V27, P115, DOI 10.1042/bst0270115; Day AJ, 1998, WENN GR INT, V72, P141; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DUDHIA J, 1990, NUCLEIC ACIDS RES, V18, P1292, DOI 10.1093/nar/18.5.1292; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; Gary SC, 2000, GENE, V256, P139, DOI 10.1016/S0378-1119(00)00362-0; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GROVER J, 1994, BIOCHEM J, V300, P317, DOI 10.1042/bj3000317; HARDINGHAM TE, 1976, BIOCHEM J, V157, P127, DOI 10.1042/bj1570127; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Kahmann JD, 1997, PROTEIN EXPRES PURIF, V9, P315, DOI 10.1006/prep.1996.0694; Kahmann JD, 2000, STRUCTURE, V8, P763, DOI 10.1016/S0969-2126(00)00163-5; Knudson W, 1996, EXP CELL RES, V228, P216, DOI 10.1006/excr.1996.0320; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE TH, 1992, J CELL BIOL, V116, P545, DOI 10.1083/jcb.116.2.545; LYON M, 1986, BIOCHIM BIOPHYS ACTA, V881, P22, DOI 10.1016/0304-4165(86)90092-9; MORGELIN M, 1988, BIOCHEM J, V253, P175; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; NEAME PJ, 1986, J BIOL CHEM, V261, P3519; Parkar AA, 1998, FEBS LETT, V428, P171, DOI 10.1016/S0014-5793(98)00523-7; Parkar AA, 1997, FEBS LETT, V410, P413, DOI 10.1016/S0014-5793(97)00621-2; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; Poveda A, 1998, CHEM SOC REV, V27, P133, DOI 10.1039/a827133z; Prange CK, 1998, GENE, V221, P199, DOI 10.1016/S0378-1119(98)00455-7; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; Watanabe H, 1997, J BIOL CHEM, V272, P28057, DOI 10.1074/jbc.272.44.28057; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; YU Q, 1995, BIOTECHNIQUES, V19, P122; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	50	78	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22764	22771		10.1074/jbc.M100666200	http://dx.doi.org/10.1074/jbc.M100666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11287417	hybrid			2022-12-25	WOS:000169412700105
J	Kniemeyer, O; Heider, J				Kniemeyer, O; Heider, J			Ethylbenzene dehydrogenase, a novel hydrocarbon-oxidizing molybdenum/iron-sulfur/heme enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM THAUERA-AROMATICA; DENITRIFYING BACTERIUM; INITIAL REACTIONS; ANAEROBIC METABOLISM; OXIDOREDUCTASE; PURIFICATION; OXIDATION; SELENATIS; REDUCTASE; COENZYME	The initial enzyme of ethylbenzene metabolism in denitrifying Azoarcus strain EbN1, ethylbenzene dehydrogenase, was purified and characterized. The soluble periplasmic enzyme is the first known enzyme oxidizing a nonactivated hydrocarbon without molecular oxygen as cosubstrate, It is a novel molybdenum/iron-sulfur/ heme protein of 155 kDa, which consists of three subunits (96, 43, and 23 kDa) in an alpha beta gamma structure. The N-terminal amino acid sequence of the alpha subunit is similar to that of other molybdenum proteins such as selenate reductase from the related species Thauera selenatis, Ethylbenzene dehydrogenase is unique in that it oxidizes the hydrocarbon ethylbenzene, a compound without functional groups, to (S)-1-phenylethanol. Formation of the product was evident by coupling tot an enantiomer-specific (S)-1-phenylethanol dehydrogenase from the same organism. The apparent K-m of the enzyme for ethylbenzene is very low at <2 <mu>M, Oxygen does not affect ethylbenzene dehydrogenase activity in extracts but inactivates the purified enzyme, if the heme b cofactor is in the reduced state. A variant of ethylbenzene dehydrogenase exhibiting significant activity also with the homolog n-propylbenzene was detected in a related Azoarcus strain (PbN1).	Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Max Planck Inst Marine Mikrobiol, D-28359 Bremen, Germany	University of Freiburg; Max Planck Society	Heider, J (corresponding author), Univ Freiburg, Inst Biol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	heiderj@uni-freiburg.de	Heider, Johann/A-1833-2012; Heider, Johann/Y-2291-2018; Kniemeyer, Olaf/K-1253-2013; Heider, Johann/ABA-7877-2021	Heider, Johann/0000-0001-8328-9716; Heider, Johann/0000-0001-8328-9716; Kniemeyer, Olaf/0000-0002-9493-6402; 				Ball HA, 1996, J BACTERIOL, V178, P5755, DOI 10.1128/jb.178.19.5755-5761.1996; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; Beller HR, 1997, J BACTERIOL, V179, P670, DOI 10.1128/jb.179.3.670-676.1997; Biegert T, 1996, EUR J BIOCHEM, V238, P661, DOI 10.1111/j.1432-1033.1996.0661w.x; Boll M, 1995, EUR J BIOCHEM, V234, P921, DOI 10.1111/j.1432-1033.1995.921_a.x; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; Champion Kathleen M., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P157; CLARK LJ, 1955, ANAL CHEM, V27, P2000, DOI 10.1021/ac60108a046; Coligan JE, 1999, CURRENT PROTOCOLS PR; Hanlon SP, 1996, EUR J BIOCHEM, V239, P391, DOI 10.1111/j.1432-1033.1996.0391u.x; Heider J, 1998, FEMS MICROBIOL REV, V22, P459, DOI 10.1111/j.1574-6976.1998.tb00381.x; Johnson HA, 1999, J BACTERIOL, V181, P5662, DOI 10.1128/JB.181.18.5662-5668.1999; Krafft T, 2000, DNA Seq, V10, P365, DOI 10.3109/10425170009015604; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LOVENBERG W, 1963, J BIOL CHEM, V193, P265; MACKAY D, 1981, J PHYS CHEM REF DATA, V10, P1175, DOI 10.1063/1.555654; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHEL TA, 1990, J MICROBIOL METH, V11, P37, DOI 10.1016/0167-7012(90)90045-8; Rabus R, 1998, ARCH MICROBIOL, V170, P377, DOI 10.1007/s002030050656; RABUS R, 1995, ARCH MICROBIOL, V163, P96, DOI 10.1007/BF00381782; RECH SA, 1992, J BACTERIOL, V174, P7316, DOI 10.1128/jb.174.22.7316-7320.1992; Rhee SK, 1999, EUR J BIOCHEM, V262, P507, DOI 10.1046/j.1432-1327.1999.00399.x; Schroder I, 1997, J BIOL CHEM, V272, P23765, DOI 10.1074/jbc.272.38.23765; SMITH L, 1978, METHOD ENZYMOL, V23, P202	24	137	148	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21381	21386		10.1074/jbc.M101679200	http://dx.doi.org/10.1074/jbc.M101679200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294876	hybrid			2022-12-25	WOS:000169297900079
J	Caselli, A; Taddei, ML; Manao, G; Camici, G; Ramponi, G				Caselli, A; Taddei, ML; Manao, G; Camici, G; Ramponi, G			Tyrosine-phosphorylated caveolin is a physiological substrate of the low M-r protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; AMINO-ACID-SEQUENCE; ROUS-SARCOMA VIRUS; IN-VIVO; SIGNALING COMPLEXES; TRANSFORMED-CELLS; TRAPPING MUTANTS; PLASMA-MEMBRANE; 3T3 CELLS; PTP-PEST	Low phosphotyrosine-protein phosphatase is involved in the regulation of several tyrosine kinase growth factor receptors. The best characterized action of this enzyme is on the signaling pathways activated by platelet-derived growth factor, where it plays multiple roles. In this study we identify tyrosine-phosphorylated caveolin as a new potential substrate for low M-r phosphotyrosine-protein phosphatase. Caveolin is tyrosine-phosphorylated in vivo by Src kinases, recruits into caveolae, and hence regulates the activities of several proteins involved in cellular signaling cascades. Our results demonstrate that caveolin and low M-r phosphotyrosine-protein phosphatase coimmunoprecipitate from cell lysates, and that a fraction of the enzyme localizes in caveolae. Furthermore, in a cell line sensitive to insulin, the overexpression of the C12S dominant negative mutant of low M-r phosphotyrosine-protein phosphatase (a form lacking activity but able to bind substrates) causes the enhancement of tyrosine-phosphorylated caveolin. Insulin stimulation of these cells induces a strong increase of caveolin phosphorylation. The localization of low M-r phosphotyrosine-protein phosphatase in caveolae, the in vivo interaction between this enzyme and caveolin, and the capacity of this enzyme to rapidly dephosphorylate phosphocaveolin, all indicate that tyrosine-phosphorylated caveolin is a relevant substrate for this phosphatase.	Univ Florence, Dipartimento Sci Biochim, I-50134 Florence, Italy	University of Florence	Camici, G (corresponding author), Univ Florence, Dipartimento Sci Biochim, Viale Morgagni 50, I-50134 Florence, Italy.	camici@scibio.unifi.it	Caselli, Anna/O-7512-2014; Camici, Giovanni/H-1631-2018	Caselli, Anna/0000-0001-8140-3415; Camici, Giovanni/0000-0002-0523-0695				ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Bugert P, 1997, FEBS LETT, V400, P252, DOI 10.1016/S0014-5793(96)01398-1; Carman CV, 1999, J BIOL CHEM, V274, P8858, DOI 10.1074/jbc.274.13.8858; CASELLI A, 1994, J PROTEIN CHEM, V13, P107, DOI 10.1007/BF01891998; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DISSING J, 1991, J BIOL CHEM, V266, P20619; Fauman EB, 1996, TRENDS BIOCHEM SCI, V21, P413, DOI 10.1016/S0968-0004(96)10059-1; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P3863; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Marzocchini R, 1998, FEBS LETT, V426, P52, DOI 10.1016/S0014-5793(98)00308-1; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONDESERT O, 1994, J BIOL CHEM, V269, P27996; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; OSTANIN K, 1995, J BIOL CHEM, V270, P18491, DOI 10.1074/jbc.270.31.18491; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; Rigacci S, 1999, FEBS LETT, V459, P191, DOI 10.1016/S0014-5793(99)01234-X; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rovida E, 1998, BIOCHEM BIOPH RES CO, V253, P300, DOI 10.1006/bbrc.1998.9736; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; Sasaoka T, 1996, J BIOL CHEM, V271, P20082, DOI 10.1074/jbc.271.33.20082; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; Vepa S, 1997, FREE RADICAL BIO MED, V22, P25, DOI 10.1016/S0891-5849(96)00241-9; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263	58	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18849	18854		10.1074/jbc.M100705200	http://dx.doi.org/10.1074/jbc.M100705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279120	hybrid, Green Published			2022-12-25	WOS:000169091000028
J	Li, J; Peet, GW; Balzarano, D; Li, XN; Massa, P; Barton, RW; Marcu, KB				Li, J; Peet, GW; Balzarano, D; Li, XN; Massa, P; Barton, RW; Marcu, KB			Novel NEMO/I kappa B kinase and NF-kappa B target genes at the pre-B to immature B cell transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							LEUKOCYTE PROTEASE INHIBITOR; HELIX-LOOP-HELIX; SIGNAL-TRANSDUCTION; IKK-BETA; IMMUNOGLOBULIN EXPRESSION; TRANSCRIPTION FACTORS; LEUCINE-ZIPPER; C-MYC; MICROFILAMENT REORGANIZATION; METASTASIS SUPPRESSOR	The I kappaB kinase (IKK) signaling complex is responsible for activating NF-kappaB-dependent gene expression programs. Even though NF-kappaB-responsive genes are known to orchestrate stress-like responses, critical gaps in our knowledge remain about the global effects of NF-kappaB activation on cellular physiology. DNA microarrays were used to compare gene expression programs in a model system of 70Z/3 murine pre-B cells versus their IKK signaling-defective 1.3E2 variant with lipopolysaccharide (LPS), interleukin-l (IL-1), or a combination of LPS + phorbol 12-myristate 13-acetate under brief (2 h) or long term (12 h) stimulation. 70Z/3-1.3E2 cells lack expression of NEMO/IKK gamma /IKKAP-1/FIP-3, an essential positive effector of the IKK complex. Some stimulated hits were known NF-kappaB target genes, but remarkably, the vast majority of the up-modulated genes and an unexpected class of repressed genes were all novel targets of this signaling pathway, encoding transcription factors, receptors, extracellular ligands, and intracellular signaling factors. Thirteen stimulated (B-ATF, Pim-2, MyD118, Pea-15/MAT1, CD82, CD40L, Wnt10a, Notch 1, R-ras, Rgs-16, PAC-I, ISG15, and CD36) and five repressed (CCR2, VpreB, lambda5, SLPI, and CMAP/Cystatin7) genes, respectively, were bona fide NF-kappaB targets by virtue of their response to a transdominant I kappaB alpha SR (super repressor). MyD118 and ISG15, although directly induced by LPS stimulation, were unaffected by IL-1, revealing the existence of direct NF-kappaB target genes, which are not coinduced by the LPS and IL-1 Toll-like receptors.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Grad Program Genet, Stony Brook, NY 11794 USA; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Boehringer Ingelheim	Marcu, KB (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.							Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; AHRENS PB, 1990, J GEN VIROL, V71, P1675, DOI 10.1099/0022-1317-71-8-1675; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; Beadling C, 1999, J IMMUNOL, V162, P2677; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; Devergne O, 1997, P NATL ACAD SCI USA, V94, P12041, DOI 10.1073/pnas.94.22.12041; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dorsey MJ, 1995, ONCOGENE, V11, P2255; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hsing Y, 1999, J IMMUNOL, V162, P2804; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Ihle JN, 1996, BIOESSAYS, V18, P95, DOI 10.1002/bies.950180204; Janabi M, 2000, ARTERIOSCL THROM VAS, V20, P1953, DOI 10.1161/01.ATV.20.8.1953; Jin FY, 1998, INFECT IMMUN, V66, P2447, DOI 10.1128/IAI.66.6.2447-2452.1998; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kehry M R, 1994, Semin Immunol, V6, P287, DOI 10.1006/smim.1994.1037; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; KUNIMOTO DY, 1988, J IMMUNOL, V141, P713; Lentsch AB, 1999, AM J PATHOL, V154, P239, DOI 10.1016/S0002-9440(10)65270-4; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li X, 2000, BRAIN RES PROTOC, V5, P211, DOI 10.1016/S1385-299X(00)00015-5; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liebermann DA, 1998, ONCOGENE, V17, P3319, DOI 10.1038/sj.onc.1202574; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lombardi DP, 1999, CANCER RES, V59, P5724; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; Mahadevappa M, 1999, NAT BIOTECHNOL, V17, P1134, DOI 10.1038/15124; MAINS PE, 1983, J BIOL CHEM, V258, P5027; MAINS PE, 1983, SOMAT CELL GENET, V9, P699, DOI 10.1007/BF01539475; Malynn BA, 2000, GENE DEV, V14, P1390; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; MCFARLAND EC, 1994, CHEM IMMUNOL, V59, P40; McKenzie FR, 2000, MOL CELL BIOL, V20, P2635, DOI 10.1128/MCB.20.8.2635-2649.2000; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Morita M, 1999, CANCER RES, V59, P151; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Muda M, 1996, J BIOL CHEM, V271, P4319; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAIGE CJ, 1978, J IMMUNOL, V121, P641; PAIGE CJ, 1981, NATURE, V292, P631, DOI 10.1038/292631a0; Panetta R, 1999, BIOCHEM BIOPH RES CO, V259, P550, DOI 10.1006/bbrc.1999.0817; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; SAKAGUCHI N, 1980, J IMMUNOL, V125, P2654; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Sgorbissa A, 1999, J CELL SCI, V112, P4475; Shirogane T, 1999, IMMUNITY, V11, P709, DOI 10.1016/S1074-7613(00)80145-4; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Suzuki R, 1999, LEUKEMIA, V13, P1335, DOI 10.1038/sj.leu.2401485; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VASSALLI JD, 1993, EMBO J, V12, P1871, DOI 10.1002/j.1460-2075.1993.tb05835.x; Wang JW, 1996, ONCOGENE, V13, P1537; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang ZY, 1996, GENOMICS, V35, P156, DOI 10.1006/geno.1996.0334; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEEKS RS, 1987, SOMAT CELL MOLEC GEN, V13, P205, DOI 10.1007/BF01535203; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	102	133	138	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18579	18590		10.1074/jbc.M100846200	http://dx.doi.org/10.1074/jbc.M100846200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279141	hybrid			2022-12-25	WOS:000168866500128
J	Reinelt, S; Dedier, S; Asuni, G; Folkers, G; Rognan, D				Reinelt, S; Dedier, S; Asuni, G; Folkers, G; Rognan, D			Mutation of Cys-67 alters the thermodynamic stability of the human leukocyte antigen HLA-B*2705	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HLA-B27 TRANSGENIC MICE; CLASS-II MOLECULES; HLA CLASS-I; ANKYLOSING-SPONDYLITIS; PEPTIDE BINDING; INFLAMMATORY DISEASE; HEAVY-CHAINS; MHC; ASSOCIATION; SPONDYLOARTHROPATHIES	The B pocket of the class I major histocompatibility complex-encoded protein HLA-B*2705 has recently been suggested to be responsible for the misfolding of this HLA haplotype and thus to induce susceptibility to autoimmune inflammatory diseases. Four mutants of the B*2705 heavy chain were refolded in the presence of three control peptides, The monitoring of the thermal unfolding of the B*2705-peptide complexes by circular dichroism spectroscopy showed that all heterotrimeric mutants were markedly less stable than the corresponding complexes with the wild-type heavy chain. Among the four heavy chain mutations, the C67S change was investigated for unfolding and peptide binding properties because this position may mediate disulfide pair bridging and alter T-cell recognition of HLA-B*2705. Wild-type heterotrimers completely unfold in a single transition at mild acidic pH whereas increase of the pH to mild basic conditions induce only a partial biphasic unfolding. Cys-67 seems to play a crucial role in controlling the thermodynamic stability of the B*2705-peptide complexes as the C67S mutant unfolds faster and with a single transition, independent of pH. Fluorescence polarization and size exclusion chromatography of unfolding intermediates suggest that the peculiar unfolding of the B*2705 wild-type heavy chain cannot be explained by modified peptide binding properties but more likely by the formation of high molecular weight species.	ULP, Lab Pharmacochim Commun Cellulaire, CNRS, UMR 7081, F-67401 Illkirch Graffenstaden, France; Swiss Fed Inst Technol, Dept Appl Biosci, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Rognan, D (corresponding author), ULP, Lab Pharmacochim Commun Cellulaire, CNRS, UMR 7081, 74 Route Rhin, F-67401 Illkirch Graffenstaden, France.		Rognan, Didier/B-9939-2014	Folkers, Gerd/0000-0002-3620-705X				Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2000, CURR OPIN RHEUMATOL, V12, P248, DOI 10.1097/00002281-200007000-00003; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; BREWERTON DA, 1973, LANCET, V1, P904; BUXTON SE, 1992, J EXP MED, V175, P809, DOI 10.1084/jem.175.3.809; CAPPS GG, 1993, J IMMUNOL, V151, P159; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; COLBERT RA, 1993, P NATL ACAD SCI USA, V90, P6879, DOI 10.1073/pnas.90.14.6879; de Castro JAL, 1998, CURR OPIN IMMUNOL, V10, P59, DOI 10.1016/S0952-7915(98)80033-2; Dedier S, 2000, J BIOL CHEM, V275, P27055; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Gao XM, 1996, EUR J IMMUNOL, V26, P1443, DOI 10.1002/eji.1830260707; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; Khan MA, 2000, J RHEUMATOL, V27, P1110; Khare SD, 1998, J IMMUNOL, V160, P101; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Mear JP, 1999, J IMMUNOL, V163, P6665; Morgan CS, 1997, PROTEIN SCI, V6, P1771, DOI 10.1002/pro.5560060819; Nasir MS, 1999, COMB CHEM HIGH T SCR, V2, P177; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; PACE NC, 1997, PROTEIN STRUCTURE PR, P299; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; Taurog JD, 1999, IMMUNOL REV, V169, P209; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; VILLADANGOS JA, 1995, EUR J IMMUNOL, V25, P2370, DOI 10.1002/eji.1830250837; Weiss GA, 1996, P NATL ACAD SCI USA, V93, P10945, DOI 10.1073/pnas.93.20.10945; WHELAN MA, 1993, EUR J IMMUNOL, V23, P3278, DOI 10.1002/eji.1830231233	34	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18472	18477		10.1074/jbc.M101282200	http://dx.doi.org/10.1074/jbc.M101282200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279190	hybrid			2022-12-25	WOS:000168866500114
J	Zitzer, A; Bittman, R; Verbicky, CA; Erukulla, RK; Bhakdi, S; Weis, S; Valeva, A; Palmer, M				Zitzer, A; Bittman, R; Verbicky, CA; Erukulla, RK; Bhakdi, S; Weis, S; Valeva, A; Palmer, M			Coupling of cholesterol and cone-shaped lipids in bilayers augments membrane permeabilization by the cholesterol-specific toxins streptolysin O and Vibrio cholerae cytolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; STRUCTURAL REQUIREMENTS; CONTAINING LIPOSOMES; MAXIMUM SOLUBILITY; FUSION; BINDING; PORE; SPHINGOLIPIDS; INDUCTION; DAMAGE	Vibrio cholerae cytolysin (VCC) forms oligomeric pores in lipid bilayers containing cholesterol, Membrane permeabilization is inefficient if the sterol is embedded within bilayers prepared from phosphatidylcholine only but is greatly enhanced if the target membrane also contains ceramide, Although the enhancement of VCC action is stereospecific with respect to cholesterol, we show here that no such specificity applies to the two stereocenters in ceramide; all four stereoisomers of ceramide enhanced VCC activity in cholesterol-containing bilayers, A wide variety of ceramide analogs were as effective as D-erythro-ceramide, as was diacylglycerol, suggesting that the effect of ceramide exemplifies a general trend of lipids with a small headgroup to augment the activity of VCC, Incorporation of these cone-shaped lipids into cholesterol-containing bilayers also gave similar effects with streptolysin O, another cholesterol-specific but structurally unrelated cytolysin, In contrast, the activity of staphylococcal alpha -hemolysin, which does not share with the other toxins the requirement for cholesterol, was far less affected by the presence of lipids with a conical shape. The collective data indicate that sphingolipids and glycerolipids do not interact with the cytolysins specifically, Instead, lipids that have a conical molecular shape appear to effect a change in the energetic state of membrane cholesterol that in turn augments the interaction of the sterol with the cholesterol-specific cytolysins.	Johannes Gutenberg Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	Johannes Gutenberg University of Mainz; City University of New York (CUNY) System; Queens College NY (CUNY)	Palmer, M (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.	mpalmer@medicine.tamu.edu						Alonso A, 2000, BIOCHEMISTRY-US, V39, P14019, DOI 10.1021/bi001739o; Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; Berger A, 1996, MOL PHARMACOL, V50, P451; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Chun J, 2000, J ORG CHEM, V65, P7634, DOI 10.1021/jo001227f; CLEJAN S, 1984, J BIOL CHEM, V259, P823; Corbin J, 1998, BBA-BIOMEMBRANES, V1414, P65, DOI 10.1016/S0005-2736(98)00153-9; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; DORFLER HD, 1990, ADV COLLOID INTERFAC, V31, P1, DOI 10.1016/0001-8686(90)80003-I; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FUGLER L, 1985, J BIOL CHEM, V260, P4098; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; He LL, 1999, J AM CHEM SOC, V121, P3897, DOI 10.1021/ja981493z; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Holopainen JM, 1997, CHEM PHYS LIPIDS, V88, P1, DOI 10.1016/S0009-3084(97)00040-6; Hong-wei S, 1975, Biochemistry, V14, P847; Huang JY, 1999, BIOPHYS J, V76, P2142, DOI 10.1016/S0006-3495(99)77369-8; Huang JY, 1999, BBA-BIOMEMBRANES, V1417, P89, DOI 10.1016/S0005-2736(98)00260-0; Ikigai H, 1996, INFECT IMMUN, V64, P2968, DOI 10.1128/IAI.64.8.2968-2973.1996; Jarvis WD, 1996, J BIOL CHEM, V271, P8275, DOI 10.1074/jbc.271.14.8275; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Karasavvas N, 1996, CELL DEATH DIFFER, V3, P149; Karasavvas N, 1996, EUR J BIOCHEM, V236, P729, DOI 10.1111/j.1432-1033.1996.00729.x; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LEE YC, 1993, BIOPHYS J, V65, P1429, DOI 10.1016/S0006-3495(93)81206-2; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; OHNOIWASHITA Y, 1992, BIOCHIM BIOPHYS ACTA, V1109, P81, DOI 10.1016/0005-2736(92)90190-W; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; PALMER M, 1993, J BIOL CHEM, V268, P11963; PRIGENT D, 1976, BIOCHIM BIOPHYS ACTA, V443, P288, DOI 10.1016/0005-2736(76)90511-3; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; SILVIUS JR, 1992, BIOCHEMISTRY-US, V31, P3398, DOI 10.1021/bi00128a014; WATSON KC, 1974, BIOCHEM J, V140, P95, DOI 10.1042/bj1400095; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x; WILSCHUT J, 1995, MOL MEMBR BIOL, V12, P143, DOI 10.3109/09687689509038510; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375; Zitzer A, 1997, EUR J BIOCHEM, V247, P209, DOI 10.1111/j.1432-1033.1997.00209.x; Zitzer A, 2000, BBA-BIOMEMBRANES, V1509, P264, DOI 10.1016/S0005-2736(00)00303-5	40	69	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14628	14633		10.1074/jbc.M100241200	http://dx.doi.org/10.1074/jbc.M100241200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279036	hybrid			2022-12-25	WOS:000168528800016
J	Shichiri, M; Hirata, Y				Shichiri, M; Hirata, Y			Antiangiogenesis signals by endostatin	FASEB JOURNAL			English	Article						endostatin; angiogenesis; angiogstatin; c-myc	TARGETED HOMOLOGOUS RECOMBINATION; ENDOTHELIAL-CELL APOPTOSIS; C-MYC EXPRESSION; SURVIVAL FACTOR; TUMOR-GROWTH; NITRIC-OXIDE; ANGIOGENESIS; CYCLE; ADRENOMEDULLIN; MIGRATION	Endostatin is a potent endogenous angiogenesis inhibitor that induces regression of tumors in mice. Neither an extracellular receptor for endostatin nor intracellular signals that result in the regression of tumor vascular beds have been identified. We dem onstrate that endostatin, but not angiostatin, at comparable concentrations to those used in in vivo animal trials, rapidly down-regulates many genes in exponentially growing endothelial cells. These include immediate early response genes, cell cycle-related genes, and genes regulating apoptosis inhibitors, mitogen-activated protein kinases, focal adhesion kinase, G-protein-coupled receptors mediating endothelial growth, a mitogenic factor, adhesion molecules, and cell structure components. Suppression of both apoptosis inhibitors and cell proliferation genes may have a limited contribution to the antiangiogenesis process because endostatin induces neither apoptosis nor growth inhibition, unless studied under reduced serum conditions. In contrast, the antimigratory effect of endostatin was rapid and potent even under serum-supplemented conditions. Endostatin caused gene suppression and migration arrest exclusively in endothelial cells, most profoundly in microvascular endothelial cells. The c-myc null fibroblasts obtained by targeted homologous recombination showed an attenuated migration rate compared with isogenic parental cells, whereas the introduction of the c-myc gene into endothelial cells abrogated the antimigratory effect of endostatin. Inhibition of E-box-driven transcription by overexpressing max or mad suppressed endothelial migration. Thus, rapid down-regulation of gems by endostatin neither restores proliferating endothelial cells to their resting states nor induces apoptosis; rather, it potently inhibits endothelial cell migration partly via suppression of c-myc expression.	Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU)	Shichiri, M (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Dept Clin & Mol Endocrinol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	mshichiri.cme@tmd.ac.jp		Shichiri, Masayoshi/0000-0002-5704-1378				Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Goligorsky MS, 1999, CLIN EXP PHARMACOL P, V26, P269, DOI 10.1046/j.1440-1681.1999.03029.x; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Nedelec FJ, 1997, NATURE, V389, P305, DOI 10.1038/38532; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PROUTY SM, 1993, ONCOGENE, V8, P899; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; SHICHIRI M, 1993, CELL GROWTH DIFFER, V4, P93; Shichiri M, 1999, MOL ENDOCRINOL, V13, P1353, DOI 10.1210/me.13.8.1353; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; SHICHIRI M, 1991, J CLIN INVEST, V87, P1867, DOI 10.1172/JCI115210; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	25	190	216	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1044	1053		10.1096/fj.99-1083com	http://dx.doi.org/10.1096/fj.99-1083com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292666				2022-12-25	WOS:000167959300020
J	Cremesti, A; Paris, F; Grassme, H; Holler, N; Tschopp, J; Fuks, Z; Gulbins, E; Kolesnick, R				Cremesti, A; Paris, F; Grassme, H; Holler, N; Tschopp, J; Fuks, Z; Gulbins, E; Kolesnick, R			Ceramide enables Fas to cap and kill	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; GPI-ANCHORED PROTEINS; CAVEOLAE-LIKE DOMAINS; ACIDIC SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; MEMBRANE DOMAINS; TYROSINE PHOSPHORYLATION; CD95-MEDIATED APOPTOSIS; HUMAN-LYMPHOCYTES; DEATH DOMAIN	Recent studies suggest that trimerization of Fas is insufficient for apoptosis induction and indicate that super-aggregation of trimerized Fas might be prerequisite. For many cell surface receptors, cross-linking by multivalent ligands or antibodies induces their lateral segregation within the plasma membrane and co-localization into "caps" on one pole of the cell. In this study, we show that capping of Fas is essential for optimal function and that capping is ceramide-dependent. in Jurkat T lymphocytes and in primary cultures of hepatocytes, ceramide elevation was detected as early as 15-30 s and peaked at 1 min after CH-11 and Jo2 anti-Fas antibody treatment, respectively. Capping was detected 30 s after Fas ligation, peaked at 2 min, and was maintained at a lower level for as long as 30 min in both cell types, Ceramide generation appeared essential for capping. Acid sphingomyelinase(-/-) hepatocytes were defective in Jo2-induced ceramide generation, capping, and apoptosis, and nanomolar concentrations of C-16-ceramide restored these events. To further explore the role of ceramide in capping of Fas, we employed FLAG-tagged soluble Fas ligand (sFasL), which binds trimerized Fas but is unable to induce capping or apoptosis in Jurkat cells, Cross-linking of sFasL with M2 anti-FLAG antibody induced both events. Pretreatment of cells with natural C-16-ceramide bypassed the necessity for forced antibody cross-linking and enabled sFasL to cap and kill. The presence of intact sphingolipid-enriched membrane domains may be essential for Fas capping since their disruption with cholesterol-depleting agents abrogated capping and prevented apoptosis, These data suggest, that capping is a ceramide-dependent event required for optimal Fas signaling in some cells.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Lausanne, Inst Biochem, CH-1066 Epalinges, Switzerland	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital; University of Lausanne	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	r-kolesnick@ski.mskcc.org	Gulbins, Erich/L-6989-2014; Paris, francois E/L-4915-2015	Gulbins, Erich/0000-0002-3117-1342; Paris, francois E/0000-0002-0176-7348	NATIONAL CANCER INSTITUTE [R01CA052462] Funding Source: NIH RePORTER; NCI NIH HHS [CA52462, CA42385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belka C, 1998, RADIAT RES, V149, P588, DOI 10.2307/3579905; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BOURGUIGNON LYW, 1988, J CELL BIOCHEM, V37, P131, DOI 10.1002/jcb.240370202; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; Deckert M, 1996, J CELL BIOL, V133, P791, DOI 10.1083/jcb.133.4.791; Drzewiecka A, 1999, ACTA BIOCHIM POL, V46, P107, DOI 10.18388/abp.1999_4188; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; GOLDSTEIN P, 2000, SCIENCE, V288, P2328; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HOOVER RL, 1983, J CELL BIOL, V97, P73, DOI 10.1083/jcb.97.1.73; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; HUANG H, 1996, EUR BIOPHYS J, V27, P361; Huang J, 2000, EUR J IMMUNOL, V30, P50, DOI 10.1002/1521-4141(200001)30:1<50::AID-IMMU50>3.3.CO;2-9; HUBER R, 1976, NATURE, V264, P415, DOI 10.1038/264415a0; Huby RDJ, 1999, J BIOL CHEM, V274, P22591, DOI 10.1074/jbc.274.32.22591; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Johns DG, 1998, EUR J PHARMACOL, V349, pR9, DOI 10.1016/S0014-2999(98)00299-4; Junge S, 1999, CELL SIGNAL, V11, P301, DOI 10.1016/S0898-6568(98)00068-0; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Ko YG, 1999, J IMMUNOL, V162, P7217; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Krammer PH, 1998, TOXICOL LETT, V103, P131, DOI 10.1016/S0378-4274(98)00297-5; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; LURHUMA AZ, 1976, CLIN EXP IMMUNOL, V25, P212; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; RATCLIFFE MJH, 1992, J IMMUNOL, V148, P1643; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; tenGrotenhuis E, 1996, BIOPHYS J, V71, P1389, DOI 10.1016/S0006-3495(96)79341-4; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; von Reyher U, 1998, CANCER RES, V58, P526; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yasuhara S, 1999, J BURN CARE REHABIL, V20, P462, DOI 10.1097/00004630-199920060-00007; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	64	304	322	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23954	23961		10.1074/jbc.M101866200	http://dx.doi.org/10.1074/jbc.M101866200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11287428	hybrid			2022-12-25	WOS:000169531100097
J	Marin, EP; Krishna, AG; Archambault, V; Simuni, E; Fu, WY; Sakmar, TP				Marin, EP; Krishna, AG; Archambault, V; Simuni, E; Fu, WY; Sakmar, TP			The function of interdomain interactions in controlling nucleotide exchange rates in transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ACTIVATION; G-PROTEIN; ALPHA-SUBUNIT; PROTEOLYTIC DIGESTION; STRUCTURAL-ANALYSIS; CRYSTAL-STRUCTURE; EFFECTOR-BINDING; GDP RELEASE; TURN-ON; RHODOPSIN	The intramolecular contacts in heterotrimeric G proteins that determine the rates of basal and receptor-stimulated nucleotide exchange are not fully understood. The alpha subunit of heterotrimeric G proteins consists of two domains: a Ras-like domain with structural homology to the monomeric G protein Ras and a helical domain comprised of six alpha -helices. The bound nucleotide lies in a deep cleft between the two domains. Exchange of the bound nucleotide may involve opening of this cleft. Thus interactions between the domains may affect the rate of nucleotide exchange in G proteins. We have tested this hypothesis in the alpha subunit of the rod cell G protein transducin (G alpha (t)). Site-directed mutations were prepared in a series of residues located at the interdomain interface. The proteins were expressed in vitro in a reticulocyte lysate system. The rates of basal and rhodopsin-catalyzed nucleotide exchange were determined using a trypsin digestion assay specifically adapted for kinetic measurements, Charge-altering substitutions of two residues at the interdomain interface, Lys(273) and Lys(276), increased basal nucleotide exchange rates modestly (5-10-fold), However, we found no evidence that interactions spanning the two domains in Cat significantly affected either basal or rhodopsin-catalyzed nucleotide exchange rates. These results suggest that opening of the interdomain cleft is not an energetic barrier to nucleotide exchange in G alpha (t). Experiments with Gal, suggest by comparison that the organization and function of the interdomain region differ among various G protein subtypes.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Biol & Biochem, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	Sakmar, TP (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave,Box 284, New York, NY 10021 USA.		Sakmar, Thomas P/D-1833-2015	Sakmar, Thomas P/0000-0002-2836-8953; Aradhyam, Gopala Krishna/0000-0001-8232-3935	NIGMS NIH HHS [GM07982, GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1993, NATURE, V366, P628, DOI 10.1038/366628a0; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FAUROBERT E, 1993, EMBO J, V12, P4191, DOI 10.1002/j.1460-2075.1993.tb06103.x; FUNG BKK, 1983, J BIOL CHEM, V258, P503; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; Grishina G, 1998, J BIOL CHEM, V273, P15053, DOI 10.1074/jbc.273.24.15053; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; IIRI T, 1994, NATURE, V371, P164, DOI 10.1038/371164a0; Kazmi MA, 2000, BIOCHEMISTRY-US, V39, P3734, DOI 10.1021/bi992354c; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Li QB, 1997, J BIOL CHEM, V272, P21673, DOI 10.1074/jbc.272.35.21673; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; MARIN EP, 2001, IN PRESS J BIOL CHEM, V276; Marsh SR, 1998, MOL PHARMACOL, V53, P981; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Mazzoni MR, 1996, J BIOL CHEM, V271, P30034, DOI 10.1074/jbc.271.47.30034; MERRITT ERA, METHODS ENZYMOL, V277, P505; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; NEER EJ, 1994, METHOD ENZYMOL, V237, P226; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Osawa S, 1995, J BIOL CHEM, V270, P31052, DOI 10.1074/jbc.270.52.31052; Posner BA, 1998, J BIOL CHEM, V273, P21752, DOI 10.1074/jbc.273.34.21752; RAMDAS L, 1991, BIOCHEMISTRY-US, V30, P11637, DOI 10.1021/bi00114a005; Remmers AE, 1999, BIOCHEMISTRY-US, V38, P13795, DOI 10.1021/bi990887f; SAKMAR TP, 1988, NUCLEIC ACIDS RES, V16, P6361, DOI 10.1093/nar/16.14.6361; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Warner DR, 1999, P NATL ACAD SCI USA, V96, P4268, DOI 10.1073/pnas.96.8.4268; Warner DR, 1998, J BIOL CHEM, V273, P23976, DOI 10.1074/jbc.273.37.23976	34	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23873	23880		10.1074/jbc.M101197200	http://dx.doi.org/10.1074/jbc.M101197200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11290746	hybrid			2022-12-25	WOS:000169531100087
J	Saveanu, L; Daniel, S; van Endert, PM				Saveanu, L; Daniel, S; van Endert, PM			Distinct functions of the ATP binding cassettes of transporters associated with antigen processing - A mutational analysis of Walker A and B sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I MOLECULES; RESISTANCE PROTEIN MRP1; NUCLEOTIDE-BINDING; P-GLYCOPROTEIN; ABC TRANSPORTER; CRYSTAL-STRUCTURE; INSECT CELLS; PEPTIDE; DOMAINS; EXPRESSION	The transporters associated with antigen processing (TAP1/TAP2) provide peptides to MHC class I molecules in the endoplasmic reticulum, Like other ATP-binding cassette proteins, TAP uses ATP hydrolysis to power transport. We have studied peptide binding to as well as translocation by TAP proteins with mutations in the Walker A and B sequences that are known to mediate ATP binding and hydrolysis. We show that a mutation in the TAP1 Walker B sequence reported to abrogate class I expression by a lung tumor does not affect ATP binding affinity, suggesting a defect restricted to ATP hydrolysis, This mutation reduces peptide transport by only 50%, suggesting that TAP function can be highly limiting for antigen presentation in non-lymphoid cells, Single substitutions in Walker A sequences (TAP1K544A, TAP2K509A), or their complete replacements, abrogate nucleotide binding to each subunit, Although all of these mutations abrogate peptide transport, they reveal distinct roles for nucleotide binding to the two transporter subunits in TAP folding and in regulation of peptide substrate affinity, respectively. Alteration of the TAP1 Walker A motif can have strong effects on TAP1 and thereby TAP complex folding. However, TAP1 Walker A mutations compatible with correct folding do not affect peptide binding. In contrast, abrogation of the TAPS nucleotide binding capacity has little or no effect on TAP folding but eliminates peptide binding to TAP at 37 degreesC in the presence of nucleotides. Thus, nucleotide binding to TAPS but not to TAP1 is a prerequisite for peptide binding to TAP, Based on these results, we propose a model in which nucleotide and peptide release from TAP are coupled and followed by ATP binding to TAPS, which induces high peptide affinity and initiates the transport cycle.	INSERM, U25, F-75743 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	van Endert, PM (corresponding author), INSERM, U25, 161 Rue Sevres, F-75743 Paris 15, France.		Saveanu, Loredana/K-6821-2017; SAVEANU, Loredana/Q-1241-2019; van Endert, Peter/R-4606-2017	SAVEANU, Loredana/0000-0003-3138-7968; van Endert, Peter/0000-0003-3782-0750				Algarra I, 2000, HUM IMMUNOL, V61, P65, DOI 10.1016/S0198-8859(99)00156-1; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; Bach JM, 1997, J AUTOIMMUN, V10, P375, DOI 10.1006/jaut.1997.0143; Chen HL, 1996, NAT GENET, V13, P210, DOI 10.1038/ng0696-210; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Daniel S, 1997, J IMMUNOL, V159, P2350; Daniel S, 1998, J IMMUNOL, V161, P617; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Elliott T, 1997, ADV IMMUNOL, V65, P47, DOI 10.1016/S0065-2776(08)60741-5; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Garrido F, 1997, IMMUNOL TODAY, V18, P89, DOI 10.1016/S0167-5699(96)10075-X; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Lauvau G, 1999, J BIOL CHEM, V274, P31349, DOI 10.1074/jbc.274.44.31349; MEYER TH, 1994, FEBS LETT, V351, P443, DOI 10.1016/0014-5793(94)00908-2; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; Schneider E, 1998, FEMS MICROBIOL REV, V22, P1; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; van Endert PM, 1999, J BIOL CHEM, V274, P14632, DOI 10.1074/jbc.274.21.14632; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; VANENDERT PM, 1994, IMMUNITY, V1, P491, DOI 10.1016/1074-7613(94)90091-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	31	43	44	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22107	22113		10.1074/jbc.M011221200	http://dx.doi.org/10.1074/jbc.M011221200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11290739	hybrid			2022-12-25	WOS:000169412700019
J	Granovsky, AE; Artemyev, NO				Granovsky, AE; Artemyev, NO			Partial reconstitution of photoreceptor cGMP phosphodiesterase characteristics in cGMP phosphodiesterase-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; CYCLIC-GMP; AMINO-ACIDS; BINDING; INHIBITION; MECHANISM; SITES; IDENTIFICATION; MUTAGENESIS; PROTEINS	Photoreceptor cGMP phosphodiesterases (PDE6) are uniquely qualified to serve as effector enzymes in the vertebrate visual transduction cascade. In the dark-adapted photoreceptors, the activity of PDE6 is blocked via tight association with the inhibitory gamma -subunits (P gamma), The P gamma block is removed in the light-activated PDE6 by the visual G protein, transducin, Transducin-activated PDE6 exhibits an exceptionally high catalytic rate of cGMP hydrolysis ensuring high signal amplification. To identify the structural determinants for the inhibitory interaction with P gamma and the remarkable cGMP hydrolytic ability, we sought to reproduce the PDE6 characteristics by mutagenesis of PDE5, a related cyclic GMP-specific, cGMP-binding PDE, PDE5 is insensitive to P gamma and has a more than 100-fold lower k(cat) for cGMP hydrolysis, Our mutational analysis of chimeric PDE5/PDE6 alpha' enzymes revealed that the inhibitory interaction of cone PDE6 catalytic subunits (PDE6 alpha') with P gamma is mediated primarily by three hydrophobic residues at the entry to the catalytic pocket, Met(758), Phe(777), and Phe(781), The maximal catalytic rate of PDE5 was enhanced by at least 10-fold with substitutions of PDE5-specific glycine residues for the corresponding PDE5 alanine residues, Ala(608) and Ala(612). The Gly residues are adjacent to the highly conserved metal binding motif His-Asn-X-X-His, which is essential for cGMP hydrolysis. Our results suggest that the unique Gly residues allow the PDE6 metal binding site to adopt a more favorable conformation for cGMP hydrolysis.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.	nikolai-artemyev@uiowa.edu	Alex, Granovsky/EUV-7323-2022	Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-10843] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY010843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1998, METHODS, V14, P93, DOI 10.1006/meth.1997.0568; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; DUMKE CL, 1994, J GEN PHYSIOL, V103, P1071, DOI 10.1085/jgp.103.6.1071; Francis SH, 2000, BIOCHEMISTRY-US, V39, P9591, DOI 10.1021/bi000392m; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; GILLESPIE PG, 1989, MOL PHARMACOL, V36, P773; Granovsky AE, 1998, J BIOL CHEM, V273, P24485, DOI 10.1074/jbc.273.38.24485; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Granovsky AE, 2000, J BIOL CHEM, V275, P41258, DOI 10.1074/jbc.M008094200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; He F, 2000, J BIOL CHEM, V275, P20572, DOI 10.1074/jbc.M000440200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leskov IB, 2000, NEURON, V27, P525, DOI 10.1016/S0896-6273(00)00063-5; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Natochin M, 2000, METHOD ENZYMOL, V315, P539; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; QIN N, 1994, J BIOL CHEM, V269, P3265; Rost B, 1996, METHOD ENZYMOL, V266, P525; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turko IV, 1999, MOL PHARMACOL, V56, P124, DOI 10.1124/mol.56.1.124; Turko IV, 1996, J BIOL CHEM, V271, P22240, DOI 10.1074/jbc.271.36.22240; Turko IV, 1998, J BIOL CHEM, V273, P6460, DOI 10.1074/jbc.273.11.6460; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	32	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21698	21703		10.1074/jbc.M100626200	http://dx.doi.org/10.1074/jbc.M100626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11285263	hybrid			2022-12-25	WOS:000169297900120
J	Grzeszkiewicz, TM; Kirschling, DJ; Chen, NY; Lau, LF				Grzeszkiewicz, TM; Kirschling, DJ; Chen, NY; Lau, LF			CYR61 stimulates human skin fibroblast migration through integrin alpha(v)beta(5) and enhances mitogenesis through integrin alpha(v)beta(3), independent of its carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; CELL-SURFACE; MATRIX METALLOPROTEINASE; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; CUTANEOUS WOUNDS; TUMOR-GROWTH; CCN FAMILY; EXPRESSION	CYR61, an angiogenic factor and a member of the CCN protein family, is an extracellular matrix-associated, heparin-binding protein that mediates cell adhesion, promotes cell migration, and enhances growth factor-stimulated cell proliferation. CYR61 induces angiogenesis and promotes tumor growth in vivo and is expressed in dermal fibroblasts during cutaneous wound healing. It has been demonstrated recently that adhesion of primary skin fibroblasts to CYR61 is mediated through integrin alpha (6)beta (1) and cell surface heparan sulfate proteoglycans, resulting in adhesive signaling and up-regulation of matrix metalloproteinases 1 and 3, CYR61 is composed of four discrete structural domains that bear sequence similarities to the insulin-like growth factor-binding proteins, von Willebrand factor type C repeat, thrombospondin type 1 repeat, and a carboxyl-terminal (CT) domain that resembles cysteine knots found in some growth factors, In this study, we show that a CYR61 mutant (CYR61 Delta CT) that has the CT domain deleted is unable to support adhesion of primary human skin fibroblasts but is still able to stimulate chemotaxis and enhance basic fibroblast growth factor-induced mitogenesis similar to wild type. In addition, fibroblast migration to CYR61 is mediated through integrin alpha (v)beta (5) but not integrins alpha (6)beta (1) or alpha (v)beta (3). Furthermore, we show that CYR61 binds directly to purified integrin alpha (v)beta (5) in vitro, By contrast, CYR61 enhancement of basic fibroblast growth factor-induced DNA synthesis is mediated through integrin alpha (v)beta (3), a known receptor for CYR61 that mediates CYR61-dependent cell adhesion and chemotaxis in vascular endothelial cells. Thus, CYR61 promotes primary human fibroblast adhesion, migration, and mitogenesis through integrins alpha (6)beta (1), alpha (v)beta (5), and alpha (v)beta (3), respectively. Together, these findings establish CYR61 as a novel ligand for integrin alpha (v)beta (5) and show that CYR61 interacts with distinct integrins to mediate disparate activities in a cell type-specific manner.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Munin Corp, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA80080, CA78044, CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565, R43CA078044, R44CA078044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Ball DK, 1998, BIOL REPROD, V59, P828, DOI 10.1095/biolreprod59.4.828; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; Blaschuk KL, 2000, DEVELOPMENT, V127, P1961; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 1997, J BIOL CHEM, V272, P20275, DOI 10.1074/jbc.272.32.20275; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Carron CP, 1998, CANCER RES, V58, P1930; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; Clark RAF, 1996, AM J PATHOL, V148, P1407; Clark RAF, 1996, BRIT J DERMATOL, V135, P46; DHANABAL M, 1995, J IMMUNOL METHODS, V182, P165, DOI 10.1016/0022-1759(95)00036-A; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GAILIT J, 1994, J INVEST DERMATOL, V103, P221, DOI 10.1111/1523-1747.ep12393176; GAN ZR, 1988, J BIOL CHEM, V263, P19827; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kibe Y, 2000, BRIT J DERMATOL, V143, P720, DOI 10.1046/j.1365-2133.2000.03824.x; KIM JP, 1994, J BIOL CHEM, V269, P26926; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Kothapalli D, 2000, J CELL PHYSIOL, V182, P119, DOI 10.1002/(SICI)1097-4652(200001)182:1<119::AID-JCP13>3.0.CO;2-4; LARJAVA H, 1993, J CLIN INVEST, V92, P1425, DOI 10.1172/JCI116719; LATINKIC BV, 2001, IN PRESS ENDOCRINOLO; LATINKIC BV, 1994, THESIS U ILLINOIS CH; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Milner R, 1999, J CELL SCI, V112, P4271; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; PIALI L, 1995, J CELL BIOL, V130, P451, DOI 10.1083/jcb.130.2.451; Pilcher BK, 1999, ANN NY ACAD SCI, V878, P12, DOI 10.1111/j.1749-6632.1999.tb07671.x; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; RABINOWICH H, 1995, J IMMUNOL, V154, P1124; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shahan TA, 1999, CANCER RES, V59, P4584; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Steffen CL, 1998, GROWTH FACTORS, V15, P199, DOI 10.3109/08977199809002117; Stuiver I, 1996, J CELL PHYSIOL, V168, P521, DOI 10.1002/(SICI)1097-4652(199609)168:3<521::AID-JCP4>3.0.CO;2-R; Sung V, 1998, J CELL PHYSIOL, V176, P482, DOI 10.1002/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K; THERIAULT NY, 1988, BIOTECHNIQUES, V6, P470; Triantafilou M, 2000, HUM IMMUNOL, V61, P453, DOI 10.1016/S0198-8859(00)00103-8; Vaalamo M, 1996, BRIT J DERMATOL, V135, P52; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	61	136	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21943	21950		10.1074/jbc.M100978200	http://dx.doi.org/10.1074/jbc.M100978200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287419	hybrid			2022-12-25	WOS:000169297900149
J	Lamb, JR; Fu, V; Wirtz, E; Bangs, JD				Lamb, JR; Fu, V; Wirtz, E; Bangs, JD			Functional analysis of the trypanosomal AAA protein TbVCP with trans-dominant ATP hydrolysis mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE FUSION PROTEIN; TRANSITIONAL ENDOPLASMIC-RETICULUM; VALOSIN-CONTAINING PROTEIN; MITOTIC GOLGI FRAGMENTS; MEMBRANE-FUSION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PEROXISOME BIOGENESIS; VESICULAR TRANSPORT; GENE-EXPRESSION	TbVCP is a member of the AAA ((A) under bar TPases (A) under bar ssociated with a variety of cellular (A) under bar ctivities) family of proteins containing two ATPase domains. Southern analysis indicates TbVCP to have a single-locus, two-copy, genomic organization. One copy, but not both, can be disrupted by targeted gene replacement, suggesting that TbVCP is essential for trypanosome viability, Site-directed mutagenesis of the ATP hydrolysis motifs indicates that the second conserved ATPase domain is essential for TbVCP activity. Constitutive overexpression of TbVCP with a single mutation in the second hydrolysis motif or with mutations in both hydrolysis motifs was not possible. Regulated overexpression of these mutants resulted in cell death as a dominant negative phenotype, In each case cell growth arrested at 24-h post-induction and at all stages of the cell cycle as judged by replication of nuclear and kinetoplast genomes. Onset of growth arrest coincided with the development of severe and characteristic morphological alterations for each mutant. Neither constitutive nor regulated overexpression of wild type TbVCP or the single first hydrolysis domain mutant had any overt effect on cell viability or morphology, However, the distinct phenotype of the double mutant indicates that the first hydrolysis domain, although not essential, does modulate overall TbVCP function. Finally, yeast complementation studies demonstrated that TbVCP can functionally replace the yeast homologue Cdc48p, indicating that protein protein interactions essential to function have been maintained over great phylogenetic distances.	Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, Madison, WI 53706 USA; Rockefeller Univ, Mol Parasitol Lab, New York, NY 10021 USA	University of Wisconsin System; University of Wisconsin Madison; Rockefeller University	Bangs, JD (corresponding author), Univ Wisconsin, Sch Med, Dept Med Microbiol & Immunol, 1300 Univ Ave, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035739, T32AI007414, R01AI035739] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI035739, AI07414, AI35739] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bangs JD, 1997, EMBO J, V16, P4285, DOI 10.1093/emboj/16.14.4285; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOOTHROYD JC, 1989, NUCL ACIDS MOL BIOL, V3, P216; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CORMACK B, 1997, CURRENT PROTOCOLS MO; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FEILER HS, 1995, EMBO J, V14, P5626, DOI 10.1002/j.1460-2075.1995.tb00250.x; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Golbik R, 1999, BIOL CHEM, V380, P1049, DOI 10.1515/BC.1999.131; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOLLER KJ, 1987, NATURE, V325, P542, DOI 10.1038/325542a0; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KRAUSE T, 1994, YEAST, V10, P1613, DOI 10.1002/yea.320101210; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; MADEO F, 1997, GENE, V204, P9456; McDowell MA, 1998, BIOCHEM J, V335, P681, DOI 10.1042/bj3350681; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; MINET M, 1992, PLANT J, V2, P417; MOIR D, 1982, GENETICS, V100, P547; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PLEASURE IT, 1993, NATURE, V365, P459, DOI 10.1038/365459a0; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Roggy JL, 1999, MOL BIOCHEM PARASIT, V98, P1, DOI 10.1016/S0166-6851(98)00114-5; Rouiller I, 2000, MOL CELL, V6, P1485, DOI 10.1016/S1097-2765(00)00144-1; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; RUDENKO G, 1994, EMBO J, V13, P5470, DOI 10.1002/j.1460-2075.1994.tb06882.x; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TSCHUDI C, 1994, INFECT AGENT DIS, V3, P181; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49; ZHANG L, 1994, J CELL BIOL, V127, P1871, DOI 10.1083/jcb.127.6.1871; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	48	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21512	21520		10.1074/jbc.M100235200	http://dx.doi.org/10.1074/jbc.M100235200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279035	hybrid			2022-12-25	WOS:000169297900096
J	Liaw, PCY; Becker, DL; Stafford, AR; Fredenburgh, JC; Weitz, JI				Liaw, PCY; Becker, DL; Stafford, AR; Fredenburgh, JC; Weitz, JI			Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEEP-VEIN THROMBOSIS; TERNARY COMPLEX; ANTITHROMBIN-III; WEIGHT HEPARINS; ALPHA-THROMBIN; INHIBITION; RESIDUES; PREVENTION; BINDING; MONOMER	Although fibrin-bound thrombin is resistant to inactivation by heparin antithrombin and heparin.heparin cofactor II complexes, indirect studies in plasma systems suggest that the dermatan sulfate.heparin cofactor II complex can inhibit fibrin-bound thrombin, Herein we demonstrate that fibrin monomer produces a 240-fold decrease in the heparin-catalyzed rate of thrombin inhibition by heparin cofactor II but reduces the dermatan sulfate-catalyzed rate only 3-fold. The protection of fibrin-bound thrombin from inhibition by heparin.heparin co-factor II reflects heparin-mediated bridging of thrombin to fibrin that results in the formation of a ternary heparin.thrombin.fibrin complex. This compiler, formed as a result of three binary interactions (thrombin. fibrin, thrombin.heparin, and heparin.fibrin), limits accessibility of heparin-catalyzed inhibitors to thrombin and induces conformational changes at the active site of the enzyme, In contrast, dermatan sulfate binds to thrombin but does not bind to fibrin. Although a ternary dermatan sulfate.thrombin.fibrin complex forms, without dermatan sulfate-mediated bridging of thrombin to fibrin, only two binary interactions exist (thrombin.fibrin and thrombin.dermatan sulfate). Consequently, thrombin remains susceptible to inactivation by heparin cofactor II. This study explains why fibrin-bound thrombin is susceptible to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin.	Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada	McMaster University	Weitz, JI (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	jweitz@thrombosis.hhscr.org	Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				AGNELLI G, 1992, THROMB HAEMOSTASIS, V67, P203; Becker DL, 1999, J BIOL CHEM, V274, P6226, DOI 10.1074/jbc.274.10.6226; BENDAYAN P, 1994, THROMB HAEMOSTASIS, V71, P576; CADROY Y, 1993, ARTERIOSCLER THROMB, V13, P1213, DOI 10.1161/01.ATV.13.8.1213; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; Collins R, 1996, BMJ-BRIT MED J, V313, P652; COSMI B, 1993, THROMB HAEMOSTASIS, V70, P443; Di Carlo V, 1999, THROMB HAEMOSTASIS, V82, P30, DOI 10.1055/s-0037-1614625; EISENBERG PR, 1993, J CLIN INVEST, V91, P1877, DOI 10.1172/JCI116404; Fredenburgh JC, 1997, J BIOL CHEM, V272, P25493, DOI 10.1074/jbc.272.41.25493; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; Hogg PJ, 1996, J BIOL CHEM, V271, P26088, DOI 10.1074/jbc.271.42.26088; HOGG PJ, 1990, J BIOL CHEM, V265, P241; Hogg PJ, 1997, THROMB HAEMOSTASIS, V77, P424; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUNT D, 1992, LANCET, V339, P753; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; KAWASAKI K, 1992, CHEM PHARM BULL, V40, P3253, DOI 10.1248/cpb.40.3253; LANE DA, 1992, LANCET, V339, P334, DOI 10.1016/0140-6736(92)91650-W; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; MERTON RE, 1987, THROMB HAEMOSTASIS, V58, P839; NAGASAWA K, 1978, BIOCHIM BIOPHYS ACTA, V544, P430, DOI 10.1016/0304-4165(78)90110-1; NASKI MC, 1990, J BIOL CHEM, V265, P13484; Odrljin TM, 1996, BLOOD, V88, P2050, DOI 10.1182/blood.V88.6.2050.bloodjournal8862050; OKWUSIDI JI, 1991, J LAB CLIN MED, V117, P359; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; Popma JJ, 2001, CHEST, V119, p321S, DOI 10.1378/chest.119.1_suppl.321S; PRANDONI P, 1992, BRIT J SURG, V79, P505, DOI 10.1002/bjs.1800790610; ROSENBERG RD, 1987, HAEMOSTASIS THROMBOS, P1377; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; VANDEWERF F, 1990, LANCET, V336, P71; VANRYNMCKENNA J, 1989, ANN NY ACAD SCI, V556, P304; Weitz JI, 1999, CIRCULATION, V99, P682, DOI 10.1161/01.CIR.99.5.682; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; YE J, 1994, J BIOL CHEM, V269, P17965	39	84	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20959	20965		10.1074/jbc.M010584200	http://dx.doi.org/10.1074/jbc.M010584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294849	hybrid			2022-12-25	WOS:000169297900023
J	Nakahata, S; Katsu, Y; Mita, K; Inoue, K; Nagahama, Y; Yamashita, M				Nakahata, S; Katsu, Y; Mita, K; Inoue, K; Nagahama, Y; Yamashita, M			Biochemical identification of Xenopus pumilio as a sequence-specific cyclin B1 mRNA-binding protein that physically interacts with a nanos homolog, Xcat-2, and a cytoplasmic polyadenylation element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATURATION-PROMOTING FACTOR; GERM PLASM COMPONENT; OOCYTE MATURATION; MEIOTIC MATURATION; C-MOS; MAP KINASE; CELL-CYCLE; TRANSLATIONAL REPRESSION; MOLECULAR-MECHANISMS; DROSOPHILA	Translational activation of dormant cyclin B1 mRNA stored in oocytes is a prerequisite for the initiation or promotion of oocyte maturation in many vertebrates. Using a monoclonal antibody against the domain highly homologous to that of Drosophila Pumilio, we have shown for the first time in any vertebrate that a homolog of Pumilio is expressed in Xenopus oocytes, This 137-kDa protein binds to the region including the sequence UGUA at nucleotides 1335-1338 in the 3'-untranslated region of cyclin B1 mRNA, which is close to but does not overlap the cytoplasmic polyadenylation elements (CPEs). Physical in vitro association of Xenopus Pumilio with a Xenopus homolog of Nanos (Xcat-2) was demonstrated by a protein pull-down assay. The results of immunoprecipitation experiments showed in vivo interaction between Xenopus Pumilio and CPE-binding protein (CPEB), a key regulator of translational repression and activation of mRNAs stared in oocytes, This evidence provides a new insight into the mechanism of translational regulation through the 3'-end of mRNA during oocyte maturation. These results also suggest the generality of the function of Pumilio as a translational regulator of dormant mRNAs in both invertebrates and vertebrates.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Nara Inst Sci & Technol, Grad Sch Biosci, Ikoma 6300101, Japan; Natl Inst Basic Biol, Ctr Integrat Biol, Okazaki, Aichi 4448585, Japan; Natl Inst Basic Biol, Reprod Biol Lab, Okazaki, Aichi 4448585, Japan	Hokkaido University; Nara Institute of Science & Technology; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Yamashita, M (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	myama@sci.hokudai.ac.jp	Katsu, Yoshinao/F-9122-2012; Yamashita, Masakane/A-4556-2012	Katsu, Yoshinao/0000-0003-2625-4626; Yamashita, Masakane/0000-0002-3696-451X				Abrieu A, 1998, J CELL SCI, V111, P1751; Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; Ballantyne S, 1997, MOL BIOL CELL, V8, P1633, DOI 10.1091/mbc.8.8.1633; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; Barkoff AF, 2000, DEV BIOL, V220, P97, DOI 10.1006/dbio.2000.9613; CYERT MS, 1988, CELL, V53, P185, DOI 10.1016/0092-8674(88)90380-7; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; de Moor CH, 1999, EMBO J, V18, P2294, DOI 10.1093/emboj/18.8.2294; deMoor CH, 1997, MOL CELL BIOL, V17, P6419, DOI 10.1128/MCB.17.11.6419; DESCHAMPS S, 1992, J BIOL CHEM, V267, P13799; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; Forbes A, 1998, DEVELOPMENT, V125, P679; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; Gavin AC, 1999, MOL BIOL CELL, V10, P2971, DOI 10.1091/mbc.10.9.2971; GOTOH Y, 1995, J BIOL CHEM, V270, P25898, DOI 10.1074/jbc.270.43.25898; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; Hake LE, 1997, BBA-REV CANCER, V1332, pM31, DOI 10.1016/S0304-419X(96)00039-X; HAMPL A, 1995, MOL REPROD DEV, V40, P9, DOI 10.1002/mrd.1080400103; HIRAI T, 1992, MOL REPROD DEV, V33, P131, DOI 10.1002/mrd.1080330204; Houston DW, 1998, DEVELOPMENT, V125, P171; Howard EL, 1999, MOL CELL BIOL, V19, P1990; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; Ihara J, 1998, MOL REPROD DEV, V50, P499, DOI 10.1002/(SICI)1098-2795(199808)50:4<499::AID-MRD14>3.0.CO;2-Y; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; Karaiskou A, 1999, J CELL SCI, V112, P3747; Katsu Y, 1997, EUR J BIOCHEM, V249, P854, DOI 10.1111/j.1432-1033.1997.00854.x; Keiper BD, 1999, DEV BIOL, V206, P1, DOI 10.1006/dbio.1998.9131; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; Kraemer B, 1999, CURR BIOL, V9, P1009, DOI 10.1016/S0960-9822(99)80449-7; Kuge H, 1998, NUCLEIC ACIDS RES, V26, P3208, DOI 10.1093/nar/26.13.3208; MacArthur H, 1999, MECH DEVELOP, V84, P75, DOI 10.1016/S0925-4773(99)00075-1; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; MINSHULL J, 1989, CELL, V56, P947, DOI 10.1016/0092-8674(89)90628-4; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; Mita K, 2000, ZOOL SCI, V17, P365, DOI 10.2108/jsz.17.365; Mita K, 2000, MECH DEVELOP, V94, P251, DOI 10.1016/S0925-4773(00)00295-1; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; MURRAY MT, 1992, P NATL ACAD SCI USA, V89, P11, DOI 10.1073/pnas.89.1.11; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nakahata S, 2001, ZOOL SCI, V18, P337, DOI 10.2108/zsj.18.337; Olivas W, 2000, EMBO J, V19, P6602, DOI 10.1093/emboj/19.23.6602; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Parisi M, 2000, CURR BIOL, V10, pR81, DOI 10.1016/S0960-9822(00)00283-9; Polanski Z, 1998, DEVELOPMENT, V125, P4989; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Richter JD, 2000, COLD SPRING HARBOR M, V39, P785; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sakamoto I, 1998, DEV BIOL, V195, P60, DOI 10.1006/dbio.1997.8835; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Tadauchi T, 2001, EMBO J, V20, P552, DOI 10.1093/emboj/20.3.552; Taieb F, 1997, MOL REPROD DEV, V48, P397, DOI 10.1002/(SICI)1098-2795(199711)48:3&lt;397::AID-MRD14&gt;3.0.CO;2-T; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; Tay J, 2000, DEV BIOL, V221, P1, DOI 10.1006/dbio.2000.9669; Walker J, 1996, DEV BIOL, V173, P292, DOI 10.1006/dbio.1996.0024; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; Wharton RP, 1998, MOL CELL, V1, P863, DOI 10.1016/S1097-2765(00)80085-4; Wreden C, 1997, DEVELOPMENT, V124, P3015; Yamashita M, 2000, ZOOL SCI, V17, P841, DOI 10.2108/zsj.17.841; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617; Yamashita M, 2000, Prog Cell Cycle Res, V4, P115; YAMASHITA M, 1992, DEV BIOL, V149, P8, DOI 10.1016/0012-1606(92)90259-J; Yamashita M, 1998, SEMIN CELL DEV BIOL, V9, P569, DOI 10.1006/scdb.1998.0251; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; Zamore PD, 1999, BIOCHEMISTRY-US, V38, P596, DOI 10.1021/bi982264s; Zamore PD, 1997, RNA, V3, P1421; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297; Zhou Y, 1996, DEVELOPMENT, V122, P2947	79	135	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20945	20953		10.1074/jbc.M010528200	http://dx.doi.org/10.1074/jbc.M010528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283000	hybrid			2022-12-25	WOS:000169297900021
J	Silvin, C; Belisle, B; Abo, A				Silvin, C; Belisle, B; Abo, A			A role for Wiskott-Aldrich syndrome protein in T-cell receptor-mediated transcriptional activation independent of actin polymerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WASP-RELATED PROTEIN; ARP2/3 COMPLEX; BINDING; CYTOSKELETON; DEFECTS; DOMAIN; CDC42; VASP; REORGANIZATION; FAMILY	Wiskott-Aldrich syndrome protein (WASP) plays a key role in cytoskeletal rearrangement and transcriptional activation in T-cells. Recent evidence links WASP and related proteins to actin polymerization by the Arp2/3 complex. To study whether the role of WASP in actin polymerization is coupled to T-cell receptor (TCR)-mediated transcriptional activation, we made a series of WASP deletion mutants and tested them for actin colocalization, actin polymerization, and transcriptional activation of NFAT, A WASP mutant with a deletion in the C-terminal region (WASP DeltaC) that is defective in actin polymerization potentiated NFAT transcription following TCR activation by anti-CD3 and anti-CD3/CD28 antibodies, but not by phorbol 12-myristate 13-acetate/ionomycin, Furthermore, cotransfection of a dominant-active mutant (WASP-WH2-C) for Arp2/3 polymerization did not inhibit NFAT activation. Finally, by analyzing a series of WASP double-domain deletion mutants, we determined that the WASP homology-l domain is responsible for NFAT transcriptional activation. Our results suggest that WASP activates transcription following TCR stimulation in a manner that is independent of its role in Arp2/3-directed actin polymerization.	Onyx Pharmaceut, Richmond, CA 94806 USA		Abo, A (corresponding author), Onyx Pharmaceut, 3031 Res Dr, Richmond, CA 94806 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056478] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM56478-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abo A, 1998, CELL MOL LIFE SCI, V54, P1145, DOI 10.1007/s000180050242; Bear JE, 1998, J CELL BIOL, V142, P1325, DOI 10.1083/jcb.142.5.1325; Belisle B, 2000, J BIOL CHEM, V275, P26225, DOI 10.1074/jbc.M002743200; Callebaut I, 1998, FEBS LETT, V441, P181, DOI 10.1016/S0014-5793(98)01541-5; Carl UD, 1999, CURR BIOL, V9, P715, DOI 10.1016/S0960-9822(99)80315-7; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hoffman GR, 2000, CELL, V102, P403, DOI 10.1016/S0092-8674(00)00045-3; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Kato M, 1999, J BIOL CHEM, V274, P27225, DOI 10.1074/jbc.274.38.27225; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; Penninger JM, 1999, CELL, V96, P9, DOI 10.1016/S0092-8674(00)80954-X; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; RemoldODonnell E, 1996, BLOOD, V87, P2621, DOI 10.1182/blood.V87.7.2621.bloodjournal8772621; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Savoy DN, 2000, J IMMUNOL, V164, P2866, DOI 10.4049/jimmunol.164.6.2866; Sechi AS, 2000, J CELL SCI, V113, P3685; Snapper SB, 1998, IMMUNITY, V9, P81, DOI 10.1016/S1074-7613(00)80590-7; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Zhang J, 1999, J EXP MED, V190, P1329, DOI 10.1084/jem.190.9.1329	31	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21450	21457		10.1074/jbc.M010729200	http://dx.doi.org/10.1074/jbc.M010729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283014	hybrid			2022-12-25	WOS:000169297900088
J	Walker, EA; Clark, AM; Hewison, M; Ride, JP; Stewart, PM				Walker, EA; Clark, AM; Hewison, M; Ride, JP; Stewart, PM			Functional expression, characterization, and purification of the catalytic domain of human 11-beta-hydroxysteroid dehydrogenase type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CYTOPLASM; ENZYMATIC-ACTIVITY; GENE; THIOREDOXIN; REDUCTASE; CELLS; FORM; LOCALIZATION; ORIENTATION; SEQUENCES	11-beta -hydroxysteroid dehydrogenase type 1 catalyzes the conversion of cortisone to hormonally active cortisol and has been implicated in the pathogenesis of a number of disorders including insulin resistance and obesity. The enzyme is a glycosylated membrane-bound protein that has proved difficult to purify in an active state. Extracted enzyme typically loses the reductase properties seen in intact cells and shows principally dehydrogenase activity. The C-terminal catalytic domain is known to contain a disulfide bond and is located within the lumen of the endoplasmic reticulum, anchored to the membrane by a single N-terminal transmembrane domain. We report here the functional expression of the catalytic domain of the human enzyme, without the transmembrane domain and the extreme N terminus, in Escherichia coli, Moderate levels of soluble active protein were obtained using an N-terminal fusion with thioredoxin and a 6xHis tag. In contrast, the inclusion of a 6xHis tag at the C terminus adversely affected protein solubility and activity. However, the highest levels of active protein were obtained using a construct expressing the untagged catalytic domain. Nonreducing electrophoresis revealed the presence of both monomeric and dimeric disulfide bonded forms; however, mutation of a nonconserved cysteine residue resulted in a recombinant protein with no intermolecular disulfide bonds but full enzymatic activity. Using the optimal combination of plasmid construct and E, coli host strain, the recombinant protein was purified to apparent homogeneity by single step affinity chromatography, The purified protein possessed both dehydrogenase and reductase activities with a K-m of 1.4 muM for cortisol and 9.5 muM for cortisone. This study indicates that glycosylation, the N-terminal region including the transmembrane helix, and intermolecular disulfide bonds are not essential for enzyme activity and that expression in bacteria can provide active recombinant protein for future structural and functional studies.	Univ Birmingham, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Stewart, PM (corresponding author), Univ Birmingham, Div Med Sci, POB 363, Birmingham B15 2TT, W Midlands, England.	p.m.stewart@bham.ac.uk						Abdulaev NG, 2000, J BIOL CHEM, V275, P39354, DOI 10.1074/jbc.M005642200; AGARWAL AK, 1995, BBA-PROTEIN STRUCT M, V1248, P70, DOI 10.1016/0167-4838(95)00005-F; AGARWAL AK, 1990, MOL ENDOCRINOL, V4, P1827, DOI 10.1210/mend-4-12-1827; Blum A, 2000, TOXICOLOGY, V144, P113, DOI 10.1016/S0300-483X(99)00197-3; Blum A, 2000, BIOCHEM BIOPH RES CO, V276, P428, DOI 10.1006/bbrc.2000.3491; Bujalska IJ, 1999, ENDOCRINOLOGY, V140, P3188, DOI 10.1210/en.140.7.3188; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; Bujalska O, 1997, STEROIDS, V62, P77, DOI 10.1016/S0039-128X(96)00163-8; Condon J, 1997, MOL CELL ENDOCRINOL, V127, P121, DOI 10.1016/S0303-7207(97)04000-8; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Diederich S, 2000, EUR J ENDOCRINOL, V142, P200, DOI 10.1530/eje.0.1420200; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Kotelevtsev Y, 1997, P NATL ACAD SCI USA, V94, P14924, DOI 10.1073/pnas.94.26.14924; KROZOWSKI Z, 1994, J STEROID BIOCHEM, V51, P125, DOI 10.1016/0960-0760(94)90084-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; MERCER W, 1993, MOL CELL ENDOCRINOL, V92, P247, DOI 10.1016/0303-7207(93)90015-C; MOORE CCD, 1993, ENDOCRINOLOGY, V133, P368, DOI 10.1210/en.133.1.368; Morris JC, 1996, EXP HEMATOL, V24, P1369; OBEID J, 1993, MOL ENDOCRINOL, V7, P154, DOI 10.1210/me.7.2.154; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; Pasquarette MM, 1996, J MOL ENDOCRINOL, V16, P269, DOI 10.1677/jme.0.0160269; Phillipov G, 1996, J CLIN ENDOCR METAB, V81, P3855, DOI 10.1210/jc.81.11.3855; Rajan V, 1996, J NEUROSCI, V16, P65; Ribas AV, 2000, BIOTECHNOL APPL BIOC, V31, P91, DOI 10.1042/BA19990084; Ricketts ML, 1998, J CLIN ENDOCR METAB, V83, P1325, DOI 10.1210/jc.83.4.1325; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Stewart PM, 1999, VITAM HORM, V57, P249; Stewart PM, 1996, LANCET, V347, P88, DOI 10.1016/S0140-6736(96)90211-1; STEWART PM, 1994, J CLIN ENDOCR METAB, V79, P480, DOI 10.1210/jc.79.2.480; Tanabe T, 1998, J BIOCHEM, V124, P634, DOI 10.1093/oxfordjournals.jbchem.a022159; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; WALKER BR, 1995, J CLIN ENDOCR METAB, V80, P3155, DOI 10.1210/jc.80.11.3155	38	54	55	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21343	21350		10.1074/jbc.M011142200	http://dx.doi.org/10.1074/jbc.M011142200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294832	hybrid			2022-12-25	WOS:000169297900074
J	Wood, JL; Russo, AF				Wood, JL; Russo, AF			Autoregulation of cell-specific MAP kinase control of the tryptophan hydroxylase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CAMP-RESPONSIVE ELEMENT; MESSENGER-RNA LEVELS; BINDING TRANSCRIPTION FACTORS; HELIX-LOOP-HELIX; NF-Y; CCAAT BOX; RAT-BRAIN; SERINE-133 PHOSPHORYLATION; DEVELOPMENTAL REGULATION	The neurotransmitter serotonin controls a wide range of biological systems, including its own synthesis and release. As the rate-limiting enzyme in serotonin biosynthesis, tryptophan hydroxylase (TPH) is a potential target for this autoregulation, Using the serotonergic neuron-like CA77 cell line, we have demonstrated that treatment with a B-hydroxytryptamine autoreceptor agonist, CGS 12066A, can lower TPH mRNA levels and promoter activity. We reasoned that this repression might involve inhibition of MAP kinases, since 5-HT1 receptors can increase mitogen-activated protein (MAP) kinase phosphatase levels. To test this hypothesis, we first showed that the TPH promoter can be activated 20-fold by mitogen-activated extracellular-signal regulated kinase kinase kinase (MEKK), an activator of MAP kinases. This activation was then blocked by CGS 12066A The maximal MAP kinase and CGS repression regulatory region was mapped to between -149 and -45 base pairs upstream of the transcription start site. The activation by MEKK appears to be cell-specific, because MEKK did not activate the TPH promoter in nonneuronal cell lines. At least part, but not all, of the MAP kinase responsiveness was mapped to an inverted CCAAT box that binds the transcription factor NF-Y. These data suggest a model for the autoregulation of serotonin biosynthesis by repression of MAP kinase stimulation of the TPH promoter.	Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Genet PhD Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Russo, AF (corresponding author), Univ Iowa, Dept Physiol & Biophys, 5-632 BSB, Iowa City, IA 52242 USA.			Russo, Andrew/0000-0002-8156-5649	NICHD NIH HHS [HD 25969] Funding Source: Medline; NIDDK NIH HHS [DK 25295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZMITIA EC, 1991, J CLIN PSYCHIAT, V52, P4; Banik U, 1997, J BIOL CHEM, V272, P26219, DOI 10.1074/jbc.272.42.26219; BOADLEBIBER MC, 1989, BRAIN RES, V482, P306, DOI 10.1016/0006-8993(89)91193-1; BOADLEBIBER MC, 1993, PROG BIOPHYS MOL BIO, V60, P1, DOI 10.1016/0079-6107(93)90009-9; BOESS FG, 1994, NEUROPHARMACOLOGY, V33, P275, DOI 10.1016/0028-3908(94)90059-0; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; Chamas F, 1999, NEUROSCI LETT, V267, P157, DOI 10.1016/S0304-3940(99)00340-7; Chang ZF, 1999, J CELL BIOCHEM, V75, P300, DOI 10.1002/(SICI)1097-4644(19991101)75:2<300::AID-JCB12>3.0.CO;2-Z; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; Clark Michael S., 1995, Methods (Orlando), V7, P253, DOI 10.1006/meth.1995.1030; CLARK MS, 1995, J NEUROSCI, V15, P6167; CORTES R, 1993, J NEUROCHEM, V60, P761, DOI 10.1111/j.1471-4159.1993.tb03213.x; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DARMON MC, 1988, J NEUROCHEM, V51, P312, DOI 10.1111/j.1471-4159.1988.tb04871.x; di Silvio A, 1999, NUCLEIC ACIDS RES, V27, P2578; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Durham PL, 1999, J NEUROSCI, V19, P3423; Durham PL, 1998, MOL ENDOCRINOL, V12, P1002, DOI 10.1210/me.12.7.1002; Durham PL, 1997, J NEUROSCI, V17, P9545; DURHAM PL, 1992, EXP LUNG RES, V18, P775, DOI 10.3109/01902149209031707; Eggers A, 1998, J BIOL CHEM, V273, P18499, DOI 10.1074/jbc.273.29.18499; EHRET M, 1989, J NEUROCHEM, V52, P1886, DOI 10.1111/j.1471-4159.1989.tb07272.x; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Gerhardt CC, 1997, EUR J PHARMACOL, V334, P1, DOI 10.1016/S0014-2999(97)01115-1; Graeff FG, 1996, PHARMACOL BIOCHEM BE, V54, P129, DOI 10.1016/0091-3057(95)02135-3; HOYER D, 1994, PHARMACOL REV, V46, P157; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; HUFTON SE, 1995, BIOCHEM J, V311, P353, DOI 10.1042/bj3110353; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; JOHANSEN PA, 1995, J NEUROCHEM, V65, P882; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LANIGAN TM, 1993, MOL CELL BIOL, V13, P6079, DOI 10.1128/MCB.13.10.6079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Nankova BB, 1998, STRESS, V2, P289, DOI 10.3109/10253899809167293; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PARK DH, 1994, MOL BRAIN RES, V22, P20, DOI 10.1016/0169-328X(94)90028-0; REED GE, 1995, BRAIN RES, V682, P1, DOI 10.1016/0006-8993(95)00284-W; Rind HB, 2000, NEUROSCIENCE, V101, P665, DOI 10.1016/S0306-4522(00)00402-4; RUSSO AF, 1992, MOL ENDOCRINOL, V6, P207, DOI 10.1210/me.6.2.207; SAUDOU F, 1994, SCIENCE, V265, P1875, DOI 10.1126/science.8091214; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seternes OM, 1999, MOL ENDOCRINOL, V13, P1071, DOI 10.1210/me.13.7.1071; Siuciak JA, 1998, J NEUROSCI RES, V52, P149; STOLL J, 1991, J NEUROSCI RES, V28, P457, DOI 10.1002/jnr.490280402; Teerawatanasuk N, 1999, J NEUROCHEM, V72, P29, DOI 10.1046/j.1471-4159.1999.0720029.x; Teerawatanasuk N, 1998, MOL BRAIN RES, V55, P61, DOI 10.1016/S0169-328X(97)00364-1; THOPMSON JF, 1991, GENE, V103, P171; TVERBERG LA, 1993, J BIOL CHEM, V268, P15965; TYCE GM, 1990, J CARDIOVASC PHARM, V16, pS1, DOI 10.1097/00005344-199006163-00002; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; ZGOMBICK JM, 1993, MOL PHARMACOL, V44, P575	56	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21262	21271		10.1074/jbc.M007520200	http://dx.doi.org/10.1074/jbc.M007520200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283010	hybrid			2022-12-25	WOS:000169297900063
J	Denecker, G; Declercq, W; Geuijen, CAW; Boland, A; Benabdillah, R; van Gurp, M; Sory, MP; Vandenabeele, P; Cornelis, GR				Denecker, G; Declercq, W; Geuijen, CAW; Boland, A; Benabdillah, R; van Gurp, M; Sory, MP; Vandenabeele, P; Cornelis, GR			Yersinia enterocolitica YopP-induced apoptosis of macrophages involves the apoptotic signaling cascade upstream of Bid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; NF-KAPPA-B; TOLL-LIKE RECEPTOR-2; CELL-DEATH; ALPHA PRODUCTION; TNF RECEPTOR; COMPLEX DISC; ACTIVATION; PROTEIN; INHIBITION	Yersinia enterocolitica induces apoptosis in macrophages by injecting the plasmid-encoded YopP (YopJ in other Yersinia species). Recently it was reported that YopP/J is a member of an ubiquitin-like protein cysteine protease family and that the catalytic core of YopP/J is required for its inhibition of the MAPK and NF-kappaB pathways. Here we analyzed the YopP/J-induced apoptotic signaling pathway. YopP-mediated cell death could be inhibited by addition of the zVAD caspase inhibitor, but not by DEM or YVAD, Generation of truncated Bid (tBid) was the first apoptosis-related event that we observed. The subsequent translocation of tBid to the mitochondria induced the release of cytochrome c, leading to the activation of procaspase-9 and the executioner procaspase-3 and -7. Inhibition of the postmitochondrial executioner caspases-3 and -7 did not affect Bid cleavage. Bid cleavage could not be observed in a yopP-deficient Y. enterocolitica strain, showing that this event requires YopP, Disruption of the catalytic core of YopP abolished the rapid generation of tBid, thereby hampering induction of apoptosis by Y. enterocolitica. This finding supports the idea that YopP/J induces apoptosis by directly acting on cell death pathways, rather than being the mere consequence of gene induction inhibition in combination with microbial stimulation of the macrophage.	Univ Catholique Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, B-1200 Brussels, Belgium; Flanders Interuniv Inst Biotechnol, Dept Mol Biol, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Universite Catholique Louvain; Ghent University	Cornelis, GR (corresponding author), Univ Catholique Louvain, Christian de Duve Inst Cellular Pathol, Microbial Pathogenesis Unit, Ave Hippocrate 74, B-1200 Brussels, Belgium.		Denecker, Geertrui/E-8134-2010; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Denecker, Geertrui/0000-0002-2515-2911				Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Boland A, 1998, INFECT IMMUN, V66, P1878, DOI 10.1128/IAI.66.5.1878-1884.1998; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Carpentier I, 1999, FEBS LETT, V460, P246, DOI 10.1016/S0014-5793(99)01356-3; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Heibein JA, 2000, J EXP MED, V192, P1391, DOI 10.1084/jem.192.10.1391; Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; ICHINOHE H, 1991, J CLIN MICROBIOL, V29, P846, DOI 10.1128/JCM.29.4.846-847.1991; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; Monack DM, 1998, J EXP MED, V188, P2127, DOI 10.1084/jem.188.11.2127; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Navarre WW, 2000, CELL MICROBIOL, V2, P265, DOI 10.1046/j.1462-5822.2000.00056.x; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1998, MOL MICROBIOL, V27, P953, DOI 10.1046/j.1365-2958.1998.00740.x; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Ruckdeschel K, 1998, J EXP MED, V187, P1069, DOI 10.1084/jem.187.7.1069; Ruckdeschel K, 2001, J IMMUNOL, V166, P1823, DOI 10.4049/jimmunol.166.3.1823; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	104	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19706	19714		10.1074/jbc.M101573200	http://dx.doi.org/10.1074/jbc.M101573200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279213	hybrid			2022-12-25	WOS:000169135100006
J	Lowenson, JD; Kim, E; Young, SG; Clarke, S				Lowenson, JD; Kim, E; Young, SG; Clarke, S			Limited accumulation of damaged proteins in L-isoaspartyl (D-aspartyl) O-methyltransferase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ASPARTYL; TRANSGENIC MICE; PEPTIDES; DEGRADATION; ASPARAGINYL; EXPRESSION; REPAIR; MODEL; PURIFICATION; DEAMIDATION	L-Isoaspartyl (D-aspartyl) O-methyltransferase (PCMT1) can initiate the conversion of damaged aspartyl and asparaginyl residues to normal L-aspartyl residues. Mice lacking this enzyme (Pcmt1-/- mice) have elevated levels of damaged residues and die at a mean age of 42 days from massive tonic-clonic seizures. To extend the lives of the knockout mice so that the long term effects of damaged residue accumulation could be investigated, we produced transgenic mice with a mouse Pcmt1 cDNA under the control of a neuron specific promoter. Pcmt1 transgenic mice that were homozygous for the endogenous Pcmt1 knockout mutation ("transgenic Pcmt1-/- mice") had brain PCMT1 activity levels that were 6.5-13% those of mild-type mice but had little or no activity in other tissues. The transgenic Pcmt1-/- mice lived, on average, B-fold longer than nontransgenic Pcmt1-/- mice and accumulated only half as many damaged aspartyl residues in their brain proteins. The concentration of damaged residues in heart, testis, and brain proteins in transgenic Pcmt1-/- mice initially increased with age but unexpectedly reached a plateau by 100 days of age. Urine from Pcmt1-/- mice contained increased amounts of peptides with damaged aspartyl residues, apparently enough to account for proteins that were not repaired intracellularly. In the absence of PCMT1, proteolysis may limit the intracellular accumulation of damaged proteins but less efficiently than in wild-type mice having PCMT1-mediated repair.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Clarke, S (corresponding author), 640 Paul D Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	clarke@mbi.ucla.edu	Lowenson, Jonathan/AAN-6768-2020	Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG15451, AG18000] Funding Source: Medline; NIGMS NIH HHS [GM26020] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026020, R37GM026020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG018000, R01AG015451] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andra K, 1996, NEUROBIOL AGING, V17, P183, DOI 10.1016/0197-4580(95)02066-7; Aswad DW, 2000, J PHARMACEUT BIOMED, V21, P1129, DOI 10.1016/S0731-7085(99)00230-7; BONSNES RW, 1945, J BIOL CHEM, V158, P581; BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223; BUCHANAN DL, 1962, BIOCHEMISTRY-US, V1, P612, DOI 10.1021/bi00910a011; Chain DG, 1999, MOL NEUROBIOL, V20, P125, DOI 10.1007/BF02742438; Clarke S., 1999, S ADENOSYLMETHIONINE, P123; CRISPENS CG, 1975, HDB LAB MOUSE, P131; DORER FE, 1966, BIOCHEMISTRY-US, V5, P3236, DOI 10.1021/bi00874a025; FORSSPETTER S, 1990, NEURON, V5, P187, DOI 10.1016/0896-6273(90)90308-3; Friguet B, 2000, ANN NY ACAD SCI, V908, P143; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; GEIGER T, 1987, J BIOL CHEM, V262, P785; HALEY EE, 1966, BIOCHEMISTRY-US, V5, P3229, DOI 10.1021/bi00874a024; HIGGINS LS, 1993, ANN NY ACAD SCI, V695, P224, DOI 10.1111/j.1749-6632.1993.tb23056.x; Hogan B, 1994, MANIPULATING MOUSE E; JOHNSON BA, 1987, J BIOL CHEM, V262, P5622; JOHNSON BA, 1990, BIOCHEMISTRY-US, V29, P4373, DOI 10.1021/bi00470a017; Kandel ER, 1991, PRINCIPLES NEURAL SC, P22; Kim E, 1997, P NATL ACAD SCI USA, V94, P6132, DOI 10.1073/pnas.94.12.6132; Kim E, 1999, J BIOL CHEM, V274, P20671, DOI 10.1074/jbc.274.29.20671; LOEFFLER M, 1989, CELL TISSUE KINET, V22, P13, DOI 10.1111/j.1365-2184.1989.tb00198.x; Lowenson J. D., 1995, DEAMIDATION ISOASPAR, P47; Lowenson JD, 1999, METHOD ENZYMOL, V309, P89; MACLAREN DC, 1995, PROTEIN EXPRES PURIF, V6, P99, DOI 10.1006/prep.1995.1013; Mamula MJ, 1999, J BIOL CHEM, V274, P22321, DOI 10.1074/jbc.274.32.22321; MCFADDEN PN, 1987, P NATL ACAD SCI USA, V84, P2595, DOI 10.1073/pnas.84.9.2595; Moskovitz J, 1998, P NATL ACAD SCI USA, V95, P14071, DOI 10.1073/pnas.95.24.14071; PATEL K, 1990, PHARMACEUT RES, V7, P703, DOI 10.1023/A:1015807303766; PISANO JJ, 1966, ARCH BIOCHEM BIOPHYS, V117, P394, DOI 10.1016/0003-9861(66)90427-9; ROMANIK EA, 1992, GENE, V118, P217, DOI 10.1016/0378-1119(92)90191-Q; Rosenquist C, 1998, CLIN CHEM, V44, P2281; Sano H, 1999, MECH AGEING DEV, V107, P333, DOI 10.1016/S0047-6374(99)00011-1; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Shimizu T, 2000, ARCH BIOCHEM BIOPHYS, V381, P225, DOI 10.1006/abbi.2000.1955; Stadtman ER, 2000, ANN NY ACAD SCI, V899, P191; STEPHENSON RC, 1989, J BIOL CHEM, V264, P6164; Szymanska G, 1998, J BIOL CHEM, V273, P28516, DOI 10.1074/jbc.273.43.28516; TANAKA T, 1978, J BIOCHEM-TOKYO, V84, P617, DOI 10.1093/oxfordjournals.jbchem.a132166; Tarcsa E, 2000, J BIOL CHEM, V275, P20295, DOI 10.1074/jbc.M001555200; VISICK JE, 1995, MOL MICROBIOL, V16, P835, DOI 10.1111/j.1365-2958.1995.tb02311.x; Volkin DB, 1997, MOL BIOTECHNOL, V8, P105, DOI 10.1007/BF02752255; Yamamoto A, 1998, J NEUROSCI, V18, P2063	43	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20695	20702		10.1074/jbc.M100987200	http://dx.doi.org/10.1074/jbc.M100987200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279164	hybrid			2022-12-25	WOS:000169135100136
J	Meddows, E; Le Bourdelles, B; Grimwood, S; Wafford, K; Sandhu, S; Whiting, P; McIlhinney, RAJ				Meddows, E; Le Bourdelles, B; Grimwood, S; Wafford, K; Sandhu, S; Whiting, P; McIlhinney, RAJ			Identification of molecular determinants that are important in the assembly of N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; GLUTAMATE-RECEPTOR; NMDA RECEPTOR; NR1 SUBUNIT; EXPRESSION; SITE; TOPOLOGY; FORM; NR2A	To determine which domains of the N-methyl-D-aspartate (NMDA) receptor are important for the assembly of functional receptors, a number of N- and C-terminal truncations of the NR1a subunit have been produced. Truncations containing a complete ligand binding domain bound glycine antagonist and gave binding constants similar to those of the native subunit, suggesting they were folding to form antagonist binding sites. Since NR2A is not transported to the cell surface unless it is associated with NR1 (McIlhinney, R, A. J,, Le Bourdelles, E,, Tricuad, N,, Molnar, E,, Streit, P,, and Whiting, P, J, (1998) Neuropharmacology 37, 1355-1367), surface expression of NR2A can be used to monitor the association of the subunits, There was progressive loss of NR2A cell surface expression as the N terminus of NR1a was shortened, with complete loss when truncated beyond residue 380, Removal of the C terminus and/or the last transmembrane domain did not affect NR2A surface expression. Similar results were obtained in co-immunoprecipitation experiments. The oligomerization status of the co-expressed NR1a constructs and NR2A subunits was investigated using a non-denaturing gel electrophoresis system (blue native-polyacrylamide gel electrophoresis) and sucrose density gradient centrifugation, The blue native-polyacrylamide gel electrophoresis system also showed that the NR1a subunits could form a homodimer, which was confirmed using soluble constructs of the NR1a subunit, Together these results suggest the residues N-terminal of residue 380 are important for the association of NR2A with NR1a and that the complete N-terminal domain of the NR1a subunit is required for oligomerization with NR2A.	MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; Merck Sharp & Dohme Ltd, Neurosci Res Ctr, Harlow CM20 2QR, Essex, England	Merck & Company	McIlhinney, RAJ (corresponding author), MRC, Anat Neuropharmacol Unit, Mansfield Rd, Oxford OX1 3TH, England.	jeff.mcilhinney@pharm.ox.ac.uk	Schaack, Beatrice/C-1801-2014	Whiting, Paul/0000-0002-4121-1379; Wafford, Keith/0000-0003-4537-4690				Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; BEHE P, 1995, P ROY SOC B-BIOL SCI, V262, P205, DOI 10.1098/rspb.1995.0197; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BENVENISTE M, 1991, BRIT J PHARMACOL, V104, P207, DOI 10.1111/j.1476-5381.1991.tb12409.x; Blahos J, 1996, J BIOL CHEM, V271, P15669, DOI 10.1074/jbc.271.26.15669; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; Coleman SK, 2000, EUR J NEUROSCI, V12, P37; Dingledine R, 1999, PHARMACOL REV, V51, P7; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; GRIMWOOD S, 1995, J NEUROCHEM, V64, P525; Hawkins LM, 1999, J BIOL CHEM, V274, P27211, DOI 10.1074/jbc.274.38.27211; Hirai H, 1996, P NATL ACAD SCI USA, V93, P6031, DOI 10.1073/pnas.93.12.6031; HOLLMANN M, 1997, INOTROPIC GLUTAMATE; Ivanovic A, 1998, J BIOL CHEM, V273, P19933, DOI 10.1074/jbc.273.32.19933; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Miyazaki J, 1999, BIOCHEM J, V340, P687, DOI 10.1042/0264-6021:3400687; MOLNAR E, 1994, J NEUROCHEM, V63, P683; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; Nicke A, 1999, J RECEPT SIGNAL TR R, V19, P493, DOI 10.3109/10799899909036667; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; Robbins MJ, 1999, J NEUROCHEM, V72, P2539, DOI 10.1046/j.1471-4159.1999.0722539.x; Sandhu S, 1999, J NEUROCHEM, V72, P1694, DOI 10.1046/j.1471-4159.1999.721694.x; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Varney MA, 1996, J PHARMACOL EXP THER, V279, P367; WAFFORD KA, 1995, MOL PHARMACOL, V47, P374; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154	43	98	106	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18795	18803		10.1074/jbc.M101382200	http://dx.doi.org/10.1074/jbc.M101382200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279200	hybrid			2022-12-25	WOS:000169091000021
J	Spirito, F; Chavanas, S; Prost-Squarcioni, C; Pulkkinen, L; Fraitag, S; Bodemer, C; Ortonne, JP; Meneguzzi, G				Spirito, F; Chavanas, S; Prost-Squarcioni, C; Pulkkinen, L; Fraitag, S; Bodemer, C; Ortonne, JP; Meneguzzi, G			Reduced expression of the epithelial adhesion ligand laminin 5 in the skin causes intradermal tissue separation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL EPIDERMOLYSIS-BULLOSA; BASEMENT-MEMBRANE; CELL-ADHESION; GENE-TRANSFER; VII COLLAGEN; INTEGRIN; KERATINOCYTES; MUTATIONS; HEMIDESMOSOMES; KALININ	Laminin 5, the major keratinocyte adhesion ligand, is found in the lamina lucida subregion of the epidermal basement membrane of the skin, where it colocalizes with the anchoring filaments. Mutations in the genes encoding laminin 5 cause junctional epidermolysis bullosa, an inherited skin blistering disease characterized by abnormal hemidesmosomes and cleavage of the lamina lucida leading to epidermal detachment. In this work we describe the genetic basis of a new subtype of lethal inherited epidermolysis bullosa associated with reduced skin reactivity to laminin 5, presence of mature hemidesmosomes, and intradermal cleavage of the skin. The epidermolysis bullosa patients were heterozygous for a nonsense mutation (Q896X) and a splice site mutation (764-10T -->G) in the gene (LAMC2) for the gamma2 chain of laminin 5. The nonsense mutation causes accelerated decay of the corresponding mRNA, while the splice site mutation results in maturation of a cryptic wild-type gamma2 mRNA leading to reduced expression of wild-type laminin 5. In vitro studies using the probands' keratinocytes showed that secretion of reduced amounts of functional laminin 5 in the patient, although permitting formation of hemidesmosomes, fail to restore efficient cell adhesion. Our results provide the first evidence that laminin 5 contributes to the firm adhesion of the epithelial basement membrane to the underlying stroma, They also show that a low expression level of laminin 5 induces assembly of mature hemidesmosomes in vivo but fails to assure a stable cohesion of the dermal-epidermal junction.	Fac Med, UFR Med, INSERM U385, F-06107 Nice 2, France; Hop Necker Enfants Malad, Serv Dermatol, F-75730 Paris 15, France; Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; Fac Med Lariboisiere, Dept Histol Embryol & Cytogenet, F-75730 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Jefferson University; UDICE-French Research Universities; Universite Paris Cite	Meneguzzi, G (corresponding author), Fac Med, UFR Med, INSERM U385, Ave Valombrose, F-06107 Nice 2, France.	meneguzz@unice.fr	Chavanas, stephane/K-1183-2014	Meneguzzi, Guerrino/0000-0002-1609-6540; chavanas, stephane/0000-0003-4323-2656				ABERDAM D, 1994, NAT GENET, V6, P299, DOI 10.1038/ng0394-299; Baker SE, 1996, J CELL SCI, V109, P2509; BAUDOIN C, 1994, HUM MOL GENET, V3, P1909, DOI 10.1093/hmg/3.10.1909; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; Champliaud MF, 1996, J CELL BIOL, V132, P1189, DOI 10.1083/jcb.132.6.1189; Chavanas S, 1999, HUM MOL GENET, V8, P2097, DOI 10.1093/hmg/8.11.2097; Chen M, 1997, J BIOL CHEM, V272, P14516, DOI 10.1074/jbc.272.23.14516; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Cooper D. N., 1993, HUMAN GENE MUTATION; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; El-Ghannam A, 1998, J BIOMED MATER RES, V41, P30, DOI 10.1002/(SICI)1097-4636(199807)41:1<30::AID-JBM4>3.0.CO;2-R; Fine JD, 2000, J AM ACAD DERMATOL, V42, P1051, DOI 10.1016/S0190-9622(00)90302-5; Fleischmajer R, 1998, J CELL SCI, V111, P1929; Gache Y, 1996, J CLIN INVEST, V97, P2289, DOI 10.1172/JCI118671; GagnouxPalacios L, 1996, J BIOL CHEM, V271, P18437, DOI 10.1074/jbc.271.31.18437; GagnouxPalacios L, 1997, LAB INVEST, V77, P459; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Gardella R, 1996, AM J HUM GENET, V59, P292; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; HORMIA M, 1995, J INVEST DERMATOL, V105, P557, DOI 10.1111/1523-1747.ep12323451; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; Koshikawa N, 1999, CANCER RES, V59, P5596; LEIGH IM, 1988, J INVEST DERMATOL, V90, P639, DOI 10.1111/1523-1747.ep12560795; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MATSUI C, 1995, J BIOL CHEM, V270, P23496, DOI 10.1074/jbc.270.40.23496; Mellerio JE, 1999, CLIN EXP DERMATOL, V24, P25; Meneguzzi G, 2001, SKIN AND GENE THERAPY, P97; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Nievers MG, 1999, MATRIX BIOL, V18, P5, DOI 10.1016/S0945-053X(98)00003-1; OToole EA, 1997, EXP CELL RES, V233, P330, DOI 10.1006/excr.1997.3586; Pulkkinen L, 1997, MOL MED, V3, P124, DOI 10.1007/BF03401804; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1994, AM J PATHOL, V145, P782; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; Rheinwald JG., 1989, CELL GROWTH DIVISION, P81; ROUSSELLE P, 1994, J CELL BIOL, V125, P205, DOI 10.1083/jcb.125.1.205; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; Rousselle P, 1997, J CELL BIOL, V138, P719, DOI 10.1083/jcb.138.3.719; Ryan MC, 1999, J CELL BIOL, V145, P1309, DOI 10.1083/jcb.145.6.1309; Shimizu H, 1997, LAB INVEST, V76, P753; SMITH LT, 1993, ARCH DERMATOL, V129, P1578, DOI 10.1001/archderm.129.12.1578; SONNENBERG A, 1993, J CELL SCI, V106, P1083; SONNENBERG A, 1987, J BIOL CHEM, V262, P10376; Spirito F, 2001, J GENE MED, V3, P21, DOI 10.1002/1521-2254(2000)9999:9999<::AID-JGM156>3.0.CO;2-I; Stahl S, 1997, J CELL SCI, V110, P55; TIDMAN MJ, 1986, J INVEST DERMATOL, V86, P51, DOI 10.1111/1523-1747.ep12283807; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Vailly J, 1998, GENE THER, V5, P1322, DOI 10.1038/sj.gt.3300730; van der Neut R, 1999, J CELL SCI, V112, P3911; VERRANDO P, 1993, J INVEST DERMATOL, V101, P738, DOI 10.1111/1523-1747.ep12371685; VERRANDO P, 1991, LAB INVEST, V64, P85; VIDAL F, 1995, NAT GENET, V10, P229, DOI 10.1038/ng0695-229; ZAMBRUNO G, 1998, DIAGNOSTIC IMMUNOHIS, P126; Zhang K, 1996, EXP CELL RES, V227, P309, DOI 10.1006/excr.1996.0280	56	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18828	18835		10.1074/jbc.M100381200	http://dx.doi.org/10.1074/jbc.M100381200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279058	hybrid			2022-12-25	WOS:000169091000025
J	Mullick, J; Anandatheerthavarada, HK; Amuthan, G; Bhagwat, SV; Biswas, G; Camasamudram, V; Bhat, NK; Reddy, SEP; Rao, V; Avadhani, NG				Mullick, J; Anandatheerthavarada, HK; Amuthan, G; Bhagwat, SV; Biswas, G; Camasamudram, V; Bhat, NK; Reddy, SEP; Rao, V; Avadhani, NG			Physical interaction and functional synergy between glucocorticoid receptor and Ets2 proteins for transcription activation of the rat cytochrome P-450c27 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; HEPATIC STEROL 27-HYDROXYLASE; BILE-ACID BIOSYNTHESIS; DNA-BINDING DOMAIN; RNA-POLYMERASE-II; NF-KAPPA-B; NUCLEAR FACTOR; MESSENGER-RNA; RESPONSIVE UNITS; C-JUN	We demonstrate that dexamethasone-mediated transcription activation of the cytochrome P-450c27 promoter involves a physical interaction and functional synergy between glucocorticoid receptor (GR) and Ets2 factor. Ets2 protein binding to a "weak" Ets-like site of the promoter is dependent on Oh bound to the adjacent cryptic glucocorticoid response element. Coimmunoprecipitation and chemical cross-linking experiments show physical interaction between GR and Ets2 proteins. Mutational analyses show synergistic effects of Ets2 and GR in dexamethasone-mediated activation of the cytochrome P-450c27 promoter. The DNA-binding domain of GR, lacking the transcription activation and ligand-binding domains, was fully active in synergistic activation of the promoter with intact Ets2. The DNA-binding domain of Ets2 lacking the transcription activation domain showed a dominant negative effect on the transcription activity. Finally, a fusion protein consisting of the GR DNA-binding domain and the transcription activation domain of Ets2 fully supported the transcription activity, suggesting a novel synergy between the two proteins, which does not require the transactivation domain of GR. Our results also provide new insights on the role of putative weak consensus Ets sites in transcription activation, possibly through synergistic interaction with other gene-specific transcription activators.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA; Sci Applicat Int Corp, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Med Coll Penn & Hahnemann Univ, Ctr Canc, Program Canc Genet, Philadelphia, PA 19102 USA	University of Pennsylvania; University of Pennsylvania; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Drexel University	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St, Philadelphia, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA022762, R37CA022762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER; NCI NIH HHS [CA22762] Funding Source: Medline; NIGMS NIH HHS [GM34883] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anandatheerthavarada HK, 1998, BIOCHEMISTRY-US, V37, P1150, DOI 10.1021/bi972046j; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BJORKHEM I, 1992, J LIPID RES, V33, P455; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Carey M, 1998, CELL, V92, P5, DOI 10.1016/S0092-8674(00)80893-4; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; ESPINAS ML, 1995, MOL CELL BIOL, V15, P5346; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GRANGE T, 1989, NUCLEIC ACIDS RES, V17, P8695, DOI 10.1093/nar/17.21.8695; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lenka N, 1996, J BIOL CHEM, V271, P30281, DOI 10.1074/jbc.271.47.30281; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; MAYO KE, 1981, J BIOL CHEM, V256, P2621; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; MULLICK J, 1995, BIOCHEMISTRY-US, V34, P13729, DOI 10.1021/bi00042a003; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Pearce D, 1998, J BIOL CHEM, V273, P30081, DOI 10.1074/jbc.273.46.30081; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao YP, 1999, J STEROID BIOCHEM, V70, P1, DOI 10.1016/S0960-0760(99)00099-0; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; REDDY ESP, 1988, ONCOGENE RES, V3, P239; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHAYIQ RM, 1992, J BIOL CHEM, V267, P2421; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Sucharov C, 1995, GENE EXPRESSION, V5, P93; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, pG646, DOI 10.1152/ajpgi.1996.270.4.G646; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607	65	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18007	18017		10.1074/jbc.M100671200	http://dx.doi.org/10.1074/jbc.M100671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279115	hybrid			2022-12-25	WOS:000168866500053
J	Nasser, W; Schneider, R; Travers, A; Muskhelishvili, G				Nasser, W; Schneider, R; Travers, A; Muskhelishvili, G			CRP modulates fis transcription by alternate formation of activating and repressing nucleoprotein complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; STABLE RNA OPERONS; COLI HOST FACTOR; ESCHERICHIA-COLI; CYCLIC-AMP; DNA INVERSION; STRINGENT CONTROL; PROMOTER REGION; GROWTH; GENE	The DNA architectural proteins FIS and CRP are global regulators of transcription in Escherichia coli involved in the adjustment of cellular metabolism to varying growth conditions. We have previously demonstrated that FIS modulates the expression of the clp gene by functioning as its transcriptional repressor. Here we show that in turn, CRP is required to maintain the growth phase pattern of fis expression. We demonstrate the existence of a divergent promoter in the fis regulatory region, which reduces transcription of the fis promoter. In the absence of FIS, CRP activates fis transcription, thereby displacing the polymerase from the divergent promoter, whereas together FIS and CRP synergistically repress fis gene expression. These results provide evidence for a direct cross-talk between global regulators of cellular transcription during the growth phase. This cross-talk is manifested in alternate formation of functional nucleoprotein complexes exerting either activating or repressing effects on transcription.	Univ Munich, Inst Genet & Mikrobiol, D-80638 Munich, Germany; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Munich; MRC Laboratory Molecular Biology	Muskhelishvili, G (corresponding author), Max Planck Inst Terr Microbiol, Karl von Frisch Str, D-35043 Marburg, Germany.		NASSER, William/C-9611-2019	NASSER, William/0000-0001-9848-3597				AIBA H, 1983, CELL, V32, P141, DOI 10.1016/0092-8674(83)90504-4; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; Browning DF, 2000, MOL MICROBIOL, V37, P1258, DOI 10.1046/j.1365-2958.2000.02087.x; Buettner M. J., 1973, J BACTERIOL, V14, P1068; Caramel A, 2000, MOL MICROBIOL, V36, P85, DOI 10.1046/j.1365-2958.2000.01827.x; CASHEL M, 1996, STRINGENT RESPONSE E, P1458; Claret L, 1996, J MOL BIOL, V263, P126, DOI 10.1006/jmbi.1996.0564; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; Deufel A, 1997, NUCLEIC ACIDS RES, V25, P3832, DOI 10.1093/nar/25.19.3832; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; DUMITRU I, 1994, NUCLEIC ACIDS RES, V22, P1450; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; Froelich JM, 1996, J BACTERIOL, V178, P6006, DOI 10.1128/jb.178.20.6006-6012.1996; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; GomezGomez JM, 1996, J BACTERIOL, V178, P3331, DOI 10.1128/jb.178.11.3331-3334.1996; Gonzalez-Gil G, 1998, EMBO J, V17, P2877, DOI 10.1093/emboj/17.10.2877; GonzalezGil G, 1996, MOL MICROBIOL, V22, P21, DOI 10.1111/j.1365-2958.1996.tb02652.x; HANAMURA A, 1991, NUCLEIC ACIDS RES, V19, P4413, DOI 10.1093/nar/19.16.4413; Ishihama A, 1999, GENES CELLS, V4, P135, DOI 10.1046/j.1365-2443.1999.00247.x; ISHIZUKA H, 1993, MOL MICROBIOL, V10, P341, DOI 10.1111/j.1365-2958.1993.tb01960.x; KOCH C, 1986, J BIOL CHEM, V261, P5673; KOCH C, 1988, P NATL ACAD SCI USA, V85, P4237, DOI 10.1073/pnas.85.12.4237; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LAZARUS LR, 1993, EMBO J, V12, P2483, DOI 10.1002/j.1460-2075.1993.tb05903.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; McLeod SM, 2000, J BACTERIOL, V182, P4180, DOI 10.1128/JB.182.15.4180-4187.2000; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Miller J.H., 1972, EXPT MOL GENETICS; MUSKHELISHVILI G, 1995, EMBO J, V14, P1446, DOI 10.1002/j.1460-2075.1995.tb07131.x; NILSSON L, 1990, EMBO J, V9, P727, DOI 10.1002/j.1460-2075.1990.tb08166.x; NILSSON L, 1992, J BACTERIOL, V174, P921, DOI 10.1128/jb.174.3.921-929.1992; NINNEMANN O, 1992, EMBO J, V11, P1075, DOI 10.1002/j.1460-2075.1992.tb05146.x; OSUNA R, 1995, J BACTERIOL, V177, P2021, DOI 10.1128/jb.177.8.2021-2032.1995; Pemberton IK, 2000, J MOL BIOL, V299, P859, DOI 10.1006/jmbi.2000.3780; Pratt TS, 1997, J BACTERIOL, V179, P6367, DOI 10.1128/jb.179.20.6367-6377.1997; Richet E, 2000, EMBO J, V19, P5222, DOI 10.1093/emboj/19.19.5222; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; SADLER JR, 1965, J MOL BIOL, V12, P305, DOI 10.1016/S0022-2836(65)80255-8; Schneider R, 1999, MOL MICROBIOL, V34, P953, DOI 10.1046/j.1365-2958.1999.01656.x; Schneider R, 1997, MOL MICROBIOL, V26, P519, DOI 10.1046/j.1365-2958.1997.5951971.x; Schneider R, 2000, MOL MICROBIOL, V38, P167, DOI 10.1046/j.1365-2958.2000.02129.x; Travers A, 1998, J MOL BIOL, V279, P1027, DOI 10.1006/jmbi.1998.1834; ULLMANN A, 1983, ADV CYCL NUCL RES<D>, V15, P1; VANET A, 1993, J BACTERIOL, V175, P7178, DOI 10.1128/JB.175.22.7178-7188.1993; Walker KA, 1999, J BACTERIOL, V181, P1269, DOI 10.1128/JB.181.4.1269-1280.1999; XU JM, 1995, J BACTERIOL, V177, P938, DOI 10.1128/jb.177.4.938-947.1995; XU JM, 1995, J BACTERIOL, V177, P3166, DOI 10.1128/jb.177.11.3166-3175.1995; ZHANG X, 1996, J MOL BIOL, V259, P276	50	51	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17878	17886		10.1074/jbc.M100632200	http://dx.doi.org/10.1074/jbc.M100632200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279109	hybrid			2022-12-25	WOS:000168866500037
J	Beylot, B; Spassky, A				Beylot, B; Spassky, A			Chemical probing shows that the intron-encoded endonuclease I-SceI distorts DNA through binding in monomeric form to its homing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ESCHERICHIA-COLI; RNA-POLYMERASE; 1,10-PHENANTHROLINE-COPPER ION; DEOXYRIBONUCLEASE ACTIVITY; SEQUENCE SPECIFICITY; CRYSTAL-STRUCTURE; NUCLEASE ACTIVITY; MOLECULAR-WEIGHT; PROTEIN	Despite its small size (27.6 kDa), the group I intron-encoded I-SceI endonuclease initiates intron homing by recognizing and specifically cleaving a large intronless DNA sequence. Here, we used gel shift assays and footprinting experiments to analyze the interaction between I-SceI and its target. I-SceI was found to bind to its substrate in monomeric form. Footprinting using DNase I, hydroxyl radical, phenanthroline copper complexes, UV/DH-MePyPs photosensitizer, and base-modifying reagents revealed the asymmetric nature of the interaction and provided a first glimpse into the architecture of the complex. The protein interacts in the minor and major grooves and distorts DNA at three distinct sites: one at the intron insertion site and the other two, respectively, downstream (-8, -9) and upstream (+9, +10) from this site. The protein appears to stabilize the DNA curved around it by bridging the minor groove on one face of the helix. The scissile phosphates would lie on the outside of the bend, facing in the same direction relative to the DNA helical axis, as expected for an endonuclease that generates 3' overhangs. An internally consistent model is proposed in which the protein would take advantage of the concerted flexibility of the DNA sequence to induce a synergistic binding/kinking process, resulting in the correct positioning of the enzyme active site.	Inst Gustave Roussy, Lab Pharmacol Macromol Biol, F-94805 Villejuif, France	UNICANCER; Gustave Roussy	Spassky, A (corresponding author), Inst Gustave Roussy, Lab Pharmacol Macromol Biol, Rue Camille Desmoulins, F-94805 Villejuif, France.							BADING H, 1988, NUCLEIC ACIDS RES, V16, P5241, DOI 10.1093/nar/16.12.5241; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BURKHOFF AM, 1988, NATURE, V331, P455, DOI 10.1038/331455a0; COLLEAUX L, 1986, CELL, V44, P521, DOI 10.1016/0092-8674(86)90262-X; COLLEAUX L, 1988, P NATL ACAD SCI USA, V85, P6022, DOI 10.1073/pnas.85.16.6022; DEMARET JP, 1989, PHOTOCHEM PHOTOBIOL, V50, P7, DOI 10.1111/j.1751-1097.1989.tb04124.x; DESANTIS P, 1990, BIOCHEMISTRY-US, V29, P9269, DOI 10.1021/bi00491a023; DOETSCH PW, 1985, NUCLEIC ACIDS RES, V13, P3285, DOI 10.1093/nar/13.9.3285; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; DUJON B, 1985, ACHIEVEMENTS PERSPEC, V2, P215; FERGUSON KA, 1964, METABOLISM, V13, P985, DOI 10.1016/S0026-0495(64)80018-4; Flick KE, 1998, NATURE, V394, P96, DOI 10.1038/27952; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3037; GUILLO LA, 1995, PHOTOCHEM PHOTOBIOL, V61, P331, DOI 10.1111/j.1751-1097.1995.tb08617.x; Guillo LA, 1996, PHOTOCHEM PHOTOBIOL, V64, P349, DOI 10.1111/j.1751-1097.1996.tb02470.x; Heath PJ, 1997, NAT STRUCT BIOL, V4, P468, DOI 10.1038/nsb0697-468; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LykkeAndersen J, 1997, EMBO J, V16, P3272, DOI 10.1093/emboj/16.11.3272; MCCARTHY JG, 1990, BIOCHEMISTRY-US, V29, P6071, DOI 10.1021/bi00477a027; MONTEILHET C, 1990, NUCLEIC ACIDS RES, V18, P1407, DOI 10.1093/nar/18.6.1407; MUELLER JE, 1995, EMBO J, V14, P5724, DOI 10.1002/j.1460-2075.1995.tb00259.x; MUELLER JE, 1993, NUCLEASES, P111; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; Nielsen P E, 1990, J Mol Recognit, V3, P1, DOI 10.1002/jmr.300030102; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; PERRIN A, 1993, EMBO J, V12, P2939, DOI 10.1002/j.1460-2075.1993.tb05956.x; PHILLIPS SEV, 1994, ANNU REV BIOPH BIOM, V23, P671, DOI 10.1146/annurev.bb.23.060194.003323; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1123; SANDERS CM, 1994, NUCLEIC ACIDS RES, V22, P4890, DOI 10.1093/nar/22.23.4890; Schaeffer F, 1996, J MOL BIOL, V260, P523, DOI 10.1006/jmbi.1996.0419; SIGMAN DS, 1989, NUCLEIC ACIDS MOL BI, V3, P13; SIGMAN DS, 1990, BIOCHEMISTRY-US, V29, P9098; Silva GH, 1999, J MOL BIOL, V286, P1123, DOI 10.1006/jmbi.1998.2519; SPASSKY A, 1985, BIOCHEMISTRY-US, V24, P8050, DOI 10.1021/bi00348a032; Spassky A, 1997, BIOCHEMISTRY-US, V36, P6571, DOI 10.1021/bi962761d; SPASSKY A, 1984, EMBO J, V3, P43, DOI 10.1002/j.1460-2075.1984.tb01759.x; SPASSKY A, 1992, BIOCHEMISTRY-US, V31, P10502, DOI 10.1021/bi00158a013; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; THEDERAHN T, 1990, BIOCHEM BIOPH RES CO, V168, P756, DOI 10.1016/0006-291X(90)92386-E; THIERRY A, 1991, NUCLEIC ACIDS RES, V19, P189, DOI 10.1093/nar/19.1.189; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5489; WANG SQ, 1995, BIOCHEMISTRY-US, V34, P13082, DOI 10.1021/bi00040a020; Werner MH, 1996, SCIENCE, V271, P778, DOI 10.1126/science.271.5250.778; WITHERS BE, 1995, NUCLEIC ACIDS RES, V23, P3571, DOI 10.1093/nar/23.17.3571; YANG CC, 1989, CELL, V57, P869, DOI 10.1016/0092-8674(89)90801-5; YOON C, 1990, BIOCHEMISTRY-US, V29, P2116, DOI 10.1021/bi00460a022; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739	52	16	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25243	25253		10.1074/jbc.M101200200	http://dx.doi.org/10.1074/jbc.M101200200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11279183	hybrid			2022-12-25	WOS:000169800700109
J	Khare, V; Eckert, KA				Khare, V; Eckert, KA			The 3 '-> 5 ' exonuclease of T4 DNA polymerase removes premutagenic alkyl mispairs and contributes to futile cycling at O-6-methylguanine lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLATING AGENTS; KLENOW FRAGMENT; MISMATCH REPAIR; REPLICATION; DUPLEX; TOLERANCE; DAMAGE; BACTERIOPHAGE-T4; RESISTANCE; DEFECTS	We have studied the processing of O-6-methylguanine (m6G)-containing oligonucleotides and N-methyl-N-nitrosourea (MNU)-treated DNA templates by the 3' --> 5' exonuclease of T4 DNA polymerase. In vitro biochemical analyses demonstrate that the exonuclease can remove bases opposite a defined m6G lesion. The efficiency of excision of a terminal m6G .T was similar to that of m6G .C, and both mere excised as efficiently as a GT substrate. Partitioning assays between the polymerase and exonuclease activities, performed in the presence of dNTPs, resulted in repeated incorporation and excision events opposite the m6G lesion. This idling produces dramatically less full-length product, relative to natural substrates, indicating that the 3' --> 5' exonuclease may contribute to DNA synthesis inhibition by alkylating agents. Genetic data obtained using an in vitro herpes simplex virus-thymidine kinase assay support the inefficiency of the exonuclease as a "proofreading" activity for m6G, since virtually all mutations produced by the native enzyme using MNU-treated templates were G --> A transitions. Comparison of MNU dose-response curves for exonuclease-proficient and -deficient forms of T4 polymerase reveals that the exonuclease efficiently removes 50-86% of total premutagenic alkyl mispairs. We propose that idling of exonuclease-proficient polymerases at m6G lesions during repair DNA synthesis provides the biochemical explanation for cellular cytotoxicity of methylating agents.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pathol,Gittlen Canc Res Inst, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Eckert, KA (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pathol,Gittlen Canc Res Inst, 500 Univ Dr, Hershey, PA 17033 USA.							Baker RP, 1998, P NATL ACAD SCI USA, V95, P3507, DOI 10.1073/pnas.95.7.3507; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CECCOTTI S, 1993, BIOCHEMISTRY-US, V32, P13644; Eckert KA, 1997, NUCLEIC ACIDS RES, V25, P1450, DOI 10.1093/nar/25.7.1450; Eckert KA, 1998, MUTAT RES-FUND MOL M, V422, P255, DOI 10.1016/S0027-5107(98)00206-1; Elisseeva E, 1999, J BIOL CHEM, V274, P25151, DOI 10.1074/jbc.274.35.25151; GINELL SL, 1990, BIOCHEMISTRY-US, V29, P10461, DOI 10.1021/bi00498a005; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Haracska L, 2000, MOL CELL BIOL, V20, P8001, DOI 10.1128/MCB.20.21.8001-8007.2000; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KARRAN P, 1993, J BIOL CHEM, V268, P15878; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LEONARD GA, 1990, P NATL ACAD SCI USA, V87, P9573, DOI 10.1073/pnas.87.24.9573; Morales JC, 2000, BIOCHEMISTRY-US, V39, P2626, DOI 10.1021/bi992173a; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1036, DOI 10.1021/bi00353a013; REBAKRANTZ LJ, 1998, J BIOL CHEM, V273, P22969; RehaKrantz LJ, 1996, J BIOL CHEM, V271, P20088, DOI 10.1074/jbc.271.33.20088; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; Sattar AKMA, 1996, BIOCHEMISTRY-US, V35, P16621, DOI 10.1021/bi961552q; SINGER B, 1983, MOL BIOL MUTAGENS CA, P67; SNOW ET, 1984, J BIOL CHEM, V259, P8095; SWANN PF, 1990, MUTAT RES, V233, P81, DOI 10.1016/0027-5107(90)90153-U; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; VOIGT JM, 1990, BIOCHEMISTRY-US, V29, P5012, DOI 10.1021/bi00473a003; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	32	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24286	24292		10.1074/jbc.M011025200	http://dx.doi.org/10.1074/jbc.M011025200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11290737	hybrid			2022-12-25	WOS:000169531100139
J	Kraev, A; Quednau, BD; Leach, S; Li, XF; Dong, H; Winkfein, R; Perizzolo, M; Cai, XJ; Yang, RM; Philipson, KD; Lytton, J				Kraev, A; Quednau, BD; Leach, S; Li, XF; Dong, H; Winkfein, R; Perizzolo, M; Cai, XJ; Yang, RM; Philipson, KD; Lytton, J			Molecular cloning of a third member of the potassium-dependent sodium-calcium exchanger gene family, NCKX3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; NA-CA EXCHANGER; NA+/CA2+ EXCHANGER; NA+-CA2+ EXCHANGER; FUNCTIONAL EXPRESSION; CDNA CLONING; K EXCHANGER; NCX1; ISOFORMS; BRAIN	We describe here the identification and characterization of a novel member of the family of K+-dependent Na+/Ca2+ exchangers, NCKX3 (gene SLC24A3). Human NCKX3 encodes a protein of 644 amino acids that displayed a high level of sequence identity to the other family members, rod NCKX1 and cone/neuronal NCKX2, in the hydrophobic regions surrounding the "alpha -repeat" sequences thought to form the ion binding pocket far transport. Outside of these regions NCKX3 showed no significant identity to other known proteins. As anticipated from this sequence similarity, NCKX3 displayed K+-dependent Na+/Ca2+ exchanger activity when assayed in heterologous expression systems, using digital imaging of fura-2 fluorescence, electrophysiology, or radioactive Ca-45(2+) uptake. The N-terminal region of NCKX3, although not essential for expression, increased functional activity at least 10-fold and may represent a cleavable signal sequence. NCKX3 transcripts were most abundant in brain, with highest levels found in selected thalamic nuclei, in hippocampal CA1 neurons, and in layer IV of the cerebral cortex. Many other tissues also expressed NCKX3 at lower levels, especially aorta, uterus, and intestine, which are rich in smooth muscle. The discovery of NCKX3 thus expands the K+-dependent Na+/Ca2+ exchanger family and suggests this class of transporter has a more widespread role in cellular Ca2+ handling than previously appreciated.	Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Cardiovasc Res Labs, Los Angeles, CA 90095 USA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lytton, J (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	jlytton@ucalgary.ca	Cai, Xinjiang/F-4843-2010; Cai, Xinjiang/A-9617-2008	Cai, Xinjiang/0000-0001-8933-7133; Lytton, Jonathan/0000-0003-4770-2512	NHLBI NIH HHS [HL48509] Funding Source: Medline; PHS HHS [L4901] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048509, R37HL048509] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F. M., 2001, CURRENT PROTOCOLS MO; Barnes KV, 1997, J BIOL CHEM, V272, P11510, DOI 10.1074/jbc.272.17.11550; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; CERVETTO L, 1989, NATURE, V337, P740, DOI 10.1038/337740a0; Cooper CB, 1999, BIOCHEMISTRY-US, V38, P6276, DOI 10.1021/bi983068o; DAHAN D, 1991, J BIOL CHEM, V266, P2067; Dyck C, 1999, J GEN PHYSIOL, V114, P701, DOI 10.1085/jgp.114.5.701; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; FURMAN I, 1995, J BIOL CHEM, V270, P19120, DOI 10.1074/jbc.270.32.19120; Haug-Collet K, 1999, J CELL BIOL, V147, P659, DOI 10.1083/jcb.147.3.659; Iwamoto T, 2000, J BIOL CHEM, V275, P38571, DOI 10.1074/jbc.M003788200; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Iwamoto T, 1998, AM J PHYSIOL-CELL PH, V275, pC423, DOI 10.1152/ajpcell.1998.275.2.C423; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; KIMURA M, 1993, J BIOL CHEM, V268, P6874; Kimura M, 1999, AM J PHYSIOL-HEART C, V277, pH911, DOI 10.1152/ajpheart.1999.277.3.H911; KOFUJI P, 1992, AM J PHYSIOL, V263, pC1241, DOI 10.1152/ajpcell.1992.263.6.C1241; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kraev A, 1996, GENOMICS, V37, P105, DOI 10.1006/geno.1996.0526; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEE SL, 1994, J BIOL CHEM, V269, P14849; Li XF, 1999, J BIOL CHEM, V274, P8153, DOI 10.1074/jbc.274.12.8153; LI ZP, 1994, J BIOL CHEM, V269, P17434; Linck B, 1998, AM J PHYSIOL-CELL PH, V274, pC415, DOI 10.1152/ajpcell.1998.274.2.C415; LOO TW, 1995, J BIOL CHEM, V270, P19345, DOI 10.1074/jbc.270.33.19345; MARLIER LNJL, 1993, MOL BRAIN RES, V20, P21, DOI 10.1016/0169-328X(93)90107-Z; Nicholas SB, 1998, AM J PHYSIOL-HEART C, V274, pH217, DOI 10.1152/ajpheart.1998.274.1.H217; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; Nicoll DA, 1996, J BIOL CHEM, V271, P24914, DOI 10.1074/jbc.271.40.24914; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Poon S, 2000, AM J PHYSIOL-CELL PH, V278, pC651, DOI 10.1152/ajpcell.2000.278.4.C651; Prinsen CFM, 2000, J NEUROSCI, V20, P1424; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; QUI Z, 2001, J BIOL CHEM, V276, P194; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scheller T, 1998, J BIOL CHEM, V273, P7643, DOI 10.1074/jbc.273.13.7643; SCHNETKAMP PPM, 1991, J BIOL CHEM, V266, P22975; SCHNETKAMP PPM, 1989, AM J PHYSIOL, V257, pC153, DOI 10.1152/ajpcell.1989.257.1.C153; SCHNETKAMP PPM, 1995, CELL CALCIUM, V18, P322, DOI 10.1016/0143-4160(95)90028-4; Schwarz EM, 1997, P NATL ACAD SCI USA, V94, P10249, DOI 10.1073/pnas.94.19.10249; Szerencsei RT, 2000, J BIOL CHEM, V275, P669, DOI 10.1074/jbc.275.1.669; Tashiro M, 2000, PFLUG ARCH EUR J PHY, V440, P819, DOI 10.1007/s004240000384; Tsoi M, 1998, J BIOL CHEM, V273, P4155, DOI 10.1074/jbc.273.7.4155; Tucker JE, 1998, HUM GENET, V103, P411, DOI 10.1007/s004390050842; Tucker JE, 1998, INVEST OPHTH VIS SCI, V39, P435; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333	54	84	88	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23161	23172		10.1074/jbc.M102314200	http://dx.doi.org/10.1074/jbc.M102314200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294880	hybrid			2022-12-25	WOS:000169412700157
J	Zambrano, N; Bruni, P; Minopoli, G; Mosca, R; Molino, D; Russo, C; Schettini, G; Sudol, M; Russo, T				Zambrano, N; Bruni, P; Minopoli, G; Mosca, R; Molino, D; Russo, C; Schettini, G; Sudol, M; Russo, T			The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells expressing a constitutively active form of the Abl protoncogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; PROLINE-RICH MOTIFS; KINASE C-ABL; SIGNAL-TRANSDUCTION; ALZHEIMERS-DISEASE; APOPTOTIC RESPONSE; CYTOPLASMIC DOMAIN; FE65 PROTEIN; DNA-DAMAGE; SUBSTRATE	The cytosolic domain of the beta -amyloid precursor protein APP interacts with three PTB (phosphotyrosine binding domain) containing adaptor proteins, Fe65, X11, and mDab1, Through these adaptors, other molecules can be recruited at the cytodomain of APP; one of them is Mena, that binds to the WW domain (a protein module with two conserved tryptophans) of Fe65, The enabled and disabled genes of Drosophila, homologues of the mammalian Mena and mDab1 genes, respectively, are genetic modulators of the phenotype observed in flies null for the Abl tyrosine kinase gene. The involve ment of Mena and mDab1 in the APP-centered protein-protein interaction network suggests the possibility that Abl plays a role in APP biology, We show that Fe65, through its WW domain, binds in vitro and in vivo the active form of Abl, Furthermore, in cells expressing the active form of Abl, APP is tyrosine-phosphorylated, Phosphopeptide analysis and site-directed mutagenesis support the hypothesis that Tyr(682) Of APP(695) is the target of this phosphorylation. Co-immunoprecipitation experiments demonstrate that active Abl and tyrosine-phosphorylated APP also form a stable complex, which could result from the interaction of the pYENP motif of the APP cytodomain with the SH2 domain of Abl, These results suggest that Abl, Mena, and mDabl are involved in a common molecular machinery and that APP can play a role in tyrosine kinase-mediated signaling.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Genoa, Dept Oncol Biol & Genet, Pharmacol Sect, I-16132 Genoa, Italy; IST, Serv Pharmacol & Neurosci, I-16132 Genoa, Italy; CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA	University of Naples Federico II; University of Genoa; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	russot@dbbm.unina.it	Russo, Claudio/AIA-1429-2022; Zambrano, Nicola/B-9352-2014; Russo, Tommaso/K-1331-2016	Zambrano, Nicola/0000-0001-9395-3481; Russo, Tommaso/0000-0003-4426-0106; russo, claudio/0000-0002-2520-2958				Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Bothwell M, 2000, CELL, V102, P271, DOI 10.1016/S0092-8674(00)00032-5; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cortes JE, 1996, AM J MED, V100, P555, DOI 10.1016/S0002-9343(96)00061-7; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1990, SCIENCE, V248, P857, DOI 10.1126/science.2188361; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gong JG, 1999, NATURE, V399, P806; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; McLoughlin DM, 1996, FEBS LETT, V397, P197; MIAO YJ, 1996, J BIOL CHEM, V272, P8905; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; PONZIAK C, 2000, SCIENCE, V289, P304; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shaul Y, 2000, CELL DEATH DIFFER, V7, P10, DOI 10.1038/sj.cdd.4400626; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Suzuki T, 1997, BIOCHEMISTRY-US, V36, P4643, DOI 10.1021/bi962618k; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Van Etten RA, 1999, TRENDS CELL BIOL, V9, P179, DOI 10.1016/S0962-8924(99)01549-4; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	109	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19787	19792		10.1074/jbc.M100792200	http://dx.doi.org/10.1074/jbc.M100792200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279131	hybrid			2022-12-25	WOS:000169135100016
J	Howard, PW; Maurer, RA				Howard, PW; Maurer, RA			A point mutation in the LIM domain of Lhx3 reduces activation of the glycoprotein hormone alpha-subunit promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN TRANSCRIPTION FACTOR; DIFFERENTIAL ACTIVATION; PROTEIN INTERACTIONS; BINDING-PROTEIN; PITUITARY; GENE; EXPRESSION; PATHWAY; CELLS; LDB1	Lhx3, a member of the LIM homeodomain family of transcription factors, is required for development of the pituitary in mice. A recent report has described a point mutation in the human LHX3 gene that is associated with a combined pituitary hormone disorder. The mutation is predicted to lead to the replacement of a tyrosine residue with a cysteine in the second LIM domain of LHX3, We have characterized the effects of this point mutation (Y114C) when analyzed in the context of the mouse Lhx3 coding sequence. Mobility shift assays demonstrated that the Lhx3 Y114C mutant is capable of binding DNA, although a decrease in the formation of a specific complex was observed. Transfection assays using an expression vector for either full-length Lhx3 or a GAL4-Lhx3 LIM domain fusion provided evidence that the Lhx3 Y114C mutant has a decreased ability to stimulate transcription. In particular, a GAL4-Lhx3 Y114C LIM mutant was unable to support Ras responsiveness of a modified glycoprotein hormone cu-subunit reporter gene. Protein interaction studies suggest that the Y114C mutation may modestly reduce binding to the POU transcription factor, Pit-1. Interestingly, the Y114C mutation essentially abrogated binding to the putative co-activator/adapter, selective LIM-binding protein. The findings provide insights into the mechanisms mediating transcriptional activation by Lhx3 and suggest that the observed phenotype of the human mutation probably involves reduced transcriptional activity of the mutant LHX3.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Maurer, RA (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036407, R01DK040339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40339, DK36407] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; BACH I, 1995, P NATL ACAD SCI USA, V92, P2720, DOI 10.1073/pnas.92.7.2720; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Breen JJ, 1998, J BIOL CHEM, V273, P4712, DOI 10.1074/jbc.273.8.4712; Dawid IB, 1998, TRENDS GENET, V14, P480, DOI 10.1016/S0168-9525(98)01615-1; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Girardin SE, 1998, FEBS LETT, V431, P333, DOI 10.1016/S0014-5793(98)00787-X; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; Howard PW, 2000, J BIOL CHEM, V275, P13336, DOI 10.1074/jbc.275.18.13336; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; Jurata LW, 1998, CURR TOP MICROBIOL, V228, P75; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Jurata LW, 1997, MOL CELL BIOL, V17, P5688, DOI 10.1128/MCB.17.10.5688; Meier BC, 1999, MOL CELL ENDOCRINOL, V147, P65, DOI 10.1016/S0303-7207(98)00213-5; Milan M, 1999, MOL CELL, V4, P267, DOI 10.1016/S1097-2765(00)80374-3; MORCILLO P, 1997, GENE DEV, V11, P2720; Netchine I, 2000, NAT GENET, V25, P182, DOI 10.1038/76041; PerezAlvarado GC, 1996, J MOL BIOL, V257, P153, DOI 10.1006/jmbi.1996.0153; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SCHODERBEK WE, 1993, J BIOL CHEM, V268, P3903; SEIDAH NG, 1994, DNA CELL BIOL, V13, P1163, DOI 10.1089/dna.1994.13.1163; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheng HZ, 1997, SCIENCE, V278, P1809, DOI 10.1126/science.278.5344.1809; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; Sloop KW, 1999, MOL ENDOCRINOL, V13, P2212, DOI 10.1210/me.13.12.2212; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; van Meyel DJ, 1999, MOL CELL, V4, P259, DOI 10.1016/S1097-2765(00)80373-1; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597	34	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19020	19026		10.1074/jbc.M101782200	http://dx.doi.org/10.1074/jbc.M101782200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279219	hybrid			2022-12-25	WOS:000169091000051
J	Koc, EC; Burkhart, W; Blackburn, K; Moseley, A; Spremulli, LL				Koc, EC; Burkhart, W; Blackburn, K; Moseley, A; Spremulli, LL			The small subunit of the mammalian mitochondrial ribosome - Identification of the full complement of ribosomal proteins present	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRESPONDING GENE-SEQUENCES; INDUCED CELL-DEATH; NUCLEAR GENES; MASS-SPECTROMETRY; YEAST; CHLOROPLAST; MRPS; DAP3; S12; RNA	Identification of all the protein components of the small subunit (28 S) of the mammalian mitochondrial ribosome has been achieved by carrying out proteolytic digestions of whole 28 S subunits followed by analysis of the resultant peptides by liquid chromatography and tandem mass spectrometry (LC/MS/MS). Peptide sequence information was used to search the human EST data bases and complete coding sequences of the proteins were assembled. The human mitochondrial ribosome has 29 distinct proteins in the small subunit, Fourteen of this group of proteins are homologs of the Escherichia coli 30 S ribosomal proteins S2, S5, S6, S7, S9, S10, S11, S12, S14, S15, S16, S17, S18, and S21, All of these proteins have homologs in Drosophila melanogaster, Caenorhabditis elegans, and Saccharomyces cerevisiae mitochondrial ribosomes, Surprisingly, three variants of ribosomal protein S18 are found in the mammalian and D. melanogaster mitochondrial ribosomes while C. elegans has two S18 homologs. The S18 homologs tend to be more closely related to chloroplast S18s than to prokaryotic S18s. No mitochondrial homologs to prokaryotic ribosomal proteins S1, S3, S4, S8, S13, S19, and S20 could be found in the peptides obtained from the whole 28 S subunit digests or by analysis of the available data bases. The remaining 15 proteins present in mammalian mitochondrial 28 S subunits (MRP-S22 through MRP-S36) are specific to mitochondrial ribosomes, Proteins in this group have no apparent homologs in bacterial, chloroplast, archaebacterial, or cytosolic ribosomes, All but two of these proteins have a clear homolog in D. melanogaster while all but three can be found in the genome of C. elegans. Five of the mitochondrial. specific ribosomal proteins have homologs in S. cerevisiae.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; GlaxoSmithKline Res & Dev, Dept Struct Chem, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline	Spremulli, LL (corresponding author), Univ N Carolina, Dept Chem, Campus Box 3290, Chapel Hill, NC 27599 USA.				NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard P, 2000, STRUCT FOLD DES, V8, P875, DOI 10.1016/S0969-2126(00)00177-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arden SD, 1996, J CLIN INVEST, V97, P551, DOI 10.1172/JCI118448; BEHAL RH, 1994, J BIOL CHEM, V269, P31372; BURKHART W, 1992, TECHNIQUES PROTEIN C, V4, P399; CAHILL A, 1995, ANAL BIOCHEM, V232, P47, DOI 10.1006/abio.1995.9962; CLAROS MG, 1996, EUR J BIOCHEM, V241, P770, DOI DOI 10.1111/J.1432-1033.1996.00779.X; DEVRIES H, 1973, BIOCHEM BIOPH RES CO, V54, P308, DOI 10.1016/0006-291X(73)90924-8; FEARON K, 1992, J BIOL CHEM, V267, P5162; *GEN COMP GROUP, 1999, WISC PACK VERS 10; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1998, BIOCHEM J, V329, P433, DOI 10.1042/bj3290433; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Jiang XY, 1996, J MASS SPECTROM, V31, P1309, DOI 10.1002/(SICI)1096-9888(199611)31:11<1309::AID-JMS423>3.0.CO;2-R; KANG C, 1979, J BIOL CHEM, V254, P6667; KISSIL JL, 1995, J BIOL CHEM, V270, P27932, DOI 10.1074/jbc.270.46.27932; Kissil JL, 1999, EMBO J, V18, P353, DOI 10.1093/emboj/18.2.353; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; Koc EC, 2001, FEBS LETT, V492, P166, DOI 10.1016/S0014-5793(01)02250-5; Koc EC, 2001, PROTEIN SCI, V10, P471, DOI 10.1110/ps.35301; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Mariottini P, 1999, J BIOL CHEM, V274, P31853, DOI 10.1074/jbc.274.45.31853; MATSUSHITA Y, 1989, MOL GEN GENET, V219, P119, DOI 10.1007/BF00261166; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN TW, 1976, GENETICS BIOGENESIS, P741; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PEL HJ, 1994, MOL BIOL REP, V19, P183, DOI 10.1007/BF00986960; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PIETROMONACO SF, 1991, BIOCHIMIE, V73, P827, DOI 10.1016/0300-9084(91)90062-6; RAMAKRISHNAN V, 1986, J BIOL CHEM, V261, P5049; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Shah ZH, 1997, GENE, V204, P55, DOI 10.1016/S0378-1119(97)00521-0; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tong W, 1999, ANAL CHEM, V71, P2270, DOI 10.1021/ac9901182; VANACKEN U, 1975, MOL GEN GENET, V140, P61, DOI 10.1007/BF00268989; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yamaguchi K, 2000, J BIOL CHEM, V275, P28455, DOI 10.1074/jbc.M004350200; Yamaguchi K, 2000, J BIOL CHEM, V275, P28466, DOI 10.1074/jbc.M005012200; ZWEIB C, 1981, NUCLEIC ACIDS RES, V9, P3621	44	180	228	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19363	19374		10.1074/jbc.M100727200	http://dx.doi.org/10.1074/jbc.M100727200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279123	Green Submitted			2022-12-25	WOS:000169091000097
J	Ghosh, D; Sawicki, M; Pletnev, V; Erman, M; Ohno, S; Nakajin, S; Duax, WL				Ghosh, D; Sawicki, M; Pletnev, V; Erman, M; Ohno, S; Nakajin, S; Duax, WL			Porcine carbonyl reductase - Structural basis for a functional monomer in short chain dehydrogenases/reductases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEONATAL PIG TESTIS; HUMAN 17-BETA-HYDROXYSTEROID-DEHYDROGENASE TYPE-1; X-RAY-DIFFRACTION; 20-BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURE; 3-ALPHA,20-BETA-HYDROXYSTEROID DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE; DROSOPHILA-LEBANONENSIS; 3-DIMENSIONAL STRUCTURE; ALCOHOL-DEHYDROGENASE	Porcine testicular carbonyl reductase (PTCR) belongs to the short chain dehydrogenases/reductases (SDR) superfamily and catalyzes the NADPH-dependent reduction of ketones on steroids and prostaglandins. The enzyme shares nearly 85% sequence identity with the NADPH-dependent human 15-hydroxyprostaglandin dehydrogenase/carbonyl reductase. The tertiary structure of the enzyme at 2.3 Angstrom reveals a fold characteristic of the SDR superfamily that uses a Tyr-Lys-Ser triad as catalytic residues, but exhibits neither the functional homotetramer nor the homodimer that distinguish all SDRs. It is the first known monomeric structure in the SDR superfamily. In PTCR, which is also active as a monomer, a 41-residue insertion immediately before the catalytic Tyr describes an ah-helix subdomain that packs against interfacial helices, eliminating the four-helix bundle interface conserved in the superfamily, An additional anti-parallel strand in the PTCR structure also blocks the other strand-mediated interface. These novel structural features provide the basis for the scaffolding of one catalytic site within a single molecule of the enzyme.	Hauptman Woodward Med Res Inst, Dept Biol Struct, Buffalo, NY 14203 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA; Nihon Univ, Fac Pharmaceut Sci, Dept Clin Pharmaceut, Chiba 2748555, Japan; Hoshi Univ, Fac Pharmaceut Sci, Dept Biochem, Shinagawa Ku, Tokyo 1428501, Japan	Hauptman Woodward Medical Research Institute; Roswell Park Cancer Institute; Nihon University; Hoshi University	Ghosh, D (corresponding author), Hauptman Woodward Med Res Inst, Dept Biol Struct, 73 High St, Buffalo, NY 14203 USA.	ghosh@hwi.buffalo.edu	Pletnev, Vladimir/Q-6151-2016		NIDDK NIH HHS [DK26546] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026546, R01DK026546] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benach J, 1998, J MOL BIOL, V282, P383, DOI 10.1006/jmbi.1998.2015; BRUNGER A, 1992, T X PLOR USERS GUIDE; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GHOSH D, 1994, STRUCTURE, V2, P973, DOI 10.1016/S0969-2126(94)00099-9; GHOSH D, 1993, J STEROID BIOCHEM, V46, P103, DOI 10.1016/0960-0760(93)90214-H; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1994, STRUCTURE, V2, P629, DOI 10.1016/S0969-2126(00)00064-2; Ghosh D, 2001, CHEM-BIOL INTERACT, V130, P637, DOI 10.1016/S0009-2797(00)00255-6; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Grimm C, 2000, J BIOL CHEM, V275, P41333, DOI 10.1074/jbc.M007559200; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KROOK M, 1993, P NATL ACAD SCI USA, V90, P502, DOI 10.1073/pnas.90.2.502; LAKSHMI V, 1988, ENDOCRINOLOGY, V123, P2390, DOI 10.1210/endo-123-5-2390; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Nakajin S, 1997, BIOL PHARM BULL, V20, P1215; NAKAJIN S, 1987, CHEM PHARM BULL, V35, P2490; NAKAJIN S, 1988, J BIOCHEM-TOKYO, V104, P565, DOI 10.1093/oxfordjournals.jbchem.a122511; OHNO S, 1991, J STEROID BIOCHEM, V38, P787, DOI 10.1016/0960-0760(91)90093-K; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Puranen T, 1997, MOL ENDOCRINOL, V11, P77, DOI 10.1210/me.11.1.77; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; Sawicki MW, 1999, P NATL ACAD SCI USA, V96, P840, DOI 10.1073/pnas.96.3.840; TANAKA M, 1992, J BIOL CHEM, V267, P13451; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; VILLARROYA A, 1989, EUR J BIOCHEM, V180, P191, DOI 10.1111/j.1432-1033.1989.tb14632.x; WERMUTH B, 1981, J BIOL CHEM, V256, P1206	31	83	86	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18457	18463		10.1074/jbc.M100538200	http://dx.doi.org/10.1074/jbc.M100538200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279087	hybrid			2022-12-25	WOS:000168866500112
J	Chang, NCA; Hung, SI; Hwa, KY; Kato, I; Chen, JE; Liu, CH; Chang, AC				Chang, NCA; Hung, SI; Hwa, KY; Kato, I; Chen, JE; Liu, CH; Chang, AC			A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; SURFACE-PLASMON RESONANCE; SMOOTH-MUSCLE CELLS; TRICHINELLA-SPIRALIS; ACTIVATED MACROPHAGES; HUMAN CHITOTRIOSIDASE; ADHESION MOLECULES; CHITINASE ACTIVITY; IDENTIFICATION; DIFFERENTIATION	Oral infections of mice with Trichinella spiralis induce activation of peritoneal exudate cells to transiently express and secrete a crystallizable protein Ym1, Purification of Ym1 to homogeneity was achieved. It is a single chain polypeptide (45 kDa) with a strong tendency to crystallize at its isoelectric point (PI 5.7). Coexpression of Ym1 with Mac-1 and scavenger receptor pinpoints macrophages as its main producer. Protein microsequencing data provide information required for full-length cDNA cloning from libraries constructed from activated peritoneal exudate cells. A single open reading frame of 398 amino acids with a leader peptide (21 residues) typical of secretory protein was deduced and later deposited in GenBank (TM) (accession number M94584) in 1992, By means of surface plasmon resonance analyses, Ym1 has been shown to exhibit binding specificity to saccharides with a free amine group, such as GlcN, GalN, or GlcN polymers, but it failed to bind to other saccharides, The interaction is pH-dependent but Ca2+ and Mg2+ ion-independent. The binding avidity of Ym1 to GlcN oligosaccharides was enhanced by more than 1000-fold due to the clustering effect. Specific binding of Ym1 to heparin suggests that heparin/heparan sulfate may be its physiological ligand in vivo during inflammation and/or tissue remodeling. Although it shares similar to 30% homology with microbial chitinases, no chitinase activity was found associated with Ym1. Genomic Southern blot analyses suggest that Ym1 may represent a member of a novel lectin gene family.	Natl Yang Ming Univ, Sch Life Sci, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Inst Neurosci, Taipei 112, Taiwan; Natl Yang Ming Univ, Sch Life Sci, Ctr Neurosci, Taipei 112, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Takara Shuzo Co Ltd, Biomed Grp, Otsu, Shiga 52021, Japan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Takara Holdings Inc.	Chang, NCA (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Microbiol & Immunol, Taipei 112, Taiwan.		Hung, Shuen-Iu/ABB-2139-2021; Hung, Shuen-Iu/HHS-9012-2022	Hung, Shuen-Iu/0000-0001-6531-5538; Hwa, Kuo-Yuan/0000-0003-1968-7909				ADAMS DO, 1987, IMMUNOL REV, V97, P5, DOI 10.1111/j.1600-065X.1987.tb00514.x; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Bell RG, 1998, ADV PARASIT, V41, P149, DOI 10.1016/S0065-308X(08)60424-8; BERGER SL, 1987, METHOD ENZYMOL, V152, P215; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; CHANG NC, 1982, FED PROC, V41, P561; CHANG NC, 1989, TRICHINELLOSIS, P604; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; Crocker PR, 1996, CURR OPIN STRUC BIOL, V6, P679, DOI 10.1016/S0959-440X(96)80036-4; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; DESPOMMIER DD, 1993, J PARASITOL, V79, P472, DOI 10.2307/3283370; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; GODING JW, 1983, MONOCLONAL ANTIBODIE, P134; GORDON S, 1995, CURR OPIN IMMUNOL, V7, P24, DOI 10.1016/0952-7915(95)80025-5; Gordon S, 1999, IMMUNOL LETT, V65, P5, DOI 10.1016/S0165-2478(98)00116-3; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Gregory CD, 1998, BIOCHEM SOC T, V26, P644, DOI 10.1042/bst0260644; Guo L, 2000, J BIOL CHEM, V275, P8032, DOI 10.1074/jbc.275.11.8032; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; II M, 1990, J BIOL CHEM, V265, P11295; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; JOHNSTONE A, 1987, IMMUNOCYTOCHEMISTRY, P261; Kaltner H, 1998, ACTA ANAT, V161, P162; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; KIRKPATRICK RB, 1995, GENE, V153, P147, DOI 10.1016/0378-1119(94)00756-I; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krause SW, 1996, J LEUKOCYTE BIOL, V60, P540, DOI 10.1002/jlb.60.4.540; KUDO S, 1992, EXPERIENTIA, V48, P277, DOI 10.1007/BF01930475; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Lawson ND, 1998, P NATL ACAD SCI USA, V95, P10129, DOI 10.1073/pnas.95.17.10129; LEE YC, 1992, FASEB J, V6, P3193, DOI 10.1096/fasebj.6.13.1397841; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MartinezPomares L, 1996, IMMUNOBIOLOGY, V195, P407, DOI 10.1016/S0171-2985(96)80012-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLIS AJT, 1985, J BIOL CHEM, V260, P3754; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORRIS L, 1991, DEVELOPMENT, V112, P517; Morrissette Naomi, 1999, Trends in Cell Biology, V9, P199, DOI 10.1016/S0962-8924(99)01540-8; Mosser DM, 1999, CURR OPIN IMMUNOL, V11, P406, DOI 10.1016/S0952-7915(99)80068-5; Naito M, 1996, J LEUKOCYTE BIOL, V59, P133, DOI 10.1002/jlb.59.2.133; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Owhashi M, 1998, PARASITOL RES, V84, P136, DOI 10.1007/s004360050370; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; RICE PA, 1990, PROTEINS, V8, P334, DOI 10.1002/prot.340080407; RUSSELL DG, 1995, CURR OPIN IMMUNOL, V7, P479, DOI 10.1016/0952-7915(95)80092-1; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; SHEPHERD VL, 1984, J BIOL CHEM, V259, P2257; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; Stahl PD, 1998, CURR OPIN IMMUNOL, V10, P50, DOI 10.1016/S0952-7915(98)80031-9; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; TRUDEL J, 1989, ANAL BIOCHEM, V178, P362, DOI 10.1016/0003-2697(89)90653-2; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; WAKELIN D, 1993, J PARASITOL, V79, P488, DOI 10.2307/3283372; WATANABE T, 1993, J BIOL CHEM, V268, P18567; WATANABE T, 1990, J BIOL CHEM, V265, P15659; YEAMAN C, 1993, J CELL BIOL, V122, P941, DOI 10.1083/jcb.122.4.941; Zeisberger E, 1998, ANN NY ACAD SCI, V856, P116, DOI 10.1111/j.1749-6632.1998.tb08320.x	79	202	214	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17497	17506		10.1074/jbc.M010417200	http://dx.doi.org/10.1074/jbc.M010417200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11297523	hybrid			2022-12-25	WOS:000168730400121
J	Mazur, DJ; Perrino, FW				Mazur, DJ; Perrino, FW			Excision of 3 ' termini by the Trex1 and TREX2 3 '-> 5 ' exonucleases - Characterization of the recombinant proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; CYTOSINE-ARABINOSIDE MONOPHOSPHATE; WERNER SYNDROME PROTEIN; COLI RNASE-T; ESCHERICHIA-COLI; MISMATCH REPAIR; IN-VIVO; 3'-5' EXONUCLEASE; CRYSTAL-STRUCTURE; USTILAGO-MAYDIS	The excision of nucleotides from DNA 3' termini is an important step in DNA replication, repair, and recombination pathways to generate correctly base paired termini for subsequent processing. The mammalian TREX1 and TREX2 proteins contain potent 3'-->5' exonucleases capable of functioning in this capacity. To study the activities of these exonucleases we have developed strategies to express and purify the recombinant mouse Trex1 and human TREX2 proteins in Escherichia coli in quantities sufficient for biochemical characterization. The Trex1 and TREX2 proteins are homodimers that exhibit robust 3' excision activities with very similar preferred reaction conditions and preferences for specific DNA substrates. In a steady-state kinetic analysis, oligonucleotide substrates were used to measure 3' nucleotide excision by Trex1 and TREX2. The Michaelis constants derived from these data indicate similar apparent k(cat) values of 22 s(-1) for Trex1 and 16 s(-1) for TREX2 using single-stranded oligonucleotides. The apparent K, values of 19 nM for Trex1 and 190 nM for TREX2 suggest relatively high affinities for DNA for both Trex1 and TREX2. An exonuclease competition assay was designed using heparin as a nonsubstrate inhibitor with a series of partial duplex DNAs to delineate the substrate structure preferences for 3' nucleotide excision by Trex1 and TREX2. The catalytic properties of the TREX proteins suggest roles for these enzymes in the 3' end-trimming processes necessary for producing correctly base paired 3' termini.	Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University	Perrino, FW (corresponding author), Wake Forest Univ, Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.				NCI NIH HHS [CA12197, CA75350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA012197, R01CA075350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; BARNES MH, 1995, GENE, V165, P45, DOI 10.1016/0378-1119(95)00530-J; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bessho T, 2000, J BIOL CHEM, V275, P7451, DOI 10.1074/jbc.275.11.7451; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; BRODY RS, 1986, J BIOL CHEM, V261, P7136; Bzymek M, 1999, J BACTERIOL, V181, P477, DOI 10.1128/JB.181.2.477-482.1999; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; FENG WY, 1995, GENETICS, V140, P1175; FERSHT A, 1985, ENZYME STRUCTURE MEC, P150; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Huang YP, 1997, FEBS LETT, V400, P94, DOI 10.1016/S0014-5793(96)01361-0; Ito J, 1998, MOL MICROBIOL, V27, P235, DOI 10.1046/j.1365-2958.1998.00673.x; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2521, DOI 10.1093/nar/21.10.2521; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEHMAN IR, 1960, J BIOL CHEM, V235, P1479; LEHMAN IR, 1964, J BIOL CHEM, V239, P2628; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mazur DJ, 2001, J BIOL CHEM, V276, P14718, DOI 10.1074/jbc.M010051200; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Miller H, 1996, BIOCHEMISTRY-US, V35, P12919, DOI 10.1021/bi960326d; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; Onel K, 1996, GENETICS, V143, P165; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; PARSONAGE D, 1993, J BIOL CHEM, V268, P3161; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Paull TT, 2000, P NATL ACAD SCI USA, V97, P6409, DOI 10.1073/pnas.110144297; Perrino Fred W., 1999, Cell Biochemistry and Biophysics, V30, P331, DOI 10.1007/BF02738118; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1992, J BIOL CHEM, V267, P23043; PETRINI JHJ, 1995, GENOMICS, V29, P80, DOI 10.1006/geno.1995.1217; Razavy H, 1996, GENETICS, V142, P333; REHAKRANTZ LJ, 1993, J BIOL CHEM, V268, P27100; REHAKRANTZ LJ, 1991, P NATL ACAD SCI USA, V88, P2417, DOI 10.1073/pnas.88.6.2417; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; SANDIGURSKY M, 1992, NUCLEIC ACIDS RES, V20, P4699, DOI 10.1093/nar/20.18.4699; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SEGEL IH, 1975, ENZYME KINETICS, P118; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Strauss BS, 1997, NUCLEIC ACIDS RES, V25, P806, DOI 10.1093/nar/25.4.806; Taft-Benz SA, 1998, NUCLEIC ACIDS RES, V26, P4005, DOI 10.1093/nar/26.17.4005; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; THELEN MP, 1994, J BIOL CHEM, V269, P747; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Viswanathan M, 1999, J BIOL CHEM, V274, P30094, DOI 10.1074/jbc.274.42.30094; Viswanathan M, 1998, J BIOL CHEM, V273, P35126, DOI 10.1074/jbc.273.52.35126; Viswanathan M, 1999, GENETICS, V151, P929; Viswanathan M, 1998, GENETICS, V149, P7; Wang J, 1996, BIOCHEMISTRY-US, V35, P8110, DOI 10.1021/bi960178r	65	115	122	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17022	17029		10.1074/jbc.M100623200	http://dx.doi.org/10.1074/jbc.M100623200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279105	hybrid			2022-12-25	WOS:000168730400056
J	Lehman, K; Ho, CK; Shuman, S				Lehman, K; Ho, CK; Shuman, S			Importance of homodimerization for the in vivo function of yeast RNA triphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; CAPPING APPARATUS; POLYMERASE-II; GUANYLYLTRANSFERASE COMPONENT; MECHANISM; ENZYMES; PHOSPHORYLATION; TRANSCRIPTION; ASSOCIATION	Saccharomyces cerevisiae RNA triphosphatase Cet1 is an essential component of the yeast mRNA capping apparatus. The active site of Cet1 resides within a topologically closed hydrophilic beta -barrel (the triphosphate tunnel) that is supported by a globular hydrophobic core. The homodimeric quaternary structure of Cet1 is formed by a network of contacts between the partner protomers. By studying the effects of alanine-cluster mutations, we highlight the contributions of two separate facets of the crystallographic dimer interface to Cet1 function in vivo. One essential facet of the interface entails hydrophobic cross dimer interactions of Cys(330) and Val(331) and a cross-dimer hydrogen bond of Asp(280) with the backbone amide of Gln(329). The second functionally relevant dimer interface involves hydrophobic side-chain interactions of Phe(272) and Leu(273). Ala-cluster mutations involving these residues elicited lethal or severe temperature-sensitive phenotypes that were suppressed completely by fusion of the mutated triphosphatases to the guanylyltransferase domain of mammalian capping enzyme. The recombinant D279A-D280A and F272A-L273A proteins retained phosphohydrolase activity but sedimented as monomers. These results indicate that a disruption of the dimer interface is uniquely deleterious when the yeast RNA triphosphatase must function in concert with the endogenous yeast guanylyltransferase. We also identify key residue pairs in the hydrophobic core of the Cet1 protomer that support the active site tunnel and stabilize the triphosphatase in vivo.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.		Ho, KIong/GPP-6051-2022					Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1	13	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14996	15002		10.1074/jbc.M100588200	http://dx.doi.org/10.1074/jbc.M100588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279098	hybrid			2022-12-25	WOS:000168528800064
J	Napper, CE; Dyson, MH; Taylor, ME				Napper, CE; Dyson, MH; Taylor, ME			An extended conformation of the macrophage mannose receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH DOMAIN; CARBOHYDRATE-RECOGNITION DOMAINS; MEMBRANE-RECEPTOR; BINDING PROTEIN; LECTIN; OLIGOSACCHARIDES; SUPERFAMILY; EXPRESSION; LUTROPIN; CLONING	The macrophage mannose receptor mediates phagocytosis of pathogenic microorganisms and endocytosis of potentially harmful soluble glycoproteins by recognition of their defining carbohydrate structures. The mannose receptor is the prototype for a family of receptors each having an extracellular region consisting of 8-10 domains related to C-type carbohydrate recognition domains (CRDs), a fibronectin type II repeat and an N-terminal cysteine-rich domain. Hydrodynamic analysis and proteolysis experiments performed on fragments of the extracellular region of the receptor have been used to investigate its conformation. Size and shape parameters derived from sedimentation and diffusion coefficients indicate that the receptor is a monomeric, elongated and asymmetric molecule. Proteolysis experiments indicate the presence of close contacts between several pairs of domains and exposed linker regions separating CRDs 3 and 6 from their neighboring domains. Hydrodynamic coefficients predicted for modeled receptor conformations are consistent with an extended conformation with close contacts between three pairs of CRDs, The N-terminal cysteine rich domain and the fibronectin type II repeat appear to increase the rigidity of the molecule. The rigid, extended conformation of the receptor places domains with different functions at distinct positions with respect to the membrane.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Oxford	Taylor, ME (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.			Taylor, Maureen/0000-0001-8300-4987				ANCIEN P, 1995, BIOCHEMISTRY-US, V44, P13146; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; BOURSIER JP, 1993, J BIOL CHEM, V268, P2013; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; Crocker PR, 1996, BIOCHEM SOC T, V24, P150, DOI 10.1042/bst0240150; DELATORRE JG, 1997, HYDRO USERS MANUAL V; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; Feinberg H, 2000, J BIOL CHEM, V275, P21539, DOI 10.1074/jbc.M002366200; Fiete D, 1997, J BIOL CHEM, V272, P14629, DOI 10.1074/jbc.272.23.14629; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; Fiete DJ, 1998, P NATL ACAD SCI USA, V95, P2089, DOI 10.1073/pnas.95.5.2089; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HARDING SE, 1995, ANAL BIOCHEM, V228, P131, DOI 10.1006/abio.1995.1324; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Liu Y, 2000, J EXP MED, V191, P1105, DOI 10.1084/jem.191.7.1105; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; MartinezPomares L, 1996, J EXP MED, V184, P1927, DOI 10.1084/jem.184.5.1927; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Mullin NP, 1997, J BIOL CHEM, V272, P5668, DOI 10.1074/jbc.272.9.5668; Ng KKS, 1998, BIOCHEMISTRY-US, V37, P17965, DOI 10.1021/bi981972a; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Pickford AR, 1997, STRUCTURE, V5, P359, DOI 10.1016/S0969-2126(97)00193-7; Roseman DS, 2000, P NATL ACAD SCI USA, V97, P9949, DOI 10.1073/pnas.170184597; Sheikh H, 2000, J CELL SCI, V113, P1021; Simpson DZ, 1999, BIOCHEM J, V343, P403, DOI 10.1042/0264-6021:3430403; Sober H. A., 1970, HDB BIOCH SELECTED D; Tanford C., 1961, PHYS CHEM MACROMOLEC; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; Taylor ME, 1997, GLYCOBIOLOGY, V7, pR5; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	41	51	54	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14759	14766		10.1074/jbc.M100425200	http://dx.doi.org/10.1074/jbc.M100425200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279067	hybrid			2022-12-25	WOS:000168528800032
J	Horton, LE; James, P; Craig, EA; Hensold, JO				Horton, LE; James, P; Craig, EA; Hensold, JO			The yeast hsp70 homologue Ssa is required for translation and interacts with Sis1 and Pab1 on translating ribosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(A) BINDING-PROTEIN; MESSENGER-RNA DECAY; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL INTERACTION; MOLECULAR CHAPERONES; IN-VIVO; DEPENDENT TRANSLATION; ATPASE ACTIVITY; INITIATION; TRANSLOCATION	The 70-kDa heat shock proteins are molecular chaperones that participate in a variety of cellular functions. This chaperone function is stimulated by interaction with hsp40 proteins. The Saccharomyces cerevisiae gene encoding the essential hsp40 homologue, SIS1, appears to function in translation initiation. Mutations in ribosomal protein L39 (rpl39) complement loss-of-function mutations in SIS1 as well as PAB1 (poly(A)-binding protein), suggesting a functional interaction between these proteins. However, while a direct interaction between Sis1 and Pab1 is not detectable, both of these proteins physically interact with the essential Ssa land not Ssb) family of hsp70 proteins. This interaction is mediated by the variable C-terminal domain of Ssa. Subcellular fractionations demonstrate that the binding of Ssa to ribosomes is dependent upon its C terminus and that its interaction with Sis1 and Pab1 occurs preferentially on translating ribosomes. Consistent with a function in translation, depletion of Ssa protein produces a general translational defect that appears similar to loss of Sis1 and Pab1 function. This translational effect of Ssa appears mediated, at least in part, by its affect on the interaction of Pab1 with the translation initiation factor, eIF4G, which is dramatically reduced in the absence of functional Ssa protein.	Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cleveland Vet Affairs Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; University of Wisconsin System; University of Wisconsin Madison	Hensold, JO (corresponding author), Dept Hematol & Oncol, 10900 Euclid Ave,BRB309B, Cleveland, OH 44106 USA.				NIDDK NIH HHS [DK09915] Funding Source: Medline; NIGMS NIH HHS [R01 GM31107] Funding Source: Medline; PHITPO CDC HHS [HK07147-21A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009915] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031107] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHITPO CDC HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; BECKER D M, 1991, P182; Becker J, 1996, MOL CELL BIOL, V16, P4378; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; Caldas T, 2000, J BIOL CHEM, V275, P855, DOI 10.1074/jbc.275.2.855; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Choi SK, 1998, SCIENCE, V280, P1757, DOI 10.1126/science.280.5370.1757; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Hensold JO, 1996, J BIOL CHEM, V271, P23246, DOI 10.1074/jbc.271.38.23246; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Kessler SH, 1998, MOL CELL BIOL, V18, P51, DOI 10.1128/MCB.18.1.51; Kim S, 1998, P NATL ACAD SCI USA, V95, P12860, DOI 10.1073/pnas.95.22.12860; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lopez-Buesa P, 1998, P NATL ACAD SCI USA, V95, P15253, DOI 10.1073/pnas.95.26.15253; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; MARTIN TE, 1970, J BIOL CHEM, V245, P1504; Mayer MP, 1998, BIOL CHEM, V379, P261; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; NELSON RJ, 1992, GENETICS, V131, P277; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Oka M, 1998, J BIOL CHEM, V273, P29727, DOI 10.1074/jbc.273.45.29727; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; STONE DE, 1990, MOL CELL BIOL, V10, P1622, DOI 10.1128/MCB.10.4.1622; Tarun SZ, 1997, P NATL ACAD SCI USA, V94, P9046, DOI 10.1073/pnas.94.17.9046; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; WERNERWASHBURNE M, 1987, MOL CELL BIOL, V7, P2568, DOI 10.1128/MCB.7.7.2568; Yan W, 1999, MOL CELL BIOL, V19, P7751; ZHONG T, 1993, CELL, V73, P1175, DOI 10.1016/0092-8674(93)90646-8	44	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14426	14433		10.1074/jbc.M100266200	http://dx.doi.org/10.1074/jbc.M100266200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11279042	hybrid			2022-12-25	WOS:000168356600121
J	Tumaney, AW; Shekar, S; Rajasekharan, R				Tumaney, AW; Shekar, S; Rajasekharan, R			Identification, purification, and characterization of monoacylglycerol acyltransferase from developing peanut cotyledons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LYSOPHOSPHATIDIC ACID; DIHYDROXYACETONE PHOSPHATE; TRIACYLGLYCEROL SYNTHESIS; GLYCEROLIPID SYNTHESIS; MIXED MICELLES; FATTY-ACIDS; BIOSYNTHESIS; KINASE; METABOLISM	Biosynthesis of diacylglycerols in plants occurs mainly through the acylation of lysophosphatidic acid in the microsomal membranes. Here we describe the first identification of diacylglycerol biosynthetic activity in the soluble fraction of developing oilseeds. This activity was NaF-insensitive and acyl-CoA-dependent Diacylglycerol formation was catalyzed by monoacylglycerol (MAG) acyltransferase (EC 2.3.1.22) that transferred an acyl moiety from acyl-CoA to MAG. The enzyme was purified by successive chromatographic separations on octyl-Sepharose, blue-Sepharose, Superdex-75, and palmitoyl-CoA-agarose to apparent homogeneity from developing peanut (Arachis hypogaea) cotyledons, The enzyme was purified to 6,608-fold with the final. specific activity of 15.86 nmol min(-1) mg(-1). The purified enzyme was electrophoretically homogeneous, and its molecular mass was 43,000 daltons, The purified MAG acyltransferase was specific for MAG and did not utilize any other acyl acceptor such as glycerol, glycerol-3-phosphate, lysophosphatidic acid, and lysophosphatidylcholine. The K-m values for 1-palmitoylglycerol and 1-oleoylglycerol were 16.39 and 5.65 phn, respectively. The K-m values for 2-monoacylglycerols were 2- to 4-fold higher than that of the corresponding 1-monoacylglycerol, The apparent K-m values for palmitoyl-, stearoyl-, and oleoyl-CoAs were 17.54, 25.66, and 9.35 muM, respectively. Fatty acids, phospholipids, and sphingosine at low concentrations stimulated the enzyme activity. The identification of MAG acyltransferase in oilseeds suggests the presence of a regulatory link between signal transduction and synthesis of complex lipids in plants.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	Rajasekharan, Ram/R-2257-2019; R, Rajasekharan/D-3420-2009	Rajasekharan, Ram/0000-0002-2124-6013; Tumaney, Ajay W./0000-0003-3708-0123				Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BHAT BG, 1995, BIOCHEMISTRY-US, V34, P11237, DOI 10.1021/bi00035a033; BHAT BG, 1994, J BIOL CHEM, V269, P13172; Bischoff KM, 1998, ANAL BIOCHEM, V260, P1, DOI 10.1006/abio.1998.2680; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRISKIN DP, 1987, METHOD ENZYMOL, V148, P542; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; COLEMAN RA, 1984, J BIOL CHEM, V259, P8934; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; DELAROCHE IA, 1973, PLANT PHYSIOL, V51, P468, DOI 10.1104/pp.51.3.468; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; FLETCHER MJ, 1968, CLIN CHIM ACTA, V22, P393, DOI 10.1016/0009-8981(68)90041-7; FRITZ PJ, 1986, J BIOL CHEM, V261, P194; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; GROSS RW, 1983, BIOCHEMISTRY-US, V22, P5641, DOI 10.1021/bi00293a028; Hiroyama M, 1998, BIOCHEM J, V336, P483, DOI 10.1042/bj3360483; Hiroyama R, 1999, J BIOL CHEM, V274, P29172, DOI 10.1074/jbc.274.41.29172; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; ICHIHARA K, 1990, BIOCHIM BIOPHYS ACTA, V1043, P227, DOI 10.1016/0005-2760(90)90021-O; ICHIHARA K, 1989, PLANT PHYSIOL, V90, P413, DOI 10.1104/pp.90.2.413; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JALINK K, 1993, P NATL ACAD SCI USA, V90, P1857, DOI 10.1073/pnas.90.5.1857; JAMDAR SC, 1992, ARCH BIOCHEM BIOPHYS, V296, P419, DOI 10.1016/0003-9861(92)90592-K; KANOH H, 1983, J BIOL CHEM, V258, P1767; KENNEDY EP, 1961, FED PROC, V20, P934; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; KNUDSEN J, 1975, BIOCHEM BIOPH RES CO, V65, P921, DOI 10.1016/S0006-291X(75)80473-6; LAPETINA EG, 1971, BIOCHEM J, V122, P171, DOI 10.1042/bj1220171; Lehner R, 1996, PROG LIPID RES, V35, P169, DOI 10.1016/0163-7827(96)00005-7; MATTSON FH, 1961, J LIPID RES, V2, P58; MURPHY DJ, 1988, LIPIDS, V23, P157, DOI 10.1007/BF02535452; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PELECH SL, 1989, TRENDS BIOCHEM SCI, V14, P28, DOI 10.1016/0968-0004(89)90086-8; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPARACE SA, 1979, PLANT PHYSIOL, V63, P963, DOI 10.1104/pp.63.5.963; Stimmel BF, 1934, J AM CHEM SOC, V56, P1724, DOI 10.1021/ja01323a022; SUNDLER R, 1975, J BIOL CHEM, V250, P8585; Tsujita T, 1996, J BIOL CHEM, V271, P2156, DOI 10.1074/jbc.271.4.2156; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WEBBER KO, 1992, METHOD ENZYMOL, V209, P92; XIA T, 1993, AM J PHYSIOL, V265, pR414, DOI 10.1152/ajpregu.1993.265.2.R414; XIE MS, 1994, ARCH BIOCHEM BIOPHYS, V312, P254, DOI 10.1006/abbi.1994.1307; [No title captured]	45	36	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10847	10852		10.1074/jbc.M100005200	http://dx.doi.org/10.1074/jbc.M100005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11283027	hybrid			2022-12-25	WOS:000167980900040
J	Tsao, TS; Li, J; Chang, KS; Stenbit, AE; Galuska, D; Anderson, JE; Zierath, JR; McCarter, RJ; Charron, MJ				Tsao, TS; Li, J; Chang, KS; Stenbit, AE; Galuska, D; Anderson, JE; Zierath, JR; McCarter, RJ; Charron, MJ			Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity	FASEB JOURNAL			English	Article						free fatty acids; EDL; glycogen synthesis; oleate oxidation	RESPONSIVE GLUCOSE-TRANSPORTER; DEPENDENT DIABETES-MELLITUS; FATTY-ACID OXIDATION; TRANSGENIC MICE; INSULIN-RESISTANCE; SUBSTRATE PATHWAYS; MESSENGER-RNA; MALONYL-COA; RAT MUSCLE; WHOLE-BODY	To understand the long-term metabolic and functional, consequences of increased GLUT4 con tent, intracellular substrate utilization was investigated in isolated muscles of transgenic mice overexpressing GLUT4 selectively in fast-twitch skeletal muscles. Rates of glycolysis, glycogen synthesis, glucose oxidation, and free fatty acid (FFA) oxidation as well as glycogen content were assessed in isolated EDL (fast-twitch) and soleus (slow-twitch) muscles from female and male MLC-GLUT4 transgenic and control mice. In male MLC-GLUT4 EDL, increased glucose influx predominantly led to increased glycolysis. In contrast, in female MLC-GLUT4 EDL increased glycogen synthesis was observed. In both sexes, GLUT4 overexpression resulted in decreased exogenous FFA oxidation rates. The decreased rate of FFA oxidation in male MLC-GLUT4 EDL was associated with increased lipid con tent in liver, but not in muscle or at the whole body level. To determine how changes in substrate metabolism and insulin action may influence energy balance in an environment that encouraged physical activity, we measured voluntary training activity, body weight, and food consumption of MLC-GLUT4 and control mice in cages equipped with training wheels. We observed a small decrease in body weight of MLC-GLUT4 mice that was paradoxically accompanied by a 45% increase in food consumption. The results were explained by a marked fourfold increase in voluntary wheel exercise. The changes in substrate metabolism and physical activity in MLC-GLUT4 mice were not associated with dramatic changes in skeletal muscle morphology. Collectively, results of this study demonstrate the feasibility of altering muscle substrate utilization by overexpression of GLUT4. The results also suggest that as a potential treatment for type II diabetes mellitus, increased skeletal muscle GLUT4 expression may provide benefits in addition to improvement of insulin action.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA; Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden; Univ Manitoba, Dept Human Anat & Cell Sci, Winnipeg, MB R3E 0W3, Canada	Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Health San Antonio; Karolinska Institutet; Karolinska University Hospital; University of Manitoba	Charron, MJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	charron@aecom.yu.edu		Tsao, Tsu-Shuen/0000-0002-1041-9687; Zierath, Juleen/0000-0001-6891-7497	NCI NIH HHS [5P30CA13330] Funding Source: Medline; NHLBI NIH HHS [5T32HL07675, HL58119] Funding Source: Medline; NIA NIH HHS [AG14674] Funding Source: Medline; NIDDK NIH HHS [DK47425] Funding Source: Medline; NIGMS NIH HHS [5T32GM07491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007675, R01HL058119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aksnes AK, 1996, AM J PHYSIOL-ENDOC M, V271, pE593, DOI 10.1152/ajpendo.1996.271.3.E593; ANDERSEN P, 1977, J PHYSIOL-LONDON, V270, P677, DOI 10.1113/jphysiol.1977.sp011975; ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; Bavenholm PN, 2000, DIABETES, V49, P1078, DOI 10.2337/diabetes.49.7.1078; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BJORNTORP P, 1995, INT J OBESITY, V19, pS6; BOGARDUS C, 1985, AM J PHYSIOL, V248, pE286, DOI 10.1152/ajpendo.1985.248.3.E286; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Chien D, 2000, AM J PHYSIOL-ENDOC M, V279, pE259, DOI 10.1152/ajpendo.2000.279.2.E259; CUENDET GS, 1976, J CLIN INVEST, V58, P1078, DOI 10.1172/JCI108559; DEEMS RO, 1994, DIABETOLOGIA, V37, P1097, DOI 10.1007/s001250050222; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399; DEVASKAR SU, 1992, PEDIATR RES, V31, P1, DOI 10.1203/00006450-199201000-00001; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ECKEL RH, 1992, LANCET, V340, P1452, DOI 10.1016/0140-6736(92)92633-Q; FELBER JP, 1993, DIABETOLOGIA, V36, P1221, DOI 10.1007/BF00400798; FUKUMOTO H, 1989, J BIOL CHEM, V264, P7776; GIBBS EM, 1995, J CLIN INVEST, V95, P1512, DOI 10.1172/JCI117823; GOODMAN MN, 1983, AM J PHYSIOL, V244, pE93, DOI 10.1152/ajpendo.1983.244.1.E93; HALLEN A, 1960, ACTA CHEM SCAND, V14, P2249, DOI 10.3891/acta.chem.scand.14-2249; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HENRIKSEN EJ, 1990, AM J PHYSIOL, V259, pE593, DOI 10.1152/ajpendo.1990.259.4.E593; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V268, pE453, DOI 10.1152/ajpendo.1995.268.3.E453; Holloszy JO, 1996, ANNU REV NUTR, V16, P121, DOI 10.1146/annurev.nu.16.070196.001005; HOLMANG A, 1993, DIABETES, V42, P1073, DOI 10.2337/diabetes.42.7.1073; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P865, DOI 10.1073/pnas.92.3.865; IVY JL, 1987, EXERCISE SPORT SCI R, V15, P29; JAMES DE, 1985, AM J PHYSIOL, V248, pE575, DOI 10.1152/ajpendo.1985.248.5.E575; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; Katz EB, 1996, J MOL MED, V74, P639, DOI 10.1007/s001090050068; KAVA RA, 1989, DIABETES, V38, P159, DOI 10.2337/diabetes.38.2.159; KELLEY DE, 1994, J CLIN INVEST, V94, P2349, DOI 10.1172/JCI117600; KRAEGEN EW, 1985, AM J PHYSIOL, V248, pE353; Leturque A, 1996, DIABETES, V45, P23, DOI 10.2337/diabetes.45.1.23; LIU ML, 1993, P NATL ACAD SCI USA, V90, P11346, DOI 10.1073/pnas.90.23.11346; Nyholm B, 1997, DIABETES, V46, P1822, DOI 10.2337/diabetes.46.11.1822; PASSONNEAU JV, 1974, ANAL BIOCHEM, V60, P405, DOI 10.1016/0003-2697(74)90248-6; RANDLE PJ, 1963, LANCET, V1, P785; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; REN JM, 1993, J BIOL CHEM, V268, P16113; Rincon J, 1996, DIABETES, V45, P615, DOI 10.2337/diabetes.45.5.615; Roberts TJ, 1996, J EXP BIOL, V199, P1651; SALMON DMW, 1985, INT J OBESITY, V9, P443; SHEPHERD PR, 1993, J BIOL CHEM, V268, P22243; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; TASKINEN MR, 1985, J CLIN INVEST, V76, P637, DOI 10.1172/JCI112016; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; TREADWAY JL, 1994, J BIOL CHEM, V269, P29956; Tsao TS, 1997, J CLIN INVEST, V100, P671, DOI 10.1172/JCI119579; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; Tsao TS, 2000, METABOLISM, V49, P340, DOI 10.1016/S0026-0495(00)90220-8; Tsao TS, 1999, DIABETES, V48, P775, DOI 10.2337/diabetes.48.4.775; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V258, P187, DOI 10.1006/bbrc.1999.0617; Utriainen T, 1996, AM J PHYSIOL-ENDOC M, V270, pE905, DOI 10.1152/ajpendo.1996.270.5.E905; Weber JM, 1996, J EXP BIOL, V199, P1659; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; YOUNG DA, 1990, DIABETES, V39, P1408, DOI 10.2337/diabetes.39.11.1408; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	67	72	74	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					958	969		10.1096/fj.00-0381	http://dx.doi.org/10.1096/fj.00-0381			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292656				2022-12-25	WOS:000167959300010
J	Csar, XF; Wilson, NJ; McMahon, KA; Marks, DC; Beecroft, TL; Ward, AC; Whitty, GA; Kanangasundarum, V; Hamilton, JA				Csar, XF; Wilson, NJ; McMahon, KA; Marks, DC; Beecroft, TL; Ward, AC; Whitty, GA; Kanangasundarum, V; Hamilton, JA			Proteomic analysis of macrophage differentiation - p46/52(Shc) tyrosine phosphorylation is required for CSF-1-mediated macrophage differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; CSF-1 RECEPTOR; NEURONAL DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; HUMAN MONOCYTES	Macrophage colony stimulating factor (M-CSF or CSF-1) acts to regulate the development and function of cells of the macrophage lineage. Murine myeloid FDC-P1 cells transfected with the CSF-1 receptor (FD/WT) adopt a macrophage-like morphology when cultured in CSF-1, This process is abrogated in FDC-P1 cells transfected with the CSF-1 receptor with a tyrosine to phenyalanine substitution at position 807 (PD/807), suggesting that a molecular interaction critical to differentiation signaling is lost (Bourette, R. P., Myles, G. M., Carlberg, K., Chen, A. R., and Rohrschneider, L. R. (1995) Cell Growth Differ, 6, (631-645). A detailed examination of lysates of CSF-1-treated FD/807 cells by two-dimensional SI)S-polyacrylamide gel electrophoresis (PAGE) revealed a number of proteins whose degree of tyrosine phosphorylation was modulated by the Y807F mutation. Included in this category were three phosphorylated proteins that co-migrated with p46/52(Sch), Immunoprecipitation, Western blotting, and in vitro binding studies suggest that they are indeed p46/52(Shc). A key regulator of differentiation in a number of cell systems, ERK was observed to exhibit an activity that correlated with the relative degree of differentiation induced by CSF-1 in the two cell types. Transfection of cells with a non-tyrosine-phosphorylatable form of p46/52(Shc) prevented the normally observed CSF-1-mediated macrophage differentiation as determined by adoption of macrophage-like morphology and expression of the monocyte/macrophage lineage cell surface marker, Mac-1. These results are the first to suggest that p46/52(Shc) may play a role in CSF-1-induced macrophage differentiation. Additionally, a number of proteins were identified by two-dimensional SDS-PAGE whose degree of tyrosine phosphorylation is also modulated by the Y807F substitution. This group of molecules may contain novel signaling molecules important in macrophage differentiation.	Univ Melbourne, Royal Melbourne Hosp, Arthrit & Inflammat Res Ctr, Dept Med, Parkville, Vic 3050, Australia; Peter MacCallum Canc Inst, Trescowthick Res Labs, Cell Cycle Proteolysis Lab, Melbourne, Vic 3006, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Chron Inflammatory Dis, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; University of Melbourne; Peter Maccallum Cancer Center; Royal Melbourne Hospital	Csar, XF (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Arthrit & Inflammat Res Ctr, Dept Med, Parkville, Vic 3050, Australia.	xfc@unimelb.edu.au	Marks, Denese C/A-5267-2018; McMahon, Kerrie-Ann/J-1821-2014	Marks, Denese C/0000-0002-3674-6934; McMahon, Kerrie-Ann/0000-0002-0833-5708; Hamilton, John A/0000-0002-9493-9224; Ward, Alister/0000-0001-7945-7975				Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Blaikie PA, 1997, J BIOL CHEM, V272, P20671, DOI 10.1074/jbc.272.33.20671; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; Cook SJ, 1999, MOL CELL BIOL, V19, P330; Csar XF, 1997, BIOCHEM J, V322, P79, DOI 10.1042/bj3220079; Csar XF, 1997, J INTERF CYTOK RES, V17, P77, DOI 10.1089/jir.1997.17.77; Csar XF, 2001, PROTEOMICS, V1, P435, DOI 10.1002/1615-9861(200103)1:3<435::AID-PROT435>3.3.CO;2-H; Durstin M, 1996, J IMMUNOL, V157, P534; FernandezValle C, 1997, J NEUROSCI, V17, P241, DOI 10.1523/JNEUROSCI.17-01-00241.1997; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Hamilton JA, 1997, J LEUKOCYTE BIOL, V62, P145, DOI 10.1002/jlb.62.2.145; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HECKER G, 1991, BIOCHEM SOC T, V19, P385, DOI 10.1042/bst0190385; Hill RJ, 1996, CELL GROWTH DIFFER, V7, P1125; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KHARBANDA S, 1995, P NATL ACAD SCI USA, V92, P6132, DOI 10.1073/pnas.92.13.6132; KIM YR, 1993, LEUKEMIA RES, V15, P409; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Leventhal PS, 1996, J BIOL CHEM, V271, P5957, DOI 10.1074/jbc.271.11.5957; LIOUBIN MN, 1994, MOL CELL BIOL, V14, P5682, DOI 10.1128/MCB.14.9.5682; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Marks D C, 1999, Mol Cell Biol Res Commun, V1, P144, DOI 10.1006/mcbr.1999.0123; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUTHON MA, 1994, BLOOD, V84, P1085; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; Novak U, 1996, ONCOGENE, V13, P2607; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1990, ONCOGENE, V5, P25; Roux S, 1997, ENDOCRINOLOGY, V138, P1476, DOI 10.1210/en.138.4.1476; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; Saragovi HU, 1998, J BIOL CHEM, V273, P34933, DOI 10.1074/jbc.273.52.34933; SHERR CJ, 1990, BLOOD, V75, P1; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; TAPLEY P, 1990, MOL CELL BIOL, V10, P2528, DOI 10.1128/MCB.10.6.2528; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Ulloa L, 1996, EUR J NEUROSCI, V8, P1441, DOI 10.1111/j.1460-9568.1996.tb01606.x; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; Vijapurkar U, 1998, J BIOL CHEM, V273, P20996, DOI 10.1074/jbc.273.33.20996; Xie B, 1998, J BIOL CHEM, V273, P11576, DOI 10.1074/jbc.273.19.11576; YamamotoYamaguchi Y, 1996, EXP HEMATOL, V24, P682; Yen A, 1998, CANCER RES, V58, P3163; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	54	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26211	26217		10.1074/jbc.M100213200	http://dx.doi.org/10.1074/jbc.M100213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11290743	hybrid, Green Submitted			2022-12-25	WOS:000169823300077
J	Kwan, CP; Venkataraman, G; Shriver, Z; Raman, R; Liu, DF; Qi, YW; Varticovski, L; Sasisekharan, R				Kwan, CP; Venkataraman, G; Shriver, Z; Raman, R; Liu, DF; Qi, YW; Varticovski, L; Sasisekharan, R			Probing fibroblast growth factor dimerization and role of heparin-like glycosaminoglycans in modulating dimerization and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FGF RECEPTOR DIMERIZATION; NECROSIS-FACTOR RECEPTOR; SULFATE OLIGOSACCHARIDES; CRYSTAL-STRUCTURE; SELF-ASSOCIATION; BINDING; ACTIVATION; COMPLEX; OLIGOMERIZATION; LIGAND	For a number of growth factors and cytokines, ligand dimerization is believed to be central to the formation of an active signaling complex. In the case of fibroblast growth factor-2 (FGF2) signaling, heparin/heparan sulfate-like glycosaminoglycans (HLGAGs) are involved through interaction with both FGF2 and its receptors (FGFRs) in assembling a tertiary complex and modulating FGF2 activity. Biochemical data have suggested different modes of HLGAG-induced FGF2 dimerization involving specific protein-protein contacts. In addition, several recent x-ray crystallography studies of FGF(.)FGFR and FGF(.)FGFR(.)HLGAG complexes have revealed other modes of molecular assemblage, with no FGF-FGF contacts. All these different biochemical and structural findings have clarified less and in fact raised more questions as to which mode of FGF2 dimerization, if any, is essential for signaling. In this study, we address the issue of FGF2 dimerization in signaling using a combination of biochemical, biophysical, and site-directed mutagenesis approaches. Our findings presented here provide direct evidence of FGF2 dimerization in mediating FGF2 signaling.	MIT, Ctr Biomed Engn, Cambridge, MA 02139 USA; Harvard Univ, MIT, Div Hlth Sci & Technol, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Dept Med, Boston, MA 02135 USA	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); St. Elizabeth's Medical Center; Tufts University	Sasisekharan, R (corresponding author), MIT, Ctr Biomed Engn, 77 Massachusetts Ave,Bldg 16-561, Cambridge, MA 02139 USA.			KWAN, CHI-PONG/0000-0002-7654-0826; Varticovski, Lyuba/0000-0002-5105-9008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059966] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL59966] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballinger MD, 1998, NAT STRUCT BIOL, V5, P938, DOI 10.1038/2911; Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; Davis JC, 1999, BIOCHEM J, V341, P613, DOI 10.1042/0264-6021:3410613; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Ernst S, 1996, BIOCHEM J, V315, P589, DOI 10.1042/bj3150589; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; Gallagher JT, 1997, BIOCHEM SOC T, V25, P1206, DOI 10.1042/bst0251206; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Herr AB, 1997, J BIOL CHEM, V272, P16382, DOI 10.1074/jbc.272.26.16382; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jiang GQ, 1999, CURR BIOL, V9, pR568, DOI 10.1016/S0960-9822(99)80357-1; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; Kenyon BM, 1996, INVEST OPHTH VIS SCI, V37, P1625; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; Moy FJ, 1996, BIOCHEMISTRY-US, V35, P13552, DOI 10.1021/bi961260p; Moy FJ, 1997, BIOCHEMISTRY-US, V36, P4782, DOI 10.1021/bi9625455; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; Padera R, 1999, FASEB J, V13, P1677, DOI 10.1096/fasebj.13.13.1677; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Sasisekharan R, 2000, CURR OPIN CHEM BIOL, V4, P626, DOI 10.1016/S1367-5931(00)00145-9; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; Venkataraman G, 1996, P NATL ACAD SCI USA, V93, P845, DOI 10.1073/pnas.93.2.845; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; WILKIE AOM, 1995, CURR BIOL, V5, P500; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446	50	38	40	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23421	23429		10.1074/jbc.M010786200	http://dx.doi.org/10.1074/jbc.M010786200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11292822	hybrid			2022-12-25	WOS:000169531100028
J	Garner, B; Merry, AH; Royle, L; Harvey, DJ; Rudd, PM; Thillet, J				Garner, B; Merry, AH; Royle, L; Harvey, DJ; Rudd, PM; Thillet, J			Structural elucidation of the N- and O-glycans of human apolipoprotein(a) - Role of O-glycans in conferring protease resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; NEPHRITIS AUTOANTIGEN GP330; HEYMANN NEPHRITIS; ATHEROSCLEROTIC LESIONS; ENDOCYTIC RECEPTOR; HUMAN-PLASMA; IN-VITRO; PLASMINOGEN; FRAGMENTS; ELASTASE	Apolipoprotein(a) (apo(a)) is a multikringle domain glycoprotein that exists covalently linked to apolipoprotein B100 of low density lipoprotein, to form the lipoprotein(a) (Lp(a)) particle, or as proteolytic fragments. Elevated plasma concentrations of apo(a) and its fragments may promote atherosclerosis, but the underlying mechanisms are incompletely understood. The factors influencing apo(a) proteolysis are also uncertain. Here we have used exoglycosidase digestion and mass spectrometry to sequence the Asn (N)-linked and Ser/Thr (O)-linked oligosaccharides of human apo(a). We also assessed the potential role of apo(a) O-glycans in protecting thermolysin sensitive regions of the polypeptide. Apo(a) contained two major N-glycans that accounted for 17% of the total oligosaccharide structures. The N-glycans were complex biantennary structures present in either a mono- or disialylated state. The O glycans were mostly (80%) represented by the mono sialylated core type 1 structure, NeuNAc2 alpha -3Gal beta1-3GalNAc, with smaller amounts of disialylated and non-sialylated O-glycans also detected. Removal of apo(a) O-glycans by sialidase and O-glycosidase treatment dramatically increased the sensitivity of the polypeptide to thermolysin digestion. These studies provide the first direct sequencing data for apo(a) glycans and indicate a novel function for apo(a) O-glycans that is potentially related to the atherogenicity of Lp(a).	Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England; Hop Pitie, INSERM Unite 551, F-75651 Paris, France	University of Oxford; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Garner, B (corresponding author), Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Harvey, David/A-5579-2013	Harvey, David/0000-0003-0544-771X				ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; Bartlett AL, 2000, ATHEROSCLEROSIS, V153, P219, DOI 10.1016/S0021-9150(00)00402-0; Bartlett AL, 1998, ATHEROSCLEROSIS, V138, P237, DOI 10.1016/S0021-9150(97)00288-8; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Bolton EJ, 1997, BBA-MOL CELL RES, V1356, P12, DOI 10.1016/S0167-4889(96)00157-7; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; CHAMOW SM, 1988, CARBOHYD RES, V176, P195, DOI 10.1016/0008-6215(88)80130-7; DOUCET C, 1994, J LIPID RES, V35, P263; Doucet C, 2000, J AM SOC NEPHROL, V11, P507, DOI 10.1681/ASN.V113507; Edelstein C, 1996, J LIPID RES, V37, P1786; Edelstein C, 1997, J BIOL CHEM, V272, P11079; Edelstein C, 1999, J BIOL CHEM, V274, P10019, DOI 10.1074/jbc.274.15.10019; ETINGIN OR, 1991, J BIOL CHEM, V266, P2459; FLESS GM, 1986, J BIOL CHEM, V261, P8712; GALIS ZS, 1995, ANN NY ACAD SCI, V748, P501; GERRITY RG, 1981, AM J PATHOL, V103, P181; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUO HC, 1989, J LIPID RES, V30, P23; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; HOFF HF, 1994, CHEM PHYS LIPIDS, V67-8, P271, DOI 10.1016/0009-3084(94)90147-3; HUBY T, 1995, BIOCHEMISTRY-US, V34, P7385, DOI 10.1021/bi00022a011; HUBY T, 1994, BIOCHEMISTRY-US, V33, P3335, DOI 10.1021/bi00177a026; KANALAS JJ, 1991, J BIOL CHEM, V266, P10825; KANALAS JJ, 1988, J IMMUNOL, V141, P4152; KANALAS JJ, 1990, J AM SOC NEPHROL, V1, P792; KANAMORI A, 1990, J BIOL CHEM, V265, P21811; KEESLER GA, 1994, ARTERIOSCLER THROMB, V14, P1337, DOI 10.1161/01.ATV.14.8.1337; Klezovitch O, 1998, J BIOL CHEM, V273, P23856, DOI 10.1074/jbc.273.37.23856; Kostner K, 2001, CLIN CHIM ACTA, V304, P29, DOI 10.1016/S0009-8981(00)00394-6; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Kramerov AA, 1996, FEBS LETT, V378, P213, DOI 10.1016/0014-5793(95)01444-6; KRATZIN H, 1987, BIOL CHEM H-S, V368, P1533, DOI 10.1515/bchm3.1987.368.2.1533; Kronenberg F, 1996, CRIT REV CL LAB SCI, V33, P495, DOI 10.3109/10408369609080056; Mattu TS, 2000, BIOCHEMISTRY-US, V39, P15695, DOI 10.1021/bi001367j; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MERRY AH, 1992, BIOCHEM SOC T, V20, P91; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; Moestrup SK, 1998, J CLIN INVEST, V102, P902, DOI 10.1172/JCI3772; Mooser V, 1996, J CLIN INVEST, V98, P2414, DOI 10.1172/JCI119055; Mooser V, 1996, J CLIN INVEST, V97, P858, DOI 10.1172/JCI118487; Niemeier A, 1999, ARTERIOSCL THROM VAS, V19, P552, DOI 10.1161/01.ATV.19.3.552; OIDA K, 1992, CLIN CHEM, V38, P2244; PHILLIPS ML, 1993, BIOCHEMISTRY-US, V32, P3722, DOI 10.1021/bi00065a026; POWERS JC, 1977, BIOCHIM BIOPHYS ACTA, V485, P156, DOI 10.1016/0005-2744(77)90203-0; Rudd PM, 1997, NATURE, V388, P205, DOI 10.1038/40677; Scanu AM, 1997, J LIPID RES, V38, P2193; SEMAN LJ, 1986, BIOCHEM CELL BIOL, V64, P999, DOI 10.1139/o86-133; Sobenin IA, 1998, J LIPID RES, V39, P2293; STEFANSSON S, 1995, J BIOL CHEM, V270, P19417, DOI 10.1074/jbc.270.33.19417; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Wang J, 1999, BIOCHEM SOC T, V27, P453, DOI 10.1042/bst0270453; WARREN L, 1959, J BIOL CHEM, V234, P1971; White AL, 1999, J LIPID RES, V40, P275; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	57	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22200	22208		10.1074/jbc.M102150200	http://dx.doi.org/10.1074/jbc.M102150200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294842	hybrid			2022-12-25	WOS:000169412700032
J	Guo, YS; Hellmich, MR; Wen, XD; Townsend, CM				Guo, YS; Hellmich, MR; Wen, XD; Townsend, CM			Activator protein-1 transcription factor mediates bombesin-stimulated cyclooxygenase-2 expression in intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIN-RELEASING-PEPTIDE; MESSENGER-RNA STABILITY; HUMAN-BREAST-CANCER; GROWTH-FACTOR; GENE-EXPRESSION; FACTOR-ALPHA; RECEPTOR SUBTYPES; KAPPA-B; KINASE; AP-1	Colorectal carcinogenesis is a complex, multistep process involving genetic alterations and progressive changes in signaling pathways regulating intestinal epithelial cell proliferation, differentiation, and apoptosis, Although cyclooxygenase-2 (COX-2), gastrin-releasing peptide (GRP), and its receptor, GRP-R, are not normally expressed by the epithelial cells lining the human colon, the levels of all three proteins are aberrantly overexpressed in premalignant adenomatous polyps and colorectal carcinomas of humans. Overexpression of these proteins is associated with altered epithelial cell growth, adhesion, and tumor cell invasiveness, both in vitro and in vivo; however, a mechanistic link between GRP-R-mediated signaling pathways and increased COX-2 overexpression has not been established, We report that bombesin, a homolog of GRP, potently stimulates the expression of COX-2 mRNA and protein as well as the release of prostaglandin E-2 from a rat intestinal epithelial cell line engineered to express GRP-R. Bombesin stimulation of COX-2 expression requires an increase in [Ca2+](i), activation of extracellular signal-regulated kinase (ERR)-1 and -2 and p38(MAPK), and increased activation and expression of the transcription factors Elk-1, ATF-S, c-Fos, and c-Jun, These data suggest that the expression of GRP-R in intestinal epithelial cells may play a role in carcinogenesis by stimulating COX-2 overexpression through an activator protein-1-dependent pathway.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Townsend, CM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	ctownsen@utmb.edu			NIDDK NIH HHS [P01 DK35608, R01 DK48345] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345, P01DK035608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; BLAY J, 1984, CELL BIOL INT REP, V8, P551, DOI 10.1016/0309-1651(84)90054-7; Boolbol SK, 1996, CANCER RES, V56, P2556; Carroll RE, 1999, AM J PHYSIOL-GASTR L, V276, pG655, DOI 10.1152/ajpgi.1999.276.3.G655; Castano E, 1997, J PHARMACOL EXP THER, V280, P366; Chan G, 1999, CANCER RES, V59, P991; Cheng HF, 2000, J CLIN INVEST, V106, P681, DOI 10.1172/JCI10318; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EVERS BM, 1995, MOL CELL BIOL, V15, P3870; FRUCHT H, 1992, CANCER RES, V52, P1114; Fujita T, 1998, CANCER RES, V58, P4823; GIACCHETTI S, 1990, INT J CANCER, V46, P293, DOI 10.1002/ijc.2910460226; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; GUO YS, 1995, J AM COLL SURGEONS, V181, P145; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; Hecht JR, 1997, PROSTAG OTH LIPID M, V54, P757, DOI 10.1016/S0090-6980(97)00162-7; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Jacoby RF, 1996, CANCER RES, V56, P710; Jian XY, 1999, J BIOL CHEM, V274, P11573, DOI 10.1074/jbc.274.17.11573; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KROOG GS, 1995, MED RES REV, V15, P389, DOI 10.1002/med.2610150502; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lukiw WJ, 1998, P NATL ACAD SCI USA, V95, P3914, DOI 10.1073/pnas.95.7.3914; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; MOGHIMZADEH E, 1983, NEUROSCIENCE, V10, P553, DOI 10.1016/0306-4522(83)90152-5; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murata H, 1999, AM J GASTROENTEROL, V94, P451; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PANG L, 1993, BIOCHEM J, V289, P283, DOI 10.1042/bj2890283; PENNYPACKER KR, 1994, FASEB J, V8, P475, DOI 10.1096/fasebj.8.8.8181665; Preston SR, 1996, CRIT REV ONCOL HEMAT, V23, P225, DOI 10.1016/1040-8428(96)00204-1; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; ROLLAND PH, 1980, JNCI-J NATL CANCER I, V64, P1061; Rozengurt E, 1998, J CELL PHYSIOL, V177, P507, DOI 10.1002/(SICI)1097-4652(199812)177:4<507::AID-JCP2>3.0.CO;2-K; Sawaoka H, 1999, LAB INVEST, V79, P1469; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Strakova Z, 1998, AM J PHYSIOL-ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634; Sun BD, 2000, PROSTATE, V42, P295; Tomozawa S, 2000, BRIT J CANCER, V83, P324, DOI 10.1054/bjoc.2000.1270; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; von Knethen A, 1999, J IMMUNOL, V163, P2858; von Knethen A, 2000, BIOCHEMISTRY-US, V39, P1532, DOI 10.1021/bi990820s; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wolff H, 1998, CANCER RES, V58, P4997; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; YANG Y, 2000, J BIOL CHEM, V275, P28281; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	68	115	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22941	22947		10.1074/jbc.M101801200	http://dx.doi.org/10.1074/jbc.M101801200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292836	hybrid			2022-12-25	WOS:000169412700128
J	Keifer, JA; Guttridge, DC; Ashburner, BP; Baldwin, AS				Keifer, JA; Guttridge, DC; Ashburner, BP; Baldwin, AS			Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; COLLAGEN-INDUCED ARTHRITIS; ERYTHEMA-NODOSUM LEPROSUM; TRANSCRIPTION FACTOR; TNF-ALPHA; ACTIVATION; ANGIOGENESIS; CELL; VITRO; PROTEINS	The sedative and anti-nausea drug thalidomide, which causes birth defects in humans, has been shown to have both anti-inflammatory and anti-oncogenic properties. The anti-inflammatory effect of thalidomide is associated with suppression of cytokine expression and the anti-oncogenic effect with inhibition of angio genesis. It is presently unclear whether the teratogenic properties of thalidomide are connected in any way to the beneficial, anti-disease characteristics of this drug. The transcription factor NF-kappaB has been shown to be a key regulator of inflammatory genes such as tumor ne crosis factor-alpha and interleukin-8. Inhibition of NF-kappaB is associated with reduced inflammation in animal models, such as those for rheumatoid arthritis. We show here that thalidomide can block NF-kappaB activation through a mechanism that involves the inhibition of activity of the I kappaB kinase. Consistent with the observed inhibition of NF-kappaB, thalidomide blocked the cytokine-induced expression of NF-kappaB-regulated genes such as those encoding interleukin-8, TRAF1, and c-IAP2. These data indicate that the therapeutic potential for thalidomide may be based on its ability to block NF-kappaB activation through suppression of I kappaB kinase activity.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.			Guttridge, Denis/0000-0002-7276-6609	NATIONAL CANCER INSTITUTE [R01CA072771, R01CA075080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER; NCI NIH HHS [CA72771, CA75080] Funding Source: Medline; NIGMS NIH HHS [T32 GM07092] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashby J, 1997, MUTAT RES-FUND MOL M, V396, P45, DOI 10.1016/S0027-5107(97)00174-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Calabrese L, 2000, AM J MED, V108, P487, DOI 10.1016/S0002-9343(99)00408-8; Calderon P, 1997, INT J DERMATOL, V36, P881, DOI 10.1046/j.1365-4362.1997.00298.x; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; Corral LG, 1999, J IMMUNOL, V163, P380; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Eisen T, 2000, BRIT J CANCER, V82, P812, DOI 10.1054/bjoc.1999.1004; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hales BF, 1999, NAT MED, V5, P489, DOI 10.1038/8371; Hauschild A, 1997, CLIN EXP IMMUNOL, V108, P428, DOI 10.1046/j.1365-2249.1997.3781274.x; Joussen AM, 1999, GRAEF ARCH CLIN EXP, V237, P952, DOI 10.1007/s004170050330; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; Kroger H, 1996, INFLAMMATION, V20, P203, DOI 10.1007/BF01487406; LENZ W, 1988, TERATOLOGY, V38, P203, DOI 10.1002/tera.1420380303; Marriott JB, 1999, IMMUNOL TODAY, V20, P538, DOI 10.1016/S0167-5699(99)01531-5; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; MCBRIDE WG, 1977, TERATOLOGY, V16, P79, DOI 10.1002/tera.1420160113; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Minchinton AI, 1996, ANTI-CANCER DRUG, V7, P339, DOI 10.1097/00001813-199605000-00015; Moller DR, 1997, J IMMUNOL, V159, P5157; Moreira AL, 1997, AIDS RES HUM RETROV, V13, P857, DOI 10.1089/aid.1997.13.857; Moreira AL, 1999, J NEURO-ONCOL, V43, P109, DOI 10.1023/A:1006202700039; Oliveira RB, 1999, J LEUKOCYTE BIOL, V65, P364, DOI 10.1002/jlb.65.3.364; Oliver SJ, 1998, J RHEUMATOL, V25, P964; Oliver SJ, 1999, CLIN EXP IMMUNOL, V118, P315; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; Rovelli A, 1998, BONE MARROW TRANSPL, V21, P577, DOI 10.1038/sj.bmt.1701138; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; SAMPAIO EP, 1993, J INFECT DIS, V168, P408, DOI 10.1093/infdis/168.2.408; Sauer H, 2000, AM J PATHOL, V156, P151, DOI 10.1016/S0002-9440(10)64714-1; SCHULER U, 1995, DRUG SAFETY, V12, P364, DOI 10.2165/00002018-199512060-00002; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHANNON EJ, 1992, LEPROSY REV, V63, P5; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Tavares JL, 1997, RESP MED, V91, P31, DOI 10.1016/S0954-6111(97)90134-7; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015	53	388	415	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22382	22387		10.1074/jbc.M100938200	http://dx.doi.org/10.1074/jbc.M100938200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297551	Green Published, hybrid			2022-12-25	WOS:000169412700056
J	Bravo, A; Serrano-Heras, G; Salas, M				Bravo, A; Serrano-Heras, G; Salas, M			A single amino acid substitution within a coiled-coil motif changes the assembly of a 53-amino acid protein from two-dimensional sheets to filamentous structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL-DIVISION; ELECTRON CRYSTALLOGRAPHY; INTERMEDIATE FILAMENTS; PROTOFILAMENT SHEETS; CRYSTAL-STRUCTURE; DNA-REPLICATION; NUCLEAR LAMINS; TUBULIN; FTSZ; DIMER	The bacteriophage phi 29 replication protein pi self-interacts in vitro, generating highly ordered structures. Specifically, the 53-amino acid protein p1 Delta N33, which retains the sequence of p1 spanning amino acids Met(34) to Lys(85), assembles into two-dimensional protofilament sheets. The region of protein p1 located between residues Glu(38) and Asn(65) presumably forms an alpha -helical coiled-coil structure. Here we have examined the role of this coiled-coil sequence in the formation of protofilament sheets. Using sedimentation assays and negative-stain electron microscopy analysis, we demonstrate that residues Leu(46), Met(53), and Leu(60), but not Leu(39), are essential for p1 Delta N33 assembly into sheets. Remarkably, replacement of Leu(46) by Val shifts the pathway of molecular assembly, leading to the formation of filamentous polymers similar to 10 nn in diameter. These results show, for the first time, that a short coiled-coil moth can mediate protein assembly into protofilament sheet structures.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, SIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Salas, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, SIC, E-28049 Madrid, Spain.		Salas, Margarita/J-9873-2014; Bravo, Alicia/Y-5060-2019; Garcia, Pedro/L-2808-2017	Salas, Margarita/0000-0001-5939-3441; Bravo, Alicia/0000-0002-4410-3584; Serrano-Heras, Gemma/0000-0001-9368-4832; Garcia, Pedro/0000-0001-6717-8717	NIGMS NIH HHS [2RO1 GM27242-21] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BAKER TS, 1978, J MOL BIOL, V123, P86; BORDO D, 1991, J MOL BIOL, V217, P721, DOI 10.1016/0022-2836(91)90528-E; Bravo A, 1997, J MOL BIOL, V269, P102, DOI 10.1006/jmbi.1997.1032; Bravo A, 1998, EMBO J, V17, P6096, DOI 10.1093/emboj/17.20.6096; Bravo A, 2000, EMBO J, V19, P5575, DOI 10.1093/emboj/19.20.5575; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; Cohen C, 1998, J STRUCT BIOL, V122, P3, DOI 10.1006/jsbi.1998.3975; CROSS RA, 1991, EMBO J, V10, P747, DOI 10.1002/j.1460-2075.1991.tb08006.x; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; GASKIN F, 1977, J BIOL CHEM, V252, P6918; GOLDMAN AE, 1986, P NATL ACAD SCI USA, V83, P3839, DOI 10.1073/pnas.83.11.3839; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Herrmann H, 2000, CURR OPIN CELL BIOL, V12, P79, DOI 10.1016/S0955-0674(99)00060-5; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Moir RD, 2000, J STRUCT BIOL, V129, P324, DOI 10.1006/jsbi.2000.4251; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; NOGALES E, 1995, J STRUCT BIOL, V115, P199, DOI 10.1006/jsbi.1995.1044; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2	30	7	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21250	21256		10.1074/jbc.M011296200	http://dx.doi.org/10.1074/jbc.M011296200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283004	hybrid, Green Published			2022-12-25	WOS:000169297900061
J	Hirota, K; Semenza, GL				Hirota, K; Semenza, GL			Rac1 activity is required for the activation of hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FACTOR-I; TRANSCRIPTIONAL ACTIVITY; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SMALL GTPASES; DNA-BINDING; EXPRESSION; ALPHA; CDC42	Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that mediates cellular and systemic homeostatic responses (including erythropoiesis, angiogenesis, and glycolysis) to reduced O-2 availability in mammals. Hypoxia induces both the protein expression and transcriptional activity of the HIF-1 alpha subunit. However, the molecular mechanisms of sensing and signal transduction by which changes in O-2 concentration result in changes in HIF-1 activity are poorly understood. We report here that the small GTPase Rad is activated in response to hypoxia and is required for the induction of HIF-1 alpha protein expression and transcriptional activity in hypoxic cells.	Johns Hopkins Univ, Sch Med, Dept Pediat & Med, Inst Med Genet, Baltimore, MD 21287 USA; Kyoto Univ, Kyoto Univ Hosp, Dept Anesthesia, Kyoto 6068507, Japan	Johns Hopkins University; Kyoto University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat & Med, Inst Med Genet, Baltimore, MD 21287 USA.	gsemenza@jhmi.edu	Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827	NHLBI NIH HHS [R01-HL55338] Funding Source: Medline; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Ehleben W, 1998, RESP PHYSIOL, V114, P25, DOI 10.1016/S0034-5687(98)00078-4; FANDREY J, 1994, BIOCHEM J, V303, P507, DOI 10.1042/bj3030507; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim KS, 1998, J CLIN INVEST, V101, P1821, DOI 10.1172/JCI1830; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ozaki M, 2000, J BIOL CHEM, V275, P35377, DOI 10.1074/jbc.M005287200; Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sodhi A, 2000, CANCER RES, V60, P4873; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	47	137	147	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21166	21172		10.1074/jbc.M100677200	http://dx.doi.org/10.1074/jbc.M100677200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283021	hybrid			2022-12-25	WOS:000169297900051
J	Schotte, P; Schauvliege, R; Janssens, S; Beyaert, R				Schotte, P; Schauvliege, R; Janssens, S; Beyaert, R			The cathepsin B inhibitor z-FA.fmk inhibits cytokine production in macrophages stimulated by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; PEPTIDYL FLUOROMETHYL KETONES; RHEUMATOID-ARTHRITIS; TRANSCRIPTION FACTOR; DEPENDENT TRANSCRIPTION; ALPHA DEGRADATION; GENE-EXPRESSION; ACTIVATION; CELLS	Cathepsin B has previously been shown to proteolytically activate the proinflammatory caspase-11 in vitro, Here we show that cathepsin B is not involved in activation of caspase-11 induced by lipopolysaccharide (LPS) and subsequent maturation of interleukin (IL)-1 beta in macrophages. Nevertheless, we found that the cathepsin B inhibitor benzyloxycarbonyl-Phe-Ala-fluoromethylketone (z-FA.fmk) prevents LPS-induced production of IL-1 alpha, IL-1 beta, and tumor necrosis factor at the transcriptional level. The latter was not because of cathepsin B inhibition, but was mediated by inhibition of the transactivation potential of the nuclear factor kappaB (NF-kappaB). z-FA.fmk did not prevent LPS-induced activation of p38 mitogen-activated protein kinase, which was shown to be involved in NF-kappaB transactivation in response to LPS. These results suggest that the previously described therapeutic effect of z-FA.fmk in the treatment of rheumatoid arthritis might not only result from inhibition of cathepsin B but also implicates an important contribution from the inhibition of NF-kappaB-dependent gene expression.	Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signal Transduct Inflammat, B-9000 Ghent, Belgium; State Univ Ghent, B-9000 Ghent, Belgium	Ghent University	Beyaert, R (corresponding author), Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Unit Mol Signal Transduct Inflammat, KL Ledeganckstr 35, B-9000 Ghent, Belgium.		Beyaert, Rudi/B-2589-2009; Janssens, Sophie/HHN-1756-2022	Beyaert, Rudi/0000-0002-5704-582X				AHMED NK, 1992, BIOCHEM PHARMACOL, V44, P1201, DOI 10.1016/0006-2952(92)90385-V; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Brennan P, 1998, BIOCHEM PHARMACOL, V55, P965, DOI 10.1016/S0006-2952(97)00535-2; Codorean E, 1985, Morphol Embryol (Bucur), V31, P269; Desmedt M, 1998, J IMMUNOL, V160, P5300; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; ESSER RE, 1993, J RHEUMATOL, V20, P1176; Gabay C, 1998, SPRINGER SEMIN IMMUN, V20, P229, DOI 10.1007/s002810050032; Goto M, 1999, CYTOKINE, V11, P16, DOI 10.1006/cyto.1998.0390; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Lemaire R, 1997, BRIT J RHEUMATOL, V36, P735; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Mort J S, 1985, Prog Clin Biol Res, V180, P243; MORT JS, 1984, ARTHRITIS RHEUM, V27, P509, DOI 10.1002/art.1780270505; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; SHAW E, 1986, BIOMED BIOCHIM ACTA, V45, P1397; SHINAGAWA T, 1990, P NATL ACAD SCI USA, V87, P1927, DOI 10.1073/pnas.87.5.1927; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRABANDT A, 1991, ARTHRITIS RHEUM, V34, P1444; VANDENABEELE P, 1990, J IMMUNOL METHODS, V135, P25, DOI 10.1016/0022-1759(90)90252-Q; VANNOORDEN CJF, 1988, J RHEUMATOL, V15, P1525; Votta BJ, 1997, J BONE MINER RES, V12, P1396, DOI 10.1359/jbmr.1997.12.9.1396; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Watkins LR, 1999, LIFE SCI, V65, P449, DOI 10.1016/S0024-3205(99)00095-8	37	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21153	21157		10.1074/jbc.M102239200	http://dx.doi.org/10.1074/jbc.M102239200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290751	hybrid			2022-12-25	WOS:000169297900049
J	Sharma, AK; Kuhns, JJ; Yan, SQ; Friedline, RH; Long, B; Tisch, R; Collins, EJ				Sharma, AK; Kuhns, JJ; Yan, SQ; Friedline, RH; Long, B; Tisch, R; Collins, EJ			Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE BINDING; STRUCTURAL BASIS; 3-DIMENSIONAL STRUCTURE; REVERSE-TRANSCRIPTASE; ANGSTROM RESOLUTION; ANTITUMOR IMMUNITY; CRYSTAL-STRUCTURES; VIRAL PEPTIDES; HIGH-AFFINITY; ANTIGEN	An immunogenic peptide (GP2) derived from HER-2/neu binds to HLA-A2.1 very poorly. Some altered-peptide ligands (APL) of GP2 have increased binding affinity and generate improved cytotoxic T lymphocyte recognition of GP2-presenting tumor cells, but most do not. Increases in binding affinity of single-substitution APL are not additive in double-substitution APL. A common first assumption about peptide binding to class I major histocompatibility complex is that each residue binds independently. In addition, immunologists interested in immunotherapy frequently assume that anchor substitutions do not affect T cell receptor contact residues. However, the crystal structures of two GP2 APL show that the central residues change position depending on the identity of the anchor residue(s), Thus it is clear that subtle changes in the identity of anchor residues may have significant effects on the positions of the T cell receptor contact residues.	Univ N Carolina, Dept Microbiol & Immunol, CB 7290, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Collins, EJ (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, CB 7290, 804 ME Jones Bldg, Chapel Hill, NC 27599 USA.	edward_collins@med.unc.edu						Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Batalia MA, 1997, BIOPOLYMERS, V43, P281, DOI 10.1002/(SICI)1097-0282(1997)43:4<281::AID-BIP3>3.0.CO;2-R; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; Bouvier M, 1998, PROTEINS, V33, P97, DOI 10.1002/(SICI)1097-0134(19981001)33:1<97::AID-PROT9>3.0.CO;2-I; BOUVIER M, 1994, SCIENCE, V265, P398, DOI 10.1126/science.8023162; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN WS, 1994, MOL IMMUNOL, V31, P1069; Clay TM, 1999, J IMMUNOL, V162, P1749; COLBERT RA, 1994, IMMUNITY, V1, P121, DOI 10.1016/1074-7613(94)90105-8; Collins EJ, 1999, J IMMUNOL, V162, P331; Dannull J, 2000, CANCER RES, V60, P5522; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Dodson EJ, 1997, METHOD ENZYMOL, V277, P620, DOI 10.1016/S0076-6879(97)77034-4; El-Shami KM, 2000, INT J CANCER, V85, P236, DOI 10.1002/(SICI)1097-0215(20000115)85:2<236::AID-IJC14>3.3.CO;2-X; Fong L, 1997, J IMMUNOL, V159, P3113; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garboczi DN, 1999, IMMUNITY, V10, P1, DOI 10.1016/S1074-7613(00)80001-1; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; Harada M, 2001, CANCER RES, V61, P1089; Heukamp LC, 2001, INT J CANCER, V91, P385, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1051>3.0.CO;2-Z; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kessler JH, 2001, J EXP MED, V193, P73, DOI 10.1084/jem.193.1.73; Khan AR, 2000, J IMMUNOL, V164, P6398, DOI 10.4049/jimmunol.164.12.6398; Kirksey TJ, 1999, J BIOL CHEM, V274, P37259, DOI 10.1074/jbc.274.52.37259; Kuhns JJ, 1999, J BIOL CHEM, V274, P36422, DOI 10.1074/jbc.274.51.36422; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; Lehner PJ, 1998, CURR BIOL, V8, pR605, DOI 10.1016/S0960-9822(98)70387-2; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Micheletti F, 1999, EUR J IMMUNOL, V29, P2579, DOI 10.1002/(SICI)1521-4141(199908)29:08<2579::AID-IMMU2579>3.0.CO;2-E; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ono T, 1998, J IMMUNOL, V161, P5454; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PARKER KC, 1994, J IMMUNOL, V152, P163; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P432, DOI 10.1073/pnas.92.2.432; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; POGUE RR, 1995, P NATL ACAD SCI USA, V92, P8166, DOI 10.1073/pnas.92.18.8166; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; STUBER G, 1994, EUR J IMMUNOL, V24, P765, DOI 10.1002/eji.1830240341; YOSHINO I, 1994, CANCER RES, V54, P3387; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6	60	50	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21443	21449		10.1074/jbc.M010791200	http://dx.doi.org/10.1074/jbc.M010791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287414	hybrid, Green Published			2022-12-25	WOS:000169297900087
J	Subramaniam, V; Jovin, TM; Rivera-Pomar, RV				Subramaniam, V; Jovin, TM; Rivera-Pomar, RV			Aromatic amino acids are critical for stability of the bicoid homeodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; DNA-BINDING SPECIFICITY; ULTRAVIOLET CIRCULAR-DICHROISM; ANTENNAPEDIA HOMEODOMAIN; ENGRAILED HOMEODOMAIN; ANGSTROM RESOLUTION; DROSOPHILA EMBRYO; RECOGNITION HELIX; BURIED TRYPTOPHAN; CRYSTAL-STRUCTURE	The Drosophila Bicoid (Bcd) protein plays a dual role as a transcription and translation factor dependent on the unique DNA and RNA binding properties of the homeodomain (HD). We have used circular dichroism and fluorescence spectroscopy to probe the structure and stability of the Bcd-HD, for which a high resolution structure is not yet available. The fluorescence from the single tryptophan residue in the HD (Trp-48) is strongly quenched in the native state but is dramatically enhanced (similar to 20-fold) upon denaturation. Similar results were obtained with the Ultrabithorax HD (Ubx-HD), suggesting that the unusual tryptophan fluorescence may be a general phenomenon of HD proteins. We have used site-directed mutagenesis to explore the role of aromatic acids in the structure of the Bcd-HD and to evaluate the proposal that interactions between the strictly conserved Trp residue in HDs and nearby aromatic residues are responsible for the fluorescence quenching in the native state. We determined that both Trp-48 and Phe-8 in the N-terminal region of the HD are individually necessary for structural stability of the Bcd-HD, the latter most likely as a factor coordinating the orientation of the N-terminal helix I and the recognition helix for efficient binding to a DNA target.	Max Planck Inst Biophys Chem, Dept Mol Biol, D-37077 Gottingen, Germany	Max Planck Society	Rivera-Pomar, RV (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Biol, Fassberg 11, D-37077 Gottingen, Germany.		Subramaniam, Vinod/B-4197-2010	Subramaniam, Vinod/0000-0001-6712-7266				ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; BILLETER M, 1990, J MOL BIOL, V214, P183, DOI 10.1016/0022-2836(90)90155-F; Billeter M, 1996, PROG BIOPHYS MOL BIO, V66, P211, DOI 10.1016/S0079-6107(97)00006-0; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; Burz DS, 1998, EMBO J, V17, P5998, DOI 10.1093/emboj/17.20.5998; Carra JH, 1997, BIOCHEMISTRY-US, V36, P526, DOI 10.1021/bi962206b; CHAKRABARTTY A, 1993, BIOCHEMISTRY-US, V32, P5560, DOI 10.1021/bi00072a010; Chan SK, 1997, NATURE, V388, P634, DOI 10.1038/41692; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; DAMANTE G, 1994, FEBS LETT, V354, P293, DOI 10.1016/0014-5793(94)01145-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; FERNANDO T, 1992, BIOCHEMISTRY, V31; Fraenkel E, 1998, J MOL BIOL, V284, P351, DOI 10.1006/jmbi.1998.2147; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Gryczynski I, 1996, BIOSPECTROSCOPY, V2, P9, DOI 10.1002/(SICI)1520-6343(1996)2:1<9::AID-BSPY2>3.0.CO;2-6; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; Morgan CG, 1996, REV SCI INSTRUM, V67, P41, DOI 10.1063/1.1147228; MORGAN CG, 1995, REV SCI INSTRUM, V66, P48, DOI 10.1063/1.1146325; Nanda V, 1999, BIOPHYS J, V76, pA448; Nanda V, 2000, PROTEINS, V40, P112, DOI 10.1002/(SICI)1097-0134(20000701)40:1<112::AID-PROT130>3.0.CO;2-C; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTTING G, 1988, EMBO J, V7, P4305, DOI 10.1002/j.1460-2075.1988.tb03329.x; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; Rouviere N, 1997, BIOCHEMISTRY-US, V36, P7339, DOI 10.1021/bi962289w; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; Subramaniam V, 1999, BIOPHYS J, V76, pA108; SUWAIYAN A, 1989, CHEM PHYS LETT, V159, P244, DOI 10.1016/0009-2614(89)87418-4; TREISMAN J, 1989, CELL, V59, P553; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; VANDUUREN B, 1961, J ORG CHEM, V26, P2954, DOI 10.1021/jo01066a079; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOODY RW, 1978, BIOPOLYMERS, V17, P1451, DOI 10.1002/bip.1978.360170606; YANG JT, 1986, METHOD ENZYMOL, V130, P208	45	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21506	21511		10.1074/jbc.M102292200	http://dx.doi.org/10.1074/jbc.M102292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294843	Green Published, hybrid			2022-12-25	WOS:000169297900095
J	Albert, T; Wells, J; Funk, JO; Pullner, A; Raschke, EE; Stelzer, G; Meisterernst, I; Farnham, PJ; Eick, D				Albert, T; Wells, J; Funk, JO; Pullner, A; Raschke, EE; Stelzer, G; Meisterernst, I; Farnham, PJ; Eick, D			The chromatin structure of the dual c-myc promoter P1/P2 is regulated by separate elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; ZINC-FINGER PROTEIN; TARGET GENE SPECIFICITY; YEAST SWI/SNF COMPLEX; TRANSCRIPTIONAL REPRESSION; PREMATURE TERMINATION; REMODELING COMPLEX; FAMILY PROTEINS; HISTONE OCTAMER; BINDING SITE	The proto-oncogene c-myc is transcribed from a dual promoter P1/P2, with transcription initiation sites 160 base pairs apart. Here we have studied the transcriptional activation of both promoters on chromatin templates, c-myc chromatin was reconstituted on stably transfected, episomal, Epstein-Barr virus-derived vectors in a B cell line. Episomal P1 and P2 promoters showed only basal activity but were strongly inducible by histone deacetylase inhibitors. The effect of promoter mutations on c-myc activity, chromatin structure, and E2F binding was studied, The ME1a1 binding site between PI and P2 was required for the maintenance of an open chromatin configuration of the dual c-myc promoters. Mutation of this site strongly reduced the sensitivity of the core promoter region of P1/P2 to micrococcal nuclease and prevented binding of polymerase II (pol II) at the P2 promoter, In contrast, mutation of the P2 TATA box also abolished binding of pol II at the P2 promoter but did not affect the chromatin structure of the P1/P2 core promoter region. The E2F binding site adjacent to ME1a1 is required for repression of the P2 promoter but not the p1 promoter, likely by recruitment of histone deacetylase activity. Chromatin precipitation experiments with E2F-specific antibodies revealed binding of E2F-1, E2F-2, and E2F-4 to the E2F site of the c-myc promoter in vivo if the E2F site was intact. Taken together, the analyses support a model with a functional hierarchy for regulatory elements in the c-myc promoter region; binding of proteins to the ME1a1 site provides a nncleosome-free region of chromatin near the P2 start site, binding of E2F results in transcriptional repression without affecting polymerase recruitment, and the TATA box is required for polymerase recruitment.	GSF Munich, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, D-81377 Munich, Germany; GSF Munich, Res Ctr Environm & Hlth, Dept Prot Chem, D-81377 Munich, Germany; Univ Wisconsin, Sch Med, Mcardle Lab Canc Res, Madison, WI 53706 USA	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Wisconsin System; University of Wisconsin Madison	Eick, D (corresponding author), GSF Munich, Res Ctr Environm & Hlth, Inst Clin Mol Biol & Tumor Genet, Marchioninistr 25, D-81377 Munich, Germany.	eick@gsf.de		Albert, Thomas Karl/0000-0002-2488-0706; Farnham, Peggy/0000-0003-4469-7914				Albert T, 1997, MOL CELL BIOL, V17, P4363, DOI 10.1128/MCB.17.8.4363; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; Geltinger C, 1996, GENE EXPRESSION, V6, P113; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Komatsu M, 1997, ONCOGENE, V15, P1123, DOI 10.1038/sj.onc.1201283; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LAVENU A, 1995, MOL CELL BIOL, V15, P4410; Levens D, 1997, CURR TOP MICROBIOL, V224, P33; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lutz M, 2000, NUCLEIC ACIDS RES, V28, P1707, DOI 10.1093/nar/28.8.1707; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MOBERG KH, 1992, ONCOGENE, V7, P411; OSWALD F, 1994, ONCOGENE, V9, P2029; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PLET A, 1995, ONCOGENE, V10, P319; Pullner A, 1996, J BIOL CHEM, V271, P31452, DOI 10.1074/jbc.271.49.31452; Raschke EE, 1999, J IMMUNOL, V163, P4375; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1993, ONCOGENE, V8, P1437; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; Takahashi Y, 2000, GENE DEV, V14, P804; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WOLF DA, 1995, NUCLEIC ACIDS RES, V23, P3373, DOI 10.1093/nar/23.17.3373; Xie J, 2000, EMBO J, V19, P672, DOI 10.1093/emboj/19.4.672; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	52	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20482	20490		10.1074/jbc.M100265200	http://dx.doi.org/10.1074/jbc.M100265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279041	hybrid			2022-12-25	WOS:000169135100109
J	Sadowski, CL; Choi, TS; Le, M; Wheeler, TT; Wang, LH; Sadowski, HB				Sadowski, CL; Choi, TS; Le, M; Wheeler, TT; Wang, LH; Sadowski, HB			Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY-ELEMENT; EPIDERMAL GROWTH-FACTOR; TRANSCRIPTION FACTOR FKHR; GENE-EXPRESSION; TYROSINE PHOSPHORYLATION; GLUCOCORTICOID RECEPTOR; DIFFERENTIAL REGULATION; SIGNAL-TRANSDUCTION; NEGATIVE REGULATION; BINDING PROTEIN-1C	Previously, by a yeast 2-hybrid screen, we identified signal transducer and activator of transcription 5b (Stat5b) as a substrate of the insulin receptor (IR). We demonstrated that refeeding of fasted mice leads to rapid activation of Stat5 proteins in liver, skeletal muscle, and fat, suggesting that Stat5b is a physiological target of insulin. Here, we show that injection of glucose or insulin into fasted mice leads to robust activation of both Stat5a and Stat5b in skeletal muscle. In C2C12 myotubes, we find that insulin stimulates tyrosine phosphorylation of Stat5a and Stat5b by 3-5-fold. This degree of Stat5 activation in vitro is significantly lower than what we observe in vivo and inversely correlates with IRS-1/2 levels. We can recapitulate robust insulin activation of Stat5 in C2C12 cells by stable overexpression of the human IR (hIR). To identify insulin-activated genes that are Stat5 targets, we also overexpressed an IR mutant (LA-hIR) that signals normally for mitogen-activated protein kinase- and phosphatidylinositol 3-kinase-dependent pathways but is deficient in Stat5 signaling in response to insulin. We demonstrate that insulin induces the expression of SOCS-2 mRNA in the wild type hIR but not in the LA-hIR-overexpressing cells. The induction of SOCS-3 by insulin is reduced but not lost in the LA-hIR cells. Therefore, our results suggest that insulin induction of SOCS-2, and in part SOCS-3 mRNA expression, is mediated by Stat5 and can be independent of mitogen activated protein kinase and phosphatidylinositol 3-kinase-signaling pathways.	Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; AgRes, Dairy Sci Grp, Hamilton, New Zealand	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; AgResearch - New Zealand	Sadowski, HB (corresponding author), Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010499] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53000] Funding Source: Medline; NINDS NIH HHS [NS10499] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams TE, 1998, J BIOL CHEM, V273, P1285, DOI 10.1074/jbc.273.3.1285; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Azzout-Marniche D, 2000, BIOCHEM J, V350, P389, DOI 10.1042/0264-6021:3500389; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Chan JLK, 1997, J BIOL CHEM, V272, P146; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chin H, 1997, BLOOD, V89, P4327, DOI 10.1182/blood.V89.12.4327; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Emanuelli B, 2000, J BIOL CHEM, V275, P15985, DOI 10.1074/jbc.275.21.15985; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; KELLER SR, 1991, J BIOL CHEM, V266, P12817; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Lechner J, 1997, J BIOL CHEM, V272, P20954, DOI 10.1074/jbc.272.33.20954; Lopaczynski W, 1999, ACTA BIOCHIM POL, V46, P51, DOI 10.18388/abp.1999_4183; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Moutoussamy S, 1998, EUR J BIOCHEM, V255, P1, DOI 10.1046/j.1432-1327.1998.2550001.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; NICHOLSON SE, 1996, J BIOL CHEM, V271, P947; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; Paukku K, 2000, BIOCHEM J, V345, P759, DOI 10.1042/0264-6021:3450759; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200; Shimomura I, 2000, MOL CELL, V6, P77, DOI 10.1016/S1097-2765(00)00009-5; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Stoecklin Elisabeth, 1996, Nature (London), V383, P726; Storz P, 1998, FEBS LETT, V440, P41, DOI 10.1016/S0014-5793(98)01421-5; Storz P, 1999, FEBS LETT, V464, P159, DOI 10.1016/S0014-5793(99)01689-0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; White MF, 1998, RECENT PROG HORM RES, V53, P119; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	47	57	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20703	20710		10.1074/jbc.M101014200	http://dx.doi.org/10.1074/jbc.M101014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279166	hybrid			2022-12-25	WOS:000169135100137
J	Streeper, RS; Hornbuckle, LA; Svitek, CA; Goldman, JK; Oeser, JK; O'Brien, RM				Streeper, RS; Hornbuckle, LA; Svitek, CA; Goldman, JK; Oeser, JK; O'Brien, RM			Protein kinase A phosphorylates hepatocyte nuclear factor-6 and stimulates glucose-6-phosphatase catalytic subunit gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-STORAGE-DISEASE; RAT-LIVER GLUCOSE-6-PHOSPHATASE; CUT HOMEODOMAIN PROTEINS; CAMP RESPONSE ELEMENT; GROWTH-HORMONE; DNA-BINDING; GLUCOSE-METABOLISM; MESSENGER-RNA; DIABETIC RATS; FACTOR-I	Glucose-6-phosphatase is a multicomponent system that catalyzes the terminal step in gluconeogenesis. To examine the effect of the cAMP signal transduction pathway on expression of the gene encoding the mouse glucose-6-phosphatase catalytic subunit (G6Pase), the liver-derived HepG2 cell line was transiently co-transfected with a series of G6Pase-chloramphenicol acetyltransferase fusion genes and an expression vector encoding the catalytic subunit of cAMP-dependent protein kinase A (PKA). PKA markedly stimulated G6Pase-chloramphenicol acetyltransferase fusion gene expression, and mutational analysis of the G6Pase promoter revealed that multiple cis-acting elements were required for this response. One of these elements was mapped to the G6Pase promoter region between -114 and -99, and this sequence was shown to bind hepatocyte nuclear factor (HNF)-6. This HNF-6 binding site was able to confer a stimulatory effect of PKA on the expression of a heterologous fusion gene; a mutation that abolished HNF-6 binding also abolished the stimulatory effect of PKA, Further investigation revealed that PKA phosphorylated HNF-6 in vitro. Site-directed mutation of three consensus PKA phosphorylation sites in the HNF-6 carboxyl terminus markedly reduced this phosphorylation. These results suggest that the stimulatory effect of PKA on G6Pase fusion gene transcription in HepG2 cells may be mediated in part by the phosphorylation of HNF-6.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Vanderbilt University	O'Brien, RM (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 761 MRB 2, Nashville, TN 37232 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007563, P60DK020593, R01DK056374] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593, P60 DK20593, DK56374, 5 T 32 DK07563-12] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; BERGLUND L, 1977, J BIOL CHEM, V252, P613; BYUS CV, 1978, J CYCLIC NUCL PROT, V4, P45; Chapman SC, 1999, J BIOL CHEM, V274, P18625, DOI 10.1074/jbc.274.26.18625; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; CHEN YT, 1991, PEDIATR NEPHROL, V5, P71, DOI 10.1007/BF00852851; Chou JY, 1999, TRENDS ENDOCRIN MET, V10, P104; CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; Coqueret O, 1996, J BIOL CHEM, V271, P24862, DOI 10.1074/jbc.271.40.24862; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; Felinski EA, 2001, MOL CELL BIOL, V21, P1001, DOI 10.1128/MCB.21.4.1001-1010.2001; Foster JD, 1997, P SOC EXP BIOL MED, V215, P314; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hiraiwa H, 1999, J BIOL CHEM, V274, P5532, DOI 10.1074/jbc.274.9.5532; Kim JA, 2000, P NATL ACAD SCI USA, V97, P11292, DOI 10.1073/pnas.97.21.11292; Lahuna O, 1997, P NATL ACAD SCI USA, V94, P12309, DOI 10.1073/pnas.94.23.12309; Lahuna O, 2000, MOL ENDOCRINOL, V14, P285, DOI 10.1210/me.14.2.285; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; Lannoy VJ, 2000, J BIOL CHEM, V275, P22098, DOI 10.1074/jbc.M000855200; Lannoy VJ, 1998, J BIOL CHEM, V273, P13552, DOI 10.1074/jbc.273.22.13552; Lemaigre FP, 1996, P NATL ACAD SCI USA, V93, P9460, DOI 10.1073/pnas.93.18.9460; Lin BC, 1999, HUM GENET, V105, P515, DOI 10.1007/s004390051140; Lin BC, 1997, BIOCHEMISTRY-US, V36, P14096, DOI 10.1021/bi9703249; Liu LS, 1998, J BIOL CHEM, V273, P31160, DOI 10.1074/jbc.273.47.31160; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Puskas F, 1999, J BIOL CHEM, V274, P117, DOI 10.1074/jbc.274.1.117; Rastegar M, 2000, ENDOCRINOLOGY, V141, P1686, DOI 10.1210/en.141.5.1686; Rastegar M, 1998, BIOCHEM J, V334, P565, DOI 10.1042/bj3340565; Rausa F, 1997, DEV BIOL, V192, P228, DOI 10.1006/dbio.1997.8744; Samadani U, 1996, MOL CELL BIOL, V16, P6273; Sambrook J., 2002, MOL CLONING LAB MANU; Schmoll D, 1999, BIOCHEM J, V338, P457, DOI 10.1042/0264-6021:3380457; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; Seoane J, 1997, J BIOL CHEM, V272, P26972, DOI 10.1074/jbc.272.43.26972; SINGH TJ, 1977, J BIOL CHEM, V252, P625; SINGH TJ, 1984, J BIOL CHEM, V259, P2857; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 2000, J BIOL CHEM, V275, P12108, DOI 10.1074/jbc.275.16.12108; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Trinh KY, 1998, J BIOL CHEM, V273, P31615, DOI 10.1074/jbc.273.47.31615	54	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19111	19118		10.1074/jbc.M101442200	http://dx.doi.org/10.1074/jbc.M101442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279202	hybrid			2022-12-25	WOS:000169091000065
J	Gmachl, MJS; Wimmer, C				Gmachl, MJS; Wimmer, C			Sequential involvement of P115, SNAREs, and Rab proteins in intra-Golgi protein transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SENSITIVE FUSION PROTEIN; DISSOCIATION INHIBITOR ISOFORM; HOMOTYPIC VACUOLE FUSION; CELL-FREE SYSTEM; MEMBRANE-FUSION; VESICULAR TRANSPORT; ALPHA-SNAP; MOLECULAR-CLONING; SYNTAXIN FAMILY	Delivery of transport vesicles to their receptor compartment involves tethering, priming, and fusion. Soluble NSF attachment protein-alpha (alpha SNAP) mediates the disruption of SNAREs by N-ethylmaleimide sensitive factor (NSF) and was employed to determine the hierarchy of proteins responsible for intra-Golgi protein transport. The N-terminal 23 amino acids of alpha SNAP are necessary for SNARE binding. The antibody 2F10 recognizes this SNARE interaction domain of alpha SNAP and inhibits intra-Golgi protein transport reversibly. This antibody was applied to modify the transport assay to determine the protein requirements relative to the action of alpha SNAP and NSF. We found that 1) p115 acts independently of alpha SNAP and NSF, 2) SNAREs are required after tethering and interact selectively after activation by alpha SNAP and NSF, and 3) Rab proteins act after SNARE activation and before fusion.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wimmer, C (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.	wimmer@bii.ch						ANTONY C, 1992, J CELL SCI, V103, P785; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALCH WE, 1984, CELL, V39, P525, DOI 10.1016/0092-8674(84)90459-8; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brennwald P, 2000, J CELL BIOL, V149, P1, DOI 10.1083/jcb.149.1.1; BURTON J, 1993, NATURE, V361, P464, DOI 10.1038/361464a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CHEN YT, 1993, P NATL ACAD SCI USA, V90, P6508, DOI 10.1073/pnas.90.14.6508; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; CLARY DO, 1990, J BIOL CHEM, V265, P10109; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; FRIES E, 1980, P NATL ACAD SCI-BIOL, V77, P3870, DOI 10.1073/pnas.77.7.3870; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Lane J, 1998, BBA-REV BIOMEMBRANES, V1376, P27, DOI 10.1016/S0304-4157(97)00010-5; Lin CC, 1999, J CELL BIOL, V147, P1457, DOI 10.1083/jcb.147.7.1457; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mayer T, 1996, J BIOL CHEM, V271, P16097, DOI 10.1074/jbc.271.27.16097; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; Morgan A, 1996, NATURE, V382, P680, DOI 10.1038/382680a0; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; OLKKONEN VM, 1993, J CELL SCI, V106, P1249; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Pfeffer SR, 1995, COLD SPRING HARB SYM, V60, P221, DOI 10.1101/SQB.1995.060.01.025; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SASAKI T, 1990, J BIOL CHEM, V265, P2333; Sato K, 1998, SCIENCE, V281, P700, DOI 10.1126/science.281.5377.700; SEOG DH, 1994, J BIOCHEM-TOKYO, V116, P1341, DOI 10.1093/oxfordjournals.jbchem.a124685; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; Simonsen A, 1998, EUR J CELL BIOL, V75, P223, DOI 10.1016/S0171-9335(98)80116-7; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Tang BL, 1998, BIOCHEM BIOPH RES CO, V242, P345, DOI 10.1006/bbrc.1997.7966; Tang BL, 1998, BIOCHEM BIOPH RES CO, V242, P673, DOI 10.1006/bbrc.1997.8029; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Ungermann C, 2000, P NATL ACAD SCI USA, V97, P8889, DOI 10.1073/pnas.160269997; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; White J, 1999, J CELL BIOL, V147, P743, DOI 10.1083/jcb.147.4.743; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; Wong SH, 1999, MOL BIOL CELL, V10, P119, DOI 10.1091/mbc.10.1.119; Xu Y, 1997, J BIOL CHEM, V272, P20162, DOI 10.1074/jbc.272.32.20162; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	87	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18178	18184		10.1074/jbc.M101513200	http://dx.doi.org/10.1074/jbc.M101513200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279210	hybrid			2022-12-25	WOS:000168866500076
J	Isaacs, JS; Saito, S; Neckers, LM				Isaacs, JS; Saito, S; Neckers, LM			Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NUCLEAR EXPORT SIGNAL; RING-FINGER DOMAIN; DNA-DAMAGE; CELL-LINES; MDM2-MEDIATED DEGRADATION; APOPTOTIC FUNCTION; DOUBLE MINUTE-2; ACTIVATES P53; UV-RADIATION	The wild type p53 tumor suppressor protein is rapidly degraded in normal cells by MDM2, the ubiquitin ligase that serves as the key regulator of p53 function by modulating protein stability. Cellular exposure to genotoxic stress triggers the stabilization of p53 by multiple pathways that converge upon interference with MDM2 function. In this study, we first investigated the ability of HDM2 (MDM2 human homologue) to degrade endogenous p53 in neuroblastoma (NB), Although the p53 protein in NE has been reported to be constitutively stabilized, we find that HDM2 in NE is functional and facilitates the rapid turnover of p53 in nonstressed cells via the proteasome pathway. Second, we examined the relationship between p53 and HDM2 in the adriamycin-mediated stabilization of p53 in NE. We demonstrate that while p53 stabilization depends neither upon the phosphorylation of specific N-terminal sites nor upon dissociation from HDM2, it requires inactivation of functional HDM2, In support of this notion, p53 stabilization following adriamycin resulted in an inhibition of both p53 ubiquitination and HDM2 ligase activity. Taken together, these data implicate a requirement for enzymatic inactivation of HDM2 as a novel mechanism for p53 stabilization in the DNA damage response pathway.	NCI, Tumor Cell Biol Sect, Med Branch, NIH, Rockville, MD 20850 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, LM (corresponding author), NCI, Tumor Cell Biol Med Branch, NIH, KWC Ste 300,9610 Med Ctr Dr, Rockville, MD 20850 USA.							Alarcon R, 1999, CANCER RES, V59, P6046; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen F, 2000, CELL GROWTH DIFFER, V11, P239; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DOVER R, 1994, J CELL SCI, V107, P1181; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Goldman SC, 1996, AM J PATHOL, V148, P1381; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Isaacs JS, 1998, CELL GROWTH DIFFER, V9, P545; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; KOMURO H, 1993, CANCER RES, V53, P5284; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Liu GZ, 2000, CANCER RES, V60, P1810; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maki CG, 1999, J BIOL CHEM, V274, P16531, DOI 10.1074/jbc.274.23.16531; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKenzie PP, 1999, CLIN CANCER RES, V5, P4199; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1996, MOL CELL BIOL, V16, P1669; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474	60	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18497	18506		10.1074/jbc.M100638200	http://dx.doi.org/10.1074/jbc.M100638200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279110	hybrid			2022-12-25	WOS:000168866500118
J	Kim, YC; Masutani, H; Yamaguchi, Y; Itoh, K; Yamamoto, M; Yodoi, J				Kim, YC; Masutani, H; Yamaguchi, Y; Itoh, K; Yamamoto, M; Yodoi, J			Hemin-induced activation of the thioredoxin gene by Nrf2 - A differential regulation of the antioxidant responsive element by a switch of its binding factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR NRF2; PROTEIN-KINASE-C; OXIDATIVE STRESS; NF-E2-RELATED FACTOR-2; MEDIATED EXPRESSION; OXYGENASE-1 GENE; ENCODING GENE; SUBUNIT GENE; FACTOR ADF; MAF	Thioredoxin plays an important role in various cellular processes through redox regulation. Here, we have demonstrated that thioredoxin expression is transcriptionally induced in K562 cells by hemin (ferriprotoporphyrin IX) through activation of a regulatory region positioned from -452 to -420 bp of the thioredoxin gene. Insertion of a mutation in the antioxidant responsive element (ARE)/AP-1 consensus binding sequence in this region abolished the response to hemin. With electrophoretic mobility shift and DNA affinity assays, we have shown that the NF-E2p45/small Maf complex constitutively binds to the ARE. The binding of the Nrf2/small Maf complex to ARE was induced by hemin, whereas the binding of Jun/Fos proteins to ARE was induced by phorbol 12-myristate 13-acetate, but not hemin, Hemin induced nuclear translocation of Nrf2 but did not affect nuclear expression of Jun/Fos proteins. Overexpression of Nrf2 augmented the response to hemin in a dose-dependent manner. In contrast, overexpression of the dominant negative mutant of Nrf2 suppressed hemin-induced activation through the ARE. We show here hemin-induced activation of the thioredoxin gene by Nrf2 through the ARE and propose a novel mechanism of the regulation of the ARE through a switch of its binding factors.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan	Kyoto University; University of Tsukuba; University of Tsukuba	Masutani, H (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, 53 Shogoin,Kawahara Cho, Kyoto 6068507, Japan.	hmasutan@virusl.virus.kyoto-u.ac.jp	Itoh, Ken/B-9506-2013; Masutani, Hiroshi/B-5114-2014; Yamamoto, Masayuki/A-4873-2010	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436				Alam J, 2000, J BIOL CHEM, V275, P27694; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BENSIMON C, 1989, J IMMUNOL, V142, P2290; CHUI DHK, 1995, BIOCHEM BIOPH RES CO, V209, P40, DOI 10.1006/bbrc.1995.1467; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GUTTERIDGE JMC, 1988, BIOCHEM J, V256, P861, DOI 10.1042/bj2560861; Hashimoto S, 1999, BIOCHEM BIOPH RES CO, V258, P443, DOI 10.1006/bbrc.1999.0658; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P199; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; IGARASHI K, 1995, P NATL ACAD SCI USA, V92, P7445, DOI 10.1073/pnas.92.16.7445; Inamdar NM, 1996, BIOCHEM BIOPH RES CO, V221, P570, DOI 10.1006/bbrc.1996.0637; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; KAGHAD M, 1994, GENE, V140, P273, DOI 10.1016/0378-1119(94)90557-6; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Leppa S, 1997, J BIOL CHEM, V272, P30400, DOI 10.1074/jbc.272.48.30400; Masutani H, 1997, ONCOGENE, V15, P1661, DOI 10.1038/sj.onc.1201328; MASUTANI H, 1999, ANTIOXIDANT REDOX RE, P297; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MATSUI M, 1995, GENE, V152, P165, DOI 10.1016/0378-1119(94)00707-Y; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MITSUI A, 1992, BIOCHEM BIOPH RES CO, V186, P1220, DOI 10.1016/S0006-291X(05)81536-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NAKAMURA H, 1994, IMMUNOL LETT, V42, P75, DOI 10.1016/0165-2478(94)90038-8; OHIRA A, 1994, LAB INVEST, V70, P279; PACKER L, 1999, REDOX REGULATION CEL, P251; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; Takagi Y, 1999, P NATL ACAD SCI USA, V96, P4131, DOI 10.1073/pnas.96.7.4131; Taniguchi Y, 1996, NUCLEIC ACIDS RES, V24, P2746, DOI 10.1093/nar/24.14.2746; TAPPEL AL, 1955, J BIOL CHEM, V217, P721; THEODORAKIS NG, 1989, MOL CELL BIOL, V9, P3166, DOI 10.1128/MCB.9.8.3166; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; TONISSEN KF, 1991, GENE, V102, P221, DOI 10.1016/0378-1119(91)90081-L; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; WADA H, 1995, CHEST, V108, P810, DOI 10.1378/chest.108.3.810; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; Wiesel P, 2000, J BIOL CHEM, V275, P24840, DOI 10.1074/jbc.M000835200; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; WOLLMAN EE, 1988, J BIOL CHEM, V263, P15506; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612	52	253	263	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18399	18406		10.1074/jbc.M100103200	http://dx.doi.org/10.1074/jbc.M100103200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279008	hybrid			2022-12-25	WOS:000168866500104
J	Dressel, U; Bailey, PJ; Wang, SCM; Downes, M; Evans, RM; Muscat, GEO				Dressel, U; Bailey, PJ; Wang, SCM; Downes, M; Evans, RM; Muscat, GEO			A dynamic role for HDAC7 in MEF2-mediated muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCYTE ENHANCER FACTOR-2; MEF2 TRANSCRIPTION FACTOR; MYOD GENE FAMILY; SKELETAL-MUSCLE; HISTONE DEACETYLASE-4; MOUSE EMBRYOGENESIS; ORPHAN RECEPTOR; BHLH PROTEINS; MADS-BOX; EXPRESSION	The overlapping expression profile of MEF2 and the class-II histone deacetylase, HDAC7, led us to investigate the functional interaction and relationship between these regulatory proteins. HDAC7 expression inhibits the activity of MEF2 (-A, -C, and -D), and in contrast MyoD and Myogenin activities are not affected. Glutathione S-transferase pulldown and immunoprecipitation demonstrate that the repression mechanism involves direct interactions between MEF2 proteins and HDAC7 and is associated with the ability of MEF2 to interact with the N-terminal 121 amino acids of HDAC7 that encode repression domain 1. The MADS domain of MEF2 mediates the direct interaction of MEF2 with HDAC7, MEF2 inhibition by HDAC7 is dependent on the N-terminal repression domain and surprisingly does not involve the C-terminal deacetylase domain. HDAC7 interacts with CtBP and other class-I and -II HDACs suggesting that silencing of MEF2 activity involves corepressor recruitment. Furthermore, we show that induction of muscle differentiation by serum withdrawal leads to the translocation of HDAC7 from the nucleus into the cytoplasm. This work demonstrates that HDAC7 regulates the function of MEF2 proteins and suggests that this class-II HDAC regulates this important transcriptional (and pathophysiological) target in heart and muscle tissue. The nucleocytoplasmic trafficking of HDAC7 and other class-II HDACs during myogenesis provides an ideal mechanism for the regulation of HDAC targets during mammalian development and differentiation.	Univ Queensland, Inst Mol Biosci, Richie Res Lab, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Salk Inst, Howard Hughes Med Inst, Gene Express Lab, San Diego, CA 92186 USA	University of Queensland; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Salk Institute	Muscat, GEO (corresponding author), Univ Queensland, Inst Mol Biosci, Richie Res Lab, Ctr Cellular & Mol Biol, B402A, St Lucia, Qld 4072, Australia.		Evans, Ronald/AAF-4001-2019; Dressel, Uwe/C-1555-2016; Muscat, George/A-6401-2017; Wang, Shu-Ching/C-6082-2017	Evans, Ronald/0000-0002-9986-5965; Dressel, Uwe/0000-0003-4505-7855; Bailey, Peter/0000-0002-0857-2041; Muscat, George/0000-0002-5829-5695; Wang, Shu-Ching/0000-0002-7871-3735				Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Black BL, 1998, MOL CELL BIOL, V18, P69, DOI 10.1128/MCB.18.1.69; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; Burke L, 1996, NUCLEIC ACIDS RES, V24, P3481, DOI 10.1093/nar/24.18.3481; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Chen SL, 2000, GENE DEV, V14, P1209; Dangond F, 1998, BIOCHEM BIOPH RES CO, V242, P648, DOI 10.1006/bbrc.1997.8033; DOWNES M, 1995, MOL ENDOCRINOL, V9, P1666, DOI 10.1210/me.9.12.1666; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kao HY, 2000, GENE DEV, V14, P55; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; Muscat GEO, 2000, NAT MED, V6, P1216, DOI 10.1038/81312; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; ONATE SA, 1995, SCIENCE, V270, P1354; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Subramanian SV, 1996, MECH DEVELOP, V57, P103, DOI 10.1016/0925-4773(96)00542-4; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200	52	156	160	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17007	17013		10.1074/jbc.M101508200	http://dx.doi.org/10.1074/jbc.M101508200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279209	hybrid			2022-12-25	WOS:000168730400054
J	Handa, P; Acharya, N; Varshney, U				Handa, P; Acharya, N; Varshney, U			Chimeras between single-stranded DNA-binding proteins from Escherichia coli and Mycobacterium tuberculosis reveal that their C-terminal domains interact with uracil DNA glycosylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SSB-GENE; REPLICATION; PURIFICATION; MUTAGENESIS; EXPRESSION; OLIGOMERS; SEQUENCE; COMPLEX; NMR	Uracil, a promutagenic base in DNA can arise by spontaneous deamination of cytosine or incorporation of dUMP by DNA polymerase. Uracil is removed from DNA by uracil DNA glycosylase (UDG), the first enzyme in the uracil excision repair pathway. We recently reported that the Escherichia coli single-stranded DNA binding protein (SSB) facilitated uracil excision from certain structured substrates by E, coli UDG; (EcoUDG) and suggested the existence of interaction between SSB and UDG. In this study, we have made use of the chimeric proteins obtained by fusion of N- and C-terminal domains of SSBs from E, coli and Mycobacterium tuberculosis to investigate interactions between SSBs and UDGs, The EcoSSB or a chimera containing its C-terminal domain interacts with EcoUDG in a binary (SSB-UDG) or a ternary (DNA-SSB-UDG) complex. However, the chimera containing the N-terminal domain from EcoSSB showed no interactions with EcoUDG. Thus, the C-terminal domain (48 amino acids) of EcoSSB is necessary and sufficient for interaction with EcoUDG. The data also suggest that the C-terminal domain (34 amino acids) of MtuSSB is a predominant determinant for mediating its interaction with MtuUDG. The mechanism of how the interactions between SSB and UDG could be important in uracil excision repair pathway has been discussed.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Varshney, U (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.		Varshney, Umesh/Q-6914-2019; Varshney, Umesh/A-8062-2009					Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; Ghosh M, 1999, NUCLEIC ACIDS RES, V27, P3938, DOI 10.1093/nar/27.19.3938; Ghosh M, 2000, NUCLEIC ACIDS RES, V28, P1906, DOI 10.1093/nar/28.9.1906; Handa P, 2001, J BIOL CHEM, V276, P17324, DOI 10.1074/jbc.M011166200; Handa P, 2000, NUCLEIC ACIDS RES, V28, P3823, DOI 10.1093/nar/28.19.3823; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Krokan HE, 1997, BIOCHEM J, V325, P1; KUMAR NV, 1994, NUCLEIC ACIDS RES, V22, P3737, DOI 10.1093/nar/22.18.3737; Kumar NV, 1997, NUCLEIC ACIDS RES, V25, P2336, DOI 10.1093/nar/25.12.2336; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Matsumoto T, 2000, J BIOCHEM, V127, P329, DOI 10.1093/oxfordjournals.jbchem.a022611; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Purnapatre K, 1999, NUCLEIC ACIDS RES, V27, P3487, DOI 10.1093/nar/27.17.3487; Purnapatre K, 1999, EUR J BIOCHEM, V264, P591, DOI 10.1046/j.1432-1327.1999.00684.x; QUINONES A, 1987, J BASIC MICROB, V27, P263, DOI 10.1002/jobm.3620270508; Roy S, 1998, PROTEIN EXPRES PURIF, V13, P155, DOI 10.1006/prep.1998.0878; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; Sarov-Blat L, 1998, J BIOL CHEM, V273, P5520, DOI 10.1074/jbc.273.10.5520; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TROVCEVIC Z, 1991, BIOCHIMIE, V73, P515, DOI 10.1016/0300-9084(91)90122-H; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	34	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16992	16997		10.1074/jbc.M100393200	http://dx.doi.org/10.1074/jbc.M100393200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279060	hybrid			2022-12-25	WOS:000168730400052
J	Ogra, Y; Suzuki, K; Gong, PF; Otsuka, F; Koizumi, S				Ogra, Y; Suzuki, K; Gong, PF; Otsuka, F; Koizumi, S			Negative regulatory role of Sp1 in metal responsive element-mediated transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOTHIONEIN-IIA GENE; BOX-BINDING-PROTEINS; LONG TERMINAL REPEAT; I GENE; GLUCOCORTICOID RECEPTOR; PROMOTER SEQUENCES; DNA; EXPRESSION; INTERACTS; CLONING	Transcription of mammalian metallothionein (MT) genes is activated by heavy metals via multiple copies of a cis-acting DNA element, the metal-responsive element (MRE), Our previous studies have shown that certain MREs of the human MT-IIA gene (MREb, MREc, MREd, and MREf) are less active than the others (MREa, MREe, and MREg). Gel shift analysis of HeLa cell nuclear proteins revealed that whereas the active MREs strongly bind the transcription factor MTF-1 essential for metal regulation, the less active MREs bind another distinct protein, MREb-BF. This protein recognizes the GC-rich region of MREb rather than the MRE core required for MTF-1 binding. All the MREs recognized by MREb-BF contain the CGCCC and/or CACCC motif, suggesting that the MREb-BF-MRE complex contains Sp1 or related proteins. Supershift analysis using antibodies against Sp1 family proteins as well as gel shift analysis using the recombinant Sp1 demonstrated that Sp1 represents the majority of MREb-BF activity. An MREb mutant with reduced affinity to Sp1 mediated zinc-inducible transcription much more actively than the wild-type MREb, Furthermore, when placed in the native promoter, this mutant MREb raised the overall promoter activity. These results strongly suggest that Sp1 acts as a negative regulator of transcription mediated by specific MREs.	Natl Inst Ind Hlth, Div Hazard Assessment, Tama Ku, Kawasaki, Kanagawa 2148585, Japan; Natl Inst Ind Hlth, Div Hlth Effects Res, Tama Ku, Kawasaki, Kanagawa 2148585, Japan; Teikyo Univ, Fac Pharmaceut Sci, Dept Environm Toxicol, Kanagawa 1990195, Japan	Teikyo University	Koizumi, S (corresponding author), Natl Inst Ind Hlth, Div Hazard Assessment, Tama Ku, 6-21-1 Nagao, Kawasaki, Kanagawa 2148585, Japan.	koizumi@niih.go.jp	Ogra, Yasumitsu/A-2747-2017	Ogra, Yasumitsu/0000-0002-8268-1828				Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chun RF, 1998, J VIROL, V72, P2615, DOI 10.1128/JVI.72.4.2615-2629.1998; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; DYNAN WS, 1985, P NATL ACAD SCI USA, V82, P4915, DOI 10.1073/pnas.82.15.4915; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; Husmann M, 1996, EUR J IMMUNOL, V26, P3008, DOI 10.1002/eji.1830261228; INOUYE C, 1994, DNA CELL BIOL, V13, P731, DOI 10.1089/dna.1994.13.731; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOIZUMI S, 1991, CHEM-BIOL INTERACT, V80, P145, DOI 10.1016/0009-2797(91)90021-X; Koizumi S, 1999, EUR J BIOCHEM, V259, P635, DOI 10.1046/j.1432-1327.1999.00069.x; KOIZUMI S, 1995, GENETIC RESPONSE TO METALS, P397; KOIZUMI S, 1992, EUR J BIOCHEM, V210, P555, DOI 10.1111/j.1432-1033.1992.tb17454.x; KOIZUMI S, 1993, METALLOTHIONEIN, V3, P457; Kumar AP, 1997, NUCLEIC ACIDS RES, V25, P2012, DOI 10.1093/nar/25.10.2012; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MURATA Y, 1994, J BIOL CHEM, V269, P20674; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; Okumura K, 1996, J BIOL CHEM, V271, P12944, DOI 10.1074/jbc.271.22.12944; OTSUKA F, 1994, J BIOL CHEM, V269, P23700; OTSUKA F, 1993, IND HEALTH, V31, P133, DOI 10.2486/indhealth.31.133; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; Searle P F, 1987, Experientia Suppl, V52, P407; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; SUZUKI M, 1995, MOL CELL BIOL, V15, P5423; XU C, 1993, DNA CELL BIOL, V12, P517, DOI 10.1089/dna.1993.12.517; YU CY, 1991, J BIOL CHEM, V266, P8907	51	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16534	16539		10.1074/jbc.M100570200	http://dx.doi.org/10.1074/jbc.M100570200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279094	hybrid			2022-12-25	WOS:000168623100128
J	Aleksandrov, L; Mengos, A; Chang, XB; Aleksandrov, A; Riordan, JR				Aleksandrov, L; Mengos, A; Chang, XB; Aleksandrov, A; Riordan, JR			Differential interactions of nucleotides at the two nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE PROTEIN MRP1; SULFONYLUREA RECEPTOR; CHLORIDE CHANNEL; ATP HYDROLYSIS; P-GLYCOPROTEIN; ACTIVE ATPASE; CFTR; SITES; KINASE; PHOSPHORYLATION	After phosphorylation by protein kinase A, gating of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel is regulated by the interaction of ATP with its nucleotide binding domains (NBDs), Models of this gating regulation have proposed that ATP hydrolysis at NBD1 and NBD2 may drive channel opening and closing, respectively (reviewed in Nagel, G. (1999) Biochim, Biophys, Acta: 1461, 263-274), However, as yet there has been little biochemical confirmation of the predictions of these models. We have employed photoaffinity labeling with 8-azido-ATP, which supports channel gating as effectively as ATP to evaluate interactions with each NBD in intact membrane-bound CFTR, Mutagenesis of Walker A lysine residues crucial for azido-ATP hydrolysis to generate the azido-ADP that is trapped by vanadate indicated a greater role of NBD1 than NBD2, Separation of the domains by limited trypsin digestion and enrichment by immunoprecipitation confirmed greater and more stable nucleotide trapping at NBD1, This asymmetry of the two domains in interactions with nucleotides was reflected most emphatically in the response to the nonhydrolyzable ATP analogue, 5 ' -adenylyl-beta,gamma -imidodiphosphate (AMP-PNP), which in the gating models was proposed to bind with high affinity to NBD2 causing inhibition of ATP hydrolysis there postulated to drive channel closing. Instead we found a strong competitive inhibition of nucleotide hydrolysis and trapping at NBD1 and a simultaneous enhancement at NBD2, This argues strongly that AMP-PNP does not inhibit ATP hydrolysis at NBD2 and thereby questions the relevance of hydrolysis at that domain to channel closing.	Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Riordan, JR (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.				NIDDK NIH HHS [DK51619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051619] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Gadsby David C., 1999, Physiological Reviews, V79, pS77; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Julien M, 2000, BIOCHEMISTRY-US, V39, P4559, DOI 10.1021/bi992744z; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Mathews CJ, 1998, J PHYSIOL-LONDON, V508, P365, DOI 10.1111/j.1469-7793.1998.365bq.x; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Nagel G, 1999, BBA-BIOMEMBRANES, V1461, P263, DOI 10.1016/S0005-2736(99)00162-5; Ostedgaard LS, 1997, BIOCHEMISTRY-US, V36, P1287, DOI 10.1021/bi962174s; Ramjeesingh M, 1999, BIOCHEMISTRY-US, V38, P1463, DOI 10.1021/bi982243y; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55	29	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12918	12923		10.1074/jbc.M100515200	http://dx.doi.org/10.1074/jbc.M100515200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11279083	hybrid			2022-12-25	WOS:000168198600065
J	Porsch-Ozcurumez, M; Langmann, T; Heimerl, S; Borsukova, H; Kaminski, WE; Drobnik, W; Honer, C; Schumacher, C; Schmitz, G				Porsch-Ozcurumez, M; Langmann, T; Heimerl, S; Borsukova, H; Kaminski, WE; Drobnik, W; Honer, C; Schumacher, C; Schmitz, G			The zinc finger protein 202 (ZNF202) is a transcriptional repressor of ATP binding cassette transporter A1 (ABCA1) and ABCG1 gene expression and a modulator of cellular lipid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANGIER-DISEASE PATIENTS; DENSITY-LIPOPROTEIN; CHOLESTEROL EFFLUX; MOLECULAR-CLONING; PLASMA-MEMBRANE; APOA-I; PROMOTER; DOMAIN; COREPRESSOR; MACROPHAGES	The zinc finger gene 202 (ZNF202) located within a hypoalphalipoproteinemia susceptibility locus on chromosome 11q23 is a transcriptional repressor of various genes involved in lipid metabolism. To provide further evidence for a functional linkage between ZNF202 and hypoalphalipoproteinemia, we investigated the effect of ZNF202 expression on ATP binding cassette transporter A1 (ABCA1) and ABCG1, ABCA1 is a key regulator of the plasma high density lipoprotein pool size, whereas ABCG1 is another mediator of cellular cholesterol and phospholipid efflux in human macrophage. We demonstrate here that the full-length ZNF202m1 isoform binds to GnT repeats within the promoters of ABCA1 (-229/ -210) and ABCG1 (-572/-552), ZNF202m1 expression in HepG2 cells dose-dependently repressed the promotor activities of ABCA1 and ABCG1, This transcriptional effect required the presence of the SCAN domain in ZNF202 and the functional integrity of a TATA box at position -24 of ABCA1, whereas the presence of GnT binding motifs was nonessential. The state of ZNF202 SCAN domain oligomerization affected the ability of the adjacent ZNF202 Kruppel-associated box domain to recruit the transcriptional corepressor KAP1, Overexpression of ZNF202m1 in RAW264.7 macrophages prevented the induction of ABCA1 gene expression by 20(S)OH-cholesterol and 9-cis-retinoic acid, further substantiating the interference of ZNF202 in critical elements of transcriptional activation, Finally, HDL and apoAI-mediated lipid efflux was significantly reduced in RAW264.7 cells stably expressing ZNF202m1, In conclusion, we have identified ABCA1 and ABCG1 as target genes for ZNF202-mediated repression and thus, provide evidence for a functional linkage between ZNF202 and hypoalphalipoproteinemia.	Univ Regensburg, Inst Clin Chem, D-8400 Regensburg, Germany; Novartis Inst Biomed Res, Summit, NJ 07901 USA	University of Regensburg; Novartis	Schmitz, G (corresponding author), Univ Klinikum Regensburg, Inst Klin Chem & Blutbank, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.		Özcürümez, Mustafa/AAQ-3250-2021; Özcürümez, Mustafa K./GRS-4840-2022; Langmann, Thomas/HHZ-9814-2022	Özcürümez, Mustafa/0000-0002-4360-5005; Özcürümez, Mustafa K./0000-0002-4360-5005; Langmann, Thomas/0000-0001-6826-529X; Schmitz, Gerd/0000-0002-1325-1007				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Costet P, 2000, J BIOL CHEM, V275, P28240; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Funke H, 1997, CURR OPIN LIPIDOL, V8, P189, DOI 10.1097/00041433-199706000-00010; Honer C, 2001, BBA-GENE STRUCT EXPR, V1517, P441, DOI 10.1016/S0167-4781(00)00274-8; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Langmann T, 2000, BBA-GENE STRUCT EXPR, V1494, P175, DOI 10.1016/S0167-4781(00)00215-3; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Monaco C, 1998, GENOMICS, V52, P358, DOI 10.1006/geno.1998.5419; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; Pengue G, 1996, P NATL ACAD SCI USA, V93, P1015, DOI 10.1073/pnas.93.3.1015; Repa JJ, 1999, CURR OPIN BIOTECH, V10, P557, DOI 10.1016/S0958-1669(99)00031-2; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Schumacher C, 2000, J BIOL CHEM, V275, P17173, DOI 10.1074/jbc.M000119200; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; Venkateswaran A, 2000, J BIOL CHEM, V275, P14700, DOI 10.1074/jbc.275.19.14700; Wagner S, 2000, J BIOL CHEM, V275, P15685, DOI 10.1074/jbc.M910152199; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WILLIAMS SC, 1986, MOL CELL BIOL, V6, P3807, DOI 10.1128/MCB.6.11.3807	26	82	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12427	12433		10.1074/jbc.M100218200	http://dx.doi.org/10.1074/jbc.M100218200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11279031	hybrid			2022-12-25	WOS:000168081800131
J	Choi, DH; Whittier, PS; Oshima, J; Funk, WD				Choi, DH; Whittier, PS; Oshima, J; Funk, WD			Telomerase expression prevents replicative senescence but does not fully reset mRNA expression patterns in Werner syndrome cell strains	FASEB JOURNAL			English	Article							VARIEGATED TRANSLOCATION MOSAICISM; CULTURED SKIN FIBROBLASTS; SYNDROME PROTEIN; SYNDROME GENE; DNA; HELICASE; LINES; TOPOISOMERASE; HYBRIDIZATION; LOCALIZATION	Reduced replicative capacity is a consistent characteristic of cells derived from patients with Werner syndrome, This premature senescence is phenotypically similar to replicative senescence observed in normal cell strains and includes altered cell morphology and gene expression patterns. Telomeres shorten with in vitro passaging of both WRN and normal cell strains; however, the rate of shortening has been reported to be faster in WRN cell strains, and the length of telomeres in senescent WRN cells appears to be longer than that observed in normal strains, leading to the suggestion that senescence in WRN cell strains may not be exclusively associated with telomere effects. We report here that the telomere restriction fragment length in senescent WRN fibroblasts cultures is within the size range observed for normal fibroblasts strains and that the expression of a telomerase transgene in WRN cell strains results in lengthened telomeres and replicative immortalization, thus indicating that telomere effects are the predominant trigger of premature senescence in WRN cells, Microarray analyses showed that mRNA expression patterns induced in senescent WRN cells appeared similar to those in normal strains and that hTERT expression could prevent the induction of most of these genes. However, substantial differences in expression were seen in comparisons of early-passage and telomerase-immortalized derivative lines, indicating that telomerase expression does not prevent the phenotypic drift, or destabilized genotype, resulting from the WRN defect.	Geron Corp, Menlo Park, CA 94025 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Geron Corporation; University of Washington; University of Washington Seattle	Choi, DH (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.	dchoi@geron.com			NIA NIH HHS [R01 AG14446] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014446] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Bennett SE, 1997, CANCER RES, V57, P2956; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HOEHN H, 1975, CYTOGENET CELL GENET, V15, P282, DOI 10.1159/000130526; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kodama S, 1998, CANCER RES, V58, P5188; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LeckaCzernik B, 1996, EXP GERONTOL, V31, P159, DOI 10.1016/0531-5565(95)02014-4; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Martin GM, 1997, MOL MED, V3, P356, DOI 10.1007/BF03401682; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mukherjee AB, 1997, EXP CELL RES, V235, P161, DOI 10.1006/excr.1997.3673; Oshima J, 1996, HUM MOL GENET, V5, P1909, DOI 10.1093/hmg/5.12.1909; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1981, HUM GENET, V58, P310, DOI 10.1007/BF00294930; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; SCHONBERG S, 1984, AM J HUM GENET, V36, P387; Schulz VP, 1996, HUM GENET, V97, P750; Shalon D, 1996, GENOME RES, V6, P639, DOI 10.1101/gr.6.7.639; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; THOMPSON KVA, 1983, GERONTOLOGY, V29, P73, DOI 10.1159/000213096; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P168; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; YANG L, 2000, GENETICS, V154, P357; Yu CE, 1997, AM J HUM GENET, V60, P330; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	39	61	62	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1014	1020		10.1096/fj.00-0104com	http://dx.doi.org/10.1096/fj.00-0104com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292662				2022-12-25	WOS:000167959300016
J	Pibiri, M; Ledda-Columbano, GM; Cossu, C; Simbula, G; Menegazzi, M; Shinozuka, H; Columbano, A				Pibiri, M; Ledda-Columbano, GM; Cossu, C; Simbula, G; Menegazzi, M; Shinozuka, H; Columbano, A			Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3)	FASEB JOURNAL			English	Article						nuclear receptor; cell cycle; liver	TUMOR-NECROSIS-FACTOR; ALPHA C/EBP-ALPHA; LIVER-REGENERATION; IN-VIVO; CELL-PROLIFERATION; DEPENDENT KINASES; GENE-EXPRESSION; HEPATIC REGENERATION; CYPROTERONE-ACETATE; PARTIAL-HEPATECTOMY	The thyroid hormone (T3) affects cell growth, differentiation, and regulates metabolic functions via its interaction with the thyroid hormone nuclear receptors (TRs). The mechanism by which TRs mediate cell growth is unknown. To investigate the mechanisms responsible for the mitogenic effect of T3, we have determined changes in activation of transcription factors, mRNA levels of immediate early genes, and levels of proteins involved in the progression from G1 to S phase of the cell cycle. We show that hepatocyte proliferation induced by a single administration of T3 to Wistar rats occurred in the absence of activation of AP-1, NF-kappaB, and STAT3 or changes in the mRNA levels of the immediate early genes c-fos, c-jun, and c-myc These genes are considered to be essential for liver regeneration after partial hepatectomy (PH). On the other hand, T3 treatment caused an increase in cyclin D1 mRNA and protein levels that occurred much more rapidly compared to liver regeneration after 2/3 PH. The early increase in cyclin D1 expression was associated with accelerated onset of DNA synthesis, as demonstrated by a 20-fold increase of bromodeoxyuridine-positive hepatocytes at 12 h after T3 treatment and by a 20-fold increase in mitotic activity at 18 h. An early increase of cyclin D1 expression was also observed after treatment with nafenopin, a ligand of a nuclear receptor (peroxisome proliferator-activated receptor alpha) of the same superfamily of steroid/thyroid receptors. T3 treatment also resulted in increased expression of cyclin E, E2F, and p107 and enhanced phosphorylation of pRb, the ultimate substrate in the pathway leading to transition from G1 to S phase. The results demonstrate that cyclin D1 induction is one of the earlier events in hepatocyte proliferation induced by T3 and suggest that this cyclin might be a common target responsible for the mitogenic activity of ligands of nuclear receptors.	Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, I-09124 Cagliari, Italy; Univ Verona, Dept Neurol Sci, I-37100 Verona, Italy; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15260 USA	University of Cagliari; University of Verona; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Columbano, A (corresponding author), Univ Cagliari, Dept Toxicol, Oncol & Mol Pathol Unit, Sez Oncol & Patol Mol, Via Porcell 4, I-09124 Cagliari, Italy.	columbano@unica.it	Simbula, Gabriella/AAN-4390-2020; Menegazzi, Marta/AAE-7079-2019; Columbano, Amedeo/C-7463-2011	Simbula, Gabriella/0000-0003-4946-532X; Menegazzi, Marta/0000-0003-1310-9227; Columbano, Amedeo/0000-0002-6956-9030; PIBIRI, MONICA/0000-0002-9660-9616				AKERMAN P, 1992, AM J PHYSIOL, V263, pG579, DOI 10.1152/ajpgi.1992.263.4.G579; Albrecht JH, 1998, ONCOGENE, V16, P2141, DOI 10.1038/sj.onc.1201728; Albrecht JH, 1997, HEPATOLOGY, V25, P557, DOI 10.1002/hep.510250311; Barrera-Hernandez G, 1999, ENDOCRINOLOGY, V140, P5267, DOI 10.1210/en.140.11.5267; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Columbano A, 1996, FASEB J, V10, P1118, DOI 10.1096/fasebj.10.10.8751714; Columbano A, 1997, ONCOGENE, V14, P857, DOI 10.1038/sj.onc.1200891; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Fausto N, 1995, FASEB J, V9, P1527, DOI 10.1096/fasebj.9.15.8529831; Forbes SJ, 1998, GENE THER, V5, P552, DOI 10.1038/sj.gt.3300613; FRANCAVILLA A, 1994, HEPATOLOGY, V20, P1237, DOI 10.1002/hep.1840200521; GRANA X, 1995, ONCOGENE, V11, P211; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Higgins GM, 1931, ARCH PATHOL, V12, P186; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; Ledda-Columbano GM, 2000, AM J PATHOL, V156, P91, DOI 10.1016/S0002-9440(10)64709-8; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; LEVINE WG, 1977, BIOCHEM PHARMACOL, V26, P939, DOI 10.1016/0006-2952(77)90470-1; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MANGELSDORF DJ, 1984, RETINOIDS BIOL CHEM, P319; Martin-Castellanos C, 1997, TRENDS CELL BIOL, V7, P95, DOI 10.1016/S0962-8924(96)10055-6; Menegazzi M, 1997, HEPATOLOGY, V25, P585, DOI 10.1002/hep.510250316; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Oppenheimer Jack H., 1996, P162; Oren R, 1999, HEPATOLOGY, V30, P903, DOI 10.1002/hep.510300418; PEREZ P, 1993, J BIOL CHEM, V268, P135; Peters JM, 1997, CARCINOGENESIS, V18, P2029, DOI 10.1093/carcin/18.11.2029; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; Rao MS, 1996, ANN NY ACAD SCI, V804, P573, DOI 10.1111/j.1749-6632.1996.tb18646.x; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHORT J, 1972, J BIOL CHEM, V247, P1757; Skrtic S, 1997, J HEPATOL, V27, P903, DOI 10.1016/S0168-8278(97)80329-7; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TRAUTWEIN C, 1994, GUT, V35, P1163, DOI 10.1136/gut.35.9.1163; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441	48	114	121	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1006	1013		10.1096/fj.00-0416com	http://dx.doi.org/10.1096/fj.00-0416com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292661				2022-12-25	WOS:000167959300015
J	Keizer, DW; Slupsky, CM; Kalisiak, M; Campbell, AP; Crump, MP; Sastry, PA; Hazes, B; Irvin, RT; Sykes, BD				Keizer, DW; Slupsky, CM; Kalisiak, M; Campbell, AP; Crump, MP; Sastry, PA; Hazes, B; Irvin, RT; Sykes, BD			Structure of a pilin monomer from Pseudomonas aeruginosa - Implications for the assembly of pili	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; SYNTHETIC VACCINE DESIGN; NMR SOLUTION STRUCTURE; C-TERMINAL REGION; NEISSERIA-GONORRHOEAE; TWITCHING MOTILITY; NATURAL TRANSFORMATION; BACTERIAL CONJUGATION; MORAXELLA-BOVIS; GENE CONVERSION	Type TV pilin monomers assemble to form fibers called pill that are required far a variety of bacterial functions. Pilin monomers oligomerize due to the interaction of part of their hydrophobic N-terminal alpha -helix. Engineering of a truncated pilin from Pseudomonas aeruginosa strain K122-4, where the first 28 residues are removed from the N terminus, yields a soluble, monomeric protein. This truncated pilin is shown to bind to its receptor and to decrease morbidity and mortality in mice upon administration 15 min before challenge with a heterologous strain of Pseudomonas. The structure of this truncated pilin reveals an alpha -helix at the N terminus that lies across a 4-stranded antiparallel beta -sheet. A model for a pilus is proposed that takes into account both electrostatic and hydrophobic interactions of pilin subunits as well as previously published x-ray fiber diffraction data. Our model indicates that DNA or RNA cannot pass through the center of the pilus, however, the possibility exists for small organic molecules to pass through indicating a potential mechanism for signal transduction.	Univ Alberta, Heritage Med Res Ctr 713, PENCE, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2H7, Canada; Univ Southampton, Dept Biochem, Southampton S016 7PX, Hants, England; Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA	University of Alberta; University of Alberta; University of Southampton; University of Washington; University of Washington Seattle	Sykes, BD (corresponding author), Univ Alberta, Heritage Med Res Ctr 713, PENCE, Edmonton, AB T6G 2S2, Canada.		Keizer, David/P-9196-2014	Keizer, David/0000-0002-0442-0999; Crump, Matthew/0000-0002-7868-5818				Alonso A, 1999, MICROBIOL-SGM, V145, P2857, DOI 10.1099/00221287-145-10-2857; BEARD MKM, 1990, J BACTERIOL, V172, P2601, DOI 10.1128/jb.172.5.2601-2607.1990; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BODEY GP, 1983, REV INFECT DIS, V5, P279; BRADLEY DE, 1980, CAN J MICROBIOL, V26, P146, DOI 10.1139/m80-022; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Cachia PJ, 1998, J PEPT RES, V52, P289; Campbell AP, 1997, J MOL BIOL, V267, P382, DOI 10.1006/jmbi.1996.0871; Campbell AP, 1995, BIOCHEMISTRY-US, V34, P16255, DOI 10.1021/bi00050a005; Campbell AP, 1996, INT J PEPT PROT RES, V48, P539; CRYZ SJ, 1983, INFECT IMMUN, V39, P1072, DOI 10.1128/IAI.39.3.1072-1079.1983; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DURRENBERGER MB, 1991, J STRUCT BIOL, V107, P146, DOI 10.1016/1047-8477(91)90018-R; FARINHA MA, 1994, INFECT IMMUN, V62, P4118, DOI 10.1128/IAI.62.10.4118-4123.1994; FINKE M, 1991, INFECT IMMUN, V59, P1251, DOI 10.1128/IAI.59.4.1251-1254.1991; FOLKHARD W, 1981, J MOL BIOL, V149, P79, DOI 10.1016/0022-2836(81)90261-8; Forest KT, 1997, GENE, V192, P165, DOI 10.1016/S0378-1119(97)00008-5; Fussenegger M, 1997, GENE, V192, P125, DOI 10.1016/S0378-1119(97)00038-3; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; HAAS R, 1987, P NATL ACAD SCI USA, V84, P9079, DOI 10.1073/pnas.84.24.9079; HAASE J, 1995, J BACTERIOL, V177, P4779, DOI 10.1128/jb.177.16.4779-4791.1995; Hazes B, 2000, J MOL BIOL, V299, P1005, DOI 10.1006/jmbi.2000.3801; IRVIN RT, 1993, PSEUDOMONAS AERUGINO, P19; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Karaolis DKR, 1999, NATURE, V399, P375, DOI 10.1038/20715; Keizer DW, 2001, J BIOMOL NMR, V19, P385, DOI 10.1023/A:1011285803129; Kim SR, 1997, J BACTERIOL, V179, P3594, DOI 10.1128/jb.179.11.3594-3603.1997; Klimke WA, 1998, J BACTERIOL, V180, P4036, DOI 10.1128/JB.180.16.4036-4043.1998; LEE KK, 1989, MOL MICROBIOL, V3, P1493, DOI 10.1111/j.1365-2958.1989.tb00135.x; LEE KK, 1994, MOL MICROBIOL, V11, P705, DOI 10.1111/j.1365-2958.1994.tb00348.x; Long CD, 1998, INFECT IMMUN, V66, P1918, DOI 10.1128/IAI.66.5.1918-1927.1998; LYDICK E, 1985, J INFECT DIS, V151, P375, DOI 10.1093/infdis/151.2.375; MARRS CF, 1988, J BACTERIOL, V170, P3032, DOI 10.1128/jb.170.7.3032-3039.1988; MARRS CF, 1990, J BACTERIOL, V172, P4370, DOI 10.1128/jb.172.8.4370-4377.1990; Mattick JS, 1996, GENE, V179, P147, DOI 10.1016/S0378-1119(96)00441-6; MCINNES C, 1993, BIOCHEMISTRY-US, V32, P13432, DOI 10.1021/bi00212a008; Merz AJ, 2000, NATURE, V407, P98, DOI 10.1038/35024105; MEYER TF, 1990, ANNU REV MICROBIOL, V44, P451; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; PARANCHYCH W, 1986, CLIN INVEST MED, V9, P113; PARANCHYCH W, 1979, CAN J MICROBIOL, V25, P1175, DOI 10.1139/m79-182; PARGE HE, 1995, NATURE, V378, P32, DOI 10.1038/378032a0; PASLOSKE BL, 1989, J BACTERIOL, V171, P2142, DOI 10.1128/jb.171.4.2142-2147.1989; PENNINGTON JE, 1979, J INFECT DIS, V139, P396, DOI 10.1093/infdis/139.4.396; PIER GB, 1983, J INFECT DIS, V148, P206, DOI 10.1093/infdis/148.2.206; PIER GB, 1985, J INFECT DIS, V151, P575, DOI 10.1093/infdis/151.4.575; PUGH GW, 1977, AM J VET RES, V38, P1519; RAMPHAL R, 1984, INFECT IMMUN, V44, P38, DOI 10.1128/IAI.44.1.38-40.1984; RAMPHAL R, 1991, INFECT IMMUN, V59, P700, DOI 10.1128/IAI.59.2.700-704.1991; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RONCERO C, 1990, J BACTERIOL, V172, P1899, DOI 10.1128/jb.172.4.1899-1904.1990; Sheth H B, 1995, Biomed Pept Proteins Nucleic Acids, V1, P141; SHETH HB, 1994, MOL MICROBIOL, V11, P715, DOI 10.1111/j.1365-2958.1994.tb00349.x; Silverman PM, 1997, MOL MICROBIOL, V23, P423, DOI 10.1046/j.1365-2958.1997.2411604.x; Suh JY, 2001, BIOCHEMISTRY-US, V40, P3985, DOI 10.1021/bi002524h; SWANSON J, 1987, J EXP MED, V165, P1016, DOI 10.1084/jem.165.4.1016; Tripet B, 1996, PROTEIN ENG, V9, P1029, DOI 10.1093/protein/9.11.1029; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WATTS TH, 1982, J BACTERIOL, V151, P1508, DOI 10.1128/JB.151.3.1508-1513.1982; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P687; Wolfgang M, 1999, MOL MICROBIOL, V31, P1345, DOI 10.1046/j.1365-2958.1999.01269.x; Wolfgang M, 1998, MOL MICROBIOL, V29, P321, DOI 10.1046/j.1365-2958.1998.00935.x; YU L, 1994, INFECT IMMUN, V62, P5213, DOI 10.1128/IAI.62.12.5213-5219.1994	64	90	98	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24186	24193		10.1074/jbc.M100659200	http://dx.doi.org/10.1074/jbc.M100659200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294863	hybrid			2022-12-25	WOS:000169531100127
J	Forgues, M; Marrogi, AJ; Spillare, EA; Wu, CG; Yang , Q; Yoshida, M; Wang, XW				Forgues, M; Marrogi, AJ; Spillare, EA; Wu, CG; Yang , Q; Yoshida, M; Wang, XW			Interaction of the hepatitis B virus X protein with the Crm1-dependent nuclear export pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; NF-KAPPA-B; HEPATOCELLULAR-CARCINOMA; MESSENGER-RNA; TRANSACTIVATION FUNCTION; SIGNALING PATHWAY; REV PROTEIN; GENE; DNA; ACTIVATION	The leucine-rich nuclear export signal (NES) is used to shuttle large cellular proteins from the nucleus to the cytoplasm. The nuclear export receptor Crm1 is essential in this process by recognizing the NES motif. Here, we show that the oncogenic hepatitis B virus (HBV)X protein (HBx) contains a functional NES motif. We found that the predominant cytoplasmic localization of HBx is sensitive to the drug leptomycin B (LMB), which specifically inactivates Crm1. Mutations at the two con served leucine residues to alanine at the NES motif (L98A,L100A) resulted in a nuclear redistribution of HBx. A recombinant HBx protein binds to Crm1 in vitro. In addition, ectopic expression of HBx sequesters Crm1 in the cytoplasm. Furthermore, HBx activates NF kappaB by inducing its nuclear translocation in a NES-dependent manner. Abnormal cytoplasmic sequestration of Crm1, accompanied by a nuclear localization of NF kappaB, was also observed in hepatocytes from HBV-positive liver samples with chronic active hepatitis. We suggest that Crm1 may play a role in HBx-mediated liver carcinogenesis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Tokyo, Dept Biotechnol, Tokyo, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tokyo	Wang, XW (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,MSC 4255,Bldg 37,Rm 2C07, Bethesda, MD 20892 USA.	xin_wei_wang@nih.gov	Wang, Xin Wei/B-6162-2009; Yoshida, Minoru/C-8049-2014	Wang, Xin Wei/0000-0001-9735-606X; Yoshida, Minoru/0000-0002-4376-5674				ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; Andrisani OM, 1999, INT J ONCOL, V15, P373; Bangs P, 1998, J CELL BIOL, V143, P1801, DOI 10.1083/jcb.143.7.1801; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GRECO A, 1992, ONCOGENE, V7, P237; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; MEYER M, 1992, EMBO J, V11, P2991, DOI 10.1002/j.1460-2075.1992.tb05369.x; Montesano R, 1997, JNCI-J NATL CANCER I, V89, P1844, DOI 10.1093/jnci/89.24.1844; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qadri I, 1996, P NATL ACAD SCI USA, V93, P10578, DOI 10.1073/pnas.93.20.10578; RITTER SE, 1991, VIROLOGY, V182, P841, DOI 10.1016/0042-6822(91)90626-M; Robinson WS, 1999, MICROBES AND MALIGNANCY, P232; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; SCHEUER PJ, 1991, J HEPATOL, V13, P372, DOI 10.1016/0168-8278(91)90084-O; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; TAKADA S, 1990, P NATL ACAD SCI USA, V87, P5628, DOI 10.1073/pnas.87.15.5628; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; UNSAL H, 1994, P NATL ACAD SCI USA, V91, P822, DOI 10.1073/pnas.91.2.822; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	52	76	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22797	22803		10.1074/jbc.M101259200	http://dx.doi.org/10.1074/jbc.M101259200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11287420	hybrid			2022-12-25	WOS:000169412700109
J	Twining, SS; Goryshin, IY; Bhasin, A; Reznikoff, WS				Twining, SS; Goryshin, IY; Bhasin, A; Reznikoff, WS			Functional characterization of arginine 30, lysine 40, and arginine 62 in Tn5 transposase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE SYNAPTIC COMPLEX; DNA-BINDING; RECOGNITION; MULTIMERIZATION; IDENTIFICATION; INTERMEDIATE; DOMAINS; END	Three N-terminal basic residues of Tn5 transposase, which are associated with proteolytic cleavages by Escherichia coli proteinases, were mutated to glutamine residues with the goal of producing more stable transposase molecules. Mutation of either arginine 30 or arginine 62 to glutamine produced transposase molecules that were more stable toward E. coli proteinases than the parent hyperactive Tn5 transposase, however, they were inactive in vivo. In vitro analysis revealed these mutants were inactive, because both Arg(30) and Arg(62) are required for formation of the paired ends complexes when the transposon is attached to the donor backbone. These results suggest Arg(30) and Arg(62) play critical roles in DNA binding and/or synaptic complex formation. Mutation of lysine 40 to glutamine did not increase the overall stability of the transposase to E. coli proteinases. This mutant transposase was only about 1% as active as the parent hyperactive transposase in vivo; however, it retained nearly full activity in vitro, These results suggest that lysine 40 is important for a step in the transposition mechanism that is bypassed in the in vitro assay system, such as the removal of the transposase molecule from DNA following strand transfer.	Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	reznikoff@biochem.wisc.edu			NEI NIH HHS [EY12931] Funding Source: Medline; NIGMS NIH HHS [GM50692] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Braam LAM, 1998, J BIOL CHEM, V273, P10908, DOI 10.1074/jbc.273.18.10908; Braam LAM, 1999, J BIOL CHEM, V274, P86, DOI 10.1074/jbc.274.1.86; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; DERBYSHIRE KM, 1990, P NATL ACAD SCI USA, V87, P4048, DOI 10.1073/pnas.87.11.4048; Goryshin IY, 1998, P NATL ACAD SCI USA, V95, P10716, DOI 10.1073/pnas.95.18.10716; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; Goryshin IY, 2000, NAT BIOTECHNOL, V18, P97, DOI 10.1038/72017; Heinrikson R L, 1977, Methods Enzymol, V47, P175; Jilk RA, 1996, J BACTERIOL, V178, P1671, DOI 10.1128/jb.178.6.1671-1679.1996; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Naumann TA, 2000, P NATL ACAD SCI USA, V97, P8944, DOI 10.1073/pnas.160107997; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Steiniger-White M, 2000, J BIOL CHEM, V275, P23127, DOI 10.1074/jbc.M003411200; Stellwagen AE, 1998, TRENDS BIOCHEM SCI, V23, P486, DOI 10.1016/S0968-0004(98)01325-5; WEINREICH MD, 1994, J MOL BIOL, V241, P166, DOI 10.1006/jmbi.1994.1486; WEINREICH MD, 1994, GENE DEV, V8, P2363, DOI 10.1101/gad.8.19.2363; Yigit H, 1999, J BACTERIOL, V181, P3185, DOI 10.1128/JB.181.10.3185-3192.1999; York D, 1997, NUCLEIC ACIDS RES, V25, P2153, DOI 10.1093/nar/25.11.2153; York D, 1996, NUCLEIC ACIDS RES, V24, P3790, DOI 10.1093/nar/24.19.3790; York D, 1998, NUCLEIC ACIDS RES, V26, P1927, DOI 10.1093/nar/26.8.1927; Zhou M, 1998, J MOL BIOL, V276, P913, DOI 10.1006/jmbi.1997.1579	25	15	19	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23135	23143		10.1074/jbc.M010748200	http://dx.doi.org/10.1074/jbc.M010748200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11283001	hybrid			2022-12-25	WOS:000169412700154
J	Tian, GC; Haffner, CD				Tian, GC; Haffner, CD			Linear relationships between the ligand binding energy and the activation energy of time-dependent inhibition of steroid 5 alpha-reductase by Delta(l)-4-azasteroids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 HUMAN 5-ALPHA-REDUCTASE; 5 ALPHA-REDUCTASE; FINASTERIDE; MECHANISM; 6-AZASTEROIDS; OPTIMIZATION	The inhibition of steroid 5 alpha -reductase (5AR) by Delta (1)-4-azasteroids is characterized by a two-step time-dependent kinetic mechanism where inhibitor combines with enzyme in a fast equilibrium, defined by the inhibition constant K-i, to form an initial reversible enzyme-inhibitor complex, which subsequently undergoes a time-dependent chemical rearrangement, defined by the rate constant k(3), leading to the formation of an apparently irreversible, tight-binding enzyme-inhibitor complex (Tian, G,, Mook, R, A., Jr,, Moss, M, L,, and Frye, S. V. (1995) Biochemistry 34, 13453-13459). A detailed kinetic analysis of this process with a series of Delta (1)-4-azasteroids having different C-17 substituents was performed to understand the relationships between the rate of time-dependent inhibition and the affinity of the time-dependent inhibitors for the enzyme. A linear correlation was observed between In(1/K-i), which is proportional to the ligand binding energy for the formation of the enzyme-inhibitor complex, and In(1/(k(3)/K-i)), which is proportional to the activation energy for the inhibition reaction under the second order reaction condition, which leads to the formation of the irreversible, tight-binding enzyme-inhibitor complex. The coefficient of the correlation was -0.88 +/- 0.07 for type 1 5AR and -1.0 +/- 0.2 for type 2 5AR, In comparison, there was no obvious correlation between In(1/K-i) and ln(1/k(3)), which is proportional to the activation energy of the second, time-dependent step of the inhibition reaction. These data are consistent with a model where ligand binding energies provided at C-17 of Delta (1)-4-azasteroids is fully expressed to lower the activation energy of k(3)/K-i with little perturbation of the energy barrier of the second, time-dependent step.	GlaxoSmithKlin Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; GlaxoSmithKlin Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline	Tian, GC (corresponding author), Astrazeneca, Dept Lead Discovery, Wilmington, DE 19850 USA.	gaochao.tian@astrazeneca.com						ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; BATCHELOR KW, 1993, Patent No. 9507926; BATCHELOR KW, 1993, Patent No. 9507927; Bull HG, 1996, J AM CHEM SOC, V118, P2359, DOI 10.1021/ja953069t; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; FALLER B, 1993, BIOCHEMISTRY-US, V32, P5705, DOI 10.1021/bi00072a028; Frye S V, 1998, Pharm Biotechnol, V11, P393; FRYE SV, 1994, J MED CHEM, V37, P2352, DOI 10.1021/jm00041a014; FRYE SV, 1995, J MED CHEM, V38, P2621, DOI 10.1021/jm00014a015; FRYE SV, 1993, J MED CHEM, V36, P4313, DOI 10.1021/jm00078a022; GELLER J, 1991, J AM GERIATR SOC, V39, P1208, DOI 10.1111/j.1532-5415.1991.tb03576.x; KALIR A, 1981, ORG SYNTH, V60, P104; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Moss ML, 1996, BIOCHEMISTRY-US, V35, P3457, DOI 10.1021/bi952472+; RASMUSSON GH, 1986, J MED CHEM, V29, P2298, DOI 10.1021/jm00161a028; REETZ MT, 1980, ANGEW CHEM INT EDIT, V19, P901, DOI 10.1002/anie.198009011; THIGPEN AE, 1993, J CLIN INVEST, V92, P903, DOI 10.1172/JCI116665; Tian GC, 1996, J PHARM SCI, V85, P106, DOI 10.1021/js950100g; TIAN GC, 1994, BIOCHEMISTRY-US, V33, P2291, DOI 10.1021/bi00174a041; TIAN GC, 1995, J AM CHEM SOC, V117, P2369, DOI 10.1021/ja00113a034; TIAN GC, 1995, BIOCHEMISTRY-US, V34, P13453, DOI 10.1021/bi00041a024	23	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21359	21364		10.1074/jbc.M100793200	http://dx.doi.org/10.1074/jbc.M100793200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279132	hybrid			2022-12-25	WOS:000169297900076
J	Krueger, A; Schmitz, I; Baumann, S; Krammer, PH; Kirchhoff, S				Krueger, A; Schmitz, I; Baumann, S; Krammer, PH; Kirchhoff, S			Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; C-FLIP; EFFECTOR DOMAINS; UP-REGULATION; IN-VIVO; RECEPTOR; FADD; INTERACTS	Upon stimulation, CD95 (APO-1/Fas) recruits the adapter molecule FADD/MORT1, procaspase-8, and the cellular FLICE-inhibitory proteins (c-FLIP) into the death-inducing signaling complex (DISC), According to the induced proximity model, procaspase-8 is activated in the DISC in an autoproteolytic manner by two subsequent cleavage steps. c-FLIP proteins exist as a long (c-FLIPL) and a short (c-FLIP,) splice variant, both of them capable of protecting cells from death receptor-mediated apoptosis. In stably transfected BJAB cells, both c-FLIPL and c-FLIPS block procaspase-8 activation at the DISC. However, cleavage is blocked at different steps. c-FLIPL allows the first cleavage step of procaspase-8, leading to the generation of the p10 subunit. In contrast, c-FLIPS completely inhibits cleavage of procaspase-8, Interestingly, p43-c-FLIPL lacking the p12 subunit also prevents cleavage of procaspase-8, In contrast, a nonprocessable mutant of c-FLIPL allows the first cleavage of procaspase-8, In conclusion, both c-FLIP proteins prevent caspase-8 activation at different levels of procaspase-8 processing at the DISC. Our results indicate that c-FLIPL induces a conformation of procaspase-8 that allows partial but not complete proteolytical processing, whereas in contrast c-FLIPS even prevents partial procaspase-8 activation at the DISC.	German Canc Res Ctr, Tumor Immunol Program, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Kirchhoff, S (corresponding author), German Canc Res Ctr, Tumor Immunol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Krueger, Andreas/B-9427-2009; Krueger, Andreas/M-9769-2019; Schmitz, Ingo/G-2093-2013	Krueger, Andreas/0000-0001-7873-7334; Krueger, Andreas/0000-0001-7873-7334; Schmitz, Ingo/0000-0002-5360-0419				Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; PETER ME, 1998, APOPTOSIS PROBLEMS D, P25; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmitz I, 2000, INT J BIOCHEM CELL B, V32, P1123, DOI 10.1016/S1357-2725(00)00048-0; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; SRINIVASULA SM, 1996, J BIOL CHEM, V271, P20799; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9	44	450	468	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20633	20640		10.1074/jbc.M101780200	http://dx.doi.org/10.1074/jbc.M101780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279218	hybrid			2022-12-25	WOS:000169135100129
J	Talfournier, F; Munro, AW; Basran, J; Sutcliffe, MJ; Daff, S; Chapman, SK; Scrutton, NS				Talfournier, F; Munro, AW; Basran, J; Sutcliffe, MJ; Daff, S; Chapman, SK; Scrutton, NS			alpha Arg-237 in Methylophilus methylotrophus (sp W3A1) electron-transferring flavoprotein affords similar to 200-millivolt stabilization of the FAD anionic semiquinone and a kinetic block on full reduction to the dihydroquinone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-BEIJERINCKII FLAVODOXIN; FLAVIN MONONUCLEOTIDE COFACTOR; TRIMETHYLAMINE DEHYDROGENASE; OXIDATION-REDUCTION; PARACOCCUS-DENITRIFICANS; REDOX POTENTIALS; PIG-LIVER; PURIFICATION; MODULATION; GENES	The midpoint reduction potentials of the FAD cofactor wild-type Methylophilus methylotrophus (sp. W3A1) electron-transferring flavoprotein (ETF) and the alpha R237A mutant were determined by anaerobic redox titration. The FAD reduction potential of the oxidized-semiquinone couple in wild-type ETF (E'(1)) is + 153 +/- 2 mV, indicating exceptional stabilization of the flavin anionic semiquinone species. Conversion to the dihydroquinone is incomplete (E'(2) < -250 mV), because of the presence of both kinetic and thermodynamic blocks on full reduction of the FAD, A structural model of ETF (Chohan, K. K., Scrutton, N. S., and Sutcliffe, M. J. (1998) Protein Pept. Lett. 5, 231-236) suggests that the guanidinium group of Arg-237, which is located over the si face of the flavin isoalloxazine ring, plays a key role in the exceptional stabilization of the anionic semiquinone in wild-type ETF, The major effect of exchanging <alpha>Arg-237 for Ala in M, methylotrophus ETF is to engineer a remarkable similar to 200-mV destabilization of the flavin anionic semiquinone (E'(2) = -31 +/- 2 mV, and E'(1) = -43 +/- 2 mV). In addition, reduction to the FAD dihydroquinone in alpha R237A ETF is relatively facile, indicating that the kinetic block seen in wild-type ETF is substantially removed in the alpha R237A ETF, Thus, kinetic (as well as thermodynamic) considerations are important in populating the redox forms of the protein-bound flavin, Additionally, we show that electron transfer from trimethylamine dehydrogenase to alpha R237A ETF is severely compromised, because of impaired assembly of the electron transfer complex.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England; Univ Strathclyde, Royal Coll, Dept Pure & Appl Chem, Glasgow G1 1XL, Lanark, Scotland; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	University of Leicester; University of Leicester; University of Strathclyde; University of Edinburgh	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	nss4@le.ac.uk	Munro, Andrew/G-5639-2019	Munro, Andrew/0000-0002-4642-180X				BARBER MJ, 1988, BIOCHEM J, V256, P657, DOI 10.1042/bj2560657; Basran J, 2000, BIOCHEMISTRY-US, V39, P9188, DOI 10.1021/bi0006868; Bradley LH, 1999, BIOCHEMISTRY-US, V38, P12377, DOI 10.1021/bi991172f; BYRON CM, 1989, BIOCHEMISTRY-US, V28, P8582, DOI 10.1021/bi00447a047; Chang FC, 1999, BIOCHEMISTRY-US, V38, P7168, DOI 10.1021/bi982203u; Chohan KK, 1998, PROTEIN PEPTIDE LETT, V5, P231; Daff SN, 1997, BIOCHEMISTRY-US, V36, P13816, DOI 10.1021/bi971085s; DAVIDSON VL, 1986, J BACTERIOL, V166, P812, DOI 10.1128/jb.166.3.812-817.1986; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; DUTTON PL, 1978, METHOD ENZYMOL, V54, P422; Dwyer TM, 1999, BIOCHEMISTRY-US, V38, P9735, DOI 10.1021/bi9903906; Dwyer TM, 1999, BBA-PROTEIN STRUCT M, V1433, P139, DOI 10.1016/S0167-4838(99)00139-9; EARL CD, 1987, J BACTERIOL, V169, P1127, DOI 10.1128/jb.169.3.1127-1136.1987; EICHLER K, 1995, J BASIC MICROB, V35, P217, DOI 10.1002/jobm.3620350404; GORELICK RJ, 1982, BIOCHEMISTRY-US, V21, P6936, DOI 10.1021/bi00269a049; HUSAIN M, 1985, J BACTERIOL, V163, P709, DOI 10.1128/JB.163.2.709-715.1985; HUSAIN M, 1983, BIOCHEM J, V209, P541, DOI 10.1042/bj2090541; HUSAIN M, 1984, BIOCHEM J, V219, P1043, DOI 10.1042/bj2191043; Jang MH, 2000, J BIOL CHEM, V275, P12546, DOI 10.1074/jbc.275.17.12546; Jones M, 2000, J BIOL CHEM, V275, P21349, DOI 10.1074/jbc.M001564200; Kasim M, 2000, BIOCHEMISTRY-US, V39, P15322, DOI 10.1021/bi001519a; Lostao A, 1997, BIOCHEMISTRY-US, V36, P14334, DOI 10.1021/bi971384h; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MASSEY V, 1991, FLAVINS AND FLAVOPROTEINS 1990, P59; Mayhew S. G., 1992, CHEM BIOCH FLAVOENZY, V3, P389; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; O'Farrell PA, 1998, BIOCHEMISTRY-US, V37, P8405, DOI 10.1021/bi973193k; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Roberts DL, 1999, BIOCHEMISTRY-US, V38, P1977, DOI 10.1021/bi9820917; Roberts DL, 1996, P NATL ACAD SCI USA, V93, P14355, DOI 10.1073/pnas.93.25.14355; SATO K, 1993, J BIOCHEM, V114, P215, DOI 10.1093/oxfordjournals.jbchem.a124157; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; SWENSON RP, 1994, BIOCHEMISTRY-US, V33, P8505, DOI 10.1021/bi00194a015; Thorpe C, 1991, CHEM BIOCH FLAVOENZY, P471; TSAI MH, 1995, RES MICROBIOL, V146, P397, DOI 10.1016/0923-2508(96)80285-3; WATMOUGH NJ, 1992, EUR J BIOCHEM, V205, P1089, DOI 10.1111/j.1432-1033.1992.tb16877.x; Weidenhaupt M, 1996, ARCH MICROBIOL, V165, P169, DOI 10.1007/s002030050312; WHITE SA, 1994, J MOL BIOL, V240, P265, DOI 10.1006/jmbi.1994.1440; WHITFIELD CD, 1974, J BIOL CHEM, V249, P2801; Wilson EK, 1997, BIOCHEMISTRY-US, V36, P41, DOI 10.1021/bi961224q	40	30	30	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20190	20196		10.1074/jbc.M010853200	http://dx.doi.org/10.1074/jbc.M010853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11285259	hybrid			2022-12-25	WOS:000169135100071
J	Araki, M; Masutani, C; Takemura, M; Uchida, A; Sugasawa, K; Kondoh, J; Ohkuma, Y; Hanaoka, F				Araki, M; Masutani, C; Takemura, M; Uchida, A; Sugasawa, K; Kondoh, J; Ohkuma, Y; Hanaoka, F			Centrosome protein centrin 2/caltractin 1 is part of the xeroderma pigmentosum group C complex that initiates global genome nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ORGANIZING CENTER; MITOTIC SPINDLE POLES; UBIQUITIN-LIKE DOMAIN; EF-HAND PROTEIN; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; CONTRACTILE FIBERS; MOLECULAR-CLONING; HUMAN HOMOLOGS; CDC31 GENE	Nucleotide excision repair (NER) is carried out by xeroderma pigmentosum (XP) factors. Before the excision reaction, DNA damage is recognized by a complex originally thought to contain the XP group C responsible gene product (XPC) and the human homologue of Rad23 B (HR23B). Here, we show that centrin 2/caltractin 1 (CEN2) is also a component of the XPC repair complex. We demonstrate that nearly all XPC complexes contain CEN2, that CEN2 interacts directly with XPC, and that CEN2, in cooperation with HR23B, stabilizes XPC, which stimulates XPC NER activity in vitro. CEN2 has been shown to play an important role in centrosome duplication. Thus, those findings suggest that the XPC-CEN2 interaction may reflect coupling of cell division and NER.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Mitsubishi Tokyo Pharmaceut Inc, Yokohama Res Ctr, Aoba Ku, Yokohama, Kanagawa 2278502, Japan; RIKEN, Wako, Saitama 3510198, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.		Masutani, Chikahide/I-6160-2014; Araki, Marito/T-4283-2019	Araki, Marito/0000-0002-3502-5000; Masutani, Chikahide/0000-0002-8600-8227				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Araki M, 2000, MUTAT RES-DNA REPAIR, V459, P147, DOI 10.1016/S0921-8777(99)00067-1; Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; BARON AT, 1995, METHOD CELL BIOL, V47, P341, DOI 10.1016/S0091-679X(08)60828-6; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; ERRABOLU R, 1994, J CELL SCI, V107, P9; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P634; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; HUANG B, 1988, J CELL BIOL, V107, P133, DOI 10.1083/jcb.107.1.133; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laoukili J, 2000, J CELL SCI, V113, P1355; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P51, DOI 10.1016/0005-2744(81)90107-8; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1997, MOL CELL BIOL, V17, P6915, DOI 10.1128/MCB.17.12.6915; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; MIDDENDORP S, 2000, J CELL SCI, V148, P505; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Paoletti A, 1996, J CELL SCI, V109, P3089; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SALISBURY JL, 1988, J CELL BIOL, V107, P635, DOI 10.1083/jcb.107.2.635; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; SHIVJI MKK, 1994, J BIOL CHEM, V269, P22749; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; SUGASAWA K, 1993, J BIOL CHEM, V268, P9098; Sugasawa K, 1997, MOL CELL BIOL, V17, P6924, DOI 10.1128/MCB.17.12.6924; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; VALLEN EA, 1994, GENETICS, V137, P407; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Watanabe Y, 2000, GENES CELLS, V5, P407, DOI 10.1046/j.1365-2443.2000.00336.x; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; Wolfrum U, 1998, EXP CELL RES, V242, P10, DOI 10.1006/excr.1998.4038; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870	51	274	288	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18665	18672		10.1074/jbc.M100855200	http://dx.doi.org/10.1074/jbc.M100855200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279143	hybrid			2022-12-25	WOS:000169091000004
J	Nickerson, K; Sisk, TJ; Inohara, N; Yee, CSK; Kennell, J; Cho, MC; Yannie, PJ; Nunez, G; Chang, CH				Nickerson, K; Sisk, TJ; Inohara, N; Yee, CSK; Kennell, J; Cho, MC; Yannie, PJ; Nunez, G; Chang, CH			Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; GTP-BINDING; CIITA; EXPRESSION; GENES; ACTIVATION; DEFICIENCY; PROMOTERS; MUTANTS; RICH	The MHC class II transactivator (CIITA) is a critical transcription factor that regulates genes involved in antigen presentation function. At least three functional forms of CIITA gene products are transcribed from three different promoters. The CIITA gene expressed in dendritic cells (DC-CIITA) has a unique first exon encoding an extended N-terminal region of CIITA, Here, we show that the N terminus of DC-CIITA has high homology to a caspase recruitment domain (CARD) found in components of apoptosis and nuclear factor-KB signaling pathways. However, DC-CIITA does not regulate cell death, nor does it induce nuclear factor-KB activity. Instead, DC-CIITA is transcriptionally a more potent activator of the MHC class II gene than the form expressed in B cells. A single amino acid substitution in the CARD of DC-CIITA, predicted to disrupt CARD-CARD interactions, diminished the transactivation potential of DC-CIITA, These results indicate that the CARD in the context of CIITA serves as a regulatory domain for transcriptional activity and may function to selectively enhance MHC class II gene expression in dendritic cells.	Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chang, CH (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA.		Nickerson, Kevin M/B-1351-2009; Nuñez, Gabriel/A-7160-2014	Nickerson, Kevin M/0000-0002-0114-2671; Kennell, Jennifer/0000-0001-9793-6259	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI041510, T32AI007413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007863, T32GM007544] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41510, T32-AI07413] Funding Source: Medline; NIGMS NIH HHS [T32-GM07863, 5-T32-GM07544] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1983, J EXP MED, V157, P1053, DOI 10.1084/jem.157.3.1053; CHANG CH, 1995, J EXP MED, V181, P765, DOI 10.1084/jem.181.2.765; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; Chen BG, 1998, BLOOD, V91, P4652, DOI 10.1182/blood.V91.12.4652.412a03_4652_4661; Chin KC, 1997, J IMMUNOL, V159, P2789; Chin KC, 1997, P NATL ACAD SCI USA, V94, P2501, DOI 10.1073/pnas.94.6.2501; CHIN KC, 1994, IMMUNITY, V2, P533; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Gourley T, 1999, IMMUNITY, V10, P377, DOI 10.1016/S1074-7613(00)80037-0; GOURLEY TS, 2001, IN PRESS J IMMUNOL; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 1999, SCIENCE, V285, P1402, DOI 10.1126/science.285.5432.1402; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; RILEY JL, 1995, IMMUNITY, V2, P533, DOI 10.1016/1074-7613(95)90033-0; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Thery C, 2001, CURR OPIN IMMUNOL, V13, P45, DOI 10.1016/S0952-7915(00)00180-1; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; Zhou H, 1997, J IMMUNOL, V158, P4741; ZHOU H, 1995, IMMUNITY, V2, P545, DOI 10.1016/1074-7613(95)90034-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	31	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19089	19093		10.1074/jbc.M101295200	http://dx.doi.org/10.1074/jbc.M101295200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279191	hybrid			2022-12-25	WOS:000169091000062
J	Tang, CJC; Chuang, CK; Hu, HM; Tang, TK				Tang, CJC; Chuang, CK; Hu, HM; Tang, TK			The zinc finger domain of Tzfp binds to the tbs motif located at the upstream flanking region of the Aie1 (aurora-C) kinase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; CHROMOSOME SEGREGATION REGULATORS; CYCLE-DEPENDENT EXPRESSION; HUMAN PROTEIN-KINASE; DNA-BINDING; YEAST IPL1; RAR-ALPHA; PLZF; LOCALIZATION; DROSOPHILA	Our previous studies showed that Aiel (aurora-C), is a novel. testis kinase belonging to the aurora kinase family (1). In this report, we describe a testis zinc finger protein (Tzfp) that binds to the upstream flanking sequence of the Aiel gene. The mouse Tzfp gene, mapped to chromosome 7 B2-B3, encodes a 465-amino acid transcription factor containing a conserved N-terminal BTB/POZ domain and three C-terminal PLZF-like C2H2 zinc fingers. The zinc finger domain of Tzfp binds to the TGTA-CAGTGT motif (Tzfp binding site, termed tbs) located at the upstream flanking sequence of the Aiel gene by gel mobility shift, DNase I footprinting, and competition analyses. When the C-terminal zinc fingers of Tzfp were fused to the transactivation domain of VP16, the chimera activated transcription of a reporter construct containing multiple copies of the tbs. In contrast, the same chimera did not activate the reporter gene when an essential nucleotide fifth C was mutated to A at the tbs. Furthermore, we showed that the N-terminal BTB/POZ domain of TZFP has a repressor activity. Taken together, our results indicate that Tzfp recognizes a sequence-specific motif (tbs) and may play a role in the regulation of the genes carrying the tbs.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan	Tang, TK (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Yen Chiu Yuan Rd,Sec 2, Taipei 115, Taiwan.		Tang, Tang K./S-7012-2018	Tang, Tang K./0000-0002-3660-0695				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 1999, J CELL SCI, V112, P3591; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hu HM, 2000, DNA CELL BIOL, V19, P679, DOI 10.1089/10445490050199063; Hung LY, 2000, MOL CELL BIOL, V20, P7813, DOI 10.1128/MCB.20.20.7813-7825.2000; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kimura M, 1998, CYTOGENET CELL GENET, V82, P147, DOI 10.1159/000015089; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Lin WC, 1999, BIOCHEM BIOPH RES CO, V264, P789, DOI 10.1006/bbrc.1999.1594; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Tang CJC, 1998, BLOOD, V92, P1442, DOI 10.1182/blood.V92.4.1442.416k14_1442_1447; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tseng TC, 1998, DNA CELL BIOL, V17, P823, DOI 10.1089/dna.1998.17.823; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	31	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19631	19639		10.1074/jbc.M100170200	http://dx.doi.org/10.1074/jbc.M100170200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279021	hybrid			2022-12-25	WOS:000169091000129
J	Triplett, TL; Sgrignoli, AR; Gao, FB; Yang, YB; Tai, PC; Gierasch, LM				Triplett, TL; Sgrignoli, AR; Gao, FB; Yang, YB; Tai, PC; Gierasch, LM			Functional signal peptides bind a soluble n-terminal fragment of SecA and inhibit its ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI MEMBRANE-VESICLES; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; WILD-TYPE; RECOGNITION PARTICLE; SECONDARY STRUCTURE; PRECURSOR PROTEINS; HYDROPHOBIC REGION; PLASMA-MEMBRANE; MODEL MEMBRANES	The selective recognition of pre-secretory proteins by SecA is essential to the process of protein export from Escherichia coli, yet very little is known about the requirements for recognition and the mode of binding of precursors to SecA, The major reason for this is the lack of a soluble system suitable for biophysical study of the SecA-precursor complex. Complicating the development of such a system is the likelihood that SecA interacts with the precursor in a high affinity, productive manner only when it is activated by binding to membrane and SecYEG. A critical aspect of the precursor/SecA interaction is that it is regulated by various SecA ligands (nucleotide, lipid, SecYEG) to facilitate the release of the precursor, most likely in a stepwise fashion, for translocation, Several recent reports show that functions of SecA can be studied using separated domains. Using this approach, we have isolated a proteolytically generated N-terminal fragment of SecA, which is stably folded, has high ATPase activity, and represents an activated version of SecA, We report here that this fragment, termed SecA64, binds signal peptides with significantly higher affinity than does SecA, Moreover, the ATPase activity of SecA64 is inhibited by signal peptides to an extent that correlates with the ability of these signal peptides to inhibit either SecA translocation ATPase or in vitro protein translocation, arguing that the interaction with SecA64 is functionally significant. Thus, SecA64 offers a soluble, well defined system to study the mode of recognition of signal peptides by SecA and the regulation of signal peptide release.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Program Mol Biophys, Dallas, TX 75235 USA; Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Georgia; Georgia State University	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NIGMS NIH HHS [GM08297, GM34766, GM34962] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008297, R01GM034962, R01GM034766] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITA M, 1990, J BIOL CHEM, V265, P8164; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; BRIGGS MS, 1984, BIOCHEMISTRY-US, V23, P3111, DOI 10.1021/bi00309a001; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CHEN LL, 1987, J BIOL CHEM, V262, P1427; CHEN LL, 1985, P NATL ACAD SCI USA, V82, P4384, DOI 10.1073/pnas.82.13.4384; Chen XC, 1996, J BIOL CHEM, V271, P29698, DOI 10.1074/jbc.271.47.29698; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; Dapic V, 2000, J BIOL CHEM, V275, P25000, DOI 10.1074/jbc.M001100200; DenBlaauwen T, 1996, ARCH MICROBIOL, V165, P1, DOI 10.1007/s002030050289; Duong F, 1997, CELL, V91, P567, DOI 10.1016/S0092-8674(00)80444-4; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; EMR SD, 1983, P NATL ACAD SCI-BIOL, V80, P4599, DOI 10.1073/pnas.80.15.4599; ERNST F, 1994, J BIOL CHEM, V269, P12840; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GOLDSTEIN J, 1991, J BIOL CHEM, V266, P14413; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HOYT DW, 1991, J BIOL CHEM, V266, P14406; HOYT DW, 1991, BIOCHEMISTRY-US, V30, P10155, DOI 10.1021/bi00106a012; Izard JW, 1996, J BIOL CHEM, V271, P21579, DOI 10.1074/jbc.271.35.21579; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; KIMURA E, 1991, J BIOL CHEM, V266, P6600; LAFORET GA, 1991, J BIOL CHEM, V266, P1326; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEHNHARDT S, 1987, J BIOL CHEM, V262, P1716; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MCKNIGHT CJ, 1989, J BIOL CHEM, V264, P17293; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; MORI H, 1998, BIOCHIM BIOPHYS ACTA, V1326, P23; NORBY JG, 1988, J BACTERIOL, V176, P4197; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; van der Does C, 2000, J BIOL CHEM, V275, P2472, DOI 10.1074/jbc.275.4.2472; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; WEAVER AJ, 1992, J STRUCT BIOL, V109, P87, DOI 10.1016/1047-8477(92)90040-H; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	50	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19648	19655		10.1074/jbc.M100098200	http://dx.doi.org/10.1074/jbc.M100098200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279006	hybrid			2022-12-25	WOS:000169091000131
J	Curman, D; Cinel, B; Williams, DE; Rundle, N; Block, WD; Goodarzi, AA; Hutchins, JR; Clarke, PR; Zhou, BB; Lees-Miller, SP; Andersen, RJ; Roberge, M				Curman, D; Cinel, B; Williams, DE; Rundle, N; Block, WD; Goodarzi, AA; Hutchins, JR; Clarke, PR; Zhou, BB; Lees-Miller, SP; Andersen, RJ; Roberge, M			Inhibition of the G(2) DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; INDUCED MITOTIC DELAY; BHK CELLS; CHROMOSOME CONDENSATION; RADIOSENSITIZING AGENT; H3 PHOSPHORYLATION; CDC25 PHOSPHATASE; DEPENDENT KINASES; MAMMALIAN-CELLS; 14-3-3 BINDING	Cells can respond to DNA damage by activating checkpoints that delay cell cycle progression and allow time for DNA repair. Chemical inhibitors of the G(2) phase DNA damage checkpoint may be used as tools to understand better how the checkpoint is regulated and may be used to sensitize cancer cells to DNA-damaging therapies. However, few inhibitors are known. We used a cell-based assay to screen natural extracts for G(2) checkpoint inhibitors and identified debromohymenialdisine (DBH) from a marine sponge. DBH is distinct structurally from previously known G(2) checkpoint inhibitors. It inhibited the G(2) checkpoint with an IC50 of 8 muM and showed moderate cytotoxicity (IC50 = 25 muM) toward MCF-7 cells. DBH inhibited the checkpoint kinases Chk1 (IC50 = 3 muM) and Chk2 (IC50 = 3.5 muM) but not ataxia-telangiectasia mutated (ATM), ATM-Rads-related protein, or DNA-dependent protein kinase in vitro, indicating that it blocks two major branches of the checkpoint pathway downstream of ATM. It did not cause the activation or inhibition of different signal transduction proteins, as determined by mobility shift analysis in Western blots, suggesting that it inhibits a narrow range of protein kinases in vivo.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Oceanog Earth & Ocean Sci, Vancouver, BC V6T 1Z1, Canada; Univ Dundee, Biomed Res Ctr, Dundee DD1 9SY, Scotland; SmithKline Beecham Pharmaceut, Dept Oncol Res, King Of Prussia, PA 19406 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of British Columbia; University of British Columbia; University of British Columbia; University of Dundee; GlaxoSmithKline; University of Calgary	Roberge, M (corresponding author), 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.		Clarke, Paul R./AAA-6803-2020; Clarke, Paul/B-1684-2009	Clarke, Paul/0000-0003-3525-2622; Lees-Miller, Susan/0000-0001-5809-2516				AKINAGA S, 1991, CANCER RES, V51, P4888; Anderson HJ, 1997, CANCER CHEMOTH PHARM, V39, P223; Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; ANDREASSEN PR, 1992, P NATL ACAD SCI USA, V89, P2272, DOI 10.1073/pnas.89.6.2272; BARRIOSSOSA AC, 1999, J ORG CHEM, V65, P610; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Busby EC, 2000, CANCER RES, V60, P2108; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Clarke DJ, 2000, BIOESSAYS, V22, P351, DOI 10.1002/(SICI)1521-1878(200004)22:4<351::AID-BIES5>3.0.CO;2-W; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Gowdy PM, 1998, J CELL SCI, V111, P3401; GRAVES PR, 2000, J BIOL CHEM, P275; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Jackson JR, 2000, CANCER RES, V60, P566; Jiang XX, 2000, INT J ONCOL, V16, P971; Kao GD, 1997, CANCER RES, V57, P753; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu QH, 2000, GENE DEV, V14, P1448; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijer L, 2000, CHEM BIOL, V7, P51, DOI 10.1016/S1074-5521(00)00063-6; MIZUNO K, 1995, FEBS LETT, V359, P259, DOI 10.1016/0014-5793(95)00042-8; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Raleigh JM, 2000, J CELL SCI, V113, P1727; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; Roberge M, 1998, CANCER RES, V58, P5701; ROWLEY R, 1984, RADIAT RES, V97, P178, DOI 10.2307/3576199; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SHARMA GM, 1980, J CHEM SOC CHEM COMM, P435, DOI 10.1039/c39800000435; Shieh SY, 2000, GENE DEV, V14, P289; Takai H, 2000, GENE DEV, V14, P1439; TAM SW, 1992, CELL GROWTH DIFFER, V3, P811; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; ZAMPETTIBOSSELER F, 1985, MUTAT RES, V143, P251, DOI 10.1016/0165-7992(85)90089-2; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	61	118	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17914	17919		10.1074/jbc.M100728200	http://dx.doi.org/10.1074/jbc.M100728200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279124	hybrid			2022-12-25	WOS:000168866500042
J	Fitzpatrick, TB; Killer, P; Thomas, RM; Jelesarov, I; Amrhein, N; Macheroux, P				Fitzpatrick, TB; Killer, P; Thomas, RM; Jelesarov, I; Amrhein, N; Macheroux, P			Chorismate synthase from the hyperthermophile Thermotoga maritima combines thermostability and increased rigidity with catalytic and spectral properties similar to mesophilic counterparts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYDALIS-SEMPERVIRENS PERS; FLAVIN; PLANT; INTERMEDIATE; PURIFICATION; SUBSTRATE; STABILITY; PROTEINS; SEQUENCE; BINDING	Chorismate synthase, the last enzyme in the shikimate pathway, catalyzes the transformation of 5-enolpyruvylshikimate 3-phosphate to chorismate, a biochemically unique reaction in that it requires reduced FMN as a cofactor. Here we report on the cloning, expression, and characterization of the protein for the first time from an extremophilic organism Thermotoga maritima which is also one of the oldest and most slowly evolving eubacteria, The protein is monofunctional in that it does not have an intrinsic ability to reduce the FMN cofactor and thereby reflecting the nature of the ancestral enzyme. Circular dichroism studies indicate that the melting temperature of the T. maritima protein is above 92 degreesC compared with 54 degreesC for the homologous Escherichia coli protein while analytical ultracentrifugation showed that both proteins have the same quaternary structure, Interestingly, UV-visible spectral studies revealed that the dissociation constants for both oxidized FMN and 5-enolpyruvylshikimate 3-phosphate decrease 46- and 10-fold, respectively, upon heat treatment of the T, maritima protein. The heat treatment also results in the trapping of the flavin cofactor in an apolar environment, a feature which is enhanced by the presence of the substrate 5-enolpyruvylshikimate 3-phosphate, Nevertheless, stopped-flow spectrophotometric evidence suggests that the mechanism of the T. maritima protein is similar to that of the E. coli protein. In essence, the study shows that T. maritima chorismate synthase exhibits considerably higher rigidity and thermostability while it has conserved features relevant to its catalytic function.	Swiss Fed Inst Technol, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Polymere, CH-8092 Zurich, Switzerland; Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Macheroux, P (corresponding author), Swiss Fed Inst Technol, Inst Pflanzenwissensch, Univ Str 2, CH-8092 Zurich, Switzerland.	macheroux@ipw.biol.ethz.ch	Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X				ACHENBACHRICHTER L, 1987, SYST APPL MICROBIOL, V9, P34, DOI 10.1016/S0723-2020(87)80053-X; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Dams T, 1999, BIOCHEMISTRY-US, V38, P9169, DOI 10.1021/bi990635e; GAERTNER FH, 1987, METHOD ENZYMOL, V142, P362; GAERTNER FH, 1973, J BIOL CHEM, V248, P4602; HARBURY HA, 1959, P NATL ACAD SCI USA, V45, P1708, DOI 10.1073/pnas.45.12.1708; HILL RK, 1969, J AM CHEM SOC, V91, P5893, DOI 10.1021/ja01049a045; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu NK, 1998, PROTEIN SCI, V7, P1214, DOI 10.1002/pro.5560070517; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; Macheroux P, 1999, PLANTA, V207, P325, DOI 10.1007/s004250050489; Macheroux P, 1998, BIOCHEM J, V335, P319, DOI 10.1042/bj3350319; Macheroux P, 1996, J BIOL CHEM, V271, P25850, DOI 10.1074/jbc.271.42.25850; MORELL H, 1967, J BIOL CHEM, V242, P82; MOUSDALE DM, 1986, FEBS LETT, V205, P328, DOI 10.1016/0014-5793(86)80922-X; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; ONDERKA DK, 1969, J AM CHEM SOC, V91, P5894, DOI 10.1021/ja01049a046; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHALLER A, 1991, PLANT PHYSIOL, V97, P1271, DOI 10.1104/pp.97.4.1271; SCHALLER A, 1991, J BIOL CHEM, V266, P21434; SCHALLER A, 1990, ARCH BIOCHEM BIOPHYS, V282, P437, DOI 10.1016/0003-9861(90)90141-K; WEBER G, 1966, FLAVINS FLAVOPROTEIN, P15; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8; WHITE PJ, 1988, BIOCHEM J, V251, P313, DOI 10.1042/bj2510313	28	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18052	18059		10.1074/jbc.M100867200	http://dx.doi.org/10.1074/jbc.M100867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279147	Green Published, hybrid			2022-12-25	WOS:000168866500059
J	Salazar, EP; Rozengurt, E				Salazar, EP; Rozengurt, E			Src family kinases are required for integrin-mediated but not for G protein-coupled receptor stimulation of focal adhesion kinase autophosphorylation at Tyr-397	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SWISS 3T3 CELLS; PAXILLIN TYROSINE PHOSPHORYLATION; ACTIVATION LOOP PHOSPHORYLATION; STRESS FIBER FORMATION; GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAYS; ACTIN CYTOSKELETON; PHOSPHATIDYLINOSITOL 3'-KINASE; EXTRACELLULAR-MATRIX	Plating suspended Swiss 3T3 cells onto fibronectin-coated dishes promoted phosphorylation of endogenous focal adhesion kinase (FAK) at Tyr-397, the major autophosphorylation site, and at Tyr-577, located in the activation loop, as revealed by site-specific antibodies that recognize the phosphorylated form of these residues. Treatment with the selective Src family kinase inhibitor pyrazolopyrimidine 2 (PP-2) markedly reduced the phosphorylation of both Tyr-397 and Tyr-577 induced by fibronectin, Furthermore, fibronectin-mediated FAK phosphorylation at Tyr-397 was dramatically reduced in SYF cells (deficient in Src, Yes, and Fyn expression). Stimulation of Swiss 3T3 cells with bombesin also induced a rapid increase in the phosphorylation of endogenous FAK at Tyr-397. In contrast to the results obtained with fibronectin, PP-2 did not prevent FAK Tyr-397 phosphorylation stimulated by bombesin at a concentration (10 muM) that suppressed bombesin-induced FAK Tyr-577 phosphorylation, Similarly, PP-2 did not prevent Tyr-397 phosphorylation in Swiss 3T3 cells stimulated with other G protein-coupled receptor agonists including vasopressin, bradykinin, endothelin, and lysophosphatidic acid. Lysophosphatidic acid also induced FAK phosphorylation at Tyr-397 in SYF cells. Our results identify, for first time, the existence of Src-dependent and Src-independent pathways leading to FAK autophosphorylation at Tyr-397 stimulated by adhesion-dependent signals and G protein-coupled receptor agonists in the same cell.	Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Warren Hall Rm 11-124,900 Vet Ave, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056930, R37DK017294, R01DK017294] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 55003, DK 56930, DK 17294] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Casamassima A, 1997, J BIOL CHEM, V272, P9363; Charlesworth A, 1996, ONCOGENE, V12, P1337; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P24328; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Ojaniemi M, 1997, J BIOL CHEM, V272, P25993, DOI 10.1074/jbc.272.41.25993; Owen JD, 1999, MOL CELL BIOL, V19, P4806; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RANKIN S, 1994, J BIOL CHEM, V269, P704; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Rozengurt E, 1998, AM J PHYSIOL-GASTR L, V275, pG177, DOI 10.1152/ajpgi.1998.275.2.G177; ROZENGURT E, 1995, CANCER SURV, V24, P81; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Tsuda T, 1997, BIOCHEMISTRY-US, V36, P16328, DOI 10.1021/bi971448o; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	65	110	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17788	17795		10.1074/jbc.M100984200	http://dx.doi.org/10.1074/jbc.M100984200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279163	hybrid			2022-12-25	WOS:000168866500024
J	Lei, WB; Talley, EM; Bayliss, DA				Lei, WB; Talley, EM; Bayliss, DA			Receptor-mediated inhibition of G protein-coupled inwardly rectifying potassium channels involves G alpha(q) family subunits, phospholipase C, and a readily diffusible messenger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; K+-CHANNEL; ION CHANNELS; RGS PROTEINS; ACTIVATION; CURRENTS; NEURONS; COMBINATIONS; BINDING; DOMAINS	G protein-coupled inwardly rectifying K+ (GIRK) channels can be activated or inhibited by distinct classes of receptor (G alpha (i/o)- and G alpha (q)-coupled), providing dynamic regulation of cellular excitability. Receptor-mediated activation involves direct effects of G betay subunits on GIRK channels, but mechanisms involved in GIRK channel inhibition have not been fully elucidated, An HEK293 cell line that stably expresses GIRK1/4 channels was used to test G protein mechanisms that mediate GIRK channel inhibition. In cells transiently or stably cotransfected with 5-HT1A (G alpha (i/o)-coupled) and TRH-R1 (G alpha (q)-coupled) receptors, 5-HT (5-hydroxytryptamine; serotonin) enhanced GIRK channel currents, whereas thyrotropin-releasing hormone (TRH) inhibited both basal and B-HT-activated GIRK channel currents. Inhibition of GIRK channel currents by TRH primarily involved signaling by G alpha (q) family subunits, rather than G beta gamma dimers: GIRK channel current inhibition was diminished by Pasteurella multocida toxin, mimicked by constitutively active members of the G alpha (q) family, and reduced by minigene constructs that disrupt G alpha (q) signaling, but was completely preserved in cells expressing constructs that interfere with signaling by G beta gamma subunits. Inhibition of GIRK channel currents by TRH and constitutively active G alpha (q) was reduced by U73122, an inhibitor of phospholipase C (PLC), Moreover, TRH-R1-mediated GIRK channel inhibition was diminished by minigene constructs that reduce membrane levels of the PLC substrate phosphatidylinositol bisphosphate, further implicating PLC. However, we found no evidence for involvement of protein kinase C, inositol trisphosphate, or intracellular calcium. Although these downstream signaling intermediaries did not contribute to receptor-mediated GIRK channel inhibition, bath application of TRH decreased GIRK channel activity in cell-attached patches. Together, these data indicate that receptor-mediated inhibition of GIRK channels involves PLC activation by G alpha subunits of the G alpha (q) family and suggest that inhibition may be communicated at a distance to GIRK channels via unbinding and diffusion of phosphatidylinositol bisphosphate away from the channel.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Bayliss, DA (corresponding author), Univ Virginia, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.				NIMH NIH HHS [MH12091] Funding Source: Medline; NINDS NIH HHS [NS39553, R01 NS039553] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012091] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039553] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bommakanti RK, 2000, J BIOL CHEM, V275, P38870, DOI 10.1074/jbc.M007403200; BRAUN AP, 1992, PFLUG ARCH EUR J PHY, V421, P431, DOI 10.1007/BF00370253; Bunemann M, 2000, J BIOL CHEM, V275, P12537, DOI 10.1074/jbc.275.17.12537; Cho H, 2001, J BIOL CHEM, V276, P159, DOI 10.1074/jbc.M004826200; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Farkas RH, 1997, NEUROSCI LETT, V231, P21, DOI 10.1016/S0304-3940(97)00530-2; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Melliti K, 2000, J NEUROSCI, V20, P7167; Meyer T, 2001, J BIOL CHEM, V276, P5650, DOI 10.1074/jbc.M009179200; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Ruiz-Velasco V, 2000, J NEUROSCI, V20, P2183; Sambrook J., 2002, MOL CLONING LAB MANU; Schreibmayer W, 1996, NATURE, V380, P624, DOI 10.1038/380624a0; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Toby G, 1998, BIOTECHNIQUES, V24, P637, DOI 10.2144/98244st05; VANNER S, 1993, J NEUROPHYSIOL, V69, P1632, DOI 10.1152/jn.1993.69.5.1632; VELIMIROVIC BM, 1995, P NATL ACAD SCI USA, V92, P1590, DOI 10.1073/pnas.92.5.1590; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; WU DQ, 1993, J BIOL CHEM, V268, P3704; Xie LH, 1999, P NATL ACAD SCI USA, V96, P15292, DOI 10.1073/pnas.96.26.15292; Yamaguchi H, 1997, AM J PHYSIOL-HEART C, V273, pH1745, DOI 10.1152/ajpheart.1997.273.4.H1745; Zhang HL, 1999, NAT CELL BIOL, V1, P183, DOI 10.1038/11103; Zhou JY, 2000, J NEUROSCI, V20, P7143	42	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16720	16730		10.1074/jbc.M100207200	http://dx.doi.org/10.1074/jbc.M100207200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279027	hybrid			2022-12-25	WOS:000168730400019
J	Sugiura, N; Patel, RG; Corriveau, RA				Sugiura, N; Patel, RG; Corriveau, RA			N-methyl-D-aspartate receptors regulate a group of transiently expressed genes in the developing brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL NMDA RECEPTORS; LONG-TERM-MEMORY; CLASS-I MHC; APOPTOTIC NEURODEGENERATION; ELECTRICAL-ACTIVITY; NEURONAL PATTERNS; CRITICAL PERIOD; DENTATE GYRUS; MICE; PLASTICITY	Mammalian brain development requires the transmission of electrical signals between neurons via the N-methyl-D-aspartate (NMDA) class of glutamate receptors. However, little is known about how NMDA receptors carry out this role. Here we report the first genes shown to be regulated by physiological levels of NMDA receptor function in developing neurons in vivo: NMDA receptor-regulated gene 1 (NARG1), NARG2, and NARG3. These genes share several striking regulatory features. All three are expressed at high levels in the neonatal brain in regions of neuronal proliferation and migration, are dramatically down-regulated during early postnatal development, and are down-regulated by NMDA receptor function. NARG2 and NARG3 appear to be novel, while NARG1 is the mammalian homologue of a yeast N-terminal acetyltransferase that regulates entry into the G(o) phase of the cell cycle. The results suggest that highly specific NMDA receptor-dependent regulation of gene expression plays an important role in the transition from proliferation of neuronal precursors to differentiation of neurons.	Wayne State Univ, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Wayne State University	Corriveau, RA (corresponding author), Wayne State Univ, Dept Anat & Cell Biol, Detroit, MI 48201 USA.							Aparicio SAJR, 2000, NAT GENET, V25, P129, DOI 10.1038/75949; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Buonanno A, 1999, CURR OPIN NEUROBIOL, V9, P110, DOI 10.1016/S0959-4388(99)80014-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Constantine-Paton M, 1998, CURR OPIN NEUROBIOL, V8, P139, DOI 10.1016/S0959-4388(98)80017-2; Corriveau RA, 1999, J NEUROSCI, V19, P7999, DOI 10.1523/jneurosci.19-18-07999.1999; CORRIVEAU RA, 1993, J NEUROSCI, V13, P2662, DOI 10.1523/JNEUROSCI.13-06-02662.1993; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Corriveau RA, 1999, J NEUROBIOL, V41, P148, DOI 10.1002/(SICI)1097-4695(199910)41:1<148::AID-NEU18>3.0.CO;2-6; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; Gall C M, 1997, Adv Neurol, V72, P9; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; Gould E, 1997, BEHAV NEUROSCI, V111, P49; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hubel DH, 1998, NEURON, V20, P401, DOI 10.1016/S0896-6273(00)80984-8; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ikonomidou C, 2000, SCIENCE, V287, P1056, DOI 10.1126/science.287.5455.1056; Iwasato T, 2000, NATURE, V406, P726, DOI 10.1038/35021059; Iwasato T, 1997, NEURON, V19, P1201, DOI 10.1016/S0896-6273(00)80412-2; Kennedy MB, 1998, BRAIN RES REV, V26, P243, DOI 10.1016/S0165-0173(97)00043-X; KILLACKEY HP, 1995, TRENDS NEUROSCI, V18, P402, DOI 10.1016/0166-2236(95)93937-S; Komuro H, 1998, J NEUROBIOL, V37, P110, DOI 10.1002/(SICI)1097-4695(199810)37:1<110::AID-NEU9>3.3.CO;2-Q; Koshiba-Takeuchi K, 2000, SCIENCE, V287, P134, DOI 10.1126/science.287.5450.134; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; Messersmith EK, 1997, MOL CELL NEUROSCI, V9, P347, DOI 10.1006/mcne.1997.0646; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Okabe S, 1998, EUR J NEUROSCI, V10, P2192, DOI 10.1046/j.1460-9568.1998.00233.x; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; Pham TA, 1999, NEURON, V22, P63, DOI 10.1016/S0896-6273(00)80679-0; Poon CS, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-09-j0003.2000; PUJIC Z, 1993, NEUROSCI LETT, V162, P67, DOI 10.1016/0304-3940(93)90561-X; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Schulte D, 1999, NEURON, V24, P541, DOI 10.1016/S0896-6273(00)81111-3; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Sheng M, 2000, NAT NEUROSCI, V3, P633, DOI 10.1038/76576; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; Single FN, 2000, J NEUROSCI, V20, P2558; SQUIRE LR, 1995, COGNITIVE NEUROSCIEN; Weimann JM, 1999, NEURON, V24, P819, DOI 10.1016/S0896-6273(00)81030-2; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; Yuzaki M, 1996, J NEUROSCI, V16, P4651	52	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14257	14263		10.1074/jbc.M100011200	http://dx.doi.org/10.1074/jbc.M100011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297529	hybrid			2022-12-25	WOS:000168356600099
J	Remboutsika, E; Jacq, X; Tora, L				Remboutsika, E; Jacq, X; Tora, L			Chromatin is permissive to TATA-binding protein (TBP)-mediated transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TBP-LIKE FACTOR; COMPLEX; ACTIVATION; PROMOTER; FACT; ELONGATION; FORMS	Preinitiation complex assembly is nucleated by the binding of TFIID to the promoters of protein coding genes transcribed by RNA polymerase II, TFIID is comprised of the TATA-binding protein (TBP) and TBP-associated factors (TAF(II)s), We investigated the transcription properties of TBP and TFIID on chromatin templates. On naked templates both TBP and purified TFIID are able to initiate basal transcription. However, on chromatin templates only TBP mediates transcription initiation in a heat-treated extract, whereas TFIID does not. Moreover, TBP-mediated chromatin transcription is blocked in a nontreated extract. These observations suggest that a chromatin-targeted repressor is present in crude extracts and that chromatin per se is not refractory to transcription mediated by TBP, As TSP can function through TAF(II)-independent and TAF(II)-dependent pathways, the repression of TBP-mediated basal transcription may be an additional level to the control of Pol II transcription initiation on chromatin.	ULP, INSERM, CNRS,Dept Transcript & Post Transcript Control Ge, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, Communaute Urba, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Tora, L (corresponding author), ULP, INSERM, CNRS,Dept Transcript & Post Transcript Control Ge, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, Communaute Urba, France.	laszlo@igbmc.u-strasbg.fr	Tora, Laszlo/E-9999-2018	Tora, Laszlo/0000-0001-7398-2250				Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HAWLEY DK, 1987, J BIOL CHEM, V262, P3452; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mitsiou DJ, 2000, MOL CELL, V6, P527, DOI 10.1016/S1097-2765(00)00052-6; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wieczorek E, 1998, NATURE, V393, P187, DOI 10.1038/30283; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	28	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12781	12784		10.1074/jbc.M100481200	http://dx.doi.org/10.1074/jbc.M100481200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11279078	hybrid			2022-12-25	WOS:000168198600045
J	Guo, FF; Kumahara, E; Saffen, D				Guo, FF; Kumahara, E; Saffen, D			A Ca1DAG-GEFI/Rap1/B-Raf cassette couples M-1 muscarinic acetylcholine receptors to the activation of ERK1/2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE-C; LONG-TERM POTENTIATION; NUCLEOTIDE EXCHANGE FACTORS; MAPK SIGNALING PATHWAY; B-RAF; MEMBRANE DEPOLARIZATION; DEPENDENT ACTIVATION; CALCIUM INFLUX; CYCLIC-AMP	In this study we examine signaling pathways linking the M-1 subtype of muscarinic acetylcholine receptor (M-1 mAChR) to activation of extracellular signal-regulated kinases (ERK) 1 and 2 in neuronal PC12D cells. We first show that activation of ERK1/2 by the M-1 mAChR agonist carbachol takes place primarily via a Res-independent pathway that depends largely upon Rap1, another small GTP-binding protein in the Res family. Rap1 in turn activates B-Raf, an upstream activator of ERK1/2. Consistent with these results, carbachol was found to activate Rap1 more potently than Res. Similar to other small GTP-binding proteins, activation of Rap1 requires a guanine nucleotide exchange factor (GEF) to promote its conversion from the GDP- to GTP-bound form. Using specific antibodies, we show that a recently identified Rap1 GEF, (cal) under bar cium- and (d) under bari (a) under bar cylglycerol-regulated guanine nucleotide (e) under bar xchange (f) under bar actor (I) under bar (CalDAG-GEFI), is expressed in PC12D cells and that carbachol stimulates the formation of a complex containing CalDAG-GEFI, Rap1, and activated B-Raf. Finally, we show that expression of CalDAG-GEFI antisense RNA largely blocks carbachol-stimulated activation of hemagglutinin (HA)1-tagged B-Raf and formation of the CalDAG-GEFI/Rap1/HA1-tagged B-Raf complex. Together, these data define a novel signaling pathway for M-1 mAChR, where increases in Ca2+ and diacylglycerol stimulate the sequential activation of CalDAG-GEFI, Rap1, and B-Raf, resulting in the activation of MEK and ERK1/2.	Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Guo, FF (corresponding author), Univ Tokyo, Fac Med, Dept Neurochem, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.							ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BERG MM, 1992, J BIOL CHEM, V267, P13; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; CHANDLER CE, 1983, J CELL PHYSIOL, V114, P321, DOI 10.1002/jcp.1041140311; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Ebihara T, 1997, J NEUROCHEM, V68, P1001; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; EYCHENE A, 1995, ONCOGENE, V10, P1159; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FELDER CC, 1995, FASEB J, V9, P619, DOI 10.1096/fasebj.9.8.7768353; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haring R, 1998, J NEUROCHEM, V71, P2094; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kumahara E, 1999, J BIOL CHEM, V274, P10430, DOI 10.1074/jbc.274.15.10430; Kumahara E, 1999, J BIOCHEM, V125, P541, DOI 10.1093/oxfordjournals.jbchem.a022319; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMBERT DG, 1992, BIOCHEM SOC T, V20, P130, DOI 10.1042/bst0200130; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liao YH, 1999, J BIOL CHEM, V274, P37815, DOI 10.1074/jbc.274.53.37815; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Marino MJ, 1998, P NATL ACAD SCI USA, V95, P11465, DOI 10.1073/pnas.95.19.11465; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAX SI, 1993, J NEUROSCI, V13, P4293; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MRZLJAK L, 1993, P NATL ACAD SCI USA, V90, P5194, DOI 10.1073/pnas.90.11.5194; O'Donovan KJ, 1999, TRENDS NEUROSCI, V22, P167, DOI 10.1016/S0166-2236(98)01343-5; Ohtsuka T, 1999, BIOCHEM BIOPH RES CO, V265, P38, DOI 10.1006/bbrc.1999.1619; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rosenblum K, 2000, J NEUROSCI, V20, P977, DOI 10.1523/JNEUROSCI.20-03-00977.2000; Rouse ST, 1998, NEUROSCIENCE, V86, P221, DOI 10.1016/S0306-4522(97)00681-7; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	92	64	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25568	25581		10.1074/jbc.M101277200	http://dx.doi.org/10.1074/jbc.M101277200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11292831	hybrid			2022-12-25	WOS:000169800700148
J	Jiang, JG; Johnson, C; Zarnegar, R				Jiang, JG; Johnson, C; Zarnegar, R			Peroxisome proliferator-activated receptor gamma-mediated transcriptional up-regulation of the hepatocyte growth factor gene promoter via a novel composite cis-acting element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; FACTOR MESSENGER-RNA; PPAR-GAMMA; ORPHAN RECEPTORS; SCATTER FACTOR; RETINOIC ACID; COLON-CANCER; EXPRESSION; LIVER; FAMILY	Hepatocyte growth factor (HGF) is a pleotropic polypeptide that can function as a morphogen, motogen, mitogen, angiogen, carcinogen, and tumor suppressor, depending on the target cell and tissue. Previous studies from our laboratory using transgenic mice have shown that HGF gene expression is tightly regulated at the transcriptional level and that the upstream regulatory elements are crucial for the control of HGF gene transcription, In the present study, we have identified and characterized one of these elements as a peroxisome proliferator-activated receptor gamma (PPAR gamma)-responsive element. This regulatory element was localized at -246 to -233 base pairs upstream from the transcription start site of the HGF gene promoter having the sequence GGGCCAGGTGACCT. Gel mobility shift and supershift assays demonstrated that this cis-acting element strongly binds to the PPAR gamma isoforms as well as to chicken ovalbumin upstream promoter-transcription factor, a member of the orphan nuclear receptor subfamily. Mutational analysis and gel mobility band shift assays indicated that the binding site is an inverted repeat of the AGGTCA motif with two spacers (inverted repeat 2 configuration) and that the two spacers are important for PPAR gamma binding. This binding site overlaps with functional binding sites for activating protein-2, nuclear factor 1, and upstream stimulatory factor, and together, they constitute a multifunctional composite binding site through which these different transcription factors exert their regulatory effects on HGF promoter activity. Functional assays revealed that PPAR gamma, with its ligand, 15-deoxy-prostaglandin J2, strongly stimulates HGF promoter activity. On the other hand, nuclear factor 1, activating protein-2, and chicken ovalbumin upstream promoter-transcription factor transcription factors repress the stimulatory action of PPAR gamma by competing with PPAR gamma for their overlapping binding sites. Furthermore, for the first time, our studies demonstrate that the PPAR gamma ligand, 15-deoxy-prostaglandin J2, induces endogenous HGF mRNA and protein expression in fibroblasts in culture.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, S Biomed Sci Tower,Rm S411A, Pittsburgh, PA 15261 USA.		Jiang, Jie-Gen/K-3845-2019		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006109] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES 06109] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Bell AW, 1998, J BIOL CHEM, V273, P6900, DOI 10.1074/jbc.273.12.6900; GOHDA E, 1994, CYTOKINE, V6, P633, DOI 10.1016/1043-4666(94)90051-5; GREENWEL P, 1991, LAB INVEST, V65, P644; GREENWEL P, 1993, LAB INVEST, V69, P210; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jiang JG, 1997, J BIOL CHEM, V272, P3928, DOI 10.1074/jbc.272.7.3928; Jiang JG, 2000, ONCOGENE, V19, P2786, DOI 10.1038/sj.onc.1203581; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KONO S, 1992, BIOCHEM BIOPH RES CO, V186, P991, DOI 10.1016/0006-291X(92)90844-B; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LIU YH, 1994, J BIOL CHEM, V269, P4152; LIU YH, 1994, MOL CELL ENDOCRINOL, V104, P173, DOI 10.1016/0303-7207(94)90120-1; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MATSUMOTO K, 1992, J BIOL CHEM, V267, P24917; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; PLASCHKESCHLUTTER A, 1995, J BIOL CHEM, V270, P830, DOI 10.1074/jbc.270.2.830; Rosen ED, 2000, GENE DEV, V14, P1293; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; TAMURA M, 1993, J BIOL CHEM, V268, P8140; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	38	45	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25049	25056		10.1074/jbc.M101611200	http://dx.doi.org/10.1074/jbc.M101611200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11292834	hybrid			2022-12-25	WOS:000169800700083
J	Biemel, KM; Reihl, O; Conrad, J; Lederer, MO				Biemel, KM; Reihl, O; Conrad, J; Lederer, MO			Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes - Unraveling the structure of a pentosidine precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; D-GLUCOSE; PROTEINS; GLYOXAL; METHYLGLYOXAL; MECHANISM; 3-DEOXYGLUCOSONE; IDENTIFICATION; QUANTIFICATION; FLUOROPHORE	Covalently cross-linked proteins are among the major modifications caused by the advanced Maillard reaction. So far, the chemical nature of these aggregates and their formation pathways are largely unknown. Synthesis and unequivocal structural characterization are reported for the lysine-arginine cross-links N-6-{2-{[(4S)-4-ammonio-5-oxido-5-oxopentyl] amino]-5-[(2S,3R)-2,3,4. trihydroxybutyl]-3,5-dihydro-4H-imidazol-4-ylidene}-L-lysinate (DOGIC 12), N-6-{2-{[(4S)-4-ammonio-5-oxido-5-oxopentyl]amino}-5-[(2S)-2,3-dihydroxypropyl] -3-5-dihrdro-4H-imidazol-4-ylidene}-L-lysinate (DOPDIC 13), and 6-((6S)-2-{[(4S)-4-ammonio-5-oxido-5-oxopentyl] amino] 6-hydroxy-5,6,7,7a-tetrahydro-4H-imidazo[4,5-b] pyridin-4-yl)-L-norleucinate (pentosinane 10). For these compounds, as well as for glucosepane 9 and pentosidine 11, the formation pathways could be established by starting from native carbohydrates, Amadori products, and 3-deoxyosones, respectively, Pentosinane 10 was unequivocally proven to be an important precursor of pentosidine 11, which is a well established fluorescent indicator for advanced glycation processes in vivo, The Amadori products are shown to be the pivots in the formation of the various cross-links 9-13. The bicyclic structures 9-11 are directly derived from aminoketoses, whereas 12 and 13 stem from reaction with the 3-deoxyosones, All products 9-13 were identified and quantified from incubations of bovine serum albumin with the respective 3-deoxyosone or carbohydrate, From these results it seems fully justified to expect both glucosepane 9 and DOGDIC 12 to constitute important in vivo cross-links.	Univ Hohenheim, Inst Lebensmittelchem 170, D-70593 Stuttgart, Germany; Univ Hohenheim, Inst Chem 130, D-70593 Stuttgart, Germany	University Hohenheim; University Hohenheim	Lederer, MO (corresponding author), Univ Hohenheim, Inst Lebensmittelchem 170, Garbenstr 28, D-70593 Stuttgart, Germany.							Braun S., 1998, 150 MORE BASIC NMR E; BRINKMANN E, J CHEM SOC P1, P2817; Buettner Ulf, 1997, Carbohydrate Research, V300, P265; Chellan P, 2001, J BIOL CHEM, V276, P3895, DOI 10.1074/jbc.M008626200; DYER DG, 1991, J BIOL CHEM, V266, P11654; Friedman M, 1996, J AGR FOOD CHEM, V44, P631, DOI 10.1021/jf950394r; GLOMB M, 1992, THESIS U STUTTGART G; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; Henle T, 1997, Z LEBENSM UNTERS F A, V204, P95, DOI 10.1007/s002170050043; KATO H, 1987, AGR BIOL CHEM TOKYO, V51, P2009, DOI 10.1080/00021369.1987.10868313; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P1081, DOI 10.1016/S0968-0896(99)00040-1; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; Lederer MO, 1998, BIOORGAN MED CHEM, V6, P993, DOI 10.1016/S0968-0896(98)00058-3; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; Litchfield JE, 1999, INT J BIOCHEM CELL B, V31, P1297, DOI 10.1016/S1357-2725(99)00091-6; MADSON MA, 1981, CARBOHYD RES, V94, P183, DOI 10.1016/S0008-6215(00)80716-8; MAY PM, 1977, J CHEM SOC DALTON, P588, DOI 10.1039/dt9770000588; MCKAY E, 1964, CLIN CHIM ACTA, V10, P320, DOI 10.1016/0009-8981(64)90062-2; MONNIER VM, 1996, DIABETES, V45, P67; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; Nagaraj RH, 1996, J BIOL CHEM, V271, P19338, DOI 10.1074/jbc.271.32.19338; Nagaraj RH, 1996, ARCH BIOCHEM BIOPHYS, V325, P152, DOI 10.1006/abbi.1996.0019; NISSL J, 1995, CARBOHYD RES, V270, pC1, DOI 10.1016/0008-6215(95)00058-2; Odani H, 1998, FEBS LETT, V427, P381, DOI 10.1016/S0014-5793(98)00416-5; SELL DR, 1991, DIABETES METAB REV, V7, P239, DOI 10.1002/dmr.5610070404; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shamsi FA, 1999, CURR EYE RES, V19, P276, DOI 10.1076/ceyr.19.3.276.5315; Skovsted IC, 1998, CELL MOL BIOL, V44, P1159; Slatter DA, 1998, FEBS LETT, V421, P180, DOI 10.1016/S0014-5793(97)01554-8; Smallcombe SH, 1995, J MAGN RESON SER A, V117, P295, DOI 10.1006/jmra.1995.0759; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; Tyler AN, 1996, ANAL CHEM, V68, P3561, DOI 10.1021/ac9603791; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; WALTER HF, 1991, RUCKSTANDSANALYTIK P, P1; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WELLSKNECHT KJ, 1995, J ORG CHEM, V60, P6246, DOI 10.1021/jo00125a001; Yamaguchi M, 1998, DIABETIC MED, V15, P458, DOI 10.1002/(SICI)1096-9136(199806)15:6<458::AID-DIA601>3.0.CO;2-Q	38	116	122	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23405	23412		10.1074/jbc.M102035200	http://dx.doi.org/10.1074/jbc.M102035200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11279247	hybrid			2022-12-25	WOS:000169531100026
J	Krane, CM; Melvin, JE; Nguyen, HV; Richardson, L; Towne, JE; Doetschman, T; Menon, AG				Krane, CM; Melvin, JE; Nguyen, HV; Richardson, L; Towne, JE; Doetschman, T; Menon, AG			Salivary acinar cells from aquaporin 5-deficient mice have decreased membrane water permeability and altered cell volume regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; TARGETED DISRUPTION; CHANNEL; LACKING; SECRETION; PROTEINS; EXCHANGE; CLONING; AQP5	Aquaporins (AQPs) are channel proteins that regulate the movement of water through the plasma membrane of secretory and absorptive cells in response to osmotic gradients. In the salivary gland, AQP5 is the major aquaporin expressed on the apical membrane of acinar cells. Previous studies have shown that the volume of saliva secreted by AQP5-deficient mice is decreased, indicating a role for AQP5 in saliva secretion; however, the mechanism by which AQP5 regulates water transport in salivary acinar cells remains to be determined. Here we show that the decreased salivary flow rate and increased tonicity of the saliva secreted by Aqp5(-/-) mice in response to pilocarpine stimulation are not caused by changes in whole body fluid homeostasis, indicated by similar blood gas and electrolyte concentrations in urine and blood in wild-type and AQPB-deficient mice. In contrast, the water permeability in parotid and sublingual acinar cells isolated from Aqp5(-/-) mice is decreased significantly. Water permeability decreased by 65% in parotid and 77% in sublingual acinar cells from Aqp5(-/-) mice in response to hypertonicity-induced cell shrinkage and hypotonicity-induced cell swelling. These data show that AQP5 is the major pathway for regulating the water permeability in acinar cells, a critical property of the plasma membrane which determines the flow rate and ionic composition of secreted saliva.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Rochester, Sch Med & Dent, Ctr Oral Biol, Rochester, NY 14642 USA	University System of Ohio; University of Cincinnati; University of Rochester	Menon, AG (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Bethesda Ave,3110 MSB,POB 670524, Cincinnati, OH 45267 USA.	Anil.Menon@UC.edu			NHLBI NIH HHS [HL61781] Funding Source: Medline; NIDCR NIH HHS [R01 DE138283, R01 DEO8921] Funding Source: Medline; NIEHS NIH HHS [ES06096] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE008921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006096] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASKEW GR, 1993, MOL CELL BIOL, V13, P4115, DOI 10.1128/MCB.13.7.4115; Astor F C, 1999, Ear Nose Throat J, V78, P476; Bivona P L, 1998, N Y State Dent J, V64, P46; Cook D. I., 1994, P1061; Evans RL, 1999, J BIOL CHEM, V274, P29025, DOI 10.1074/jbc.274.41.29025; Evans RL, 2000, J BIOL CHEM, V275, P26720; Fischer D, 1997, Spec Care Dentist, V17, P58, DOI 10.1111/j.1754-4505.1997.tb00868.x; FOSKETT JK, 1990, AM J PHYSIOL, V259, pC998; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; Fox PC, 1998, ANN NY ACAD SCI, V842, P132, DOI 10.1111/j.1749-6632.1998.tb09641.x; He XJ, 1997, PFLUG ARCH EUR J PHY, V433, P260; Heymann JB, 2000, J MOL BIOL, V295, P1039, DOI 10.1006/jmbi.1999.3413; JUNG JS, 1994, J BIOL CHEM, V269, P14648; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; Krane CM, 1999, MAMM GENOME, V10, P498, DOI 10.1007/s003359901030; Lee MD, 1997, MEDICINE, V76, P141, DOI 10.1097/00005792-199705000-00001; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Matsuzaki T, 1999, CELL TISSUE RES, V295, P513, DOI 10.1007/s004410051257; RAINA S, 1995, J BIOL CHEM, V270, P1908, DOI 10.1074/jbc.270.4.1908; SCHREIBER R, 1999, J BIOL CHEM, V270, P1908; Schultheis PJ, 1998, J CLIN INVEST, V101, P1243, DOI 10.1172/JCI1249; SILANIKOVE N, 1989, AM J PHYSIOL, V256, pR809, DOI 10.1152/ajpregu.1989.256.4.R809; Spicer Z, 2000, J BIOL CHEM, V275, P21555, DOI 10.1074/jbc.M001558200; Steward MC, 1998, EUR J MORPHOL, V36, P103; STEWART CL, 1993, METHOD ENZYMOL, V225, P823; TURNER RJ, 1993, CRIT REV ORAL BIOL M, V4, P385, DOI 10.1177/10454411930040031801; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045	30	246	256	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23413	23420		10.1074/jbc.M008760200	http://dx.doi.org/10.1074/jbc.M008760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11290736	hybrid			2022-12-25	WOS:000169531100027
J	Ramachandran, A; Jain, A; Arora, P; Bashyam, MD; Chatterjee, U; Ghosh, S; Parnaik, VK; Hasnain, SE				Ramachandran, A; Jain, A; Arora, P; Bashyam, MD; Chatterjee, U; Ghosh, S; Parnaik, VK; Hasnain, SE			Novel Sp family-like transcription factors are present in adult insect cells and are involved in transcription from the polyhedrin gene initiator promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; 30-KDA PROTEIN-BINDING; SV40 EARLY PROMOTER; HOST FACTOR; SEQUENCE REQUIREMENTS; MEDIATED EXPRESSION; FUNCTIONAL-ANALYSIS; FIREFLY LUCIFERASE; BACULOVIRUS VECTOR; MOLECULAR-CLONING	We earlier documented the involvement of a cellular factor, polyhedrin (polh) promoter-binding protein, in transcription from the Autographa californica nuclear polyhedrosis virus polh gene promoter. Sequences upstream of the polh promoter were found to influence polh promoter-driven transcription. Analysis of one such region, which could partially compensate for the mutated polh promoter and also activate transcription from the wild-type promoter, revealed a sequence (AcSp) containing a CACCC motif and a loose GC box resembling the binding motifs of the transcription factor Sp1, AcSp and the consensus Spl sequence (cSp) specifically bound factor(s) in HeLa and Spodoptera frugiperda (Sf9) insect cell nuclear extracts to generate identical binding patterns, indicating the similar nature of the factor(s) interacting with these sequences. The AcSp and cSp oligonucleotides enhanced in vivo expression of a polh promoter-driven luciferase gene. In vivo mopping of these factor(s) significantly reduced transcription from the polh promoter. Recombinant viruses carrying deletions in the upstream AcSp sequence confirmed the requirement of these factor(s) in polh promoter-driven transcription in the viral context. We demonstrate for the first time DNA-protein interactions involving novel members of the Sp family of proteins in adult insect cells and their involvement in transcription from the polh promoter.	Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India; Ctr DNA Fingerprinting & Diagnost, Mol & Cellular Biol Lab, Hyderabad 500076, Andhra Pradesh, India; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Hasnain, SE (corresponding author), Natl Inst Immunol, Eukaryot Gene Express Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	ehtesham@www.cdfd.org.in	HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRONNER G, 1994, NATURE, V369, P664, DOI 10.1038/369664a0; BURMA S, 1994, J BIOL CHEM, V269, P2750; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; ETKIN E, 1994, VIRUS RES, V31, P343, DOI 10.1016/0168-1702(94)90027-2; GEARING KL, 1990, J GEN VIROL, V71, P251, DOI 10.1099/0022-1317-71-2-251; Ghosh S, 1998, J VIROL, V72, P7484, DOI 10.1128/JVI.72.9.7484-7493.1998; Guarino LA, 1998, J VIROL, V72, P7985, DOI 10.1128/JVI.72.10.7985-7991.1998; Habib S, 1996, J BIOL CHEM, V271, P28250, DOI 10.1074/jbc.271.45.28250; Habib S, 1996, DNA CELL BIOL, V15, P737, DOI 10.1089/dna.1996.15.737; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAM J, 1994, EMBO J, V13, P147, DOI 10.1002/j.1460-2075.1994.tb06244.x; Hasnain SE, 1997, GENE, V190, P113, DOI 10.1016/S0378-1119(96)00827-X; Hasnain SE, 1996, METHOD ENZYMOL, V274, P20; HASNAIN SE, 1994, DNA CELL BIOL, V13, P275, DOI 10.1089/dna.1994.13.275; HASNAIN SE, 1990, GENE, V91, P135, DOI 10.1016/0378-1119(90)90175-Q; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jain A, 1996, EUR J BIOCHEM, V239, P384, DOI 10.1111/j.1432-1033.1996.0384u.x; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; LU A, 1995, J VIROL, V69, P975, DOI 10.1128/JVI.69.2.975-982.1995; MAOUCHE L, 1995, EUR J BIOCHEM, V233, P793, DOI 10.1111/j.1432-1033.1995.793_3.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCLACHLIN JR, 1994, J VIROL, V68, P7746, DOI 10.1128/JVI.68.12.7746-7756.1994; MORRIS TD, 1994, GENE, V140, P147, DOI 10.1016/0378-1119(94)90538-X; MUKHERJEE B, 1995, DNA CELL BIOL, V14, P7, DOI 10.1089/dna.1995.14.7; MUKHERJEE B, 1995, J BIOL CHEM, V270, P4405, DOI 10.1074/jbc.270.9.4405; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PASSARELLI AL, 1994, J VIROL, V68, P4673, DOI 10.1128/JVI.68.7.4673-4678.1994; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; RANKIN C, 1988, GENE, V70, P39, DOI 10.1016/0378-1119(88)90102-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SRIDHAR P, 1994, J BIOSCIENCES, V19, P603; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; TODD JW, 1995, J VIROL, V69, P968, DOI 10.1128/JVI.69.2.968-974.1995; Turner J, 1999, TRENDS BIOCHEM SCI, V24, P236, DOI 10.1016/S0968-0004(99)01406-1; Wimmer EA, 1996, MECH DEVELOP, V59, P53, DOI 10.1016/0925-4773(96)00575-8; WIMMER EA, 1995, MECH DEVELOP, V53, P235, DOI 10.1016/0925-4773(95)00439-8; Yang S, 1999, J VIROL, V73, P3404, DOI 10.1128/JVI.73.4.3404-3409.1999; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841; Zhang SR, 1999, GENE, V227, P231, DOI 10.1016/S0378-1119(98)00590-3	57	19	19	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23440	23449		10.1074/jbc.M101537200	http://dx.doi.org/10.1074/jbc.M101537200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294840	hybrid			2022-12-25	WOS:000169531100030
J	Bremer, AA; Leeman, SE; Boyd, ND				Bremer, AA; Leeman, SE; Boyd, ND			Evidence for spatial proximity of two distinct receptor regions in the substance P (SP)center dot neurokinin-1 receptor (NK-1R) complex obtained by photolabeling the NK-1R with p-benzoylphenylalanine(3)-SP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOCHEMICAL-CHARACTERIZATION; MOLECULAR CHARACTERIZATION; FUNCTIONAL CDNA; G-PROTEINS; ANALOG; CELLS; TACHYKININS; SITE	Substance P (SP) belongs to the tachykinin family of bioactive peptides and exerts its many biological effects through functional interaction with its cell-surface, Gr protein-coupled neurokinin-l receptor (NK-1R). Previous studies from our laboratory have shown that I-125-Bolton-Hunter reagent-labeled p-benzoylphenylalanine(8)-SP (Bpa(8)SP) covalently attaches to Met(181), whereas I-125-Bolton-Hunter reagent-labeled Bpa(4)SP covalently attaches to Met(174), both of which are located on the second extracellular loop (EC2) of the NR-1R, In this study, evidence has been obtained that at equilibrium, the photoreactive SP analogue I-125-[D-Tyr(0)]Bpa(3)Sp covalently labels residues in two distinct extracellular regions of the NK-1R, One site of I-125-[D-Tyr(0)]Epa3Sp photoinsertion is located on EC2 within a segment of the receptor extending from residues 173 to 177; a second site of I-125-[D-Tyr(0)]BpaSP photoinsertion is located on the extracellular N terminus within a segment of the receptor extending from residues 11 to 21, a sequence that contains both potential sites for N-linked glycosylation, Since competition binding data presented in this study do not suggest the existence of multiple peptide NK-1R complexes, it is reasonable to assume that the receptor sequences within EC2 and N terminus identified by peptide mapping are in close proximity in the equilibrium complex.	Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA	Boston University	Boyd, ND (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, L-611,80 E Concord St, Boston, MA 02118 USA.			Leeman, Susan/0000-0002-0951-5364	NINDS NIH HHS [NS-31346] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031346] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; BOYD ND, 1991, ANN NY ACAD SCI, V632, P79, DOI 10.1111/j.1749-6632.1991.tb33096.x; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; ERSPAMER V, 1971, ANNU REV PHARMACOLOG, V11, P327, DOI 10.1146/annurev.pa.11.040171.001551; ERSPAMER V, 1981, TRENDS NEUROSCI, V4, P267, DOI 10.1016/0166-2236(81)90084-9; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KAGE R, 1993, J NEUROCHEM, V60, P347, DOI 10.1111/j.1471-4159.1993.tb05857.x; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KAGE R, 1995, J NEUROCHEM, V64, P316; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li HZ, 2001, J BIOL CHEM, V276, P10589, DOI 10.1074/jbc.M007397200; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MAGGIO JE, 1988, ANNU REV NEUROSCI, V11, P13, DOI 10.1146/annurev.neuro.11.1.13; NAKANISHI S, 1987, PHYSIOL REV, V67, P1117, DOI 10.1152/physrev.1987.67.4.1117; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; Pellegrini M, 2001, J BIOL CHEM, V276, P22862, DOI 10.1074/jbc.M101057200; PERNOW B, 1983, PHARMACOL REV, V35, P85; Quartara L, 1998, NEUROPEPTIDES, V32, P1, DOI 10.1016/S0143-4179(98)90015-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	27	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22857	22861		10.1074/jbc.M100824200	http://dx.doi.org/10.1074/jbc.M100824200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294866	hybrid			2022-12-25	WOS:000169412700117
J	Cram, EJ; Liu, BD; Bjeldanes, LF; Firestone, GL				Cram, EJ; Liu, BD; Bjeldanes, LF; Firestone, GL			Indole-3-carbinol inhibits CDK6 expression in human MCF-7 breast cancer cells by disrupting Sp1 transcription factor interactions with a composite element in the CDK6 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE CDK6; ESTROGEN-RECEPTOR SP1; CYCLIN D1 ONCOGENE; BINDING PROTEIN; FAMILY; ACTIVATION; CARCINOGENESIS; INDUCTION; COMPLEX; ARREST	Indole-3-carbinol (I3C), a compound naturally occurring in Brassica vegetables, can induce a G(1) cell cycle arrest of human MCF-7 breast cancer cells that is accompanied by the selective inhibition of cyclin-dependent kinase 6 (CDK6) expression. Reverse transcriptase-polymerase chain reaction analysis of CDK6 mRNA de cay rates revealed that I3C had no effect on CDK6 transcript stability. We report the first identification and functional characterization of the CDK6 promoter in order to determine whether I3C inhibits CDK6 transcription. In MCF-7 cells stably transfected with CDK6 promoter-linked luciferase reporter plasmids, I3C inhibited CDK6 promoter activity in an I3C specific response that was not a consequence of the growth-arrested state of the cells. Deletion analysis revealed a 167-base pair I3C-responsive region of the CDK6 promoter between -805 and -638, Site-specific mutations within this region revealed that both Sp1 and Ets-like sites, which are spaced 5 base pairs apart, were necessary for I3C responsiveness in the context of the CDK6 promoter. Electrophoretic mobility shift analysis of protein-DNA complexes formed with nuclear proteins isolated from I3C-treated and -untreated cells, in combination with supershift assays using Spl antibodies, demonstrated that the Sp1-binding site in the CDK6 promoter forms a specific I3C-responsive DNA-protein complex that contains the Sp1 transcription factor. Taken together, our results suggest that I3C down-regulates CDKG transcription by targeting Sp1 at a composite DNA site in the CDK6 promoter.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Nutr & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.	glfire@uclink4.berkeley.edu			NATIONAL CANCER INSTITUTE [R01CA069056] Funding Source: NIH RePORTER; NCI NIH HHS [CA69056-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1996, ONCOGENE, V13, P399; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradlow HL, 1995, ANN NY ACAD SCI, V768, P180, DOI 10.1111/j.1749-6632.1995.tb12121.x; BRADLOW HL, 1994, CANCER EPIDEM BIOMAR, V3, P591; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Broadbent TA, 1998, CURR MED CHEM, V5, P337; Broadbent TA, 1998, CURR MED CHEM, V5, P469; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Cover CM, 1999, CANCER RES, V59, P1244; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Davie JR, 1998, J CELL BIOCHEM, P203; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; Hamel PA, 1997, CANCER INVEST, V15, P143, DOI 10.3109/07357909709115767; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HORIGUCHIYAMADA J, 1994, MOL CELL BIOCHEM, V132, P31, DOI 10.1007/BF00925672; ISHIDA T, 1995, J IMMUNOL, V155, P5527; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; Kwon TK, 1996, GENE, V180, P113, DOI 10.1016/S0378-1119(96)00416-7; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; Meng QH, 2000, J MOL MED, V78, P155, DOI 10.1007/s001090000088; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muller C, 1999, J BIOL CHEM, V274, P11220, DOI 10.1074/jbc.274.16.11220; Oyama T, 1998, CANCER RES, V58, P2876; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; SHARMA S, 1994, CANCER RES, V54, P5848; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shiffman D, 1996, J BIOL CHEM, V271, P12199, DOI 10.1074/jbc.271.21.12199; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Srivastava BH, 1998, CANCER LETT, V134, P91, DOI 10.1016/S0304-3835(98)00247-X; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Takahashi Y, 2000, GENE DEV, V14, P804; TANGUAY DA, 1994, MOL IMMUNOL, V31, P643, DOI 10.1016/0161-5890(94)90173-2; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Thomas JW, 1999, MAMM GENOME, V10, P764, DOI 10.1007/s003359901088; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xie W, 1999, ENDOCRINOLOGY, V140, P219, DOI 10.1210/en.140.1.219; Zhu XL, 1998, MODERN PATHOL, V11, P1082	70	91	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22332	22340		10.1074/jbc.M010539200	http://dx.doi.org/10.1074/jbc.M010539200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297539	hybrid			2022-12-25	WOS:000169412700050
J	Huang, ZM; Cheng, SL; Slatopolsky, E				Huang, ZM; Cheng, SL; Slatopolsky, E			Sustained activation of the extracellular signal-regulated kinase pathway is required for extracellular calcium stimulation of human osteoblast proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR; CA2+-SENSING RECEPTOR; SENSING RECEPTORS; (CA-O(2+))-SENSING RECEPTOR; MC3T3-E1 OSTEOBLASTS; CELL-PROLIFERATION; BONE; INHIBITOR; DIFFERENTIATION	Elevated levels of [Ca2+](o) in bone milieu as a result of the resorptive action of osteoclasts are implicated in promoting proliferation and migration of osteoblasts during bone remodeling. However, mitogenic effects of [Ca2+](o) have only been shown in some, but not all, clonal osteoblast-like cells, and the molecular mechanisms underlying [Ca2+](o)-induced mitogenic signaling are largely unknown. In this study we demonstrated for the first time that [Ca2+](o) stimulated proliferation of primary human osteoblasts and selectively activated extracellular signal-regulated kinases (ERKs), Neither p38 mitogen-activated protein (MAP) kinase nor stress-activated protein kinase was activated by [Ca2+](o). Treatment of human osteoblasts with a MAP kinase kinase inhibitor, PD98059, impaired both basal and [Ca2+](o)-stimulated phosphorylation of ERKs and also reduced both basal and [Ca2+](o)-stimulated proliferation. [Ca2+](o) treatment resulted in two distinctive phases of ERK activation: an acute phase and a sustained phase. An inhibition time course revealed that it was the sustained phase, not the acute phase, that was critical for [Ca2+](o)-stimulated osteoblast proliferation. Our results demonstrate that mitogenic responsiveness to [Ca2+](o) is present in primary human osteoblasts and is mediated via prolonged activation of the MAP kinase kinase/ERK signal pathway.	Washington Univ, Sch Med, Dept Med, Div Renal, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Huang, ZM (corresponding author), Washington Univ, Sch Med, Dept Med, Div Renal, 660 S Euclid Ave,Box 8126, St Louis, MO 63110 USA.				NIDDK NIH HHS [DK-09976, DK-30178, DK-07126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007126, R01DK030178, P01DK009976] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brown EM, 1996, KIDNEY INT, V49, P1042, DOI 10.1038/ki.1996.152; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, VITAM HORM, V55, P1; Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dikic Ivan, 1999, Cell Biochemistry and Biophysics, V30, P369, DOI 10.1007/BF02738120; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Godwin SL, 1997, J BIOL CHEM, V272, P11307; Habel B, 1998, EUR BIOPHYS J BIOPHY, V27, P411, DOI 10.1007/s002490050149; Hartle JE, 1996, J BONE MINER RES, V11, P789; HONDA Y, 1995, J BONE MINER RES, V10, P1660; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KANATANI M, 1991, BIOCHEM BIOPH RES CO, V181, P1425, DOI 10.1016/0006-291X(91)92098-5; Katoh S, 1999, BIOCHEM J, V338, P465, DOI 10.1042/0264-6021:3380465; KIMOTO S, 1994, ENDOCRINOLOGY, V135, P2423, DOI 10.1210/en.135.6.2423; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; Maher P, 1999, J BIOL CHEM, V274, P17491, DOI 10.1074/jbc.274.25.17491; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Orsini MJ, 1999, AM J PHYSIOL-LUNG C, V277, pL479, DOI 10.1152/ajplung.1999.277.3.L479; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Quarles LD, 1997, J BONE MINER RES, V12, P1971, DOI 10.1359/jbmr.1997.12.12.1971; QUARLES LD, 1994, J CELL BIOCHEM, V56, P106, DOI 10.1002/jcb.240560115; Quarles LD, 1997, J BONE MINER RES, V12, P393, DOI 10.1359/jbmr.1997.12.3.393; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SUGIMOTO T, 1994, AM J PHYSIOL, V266, pE709, DOI 10.1152/ajpendo.1994.266.5.E709; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530; Yamaguchi T, 1998, ENDOCRINOLOGY, V139, P3561, DOI 10.1210/en.139.8.3561; Yamaguchi T, 1998, BIOCHEM BIOPH RES CO, V243, P753, DOI 10.1006/bbrc.1998.8178; Yamaguchi T, 2001, AM J PHYSIOL-CELL PH, V280, pC382, DOI 10.1152/ajpcell.2001.280.2.C382; ZAIDI M, 1995, J CLIN INVEST, V96, P1582, DOI 10.1172/JCI118197	39	75	79	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21351	21358		10.1074/jbc.M010921200	http://dx.doi.org/10.1074/jbc.M010921200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11292824	hybrid			2022-12-25	WOS:000169297900075
J	Kang, TB; Yi, J; Guo, A; Wang, X; Overall, CM; Jiang, WP; Elde, R; Borregaard, N; Pei, DQ				Kang, TB; Yi, J; Guo, A; Wang, X; Overall, CM; Jiang, WP; Elde, R; Borregaard, N; Pei, DQ			Subcellular distribution and cytokine- and chemokine-regulated secretion of leukolysin/MT6-MMP/MMP-25 in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MATRIX-METALLOPROTEINASES; EXPRESSION; COLLAGENASE; GRANULES; IDENTIFICATION; PROGELATINASE; PURIFICATION; FIBROBLASTS; ACTIVATION	Leukolysin, originally isolated from human leukocytes, is the sixth member of the membrane-type matrix metalloproteinase (MT-MMP) subfamily with a potential glycosylphosphatidylinositol (GPI) anchor. To understand its biological functions, we screened subpopulations of leukocytes and localized the expression of leukolysin at the mRNA level to neutrophils. Polyclonal and mono-specific antisera raised against a synthetic peptide from its hinge region recognized a major protein species at 56 kDa and several minor forms between 38 and 45 kDa in neutrophil lysates, In resting neutrophils, leukolysin is distributed among specific granules (similar to 10%), gelatinase granules (similar to 40%), secretory vesicles (similar to 30%), and the plasma membrane (similar to 20%), a pattern distinct from that of neutrophil MMP-8 and MMP-9. Consistent with its membrane localization and its reported GPI anchor, leukolysin partitions into the detergent phase of Triton X-114 and can be released from intact resting neutrophils by glycosylphosphatidylinositol-specific phospholipase C. Phorbol myristate acetate stimulates neutrophils to discharge 100% of leukolysin from specific and gelatinase granules and similar to 50% from the secretory vesicles and plasma membrane, suggesting that leukolysin can be mobilized by physiological signals to the extracellular milieu as a soluble enzyme. Indeed, interleukin 8, a neutrophil chemoattractant, triggered a release of similar to 85% of cellular leukolysins by a process resistant to a mixture of proteinase inhibitors, including aprotinin, BB-94, pepstatin, and E64. Finally, purified recombinant leukolysin can degrade components of the extracellular matrix. These results not only establish leukolysin as the first neutrophil-specific MT-MMP but also implicate it as a cytokine/chemokine-regulated effector during innate immune responses or tissue injury.	Univ Minnesota, Dept Pharmacol, Sch Med, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Sch Med, Minneapolis, MN 55455 USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; R&D Syst, Minneapolis, MN 55413 USA; Natl Univ Hosp, Finsen Ctr, Dept Hematol, Copenhagen, Denmark	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of British Columbia	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, Sch Med, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	peixx003@tc.umn.edu	Wang, Xing/G-2917-2015		NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Betsuyaku T, 1999, AM J RESP CELL MOL, V20, P1303, DOI 10.1165/ajrcmb.20.6.3558; BIRKEDALHANSEN H, 1993, J PERIODONTOL, V64, P474, DOI 10.1902/jop.1993.64.5s.474; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; BRINCKERHOFF C E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P145; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hanemaaijer R, 1997, J BIOL CHEM, V272, P31504, DOI 10.1074/jbc.272.50.31504; HASTY KA, 1990, J BIOL CHEM, V265, P11421; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Kinoshita T, 1997, J BIOCHEM-TOKYO, V122, P251; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; LAZARUS GS, 1968, SCIENCE, V159, P1483, DOI 10.1126/science.159.3822.1483; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; MAINARDI CL, 1984, COLLAGEN REL RES, V4, P479; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MATRISIAN LM, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P152; MURPHY G, 1977, BIOCHEM J, V162, P195, DOI 10.1042/bj1620195; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Parkos CA, 1997, BIOESSAYS, V19, P865, DOI 10.1002/bies.950191006; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Schonermark M, 1996, ACTA OTO-LARYNGOL, V116, P451, DOI 10.3109/00016489609137872; Sengelov H, 1999, J IMMUNOL METHODS, V232, P145, DOI 10.1016/S0022-1759(99)00172-6; Shlopov BV, 1997, ARTHRITIS RHEUM-US, V40, P2065, DOI 10.1002/art.1780401120; TSCHESCHE H, 1995, METHOD ENZYMOL, V248, P431; Velasco G, 2000, CANCER RES, V60, P877; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang X, 1999, FEBS LETT, V462, P261, DOI 10.1016/S0014-5793(99)01534-3; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	41	97	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21960	21968		10.1074/jbc.M007997200	http://dx.doi.org/10.1074/jbc.M007997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11282999	hybrid			2022-12-25	WOS:000169297900151
J	Wang, T; Arifoglu, P; Ronai, Z; Tew, KD				Wang, T; Arifoglu, P; Ronai, Z; Tew, KD			Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; H2O2-INDUCED CELL-DEATH; TRANSCRIPTION FACTOR; TRANSDUCTION; APOPTOSIS; PATHWAY; DOMAIN; ATF2; P53	c-Jun N-terminal kinase (JNK)-mediated cell signaling pathways are regulated endogenously in part by protein-protein interactions with glutathione S-transferase P1-1 (GSTP1-1) (1). Using purified recombinant proteins, combined with fluorescence resonance energy transfer technology, we have found that the C terminus of JNK is critical to the interaction with GSTP1-1. The apparent K-d for full-length JNK was 188 nM and for a C-terminal fragment (residues 200-424) 217 nM. An N-terminal fragment (residues 1-206) did not bind to GSTP1-1. Increased expression of the C-terminal JNK fragment in a tetracycline-inducible transfected NIH3T3 cell line produced a concentration-dependent increase in the kinase activity of JNK under normal, unstressed growth conditions indicating a dominant-negative effect. This suggests that the fragment can compete with endogenous full-length functional JNK resulting in dissociation of the GSTP1-1-JNK interaction and concomitant JNK enzyme activation. By using an antibody to hemagglutinin-tagged C-JNK, a concentration-dependent co-immunoprecipitation of GSTP1-1 was achieved. These data provide evidence for direct interactions between the C-terminal of JNK and GSTP1-1 and a rationale for considering GSTP1-1 as a critical ligand-binding protein with a role in regulating kinase pathways.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA; CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA	Fox Chase Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Tew, KD (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.			RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA085660, R01CA077389, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA85660, CA77389] Funding Source: Medline; NCRR NIH HHS [RR05539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Bernardini S, 2000, J CELL BIOCHEM, V77, P645, DOI 10.1002/(SICI)1097-4644(20000615)77:4<645::AID-JCB12>3.3.CO;2-0; Buschmann T, 2000, J BIOL CHEM, V275, P16590, DOI 10.1074/jbc.M910045199; CHO SG, 2001, IN PRESS J BIOL CHEM; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Janknecht R, 1997, J BIOL CHEM, V272, P4219, DOI 10.1074/jbc.272.7.4219; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MERELO JJ, 1994, NEUROCOMPUTING, V6, P443, DOI 10.1016/0925-2312(94)90021-3; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Monaco R, 1999, J PROTEIN CHEM, V18, P859, DOI 10.1023/A:1020679229110; Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; TEW KD, 1994, CANCER RES, V54, P4313; Wang T, 1999, P NATL ACAD SCI USA, V96, P7843, DOI 10.1073/pnas.96.14.7843; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xie XL, 1998, STRUCTURE, V6, P983, DOI 10.1016/S0969-2126(98)00100-2; Yin ZM, 2000, CANCER RES, V60, P4053	24	255	258	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20999	21003		10.1074/jbc.M101355200	http://dx.doi.org/10.1074/jbc.M101355200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279197	hybrid			2022-12-25	WOS:000169297900028
J	Ahmad, Z; Sherman, F				Ahmad, Z; Sherman, F			Role of Arg-166 in yeast cytochrome c(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; RHODOBACTER-CAPSULATUS; BC(1) COMPLEX; MEMBRANE-PROTEIN; INNER MEMBRANE; BC1 COMPLEX; DNA; BINDING; DOMAIN	A systematic screen for dominant-negative mutations of the CYT1 gene, which encodes cytochrome c(1), revealed seven mutants after testing similar to 10(4) Saccharomyces cerevisiae strains transformed with a library of mutagenized multicopy plasmids. DNA sequence analysis revealed multiple nucleotide substitutions with six of the seven altered Cyt1p having a common R166G replacement, either by itself or accompanied with other amino acid replacements. A single R166G replacement produced by site-directed mutagenesis demonstrated that this change produced a nearly nonfunctional cytochrome c(1), with diminished growth on glycerol medium and diminished respiration but with the normal or near normal level of cytochrome c(1) having an attached heme group. In contrast, R166K, R166M, or R166L replacements resulted in normal or near normal function. Arg-166 is conserved in all cytochromes c(1) and lies on the surface of Cyt1p in close proximity to the heme group but does not seem to interact directly with any of the physiological partners of the cytochrome bc(1) complex. Thus, the large size of the side chain at position 166 is critical for the function of cytochrome c(1) but not for its assembly in the cytochrome bc(1) complex.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Sherman, F (corresponding author), Univ Rochester, Sch Med, Dept Biochem & Biophys, POB 712, Rochester, NY 14642 USA.	Fred_Sherman@urmc.rochester.edu		Ahmad, Zulfiqar/0000-0001-7306-8151	NIGMS NIH HHS [R15 GM085771, R01 GM12702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM085771, R01GM012702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; Arnold I, 1998, J BIOL CHEM, V273, P1469, DOI 10.1074/jbc.273.3.1469; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; BOSSHARD HR, 1979, BIOCHEM BIOPH RES CO, V89, P250, DOI 10.1016/0006-291X(79)90971-9; BRANDT U, 1994, J BIOL CHEM, V269, P12947; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; BROGER C, 1983, EUR J BIOCHEM, V131, P349, DOI 10.1111/j.1432-1033.1983.tb07269.x; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Darrouzet E, 1999, BIOCHEMISTRY-US, V38, P7908, DOI 10.1021/bi990211k; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DUMONT ME, 1993, MOL CELL BIOL, V13, P6442, DOI 10.1128/MCB.13.10.6442; Gao F, 1999, BBA-PROTEIN STRUCT M, V1430, P203, DOI 10.1016/S0167-4838(98)00284-2; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; GRAY KA, 1992, BIOCHEMISTRY-US, V31, P11864, DOI 10.1021/bi00162a027; HASE T, 1987, J BIOCHEM, V102, P401, DOI 10.1093/oxfordjournals.jbchem.a122067; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HICKEY DR, 1991, GENE, V105, P73, DOI 10.1016/0378-1119(91)90515-D; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Iwata S, 1996, STRUCTURE, V4, P567, DOI 10.1016/S0969-2126(96)00062-7; KONISHI K, 1991, J BIOL CHEM, V266, P14270; KOPPENOL WH, 1982, J BIOL CHEM, V257, P4426; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; Maniatis T., 1982, MOL CLONING LAB MANU; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NAKAI M, 1993, J BIOCHEM-TOKYO, V114, P919, DOI 10.1093/oxfordjournals.jbchem.a124277; NAKAI M, 1989, J BIOCHEM-TOKYO, V106, P181, DOI 10.1093/oxfordjournals.jbchem.a122811; NAKAI M, 1990, J BIOCHEM-TOKYO, V108, P798, DOI 10.1093/oxfordjournals.jbchem.a123283; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERMAN F, 1964, BIOCHIM BIOPHYS ACTA, V90, P1, DOI 10.1016/0304-4165(64)90113-8; SHERMAN F, 1974, GENETICS, V77, P255; SHERMAN F, 1987, METHODS YEAST GENETI; Sherman F., 1997, ENCY MOL BIOL MOL ME, V6, P302; SIKORSKI RS, 1989, GENETICS, V122, P19; STONEHUERNER J, 1985, J BIOL CHEM, V260, P5392; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; VANLOON APGM, 1987, EMBO J, V6, P2441, DOI 10.1002/j.1460-2075.1987.tb02523.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	44	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18450	18456		10.1074/jbc.M100550200	http://dx.doi.org/10.1074/jbc.M100550200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279090	hybrid			2022-12-25	WOS:000168866500111
J	Sidis, Y; Schneyer, AL; Sluss, PM; Johnson, LN; Keutmann, HT				Sidis, Y; Schneyer, AL; Sluss, PM; Johnson, LN; Keutmann, HT			Follistatin: Essential role for the N-terminal domain in activin binding and neutralization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-MORPHOGENETIC PROTEIN; EARLY XENOPUS EMBRYO; CELL-LINE PA-1; II RECEPTORS; HEPARAN-SULFATE; GROWTH-FACTOR; INHIBIN; AGRIN; SITE; IDENTIFICATION	Follistatin is recognized to be an important regulator of cellular differentiation and secretion through its potent ability to bind and bioneutralize activin with which it is colocalized in many tissue systems. The 288-residue follistatin molecule is comprised of a 63-residue N-terminal segment followed by three repeating 10-cysteine "follistatin domains" also represented in several extracellular matrix proteins. We have used chemical modifications and mutational analyses to define structural requirements for follistatin bioactivity that previously have not been investigated systematically. Mutant follistatins were stably expressed fi om Chinese hamster ovary cell cultures and assayed for activin binding in a solid-phase competition assay. Biological activities were determined by inhibition of activin-mediated transcriptional activity and by suppression of follicle-stimulating hormone secretion by cultured anterior pituitary cells. Deletion of the entire N-terminal domain, disruption of N-terminal disulfides, and deletion of the first two residues each reduced activin binding to <5 % of expressed wild-type follistatin and abolished the ability of the respective mutants to suppress activin-mediated responses in both bioassay systems. Hence, the three follistatin domains inherently lack the ability to bind or neutralize activin. Activin binding was impaired after oxidation of at least one tryptophan, at position 4, in FS-288, Mutation of Trp to Ala or Asp at either positions 4 or 36 eliminated activin binding and bioactivity, Mutation of a third hydrophobic residue, Phe-52, reduced binding to 20% whereas substitutions for the individual Lys and Arg residues in the N-terminal region were tolerated. These results establish that hydrophobic residues within the N-terminal domain constitute essential activin-binding determinants in the follistatin molecule. The correlation among the effects of mutation on activin binding, activin transcriptional responses, and follicle-stimulating hormone secretion substantiates the concept that, at least in the pituitary, the biological activity of follistatin is attributable to its ability to bind and bioneutralize activin.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Natl Ctr Infertil Res, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Keutmann, HT (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, Wellman 501, Boston, MA 02114 USA.	Keutmann@helix.mgh.harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053828] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-53828] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLIEL PM, 1993, EUR J BIOCHEM, V214, P347, DOI 10.1111/j.1432-1033.1993.tb17930.x; Burgess RW, 2000, J CELL BIOL, V151, P41, DOI 10.1083/jcb.151.1.41; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Delbaere A, 1999, ENDOCRINOLOGY, V140, P2463, DOI 10.1210/en.140.6.2463; Denzer AJ, 1998, EMBO J, V17, P335, DOI 10.1093/emboj/17.2.335; DePaolo LV, 1997, P SOC EXP BIOL MED, V214, P328; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; Eib DW, 1996, J NEUROCHEM, V67, P1047; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; FEDERMAN S, 2000, P 22 ANN M AM SOC BO; Gamer LW, 1999, DEV BIOL, V208, P222, DOI 10.1006/dbio.1998.9191; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; Haaijman A, 1997, J BONE MINER RES, V12, P1815, DOI 10.1359/jbmr.1997.12.11.1815; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; Hayette S, 1998, ONCOGENE, V16, P2949, DOI 10.1038/sj.onc.1201807; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; HUANG HJ, 2001, IN PRESS ENDOCRINOLO; Iemura S, 1999, J BIOL CHEM, V274, P26843, DOI 10.1074/jbc.274.38.26843; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INOUYE S, 1991, BIOCHEM BIOPH RES CO, V179, P352, DOI 10.1016/0006-291X(91)91377-O; INOUYE S, 1992, MOL CELL ENDOCRINOL, V90, P1, DOI 10.1016/0303-7207(92)90094-M; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; McConnell DS, 1998, J CLIN ENDOCR METAB, V83, P851, DOI 10.1210/jc.83.3.851; MERIGGIOLA MC, 1994, ENDOCRINOLOGY, V134, P1967, DOI 10.1210/en.134.4.1967; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NEUMANN NP, 1962, BIOCHEMISTRY-US, V1, P68, DOI 10.1021/bi00907a011; PATTHY L, 1993, TRENDS NEUROSCI, V16, P76, DOI 10.1016/0166-2236(93)90021-D; Peng C, 2000, BIOCHEM CELL BIOL, V78, P261, DOI 10.1139/bcb-78-3-261; PURNANANDA G, 1992, BIOCHEMISTRY-US, V31, P4296; SCHNEYER A, 2001, IN PRESS MOL CELL EN; SCHNEYER AL, 1994, ENDOCRINOLOGY, V135, P667, DOI 10.1210/en.135.2.667; SCOTT RS, 1980, ENDOCRINOLOGY, V107, P1536, DOI 10.1210/endo-107-5-1536; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392; Tsuchida K, 2000, J BIOL CHEM, V275, P40788, DOI 10.1074/jbc.M006114200; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; VALE W, 1988, RECENT PROG HORM RES, V44, P1; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Wang QF, 1996, J CLIN ENDOCR METAB, V81, P1434, DOI 10.1210/jc.81.4.1434; WANG QF, 2000, INT C BON MORPH PROT, P30; Wozney JM, 1998, CLIN ORTHOP RELAT R, P26; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201	50	57	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17718	17726		10.1074/jbc.M100736200	http://dx.doi.org/10.1074/jbc.M100736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279126	hybrid			2022-12-25	WOS:000168866500015
J	Vilar, M; Esteve, V; Pallas, V; Marcos, JF; Perez-Paya, E				Vilar, M; Esteve, V; Pallas, V; Marcos, JF; Perez-Paya, E			Structural properties of carnation mottle virus p7 movement protein and its RNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOBACCO MOSAIC-VIRUS; CELL-TO-CELL; ALPHA-HELIX STABILITY; SINGLE-STRANDED-DNA; SUBCELLULAR-LOCALIZATION; VIRAL MOVEMENT; AMINO-ACIDS; ENDOPLASMIC-RETICULUM; CIRCULAR-DICHROISM; TRANSGENIC PLANTS	Plant viral movement proteins (MPs) participate actively in the intra- and intercellular movement of RNA plant viruses to such an extent that MP dysfunction impairs viral infection. However, the molecular mechanism(s) of their interaction with cognate nucleic acids are not well understood, partly due to the lack of structural information. In this work, a protein dissection approach was used to gain information on the structural and RNA-binding properties of this class of proteins, as exemplified by the 61-amino acid residue p7 MP from carnation mottle virus (CarMV). Circular dichroism spectroscopy showed that CarMV p7 is an alpha/beta RNA-binding soluble protein. Using synthetic peptides derived from the p7 sequence, we have identified three distinct putative domains within the protein. EMSA showed that the central region, from residue 17 to 35 (represented by peptide p(17-35)), is responsible for the RNA binding properties of CarMV p7, This binding peptide populates a nascent alpha -helix in water solution that is further stabilized in the presence of either secondary structure inducers, such as trifluoroethanol and monomeric SDS, or RNA (which also changes its conformation upon binding to the peptide). Thus, the RNA recognition appears to occur via an "adaptive binding" mechanism. Interestingly, the amino acid sequence and structural properties of the RNA-binding domain of p7 seem to be conserved among carmoviruses and some other RNA-binding proteins and peptides, The low conserved N terminus of p7 (peptide p7(1-16)) is unstructured in solution. In contrast, the highly conserved C terminus motif (peptide p7(40-61)) adopts a beta -sheet conformation in aqueous solution. Alanine scanning mutagenesis of the RNA-binding motif showed how selected positive charged amino acids are more relevant than others in the RNA binding process and how hydrophobic amino acid side chains would participate in the stabilization of the protein-RNA complex.	Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain; Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, E-46022 Valencia, Spain; CSIC, Inst Agroquim & Tecnol Alimentos, Dept Ciencia Alimentos, E-46100 Valencia, Spain	University of Valencia; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP); Consejo Superior de Investigaciones Cientificas (CSIC); Instituto de Agroquimica y Tecnologia de los Alimentos (IATA)	Perez-Paya, E (corresponding author), Univ Valencia, Dept Bioquim & Biol Mol, E-46100 Valencia, Spain.	paya@uv.es	Marcos, Jose F./A-7121-2011; Pallas, Vicente/N-1317-2014; Vilar, Marçal/B-4581-2016; Esteve, Vicent/I-2728-2015	Marcos, Jose F./0000-0003-3339-2584; Pallas, Vicente/0000-0003-4954-989X; Vilar, Marçal/0000-0002-9376-6544; Esteve, Vicent/0000-0003-4740-0936				Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERNA A, 1991, VIROLOGY, V182, P682, DOI 10.1016/0042-6822(91)90609-F; BLONDELLE SE, 1995, BIOPHYS J, V68, P351, DOI 10.1016/S0006-3495(95)80194-3; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; Brill LM, 2000, P NATL ACAD SCI USA, V97, P7112, DOI 10.1073/pnas.130187897; Cai ZP, 1998, NAT STRUCT BIOL, V5, P203, DOI 10.1038/nsb0398-203; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; DALY TJ, 1990, BIOCHEMISTRY-US, V29, P9791, DOI 10.1021/bi00494a005; DEOM CM, 1987, SCIENCE, V237, P389, DOI 10.1126/science.237.4813.389; DEOM CM, 1990, P NATL ACAD SCI USA, V87, P3284, DOI 10.1073/pnas.87.9.3284; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRANKEL AD, 1992, P NATL ACAD SCI USA, V89, P11653, DOI 10.1073/pnas.89.24.11653; GIESMANCOOKMEYER D, 1993, PLANT CELL, V5, P973, DOI 10.1105/tpc.5.8.973; HACKER DL, 1992, VIROLOGY, V186, P1, DOI 10.1016/0042-6822(92)90055-T; Hefferon KL, 1997, ARCH VIROL, V142, P425, DOI 10.1007/s007050050089; Heinlein M, 1998, PLANT CELL, V10, P1107, DOI 10.1105/tpc.10.7.1107; HEINLEIN M, 1995, SCIENCE, V270, P1983, DOI 10.1126/science.270.5244.1983; Jackson D, 2000, CURR OPIN PLANT BIOL, V3, P394, DOI 10.1016/S1369-5266(00)00102-3; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kahn TW, 1998, PLANT J, V15, P15, DOI 10.1046/j.1365-313X.1998.00172.x; KNEALE GG, 1992, CURR OPIN STRUC BIOL, V2, P124; KOONIN EV, 1991, J GEN VIROL, V72, P2895, DOI 10.1099/0022-1317-72-12-2895; LAPIDOT M, 1993, PLANT J, V4, P959, DOI 10.1046/j.1365-313X.1993.04060959.x; Leisner S. M., 1999, MOL BIOL PLANT VIRUS, P161; Li VZ, 1998, VIROLOGY, V244, P405, DOI 10.1006/viro.1998.9125; Marcos JF, 1999, VIROLOGY, V255, P354, DOI 10.1006/viro.1998.9596; Mas P, 1999, J CELL BIOL, V147, P945, DOI 10.1083/jcb.147.5.945; McLean BG, 1995, PLANT CELL, V7, P2101, DOI 10.1105/tpc.7.12.2101; Melcher U, 2000, J GEN VIROL, V81, P257, DOI 10.1099/0022-1317-81-1-257; MESHI T, 1987, EMBO J, V6, P2557, DOI 10.1002/j.1460-2075.1987.tb02544.x; MULLER L, 1979, J AM CHEM SOC, V101, P4481; MUNOZ V, 1994, PROTEINS, V20, P301, DOI 10.1002/prot.340200403; MUNOZ V, 1994, NAT STRUCT BIOL, V1, P399, DOI 10.1038/nsb0694-399; MUSHEGIAN AR, 1993, ARCH VIROL, V133, P239, DOI 10.1007/BF01313766; Oliver AW, 1999, BIOCHEM J, V339, P525, DOI 10.1042/0264-6021:3390525; Padidam M, 1999, J VIROL, V73, P1609, DOI 10.1128/JVI.73.2.1609-1616.1999; Pallas V, 1998, METH MOL B, V81, P461; PEREZPAYA E, 1995, J BIOL CHEM, V270, P1048, DOI 10.1074/jbc.270.3.1048; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PLYTE SE, 1991, PROTEIN ENG, V4, P553, DOI 10.1093/protein/4.5.553; Qu F, 1999, ENCY VIROLOGY, P243; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; ROULEAU M, 1994, VIROLOGY, V204, P254, DOI 10.1006/viro.1994.1530; RUSSO M, 1994, ADV VIRUS RES, V44, P381, DOI 10.1016/S0065-3527(08)60334-6; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; Soengas MS, 1997, J BIOL CHEM, V272, P303; Su LL, 1997, BIOCHEMISTRY-US, V36, P12722, DOI 10.1021/bi971408k; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1992, BIOCHEMISTRY-US, V31, P10288, DOI 10.1021/bi00157a016; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; VANDERGRAAF M, 1992, BIOCHEMISTRY-US, V31, P9177, DOI 10.1021/bi00153a009; Waigmann E, 1995, PLANT CELL, V7, P2069; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; Weiss MA, 1998, BIOPOLYMERS, V48, P167, DOI 10.1002/(SICI)1097-0282(1998)48:2<167::AID-BIP6>3.0.CO;2-8; Wobbe KK, 1998, J VIROL, V72, P6247, DOI 10.1128/JVI.72.7.6247-6250.1998; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Xoconostle-Cazares B, 1999, SCIENCE, V283, P94, DOI 10.1126/science.283.5398.94	66	29	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18122	18129		10.1074/jbc.M100706200	http://dx.doi.org/10.1074/jbc.M100706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279121	hybrid			2022-12-25	WOS:000168866500069
J	Graschopf, A; Stadler, JA; Hoellerer, MK; Eder, S; Sieghardt, M; Kohlwein, SD; Schweyen, RJ				Graschopf, A; Stadler, JA; Hoellerer, MK; Eder, S; Sieghardt, M; Kohlwein, SD; Schweyen, RJ			The yeast plasma membrane protein Alr1 controls Mg2+ homeostasis and is subject to Mg2+-dependent control of its synthesis and degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; INDUCED INACTIVATION; MAGNESIUM TRANSPORT; URACIL PERMEASE; CELLULAR MG2+; BUDDING YEAST; ENDOCYTOSIS; GENE; UBIQUITINATION; LOCALIZATION	The Saccharomyces cerevisiae ALR1 (YOL130w) gene product Alr1p is the first known candidate for a Mg2+ transport system in eukaryotic cells and is distantly related to the bacterial CorA Mg2+ transporter family. Here we provide the first experimental evidence for the location of Alr1p in the yeast plasma membrane and for the tight control of its expression and turnover by Mg2+. Using well characterized npi1 and end3 mutants deficient in the endocytic pathway, we demonstrate that Alr1 protein turnover is dependent on ubiquitination and endocytosis. Furthermore, cells lacking the vacuolar protease Pep4p accumulated Alr1p in the vacuole. Mutants lacking Alr1p (Delta alr1) showed a 60% reduction of total intracellular Mg2+ compared with the wild type and failed to grow in standard media. When starved of Mg2+, mutant and wild-type cells had similar low levels of intracellular Mg2+; but upon addition of Mg2+, wild-type cells replenished the intracellular Mg2+ pool within a few hours, whereas Delta alr1 mutant cells did not. Expression of the bacterial Mg2+ transporter CorA in the yeast Delta alr1 mutant partially restored growth in standard media. The results are discussed in terms of Alr1p being a plasma membrane transporter with high selectivity for Mg2+.	Univ Vienna, Inst Microbiol & Genet, Vienna Bioctr, A-1030 Vienna, Austria; Graz Tech Univ, Dept Biochem, Biomembrane Res Ctr SFB, A-8010 Graz, Austria; Univ Agr Sci, Inst Forest Ecol, A-1180 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Graz University of Technology; University of Natural Resources & Life Sciences, Vienna	Schweyen, RJ (corresponding author), Univ Vienna, Inst Microbiol & Genet, Vienna Bioctr, Waehringer Guertel 18, A-1030 Vienna, Austria.		Graschopf, Anton/C-5637-2008	Kohlwein, Sepp Dieter/0000-0002-1030-0598				BEELER T, 1994, J BIOL CHEM, V269, P7279; Beeler T, 1997, BBA-BIOMEMBRANES, V1323, P310, DOI 10.1016/S0005-2736(96)00199-X; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Cefaratti C, 1998, AM J PHYSIOL-CELL PH, V275, pC995, DOI 10.1152/ajpcell.1998.275.4.C995; Cefaratti C, 2000, J BIOL CHEM, V275, P3772, DOI 10.1074/jbc.275.6.3772; Chiang HL, 1996, J BIOL CHEM, V271, P9934, DOI 10.1074/jbc.271.17.9934; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Fatholahi M, 2000, ARCH BIOCHEM BIOPHYS, V374, P395, DOI 10.1006/abbi.1999.1619; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gregan J, 2001, MOL GEN GENET, V264, P773, DOI 10.1007/s004380000366; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUNTHER T, 1995, BBA-BIOMEMBRANES, V1234, P105, DOI 10.1016/0005-2736(94)00267-S; GUNTHER T, 1993, MINER ELECTROL METAB, V19, P259; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; JONES EW, 1982, GENETICS, V102, P665; Kohlwein SD, 2000, MICROSC RES TECHNIQ, V51, P511, DOI 10.1002/1097-0029(20001215)51:6<511::AID-JEMT3>3.3.CO;2-P; Liu XF, 1999, J BIOL CHEM, V274, P4863, DOI 10.1074/jbc.274.8.4863; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; Medintz I, 1996, J BACTERIOL, V178, P2245, DOI 10.1128/jb.178.8.2245-2254.1996; Nelson N, 1999, EMBO J, V18, P4361, DOI 10.1093/emboj/18.16.4361; Niedenthal RK, 1996, YEAST, V12, P773, DOI 10.1002/(SICI)1097-0061(19960630)12:8<773::AID-YEA972>3.3.CO;2-C; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; RODRIGUEZNAVARRO A, 1979, BIOCHIM BIOPHYS ACTA, V552, P322, DOI 10.1016/0005-2736(79)90286-4; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Schweigel M, 2000, AM J PHYSIOL-GASTR L, V278, pG400, DOI 10.1152/ajpgi.2000.278.3.G400; Shaul O, 1999, EMBO J, V18, P3973, DOI 10.1093/emboj/18.14.3973; SHERMAN F, 1991, METHOD ENZYMOL, V94, P3; Smith RL, 1998, MOL MICROBIOL, V28, P217, DOI 10.1046/j.1365-2958.1998.00810.x; Springael JY, 1998, MOL BIOL CELL, V9, P1253, DOI 10.1091/mbc.9.6.1253; Tashiro M, 1997, BIOPHYS J, V73, P3371, DOI 10.1016/S0006-3495(97)78361-9; VanDenHazel HB, 1996, YEAST, V12, P1, DOI 10.1002/(SICI)1097-0061(199601)12:1<1::AID-YEA902>3.0.CO;2-N; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKER GM, 1986, MAGNESIUM, V5, P9; Wendland B, 1998, CURR OPIN CELL BIOL, V10, P513, DOI 10.1016/S0955-0674(98)80067-7; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Zhao H, 1998, J BIOL CHEM, V273, P28713, DOI 10.1074/jbc.273.44.28713	42	98	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16216	16222		10.1074/jbc.M101504200	http://dx.doi.org/10.1074/jbc.M101504200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279208	hybrid			2022-12-25	WOS:000168623100087
J	Mehta, S; Wu, HJ; Garner, CC; Marshall, J				Mehta, S; Wu, HJ; Garner, CC; Marshall, J			Molecular mechanisms regulating the differential association of kainate receptor subunits with SAP90/PSD-95 and SAP97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPSE-ASSOCIATED PROTEIN; TUMOR-SUPPRESSOR PROTEIN; KINASE-LIKE DOMAIN; POSTSYNAPTIC DENSITY; INTRAMOLECULAR INTERACTION; TYROSINE KINASE; SH3 DOMAINS; PSD-95; BINDING; FAMILY	Recent studies have demonstrated that kainate receptors are associated with members of the SAP90/PSD-95 family (synapse-associated proteins (SAPs)) in neurons and that SAP90 can cluster and modify the electrophysiological properties of GluR6/KA2 kainate receptors when co-expressed in transfected cells. In vivo, SAP90 tightly binds kainate receptor subunits, while SAP97 is only weakly associated, suggesting that this glutamate receptor differentially associates with SAP90/PSD-95 family members. Here, green fluorescent protein (GFP)-tagged chimeras and deletion mutants of SAP97 and SAP90 were employed to define the molecular mechanism underlying their differential association with kainate receptors. Our results show that a weak interaction between GluR6 and the PDZ1 domain of SAP97 can account for the weak association of GluR6 with the full-length SAP97 observed in vivo, Expression studies in HEK293 cells and in vitro binding studies further show that although the individual Src homology 3 and guanylate kinase domains in SAP97 can interact with the C-terminal tail of KA2 subunit, specific intramolecular interactions in SAP97 (e.g. the SAP97 N terminus (S97N) binding to the Src homology 3 domain) interfere with KA2 binding to the full-length molecule. Because receptor subunits are known to segregate to different parts of the neuron, our results imply that differential association of kainate receptors with SAP family proteins may be one mechanism of subcellular localization.	Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL 35294 USA	Brown University; University of Alabama System; University of Alabama Birmingham	Marshall, J (corresponding author), Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.			Garner, Craig/0000-0003-1970-5417	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG012978] Funding Source: NIH RePORTER; NIA NIH HHS [AG 12978-02, AG 06569-09, AG12978-02] Funding Source: Medline; NICHD NIH HHS [P50 HD32901] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andreotti AH, 1997, NATURE, V385, P93, DOI 10.1038/385093a0; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 2000, J BIOL CHEM, V275, P20045, DOI 10.1074/jbc.M910153199; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Kuhlendahl S, 1998, EUR J BIOCHEM, V252, P305, DOI 10.1046/j.1432-1327.1998.2520305.x; Lau LF, 1996, J BIOL CHEM, V271, P21622, DOI 10.1074/jbc.271.35.21622; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Sheng M, 1999, ANN NY ACAD SCI, V868, P483, DOI 10.1111/j.1749-6632.1999.tb11317.x; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Wu HJ, 2000, EMBO J, V19, P5740, DOI 10.1093/emboj/19.21.5740; Wu HJ, 1998, J CELL SCI, V111, P2365	28	60	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16092	16099		10.1074/jbc.M100643200	http://dx.doi.org/10.1074/jbc.M100643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279111	hybrid			2022-12-25	WOS:000168623100072
J	Singh, P; Chan, SW; Hong, WJ				Singh, P; Chan, SW; Hong, WJ			Retinoblastoma protein is functionally distinct from its homologues in affecting glucocorticoid receptor-mediated transcription and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE FAMILY; NUCLEOSOME DISRUPTION; DNA ELEMENT; PRB-FAMILY; COMPLEX; BINDING; ACTIVATION; CLONING; DOMAIN; GROWTH	The cell cycle regulator, retinoblastoma protein, is known to potentiate glucocorticoid receptor-activated transcription through the interaction of its pocket domain with the transcription coactivator, hBRM. We now show that glucocorticoid receptor-induced apoptosis is also dependent on both the retinoblastoma protein and hBRM. p107 and p130, which share extensive sequence homology with the pocket domain of the retinoblastoma protein but not its N-terminal region, also interact with hBRM but do not support either glucocorticoid receptor-dependent activity. This difference arises from the divergent N-terminal domain of the retinoblastoma protein, which, when fused to the pocket domains, confers upon p107 and p130 the ability to influence glucocorticoid receptor activities. This effect probably results from the promotion of glucocorticoid receptor-targeted chromatin remodeling by the hBRM-containing SWI/SNF complex because the N-terminal domain of the retinoblastoma protein enhances glucocorticoid receptor-hBRM interactions. These results highlight that, besides the interaction between hBRM and the pocket; domain. of RE, the N-terminal region of the retinoblastoma protein is also essential for; glucocorticoid receptor-induced apoptosis and the potentiation of glucocorticoid receptor-mediated transcription and provide a basis for functional distinction between the retinoblastoma protein and its homologues.	Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 117609, Singapore	Agency for Science Technology & Research (ASTAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Singh, P (corresponding author), Inst Mol & Cell Biol, Membrane Biol Lab, 30 Med Dr, Singapore 117609, Singapore.		HONG, Wanjin/E-9927-2010					BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DROUIN J, 1993, EMBO J, V12, P145, DOI 10.1002/j.1460-2075.1993.tb05640.x; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MAYOL X, 1993, ONCOGENE, V8, P2561; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; REIK A, 1991, EMBO J, V10, P2569, DOI 10.1002/j.1460-2075.1991.tb07797.x; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; UAUSUBEL FM, 1993, CURRENT PROTOCOLS MO; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	49	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13762	13770		10.1074/jbc.M100137200	http://dx.doi.org/10.1074/jbc.M100137200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11279017	hybrid			2022-12-25	WOS:000168356600037
J	Xie, D; Miller, CW; O'Kelly, J; Nakachi, K; Sakashita, A; Said, JW; Gornbein, J; Koeffler, HP				Xie, D; Miller, CW; O'Kelly, J; Nakachi, K; Sakashita, A; Said, JW; Gornbein, J; Koeffler, HP			Breast cancer - Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; VEIN ENDOTHELIAL-CELLS; INTEGRIN ALPHA(V)BETA(3); NOV PROTOONCOGENE; TUMOR-GROWTH; IN-VIVO; EXPRESSION; ADHESION; PRODUCT	To identify genes involved in breast cancer, polymerase chain reaction-selected cDNA subtraction was utilized to construct a breast cancer-subtracted library. Differential screening of the library isolated the growth factor-inducible immediate-early gene Cyr61, a secreted, cysteine-rich, heparin binding protein that promotes endothelial cell adhesion, migration, and neovascularization, Northern analysis revealed that Cyr61 was expressed highly in the invasive breast cancer cell lines MDA-MB-231, T47D, and MDA-MB-157; very low levels were found in the less tumorigenic MCF-7 and BT-20 breast cancer cells and barely detectable amounts were expressed in the normal breast cells, MCF-12A, Univariate analysis showed a significant or borderline significant association between Cyr61 expression and stage, tumor size, lymph node positivity, age, and estrogen receptor levels. Interestingly, expression of Cyr61 mRNA increased 8- to 12-fold in MCF-12A and 3- to 5-fold in MCF-7 cells after 24 and 48-h exposure to estrogen, respectively. Induction of Cyr61 mRNA was blocked by tamoxifen and ICI182,780, inhibitors of the estrogen receptor. Stable expression of Cyr61 cDNA under the regulation of a constitutive promoter in MCF-7 cells enhanced anchorage independent cell growth in soft agar and significantly increased tumorigenicity and vascularization of these tumors in nude mice. Moreover, overexpression of Cyr61 in MCF-12A normal breast cells induced their tumor formation and vascularization in nude mice. In summary, these results suggest that Cyr61 may play a role in the progression of breast cancer and may be involved in estrogen-mediated tumor development.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90048 USA; Saitama Canc Ctr, Ina, Saitama 362, Japan	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Xie, D (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA.			Xie, Dong/0000-0002-1150-8657				ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; Hartmann A, 1997, TRENDS GENET, V13, P27, DOI 10.1016/S0168-9525(96)10043-3; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Kolesnikova TV, 1998, ONCOGENE, V16, P747, DOI 10.1038/sj.onc.1201572; Kubo M, 1998, BRIT J DERMATOL, V139, P192; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUNKER R, 1986, J CLIN INVEST, V78, P424, DOI 10.1172/JCI112593; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; RAMACHANDRA S, 1990, J PATHOL, V161, P7, DOI 10.1002/path.1711610104; Rivera-Gonzalez R, 1998, J STEROID BIOCHEM, V64, P13, DOI 10.1016/S0960-0760(97)00142-8; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Scholz G, 1996, MOL CELL BIOL, V16, P481; Tsai MS, 2000, CANCER RES, V60, P5603; Varner J., 1997, REGULATION ANGIOGENE, P361; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu LF, 2000, GENE DEV, V14, P585; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131	39	136	143	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14187	14194		10.1074/jbc.M009755200	http://dx.doi.org/10.1074/jbc.M009755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297518	hybrid			2022-12-25	WOS:000168356600091
J	Morris, MA; Liu, JX; Kumar, V; Bennett, M				Morris, MA; Liu, JX; Kumar, V; Bennett, M			The B6 strain-Ly491 NK inhibitory gene expression on T Cells in FVB.LY491(B6) transgenic mice fails to prevent normal T cell functions.	FASEB JOURNAL			English	Meeting Abstract									Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Univ Chicago, Chicago, IL 60637 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Chicago									0	14	15	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 8	2001	15	5	2				A1026	A1026		10.1096/fj.00-0603fje	http://dx.doi.org/10.1096/fj.00-0603fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410TA	11292674				2022-12-25	WOS:000167454201807
J	Cacan, R; Duvet, S; Labiau, O; Verbert, A; Krag, SS				Cacan, R; Duvet, S; Labiau, O; Verbert, A; Krag, SS			Monoglucosylated oligomannosides are released during the degradation process of newly synthesized glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE POLYMANNOSE OLIGOSACCHARIDES; D-GLUCOSAMINIDASE ACTIVITY; RAT-LIVER; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONE; CYTOSOLIC LOCATION; HEPG2 CELLS; TRANSPORT; LYSOSOMES; CALNEXIN	The Chinese hamster ovary mutant MI8-5 is known to synthesize Man(9)GlcNAc(2)-P-P-dolichol rather than the fully glucosylated lipid intermediate Glc(3)Man(9)GlcNAc(2)-P-P-dolichol. This nonglucosylated oligosaccharide lipid precursor is used as donor for N-glycosylation. In this paper we demonstrate that a significant part of the glycans bound to the newly synthesized glycoproteins in MI8-5 cells are monoglucosylated, The presence of monoglucosylated glycans on glycoproteins determines their binding to calnexin as part of the quality control machinery. Furthermore, we point out the presence of Glc(1)Man(5)GlcNAc(1) in the cytosol of MI8-5 cells. This indicates that part of the monoglucosylated glycoproteins can be directed toward a deglycosylation process that occurs in the cytosol, Besides studies on glycoprotein degradation based on the disappearance of protein moieties, MI8-5 cells can be used as a tool to elucidate the various step leading to glycoprotein degradation by studying the fate of the glycan moieties.	Univ Sci & Technol Lille, CNRS UMR 8576, Chim Biol Lab, F-59655 Villeneuve Dascq, France; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Johns Hopkins University	Cacan, R (corresponding author), Univ Sci & Technol Lille, CNRS UMR 8576, Chim Biol Lab, F-59655 Villeneuve Dascq, France.				NATIONAL CANCER INSTITUTE [R01CA020421] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 20421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANUMULA KR, 1983, J BIOL CHEM, V258, P5274; Burda P, 1998, J CLIN INVEST, V102, P647, DOI 10.1172/JCI2266; Cacan R, 1999, BIOCHEM BIOPH RES CO, V258, P1, DOI 10.1006/bbrc.1999.0549; Cacan R, 1996, BIOCHEM J, V313, P597, DOI 10.1042/bj3130597; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Duvet S, 1998, BIOCHEM J, V335, P389, DOI 10.1042/bj3350389; Grard T, 1996, BIOCHEM J, V316, P787, DOI 10.1042/bj3160787; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Karaivanova VK, 2000, GLYCOBIOLOGY, V10, P727, DOI 10.1093/glycob/10.7.727; KMIECIK D, 1995, GLYCOBIOLOGY, V5, P483, DOI 10.1093/glycob/5.5.483; LIANG CJ, 1979, J BIOL CHEM, V254, P6414; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Moore SEH, 1999, TRENDS CELL BIOL, V9, P441, DOI 10.1016/S0962-8924(99)01648-7; MOORE SEH, 1995, EMBO J, V14, P6034, DOI 10.1002/j.1460-2075.1995.tb00292.x; PIERCE RJ, 1980, BIOCHEM J, V185, P261, DOI 10.1042/bj1850261; PIERCE RJ, 1979, BIOCHEM J, V180, P673, DOI 10.1042/bj1800673; Quellhorst GJ, 1999, GLYCOBIOLOGY, V9, P65, DOI 10.1093/glycob/9.1.65; RAY MK, 1991, J BIOL CHEM, V266, P22818; Saint-Pol A, 1999, J BIOL CHEM, V274, P13547, DOI 10.1074/jbc.274.19.13547; SaintPol A, 1997, J CELL BIOL, V136, P45, DOI 10.1083/jcb.136.1.45; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Verbert A, 1999, BBA-GEN SUBJECTS, V1473, P137, DOI 10.1016/S0304-4165(99)00174-9; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5	26	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22307	22312		10.1074/jbc.M101077200	http://dx.doi.org/10.1074/jbc.M101077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294837	hybrid			2022-12-25	WOS:000169412700046
J	Hikita, T; Tadano-Aritomi, K; Iida-Tanaka, N; Anand, JK; Ishizuka, I; Hakomori, S				Hikita, T; Tadano-Aritomi, K; Iida-Tanaka, N; Anand, JK; Ishizuka, I; Hakomori, S			A novel plasmal conjugate to glycerol and psychosine ("glyceroplasmalopsychosine") - Isolation and characterization from bovine brain white matter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; MASS-SPECTROMETRIC ANALYSIS; CHAIN CYCLIC ACETALS; PROTEIN KINASE-C; NMR-SPECTROSCOPY; LIQUID-CHROMATOGRAPHY; METHYLATION ANALYSIS; GROWTH-FACTOR; EQUINE BRAIN; RAT-KIDNEY	A novel plasmal conjugate of glycosphingolipid having cationic lipid properties was isolated from the white matter of bovine brain. Linkage analysis of galactosyl residue by methylation, liquid secondary ion, and electrospray ionization mass spectrometry of intact and methylated derivatives, and by H-1- and C-13-NMR spectroscopy, identified the structure unambiguously as an O-acetal conjugate of plasmal to the primary hydroxyl group of glycerol and to the 6-hydroxyl group of galactosyl residue of beta -galactosyl 1 -->1 sphingosine (psycho sine). This novel compound is hereby termed "glyceroplasmalopsychosine"; its structure is shown below.	Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Teikyo Univ, Sch Med, Dept Biochem, Tokyo 1738605, Japan	University of Washington; University of Washington Seattle; Teikyo University	Hakomori, S (corresponding author), Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA.	hakomori@u.washington.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039560] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39560] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BJORNDAL H, 1970, ANGEW CHEM INT EDIT, V9, P610, DOI 10.1002/anie.197006101; DEBUCH H, 1956, H-S Z PHYSIOL CHEM, V304, P109, DOI 10.1515/bchm2.1956.304.1-2.109; Debuch H., 1972, ETHER LIPIDS CHEM BI, P1, DOI [10.1016/b978-0-12-654150-2.50008-7, DOI 10.1016/B978-0-12-654150-2.50008-7]; DOMON B, 1988, GLYCOCONJUGATE J, V5, P397, DOI 10.1007/BF01049915; Feulgen R, 1929, H-S Z PHYSIOL CHEM, V180, P161, DOI 10.1515/bchm2.1929.180.4-6.161; Feulgen R, 1924, PFLUG ARCH GES PHYS, V206, P389, DOI 10.1007/BF01722779; FOLCH J, 1957, J BIOL CHEM, V226, P497; GRAY GM, 1958, BIOCHEM J, V70, P425, DOI 10.1042/bj0700425; HANAHAN DJ, 1960, LIPIDE CHEM, P92; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; Hikita T, 2000, ANAL BIOCHEM, V281, P193, DOI 10.1006/abio.2000.4561; HOLMGREN J, 1980, P NATL ACAD SCI-BIOL, V77, P1947, DOI 10.1073/pnas.77.4.1947; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IGARASHI Y, 1989, METHOD ENZYMOL, V179, P521; IIDA N, 1989, J BIOL CHEM, V264, P5974; Iida-Tanaka N, 2000, EUR J BIOCHEM, V267, P6790, DOI 10.1046/j.1432-1327.2000.01773.x; Iida-Tanaka N, 2000, CARBOHYD RES, V324, P218, DOI 10.1016/S0008-6215(99)00291-8; Jansson P-E., 1976, CHEM COMMUN U STOCKH, V8, P1; KOCHANOWSKI B, 1993, EUR J BIOCHEM, V214, P747, DOI 10.1111/j.1432-1033.1993.tb17976.x; Kogelberg H, 1996, BIOCHEMISTRY-US, V35, P1954, DOI 10.1021/bi9521598; LEVERY SB, 1987, METHOD ENZYMOL, V138, P13, DOI 10.1016/0076-6879(87)38004-8; LEVERY SB, 1992, BIOCHEMISTRY-US, V31, P5335, DOI 10.1021/bi00138a013; Martonosi, 1985, ENZYMES BIOL MEMBR, V2, P1; Matsuda K, 1997, BBA-LIPID LIPID MET, V1349, P1, DOI 10.1016/S0005-2760(97)00088-X; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; NUDELMAN ED, 1992, J BIOL CHEM, V267, P11007; Orfi L, 1997, LIPIDS, V32, P1035, DOI 10.1007/s11745-997-0133-x; RAPPORT MM, 1957, J BIOL CHEM, V225, P851; SADOZAI KK, 1993, CARBOHYD RES, V241, P301, DOI 10.1016/0008-6215(93)80120-4; Sadozai KK, 1996, J CARBOHYD CHEM, V15, P715, DOI 10.1080/07328309608005687; Sakakura C, 1996, J BIOL CHEM, V271, P946, DOI 10.1074/jbc.271.2.946; SHERMA J, 1974, ANAL LETT, V7, P279, DOI 10.1080/00032717408058188; SNYDER E, 1996, BIOCH LIPIDS LIPOPRO, P183; STROUD MR, 1994, BIOCHEMISTRY-US, V33, P10672, DOI 10.1021/bi00201a015; Tadano-Aritomi K, 1998, GLYCOBIOLOGY, V8, P341, DOI 10.1093/glycob/8.4.341; TADANOARITOMI K, 1995, CARBOHYD RES, V273, P41, DOI 10.1016/0008-6215(95)00106-4; Taketomi T, 1998, ACTA BIOCHIM POL, V45, P987, DOI 10.18388/abp.1998_4356; TAKETOMI T, 1990, J BIOCHEM-TOKYO, V107, P680, DOI 10.1093/oxfordjournals.jbchem.a123107; TAKI T, 1995, ANAL BIOCHEM, V225, P24, DOI 10.1006/abio.1995.1102; THANNHAUSER SJ, 1946, J BIOL CHEM, V166, P669; Yachida Y, 1998, J LIPID RES, V39, P1039; Yachida Y, 1999, J LIPID RES, V40, P2271	45	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23084	23091		10.1074/jbc.M101288200	http://dx.doi.org/10.1074/jbc.M101288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294874	hybrid			2022-12-25	WOS:000169412700146
J	Leimkuhler, S; Rajagopalan, KV				Leimkuhler, S; Rajagopalan, KV			A sulfurtransferase is required in the transfer of cysteine sulfur in the in vitro synthesis of molybdopterin from precursor Z in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SULFITE OXIDASE; FE-S CLUSTER; MOLYBDENUM COFACTOR; SELENOCYSTEINE LYASE; STRUCTURAL-CHARACTERIZATION; CONVERTING FACTOR; GENE CLONING; NIFS GENE; BIOSYNTHESIS; PROTEIN	It has been shown that conversion of precursor Z to molybdopterin (MPT) by Escherichia coli MPT synthase entails the transfer of the sulfur atom of the C-terminal thiocarboxylate from the small subunit of the synthase to generate the dithiolene group of MPT and that the moeB mutant E. coli contains inactive MPT synthase devoid of the thiocarboxylate. The data presented here demonstrate that L-cysteine can serve as the source of the sulfur for the biosynthesis of MPT in vitro but only in the presence of a persulfide containing sulfurtransferase such as IscS, cysteine sulfinate desulfinase (CSD), or CsdB. A fully defined in vitro system has been developed in which an inactive form of MPT synthase can be activated by incubation with MoeB, Mg ATP, L-cysteine, and one of the NifS-like sulfurtransferases, and the addition of precursor Z to the in vitro system gives rise to MPT formation. The use of radiolabeled L-[S-35]cysteine has demonstrated that both sulfurs of the dithiolene group of MPT originate from L-cysteine. It was found that MPT can be produced from precursor Z in an E. coli iscS mutant strain, indicating that IscS is not required for the in vivo sulfuration of RIFT synthase. A comparison of the ability of the three sulfurtransferases to provide the sulfur for MPT formation showed the highest activity for CSD in the in vitro system.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Rajagopalan, KV (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raj@biochem.duke.edu		Leimkuhler, Silke/0000-0003-3238-2122	NIGMS NIH HHS [GM44283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044283] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Flint DH, 1996, J BIOL CHEM, V271, P16068; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JONES HP, 1977, J BIOL CHEM, V252, P4988; JONES RW, 1977, BIOCHEM J, V164, P199, DOI 10.1042/bj1640199; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Leimkuhler S, 2001, J BIOL CHEM, V276, P1837, DOI 10.1074/jbc.M007304200; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; Rajagopalan KV, 1997, BIOCHEM SOC T, V25, P757, DOI 10.1042/bst0250757; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; STEWART V, 1988, MICROBIOL REV, V52, P190, DOI 10.1128/MMBR.52.2.190-232.1988; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	24	101	107	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22024	22031		10.1074/jbc.M102072200	http://dx.doi.org/10.1074/jbc.M102072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11290749	hybrid			2022-12-25	WOS:000169412700007
J	Antoniv, TT; De Val, S; Wells, D; Denton, CP; Rabe, C; de Crombrugghe, B; Ramirez, F; Bou-Gharios, G				Antoniv, TT; De Val, S; Wells, D; Denton, CP; Rabe, C; de Crombrugghe, B; Ramirez, F; Bou-Gharios, G			Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; TRANSGENIC MICE; REPORTER GENES; EXPRESSION; PROMOTER; CHROMATIN; TRANSCRIPTION; CELLS; ELEMENTS	We have examined the chromatin structure around and upstream of the transcriptional start site of the human alpha2(I) collagen (COL1A2) gene. Four strong DNase I-hypersensitive sites (HS2-5) were only detected in fibroblasts, and a weaker one (HS1) was identified in type I collagen-negative cells. Another hypersensitive site potentially involved in COL1A2 silencing was found in intron 1 (HS(In)), HS1 and HS2 were mapped within conserved promoter sequences and at locations comparable to the mouse gene. HS3, HS4, and HS5 were likewise mapped similar to 20 kilobases upstream of COL1A2 at about the same position as the mouse far-upstream enhancer and within a remarkably homologous genomic segment. DNase I footprinting identified twelve areas of nuclease protection in the far-upstream region (FU1-12) and within stretches nearly identical to the mouse sequence. The region containing HS3-5 was found to confer high and tissue-specific expression in transgenic mice to the otherwise minimally active COL1A2 promoter. Characterization of the human element documented functional differences with the mouse counterpart. Enhancer activity substantially decreased without the segment containing FU1-7 and HS5, and inclusion of AluI repeats located 3' of HS3 augmented position-independent expression of the transgene. Hence, subtle differences may characterize the regulation of mammalian alpha2(I) collagen genes by evolutionarily conserved sequences.	NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, New York, NY 10029 USA; Imperial Coll Sch Med, Ctr Clin Sci, MRC, London W12 0NN, England; Imperial Coll Sch Med, Dept Neuromuscular Dis, Gene Targeting Grp, London W6 4RF, England; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77020 USA	Icahn School of Medicine at Mount Sinai; New York University; Imperial College London; Imperial College London; University of Texas System; UTMD Anderson Cancer Center	Antoniv, TT (corresponding author), NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, Brookdale Ctr, 1 Gustave L Levy Pl,Box 1020, New York, NY 10029 USA.	ramirf01@doc.mssm.edu		Wells, Dominic/0000-0002-1425-6344	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR044888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41262] Funding Source: Medline; NIAMS NIH HHS [AR44888, AR386481] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEDALOV A, 1994, J BIOL CHEM, V269, P4903; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; Bonifer C, 1996, J MOL MED, V74, P663, DOI 10.1007/s001090050070; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Droge P, 2001, BIOESSAYS, V23, P179, DOI 10.1002/1521-1878(200102)23:2<179::AID-BIES1025>3.0.CO;2-6; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Festenstein R, 2000, CURR OPIN GENET DEV, V10, P199, DOI 10.1016/S0959-437X(00)00060-5; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSS DS, 1987, TRENDS BIOCHEM SCI, V12, P293, DOI 10.1016/0968-0004(87)90144-7; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; Hogan B, 1994, MANIPULATING MOUSE E; HOWARD B H, 1990, New Biologist, V2, P759; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Krempen K, 1999, GENE EXPRESSION, V8, P151; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; NIEDERREITHER K, 1992, J CELL BIOL, V119, P1361, DOI 10.1083/jcb.119.5.1361; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHERWOOD AL, 1990, GENE, V89, P239, DOI 10.1016/0378-1119(90)90011-F; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200	32	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21754	21764		10.1074/jbc.M101397200	http://dx.doi.org/10.1074/jbc.M101397200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279244	hybrid			2022-12-25	WOS:000169297900126
J	Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A				Daily, D; Vlamis-Gardikas, A; Offen, D; Mittelman, L; Melamed, E; Holmgren, A; Barzilai, A			Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the Ras-phosphoinositide 3-kinase and jun N-terminal kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							DNA-BINDING ACTIVITY; I-KAPPA-B; C-JUN; TRANSCRIPTION FACTOR; REDOX REGULATION; CELL-DEATH; PHOSPHATIDYLINOSITOL 3-KINASE; NUCLEAR TRANSLOCATION; SYMPATHETIC NEURONS; SIGNAL-TRANSDUCTION	Glutaredoxin 2 (Grx2) from Escherichia coli protects cerebellar neurons from dopamine-induced apoptosis via nuclear factor kappa B (NF-kappaB) activation, which is mediated by the expression of redox factor-1 (Ref-1), An analysis of the mechanisms underlying Grx2 protective activity revealed dual activation of signal transduction pathways. Grx2 significantly activated the Ras/phosphoinositide 3-kinase/Akt/NF-kappaB cascade in parallel to the Jun N-terminal kinase (JNK)/AP1 cascade. Dopamine, in comparison, down-regulated both pathways. Treatment of neurons with Ref-1 antisense oligonucleotide reduced the ability of Grx2 to activate Akt and AP-1 but had no effect on the phosphorylation of JNK1/2, suggesting that Akt/NF-kappaB and AP-1 are regulated by Ref-1. Exposure of the neurons to JNK1/2 antisense oligonucleotide in the presence of Grx2 significantly reduced AP-1 and NF-kappaB DNA binding activities and abolished Grx2 protection. These results demonstrate that dual activation of Ras/phosphoinositide 3-kinase and AP-1 cascades, which are mediated by Ref-1, is an essential component of the Grx2 mechanism of action.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Dept Neurol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Rabin Med Ctr, Felsenstein Med Res Inst, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Interdepartmental Core Facil, IL-69978 Tel Aviv, Israel; Karolinska Inst, Med Nobel Inst Biochem, Dept Biochem & Biophys, S-17177 Stockholm, Sweden	Tel Aviv University; Tel Aviv University; Rabin Medical Center; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Karolinska Institutet	Barzilai, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	barzilai@post.tau.ac.il	Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459				ADAMS JD, 1991, FREE RADICAL BIO MED, V10, P161, DOI 10.1016/0891-5849(91)90009-R; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BENSHACHAR D, 1995, J NEUROCHEM, V64, P718, DOI 10.1046/j.1471-4159.1995.64020718.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BUISSON A, 1992, J NEUROCHEM, V59, P1153, DOI 10.1111/j.1471-4159.1992.tb08358.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang NS, 1999, BIOCHEM BIOPH RES CO, V263, P107, DOI 10.1006/bbrc.1999.1288; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Crowder RJ, 1998, J NEUROSCI, V18, P2933; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DRAGUNOW M, 1995, NEUROSCI LETT, V191, P189, DOI 10.1016/0304-3940(95)11589-O; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUGUID JR, 1995, CANCER RES, V55, P6097; EFLER R, 1999, J CELL BIOL, V145, P1049; Eilers A, 1998, J NEUROSCI, V18, P1713; FILLOUX F, 1991, SYNAPSE, V8, P281, DOI 10.1002/syn.890080406; FILLOUX F, 1993, EXP NEUROL, V119, P79, DOI 10.1006/exnr.1993.1008; Foulstone EJ, 1999, NEUROSCI LETT, V264, P125, DOI 10.1016/S0304-3940(99)00166-4; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fritz G, 1999, ONCOGENE, V18, P1033, DOI 10.1038/sj.onc.1202394; Gamaley IA, 1999, INT REV CYTOL, V188, P203; Garcia-Pardo L, 1999, MOL HUM REPROD, V5, P914, DOI 10.1093/molehr/5.10.914; GASDASKA JR, 1995, CELL GROWTH DIFFER, V6, P1643; GRILLI M, 1993, INT REV CYTOL, V143, P1; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Harlow E., 1988, ANTIBODIES LAB MANUA; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Ikeuchi T, 1998, Hum Cell, V11, P125; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lander HM, 1997, J BIOL CHEM, V272, P4323, DOI 10.1074/jbc.272.7.4323; LASHER RS, 1972, BRAIN RES, V41, P482, DOI 10.1016/0006-8993(72)90521-5; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Makino Y, 1999, J BIOL CHEM, V274, P3182, DOI 10.1074/jbc.274.5.3182; MASAMI H, 1996, J BIOL CHEM, V271, P13234; Masserano JM, 1996, MOL PHARMACOL, V50, P1309; McLaughlin BA, 1998, J NEUROCHEM, V70, P2406; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MYTILINEOU C, 1993, J NEUROCHEM, V61, P1470, DOI 10.1111/j.1471-4159.1993.tb13642.x; Nakamura H, 1998, FREE RADICAL BIO MED, V24, P1176, DOI 10.1016/S0891-5849(97)00429-2; Nakamura T, 1999, FREE RADICAL RES, V31, P357, DOI 10.1080/10715769900300931; OFFEN D, 1995, BBA-MOL CELL RES, V1268, P171, DOI 10.1016/0167-4889(95)00075-4; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Oo TF, 1999, J NEUROCHEM, V72, P557, DOI 10.1046/j.1471-4159.1999.0720557.x; PADILLA CA, 1992, MOL CELL ENDOCRINOL, V85, P1, DOI 10.1016/0303-7207(92)90119-Q; Perez-Sala D, 1999, CELL DEATH DIFFER, V6, P722, DOI 10.1038/sj.cdd.4400557; POWIS G, 1994, ONCOL RES, V6, P539; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; Rong YQ, 1996, J NEUROCHEM, V67, P662; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; ROZELL B, 1993, EUR J CELL BIOL, V62, P314; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; SCHRAMM M, 1990, P NATL ACAD SCI USA, V87, P1193, DOI 10.1073/pnas.87.3.1193; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shan RJ, 1999, BLOOD, V94, P4067, DOI 10.1182/blood.V94.12.4067.424k12_4067_4076; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Shimoke K, 1998, FEBS LETT, V437, P221, DOI 10.1016/S0014-5793(98)01235-6; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Shinkai T, 1997, J NEUROSCI RES, V47, P393; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Takagi Y, 1999, BIOCHEM BIOPH RES CO, V258, P390, DOI 10.1006/bbrc.1999.0646; TANAKA M, 1991, J NEUROL SCI, V101, P198, DOI 10.1016/0022-510X(91)90046-A; Terai K, 1996, BRAIN RES, V735, P159; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Watson A, 1998, J NEUROSCI, V18, P751; Wei SJ, 2000, CANCER RES, V60, P6688; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.0.CO;2-9; ZilkhaFalb R, 1997, CELL MOL NEUROBIOL, V17, P101, DOI 10.1023/A:1026333222008; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	110	65	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21618	21626		10.1074/jbc.M101400200	http://dx.doi.org/10.1074/jbc.M101400200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290748	hybrid			2022-12-25	WOS:000169297900109
J	Navdaev, A; Clemetson, JM; Polgar, J; Kehrel, BE; Glauner, M; Magnenat, E; Wells, TNC; Clemetson, KJ				Navdaev, A; Clemetson, JM; Polgar, J; Kehrel, BE; Glauner, M; Magnenat, E; Wells, TNC; Clemetson, KJ			Aggretin, a heterodimeric C-type lectin from Calloselasma rhodostoma (Malayan pit viper), stimulates platelets by binding to alpha(2)beta(1) integrin and glycoprotein Ib, activating Syk and phospholipase C gamma 2, but does not involve the glycoprotein VI/Fc receptor gamma chain collagen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; TYROSINE PHOSPHORYLATION; AGGREGATION INDUCER; SIGNAL-TRANSDUCTION; MONOCLONAL-ANTIBODY; FLOW CONDITIONS; ADHESION; VI; VENOM; CELLS	Aggretin, a potent platelet activator, was isolated from Calloselasma rhodostoma venom, and 30-amino acid N-terminal sequences of both subunits were determined. Aggretin belongs to the heterodimeric snake C-type lectin family and is thought to activate platelets by binding to platelet glycoprotein alpha (2)beta (1). We now show that binding to glycoprotein (GP) Ib is also required. Aggretin-induced platelet activation was inhibited by a monoclonal antibody to GPIb as well as by antibodies to alpha (2)beta (1). Binding of both of these platelet receptors to aggretin was confirmed by affinity chromatography. No binding of other major platelet membrane glycoproteins, in particular GPVI, to aggretin was detected. Aggretin also activates platelets from Fc receptor gamma chain (Fc gamma)-deficient mice to a greater extent than those from normal control mice, showing that it does not use the GPVI/Fc gamma pathway. Platelets from Fc gamma -deficient mice expressed fibrinogen receptors normally in response to collagen, although they did not aggregate, indicating that these platelets may partly compensate via other receptors including alpha (2)beta (1) or GPIb for the lack of the Fc gamma pathway. Signaling by aggretin involves a dose-dependent lag phase followed by rapid tyrosine phosphorylation of a number of proteins. Among these are p72(SYK), p125(FAK) and PLC gamma2, whereas, in comparison with collagen anc; convulxin, the Fc gamma subunit neither is phosphorylated nor coprecipitates with p72(SYK). This supports an independent, GPIb- and integrin-based pathway for activation of p72(SYK) not involving the Fc gamma receptor.	Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Univ Munster, Klin & Polyklin Anasthesiol & Operat Intens Med E, D-48149 Munster, Germany; Serono Pharmaceut Res Inst SA, CH-1228 Geneva, Switzerland	University of Bern; University of Munster	Clemetson, KJ (corresponding author), Univ Bern, Theodor Kocher Inst, Freiestr 1, CH-3012 Bern, Switzerland.			Wells, Timothy/0000-0001-9796-847X				Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Benda B, 1996, TRANSPLANTATION, V62, P1207, DOI 10.1097/00007890-199611150-00003; Chung CH, 1999, BIOCHEM BIOPH RES CO, V263, P723, DOI 10.1006/bbrc.1999.1457; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Ichinohe T, 1997, J BIOL CHEM, V272, P63; Inoue K, 1999, BIOCHEM BIOPH RES CO, V256, P114, DOI 10.1006/bbrc.1999.0295; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Kato Y, 1998, BIOCHEM BIOPH RES CO, V242, P250, DOI 10.1006/bbrc.1997.7917; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Kehrel B, 1998, BLOOD, V91, P491; KEHREL B, 1995, SEMIN THROMB HEMOST, V21, P123, DOI 10.1055/s-2007-1000386; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; MAZUROV AV, 1991, THROMB RES, V62, P673, DOI 10.1016/0049-3848(91)90371-3; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Moroi M, 1997, BLOOD, V90, P4413; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1989, BIOCHEM J, V258, P157, DOI 10.1042/bj2580157; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nakamura T, 1998, J BIOL CHEM, V273, P4338, DOI 10.1074/jbc.273.8.4338; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; PolanowskaGrabowska R, 1997, BLOOD, V90, P1516, DOI 10.1182/blood.V90.4.1516.1516_1516_1526; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Polgar J, 1997, BIOCHEM J, V323, P533, DOI 10.1042/bj3230533; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Shin Y, 1998, BIOCHEM BIOPH RES CO, V245, P741, DOI 10.1006/bbrc.1998.8516; Suzuki-Inoue K, 2001, J BIOL CHEM, V276, P1643, DOI 10.1074/jbc.M006191200; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TENG CM, 1993, THROMB HAEMOSTASIS, V69, P286; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Tuckwell DS, 1996, EUR J BIOCHEM, V241, P732, DOI 10.1111/j.1432-1033.1996.00732.x; WHITE JG, 1993, LAB INVEST, V68, P497; XIA ZM, 1994, BIOPHYS J, V66, P2190, DOI 10.1016/S0006-3495(94)81015-X	43	65	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20882	20889		10.1074/jbc.M101585200	http://dx.doi.org/10.1074/jbc.M101585200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287424	hybrid			2022-12-25	WOS:000169297900014
J	Saint-Dic, D; Chang, SC; Taylor, GS; Provot, MM; Ross, TS				Saint-Dic, D; Chang, SC; Taylor, GS; Provot, MM; Ross, TS			Regulation of the Src homology 2-containing inositol 5-phosphatase SHIP1 in HIP1/PDGF beta R-transformed cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOMONOCYTIC LEUKEMIA; PDGF-BETA-R; POLYPHOSPHATE 5-PHOSPHATASE; MYELOGENOUS LEUKEMIA; RECEPTOR-BETA; FUSION; PROTEIN; GENE; PHOSPHATASE; ACTIVATION	It has been shown previously that the Huntingtin interacting protein 1 gene (HIP1) was fused to the platelet-derived growth factor beta receptor gene (PDGF betaR) in leukemic cells of a patient with chronic myelomonocytic leukemia. This resulted in the expression of the chimeric HIP1/PDGF betaR protein, which oligomerizes, is constitutively tyrosine-phosphorylated, and transforms the Ba/F3 murine hematopoietic cell line to interleukin-3-independent growth. Tyrosine phosphorylation of a 130-kDa protein (p130) correlates with transformation by HIP1/PDGF betaR and related transforming mutants. We report here that the p130 band is immunologically related to the 125-kDa isoform of the Src homology 2-containing inositol B-phosphatase, SHIP1. We have found that SHIP1 associates and colocalizes with the HIP1/ PDGF betaR fusion protein and related transforming mutants, These mutants include a mutant that has eight Src homology 2-binding phosphotyrosines mutated to phenylalanine, In contrast, SHIP1 does not associate with WP(KI), the kinase-dead form of HIP1/PDGF betaR. We also report that phosphorylation of SHIP1 by HIP1/PDGF betaR does not change its 5-phosphatase-specific activity. This suggests that phosphorylation and possible PDGF betaR-mediated sequestration of SHIP1 from its substrates (PtdIns(3,4,5)P-3 and Ins(1,3,4,5)P-4) might alter the levels of these inositol-containing signal transduction molecules, resulting in activation of downstream effecters of cellular proliferation and/or survival.	Univ Michigan, Ctr Canc, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Ross, TS (corresponding author), Univ Michigan, Ctr Canc, Sch Med, Dept Internal Med, 4217 CCGC Box 0936,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	tsross@umich.edu		Ross, Theodora/0000-0002-9166-1802	NCI NIH HHS [K08 CA76025-01, R01 CA82363-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082363, K08CA076025] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe A, 1997, BLOOD, V90, P4271, DOI 10.1182/blood.V90.11.4271.4271_4271_4277; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chacko GW, 1996, J IMMUNOL, V157, P2234; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Damen JE, 1998, BLOOD, V92, P1199, DOI 10.1182/blood.V92.4.1199.416k16_1199_1205; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; delPeso L, 1996, J CELL BIOCHEM, V61, P599, DOI 10.1002/(SICI)1097-4644(19960616)61:4<599::AID-JCB14>3.0.CO;2-B; Geier SJ, 1997, BLOOD, V89, P1876, DOI 10.1182/blood.V89.6.1876; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Lamkin TD, 1997, J BIOL CHEM, V272, P10396; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu QR, 1998, BLOOD, V91, P2753, DOI 10.1182/blood.V91.8.2753.2753_2753_2759; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; Ross TS, 1999, J BIOL CHEM, V274, P22328, DOI 10.1074/jbc.274.32.22328; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Wilbanks AM, 2000, EXP HEMATOL, V28, P584, DOI 10.1016/S0301-472X(00)00138-7; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	27	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21192	21198		10.1074/jbc.M008336200	http://dx.doi.org/10.1074/jbc.M008336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287412	hybrid			2022-12-25	WOS:000169297900054
J	Whittle, E; Shanklin, J				Whittle, E; Shanklin, J			Engineering Delta(9)-16 : 0-acyl carrier protein (ACP) desaturase specificity based on combinatorial saturation mutagenesis and logical redesign of the castor Delta(9)-18 : 0-ACP desaturase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHESIS; SUBSTRATE-SPECIFICITY; DIRECTED EVOLUTION; ESCHERICHIA-COLI; SEED; EXPRESSION; PLANTS; GENE; BIOSYNTHESIS; FERREDOXIN	Six amino acid locations in the soluble castor Delta (9)-18:0-acyl carrier protein (ACP) desaturase were identified that can affect substrate specificity. Combinatorial saturation mutagenesis of these six amino acids, in conjunction with selection, using an unsaturated fatty acid auxotroph system, led to the isolation of variants with up to Iii-fold increased specific activity toward 16-carbon substrates. The most improved mutant, com2, contained two substitutions (T117R/G188L) common to five of the 19 complementing variants subjected to further analysis. These changes, when engineered into otherwise wild-type 18:0-ACP desaturase to make mutant 5,2, produced a 35-fold increase in specific activity with respect to le-carbon substrates, Kinetic analysis revealed changes in both k(cat) and K-m that result in an 82-fold improvement in specificity factor for Is-carbon substrate compared with wild-type enzyme. Improved substrate orientation apparently compensated for loss of binding energy that results from the loss of desolvation energy for 16-carbon substrates. Mutant 5.2 had specific activity for 16-carbon substrates 2 orders of magnitude higher than those of known natural 16-carbon specific desaturases. These data support the hypothesis that it should be possible to reengineer archetypal enzymes to achieve substrate specificities characteristic of recently evolved enzymes while retaining the desired stability and/or turnover characteristics of a parental paralog.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463,50 Bell Ave, Upton, NY 11973 USA.			Shanklin, John/0000-0002-6774-8043				Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Arnold FH, 1999, CURR OPIN CHEM BIOL, V3, P54, DOI 10.1016/S1367-5931(99)80010-6; Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; BEREMAND PD, 1987, ARCH BIOCHEM BIOPHYS, V256, P90, DOI 10.1016/0003-9861(87)90428-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Broadwater JA, 1998, FETT-LIPID, V100, P103; Cahoon EB, 1997, PLANT MOL BIOL, V33, P1105, DOI 10.1023/A:1005821007291; Cahoon EB, 1998, PLANT PHYSIOL, V117, P593, DOI 10.1104/pp.117.2.593; Cahoon EB, 2000, P NATL ACAD SCI USA, V97, P12350, DOI 10.1073/pnas.210276297; Cahoon EB, 1997, P NATL ACAD SCI USA, V94, P4872, DOI 10.1073/pnas.94.10.4872; Cahoon EB, 1996, J BACTERIOL, V178, P936, DOI 10.1128/jb.178.3.936-939.1996; CAHOON EB, 1992, P NATL ACAD SCI USA, V89, P11184, DOI 10.1073/pnas.89.23.11184; CAHOON EB, 1994, PROG LIPID RES, V33, P155, DOI 10.1016/0163-7827(94)90018-3; CAHOON EB, 1994, J BIOL CHEM, V269, P27519; Cannon WR, 1996, NAT STRUCT BIOL, V3, P821, DOI 10.1038/nsb1096-821; GIBSON KJ, 1993, BIOCHIM BIOPHYS ACTA, V1169, P231, DOI 10.1016/0005-2760(93)90245-5; GOLDSTEIN RA, 2001, IN PRESS PROTEIN FOL; Govindarajan S, 1998, P NATL ACAD SCI USA, V95, P5545, DOI 10.1073/pnas.95.10.5545; Haas JA, 1999, BIOCHEMISTRY-US, V38, P12833, DOI 10.1021/bi991318a; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; MCKEON TA, 1982, J BIOL CHEM, V257, P2141; Minshull J, 1999, CURR OPIN CHEM BIOL, V3, P284, DOI 10.1016/S1367-5931(99)80044-1; Miyazaki K, 1999, J MOL EVOL, V49, P716, DOI 10.1007/PL00006593; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROUGHAN G, 1990, ARCH BIOCHEM BIOPHYS, V276, P38, DOI 10.1016/0003-9861(90)90007-L; Schultz DJ, 2000, PLANT PHYSIOL, V124, P681, DOI 10.1104/pp.124.2.681; Schultz DJ, 1996, P NATL ACAD SCI USA, V93, P8771, DOI 10.1073/pnas.93.16.8771; Shanklin J, 2000, CURR OPIN PLANT BIOL, V3, P243, DOI 10.1016/S1369-5266(00)00071-6; SHANKLIN J, 1991, P NATL ACAD SCI USA, V88, P2510, DOI 10.1073/pnas.88.6.2510; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Suh MC, 1999, PLANT J, V17, P679, DOI 10.1046/j.1365-313X.1999.00418.x; WHITTY A, 1995, BIOCHEMISTRY-US, V34, P11678, DOI 10.1021/bi00037a005; YAMAMOTO K, 1991, CHEM PHYS LIPIDS, V60, P39, DOI 10.1016/0009-3084(91)90013-2	36	72	92	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21500	21505		10.1074/jbc.M102129200	http://dx.doi.org/10.1074/jbc.M102129200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294879	hybrid			2022-12-25	WOS:000169297900094
J	Spada, F; Steen, H; Troedsson, C; Kallesoe, T; Spriet, E; Mann, M; Thompson, EM				Spada, F; Steen, H; Troedsson, C; Kallesoe, T; Spriet, E; Mann, M; Thompson, EM			Molecular patterning of the oikoplastic epithelium of the larvacean tunicate Oikopleura dioica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE POLYACRYLAMIDE GELS; HUMAN ARTICULAR-CARTILAGE; MUCIN GENE FAMILY; EVOLUTIONARY HISTORY; LOCALIZATION; PROTEINS; PEPTIDES; SIGNAL; SITES	Appendicularia are protochordates that rely on a complex mucous secretion, the house, to filter food particles from seawater. A monolayer of cells covering the trunk of the animal, the oikoplastic epithelium, secretes the house. This epithelium contains a fixed number of cells arranged in characteristic patterns with distinct sizes and nuclear morphologies, Certain house structures appear to be spatially related to defined, underlying groups of cells in the epithelium, We show that the house is composed of at least 20 polypeptides, a number of which are highly glycosylated, with glycosidase treatments resulting in molecular mass shifts exceeding 100 kDa. Nanoelectrospray tandem mass spectrometric microsequencing of house polypeptides was used to design oligonucleotides to screen an adult Oikopleura dioica cDNA library, This resulted in the isolation of cDNAs coding for three different proteins, oikosin 1, oikosin 2, and oikosin 3, The latter two are novel proteins unrelated to any known data base entries. Oikosin 1 has 13 repeats of a Cys domain, previously identified as a subunit of repeating sequences in some vertebrate mucins, We also find one repeat of this Cys domain in human cartilage intermediate layer protein but find no evidence of this domain in any invertebrate species, including those for which entire genomes have been sequenced, The three oikosins show distinct and complementary expression patterns restricted to the oikoplastic epithelium, This easily accessible epithelium, with differential gene expression patterns in readily identifiable groups of cells with distinctive nuclear morphologies, is a highly attractive model system for molecular studies of pattern formation.	Bergen High Technol Ctr, Sars Int Ctr Marine Mol Biol, N-5008 Bergen, Norway; Univ So Denmark Odense, Dept Biochem & Mol Biol, Prot Interact Lab, DK-5230 Odense, Denmark	University of Southern Denmark	Thompson, EM (corresponding author), Bergen High Technol Ctr, Sars Int Ctr Marine Mol Biol, N-5008 Bergen, Norway.		Spada, Fabio/J-4354-2013; Mann, Matthias/A-3454-2013	Spada, Fabio/0000-0002-7148-9013; Mann, Matthias/0000-0003-1292-4799; Steen, Hanno/0000-0003-0179-6648				ALLDREDGE AL, 1977, J ZOOL, V181, P175; BAYLISS MT, 1983, BIOCHEM J, V209, P387, DOI 10.1042/bj2090387; Buisine MP, 1998, BIOCHEM J, V332, P729, DOI 10.1042/bj3320729; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; Christen R., 1998, P265; Csikos G, 1999, J CELL SCI, V112, P2113; Desseyn JL, 1998, J MOL EVOL, V46, P102, DOI 10.1007/PL00006276; Desseyn JL, 2000, MOL BIOL EVOL, V17, P1175, DOI 10.1093/oxfordjournals.molbev.a026400; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; FENAUX R, 1985, B MAR SCI, V37, P498; FENAUX R, 1971, Z MORPHOL TIERE, V69, P184; Flood Per R., 1998, P105; FLOOD PR, 1991, MAR BIOL, V111, P95, DOI 10.1007/BF01986351; JAY GD, 1990, ANAL BIOCHEM, V185, P324, DOI 10.1016/0003-2697(90)90302-P; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krumbach, 1933, HDB ZOOLOGIE, P15; LOCKE M, 1994, TISSUE CELL, V26, P707, DOI 10.1016/0040-8166(94)90055-8; LOHMANN H., 1926, DEUTSCHE SUDPOLAR EXPED 1901 1903, V18, P63; Lohmann H., 1899, SCHR NATURW VER SCHL, V11, P347; Lorenzo P, 1998, J BIOL CHEM, V273, P23463, DOI 10.1074/jbc.273.36.23463; MARTINI E, 1909, Z WISS ZOOL, V94, P563; MOLLER HJ, 1995, ANAL BIOCHEM, V226, P371, DOI 10.1006/abio.1995.1238; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PILAR L, 1998, J BIOL CHEM, V273, P23469; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHEVCHENKO A, 1997, RAPID COMMUN MASS SP, V11, P105; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	30	50	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20624	20632		10.1074/jbc.M100438200	http://dx.doi.org/10.1074/jbc.M100438200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279070	hybrid			2022-12-25	WOS:000169135100128
J	Stewart, J; Hingorani, MM; Kelmann, Z; O'Donnell, M				Stewart, J; Hingorani, MM; Kelmann, Z; O'Donnell, M			Mechanism of beta clamp opening by the delta subunit of Escherichia coli DNA polymerase III holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL REPLICATION MACHINE; SLIDING CLAMPS; CRYSTAL-STRUCTURE; PROCESSIVITY FACTOR; ACCESSORY PROTEINS; LAGGING-STRAND; COMPLEX; LOADER; CHI; TAU	The beta sliding clamp encircles the primer-template and tethers DNA polymerase III holoenzyme to DNA for processive replication of the Escherichia coli genome. The clamp is formed via hydrophobic and ionic interactions between two semicircular beta monomers, This report demonstrates that the beta dimer is a stable closed ring and is not monomerized when the gamma complex clamp loader (gamma (3)delta (1)delta (1)chi (1)psi (1)) assembles the beta ring around DNA. delta is the subunit of the gamma complex that binds beta and opens the ring; it also does not appear to monomerize beta. Point mutations were introduced at the beta dimer interface to test its structural integrity and gain insight into its interaction with delta, Mutation of two residues at the dimer interface of beta, I272A/L273A, yields a stable beta monomer, We find that delta binds the beta monomer mutant at least 50-fold tighter than the beta dimer. These findings suggest that when delta interacts with the p clamp, it binds one beta subunit with high affinity and utilizes some of that binding energy to perform work on the dimeric clamp, probably cracking one dimer interface open.	Rockefeller Univ, New York, NY 10021 USA; Cornell Univ, Med Coll, Dept Microbiol, New York, NY 10021 USA; Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Rockefeller University; Cornell University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; CAI M, 1997, J BIOL CHEM, V272, P18974; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HINORANI MM, 2000, CURR BIOL, V10, P25; KELMAN Z, 1995, GENE, V166, P177, DOI 10.1016/0378-1119(95)00556-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1987, P NATL ACAD SCI USA, V84, P2713, DOI 10.1073/pnas.84.9.2713; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; MAKI H, 1985, J BIOL CHEM, V260, P2987; MAKI S, 1988, J BIOL CHEM, V263, P6555; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V252, P6478; Moarefi I, 2000, J MOL BIOL, V296, P1215, DOI 10.1006/jmbi.1999.3511; Naktinis V, 1996, CELL, V84, P137, DOI 10.1016/S0092-8674(00)81000-4; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; ODONNELL M, 1990, J BIOL CHEM, V265, P1179; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; XIAO H, 1993, J BIOL CHEM, V268, P11773; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; Zuccola HJ, 2000, MOL CELL, V5, P267, DOI 10.1016/S1097-2765(00)80422-0	53	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19182	19189		10.1074/jbc.M100592200	http://dx.doi.org/10.1074/jbc.M100592200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279099	hybrid			2022-12-25	WOS:000169091000074
J	Lemasson, I; Nyborg, JK				Lemasson, I; Nyborg, JK			Human T-cell leukemia virus type I tax repression of p73 beta is mediated through competition for the C/H1 domain of CBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CREB BINDING-PROTEIN; WILD-TYPE P53; LONG TERMINAL REPEAT; KINASE C-ABL; HTLV-I; FUNCTIONAL IMPAIRMENT; COACTIVATOR CBP; P73 GENE; TRANSCRIPTIONAL ACTIVATION	The Tax protein, encoded by the human T-cell leukemia virus type I (HTLV-I), is required for high level viral transcription and HTLV-I-associated malignant transformation. Although the precise mechanism of malignant transformation by Tax is unclear, it is well established that Tax represses the transcription function of the tumor suppressor p53, possibly accelerating the accumulation of genetic mutations that are critical in HTLV-I-mediated malignant transformation. Tax repression of p53 transcription function appears to occur, at least in part, through competition for the cellular coactivator CBP/p300. In this study, we characterize the effect of Tax on the p53 family member, p73. We demonstrate that Tax also represses the transcription function of p73 beta and that the repression is reciprocal in vivo, consistent with the idea that both transcription factors may compete for CBP/p300 in vivo. We provide evidence showing that both Tax and p73 interact strongly with the C/H1 domain of CBP and that their binding to this region is mutually exclusive in vitro. This finding provides evidence supporting the idea that reciprocal transcriptional repression between Tax and p73 is mediated through coactivator competition.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Lemasson, I (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.		Lemasson, Isabelle/N-1355-2013					Agami R, 1999, NATURE, V399, P809; Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Akagi T, 1996, ONCOGENE, V12, P1645; Aldridge DR, 1998, CANCER RES, V58, P2817; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BHAT NK, 1993, VIROLOGY, V196, P15, DOI 10.1006/viro.1993.1450; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; Cereseto A, 1999, ONCOGENE, V18, P2441, DOI 10.1038/sj.onc.1202567; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; Corn PG, 1999, CANCER RES, V59, P3352; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; Gong JG, 1999, NATURE, V399, P806; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Harrod R, 1998, MOL CELL BIOL, V18, P5052, DOI 10.1128/MCB.18.9.5052; Herranz M, 1999, CANCER RES, V59, P2068; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; Kawano S, 1999, BLOOD, V94, P1113; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 1999, CELL DEATH DIFFER, V6, P1146, DOI 10.1038/sj.cdd.4400624; Levrero M, 2000, J CELL SCI, V113, P1661; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mesnard JM, 1999, VIROLOGY, V257, P277, DOI 10.1006/viro.1999.9685; MIWA M, 1984, GANN, V75, P752; Mori N, 1997, BLOOD, V90, P4924, DOI 10.1182/blood.V90.12.4924.4924_4924_4932; Mori N, 1997, EUR J HAEMATOL, V58, P114; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; Neuveut C, 1998, MOL CELL BIOL, V18, P3620, DOI 10.1128/MCB.18.6.3620; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; Pise-Masison CA, 2001, J BIOL CHEM, V276, P200, DOI 10.1074/jbc.M005601200; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; REID RL, 1993, ONCOGENE, V8, P3029; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; Schmitt I, 1998, J VIROL, V72, P633, DOI 10.1128/JVI.72.1.633-640.1998; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Takemoto S, 2000, BLOOD, V95, P3939; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Van Orden K, 1999, J BIOL CHEM, V274, P26321, DOI 10.1074/jbc.274.37.26321; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; Watanabe T, 1997, INT J HEMATOL, V66, P257; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; YEARGIN J, 1992, LEUKEMIA, V6, P855; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zerby D, 1999, MOL CELL BIOL, V19, P1617; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445; Zhu JH, 1998, CANCER RES, V58, P5061	91	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15720	15727		10.1074/jbc.M100131200	http://dx.doi.org/10.1074/jbc.M100131200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279015				2022-12-25	WOS:000168623100021
J	Bannerman, DD; Tupper, JC; Ricketts, WA; Bennett, CF; Winn, RK; Harlan, JM				Bannerman, DD; Tupper, JC; Ricketts, WA; Bennett, CF; Winn, RK; Harlan, JM			A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; DISSEMINATED INTRAVASCULAR COAGULATION; MULTIPLE ORGAN FAILURE; BACTERIAL LIPOPOLYSACCHARIDE; ESCHERICHIA-COLI; CYTOCHROME-C; FACTOR-ALPHA; LUNG INJURY; ANTISENSE OLIGONUCLEOTIDES	Lipopolysaccharide (LPS) has been implicated as the bacterial component responsible for much of the endothelial cell injury/dysfunction associated with Gramnegative bacterial infections. Protein synthesis inhibition is required to sensitize the endothelium to lipopolysaccharide-induced apoptosis, suggesting that a constitutive or inducible cytoprotective protein(s) is required for endothelial survival. We have identified two known endothelial anti-apoptotic proteins, c-FLIP and Mcl-1, the expression of which is decreased markedly in the presence of cycloheximide. Decreased expression of both proteins preceded apoptosis evoked by lipopolysaccharide + cycloheximide, Caspase inhibition protected against apoptosis, but not the decreased expression of c-FLIP and Mcl-1, suggesting that they exert protection upstream of caspase activation. Inhibition of the degradation of these two proteins with the proteasome inhibitor, lactacystin, prevented lipopolysaccharide + cycloheximide-induced apoptosis, Similarly, lactacystin protected against endothelial apoptosis induced by either tumor necrosis factor-alpha or interleukin-1 beta in the presence of cycloheximide. That apoptosis could be blocked in the absence of new protein synthesis by inhibition of the proteasome degradative pathway implicates the requisite involvement of a constitutively expressed protein(s) in the endothelial cytoprotective pathway. Finally, reduction of FLIP expression with antisense oligonucleotides sensitized endothelial cells to LPS killing, demonstrating a definitive role for FLIP in the protection of endothelial cells from LPS-induced apoptosis.	Univ Washington, Div Hematol, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98104 USA; Univ Washington, Sch Med, Dept Surg, Seattle, WA 98104 USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Isis Pharmaceuticals Inc	Bannerman, DD (corresponding author), Univ Washington, Div Hematol, Box 359756,Harborview R&T Bldg,Rm 521,325 9th Ave, Seattle, WA 98104 USA.	dbannerm@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042686] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03174, HL59969] Funding Source: Medline; NIGMS NIH HHS [GM42686, GM07037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; ASHANY D, 1995, P NATL ACAD SCI USA, V92, P11225, DOI 10.1073/pnas.92.24.11225; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bannerman DD, 1999, LAB INVEST, V79, P1181; Bannerman DD, 1998, J BIOL CHEM, V273, P35371, DOI 10.1074/jbc.273.52.35371; BENNETT CF, 1994, J IMMUNOL, V152, P3530; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3, DOI 10.1165/ajrcmb.17.1.f132; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRIGHAM KL, 1986, AM REV RESPIR DIS, V133, P913; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; CREASEY AA, 1991, CIRC SHOCK, V33, P84; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Frey EA, 1998, MICROB PATHOGENESIS, V24, P101, DOI 10.1006/mpat.1997.0178; Fujita M, 1998, INT ARCH ALLERGY IMM, V117, P202, DOI 10.1159/000024011; GAYNOR E, 1970, SCIENCE, V170, P986, DOI 10.1126/science.170.3961.986; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; Hinshaw LB, 1996, CRIT CARE MED, V24, P1072, DOI 10.1097/00003246-199606000-00031; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hotchkiss RS, 1999, CRIT CARE MED, V27, P1230, DOI 10.1097/00003246-199907000-00002; Hotchkiss RS, 1997, CRIT CARE MED, V25, P1298, DOI 10.1097/00003246-199708000-00015; Hoyt DG, 1996, AM J PHYSIOL-LUNG C, V270, pL689, DOI 10.1152/ajplung.1996.270.4.L689; HOYT DG, 1995, AM J PHYSIOL-LUNG C, V269, pL171, DOI 10.1152/ajplung.1995.269.2.L171; Hu XL, 1998, BLOOD, V92, P2759, DOI 10.1182/blood.V92.8.2759.420k29_2759_2765; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kalogeris TJ, 1999, AM J PHYSIOL-CELL PH, V276, pC856, DOI 10.1152/ajpcell.1999.276.4.C856; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1997, AM J PATHOL, V151, P1775; Kawasaki M, 2000, AM J PATHOL, V157, P597, DOI 10.1016/S0002-9440(10)64570-1; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; LEVI M, 1993, JAMA-J AM MED ASSOC, V270, P975, DOI 10.1001/jama.270.8.975; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pammer J, 1999, BIOCHEM BIOPH RES CO, V264, P139, DOI 10.1006/bbrc.1999.1436; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REIDY MA, 1983, LAB INVEST, V48, P25; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thijs L G, 1993, Intensive Care Med, V19 Suppl 1, pS8, DOI 10.1007/BF01738944; Thijs LG, 1996, CURR TOP MICROBIOL, V216, P209; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; ULEVITCH RJ, 1975, J EXP MED, V142, P1570, DOI 10.1084/jem.142.6.1570; Vaishnaw AK, 1999, J CLIN INVEST, V103, P355, DOI 10.1172/JCI5121; VAN AD, 1996, SCIENCE, V274, P787; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611; ZHANG XM, 1994, MICROBIOL IMMUNOL, V38, P669, DOI 10.1111/j.1348-0421.1994.tb01838.x; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	72	94	102	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14924	14932		10.1074/jbc.M100819200	http://dx.doi.org/10.1074/jbc.M100819200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279137	hybrid			2022-12-25	WOS:000168528800055
J	Tanabe, M; Nishio, K; Iko, Y; Sambongi, Y; Iwamoto-Kihara, A; Wada, Y; Futai, M				Tanabe, M; Nishio, K; Iko, Y; Sambongi, Y; Iwamoto-Kihara, A; Wada, Y; Futai, M			Rotation of a complex of the gamma subunit and c ring of Escherichia coli ATP synthase - The rotor and stator are interchangeable	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; PROTON TRANSLOCATION; EPSILON-SUBUNIT; CROSS-LINKING; F-ATPASE; ENERGY TRANSDUCTION; STRUCTURAL-CHANGES; MOLECULAR MACHINE; F1F0; OLIGOMER	ATP synthase (F0F1) transforms an electrochemical proton gradient into chemical energy (ATP) through the rotation of a subunit assembly. It has been suggested that a complex of the gamma subunit and c ring (c(10-14)) of F0F1 could rotate together during ATP hydrolysis and synthesis (Sambongi, Y., Iko, Y., Tanabe, M., Omote, H., Iwamoto-Kihara, A., Ueda, I., Yanagida, T,, Wade, Y., and Futai, M. (1899) Science 286, 1722-1724), We observed that the rotation of the c ring with the cI28T mutation (c subunit cIle-28 replaced by Thr) was less sensitive to venturicidin than that of the wild type, consistent with the antibiotic effect on the cI28T mutant and wild-type ATPase activities (Fillingame, R. H., Oldenburg, M., and Fraga, D, (1991) J, Biol. Chem. 266, 20934-20939), Furthermore, we engineered F0F1 to see the alpha (3)beta (3) hexamer rotation; a biotin tag was introduced into the alpha or beta subunit, and a His tag was introduced into the c subunit, The engineered enzymes could be purified by metal affinity chromatography and density gradient centrifugation. They were immobilized on a glass surface through the c subunit, and an actin filament was connected to the alpha or beta subunit, The filament rotated upon the addition of ATP and generated essentially the same frictional torque as one connected to the c ring. These results indicate that the gamma epsilonc(10-14) complex is a mechanical unit of the enzyme and that it can be used as a rotor or a stator experimentally, depending on the subunit immobilized.	Osaka Univ, ISIR, Div Biol Sci, Osaka 5670047, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	Osaka University; University of Tokyo	Futai, M (corresponding author), Osaka Univ, ISIR, Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Altendorf K, 2000, J EXP BIOL, V203, P19; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 2000, BBA-BIOENERGETICS, V1458, P387, DOI 10.1016/S0005-2728(00)00089-X; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1991, J BIOL CHEM, V266, P20934; FRIEDL P, 1983, EMBO J, V2, P99, DOI 10.1002/j.1460-2075.1983.tb01388.x; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; FUTAI M, 1974, J MEMBRANE BIOL, V15, P15, DOI 10.1007/BF01870079; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NEGRIN RS, 1980, J BIOL CHEM, V255, P5643; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 1999, BIOCHEM BIOPH RES CO, V260, P597, DOI 10.1006/bbrc.1999.0885; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SCHNEIDER E, 1985, EMBO J, V4, P515, DOI 10.1002/j.1460-2075.1985.tb03658.x; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	43	56	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15269	15274		10.1074/jbc.M100289200	http://dx.doi.org/10.1074/jbc.M100289200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279047	hybrid			2022-12-25	WOS:000168528800099
J	Lambert, V; Munaut, C; Noel, A; Frankenne, F; Bajou, K; Gerard, R; Carmeliet, P; Defresne, MP; Foidart, JM; Rakic, JM				Lambert, V; Munaut, C; Noel, A; Frankenne, F; Bajou, K; Gerard, R; Carmeliet, P; Defresne, MP; Foidart, JM; Rakic, JM			Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization	FASEB JOURNAL			English	Article						angiogenesis; retinal disease; proteases; viral vector; macular degeneration	ENDOTHELIAL GROWTH-FACTOR; RETINAL NEOVASCULARIZATION; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; INTEGRIN ALPHA(V)BETA(3); CANCER INVASION; MURINE MODEL; TISSUE; GENE; ANGIOGENESIS	High levels of the plasminogen activators, but also their inhibitor, plasminog en activator inhibitor 1 (PAI-1), have been documented in neovascularization of severe ocular pathologies such as diabetic retinopathy or age-related macular degeneration (AMD). AMD is the primary cause of irreversible photoreceptors loss, and current therapies are limited. PAI-1 has recently been shown to be essential for tumoral angiogenesis. We report here that deficient PAI-1 expression in mice prevented the development of subretinal choroidal angiogenesis induced by laser photocoagulation. When systemic and local PAI-1 expression was achieved by intravenous injection of a replication-defective adenoviral vector expressing human PAI-1 cDNA, the wild-type pattern of choroidal angiogenesis was restored. These observations demonstrate the proangiogenic activity of PAI-1 not only in tumoral models, but also in choroidal experimental neovascularization sharing similarities with human AMD. They identify therefore PAI-1 as a potential target for therapeutic ocular anti-angiogenic strategies.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium; Univ Liege, Lab Cytol & Histol, B-4000 Liege, Belgium; Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium	University of Liege; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Liege; University of Liege	Lambert, V (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Pathol Tower,B23, B-4000 Liege, Belgium.	vincent.lambert@ulg.ac.be	Munaut, Carine/K-8138-2019; Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BULLARD LE, 1999, INVEST OPHTH VIS SCI, V40, P3255; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Gately S, 1997, P NATL ACAD SCI USA, V94, P10868, DOI 10.1073/pnas.94.20.10868; Grant MB, 1996, EXP EYE RES, V63, P233, DOI 10.1006/exer.1996.0112; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hattenbach LO, 1999, RETINA-J RET VIT DIS, V19, P383, DOI 10.1097/00006982-199909000-00003; Iijima H, 1999, AM J OPHTHALMOL, V127, P477, DOI 10.1016/S0002-9394(98)00378-X; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kosano H, 1999, LIFE SCI, V64, P2307, DOI 10.1016/S0024-3205(99)00184-8; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Luna J, 1996, LAB INVEST, V75, P563; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; Noel A, 1999, FIBRINOLYSIS PROTEOL, V13, P220, DOI 10.1054/fipr.2000.0043; Okamoto N, 1997, AM J PATHOL, V151, P281; PEDERSEN H, 1994, CANCER RES, V54, P4671; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552; SMALLEY DM, 1994, INVEST OPHTH VIS SCI, V35, P48; Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194; Steinkamp G. W. K., 1993, Ophthalmologe, V90, P73; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352	33	80	84	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1021	1027		10.1096/fj.00-0393com	http://dx.doi.org/10.1096/fj.00-0393com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292663	Green Submitted			2022-12-25	WOS:000167959300017
J	Fisher, EA; Pan, M; Chen, XL; Wu, XY; Wang, HX; Jamil, H; Sparks, JD; Williams, KJ				Fisher, EA; Pan, M; Chen, XL; Wu, XY; Wang, HX; Jamil, H; Sparks, JD; Williams, KJ			The triple threat to nascent apolipoprotein B - Evidence for multiple, distinct degradative pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE TRANSFER PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; UBIQUITIN-PROTEASOME PATHWAY; PLACEBO-CONTROLLED TRIAL; N-3 FATTY-ACIDS; HEP G2 CELLS; INTRACELLULAR DEGRADATION; INSULIN-RESISTANCE; RAT HEPATOCYTES	We previously showed that Omega -3 fatty acids reduce secretion of apolipoprotein B (apoB) from cultured hepatocytes by stimulating post-translational degradation. In this report, we now characterize this process, particularly in regard to the two known processes that degrade newly synthesized apoB, endoplasmic reticulum (ER)-associated degradation and re-uptake from the cell surface. First, we found that Omega -3-induced degradation preferentially reduces the secretion of large, assembled apoB-lipoprotein particles, and apoB polypeptide length is not a determinant. Second, based on several experimental approaches, ER-associated degradation is not involved. Third, re-uptake, the only process known to destroy fully assembled nascent lipoproteins, was clearly active in primary hepatocytes, but Omega -3-induced degradation of apoB continued even when re-uptake was blocked. Cell fractionation showed that Omega -3 fatty acids induced a striking loss of apoB(100) from the Golgi, while sparing apoB(100) in the ER, indicating a post-ER process. To determine the signaling involved, we used wortmannin, a phosphatidylinositol 3-kinase (PI3K) inhibitor, which blocked most, if not all, of the Omega -3 fatty acid effect. Therefore, nascent apoB is subject to ER-associated degradation, re-uptake, and a third distinct degradative pathway that appears to target lipoproteins after considerable assembly and involves a post-ER compartment and PI3K signaling. Physiologic, pathophysiologic, and pharmacologic regulation of net apoB secretion may involve alterations in any of these three degradative steps.	Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Lab Lipoprot Res, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Bristol Myers Squibb Co, Div Metab Dis, Princeton, NJ 08543 USA; Univ Rochester, Sch Med, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Res Labs, Div Endocrinol Diabet & Metab Dis, Philadelphia, PA 19107 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Bristol-Myers Squibb; University of Rochester; Jefferson University	Fisher, EA (corresponding author), Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, Lab Lipoprot Res, 1 Gustave Levy Pl,Box 1269, New York, NY 10029 USA.	edward.fisher@mssm.edu	Fisher, Edward/ABE-7469-2020	Williams, Kevin Jon/0000-0002-0000-2159; Fisher, Edward/0000-0001-9802-143X; Sparks, Janet/0000-0002-0072-766X	NHLBI NIH HHS [HL58884, HL38956, HL22263, HL58541, T32-HL07824] Funding Source: Medline; NIDDK NIH HHS [DK50376] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058884, T32HL007824, R01HL058541, R01HL038956, R29HL038956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050376] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Berriot-Varoqueaux N, 2000, ANNU REV NUTR, V20, P663, DOI 10.1146/annurev.nutr.20.1.663; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Brunzell JD, 1999, DIABETES CARE, V22, pC10; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Cartwright IJ, 1996, BIOCHEM J, V314, P977, DOI 10.1042/bj3140977; Chauhan V, 1998, BIOCHEMISTRY-US, V37, P3735, DOI 10.1021/bi9718853; Chirieac DV, 2000, AM J PHYSIOL-ENDOC M, V279, pE1003, DOI 10.1152/ajpendo.2000.279.5.E1003; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FAZIO S, 1992, J BIOL CHEM, V267, P6941; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; HARRIS WS, 1989, J LIPID RES, V30, P785; HARRISON JC, 1988, J LIPID RES, V29, P1439; HOEG JM, 1988, J LIPID RES, V29, P1215; Horton JD, 1999, J CLIN INVEST, V103, P1067, DOI 10.1172/JCI6246; HUFF MW, 1992, ARTERIOSCLER THROMB, V12, P902, DOI 10.1161/01.ATV.12.8.902; HUSSAIN MM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P90; James MJ, 2000, AM J CLIN NUTR, V71, p343S, DOI 10.1093/ajcn/71.1.343s; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Jamil H, 1998, J LIPID RES, V39, P1448; JANERO DR, 1983, J BIOL CHEM, V258, P4496; KAMANNA VS, 1989, BIOCHEM BIOPH RES CO, V162, P1508, DOI 10.1016/0006-291X(89)90845-0; KLEINMAN Y, 1988, J LIPID RES, V29, P729; Liang JS, 1998, J BIOL CHEM, V273, P35216, DOI 10.1074/jbc.273.52.35216; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGUIRE GF, 1989, J LIPID RES, V30, P757; Mahley RW, 1999, J LIPID RES, V40, P1; Mensenkamp AR, 1999, J BIOL CHEM, V274, P35711, DOI 10.1074/jbc.274.50.35711; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Mulligan K, 2000, J ACQ IMMUN DEF SYND, V23, P35, DOI 10.1097/00042560-200001010-00005; NEURATH H, 1989, PROTEOLYTIC ENZYMES, P1; Phung TL, 1997, J BIOL CHEM, V272, P30693, DOI 10.1074/jbc.272.49.30693; Rustaeus S, 1999, J NUTR, V129, p463S, DOI 10.1093/jn/129.2.463S; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SATO R, 1990, J BIOL CHEM, V265, P11880; Singh RB, 1997, CARDIOVASC DRUG THER, V11, P485, DOI 10.1023/A:1007757724505; SORCITHOMAS M, 1992, J LIPID RES, V33, P1147; SPARKS JD, 1986, ATHEROSCLEROSIS, V61, P205, DOI 10.1016/0021-9150(86)90139-5; SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731; Sparks JD, 1996, BIOCHEM J, V313, P567, DOI 10.1042/bj3130567; SPARKS JD, 1990, J BIOL CHEM, V265, P8854; SPARKS JD, 1994, BBA-LIPID LIPID MET, V1215, P9, DOI 10.1016/0005-2760(94)90088-4; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Taghibiglou C, 2000, J BIOL CHEM, V275, P8416, DOI 10.1074/jbc.275.12.8416; Tsukamoto K, 2000, J LIPID RES, V41, P253; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; VANCE JE, 1990, ANNU REV NUTR, V10, P337, DOI 10.1146/annurev.nu.10.070190.002005; VENTURA MA, 1989, J CLIN INVEST, V84, P528, DOI 10.1172/JCI114195; VERKADE HJ, 1993, J BIOL CHEM, V268, P24990; Vermeulen PS, 1997, J LIPID RES, V38, P447; Vigouroux C, 1999, DIABETES METAB, V25, P225; von Schacky C, 1999, ANN INTERN MED, V130, P554, DOI 10.7326/0003-4819-130-7-199904060-00003; WANG HX, 1993, J CLIN INVEST, V91, P1380, DOI 10.1172/JCI116340; WANG HX, 1994, J BIOL CHEM, V269, P18514; WETTERAU JR, 1992, SCIENCE, V258, P999; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WILLIAMS KJ, 1990, J BIOL CHEM, V265, P16741; Williams KJ, 1999, CIRCULATION, V100, P109; Williams KJ, 2001, CURR OPIN LIPIDOL, V12, P235, DOI 10.1097/00041433-200104000-00018; WILLIAMS KJ, 1991, J CLIN INVEST, V88, P1300, DOI 10.1172/JCI115434; WONG SH, 1989, ARTERIOSCLEROSIS, V9, P836, DOI 10.1161/01.ATV.9.6.836; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; Zhao Y, 2000, MOL BIOL CELL, V11, P721, DOI 10.1091/mbc.11.2.721; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649; Ziegler O, 1996, DIABETES METAB, V22, P179	82	158	209	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27855	27863		10.1074/jbc.M008885200	http://dx.doi.org/10.1074/jbc.M008885200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	456QH	11285257	hybrid			2022-12-25	WOS:000170093400017
J	Bahring, R; Milligan, CJ; Vardanyan, V; Engeland, B; Young, BA; Dannenberg, J; Waldschutz, R; Edwards, JP; Wray, D; Pongs, O				Bahring, R; Milligan, CJ; Vardanyan, V; Engeland, B; Young, BA; Dannenberg, J; Waldschutz, R; Edwards, JP; Wray, D; Pongs, O			Coupling of voltage-dependent potassium channel inactivation and oxidoreductase active site of Kv beta subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; K+ CHANNELS; RAT-BRAIN; ALPHA-SUBUNITS; DOMAIN; MUTAGENESIS; EXPRESSION; MODULATION	The accessory beta subunits of voltage-dependent potassium (Kv) channels form tetramers arranged with 4-fold rotational symmetry like the membrane-integral and pore-forming alpha subunits (Gulbis, J. M., Mann, S., and MacKinnon, R. (1999) Cell. 90, 943-952). The crystal structure of the Kv beta2 subunit shows that Kv beta subunits are oxidoreductase enzymes containing an active site composed of conserved catalytic residues, a nicotinamide (NADPH)-cofactor, and a substrate binding site. Also, Kv beta subunits with an N-terminal inactivating do main like Kv beta1.1 (Rettig, J., Heinemann, S. H., Wunder, F., Lorra, C., Parcej, D. N., Dolly, O., and Pongs, O. (1994) Nature 369, 289-294) and Kv beta3.1 (Heinemann, S. H., Rettig, J., Graack, H. R,, and Pongs, O. (1996) J. Physiol. (Lond.) 493, 625-633) confer rapid N-type inactivation to otherwise non-inactivating channels. Here we show by a combination of structural modeling and electrophysiological characterization of structure-based mutations that changes in Kv beta oxidoreductase activity may markedly influence the gating mode of Kv channels. Amino acid substitutions of the putative catalytic residues in the Kv beta1.1 oxidoreductase active site attenuate the inactivating activity of Kv beta1.1 in Xenopus oocytes. Conversely, mutating the substrate binding domain and/or the cofactor binding domain rescues the failure of Kv beta3.1 to confer rapid inactivation to Kv1.5 channels in Xenopus oocytes. We propose that Kv beta oxidoreductase activity couples Kv channel inactivation to cellular redox regulation.	Univ Hamburg, Zentrum Mol Neurobiol, Inst Neurale Signalverarbeit, D-20246 Hamburg, Germany; Univ Leeds, Dept Physiol, Inst Pharmacol, Leeds LS2 9JT, W Yorkshire, England	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Leeds	Pongs, O (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Inst Neurale Signalverarbeit, Martinistr 52, D-20246 Hamburg, Germany.		Bähring, Robert/F-7146-2010	Bahring, Robert/0000-0002-0406-5958				Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; DEMO SD, 1991, NEURON, V7, P743, DOI 10.1016/0896-6273(91)90277-7; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI T, 1991, NEURON, V7, P547, DOI 10.1016/0896-6273(91)90367-9; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Leicher T, 1998, J BIOL CHEM, V273, P35095, DOI 10.1074/jbc.273.52.35095; Leicher T, 1996, NEUROPHARMACOLOGY, V35, P787, DOI 10.1016/0028-3908(96)00133-5; Levin G, 1996, J BIOL CHEM, V271, P29321, DOI 10.1074/jbc.271.46.29321; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; McCormack T, 1999, J BIOL CHEM, V274, P20123, DOI 10.1074/jbc.274.29.20123; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Peri R, 2001, J BIOL CHEM, V276, P738, DOI 10.1074/jbc.M008445200; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roeper J, 1998, NATURE, V391, P390, DOI 10.1038/34916; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Trimmer JS, 1998, CURR OPIN NEUROBIOL, V8, P370, DOI 10.1016/S0959-4388(98)80063-9; Uebele VN, 1998, AM J PHYSIOL-CELL PH, V274, pC1485, DOI 10.1152/ajpcell.1998.274.6.C1485; WILSON GG, 1994, PFLUG ARCH EUR J PHY, V428, P186, DOI 10.1007/BF00374857; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	29	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22923	22929		10.1074/jbc.M100483200	http://dx.doi.org/10.1074/jbc.M100483200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294861	hybrid			2022-12-25	WOS:000169412700126
J	Chiang, GG; Sefton, BM				Chiang, GG; Sefton, BM			Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; TCR SIGNALING THRESHOLDS; INTRAMOLECULAR REGULATION; T-CELLS; C-SRC; PHOSPHORYLATION; ACTIVATION; ZAP-70; SUBSTRATE	The protein-tyrosine phosphatase SHP-1 has been shown to be a negative regulator of multiple signaling pathways in hematopoietic cells. In this study, we demonstrate that SHP-1 dephosphorylates the lymphoid-specific Src family kinase Lck at Tyr-394 when both are transiently co-expressed in nonlymphoid cells. We also demonstrate that a GST-SHP-1 fusion protein specifically dephosphorylates Lck at Tyr-394 in vitro. Because phosphorylation of Tyr-394 activates Lck, the fact that SHP-1 specifically dephosphorylates this site suggests that SHP-1 is a negative regulator of Lck. The failure of SHP-1 to inactivate Lck may contribute to some of the lymphoid abnormalities observed in motheaten mice.	Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92037 USA	Salk Institute; University of California System; University of California San Diego	Chiang, GG (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Chiang, Gary/0000-0003-3004-7400	NCI NIH HHS [T32-CA09435, CA14195, CA42350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R01CA042350, T32CA009435] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Baker M, 2000, EMBO J, V19, P4644, DOI 10.1093/emboj/19.17.4644; Berg KL, 1999, J BIOL CHEM, V274, P35855, DOI 10.1074/jbc.274.50.35855; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; Binstadt BA, 1998, J BIOL CHEM, V273, P27518, DOI 10.1074/jbc.273.42.27518; Carter JD, 1999, INT IMMUNOL, V11, P1999, DOI 10.1093/intimm/11.12.1999; CASNELLIE JE, 1982, J BIOL CHEM, V257, P3877; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN S, 1987, MOL CELL PROBE, V1, P73, DOI 10.1016/0890-8508(87)90008-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HARRISON T, 1977, VIROLOGY, V77, P319, DOI 10.1016/0042-6822(77)90428-7; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HURLEY TR, 1989, ONCOGENE, V4, P265; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Johnson KG, 1999, J IMMUNOL, V162, P3802; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; LUO K, 1990, ONCOGENE, V5, P921; Martin A, 1999, J BIOL CHEM, V274, P21725, DOI 10.1074/jbc.274.31.21725; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Neel BG, 1997, CURR OPIN IMMUNOL, V9, P405, DOI 10.1016/S0952-7915(97)80088-X; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; Plas DR, 1999, J IMMUNOL, V162, P5680; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; REINHERZ EL, 1979, P NATL ACAD SCI USA, V76, P4061, DOI 10.1073/pnas.76.8.4061; Shultz LD, 1997, TRENDS BIOTECHNOL, V15, P302, DOI 10.1016/S0167-7799(97)01060-3; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VEILLETTE A, 1992, ONCOGENE, V7, P971; VORONOVA AF, 1984, MOL CELL BIOL, V4, P2705, DOI 10.1128/MCB.4.12.2705; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WATTS JD, 1993, J BIOL CHEM, V268, P23275; Wu YJ, 1998, CURR BIOL, V8, P1009, DOI 10.1016/S0960-9822(07)00421-6; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yang J, 2000, J BIOL CHEM, V275, P4066, DOI 10.1074/jbc.275.6.4066; Zhang JY, 1999, J IMMUNOL, V163, P3012	53	95	100	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23173	23178		10.1074/jbc.M101219200	http://dx.doi.org/10.1074/jbc.M101219200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294838	hybrid			2022-12-25	WOS:000169412700158
J	Lai, WS; Blackshear, PJ				Lai, WS; Blackshear, PJ			Interactions of CCCH zinc finger proteins with mRNA - Tristetraprolin-mediated Au-rich element-dependent mRNA degradation can occur in the absence of a poly(A) tail	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MESSENGER-RNA DECAY; NUCLEOTIDE-SEQUENCE; GENE; DESTABILIZATION; DEADENYLATION; EXPRESSION; STABILITY; BINDING; TIS11	The CCCH family of tandem zinc finger proteins has recently been shown to promote the turnover of certain mRNAs containing class II AU-rich elements (AREs). In the case of one member of this family, tristetraprolin (TTP), absence of the protein in knockout mice leads to stabilization of two mRNAs containing AREs of this type, those encoding tumor necrosis factor alpha (TNF alpha) and granulocyte-macrophage colony-stimulating factor. To bean to decipher the mechanism by which these zinc finger proteins stimulate the breakdown of this class of mRNAs, we co-transfected TTP and its related CCCH proteins into 293 cells with vectors encoding full-length TNF alpha, granulocyte-macrophage colony-stimulating factor, and interleukin-3 mRNAs. Go-expression of the CCCH proteins caused the rapid turnover of these ARE-containing mRNAs and also promoted the accumulation of stable breakdown intermediates that were truncated at the 3'-end of the mRNA, even further 5' than the 5'-end of the poly(A) tail. To determine whether an intact poly(A) tail was necessary for TTP to promote this type of mRNA degradation, we inserted the TNF alpha ARE into a nonpolyadenylated histone mRNA and also attached a histone 3'-end-processing sequence to the 3'-end of nonpolyadenylated interleukin-3 and TNF alpha mRNAs. In all three cases, TTP stimulated the turnover of the ARE-containing mRNAs, despite the demonstrated absence of a poly(A) tail. These studies indicate that members of this class of CCCH proteins can promote class II ARE containing mRNA turnover even in the absence of a poly(A) tail, suggesting that the processive removal of the poly(A) tail may not be required for this type of CCCH protein-stimulated mRNA turnover.	NIEHS A205, Off Clin REs & Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med & Biochem, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University	Blackshear, PJ (corresponding author), NIEHS A205, Off Clin REs & Lab Signal Transduct, NIH, 111 Alexandre Dr, Res Triangle Pk, NC 27709 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; Dominski Z, 1999, GENE, V239, P1, DOI 10.1016/S0378-1119(99)00367-4; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; HURT MM, 1989, NUCLEIC ACIDS RES, V17, P8876, DOI 10.1093/nar/17.21.8876; Jarrousse AS, 1999, J BIOL CHEM, V274, P5925, DOI 10.1074/jbc.274.9.5925; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MA QF, 1991, ONCOGENE, V6, P1277; Marzluff William F., 1992, Gene Expression, V2, P93; Mitchell P, 2000, CURR OPIN GENET DEV, V10, P193, DOI 10.1016/S0959-437X(00)00063-0; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; Stoecklin G, 2000, MOL CELL BIOL, V20, P3753, DOI 10.1128/MCB.20.11.3753-3763.2000; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VARNUM BC, 1989, ONCOGENE, V4, P119; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Yang L, 1996, MOL CELL BIOL, V16, P3300	23	118	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23144	23154		10.1074/jbc.M100680200	http://dx.doi.org/10.1074/jbc.M100680200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11279239	hybrid			2022-12-25	WOS:000169412700155
J	Nozawa, K; Maehara, K; Isobe, K				Nozawa, K; Maehara, K; Isobe, K			Mechanism for the reduction of telomerase expression during muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC MESSENGER-RNA; REVERSE-TRANSCRIPTASE GENE; C-MYC; MOUSE TELOMERASE; CATALYTIC SUBUNIT; MYOGENIC DIFFERENTIATION; MAMMALIAN TELOMERASE; CODING ELEMENTS; SP-FAMILY; ACTIVATION	Telomerase, the reverse transcriptase that maintains telomere DNA, is usually undetectable in adult human tissues, but is positive in embryonic tissues and in cancers. However, in rodents, several organs of normal adult animals express substantial amounts of telomerase activity. To elucidate relevant control mechanisms operating on the tissue specific expression of telomerase in rodents, we examined the transcriptional regulation of telomerase reverse transcriptase (mTERT) gene in muscle cell differentiation. Reverse transcriptase-polymerase chain reaction analysis showed that the reduction of telomerase activity was caused by the decrease of mTERT mRNA level during myogenesis. Transfections of mTERT promoter showed that the proximal 225-base pair region is the core promoter responsible for basal transcriptional activity and also participates in the reduced transcription after muscle differentiation. Electrophoretic mobility shift assays showed that this region contained the GC-boxes, which bind to Spl family proteins, and the E-box, which binds to c-Myc. Furthermore, DNA binding activities of Sp1, Sp3, and c-Myc were down-regulated during myogenesis. These data suggest that Spl, Sp3, and c-Myc have critical roles of TERT transactivation in mouse, and the lack of these transcription factors cause down-regulation of mTERT gene expression in muscle cells differentiation.	Natl Inst Longev Sci, Dept Basic Gerontol, Morioka, Aichi 4748522, Japan		Isobe, K (corresponding author), Natl Inst Longev Sci, Dept Basic Gerontol, 36-3 Gengo, Morioka, Aichi 4748522, Japan.		isobe, ken-ichi/A-6685-2011	isobe, ken-ichi/0000-0002-8150-2496				Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; Bestilny LJ, 1996, CANCER RES, V56, P3796; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CHADENEAU C, 1995, ONCOGENE, V11, P893; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Dang CV, 1999, MOL CELL BIOL, V19, P1; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Fandos C, 1999, J MOL BIOL, V294, P103, DOI 10.1006/jmbi.1999.3216; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Horikawa I, 1999, CANCER RES, V59, P826; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Liang YX, 1996, J BIOL CHEM, V271, P11792, DOI 10.1074/jbc.271.20.11792; Maehara K, 2000, J CELL BIOCHEM, V77, P474, DOI 10.1002/(SICI)1097-4644(20000601)77:3<474::AID-JCB12>3.0.CO;2-H; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nozawa K, 1999, J BIOCHEM, V126, P361, DOI 10.1093/oxfordjournals.jbchem.a022458; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Parks CL, 1996, J BIOL CHEM, V271, P4417; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 1998, CANCER RES, V58, P1558; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WISDOM R, 1990, J BIOL CHEM, V265, P19015; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yamaguchi Y, 1998, EXP CELL RES, V242, P120, DOI 10.1006/excr.1998.4102; Yeilding NM, 1998, J BIOL CHEM, V273, P15749, DOI 10.1074/jbc.273.25.15749; Yeilding NM, 1997, MOL CELL BIOL, V17, P2698, DOI 10.1128/MCB.17.5.2698; Yeilding NM, 1996, MOL CELL BIOL, V16, P3511; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200	52	34	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22016	22023		10.1074/jbc.M011181200	http://dx.doi.org/10.1074/jbc.M011181200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11279234	hybrid			2022-12-25	WOS:000169412700006
J	Shiroishi, M; Yokota, A; Tsumoto, K; Kondo, H; Nishimiya, Y; Horii, K; Matsushima, M; Ogasahara, K; Yutani, K; Kumagai, I				Shiroishi, M; Yokota, A; Tsumoto, K; Kondo, H; Nishimiya, Y; Horii, K; Matsushima, M; Ogasahara, K; Yutani, K; Kumagai, I			Structural evidence for entropic contribution of salt bridge formation to a protein antigen-antibody interaction - The case of hen lysozyme-HyHEL-10 Fv complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTILYSOZYME MONOCLONAL-ANTIBODY; EGG-WHITE LYSOZYME; CRYSTAL-STRUCTURE; BINDING; WATER; RECOGNITION; ASSOCIATION; EXPRESSION; RESIDUES; HYHEL-5	A structural and thermodynamic study of the entropic contribution of salt bridge formation to the interaction between hen egg white lysozyme (HEL) and the variable domain fragment (Fv) of anti-MEL antibody, HyMEL-10, was carried out. Three Fv mutants (HD32A, HD96A, and MD32AD96A) were prepared, and the interactions between the mutant Fvs and HEL were investigated. Crystallography revealed that the overall structures of these mutant complexes were almost identical to that of wildtype Fv, Little structural changes were observed in the HD32AD96A mutant-MEL complex, and two water molecules were introduced into the mutation site, indicating that the two water molecules structurally compensated for the complete removal of the salt bridges. This result suggests that the entropic contribution of the salt bridge originates from dehydration. In the singly mutated complexes, one water molecule was also introduced into the mutated site, bridging the antigen-antibody interface. However, a local structural difference was observed in the MD32A FV-HEL complex, and conformational changes occurred due to changes in the relative orientation of the heavy chain to the light chain upon complexation in HD96A Fv-HEL complexes. The reduced affinity of these single mutants for the antigen originates from the increase in entropy loss, indicating that these structural changes also introduced an increase in entropy loss. These results suggest that salt bridge formation makes an entropic contribution to the protein antigen-antibody interaction through reduction of entropy loss due to dehydration and structural changes.	Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Sendai, Miyagi 9808579, Japan; Hokkaido Natl Ind Res Inst, Sapporo, Hokkaido 0118511, Japan; Rat Drug Design Lab, Fukushima 9601242, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Tohoku University; National Institute of Advanced Industrial Science & Technology (AIST); Osaka University	Tsumoto, K (corresponding author), Tohoku Univ, Grad Sch Engn, Dept Biomol Engn, Aoba Ku, Aoba Yama 07, Sendai, Miyagi 9808579, Japan.	tsumoto@mail.cc.tohoku.ac.jp; kmiz@mail.cc.tohoku.ac.jp	Nishimiya, Yoshiyuki/M-4173-2018; Kondo, Hidemasa/M-7465-2018	Nishimiya, Yoshiyuki/0000-0002-0701-7775; Kondo, Hidemasa/0000-0003-2799-1775; Shiroishi, Mitsunori/0000-0002-3133-157X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker BM, 1997, J MOL BIOL, V268, P557, DOI 10.1006/jmbi.1997.0977; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR MANUAL; CHACKO S, 1995, J MOL BIOL, V245, P261, DOI 10.1006/jmbi.1994.0022; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; Cordes MHJ, 1999, SCIENCE, V284, P325, DOI 10.1126/science.284.5412.325; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DUNITZ JD, 1994, SCIENCE, V264, P670, DOI 10.1126/science.264.5159.670; Fischer S, 1999, P NATL ACAD SCI USA, V96, P9613, DOI 10.1073/pnas.96.17.9613; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; Goldbaum FA, 1996, J MOL RECOGNIT, V9, P6, DOI 10.1002/(SICI)1099-1352(199601)9:1<6::AID-JMR240>3.3.CO;2-M; Holdgate GA, 1997, BIOCHEMISTRY-US, V36, P9663, DOI 10.1021/bi970294+; Hubbard S, 1996, NACCESS VERSION 2 1; Imoto T., 1972, ENZYMES, V7, P665; JANIN J, 1990, J BIOL CHEM, V265, P16027; KABAT EA, NIH PUBLICATION; KAMMORGAN LNW, 1993, P NATL ACAD SCI USA, V90, P3958, DOI 10.1073/pnas.90.9.3958; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; Merk H, 1999, J BIOCHEM, V125, P328, DOI 10.1093/oxfordjournals.jbchem.a022290; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; NAVAZA J, 1994, ACTA CRYSTALLOGR D, V50, P805; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; Perozzo R, 2000, J BIOL CHEM, V275, P16139, DOI 10.1074/jbc.M000509200; Pons J, 1999, PROTEIN SCI, V8, P958, DOI 10.1110/ps.8.5.958; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; Sharp KA, 1998, PROTEINS, V33, P39, DOI 10.1002/(SICI)1097-0134(19981001)33:1<39::AID-PROT4>3.3.CO;2-K; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; SMITHGILL SJ, 1984, J IMMUNOL, V133, P384; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Stites WE, 1997, CHEM REV, V97, P1233, DOI 10.1021/cr960387h; STURTEVANT JM, 1994, CURR OPIN STRUC BIOL, V4, P69, DOI 10.1016/S0959-440X(94)90062-0; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; Takano K, 2000, BIOCHEMISTRY-US, V39, P12375, DOI 10.1021/bi000849s; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; Ueda H, 1996, NAT BIOTECHNOL, V14, P1714, DOI 10.1038/nbt1296-1714; UEDA Y, 1993, GENE, V129, P129; Vajda S, 1997, CURR OPIN STRUC BIOL, V7, P222, DOI 10.1016/S0959-440X(97)80029-2; Vaughan CK, 1999, J MOL BIOL, V286, P1487, DOI 10.1006/jmbi.1998.2559; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; Wibbenmeyer JA, 1999, J BIOL CHEM, V274, P26838, DOI 10.1074/jbc.274.38.26838; Willcox BE, 1999, IMMUNITY, V10, P357, DOI 10.1016/S1074-7613(00)80035-7; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xavier KA, 1998, BIOPHYS J, V74, P2036; Xavier KA, 1997, BIOPHYS J, V73, P2116, DOI 10.1016/S0006-3495(97)78242-0; Ye H, 2000, P NATL ACAD SCI USA, V97, P8961, DOI 10.1073/pnas.160241997; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412	66	32	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23042	23050		10.1074/jbc.M100480200	http://dx.doi.org/10.1074/jbc.M100480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297547	hybrid			2022-12-25	WOS:000169412700141
J	Rufo, C; Teran-Garcia, M; Nakamura, MT; Koo, SH; Towle, HC; Clarke, SD				Rufo, C; Teran-Garcia, M; Nakamura, MT; Koo, SH; Towle, HC; Clarke, SD			Involvement of a unique carbohydrate-responsive factor in the glucose regulation of rat liver fatty-acid synthase gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; ACETYL-COA CARBOXYLASE; STEROL REGULATION; PYRUVATE-KINASE; IN-VIVO; EXPRESSION; PROMOTER; IDENTIFICATION; LIPOGENESIS; INDUCTION	Refeeding carbohydrate to fasted rats induces the transcription of genes encoding enzymes of fatty acid biosynthesis, e.g. fatty-acid synthase (FAS). part of this transcriptional induction is mediated by insulin, An insulin response element has been described for the fatty-acid synthase gene region of -600 to +65, but the 2-3-fold increase in fatty-acid synthase promoter activity attributable to this region is small compared with the 20-30-fold induction in fatty-acid synthase gene transcription observed in fasted rats refed carbohydrate. We have previously reported that the fatty-acid synthase gene region between -7382 and -6970 was essential for achieving high in vivo rates of gene transcription. The studies of the current report demonstrate that the region of -7382 to -6970 of the fatty-acid synthase gene contains a carbohydrate response element (CHO-REFAS) with a palindrome sequence (CATGTGn(5)GGCGTG) that is nearly identical to the CHO-RE of the L-type pyruvate kinase and S-14 genes. The glucose responsiveness imparted by CHO-REFAS was independent of insulin. Moreover, CHO-REFAS conferred glucose responsiveness to a heterologous promoter (i.e. L-type pyruvate kinase). Electrophoretic mobility shift assays demonstrated that CHO-RE, readily bound a unique hepatic ChoRF and that CHO-REFAS competed with the CHO-RE of the L-type pyruvate kinase and S-14 genes for ChoRF binding. In vivo footprinting revealed that fasting reduced and refeeding increased ChoRF binding to CHO-RE,. Thus, carbohydrate responsiveness of rat liver fatty-acid synthase appears to require both insulin and glucose signaling pathways. More importantly, a unique hepatic ChoRF has now been shown to recognize glucose responsive sequences that are common to three different genes: fatty-acid synthase, L-type pyruvate kinase, and S-14.	Univ Texas, Div Nutr Sci, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Minnesota, Dept Mol Biol & Biophys, Minneapolis, MN 55455 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Minnesota System; University of Minnesota Twin Cities	Clarke, SD (corresponding author), Univ Texas, Div Nutr Sci, 115 Gearing, Austin, TX 78712 USA.	stevedclarke@mail.utexas.edu	Koo, Seung-Hoi/E-2763-2015; Teran-Garcia, Margarita/B-5344-2009; Rufo, Caterina/O-4602-2017	Koo, Seung-Hoi/0000-0001-8769-2879; Teran-Garcia, Margarita/0000-0002-8196-7605; Rufo, Caterina/0000-0001-9044-8818	NIDDK NIH HHS [DK 09723, DK 26919, DK 53872] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026919, F32DK009723, R01DK053872] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG MK, 1991, BIOCHEM BIOPH RES CO, V177, P1056, DOI 10.1016/0006-291X(91)90645-N; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; CLARKE BA, 1982, ARCH BIOCHEM BIOPHYS, V218, P92, DOI 10.1016/0003-9861(82)90324-1; CLARKE SD, 1990, J NUTR, V120, P218, DOI 10.1093/jn/120.2.218; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Foretz M, 1999, MOL CELL BIOL, V19, P3760; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; Girard J, 1997, ANNU REV NUTR, V17, P325, DOI 10.1146/annurev.nutr.17.1.325; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; JUMP DB, 1994, J LIPID RES, V35, P1076; JUMP DB, 1987, J BIOL CHEM, V262, P778; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; JUMP DB, 1990, MOL ENDOCRINOL, V4, P1655, DOI 10.1210/mend-4-11-1655; KATSURADA A, 1990, EUR J BIOCHEM, V190, P427, DOI 10.1111/j.1432-1033.1990.tb15592.x; Kaytor EN, 1997, J BIOL CHEM, V272, P7525, DOI 10.1074/jbc.272.11.7525; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Koo SH, 2001, J BIOL CHEM, V276, P9437, DOI 10.1074/jbc.M010029200; Latasa MJ, 2000, P NATL ACAD SCI USA, V97, P10619, DOI 10.1073/pnas.180306597; LIU ZR, 1993, J BIOL CHEM, V268, P12787; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Moon YS, 2000, J BIOL CHEM, V275, P10121, DOI 10.1074/jbc.275.14.10121; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MUELLER PR, 1992, CURRENT PROTOCOLS MO; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Rufo C, 1999, BIOCHEM BIOPH RES CO, V261, P400, DOI 10.1006/bbrc.1999.1034; SALATI LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P82, DOI 10.1016/0003-9861(86)90451-0; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Shimano H, 1999, J BIOL CHEM, V274, P35832, DOI 10.1074/jbc.274.50.35832; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SPENCE JT, 1982, EUR J BIOCHEM, V128, P15; Towle HC, 1997, ANNU REV NUTR, V17, P405, DOI 10.1146/annurev.nutr.17.1.405; WILLIAMS BH, 1982, J NUTR, V112, P534, DOI 10.1093/jn/112.3.534; WILSON MD, 1986, J NUTR, V116, P1511, DOI 10.1093/jn/116.8.1511; Yin DZ, 1998, BIOCHEM J, V331, P815, DOI 10.1042/bj3310815; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	43	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21969	21975		10.1074/jbc.M100461200	http://dx.doi.org/10.1074/jbc.M100461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279238	hybrid			2022-12-25	WOS:000169297900152
J	Tang, J; Lin, YK; Zhang, ZM; Tikunova, S; Birnbaumer, L; Zhu, MX				Tang, J; Lin, YK; Zhang, ZM; Tikunova, S; Birnbaumer, L; Zhu, MX			Identification of common binding sites for calmodulin and inositol 1,4,5-trisphosphate receptors on the carboxyl termini of Trp channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; CALCIUM INFLUX FACTOR; TRANSIENT RECEPTOR; PLASMA-MEMBRANE; CATION CHANNEL; CA2+-DEPENDENT INACTIVATION; INSP(3) RECEPTOR; DROSOPHILA TRP; POTENTIAL TRP; ACTIVATION	Homologues of Drosophila Trp (transient receptor potential) form plasma membrane channels that mediate Ca2+ entry following the activation of phospholipase C by cell surface receptors, Among the seven Trp homologous found in mammals, Trp3 has been shown to interact with and respond to IP3 receptors (IP(3)Rs) for activation. Here we show that Trp4 and other Trp proteins also interact with IP(3)Rs. The IP3R-binding domain also interacts with calmodulin (CaM) in a Ca2+-dependent manner with affinities ranging from 10 nM for Trp2 to 290 nM for Trp6, In addition, other binding sites for CaM and IP(3)Rs are present in the alpha but not the beta isoform of Trp4, In the presence of Ca2+, the Trp-IP3R interaction is inhibited by CaM, However, a synthetic peptide representing a Trp-binding domain of IP(3)Rs inhibited the binding of CaM to Trp3, -6, and -7 more effectively than that to Trp1, -2, -4, and -5, In inside-out membrane patches, Trp4 is activated strongly by calmidazolium, an antagonist of CaM, and a high (50 muM) but not a low (5 muM) concentration of the Trp-binding peptide of the IP3R. Our data support the view that both CaM and IP(3)Rs play important roles in controlling the gating of Trp-based channels. However, the sensitivity and responses to CaM and IP(3)Rs differ for each Trp.	Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Univ Calif Los Angeles, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Cellular & Dev Biol, Los Angeles, CA 90095 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Zhu, MX (corresponding author), Ohio State Univ, Neurobiotechnol Ctr, 168 Rightmire Hall,1060 Carmack Rd, Columbus, OH 43210 USA.	zhu.55@osu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45198] Funding Source: Medline; NIGMS NIH HHS [GM54235] Funding Source: Medline; NINDS NIH HHS [R01 NS042183] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acharya JK, 1997, NEURON, V18, P881, DOI 10.1016/S0896-6273(00)80328-1; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 1999, PFLUG ARCH EUR J PHY, V437, P305, DOI 10.1007/s004240050784; Kiselyov KI, 1997, FEBS LETT, V407, P309, DOI 10.1016/S0014-5793(97)00366-9; Krupp JJ, 1999, J NEUROSCI, V19, P1165; LEE SH, 1995, J BIOL CHEM, V270, P21806, DOI 10.1074/jbc.270.37.21806; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Meissner G, 1995, BIOSCIENCE REP, V15, P399, DOI 10.1007/BF01788371; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Raghu P, 2000, MOL CELL NEUROSCI, V15, P429, DOI 10.1006/mcne.2000.0846; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; SANFORD J, 1991, J BIOL CHEM, V266, P9570; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Thrower EC, 2000, J BIOL CHEM, V275, P36049, DOI 10.1074/jbc.M000970200; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Trost C, 1999, FEBS LETT, V451, P257, DOI 10.1016/S0014-5793(99)00588-8; Vaca L, 1996, FEBS LETT, V390, P289, DOI 10.1016/0014-5793(96)00675-8; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Varnum MD, 1997, SCIENCE, V278, P110, DOI 10.1126/science.278.5335.110; Warr CG, 1996, BIOCHEM J, V314, P497, DOI 10.1042/bj3140497; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zhang ZM, 2001, P NATL ACAD SCI USA, V98, P3168, DOI 10.1073/pnas.051632698; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; Zubov AI, 1999, J BIOL CHEM, V274, P25983, DOI 10.1074/jbc.274.37.25983; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209	56	245	259	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21303	21310		10.1074/jbc.M102316200	http://dx.doi.org/10.1074/jbc.M102316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290752	hybrid, Green Accepted			2022-12-25	WOS:000169297900068
J	Rogers, MA; Langbein, L; Winter, H; Ehmann, C; Praetzel, S; Korn, B; Schweizer, J				Rogers, MA; Langbein, L; Winter, H; Ehmann, C; Praetzel, S; Korn, B; Schweizer, J			Characterization of a cluster of human high/ultrahigh sulfur keratin-associated protein genes embedded in the type I keratin gene domain on chromosome 17q12-21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE-RICH PROTEINS; HAIR FOLLICLE; DIFFERENTIAL EXPRESSION; SHEEP WOOL; SEQUENCE; FAMILY; LINKAGE; HUMAN-CHROMOSOME-21; ORGANIZATION; CARCINOMAS	Low stringency screening of a human PI artificial chromosome library using a human hair keratin-associated protein (hKAP1. 1A) gene probe resulted in the isolation of six PI artificial chromosome clones. End sequencing and EMBO/GenBank (TM) data base analysis showed these clones to be contained in four previously sequenced human bacterial artificial chromosome clones present on chromosome 17q12-21 and arrayed into two large contigs of 290 and 225 kilobase pairs (kb) in size. A fifth, partially sequenced human bacterial artificial chromosome clone data base sequence overlapped and closed both of these contigs, One end of this 600-kb cluster harbored six gene loci for previously described human type I hair keratin genes. The other end of this cluster contained the human type I cytokeratin K20 and K12 gene loci. The center of the cluster, starting 35 kb downstream of the hHa3-I hair keratin gene, contained 37 genes for high/ultrahigh sulfur hair keratin-associated proteins (KAPs), which could be divided into a total of 7 KAP multigene families based on amino acid homology comparisons with previously identified sheep, mouse, and rabbit KAPs. To date, 26 human KAP cDNA clones have been isolated through screening of an arrayed human scalp cDNA library by means of specific 3'-noncoding region polymerase chain reaction probes derived from the identified KAP gene sequences. This screening also yielded four additional cDNA sequences whose genes were not present on this gene cluster but belonged to specific KAP gene families present on this contig. Hair follicle in situ hybridization data for single members of five different KAP multigene families all showed localization of the respective mRNAs to the upper cortex of the hair shaft.	German Canc Res Ctr, Div Biochem Tissue Specif Regulat, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany; German Canc Res Ctr, Resource Ctr Human Genome Res, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Rogers, MA (corresponding author), German Canc Res Ctr, Div Biochem Tissue Specif Regulat, 5th Floor,Rm 522,Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				Aoki N, 1997, J BIOL CHEM, V272, P30512, DOI 10.1074/jbc.272.48.30512; Aoki N, 1998, J INVEST DERMATOL, V111, P804, DOI 10.1046/j.1523-1747.1998.00387.x; BOULAY A, 2000, THESIS U STRASSBURG; Cole SE, 1998, GENOMICS, V54, P437, DOI 10.1006/geno.1998.5590; Corden LD, 2000, EXP EYE RES, V70, P41, DOI 10.1006/exer.1999.0769; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRATINI A, 1994, J INVEST DERMATOL, V102, P178, DOI 10.1111/1523-1747.ep12371759; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUH N, 1994, J INVEST DERMATOL, V102, P716, DOI 10.1111/1523-1747.ep12375385; JENKINS BJ, 1994, J INVEST DERMATOL, V103, P310, DOI 10.1111/1523-1747.ep12394770; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; LESSIN SR, 1988, J INVEST DERMATOL, V91, P572, DOI 10.1111/1523-1747.ep12477087; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; MACKINNON PJ, 1995, MAMM GENOME, V1, P53; MCNAB AR, 1990, P NATL ACAD SCI USA, V87, P6848, DOI 10.1073/pnas.87.17.6848; MCNAB AR, 1989, J INVEST DERMATOL, V92, P263, DOI 10.1111/1523-1747.ep12276832; Mitsui S, 1998, GENE, V208, P123, DOI 10.1016/S0378-1119(97)00607-0; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; PARSONS YM, 1994, GENOMICS, V20, P500, DOI 10.1006/geno.1994.1209; Perez C, 1999, GENE, V227, P137, DOI 10.1016/S0378-1119(98)00616-7; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; Regnier CH, 1998, BRIT J CANCER, V78, P1640, DOI 10.1038/bjc.1998.736; ROGERS MA, 1995, EXP CELL RES, V220, P357, DOI 10.1006/excr.1995.1326; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; SWART LS, 1973, BIOCHEM J, V133, P641, DOI 10.1042/bj1330641; SWART LS, 1976, P 5 INT WOOL TEXT RE, P254; Swift JA, 1977, CHEM NATURAL PROTEIN, P81; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZHUMABAEVA BD, 1992, MOL BIOL+, V26, P550	40	84	117	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19440	19451		10.1074/jbc.M100657200	http://dx.doi.org/10.1074/jbc.M100657200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279113	hybrid			2022-12-25	WOS:000169091000106
J	Tryggvason, K; Romert, A; Eriksson, U				Tryggvason, K; Romert, A; Eriksson, U			Biosynthesis of 9-cis-retinoic acid in vivo - The roles of different retinol dehydrogenases and a structure-activity analysis of microsomal retinol dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCOHOL-DEHYDROGENASE; CDNA CLONING; MEMBRANE TOPOLOGY; MESSENGER-RNA; GENE; EXPRESSION; IDENTIFICATION; LOCALIZATION; PATHWAY; ADH4	Retinoic acid is generated by a two-step mechanism. First, retinol is converted into retinal by a retinol dehydrogenase, and, subsequently, retinoic acid is formed by a retinal dehydrogenase. In vitro, several enzymes are suggested to act in this metabolic pathway. However, little is known regarding their capacity to contribute to retinoic acid biosynthesis in vivo. We have developed a versatile cell reporter system to analyze the role of several of these enzymes in 9-cis-retinoic acid biosynthesis in vivo. Using a Gal4-retinoid X receptor fusion protein-based luciferase reporter assay, the formation of 9-cis-retinoic acid from g-cis-retinol was measured in cells transfected with expression plasmids encoding different combinations of retinol and retinal dehydrogenases. The results suggested that efficient formation of 9-cis-retinoic acid required co-expression of retinol and retinal dehydrogenases. Interestingly, the cytosolic alcohol dehydrogenase 4 failed to efficiently catalyze 9-cis-retinol oxidation. A structure-activity analysis showed that mutants of two retinol dehydrogenases, devoid of the carboxyl-terminal cytoplasmic tails, displayed greatly reduced enzymatic activities in vivo, but were active in vitro. The cytoplasmic tails mediate efficient endoplasmic reticulum localization of the enzymes, suggesting that the unique milieu in the endoplasmic reticulum compartment is necessary for in vivo activity of microsomal retinol dehydrogenases.	Ludwig Inst Canc Res, S-17177 Stockholm, Sweden	Ludwig Institute for Cancer Research	Eriksson, U (corresponding author), Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	ueri@licr.ki.se						BUBLITZ C, 1987, BIOCHEM J, V245, P263, DOI 10.1042/bj2450263; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Gonzalez-Fernandez F, 1999, MOL VIS, V5, pU1; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Hofmann Clementine, 1994, P387; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Mangelsdorf David J., 1994, P319; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; MOORE T, 1957, VITAMIN A, P295; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Romert A, 2000, EXP CELL RES, V256, P338, DOI 10.1006/excr.2000.4817; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; Saari John C., 1994, P351; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; Simon A, 1999, J CELL SCI, V112, P549; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wada Y, 2000, INVEST OPHTH VIS SCI, V41, P1894; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	32	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19253	19258		10.1074/jbc.M100215200	http://dx.doi.org/10.1074/jbc.M100215200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279029	hybrid			2022-12-25	WOS:000169091000083
J	Bienvenu, F; Gascan, H; Coqueret, O				Bienvenu, F; Gascan, H; Coqueret, O			Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; V-SRC; INHIBITION; KINASE; G1; PHOSPHORYLATION; TRANSFORMATION	STAT3 transcription factors are cytoplasmic proteins that induce gene activation in response to cytokine receptor stimulation. Following tyrosine phosphorylation, STAT3 proteins dimerize, translocate into the nucleus, and activate specific target genes. Activation is transient, and down-regulation of STAT3 signaling occurs within a few hours. In this study, we show that cyclin D1 inhibits STAT3 activation. In co-immunoprecipitation and pull-down assays, cyclin D1 was found to associate with the activation domain of STAT3 upon interleukin-6 stimulation. Overexpression of cyclin D1 inhibited transcriptional activation by STAT3 proteins. This effect was not shared by cyclin E, was independent of association with Cdk4, and was unaffected by inhibitors of Cdk4, Whereas cyclin D1 had no effect on the steady-state level of STAT3 proteins in the cytoplasm, it was found to reduce the STAT3 nuclear level in HepG2 cells. These results suggest a model by which cyclin D1 is part of a feedback network controlling the down-regulation of STAT3 activity and highlight a new activity for this cell cycle regulatory protein.	CHU Angers, INSERM, EMI U 9928, F-49033 Angers, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Coqueret, O (corresponding author), CHU Angers, INSERM, EMI U 9928, 4 Rue Larrey, F-49033 Angers, France.		Coqueret, Olivier/K-9660-2015	Coqueret, Olivier/0000-0002-2843-7867				Bernards R, 1999, BBA-REV CANCER, V1424, pM17, DOI 10.1016/S0304-419X(99)00024-4; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Robledo O, 1996, J NEUROCHEM, V66, P1391; SHERR CJ, 1994, CELL, V79, P547; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6; Zwijsen RML, 1998, GENE DEV, V12, P3488, DOI 10.1101/gad.12.22.3488	40	104	105	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16840	16847		10.1074/jbc.M100795200	http://dx.doi.org/10.1074/jbc.M100795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279133	hybrid			2022-12-25	WOS:000168730400034
J	Lalev, AI; Nazar, RN				Lalev, AI; Nazar, RN			A chaperone for ribosome maturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTERNAL TRANSCRIBED SPACER; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL FEATURES; RNA; PURIFICATION; CLEAVAGE; PROTEINS; SYSTEM	The nascent pre-rRNA of eukaryotic ribosomes is fully transcribed and assembled into an 80-90 S nucleolar particle before being cleaved into mature ribosomal RNA. The interdependence of steps in the processing of this precursor RNA indicates that RNA processing, at least in part, acts as a quality control mechanism that helps ensure that only functional RNA is incorporated into mature ribosomes, In search of structural components that underlie this interdependence using the Schizosaccharomyces pombe internal transcribed spacer 1 (ITS) as a ligand for affinity chromatography of ITS1-specific proteins, we have isolated a large spliceosome-like protein complex, a ribosome assembly chaperone (RAC) of 20 or more polypeptides (Lalev, PL I., Abeyrathne, P, D,, and Nazar, R, N, (2000) J, Mol. Biol, 302, 65-77), When the ITS2 spacer was used in the present study to isolate ITS2-specific proteins, the same proteins were identified consistent with a complex containing multiple specific binding sites, Subsequent competition binding studies indicated that the protein complex actually contains independent binding sites for all four of the transcribed spacers in the pre-rRNA Because disruption of protein-binding sites in these spacer RNAs is known to severely affect rRNA processing, taken together these results suggest that the RAC complex is a chaperone for ribosome maturation acting as a "rack" on which critical structure is organized.	Univ Guelph, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Guelph	Nazar, RN (corresponding author), Univ Guelph, Dept Mol Biol & Genet, Axelrod Bldg, Guelph, ON N1G 2W1, Canada.							AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; Good L, 1997, J MOL BIOL, V273, P782, DOI 10.1006/jmbi.1997.1351; Hitchen J, 1997, J MOL BIOL, V274, P481, DOI 10.1006/jmbi.1997.1376; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; Intine RVA, 1999, J MOL BIOL, V286, P695, DOI 10.1006/jmbi.1998.2502; KUMAR A, 1972, J MOL BIOL, V63, P233, DOI 10.1016/0022-2836(72)90372-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalev AI, 1999, NUCLEIC ACIDS RES, V27, P3071, DOI 10.1093/nar/27.15.3071; Lalev AI, 1998, J MOL BIOL, V284, P1341, DOI 10.1006/jmbi.1998.2222; Lalev AI, 2000, J MOL BIOL, V302, P65, DOI 10.1006/jmbi.2000.4015; Liang WQ, 1997, P NATL ACAD SCI USA, V94, P2864, DOI 10.1073/pnas.94.7.2864; MELEKHOVETS YF, 1994, J MOL BIOL, V239, P170, DOI 10.1006/jmbi.1994.1361; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERRILL CR, ANAL BIOCH, V110, P201; Moore M., 1993, RNA WORLD, P303; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; NAZAR RN, 1996, RNA 96 1 ANN M RNA S; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; VANNUES RW, 1995, J MOL BIOL, V250, P24, DOI 10.1006/jmbi.1995.0355; VANNUES RW, 1993, TRANSLATIONAL APPARATUS, P151; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261	24	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16655	16659		10.1074/jbc.M101157200	http://dx.doi.org/10.1074/jbc.M101157200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279180	hybrid			2022-12-25	WOS:000168730400010
J	Blank, M; Weinschenk, T; Priemer, M; Schluesener, H				Blank, M; Weinschenk, T; Priemer, M; Schluesener, H			Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels - Selective targeting of endothelial regulatory protein pigpen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT ANTIBODY FRAGMENTS; IN-VITRO SELECTION; ANGIOGENESIS; AFFINITY; VASCULATURE; MECHANISMS; COMPLEX; CANCER; CELLS	Tumor microvessels differ in structure and metabolic function from normal vasculature, and neoangiogenesis is associated with quantitative and qualitative changes in expression of endothelial proteins. Such molecules could serve as molecular addresses differentiating the tumor vasculature from those of the normal brain. We have applied Systematic Evolution of Ligands by EXponential enrichment (SELEX) against transformed endothelial cells as a complex target to select single-stranded DNA-ligands (aptamers) that function as histological markers to detect microvessels of rat experimental glioma, a fatal brain tumor that is highly vascularized. Both the SELEX selection procedure as well as subsequent deconvolution-SELEX were analyzed by fluorescence based methods (flow cytometry and fluorescence microscopy), Of 25 aptamers analyzed, one aptamer was selected that selectively bound microvessels of rat brain glioblastoma but not the vasculature of the normal rat brain including peritumoral areas. The molecular target protein of aptamer III.1 was isolated from endothelial cells by ligand-mediated magnetic DNA affinity purification. This protein was identified by mass spectrometry as rat homologue of mouse pigpen, a not widely known endothelial protein the expression of which parallels the transition from quiescent to angiogenic phenotypes in vitro, Because neoangiogenesis, the formation of new blood vessels, is a key feature of tumor development, the presented aptamer can be used as a probe to analyze pathological angiogenesis of glioblastoma, The presented data show that pigpen is highly expressed in tumor microvessels of experimental rat brain glioblastoma and may play an important role in warranting blood supply, thus growth of brain tumors.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Univ Tubingen, Dept Immunol, Inst Cell Biol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Mol Biol, Inst Cell Biol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen	Blank, M (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	hirnforschung@uni-tuebingen.de						Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; Alliegro MC, 2000, EXP CELL RES, V255, P270, DOI 10.1006/excr.1999.4776; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Birchler M, 1999, NAT BIOTECHNOL, V17, P984, DOI 10.1038/13679; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; BROWN TA, DNA SEQUENCING BASIC; Conrad RC, 1996, METHOD ENZYMOL, V267, P336; CRAMERI A, 1993, NUCLEIC ACIDS RES, V21, P4410, DOI 10.1093/nar/21.18.4410; Davis KA, 1996, NUCLEIC ACIDS RES, V24, P702, DOI 10.1093/nar/24.4.702; Davis KA, 1998, NUCLEIC ACIDS RES, V26, P3915, DOI 10.1093/nar/26.17.3915; Ferrari D, 1996, J IMMUNOL, V156, P1531; Fitzwater T, 1996, METHOD ENZYMOL, V267, P275; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; Hicke BJ, 1996, J CLIN INVEST, V98, P2688, DOI 10.1172/JCI119092; Jayasena SD, 1999, CLIN CHEM, V45, P1628; Klocker N, 1999, J NEUROSCI, V19, P8517; KOCH CJ, 1995, BRIT J CANCER, V72, P869, DOI 10.1038/bjc.1995.426; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; LAMPSON LA, 1992, CANCER RES, V52, P1018; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Lund EL, 1998, ACTA NEUROL SCAND, V97, P52; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; Morris KN, 1998, P NATL ACAD SCI USA, V95, P2902, DOI 10.1073/pnas.95.6.2902; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; PAN WH, 1995, P NATL ACAD SCI USA, V92, P11509, DOI 10.1073/pnas.92.25.11509; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thorpe PE, 1997, J CONTROL RELEASE, V48, P277, DOI 10.1016/S0168-3659(97)00038-2; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Viti F, 1999, CANCER RES, V59, P347; Yamazaki Kosuke, 1995, In Vivo (Attiki), V9, P421; Zetter BR, 1997, NAT BIOTECHNOL, V15, P1243, DOI 10.1038/nbt1197-1243	36	275	322	4	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16464	16468		10.1074/jbc.M100347200	http://dx.doi.org/10.1074/jbc.M100347200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279054	hybrid			2022-12-25	WOS:000168623100119
J	Ghosh, N; Gyory, I; Wright, G; Wood, J; Wright, KL				Ghosh, N; Gyory, I; Wright, G; Wood, J; Wright, KL			Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; GENE-EXPRESSION; PLASMA-CELLS; PR DOMAIN; B-CELLS; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; ACTIVE SUPPRESSION; IFN-GAMMA; CIITA	The major histocompatibility complex (MHC) class II transactivator (CIITA) acts as a master switch to activate expression of the genes required for MHC-II antigen presentation. During B-cell to plasma cell differentiation, MHC-II expression is actively silenced, but the mechanism has been unknown. In plasma cell tumors such as multiple myeloma the repression of MHC-II is associated with the loss of CIITA. We have identified that positive regulatory domain I binding factor I (PRDI-BF1), a transcriptional repressor, inhibits CIITA expression in multiple myeloma cell lines. Repression of CIITA depends on the DNA binding activity of PRDI-BF1 and its specific binding site in the CIITA promoter. Deletion of a histone deacetylase recruitment domain in PRDI-BF1 does not inhibit repression of CIITA nor does blocking histone deacetylase activity. This is in contrast to PRDI-BF1 repression of the c-myc promoter. Repression of CIITA requires either the N-terminal acidic and conserved PR motif or the proline-rich domain. PRDI-BF1 has been shown to be a key regulator of B-cell and macrophage differentiation. These findings now indicate that PRDI-BF1 has at least two mechanisms of repression whose function is dependent on the nature of the target promoter. Importantly, PRDI-BF1 is defined as the key molecule in silencing CIITA and thus MHC-II in multiple myeloma cells.	Univ S Florida, H Lee Moffitt Canc Ctr, Interdisciplinary Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Wright, KL (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Interdisciplinary Oncol Program, 12902 Magnolia Dr,MRC 4072, Tampa, FL 33612 USA.				NCI NIH HHS [CA80990-R01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080990] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Burrows P D, 1990, Semin Immunol, V2, P189; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CHANG CH, 1994, J EXP MED, V180, P1367, DOI 10.1084/jem.180.4.1367; CHANG CH, 1992, J EXP MED, V176, P1465, DOI 10.1084/jem.176.5.1465; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; DELLABONA P, 1989, J IMMUNOL, V142, P2902; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; Ghosh N, 1999, J BIOL CHEM, V274, P32342, DOI 10.1074/jbc.274.45.32342; HALPER J, 1978, J IMMUNOL, V120, P1480; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Jayachandra S, 1999, P NATL ACAD SCI USA, V96, P11566, DOI 10.1073/pnas.96.20.11566; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; LATRON F, 1988, P NATL ACAD SCI USA, V85, P2229, DOI 10.1073/pnas.85.7.2229; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Piskurich JF, 1998, J IMMUNOL, V160, P233; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Sartoris S, 1996, EUR J IMMUNOL, V26, P2456, DOI 10.1002/eji.1830261028; SILACCI P, 1994, J EXP MED, V180, P1329, DOI 10.1084/jem.180.4.1329; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; VENKITARAMAN AR, 1987, EUR J IMMUNOL, V17, P1441, DOI 10.1002/eji.1830171009; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360; Yu J, 2000, MOL CELL BIOL, V20, P2592, DOI 10.1128/MCB.20.7.2592-2603.2000	31	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15264	15268		10.1074/jbc.M100862200	http://dx.doi.org/10.1074/jbc.M100862200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279146	hybrid			2022-12-25	WOS:000168528800098
J	Nayak, S; Hildebrand, EL; Bryant, FR				Nayak, S; Hildebrand, EL; Bryant, FR			ADP-dependent DNA strand exchange by the mutant [P67G/E68A]RecA protein - Evidence for an involvement of ADP in RecA protein-mediated branch migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTED ATP HYDROLYSIS; ESCHERICHIA-COLI; STABLE COMPLEXES; NTP HYDROLYSIS; BINDING; INHIBITION; PHASE	We have prepared a mutant RecA protein in which proline 67 and glutamic acid 68 in the NTP binding site were replaced by a glycine and alanine residue, respectively, The [P67G/E68A]RecA protein catalyzes the single-stranded DNA-dependent hydrolysis of ATP and is able to promote the standard ATP-dependent three-strand exchange reaction between a circular bacteriophage phi X174 (phiX) single-stranded DNA molecule and a homologous linear phiX double-stranded (ds) DNA molecule (5.4 kilobase pairs). The strand exchange activity differs from that of the wild type RecA protein, however, in that it is (i) completely inhibited by an ATP regeneration system, and (ii) strongly stimulated by the addition of high concentrations of ADP to the reaction solution. These results indicate that the strand exchange activity of the [P67G/E68A]RecA protein is dependent on the presence of both ATP and ADP. The ADP dependence of the reaction is reduced or eliminated when (i) a shorter linear phiX dsDNA fragment (1.1 kilobase pairs) is substituted for the full-length linear phiX dsDNA substrate, or (ii) the Mg2+ concentration is reduced to a level just sufficient to complex the ATP present in the reaction solution. These results indicate that it is the branch migration phase (and not the initial pairing step) of the [P67G/E68A]RecA protein-promoted strand exchange reaction that is dependent on ADP. It is likely that the [P67G/E68A]RecA mutation has revealed a requirement for ADP that also exists (but is not as readily apparent) in the strand exchange reaction of the wild type RecA protein.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Bryant, FR (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.				NIGMS NIH HHS [GM36516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036516] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; COX MM, 1983, J BIOL CHEM, V258, P2586; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7666, DOI 10.1021/bi00485a016; Nayak S, 1999, J BIOL CHEM, V274, P25979, DOI 10.1074/jbc.274.37.25979; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126	15	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14933	14938		10.1074/jbc.M100470200	http://dx.doi.org/10.1074/jbc.M100470200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279076	hybrid			2022-12-25	WOS:000168528800056
J	Rose, K; Allan, A; Gauldie, S; Stapleton, G; Dobbie, L; Dott, X; Martin, C; Wang, L; Hedlund, E; Seckl, JR; Gustafsson, JA; Lathe, R				Rose, K; Allan, A; Gauldie, S; Stapleton, G; Dobbie, L; Dott, X; Martin, C; Wang, L; Hedlund, E; Seckl, JR; Gustafsson, JA; Lathe, R			Neurosteroid hydroxylase CYP7B - Vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-SPECIFIC INHIBITION; MOUSE-LIVER MICROSOMES; CENTRAL-NERVOUS-SYSTEM; ADIPOSE STROMAL CELLS; BILE-ACID SYNTHESIS; DEHYDROEPIANDROSTERONE-SULFATE; CYTOCHROME-P450 INHIBITORS; BRAIN CYTOCHROME-P450; PROSTATE MICROSOMES; MOLECULAR-CLONING	The major adrenal steroid dehydroepiandrosterone (DHEA) enhances memory and immune function but has no known dedicated receptor; local metabolism may govern its activity. We described a cytochrome P450 expressed in brain and other tissues, CYP7B, that catalyzes the 7 alpha -hydroxylation of oxysterols and 3 beta -hydroxysteroids including DHEA, We report here that CYP7B mRNA and 7 alpha -hydroxylation activity are widespread in rat tissues. However, steroids related to DHEA are reported to be modified at positions other than 7 alpha, exemplified by prominent 6 alpha -hydroxylation of 5 alpha -androstane-3 beta ,17 beta -diol (A/anediol) in some rodent tissues including brain. To determine whether CYP7B is responsible for these and other activities we disrupted the mouse Cyp7b gene by targeted insertion of an IRES-lacZ reporter cassette, placing reporter enzyme activity (beta -galactosidase) under Cyp7b promoter control. In heterozygous mouse brain, chromogenic detection of reporter activity was strikingly restricted to the dentate gyrus. Staining did not exactly reproduce the in situ hybridization expression pattern; post-transcriptional control is inferred. Lower level staining was detected in cerebellum, liver, and kidney, and which largely paralleled mRNA distribution. Liver and kidney expression was sexually dimorphic. Mice homozygous for the insertion are viable and superficially normal, but ex vivo metabolism of DHEA to 7 alpha -hydroxy-DHEA was abolished in brain, spleen, thymus, heart, lung, prostate, uterus, and mammary gland; lower abundance metabolites were also eliminated. 7 alpha -Hydroxylation of 25-hydroxycholesterol and related substrates was also abolished, as was presumed 6 alpha -hydroxylation of A/anediol. These different enzyme activities therefore derive from the Cyp7b gene. CYP7B is thus a major extrahepatic steroid and oxysterol hydroxylase and provides the predominant route for local metabolism of DHEA and related molecules in brain and other tissues.	Univ Edinburgh, Ctr Genome Res, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Edinburgh, Ctr Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland; Huddinge Hosp, Karolinska Inst, S-14186 Huddinge, Sweden; Transgene SA, F-67000 Strasbourg, France; Western Gen Hosp, Mol Med Ctr, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; Karolinska Institutet; Transgene SA; University of Edinburgh	Lathe, R (corresponding author), Univ Edinburgh, Ctr Genome Res, Kings Bldgs,W Mains Rd, Edinburgh EH9 3JQ, Midlothian, Scotland.	Rlathe@ed.ac.uk	Seckl, Jonathan R/C-3555-2013	Hedlund, Eva/0000-0001-6347-0075; Lathe, Richard/0000-0001-9698-9834				AKWA Y, 1992, BIOCHEM J, V288, P959, DOI 10.1042/bj2880959; AKWA Y, 1993, J CELL BIOL, V121, P135, DOI 10.1083/jcb.121.1.135; Axelson M, 1996, J BIOL CHEM, V271, P12724, DOI 10.1074/jbc.271.22.12724; Baulieu EE, 2000, P NATL ACAD SCI USA, V97, P4279, DOI 10.1073/pnas.97.8.4279; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; BAULIEU EE, 1990, J STEROID BIOCHEM, V37, P395, DOI 10.1016/0960-0760(90)90490-C; BJORKHEM I, 1994, SCAND J GASTROENTERO, V29, P68, DOI 10.3109/00365529409103629; Chang HC, 1999, P NATL ACAD SCI USA, V96, P11173, DOI 10.1073/pnas.96.20.11173; CHURCH GM, 1986, P NATL ACAD SCI USA, V81, P1991; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; DANENBERG HD, 1995, VACCINE, V13, P1445, DOI 10.1016/0264-410X(95)00063-7; DAYNES RA, 1990, EUR J IMMUNOL, V20, P793, DOI 10.1002/eji.1830200413; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Dombroski R, 1997, J CLIN ENDOCR METAB, V82, P1338, DOI 10.1210/jc.82.5.1338; Doostzadeh J, 1996, STEROIDS, V61, P613, DOI 10.1016/S0039-128X(96)00122-5; Doostzadeh J, 1997, J NEUROENDOCRINOL, V9, P923, DOI 10.1046/j.1365-2826.1997.00661.x; Doostzadeh J, 1998, STEROIDS, V63, P608, DOI 10.1016/S0039-128X(98)00071-3; Doostzadeh J, 1998, STEROIDS, V63, P383, DOI 10.1016/S0039-128X(98)00012-9; Eggertsen G, 1996, J BIOL CHEM, V271, P32269, DOI 10.1074/jbc.271.50.32269; FLOOD JF, 1988, BRAIN RES, V448, P178, DOI 10.1016/0006-8993(88)91116-X; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; FLOOD JF, 1992, P NATL ACAD SCI USA, V89, P1567, DOI 10.1073/pnas.89.5.1567; GEMZIK B, 1992, ARCH BIOCHEM BIOPHYS, V296, P374, DOI 10.1016/0003-9861(92)90587-M; GEMZIK B, 1992, ARCH BIOCHEM BIOPHYS, V296, P355, DOI 10.1016/0003-9861(92)90585-K; GUIRAUD JM, 1982, STEROIDS, V40, P625, DOI 10.1016/0039-128X(82)90003-4; Hinson JP, 1999, J ENDOCRINOL, V163, P1, DOI 10.1677/joe.0.1630001; ISAACS JT, 1979, STEROIDS, V33, P675, DOI 10.1016/0039-128X(79)90116-8; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; KHALIL MW, 1993, J STEROID BIOCHEM, V46, P585, DOI 10.1016/0960-0760(93)90186-Z; KILLINGER DW, 1995, J STEROID BIOCHEM, V52, P195, DOI 10.1016/0960-0760(94)00164-H; Kurose K, 1999, ARCH BIOCHEM BIOPHYS, V371, P270, DOI 10.1006/abbi.1999.1457; Lane MA, 1997, J CLIN ENDOCR METAB, V82, P2093, DOI 10.1210/jc.82.7.2093; LARDY H, 1995, P NATL ACAD SCI USA, V92, P6617, DOI 10.1073/pnas.92.14.6617; LATHE R, 2001, IN PRESS GENETICS ST; LI K, 1978, STEROIDS, V31, P113; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16543, DOI 10.1074/jbc.M001810200; Li-Hawkins J, 2000, J BIOL CHEM, V275, P16536, DOI 10.1074/jbc.M001811200; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MARTEL C, 1992, J STEROID BIOCHEM, V41, P597, DOI 10.1016/0960-0760(92)90390-5; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; MORALES AJ, 1994, J CLIN ENDOCR METAB, V78, P1360, DOI 10.1210/jc.78.6.1360; Nehls M, 1996, SCIENCE, V272, P886, DOI 10.1126/science.272.5263.886; ORENTREICH N, 1992, J CLIN ENDOCR METAB, V75, P1002, DOI 10.1210/jc.75.4.1002; Padgett DA, 1998, J NEUROIMMUNOL, V84, P61, DOI 10.1016/S0165-5728(97)00244-0; PAYNE DW, 1995, J BIOL CHEM, V270, P18888, DOI 10.1074/jbc.270.32.18888; PEREIRA B, 1994, BIOCHEM BIOPH RES CO, V203, P59, DOI 10.1006/bbrc.1994.2148; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; SAPOLSKY RM, 1993, J GERONTOL, V48, pB196, DOI 10.1093/geronj/48.5.B196; Schwarz M, 1997, J BIOL CHEM, V272, P23995, DOI 10.1074/jbc.272.38.23995; Setchell KDR, 1998, J CLIN INVEST, V102, P1690, DOI 10.1172/JCI2962; Shi J, 2000, STEROIDS, V65, P124, DOI 10.1016/S0039-128X(99)00094-X; SONDERFAN AJ, 1989, ENDOCRINOLOGY, V125, P857, DOI 10.1210/endo-125-2-857; Song C, 2000, STEROIDS, V65, P423, DOI 10.1016/S0039-128X(00)00127-6; Song W, 1998, J BIOL CHEM, V273, P16223, DOI 10.1074/jbc.273.26.16223; STAPLETON G, 1995, J BIOL CHEM, V270, P29739, DOI 10.1074/jbc.270.50.29739; STAPLETON G, 1994, THESIS U EDINBURGH; Steel M, 1998, HIPPOCAMPUS, V8, P444, DOI 10.1002/(SICI)1098-1063(1998)8:5<444::AID-HIPO5>3.0.CO;2-X; STROMSTEDT M, 1993, MOL PHARMACOL, V44, P1077; SUNDIN M, 1987, J BIOL CHEM, V262, P12293; WARNER M, 1989, ENDOCRINOLOGY, V124, P2699, DOI 10.1210/endo-124-6-2699; Wolf OT, 1998, J GERONTOL A-BIOL, V53, pM385, DOI 10.1093/gerona/53A.5.M385; Wolf OT, 1997, J CLIN ENDOCR METAB, V82, P2363, DOI 10.1210/jc.82.7.2363; Wu ZL, 1999, J LIPID RES, V40, P2195; ZHANG J, 1995, BBA-LIPID LIPID MET, V1256, P353	65	69	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23937	23944		10.1074/jbc.M011564200	http://dx.doi.org/10.1074/jbc.M011564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11290741	hybrid			2022-12-25	WOS:000169531100095
J	Cok, SJ; Morrison, AR				Cok, SJ; Morrison, AR			The 3 '-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; JUN NH2-TERMINAL KINASE; 3' UNTRANSLATED REGION; RENAL MESANGIAL CELLS; NECROSIS-FACTOR-ALPHA; UA-RICH SEQUENCES; N-TERMINAL KINASE; GROWTH-FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL REGULATION	Renal mesangial cells regulate their expression of the pro-inflammatory gene cyclooxygenase-2 (COX-2) through mechanisms involving gene transcription and post-transcriptional events. Post-transcriptional regulation of COX-2 is dependent, in part, on sequences within the 3'-untranslated region (3'-UTR) of the COX-2 mRNA Insertion of the entire 3'-UTR of COX-2 into the 3'-UTR of luciferase resulted in a 70% decrease in luciferase enzymatic activity. Measurement of steady-state reporter gene mRNA levels suggested that the loss of activity was due to decreased translational efficiency. Deletion analysis identified the first 60 nucleotides of the 3'-UTR of COX-2 as a major translational control element. This region of the 3'-UTR of COX-2 is highly conserved across species; is AU-rich; and contains multiple repeats of the regulatory sequence AUUUA, reported to confer post-transcriptional control. In addition, we identified regions of the 3'-UTR of COX-2 outside of the first 60 nucleotides that altered message stability. Some of these regions contained AUUUA consensus sequences, whereas others did not, and represent novel control elements. These results suggest that expression of COX-2 in mesangial cells depends on the complex integration of multiple signals derived from the 3'-UTR of the message.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Morrison, AR (corresponding author), Barnes Jewish Hosp, 822 Yalem Res Bldg,216 S Kingshighway, St Louis, MO 63110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050606, P01DK009976] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50606, DK 09976] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balmer LA, 2001, MOL CELL BIOL, V21, P2070, DOI 10.1128/MCB.21.6.2070-2084.2001; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Diaz A, 1998, EXP CELL RES, V241, P222, DOI 10.1006/excr.1998.4050; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HERSCHMAN HR, 1995, BIOESSAYS, V17, P1031, DOI 10.1002/bies.950171207; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Izquierdo JM, 1997, MOL CELL BIOL, V17, P5255, DOI 10.1128/MCB.17.9.5255; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; Mbella EGM, 2000, MOL CELL BIOL, V20, P4572, DOI 10.1128/MCB.20.13.4572-4579.2000; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; Morris JK, 1996, J BIOL CHEM, V271, P16633, DOI 10.1074/jbc.271.28.16633; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Pages G, 2000, J BIOL CHEM, V275, P26484, DOI 10.1074/jbc.M002104200; *PE BIOS, 1997, PE BIOS US B 2; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; Subbaramaiah K, 1998, J BIOL CHEM, V273, P32943, DOI 10.1074/jbc.273.49.32943; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	48	182	191	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23179	23185		10.1074/jbc.M008461200	http://dx.doi.org/10.1074/jbc.M008461200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294846	hybrid			2022-12-25	WOS:000169412700159
J	Tasken, KA; Collas, P; Kemmners, WA; Witczak, O; Conti, M; Tasken, K				Tasken, KA; Collas, P; Kemmners, WA; Witczak, O; Conti, M; Tasken, K			Phosphodiesterase 4D and protein kinase A type II constitute a signaling unit in the Centrosomal Area	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORING PROTEIN; SUBCELLULAR-LOCALIZATION; DIFFERENTIAL EXPRESSION; CAMP; ASSOCIATION; IDENTIFICATION; ACTIVATION; INTERACTS; SUBUNITS; HORMONE	The mediation of cAMP effects by specific pools of protein kinase A (PRA) targeted to distinct subcellular domains raises the question of how inactivation of the cAMP signal is achieved locally and whether similar targeting of phosphodiesterases (PDEs) to sites of cAMP/PKA action could be observed. Here, we demonstrate that Sertoli cells of the testis contain an insoluble PDE4D3 isoform, which is shown by immunofluorescence to target to centrosomes. Staining of PDE4D and PKA shows co-localization of PDE4D with PKA-RII alpha and RII beta in the centrosomal region. Go-precipitation of RII subunits and PDE4D3 from cytoskeletal extracts indicates a physical association of the two proteins. Distribution of PDE4D overlaps with that of the centrosomal PKA-anchoring protein, AKAP450, and AKAP450, PDE4D3, and PRA-RII alpha co-immunoprecipitate. Finally, both PDE4D8 and PRA co-precipitate with a soluble fragment of AKAP450 encompassing amino acids 1710 to 2872 when co-expressed in 293T cells. Thus, a centrosomal complex that includes PDE4D and PKA constitutes a novel signaling unit that may provide accurate spatiotemporal modulation of cAMP signals.	Univ Oslo, Inst Med Biochem, N-0317 Oslo, Norway; Max Planck Inst Dev Biol, Dept Biochem, D-72076 Tubingen, Germany; Stanford Univ, Med Ctr, Dept Gynecol & Obstet, Stanford, CA 94305 USA	University of Oslo; Max Planck Society; Stanford University	Tasken, K (corresponding author), Univ Oslo, Inst Med Biochem, POB 1112, N-0317 Oslo, Norway.	kjetil.tasken@basalmed.uio.no		Tasken, Kjetil/0000-0003-2841-4697	NICHD NIH HHS [HD20778] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Collas P, 1996, J CELL BIOL, V135, P1715, DOI 10.1083/jcb.135.6.1715; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; DORRINGTON JH, 1975, MOL CELL ENDOCRINOL, V3, P57, DOI 10.1016/0303-7207(75)90031-3; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Fernandez A, 1995, Prog Cell Cycle Res, V1, P241; Gavet O, 1998, J CELL SCI, V111, P3333; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; LANDMARK BF, 1991, ENDOCRINOLOGY, V129, P2345, DOI 10.1210/endo-129-5-2345; MARO B, 1980, BIOL CELLULAIRE, V39, P287; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; OYEN O, 1987, BIOL REPROD, V37, P947, DOI 10.1095/biolreprod37.4.947; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; TASKEN KA, 1991, MOL ENDOCRINOL, V5, P21, DOI 10.1210/mend-5-1-21; Tassin AM, 1999, BIOL CELL, V91, P343, DOI 10.1016/S0248-4900(99)80095-1; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Vicini E, 1997, MOL ENDOCRINOL, V11, P839, DOI 10.1210/me.11.7.839; WALTER U, 1983, METHOD ENZYMOL, V99, P154; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909	33	185	197	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					21999	22002		10.1074/jbc.C000911200	http://dx.doi.org/10.1074/jbc.C000911200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11285255	hybrid			2022-12-25	WOS:000169412700003
J	Kleene, R; Yang, HB; Kutsche, M; Schachner, M				Kleene, R; Yang, HB; Kutsche, M; Schachner, M			The neural recognition molecule L1 is a sialic acid-binding lectin for CD24, which induces promotion and inhibition of neurite outgrowth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; AXON GUIDANCE; MOUSE CD24; GENE; NEURONS; HOMOLOGY; DOMAINS; PROTEIN; MEMBER; BRAIN	Among the recognition molecules that determine a neuron's interaction with other cells, L1 and CD24 have been suggested to cooperate with each other in neurite outgrowth and signal transduction, Here we report that binding of CD24 to L1 depends on alpha2,3-sialic acid on CD24, which determines the CD24 induced and cell type-specific promotion or inhibition of neurite outgrowth. Using knockout mutants, we could show that the CD24-induced effects on neurite outgrowth are mediated via L1, and not GPI-linked CD24, by trans-interaction of L1 with sialylated CD24, This glycoform is excluded together with L1 from raft microdomains, suggesting that molecular compartmentation in the surface membrane could play a role in signal transduction.	Univ Hamburg, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Schachner, M (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.							Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Castellani V, 2000, NEURON, V27, P237, DOI 10.1016/S0896-6273(00)00033-7; Cohen NR, 1998, CURR BIOL, V8, P26, DOI 10.1016/S0960-9822(98)70017-X; CONSTAM DB, 1994, EUR J NEUROSCI, V6, P766, DOI 10.1111/j.1460-9568.1994.tb00988.x; CROCKER PR, 1998, GLYCOBIOLOGY, V8, P211; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Doherty P, 1996, PERSPECT DEV NEUROBI, V4, P157; Du YZ, 1998, HUM MUTAT, V11, P222, DOI 10.1002/(SICI)1098-1004(1998)11:3<222::AID-HUMU7>3.3.CO;2-M; Eudy JD, 1998, SCIENCE, V280, P1753, DOI 10.1126/science.280.5370.1753; FILBIN MT, 1993, J CELL BIOL, V122, P451, DOI 10.1083/jcb.122.2.451; Finckh U, 2000, AM J MED GENET, V92, P40, DOI 10.1002/(SICI)1096-8628(20000501)92:1<40::AID-AJMG7>3.0.CO;2-R; Fortini ME, 2000, NATURE, V406, P357, DOI 10.1038/35019233; FRANCO B, 1991, NATURE, V353, P529, DOI 10.1038/353529a0; Fransen E, 1998, HUM MOL GENET, V7, P999, DOI 10.1093/hmg/7.6.999; Haney CA, 1999, J CELL BIOL, V146, P1173, DOI 10.1083/jcb.146.5.1173; Haspel J, 2000, J NEUROBIOL, V42, P287, DOI 10.1002/(SICI)1097-4695(20000215)42:3<287::AID-NEU1>3.3.CO;2-O; Heiland PC, 1998, EUR J CELL BIOL, V75, P97, DOI 10.1016/S0171-9335(98)80052-6; Henrick K, 1998, GLYCOBIOLOGY, V8, P45, DOI 10.1093/glycob/8.1.45; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; HUBER AH, 1994, NEURON, V12, P717, DOI 10.1016/0896-6273(94)90326-3; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KADMON G, 1995, EUR J NEUROSCI, V7, P993, DOI 10.1111/j.1460-9568.1995.tb01087.x; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; NEDELEC J, 1992, EUR J BIOCHEM, V203, P433, DOI 10.1111/j.1432-1033.1992.tb16567.x; Nguyen DNT, 1997, DEVELOPMENT, V124, P3303; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; PULIDO R, 1995, P NATL ACAD SCI USA, V92, P11686, DOI 10.1073/pnas.92.25.11686; Sammar M, 1997, BBA-PROTEIN STRUCT M, V1337, P287, DOI 10.1016/S0167-4838(96)00177-X; Shewan D, 1996, J NEUROSCI, V16, P2624; Soussi-Yanicostas N, 1998, J CELL SCI, V111, P2953; TANNAHILL L, 1995, EUR J NEUROSCI, V7, P1424, DOI 10.1111/j.1460-9568.1995.tb01136.x; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; WENGER RH, 1995, TRANSGENIC RES, V4, P173, DOI 10.1007/BF01968782	37	113	113	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21656	21663		10.1074/jbc.M101790200	http://dx.doi.org/10.1074/jbc.M101790200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283023	hybrid			2022-12-25	WOS:000169297900114
J	Paria, BC; Song, H; Wang, X; Schmid, PC; Krebsbach, RJ; Schmid, HHO; Bonner, TI; Zimmer, A; Dey, SK				Paria, BC; Song, H; Wang, X; Schmid, PC; Krebsbach, RJ; Schmid, HHO; Bonner, TI; Zimmer, A; Dey, SK			Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREIMPLANTATION MOUSE EMBRYO; LEUKEMIA INHIBITORY FACTOR; BLASTOCYST IMPLANTATION; CB1 RECEPTOR; UTERUS; EXPRESSION; ANANDAMIDE; PHARMACOLOGY; ACTIVATION; BINDS	The mechanisms by which synchronized embryonic development to the blastocyst stage, preparation of the uterus for the receptive state, and reciprocal embryo-uterine interactions for implantation are coordinated are still unclear. We show in this study that preimplantation embryo development became asynchronous in mice that are deficient in brain-type (CB1) and/or spleen-type (CB2) cannabinoid receptor genes. Furthermore, whereas the levels of uterine anandamide (endocannabinoid) and blastocyst CB1 are coordinately down-regulated with the onset of uterine receptivity and blastocyst activation prior to implantation, these levels remained high in the nonreceptive uterus and in dormant blastocysts during delayed implantation and in pregnant, leukemia inhibitory factor (LIF)-deficient mice with implantation failure. These results suggest that a tight regulation of endocannabinoid signaling is important for synchronizing embryo development with uterine receptivity for implantation. Indeed this is consistent with our finding that while an experimentally induced, sustained level of an exogenously administered, natural cannabinoid inhibited implantation in wild-type mice, it failed to do so in CB1(-/-)/CB2(-/-) double mutant mice. The present study is clinically important because of the widely debated medicinal use of cannabinoids and their reported adverse effects on pregnancy.	Univ Kansas, Med Ctr, Ralph L Smith Res Ctr, Dept Mol & Intergrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pediat, Kansas City, KS 66160 USA; Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; NIMH, Genet Lab, Bethesda, MD 20892 USA; Univ Bonn, Psychiat Clin, Mol Neurobiol Lab, D-53105 Bonn, Germany	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Minnesota System; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of Bonn	Dey, SK (corresponding author), Univ Kansas, Med Ctr, Ralph L Smith Res Ctr, Dept Mol & Intergrat Physiol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.		Zimmer, Andreas/B-8357-2009	Song, Haengseok/0000-0002-5027-7310	NICHD NIH HHS [HD 1 2304, HD 37394, HD 33994, HD 02528, HD 29968] Funding Source: Medline; NIDA NIH HHS [DA 06668] Funding Source: Medline; NIGMS NIH HHS [GM 45741] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD002528] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD012304, R01HD037394, R37HD012304, U01HD029968] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006668, R37DA006668] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BHATT H, 1991, P NATL ACAD SCI USA, V88, P11408, DOI 10.1073/pnas.88.24.11408; BOUABOULA M, 1995, BIOCHEM J, V312, P637, DOI 10.1042/bj3120637; Calignano A, 2000, NATURE, V408, P96, DOI 10.1038/35040576; DAS SK, 1995, P NATL ACAD SCI USA, V92, P4332, DOI 10.1073/pnas.92.10.4332; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; FELDER CC, 1992, MOL PHARMACOL, V42, P838; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; HOWLETT AC, 1995, ANNU REV PHARMACOL, V35, P607, DOI 10.1146/annurev.pharmtox.35.1.607; Maccarrone M, 2000, LANCET, V355, P1326, DOI 10.1016/S0140-6736(00)02115-2; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; PARIA BC, 1995, P NATL ACAD SCI USA, V92, P9460, DOI 10.1073/pnas.92.21.9460; Paria BC, 1996, MOL REPROD DEV, V45, P183, DOI 10.1002/(SICI)1098-2795(199610)45:2&lt;183::AID-MRD11&gt;3.0.CO;2-2; Paria BC, 1998, BIOL REPROD, V58, P1490, DOI 10.1095/biolreprod58.6.1490; PARIA BC, 1993, P NATL ACAD SCI USA, V90, P10159, DOI 10.1073/pnas.90.21.10159; Paria BC, 1999, MARIHUANA AND MEDICINE, P393; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; PSYCHOYOS A, 1973, HDB PHYSL, P187; Schmid PC, 1997, P NATL ACAD SCI USA, V94, P4188, DOI 10.1073/pnas.94.8.4188; Schmid PC, 2000, CHEM PHYS LIPIDS, V104, P185, DOI 10.1016/S0009-3084(99)00124-3; Song HS, 2000, MOL ENDOCRINOL, V14, P1147, DOI 10.1210/me.14.8.1147; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sulcova E, 1998, PHARMACOL BIOCHEM BE, V59, P347, DOI 10.1016/S0091-3057(97)00422-X; Wang J, 1999, BIOL REPROD, V60, P839, DOI 10.1095/biolreprod60.4.839; Yang ZM, 1996, BIOL REPROD, V55, P756, DOI 10.1095/biolreprod55.4.756; Yoshinaga K., 1980, PROGR REPRODUCTIVE B, V7, P189; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	30	148	154	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20523	20528		10.1074/jbc.M100679200	http://dx.doi.org/10.1074/jbc.M100679200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279117	hybrid			2022-12-25	WOS:000169135100114
J	Ho, MWY; Kaetzel, MA; Armstrong, DL; Shears, SB				Ho, MWY; Kaetzel, MA; Armstrong, DL; Shears, SB			Regulation of a human chloride channel - A paradigm for integrating input from calcium, type II calmodulin-dependent protein kinase, and inositol 3,4,5,6-tetrakisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+-DEPENDENT CL CHANNELS; COLONIC CELLS HT-29; CYSTIC-FIBROSIS; CAM KINASE; INS(3,4,5,6)P-4; CONDUCTANCE; ACTIVATION; CLONING; LINE; CA2+	We have studied the regulation of Ca2+-dependent chloride (Cl-Ca) channels in a human pancreatoma epithelial cell line (CFPAC-1), which does not express functional cAMP-dependent cystic fibrosis transmembrane conductance regulator chloride channels. In cell-free patches from these cells, physiological Ca2+ concentrations activated a single class of 1-picosiemens Cl--selective channels. The same channels were also stimulated by a purified type II calmodulin-dependent protein kinase (CaMKII), and in cell-attached patches by purinergic agonists. In whole-cell recordings, both Ca2+- and CaMKII-dependent mechanisms contributed to chloride channel stimulation by Ca2+, but the CaMKII-dependent pathway was selectively inhibited by inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4). This inhibitory effect of Ins(3,4,5,6)P, on Cl-Ca channel stimulation by CaMKII was reduced by raising [Ca2+] and prevented by inhibition of protein phosphatase activity with 100 nM okadaic acid. These data provide a new context for understanding the physiological relevance of Ins(3,4,5,6)P, in the longer term regulation of Ca2+-dependent Cl- fluxes in epithelial cells.	NIEHS, Inositide Signaling Grp, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Membrane Signaling Grp, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; Univ Cincinnati, Coll Med, Dept Cellular & Mol Physiol, Cincinnati, OH 45267 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Cincinnati	Ho, MWY (corresponding author), NIEHS, Inositide Signaling Grp, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080043, ZIAES080043, ZIAES080046, Z01ES080046] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46433] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arreola J, 1996, J PHYSIOL-LONDON, V490, P351, DOI 10.1113/jphysiol.1996.sp021149; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1796, DOI 10.1164/ajrccm.153.6.8665037; BEVAN S, 1984, PROC R SOC SER B-BIO, V222, P349, DOI 10.1098/rspb.1984.0068; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Carew MA, 2000, J BIOL CHEM, V275, P26906; CHAN HC, 1994, J BIOL CHEM, V269, P32464; Collier ML, 1996, CIRC RES, V78, P936, DOI 10.1161/01.RES.78.5.936; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Devor DC, 1996, AM J PHYSIOL-LUNG C, V271, pL785, DOI 10.1152/ajplung.1996.271.5.L785; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Fuller CM, 2000, CLIN EXP PHARMACOL P, V27, P906, DOI 10.1046/j.1440-1681.2000.03359.x; FULLER CM, 1994, J BIOL CHEM, V269, P26642; Gotter AL, 1997, COMP BIOCHEM PHYS A, V118, P81, DOI 10.1016/S0300-9629(96)00411-2; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; Ho MWY, 1997, AM J PHYSIOL-CELL PH, V272, pC1160, DOI 10.1152/ajpcell.1997.272.4.C1160; HO MWY, 2000, FRONTIERS MOL BIOL B, P298; Ismailov II, 1996, P NATL ACAD SCI USA, V93, P10505, DOI 10.1073/pnas.93.19.10505; Kidd JF, 2000, ANNU REV PHYSIOL, V62, P493, DOI 10.1146/annurev.physiol.62.1.493; Kotlikoff MI, 1998, AM J RESP CRIT CARE, V158, pS109, DOI 10.1164/ajrccm.158.supplement_2.13tac600; LING BN, 1993, J CLIN INVEST, V92, P2141, DOI 10.1172/JCI116815; MORRIS AP, 1993, AM J PHYSIOL, V264, pC968, DOI 10.1152/ajpcell.1993.264.4.C968; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; Schlenker T, 1996, AM J PHYSIOL-GASTR L, V271, pG304, DOI 10.1152/ajpgi.1996.271.2.G304; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SINGH AK, 1991, AM J PHYSIOL, V260, pC51; TALEB O, 1988, PFLUG ARCH EUR J PHY, V412, P641, DOI 10.1007/BF00583766; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WELSH N, 1988, BIOCHEM J, V252, P701, DOI 10.1042/bj2520701; Xie WW, 1998, J PHYSIOL-LONDON, V510, P661, DOI 10.1111/j.1469-7793.1998.661bj.x; Xie WW, 1996, J BIOL CHEM, V271, P14092, DOI 10.1074/jbc.271.24.14092; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551	37	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18673	18680		10.1074/jbc.M101128200	http://dx.doi.org/10.1074/jbc.M101128200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279175	hybrid			2022-12-25	WOS:000169091000005
J	Kojima, H; Nemoto, A; Uemura, T; Honma, R; Ogura, M; Liu, YK				Kojima, H; Nemoto, A; Uemura, T; Honma, R; Ogura, M; Liu, YK			rDRAK1, a novel kinase related to apoptosis, is strongly expressed in active osteoclasts and induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; BONE-RESORBING ACTIVITY; MATURE OSTEOCLASTS; IN-VITRO; INHIBITORY FACTOR; SERINE/THREONINE KINASE; MEVALONATE PATHWAY; PROTEIN-KINASE; BISPHOSPHONATES INHIBIT; OSTEOPROTEGERIN LIGAND	This is the first report of a novel serine/threonine kinase, rabbit death-associated protein (DAP) kinase-related apoptosis-inducing protein kinase 1 (rDRAK1), involved in osteoclast apoptosis, We searched for osteoclast-specific genes from a cDNA library of highly enriched rabbit osteoclasts cultured on ivory. One of the cloned genes has a high homology with human DRAK1 (hDRAK1), which belongs to the DAP kinase subfamily of serine/threonine kinases, By screening a rabbit osteoclast cDNA library and 5 ' -RACE (rapid amplification of cDNA ends), we obtained a full length of this cDNA, termed rDRAK1. The sequencing data indicated that rDRAK1 has 88.0, 44.6, 38.7, and 42.3% identity with hDRAK1, DAP kinase, DRP-1, and ZIP (zipper-interacting protein) kinase, respectively. To clarify the role of DRAK1 in osteoclasts, we examined the effect of three osteoclast survival factors (interleukin-l, macrophage colony-stimulating factor, and osteoclast differentiation-inducing factor) on rDRAK1 mRNA expression and the effect of rDRAK1 overexpression on osteoclast apoptosis, The results suggested that these three survival factors were proved to inhibit rDRAK1 expression in rabbit osteoclasts. After transfection of a rDRAK1 expression vector into cultured osteoclasts, overexpressed rDRAK1 was localized exclusively to the nuclei and induced apoptosis, Hence, rDRAK1 may play an important role in the core apoptosis program in osteoclast.	Natl Inst Adv Ind Sci & Technol, Tissue Engn Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Med, Dept Biomed Engn, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Shanghai Med Univ, Liver Canc Inst, Shanghai 200032, Peoples R China	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); University of Tokyo; University of Tsukuba; Fudan University	Uemura, T (corresponding author), Natl Inst Adv Ind Sci & Technol, Tissue Engn Res Ctr, 1-1-1 Higashi, Tsukuba, Ibaraki 3058562, Japan.							Akatsu T, 1998, BIOCHEM BIOPH RES CO, V250, P229, DOI 10.1006/bbrc.1998.9294; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Boissier S, 2000, CANCER RES, V60, P2949; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; Haertel-Wiesmann M, 2000, J BIOL CHEM, V275, P32046, DOI 10.1074/jbc.M000074200; Hiroi-Furuya E, 1999, CALCIFIED TISSUE INT, V64, P219, DOI 10.1007/s002239900606; HUGHES DE, 1995, J BONE MINER RES, V10, P1478; Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096-1132; Inbal B, 2000, MOL CELL BIOL, V20, P1044, DOI 10.1128/MCB.20.3.1044-1054.2000; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320; Kakudo S, 1996, J BONE MINER METAB, V14, P129, DOI [10.1007/BF02239480, DOI 10.1007/BF02239480]; KAMEDA T, 1995, BIOCHEM BIOPH RES CO, V207, P753, DOI 10.1006/bbrc.1995.1251; Kameda T, 1998, BIOCHEM BIOPH RES CO, V245, P419, DOI 10.1006/bbrc.1998.8448; Kameda T, 1997, J EXP MED, V186, P489, DOI 10.1084/jem.186.4.489; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Kobayashi Y, 2000, J BONE MINER RES, V15, P1924, DOI 10.1359/jbmr.2000.15.10.1924; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; Mano H, 2000, J BIOL CHEM, V275, P8126, DOI 10.1074/jbc.275.11.8126; Mano M, 2000, CALCIFIED TISSUE INT, V67, P85, DOI 10.1007/s00223001102; Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335; Murakami T, 1998, BIOCHEM BIOPH RES CO, V252, P747, DOI 10.1006/bbrc.1998.9723; Murata-Hori M, 1999, FEBS LETT, V451, P81, DOI 10.1016/S0014-5793(99)00550-5; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Okahashi N, 1998, BONE, V23, P33, DOI 10.1016/S8756-3282(98)00069-6; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Sakai H, 2000, BIOCHEM BIOPH RES CO, V270, P550, DOI 10.1006/bbrc.2000.2485; SALENDAR KS, 1996, MOL PHARMACOL, V50, P1127; Sanjo H, 1998, J BIOL CHEM, V273, P29066, DOI 10.1074/jbc.273.44.29066; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; SUDA T, 1995, ENDOCRINE REV MONOGR, V4, P266; Suda Tatsuo, 1996, P87; Tsuda E, 1997, BIOCHEM BIOPH RES CO, V234, P137, DOI 10.1006/bbrc.1997.6603; UEMURA T, 2000, 27 EUR S CALC TISS T, V66, pS103; Vaananen HK, 1998, MAT SCI ENG C-BIO S, V6, P205, DOI 10.1016/S0928-4931(98)00052-6; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Yasuda H, 1998, ENDOCRINOLOGY, V139, P1329, DOI 10.1210/en.139.3.1329; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U; Zaidi M, 1999, J BONE MINER RES, V14, P669, DOI 10.1359/jbmr.1999.14.5.669; [No title captured]	52	14	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19238	19243		10.1074/jbc.M101023200	http://dx.doi.org/10.1074/jbc.M101023200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279167	hybrid			2022-12-25	WOS:000169091000081
J	Oakley, RH; Laporte, SA; Holt, JA; Barak, LS; Caron, MG				Oakley, RH; Laporte, SA; Holt, JA; Barak, LS; Caron, MG			Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE PHOSPHORYLATION SITES; GREEN FLUORESCENT PROTEIN; SUBSTANCE-P RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; DEPENDENT ENDOCYTOSIS; ACTIVATED RECEPTOR-2; MEDIATED ENDOCYTOSIS; CLATHRIN ADAPTER; VISUAL ARRESTIN; INTERNALIZATION	beta -Arrestins bind agonist-activated G protein-coupled receptors (GPCRs) and mediate their desensitization and internalization. Although beta -arrestins dissociate from some receptors at the plasma membrane, such as the beta2 adrenergic receptor, they remain associated with other GPCRs and internalize with them into endocytic vesicles. Formation of stable receptor-beta -arrestin complexes that persist inside the cell impedes receptor resensitization, and the aberrant formation of these complexes may play a role in GPCR-based diseases (Barak, L, S., Oakley, R, H,, Laporte, S. A., and Caron, M. G. (2001) Proc. Natl. Acad, Sci, U, S, A. 98, 93-98), Here, we investigate the molecular determinants responsible for sustained receptor/beta -arrestin interactions. We show in real time and in live human embryonic kidney (HEK-293) cells that a beta -arrestin-2-green fluorescent protein conjugate internalizes into endocytic vesicles with agonist-activated neurotensin-1 receptor, oxytocin receptor, angiotensin II type 1A receptor, and substance P receptor. Using receptor mutagenesis, we demonstrate that the ability of beta -arrestin to remain associated with these receptors is mediated by specific clusters of serine and threonine residues located in the receptor carboxyl-terminal tail. These clusters are remarkably conserved in their position within the carboxyl-terminal domain and serve as primary sites of agonist-dependent receptor phosphorylation. In addition, we identify a beta -arrestin mutant with enhanced affinity for the agonist-activated beta -adrenergic receptor that traffics into endocytic vesicles with receptors that lack serine/threonine clusters and normally dissociate from wild-type beta -arrestin at the plasma membrane, By identifying receptor and beta -arrestin residues critical for the formation of stable receptor-beta -arrestin complexes, these studies provide novel targets for regulating GPCR responsiveness and treating diseases resulting from abnormal GPCR/beta -arrestin interactions.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3287, Durham, NC 27710 USA.		Laporte, Stephane A/F-3282-2012; Laporte, Stephane/ABC-4228-2021	Laporte, Stephane/0000-0002-0633-543X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019576] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 61365] Funding Source: Medline; NINDS NIH HHS [NS 19576] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Botto JM, 1998, BIOCHEM BIOPH RES CO, V243, P585, DOI 10.1006/bbrc.1997.8071; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krueger KM, 1997, J BIOL CHEM, V272, P5; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McConalogue K, 1999, J BIOL CHEM, V274, P16257, DOI 10.1074/jbc.274.23.16257; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; Roush ED, 1999, MOL PHARMACOL, V55, P855; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; VIGNA SR, 1994, J NEUROSCI, V14, P834; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Walker JKL, 1999, J BIOL CHEM, V274, P31515, DOI 10.1074/jbc.274.44.31515; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1999, J BIOL CHEM, V274, P10999, DOI 10.1074/jbc.274.16.10999; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	44	346	363	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19452	19460		10.1074/jbc.M101450200	http://dx.doi.org/10.1074/jbc.M101450200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279203	hybrid			2022-12-25	WOS:000169091000107
J	Dermine, JF; Duclos, S; Garin, J; St-Louis, F; Rea, S; Parton, RG; Desjardins, M				Dermine, JF; Duclos, S; Garin, J; St-Louis, F; Rea, S; Parton, RG; Desjardins, M			Flotillin-1-enriched lipid raft domains accumulate on maturing phagosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; LEISHMANIA-DONOVANI; FUSION PROPERTIES; PLASMA-MEMBRANE; MACROPHAGES; CAVEOLAE; LIPOPHOSPHOGLYCAN; CELLS; PHAGOLYSOSOMES; PHAGOCYTOSIS	Flotillin-1 was recently shown to be enriched on detergent-resistant domains of the plasma membrane called lipid rafts. These rafts, enriched in sphingolipids and cholesterol, sequester certain proteins while excluding others. Lipid rafts have been implicated in numerous cellular processes including signal transduction, membrane trafficking and molecular sorting. In this study, we demonstrate both morphologically and biochemically that lipid rafts are present on phagosomes, These structures are enriched in flotillin-1 and devoid of the main phagosomes membrane protein lysosomal-associated membrane protein (LAMP1), The flotillin-1 present on phagosomes does not originate from the plasma membrane during phagocytosis but accumulates gradually on maturing phagosomes, Treatment with bafilomycin A1, a compound that inhibits the proton pump ATPase and prevents the fusion of phagosomes with late endocytic organelles, prevents the acquisition of flotillin-1 by phagosomes, indicating that this protein might be recruited on phagosomes from endosomal organelles. A proteomic characterization of the lipid rafts of phagosomes indicates that actin, the alpha- and beta -subunits of heterotrimeric G proteins, as well as subunits of the proton pump V-ATPase are among the constituents of these domains. Remarkably, the intracellular parasite Leishmania donovani can actively inhibit the acquisition of flotillin-1-enriched lipid rafts by phagosomes and the maturation of these organelles. These results indicate that specialized functions required for phagolysosome biogenesis may occur at focal points on the phagosome membrane, and therefore represent a potential target of intracellular pathogens.	Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada; CEA, Lab Chim Prot, F-38054 Grenoble, France; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, Brisbane, Qld 4072, Australia	Universite de Montreal; CEA; University of Queensland; University of Queensland	Desjardins, M (corresponding author), Univ Montreal, Dept Pathol & Biol Cellulaire, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Rea, Shane/F-4073-2014; Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; Desjardins, Michel/0000-0002-5684-5980				Allen LAH, 1996, J EXP MED, V184, P627, DOI 10.1084/jem.184.2.627; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BERTHIAUME EP, 1995, J CELL BIOL, V129, P989, DOI 10.1083/jcb.129.4.989; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; Dermine JF, 2000, CELL MICROBIOL, V2, P115, DOI 10.1046/j.1462-5822.2000.00037.x; Desjardins M, 1997, J CELL SCI, V110, P2303; DESJARDINS M, 1995, TRENDS CELL BIOL, V5, P183, DOI 10.1016/S0962-8924(00)88989-8; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DESJARDINS M, 1997, J EXP MED, V185, P206; Duclos S, 2000, J CELL SCI, V113, P3531; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; MIAO L, 1995, BIOCHEMISTRY-US, V34, P4676, DOI 10.1021/bi00014a022; NANAVATI C, 1992, BIOPHYS J, V63, P1118, DOI 10.1016/S0006-3495(92)81679-X; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Pasquali C, 1997, ELECTROPHORESIS, V18, P2573, DOI 10.1002/elps.1150181413; Roberts RL, 1999, J CELL SCI, V112, P3667; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Snyers L, 1999, EUR J CELL BIOL, V78, P802, DOI 10.1016/S0171-9335(99)80031-4; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; TERASHIMA M, 1994, EMBO J, V13, P3782, DOI 10.1002/j.1460-2075.1994.tb06689.x; TOLSON DL, 1989, MOL BIOCHEM PARASIT, V35, P109, DOI 10.1016/0166-6851(89)90113-8; WANG YL, 1987, J CELL BIOL, V104, P1749, DOI 10.1083/jcb.104.6.1749; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	41	248	255	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18507	18512		10.1074/jbc.M101113200	http://dx.doi.org/10.1074/jbc.M101113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279173	hybrid			2022-12-25	WOS:000168866500119
J	Mikhailov, V; Mikhailova, M; Pulkrabek, DJ; Dong, Z; Venkatachalam, MA; Saikumar, P				Mikhailov, V; Mikhailova, M; Pulkrabek, DJ; Dong, Z; Venkatachalam, MA; Saikumar, P			Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CHANNEL-FORMING ACTIVITY; PERMEABILITY TRANSITION; FAMILY PROTEINS; APOPTOSIS; TRANSLOCATION; ACTIVATION; BCL-X(L); CYTOSOL; DEATH	ATP depletion results in Bax translocation from cytosol to mitochondria and release of cytochrome c from mitochondria into cytosol in cultured kidney cells. Overexpression of Bcl-2 prevents cytochrome c release, without ameliorating ATP depletion or Bax translocation, with little or no association between Bcl-2 and Bax as demonstrated by immunoprecipitation (Saikumar, P,, Dong, Z,, Patel, Y,, Hall, K,, Hopfer, U,, Weinberg, J, M,, and Venkatachalam, M, A. (1998) Oncogene 17, 3401-3415). Now we show that translocated Bax forms homooligomeric structures, stabilized as chemical adducts by bifunctional cross-linkers in ATP-depleted wild type cells, but remains monomeric in Bcl-2-overexpressing cells. The protective effects of Bcl-2 did not require Bcl-2/Bax association, at least to a degree of proximity or affinity that was stable to conditions of immunoprecipitation or adduct formation by eight cross-linkers of diverse spacer lengths and chemical reactivities. On the other hand, nonionic detergents readily induced homodimers and heterodimers of Bax and Bcl-2, Moreover, associations between translocated Bax and the voltage-dependent anion channel protein or the adenine nucleotide translocator protein could not be demonstrated by immunoprecipitation of Bax, or by using bifunctional cross-linkers. Our data suggest that the in vivo actions of Bax are at least in part dependent on the formation of homo-oligomers without requiring associations with other molecules and that Bcl-2 cytoprotection involves mechanisms that prevent Bax oligomerization.	Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Saikumar, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pathol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037139, R01DK054472, R37DK037139] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37139, DK54472] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cregan SP, 1999, J NEUROSCI, V19, P7860; DURAN MA, 1990, TOXICOL APPL PHARM, V105, P183, DOI 10.1016/0041-008X(90)90180-3; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Haldar S, 1996, CANCER RES, V56, P1253; Hengartner MO, 1999, RECENT PROG HORM RES, V54, P213; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Nissim I, 1996, KIDNEY INT, V49, P684, DOI 10.1038/ki.1996.97; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X; Saikumar P, 1998, ONCOGENE, V17, P3401, DOI 10.1038/sj.onc.1202590; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VENKATACHALAM MA, 1993, SURVIVING HYPOXIA, P473; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482	43	270	292	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18361	18374		10.1074/jbc.M100655200	http://dx.doi.org/10.1074/jbc.M100655200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279112	hybrid			2022-12-25	WOS:000168866500100
J	Dong, JF; Ye, P; Schade, AJ; Gao, S; Romo, GM; Turner, NT; McIntire, LV; Lopez, JA				Dong, JF; Ye, P; Schade, AJ; Gao, S; Romo, GM; Turner, NT; McIntire, LV; Lopez, JA			Tyrosine sulfation of glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; HUMAN-PLATELET MEMBRANE; IX-V COMPLEX; AMINO-ACID-SEQUENCE; VONWILLEBRAND-FACTOR; P-SELECTIN; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; THROMBIN-BINDING; 4TH COMPONENT	Glycoprotein Ib alpha (GP Ib alpha), the ligand binding subunit of the platelet glycoprotein Ib-M-V complex, is sulfated on three tyrosine residues (Tyr-276, Tyr-278, and Tyr-279). This posttranslational modification is known to be critical for von Willebrand factor (VWF) binding; yet it remains unclear whether it provides a specific structure or merely contributes negative charges. To investigate this issue, we constructed cell lines expressing GP Ib alpha polypeptides with the three tyrosine residues converted to either Glu or Phe and studied the ability of these mutants to bind vWF in the presence of modulators or shear stress. The mutants were expressed normally on the cell surface as GP m-M complexes, with the conformation of the ligand-binding domain preserved, as judged by the binding of conformation-sensitive monoclonal antibodies. In contrast to their normal expression, both mutants were functionally abnormal. Cells expressing the Phe mutant failed to bind vWF in the presence of either ristocetin or botrocetin. These cells adhered to and rolled on immobilized vWF only when their surface receptor density was increased to twice the level that supported adhesion of cells expressing the wild-type receptor and even then only 20% as many rolled and rolled significantly faster than wild-type cells. Cells expressing the Glu mutant, on the other hand, were normal with respect to ristocetin-induced vWF binding and adhesion to immobilized VWF but were markedly defective in botrocetin-induced vWF binding. These results indicate that GP Ib alpha tyrosine sulfation influences the interaction of this polypeptide with vWF primarily by contributing negative charges under physiological conditions and when the interaction is induced by ristocetin but contributes a specific structure to the botrocetin-induced interaction.	Baylor Coll Med, Dept Med, Thrombosis Res Sect, Div Thrombosis Res, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Rice Univ, Cox Lab Bioengn, Houston, TX 77005 USA	Baylor College of Medicine; Baylor College of Medicine; Rice University	Lopez, JA (corresponding author), Baylor Coll Med, Dept Med, Thrombosis Res Sect, Div Thrombosis Res, BCM286,N1319,1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002463, R29HL046416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02463, HL46416, HL18673] Funding Source: Medline; NINDS NIH HHS [NS23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; CARDELLI JA, 1990, J BIOL CHEM, V265, P8847; CAREW JA, 1990, BLOOD, V76, P2530; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; HAN KK, 1992, INT J BIOCHEM, V24, P1349, DOI 10.1016/0020-711X(92)90060-E; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HORTIN G, 1986, J BIOL CHEM, V261, P1786; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HORTIN GL, 1990, BLOOD, V76, P946; HUTTNER WB, 1987, TRENDS BIOCHEM SCI, V12, P361, DOI 10.1016/0968-0004(87)90166-6; JONES DA, 1993, BIOPHYS J, V65, P1560, DOI 10.1016/S0006-3495(93)81195-0; Kukreti S, 1997, BLOOD, V89, P4104, DOI 10.1182/blood.V89.11.4104; LANZA F, 1993, J BIOL CHEM, V268, P20801; LEYTE A, 1991, J BIOL CHEM, V266, P740; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Lopez J A, 1997, Curr Opin Hematol, V4, P323; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MILLER JL, 1983, J CLIN INVEST, V72, P1532, DOI 10.1172/JCI111112; Romo GM, 1999, J EXP MED, V190, P803, DOI 10.1084/jem.190.6.803; RUAN C, 1981, BRIT J HAEMATOL, V49, P511, DOI 10.1111/j.1365-2141.1981.tb07259.x; RUAN CG, 1987, BLOOD, V69, P570; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Simon DI, 2000, J EXP MED, V192, P193, DOI 10.1084/jem.192.2.193; SLACK SM, 1994, THROMB HAEMOSTASIS, V72, P777; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; TITANI K, 1987, P NATL ACAD SCI USA, V84, P5610, DOI 10.1073/pnas.84.16.5610; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; YAMAMOTO K, 1986, THROMB HAEMOSTASIS, V55, P162	40	44	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16690	16694		10.1074/jbc.M101035200	http://dx.doi.org/10.1074/jbc.M101035200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279169	hybrid			2022-12-25	WOS:000168730400015
J	Angata, K; Yen, TY; El-Battari, A; Macher, BA; Fukuda, M				Angata, K; Yen, TY; El-Battari, A; Macher, BA; Fukuda, M			Unique disulfide bond structures found in ST8Sia IV polysialyltransferase are required for its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DEVELOPMENTALLY-REGULATED MEMBER; POLYSIALIC ACID; SYNAPTIC PLASTICITY; CYSTEINE RESIDUES; 2 POLYSIALYLTRANSFERASES; EXPRESSION CLONING; CATALYTIC DOMAIN; OLFACTORY-BULB; NERVOUS-SYSTEM	NCAM polysialylation plays a critical role in neuronal development and regeneration, Polysialylation of the neural cell adhesion molecule (NCAM) is catalyzed by two polysialyltransferases, ST8Sia II (STX) and ST8Sia IV (PST), which contain sialylmotifs L and S conserved in all members of the sialyltransferases. The members of the ST8Sia gene family, including ST8Sia II and ST8Sia IV are unique in having three cysteines in sialylmotif L, one cysteine in sialylmotif S, and one cysteine at the COOH terminus. However, structural information, including how disulfide bonds are formed, has not been determined for any of the sialyltransferases, To obtain insight into the structure/function of ST8Sia IV, we expressed human ST8Sia IV in insect cells, Trichoplusia ni, and found that the enzyme produced in the insect cells catalyzes NCAM polysialylation, although it cannot polysialylate itself ("autopolysialylation"). We also found that ST8Sia IV does not form a dimer through disulfide bonds. By using the same enzyme preparation and performing mass spectrometric analysis, we found that the first cysteine in sialylmotif L and the cysteine in sialylmotif S form a disulfide bridge, whereas the second cysteine in sialylmotif L and the cysteine at the COOH terminus form a second disulfide bridge, Site-directed mutagenesis demonstrated that mutation at cysteine residues involved in the disulfide bridges completely inactivated the enzyme, Moreover, changes in the position of the COOH-terminal cysteine abolished its activity. By contrast, the addition of green fluorescence protein at the COOH terminus of ST8Sia IV did not render the enzyme inactive. These results combined indicate that the sterical structure formed by intramolecular disulfide bonds, which bring the sialylmotifs and the COOH terminus within close proximity, is critical for the catalytic activity of ST8Sia IV.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA; Fac Med Marseille, INSERM, U260, F-13385 Marseille 5, France	Sanford Burnham Prebys Medical Discovery Institute; California State University System; San Francisco State University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	minoru@burnham.org	Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NCI NIH HHS [R01 CA33895] Funding Source: Medline; NCRR NIH HHS [P20 RR11805] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011805] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; BIEMANN K, 1990, METHOD ENZYMOL, V193, P886, DOI 10.1016/0076-6879(90)93460-3; Chen C, 2000, J BIOL CHEM, V275, P13819, DOI 10.1074/jbc.275.18.13819; CHUNG WW, 1991, J COMP NEUROL, V314, P290, DOI 10.1002/cne.903140207; Close BE, 2000, J BIOL CHEM, V275, P4484, DOI 10.1074/jbc.275.6.4484; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDELMAN GM, 1984, ANNU REV NEUROSCI, V7, P339; Fambrough D, 1996, CELL, V87, P1049, DOI 10.1016/S0092-8674(00)81799-7; FINNE J, 1982, J BIOL CHEM, V257, P1966; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; Hildebrandt H, 1998, CANCER RES, V58, P779; Hildebrandt H, 1998, J NEUROCHEM, V71, P2339; Holmes EH, 2000, J BIOL CHEM, V275, P24237, DOI 10.1074/jbc.M000888200; Hsu TA, 1997, J BIOL CHEM, V272, P9062; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; Kono M, 1996, J BIOL CHEM, V271, P29366, DOI 10.1074/jbc.271.46.29366; Korczak B, 2000, GLYCOBIOLOGY, V10, P595, DOI 10.1093/glycob/10.6.595; Li JH, 2000, J BIOL CHEM, V275, P41476, DOI 10.1074/jbc.M007480200; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Muhlenhoff M, 1996, EMBO J, V15, P6943, DOI 10.1002/j.1460-2075.1996.tb01086.x; Muhlenhoff M, 1996, CURR BIOL, V6, P1188, DOI 10.1016/S0960-9822(02)70687-8; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; Ong E, 1998, GLYCOBIOLOGY, V8, P415, DOI 10.1093/glycob/8.4.415; Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; ROBBINS JB, 1974, NEW ENGL J MED, V290, P1216, DOI 10.1056/NEJM197405302902202; ROTH J, 1988, P NATL ACAD SCI USA, V85, P2999, DOI 10.1073/pnas.85.9.2999; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SCHEIDEGGER EP, 1994, LAB INVEST, V70, P95; SEKI T, 1993, NEUROSCI RES, V17, P265, DOI 10.1016/0168-0102(93)90111-3; Sevigny MB, 1998, GLYCOBIOLOGY, V8, P857, DOI 10.1093/glycob/8.9.857; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; Tanaka F, 2000, CANCER RES, V60, P3072; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; Windfuhr M, 2000, J BIOL CHEM, V275, P32861, DOI 10.1074/jbc.M003507200; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	58	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15369	15377		10.1074/jbc.M100576200	http://dx.doi.org/10.1074/jbc.M100576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279095	hybrid			2022-12-25	WOS:000168528800112
J	Horino, K; Kindezelskii, AL; Elner, VM; Hughes, BA; Petty, HR				Horino, K; Kindezelskii, AL; Elner, VM; Hughes, BA; Petty, HR			Tumor cell invasion of model 3-dimensional matrices: demonstration of migratory pathways, collagen disruption, and intercellular cooperation	FASEB JOURNAL			English	Article						transmigration; metalloproteinase; HT1080 cells; T-47D cells; gelatin-nylon mesh matrix	PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; INVITRO ASSAY; METALLOPROTEINASES; METASTASIS; UROKINASE; PROTEOLYSIS; PROTEASE; RECEPTOR	We report a novel 3-dimensional model for visualizing tumor cell migration across a nylon mesh-supported gelatin matrix. To visualize migration across these model barriers, cell proteolytic activity of the pericellular matrix was detected using Bodipy-BSA (fluorescent upon proteolysis) and DQ (TM) collagen (fluorescent upon collagenase activity). For 3-dimensional image reconstruction, multiple optical images at sequential z axis positions were deconvoluted by computer analysis. Specificity was indicated using well known inhibitors. Using these fluorescent proteolysis markers and imaging methods, we have directly demonstrated proteolytic and collagenolytic activity during tumor cell invasion. Moreover, it is possible to visualize migratory pathways followed by tumor cells during matrix invasion. Using cells of differing invasive potentials (uPAR-negative T-47D wild-type and uPAR-positive T-47D A2-1 cells), we show that the presence of the T47D-A2-1 cells facilitates the entry of T-47D wild-type cells into the matrix. In some cases, wild-type cells follow T-47D A2-1 cells into the matrix whereas other T-47D-wild-type cells appear to enter without the direct intervention of T-47D AZ-l cells. Thus, we have developed a new 3-dimensional model of tumor cell invasion, demonstrated protein and collagen disruption, mapped the pathways followed by tumor cells during migration through an extracellular matrix, and illustrated cross-talk among tumor cell populations during invasion.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA; Univ Michigan, Dept Ophthalmol, Ann Arbor, MI USA	Wayne State University; University of Michigan System; University of Michigan	Petty, HR (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.	hpetty@biology.biosci.wayne.edu		Hughes, Bret/0000-0002-6913-4467; Elner, Victor/0000-0001-7708-1898	NEI NIH HHS [EY09441, EY007003] Funding Source: Medline; NIAID NIH HHS [AI27409] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027409] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBINI A, 1987, CANCER RES, V47, P3239; BARAMOVA E, 1995, CELL BIOL INT, V19, P239; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; ERKELL LJ, 1988, CANCER RES, V48, P6933; Garbett EA, 1999, BRIT J CANCER, V81, P287, DOI 10.1038/sj.bjc.6690689; GOLDBERG GI, 1990, ANN NY ACAD SCI, V580, P375, DOI 10.1111/j.1749-6632.1990.tb17945.x; HADDOX JL, 1991, J IMMUNOL METHODS, V141, P41, DOI 10.1016/0022-1759(91)90208-W; Kennedy S, 1998, BRIT J CANCER, V77, P1638, DOI 10.1038/bjc.1998.268; Kindzelskii AL, 2000, J IMMUNOL, V164, P953, DOI 10.4049/jimmunol.164.2.953; Kindzelskii AL, 1998, BIOPHYS J, V74, P90, DOI 10.1016/S0006-3495(98)77770-7; Kuriyama S, 1998, ANTICANCER RES, V18, P4181; LIOTTA LA, 1980, CANCER LETT, V11, P141, DOI 10.1016/0304-3835(80)90105-6; MACKAY AR, 1990, CANCER RES, V50, P5997; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MONSKY WL, 1994, CANCER RES, V54, P5702; MONTGOMERY AMP, 1993, CANCER RES, V53, P693; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; OSSOWSKI L, 1980, CANCER RES, V40, P2300; PARK JK, 1992, J CARDIOVASC ELECTR, V3, P306, DOI 10.1111/j.1540-8167.1992.tb00976.x; POSTE G, 1980, CANCER RES, V40, P1636; REICH R, 1988, CANCER RES, V48, P3307; ROMER J, 1994, INT J CANCER, V57, P553, DOI 10.1002/ijc.2910570419; STARKEY JR, 1984, CANCER RES, V44, P1585; SZATROWSKI TP, 1991, CANCER RES, V51, P794; TOWLE MJ, 1993, CANCER RES, V53, P2553; Xue W, 1997, CANCER RES, V57, P1682	30	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					932	939		10.1096/fj.00-0392com	http://dx.doi.org/10.1096/fj.00-0392com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292653	Green Submitted			2022-12-25	WOS:000167959300007
J	Negrisolo, E; Pallavicini, A; Barbato, R; Dewilde, S; Ghiretti-Magaldi, A; Moens, L; Lanfranchi, G				Negrisolo, E; Pallavicini, A; Barbato, R; Dewilde, S; Ghiretti-Magaldi, A; Moens, L; Lanfranchi, G			The evolution of extracellular hemoglobins of annelids, vestimentiferans, and pogonophorans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC COMPOSITION; AMINO-ACID-SEQUENCE; 2 GLOBIN STRAINS; CHAIN; EARTHWORM; ALIGNMENT; SITE	The evolution of extracellular hemoglobins of annelids, vestimentiferans, and pogonophorans was investigated by applying cladistic and distance-based approaches to reconstruct the phylogenetic relationships of this group of respiratory pigments. We performed this study using the aligned sequences of globin and linker chains that are the constituents of these complex molecules. Three novel globin and two novel linker chains of Sabella spallanzanii described in an accompanying paper (Pallavicini, A., Negrisolo, E., Barbato, R., Dewilde, S., Ghiretti-Magaldi, A., Moens, L., and Lanfranchi, G. (2001) J. Biol. Chem 276, 26384-26390) were also included. Our results allowed us to test previous hypotheses on the evolutionary pathways of these proteins and to formulate a new most parsimonious model of molecular evolution. According to this novel model, the genes coding for the polypeptides forming these composite molecules were already present in the common ancestor of annelids, vestimentiferans, and pogonophorans.	Univ Padua, Dipartimento Biol, I-35131 Padua, Italy; Univ Padua, Ctr Ric Interdipartimentale Biotecnol Innovat, I-35131 Padua, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy; Univ Padua, CNR, Ctr Study Metalloprot, I-35131 Padua, Italy; Univ Instelling Antwerp, Dept Biochem, B-2610 Wilrijk, Belgium	University of Padua; University of Padua; University of Eastern Piedmont Amedeo Avogadro; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Antwerp	Lanfranchi, G (corresponding author), Univ Padua, Dipartimento Biol, Via Ugo Bassi 58-B, I-35131 Padua, Italy.		Pallavicini, Alberto/J-4158-2012; Pallavicini, Alberto/H-9281-2019; Negrisolo, Enrico/K-8124-2015	Pallavicini, Alberto/0000-0001-7174-4603; Pallavicini, Alberto/0000-0001-7174-4603; Negrisolo, Enrico/0000-0002-6244-805X				FARIS JF, 1989, CLADISTICS, V5, P417; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; GOTOH T, 1987, BIOCHEM J, V241, P441, DOI 10.1042/bj2410441; GOTOH T, 1991, STRUCTURE AND FUNCTION OF INVERTEBRATE OXYGEN CARRIERS, P279; KAPP OH, 1995, PROTEIN SCI, V4, P2179, DOI 10.1002/pro.5560041024; KLUGE AG, 1969, SYST ZOOL, V18, P1, DOI 10.2307/2412407; Lamy JN, 1996, CHEM REV, V96, P3113, DOI 10.1021/cr9600058; Li W. H, 1997, MOL EVOLUTION; MADISON WP, 1992, MACCLADE ANAL PHYLOG; Martin PD, 1996, J MOL BIOL, V255, P154, DOI 10.1006/jmbi.1996.0013; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; Pallavicini A, 2001, J BIOL CHEM, V276, P26384, DOI 10.1074/jbc.M006939200; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shishikura F, 1997, ZOOL SCI, V14, P923, DOI 10.2108/zsj.14.923; Shishikura F, 1996, ZOOL SCI, V13, P849, DOI 10.2108/zsj.13.849; Shishikura F, 1996, ZOOL SCI, V13, P551, DOI 10.2108/zsj.13.551; SUZUKI T, 1990, BIOCHEM J, V266, P221, DOI 10.1042/bj2660221; SUZUKI T, 1993, J BIOL CHEM, V268, P13548; SWOFFORD DL, 1993, POLYGENETIC ANAL USI; TAKAGI T, 1991, STRUCTURE AND FUNCTION OF INVERTEBRATE OXYGEN CARRIERS, P245; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V3, P227; VINOGRADOV SN, 1985, COMP BIOCHEM PHYS B, V82, P1, DOI 10.1016/0305-0491(85)90120-8; Yuasa HJ, 1996, BBA-PROTEIN STRUCT M, V1296, P235, DOI 10.1016/0167-4838(96)00081-7; Zal F, 1997, PROTEINS, V29, P562, DOI 10.1002/(SICI)1097-0134(199712)29:4<562::AID-PROT15>3.0.CO;2-K	25	12	12	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26391	26397		10.1074/jbc.M100557200	http://dx.doi.org/10.1074/jbc.M100557200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11294835	hybrid, Green Published			2022-12-25	WOS:000169823300099
J	Harris, FM; Smith, SK; Bell, JD				Harris, FM; Smith, SK; Bell, JD			Physical properties of erythrocyte ghosts that determine susceptibility to secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-II PHOSPHOLIPASE-A2; S49 CELL-MEMBRANES; AGKISTRODON-PISCIVORUS; PLASMA-MEMBRANE; PALMITIC ACID; GENERALIZED POLARIZATION; FLUORESCENT-PROBES; VESICLES; CALCIUM; LYSOLECITHIN	Artificial membranes may be resistant or susceptible to catalytic attack by secretory phospholipase A, (sPLA(2)) depending on the physical properties of the membrane. Living cells are normally resistant but become susceptible during trauma, apoptosis, and/or a significant elevation of intracellular calcium. Intact erythrocytes and ghosts were studied to determine whether the principles learned from artificial systems apply to biological membranes. Membrane properties such as phospholipid and/or protein composition, morphology, and microscopic characteristics (e.g, fluidity) were manipulated by preparing ghosts under different experimental conditions such as in the presence or absence of divalent cations with or without ATP. The properties of each membrane preparation were assessed by biochemical and physical means (fluorescence spectroscopy and electron and two-photon microscopy using the membrane probes bis-pyrene and laurdan) and compared with sPLA(2) activity. The properties that appeared most relevant were the degree of phosphatidylserine exposure on the outer face of the membrane and changes to the membrane physical state detected by bis pyrene and laurdan, Specifically, vulnerability to hydrolysis by sPLA(2) was associated with an increase in bilayer order apparently reflective of expansion of membrane regions of diminished fluidity, These results argue that the general principles identified from studies with artificial membranes apply to biological systems.	Brigham Young Univ, Dept Zool, Provo, UT 84602 USA	Brigham Young University	Bell, JD (corresponding author), Brigham Young Univ, Dept Zool, Provo, UT 84602 USA.	john_bell@byu.edu						Abe T, 1997, INT J CANCER, V74, P245, DOI 10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO;2-Z; ANDERSEN S, 1994, INFLAMMATION, V18, P1, DOI 10.1007/BF01534593; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; BELL JD, 1989, J BIOL CHEM, V264, P225; Bell JD, 1996, BIOCHEMISTRY-US, V35, P4945, DOI 10.1021/bi952274i; BELL JD, 1995, BIOCHEMISTRY-US, V34, P11551, DOI 10.1021/bi00036a031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURACK WR, 1995, BIOCHEMISTRY-US, V34, P14819, DOI 10.1021/bi00045a024; BURACK WR, 1994, CHEM PHYS LIPIDS, V73, P209, DOI 10.1016/0009-3084(94)90182-1; BUTIKOFER P, 1989, BLOOD, V74, P1481; CHONG PLG, 1993, BIOCHIM BIOPHYS ACTA, V1149, P260, DOI 10.1016/0005-2736(93)90209-I; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; CONNOR J, 1994, J BIOL CHEM, V269, P2399; DEJONG K, 1993, FEBS LETT, V334, P183, DOI 10.1016/0014-5793(93)81708-8; DENKAMP JAO, 1979, ANNU REV BIOCHEM, V45, P47; DUMASWALA UJ, 1984, TRANSFUSION, V24, P490, DOI 10.1046/j.1537-2995.1984.24685066807.x; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FRANCK PF, 1995, J CLIN INVEST, V75, P183; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Ghomashchi F, 1998, BIOCHEMISTRY-US, V37, P6697, DOI 10.1021/bi972525i; GRAINGER DW, 1989, FEBS LETT, V252, P73, DOI 10.1016/0014-5793(89)80892-0; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; Haapamaki MM, 1997, GUT, V40, P95, DOI 10.1136/gut.40.1.95; HAGERSTRAND H, 1994, BBA-BIOMEMBRANES, V1190, P409, DOI 10.1016/0005-2736(94)90101-5; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Henshaw JB, 1998, BIOCHEMISTRY-US, V37, P10709, DOI 10.1021/bi9728809; Honger T, 1996, BIOCHEMISTRY-US, V35, P9003, DOI 10.1021/bi960866a; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V980, P23, DOI 10.1016/0005-2736(89)90195-8; Krasnowska EK, 1998, BIOPHYS J, V74, P1984, DOI 10.1016/S0006-3495(98)77905-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MELNICK RL, 1981, BIOPHYS J, V34, P499, DOI 10.1016/S0006-3495(81)84864-3; MENASHE M, 1986, J BIOL CHEM, V261, P5328; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; NEVALAINEN TJ, 1993, GUT, V34, P1133, DOI 10.1136/gut.34.8.1133; Nielson KH, 2000, BBA-MOL CELL BIOL L, V1484, P163, DOI 10.1016/S1388-1981(00)00004-4; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; RICHIERI GV, 1995, ANAL BIOCHEM, V229, P256, DOI 10.1006/abio.1995.1410; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHEFFIELD MJ, 1995, BIOCHEMISTRY-US, V34, P7796, DOI 10.1021/bi00024a003; SHUKLA SD, 1982, ARCH BIOCHEM BIOPHYS, V214, P335, DOI 10.1016/0003-9861(82)90038-8; Smith SK, 2001, J BIOL CHEM, V276, P22732, DOI 10.1074/jbc.M010880200; Steck T L, 1974, Methods Enzymol, V31, P172; TEST ST, 1991, BLOOD, V78, P3056; WHATMORE JL, 1994, BBA-BIOMEMBRANES, V1192, P88, DOI 10.1016/0005-2736(94)90146-5; WILLIAMSON P, 1985, J CELL PHYSIOL, V123, P209, DOI 10.1002/jcp.1041230209; Wilson HA, 1997, BBA-LIPID LIPID MET, V1349, P142, DOI 10.1016/S0005-2760(97)00089-1; Wilson HA, 1999, J BIOL CHEM, V274, P11494, DOI 10.1074/jbc.274.17.11494; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; Yu WM, 1996, BIOPHYS J, V70, P626, DOI 10.1016/S0006-3495(96)79646-7; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	53	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22722	22731		10.1074/jbc.M010879200	http://dx.doi.org/10.1074/jbc.M010879200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294853	hybrid			2022-12-25	WOS:000169412700100
J	Lelievre, E; Plun-Favreau, H; Chevalier, S; Froger, J; Guillet, C; Elson, GCA; Gauchat, JF; Gascan, H				Lelievre, E; Plun-Favreau, H; Chevalier, S; Froger, J; Guillet, C; Elson, GCA; Gauchat, JF; Gascan, H			Signaling pathways recruited by the cardiotrophin-like cytokine/cytokine-like factor-1 composite cytokine - Specific requirement of the membrane-bound form of ciliary neurotrophic factor receptor alpha component	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; TYROSINE-PHOSPHATASE SHP-2; ACTIVATED PROTEIN-KINASE; ONCOSTATIN-M; CNTF RECEPTOR; MICE LACKING; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; MOLECULAR-CLONING; TRANSDUCER GP130	Ciliary neurotrophic factor (CNTF) is a cytokine sup porting the differentiation and survival of a number of neural cell types. Its receptor complex consists of a ligand-binding component, CNTF receptor (CNTFR), associated with two signaling receptor components, gp130 and leukemia inhibitory factor receptor (LIFR), Striking phenotypic differences between CNTF- and CNTFR-deficient mice suggest that CNTFR serves as a receptor for a second developmentally important ligand, We recently demonstrated that cardiotrophin-like cytokine (CLC) associates with the soluble orphan receptor cytokine-like factor-1 (CLF) to form a heterodimeric cytokine that displayed activities only on cells expressing the tripartite CNTF receptor on their surface. In this present study we examined the membrane binding of the CLC/CLF composite cytokine and observed a preferential interaction of the cytokine with the CNTFR subunit. Signaling pathways recruited by the CLC/CLF complex in human neuroblastoma cell lines were also analyzed in detail. The results obtained showed an activation of Janus kinases (JAK1, JAK2, and TYK2) leading to a tyrosine phosphorylation of the gp130 and LIFR, The phosphorylated signaling receptors served in turn as docking proteins for signal transducing molecules such as STAT3 and SHP-2, In vitro analysis revealed that the gp130-LIFR pathway could also stimulate the phosphatidylinositol 3-kinase and the mitogen-activated protein kinase pathways. In contrast to that reported before for CNTF, soluble CNTFR failed to promote the action CLC/CLF, and an absolute requirement of the membrane form of CNTFR was required to generate a functional response to the composite cytokine. This study reinforces the functional similarity between CNTF and the CLC/CLF composite cytokine defining the second ligand for CNTFR.	CHU Angers, INSERM EMI 9928, F-49003 Angers, France; Ctr Immunol Pierre Fabre, F-74164 St Julien En Genevois, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre d'Immunologie Pierre Fabre	Gascan, H (corresponding author), CHU Angers, INSERM E 9928, 4 Rue Larrey, F-49033 Angers, France.		Plun-Favreau, Helene/Q-4111-2016; Lelievre, Eric/M-2878-2015; PLUN-FAVREAU, Helene/C-8513-2009	Plun-Favreau, Helene/0000-0002-1401-9656; lelievre, eric/0000-0002-4132-4023				Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Coqueret O, 2000, J BIOL CHEM, V275, P18794, DOI 10.1074/jbc.M001601200; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Elson GCA, 1998, J IMMUNOL, V161, P1371; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Guillet C, 1999, J NEUROSCI, V19, P1257; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim HK, 1998, MOL CELL BIOL, V18, P1525, DOI 10.1128/MCB.18.3.1525; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LARKFORS L, 1994, EUR J NEUROSCI, V6, P1015, DOI 10.1111/j.1460-9568.1994.tb00596.x; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; Miyakawa Y, 2001, J BIOL CHEM, V276, P2494, DOI 10.1074/jbc.M002633200; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Olivier C, 2000, J BIOL CHEM, V275, P5648, DOI 10.1074/jbc.275.8.5648; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Schaper F, 1998, BIOCHEM J, V335, P557, DOI 10.1042/bj3350557; SCHIEMANN WP, 1995, P NATL ACAD SCI USA, V92, P5361, DOI 10.1073/pnas.92.12.5361; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Sendtner M, 1997, J NEUROSCI, V17, P6999; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1994, J NEUROBIOL, V25, P1436, DOI 10.1002/neu.480251110; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Simon R, 1995, NEUROREPORT, V7, P153, DOI 10.1097/00001756-199512000-00037; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; THOMA B, 1994, J BIOL CHEM, V269, P6215; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Timmermann A, 2000, FEBS LETT, V468, P120, DOI 10.1016/S0014-5793(00)01205-9; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	74	79	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22476	22484		10.1074/jbc.M101681200	http://dx.doi.org/10.1074/jbc.M101681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294841	hybrid			2022-12-25	WOS:000169412700068
J	Mueller, S; Pantopoulos, K; Hubner, CA; Stremmel, W; Hentze, MW				Mueller, S; Pantopoulos, K; Hubner, CA; Stremmel, W; Hentze, MW			IRP1 activation by extracellular oxidative stress in the perfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON REGULATORY PROTEIN-1; HYDROGEN-PEROXIDE; FERRITIN SYNTHESIS; NITRIC-OXIDE; METABOLISM; H2O2; INFLAMMATION; CATALASE; PATHOGENESIS; MECHANISM	The expression of several proteins with critical functions in iron metabolism is regulated post-transcriptionally by the binding of iron regulatory proteins, IRP1 and IRP2, to mRNA iron responsive elements (IREs). In iron deficient tissues and cultured cells, both IRP1 and IRP2 are activated for high affinity IRE binding. Previous work showed that IRP1 is also activated when cultured cells are exposed to H2O2. The well established role of iron and H2O2 in tissue injury (based on Fenton chemistry) suggests that this response may have important pathophysiological implications. This is particularly relevant in inflammation, where cytotoxic immune cells release large amounts of reactive oxygen species. Here, we describe a rat liver perfusion model to study IRP1 activation under H2O2 generation conditions that mimic a physiological inflammatory response, using steady-state concentrations of H2O2 produced by a glucose/ glucose oxidase/catalase system. We show first that stimulated neutrophils are able to increase serum levels of H2O2 by a factor of 10, even in the presence of H2O2-degrading erythrocytes. We further show that perfusion of rat liver with glucose oxidase leads to a rapid activation of IRE binding activity in the intact organ. Mobility shift assays with liver extracts and IRP1 or IRP2-specific probes indicate that only IRP1 responds to H2O2. Our study demonstrates a principal existence of iron regulation by oxidative stress at the intact organ level. It also provides a link between iron metabolism and the inflammatory response, as H2O2 is a major product of the oxidative burst of neutrophils and macrophages.	Heidelberg Univ, Dept Internal Med 4, D-69115 Heidelberg, Germany; European Mol Biol Lab, Gene Express Programme, D-699117 Heidelberg, Germany	Ruprecht Karls University Heidelberg; European Molecular Biology Laboratory (EMBL)	Mueller, S (corresponding author), Heidelberg Univ, Dept Internal Med 4, Bergheimer Str 58, D-69115 Heidelberg, Germany.	mueller@urz.uni-heidelberg.de	Hübner, Christian/A-2950-2017; Hentze, Matthias W/V-3980-2017; Pantopoulos, Kostas/A-9668-2008	Hübner, Christian/0000-0002-1030-4943; Hentze, Matthias W/0000-0002-4023-7876; Pantopoulos, Kostas/0000-0002-2305-0057; Stremmel, Wolfgang/0000-0002-8545-1753				AEBI H, 1984, METHOD ENZYMOL, V105, P121; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; Barisani D, 1996, DIGEST DIS, V14, P304, DOI 10.1159/000171561; Bartosek I, 1973, ISOLATED LIVER PERFU; BEERS RF, 1952, J BIOL CHEM, V195, P133; BOTHWELL TH, 1995, NUTR REV, V53, P237, DOI 10.1111/j.1753-4887.1995.tb05480.x; BOYUM A, 1991, BLOOD SEPARATION PLA, P217; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Cairo G, 1996, FASEB J, V10, P1326, DOI 10.1096/fasebj.10.11.8836047; Cairo G, 1998, ANN NY ACAD SCI, V851, P179, DOI 10.1111/j.1749-6632.1998.tb08992.x; Caltagirone A, 2001, J BIOL CHEM, V276, P19738, DOI 10.1074/jbc.M100245200; DASILVA JJR, 1991, BIOL CHEM ELEMENTS I, P319; GREEN JG, 1984, METHOD ENZYMOL, V105, P4; GUO B, 1994, J BIOL CHEM, V269, P24252; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; Henderson ER, 1996, J BIOL CHEM, V271, P4900; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KONIJN AM, 1981, BRIT J HAEMATOL, V49, P361, DOI 10.1111/j.1365-2141.1981.tb07238.x; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Mueller S, 1997, BIOLUMINESCENCE AND CHEMILUMINESCENCE, P338; Mueller S, 1997, ANAL BIOCHEM, V245, P55, DOI 10.1006/abio.1996.9939; Mueller S, 2000, FREE RADICAL BIO MED, V29, P410, DOI 10.1016/S0891-5849(00)00261-6; MUELLER S, 1995, J BIOLUM CHEMILUM, V10, P229, DOI 10.1002/bio.1170100406; Mueller S, 1997, BLOOD, V90, P4973, DOI 10.1182/blood.V90.12.4973.4973_4973_4978; MUELLER S, 2001, IN PRESS METHODS ENZ; Pantopoulos K, 1998, P NATL ACAD SCI USA, V95, P10559, DOI 10.1073/pnas.95.18.10559; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Pirisi M, 2000, AM J CLIN PATHOL, V113, P546, DOI 10.1309/TRB1-JXUJ-L9R6-9NHX; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Tacchini L, 1997, GASTROENTEROLOGY, V113, P946, DOI 10.1016/S0016-5085(97)70191-4; TEST ST, 1984, J BIOL CHEM, V259, P399	40	66	69	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23192	23196		10.1074/jbc.M100654200	http://dx.doi.org/10.1074/jbc.M100654200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297549	hybrid			2022-12-25	WOS:000169412700161
J	Pullar, JM; Vissers, MCM; Winterbourn, CC				Pullar, JM; Vissers, MCM; Winterbourn, CC			Glutathione oxidation by hypochlorous acid in endothelial cells produces glutathione sulfonamide as a major product but not glutathione disulfide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SKIN FIBROBLASTS; PROTEIN S-THIOLATION; REDUCED GLUTATHIONE; GROWTH ARREST; NEUTROPHILS; CHLORIDE; THIOLS; STRESS	Treatment of cells with hypochlorous acid (HOCl) at sublethal doses causes a concentration-dependent loss in reduced glutathione (GSH) levels. We have investigated the products of the reaction of HOCl with GSH in human umbilical vein endothelial cells. Despite a complete loss of GSH, there were only very small increases in intracellular and extracellular glutathione disulfide and glutathione sulfonic acid after exposure to HOCl. S-35 labeling of the GSH pool showed only a minimal increase in protein-bound GSH, suggesting that S-thiolation was not a major contributor to HOCl-mediated loss of GSH in endothelial cells. Rather, the products of the reaction were mostly exported from cells and included a peak that co-eluted with the cyclic sulfonamide that is a product of the reaction of GSH with reagent HOCl. Evidence of this species in endothelial cell supernatants after HOCl treatment was also obtained using electrospray mass spectrometry. In conclusion, expo sure to HOCl causes the irreversible loss of cellular GSH with the formation of novel products that are rapidly exported from the cell, and resynthesis of GSH will be required to restore levels. The loss of GSH would alter the redox state of the cell and compromise its defenses against further oxidative stress.	Christchurch Sch Med, Dept Pathol, Free Rad Res Grp, Christchurch, New Zealand	University of Otago	Pullar, JM (corresponding author), Christchurch Sch Med, Dept Pathol, Free Rad Res Grp, POB 4345, Christchurch, New Zealand.		Vissers, Margreet C M/T-4159-2017					Armesto XL, 2000, TETRAHEDRON, V56, P1103, DOI 10.1016/S0040-4020(99)01066-2; Carr AC, 1997, BIOCHEM J, V327, P275, DOI 10.1042/bj3270275; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; FOLKES LK, 1995, ARCH BIOCHEM BIOPHYS, V323, P120, DOI 10.1006/abbi.1995.0017; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; MARTIN J, 1991, J CHROMATOGR-BIOMED, V568, P219, DOI 10.1016/0378-4347(91)80356-H; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Prutz WA, 1996, ARCH BIOCHEM BIOPHYS, V332, P110, DOI 10.1006/abbi.1996.0322; Pullar JM, 1999, AM J PHYSIOL-HEART C, V277, pH1505, DOI 10.1152/ajpheart.1999.277.4.H1505; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SILVERSTEIN RM, 1974, BIOCHEMISTRY-US, V13, P5069, DOI 10.1021/bi00722a001; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597, DOI 10.1152/ajpheart.1994.267.4.H1597; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; Vile GF, 1998, ARCH BIOCHEM BIOPHYS, V359, P51, DOI 10.1006/abbi.1998.0881; Vile GF, 2000, ARCH BIOCHEM BIOPHYS, V377, P122, DOI 10.1006/abbi.2000.1706; VISSERS MCM, 1990, FREE RADICAL BIO MED, V8, P331, DOI 10.1016/0891-5849(90)90098-4; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; Vissers MCM, 1999, BIOCHEM J, V344, P443, DOI 10.1042/0264-6021:3440443; VISSERS MCM, 1995, BIOCHEM J, V307, P57, DOI 10.1042/bj3070057; Winterbourn CC, 1997, BIOCHEM J, V326, P87, DOI 10.1042/bj3260087; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5	23	78	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22120	22125		10.1074/jbc.M102088200	http://dx.doi.org/10.1074/jbc.M102088200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11283008	hybrid			2022-12-25	WOS:000169412700021
J	Abe, MK; Kahle, KT; Saelzler, MP; Orth, K; Dixon, JE; Rosner, MR				Abe, MK; Kahle, KT; Saelzler, MP; Orth, K; Dixon, JE; Rosner, MR			ERK7 is an autoactivated member of the MAPK family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; GENE-PRODUCT; PROTEIN-KINASE-1 BMK1; DUAL PHOSPHORYLATION; MITOGEN; TYROSINE; AUTOPHOSPHORYLATION; CASCADES; INVITRO	Extracellular signal-regulated kinase 7 (ERK7) shares significant sequence homology with other members of the ERK family of signal transduction proteins, including the signature TEY activation motif. However, ERK7 has several distinguishing characteristics. Unlike other ERKs, ERK7 has been shown to have significant constitutive activity in serum-starved cells, which is not increased further by extracellular stimuli that typically activate other members of the mitogen-activated protein kinase (MAPK) family. On the other hand, ERK7's activation state and kinase activity appear to be regulated by its ability to utilize ATP and the presence of its extended C-terminal region. In this study, we investigated the mechanism of ERK7 activation, The results suggest that 1) MAPK kinase (MEK) inhibitors do not suppress ERK7 kinase activity; 2) intramolecular autophosphorylation is sufficient for activation of ERK7 in the absence of an upstream MEK; and 3) multiple regions of the C-terminal domain of ERK7 regulate its kinase activity. Taken together, these results indicate that autophosphorylation is sufficient for ERK7 activation and that the C-terminal domain regulates its kinase activity through multiple interactions.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Michigan System; University of Michigan; University of Chicago	Rosner, MR (corresponding author), Univ Chicago, Ben May Inst Canc Res, 5841 S Maryland Ave,MC 6027, Chicago, IL 60637 USA.		Orth, Kim/AAV-4421-2021	Orth, Kim/0000-0002-0678-7620	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018024, R37DK018024] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033858] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03867, HL 56399] Funding Source: Medline; NIDDK NIH HHS [DK 18024] Funding Source: Medline; NINDS NIH HHS [NS 33858] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe MK, 1999, MOL CELL BIOL, V19, P1301; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; Chesneau V, 2000, PROTEIN EXPRES PURIF, V19, P91, DOI 10.1006/prep.2000.1217; Cobb M H, 1996, Adv Pharmacol, V36, P49, DOI 10.1016/S1054-3589(08)60576-1; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Orth K, 1999, SCIENCE, V285, P1920, DOI 10.1126/science.285.5435.1920; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Peng X, 1996, J NEUROCHEM, V66, P1191; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	40	57	60	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21272	21279		10.1074/jbc.M100026200	http://dx.doi.org/10.1074/jbc.M100026200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287416	hybrid			2022-12-25	WOS:000169297900064
J	Aicher, LD; Campbell, JS; Yeung, RS				Aicher, LD; Campbell, JS; Yeung, RS			Tuberin phosphorylation regulates its interaction with hamartin - Two proteins involved in tuberous sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSC2 GENE; PRODUCT; IDENTIFICATION	Hamartin and tuberin are products of the tumor suppressor genes, TSC1 and TSC2, respectively. When mutated, a characteristic spectrum of tumor-like growths develop resulting in the syndrome of tuberous sclerosis complex. The phenotypes associated with TSC1 and TSC2 mutations are largely indistinguishable suggesting a common biochemical pathway. Indeed, hamartin and tuberin have been shown to interact stably in vitro and in vivo. Factors that regulate their interaction are likely critical to the understanding of disease pathogenesis, In this study, we showed that tuberin is phosphorylated at serine and tyrosine residues in response to serum and other factors, and it undergoes serial phosphorylation that can be detected by differences in electrophoretic mobilities. A disease-related TSC2 mutation (Y1571H) nearly abolished tuberin phosphorylation when stimulated with pervanadate, Expression of this mutant tuberin caused a marked reduction in TSC1-TSC2 interaction compared with wild-type protein and significantly curtailed the growth inhibitory effects of tuberin when overexpressed in COS1 cells, consistent with a loss of function mutation. Examination of a second pathologic mutation, P1675L, revealed a similar relationship between limited phosphorylation and reduced interaction with hamartin, Our data show for the first time that 1) tuberin is phosphorylated at tyrosine and serine residues, 2) TSC1-TSC2 interaction is regulated by tuberin phosphorylation, and 3) defective phosphorylation of tuberin is associated with loss of its tumor suppressor activity. These findings suggest that phosphorylation may be a key regulatory mechanism controlling TSC1-TSC2 function.	Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Yeung, RS (corresponding author), Univ Washington, Dept Surg, 1959 NE Pacific St,Box 356410, Seattle, WA 98195 USA.	ryeung@u.washington.edu		Campbell, Jean/0000-0002-9187-2204	NCI NIH HHS [CA77882] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077882] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Gomez M.R., 1999, TUBEROUS SCLEROSIS C, V3rd, P10; Grangeasse C, 1999, BIOTECHNIQUES, V27, P62, DOI 10.2144/99271bm12; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hodges AK, 2000, AM J HUM GENET, V67, P406; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; MacKintosh C, 1996, FEBS LETT, V397, P235, DOI 10.1016/S0014-5793(96)01175-1; NELLIST M, 1993, CELL, V75, P1305; Orimoto K, 1996, BIOCHEM BIOPH RES CO, V219, P70, DOI 10.1006/bbrc.1996.0183; Plank TL, 1998, CANCER RES, V58, P4766; Rennebeck G, 1998, P NATL ACAD SCI USA, V95, P15629, DOI 10.1073/pnas.95.26.15629; Roach ES, 1998, J CHILD NEUROL, V13, P624, DOI 10.1177/088307389801301206; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	21	78	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21017	21021		10.1074/jbc.C100136200	http://dx.doi.org/10.1074/jbc.C100136200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290735	hybrid			2022-12-25	WOS:000169297900031
J	Bottero, V; Rossi, F; Samson, M; Mari, M; Hofman, P; Peyron, JF				Bottero, V; Rossi, F; Samson, M; Mari, M; Hofman, P; Peyron, JF			I kappa B-alpha, the NF-kappa B inhibitors subunit, interacts with ANT, the mitochondrial ATP/ADP translocator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION; TRANSCRIPTION FACTORS; INDUCED APOPTOSIS; CELL-SURVIVAL; KINASE IKK; PROTEIN; ACTIVATION; INDUCTION; MEMBRANE; THERAPY	The transcription factor NF-kappaB regulates a wide set of genes involved in the establishment of many cellular processes that control cell activation, proliferation, and apoptosis. I kappaB inhibitory subunits integrate NF-kappaB activation signals through phosphorylation and ubiquitination of its N-terminal domain. Using the two-hybrid system in yeast, we searched for I kappaB-alpha N-terminal domain interactors and therefore potential NF-kappaB regulators. An interaction of I kappaB-alpha with the mitochondrial ATP/ADP translocator ANT was detected in yeast and confirmed in glutathione S-transferase pull-down assays and co-precipitation experiments in transfected cells. Subcellular cell fractionation, resistance to proteinase K treatment, and electron microscopy experiments demonstrated the presence of I kappaB-alpha and associated p65 NF-kappaB in the mitochondrial intermembrane space. I kappaB-. alpha .NF-kappaB appeared to be released from mitochondria upon the induction of apoptosis by engagement of the Fas receptor. These data suggest that the mitochondrial I kappaB-alpha .NF-kappaB pool participates in the regulation of apoptosis.	Fac Med Pasteur, INSERM, U526, F-06107 Nice 2, France; Fac Med Pasteur, INSERM, U364, F-06107 Nice 2, France; Hop Louis Pasteur, Lab Anatomopathol, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Peyron, JF (corresponding author), Fac Med Pasteur, INSERM, U526, IFR50, F-06107 Nice 2, France.	peyron@unice.fr	Jean-Francois, Peyron/AAA-9496-2022; Hofman, Paul/P-7654-2018; Peyron, Jean-Francois/M-5682-2016	Jean-Francois, Peyron/0000-0001-6113-916X; Hofman, Paul/0000-0003-0431-9353; Peyron, Jean-Francois/0000-0001-6113-916X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; Foo SY, 1999, TRENDS GENET, V15, P229; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Martinou JC, 1999, NATURE, V399, P411, DOI 10.1038/20804; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MORIN PJ, 1993, NUCLEIC ACIDS RES, V21, P2157, DOI 10.1093/nar/21.9.2157; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Scarlett JL, 1997, FEBS LETT, V418, P282, DOI 10.1016/S0014-5793(97)01391-4; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	42	73	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21317	21324		10.1074/jbc.M005850200	http://dx.doi.org/10.1074/jbc.M005850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287411	hybrid			2022-12-25	WOS:000169297900070
J	Fierobe, HP; Mechaly, A; Tardif, C; Belaich, A; Lamed, R; Shoham, Y; Belaich, JP; Bayer, EA				Fierobe, HP; Mechaly, A; Tardif, C; Belaich, A; Lamed, R; Shoham, Y; Belaich, JP; Bayer, EA			Design and production of active cellulosome chimeras - Selective incorporation of dockerin-containing enzymes into defined functional complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-THERMOCELLUM CELLULOSOME; SITE-DIRECTED MUTAGENESIS; INTEGRATING PROTEIN CIPA; SCAFFOLDING PROTEIN; CRYSTAL-STRUCTURE; CELLULOLYTICUM CELLULOSOME; COHESIN DOMAIN; ENDOGLUCANASE; GENE; PURIFICATION	Defined chimeric cellulosomes were produced in which selected enzymes were incorporated in specific locations within a multicomponent complex, The molecular building blocks of this approach are based on complementary protein modules from the cellulosomes of two clostridia, Clostridium thermocellum and Clostridium cellulolyticum, wherein cellulolytic enzymes are incorporated into the complexes by means of high-affinity species-specific cohesin-dockerin interactions. To construct the desired complexes, a series of chimeric scaffoldins was prepared by recombinant means. The scaffoldin chimeras were designed to include two cohesin modules from the different species, optionally connected to a cellulose-binding domain. The two divergent cohesins exhibited distinct specificities such that leach recognized selectively and bound strongly to its dockerin counterpart. Using this strategy, appropriate dockerin-containing enzymes could be assembled precisely and by design into a desired complex. Compared with the mixture of free cellulases, the resultant cellulosome chimeras exhibited enhanced synergistic action on crystalline cellulose.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Inst Federatif Rech 1, Inst Biol Struct & Microbiol, CNRS, F-13402 Marseille, France; Univ Aix Marseille 1, F-13331 Marseille, France; Tel Aviv Univ, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Tel Aviv University; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Bayer, EA (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.		Shoham, Yuval/M-4409-2013; FIEROBE, Henri-Pierre/P-4372-2019					Bayer E.A., 1994, TRENDS BIOTECHNOL, V12, P378; Bayer EA, 1998, J STRUCT BIOL, V124, P221, DOI 10.1006/jsbi.1998.4065; BAYER EA, 1990, METHOD ENZYMOL, V184, P138; Bayer EA, 1998, CURR OPIN STRUC BIOL, V8, P548, DOI 10.1016/S0959-440X(98)80143-7; Beguin P, 1996, CRIT REV BIOCHEM MOL, V31, P201, DOI 10.3109/10409239609106584; BHAT MK, 1998, RRD BIOTECH BIOENG 1, V1, P59; BHAT S, 1994, INT J BIOL MACROMOL, V16, P335, DOI 10.1016/0141-8130(94)90066-3; Ciruela A, 1998, FEBS LETT, V422, P221, DOI 10.1016/S0014-5793(97)01590-1; FELIX CR, 1993, ANNU REV MICROBIOL, V47, P791, DOI 10.1146/annurev.micro.47.1.791; FIEROBE HP, 1991, J BACTERIOL, V173, P7956, DOI 10.1128/jb.173.24.7956-7962.1991; Fierobe HP, 1999, BIOCHEMISTRY-US, V38, P12822, DOI 10.1021/bi9911740; GERNGROSS UT, 1993, MOL MICROBIOL, V8, P325, DOI 10.1111/j.1365-2958.1993.tb01576.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kataeva I, 1997, BIOCHEM J, V326, P617, DOI 10.1042/bj3260617; Lytle B, 1996, J BACTERIOL, V178, P1200, DOI 10.1128/jb.178.4.1200-1203.1996; Mechaly A, 2000, PROTEINS, V39, P170, DOI 10.1002/(SICI)1097-0134(20000501)39:2<170::AID-PROT7>3.0.CO;2-H; Mechaly A, 2001, J BIOL CHEM, V276, P9883, DOI 10.1074/jbc.M009237200; Meza R, 1996, FEMS MICROBIOL LETT, V145, P333, DOI 10.1111/j.1574-6968.1996.tb08597.x; Pages S, 1999, J BACTERIOL, V181, P1801; Pages S, 1997, PROTEINS, V29, P517, DOI 10.1002/(SICI)1097-0134(199712)29:4<517::AID-PROT11>3.3.CO;2-I; Pages S, 1996, J BACTERIOL, V178, P2279, DOI 10.1128/jb.178.8.2279-2286.1996; PARK JT, 1949, J BIOL CHEM, V181, P149; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; ReverbelLeroy C, 1996, MICROBIOL-SGM, V142, P1013, DOI 10.1099/00221287-142-4-1013; ReverbelLeroy C, 1997, J BACTERIOL, V179, P46, DOI 10.1128/jb.179.1.46-52.1997; REVERBELLEROY C, 1996, THESIS U PROVENCE AI; Shimon LJW, 1997, STRUCTURE, V5, P381, DOI 10.1016/S0969-2126(97)00195-0; Shoham Y, 1999, TRENDS MICROBIOL, V7, P275, DOI 10.1016/S0966-842X(99)01533-4; Spinelli S, 2000, J MOL BIOL, V304, P189, DOI 10.1006/jmbi.2000.4191; Tavares GA, 1997, J MOL BIOL, V273, P701, DOI 10.1006/jmbi.1997.1326; WANG WK, 1993, J BACTERIOL, V175, P1293, DOI 10.1128/JB.175.5.1293-1302.1993; WU JHD, 1988, BIOCHEMISTRY-US, V27, P1703, DOI 10.1021/bi00405a048; YARON S, 1995, FEBS LETT, V360, P121, DOI 10.1016/0014-5793(95)00074-J	33	162	178	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21257	21261		10.1074/jbc.M102082200	http://dx.doi.org/10.1074/jbc.M102082200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290750	hybrid			2022-12-25	WOS:000169297900062
J	Kato, M; Frick, DN; Lee, J; Tabor, S; Richardson, CC; Ellenberger, T				Kato, M; Frick, DN; Lee, J; Tabor, S; Richardson, CC; Ellenberger, T			A complex of the bacteriophage T7 primase-helicase and DNA polymerase directs primer utilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID REPLICATION INVITRO; GENE 4 PROTEIN; DEOXYRIBONUCLEIC-ACID; CRYSTAL-STRUCTURE; DUPLEX DNA; RNA PRIMER; DOMAIN; BINDING; GENE-4-PROTEIN; HYDROLYSIS	The lagging strand of the replication fork is initially copied as short Okazaki fragments produced by the coupled activities of two template-dependent enzymes, a primase that synthesizes RNA primers and a DNA polymerase that elongates them. Gene 4 of bacteriophage T7 encodes a bifunctional primase-helicase that assembles into a ring-shaped hexamer with both DNA unwinding and primer synthesis activities. The primase is also required for the utilization of RNA primers by T7 DNA polymerase, It is not known how many subunits of the primase-helicase hexamer participate directly in the priming of DNA synthesis. In order to determine the minimal requirements for RNA primer utilization by T7 DNA polymerase, we created an altered gene 4 protein that does not form functional hexamers and consequently lacks detectable DNA unwinding activity. Remarkably, this monomeric primase readily primes DNA synthesis by T7 DNA polymerase on single-stranded templates. The monomeric gene 4 protein forms a specific and stable complex with T7 DNA polymerase and thereby delivers the RNA primer to the polymerase for the onset of DNA synthesis. These results show that a single subunit of the primase-helicase hexamer contains all of the residues required for primer synthesis and for utilization of primers by T7 DNA polymerase.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	tome@hms.harvard.edu		Frick, David/0000-0002-2434-7223				Ahnert P, 1997, J BIOL CHEM, V272, P32267, DOI 10.1074/jbc.272.51.32267; Augustin MA, 2001, NAT STRUCT BIOL, V8, P57, DOI 10.1038/83060; BAKER TA, 1992, DNA REPLICATION, P471; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; Bird LE, 1997, NUCLEIC ACIDS RES, V25, P2620, DOI 10.1093/nar/25.13.2620; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; BROWN WC, 1989, J BIOL CHEM, V264, P6748; Chowdhury K, 2000, P NATL ACAD SCI USA, V97, P12469, DOI 10.1073/pnas.230448397; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; Frick DN, 1999, J BIOL CHEM, V274, P35889, DOI 10.1074/jbc.274.50.35889; Frick DN, 1998, P NATL ACAD SCI USA, V95, P7957, DOI 10.1073/pnas.95.14.7957; Frick DN, 1999, J BIOL CHEM, V274, P35899, DOI 10.1074/jbc.274.50.35899; FULLER CW, 1982, COLD SPRING HARB SYM, V47, P669, DOI 10.1101/SQB.1983.047.01.078; GUO LH, 1982, NUCLEIC ACIDS RES, V10, P2065, DOI 10.1093/nar/10.6.2065; Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303; Hacker KJ, 1997, BIOCHEMISTRY-US, V36, P14080, DOI 10.1021/bi971644v; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; Hingorani MM, 1997, P NATL ACAD SCI USA, V94, P5012, DOI 10.1073/pnas.94.10.5012; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; KENNARD O, 1985, J BIOMOL STRUCT DYN, V3, P205, DOI 10.1080/07391102.1985.10508412; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KOLODNER R, 1977, P NATL ACAD SCI USA, V74, P1525, DOI 10.1073/pnas.74.4.1525; Kusakabe T, 1997, J BIOL CHEM, V272, P12446, DOI 10.1074/jbc.272.19.12446; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Leslie AGW, 2000, PHILOS T ROY SOC B, V355, P465, DOI 10.1098/rstb.2000.0588; Lohman TM, 1998, CELL, V93, P9, DOI 10.1016/S0092-8674(00)81139-3; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MENDELMAN LV, 1992, P NATL ACAD SCI USA, V89, P10638, DOI 10.1073/pnas.89.22.10638; NAKAI H, 1986, J BIOL CHEM, V261, P5217; NAKAI H, 1986, J BIOL CHEM, V261, P5208; Notarnicola SM, 1997, J BIOL CHEM, V272, P18425, DOI 10.1074/jbc.272.29.18425; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; Pan H, 2000, STRUCTURE, V8, P231, DOI 10.1016/S0969-2126(00)00101-5; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; RICHARDSON CC, 1983, CELL, V33, P315, DOI 10.1016/0092-8674(83)90411-7; Rogers S G, 1980, Methods Enzymol, V65, P201; ROMANO LJ, 1979, J BIOL CHEM, V254, P483; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; SCHERZINGER E, 1977, EUR J BIOCHEM, V72, P543, DOI 10.1111/j.1432-1033.1977.tb11278.x; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; TABOR S, 1981, P NATL ACAD SCI-BIOL, V78, P205, DOI 10.1073/pnas.78.1.205; TABOR S, 1987, J BIOL CHEM, V262, P16212; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; Waksman G, 2000, NAT STRUCT BIOL, V7, P20, DOI 10.1038/71215; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; Yu X, 1996, NAT STRUCT BIOL, V3, P740, DOI 10.1038/nsb0996-740	55	34	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21809	21820		10.1074/jbc.M101470200	http://dx.doi.org/10.1074/jbc.M101470200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279245	Green Published, hybrid			2022-12-25	WOS:000169297900132
J	Shackelford, RE; Innes, CL; Sieber, SO; Heinloth, AN; Leadon, SA; Paules, RS				Shackelford, RE; Innes, CL; Sieber, SO; Heinloth, AN; Leadon, SA; Paules, RS			The Ataxia telangiectasia gene product is required for oxidative stress-induced G(1) and G(2) checkpoint function in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; IONIZING-RADIATION; HYDROGEN-PEROXIDE; SKIN FIBROBLASTS; CELL; ATM; DAMAGE; CANCER; REPAIR; P53	Ataxia telangiectasia (AT) is an autosomal recessive disorder characterized by neuronal degeneration accompanied by ataxia, telangiectasias, acute cancer predisposition, and sensitivity to ionizing radiation (IR). Cells from individuals with AT show unusual sensitivity to IR, severely attenuated cell cycle checkpoint functions, and poor p53 induction in response to IR compared with normal human fibroblasts (NHFs), The gene mutated in AT (ATM) has been cloned, and its product, pATM, has IR-inducible kinase activity. The AT phenotype has been suggested to be a consequence, at least in part, of an inability to respond appropriately to oxidative damage. To test this hypothesis, we examined the ability of NHFs and AT dermal fibroblasts to respond to t-butyl hydroperoxide and IR treatment. Ar fibroblasts exhibit, in comparison to NHFs, increased sensitivity to the toxicity of t-butyl hydroperoxide, as measured by colony-forming efficiency assays. Unlike NHFs, AT fibroblasts fail to show G(1) and G(2) phase checkpoint functions or to induce p53 in response to t-butyl hydroperoxide. Treatment of NHFs with t-butyl hydroperoxide activates pATM-associated kinase activity. Our results indicate that pATM is involved in responding to certain aspects of oxidative damage and in signaling this information to downstream effecters of the cell cycle checkpoint functions. Our data further suggest that some of the pathologies seen in AT could arise as a consequence of an inability to respond normally to oxidative damage.	NIEHS, Growth Control & Canc Grp, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Paules, RS (corresponding author), NIEHS, Growth Control & Canc Grp, NIH, Mail Drop F1-05,111 Alexander Dr,POB 12233, Res Triangle Pk, NC 27709 USA.	paules@niehs.nih.gov		Paules, Richard S/0000-0001-9106-7486	NCI NIH HHS [CA40453] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021157, ZIAES021157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, pS130, DOI 10.2307/3578780; Boder E, 1970, Psychiatr Neurol Med Psychol Beih, V13-14, P8; BODER E, 1985, ATAXIA TELANGIECTASI, V19, P1; BOYER JC, 1990, CANCER RES, V50, P2593; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CONGER AD, 1952, P NATL ACAD SCI USA, V38, P289, DOI 10.1073/pnas.38.4.289; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Flattery-O'Brien JA, 1998, J BIOL CHEM, V273, P8564, DOI 10.1074/jbc.273.15.8564; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P2033, DOI 10.1093/hmg/5.12.2033; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Green MHL, 1997, FREE RADICAL BIO MED, V22, P343, DOI 10.1016/S0891-5849(96)00336-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Le XC, 1998, SCIENCE, V280, P1066, DOI 10.1126/science.280.5366.1066; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEREDITH MJ, 1987, CANCER RES, V47, P4576; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1976, BIOCHIM BIOPHYS ACTA, V418, P146, DOI 10.1016/0005-2787(76)90063-0; PAULES RS, 1995, CANCER RES, V55, P1763; Regoli F, 1999, TOXICOL APPL PHARM, V156, P96, DOI 10.1006/taap.1999.8637; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SCOTT D, 1994, INT J RADIAT BIOL, V66, pS157, DOI 10.1080/09553009414551991; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shackelford RE, 1999, ENVIRON HEALTH PERSP, V107, P5, DOI 10.2307/3434468; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; VUILLAUME M, 1987, MUTAT RES, V186, P43, DOI 10.1016/0165-1110(87)90014-5; VUILLAUME M, 1989, CARCINOGENESIS, V10, P1375, DOI 10.1093/carcin/10.8.1375; VUILLAUME M, 1986, CANCER RES, V46, P538; WARD AJ, 1994, ENVIRON MOL MUTAGEN, V24, P103, DOI 10.1002/em.2850240205; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; WINSTON GW, 1983, BIOCHEM J, V216, P415, DOI 10.1042/bj2160415; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; ZAMPETTIBOSSELER F, 1981, INT J RADIAT BIOL, V39, P547, DOI 10.1080/09553008114550651	50	101	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21951	21959		10.1074/jbc.M011303200	http://dx.doi.org/10.1074/jbc.M011303200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290740	Green Published, hybrid			2022-12-25	WOS:000169297900150
J	Chang, BY; Chiang, ML; Cartwright, CA				Chang, BY; Chiang, ML; Cartwright, CA			The interaction of Src and RACK1 is enhanced by activation of protein kinase C and tyrosine phosphorylation of RACK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; MIDDLE TUMOR-ANTIGEN; NIH 3T3 CELLS; WD-REPEAT; SIGNAL-TRANSDUCTION; SH2 DOMAIN; MONOCLONAL-ANTIBODIES; ANCHORING PROTEINS; SCAFFOLD PROTEIN	RACK1 is an intracellular receptor for the serine/threonine protein kinase C. Previously, we demonstrated that RACK1 also interacts with the Src protein-tyrosine kinase. RACK1, via its association with these protein kinases, may play a key role in signal transduction. To further characterize the Src-RACK1 interaction and to analyze mechanisms by which cross-talk occurs between the two RACK1-linked signaling kinases, we identified sites on Src and RACK1 that mediate their binding, and factors that regulate their interaction. We found that the interaction of Src and RACK1 is mediated, in part, by the SH2 domain of Src and by phosphotyrosines in the sixth WD repeat of RACK1, and is enhanced by serum or platelet-derived growth factor stimulation, protein kinase C activation, and tyrosine phosphorylation of RACK1. To the best of our knowledge, this is the first report of tyrosine phosphorylation of a member of the WD repeat family of proteins. We think that tyrosine phosphorylation of these proteins is an important mechanism of signal transduction in cells.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, CCSR Bldg,Rm 3115C,269 Campus Dr, Stanford, CA 94305 USA.				NCI NIH HHS [CA69810] Funding Source: Medline; NIDDK NIH HHS [R01 DK43743] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA069810] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1985, MOL CELL BIOL, V5, P2647, DOI 10.1128/MCB.5.10.2647; CARTWRIGHT CA, 1986, MOL CELL BIOL, V6, P1562, DOI 10.1128/MCB.6.5.1562; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; DISTNIK MH, 1994, P NATL ACAD SCI USA, V91, P559; Emkey R, 1997, J BIOL CHEM, V272, P31172, DOI 10.1074/jbc.272.49.31172; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gekeler V, 1996, BRIT J CANCER, V74, P897, DOI 10.1038/bjc.1996.454; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P231; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LIU XQ, 1993, ONCOGENE, V8, P1119; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mochly-Rosen D, 1998, ADV PHARMACOL, V44, P91, DOI 10.1016/S1054-3589(08)60126-X; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; MULLER F, 1995, MOL GEN GENET, V248, P162, DOI 10.1007/BF02190797; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Neer EJ, 1996, CELL, V84, P175, DOI 10.1016/S0092-8674(00)80969-1; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PARK J, 1995, MOL CELL BIOL, V15, P2374; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RodriguezFernandez JL, 1996, J BIOL CHEM, V271, P27895, DOI 10.1074/jbc.271.44.27895; Ron D, 1999, J BIOL CHEM, V274, P27039, DOI 10.1074/jbc.274.38.27039; RON D, 1994, J BIOL CHEM, V269, P21395; Ron D, 1999, J BIOL CHEM, V274, P19003, DOI 10.1074/jbc.274.27.19003; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Walter AO, 1999, ONCOGENE, V18, P1911, DOI 10.1038/sj.onc.1202513; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1995, METHOD ENZYMOL, V254, P523; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	61	144	149	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20346	20356		10.1074/jbc.M101375200	http://dx.doi.org/10.1074/jbc.M101375200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279199	hybrid			2022-12-25	WOS:000169135100092
J	Grassme, H; Jekle, A; Riehle, A; Schwarz, H; Berger, J; Sandhoff, K; Kolesnick, R; Gulbins, E				Grassme, H; Jekle, A; Riehle, A; Schwarz, H; Berger, J; Sandhoff, K; Kolesnick, R; Gulbins, E			CD95 signaling via ceramide-rich membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACIDIC SPHINGOMYELINASE; RECEPTOR; ASSOCIATION; CAVEOLAE; TNF; LOCALIZATION; CHOLESTEROL; PATHWAYS; PROTEINS; LIGAND	Clustering seems to be employed by many receptors for transmembrane signaling. Here, we show that acid sphingomyelinase (ASM)-released ceramide is essential for clustering of CD95, In vitro and in vivo, extracellularly orientated ceramide, released upon CD95-triggered translocation of ASM to the plasma membrane outer surface, enabled clustering of CD95 in sphingo lipid-rich membrane rafts and apoptosis induction. Whereas ASM deficiency, destruction of rafts, or neutralization of surface ceramide prevented CD95 clustering and apoptosis, natural ceramide only rescued ASM-deficient cells. The data suggest CD95-mediated clustering by ceramide is prerequisite for signaling and death.	St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Max Planck Inst Dev Biol, D-72076 Teubingen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	St Jude Children's Research Hospital; University of Bonn; Max Planck Society; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale, Memphis, TN 38105 USA.	erich.gulbins@stjude.org	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342; Jekle, Andreas/0000-0001-9416-2622	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Brenner B, 1998, EXP CELL RES, V243, P123, DOI 10.1006/excr.1998.4146; Cheng PC, 1999, J EXP MED, V190, P1549, DOI 10.1084/jem.190.11.1549; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Drzewiecka A, 1999, ACTA BIOCHIM POL, V46, P107, DOI 10.18388/abp.1999_4188; Gijon MA, 1997, SEMIN CELL DEV BIOL, V8, P297, DOI 10.1006/scdb.1997.0151; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Gulbins E, 2000, AM J PHYSIOL-RENAL, V279, pF605, DOI 10.1152/ajprenal.2000.279.4.F605; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Huang HW, 1999, BIOPHYS J, V77, P1489, DOI 10.1016/S0006-3495(99)76996-1; Ko YG, 1999, J IMMUNOL, V162, P7217; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Maxfield FR, 1997, ADV EXP MED BIOL, V419, P355; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Ni HT, 1999, J IMMUNOL, V162, P5183; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; ROSENMAN SJ, 1993, J LEUKOCYTE BIOL, V53, P1; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; Simarro M, 1999, J IMMUNOL, V162, P5149; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; tenGrotenhuis E, 1996, BIOPHYS J, V71, P1389, DOI 10.1016/S0006-3495(96)79341-4; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456	35	493	508	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20589	20596		10.1074/jbc.M101207200	http://dx.doi.org/10.1074/jbc.M101207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279185	hybrid			2022-12-25	WOS:000169135100123
J	Seitz, C; Muller, P; Krieg, RC; Mannel, DN; Hehlgans, T				Seitz, C; Muller, P; Krieg, RC; Mannel, DN; Hehlgans, T			A novel p75TNF receptor isoform mediating NF kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TNF RECEPTOR; FUNCTIONAL-CHARACTERIZATION; MOLECULAR-CLONING; VIRAL-PROTEINS; EXPRESSION; PROLIFERATION; CYTOTOXICITY; FAMILY; CELLS	We report the identification of a novel p75TNF receptor isoform termed icp75TNFR, which is generated by the use of an alternative transcriptional start site within the p75TNFR gene and characterized by regulated intracellular expression. The icp75TNFR protein has an apparent molecular mass of similar to 50 kDa and is recognized by antibodies generated against the transmembrane form of p75TNFR. The icp75TNFR binds the tumor necrosis factor(TNF) and mediates intracellular signaling. Overexpression of the icp75TNFR cDNA results in TNF-induced activation of NF kappaB in a TNF receptor-associated factor 2 (TRAF2)-dependent manner. Thus, our results provide an example for intracellular cytokine receptor activation.	Univ Regensburg, Dept Pathol Tumor Immunol, D-93042 Regensburg, Germany	University of Regensburg	Mannel, DN (corresponding author), Univ Regensburg, Dept Pathol Tumor Immunol, Franz Josef Str Allee, D-93042 Regensburg, Germany.							Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ERIKSTEIN BK, 1991, EUR J IMMUNOL, V21, P1033, DOI 10.1002/eji.1830210426; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; Haridas V, 1998, J IMMUNOL, V160, P3152; HELLER RA, 1992, CELL, V70, P47; Ledgerwood EC, 1998, LAB INVEST, V78, P1583; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MASON AT, 1995, J LEUKOCYTE BIOL, V58, P249, DOI 10.1002/jlb.58.2.249; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Seitz C, 1998, GENOMICS, V48, P111, DOI 10.1006/geno.1997.5161; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; VERCAMMEN D, 1995, CYTOKINE, V7, P463, DOI 10.1006/cyto.1995.0063	20	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19390	19395		10.1074/jbc.M101336200	http://dx.doi.org/10.1074/jbc.M101336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279196	hybrid			2022-12-25	WOS:000169091000100
J	Chen, JL; Tsai, LC; Wen, TN; Tang, JB; Yuan, HS; Shyur, LF				Chen, JL; Tsai, LC; Wen, TN; Tang, JB; Yuan, HS; Shyur, LF			Directed mutagenesis of specific active site residues on Fibrobacter succinogenes 1,3-1,4-beta-D-glucanase significantly affects catalysis and enzyme structural stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSTABLE BETA-GLUCANASE; ACID-SEQUENCE SIMILARITIES; BACILLUS-LICHENIFORMIS; ESCHERICHIA-COLI; ENDO-1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASE; CLOSTRIDIUM-THERMOCELLUM; PROTEIN STRUCTURES; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; GENE	The functional and structural significance of amino acid residues Met(39), Glu(56), Asp(58), Glu(601) and Gly(63) Of Fibrobacter succinogenes 1,3-1,4-beta -D-glucanase was explored by the approach of site-directed mutagenesis, initial rate kinetics, fluorescence spectroscopy, and CD spectrometry, Glu(56), Asp(58), Glu(60), and Gly(63) residues are conserved among known primary sequences of the bacterial and fungal enzymes. Kinetic analyses revealed that 240-, 540-, 570-, and 880-fold decreases in K-cat were observed for the E56D, E60D, D58N, and D58E mutant enzymes, respectively, with a similar substrate affinity relative to the wild type enzyme. In contrast, no detectable enzymatic activity was observed for the E56A, E56Q, D58A, E60A, and E60Q mutants. These results indicated that the carboxyl side chain at positions 56 and 60 is mandatory for enzyme catalysis, M39F, unlike the other mutants, exhibited a 5-fold increase in K-m value. Lower thermostability was found with the G63A mutant when compared with wild type or other mutant forms of F. succinogenes 1,3-1,4-beta -D-glucanase. Denatured wild type and mutant enzymes were, however, recoverable as active enzymes when 8 M urea was employed as the denaturant. Structural modeling and kinetic studies suggest that Glu(56), Asp(58) and Glu(60) residues apparently play important role(s) in the catalysis off. succinogenes 1,3-1,4-beta -D-glucanase.	Acad Sinica, Inst Bioagr Sci, Taipei 115, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Acad Sinica, Inst Bot, Taipei 115, Taiwan	Academia Sinica - Taiwan; Academia Sinica - Taiwan; Academia Sinica - Taiwan	Shyur, LF (corresponding author), Acad Sinica, Inst Bioagr Sci, Taipei 11529, Taiwan.		Yuan, Hanna S./AAA-4005-2021; Chia, linda/B-3406-2011	Yuan, Hanna S./0000-0001-9671-6967; 				BORRISS R, 1990, MOL GEN GENET, V222, P278, DOI 10.1007/BF00633829; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen HZ, 1997, J BACTERIOL, V179, P6028, DOI 10.1128/jb.179.19.6028-6034.1997; Cheng YS, 2000, J MOL BIOL, V302, P1139, DOI 10.1006/jmbi.2000.4123; DAKHOVA ON, 1993, BIOCHEM BIOPH RES CO, V194, P1359, DOI 10.1006/bbrc.1993.1974; GOSALBES MJ, 1991, J BACTERIOL, V173, P7705, DOI 10.1128/jb.173.23.7705-7710.1991; Gueguen Y, 1997, J BIOL CHEM, V272, P31258, DOI 10.1074/jbc.272.50.31258; HAHN M, 1995, J BIOL CHEM, V270, P3081, DOI 10.1074/jbc.270.7.3081; HAHN M, 1995, EUR J BIOCHEM, V232, P849, DOI 10.1111/j.1432-1033.1995.tb20883.x; HAHN M, 1994, P NATL ACAD SCI USA, V91, P10417, DOI 10.1073/pnas.91.22.10417; Heinemann U, 1996, BIOL CHEM, V377, P447; HEINEMANN U, 1995, TRENDS BIOCHEM SCI, V20, P349, DOI 10.1016/S0968-0004(00)89073-8; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOFEMEISTER J, 1986, GENE, V49, P177, DOI 10.1016/0378-1119(86)90278-7; HOJ PB, 1992, J BIOL CHEM, V267, P25059; JUNCOSA M, 1994, J BIOL CHEM, V269, P14530; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; LLOBERAS J, 1991, EUR J BIOCHEM, V197, P337, DOI 10.1111/j.1432-1033.1991.tb15916.x; LOUW ME, 1993, APPL MICROBIOL BIOT, V38, P507, DOI 10.1007/BF00242946; MALET C, 1993, BIOCHEM J, V296, P753, DOI 10.1042/bj2960753; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; NELSON M, 1992, METHOD ENZYMOL, V216, P279; Parrado J, 1996, BBA-PROTEIN STRUCT M, V1296, P145, DOI 10.1016/0167-4838(96)00062-3; Piruzian ES, 1998, MOL GEN GENET, V257, P561, DOI 10.1007/s004380050682; SANCHEZ R, 1997, T AM CRYST ASS, V32, P81; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sauer RT, 1996, FASEB J, V10, P42, DOI 10.1096/fasebj.10.1.8566546; SCHIMMING S, 1992, EUR J BIOCHEM, V204, P13, DOI 10.1111/j.1432-1033.1992.tb16600.x; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SPILLIAERT R, 1994, EUR J BIOCHEM, V224, P923, DOI 10.1111/j.1432-1033.1994.00923.x; STEWART CS, 1989, APPL MICROBIOL BIOT, V30, P433; TEATHER RM, 1990, J BACTERIOL, V172, P3837, DOI 10.1128/jb.172.7.3837-3841.1990; Viladot JL, 1998, BIOCHEMISTRY-US, V37, P11332, DOI 10.1021/bi980586q; WOLF M, 1995, MICROBIOL-UK, V141, P281, DOI 10.1099/13500872-141-2-281	39	24	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17895	17901		10.1074/jbc.M100843200	http://dx.doi.org/10.1074/jbc.M100843200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279139	hybrid			2022-12-25	WOS:000168866500039
J	Hamm, JK; Park, BH; Farmer, SR				Hamm, JK; Park, BH; Farmer, SR			A role for C/EBP beta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES ADIPOCYTE DIFFERENTIATION; PPAR-GAMMA; TRANSCRIPTION FACTORS; BINDING-PROTEINS; GENE-EXPRESSION; MESSENGER-RNA; FATTY-ACIDS; ALPHA; ISOFORMS; FIBROBLASTS	The differentiation of 3T3-L1 preadipocytes is regulated in part by a cascade of transcriptional events involving activation of the CCAAT/enhancer-binding proteins (C/EBPs) and peroxisome proliferator-activated receptor gamma (PPAR gamma) by dexamethasone (DEX), 3-isobutyl-1-methylxanthine (MIX), and insulin. In this study, we demonstrate that exposure of 3T3-L1 preadipocytes to DEX and insulin fails to induce adipogenesis as indicated by a lack of C/EBP alpha, PPAR gamma2, and adipose protein 2/fatty acid-binding protein expression; however, PPAR gamma1 is expressed. Treatment of these MM-deficient cells with a PPAR gamma ligand, troglitazone, induces C/EBP alpha expression and rescues the block in adipogenesis, In this regard, we also show that induction of C/EBP alpha gene expression by troglitazone in C3H10T1/2 cells ectopically expressing PPAR gamma occurs in the absence of ongoing protein synthesis, suggesting a direct transactivation of the C/EBP alpha gene by PPAR gamma, Furthermore, ectopic expression of a dominant negative isoform of C/EBP beta (liver-enriched transcriptional inhibitory protein (LIP)) inhibits the induction of C/EBP alpha, PPAR gamma2, and adipose protein 2/fatty acid-binding protein by DEX, MM, and insulin in 3T3-L1 cells without affecting the induction of PPAR gamma1 by DEX, Exposure of LIP-expressing preadipocytes to troglitazone along with DEX, MM, and insulin induces differentiation into adipocytes. Additionally, we show that sustained expression of C/EBP alpha in these LIP-expressing adipocytes requires constant exposure to troglitazone. Taken together, these observations suggest that inhibition of C/EBP beta activity not only blocks C/EBP alpha and PPAR gamma2 expression, but it also renders the preadipocytes dependent on an exogenous PPAR gamma ligand for their differentiation into adipocytes, We propose, therefore, an additional role for C/EBP beta in regulating PPAR gamma activity during adipogenesis, and we suggest an alternative means of inducing preadipocyte differentiation that relies on the dexamethasone-associated induction of PPAR gamma1 expression.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu		Farmer, Stephen/0000-0003-2483-2795	NIDDK NIH HHS [DK51586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK051586, R01DK051586] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elberg G, 2000, J BIOL CHEM, V275, P27815; Fajas L, 1999, MOL CELL BIOL, V19, P5495; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Morrison RF, 1999, J CELL BIOCHEM, P59; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; STUDENT AK, 1980, J BIOL CHEM, V255, P4745; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	39	204	212	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18464	18471		10.1074/jbc.M100797200	http://dx.doi.org/10.1074/jbc.M100797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279134	hybrid			2022-12-25	WOS:000168866500113
J	Jaiswal, AS; Narayan, S				Jaiswal, AS; Narayan, S			p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; DAMAGE-INDUCED PHOSPHORYLATION; CYCLIN-DEPENDENT KINASES; BETA-CATENIN; COLORECTAL-CANCER; HUMAN P53; MESSENGER-RNA; LUNG-CANCER; C-MYC; BINDING	The APC (adenomatous polyposis coli) gene product is involved in cell cycle arrest and in apoptosis, The loss of APC function is associated with the development of colorectal carcinogenesis. In previous studies, we have shown that the APC gene is inducible and that the DNA damage-induced level of APC mRNA requires p53, In the present study, we examined the role of p53 in the transcriptional regulation of APC promoter and characterized two p53-binding sites on the cloned APC promoter (pAPCP), Results of electrophoretic mobility shift assay showed specific interactions of p53 protein with p53-binding site oligonucleotides. The DNA-protein complex formed in electrophoretic mobility shift assay was competed with unlabeled excess of p53-binding site oligonucleotide, unaffected with p53-binding site mutant or Spl-binding site oligonucleotides, and supershifted with anti-p53 antibodies. In a transient transfection assay, the pAPCP promoter activity was lower in HCT-116(p53(+/+)) cells versus HCT-116(p53(-/-)) cells. p53-dependent down-regulation was further confirmed after co-transfection of pAPCP plasmid with pCMV-p53 into HCT-116(p53(-/-)) and SAOS-S (p53-negative) cells. However, the treatment of cells with DNA alkylating agents methylmethane sulfonate and N-methyl-N'-nitro-N-nitrosoguanidine, which cause phosphorylation of p53 at Ser(15) and Ser(392), induced pAPCP promoter activity in HCT-116(p53(+/+)) cells. Other than p53-binding sites, using deletion mutation constructs, we have shown that N-methyl-N'-nitro-N-nitrosoguanidine-induced transcriptional activation of the pAPCP promoter in HCT-116(p53(+/+)) cells depended upon the Sp1-binding: site and the E-box B site. From these results, we conclude that unphosphorylated p53 can down-regulate and phosphorylated p53 can up-regulate the pAPCP promoter activity involving the p53, Sp1, or E-box B elements. These studies are important to understanding the role of p53 and APC in DNA damage-induced cell cycle arrest and/or apoptosis of cancer cells.	Univ Florida, Coll Med, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Narayan, S (corresponding author), Univ Florida, Coll Med, Shands Canc Ctr, Acad Res Bldg,Rm R4-216,POB 100232, Gainesville, FL 32610 USA.				NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NCI NIH HHS [CA77721] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; EIBNER M, 1994, MED GENET, V6, P155; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Furuuchi K, 2000, AM J PATHOL, V156, P1997, DOI 10.1016/S0002-9440(10)65072-9; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1995, CANCER RES, V55, P1531; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; HARGEST R, 1995, GUT, V37, P826, DOI 10.1136/gut.37.6.826; HARPER JW, 1993, CELL, V75, P805; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecker D, 1996, ONCOGENE, V12, P953; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Ichii Shigetoshi, 1992, Human Molecular Genetics, V1, P387, DOI 10.1093/hmg/1.6.387; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Jaiswal AS, 1998, INT J ONCOL, V13, P733; Jaiswal AS, 1999, ONCOL REP, V6, P1253; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; MEDIROS AC, 1994, CANCER EPIDEM BIOMAR, V3, P331; Meek DW, 2000, PATHOL BIOL, V48, P246; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Oreffo VIC, 1998, MOL CARCINOGEN, V21, P37, DOI 10.1002/(SICI)1098-2744(199801)21:1<37::AID-MC6>3.0.CO;2-M; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prives C, 1999, J PATHOL, V187, P112; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sanz-Ortega J, 1999, PATHOL RES PRACT, V195, P677; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THLIVERIS A, 1994, CANCER RES, V54, P2991; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	65	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18193	18199		10.1074/jbc.M101298200	http://dx.doi.org/10.1074/jbc.M101298200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279192	hybrid			2022-12-25	WOS:000168866500078
J	Kumar, R; Lee, JC; Bolen, DW; Thompson, EB				Kumar, R; Lee, JC; Bolen, DW; Thompson, EB			The conformation of the glucocorticoid receptor AF1/tau1 domain induced by osmolyte binds co-regulatory proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; GENE-EXPRESSION; COMPLEX; COACTIVATORS; FRAGMENT; SEQUENCE; REGION	The activation domains of many transcription factors appear to exist naturally in an unfolded or only partially folded state. This seems to be the case for AF1/tau1, the major transactivation domain of the human glucocorticoid receptor. We show here that in buffers containing the natural osmolyte trimethylamine N-oxide (TMAO), recombinant AF1 folds into more a compact structure, as evidenced by altered fluorescence emission, circular dichroism spectra, and ultracentrifugal analysis. This conformational transition is cooperative, a characteristic of proteins folding to natural structures. The structure resulting from incubation in TMAO causes the peptide to resist proteolysis by trypsin, chymotrypsin, endoproteinase Arg-C and endoproteinase Gluc-C. Ultracentrifugation studies indicate that AF1/tau1 exists as a monomer in aqueous solution and that the presence of TMAO does not lead to oligomerization or aggregation. It has been suggested that recombinant AF1 binds both the ubiquitous coactivator CBP and the TATA box-binding protein, TBP, Interactions with both of these are greatly enhanced in the presence of TMAO. Co-immunoadsorption experiments indicate that in TMAO each of these and the coactivator SRC-1 are found complexed with AF1. These data indicate that TMAO induces a conformation in AF1/tau1 that is important for its interaction with certain co-regulatory proteins.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Thompson, EB (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 301 Univ Blvd,605 Basic Sci Bldg, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NATIONAL CANCER INSTITUTE [R01CA041407] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058829] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1 CA 41407] Funding Source: Medline; NCRR NIH HHS [RR 08961] Funding Source: Medline; NIDDK NIH HHS [1RO1 DK58829-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; BACK JF, 1979, BIOCHEMISTRY-US, V18, P5191, DOI 10.1021/bi00590a025; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov I, 1998, BIOPHYS J, V74, P2666, DOI 10.1016/S0006-3495(98)77972-X; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chen H, 1997, J BIOL CHEM, V272, P25873, DOI 10.1074/jbc.272.41.25873; CHERVENKA CH, 1969, MANUAL METHODS ANALY, P45; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; Dalby PA, 1998, J MOL BIOL, V276, P625, DOI 10.1006/jmbi.1997.1546; Ford J, 1997, MOL ENDOCRINOL, V11, P1467, DOI 10.1210/me.11.10.1467; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; LEE JC, 1981, J BIOL CHEM, V256, P7193; LIU YF, 1995, BIOCHEMISTRY-US, V34, P12884, DOI 10.1021/bi00039a051; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; ONATE SA, 1995, SCIENCE, V270, P1354; Qu YX, 1998, P NATL ACAD SCI USA, V95, P9268, DOI 10.1073/pnas.95.16.9268; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Shen F, 1996, J BIOL CHEM, V271, P4827; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TSAI SY, 1990, J BIOL CHEM, V265, P17055; Van Holde K., 1971, PHYSICAL BIOCH, P98; Warnmark A, 2000, J BIOL CHEM, V275, P15014, DOI 10.1074/jbc.M001007200; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	42	111	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18146	18152		10.1074/jbc.M100825200	http://dx.doi.org/10.1074/jbc.M100825200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279138	hybrid			2022-12-25	WOS:000168866500072
J	Zhu, C; Gagnidze, K; Gemberling, JHM; Plevy, SE				Zhu, C; Gagnidze, K; Gemberling, JHM; Plevy, SE			Characterization of an activation protein-1-binding site in the murine interleukin-12 p40 promoter - Demonstration of novel functional elements by a reductionist approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CELL STIMULATORY FACTOR; GENE PROMOTER; MAP KINASE; TRANSCRIPTION FACTORS; ADAPTIVE IMMUNITY; CYTOKINE PATTERNS; NEGATIVE MUTANTS; INTERFERON-GAMMA; IL-12 PRODUCTION	Interleukin (IL)-12 is a heterodimeric cytokine produced by macrophages in response to intracellular pathogens and provides an obligatory signal for the differentiation of T-helper-l cells. We previously reported an analysis of the IL-12 p40 promoter in RAW264.7 macrophages, Multiple control elements were involved in activation of transcription by bacterial products. A critical control element, located between -96 and -88, interacts with C/EBP family members. In this study, using a strategy to demonstrate functional activity in a minimal promoter context, three novel cis-acting elements are found to have an important role in IL-12 p40 promoter activation by lipopolysaccharide. One of these elements is characterized in detail. Mutations from -79 to -74 in the murine IL-12 p40 promoter significantly reduce lipopolysaccharide-induced promoter activity. Electrophoretic mobility shift assays demonstrate binding of AP-1 family members to this region. Spacing between the C/EBP and AP-1 site is important for promoter activation, suggesting cooperativity between these elements. c-Jun and a mutant c-Jun molecule activate the IL-12 p40 promoter and synergistically activate the promoter when co-expressed with C/EBP beta. Finally, this region of the promoter is demonstrated to be a target for mitogen-activated protein kinase and toll-like receptor signaling pathways.	CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Plevy, SE (corresponding author), CUNY Mt Sinai Sch Med, Immunobiol Ctr, Box 1630,1 Gustave L Levy Pl, New York, NY 10029 USA.				NIDDK NIH HHS [K11 DK02358] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK002358] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Feng GJ, 1999, J IMMUNOL, V163, P6403; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Leonard DA, 1997, P NATL ACAD SCI USA, V94, P4913, DOI 10.1073/pnas.94.10.4913; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Ma XJ, 1996, ANN NY ACAD SCI, V795, P357, DOI 10.1111/j.1749-6632.1996.tb52692.x; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Nikolajczyk BS, 1996, MOL CELL BIOL, V16, P4544; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PIRMEZ C, 1993, J CLIN INVEST, V91, P1390, DOI 10.1172/JCI116341; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; Seder RA, 1996, J IMMUNOL, V157, P2745; SIELING PA, 1994, IMMUNOBIOLOGY, V191, P378, DOI 10.1016/S0171-2985(11)80443-2; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wise SC, 1998, ONCOGENE, V16, P2001, DOI 10.1038/sj.onc.1201697; WOLF SF, 1991, J IMMUNOL, V146, P3074; Wu GD, 1997, J BIOL CHEM, V272, P2396; YAN MH, 1994, NATURE, V372, P798; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Zagariya A, 1998, MOL CELL BIOL, V18, P2815, DOI 10.1128/MCB.18.5.2815; ZHANG M, 1994, J CLIN INVEST, V93, P1733, DOI 10.1172/JCI117157	48	80	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18519	18528		10.1074/jbc.M100440200	http://dx.doi.org/10.1074/jbc.M100440200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279072	hybrid			2022-12-25	WOS:000168866500121
J	Minogue, S; Anderson, JS; Waugh, MG; dos Santos, M; Corless, S; Cramer, R; Hsuan, JJ				Minogue, S; Anderson, JS; Waugh, MG; dos Santos, M; Corless, S; Cramer, R; Hsuan, JJ			Cloning of a human type II phosphatidylinositol 4-kinase reveals a novel lipid kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOINOSITIDE KINASES; CELLULAR-REGULATION; MOLECULAR-CLONING; PURIFICATION; MEMBRANES; GROWTH; PROTEIN; PHOSPHORYLATION; POLYPHOSPHOINOSITIDES; RECEPTOR	Phosphoinositide lipids regulate numerous cellular processes in all eukaryotes, The versatility of this phospholipid is provided by combinations of phosphorylation on the 3 ', 4 ', and 5 ' positions of the inositol head group. Two distinct structural families of phosphoinositide (PI) kinases have so far been identified and named after their prototypic members, the pi 3-kinase and phosphatidylinositol (PtdIns) phosphate kinase families, both of which have been found to contain structural homologues possessing PI 4-kinase activity. Nevertheless, the prevalent PtdIns 4-kinase activity in many mammalian cell types is conferred by the widespread type II PtdIns 4-kinase, which has so far resisted molecular characterization. We have partially purified the human type II isoform from plasma membrane rafts of human A431 epidermoid carcinoma cells and obtained peptide mass and sequence data. The results allowed the cDNA containing the full open reading frame to, be cloned. The predicted amino acid sequence revealed that the type II enzyme is the prototypic member of a novel, third family of PI kinases, We have named the purified protein type II alpha and a second human isoform, type II beta. The type II alpha mRNA appears to be expressed ubiquitously in human tissues, and homologues appear to be expressed in all eukaryotes.	UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Mol Cell Biol, London NW3 2PF, England; Ludwig Inst Canc Res, London W1P 8BT, England	University of London; University College London; UCL Medical School; Ludwig Institute for Cancer Research	Hsuan, JJ (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Med, Ctr Mol Cell Biol, Rowland Hill St, London NW3 2PF, England.	j.hsuan@rfc.ucl.ac.uk	dos Santos, Maria/B-7426-2012; Hsuan, Justin/C-8825-2009; Waugh, Mark/K-5232-2013	Hsuan, Justin/0000-0001-6083-7564; Cramer, Rainer/0000-0002-8037-2511; Waugh, Mark/0000-0002-7241-3168				Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Balla T, 1997, J BIOL CHEM, V272, P18358, DOI 10.1074/jbc.272.29.18358; COCHET C, 1991, J BIOL CHEM, V266, P637; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; deNeef RS, 1996, EUR J BIOCHEM, V235, P549; ENDEMANN GC, 1991, BIOCH J; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hsuan JJ, 1998, ADV CANCER RES, V74, P167, DOI 10.1016/S0065-230X(08)60767-8; KAUFFMANNZEH A, 1994, J BIOL CHEM, V269, P31243; KAUFFMANNZEH A, 1995, SCIENCE, V268, P1188, DOI 10.1126/science.7761838; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Meyers R, 1997, J BIOL CHEM, V272, P4384, DOI 10.1074/jbc.272.7.4384; Nakagawa T, 1996, J BIOL CHEM, V271, P12088, DOI 10.1074/jbc.271.20.12088; Nakagawa T, 1996, BIOCHEM J, V320, P643, DOI 10.1042/bj3200643; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PIKE LJ, 1992, ENDOCR REV, V13, P692, DOI 10.1210/er.13.4.692; PORTER FD, 1988, J BIOL CHEM, V263, P8989; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Waugh MG, 1998, J BIOL CHEM, V273, P17115, DOI 10.1074/jbc.273.27.17115; WETZKER R, 1991, EUR J BIOCHEM, V200, P179, DOI 10.1111/j.1432-1033.1991.tb21065.x; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG K, 1994, J BIOL CHEM, V269, P28878; YAMAKAWA A, 1991, J BIOL CHEM, V266, P17580; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	37	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16635	16640		10.1074/jbc.M100982200	http://dx.doi.org/10.1074/jbc.M100982200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279162	hybrid			2022-12-25	WOS:000168730400007
J	Davies, SS; Pontsler, AV; Marathe, GK; Harrison, KA; Murphy, RC; Hinshaw, JC; Prestwich, GD; St Hilaire, A; Prescott, SM; Zimmerman, GA; McIntyre, TM				Davies, SS; Pontsler, AV; Marathe, GK; Harrison, KA; Murphy, RC; Hinshaw, JC; Prestwich, GD; St Hilaire, A; Prescott, SM; Zimmerman, GA; McIntyre, TM			Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PPAR-GAMMA; HUMAN PLASMA; ANTIDIABETIC THIAZOLIDINEDIONE; ATHEROSCLEROTIC LESIONS; MONONUCLEAR PHAGOCYTES; MASS-SPECTROMETRY; GENE-EXPRESSION; FATTY-ACIDS; ALPHA	Synthetic high affinity peroxisome proliferator-activated receptor (PPAR) agonists are known, but biologic ligands are of low affinity. Oxidized low density lipoprotein (oxLDL) is inflammatory and signals through PPARs. We showed, by phospholipase A(1) digestion, that PPAR gamma agonists in oxLDL arise from the small pool of alkyl phosphatidylcholines in LDL. We identified an abundant oxidatively fragmented alkyl phospholipid in oxLDL, hexadecyl azelaoyl phosphatidylcholine (azPC), as a high affinity ligand and agonist for PPAR gamma. [H-3]azPC bound recombinant PPAR gamma with an affinity (K-d(app) approximate to 40 nM) that was equivalent to rosiglitazone (BRL49653), and competition with rosiglitazone showed that binding occurred in the ligand-binding pocket. azPC induced PPRE reporter gene expression, as did rosiglitazone, with a half-maximal effect at 100 nM. Over-expression of PPAR alpha or PPAR gamma revealed that azPC was a specific PPAR gamma agonist. The scavenger receptor CD36 is encoded by a PPRE-responsive gene, and azPC enhanced expression of CD36 in primary human monocytes. We found that anti-CD36 inhibited azPC uptake, and it inhibited PPRE reporter induction. Results with a small molecule phospholipid flippase mimetic suggest azPC acts intracellularly and that cellular azPC accumulation was efficient. Thus, certain alkyl phospholipid oxidation products in oxLDL are specific, high affinity extracellular ligands and agonists for PPAR gamma that induce PPAR-responsive genes.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; National Jewish Health	McIntyre, TM (corresponding author), Univ Utah, Dept Pathol, 4130 EIHG,15 North 2030 East, Salt Lake City, UT 84112 USA.		Murphy, Robert/AAO-5349-2020	Murphy, Robert/0000-0002-9430-6515; Marathe, Gopal/0000-0002-0025-6677; Davies, Sean/0000-0001-9879-8062	NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044525, R01HL044513, P01HL034303, R37HL044525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 42014] Funding Source: Medline; NHLBI NIH HHS [HL34303, HL 44525, HL 35217, HL44513] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; BECKMAN JK, 1994, CARCINOGENESIS, V15, P2937, DOI 10.1093/carcin/15.12.2937; Boon JM, 1999, J AM CHEM SOC, V121, P11924, DOI 10.1021/ja9933285; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; Feng JW, 2000, J LIPID RES, V41, P688; FOLCIK VA, 1994, J LIPID RES, V35, P1570; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; GLAVIND J, 1952, ACTA PATHOL MIC SC, V30, P1; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; KAYGANICHHARRISON KA, 1994, ANAL BIOCHEM, V221, P16, DOI 10.1006/abio.1994.1372; Kessel JM, 1998, J IMMUNOL, V160, P5579; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Lee H, 2000, CIRC RES, V87, P516; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lehr HA, 1997, J CLIN INVEST, V99, P2358, DOI 10.1172/JCI119417; LENZ ML, 1990, J LIPID RES, V31, P1043; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090-6980(00)00072-1; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Reginato MJ, 1998, J BIOL CHEM, V273, P32679, DOI 10.1074/jbc.273.49.32679; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Schlame M, 1996, J LIPID RES, V37, P2608; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; VALIYAYEETTIL S, 1993, ANGEW CHEM INT EDIT, V32, P900, DOI 10.1002/anie.199309001; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; YAGI K, 1984, BIOESSAYS, V1, P58, DOI 10.1002/bies.950010205; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Young PW, 1998, J PHARMACOL EXP THER, V284, P751	53	206	234	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16015	16023		10.1074/jbc.M100878200	http://dx.doi.org/10.1074/jbc.M100878200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279149	hybrid			2022-12-25	WOS:000168623100061
J	Ravanti, L; Toriseva, M; Penttinen, R; Chrombleholme, T; Foschi, M; Han, JH; Kahari, VM				Ravanti, L; Toriseva, M; Penttinen, R; Chrombleholme, T; Foschi, M; Han, JH; Kahari, VM			Expression of human collagenase-3 (MMP-13) by fetal skin fibroblasts is induced by transforming growth factor-beta via p38 mitogen-activated protein kinase	FASEB JOURNAL			English	Article						matrix metalloproteinase; collagenase; fibroblast	MATRIX-METALLOPROTEINASE EXPRESSION; SQUAMOUS-CELL CARCINOMAS; TGF-BETA; NEUTRALIZING ANTIBODY; EXTRACELLULAR-MATRIX; ADULT FIBROBLASTS; BREAST CARCINOMAS; TISSUE INHIBITOR; WOUND REPAIR; KERATINOCYTES	Human collagenase-3 (MMP-13) is characterized by wide substrate specificity and limited tissue specific expression. We have previously noted that human collagenase-3 (MMP-13) is expressed by gingival fibroblasts in culture and during gingival wound repair characterized by minimal scarring. Here we show that human MMP-13 is expressed by dermal fibroblasts during early wound repair in fetal skin grafted on SCID mice. The expression of MMP-13 by fetal skin fibroblasts in monolayer culture was enhanced by transforming growth factor b1 (TGF-beta 1) and TGF-beta 3, whereas MMP-13 expression was not detected in neonatal skin fibroblasts. Treatment of fetal skin fibroblasts with TGF-beta 1 potently activated p38 mitogen-activated protein kinase (MAPK). Induction of MMP-13 expression by TGF-beta 1 was blocked by p38 MAPK inhibitor SB203580, and by adenovirally delivered dominant negative form of p38 alpha. These observations demonstrate a remarkable difference in the regulation of collagenolytic capacity between fetal and neonatal skin fibroblasts, which suggests a role for MMP-13 in rapid turnover of collagenous matrix during repair of fetal cutaneous wounds, which heal without scar.	Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Penn, Sch Med, Childrens Inst Surg Sci, Philadelphia, PA USA; Univ Florence, Dept Internal Med, Florence, Italy; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	University of Turku; University of Turku; University of Turku; University of Pennsylvania; University of Florence; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokuta 6B, FIN-20520 Turku, Finland.	veli-matti.hahari@btk.utu.fi	Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011; Han, J/G-4671-2010	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368; Toriseva, Mervi/0000-0003-3024-6282				Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; BOSTROM PJ, 2000, INT J CANCE IN PRESS; Broker BJ, 1999, ARCH OTOLARYNGOL, V125, P676, DOI 10.1001/archotol.125.6.676; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Clark RAF, 1997, J CELL PHYSIOL, V170, P69; Cullen B, 1997, INT J BIOCHEM CELL B, V29, P241, DOI 10.1016/S1357-2725(96)00137-9; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Ellis I, 1997, DEVELOPMENT, V124, P1593; Ellis IR, 1998, CYTOKINE, V10, P281, DOI 10.1006/cyto.1997.0294; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945-053X(98)90019-1; INOUE M, 1995, J INVEST DERMATOL, V104, P479, DOI 10.1111/1523-1747.ep12605917; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Kahari VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260; Khorramizadeh MR, 1999, MOL CELL BIOCHEM, V194, P99, DOI 10.1023/A:1006909021352; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Lanning DA, 1999, J PEDIATR SURG, V34, P695, DOI 10.1016/S0022-3468(99)90358-5; LORENZ HP, 1992, DEVELOPMENT, V114, P253; Mao DL, 1999, BIOCHEM BIOPH RES CO, V261, P904, DOI 10.1006/bbrc.1999.1142; McCallion RL, 1996, MOL CELLULAR BIOL WO, P561; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; NIKKOLA J, 2000, MELANOMA RE IN PRESS; Pilcher BK, 1997, J CELL BIOL, V137, P1445, DOI 10.1083/jcb.137.6.1445; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Ravanti L, 2000, INT J MOL MED, V6, P391; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; SAARIALHOKERE UK, 1993, J CLIN INVEST, V92, P2858, DOI 10.1172/JCI116906; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schor S L, 1996, Oral Dis, V2, P155; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Sylvester KG, 2000, WOUND REPAIR REGEN, V8, P36, DOI 10.1046/j.1524-475x.2000.00036.x; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Uria JA, 1997, CANCER RES, V57, P4882; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Wu LC, 1997, ARCH SURG-CHICAGO, V132, P753; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	60	66	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1098	+		10.1096/fj.00-0588fje	http://dx.doi.org/10.1096/fj.00-0588fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292680				2022-12-25	WOS:000167959300023
J	Berg, S; Edman, M; Li, L; Wikstrom, M; Wieslander, A				Berg, S; Edman, M; Li, L; Wikstrom, M; Wieslander, A			Sequence properties of the 1,2-diacylglycerol 3-glucosyltransferase from Acholeplasma laidlawaii membranes - Recognition of a large group of lipid glycosyltransferases in eubacteria and archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; ESCHERICHIA-COLI; STRUCTURE PREDICTION; CRYSTAL-STRUCTURE; GENE; SYNTHASE; DIGLUCOSYLDIACYLGLYCEROL; CLASSIFICATION; PHOSPHOLIPIDS; EXPRESSION	Synthesis of the nonbilayer-prone alpha -monoglucosyldiacylglycerol (MGlcDAG) is crucial for bilayer packing properties and the lipid surface charge density in the membrane of Acholeplasma laidlawii. The gene for the responsible, membrane-bound glucosyltransferase (alMGS) (EC 2.4.1.157) was sequenced and functionally cloned in Escherichia coli, yielding MGlcDAG in the re combinants. Similar amino acid sequences were encoded in the genomes of several Gram-positive bacteria (especially pathogens), thermophiles, archaea, and a few eukaryotes. Ah of these contained the typical EX7E catalytic motif of the CAZy family 4 of alpha -glycosyltransferases. The synthesis of MGlcDAG by a close sequence analog from Streptococcus pneumoniae (spMGS) was verified by polymerase chain reaction cloning, corroborating a connection between sequence and functional similarity for these proteins. However, alMGS and spMGS varied in dependence on anionic phospholipid activators phosphatidylglycerol and cardiolipin, suggesting certain regulatory differences. Fold predictions strongly indicated a similarity for alMGS land spMGS) with the two-domain structure of the E. coli MurG cell envelope glycosyltransferase and several amphipathic membrane binding segments in various proteins. On the basis of this structure, the alMGS sequence charge distribution, and anionic phospholipid dependence, a model for the bilayer surface binding and activity is proposed for this regulatory enzyme.	Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Umea Univ, Dept Biochem, S-90187 Umea, Sweden	Stockholm University; Umea University	Wieslander, A (corresponding author), Univ Stockholm, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	ake@dbb.su.se	Berg, Stefan/AAU-6463-2020; Berg, Stefan O/D-3847-2011	Berg, Stefan/0000-0002-3470-7579; 				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; BRANDEN C, 1998, INTRO PROTEIN STRUCT, P47; Breton C, 1998, J BIOCHEM, V123, P1000; BRUNDISH DE, 1967, BIOCHEM J, V104, P205; BUPP K, 1993, J BACTERIOL, V175, P1841, DOI 10.1128/JB.175.6.1841-1843.1993; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Campbell RE, 2000, BIOCHEMISTRY-US, V39, P14993, DOI 10.1021/bi001627x; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; de Leeuw E, 2000, EMBO J, V19, P531, DOI 10.1093/emboj/19.4.531; DECHAVIGNY A, 1991, J BIOL CHEM, V266, P5323; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fischetti VA, 2000, GRAM-POSITIVE PATHOGENS, P11; Garner J, 1996, EMBO J, V15, P3477, DOI 10.1002/j.1460-2075.1996.tb00714.x; Grebe T, 1997, J BACTERIOL, V179, P3342, DOI 10.1128/jb.179.10.3342-3349.1997; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guler S, 2000, J BACTERIOL, V182, P543, DOI 10.1128/JB.182.2.543-545.2000; GURR MI, 1971, LIPID BIOCH INTRO, P162; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; HAUKSSON JB, 1995, BBA-LIPID LIPID MET, V1258, P1, DOI 10.1016/0005-2760(95)00074-M; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Huynen M, 1998, J MOL BIOL, V280, P323, DOI 10.1006/jmbi.1998.1884; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Karlsson OP, 1997, J BIOL CHEM, V272, P929, DOI 10.1074/jbc.272.2.929; KARLSSON OP, 1994, J BIOL CHEM, V269, P23484; KARLSSON OP, 1997, THESIS UMEA U UMEA; KAUFAM B, 1965, BIOCHEM BIOPH RES CO, V18, P312, DOI 10.1016/0006-291X(65)90705-9; Li L, 1997, J BIOL CHEM, V272, P29602, DOI 10.1074/jbc.272.47.29602; LIVERMORE BP, 1978, INFECT IMMUN, V20, P215, DOI 10.1128/IAI.20.1.215-220.1978; LIVERMORE BP, 1974, J BACTERIOL, V120, P1268, DOI 10.1128/JB.120.3.1268-1273.1974; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MENGINLECREULX D, 1991, J BACTERIOL, V173, P4625, DOI 10.1128/jb.173.15.4625-4636.1991; Miege C, 1999, EUR J BIOCHEM, V265, P990, DOI 10.1046/j.1432-1327.1999.00801.x; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; OCHSNER UA, 1994, J BIOL CHEM, V269, P19787; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Saha SK, 1996, BIOSCI BIOTECH BIOCH, V60, P111; Salamon Z, 2000, BIOPHYS J, V78, P1400, DOI 10.1016/S0006-3495(00)76693-8; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; Schultz CP, 1998, J BIOL CHEM, V273, P15661, DOI 10.1074/jbc.273.25.15661; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333; Soldo B, 1999, MOL MICROBIOL, V31, P795, DOI 10.1046/j.1365-2958.1999.01218.x; SPROTT GD, 1992, J BIOENERG BIOMEMBR, V24, P555, DOI 10.1007/BF00762348; STEINICK LE, 1980, J BACTERIOL, V143, P1200, DOI 10.1128/JB.143.3.1200-1207.1980; TANAKA R, 1991, NUCLEIC ACIDS RES, V19, P6787, DOI 10.1093/nar/19.24.6787; Teichmann SA, 2000, BIOINFORMATICS, V16, P117, DOI 10.1093/bioinformatics/16.2.117; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; Umland TC, 1997, NAT STRUCT BIOL, V4, P788, DOI 10.1038/nsb1097-788; Unligil UM, 2000, CURR OPIN STRUC BIOL, V10, P510, DOI 10.1016/S0959-440X(00)00124-X; Vikstrom S, 1999, BIOCHEMISTRY-US, V38, P5511, DOI 10.1021/bi982532m; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wakarchuk WW, 1998, PROTEIN ENG, V11, P295, DOI 10.1093/protein/11.4.295; Wilkinson S., 1988, MICROBIAL LIPIDS; Zheng WD, 2001, EMBO J, V20, P1164, DOI 10.1093/emboj/20.5.1164	58	50	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22056	22063		10.1074/jbc.M102576200	http://dx.doi.org/10.1074/jbc.M102576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294844	hybrid			2022-12-25	WOS:000169412700011
J	Pierce, KL; Tohgo, A; Ahn, S; Field, ME; Luttrell, LM; Lefkowitz, RJ				Pierce, KL; Tohgo, A; Ahn, S; Field, ME; Luttrell, LM; Lefkowitz, RJ			Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors - A co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ARRESTIN; KINASE ACTIVATION; PHOSPHORYLATION; ENDOCYTOSIS; TRANSACTIVATION; ADHESION; CLATHRIN; DYNAMIN; RELEASE; CASCADE	"Transactivation" of epidermal growth factor receptors (EGFRs) in response to activation of many G protein-coupled receptors (GPCRs) involves autocrine/ paracrine shedding of heparin binding EGF (HB-EGF). HB-EGF shedding involves proteolytic cleavage of a membrane-anchored precursor by incompletely characterized matrix metalloproteases. In COS-7 cells, alpha (2A)-adrenergic receptors (ARs) stimulate ERK phosphorylation via two distinct pathways, a transactivation pathway that involves the release of HB EGF and the EGFR and an alternate pathway that is independent of both HB-EGF and the EGFR. We have developed a mixed culture system to study the mechanism of GPCR-mediated HB-EGF shedding in COS-7 cells. In this system, alpha (2A)AR expressing "donor" cells are co-cultured with "acceptor" cells lacking the alpha (2A)AR. Each population expresses a uniquely epitope-tagged ERK2 protein, allowing the selective measurement of ERK activation in the donor and acceptor cells. Stimulation with the alpha (2)AR selective agonist UK14304 rapidly increases ERK2 phosphorylation in both the donor and the acceptor cells. The acceptor cell response is sensitive to inhibitors of both the EGFR and HB-EGF, indicating that it results from the release of HB EGF from the alpha (2A)AR-expressing donor cells. Experiments with various chemical inhibitors and dominant inhibitory mutants demonstrate that EGFR-dependent activation of the ERK cascade after alpha (2A)AR stimulation requires G beta gamma subunits upstream and dynamin dependent endocytosis downstream of HB-EGF shedding and EGFR activation, whereas Src kinase activity is required both for the release of HB-EGF and for HB-EGF-mediated ERK2 phosphorylation.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med & Biochem, Durham, NC 27710 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Durham, NC 27705 USA	Duke University; Howard Hughes Medical Institute; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Box 3821, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIDDK NIH HHS [DK55524] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055524, R56DK055524] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn S, 1999, J BIOL CHEM, V274, P1185, DOI 10.1074/jbc.274.3.1185; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; CAO W, 2000, J BIOL CHEM, V275, P15490; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Fan HZ, 1999, EMBO J, V18, P6962, DOI 10.1093/emboj/18.24.6962; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, pR179; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4	25	196	198	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23155	23160		10.1074/jbc.M101303200	http://dx.doi.org/10.1074/jbc.M101303200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11290747	hybrid			2022-12-25	WOS:000169412700156
J	Soslau, G; Class, R; Morgan, DA; Foster, C; Lord, ST; Marchese, P; Ruggeri, ZM				Soslau, G; Class, R; Morgan, DA; Foster, C; Lord, ST; Marchese, P; Ruggeri, ZM			Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ALPHA-THROMBIN; CYTOPLASMIC DOMAIN; GPIIB/IIIA ANTAGONISTS; MONOCLONAL-ANTIBODIES; ADHESION RECEPTOR; BINDING-SITES; IX COMPLEX; FIBRINOGEN; ACTIVATION	Thrombin plays a central role in normal and abnormal hemostatic processes. It is assumed that alpha -thrombin activates platelets by hydrolyzing the protease-activated receptor (PAR)-1, thereby exposing a new N-terminal sequence, a tethered ligand, which initiates a cascade of molecular reactions leading to thrombus formation. This process involves cross-linking of adjacent platelets mediated by the interaction of activated glycoprotein (GP) IIb/IIIa with distinct amino acid sequences, LG-GAKQAGDV and/or RGD, at each end of dimeric fibrinogen molecules. We demonstrate here the existence of a second alpha -thrombin-induced platelet-activating pathway, dependent on GP Ib, which does not require hydrolysis of a substrate receptor, utilizes polymerizing fibrin instead of fibrinogen, and can be inhibited by the Fab fragment of the monoclonal antibody LJIb-10 bound to the GP Ib thrombin-binding site or by the cobra venom metalloproteinase, mocarhagin, that hydrolyzes the extracellular portion of GP Ib. This alternative alpha -thrombin pathway is observed when PAR-1 or GP IIb/ IIIa is inhibited. The recognition sites involved in the cross-linking of polymerizing fibrin and surface integrins via the GP Ib pathway are different from those associated with fibrinogen, This pathway is insensitive to RGDS and anti-GP IIb/IIIa antibodies but reactive with a mutant fibrinogen, gamma 407, with a deletion of the gamma -chain sequence, AGDV, The reaction is not due to simple trapping of platelets by the fibrin clot, since ligand binding, signal transduction, and second messenger formation are required. The GP Ib pathway is accompanied by mobilization of internal calcium and the platelet release reaction. This latter aspect is not observed with ristocetin-induced GP m-von Willebrand factor agglutination nor with GP Ib-von Willebrand factor-polymerizing fibrin trapping of platelets. Human platelets also respond to gamma -thrombin, an autoproteolytic product of cu-thrombin, through PAR-4, Go-activation of the GP Ib, PAR-1, and PAR-4 pathways elicit synergistic responses. The presence of the GP Ib pathway may explain why anti-alpha -thrombin/anti-platelet regimens fail to completely abrogate thrombosis/restenosis in the cardiac patient.	Med Coll Penn & Hahnemann Univ, Dept Biochem, Biochem IMS, Philadelphia, PA 19102 USA; Med Coll Penn & Hahnemann Univ, Dept Radiat Oncol, Philadelphia, PA 19102 USA; Med Coll Penn & Hahnemann Univ, Dept Med, Div Hematol Oncol, Philadelphia, PA 19102 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Drexel University; Drexel University; Drexel University; Merck & Company; Schering Plough Corporation; University of North Carolina; University of North Carolina Chapel Hill; Scripps Research Institute; Scripps Research Institute	Soslau, G (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Biochem, Biochem IMS, Mail Stop 344,245 N 15th St, Philadelphia, PA 19102 USA.		Soslau, Gerald/A-7934-2009					Ahn HS, 1999, BIOORG MED CHEM LETT, V9, P2073, DOI 10.1016/S0960-894X(99)00339-X; ALI MN, 1995, CHEST, V108, P1409, DOI 10.1378/chest.108.5.1409; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; BASHEER AR, 1995, BBA-PROTEIN STRUCT M, V1250, P97, DOI 10.1016/0167-4838(95)00050-5; Beguin S, 1997, THROMB HAEMOSTASIS, V78, P590; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BERLINER LJ, 1985, BIOCHEMISTRY-US, V24, P7005, DOI 10.1021/bi00345a038; BODARY SC, 1989, J BIOL CHEM, V264, P18859; Bode C, 1997, CIRCULATION, V95, P800; BRASS LF, 1992, J BIOL CHEM, V267, P13795; CLEMETSON KJ, 1995, THROMB HAEMOSTASIS, V74, P111; Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; Covic L, 2000, BIOCHEMISTRY-US, V39, P5458, DOI 10.1021/bi9927078; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; DIMINNO G, 1982, BLOOD, V59, P563; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Faruqi TR, 2000, J BIOL CHEM, V275, P19728, DOI 10.1074/jbc.M909960199; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P915, DOI 10.1021/bi951504q; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; GRECO NJ, 1991, P SOC EXP BIOL MED, V198, P792; HANDA M, 1986, J BIOL CHEM, V261, P2579; HANTGAN RR, 1995, BLOOD, V86, P1001, DOI 10.1182/blood.V86.3.1001.bloodjournal8631001; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HAWIGER J, 1989, BIOCHEMISTRY-US, V28, P2909, DOI 10.1021/bi00433a024; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; JANDROTPERRUS M, 1988, EUR J BIOCHEM, V174, P359, DOI 10.1111/j.1432-1033.1988.tb14106.x; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Konstantopoulos K, 1997, BIORHEOLOGY, V34, P57, DOI 10.1016/S0006-355X(97)00004-8; Kuijper PHM, 1996, BLOOD, V87, P3271, DOI 10.1182/blood.V87.8.3271.bloodjournal8783271; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOSCALZO J, 1986, J CLIN INVEST, V78, P1112, DOI 10.1172/JCI112668; NIEWIAROWSKI S, 1981, THROMB RES, V23, P457, DOI 10.1016/0049-3848(81)90207-3; NIEWIAROWSKI S, 1972, J CLIN INVEST, V51, P685, DOI 10.1172/JCI106857; NIIYA K, 1987, BLOOD, V70, P475; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PHILLIPS DR, 1974, THROMB DIATH HAEMOST, V32, P207, DOI 10.1055/s-0038-1647686; Ramakrishnan V, 2001, P NATL ACAD SCI USA, V98, P1823, DOI 10.1073/pnas.98.4.1823; REIDY MA, 1977, ATHEROSCLEROSIS, V26, P181, DOI 10.1016/0021-9150(77)90101-0; RIGEL DF, 1993, CIRC RES, V72, P1091, DOI 10.1161/01.RES.72.5.1091; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; RUGGERI ZM, 1994, SEMIN HEMATOL, V31, P229; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; Schafer AI, 1996, AM J MED, V101, P199, DOI 10.1016/S0002-9343(96)80077-5; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Smith RA, 1997, J BIOL CHEM, V272, P22080, DOI 10.1074/jbc.272.35.22080; Smith RD, 1999, BIOCHEMISTRY-US, V38, P8936, DOI 10.1021/bi9827518; SOSLAU G, 1992, THROMB RES, V66, P15, DOI 10.1016/0049-3848(92)90151-Y; SOSLAU G, 1995, BBA-MOL CELL RES, V1268, P73, DOI 10.1016/0167-4889(95)00051-S; Soslau G, 1997, BLOOD, V90, P1251; SOSLAU G, 1982, THROMB RES, V26, P443, DOI 10.1016/0049-3848(82)90316-4; SOSLAU G, 1988, BIOCHEM BIOPH RES CO, V150, P909, DOI 10.1016/0006-291X(88)90715-2; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; WEITZ J, 1994, DRUGS, V48, P485, DOI 10.2165/00003495-199448040-00001; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	62	141	157	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21173	21183		10.1074/jbc.M008249200	http://dx.doi.org/10.1074/jbc.M008249200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283012	Green Published, hybrid			2022-12-25	WOS:000169297900052
J	Fabini, G; Raijmakers, R; Hayer, S; Fouraux, MA; Pruijn, GJM; Steiner, G				Fabini, G; Raijmakers, R; Hayer, S; Fouraux, MA; Pruijn, GJM; Steiner, G			The heterogeneous nuclear ribonucleoproteins I and K interact with a subset of the Ro ribonucleoprotein-associated Y RNAs in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; POLYMERASE-III TRANSCRIPTS; INTERNAL RIBOSOMAL ENTRY; MESSENGER-RNA; LA PROTEIN; HNRNP-K; INTRACELLULAR-LOCALIZATION; PERINUCLEOLAR COMPARTMENT; SUBCELLULAR-DISTRIBUTION; CAENORHABDITIS-ELEGANS	The hY RNAs are a group of four small cytoplasmic RNAs of unknown function that are stably associated with at least two proteins, Ro60 and La, to form Ro ribonucleoprotein complexes. Here we show that the heterogeneous nuclear ribonucleoproteins (hnRNP) I and K are able to associate with a subset of hY RNAs in vitro and demonstrate these interactions to occur also in vivo in a yeast three-hybrid system. Experiments performed in vitro and in vivo with deletion mutants of hY1 RNA revealed its pyrimidine-rich central loop to be involved in interactions with both hnRNP I and K and clearly showed their binding sites to be different from the Ro60 binding site. Both hY1 and hY3 RNAs coprecipitated with hnRNP I in immunoprecipitation experiments performed with HeLa S100 extracts and cell extracts from COS-l cells transiently transfected with VSV-G-tagged hnRNP-I, respectively. Furthermore, both anti-Ro60 and anti-La antibodies coprecipitated hnRNP I, whereas coprecipitation of hnRNP K was not observed. Taken together, these data strongly suggest that hnRNP I is a stable component of a subpopulation of Ro RNPs, whereas hnRNP K may be transiently bound or interact only with (rare) Y RNAs that are devoid of Ro60 and La. Given that functions related to translation regulation have been assigned to both proteins and also to La, our findings may provide novel clues toward understanding the role of Y RNAs and their respective RNP complexes.	Univ Hosp Vienna, Dept Internal Med 3, Div Rheumatol, A-1090 Vienna, Austria; Univ Vienna, Inst Med Biochem, A-1030 Vienna, Austria; Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands	University Hospital Vienna; University of Vienna; Radboud University Nijmegen	Steiner, G (corresponding author), Univ Hosp Vienna, Dept Internal Med 3, Div Rheumatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Guenter.Steiner@akh-wien.ac.at	Raijmakers, Reinout/A-3045-2010; Pruijn, Ger/D-6664-2012	Raijmakers, Reinout/0000-0001-6316-6663; Steiner, Guenter/0000-0002-5089-7405				Anwar A, 2000, J BIOL CHEM, V275, P34231, DOI 10.1074/jbc.M006343200; Belsham GJ, 1995, CURR TOP MICROBIOL, V203, P85; BENCHETRIT E, 1993, BRIT J RHEUMATOL, V32, P396; BENCHETRIT E, 1988, J EXP MED, V167, P1560, DOI 10.1084/jem.167.5.1560; BOIRE G, 1990, J CLIN INVEST, V85, P1182, DOI 10.1172/JCI114551; BOIRE G, 1995, CLIN EXP IMMUNOL, V100, P489; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Bouffard P, 2000, RNA, V6, P66, DOI 10.1017/S1355838200990277; Broekhuis CHD, 2000, BIOCHEMISTRY-US, V39, P3023, DOI 10.1021/bi992308c; Chen XG, 2000, GENE DEV, V14, P777; Cheng ST, 1996, J IMMUNOL, V156, P4484; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; ELLINGTON AD, 1994, CURR BIOL, V4, P427, DOI 10.1016/S0960-9822(00)00093-2; Fabini G, 2000, EUR J BIOCHEM, V267, P2778, DOI 10.1046/j.1432-1327.2000.01298.x; FARRIS AD, 1995, GENE, V154, P193, DOI 10.1016/0378-1119(94)00823-B; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; GOTTLIEB E, 1989, EMBO J, V8, P851, DOI 10.1002/j.1460-2075.1989.tb03446.x; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965; KELEKAR A, 1994, J CLIN INVEST, V93, P1637, DOI 10.1172/JCI117145; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Kim YK, 1999, J GEN VIROL, V80, P3159, DOI 10.1099/0022-1317-80-12-3159; Labbe JC, 1999, BIOCHEM CELL BIOL, V77, P349, DOI 10.1139/bcb-77-4-349; Labbe JC, 2000, P NATL ACAD SCI USA, V97, P13233, DOI 10.1073/pnas.230284297; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Lee B, 1996, P NATL ACAD SCI USA, V93, P11471, DOI 10.1073/pnas.93.21.11471; Lee MH, 1996, J BIOL CHEM, V271, P3420; Maraia RJ, 1996, P NATL ACAD SCI USA, V93, P3383, DOI 10.1073/pnas.93.8.3383; MATERA AG, 1995, J CELL BIOL, V129, P1181, DOI 10.1083/jcb.129.5.1181; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McCluskey J, 1998, IMMUNOL REV, V164, P209, DOI 10.1111/j.1600-065X.1998.tb01222.x; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; OBRIEN CA, 1994, GENE DEV, V8, P2891, DOI 10.1101/gad.8.23.2891; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Pannone BK, 1998, EMBO J, V17, P7442, DOI 10.1093/emboj/17.24.7442; PEEK R, 1993, J CELL SCI, V106, P929; PEERY T, 1993, J VIROL, V67, P3534, DOI 10.1128/JVI.67.6.3534-3543.1993; Pellizzoni L, 1996, J MOL BIOL, V259, P904, DOI 10.1006/jmbi.1996.0368; Pellizzoni L, 1998, J MOL BIOL, V281, P593, DOI 10.1006/jmbi.1998.1961; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; PFEIFLE J, 1987, BIOCHIM BIOPHYS ACTA, V928, P217, DOI 10.1016/0167-4889(87)90124-8; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; PIZER LI, 1983, MOL CELL BIOL, V3, P1235, DOI 10.1128/MCB.3.7.1235; PRUIJN GJM, 1995, EUR J BIOCHEM, V232, P611, DOI 10.1111/j.1432-1033.1995.tb20851.x; Pruijn GJM, 1997, EUR J CELL BIOL, V74, P123; PRUIJN GJM, 1991, NUCLEIC ACIDS RES, V19, P5173, DOI 10.1093/nar/19.19.5173; PRUIJN GJM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P395, DOI 10.1016/0167-4781(93)90006-Y; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Simons FHM, 1996, RNA, V2, P264; SLOBBE RL, 1992, J MOL BIOL, V227, P361, DOI 10.1016/0022-2836(92)90890-V; Svitkin YV, 1996, EMBO J, V15, P7147, DOI 10.1002/j.1460-2075.1996.tb01106.x; Teunissen SWM, 2000, NUCLEIC ACIDS RES, V28, P610, DOI 10.1093/nar/28.2.610; Timchenko LT, 1996, NUCLEIC ACIDS RES, V24, P4407, DOI 10.1093/nar/24.22.4407; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; TOPPER JN, 1990, J BIOL CHEM, V265, P13254; Valcarcel J, 1997, CURR BIOL, V7, pR705, DOI 10.1016/S0960-9822(06)00361-7; VANGELDER CWG, 1994, NUCLEIC ACIDS RES, V22, P2498, DOI 10.1093/nar/22.13.2498; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; VELDHOVEN CHA, 1995, CLIN EXP IMMUNOL, V101, P45; Wang DR, 1999, J CLIN INVEST, V104, P1265, DOI 10.1172/JCI8003; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; WOLIN SL, 1983, CELL, V32, P735, DOI 10.1016/0092-8674(83)90059-4; Xue DH, 2000, EMBO J, V19, P1650, DOI 10.1093/emboj/19.7.1650; Yu YT, 1999, RNA WORLD, P487; Zimmermann C, 1996, J RHEUMATOL, V23, P1897	70	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20711	20718		10.1074/jbc.M101360200	http://dx.doi.org/10.1074/jbc.M101360200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279198	Green Published, hybrid			2022-12-25	WOS:000169135100138
J	Nagasawa, M; Kanzaki, M; Iino, Y; Morishita, Y; Kojima, I				Nagasawa, M; Kanzaki, M; Iino, Y; Morishita, Y; Kojima, I			Identification of a novel chloride channel expressed in the endoplasmic reticulum, Golgi apparatus, and nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; CYSTIC-FIBROSIS; GENE; DOMINANT	MID-1 is a Saccharomyces cerevisiae gene encoding a stretch-activated channel. Using MID-1 as a molecular probe, we isolated rat cDNA encoding a protein with four putative transmembrane domains. This gene encoded a protein of 541 amino acids. We also cloned the human homologue, which encoded 551 amino acids. Messenger RNA for this gene was expressed abundantly in the testis and moderately in the spleen, liver, kidney, heart, brain, and lung. In the testis, immunoreactivity of the gene product was detected both in the cytoplasm and the nucleus. When expressed in Chinese hamster ovary cells, the gene product was located in intracellular compartments including endoplasmic reticulum and the Golgi apparatus. When microsome fraction obtained from the transfected cells, but not from mock-transfected cells, was incorporated into the lipid bilayer, an anion channel activity was detected. Unitary conductance was 70 picosiemens in symmetric 150 mM KCl solution. We designated this gene Mid-1-related chloride channel (MCLC). MCLC encodes a new class of chloride channel expressed in intracellular compartments.	Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan; Gunma Univ, Sch Med, Dept Emergency & Crit Care Med, Maebashi, Gumma 3718512, Japan; Gunma Univ, Sch Med, Dept Surg 2, Maebashi, Gumma 3718512, Japan	Gunma University; Gunma University; Gunma University	Kojima, I (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan.		Kanzaki, Makoto/H-6680-2017	Kanzaki, Makoto/0000-0002-6884-2955				ALAWQATI Q, 1995, CURR OPIN CELL BIOL, V7, P504, DOI 10.1016/0955-0674(95)80006-9; BRETAG AH, 1987, PHYSIOL REV, V67, P618, DOI 10.1152/physrev.1987.67.2.618; DAVID V, 1993, J BIOL CHEM, V268, P9585; EDWARDS J, 1998, AM J PHYSIOL, V276, pF398; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; FUKUHARA C, 1996, SOPHIA LIFE SCI B, V15, P79; Hosie AM, 1997, TRENDS NEUROSCI, V20, P578, DOI 10.1016/S0166-2236(97)01127-2; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; JENTSCH TJ, 1994, CURR OPIN CELL BIOL, V6, P600, DOI 10.1016/0955-0674(94)90082-5; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482, P19; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; MANNING SD, 1989, J MEMBRANE BIOL, V109, P113, DOI 10.1007/BF01870850; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R	21	30	32	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20413	20418		10.1074/jbc.M100366200	http://dx.doi.org/10.1074/jbc.M100366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279057	hybrid			2022-12-25	WOS:000169135100100
J	Yang, RY; Hsu, DK; Yu, L; Ni, J; Liu, FT				Yang, RY; Hsu, DK; Yu, L; Ni, J; Liu, FT			Cell cycle regulation by galectin-12, a new member of the galectin superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING PROTEIN; LEYDEN CRYSTAL PROTEIN; HUMAN T-LYMPHOCYTES; NUCLEAR-LOCALIZATION; ANIMAL LECTINS; GENE FAMILY; DECREASED EXPRESSION; EPITHELIAL-CELLS; COLON-CARCINOMA; BETA-GBP	Galectins are a family of beta -galactoside-binding animal lectins with conserved carbohydrate recognition domains (CRDs). Here we report the identification and characterization of a new galectin, galectin-12, which contains two domains that are homologous to the galectin CRD. The N-terminal domain contains all of the sequence elements predicted to form the two beta -sheets found in other galectins, as well as conserved carbohydrate-interacting residues. The C-terminal domain shows considerable divergence from the consensus sequence, and many of these conserved residues are not present. Nevertheless, the protein has lactose binding activity, most Likely due to the contribution of the N-terminal domain. The mRNA for galectin-12 contains features coding for proteins with growth-regulatory functions. These include start codons in a context that are suboptimal for translation initiation and AU-rich motifs in the 3'-untranslated region, which are known to confer instability to mRNA. Galectin-12 mRNA is sparingly expressed or undetectable in many tissues and cell lines tested, but it is up-regulated in cells synchronized at the G(1) phase or the G(1)/S boundary of the cell cycle. Ectopic expression of galectin-12 in cancer cells causes cell cycle arrest at the G(1) phase and cell growth suppression. We conclude that galectin-12 is a novel regulator of cellular homeostasis.	La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	La Jolla Institute for Immunology; GlaxoSmithKline; Human Genome Sciences Inc	Liu, FT (corresponding author), La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA.		Yang, Riyao/R-7593-2019; Liu, FU-TONG/A-5749-2019	Yang, Riyao/0000-0002-0278-4385; Liu, FU-TONG/0000-0002-3354-1001	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020958, R01AI039620] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR0833] Funding Source: Medline; NIAID NIH HHS [AI39620, R01 AI20958] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS M, 1995, NATURE S, V377, P6547; Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Akahani S, 1997, CANCER RES, V57, P5272; Allione A, 1998, J IMMUNOL, V161, P2114; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BAUM C, 1994, BIOTECHNIQUES, V17, P1058; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Bresalier RS, 1998, GASTROENTEROLOGY, V115, P287, DOI 10.1016/S0016-5085(98)70195-7; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Castronovo V, 1996, J PATHOL, V179, P43, DOI 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N; CASTRONOVO V, 1992, JNCI-J NATL CANCER I, V84, P1161, DOI 10.1093/jnci/84.15.1161; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; COFFINO P, 1975, P NATL ACAD SCI USA, V72, P878, DOI 10.1073/pnas.72.3.878; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COOPER HM, 1995, CURRENT PROTOCOLS IM; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Fernandez PL, 1997, J PATHOL, V181, P80; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Gitt MA, 1998, J BIOL CHEM, V273, P2961, DOI 10.1074/jbc.273.5.2961; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; Goletz S, 1997, J CELL SCI, V110, P1585; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Hsu DK, 1996, AM J PATHOL, V148, P1661; Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.3.CO;2-S; KANDROFSKE MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kim HRC, 1999, CANCER RES, V59, P4148; Konstantinov KN, 1996, AM J PATHOL, V148, P25; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; Ogden AT, 1998, J BIOL CHEM, V273, P28889, DOI 10.1074/jbc.273.44.28889; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Pesheva P, 1998, J NEUROSCI RES, V54, P639, DOI 10.1002/(SICI)1097-4547(19981201)54:5<639::AID-JNR9>3.0.CO;2-2; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SEVE AP, 1993, GLYCOBIOLOGY, V3, P23, DOI 10.1093/glycob/3.1.23; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; Than NG, 1999, PLACENTA, V20, P703, DOI 10.1053/plac.1999.0436; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOBEY RA, 1972, EXP CELL RES, V75, P460, DOI 10.1016/0014-4827(72)90453-3; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; VANDENBRULE FA, 1994, EUR J CANCER, V30A, P1096, DOI 10.1016/0959-8049(94)90464-2; VandenBrule FA, 1996, HUM PATHOL, V27, P1185, DOI 10.1016/S0046-8177(96)90313-5; Vyakarnam A, 1998, EXP CELL RES, V242, P419, DOI 10.1006/excr.1998.4111; Vyakarnam A, 1997, MOL CELL BIOL, V17, P4730, DOI 10.1128/MCB.17.8.4730; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wells V, 1999, EUR J CANCER, V35, P978, DOI 10.1016/S0959-8049(99)00020-9; XU XC, 1995, AM J PATHOL, V147, P815; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c	75	115	127	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20252	20260		10.1074/jbc.M010914200	http://dx.doi.org/10.1074/jbc.M010914200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11283015	hybrid			2022-12-25	WOS:000169135100080
J	Varrault, A; Bilanges, B; Mackay, DJG; Basyuk, E; Ahr, B; Fernandez, C; Robinson, DO; Bockaert, J; Journot, L				Varrault, A; Bilanges, B; Mackay, DJG; Basyuk, E; Ahr, B; Fernandez, C; Robinson, DO; Bockaert, J; Journot, L			Characterization of the methylation-sensitive promoter of the imprinted ZAC gene supports its role in transient neonatal diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; LONG ARM; CHROMOSOME 6Q; SOLID TUMORS; CANCER; IDENTIFICATION; DUPLICATION; EXPRESSION; MECHANISMS; LOST	ZAC is a recently isolated zinc finger protein that induces apoptosis and cell cycle arrest. The corresponding gene is imprinted maternally through an unknown mechanism and maps to 6q24-q25, within the minimal interval harboring the gene responsible for transient neonatal diabetes mellitus (TNDM) and a tumor suppressor gene involved in breast cancer, Because of its functional properties, imprinting status, and expression pattern in mammary cell lines and tumors, ZAC is the best candidate so far for both disease conditions. In the present work, we delineated ZAC genomic organization and mapped its transcriptional start site. It is noteworthy that the ZAC promoter localized to the CpG island harboring the methylation imprint associated with TNDM and methylation of this promoter silenced its activity. These data indicate that the methylation mark may have a direct effect on the silencing of the ZAC imprinted allele, Our findings further strengthen the hypothesis that ZAC is the gene responsible for TNDM and suggest a novel mechanism for ZAC inactivation in breast tumors.	UPR 6023 CNRS Ctr, INSERM Pharmacol Endocrinol, F-34094 Montpellier 05, France; Salibury Dist Hosp, Wessex Reg Gen Lab, Salisbury SP2 8BJ, Wilts, England	Centre National de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA); Institut National de la Sante et de la Recherche Medicale (Inserm); Salisbury District Hospital	Varrault, A (corresponding author), UPR 6023 CNRS Ctr, INSERM Pharmacol Endocrinol, 141 Rue Cardonille, F-34094 Montpellier 05, France.	varrault@ccipe.montp.inserm.fr	Bilanges, Benoit/AAP-6078-2020; Journot, Laurent/T-9652-2018; Mackay, Deborah JG/B-2879-2015	Journot, Laurent/0000-0003-3499-8887; Mackay, Deborah JG/0000-0003-3088-4401; Basyuk, Eugenia/0000-0001-9768-4557; Bilanges, Benoit/0000-0003-4400-3716				Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Arima T, 2000, GENOMICS, V67, P248, DOI 10.1006/geno.2000.6266; Arthur EI, 1997, EUR J HUM GENET, V5, P417, DOI 10.1159/000484801; Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899; Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X; Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933; Bilanges B, 2001, ONCOGENE, V20, P1246, DOI 10.1038/sj.onc.1204237; Brannan CI, 1999, CURR OPIN GENET DEV, V9, P164, DOI 10.1016/S0959-437X(99)80025-2; Cave H, 2000, DIABETES, V49, P108, DOI 10.2337/diabetes.49.1.108; El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; FERGUSON AW, 1970, ARCH DIS CHILD, V45, P80, DOI 10.1136/adc.45.239.80; Gardner RJ, 1998, CLIN GENET, V54, P522; Gardner RJ, 2000, HUM MOL GENET, V9, P589, DOI 10.1093/hmg/9.4.589; Gardner RJ, 1999, J MED GENET, V36, P192; HAIG D, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10a; Hermann R, 2000, PEDIATRICS, V105, P49, DOI 10.1542/peds.105.1.49; Kamiya M, 2000, HUM MOL GENET, V9, P453, DOI 10.1093/hmg/9.3.453; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; MATHEW PM, 1988, CLIN PEDIATR, V27, P148, DOI 10.1177/000992288802700307; Mertens F, 1997, CANCER RES, V57, P2765; MILNER RDG, 1971, ARCH DIS CHILD, V46, P724, DOI 10.1136/adc.46.249.724; Morison IM, 2001, NUCLEIC ACIDS RES, V29, P275, DOI 10.1093/nar/29.1.275; NIELSEN F, 1989, ACTA PAEDIATR SCAND, V78, P469, DOI 10.1111/j.1651-2227.1989.tb11114.x; PANDYA A, 1995, AM J MED GENET, V59, P38, DOI 10.1002/ajmg.1320590109; PIVNICK EK, 1990, J MED GENET, V27, P523, DOI 10.1136/jmg.27.8.523; Reik W, 2000, NATURE, V405, P408, DOI 10.1038/35013178; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; SEQUEL A, 1982, AM J DIS CHILD, V136, P626, DOI 10.1001/archpedi.1982.03970430058015; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; TEMPLE IK, 1995, NAT GENET, V9, P110, DOI 10.1038/ng0295-110; Temple IK, 2000, DIABETES, V49, P1359, DOI 10.2337/diabetes.49.8.1359; Temple IK, 1996, HUM MOL GENET, V5, P1117, DOI 10.1093/hmg/5.8.1117; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Vu TH, 2000, GENOME RES, V10, P1660, DOI 10.1101/gr.166200; Wolffe AP, 2000, CURR BIOL, V10, pR463, DOI 10.1016/S0960-9822(00)00534-0; Zneimer SM, 1998, AM J MED GENET, V80, P133, DOI 10.1002/(SICI)1096-8628(19981102)80:2<133::AID-AJMG8>3.0.CO;2-B	38	53	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18653	18656		10.1074/jbc.C100095200	http://dx.doi.org/10.1074/jbc.C100095200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11297535	hybrid			2022-12-25	WOS:000169091000002
J	Do, TQ; Hsu, AY; Jonassen, T; Lee, PT; Clarke, CF				Do, TQ; Hsu, AY; Jonassen, T; Lee, PT; Clarke, CF			A defect in coenzyme Q biosynthesis is responsible for the respiratory deficiency in Saccharomyces cerevisiae abc1 mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL ACTIVATOR PROTEINS; MITOCHONDRIAL-MEMBRANE SYSTEM; PERMEABILITY TRANSITION PORE; O-METHYLTRANSFERASE STEPS; CYTOCHROME BC(1) COMPLEX; C OXIDASE BIOGENESIS; UBIQUINONE BIOSYNTHESIS; ESCHERICHIA-COLI; PLASMA-MEMBRANE; FUNCTIONAL COMPLEMENTATION	Ubiquinone (coenzyme Q or Q) is an essential component of the mitochondrial respiratory chain in eukaryotic cells. There are eight complementation groups of Q-deficient Saccharomyces cerevisiae mutants designated coq1-coq8, Here we report that COQ8 is ABC1 (for Activity of be, complex), which was originally isolated as a multicopy suppressor of a cytochrome b mRNA translation defect (Bousquet, I., Dujardin, G,, and Slonimski, P. P. (1991) EIMBO J. 10, 2023-2031), Previous studies of abc1 mutants suggested that the mitochondrial respiratory complexes were thermosensitive and function inefficiently. Although initial characterization of the abc1 mutants revealed characteristics of Q-deficient mutants, levels of Q were reported to be similar to wild type. The suggested function of Abc1p was that it acts as a chaperone-like protein essential for the proper conformation and functioning of the be, and its neighboring complexes (Brasseur, G,, Tron, P,, Dujardin, G,, Slonimski, P, P, (1997) fur. J. Biochem. 246, 103-111). Studies presented here indicate that abc1/coq8 null mutants are defective in Q biosynthesis and accumulate 3-hexaprenyl-4-hydroxybenzoic acid as the predominant intermediate. As observed in other yeast cog mutants, supplementation of growth media with Q, rescues the abc1/coq8 null mutants for growth on nonfermentable carbon sources. Such supplementation also partially restores succinate-cytochrome c reductase activity in the abc1/coq8 null mutants. Abc1/Coq8p localizes to the mitochondria, and is proteolytically processed upon import. The findings presented here indicate that the previously reported thermosensitivity of the respiratory complexes of abc1/coq8 mutants results from the lack of Q and a general deficiency in respiration, rather than a specific phenotype due to dysfunction of the Abc1 polypeptide. These results indicate that ABC1/COQ8 is essential for Q-biosynthesis and that the critical defect of abc1/coq8 mutants is a lack of Q.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Clarke, CF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	cathy@mbi.ucla.edu			NIGMS NIH HHS [GM45952] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS A, 1997, METHODS YEAST GENETI, P145; ASHBY MN, 1992, J BIOL CHEM, V267, P4128; ASHBY MN, 1990, J BIOL CHEM, V265, P13157; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Barkovich RJ, 1997, J BIOL CHEM, V272, P9182; BELOGRUDOV GI, 2001, IN PRESS ARCH BIOCH; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; Bonnefoy N, 1996, MOL GEN GENET, V251, P204; BOUSQUET I, 1991, EMBO J, V10, P2023, DOI 10.1002/j.1460-2075.1991.tb07732.x; Brasseur G, 1997, EUR J BIOCHEM, V246, P103, DOI 10.1111/j.1432-1033.1997.t01-1-00103.x; BROWN GG, 1977, BIOCHEMISTRY-US, V16, P4449, DOI 10.1021/bi00639a019; Cardazzo B, 1998, GENE, V221, P117, DOI 10.1016/S0378-1119(98)00417-X; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLARKE CF, 1991, J BIOL CHEM, V266, P16636; COX GB, 1969, J BACTERIOL, V99, P450, DOI 10.1128/JB.99.2.450-458.1969; Dibrov E, 1997, J BIOL CHEM, V272, P9175; Do TQ, 1996, P NATL ACAD SCI USA, V93, P7534, DOI 10.1073/pnas.93.15.7534; Dutton P.L., 2001, COENZYME Q OXIDATION, P65; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ERNSTER L, 1995, BBA-MOL BASIS DIS, V1271, P195, DOI 10.1016/0925-4439(95)00028-3; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GomezDiaz C, 1997, J BIOENERG BIOMEMBR, V29, P251, DOI 10.1023/A:1022410127104; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; Hsu AY, 2000, BBA-MOL CELL BIOL L, V1484, P287, DOI 10.1016/S1388-1981(00)00019-6; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 2000, J BIOL CHEM, V275, P12381, DOI 10.1074/jbc.275.17.12381; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; JONASSEN T, 2001, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KLOECKENERGRUISSEM B, 1987, CURR GENET, V12, P311, DOI 10.1007/BF00405753; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kroger A, 1978, Methods Enzymol, V53, P579; Lenaz G., 1985, COENZYME Q, P165; Leonard CJ, 1998, GENOME RES, V8, P1038, DOI 10.1101/gr.8.10.1038; Macinga DR, 1998, J BACTERIOL, V180, P128, DOI 10.1128/JB.180.1.128-135.1998; Malaney S, 1997, J BIOL CHEM, V272, P17495, DOI 10.1074/jbc.272.28.17495; MARBOIS BN, 1994, GENE, V138, P213; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MCMULLIN TW, 1993, J BIOL CHEM, V268, P11737; MEGANATHAN R, 1996, ESCHERICHIA COLI SAL, P642; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nijhawan D, 2000, ANNU REV NEUROSCI, V23, P73, DOI 10.1146/annurev.neuro.23.1.73; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; PERLMAN PS, 1974, ARCH BIOCHEM BIOPHYS, V162, P248, DOI 10.1016/0003-9861(74)90125-8; Poon WW, 2000, J BACTERIOL, V182, P5139, DOI 10.1128/JB.182.18.5139-5146.2000; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; POON WW, 1995, ARCH BIOCHEM BIOPHYS, V320, P305, DOI 10.1016/0003-9861(95)90014-4; POON WW, 1997, J BIOL CHEM, V18, pS121; Rodel G, 1997, CURR GENET, V31, P375, DOI 10.1007/s002940050219; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Santos-Ocana C, 1998, J BIOL CHEM, V273, P8099, DOI 10.1074/jbc.273.14.8099; SIKORSKI RS, 1989, GENETICS, V122, P19; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; TRUMPOWER BL, 1979, J BIOL CHEM, V254, P8697; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Tzschoppe K, 1999, CURR GENET, V36, P201, DOI 10.1007/s002940050491; Walter L, 2000, J BIOL CHEM, V275, P29521, DOI 10.1074/jbc.M004128200; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627	67	101	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18161	18168		10.1074/jbc.M100952200	http://dx.doi.org/10.1074/jbc.M100952200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279158	hybrid			2022-12-25	WOS:000168866500074
J	Kim, JH; Lee, JN; Paik, YK				Kim, JH; Lee, JN; Paik, YK			Cholesterol biosynthesis from lanosterol - A concerted role for Sp1 and NF-Y-binding sites for sterol-mediated regulation of rat 7-dehydrocholesterol reductase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEMLI-OPITZ-SYNDROME; NUCLEAR FACTOR-Y; LIPOPROTEIN RECEPTOR PROMOTER; ACID SYNTHASE PROMOTER; MOLECULAR-CLONING; SYNERGISTIC ACTIVATION; SONIC-HEDGEHOG; DELTA-7-STEROL REDUCTASE; ASSAY-METHOD; ELEMENT	The 7-dehydrocholesterol reductase (Dhcr7) is the terminal enzyme in the pathway of cholesterol biosynthesis. We have previously reported that sterol depletion in vivo caused a significant induction of both liver mRNA and enzyme activity of Dhcr7 (Bae, S.-H., Lee, J. N., Fitzky, B. U., Seong, J., and Paik, Y.-K, (1999) J. Biol. Chem. 274, 14624-14631), In this paper, we also observed liver cell-specific sterol-mediated Dhcr7 gene induction in vitro by sterol depletion in rat hepatoma cells, suggesting the presence of sterol-mediated regulatory elements in the Dhcr7 gene. To understand the mechanisms responsible for regulating Dhcr7 expression, we have isolated the 5'-flanking region of the gene encoding rat Dhcr7 and have characterized the potential regulatory elements of the gene that are responsible for sterol-mediated regulation. The Dhcr7 promoter contains binding sites for Sp1 (at -177, -172, -125, and -20), NF-Y (at -88 and -51), and SREBP-1 or ADD1 (at -33), Deletion analysis of the Dhcr7 gene promoter (-1053/ +31), employing a nested series of Dhcr7-luciferase constructs, demonstrated that the -179 upstream region of the gene is necessary and sufficient for optimal efficient sterol-regulated transcription. DNase I footprinting and electrophoretic mobility shift assay showed that the SRE1/E box (-33/-22) involved in sterol response of many sterol-related enzyme genes was protected specifically by the overexpressed recombinant ADD1. Mutational analysis for the functional relationship between the identified cis-elements in this region indicate that one of the binding sites for Sp1 (GC box at -125) and NF-Y (CCAAT box at -88) plays a cooperative role in the sterol-mediated activation, in which the latter site also acts as a co-regulator for SREBP-activated Dhcr7 promoter activity. We believe that Dhcr7 is the first enzyme characterized with a sterol-regulatory function in the post-lanosterol pathway. This may be important for understanding the coordinated control of cholesterol biosynthesis as well as the molecular mechanism of Smith-Lemli-Opitz syndrome-related protein in mammals.	Yonsei Univ, Dept Biochem, Bioprod Res Ctr, Seoul 120749, South Korea; Yonsei Univ, Yonsei Proteome Res Ctr, Seoul 120749, South Korea	Yonsei University; Yonsei University	Paik, YK (corresponding author), Yonsei Univ, Dept Biochem, Bioprod Res Ctr, 134 Shinchon Dong, Seoul 120749, South Korea.	paikyk@yonsei.ac.kr						ALLEY TL, 1995, AM J HUM GENET, V56, P1411; Anderson AJ, 1998, AM J MED GENET, V78, P413, DOI 10.1002/(SICI)1096-8628(19980806)78:5<413::AID-AJMG4>3.0.CO;2-M; Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; Bae SH, 1999, J BIOL CHEM, V274, P14624, DOI 10.1074/jbc.274.21.14624; Bae SH, 1997, BIOCHEM J, V326, P609, DOI 10.1042/bj3260609; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; Fitzky BU, 1998, P NATL ACAD SCI USA, V95, P8181, DOI 10.1073/pnas.95.14.8181; GIBBONS GF, 1971, J BIOL CHEM, V246, P3967; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; Honda A, 1997, AM J MED GENET, V68, P288, DOI 10.1002/(SICI)1096-8628(19970131)68:3<288::AID-AJMG8>3.0.CO;2-I; IRONS M, 1994, AM J MED GENET, V50, P347, DOI 10.1002/ajmg.1320500409; Jackson SM, 1998, J LIPID RES, V39, P767; Kelley RI, 1996, AM J MED GENET, V66, P478, DOI 10.1002/(SICI)1096-8628(19961230)66:4<478::AID-AJMG22>3.0.CO;2-Q; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Lanoue L, 1997, AM J MED GENET, V73, P24; Lecain E, 1996, J BIOL CHEM, V271, P10866, DOI 10.1074/jbc.271.18.10866; Lee JN, 1997, J BIOCHEM MOL BIOL, V30, P370; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Natarajan R, 1998, BIOCHEM BIOPH RES CO, V243, P349, DOI 10.1006/bbrc.1997.8030; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; Porter JA, 1996, CELL, V86, P21, DOI 10.1016/S0092-8674(00)80074-4; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Shefer S, 1997, METABOLISM, V46, P844, DOI 10.1016/S0026-0495(97)90133-5; SMITH DW, 1964, J PEDIATR-US, V64, P210, DOI 10.1016/S0022-3476(64)80264-X; SPEAR DH, 1992, J BIOL CHEM, V267, P14462; TINT GS, 1995, J LIPID RES, V36, P89; TINT GS, 1994, NEW ENGL J MED, V330, P107, DOI 10.1056/NEJM199401133300205; WANG XD, 1993, J BIOL CHEM, V268, P14497; Wassif CA, 1998, AM J HUM GENET, V63, P55, DOI 10.1086/301936; Waterham HR, 1998, AM J HUM GENET, V63, P329, DOI 10.1086/301982; Xiong SB, 2000, P NATL ACAD SCI USA, V97, P3948, DOI 10.1073/pnas.040574197; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102	42	49	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18153	18160		10.1074/jbc.M101661200	http://dx.doi.org/10.1074/jbc.M101661200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279217	hybrid			2022-12-25	WOS:000168866500073
J	Wang, ZY; Nolan, B; Kutschke, W; Hill, JA				Wang, ZY; Nolan, B; Kutschke, W; Hill, JA			Na+-Ca2+ exchanger remodeling in pressure overload cardiac hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA-2+-ATPASE; SODIUM-CALCIUM EXCHANGE; PROTEIN-KINASE-C; NA+/CA2+ EXCHANGER; GENE-EXPRESSION; VENTRICULAR MYOCYTES; NA/CA EXCHANGE; CALSEQUESTRIN GENES; IONIC CURRENTS; CYCLOSPORINE-A	Perturbations of Ca2+ metabolism are central to the pathogenesis of cardiac hypertrophy, The electrogenic Na+-Ca2+ exchanger mediates a substantial component of transmembrane Ca2+ movement in cardiac myocytes and is up-regulated in heart failure. However, the role of the exchanger in the pathogenesis of cardiac hypertrophy is poorly understood. Thoracic aortic banding in mice induced 50-60% increases in heart mass and cardiomyocyte size. Despite the absence of myocardial dysfunction, steady-state NCX1 transcript and protein levels were increased to an extent similar to that reported in heart failure. As recent studies indicate that calcineurin is critical to the expression of Na+-Ca2+ exchanger genes, we inhibited calcineurin with cyclosporin. Calcineurin inhibition blunted the increases in NCX1 transcript and protein levels and eliminated the increases in heart mass and cell volume normally associated with pressure overload. To examine the functional significance of these changes, we measured Na+-C2+ exchanger current in two independent ways. Surprisingly, exchanger current density was decreased in hypertrophied myocytes, and this down-regulation was eliminated by calcineurin inhibition. Together, these data reveal a role for Na+-Ca2+ exchanger current in the electrical remodeling of hypertrophy and implicate calcineurin signaling therein, In addition, these data suggest the Na+-Ca2+ exchanger is functionally regulated in hypertrophy.	Univ Iowa, Coll Med, Div Cardiovasc, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Interdisciplinary Grad Program Mol Biol, Iowa City, IA 52242 USA; Dept Vet Affairs, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Hill, JA (corresponding author), Univ Iowa, Coll Med, Div Cardiovasc, Dept Internal Med, E318gh,UIHC,200 Hawkins Dr, Iowa City, IA 52242 USA.	joseph-hill@uiowa.edu			NHLBI NIH HHS [HL-03908] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1993, CIRC RES, V72, P463, DOI 10.1161/01.RES.72.2.463; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; Balke CW, 1998, CARDIOVASC RES, V37, P290, DOI 10.1016/S0008-6363(97)00272-1; Barry WH, 2000, CIRC RES, V87, P529, DOI 10.1161/01.RES.87.7.529; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; Boateng SY, 2001, AM J PHYSIOL-HEART C, V280, pH1029, DOI 10.1152/ajpheart.2001.280.3.H1029; BOERTH SR, 1994, CIRC RES, V74, P354, DOI 10.1161/01.RES.74.2.354; Bowman JC, 1997, J CLIN INVEST, V100, P2189, DOI 10.1172/JCI119755; Brown DW, 2000, AM HEART J, V140, P848, DOI 10.1067/mhj.2000.111112; Carafoli E, 1999, BIOCHEM BIOPH RES CO, V266, P624, DOI 10.1006/bbrc.1999.1879; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Dipla K, 1999, CIRC RES, V84, P435, DOI 10.1161/01.RES.84.4.435; Fatkin D, 2000, J CLIN INVEST, V106, P1351, DOI 10.1172/JCI11093; Flesch M, 1996, CIRCULATION, V94, P992, DOI 10.1161/01.CIR.94.5.992; FREY N, 2000, CIRC RES, V87, P731; Gaughan JP, 1999, AM J PHYSIOL-HEART C, V277, pH714, DOI 10.1152/ajpheart.1999.277.2.H714; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Hampton TG, 2000, AM J PHYSIOL-HEART C, V279, pH2846, DOI 10.1152/ajpheart.2000.279.6.H2846; Hasenfuss G, 1999, CIRCULATION, V99, P641, DOI 10.1161/01.CIR.99.5.641; Hill JA, 2000, CIRCULATION, V101, P2863, DOI 10.1161/01.CIR.101.24.2863; Hobai IA, 2000, CIRC RES, V87, P690, DOI 10.1161/01.RES.87.8.690; Hobai IA, 1997, AM J PHYSIOL-HEART C, V272, pH2164, DOI 10.1152/ajpheart.1997.272.5.H2164; HUSI H, 1994, J BIOL CHEM, V269, P14199; Isenberg G, 2001, CARDIOVASC RES, V49, P1, DOI 10.1016/S0008-6363(00)00284-4; Ito K, 2000, CIRC RES, V87, P588, DOI 10.1161/01.RES.87.7.588; Iwamoto T, 1996, J BIOL CHEM, V271, P13609, DOI 10.1074/jbc.271.23.13609; Janssen PML, 2000, CARDIOVASC RES, V47, P99, DOI 10.1016/S0008-6363(00)00052-3; KENT RL, 1993, AM J PHYSIOL, V265, pH1024, DOI 10.1152/ajpheart.1993.265.3.H1024; Knollmann BC, 2000, J PHYSIOL-LONDON, V525, P483, DOI 10.1111/j.1469-7793.2000.t01-1-00483.x; Ladilov Y, 1999, AM J PHYSIOL-HEART C, V276, pH1868, DOI 10.1152/ajpheart.1999.276.6.H1868; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Linck B, 1996, CARDIOVASC RES, V31, P625; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; MERCADIER JJ, 1990, J CLIN INVEST, V85, P305, DOI 10.1172/JCI114429; Mitarai S, 2000, AM J PHYSIOL-HEART C, V279, pH139, DOI 10.1152/ajpheart.2000.279.1.H139; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; MOVSESIAN MA, 1994, CIRCULATION, V90, P653, DOI 10.1161/01.CIR.90.2.653; Nabauer M, 1998, CARDIOVASC RES, V37, P324, DOI 10.1016/S0008-6363(97)00274-5; Nuss HB, 1999, AM J PHYSIOL-HEART C, V277, pH80, DOI 10.1152/ajpheart.1999.277.1.H80; O'Rourke B, 1999, CIRC RES, V84, P562, DOI 10.1161/01.RES.84.5.562; Park KS, 1999, AM J PHYSIOL-HEART C, V276, pH865, DOI 10.1152/ajpheart.1999.276.3.H865; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pieske B, 1999, CIRC RES, V85, P38; Pogwizd SM, 1999, CIRC RES, V85, P1009; Reed TD, 2000, J MOL CELL CARDIOL, V32, P453, DOI 10.1006/jmcc.1999.1095; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Schillinger W, 2000, CIRC RES, V87, P581, DOI 10.1161/01.RES.87.7.581; SCHOUTEN VJA, 1990, CARDIOVASC RES, V24, P758, DOI 10.1093/cvr/24.9.758; Schwartz K, 1996, CURR OPIN CARDIOL, V11, P227, DOI 10.1097/00001573-199605000-00002; SCHWINGER RHG, 1995, CIRCULATION, V92, P3220, DOI 10.1161/01.CIR.92.11.3220; Simpson PC, 1999, CIRCULATION, V99, P334, DOI 10.1161/01.CIR.99.3.334; Sipido KR, 2000, CIRCULATION, V102, P2137, DOI 10.1161/01.CIR.102.17.2137; STUDER R, 1994, CIRC RES, V75, P443, DOI 10.1161/01.RES.75.3.443; Su Z, 1999, J MOL CELL CARDIOL, V31, P1125, DOI 10.1006/jmcc.1999.0949; Su Z, 1998, AM J PHYSIOL-HEART C, V275, pH1808, DOI 10.1152/ajpheart.1998.275.5.H1808; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; TAKAHASHI T, 1992, J CLIN INVEST, V90, P927, DOI 10.1172/JCI115969; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; Terracciano CMN, 2001, CARDIOVASC RES, V49, P38, DOI 10.1016/S0008-6363(00)00205-4; Tomaselli GF, 1999, CARDIOVASC RES, V42, P270, DOI 10.1016/S0008-6363(99)00017-6; Wakimoto K, 2000, J BIOL CHEM, V275, P36991, DOI 10.1074/jbc.M004035200; Wickenden AD, 1998, CARDIOVASC RES, V37, P312, DOI 10.1016/S0008-6363(97)00256-3; Winslow RL, 1999, CIRC RES, V84, P571, DOI 10.1161/01.RES.84.5.571; Zygmunt AC, 2000, AM J PHYSIOL-HEART C, V278, pH1671, DOI 10.1152/ajpheart.2000.278.5.H1671	69	65	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17706	17711		10.1074/jbc.M100544200	http://dx.doi.org/10.1074/jbc.M100544200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279089	hybrid			2022-12-25	WOS:000168866500013
J	Christensen, K; Bose, HS; Harris, FM; Miller, WL; Bell, JD				Christensen, K; Bose, HS; Harris, FM; Miller, WL; Bell, JD			Binding of steroidogenic acute regulatory protein to synthetic membranes suggests an active molten globule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; LEYDIG TUMOR-CELLS; PHOSPHOLIPID-VESICLES; ALPHA-LACTALBUMIN; STAR; MECHANISM; MLN64; MITOCHONDRIA; CHOLESTEROL; PRECURSORS	Steroidogenic acute regulatory protein (StAR) mediates cholesterol transport from the outer to the inner mitochondrial membrane during steroid biosynthesis, The mechanism of StAR's action is not established, To address mechanistic issues, we assessed the binding of StAR to artificial membranes by fluorescence resonance energy transfer using endogenous StAR tryptophan residues as the donor and dansyl-phosphatidylethanolamine in the bilayer as the acceptor. Mixing StAR with dansyl-labeled vesicles composed of phosphatidylcholine increased the fluorescence intensity of dansyl emission excited at 280 nm by 10-40%, This interaction was dependent on pH, with a maximum at pH 3.0-3.5 and essentially no change above pH 5, Binding experiments at different temperatures and various combinations of phosphatidylcholine, phosphatidylglycerol, cardiolipin, and cholesterol showed that binding involves an electrostatic step and one or more other steps. Although binding prefers a thermodynamically ordered bilayer, the rate-limiting step occurs either when the bilayer is in a fluid state or when there is cholesterol-induced membrane heterogeneity, Experiments with fluorescence and light scattering indicate that StAR binding promotes ordering and aggregation of anionic membranes. The inactive StAR mutant R182L had lower affinity for the membrane, and the partially active mutant L275P had intermediate affinity. Far-UV CD spectroscopy of StAR in PC membranes show more p-structure than in aqueous buffers, and the presence of cardiolipin or cholesterol in the membrane fosters a molten globule state. Our data suggest that StAR binds to membranes in a partially unfolded molten globule state that is relevant to the activity of the protein.	Brigham Young Univ, Dept Zool, Provo, UT 84602 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Brigham Young University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Brigham Young Univ, Dept Zool, Provo, UT 84602 USA.		Miller, Walter L/J-3696-2012		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD034449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002762, R01DK037922] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD 34449] Funding Source: Medline; NIDDK NIH HHS [K01 DK02762, R01 DK37922] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; Bell JD, 1996, BIOCHEMISTRY-US, V35, P4945, DOI 10.1021/bi952274i; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1998, BIOCHEMISTRY-US, V37, P9768, DOI 10.1021/bi980588a; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FASMAN GD, 1995, J PROTEIN CHEM, V14, P595, DOI 10.1007/BF01886885; GREGORY RB, 1986, J BIOL CHEM, V261, P13963; HAUFFA BP, 1985, CLIN ENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2265.1985.tb01107.x; Heimburg T, 1996, BIOPHYS J, V70, P84, DOI 10.1016/S0006-3495(96)79551-6; HEIMBURG T, 1994, BIOCHEMISTRY-US, V33, P9477, DOI 10.1021/bi00198a013; Huang WH, 1997, BIOCHEMISTRY-US, V36, P2860, DOI 10.1021/bi962405v; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Kamen DE, 2000, BIOCHEMISTRY-US, V39, P15932, DOI 10.1021/bi001900v; Karlsson OP, 1996, BIOCHEMISTRY-US, V35, P10094, DOI 10.1021/bi9602876; KIM J, 1986, BIOCHEMISTRY-US, V25, P7867, DOI 10.1021/bi00372a012; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MoogLutz C, 1997, INT J CANCER, V71, P183, DOI 10.1002/(SICI)1097-0215(19970410)71:2<183::AID-IJC10>3.0.CO;2-J; MUDERHWA JM, 1992, J BIOL CHEM, V267, P24184; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; Stocco DM, 1999, EXP CLIN ENDOCR DIAB, V107, P229, DOI 10.1055/s-0029-1212105; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; VAZ WLC, 1978, EUR J BIOCHEM, V83, P299, DOI 10.1111/j.1432-1033.1978.tb12094.x; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Worthman LAD, 1997, BIOPHYS J, V72, P2569, DOI 10.1016/S0006-3495(97)78900-8	34	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17044	17051		10.1074/jbc.M100903200	http://dx.doi.org/10.1074/jbc.M100903200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279152	hybrid			2022-12-25	WOS:000168730400059
J	Barry, OP; Mullan, B; Sheehan, D; Kazanietz, MG; Shanahan, F; Collins, JK; O'Sullivan, GC				Barry, OP; Mullan, B; Sheehan, D; Kazanietz, MG; Shanahan, F; Collins, JK; O'Sullivan, GC			Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; PROTEIN-TYROSINE PHOSPHATASE; IN-VIVO; ESOPHAGEAL CANCER; PLATELET MICROPARTICLES; RAT-1 FIBROBLASTS; GROWTH-FACTOR; MAP KINASES; RAS; INHIBITOR	In this study, we examined the mitogen-activated protein kinase (MAPK) cascade in micrometastatic cell lines generated from rib bone marrow (RBM) of patients undergoing resection of esophagogastric malignancies, The molecular mechanism(s) involved in esophagogastric MAPK activation have not previously been investigated. Constitutive activation of both ERK1 and -2 isoforms was evident in each of the five RBM cell lines. Elk-1, a transcription factor activated by the ERK1/2 pathway was also found to be constitutively activated. Cell lines generated from metastases of involved lymph nodes (OC2) and ascites (OC1) of patients with esophageal cancer do not display, however, hyperphosphorylation of ERK1/2, Constitutive RBM ERK1/2 activation is protein kinase C and phosphatidylinositol 3-kinase dependent. Surprisingly, constitutive ERK1/2 activation is MEK-independent. Pharmacological inhibition of MEK with two specific inhibitors, PD 98059 and U0126, were both ineffective in blocking ERK activation. Similarly, the use of a dominant negative MEK mutant was without effect. Interestingly, experiments overexpressing two different dominant negative Pak1 mutants significantly reduced RBM ERK1/2 activation, albeit not to the same extent for all cell lines. We also examined the role of three different phosphatases, PAC1, MKP-1, and -2, While RBM ERK1/2 activation was found to be PAC1- and MKP-2-independent, surprisingly, MKP-1 was down-regulated in all five RBM cell lines. In conclusion, we provide evidence for the first time for a MEK-independent constitutive ERK1/2 activation pathway in esophagogastric RBM cell lines. These findings have important implications for drug treatment strategies which currently target MEK in other forms of cancer.	Natl Univ Ireland Univ Coll Cork, Cork Canc Res Ctr, Cork, Ireland; Natl Univ Ireland Univ Coll Cork, Dept Med, Cork, Ireland; Natl Univ Ireland Univ Coll Cork, Dept Microbiol, Cork, Ireland; Univ Penn, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University College Cork; University College Cork; University College Cork; University of Pennsylvania	O'Sullivan, GC (corresponding author), Mercy Hosp, Cork Canc Res Ctr, Cork, Ireland.		Shanahan, Fergus/ABF-2390-2020	Shanahan, Fergus/0000-0003-0467-0936; Barry, Orla/0000-0001-6364-3642				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; Barry OP, 1999, J BIOL CHEM, V274, P7545, DOI 10.1074/jbc.274.11.7545; BECKER S, 1991, J IMMUNOL, V147, P4307; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; Bokemeyer D, 1997, J AM SOC NEPHROL, V8, P40; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Grammer TC, 1997, ONCOGENE, V14, P1635, DOI 10.1038/sj.onc.1201000; Guan K L, 1993, Semin Cell Biol, V4, P389, DOI 10.1006/scel.1993.1046; Hu LM, 2000, CLIN CANCER RES, V6, P880; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; LAIRD AD, 1995, J BIOL CHEM, V270, P26742, DOI 10.1074/jbc.270.45.26742; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1996, AM J PATHOL, V149, P1553; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; O'Sullivan GC, 1999, GASTROENTEROLOGY, V116, P543, DOI 10.1016/S0016-5085(99)70175-7; OKA H, 1995, CANCER RES, V55, P4182; OSULLIVAN GC, 1995, GASTROENTEROLOGY, V109, P1535, DOI 10.1016/0016-5085(95)90641-X; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROECKLEIN BA, 1995, BLOOD, V85, P997, DOI 10.1182/blood.V85.4.997.bloodjournal854997; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Simon C, 1999, BRIT J CANCER, V80, P1412, DOI 10.1038/sj.bjc.6690537; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Tang Y, 1998, P NATL ACAD SCI USA, V95, P5139, DOI 10.1073/pnas.95.9.5139; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tang Y, 1999, MOL CELL BIOL, V19, P1881; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Welch DR, 2000, CANCER RES, V60, P1552; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang P, 2000, J BIOL CHEM, V275, P22479, DOI 10.1074/jbc.M910425199; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	55	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15537	15546		10.1074/jbc.M010847200	http://dx.doi.org/10.1074/jbc.M010847200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11297525	hybrid			2022-12-25	WOS:000168528800133
J	Valeva, A; Schnabel, R; Walev, I; Boukhallouk, F; Bhakdi, S; Palmer, M				Valeva, A; Schnabel, R; Walev, I; Boukhallouk, F; Bhakdi, S; Palmer, M			Membrane insertion of the heptameric staphylococcal alpha-toxin pore - A domino-like structural transition that is allosterically modulated by the target cell membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE PORE; TRANSFERRIN RECEPTOR; HEMOLYSIN; AUREUS; MUTAGENESIS; OLIGOMERIZATION; ENDOCYTOSIS; CYSTEINE; RESIDUES; TERMINUS	Staphylococcal cy toxin forms heptameric pores on eukaryotic cells. After binding to the cell membrane in its monomeric form, the toxin first assembles into a heptameric pre-pore. Subsequently, the pre-pore transforms into the final pore by membrane insertion of an amphipathic beta -barrel, which comprises the "central loop" domains of all heptamer subunits, The process of membrane insertion was analyzed here using a set of functionally altered toxin mutants. The results show that insertion may be initiated within an individual protomer when its NH2 terminus activates its central loop. The activated state is then shared with the central loops of the residual heptamer subunits, which results in cooperative membrane penetration. This cooperation of the central loops commences while these are still remote from the lipid bilayer, Nevertheless, it is subject to modulation by the target membrane, which therefore acts across a distance much like an allosteric effector. However, while allosteric transitions usually are reversible, membrane insertion of alpha -toxin is an irreversible event, and we show here that it can proceed to completion in a domino-like fashion when triggered by as little as a single foreign atom within the entire heptamer.	Univ Mainz, Inst Med Microbiol & Hyg, D-55101 Mainz, Germany; Texas A&M Univ, Inst Med Biochem & Genet, College Stn, TX 77843 USA	Johannes Gutenberg University of Mainz; Texas A&M University System; Texas A&M University College Station	Valeva, A (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.							Bayley H, 1999, CURR OPIN BIOTECH, V10, P94, DOI 10.1016/S0958-1669(99)80017-2; BHAKDI S, 1984, INFECT IMMUN, V46, P318, DOI 10.1128/IAI.46.2.318-323.1984; COLLAWN JF, 1993, J BIOL CHEM, V268, P21686; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; CORMACK B, 1987, CURRENT PROTOCOLS MO; Eroglu A, 2000, NAT BIOTECHNOL, V18, P163, DOI 10.1038/72608; FAIRWEATHER N, 1983, INFECT IMMUN, V41, P1112, DOI 10.1128/IAI.41.3.1112-1117.1983; FUESSLE R, 1981, Journal of Cell Biology, V91, P83; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Olson R, 1999, NAT STRUCT BIOL, V6, P134; PALMER M, 1993, J BIOL CHEM, V268, P11959; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; Pedelacq JD, 1999, STRUCTURE, V7, P277, DOI 10.1016/S0969-2126(99)80038-0; Russo MJ, 1997, NAT BIOTECHNOL, V15, P278, DOI 10.1038/nbt0397-278; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Valeva A, 1997, BBA-BIOMEMBRANES, V1325, P281, DOI 10.1016/S0005-2736(96)00266-0; Valeva A, 1997, P NATL ACAD SCI USA, V94, P11607, DOI 10.1073/pnas.94.21.11607; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Valeva A, 1997, BIOCHEMISTRY-US, V36, P13298, DOI 10.1021/bi971075r; VALEVA A, 1995, BBA-BIOMEMBRANES, V1236, P213, DOI 10.1016/0005-2736(95)00060-G; Vandana S, 1997, J BIOL CHEM, V272, P24858, DOI 10.1074/jbc.272.40.24858; Walev I, 1996, ANTIMICROB AGENTS CH, V40, P1116, DOI 10.1128/AAC.40.5.1116; WALKER B, 1992, J BIOL CHEM, V267, P21782; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065	25	23	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14835	14841		10.1074/jbc.M100301200	http://dx.doi.org/10.1074/jbc.M100301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279048	hybrid			2022-12-25	WOS:000168528800042
J	Bhalla, SS; Robitaille, L; Nemer, M				Bhalla, SS; Robitaille, L; Nemer, M			Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR YY1; SERUM RESPONSE FACTOR; FACTOR GENE-TRANSCRIPTION; ZINC-FINGER PROTEIN; EPSILON-GLOBIN GENE; BINDING PROTEIN; ADENOVIRUS E1A; P300 PROTEIN; EXPRESSION; CELLS	YY1, a multifunctional protein essential for embryonic development, is a known repressor or activator of transcription. In cardiac and skeletal myocytes, YY1 has been described essentially as a negative regulator of muscle-specific genes. In this study, we report that YY1 is a transcriptional activator of the B-type natriuretic peptide (BNP) gene, which encodes one of the heart major secretory products. YY1 binds an element within the proximal cardiac BNP promoter, in close proximity to the high affinity binding sites for the zinc finger GATA proteins. We show that YY1 cooperates with GATA-4 to synergistically activate BNP transcription. Structure-function analysis revealed that the DNA binding domain of YY1 is sufficient for cooperative interaction with GATA-4, likely through corecruitment of the CREB-binding protein coactivator. The results suggest that YY1 and GATA factors are components of transcriptionally active complexes present in cardiac and other GATA-containing cells.	Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; McGill University	Nemer, M (corresponding author), Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, 110 Pins Ouest, Montreal, PQ H2W 1R7, Canada.				PHS HHS [MT -13057] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; ARGENTIN S, 1991, J BIOL CHEM, V266, P23315; ARGENTIN S, 1994, MOL CELL BIOL, V14, P777, DOI 10.1128/MCB.14.1.777; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Grepin C, 1997, DEVELOPMENT, V124, P2387; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; Grondin B, 1997, J BIOL CHEM, V272, P27877, DOI 10.1074/jbc.272.44.27877; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HYDEDERUYSCHER RP, 1995, NUCLEIC ACIDS RES, V23, P4457, DOI 10.1093/nar/23.21.4457; Izumo S, 1998, J Card Fail, V4, P263, DOI 10.1016/S1071-9164(98)90231-7; Jacobsen BM, 1999, J BIOL CHEM, V274, P29984, DOI 10.1074/jbc.274.42.29984; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; Korhonen P, 1997, MOL BRAIN RES, V52, P330; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LENARDO MJ, 1989, SCIENCE, V243, P544, DOI 10.1126/science.2536195; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; LIU R, 1994, NUCLEIC ACIDS RES, V22, P2453, DOI 10.1093/nar/22.13.2453; LU SY, 1994, MOL CELL BIOL, V14, P6253, DOI 10.1128/MCB.14.9.6253; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MCBRIDE K, 1993, MOL CELL BIOL, V13, P600, DOI 10.1128/MCB.13.1.600; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Molkentin JD, 1997, CIRCULATION, V96, P3833; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; MORIN S, 2001, IN PRESS MOL CELL BI, V21; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Patten M, 1996, J BIOL CHEM, V271, P21134, DOI 10.1074/jbc.271.35.21134; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seelan RS, 1997, J BIOL CHEM, V272, P10175, DOI 10.1074/jbc.272.15.10175; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIH IM, 1993, J INVEST DERMATOL, V100, P196; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; YU CY, 1991, J BIOL CHEM, V266, P8907; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZHANG ZM, 1994, INT J INTELL SYST, V9, P1047, DOI 10.1002/int.4550091202	63	60	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11439	11445		10.1074/jbc.M100208200	http://dx.doi.org/10.1074/jbc.M100208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11279028	hybrid			2022-12-25	WOS:000167980900118
J	Alvarez-Tejado, M; Naranjo-Suarez, S; Jimenez, C; Carrera, AC; Landazuri, MO; del Peso, L				Alvarez-Tejado, M; Naranjo-Suarez, S; Jimenez, C; Carrera, AC; Landazuri, MO; del Peso, L			Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells - Protective role in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; SIGNAL-TRANSDUCTION; REGULATED KINASES; GENE-EXPRESSION; DNA-BINDING; PROTEIN; PHOSPHORYLATION; RESPONSES; DEATH; ERYTHROPOIETIN	Hypoxia is a common environmental stress that influences signaling pathways and cell function. Several cell types, including neuroendocrine chromaffin cells, have evolved to sense oxygen levels and initiate specific adaptive responses to hypoxia. Here we report that under hypoxic conditions, rat pheochromocytoma PC12 cells are resistant to apoptosis induced by serum withdrawal and chemotherapy treatment. This effect is also observed after treatment with deferoxamine, a compound that mimics many of the effects of hypoxia, The hypoxia-dependent protection from apoptosis correlates with activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which is detected after 3-4 h of hypoxic or deferoxamine treatment and is sustained while hypoxic conditions are maintained. Hypoxia-induced Akt activation can be prevented by treatment with cycloheximide or actinomycin D, suggesting that de novo protein synthesis is required. Finally, inhibition of PI3K impairs both the protection against apoptosis and the activation of Akt in response to hypoxia, suggesting a functional link between these two phenomena. Thus, reduced oxygen tension regulates apoptosis in PC12 cells through activation of the PI3K/Akt survival pathway.	Univ Autonoma Madrid, Hosp de la Princesa, Serv Inmunol, Madrid 28006, Spain; CSIC, Dept Immunol & Oncol, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	del Peso, L (corresponding author), Univ Autonoma Madrid, Hosp de la Princesa, Serv Inmunol, Madrid 28006, Spain.		Suarez, Salvador Naranjo/K-8450-2017; del Peso, Luis/K-9391-2014	Suarez, Salvador Naranjo/0000-0002-7038-0753; del Peso, Luis/0000-0003-4014-5688; Jimenez, Maria Concepcion/0000-0002-7011-9328; Carrera, Ana/0000-0002-3999-5434				Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; Beitner-Johnson D, 1998, BIOCHEM BIOPH RES CO, V242, P61, DOI 10.1006/bbrc.1997.7907; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Conrad PW, 2000, ADV EXP MED BIOL, V475, P293; CZYZYKKRZESKA MF, 1994, J BIOL CHEM, V269, P760; DEL PL, 1997, SCIENCE, V278, P687; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; ERICKSON JT, 1994, J COMP NEUROL, V348, P161, DOI 10.1002/cne.903480202; GonzalezGarcia A, 1997, J BIOL CHEM, V272, P10220; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOONG AC, 1994, CANCER RES, V54, P1425; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JM, 2000, J CLIN INVEST, V106, P723, DOI 10.1172/JCI11003; LINDENBOIM L, 1995, CANCER RES, V55, P1242; Lobner D, 2000, J NEUROSCI METH, V96, P147, DOI 10.1016/S0165-0270(99)00193-4; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Parrizas M, 1997, J BIOL CHEM, V272, P154; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Robinson J.P., 1997, CURRENT PROTOCOLS CY; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Semenza GL, 2000, J CLIN INVEST, V106, P809, DOI 10.1172/JCI11223; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WANG GL, 1993, BLOOD, V82, P3610; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Williams RS, 2000, J CLIN INVEST, V106, P813, DOI 10.1172/JCI11205; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshimura S, 1998, J BIOL CHEM, V273, P6921, DOI 10.1074/jbc.273.12.6921; Zaman K, 1999, J NEUROSCI, V19, P9821; Zundel W, 2000, GENE DEV, V14, P391	36	197	200	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22368	22374		10.1074/jbc.M011688200	http://dx.doi.org/10.1074/jbc.M011688200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294857	hybrid			2022-12-25	WOS:000169412700054
J	Chang, SH; Low, PS				Chang, SH; Low, PS			Regulation of the glycophorin C-protein 4.1 membrane-to-skeleton bridge and evaluation of its contribution to erythrocyte membrane stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANES; KINASE-C; HEREDITARY SPHEROCYTOSIS; CALCIUM; BINDING; DEFORMABILITY; ACTIVATION; SPECTRIN; ANKYRIN; BAND-3	The band 3-ankyrin-spectrin bridge and the glycophorin C protein 4.1-spectrin/actin bridge constitute the two major tethers between the erythrocyte membrane and its spectrin skeleton, Although a structural requirement for the band 3-ankyrin bridge is well established, the contribution of the glycophorin C-protein 4.1 bridge to red cell function remains to be defined, In order to explore this latter bridge further, we have identified and/or characterized five stimuli that sever the linkage in intact erythrocytes and have examined the impact of this rupture on membrane mechanical properties. We report here that elevation of cytosolic 2,3-bisphosphoglycerate, an increase in intracellular Ca2+, removal of cell O-2, a decrease in intracellular pH, and activation of erythrocyte protein kinase C all promote dissociation of protein 4.1 from glycophorin C, leading to reduced retention of glycophorin C in detergent-extracted spectrin/actin skeletons. Significantly, where mechanical studies could be performed, we also observe that rupture of the membrane-to-skeleton bridge has little or no impact on the mechanical properties of the cell, as assayed by ektacytometry and nickel mesh filtration, We, therefore, suggest that, although regulation of the glycophorin C-protein 4.1-spectrin/actin bridge likely occurs physiologically, the role of the tether and the associated regulatory changes remain to be established.	Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Low, PS (corresponding author), Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA.	plow@purdue.edu		Low, Philip/0000-0001-9042-5528	NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024417, R01GM024417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRE P, 1992, CLIN RES, V40, P176; AGRE P, 1985, NATURE, V314, P380, DOI 10.1038/314380a0; ALLOISIO N, 1993, BLOOD, V82, P1323, DOI 10.1182/blood.V82.4.1323.bloodjournal8241323; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; ARAI K, 1990, BIORHEOLOGY, V27, P47; BREWER GJ, 1971, SCIENCE, V171, P1205, DOI 10.1126/science.171.3977.1205; CHAO TS, 1991, BIOCHEMISTRY-US, V30, P10529, DOI 10.1021/bi00107a023; COETZER TL, 1988, NEW ENGL J MED, V318, P230, DOI 10.1056/NEJM198801283180407; COHEN CM, 1986, J BIOL CHEM, V261, P7701; COSTA FF, 1990, NEW ENGL J MED, V323, P1046, DOI 10.1056/NEJM199010113231507; DALEKE DL, 1994, ANAL BIOCHEM, V217, P33, DOI 10.1006/abio.1994.1080; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DISCHER D, 1993, J BIOL CHEM, V268, P7186; FAQUIN WC, 1986, BIOCHIM BIOPHYS ACTA, V887, P142, DOI 10.1016/0167-4889(86)90048-0; GARDOS G, 1958, BIOCHIM BIOPHYS ACTA, V30, P653, DOI 10.1016/0006-3002(58)90124-0; GASCARD P, 1994, BLOOD, V83, P1102; Gedde MM, 1997, BIOPHYS J, V72, P1220, DOI 10.1016/S0006-3495(97)78769-1; Han BG, 2000, ACTA CRYSTALLOGR D, V56, P187, DOI 10.1107/S090744499901495X; HORNE WC, 1985, J BIOL CHEM, V260, P9073; IMANISHI H, 1981, HEMOGLOBIN, V5, P453, DOI 10.3109/03630268108991820; INOUE H, 1987, J BIOL CHEM, V262, P7635; Jarolim P, 1996, BLOOD, V88, P4366; JOHNSON RM, 1989, METHOD ENZYMOL, V173, P35; JONES B, 1987, EXP CELL RES, V168, P309, DOI 10.1016/0014-4827(87)90003-6; KANIEWSKI WS, 1994, BIORHEOLOGY, V31, P91; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDE WM, 1982, J CLIN INVEST, V70, P1273, DOI 10.1172/JCI110726; LEW VL, 1978, CURR TOP MEMBR TRANS, V10, P217; Lijnen P, 1998, AM J HYPERTENS, V11, P81, DOI 10.1016/S0895-7061(97)00368-3; LOMBARDO CR, 1994, BBA-BIOMEMBRANES, V1196, P139, DOI 10.1016/0005-2736(94)00233-9; LORAND L, 1983, J BIOL CHEM, V258, P5300; LOW PS, 1991, BLOOD, V77, P1581; Lux SE, 1995, BLOOD PRINCIPLES PRA, P1701; MCPHERSON RA, 1992, BIOCHEMISTRY-US, V31, P512, DOI 10.1021/bi00117a030; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MOHANDAS N, 1982, BLOOD, V59, P768; MORIYAMA R, 1993, J BIOL CHEM, V268, P10990; MORROW SJ, 1997, HDB PHYSL, P485; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; PERRIN DD, 1979, BUFFERS PH METAL ION, P94; Peters LL, 1996, CELL, V86, P917, DOI 10.1016/S0092-8674(00)80167-1; PINDER JC, 1995, BIOCHEM BIOPH RES CO, V210, P478, DOI 10.1006/bbrc.1995.1685; PONNAPPA BC, 1980, BIOCHIM BIOPHYS ACTA, V598, P494, DOI 10.1016/0005-2736(80)90030-9; REID ME, 1987, BLOOD, V69, P1068; Sakashita K, 1999, JPN J PHYSIOL, V49, P113, DOI 10.2170/jjphysiol.49.113; Sauvage M, 2000, EUR J BIOCHEM, V267, P955, DOI 10.1046/j.1432-1327.2000.01084.x; SAVVIDES P, 1993, BLOOD, V82, P2953; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; Wandersee NJ, 2001, BLOOD, V97, P543, DOI 10.1182/blood.V97.2.543; WHITE JG, 1978, AM J PATHOL, V91, P571; Yi SJ, 1997, BIOCHEMISTRY-US, V36, P9596, DOI 10.1021/bi9704966; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	56	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22223	22230		10.1074/jbc.M100604200	http://dx.doi.org/10.1074/jbc.M100604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294862	hybrid			2022-12-25	WOS:000169412700035
J	Danielson, PB; Hoversten, MT; Fitzpatrick, M; Schreck, C; Akil, H; Dores, RM				Danielson, PB; Hoversten, MT; Fitzpatrick, M; Schreck, C; Akil, H; Dores, RM			Sturgeon orphanin, a molecular "fossil" that bridges the gap between the opioids and orphanin FQ/nociceptin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FQ PRECURSOR; GENE FAMILY; RECEPTOR; NOCICEPTIN; HYPERALGESIA; NEUROPEPTIDE; GENERATION; EVOLUTION; PEPTIDES; BINDING	The elucidation of the cDNA sequence for sturgeon proorphanin provides a unique window for interpreting the evolutionary history of the opioid/orphanin gene family. The molecular "fossil" status of this precursor can be seen in several ancestral sequence characteristics that point to its origin as a duplication of either a prodynorphin- or proenkephalin-like gene. The sturgeon proorphanin cDNA encodes a precursor protein of 194 residues, and the orphanin heptadecapeptide itself binds not only the opioid receptor-like 1 (ORL1) receptor but also the classical (mu, kappa, and delta) opioid receptors with near equal affinity. Allowing for this broad receptor specificity are several amino acid substitutions at key positions in the heptadecapeptide sequence, relative to its mammalian orthologs, that have been linked by amino acid scans and site directed mutagenic studies to the exclusion of mammalian orphanin FQ/nociceptin from classic opioid ligands (i.e. F1Y and L14W). The unique receptor binding profile of sturgeon orphanin not only provides insight into the evolutionary history of the opioid and opioid-related peptides but also provides an ideal context in which to investigate the under lying mechanisms by which novel and often divergent physiological functions arise in receptor-ligand systems.	Univ Denver, Dept Sci Biol, Denver, CO 80210 USA; Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Oregon State Univ, Dept Fisheries & Wildlife, Corvallis, OR 97331 USA; Oregon State Univ, Oregon Cooperat Fish & Wildlife Res Unit, US Geol Survey, Biol Resources Div, Corvallis, OR 97331 USA	University of Denver; University of Michigan System; University of Michigan; Oregon State University; Oregon State University; United States Department of the Interior; United States Geological Survey	Danielson, PB (corresponding author), Univ Denver, Dept Sci Biol, 2101 E Wesley Ave,Rm 211, Denver, CO 80210 USA.				NIDA NIH HHS [R01 DA 08920] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008920] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Akil H, 1998, DRUG ALCOHOL DEPEN, V51, P127, DOI 10.1016/S0376-8716(98)00071-4; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Danielson PB, 1999, GEN COMP ENDOCR, V113, P169, DOI 10.1006/gcen.1998.7206; DawsonBasoa M, 1997, BRAIN RES, V750, P48, DOI 10.1016/S0006-8993(96)01334-0; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DOUGLASS J, 1984, ANNU REV BIOCHEM, V53, P665; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Hara N, 1997, BRIT J PHARMACOL, V121, P401, DOI 10.1038/sj.bjp.0701146; Houtani T, 1996, BIOCHEM BIOPH RES CO, V219, P714, DOI 10.1006/bbrc.1996.0300; HRUBY VJ, 1989, MED RES REV, V9, P343, DOI 10.1002/med.2610090306; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; JAKOBSEN KS, 1994, ADV BIOMAGNETIC SEPA, P61; MARTIN FH, 1985, NUCLEIC ACIDS RES, V13, P8927, DOI 10.1093/nar/13.24.8927; Meng F, 1996, J BIOL CHEM, V271, P32016, DOI 10.1074/jbc.271.50.32016; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7; Nothacker HP, 1996, P NATL ACAD SCI USA, V93, P8677, DOI 10.1073/pnas.93.16.8677; OHTA T, 1991, J MOL EVOL, V33, P34, DOI 10.1007/BF02100193; Okuda-Ashitaka E, 1998, NATURE, V392, P286, DOI 10.1038/32660; OkudaAshitaka E, 1996, MOL BRAIN RES, V43, P96, DOI 10.1016/S0169-328X(96)00165-9; Paterson S. J., 1984, PEPTIDES ANAL SYNTHE, P147; PATERSON SJ, 1984, NEUROPEPTIDES, V5, P177, DOI 10.1016/0143-4179(84)90056-8; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Reinscheid RK, 1998, J BIOL CHEM, V273, P1490, DOI 10.1074/jbc.273.3.1490; Rossi GC, 1997, J PHARMACOL EXP THER, V282, P858; ROSSI GC, 1996, EUR J PHARMACOL, V311, P7; Stanley S.M., 1998, MACROEVOLUTION PATTE, P332; Tian JH, 1998, BRIT J PHARMACOL, V124, P21, DOI 10.1038/sj.bjp.0701788; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; Yamamoto T, 1997, NEUROSCIENCE, V81, P249, DOI 10.1016/S0306-4522(97)00166-8; Yuferov VP, 1996, DNA CELL BIOL, V15, P1105, DOI 10.1089/dna.1996.15.1105	35	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22114	22119		10.1074/jbc.M011741200	http://dx.doi.org/10.1074/jbc.M011741200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11290742	hybrid			2022-12-25	WOS:000169412700020
J	Ficzycz, A; Eskiw, C; Meyer, D; Marley, KE; Hurt, M; Ovsenek, N				Ficzycz, A; Eskiw, C; Meyer, D; Marley, KE; Hurt, M; Ovsenek, N			Expression, activity, and subcellular localization of the Yin Yang 1 transcription factor in Xenopus oocytes and embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; EPSILON-GLOBIN GENE; MAJOR DEVELOPMENTAL TRANSITION; RIBOSOMAL-PROTEIN GENES; C-MYC; FACTOR YY1; ADENOVIRUS E1A; FIRST EXON; PROMOTER; BINDING	Yin Yang 1 (YY1) is a multifunctional transcription factor that acts as an activator, repressor, or initiator of transcription of numerous cellular and viral genes. Previous studies in tissue culture model systems suggest YY1 plays a role in development and differentiation in multiple cell types, but the biological role of YY1 in vertebrate oocytes and embryos is not well understood, Here we analyzed expression, activity, and subcellular localization profiles of YY1 during Xenopus laevis development. Abundant levels of YY1 mRNA and protein were detected in early stage oocytes and in all subsequent stages of oocyte and embryonic development through to swimming larval stages. The DNA binding activity of YY1 was detected only in early oocytes (stages I and II) and in embryos after the midblastula transition (MBT), which suggested that its potential to modulate gene expression may be specifically repressed in the intervening period of development. Experiments to determine transcriptional activity showed that addition of YY1 recognition sites upstream of the thymidine kinase promoter had no stimulatory or repressive effect on basal transcription in oocytes and post-MET embryos. Although the apparent transcriptional inactivity of YY1 in oocytes could be explained by the absence of DNA binding activity at this stage of development, the lack of transcriptional activity in post-MET embryos was not expected given the ability of WI to bind its recognition elements. Subsequent Western blot and immuno cytochemical analyses showed that YY1 is localized in the cytoplasm in oocytes and in cells of developing embryos well past the MET. These findings suggest a novel mode of YY1 regulation during early development in which the potential transcriptional function of the maternally expressed factor is repressed by cytoplasmic localization.	Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, Saskatoon, SK S7N 5E5, Canada; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA	University of Saskatchewan; State University System of Florida; Florida State University	Ovsenek, N (corresponding author), Univ Saskatchewan, Dept Anat & Cell Biol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.							Adrian GS, 1996, J GERONTOL A-BIOL, V51, pB66, DOI 10.1093/gerona/51A.1.B66; Ali A, 1998, MOL CELL BIOL, V18, P4949, DOI 10.1128/MCB.18.9.4949; Austen M, 1997, CURR TOP MICROBIOL, V224, P123; Brzostowski J, 2000, EMBO J, V19, P3683, DOI 10.1093/emboj/19.14.3683; BUSHMEYER S, 1995, J BIOL CHEM, V270, P30213; Chen CY, 1997, MOL ENDOCRINOL, V11, P812, DOI 10.1210/me.11.6.812; DARASCH S, 1988, BIOCHEM CELL BIOL, V66, P862, DOI 10.1139/o88-098; De Rinaldis E, 1998, EUR J BIOCHEM, V255, P563, DOI 10.1046/j.1432-1327.1998.2550563.x; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; Eliassen KA, 1998, MOL CELL BIOL, V18, P7106, DOI 10.1128/MCB.18.12.7106; Ficzycz A, 1997, DEV BIOL, V182, P21, DOI 10.1006/dbio.1996.8459; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Galvagni F, 1998, J BIOL CHEM, V273, P33708, DOI 10.1074/jbc.273.50.33708; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Gordon S, 1997, DEV BIOL, V181, P47, DOI 10.1006/dbio.1996.8441; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; GUO B, 1995, P NATL ACAD SCI USA, V92, P10526, DOI 10.1073/pnas.92.23.10526; LEE JS, 1995, NUCLEIC ACIDS RES, V23, P925, DOI 10.1093/nar/23.6.925; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1994, ONCOGENE, V9, P1047; LEMAITRE JM, 1995, MOL CELL BIOL, V15, P5054; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Martin KA, 1997, DNA CELL BIOL, V16, P653, DOI 10.1089/dna.1997.16.653; McNeil S, 1998, J CELL BIOCHEM, V68, P500, DOI 10.1002/(SICI)1097-4644(19980315)68:4<500::AID-JCB9>3.3.CO;2-T; MELTON DA, 1979, CELL, V18, P1165, DOI 10.1016/0092-8674(79)90229-0; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; OConnor MJ, 1996, J VIROL, V70, P6529, DOI 10.1128/JVI.70.10.6529-6539.1996; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; OVSENEK N, 1988, DEV BIOL, V129, P582, DOI 10.1016/0012-1606(88)90403-4; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; Patten M, 1996, J BIOL CHEM, V271, P21134, DOI 10.1074/jbc.271.35.21134; PETERS B, 1993, J BIOL CHEM, V268, P3430; PISANESCHI G, 1994, BIOCHEM BIOPH RES CO, V205, P1236, DOI 10.1006/bbrc.1994.2797; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; Reizis B, 1999, J EXP MED, V189, P1669, DOI 10.1084/jem.189.10.1669; Schulten HJ, 1999, BIOCHEM BIOPH RES CO, V257, P871, DOI 10.1006/bbrc.1999.0556; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shrivastava A, 1996, P NATL ACAD SCI USA, V93, P10638, DOI 10.1073/pnas.93.20.10638; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; WALLACE RA, 1973, J EXP ZOOL, V184, P321, DOI 10.1002/jez.1401840305; Walowitz JL, 1998, J BIOL CHEM, V273, P6656, DOI 10.1074/jbc.273.12.6656; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; ZHOU QJ, 1995, J VIROL, V69, P7402, DOI 10.1128/JVI.69.12.7402-7409.1995; Zhu W, 1999, BLOOD, V93, P3540, DOI 10.1182/blood.V93.10.3540.410k28_3540_3549	47	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22819	22825		10.1074/jbc.M011188200	http://dx.doi.org/10.1074/jbc.M011188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294833	hybrid			2022-12-25	WOS:000169412700112
J	Tartare-Deckert, S; Chavey, C; Monthouel, MN; Gautier, N; Van Obberghen, E				Tartare-Deckert, S; Chavey, C; Monthouel, MN; Gautier, N; Van Obberghen, E			The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NECROSIS-FACTOR-ALPHA; GENE-EXPRESSION; ADIPOSE-TISSUE; INSULIN-RESISTANCE; VASCULAR-DISEASE; GROWTH-FACTOR; VISCERAL FAT; BODY-WEIGHT; SPARC	Alterations in the expression level of genes may contribute to the development and pathophysiology of obesity. To find genes differentially expressed in adipose tissue during obesity, we performed suppression subtractive hybridization on epididymal fat mRNA from goldthioglucose (GTG) obese mice and from their lean littermates. We identified the secreted protein acidic and rich in cysteine (SPARC), a protein that mediates cell-matrix interactions and plays a role in modulation of cell adhesion, differentiation, and angiogenesis. SPARC mRNA expression in adipose tissue was markedly increased (between 3- and B fold) in three different models of obesity, i.e, G;TG mice, ob/ob mice, and AKR mice, after 6 weeks of a high fat diet. Immunoblotting of adipocyte extracts revealed a similar increase in protein level, Using a SPARC-specific ELISA, we demonstrated that SPARC is secreted by isolated adipocytes, We found that insulin administration to mice increased SPARC mRNA in the adipose tissue. Food deprivation had no effect on SPARC expression, but after high fat refeeding SPARC mRNA levels were significantly increased. Our results reveal both hormonal and nutritional regulation of SPARC expression in the adipocyte, and importantly, its alteration in obesity. Finally, we show that purified SPARC increased mRNA levels of plasminogen activator inhibitor 1 (PAI-1) in cultured rat adipose tissue suggesting that elevated adipocyte expression of SPARC might contribute to the abnormal expression of PAI-1 observed in obesity, We propose that SPARC is a newly identified autocrine/paracrine factor that could affect key functions in adipose tissue physiology and pathology.	INSERM U145, IFR 50, F-06107 Nice 2, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Tartare-Deckert, S (corresponding author), INSERM U145, IFR 50, Ave Valombrose, F-06107 Nice 2, France.		TARTARE-DECKERT, Sophie/P-6057-2015	TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Chavey, Carine/0000-0002-5267-5638				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; Alessi MC, 1997, DIABETES, V46, P860, DOI 10.2337/diabetes.46.5.860; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Bouloumie A, 1998, CIRC RES, V83, P1059, DOI 10.1161/01.RES.83.10.1059; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Francki A, 1999, J BIOL CHEM, V274, P32145, DOI 10.1074/jbc.274.45.32145; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gilmour DT, 1998, EMBO J, V17, P1860, DOI 10.1093/emboj/17.7.1860; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; HASSELAAR P, 1991, J BIOL CHEM, V266, P13178; Hill JO, 1998, SCIENCE, V280, P1371, DOI 10.1126/science.280.5368.1371; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; JuhanVague I, 1997, THROMB HAEMOSTASIS, V78, P656; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; LANE TF, 1992, J BIOL CHEM, V267, P16736; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lefebvre AM, 1998, DIABETES, V47, P98, DOI 10.2337/diabetes.47.1.98; MARCHANDBRUSTEL YL, 1978, AM J PHYSIOL, V234, pE348; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; Montague CT, 1998, DIABETES, V47, P1384, DOI 10.2337/diabetes.47.9.1384; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Renz M, 2000, J BIOL CHEM, V275, P10429, DOI 10.1074/jbc.275.14.10429; Sage EH, 1997, NAT MED, V3, P144; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Samad F, 1997, MOL MED, V3, P37, DOI 10.1007/BF03401666; Samad F, 1998, P NATL ACAD SCI USA, V95, P7591, DOI 10.1073/pnas.95.13.7591; Samad F, 1999, P NATL ACAD SCI USA, V96, P6902, DOI 10.1073/pnas.96.12.6902; Samad F, 1996, MOL MED, V2, P568, DOI 10.1007/BF03401641; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Shimomura I, 1996, NAT MED, V2, P800, DOI 10.1038/nm0796-800; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; Vicent D, 1998, DIABETES, V47, P1451, DOI 10.2337/diabetes.47.9.1451; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; Wiman B, 1996, Curr Opin Hematol, V3, P372; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	47	75	80	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22231	22237		10.1074/jbc.M010634200	http://dx.doi.org/10.1074/jbc.M010634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294850	hybrid			2022-12-25	WOS:000169412700036
J	Katsamba, PS; Myszka, DG; Laird-Offringa, IA				Katsamba, PS; Myszka, DG; Laird-Offringa, IA			Two functionally distinct steps mediate high affinity binding of U1A protein to U1 hairpin II RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; A-PROTEIN; MACROMOLECULAR INTERACTIONS; MOLECULAR-DYNAMICS; KINETIC-ANALYSIS; STRUCTURAL BASIS; RECOGNITION; SEQUENCE; COMPLEX; DOMAIN	Binding of the U1A protein to its RNA target U1A.U1 hairpin II has been extensively studied as a model for a high affinity RNA/protein interaction. However, the mechanism and kinetics by which this complex is formed remain largely unknown. Here we use real-time biomolecular interaction analysis to dissect the roles various protein and RNA structural elements play in the formation of the U1A.U1 hairpin II complex. We show that neutralization of positive charges on the protein or increasing the salt concentration slows the association rate, suggesting that electrostatic interactions play an important role in bringing RNA and protein together. In contrast, removal of hydrogen bonding or stacking interactions within the RNA/protein interface, or reducing the size of the RNA loop, dramatically destabilizes the complex, as seen by a strong increase in the dissociation rate. Our data support a binding mechanism consisting of a rapid initial association based on electrostatic interactions and a subsequent locking step based on close-range interactions that occur during the induced fit of RNA and protein. Remarkably, these two steps can be clearly distinguished using U1A mutants containing single amino acid substitutions. Our observations explain the extraordinary affinity of U1A for its target and may suggest a general mechanism for high affinity RNA/protein interactions.	Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA; Univ Utah, Sch Med, Ctr Biomol Interact Anal, Salt Lake City, UT 84132 USA	University of Southern California; Utah System of Higher Education; University of Utah	Laird-Offringa, IA (corresponding author), Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA.	ilaird@hsc.usc.edu	Offringa, Ite/R-4101-2019	Katsamba, Phinikoula/0000-0003-3981-1604				Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; BENNETT MM, 1993, NUCLEIC ACIDS RES, V21, P4404, DOI 10.1093/nar/21.18.4404; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P4611, DOI 10.1093/nar/19.17.4611; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Christensen LLH, 1997, ANAL BIOCHEM, V249, P153, DOI 10.1006/abio.1997.2182; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; FLICKINGER TW, 1994, GENE DEV, V8, P914, DOI 10.1101/gad.8.8.914; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; Kranz JK, 1998, J MOL BIOL, V275, P465, DOI 10.1006/jmbi.1997.1441; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; Mittermaier A, 1999, J MOL BIOL, V294, P967, DOI 10.1006/jmbi.1999.3311; Morton TA, 1998, METHOD ENZYMOL, V295, P268; Myszka DG, 1999, J MOL RECOGNIT, V12, P390, DOI 10.1002/(SICI)1099-1352(199911/12)12:6<390::AID-JMR482>3.0.CO;2-8; Myszka DG, 1998, BIOPHYS J, V75, P583, DOI 10.1016/S0006-3495(98)77549-6; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Myszka DG, 1998, TRENDS BIOCHEM SCI, V23, P149, DOI 10.1016/S0968-0004(98)01183-9; Myszka DG, 2000, METHOD ENZYMOL, V323, P325; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Park SM, 2000, MOL CELL BIOL, V20, P4765, DOI 10.1128/MCB.20.13.4765-4772.2000; Reyes CM, 2000, J MOL BIOL, V297, P1145, DOI 10.1006/jmbi.2000.3629; Rich RL, 2000, CURR OPIN BIOTECH, V11, P54, DOI 10.1016/S0958-1669(99)00054-3; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SILLEKENS PTG, 1987, EMBO J, V6, P3841, DOI 10.1002/j.1460-2075.1987.tb02721.x; SIMPSON GG, 1995, EMBO J, V14, P4540, DOI 10.1002/j.1460-2075.1995.tb00133.x; STUMP WT, 1995, RNA, V1, P55; Tang Y, 1999, BIOPHYS J, V77, P1284, DOI 10.1016/S0006-3495(99)76979-1; TSAI DE, 1991, NUCLEIC ACIDS RES, V19, P4931, DOI 10.1093/nar/19.18.4931; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Williams DJ, 1996, J MOL BIOL, V257, P265; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575	45	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21476	21481		10.1074/jbc.M101624200	http://dx.doi.org/10.1074/jbc.M101624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11297556	hybrid			2022-12-25	WOS:000169297900091
J	Zhang, YG; Dong, ZM; Nomura, M; Zhong, SP; Chen, NY; Bode, AM; Dong, ZG				Zhang, YG; Dong, ZM; Nomura, M; Zhong, SP; Chen, NY; Bode, AM; Dong, ZG			Signal transduction pathways involved in phosphorylation and activation of p70(S6K) following exposure to UVA irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; EPIDERMAL GROWTH-FACTOR; NONMELANOMA SKIN-CANCER; N-TERMINAL KINASE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MUSCLE-CELLS; IN-VIVO; AP-1 TRANSACTIVATION; REGULATED KINASE	Ultraviolet light A (WA) plays an important role in the etiology of human skin cancer, and WA-induced signal transduction has a critical role in WA-induced skin carcinogenesis. The upstream signaling pathways leading to p70(S6K) phosphorylation and activation are not well understood. Here, we observed that WA induces phosphorylation and activation of p70(S6K). Further, UVA-stimulated p70(S6K) activity and phosphorylation at Thr(389) were blocked by wortmannin, rapamycin, PD98059, SB202190, and dominant negative mutants of phosphatidylinositol (PI) 3-kinase p85 subunit (DNM-Delta p85), ERK2 (DNM-ERK2), p38 kinase (DNM-p38), and JNK1 (DNM-JNK1) and were absent in Jnk1-/- or Jnk2-/- knockout cells. The p70(S6K) phosphorylation at Ser(411) and Thr(421)/Ser(424) was inhibited by rapamycin, PD98059, or DNM-ERK2 but not by wortmannin, SB202190, DNM-Delta p85, or DNM-p38. However, Ser(411), but not Thr(421)/Ser(424) phosphorylation, was suppressed in DNM-JNK1 and abrogated in Jnk1-/- or Jnk2-/- cells. In vitro assays indicated that Ser(411) on immunoprecipitated p70(S6K) proteins is phosphorylated by active JNKs and ERKs, but not p38 kinase, and Thr(421)/Ser(424) is phosphorylated by ERK1, but not ERK2, JNKs, or p38 kinase, Moreover, p70(S6K) co-immunoprecipitated with PI 3-kinase and possibly PDK1, The complex possibly possessed a partial basal level of phosphorylation, but not at MAPK sites, which was available for its activation by MAPKs in vitro. Thus, these results suggest that activation of MAPKs, like PI 3-kinase/mTOR, may be involved in WA-induced phosphorylation and activation of p70(S6K).	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; Henan Med Univ, Dept Pathophysiol, Zhengzhou 450052, Peoples R China	University of Minnesota System; Zhengzhou University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Zhang, Yiguo/0000-0003-3910-2779	NATIONAL CANCER INSTITUTE [R01CA077646, R01CA081064, R37CA081064] Funding Source: NIH RePORTER; NCI NIH HHS [CA77646, CA81064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Band CJ, 1999, ENDOCRINOLOGY, V140, P5626, DOI 10.1210/en.140.12.5626; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Blair AS, 1999, J BIOL CHEM, V274, P36293, DOI 10.1074/jbc.274.51.36293; Brenneisen P, 2000, J BIOL CHEM, V275, P4336, DOI 10.1074/jbc.275.6.4336; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DeLaat JMT, 1996, CANCER SURV, V26, P173; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Eguchi S, 1999, J BIOL CHEM, V274, P36843, DOI 10.1074/jbc.274.52.36843; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; FRANCO R, 1990, J BIOL CHEM, V265, P4321; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GretherBeck S, 1997, BIOL CHEM, V378, P1231; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang CS, 1997, J BIOL CHEM, V272, P4187, DOI 10.1074/jbc.272.7.4187; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Iwasaki H, 1999, ENDOCRINOLOGY, V140, P4659, DOI 10.1210/en.140.10.4659; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Loo DT, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P65; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Papst PJ, 1998, J BIOL CHEM, V273, P15077, DOI 10.1074/jbc.273.24.15077; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Runger TM, 1999, PHOTODERMATOL PHOTO, V15, P212; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SEGER R, 1995, J BIOL CHEM, V270, P28325; Sehgal SN, 1998, CLIN BIOCHEM, V31, P335, DOI 10.1016/S0009-9120(98)00045-9; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TYRRELL RM, 1996, STRESS INDUCIBLE CEL, P255; Wang XM, 1997, BIOCHEM BIOPH RES CO, V238, P207, DOI 10.1006/bbrc.1997.7273; Watts RG, 1998, ONCOGENE, V17, P3493, DOI 10.1038/sj.onc.1202259; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	73	86	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20913	20923		10.1074/jbc.M009047200	http://dx.doi.org/10.1074/jbc.M009047200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279232	hybrid			2022-12-25	WOS:000169297900018
J	Huang, YZ; Wang, Q; Xiong, WC; Mei, L				Huang, YZ; Wang, Q; Xiong, WC; Mei, L			Erbin is a protein concentrated at postsynaptic membranes that interacts with PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR SYNTHESIS; BASOLATERAL PDZ PROTEIN; SYNAPTIC BASAL LAMINA; TUMOR-SUPPRESSOR GENE; TYROSINE PHOSPHORYLATION; NEUREGULIN RECEPTORS; EXPRESSION; SUBUNIT; ARIA; KINASE	Neuregulin is a factor essential for synapse-specific transcription of acetylcholine receptor genes at the neuromuscular junction. Its receptors, ErbB receptor tyrosine kinases, are localized at the postjunctional membrane presumably to ensure localized signaling. However, the molecular mechanisms underlying synaptic localization of ErbBs are unknown. Our recent studies indicate that ErbB4 interacts with postsynaptic density (PSD)-95 (SAP90), a PDZ domain-containing protein that does not interact with ErbB2 or ErbB3. Using as bait the ErbB2 C terminus, we identified Erbin, another PDZ domain-containing protein that interacts specifically with ErbB2. Erbin is concentrated in postsynaptic membranes at the neuromuscular junction and in the central nervous system, where ErbB2 is concentrated. Expression of Erbin increases the amount of ErbB2 labeled by biotin in transfected cells, suggesting that Erbin is able to increase ErbB2 surface expression. Furthermore, we provide evidence that Erbin interacts with PSD-95 in both transfected cells and synaptosomes. Thus ErbB proteins can interact with a network of PDZ domain-containing proteins. This interaction may play an important role in regulation of neuregulin signaling and/or subcellular localization of ErbB proteins.	Univ Alabama Birmingham, Sch Med, Civitan Int Res Ctr 516, Dept Neurobiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Med, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Mei, L (corresponding author), Univ Alabama Birmingham, Sch Med, Civitan Int Res Ctr 516, Dept Neurobiol, 1719 6th Ave S, Birmingham, AL 35294 USA.	lmei@nrc.uab.edu	Mei, Lin/G-8755-2012		NINDS NIH HHS [NS34062, NS40480] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034062, R01NS040480] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; BLACKSTONE CD, 1992, J NEUROCHEM, V58, P1118, DOI 10.1111/j.1471-4159.1992.tb09370.x; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bredt DS, 1998, CELL, V94, P691, DOI 10.1016/S0092-8674(00)81727-4; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Colledge M, 1997, J NEUROSCI, V17, P5038; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; Garcia RAG, 2000, P NATL ACAD SCI USA, V97, P3596, DOI 10.1073/pnas.070042497; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; GOODEARL ADJ, 1995, J CELL BIOL, V130, P1423, DOI 10.1083/jcb.130.6.1423; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HARLOW E, 1993, ANTIBODIES LAB MANUA; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; JO SA, 1992, DEVELOPMENT, V115, P673; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Luck G, 2000, MOL CELL NEUROSCI, V16, P269, DOI 10.1006/mcne.2000.0873; MEI L, 1994, J BIOL CHEM, V269, P12254; Morris JK, 1999, NEURON, V23, P273, DOI 10.1016/S0896-6273(00)80779-5; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Ozaki M, 1997, NATURE, V390, P691, DOI 10.1038/37795; Rafael JA, 1998, NEUROREPORT, V9, P2121, DOI 10.1097/00001756-199806220-00039; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Sheng M, 2000, NAT NEUROSCI, V3, P633, DOI 10.1038/76576; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1999, J NEUROSCI, V19, P8498; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tanowitz M, 1996, BRAIN RES, V712, P299, DOI 10.1016/0006-8993(95)01475-6; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; Trinidad JC, 2000, J NEUROSCI, V20, P8762; Walikonis RS, 2001, J NEUROSCI, V21, P423, DOI 10.1523/JNEUROSCI.21-02-00423.2001; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Won S, 1999, J NEUROCHEM, V73, P2358, DOI 10.1046/j.1471-4159.1999.0732358.x; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yang X, 1998, NEURON, V20, P255, DOI 10.1016/S0896-6273(00)80454-7; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	57	82	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19318	19326		10.1074/jbc.M100494200	http://dx.doi.org/10.1074/jbc.M100494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279080	hybrid			2022-12-25	WOS:000169091000091
J	Ling, P; Meyer, CF; Redmond, LP; Shui, JW; Davis, B; Rich, RR; Hu, MCT; Wange, RL; Tan, TH				Ling, P; Meyer, CF; Redmond, LP; Shui, JW; Davis, B; Rich, RR; Hu, MCT; Wange, RL; Tan, TH			Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; GERMINAL CENTER KINASE; STE20-RELATED PROTEIN-KINASE; ADAPTER PROTEINS; ANTIGEN-RECEPTOR; GENETIC-EVIDENCE; TYROSINE KINASE; ACTIVATION; PATHWAY; HPK1	Hematopoietic progenitor kinase 1 (HPK1), a mammalian Ste20-related serine/threonine protein kinase, is a hematopoietic-specific upstream activator of the c-Jun N-terminal kinase. Here, we provide evidence to demonstrate the involvement of HPK1 in T cell receptor (TCR) signaling. HPK1 was activated and tyrosine-phosphorylated with similar kinetics following TCR/CD3 or pervanadate stimulation. Co-expression of protein-tyrosine kinases, Lck and Zap70, with HPK1 led to HPK1 activation and tyrosine phosphorylation in transfected mammalian cells. Upon TCR/CD3 stimulation, HPK1 formed inducible complexes with the adapters Nck and Grk with different kinetics, whereas it constitutively interacted with the adapters Grb2 and CrkL in Jurkat T cells. Interestingly, HPK1 also inducibly associated with linker for activation of T cells (LAT) through its proline-rich motif and translocated into glycolipid-enriched microdomains (also called lipid rafts) following TCR/CD3 stimulation, suggesting a critical role for LAT in the regulation of HPK1, Together, these results identify HPK1 as a new component of TCR signaling. T cell-specific signaling molecules Lck, Zap70, and LAT play roles in the regulation of HPK1 during TCR signaling. Differential complex formation between HPK1 and adapters highlights the possible involvement of HPK1 in multiple signaling pathways in T cells.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; NIA, Biol Chem Lab, NIH, Baltimore, MD 21224 USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA.		Shui, Jr-Wen/Q-2617-2018; Tan, Tse-Hua/ABD-7080-2021; Wange, Ronald/AAI-2505-2021; Tan, Tse-Hua/E-3983-2010	Shui, Jr-Wen/0000-0002-5243-3727; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Wange, Ronald/0000-0001-9593-3572	NIAID NIH HHS [R01-AI38649, R01-AI42532] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000509] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 2000, INT J ONCOL, V16, P651; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Gelkop S, 1999, J BIOL CHEM, V274, P21519, DOI 10.1074/jbc.274.31.21519; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ito Y, 2001, J BIOL CHEM, V276, P18130, DOI 10.1074/jbc.M007294200; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; Ling P, 1999, MOL CELL BIOL, V19, P1359; Liou J, 2000, IMMUNITY, V12, P399, DOI 10.1016/S1074-7613(00)80192-2; Liu SK, 2000, J IMMUNOL, V165, P1417, DOI 10.4049/jimmunol.165.3.1417; Ma WB, 2001, ONCOGENE, V20, P1703, DOI 10.1038/sj.onc.1204224; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; Shi CS, 1997, J BIOL CHEM, V272, P32102, DOI 10.1074/jbc.272.51.32102; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; van Leeuwen JEM, 1999, MOL CELL BIOL, V19, P6652; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Xavier R, 1999, CURR OPIN IMMUNOL, V11, P265, DOI 10.1016/S0952-7915(99)80043-0; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	41	53	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18908	18914		10.1074/jbc.M101485200	http://dx.doi.org/10.1074/jbc.M101485200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279207	hybrid			2022-12-25	WOS:000169091000036
J	Sweet, CR; Lin, S; Cotter, RJ; Raetz, CRH				Sweet, CR; Lin, S; Cotter, RJ; Raetz, CRH			A Chlamydia trachomatis UDP-N-acetylglucosamine acyltransferase selective for myristoyl-acyl carrier protein - Expression in Escherichia coli and formation of hybrid lipid A species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ENDOTOXIN BIOSYNTHESIS; SALMONELLA-TYPHIMURIUM; DISACCHARIDE SYNTHASE; MULTICOPY SUPPRESSOR; ANTIBACTERIAL AGENTS; GENOME SEQUENCE; MSBB GENE; HOST-CELL; 1ST STEP	Chlamydia trachomatis lipid A is unusual in that it is acylated with myristoyl chains at the glucosamine 3 and 3' positions, We have cloned and expressed the gene encoding UDP-N-acetylglucosamine 3-O-acyltransferase of C, trachomatis (CtlpxA), the first enzyme of lipid A biosynthesis. C. trachomatis LpxA displays similar to 20-fold selectivity for myristoyl-ACP over R/S-3-hydroxymyristoyl-ACP under standard assay conditions, consistent with the proposed structure of C, trachomatis lipid A. CtLpxA is the first reported UDP-N-acetylglucosamine acyltransferase that prefers a non-hydroxylated acyl-ACP to a hydroxyacyl-ACP. When CtlpxA was expressed in RO138, a temperature-sensitive lpxA mutant of Escherichia coli, five new hybrid lipid A species were made in vivo after 2 h at 42 degreesC, in place of Escherichia coli lipid A. These compounds were purified and analyzed by matrix-assisted laser desorption ionization/time of flight mass spectrometry. In each case, a myristoyl chain replaced one or both of the ester linked 3-hydroxymyristoyl residues of E. coli lipid A. With prolonged growth at 42 degreesC, all the ester-linked 3-hydroxymyristoyl residues were replaced with myristate chains. Re-engineering the structure of E. coli lipid A should facilitate the microbiological production of novel agonists or antagonists of the innate immunity receptor TLR-4, with possible uses as adjuvants or anti-inflammatory agents.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Duke Univ, Dept Biochem, Durham, NC 27710 USA	Johns Hopkins University; Duke University	Raetz, CRH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	raetz@biochem.duke.edu			NIGMS NIH HHS [GM-51310, GM08558, GM54882] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008558, R01GM054882, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Babinski KJ, 1998, FASEB J, V12, pA1288; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brade H, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P229; Brade H., 1999, ENDOTOXIN HLTH DIS; Clementz T, 1997, J BIOL CHEM, V272, P10353; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; CROWELL DN, 1987, J BACTERIOL, V169, P5727, DOI 10.1128/jb.169.12.5727-5734.1987; Dotson GD, 1998, J BACTERIOL, V180, P330, DOI 10.1128/JB.180.2.330-337.1998; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Hackstadt T, 1996, EMBO J, V15, P964, DOI 10.1002/j.1460-2075.1996.tb00433.x; Hatch GM, 1998, INFECT IMMUN, V66, P3727, DOI 10.1128/IAI.66.8.3727-3735.1998; Hoshino K, 1999, J IMMUNOL, V162, P3749; INGALLS RR, 1995, INFECT IMMUN, V63, P3125, DOI 10.1128/IAI.63.8.3125-3130.1995; Jackman JE, 2000, J BIOL CHEM, V275, P11002, DOI 10.1074/jbc.275.15.11002; KARIMI ST, 1989, INFECT IMMUN, V57, P1780, DOI 10.1128/IAI.57.6.1780-1785.1989; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi N, 1997, J BIOL CHEM, V272, P10594; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAY BL, 1984, J BIOL CHEM, V259, P4852; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Rund S, 1999, J BIOL CHEM, V274, P16819, DOI 10.1074/jbc.274.24.16819; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACHTER J, 1980, ANNU REV MICROBIOL, V34, P285, DOI 10.1146/annurev.mi.34.100180.001441; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Stephens RS, 1998, SCIENCE, V282, P754, DOI 10.1126/science.282.5389.754; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Wyckoff TJO, 1999, J BIOL CHEM, V274, P27047, DOI 10.1074/jbc.274.38.27047; Wylie JL, 1997, J BACTERIOL, V179, P7233, DOI 10.1128/jb.179.23.7233-7242.1997; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	54	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19565	19574		10.1074/jbc.M101868200	http://dx.doi.org/10.1074/jbc.M101868200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279221	hybrid			2022-12-25	WOS:000169091000120
J	Towne, JE; Krane, CM; Bachurski, CJ; Menon, AG				Towne, JE; Krane, CM; Bachurski, CJ; Menon, AG			Tumor necrosis factor-alpha inhibits aquaporin 5 expression in mouse lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; WATER CHANNEL; FACTOR RECEPTORS; FAMILY; AQP5; GENE; PROLIFERATION; ADENOVIRUS; INDUCTION	Aquaporin 5 (AQP5), the major water channel expressed in alveolar, tracheal, and upper bronchial epithelium, is significantly down-regulated during pulmonary inflammation and edema. The mechanisms that underlie this decrease in AQP5 levels are therefore of considerable interest. Here we show that AQP5 expression in cultured lung epithelial cells is decreased 2-fold at the mRNA level and 10-fold at the protein level by the proinflammatory cytokine tumor necrosis factor alpha (TNF-alpha). Treatment of murine lung epithelial cells (MLE-12) with TNF-alpha results in a concentration- and time-dependent decrease in AQP5 mRNA and protein expression. Activation of the p55 TNF-alpha receptor (TNFR1) with an agonist antibody is sufficient to cause decreased AQP5 expression, demonstrating that the TNF-alpha effect is mediated through TNFR1. Inhibition of nuclear factor kappaB (NF-kappaB) translocation to the nucleus blocks the effect of TNF-alpha on AQP5 expression, indicating that activation of NF-kappaB is required, whereas inhibition of extracellular signal-regulated or p38 mitogen-activated protein kinases showed no effect. These data show that TNF-alpha decreases AQP5 mRNA and protein expression and that the molecular pathway for this effect involves TNFR1 and activated NF-kappaB. The ability of inflammatory cytokines to decrease aquaporin expression may help explain the connection between inflammation and edema.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	University System of Ohio; University of Cincinnati; Cincinnati Children's Hospital Medical Center	Menon, AG (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way,3110 MSB,POB 670524, Cincinnati, OH 45267 USA.	Anil.Menon@UC.edu		Bachurski, Cindy/0000-0002-3118-0636	NHLBI NIH HHS [HL61781, R01 HL60907] Funding Source: Medline; NIDCR NIH HHS [R01 DE138283] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061781, R01HL060907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Beitz E, 1999, CURR MED CHEM, V6, P457; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; Chen AP, 1999, J BIOL CHEM, V274, P35505, DOI 10.1074/jbc.274.50.35505; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Cooney R, 1999, AM J PHYSIOL-ENDOC M, V276, pE611, DOI 10.1152/ajpendo.1999.276.4.E611; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darnay BG, 1999, ANN RHEUM DIS, V58, P2; Deen PMT, 2000, EUR J CELL BIOL, V79, P523, DOI 10.1078/0171-9335-00075; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Fiedler MA, 1998, AM J RESP CELL MOL, V19, P259, DOI 10.1165/ajrcmb.19.2.3149; Francis P, 2000, HUM MOL GENET, V9, P2329, DOI 10.1093/oxfordjournals.hmg.a018925; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; Guo DQ, 1998, J IMMUNOL, V160, P2742; Harrod KS, 1998, AM J PHYSIOL-LUNG C, V275, pL924, DOI 10.1152/ajplung.1998.275.5.L924; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; Kobuchi H, 1999, AM J PHYSIOL-CELL PH, V277, pC403, DOI 10.1152/ajpcell.1999.277.3.C403; Krane CM, 1999, MAMM GENOME, V10, P498, DOI 10.1007/s003359901030; Larsen GL, 2000, AM J RESP CRIT CARE, V162, pS2, DOI 10.1164/ajrccm.162.supplement_1.maic-1; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu RY, 2000, J BIOL CHEM, V275, P21086, DOI 10.1074/jbc.M001281200; Liu RY, 1999, J BIOL CHEM, V274, P13877, DOI 10.1074/jbc.274.20.13877; Luster MI, 1999, CRIT REV TOXICOL, V29, P491, DOI 10.1080/10408449991349258; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Marples D, 1999, AM J PHYSIOL-RENAL, V276, pF331, DOI 10.1152/ajprenal.1999.276.3.F331; Matsuzaki T, 1999, CELL TISSUE RES, V295, P513, DOI 10.1007/s004410051257; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; Rippe RA, 1999, DNA CELL BIOL, V18, P751, DOI 10.1089/104454999314890; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHEEHAN KCF, 1995, J EXP MED, V181, P607, DOI 10.1084/jem.181.2.607; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Yang GH, 2000, FASEB J, V14, pA1428; Zsengeller Z, 2000, J VIROL, V74, P9655, DOI 10.1128/JVI.74.20.9655-9667.2000	49	111	141	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18657	18664		10.1074/jbc.M100322200	http://dx.doi.org/10.1074/jbc.M100322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279049	hybrid			2022-12-25	WOS:000169091000003
J	An, JP; Tzagarakis-Foster, C; Scharschmidt, TC; Lomri, N; Leitman, DC				An, JP; Tzagarakis-Foster, C; Scharschmidt, TC; Lomri, N; Leitman, DC			Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE REPLACEMENT THERAPY; BREAST-CANCER; POSTMENOPAUSAL WOMEN; BONE LOSS; SOY PROTEIN; RALOXIFENE; BINDING; ALPHA; RISK; COACTIVATOR	Estrogens used in hormone replacement therapy regimens may increase the risk of developing breast cancer. Paradoxically, high consumption of plant-derived phytoestrogens, particularly soybean isoflavones, is associated with a low incidence of breast cancer. To explore the molecular basis for these potential different clinical outcomes, we investigated whether soybean isoflavones elicit distinct transcriptional actions from estrogens, Our results demonstrate that the estrogen 17 beta -estradiol effectively triggers the transcriptional activation and repression pathways with both estrogen receptors (ERs) ER alpha and ER beta. In contrast, soybean isoflavones (genistein, daidzein, and biochanin A) are ER beta -selective agonists of transcriptional repression and activation at physiological levels. The molecular mechanism for ER beta selectivity by isoflavones involves their capacity to create an activation function-2 surface of ER beta that has a greater affinity for coregulators than ER alpha. Phytoestrogens may act as natural selective estrogen receptor modulators that elicit distinct clinical effects from estrogens used for hormone replacement by selectively recruiting coregulatory proteins to ER beta that trigger transcriptional pathways.	Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Leitman, DC (corresponding author), Univ Calif San Francisco, Ctr Reprod Sci, Dept Obstet Gynecol & Reprod Sci, HSE 1619,POB 0556, San Francisco, CA 94143 USA.	leitmand@obgyn.ucsf.edu		Scharschmidt, Tiffany/0000-0001-5517-089X				Adlercreutz M, 1998, BAILLIERE CLIN ENDOC, V12, P605, DOI 10.1016/S0950-351X(98)80007-4; Albertazzi P, 1998, OBSTET GYNECOL, V91, P6, DOI 10.1016/S0029-7844(97)00597-8; Alekel DL, 2000, AM J CLIN NUTR, V72, P844; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Anthony MS, 1997, ARTERIOSCL THROM VAS, V17, P2524, DOI 10.1161/01.ATV.17.11.2524; Arjmandi BH, 1996, J NUTR, V126, P161, DOI 10.1093/jn/126.1.161; Baker VL, 2000, OBSTET GYNECOL SURV, V55, pS21, DOI 10.1097/00006254-200007001-00001; Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; Barnes S, 1996, ADV EXP MED BIOL, V401, P87; Barnes S, 1998, BAILLIERE CLIN ENDOC, V12, P559, DOI 10.1016/S0950-351X(98)80004-9; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Bush TL, 2000, J REPROD MED, V45, P259; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Clarkson TB, 1998, P SOC EXP BIOL MED, V217, P365; Clemett D, 2000, DRUGS, V60, P379, DOI 10.2165/00003495-200060020-00013; Colditz GA, 1999, J WOMENS HEALTH, V8, P347, DOI 10.1089/jwh.1999.8.347; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Davies GC, 1999, OBSTET GYNECOL, V93, P558, DOI 10.1016/S0029-7844(98)00476-1; Davis SR, 1999, RECENT PROG HORM RES, V54, P185; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Duncan AM, 1999, J CLIN ENDOCR METAB, V84, P3479, DOI 10.1210/jc.84.10.3479; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Foth D, 1998, AM J CLIN NUTR, V68, p1413S, DOI 10.1093/ajcn/68.6.1413S; Gee AC, 1999, MOL ENDOCRINOL, V13, P1912, DOI 10.1210/me.13.11.1912; Glass CK, 2000, GENE DEV, V14, P121; Goodman MT, 1997, AM J EPIDEMIOL, V146, P294, DOI 10.1093/oxfordjournals.aje.a009270; GREEN S, 1986, J STEROID BIOCHEM, V24, P77, DOI 10.1016/0022-4731(86)90035-X; Grodstein F, 1999, AM J MED, V106, P574, DOI 10.1016/S0002-9343(99)00063-7; Hofseth LJ, 1999, J CLIN ENDOCR METAB, V84, P4559, DOI 10.1210/jc.84.12.4559; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; Johnson SR, 1998, MED CLIN N AM, V82, P297, DOI 10.1016/S0025-7125(05)70608-8; Katzenellenbogen BS, 2000, RECENT PROG HORM RES, V55, P163; Kenny AM, 2000, RHEUM DIS CLIN N AM, V26, P569, DOI 10.1016/S0889-857X(05)70157-5; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lamartiniere CA, 1998, P SOC EXP BIOL MED, V217, P358, DOI 10.3181/00379727-217-44245; Lee MM, 2000, J NATL CANCER I, V92, P42, DOI 10.1093/jnci/92.1.42; LEITMAN DC, 1992, MOL CELL BIOL, V12, P1352, DOI 10.1128/MCB.12.3.1352; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; Makela S, 1999, P NATL ACAD SCI USA, V96, P7077, DOI 10.1073/pnas.96.12.7077; McDonnell DP, 2000, J SOC GYNECOL INVEST, V7, pS10, DOI 10.1177/1071557600007001S05; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; Nickelsen T, 1999, PSYCHONEUROENDOCRINO, V24, P115, DOI 10.1016/S0306-4530(98)00041-9; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675; Pickar JH, 1998, AM J OBSTET GYNECOL, V178, P1087, DOI 10.1016/S0002-9378(98)70553-8; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1333S, DOI 10.1093/ajcn/68.6.1333S; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Speroff L, 1998, MATURITAS, V31, P9, DOI 10.1016/S0378-5122(98)00104-2; Taylor AH, 2000, J MOL ENDOCRINOL, V24, P145, DOI 10.1677/jme.0.0240145; Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223; Upmalis DH, 2000, MENOPAUSE, V7, P236, DOI 10.1097/00042192-200007040-00005; van Duijn CM, 1999, MATURITAS, V31, P201, DOI 10.1016/S0378-5122(99)00005-5; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605	64	261	292	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17808	17814		10.1074/jbc.M100953200	http://dx.doi.org/10.1074/jbc.M100953200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279159	hybrid			2022-12-25	WOS:000168866500027
J	Varela, N; Munoz-Pinedo, C; Ruiz-Ruiz, C; Robledo, G; Pedroso, M; Lopez-Rivas, A				Varela, N; Munoz-Pinedo, C; Ruiz-Ruiz, C; Robledo, G; Pedroso, M; Lopez-Rivas, A			Interferon-gamma sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; FADD-DEPENDENT APOPTOSIS; TRAIL-INDUCED APOPTOSIS; ANTI-FAS ANTIBODY; CYTOCHROME-C; TNF-ALPHA; TUMORICIDAL ACTIVITY; MOLECULAR-CLONING; SURFACE ANTIGEN; CD95 FAS/APO-1	The role of interferon (IFN)-gamma as a sensitizing agent in apoptosis induced by ligation of death receptors has been evaluated in human myeloid leukemia cells. Incubation of U937 cells with IFN-gamma sensitized these cells to apoptosis induced by tumor necrosis factor-alpha, agonistic CD95 antibody, and tumor necrosis factor-related apoptosis-inducing ligand, Other human myeloid leukemic cells were also sensitized by IFN-gamma to death receptor-mediated apoptosis. Treatment of U937 cells with IFN-gamma up-regulated the expression of caspase-8 and potently synergized with death receptor ligation in the processing of caspase-8 and BID cleavage. Concomitantly, a marked down-regulation of BCL-2 protein was also observed in cells incubated with IFN-gamma, Furthermore, the caspase-dependent generation of a 23-kDa fragment of BCL-2 protein, the release of cytochrome c from mitochondria and the activation of caspase-9 were also enhanced upon death receptor ligation in IFN-gamma -treated cells. Ectopically expressed Bcl-2 protein inhibited IFN-gamma -induced sensitization to apoptosis. In summary, these results indicate that IFN-gamma sensitizes human myeloid leukemic cells to a death receptor-induced, mitochondria-mediated pathway of apoptosis.	CSIC, Inst Parasitol & Biomed, Granada 18001, Spain; Ctr Nacl Sanidad Agropecuaria, Havana, Cuba	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN)	Lopez-Rivas, A (corresponding author), CSIC, Inst Parasitol & Biomed, Calle Ventanilla 11, Granada 18001, Spain.	alrivas@ipb.csic.es	Munoz-Pinedo, Cristina/B-6118-2008; Hernández, Nieves Yaquelin Varela/E-4280-2018; Ruiz-Ruiz, Carmen/I-8792-2017; Lopez-Rivas, Abelardo/E-5115-2015	Munoz-Pinedo, Cristina/0000-0002-9120-664X; Hernández, Nieves Yaquelin Varela/0000-0003-3328-4751; Ruiz-Ruiz, Carmen/0000-0002-6243-6227; Lopez-Rivas, Abelardo/0000-0002-9351-9690				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker SJ, 1996, ONCOGENE, V12, P1; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen P, 1998, J BIOL CHEM, V273, P5815, DOI 10.1074/jbc.273.10.5815; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chow SC, 1999, EXP CELL RES, V246, P491, DOI 10.1006/excr.1998.4333; Dai CH, 1999, BLOOD, V93, P3309, DOI 10.1182/blood.V93.10.3309.410k04_3309_3316; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Gamen S, 1998, CELL DEATH DIFFER, V5, P241, DOI 10.1038/sj.cdd.4400344; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green WB, 1999, LEUKEMIA, V13, P1960, DOI 10.1038/sj.leu.2401596; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J EXP MED, V189, P1343, DOI 10.1084/jem.189.8.1343; Hadden JW, 1999, INT J IMMUNOPHARMACO, V21, P79, DOI 10.1016/S0192-0561(98)00077-0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Iwase S, 1999, FEBS LETT, V450, P263, DOI 10.1016/S0014-5793(99)00515-3; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kayagaki N, 1999, J EXP MED, V189, P1451, DOI 10.1084/jem.189.9.1451; Keane MM, 1996, CANCER RES, V56, P4791; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koshiji M, 1997, BIOCHEM BIOPH RES CO, V240, P376, DOI 10.1006/bbrc.1997.7657; Koshiji M, 1998, CLIN EXP IMMUNOL, V111, P211; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muhlenbeck F, 1998, J BIOL CHEM, V273, P33091, DOI 10.1074/jbc.273.49.33091; Munker R, 1996, CYTOKINES MOL THER, V2, P147; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673; RUIZRUIZ MD, 1995, MOL IMMUNOL, V32, P947; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365-2141.1997.562704.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smith DJ, 1997, J IMMUNOL, V158, P163; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.0.CO;2-Y; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephanou A, 2000, CELL DEATH DIFFER, V7, P329, DOI 10.1038/sj.cdd.4400656; STRANDER H, 1986, ADV CANCER RES, V46, pR9; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUMIMOTO SI, 1994, CELL IMMUNOL, V153, P184, DOI 10.1006/cimm.1994.1016; Tamura T, 1996, BIOCHEM BIOPH RES CO, V229, P21, DOI 10.1006/bbrc.1996.1752; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; WADLER S, 1990, CANCER RES, V50, P3473; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	79	54	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17779	17787		10.1074/jbc.M100815200	http://dx.doi.org/10.1074/jbc.M100815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279136	hybrid			2022-12-25	WOS:000168866500023
J	Xu, YQ; Liu, YL; Ridgway, ND; McMaster, CR				Xu, YQ; Liu, YL; Ridgway, ND; McMaster, CR			Novel members of the human oxysterol-binding protein family bind phospholipids and regulate vesicle transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; HAMSTER OVARY CELLS; YEAST GOLGI; MEMBRANE TRAFFICKING; KINASE-C; PATHWAY; ENCODES; DEFECTS; SAC1; IDENTIFICATION	Oxysterol-binding proteins (OSBPs) are a family of eukaryotic intracellular lipid receptors. Mammalian OSBP1 binds oxygenated derivatives of cholesterol and mediates sterol and phospholipid synthesis through as yet poorly undefined mechanisms. The precise cellular roles for the remaining members of the oxysterol-binding protein family remain to be elucidated. In yeast, a family of OSBPs has been identified based on primary sequence similarity to the ligand binding domain of mammalian OSBP1, Yeast Kes1p, an oxysterol-binding protein family member that consists of only the ligand binding domain, has been demonstrated to regulate the Sec14p pathway for Golgi-derived vesicle transport. Specifically, inactivation of the KES1 gene resulted in the ability of yeast to survive in the absence of Sec14p, a phosphatidylinositol/phosphatidylcholine transfer protein that is normally required for cell viability due to its essential requirement in transporting vesicles from the Golgi, We cloned the two human members of the OSBP family, ORP1 and ORP2, with the highest degree of similarity to yeast Kes1p, We expressed ORP1 and ORP2 in yeast lacking Sec14p and Kes1p function and found that ORP1 complemented Kes1p function with respect to cell growth and Golgi vesicle transport, whereas ORP2 was unable to do so. Phenotypes associated with overexpression of ORP2 in yeast were a dramatic decrease in cell growth and a block in Golgi-derived vesicle transport distinct from that of ORP1. Purification of ORP1 and ORP2 for ligand binding studies demonstrated ORP1 and ORP2 did not bind 25-hydroxycholesterol but instead bound phospholipids with both proteins exhibiting strong binding to phosphatidic acid and weak binding to phosphatidylinositol 3-phosphate. In Chinese hamster ovary cells, ORP1 localized to a cytosolic location, whereas ORP2 was associated with the Golgi apparatus, consistent with our vesicle transport studies that indicated ORP1 and ORP2 function at different steps in the regulation of vesicle transport.	Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, IWK Hlth Ctr, Dept Biochem, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, IWK Hlth Ctr, Dept Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada.			McMaster, Christopher/0000-0003-0822-5776; Ridgway, Neale/0000-0002-0441-6228				BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bi K, 1997, CURR BIOL, V7, P301, DOI 10.1016/S0960-9822(06)00153-9; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DAWSON PA, 1989, J BIOL CHEM, V264, P16798; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Gaynor EC, 1997, J CELL BIOL, V136, P789, DOI 10.1083/jcb.136.4.789; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Guo SL, 1999, J BIOL CHEM, V274, P12990, DOI 10.1074/jbc.274.19.12990; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; Hughes WE, 2000, J BIOL CHEM, V275, P801, DOI 10.1074/jbc.275.2.801; JIANG B, 1994, YEAST, V10, P341, DOI 10.1002/yea.320100307; Kaiser C., 1994, METHODS YEAST GENETI; Lagace TA, 1997, BIOCHEM J, V326, P205, DOI 10.1042/bj3260205; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; LEE MH, 1991, BIOCHEMISTRY-US, V30, P1041, DOI 10.1021/bi00218a023; Levine TP, 1998, CURR BIOL, V8, P729, DOI 10.1016/S0960-9822(98)70296-9; Maniatis T., 1989, MOL CLONING LAB MANU; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; Phillips SE, 1999, MOL CELL, V4, P187, DOI 10.1016/S1097-2765(00)80366-4; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; RIDGWAY ND, 1995, J BIOL CHEM, V270, P8023, DOI 10.1074/jbc.270.14.8023; Roth MG, 1997, CURR OPIN CELL BIOL, V9, P519, DOI 10.1016/S0955-0674(97)80028-2; SCHMALIX WA, 1994, BBA-GENE STRUCT EXPR, V1219, P205, DOI 10.1016/0167-4781(94)90273-9; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; TAYLOR FR, 1985, CHEM PHYS LIPIDS, V38, P187, DOI 10.1016/0009-3084(85)90066-0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WIRTZ KWA, 1974, BIOCHIM BIOPHYS ACTA, V344, P95, DOI 10.1016/0304-4157(74)90001-X; Wurmser AE, 1999, J BIOL CHEM, V274, P9129, DOI 10.1074/jbc.274.14.9129; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346	38	83	88	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18407	18414		10.1074/jbc.M101204200	http://dx.doi.org/10.1074/jbc.M101204200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279184	hybrid			2022-12-25	WOS:000168866500105
J	Larios, JM; Budhiraja, R; Fanburg, BL; Thannickal, VJ				Larios, JM; Budhiraja, R; Fanburg, BL; Thannickal, VJ			Oxidative protein cross-linking reactions involving L-tyrosine in transforming growth factor-beta 1-stimulated fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LUNG FIBROBLASTS; SMOOTH MUSCLE ACTIN; FACTOR-BETA INDUCTION; HYDROGEN-PEROXIDE; SIGNAL-TRANSDUCTION; PULMONARY FIBROSIS; LYSYL OXIDASE; HUMAN-DISEASE; TGF-BETA; GROWTH-FACTOR-BETA-1	The mechanisms by which ligand-stimulated generation of reactive oxygen species in nonphagocytic cells mediate biologic effects are largely unknown. The profibrotic cytokine, transforming growth factor-beta1 (TGF-beta1), generates extracellular hydrogen peroxide (H2O2) in contrast to intracellular reactive oxygen species production by certain mitogenic growth factors in human lung fibroblasts, To determine whether tyrosine residues in fibroblast-derived extracellular matrix (ECM) proteins may be targets of H2O2-mediated dityrosine-dependent cross-linking reactions in response to TGF-beta1, we utilized fluorophore-labeled tyramide, a structurally related phenolic compound that forms dimers with tyrosine, as a probe to detect such reactions under dynamic cell culture conditions. With this approach, a distinct pattern of fluorescent labeling that seems to target ECM proteins preferentially was observed in TGF-beta1-treated cells but not in control cells. This reaction required the presence of a heme peroxidase and was inhibited by catalase or diphenyliodonium (a flavoenzyme inhibitor), similar to the effect on TGF-beta1-induced dityrosine formation. Exogenous addition of H2O2 to control cells that do not release extracellular H2O2 produced a similar fluorescent labeling reaction. These results support the concept that, in the presence of heme peroxidases in vivo, TGF-beta1-induced H2O2 production by fibroblasts may mediate oxidative dityrosine-dependent cross-linking of ECM protein(s), This effect may be important in the pathogenesis of human fibrotic diseases characterized by overexpression/activation of TGF-beta1.	Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Dept Med,Pulm & Crit Care Div, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Thannickal, VJ (corresponding author), Tufts Univ, New England Med Ctr, Sch Med, Tupper Res Inst,Dept Med,Pulm & Crit Care Div, 750 Washington St,NEMC 257, Boston, MA 02111 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003552, R01HL042376] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL-03552, HL-42376] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bailey AJ, 2000, WOUND REPAIR REGEN, V8, P5, DOI 10.1046/j.1524-475x.2000.00005.x; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BORDER WA, 1995, J CLIN INVEST, V96, P655, DOI 10.1172/JCI118107; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; Dalton SL, 1999, J BIOL CHEM, V274, P30139, DOI 10.1074/jbc.274.42.30139; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; ELIAS JA, 1990, CHEST, V97, P1439, DOI 10.1378/chest.97.6.1439; Finlay GA, 2000, J BIOL CHEM, V275, P27650; Galbraith CG, 1998, CURR OPIN CELL BIOL, V10, P566, DOI 10.1016/S0955-0674(98)80030-6; Gauldie J, 1999, CURR TOPICS PATHOL, V93, P35; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gorin Y, 1997, BIOCHEM J, V321, P383, DOI 10.1042/bj3210383; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HALLIWELL B, 1989, FREE RADICAL BIO MED, P99; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hogaboam CM, 1998, P ASSOC AM PHYSICIAN, V110, P313; Katz BZ, 2000, MOL BIOL CELL, V11, P1047, DOI 10.1091/mbc.11.3.1047; KUHN C, 1991, AM J PATHOL, V138, P1257; LABELLA F, 1967, BIOCHEM BIOPH RES CO, V26, P748, DOI 10.1016/S0006-291X(67)80137-2; LABELLA F, 1968, BIOCHEM BIOPH RES CO, V30, P333, DOI 10.1016/0006-291X(68)90746-8; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MARIGO V, 1994, BIOCHEM BIOPH RES CO, V199, P1049, DOI 10.1006/bbrc.1994.1335; Narani N, 1999, CURR TOPICS PATHOL, V93, P47; NATHAN CF, 1987, J CLIN INVEST, V80, P1550, DOI 10.1172/JCI113241; Phan SH, 1996, KIDNEY INT, V49, pS46; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; SAUNDERS BC, 1964, PEROXIDASE PROPERTIE; SHAPIRO BM, 1991, SCIENCE, V252, P533, DOI 10.1126/science.1850548; Smith-Mungo LI, 1998, MATRIX BIOL, V16, P387, DOI 10.1016/S0945-053X(98)90012-9; Speel EJM, 1999, J HISTOCHEM CYTOCHEM, V47, P281, DOI 10.1177/002215549904700302; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thannickal VJ, 1998, J BIOL CHEM, V273, P23611, DOI 10.1074/jbc.273.36.23611; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Thannickal VJ, 1998, BIOCHEM BIOPH RES CO, V251, P437, DOI 10.1006/bbrc.1998.9443; VISSERS MCM, 1985, BLOOD, V66, P161; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123, DOI 10.1164/ajrccm.157.4.nhlbi-10	48	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17437	17441		10.1074/jbc.M100426200	http://dx.doi.org/10.1074/jbc.M100426200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279068	hybrid			2022-12-25	WOS:000168730400112
J	Lukong, KE; Landry, K; Elsliger, MA; Chang, Y; Lefrancois, S; Morales, CR; Pshezhetsky, AV				Lukong, KE; Landry, K; Elsliger, MA; Chang, Y; Lefrancois, S; Morales, CR; Pshezhetsky, AV			Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHERRY-RED SPOT; PROTEIN CATHEPSIN-A; BETA-GALACTOSIDASE; PROTECTIVE PROTEIN; NEURAMINIDASE DEFICIENCY; MYOCLONUS SYNDROME; CRYSTAL-STRUCTURE; GALACTOSIALIDOSIS; FIBROBLASTS; IDENTIFICATION	Sialidosis is an autosomal recessive disease caused by the genetic deficiency of lysosomal sialidase, which catalyzes the catabolism of sialoglycoconjugates. The disease is associated with progressive impaired vision, macular cherry-red spots, and myoclonus (sialidosis type I) or with skeletal dysplasia, Hurler-like phenotype, dysostosis multiplex, mental retardation, and hepatosplenomegaly (sialidosis type II). We analyzed the effect of the missense mutations G68V, S182G, G227R, F260Y, L270F, A298V, G328S, and L363P, which are identified in the sialidosis type I and sialidosis type II patients, on the activity, stability, and intracellular distribution of sialidase. We found that three mutations, F260Y, L270F, and A298V, which are clustered in the same region on the surface of the sialidase molecule, dramatically reduced the enzyme activity and caused a rapid intralysosomal degradation of the expressed protein. We suggested that this region might be involved in sialidase binding with lysosomal cathepsin A and/or P-galactosidase in the multienzyme lysosomal complex required for the expression of sialidase activity. Transgenic expression of mutants followed by density gradient centrifugation of cellular extracts confirmed this hypothesis and showed that sialidase deficiency in some sialidosis patients results from disruption of the lysosomal multienzyme complex.	Hop St Justine, Serv Genet Med, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	Universite de Montreal; Universite de Montreal; McGill University	Pshezhetsky, AV (corresponding author), Hop St Justine, Serv Genet Med, 3175 Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.		Morales, Carlos R./H-1055-2011	A, Pshezhetsky/0000-0002-6612-1062; Elsliger, Marc Andre/0000-0002-1989-7626				AYLSWORTH AS, 1980, J PEDIATR-US, V96, P662, DOI 10.1016/S0022-3476(80)80734-7; BECK M, 1984, EUR J PEDIATR, V143, P135, DOI 10.1007/BF00445802; Bonten E, 1996, GENE DEV, V10, P3156, DOI 10.1101/gad.10.24.3156; Bonten EJ, 2000, HUM MOL GENET, V9, P2715, DOI 10.1093/hmg/9.18.2715; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURMEISTER WP, 1992, EMBO J, V11, P49, DOI 10.1002/j.1460-2075.1992.tb05026.x; CANTZ M, 1990, J INHERIT METAB DIS, V13, P523, DOI 10.1007/BF01799510; CANTZ M, 1977, BIOCHEM BIOPH RES CO, V74, P732, DOI 10.1016/0006-291X(77)90363-1; CRENNELL SJ, 1993, P NATL ACAD SCI USA, V90, P9852, DOI 10.1073/pnas.90.21.9852; d'Azzo A., 2001, METABOLIC MOL BASES, V3, P3811; DAGROSA RM, 1992, BIOCHEM J, V285, P833, DOI 10.1042/bj2850833; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DURAND P, 1977, HELV PAEDIATR ACTA, V32, P391; FEDERICO A, 1991, DEV NEUROSCI-BASEL, V13, P320, DOI 10.1159/000112180; FEDERICO A, 1980, J NEUROL SCI, V48, P157, DOI 10.1016/0022-510X(80)90197-5; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; JOHNSON WG, 1980, AM J HUM GENET, V32, pA43; KELLY TE, 1977, AM J MED GENET, V1, P31, DOI 10.1002/ajmg.1320010105; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lukong KE, 2000, HUM MOL GENET, V9, P1075, DOI 10.1093/hmg/9.7.1075; Milner CM, 1997, J BIOL CHEM, V272, P4549, DOI 10.1074/jbc.272.7.4549; MORREAU H, 1992, J BIOL CHEM, V267, P17949; Naganawa Y, 2000, J HUM GENET, V45, P241, DOI 10.1007/s100380070034; OBRIEN JS, 1979, CLIN GENET, V14, P55; OKADA S, 1968, SCIENCE, V160, P1002, DOI 10.1126/science.160.3831.1002; OkamuraOho Y, 1996, BIOCHEM J, V313, P787, DOI 10.1042/bj3130787; OOHIRA T, 1985, HUM GENET, V70, P341, DOI 10.1007/BF00295374; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; Pshezhetsky AV, 1996, J BIOL CHEM, V271, P28359, DOI 10.1074/jbc.271.45.28359; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; PSHEZHETSKY AV, 1995, ANAL BIOCHEM, V230, P303, DOI 10.1006/abio.1995.1478; RAPIN I, 1978, ANN NEUROL, V3, P234, DOI 10.1002/ana.410030309; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; Rudenko G, 1998, P NATL ACAD SCI USA, V95, P621, DOI 10.1073/pnas.95.2.621; SOGG RL, 1979, OPHTHALMOLOGY, V86, P1861; Thomas G., 2001, DISORDERS GLYCOPROTE, P3507; TILL JS, 1987, J CLIN NEURO-OPHTHAL, V7, P40; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VARGHESE JN, 1983, NATURE, V303, P35, DOI 10.1038/303035a0; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WINTER RM, 1980, CLIN GENET, V18, P203	42	31	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17286	17290		10.1074/jbc.M100460200	http://dx.doi.org/10.1074/jbc.M100460200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279074	hybrid			2022-12-25	WOS:000168730400092
J	Kamath-Loeb, AS; Loeb, LA; Johansson, E; Burgers, PMJ; Fry, M				Kamath-Loeb, AS; Loeb, LA; Johansson, E; Burgers, PMJ; Fry, M			Interactions between the Werner syndrome helicase and DNA polymerase delta specifically facilitate copying of tetraplex and hairpin structures of the d(CGG)(n) trinucleotide repeat sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRAGILE-X-SYNDROME; SYNDROME GENE-PRODUCT; REPLICATION PROTEIN-A; SYNTHESIS IN-VITRO; SACCHAROMYCES-CEREVISIAE; TRIPLET REPEATS; S-PHASE; ESCHERICHIA-COLI; BLOOMS-SYNDROME; DISEASE GENES	Werner syndrome (WS) is an inherited disorder characterized by premature aging and genomic instability. The protein encoded by the WS gene, WRN, possesses intrinsic 3' --> 5' DNA helicase and 3' --> 5' DNA exonuclease activities. WRN helicase resolves alternate DNA structures including tetraplex and tripler DNA, and Holliday junctions. Thus, one function of WRN may be to unwind secondary structures that impede cellular DNA transactions. We report here that hairpin and G'2 bimolecular tetraplex structures of the fragile X expanded sequence, d(CGG)(n), effectively impede synthesis by three eukaryotic replicative DNA polymerases (pol): pol alpha, pol delta, and pol epsilon. The constraints imposed on pol delta -catalyzed synthesis are relieved, however, by WRN; WRN facilitates pol delta to traverse these template secondary structures to synthesize full-length DNA products. The alleviatory effect of WRN is limited to pol delta; neither pol alpha nor pol epsilon can traverse template d(CGG)(n) hairpin and tetraplex structures in the presence of WRN, Alleviation of pausing by pol delta is observed with Escherichia coli RecQ but not with UvrD helicase, suggesting a concerted action of RecQ helicases and pol delta, Our findings suggest a possible role of WRN in rescuing pol delta -mediated replication at forks stalled by unusual DNA secondary structures.	Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Fry, M (corresponding author), Univ Washington, Dept Pathol, Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA.		Burgers, Peter M/AAW-6621-2021	Johansson, Erik/0000-0002-8526-6224	NCI NIH HHS [CA80993, CA77852] Funding Source: Medline; NIGMS NIH HHS [R01 GM032431, GM58534] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080993, P01CA077852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058534, R01GM032431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRY J, 1994, J BIOL CHEM, V269, P33063; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Burgers PMJ, 1998, J BIOL CHEM, V273, P19756, DOI 10.1074/jbc.273.31.19756; CHEN FM, 1995, J BIOL CHEM, V270, P23090, DOI 10.1074/jbc.270.39.23090; CHEN XA, 1995, P NATL ACAD SCI USA, V92, P5199, DOI 10.1073/pnas.92.11.5199; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cromie GA, 2000, GENETICS, V154, P513; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FRY M, 1994, P NATL ACAD SCI USA, V91, P4950, DOI 10.1073/pnas.91.11.4950; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GACY AM, 1995, CELL, V81, P533; Gerik KJ, 1998, J BIOL CHEM, V273, P19747, DOI 10.1074/jbc.273.31.19747; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; HAN J, 1994, NUCLEIC ACIDS RES, V22, P1735, DOI 10.1093/nar/22.9.1735; Hartung F, 2000, NUCLEIC ACIDS RES, V28, P4275, DOI 10.1093/nar/28.21.4275; HENDERSON E, 1995, TELOMERES, P11; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KETTANI A, 1995, J MOL BIOL, V254, P638, DOI 10.1006/jmbi.1995.0644; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; Kusano K, 1999, GENETICS, V151, P1027; Mangel L, 1998, J BIOL CHEM, V273, P30466, DOI 10.1074/jbc.273.46.30466; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; MITAS M, 1995, BIOCHEMISTRY-US, V34, P12803, DOI 10.1021/bi00039a041; Morozov V, 1997, TRENDS BIOCHEM SCI, V22, P417, DOI 10.1016/S0968-0004(97)01128-6; Moser MJ, 2000, NUCLEIC ACIDS RES, V28, P648, DOI 10.1093/nar/28.2.648; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; NAKAYAMA H, 1984, MOL GEN GENET, V195, P474, DOI 10.1007/BF00341449; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Poot M, 1999, HUM GENET, V104, P10, DOI 10.1007/s004390050903; PURANAM KL, 1994, J BIOL CHEM, V269, P29838; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Sambrook J., 2002, MOL CLONING LAB MANU; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; TAKEUCHI F, 1982, EXP GERONTOL, V17, P473, DOI 10.1016/S0531-5565(82)80009-0; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Watt PM, 1996, GENETICS, V144, P935; Weisman-Shomer P, 2000, J BIOL CHEM, V275, P2231, DOI 10.1074/jbc.275.3.2231; Wells RD, 1996, J BIOL CHEM, V271, P2875, DOI 10.1074/jbc.271.6.2875; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; Yan H, 1998, NAT GENET, V19, P375, DOI 10.1038/1263; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	58	161	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16439	16446		10.1074/jbc.M100253200	http://dx.doi.org/10.1074/jbc.M100253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279038	hybrid			2022-12-25	WOS:000168623100116
J	Lehoux, S; Abe, J; Florian, JA; Berk, BC				Lehoux, S; Abe, J; Florian, JA; Berk, BC			14-3-3 binding to Na+/H+ exchanger isoform-1 is associated with serum-dependent activation of Na+/H+ exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR-KYOTO RATS; NA-H EXCHANGE; PROTEIN-KINASE; GROWTH-FACTORS; IMMORTALIZED LYMPHOBLASTS; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; CELLS	Na+/H+ exchanger isoform-1 (NHE1), the ubiquitous form of the Na+/H+ exchanger, has increased activity in hypertensive patients and in animal models of hypertension. Furthermore, NHE1 is activated in cells stimulated with growth factors. We showed previously that activation of the exchanger is dependent on phosphorylation of serine 703 (Ser(P)(703)) by p90 ribosomal S6 kinase (RSK). Because the NHE1 sequence at Ser(P)(703) (RIGSDP) is similar to a consensus sequence (RSXSXP) specific for 14-3-3 ligands, we evaluated whether serum stimulated 14-3-3 binding to NHE1. Five different GST-NHE1 fusion proteins spanning amino acids 515-815 were phosphorylated by RSK and used as ligands in a far Western analysis; only those containing Ser(P)(703) exhibited high affinity 14-3-3 binding. In PS127A cells (NHE1-overexpressing Chinese hamster fibroblasts) stimulated with 20% serum, NHE1 co-precipitation with GST-14-3-3 fusion protein increased at 5 min (5.2 +/- 0.4-fold versus control; p < 0.01) and persisted at 40 min (3.9 +/- 0.5-fold; p < 0.01). We confirmed that binding occurs at the RIGSDP motif using PS120 (NHE1 null) cells transfected with S703A-NHE1 or P705A-NHE1 (based on data indicating that 14-3-3 binding requires phosphoserine and +2 proline). Serum failed to stimulate association of 14-3-3 with these mutants. A GST-NHE1 fusion protein was phosphorylated by RSK and used as a ligand to assess the effect of 14-3-3 on protein phosphatase 1-mediated dephosphorylation of Ser(P)(703). GST-14-3-3 limited dephosphorylation (66% of initial state at 60 min) compared with GST alone (27% of initial state; p < 0.01). The protective effect of GST-14-3-3 was lost in the GST-NHE1 P705A mutant. Finally, the baseline rate of pH recovery in acid-loaded cells was equal in unstimulated cells expressing wild-type or P705A-NHE1, However, activation of NHE1 by serum was dramatically inhibited in cells expressing P705A-NHE1 compared with wild-type (0.13 +/- 0.02 versus 0.48 +/- 0.06 mmol of H+/min/liter, p < 0.01). These data suggest that 14-3-3 binding to NHE1 participates in serum-stimulated exchanger activation, a new function for 14-3-3.	Univ Rochester, Sch Med & Dent, Cardiol Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Berk, BC (corresponding author), Univ Rochester, Sch Med & Dent, Cardiol Res Ctr, Box 679,601 Elmwood Ave, Rochester, NY 14642 USA.			Berk, Bradford/0000-0002-2767-4115	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044721] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL44721] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aharonovitz O, 1996, J BIOL CHEM, V271, P16494, DOI 10.1074/jbc.271.28.16494; Aharonovitz O, 2000, J CELL BIOL, V150, P213, DOI 10.1083/jcb.150.1.213; BERK BC, 1989, J CLIN INVEST, V83, P822, DOI 10.1172/JCI113964; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; Bianchini L, 1997, J BIOL CHEM, V272, P271; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; GOSS G, 1996, AM J PHYSIOL-CELL PH, V39, pC1493; Howe AK, 1998, J VIROL, V72, P9637, DOI 10.1128/JVI.72.12.9637-9644.1998; Kim S, 1997, BIOCHEM BIOPH RES CO, V236, P199, DOI 10.1006/bbrc.1997.6926; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; LAPOINTE MS, 1995, KIDNEY INT, V47, P78, DOI 10.1038/ki.1995.9; LIFTON RP, 1991, HYPERTENSION, V17, P8, DOI 10.1161/01.HYP.17.1.8; Lin X, 1996, P NATL ACAD SCI USA, V93, P12631, DOI 10.1073/pnas.93.22.12631; Lucchesi PA, 1996, CIRC RES, V78, P962, DOI 10.1161/01.RES.78.6.962; LUCCHESI PA, 1994, HYPERTENSION, V24, P734, DOI 10.1161/01.HYP.24.6.734; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; Moor AN, 1999, J BIOL CHEM, V274, P22985, DOI 10.1074/jbc.274.33.22985; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Orlov SN, 2000, BBA-MOL BASIS DIS, V1500, P169, DOI 10.1016/S0925-4439(99)00101-5; Phan VN, 1997, HYPERTENSION, V29, P1265, DOI 10.1161/01.HYP.29.6.1265; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; ROSSKOPF D, 1995, CARDIOVASC RES, V29, P254, DOI 10.1016/S0008-6363(96)88578-6; ROSSKOPF D, 1993, J CLIN INVEST, V92, P2553, DOI 10.1172/JCI116865; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1991, J BIOL CHEM, V266, P19166; SICZKOWSKI M, 1995, CIRC RES, V76, P825, DOI 10.1161/01.RES.76.5.825; SICZKOWSKI M, 1994, J HYPERTENS, V12, P775; SILVA NLCL, 1995, BIOCHEMISTRY-US, V34, P10412, DOI 10.1021/bi00033a013; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; Sweeney FP, 1997, METABOLISM, V46, P297, DOI 10.1016/S0026-0495(97)90257-2; Takahashi E, 1997, CIRC RES, V81, P268, DOI 10.1161/01.RES.81.2.268; Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; Wang H, 1997, BIOCHEMISTRY-US, V36, P9151, DOI 10.1021/bi970802f; Wang HN, 1998, J BIOL CHEM, V273, P16297, DOI 10.1074/jbc.273.26.16297; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang C, 1997, J BIOL CHEM, V272, P13397, DOI 10.1074/jbc.272.20.13397; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	45	107	108	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15794	15800		10.1074/jbc.M100410200	http://dx.doi.org/10.1074/jbc.M100410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279064	hybrid			2022-12-25	WOS:000168623100031
J	Radaev, S; Sun, PD				Radaev, S; Sun, PD			Recognition of IgG by Fc gamma receptor - The role of Fc glycosylation and the binding of peptide inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EFFECTOR FUNCTIONS; CRYSTAL-STRUCTURE; IMMUNOGLOBULIN-G; IN-VIVO; FRAGMENT; COMPLEX; RIII; IDENTIFICATION; SUBCLASSES	Recently determined crystal structures of the complex between immunoglobulin constant regions (Fc) and their Fc-respective receptors (FcR) have revealed the detailed molecular interactions of this receptor-ligand pair. Of particular interest is the contribution of a glycosylation at Asn(297) of the C(H)2 domain of IgG to receptor recognition. The carbohydrate moieties are found outside the receptor Fe interface in all receptor Fe complex structures. To understand the role of glycosylation in FcR recognition, the receptor affinities of a deglycosylated IgG1 and its Fc fragment were determined by solution binding studies using surface plasmon resonance. The removal of carbohydrates resulted in a non-detectable receptor binding to the Fc alone and a 15- to 20-fold reduction of the receptor binding to IgG1, suggesting that the carbohydrates are important in the function of the Fc gamma RIII. Structurally, the carbohydrates attached to Asn(297) fill the cavity between the C(H)2 domains of Fc functioning equivalently as a hydrophobic core. This may stabilize a favorable lower hinge conformation for the receptor binding, The structure of the complex also revealed the dominance of the lower hinge region in receptor.Fc recognition, To evaluate the potential of designing small molecular ligands to inhibit the receptor function, four lower hinge peptides were investigated for their ability to bind to the receptor Fc gamma RIII, These peptides bind specifically to Fc gamma RIII with affinities 20- to 100-fold lower than IgG1 and are able to compete with Fc in receptor binding. The results of peptide binding illustrate new ways of designing therapeutic compounds to block Fc receptor activation.	NIAID, Struct Biol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Sun, PD (corresponding author), NIAID, Struct Biol Sect, Immunogenet Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000853, Z01AI000853] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], TXB RHEUMATOLOGY; BASU M, 1993, J BIOL CHEM, V268, P13118; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Fossati-Jimack L, 2000, J EXP MED, V191, P1293, DOI 10.1084/jem.191.8.1293; Galon J, 1997, EUR J IMMUNOL, V27, P1928, DOI 10.1002/eji.1830270816; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; Kato K, 2000, IMMUNOL TODAY, V21, P310, DOI 10.1016/S0167-5699(00)01666-2; KULCZYCKI A, 1981, MOL IMMUNOL, V18, P723, DOI 10.1016/0161-5890(81)90064-X; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; LUND J, 1990, MOL IMMUNOL, V27, P1145, DOI 10.1016/0161-5890(90)90103-7; McDonnell JM, 1996, NAT STRUCT BIOL, V3, P419, DOI 10.1038/nsb0596-419; POUND JD, 1993, MOL IMMUNOL, V30, P233, DOI 10.1016/0161-5890(93)90052-D; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; ROUSSEAUX J, 1983, J IMMUNOL METHODS, V64, P141, DOI 10.1016/0022-1759(83)90392-7; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; Tamm A, 1997, Int Rev Immunol, V16, P57, DOI 10.3109/08830189709045703; VAUGHAN JH, 1993, ARTHRITIS RHEUM, V36, P1, DOI 10.1002/art.1780360102	26	108	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16478	16483		10.1074/jbc.M100351200	http://dx.doi.org/10.1074/jbc.M100351200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11297533	hybrid			2022-12-25	WOS:000168623100121
J	Yakovleva, T; Pramanik, A; Kawasaki, T; Tan-No, K; Gileva, I; Lindgren, H; Langel, U; Ekstrom, TJ; Rigler, R; Terenius, L; Bakalkin, G				Yakovleva, T; Pramanik, A; Kawasaki, T; Tan-No, K; Gileva, I; Lindgren, H; Langel, U; Ekstrom, TJ; Rigler, R; Terenius, L; Bakalkin, G			p53 latency - C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; REGULATORY REGION; MUTANT P53; PROTEIN; PEPTIDE; ACTIVATION; BIOTECHNOLOGY; MICROSCOPY; INVITRO; COMPLEX	The p53 transcription factor is either latent or activated through multi-site phosphorylation and acetylation of the negative regulatory region in its C-terminal domain (CTD). How CTD modifications activate p53 binding to target DNA sequences via its core domain is still unknown. It has been proposed that nonmodified CTD interacts either with the core domain or with DNA preventing binding of the core domain to DNA and that the fragments of the CTD regulatory region activate p53 by interfering with these interactions. We here characterized the sequence and target specificity of p53 activation by CTD fragments, interaction of activating peptides with p53 and target DNA, and interactions of "latent" p53 with. DNA by a band shift assay and by fluorescence correlation spectroscopy. In addition to CTD fragments, several long basic peptides activated p53 and also transcription factor YY1. These peptides and CTD aggregated target DNA but apparently did not interact with p53. The potency to aggregate DNA correlated with the ability to activate p53, suggesting that p53 binds to target sequences upon interactions with tightly packed DNA in aggregates. Latent full-length p53 dissociated DNA aggregates via its core and CTD, and this effect was potentiated by GTP. Latent p53 also formed complexes via both its core and CTD with long nontarget DNA molecules. Such p53-DNA interactions may occur if latent p53 binding to DNA via CTD prevents the interaction of the core domain with target DNA sites but not with nonspecific DNA sequences.	Karolinska Inst, Dept Clin Neurosci, Expt Alcohol & Drug Addict Res Sect, S-17176 Stockholm, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17176 Stockholm, Sweden; Stockholm Univ, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Stockholm University	Bakalkin, G (corresponding author), Karolinska Inst, Dept Clin Neurosci, Expt Alcohol & Drug Addict Res Sect, S-17176 Stockholm, Sweden.		Ekström, Tomas/B-7764-2013	Langel, Ulo/0000-0001-6107-0844; Tan-No, Koichi/0000-0001-6724-848X; Bakalkin, Georgy/0000-0002-8074-9833				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bakalkin G, 1997, NEUROREPORT, V8, P2143; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bakalkin G, 1997, BIOCHEM BIOPH RES CO, V231, P135, DOI 10.1006/bbrc.1997.6062; BANNISTER AJ, 1992, NUCLEIC ACIDS RES, V20, P3523, DOI 10.1093/nar/20.13.3523; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bessard ACH, 1998, ONCOGENE, V16, P883, DOI 10.1038/sj.onc.1201598; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; BRAIN R, 1994, ONCOGENE, V9, P1775; Cherny DI, 1999, J MOL BIOL, V294, P1015, DOI 10.1006/jmbi.1999.3299; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; EHRENBER.M, 1974, CHEM PHYS, V4, P390, DOI 10.1016/0301-0104(74)85005-6; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Kerppola TK, 1997, EMBO J, V16, P2907, DOI 10.1093/emboj/16.10.2907; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; LIVOLANT F, 1988, BIOCHEMISTRY-US, V27, P3056, DOI 10.1021/bi00408a058; LIVOLANT F, 1984, TISSUE CELL, V16, P535, DOI 10.1016/0040-8166(84)90029-6; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Muller-Tiemann BF, 1998, P NATL ACAD SCI USA, V95, P6079, DOI 10.1073/pnas.95.11.6079; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Rigler R, 1999, P NATL ACAD SCI USA, V96, P13318, DOI 10.1073/pnas.96.23.13318; RIGLER R, 1995, J BIOTECHNOL, V41, P177, DOI 10.1016/0168-1656(95)00054-T; RIGLER R, 1993, EUR BIOPHYS J BIOPHY, V22, P169, DOI 10.1007/BF00185777; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Tjernberg LO, 1999, CHEM BIOL, V6, P53, DOI 10.1016/S1074-5521(99)80020-9; Tseng M, 1999, J BIOL CHEM, V274, P21637, DOI 10.1074/jbc.274.31.21637; Wohland T, 1999, BIOCHEMISTRY-US, V38, P8671, DOI 10.1021/bi990366s	42	41	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15650	15658		10.1074/jbc.M100482200	http://dx.doi.org/10.1074/jbc.M100482200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279079	hybrid			2022-12-25	WOS:000168623100013
J	Olsen, DR; Leigh, SD; Chang, R; McMullin, H; Ong, W; Tai, E; Chisholm, G; Birk, DE; Berg, RA; Hitzeman, RA; Toman, PD				Olsen, DR; Leigh, SD; Chang, R; McMullin, H; Ong, W; Tai, E; Chisholm, G; Birk, DE; Berg, RA; Hitzeman, RA; Toman, PD			Production of human type I collagen in yeast reveals unexpected new insights into the molecular assembly of collagen trimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOH-TERMINAL REGION; SACCHAROMYCES-CEREVISIAE; TRIPLE-HELIX; FIBRILLOGENESIS INVITRO; III COLLAGEN; PROCOLLAGEN; EXPRESSION; CELLS; SECRETION; CHAIN	Substantial evidence supports the role of the procollagen C-propeptide in the initial association of procollagen polypeptides and for triple helix formation. To evaluate the role of the propeptide domains on triple helix formation, human recombinant type I procollagen, pN-collagen (procollagen without the C-propeptides), pC-collagen (procollagen without the N-propeptides), and collagen (minus both propeptide domains) heterotrimers were expressed in Saccharomyces cerevisiae. Deletion of the N- or C-propeptide, or both propeptide domains, from both pro alpha -chains resulted in correctly aligned triple helical type I collagen. Protease digestion assays demonstrated folding of the triple helix in the absence of the N- and C-propeptides from both pro alpha -chains. This result suggests that sequences required for folding of the triple helix are located in the helical/telopeptide domains of the collagen molecule. Using a strain that does not contain prolyl hydroxylase, the same folding mechanism was shown to be operative in the absence of prolyl hydroxylase, Normal collagen fibrils were generated showing the characteristic banding pattern using this recombinant collagen. This system offers new opportunities for the study of collagen expression and maturation.	Cohes Technol Inc, Palo Alto, CA 94303 USA; Genotypes Inc, San Francisco, CA 94080 USA; Thomas Jefferson Univ, Jefferson Med Sch, Philadelphia, PA 19107 USA	Jefferson University	Toman, PD (corresponding author), Cohes Technol Inc, 2500 Faber Pl, Palo Alto, CA 94303 USA.	dtoman@cson.com	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088				BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BIRK DE, 1995, DEV DYNAM, V202, P229, DOI 10.1002/aja.1002020303; BIRK DE, 1990, J CELL SCI, V95, P649; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Bulleid NJ, 1998, MATRIX BIOL, V17, P233, DOI 10.1016/S0945-053X(98)90062-2; BYRNE MH, 1993, MATRIX, V13, P30; CHEN CY, 1984, NUCLEIC ACIDS RES, V12, P8951, DOI 10.1093/nar/12.23.8951; Doyle SA, 1998, J CELL BIOCHEM, V71, P233; Fields G B, 1992, Matrix Suppl, V1, P68; GELMAN RA, 1979, J BIOL CHEM, V254, P1741; Haralson MA, 1995, EXTRACELLULAR MATRIX, P1; HIGHBERGER JH, 1979, BIOCHEM BIOPH RES CO, V89, P202, DOI 10.1016/0006-291X(79)90964-1; HITZEMAN RA, 1990, METHOD ENZYMOL, V185, P421; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KADLER K, 1994, PROTEIN PROFILE, V1, P519; KAO WWY, 1979, J BIOL CHEM, V254, P2234; LEE ST, 1992, J BIOL CHEM, V267, P24126; LEE ST, 1988, J BIOL CHEM, V263, P13414; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; McLaughlin SH, 1998, MATRIX BIOL, V16, P369, DOI 10.1016/S0945-053X(98)90010-5; MCPHERSON JM, 1985, COLLAGEN REL RES, V5, P119; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; Myllyharju J, 1997, J BIOL CHEM, V272, P21824, DOI 10.1074/jbc.272.35.21824; ROSENBLOOM J, 1976, J BIOL CHEM, V251, P2070; SCHOFIELD JD, 1974, BIOCHEMISTRY-US, V13, P1801, DOI 10.1021/bi00706a004; Toman PD, 2000, J BIOL CHEM, V275, P23303, DOI 10.1074/jbc.M002284200; UITTO J, 1979, ARCH BIOCHEM BIOPHYS, V192, P371, DOI 10.1016/0003-9861(79)90105-X; UITTO VJ, 1981, ARCH BIOCHEM BIOPHYS, V210, P445, DOI 10.1016/0003-9861(81)90208-3; Vaughan PR, 1998, DNA CELL BIOL, V17, P511, DOI 10.1089/dna.1998.17.511; Vuorela A, 1997, EMBO J, V16, P6702, DOI 10.1093/emboj/16.22.6702; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888	34	42	50	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24038	24043		10.1074/jbc.M101613200	http://dx.doi.org/10.1074/jbc.M101613200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11279215	hybrid			2022-12-25	WOS:000169531100108
J	de Marco, MD; Kremer, L; Albar, JP; Martinez-Menarguez, JA; Ballesta, J; Garcia-Lopez, MA; Marazuela, M; Puertollano, R; Alonso, MA				de Marco, MD; Kremer, L; Albar, JP; Martinez-Menarguez, JA; Ballesta, J; Garcia-Lopez, MA; Marazuela, M; Puertollano, R; Alonso, MA			BENE, a novel raft-associated protein of the MAL proteolipid family, interacts with caveolin-1 in human endothelial-like ECV304 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; DARBY CANINE KIDNEY; APICAL TRANSPORT; PLASMA-MEMBRANE; MDCK CELLS; ANCHORED PROTEINS; CHOLESTEROL; EXPRESSION; COMPONENT; VESICLES	The MAL proteolipid, an integral protein present in glycolipid- and cholesterol-enriched membrane (GEM) rafts, is an element of the machinery necessary for apical sorting in polarized epithelial Madin-Darby canine kidney cells. MAL was the first member identified of an extended family of proteins that have significant overall sequence identity. In this study we have used a newly generated monoclonal antibody to investigate an unedited member of this family, named BENE, which was found to be expressed in endothelial-like ECV304 cells and normal human endothelium, Human BENE was characterized as a proteolipid protein predominantly present in GEM rafts in ECV304 cells, Coimmunoprecipitation experiments revealed that BENE interacted with caveolin-1, Confocal immunofluorescence and electron microscopic analyses indicated that BENE mainly accumulated into intracellular vesicular/tubular structures that partially colocalize with internal caveolin-1, In response to cell surface cholesterol oxidation, BENE redistributed to the dilated vesicular structures that concentrate most of the caveolin-1 originally on the cell surface, After cessation of cholesterol oxidation, a detectable fraction of the BENE molecules migrated to the plasmalemma accompanying caveolin-1 and then returned progressively to its steady state distribution. Together, these features highlight the BENE proteolipid as being an element of the machinery for raft-mediated trafficking in endothelial cells.	Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain; CSIC, Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain; Univ Murcia, Fac Med, Dept Cellular Biol, E-30071 Murcia, Spain; Hosp Princesa, Dept Endocrinol, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); University of Murcia; Hospital de La Princesa	Alonso, MA (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		García-López, Maria Angeles/AAB-5755-2019; Alonso, Miguel A/J-3945-2016; Kremer, Leonor/L-5445-2015	García-López, Maria Angeles/0000-0002-1417-9385; Alonso, Miguel A/0000-0002-7001-8826; Kremer, Leonor/0000-0002-2235-2010; ballesta, Jose/0000-0001-7965-5277				ALONSO MA, 1987, P NATL ACAD SCI USA, V84, P1997, DOI 10.1073/pnas.84.7.1997; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; Cheong KH, 1999, P NATL ACAD SCI USA, V96, P6241, DOI 10.1073/pnas.96.11.6241; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P8; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GAUSEPOHL H, 1992, PEPTIDE RES, V5, P315; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; Harlow E., 1988, ANTIBODIES LAB MANUA; Hughes SE, 1996, EXP CELL RES, V225, P171, DOI 10.1006/excr.1996.0168; KIM T, 1995, J NEUROSCI RES, V42, P413, DOI 10.1002/jnr.490420316; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; LAUTNERRIESKE A, 1995, GENE, V159, P199, DOI 10.1016/0378-1119(95)00161-X; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Magyar JP, 1997, GENE, V189, P269, DOI 10.1016/S0378-1119(96)00861-X; MARAZUELA M, 1995, CLIN EXP IMMUNOL, V102, P328; Martin-Belmonte F, 1998, ENDOCRINOLOGY, V139, P2077, DOI 10.1210/en.139.4.2077; Martin-Belmonte F, 2000, MOL BIOL CELL, V11, P2033, DOI 10.1091/mbc.11.6.2033; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; MartinezMenarguez JA, 1996, EUR J CELL BIOL, V71, P137; Millan J, 1997, BIOCHEM BIOPH RES CO, V233, P707, DOI 10.1006/bbrc.1997.6530; Millan J, 1998, EUR J IMMUNOL, V28, P3675, DOI 10.1002/(SICI)1521-4141(199811)28:11<3675::AID-IMMU3675>3.3.CO;2-X; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Perez P, 1997, BIOCHEM BIOPH RES CO, V232, P618, DOI 10.1006/bbrc.1997.6338; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; Puertollano R, 1999, J CELL BIOL, V145, P141, DOI 10.1083/jcb.145.1.141; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Zacchetti D, 1995, FEBS LETT, V377, P465, DOI 10.1016/0014-5793(95)01396-2	45	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23009	23017						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294831				2022-12-25	WOS:000169412700137
J	Finazzi, G; Barbagallo, RP; Bergo, E; Barbato, R; Forti, G				Finazzi, G; Barbagallo, RP; Bergo, E; Barbato, R; Forti, G			Photoinhibition of Chlamydomonas reinhardtii in State 1 and State 2 - Damages to the photosynthetic apparatus under linear and cyclic electron flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN DAMAGE; PHOTOSYSTEM-II; D1 PROTEIN; IN-VIVO; PLASTOQUINONE COMPARTMENTATION; CHLOROPLAST MEMBRANES; ENERGY-DISTRIBUTION; Q(B) SITE; LIGHT; PHOSPHORYLATION	The relationship between state transitions and photoinhibition has been studied in Chlamydomonas reinhardtii cells. In State 2, photosystem II activity was more inhibited by light than in State 1. In State 2, however, the D1 subunit was not degraded, whereas a substantial degradation was observed in State 1, These results suggest that photoinhibition occurs via the generation of an intermediate state in which photosystem II is inactive but the D1 protein is still intact. The accumulation of this state is enhanced in State 2, be cause in this State only cyclic photosynthetic electron transport is active, whereas there is no electron flow between photosystem II and the cytochrome b(6)f complex (Finazzi, G., Furia, A., Barbagallo, R, P,, and Forti, G, (1999) Biochim. Biophys. Acta 1413, 117-129). The activity of photosystem I and of cytochrome b(6)f as well as the coupling of thylakoid membranes was not affected by illumination under the same conditions. This allows repairing the damages to photosystem II thanks to cell capacity to maintain a high rate of ATP synthesis (via photosystem I-driven cyclic electron flow). This capacity might represent an important physiological tool in protecting the photosynthetic apparatus from excess of light as well. as from other a-biotic stress conditions.	CNR, Ctr Studio Biol Cellulare & Mol Piante, I-20133 Milan, Italy; Univ Padua, Dipartimento Biol, I-35100 Padua, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dipartimento Sci & Tecnol Avanzate, I-15100 Alessandria, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Eastern Piedmont Amedeo Avogadro	Finazzi, G (corresponding author), CNR, Ctr Studio Biol Cellulare & Mol Piante, Via Celoria 26, I-20133 Milan, Italy.							ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; BARBATO R, 1991, FEBS LETT, V290, P162, DOI 10.1016/0014-5793(91)81250-C; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARENYI B, 1985, PLANTA, V163, P218, DOI 10.1007/BF00393510; BENDALL DS, 1982, BIOCHIM BIOPHYS ACTA, V683, P119, DOI 10.1016/0304-4173(82)90008-8; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BENNOUN P, 1970, BIOCHIM BIOPHYS ACTA, V216, P357, DOI 10.1016/0005-2728(70)90227-6; BENNOUN P, 1994, BBA-BIOENERGETICS, V1186, P59, DOI 10.1016/0005-2728(94)90135-X; BONAVENTURA C, 1969, BIOCHIM BIOPHYS ACTA, V189, P366, DOI 10.1016/0005-2728(69)90168-6; BRACHT E, 1994, Z NATURFORSCH C, V49, P439; BULTE L, 1990, BIOCHIM BIOPHYS ACTA, V1020, P72, DOI 10.1016/0005-2728(90)90095-L; BUTLER WL, 1978, ANNU REV PLANT PHYS, V29, P345, DOI 10.1146/annurev.pp.29.060178.002021; Chow WS, 1998, AUST J PLANT PHYSIOL, V25, P775, DOI 10.1071/PP97160; CHYLLA RA, 1989, PLANT PHYSIOL, V90, P765, DOI 10.1104/pp.90.2.765; DELOSME R, 1994, BBA-BIOENERGETICS, V1185, P56, DOI 10.1016/0005-2728(94)90193-7; Delosme R, 1996, BBA-BIOENERGETICS, V1273, P150, DOI 10.1016/0005-2728(95)00143-3; DemmigAdams B, 1996, FASEB J, V10, P403, DOI 10.1096/fasebj.10.4.8647339; Endo T, 1996, PLANT CELL PHYSIOL, V37, P551, DOI 10.1093/oxfordjournals.pcp.a028979; Finazzi G, 1997, BIOCHEMISTRY-US, V36, P2867, DOI 10.1021/bi962717y; Finazzi G, 1999, BBA-BIOENERGETICS, V1413, P117, DOI 10.1016/S0005-2728(99)00089-4; FORTI G, 1963, BIOCHIM BIOPHYS ACTA, V71, P1, DOI 10.1016/0006-3002(63)90979-X; Forti G, 1999, PHOTOSYNTH RES, V59, P215, DOI 10.1023/A:1006164017455; FRANK K, 1995, PHOTOCHEM PHOTOBIOL, V61, P2, DOI 10.1111/j.1751-1097.1995.tb09237.x; Fulgosi H, 1998, EMBO J, V17, P1577, DOI 10.1093/emboj/17.6.1577; Gal A, 1997, PHYSIOL PLANTARUM, V100, P869, DOI 10.1034/j.1399-3054.1997.1000413.x; GONG HS, 1994, BIOCHIM BIOPHYS ACTA, V1118, P422; GORMAN DS, 1960, P NATL ACAD SCI USA, V46, P83; Heber U, 1995, PLANT CELL PHYSIOL, V36, P1639; HERZIG R, 1989, J PHYCOL, V25, P462, DOI 10.1111/j.1529-8817.1989.tb00251.x; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HOWARD B, 1983, FEBS LETT, V153, P221; JANSEN MAK, 1993, J BIOL CHEM, V268, P21246; Jegerschold C, 1996, BIOCHEMISTRY-US, V35, P7794, DOI 10.1021/bi960083p; JOLIOT P, 1974, BIOCHIM BIOPHYS ACTA, V357, P267, DOI 10.1016/0005-2728(74)90066-8; JOLIOT P, 1980, J CHIM PHYS PCB, V77, P209, DOI 10.1051/jcp/1980770209; JOLIOT P, 1992, BIOCHIM BIOPHYS ACTA, V1101, P1, DOI 10.1016/0167-4838(92)90460-U; JUNGE W, 1968, Z NATURFORSCH B, V24, P1038; KIRILOVSKY D, 1994, BIOCHEMISTRY-US, V33, P3087, DOI 10.1021/bi00176a043; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; LAVERGNE J, 1991, TRENDS BIOCHEM SCI, V16, P129, DOI 10.1016/0968-0004(91)90054-Y; LAVERGNE J, 1992, BIOCHIM BIOPHYS ACTA, V1101, P13, DOI 10.1016/0167-4838(92)90461-L; MATOO AK, 1984, P NATL ACAD SCI USA, V81, P1380; MISHRA NP, 1994, BBA-BIOENERGETICS, V1187, P296, DOI 10.1016/0005-2728(94)90003-5; MURATA N, 1969, BIOCHIM BIOPHYS ACTA, V172, P242, DOI 10.1016/0005-2728(69)90067-X; Niyogi KK, 1999, ANNU REV PLANT PHYS, V50, P333, DOI 10.1146/annurev.arplant.50.1.333; OHAD I, 1984, J CELL BIOL, V99, P481, DOI 10.1083/jcb.99.2.481; PELTIER G, 1991, P NATL ACAD SCI USA, V88, P4791, DOI 10.1073/pnas.88.11.4791; POWLES SB, 1984, ANNU REV PLANT PHYS, V35, P15, DOI 10.1146/annurev.pp.35.060184.000311; Sonoike K, 1996, PLANT CELL PHYSIOL, V37, P239, DOI 10.1093/oxfordjournals.pcp.a028938; SUEOKA N, 1965, P NATL ACAD SCI USA, V54, P1665; TANNER W, 1969, PROGRESS PHOTOSYNTHE, V3, P1217; TREBST A, 1988, PHOTOSYNTH RES, V18, P163, DOI 10.1007/BF00042983; VALLON O, 1991, P NATL ACAD SCI USA, V88, P8262, DOI 10.1073/pnas.88.18.8262; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6; Wykoff DD, 1998, PLANT PHYSIOL, V117, P129, DOI 10.1104/pp.117.1.129; ZER H, 1994, J BIOL CHEM, V269, P17670; ZER H, 1995, EUR J BIOCHEM, V231, P448, DOI 10.1111/j.1432-1033.1995.tb20718.x	61	44	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22251	22257		10.1074/jbc.M011376200	http://dx.doi.org/10.1074/jbc.M011376200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294855	hybrid			2022-12-25	WOS:000169412700039
J	Hu, G; Jang, GF; Cowan, CW; Wensel, TG; Palczewski, K				Hu, G; Jang, GF; Cowan, CW; Wensel, TG; Palczewski, K			Phosphorylation of RGS9-1 by an endogenous protein kinase in rod outer segments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACCELERATING PROTEIN; CYCLIN-DEPENDENT PROTEIN-KINASE-5; HETEROTRIMERIC G-PROTEINS; PHOTOTRANSDUCTION CASCADE; SIGNALING PROTEINS; REGULATORY SUBUNIT; RHODOPSIN KINASE; ACTIVATION; IDENTIFICATION; KINETICS	Inactivation of the visual Gr protein transducin, during recovery from photoexcitation, is regulated by RGS9-1, a GTPase-accelerating protein of the ubiquitous RGS protein family. Incubation of dark-adapted bovine rod outer segments with [gamma-P-32]ATP led to RGS9-1 phosphorylation by an endogenous kinase in rod outer segment membranes, with an average stoichiometry of 0.2-0.45 mol of phosphates/mol of RGS9-1. Mass spectrometry revealed a single major site of phosphorylation, Ser(475). The kinase responsible catalyzed robust phosphorylation of recombinant RGS9-1 and not of an S(475)A mutant. A synthetic peptide corresponding to the region surrounding Ser(475) was also phosphorylated, and a similar peptide with the S(475)A substitution inhibited RGS9-1 phosphorylation. The RGS9-1 kinase is a peripheral membrane protein that co-purifies with rhodopsin in sucrose gradients and can be extracted in buffers of high ionic strength. It is not inhibited or activated significantly by a panel of inhibitors or activators of protein kinase A, protein kinase G, rhodopsin kinase, CaM kinase II, casein kinase II, or cyclin dependent kinase 5, at concentrations 50 or more times higher than their reported IC50 or K-i values. It was inhibited by the protein kinase C inhibitor bisindolylmaleimide I and by lowering Ca2+ to nanomolar levels with EGTA however, it was not stimulated by the addition of phorbol ester, under conditions that significantly enhanced rhodopsin phosphorylation, A monoclonal antibody specific for the Ser475 phosphorylated form of RGS9-1 recognized RGS9-1 in immunoblots of dark-adapted mouse retina. Retinas from light-adapted mice had much lower levels of RGS9-1 phosphorylation. Thus, RGS9-1 is phosphorylated on Ser(475) in vivo, and the phosphorylation level is regulated by light and by [Ca2+], suggesting the importance of the modification in light adaptation.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	Baylor College of Medicine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Wensel, TG (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA.	twensel@bcm.tmc.edu	Hu, Guang/E-7474-2016; Cowan, Christopher W/I-2497-2014	Hu, Guang/0000-0003-0437-4723; Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07001, F32 EY007001, T32 EY007001, R01 EY011900, R01 EY008061, EY11900, EY08061] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008061, R29EY008061, R01EY011900] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Baylor DA, 1998, EYE, V12, P521, DOI 10.1038/eye.1998.140; Bell MW, 2000, J NEUROCHEM, V75, P2006, DOI 10.1046/j.1471-4159.2000.0752006.x; Benzing T, 2000, J BIOL CHEM, V275, P28167; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUCZYLKO J, 1991, P NATL ACAD SCI USA, V88, P2568, DOI 10.1073/pnas.88.6.2568; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cowan CW, 2001, PROG NUCLEIC ACID RE, V65, P341; Cowan CW, 1998, P NATL ACAD SCI USA, V95, P5351, DOI 10.1073/pnas.95.9.5351; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Gaudet R, 1999, MOL CELL, V3, P649, DOI 10.1016/S1097-2765(00)80358-5; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GrayKeller MP, 1996, NEURON, V17, P323, DOI 10.1016/S0896-6273(00)80163-4; GREENE NM, 1995, J BIOL CHEM, V270, P6710, DOI 10.1074/jbc.270.12.6710; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HE W, 2001, THESIS BAYLOR COLL M; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hollander BA, 1999, CELL MOTIL CYTOSKEL, V43, P114, DOI 10.1002/(SICI)1097-0169(1999)43:2<114::AID-CM3>3.3.CO;2-D; IDO M, 1991, BRIT J CANCER, V64, P1103, DOI 10.1038/bjc.1991.472; INAGAKI M, 1986, MOL PHARMACOL, V29, P577; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KUCHERA S, 1993, AGENTS ACTIONS, V39, pC169, DOI 10.1007/BF01972756; LIEBMAN PA, 1980, NATURE, V287, P734, DOI 10.1038/287734a0; Lyubarsky A, 1996, J GEN PHYSIOL, V107, P19, DOI 10.1085/jgp.107.1.19; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; MATESIC DF, 1992, J CELL SCI, V103, P157; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; NEWTON AC, 1991, J BIOL CHEM, V266, P17725; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; Palczewski K, 1997, CURR OPIN NEUROBIOL, V7, P500, DOI 10.1016/S0959-4388(97)80029-3; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Posewitz MC, 1999, ANAL CHEM, V71, P2883, DOI 10.1021/ac981409y; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; Rahman Z, 1999, J NEUROSCI, V19, P2016; Sagoo MS, 1997, NATURE, V389, P392, DOI 10.1038/38750; SANDBERG M, 1991, BIOCHEM J, V279, P521, DOI 10.1042/bj2790521; SATHER WA, 1987, P NATL ACAD SCI USA, V84, P9290, DOI 10.1073/pnas.84.24.9290; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Smith JK, 2000, J BIOL CHEM, V275, P154, DOI 10.1074/jbc.275.1.154; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALTER U, 1984, ADV CYCLIC NUCL PROT, V17, P249; WELLER M, 1975, P NATL ACAD SCI USA, V72, P381, DOI 10.1073/pnas.72.1.381; WILLIAMS TP, 1990, EXP EYE RES, V51, P739, DOI 10.1016/0014-4835(90)90060-8; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Womack KB, 2000, J NEUROSCI, V20, P2792; Zhang K, 1999, GENE, V240, P23, DOI 10.1016/S0378-1119(99)00393-5; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	65	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22287	22295		10.1074/jbc.M011539200	http://dx.doi.org/10.1074/jbc.M011539200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292825	Green Accepted, hybrid			2022-12-25	WOS:000169412700044
J	Kuntziger, T; Gavet, O; Sobel, A; Bornens, M				Kuntziger, T; Gavet, O; Sobel, A; Bornens, M			Differential effect of two stathmin/Op18 phosphorylation mutants on Xenopus embryo development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-DESTABILIZING ACTIVITY; CYCLE-REGULATED PHOSPHORYLATION; CELL-CYCLE; MITOTIC SPINDLE; SIGNAL-TRANSDUCTION; CYTOPLASMIC DYNEIN; DISTAL ENDS; TUBULIN; ONCOPROTEIN-18; DYNAMICS	Stathmin/Op18 destabilizes microtubules in vitro and regulates microtubule polymerization in vivo. Both a microtubule catastrophe-promoting activity and a tubulin sequestering activity were demonstrated for stathlin in vitro, and both could contribute to microtubule depolymerization in vivo. Stathmin activity can be turned down by extensive phosphorylation on its four phosphorylatable serines, and down-regulation of stathmin activity by phosphorylation is necessary for cells to proceed through mitosis. Tire show here that microinjection of a nonphosphorylatable Ser to Ala (4A) quadruple mutant in Xenopus two-cell stage embryos results in cell cleavage arrest in the injected blastomeres and aborted development, whereas injection of a pseudo-phosphorylated Ser to Glu quadruple mutant (4E) does not prevent normal development. Addition of these mutants to mitotic cytostatic factor-arrested extracts in which spindle assembly was induced led to a dramatic reduction of spindle size with 4A stathmin, and to a moderate increase with 4E stathmin, but both localized to spindle poles, interestingly the microtubule assembly-dependent phosphorylation of endogenous stathmin was abolished in the presence of 4A stathmin, but not of 4E stathmin. Altogether, this shows that the phosphorylation-mediated regulation of stathmin activity during the cell cycle is essential for early Xenopus embryonic development.	Inst Curie, CNRS, UMR 144, Sect Rech, F-75248 Paris 05, France; Inst Fer Moulin, INSERM, U440, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Bornens, M (corresponding author), Inst Curie, CNRS, UMR 144, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.		Küntziger, Thomas M/E-7286-2012; Küntziger, Thomas/H-5252-2019	Küntziger, Thomas/0000-0003-3074-9509				Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; CURMI PA, 1994, BIOCHEM J, V300, P331, DOI 10.1042/bj3000331; DiPaolo G, 1997, FEBS LETT, V416, P149, DOI 10.1016/S0014-5793(97)01188-5; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Gavet O, 1998, J CELL SCI, V111, P3333; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; Gradin HM, 1997, MOL CELL BIOL, V17, P3459, DOI 10.1128/MCB.17.6.3459; Hartman JJ, 1998, CELL, V93, P277, DOI 10.1016/S0092-8674(00)81578-0; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; Kuntziger T, 2001, MOL BIOL CELL, V12, P437, DOI 10.1091/mbc.12.2.437; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson N, 1997, MOL CELL BIOL, V17, P5530, DOI 10.1128/MCB.17.9.5530; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, FEBS LETT, V421, P55, DOI 10.1016/S0014-5793(97)01519-6; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; LUO XN, 1994, J BIOL CHEM, V269, P10312; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; McNally FJ, 1998, MOL BIOL CELL, V9, P1847, DOI 10.1091/mbc.9.7.1847; McNally FJ, 1996, J CELL SCI, V109, P561; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Paoletti A, 1996, J CELL SCI, V109, P3089; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Popov AV, 2001, EMBO J, V20, P397, DOI 10.1093/emboj/20.3.397; Saunders W, 1997, J CELL BIOL, V137, P417, DOI 10.1083/jcb.137.2.417; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaughan KT, 1999, J CELL SCI, V112, P1437	43	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22979	22984		10.1074/jbc.M101466200	http://dx.doi.org/10.1074/jbc.M101466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297553	hybrid			2022-12-25	WOS:000169412700133
J	van Spaendonk, RML; Ramesar, J; van Wigcheren, A; Eling, W; Beetsma, AL; van Gemert, GJ; Hooghof, J; Janse, CJ; Waters, AP				van Spaendonk, RML; Ramesar, J; van Wigcheren, A; Eling, W; Beetsma, AL; van Gemert, GJ; Hooghof, J; Janse, CJ; Waters, AP			Functional equivalence of structurally distinct ribosomes in the malaria parasite, Plasmodium berghei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA GENES; SACCHAROMYCES-CEREVISIAE; PEPTIDYL TRANSFERASE; PROTEIN; IDENTIFICATION; FALCIPARUM; TRANSCRIPTION; SEQUENCES; TRANSFECTION; SPOROZOITES	Unlike most eukaryotes, many apicomplexan parasites contain only a few unlinked copies of ribosomal RNA (rRNA) genes. Based on stage-specific expression of these genes and structural differences among the rRNA molecules it has been suggested that Plasmodium spp. produce functionally different ribosomes in different developmental stages. This hypothesis was investigated through comparison of the structure of the large sub unit rRNA molecules of the rodent malaria parasite, Plasmodium berghei, and by disruption of both of the rRNA gene units that are transcribed exclusively during development of this parasite in the mosquito (S type rRNA gene units). In contrast to the human parasite, Plasmodium falciparum, we did not find evidence of structural differences in core regions of the distinct large subunit rRNAs which are known to be associated with catalytic activity including the GTPase site that varies in P. falciparum. Knockout P. berghei parasites lacking either of the S-type gene units were able to complete development in both the vertebrate and mosquito hosts. These results formally exclude the hypothesis that two functionally different ribosome types distinct from the predominantly blood stage-expressed A-type ribosomes, are required for development of all Plasmodium species in the mosquito. The maintenance of two functionally equivalent rRNA genes might now be explained as a gene dosage phenomenon.	Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Univ Nijmegen St Radboud Hosp, Dept Med Microbiol, Sect Parasitol, NL-6525 ED Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Radboud University Nijmegen	Waters, AP (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Postbus 9600, NL-2300 RC Leiden, Netherlands.	Waters@lumc.nl	Waters, Andy P/C-9377-2009	Waters, Andy P/0000-0001-8900-2982; Janse, Chris J/0000-0002-6410-6205; Vervenne, Resie/0000-0002-6077-8725				ABOVICH N, 1985, MOL CELL BIOL, V5, P3429, DOI 10.1128/MCB.5.12.3429; Bishop R, 2000, GENE, V257, P299, DOI 10.1016/S0378-1119(00)00386-3; DAHLBERG AE, 1989, CELL, V57, P525, DOI 10.1016/0092-8674(89)90122-0; DALRYMPLE BP, 1990, MOL BIOCHEM PARASIT, V43, P117, DOI 10.1016/0166-6851(90)90136-A; DAME JB, 1983, J BIOL CHEM, V258, P6984; DAME JB, 1984, MOL BIOCHEM PARASIT, V11, P301, DOI 10.1016/0166-6851(84)90074-4; DAME JB, 1984, NUCLEIC ACIDS RES, V12, P5943, DOI 10.1093/nar/12.14.5943; DAME JB, 1983, MOL BIOCHEM PARASIT, V8, P263, DOI 10.1016/0166-6851(83)90048-8; ENEA V, 1991, J MOL EVOL, V32, P183, DOI 10.1007/BF02515391; Gagnon S, 1996, EXP PARASITOL, V83, P346, DOI 10.1006/expr.1996.0082; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; GUNDERSON JH, 1986, J PROTOZOOL, V33, P525, DOI 10.1111/j.1550-7408.1986.tb05656.x; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; GUTELL RR, 1988, NUCLEIC ACIDS RES, V16, pR175, DOI 10.1093/nar/16.suppl.r175; HOLMBERG L, 1994, NUCLEIC ACIDS RES, V22, P2776, DOI 10.1093/nar/22.14.2776; JANSE CJ, 1985, PARASITOLOGY, V91, P19, DOI 10.1017/S0031182000056481; JANSE CJ, 1995, PARASITOL TODAY, V11, P138, DOI 10.1016/0169-4758(95)80133-2; Le Blancq SM, 1997, MOL BIOCHEM PARASIT, V90, P463, DOI 10.1016/S0166-6851(97)00181-3; Li J, 1997, J MOL BIOL, V269, P203, DOI 10.1006/jmbi.1997.1038; LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455; LUCIOLI A, 1988, MOL CELL BIOL, V8, P4792, DOI 10.1128/MCB.8.11.4792; MCCUTCHAN TF, 1988, MOL BIOCHEM PARASIT, V28, P63, DOI 10.1016/0166-6851(88)90181-8; MCCUTCHAN TF, 1995, PARASITOL TODAY, V11, P134, DOI 10.1016/0169-4758(95)80132-4; Menard R, 1997, METHODS, V13, P148, DOI 10.1006/meth.1997.0507; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MONS B, 1985, PARASITOLOGY, V91, P423, DOI 10.1017/S0031182000062673; NOLLER HF, 1990, RIBOSOME, P73; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; PONZI M, 1990, MOL BIOCHEM PARASIT, V41, P73, DOI 10.1016/0166-6851(90)90098-7; Rogers MJ, 1996, RNA, V2, P134; SHIPPENLENTZ D, 1990, MOL BIOCHEM PARASIT, V22, P223; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; Thompson J, 1999, MOL MICROBIOL, V31, P253, DOI 10.1046/j.1365-2958.1999.01167.x; van Spaendonk RML, 2000, MOL BIOCHEM PARASIT, V105, P169, DOI 10.1016/S0166-6851(99)00175-9; van Spaendonk RML, 1999, MOL BIOCHEM PARASIT, V99, P193, DOI 10.1016/S0166-6851(99)00016-X; VANDIJK MR, 1995, SCIENCE, V268, P1358, DOI 10.1126/science.7761856; Velichutina IV, 1998, RNA, V4, P594, DOI 10.1017/S1355838298980049; Vinkenoog R, 1998, MOL BIOCHEM PARASIT, V94, P1, DOI 10.1016/S0166-6851(98)00035-8; WATERS AP, 1989, NATURE, V342, P438, DOI 10.1038/342438a0; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; WATERS AP, 1994, ADV PARASIT, V34, P33, DOI 10.1016/S0065-308X(08)60136-0; Waters AP, 1997, J BIOL CHEM, V272, P3583, DOI 10.1074/jbc.272.6.3583; WELLEMS TE, 1987, CELL, V49, P633, DOI 10.1016/0092-8674(87)90539-3; Woodson SA, 1998, CURR OPIN STRUC BIOL, V8, P294, DOI 10.1016/S0959-440X(98)80061-4	48	66	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22638	22647		10.1074/jbc.M101234200	http://dx.doi.org/10.1074/jbc.M101234200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292830	Green Published, hybrid			2022-12-25	WOS:000169412700090
J	Aphasizhev, R; Simpson, L				Aphasizhev, R; Simpson, L			Isolation and characterization of a U-specific 3 '-5 '-exonuclease from mitochondria of Leishmania tarentolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYMATIC EDITING COMPLEX; PRECURSOR MESSENGER-RNA; SMALL NUCLEAR-RNA; IN-VITRO; URIDINE INSERTION; EXONUCLEASE; MECHANISM; 3'-END; ENDONUCLEASE; PURIFICATION	We have purified a 3'-5'-exoribonuclease from mitochondrial extract of Leishmania tarentolae over 4000-fold through six column fractionations. This enzyme digested RNA in a distributive manner, showed a high level of specificity for 3'-terminal Us, and was blocked by a terminal dU; there was slight exonucleolytic activity on a S'-terminal A or C but no activity on a 3'-terminal G residue. The enzyme preferred single-stranded 3'-oligo(U) overhangs and did not digest duplex RNA. Two other 3'-5'-exoribonuclease activities were also detected in the mitochondrial extract, one of which was stimulated by a 3'-phosphate and the other of which degraded RNAs with a 3'-OH to mononucleotides in a processive manner. The properties of the distributive U-specific 3'-5'-exoribonuclease suggest an involvement in the U-deletion RNA editing reaction that occurs in the mitochondrion of these cells.	Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Simpson, L (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, 6780 MacDonald Res Labs,675 Charles Young Dr S, Los Angeles, CA 90095 USA.			Afasizhev, Ruslan/0000-0002-4595-6618	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI009102, R01AI009102] Funding Source: NIH RePORTER; NIAID NIH HHS [AI09102] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; Booth BL, 1997, J BIOL CHEM, V272, P984, DOI 10.1074/jbc.272.2.984; BRALY P, 1974, J PROTOZOOL, V21, P782, DOI 10.1111/j.1550-7408.1974.tb03752.x; Burgess MLK, 2000, RNA, V6, P1492, DOI 10.1017/S1355838200000066; Byrne EM, 1996, EMBO J, V15, P6758, DOI 10.1002/j.1460-2075.1996.tb01065.x; Cruz-Reyes J, 1998, NUCLEIC ACIDS RES, V26, P3634, DOI 10.1093/nar/26.16.3634; CruzReyes J, 1996, P NATL ACAD SCI USA, V93, P8901, DOI 10.1073/pnas.93.17.8901; Frech GC, 1996, MOL CELL BIOL, V16, P4584; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Kable ML, 1996, SCIENCE, V273, P1189, DOI 10.1126/science.273.5279.1189; Kapushoc ST, 1999, RNA, V5, P656, DOI 10.1017/S1355838299982250; Korner CG, 1997, J BIOL CHEM, V272, P10448; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Mitchell P, 1996, GENE DEV, V10, P502, DOI 10.1101/gad.10.4.502; Moser MJ, 1997, NUCLEIC ACIDS RES, V25, P5110, DOI 10.1093/nar/25.24.5110; Papadimitriou A, 1996, EUR J BIOCHEM, V242, P747, DOI 10.1111/j.1432-1033.1996.0747r.x; Piller KJ, 1996, J BIOL CHEM, V271, P4613, DOI 10.1074/jbc.271.9.4613; Rusche LN, 1997, EMBO J, V16, P4069, DOI 10.1093/emboj/16.13.4069; SEIWERT SD, 1994, SCIENCE, V266, P114, DOI 10.1126/science.7524149; Seiwert SD, 1996, CELL, V84, P831, DOI 10.1016/S0092-8674(00)81062-4; Simpson L, 1998, NUCLEIC ACIDS RES, V26, P170, DOI 10.1093/nar/26.1.170; STURM NR, 1992, CELL, V70, P469, DOI 10.1016/0092-8674(92)90171-8; Trippe R, 1998, NUCLEIC ACIDS RES, V26, P3119, DOI 10.1093/nar/26.13.3119	24	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21280	21284		10.1074/jbc.M100297200	http://dx.doi.org/10.1074/jbc.M100297200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279235	hybrid			2022-12-25	WOS:000169297900065
J	Crawford, BE; Olson, SK; Esko, JD; Pinhal, MAS				Crawford, BE; Olson, SK; Esko, JD; Pinhal, MAS			Cloning, Golgi localization, and enzyme activity of the full-length heparin/heparan sulfate-glucuronic acid C5-epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; URONOSYL C-5 EPIMERASE; HEPARAN-SULFATE; CRYSTAL-STRUCTURE; BIOSYNTHESIS; BINDING; PROTEOGLYCANS; PURIFICATION; MECHANISM; SEQUENCES	While studying the cellular localization and activity of enzymes involved in heparan sulfate biosynthesis, we discovered that the published sequence for the glucuronic acid C5-epimerase responsible for the interconversion of D-glucuronic acid and L-iduronic acid residues encodes a truncated protein. Genome analysis and 5'-rapid amplification of cDNA ends was used to clone the full-length cDNA from a mouse mastocytoma cell line. The extended cDNA encodes for an additional 174 amino acids at the amino terminus of the protein. The murine sequence is 95% identical to the human epimerase identified from genomic sequences and fits with the general size and structure of the gene from Drosophila melanogaster and Caenorhabditis elegans, Full-length epimerase is predicted to have a type II transmembrane topology with a 17-amino acid transmembrane domain and an 11-amino acid cytoplasmic tail. An assay with increased sensitivity was devised that detects enzyme activity in extracts prepared from cultured cells and in recombinant proteins. Unlike other enzymes involved in glycosaminoglycan biosynthesis, the addition of a c-myc tag or green fluorescent protein to the highly conserved COOH-terminal portion of the protein inhibits its activity. The amino-terminally truncated epimerase does not localize to any cellular compartment, whereas the full-length enzyme is in the Golgi, where heparan sulfate synthesis is thought to occur.	Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Pinhal, MAS (corresponding author), Univ Fed Sao Paulo, BR-04044020 Sao Paulo, Brazil.		Pinhal, Maria Aparecida Silva/J-1797-2012	Pinhal, Maria Aparecida Silva/0000-0003-4001-1663	NATIONAL CANCER INSTITUTE [T32CA067754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA67754] Funding Source: Medline; NIGMS NIH HHS [R37GM33063, GM08666] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; CAMPBELL P, 1994, J BIOL CHEM, V269, P26953; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hagner-McWhirter A, 2000, BIOCHEM J, V347, P69, DOI 10.1042/0264-6021:3470069; Hagner-McWhirter A, 2000, GLYCOBIOLOGY, V10, P159, DOI 10.1093/glycob/10.2.159; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Li JP, 1997, J BIOL CHEM, V272, P28158, DOI 10.1074/jbc.272.44.28158; LINDAHL U, 1976, BIOCHEM BIOPH RES CO, V70, P492, DOI 10.1016/0006-291X(76)91073-1; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MALMSTROM A, 1980, J BIOL CHEM, V255, P3878; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; Mulloy B, 2000, GLYCOBIOLOGY, V10, P1147, DOI 10.1093/glycob/10.11.1147; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1	26	44	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21538	21543		10.1074/jbc.M100880200	http://dx.doi.org/10.1074/jbc.M100880200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279150	hybrid			2022-12-25	WOS:000169297900099
J	Kaplan, MH; Zong, RT; Herrscher, RF; Scheuermann, RH; Tucker, PW				Kaplan, MH; Zong, RT; Herrscher, RF; Scheuermann, RH; Tucker, PW			Transcriptional activation by a matrix associating region-binding protein - Contextual requirements for the function of Bright	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ENHANCER; SCAFFOLD-ASSOCIATED REGIONS; IMMUNOGLOBULIN-MU ENHANCER; B-CELL SPECIFICITY; NUCLEAR MATRIX; ATTACHMENT REGIONS; CHROMATIN STRUCTURE; TOPOISOMERASE-II; DNA; GENE	Bright (B cell regulator of IgH transcription) is a B cell-specific, matrix associating region-binding protein that transactivates gene expression from the IgH intronic enhancer (E mu). We show here that Bright has multiple contextual requirements to function as a transcriptional activator. Bright cannot transactivate via out of context, concatenated binding sites. Transactivation is maximal on integrated substrates. Two of: the three previously identified binding sites in E mu are required for full Bright transactivation, The Bright DNA binding domain defined a new family, which includes SWI1, a component of the SWI.SNF complex shown to have high mobility group-like DNA binding characteristics. Similar to one group of high mobility group box proteins, Bright distorts E mu binding site-containing DNA on binding, supporting the concept that it mediates E mu remodeling. Transfection studies further implicate Bright in facilitating spatially separated promoter-enhancer interactions in both transient and stable assays. Finally, we show that overexpression of Bright leads to enhanced DNase I sensitivity of the endogenous E mu matrix associating regions. These data further suggest that Bright may contribute to increased gene expression by remodeling the immunoglobulin locus during B cell development.	Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Tucker, PW (corresponding author), Univ Texas, Inst Mol & Cellular Biol, 100 W 24th St,ESB-534, Austin, TX 78712 USA.			Scheuermann, Richard H./0000-0003-1355-892X	NCI NIH HHS [CA31534] Funding Source: Medline; NIAID NIH HHS [AI18016] Funding Source: Medline; NIGMS NIH HHS [GM50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018016, R01AI018016] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM050329, R01GM050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARIIZUMI K, 1993, MOL CELL BIOL, V13, P5629, DOI 10.1128/MCB.13.9.5629; ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BLASQUEZ VC, 1992, J BIOL CHEM, V267, P23888; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERNST P, 1995, IMMUNITY, V2, P427, DOI 10.1016/1074-7613(95)90024-1; Fernandez LA, 2001, MOL CELL BIOL, V21, P196, DOI 10.1128/MCB.21.1.196-208.2001; Fernandez LA, 1998, COLD SPRING HARB SYM, V63, P515, DOI 10.1101/sqb.1998.63.515; FORRESTER WC, 1994, SCIENCE, V265, P1221, DOI 10.1126/science.8066460; GENETTA T, 1994, MOL CELL BIOL, V14, P6153, DOI 10.1128/MCB.14.9.6153; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; HOFMANN JFX, 1989, CELL, V57, P725, DOI 10.1016/0092-8674(89)90788-5; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; Pemov A, 1998, P NATL ACAD SCI USA, V95, P14757, DOI 10.1073/pnas.95.25.14757; Peterson CL, 1998, COLD SPRING HARB SYM, V63, P545, DOI 10.1101/sqb.1998.63.545; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Roque MC, 1996, MOL CELL BIOL, V16, P3138; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; Scheuermann RH, 1999, CRIT REV EUKAR GENE, V9, P295, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.140; SCHNITZER GR, 1988, COLD SPRING HARB SYM, V63, P535; SINGH L, 1994, NUCLEIC ACIDS RES, V22, P2289, DOI 10.1093/nar/22.12.2289; Stein GS, 1998, J CELL BIOCHEM, V70, P200; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TSUTSUI K, 1993, J BIOL CHEM, V268, P12886; Wang ZY, 1999, MOL CELL BIOL, V19, P284; Webb C, 1999, COLD SPRING HARB SYM, V64, P109, DOI 10.1101/sqb.1999.64.109; Webb CF, 1998, J IMMUNOL, V160, P4747; WEBB CF, 1991, MOL CELL BIOL, V11, P5206, DOI 10.1128/MCB.11.10.5206; WEBB CF, 1991, MOL CELL BIOL, V11, P5197, DOI 10.1128/MCB.11.10.5197; WEBB CF, 1989, J IMMUNOL, V143, P3934; Webb CF, 2000, J IMMUNOL, V165, P6956, DOI 10.4049/jimmunol.165.12.6956; WEINBERGER J, 1988, MOL CELL BIOL, V8, P988, DOI 10.1128/MCB.8.2.988; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZONG RT, 1995, J BIOL CHEM, V270, P24010, DOI 10.1074/jbc.270.41.24010; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	52	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21325	21330		10.1074/jbc.M100836200	http://dx.doi.org/10.1074/jbc.M100836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294836	hybrid			2022-12-25	WOS:000169297900071
J	Suzuki, T; Terasaki, M; Takemoto-Hori, C; Hanada, T; Ueda, T; Wada, A; Watanabe, K				Suzuki, T; Terasaki, M; Takemoto-Hori, C; Hanada, T; Ueda, T; Wada, A; Watanabe, K			Structural compensation for the deficit of rRNA with proteins in the mammalian mitochondrial ribosome - Systematic analysis of protein components of the large ribosomal subunit from mammalian mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORRESPONDING GENE-SEQUENCES; TANDEM-MASS-SPECTROMETRY; DIMENSIONAL GEL-ELECTROPHORESIS; 7.5 ANGSTROM RESOLUTION; ESCHERICHIA-COLI; PEPTIDYLTRANSFERASE ACTIVITY; LIVER-MITOCHONDRIA; 70S RIBOSOME; BOVINE LIVER; IDENTIFICATION	The mammalian mitochondrial ribosome (mitoribosome) is a highly protein-rich particle in which almost half of the rRNA contained in the bacterial ribosome is replaced with proteins. It is known that mitochondrial translation factors can function on both mitochondrial and Escherichia coli ribosomes, indicating that protein components in the mitoribosome compensate the reduced rRNA chain to make a bacteria-type ribosome, To elucidate the molecular basis of this compensation, we analyzed bovine mitoribosomal large subunit proteins; 31 proteins were identified including 15 newly identified proteins with their cDNA sequences from human and mouse. The results showed that the proteins with binding sites on rRNA shortened or lost in the mitoribosome were enlarged when compared with the E. coli counterparts; this suggests the structural compensation of the rRNA deficit by the enlarged proteins in the mitoribosome.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Bunkyo Ku, Tokyo 1138656, Japan; Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; RIKEN, Yokohama Inst, Genom Sci Ctr, Prot Res Grp, Kanagawa 2300045, Japan; Osaka Med Coll, Dept Phys, Osaka 5690084, Japan	University of Tokyo; University of Tokyo; RIKEN; Osaka Medical College	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrat Biosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	suzuki@kwl.t.u-tokyo.ac.jp; kw@kwl.t.u-tokyo.ac.jp	Ueda, Takuya/K-5217-2014; Suzuki, Tsutomu/J-1776-2015	Ueda, Takuya/0000-0002-7760-8271; Suzuki, Tsutomu/0000-0002-9731-1731; Hanada, Takao/0000-0003-2732-4008				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Baranov PV, 1999, NUCLEIC ACIDS RES, V27, P184, DOI 10.1093/nar/27.1.184; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CHUNG HKJ, 1990, J BIOL CHEM, V265, P21000; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Diedrich G, 2000, EMBO J, V19, P5241, DOI 10.1093/emboj/19.19.5241; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; EGEBJERG J, 1991, J MOL BIOL, V222, P251, DOI 10.1016/0022-2836(91)90210-W; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GARRETT RA, 1995, RIBOSOMAL RNA STRUCT, P327; Gatlin CL, 2000, ANAL CHEM, V72, P757, DOI 10.1021/ac991025n; Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828; Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s; Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476; GUTELL RR, 1990, NUCLEIC ACIDS RES, V18, P2319, DOI 10.1093/nar/18.suppl.2319; HAMILTON MG, 1974, BIOCHEMISTRY-US, V13, P5400, DOI 10.1021/bi00723a024; HAMPL H, 1981, J BIOL CHEM, V256, P2284; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Koc EC, 1999, BIOCHEM BIOPH RES CO, V266, P141, DOI 10.1006/bbrc.1999.1785; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LIAO HX, 1991, J BIOL CHEM, V266, P20714; Ma JH, 1996, J BIOL CHEM, V271, P5805, DOI 10.1074/jbc.271.10.5805; Mao M, 1998, P NATL ACAD SCI USA, V95, P8175, DOI 10.1073/pnas.95.14.8175; Margulis L, 1970, ORIGIN EUKARYOTIC CE; Marty L, 1996, J BIOL CHEM, V271, P11468, DOI 10.1074/jbc.271.19.11468; Matadeen R, 1999, STRUCTURE, V7, P1575, DOI 10.1016/S0969-2126(00)88348-3; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; Mueller F, 2000, J MOL BIOL, V298, P35, DOI 10.1006/jmbi.2000.3635; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; O'Brien TW, 1999, J BIOL CHEM, V274, P36043, DOI 10.1074/jbc.274.51.36043; O'Brien TW, 2000, J BIOL CHEM, V275, P18153, DOI 10.1074/jbc.M909762199; OBRIEN TW, 1971, J BIOL CHEM, V246, P3409; OU JH, 1987, NUCLEIC ACIDS RES, V15, P8919, DOI 10.1093/nar/15.21.8919; Patel VB, 2001, J BIOL CHEM, V276, P6739, DOI 10.1074/jbc.M005781200; PIETROMONACO SF, 1991, BIOCHIMIE, V73, P827, DOI 10.1016/0300-9084(91)90062-6; Ricchetti M, 1999, NATURE, V402, P96, DOI 10.1038/47076; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; Schwartzbach C J, 1996, Methods Enzymol, V264, P248, DOI 10.1016/S0076-6879(96)64025-7; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tocilj A, 1999, P NATL ACAD SCI USA, V96, P14252, DOI 10.1073/pnas.96.25.14252; TSANG P, 1995, HUM MOL GENET, V4, P1499, DOI 10.1093/hmg/4.9.1499; WADA A, 1986, J BIOCHEM, V100, P1583, DOI 10.1093/oxfordjournals.jbchem.a121866; WADA A, 1990, P NATL ACAD SCI USA, V87, P2657, DOI 10.1073/pnas.87.7.2657; WADA A, 1986, J BIOCHEM-TOKYO, V100, P1595, DOI 10.1093/oxfordjournals.jbchem.a121867; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006	54	99	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21724	21736		10.1074/jbc.M100432200	http://dx.doi.org/10.1074/jbc.M100432200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279069	hybrid			2022-12-25	WOS:000169297900123
J	Baldwin, ME; Catimel, B; Nice, EC; Roufail, S; Hall, NE; Stenvers, KL; Karkkainen, MJ; Alitalo, K; Stacker, SA; Achen, MG				Baldwin, ME; Catimel, B; Nice, EC; Roufail, S; Hall, NE; Stenvers, KL; Karkkainen, MJ; Alitalo, K; Stacker, SA; Achen, MG			The specificity of receptor binding by vascular endothelial growth factor-D is different in mouse and man	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS IN-VIVO; VEGF-C; TUMOR ANGIOGENESIS; FACTOR FAMILY; INSTRUMENTAL BIOSENSORS; LYMPHATIC ENDOTHELIUM; TYROSINE KINASES; EXPRESSION; LIGAND; GENE	Human vascular endothelial growth factor-D (VEGF-D) binds and activates VEGFR-2 and VEGFR-3, receptors expressed on vascular and lymphatic endothelial cells. As VEGFR-2 signals for angiogenesis and VEGFR-3 is thought to signal for lymphangiogenesis, it was proposed that VEGF-D stimulates growth of blood vessels and lymphatic vessels into regions of embryos and tumors. Here we report the unexpected finding that mouse VEGF-D fails to bind mouse VEGFR-2 but binds and cross-links VEGFR-3 as demonstrated by biosensor analysis with immobilized receptor domains and bioassays of VEGFR-2 and VEGFR-3 cross-linking. Mutation of amino acids in mouse VEGF-D to those in the human homologue indicated that residues important for the VEGFR-2 interaction are clustered at, or are near, the predicted receptor-binding surface. Coordinated expression of VEGF-D and VEGFR-3 in mouse embryos was detected in the developing skin where the VEGF-D gene was expressed in a layer of cells beneath the developing epidermis and VEGFR-3 was localized on a network of vessels immediately beneath the VEGF-D-positive cells. This suggests that VEGF-D and VEGFR-3 may play a role in establishing vessels of the skin by a paracrine mechanism. Our study of receptor specificity suggests that VEGF-D may have different biological functions in mouse and man.	Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia; Univ Helsinki Hosp, FIN-00014 Helsinki, Finland; Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Helsinki; Helsinki University Central Hospital	Achen, MG (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, POB 2008, Melbourne, Vic 3050, Australia.		Nice, Edouard C/B-1026-2011; Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Achen, Marc/0000-0002-3791-803X; CATIMEL, Bruno/0000-0002-4350-6875; Hall, Nathan/0000-0001-8942-0498; Stacker, Steven/0000-0003-4096-9273				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, INT J EXP PATHOL, V79, P255, DOI 10.1046/j.1365-2613.1998.700404.x; Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Avantaggiato V, 1998, MECH DEVELOP, V73, P221, DOI 10.1016/S0925-4773(98)00049-5; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Catimel B, 1999, PROTEIN PEPTIDE LETT, V6, P319; Catimel B, 1997, J CHROMATOGR A, V776, P15, DOI 10.1016/S0021-9673(97)00087-3; Clackson T, 1998, J MOL BIOL, V277, P1111, DOI 10.1006/jmbi.1998.1669; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kubo H, 2000, BLOOD, V96, P546; Kukk E, 1996, DEVELOPMENT, V122, P3829; LI XM, 1993, NUCLEIC ACIDS RES, V21, P3745, DOI 10.1093/nar/21.16.3745; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Nice EC, 1999, BIOESSAYS, V21, P339, DOI 10.1002/(SICI)1521-1878(199904)21:4<339::AID-BIES11>3.0.CO;2-C; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Paavonen K, 2000, AM J PATHOL, V156, P1499, DOI 10.1016/S0002-9440(10)65021-3; PACIFICI RE, 1994, J BIOL CHEM, V269, P1571; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; PLATE KH, 1993, CANCER RES, V53, P5822; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Saleh M, 1996, CANCER RES, V56, P393; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Stacker SA, 1999, J BIOL CHEM, V274, P32127, DOI 10.1074/jbc.274.45.32127; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2000, GROWTH FACTORS, V18, P177, DOI 10.3109/08977190009003243; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; WALKER F, 1990, BIOCHEMISTRY-US, V29, P10635, DOI 10.1021/bi00499a009; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Witzenbichler B, 1998, AM J PATHOL, V153, P381, DOI 10.1016/S0002-9440(10)65582-4	50	141	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19166	19171		10.1074/jbc.M100097200	http://dx.doi.org/10.1074/jbc.M100097200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279005	hybrid			2022-12-25	WOS:000169091000072
J	Wang, CG; Fu, MF; Angeletti, RH; Siconolfi-Baez, L; Reutens, AT; Albanese, C; Lisanti, MP; Katzenellenbogen, BS; Kato, S; Hopp, T; Fuqua, SAW; Lopez, GN; Kushner, PJ; Pestell, RG				Wang, CG; Fu, MF; Angeletti, RH; Siconolfi-Baez, L; Reutens, AT; Albanese, C; Lisanti, MP; Katzenellenbogen, BS; Kato, S; Hopp, T; Fuqua, SAW; Lopez, GN; Kushner, PJ; Pestell, RG			Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; ACTIVATION FUNCTION 1; CYCLIN D1; HISTONE ACETYLATION; ACETYLTRANSFERASE ACTIVITY; COACTIVATORS P300; GENE ACTIVATION; RNA HELICASE; N-COR; CBP	Regulation of nuclear receptor gene expression involves dynamic and coordinated interactions with histone acetyl transferase (HAT) and deacetylase complexes. The estrogen receptor (ER alpha) contains two transactivation domains regulating ligand-independent and -dependent gene transcription (AF-1 and AF-2 (activation functions 1 and 2)). ER alpha -regulated gene expression involves interactions with cointegrators (e.g. p300/ CBP, P/CAF) that have the capacity to modify core histone acetyl groups. Here we show that the ER alpha is acetylated in vivo, p300, but not P/CAF, selectively and directly acetylated the ER alpha at lysine residues within the ER alpha hinge/ligand binding domain. Substitution of these residues with charged or polar residues dramatically enhanced ER alpha hormone sensitivity without affecting induction by MAPK signaling, suggesting that direct ER alpha acetylation normally suppresses ligand sensitivity. These ER alpha lysine residues also regulated transcriptional activation by histone deacetylase inhibitors and p300, The conservation of the ER alpha acetylation motif in a phylogenetic subset of nuclear receptors suggests that direct acetylation of nuclear receptors may contribute to additional signaling pathways involved in metabolism and development.	Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pharmacol, Bronx, NY 10461 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; Univ Illinois, Coll Med, Urbana, IL 61801 USA; Univ Tokyo, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol, CREST, Kawaguchi, Saitama 3320012, Japan; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA; Univ Calif San Francisco, Sch Med, Metab Res Unit, San Francisco, CA 94143 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Tokyo; Japan Science & Technology Agency (JST); Baylor College of Medicine; University of California System; University of California San Francisco	Pestell, RG (corresponding author), Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Chanin 302,1300 Morris Pk Ave, Bronx, NY 10461 USA.	pestell@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	NCI NIH HHS [R01-CA72038-01, CA60514, R01CA70897, R01-CA-80250, 5-P30-CA13330-26, R01CA75503] Funding Source: Medline; NHLBI NIH HHS [NIHCA18119] Funding Source: Medline; NIDDK NIH HHS [DK20541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072038, R01CA060514, R01CA070897, R01CA080250, R01CA075503, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Auwerx J, 1999, CELL, V97, P161; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fuqua SAW, 2000, CANCER RES, V60, P4026; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Glass CK, 2000, GENE DEV, V14, P121; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hung HL, 1999, MOL CELL BIOL, V19, P3496; JACKSON RH, 2000, SCIENCE, V288, P1422; Jepsen K, 2000, CELL, V102, P753, DOI 10.1016/S0092-8674(00)00064-7; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Liu L, 1999, MOL CELL BIOL, V19, P1202; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	58	278	285	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18375	18383		10.1074/jbc.M100800200	http://dx.doi.org/10.1074/jbc.M100800200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279135	hybrid			2022-12-25	WOS:000168866500101
J	Kumar, BRP; Swaminathan, V; Banerjee, S; Kundu, TK				Kumar, BRP; Swaminathan, V; Banerjee, S; Kundu, TK			p300-mediated acetylation of human transcriptional coactivator PC4 is inhibited by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; C-TERMINAL DOMAIN; ACTIVATOR-DEPENDENT TRANSCRIPTION; DNA-BINDING; P300; CBP; REPRESSION; COMPONENTS; PROTEINS; PROMOTER	The human positive coactivator 4 (PC4) acts as a general coactivator for activator-dependent transcription, the activity of which is regulated negatively by phosphorylation, We report here that PC4 can be acetylated specifically by another coactivator, p300, Interestingly, phosphorylation of PC4 by casein kinase II inhibits the p300-mediated acetylation, Mass spectral analysis revealed that there are at least two lysine residues acetylated in PC4, as a result of which its DNA binding activity is stimulated.	Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transcript & Dis Lab, Bangalore 560064, Karnataka, India	Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR)	Kundu, TK (corresponding author), Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transcript & Dis Lab, Bangalore 560064, Karnataka, India.	tapas@jncasr.ac.in	Banerjee, Sourav/AAB-7829-2022; Kumar, B R Prashantha/AAK-2805-2020	Kundu, Tapas/0000-0001-7790-214X; Venkatesh, Swaminathan/0000-0001-9837-1501; Banerjee, Sourav/0000-0002-2636-0157				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ALEXANDER CR, 1998, J BIOL CHEM, V273, P1430; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; Brandsen J, 1997, NAT STRUCT BIOL, V4, P900, DOI 10.1038/nsb1197-900; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Ge H, 1996, METHOD ENZYMOL, V274, P57; GE H, 1994, P NATL ACAD SCI USA, V91, P12691, DOI 10.1073/pnas.91.26.12691; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; Herrera JE, 1999, MOL CELL BIOL, V19, P3466; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; KAISER K, 1995, EMBO J, V14, P3520, DOI 10.1002/j.1460-2075.1995.tb07358.x; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; Kundu TK, 1999, MOL CELL BIOL, V19, P1605; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Malik S, 2000, MOL CELL, V5, P753, DOI 10.1016/S1097-2765(00)80254-3; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Werten S, 1998, EMBO J, V17, P5103, DOI 10.1093/emboj/17.17.5103; Werten S, 1998, J MOL BIOL, V276, P367, DOI 10.1006/jmbi.1997.1534; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	30	45	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16804	16809		10.1074/jbc.M100934200	http://dx.doi.org/10.1074/jbc.M100934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279157	hybrid			2022-12-25	WOS:000168730400029
J	Wartenberg, M; Ling, FC; Schallenberg, M; Baumer, AT; Petrat, K; Hescheler, J; Sauer, H				Wartenberg, M; Ling, FC; Schallenberg, M; Baumer, AT; Petrat, K; Hescheler, J; Sauer, H			Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE-1 GENE; LASER-SCANNING MICROSCOPY; POLYMERASE CHAIN-REACTION; C-FOS EXPRESSION; HYDROGEN-PEROXIDE; GROWTH-STIMULATION; BUTHIONINE SULFOXIMINE; CANCER SPHEROIDS; CELL-DEATH; DOXORUBICIN	Intrinsic expression of the multidrug resistance (MDR) transporter P-glycoprotein (Pgp) may be regulated by reactive oxygen species (ROS), A transient expression of Pgp was observed during the growth of multicellular tumor spheroids. Maximum Pgp expression occurred in tumor spheroids with a high percentage of quiescent, Ki-67-negative cells, elevated glutathione levels, increased expression of the cyclin-dependent kinase inhibitors p27(Kip1) and p21(WAF-1) as well as reduced ROS levels and minor activity of the mitogen-activated kinase (MAPK) members c-Jun amino-terminal kinase (JNK), extracellular signal-regulated kinase ERK1,2, and p38 MAPK, Raising intracellular ROS by depletion of glutathione with buthionine sulfoximine (BSO) or glutamine starvation resulted in down-regulation of Pgp and p27(Kip1), whereas ERK1,S and JNK were activated. Down-regulation of Pgp was furthermore observed with low concentrations of hydrogen peroxide and epidermal growth factor, indicating that ROS may regulate Pgp expression. The down-regulation of Pgp following BSO treatment was abolished by agents interfering with receptor tyrosine kinase signaling pathways, i,e, the protein kinase C inhibitors bisindolylmaleimide I (BIM-1) and Ro-31-8220, the p21(ras) farnesyl protein transferase inhibitor III, the c-Raf inhibitor ZM 336372 and PD98059, which inhibits ERK1,2 activation. ROS involved as second messengers in receptor tyrosine kinase signaling pathways may act as negative regulators of Pgp expression.	Univ Cologne, Dept Neurophysiol, D-50931 Cologne, Germany; Univ Cologne, Dept Internal Med 3, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Sauer, H (corresponding author), Univ Cologne, Dept Neurophysiol, Robert Koch Str 39, D-50931 Cologne, Germany.	hs@physiologie.uni-koeln.de						Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Beedassy A, 1999, SEMIN ONCOL, V26, P428; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; DHAR DK, 1995, J SURG ONCOL, V60, P50, DOI 10.1002/jso.2930600110; Dringen R, 1996, J NEUROCHEM, V67, P1375, DOI 10.1046/j.1471-4159.1996.67041375.x; FRENKEL K, 1991, FREE RADICAL RES COM, V12-3, P783, DOI 10.3109/10715769109145860; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Johnstone RW, 1999, BLOOD, V93, P1075, DOI 10.1182/blood.V93.3.1075.403k35_1075_1085; Kojima H, 1998, J BIOL CHEM, V273, P16647, DOI 10.1074/jbc.273.27.16647; MAIORINO M, 1992, ARCH BIOCHEM BIOPHYS, V295, P404, DOI 10.1016/0003-9861(92)90534-4; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; Naito S, 1999, INT J UROL, V6, P427, DOI 10.1046/j.1442-2042.1999.00088.x; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; Oda Y, 1996, DIAGN MOL PATHOL, V5, P98, DOI 10.1097/00019606-199606000-00004; ODwyer PJ, 1996, J CLIN ONCOL, V14, P249, DOI 10.1200/JCO.1996.14.1.249; PILARSKI LM, 1995, LEUKEMIA LYMPHOMA, V17, P367, DOI 10.3109/10428199509056847; Sarkadi B, 1997, SEMIN CANCER BIOL, V8, P171, DOI 10.1006/scbi.1997.0069; Sauer H, 1997, FEBS LETT, V419, P201, DOI 10.1016/S0014-5793(97)01456-7; Sauer H, 1997, BRIT J CANCER, V75, P1481, DOI 10.1038/bjc.1997.253; SIMON SM, 1994, P NATL ACAD SCI USA, V91, P3497, DOI 10.1073/pnas.91.9.3497; Smeets MEP, 1999, BLOOD, V94, P2414, DOI 10.1182/blood.V94.7.2414.417k01_2414_2423; Smyth MJ, 1998, P NATL ACAD SCI USA, V95, P7024, DOI 10.1073/pnas.95.12.7024; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; StCroix B, 1996, NAT MED, V2, P1204; Stein U, 1997, JNCI-J NATL CANCER I, V89, P807, DOI 10.1093/jnci/89.11.807; SZATROWSKI TP, 1991, CANCER RES, V51, P794; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; Volm M, 1998, ANTICANCER RES, V18, P2905; Wartenberg M, 1999, J BIOL CHEM, V274, P27759, DOI 10.1074/jbc.274.39.27759; Wartenberg M, 1996, ANTICANCER RES, V16, P573; Wartenberg M, 1998, INT J CANCER, V75, P855, DOI 10.1002/(SICI)1097-0215(19980316)75:6<855::AID-IJC7>3.3.CO;2-2; Wartenberg M, 1998, CYTOMETRY, V31, P137, DOI 10.1002/(SICI)1097-0320(19980201)31:2<137::AID-CYTO9>3.0.CO;2-J; Wartenberg M, 2000, INT J CANCER, V85, P267, DOI 10.1002/(SICI)1097-0215(20000115)85:2<267::AID-IJC19>3.0.CO;2-H; Wartenberg M, 1997, AM J PHYSIOL-REG I, V272, pR1677, DOI 10.1152/ajpregu.1997.272.5.R1677; WEI LY, 1994, BIOCHEMISTRY-US, V33, P7229, DOI 10.1021/bi00189a027; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; Ziemann C, 1999, CARCINOGENESIS, V20, P407, DOI 10.1093/carcin/20.3.407	42	99	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17420	17428		10.1074/jbc.M100141200	http://dx.doi.org/10.1074/jbc.M100141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279018	hybrid			2022-12-25	WOS:000168730400110
J	Goobes, R; Minsky, A				Goobes, R; Minsky, A			Contextual equilibrium effects in DNA molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIPLE-HELIX FORMATION; ADENINE TRACTS; DEPENDENT CURVATURE; PACKAGING PROCESSES; FLANKING SEQUENCES; NUCLEIC-ACIDS; TRANSITION; DUPLEX; CONFORMATION; CONDENSATION	The thermodynamic parameters of DNA triplex formation between oligonucleotides and double-stranded DNA segments containing adenine runs (A-tracts) were investigated to explore equilibrium structural effects exerted by flanking segments upon the A-tracts. Results obtained from isothermal titration calorimetry, temperature-dependent circular dichroism (CD), and UV melting experiments indicate that A-tracts, considered as a uniquely robust and inflexible DNA motif, can be structurally perturbed by neighboring sequences in a way that significantly affects the propensity of this motif to interact with triplex-forming oligonucleotides. These contextual equilibrium effects, which depend upon the composition and location of the flanking sequences, are likely to apply not only to the interaction of A-tracts with single-stranded DNA molecules but also to interactions with drugs and proteins. As such, the current results refine the guidelines for the design of triplex-forming oligonucleotides used for antigene strategies. More generally, they substantiate the notion that significant data might be encoded by structural DNA parameters.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Minsky, A (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.	avi.minsky@weizmann.ac.il						ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; BURD JF, 1975, J BIOL CHEM, V250, P5109; CHOMILIER J, 1992, BIOPHYS CHEM, V45, P143, DOI 10.1016/0301-4622(92)87006-5; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; Dickerson RE, 1996, J MOL BIOL, V256, P108, DOI 10.1006/jmbi.1996.0071; DIGABRIELE AD, 1993, J MOL BIOL, V231, P1024, DOI 10.1006/jmbi.1993.1349; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; FRANK HS, 1945, J CHEM PHYS, V13, P507, DOI 10.1063/1.1723985; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; HOPKINS HP, 1993, J PHYS CHEM-US, V97, P6555, DOI 10.1021/j100126a036; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; Kamiya M, 1996, J AM CHEM SOC, V118, P4532, DOI 10.1021/ja952287j; KANG S, 1992, J BIOL CHEM, V267, P19435; KOHWISHIGEMATSU T, 1985, CELL, V43, P199, DOI 10.1016/0092-8674(85)90024-8; LevinZaidman S, 1996, BIOCHEMISTRY-US, V35, P2985, DOI 10.1021/bi9525482; MA CL, 1995, BIOCHEMISTRY-US, V34, P3521, DOI 10.1021/bi00011a005; Nejedly K, 1996, J BIOMOL STRUCT DYN, V13, P1007, DOI 10.1080/07391102.1996.10508915; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PARK HS, 1987, J MOL BIOL, V197, P513, DOI 10.1016/0022-2836(87)90561-4; Plum GE, 1997, BIOPOLYMERS, V44, P241, DOI 10.1002/(SICI)1097-0282(1997)44:3<241::AID-BIP4>3.3.CO;2-W; Praseuth D, 1999, BBA-GENE STRUCT EXPR, V1489, P181, DOI 10.1016/S0167-4781(99)00149-9; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; REICH Z, 1991, BIOCHEMISTRY-US, V30, P7828, DOI 10.1021/bi00245a024; REICH Z, 1993, J BIOL CHEM, V268, P8261; REICH Z, 1992, J BIOMOL STRUCT DYN, V9, P1097, DOI 10.1080/07391102.1992.10507981; Schnell JR, 1998, BIOPHYS J, V74, P1484, DOI 10.1016/S0006-3495(98)77860-9; Sen A, 2000, BIOPHYS CHEM, V88, P69, DOI 10.1016/S0301-4622(00)00200-3; ShatzkySchwartz M, 1997, J MOL BIOL, V267, P595, DOI 10.1006/jmbi.1996.0878; SULLIVAN KM, 1986, CELL, V47, P817, DOI 10.1016/0092-8674(86)90524-6; SUN JS, 1993, CURR OPIN STRUC BIOL, V3, P345, DOI 10.1016/S0959-440X(05)80105-8; WELLS RD, 1988, J BIOL CHEM, V263, P1095; WILSON WD, 1994, J AM CHEM SOC, V116, P3607, DOI 10.1021/ja00087a060; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Young MA, 1998, J MOL BIOL, V281, P675, DOI 10.1006/jmbi.1998.1962	35	7	7	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16155	16160		10.1074/jbc.M100619200	http://dx.doi.org/10.1074/jbc.M100619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279103	hybrid			2022-12-25	WOS:000168623100079
J	Lee, FJS; Liu, F; Pristupa, ZB; Niznik, HB				Lee, FJS; Liu, F; Pristupa, ZB; Niznik, HB			Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis	FASEB JOURNAL			English	Article						DA uptake; cell death; coimmunoprecipitation; GST fusion proteins; Parkinson's disease	A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; LEWY BODIES; SUBSTANTIA-NIGRA; CELL-DEATH; CYTOCHROME-C; MICE LACKING; IN-VITRO	Mutations in alpha -synuclein, a protein highly enriched in presynaptic terminals, have been implicated in the expression of familial forms of Parkinson's disease (PD) whereas native alpha -synuclein is a major component of intraneuronal inclusion bodies characteristic of PD and other neurodegenerative disorders. Although overexpression of human a-synuclein induces dopaminergic nerve terminal degeneration, the molecular mechanism by which alpha -synuclein contributes to the degeneration of these pathways remains enigmatic, We report here that alpha -synuclein complexes with the presynaptic human dopamine transporter (hDAT) in both neurons and cotransfected cells through the direct binding of the non-A beta amyloid component of alpha -synuclein to the carboxyl-terminal tail of the hDAT, alpha -Synuclein-hDAT complex formation facilitates the membrane clustering of the DAT, thereby accelerating cellular dopamine uptake and dopamine-induced cellular apoptosis, Since the selective vulnerability of dopaminergic neurons in PD has been ascribed in part to oxidative stress as a result of the cellular overaccumulation of dopamine or dopamine-like molecules by the presynaptic DAT, these data provide mechanistic insight into the mode by which the activity of these two proteins may give rise to this process.	Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Toronto, ON M5T 1R8, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto	Lee, FJS (corresponding author), Ctr Addict & Mental Hlth, Mol Neurobiol Lab, 250 Coll St, Toronto, ON M5T 1R8, Canada.	f.lee@utoronto.ca	Lee, Frank J.S./D-5899-2017	Lee, Frank J.S./0000-0002-5768-3776				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bennett MC, 1999, J BIOL CHEM, V274, P33855, DOI 10.1074/jbc.274.48.33855; Berman SB, 1996, J NEUROCHEM, V67, P593; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bodles AM, 2000, EUR J BIOCHEM, V267, P2186, DOI 10.1046/j.1432-1327.2000.01219.x; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dougherty DD, 1999, LANCET, V354, P2132, DOI 10.1016/S0140-6736(99)04030-1; Dunnett SB, 1999, NATURE, V399, pA32, DOI 10.1038/399a032; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fang YA, 1999, J NEUROSCI, V19, P8966, DOI 10.1523/JNEUROSCI.19-20-08966.1999; Forloni G, 2000, ANN NEUROL, V47, P632, DOI 10.1002/1531-8249(200005)47:5<632::AID-ANA11>3.3.CO;2-E; Gainetdinov RR, 1999, BIOL PSYCHIAT, V46, P303, DOI 10.1016/S0006-3223(99)00122-5; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Hashimoto M, 1999, J BIOL CHEM, V274, P28849, DOI 10.1074/jbc.274.41.28849; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hersch SM, 1997, J COMP NEUROL, V388, P211; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; JAVITCH JA, 1985, P NATL ACAD SCI USA, V82, P2173, DOI 10.1073/pnas.82.7.2173; Jellinger KA, 2000, J NEURAL TRANSM, V107, P1, DOI 10.1007/s007020050001; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Jensen PH, 1997, BIOCHEM J, V323, P539, DOI 10.1042/bj3230539; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kaytor MD, 1999, J BIOL CHEM, V274, P37507, DOI 10.1074/jbc.274.53.37507; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kosel S, 1999, BIOL CHEM, V380, P865, DOI 10.1515/BC.1999.106; Kowall NW, 2000, NEUROREPORT, V11, P211, DOI 10.1097/00001756-200001170-00041; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee FJS, 1996, J BIOL CHEM, V271, P20885, DOI 10.1074/jbc.271.34.20885; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; Little KY, 1999, AM J PSYCHIAT, V156, P238; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Luo YQ, 1998, J BIOL CHEM, V273, P3756, DOI 10.1074/jbc.273.6.3756; Maruyama W, 1998, J NEUROCHEM, V70, P2510; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mezey E, 1998, NAT MED, V4, P755, DOI 10.1038/nm0798-755; MICHEL PP, 1990, J NEUROSCI RES, V26, P428, DOI 10.1002/jnr.490260405; Miller GW, 1999, TRENDS PHARMACOL SCI, V20, P424, DOI 10.1016/S0165-6147(99)01379-6; Neystat M, 1999, MOVEMENT DISORD, V14, P417, DOI 10.1002/1531-8257(199905)14:3<417::AID-MDS1005>3.0.CO;2-X; Nirenberg MJ, 1997, J NEUROSCI, V17, P5255; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; Offen D, 1999, Adv Neurol, V80, P265; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; OLANOW CW, 1994, CURR OPIN NEUROL, V7, P548, DOI 10.1097/00019052-199412000-00013; Oliver JD, 1996, J BIOL CHEM, V271, P13691, DOI 10.1074/jbc.271.23.13691; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Reith MEA, 1997, EUR J PHARMACOL, V324, P1, DOI 10.1016/S0014-2999(97)00065-4; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Withers GS, 1997, DEV BRAIN RES, V99, P87, DOI 10.1016/S0165-3806(96)00210-6; WU RM, 1993, EUR J PHARMACOL, V243, P241, DOI 10.1016/0014-2999(93)90181-G; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2	84	355	377	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					916	926		10.1096/fj.00-0334com	http://dx.doi.org/10.1096/fj.00-0334com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292651				2022-12-25	WOS:000167959300005
J	Makdessi, K; Andreesen, JR; Pich, A				Makdessi, K; Andreesen, JR; Pich, A			Tungstate uptake by a highly specific ABC transporter in Eubacterium acidaminophilum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDATE-BINDING-PROTEIN; CRYSTAL-STRUCTURE; FORMYLMETHANOFURAN DEHYDROGENASE; ARTHROBACTER NICOTINOVORANS; CLOSTRIDIUM-THERMOACETICUM; FERREDOXIN OXIDOREDUCTASE; FORMATE DEHYDROGENASE; MOLYBDENUM COFACTOR; GLYCINE REDUCTASE; MEMBRANE-PROTEINS	The Gram-positive anaerobe Eubacterium acidaminophilum contains at least two tungsten-dependent enzymes: viologen-dependent formate dehydrogenase and aldehyde dehydrogenase, W-185-Labeled tungstate was taken up by this organism with a maximum rate of 0.53 pmol min(-1) mg(-1) of protein at 36 degreesC, The uptake was not affected by equimolar amounts of molybdate, The genes tupABC coding for an ABC transporter specific for tungstate were cloned in the downstream region of genes encoding a tungsten-containing formate dehydrogenase, The substrate-binding protein, TupA, of this putative transporter was overexpressed in Escherichia coli, and its binding properties toward oxyanions were determined by a native polyacrylamide gel retardation assay. Only tungstate induced a shift of TupA mobility, suggesting that only this anion was specifically bound by TupA If molybdate and sulfate were added in high molar excess (> 1000-fold), they were also slightly bound by TupA. The K-d, value for tungstate was determined to be 0.5 muM, The genes encoding the tungstate-specific ABC transporter exhibited highest similarities to putative transporters from Methanobacterium thermoautotrophicun, Haloferax volcanii, Vibrio cholerae, and Campylobacter jejuni. These five transporters represent a separate phylogenetic group of oxyanion ABC transporters as evident from analysis of the deduced amino acid sequences of the binding proteins. Downstream of the tupABC genes, the genes moeA, moeA-1, moaA, and a truncated moaC have been identified by sequence comparison of the deduced amino acid sequences. They should participate in the biosynthesis of the pterin cofactor that is present in molybdenum- and tungsten-containing enzymes except nitrogenase.	Univ Halle Wittenberg, Inst Mikrobiol, D-06120 Halle, Germany	Martin Luther University Halle Wittenberg	Pich, A (corresponding author), Univ Halle Wittenberg, Inst Mikrobiol, Kurt Mothes Str 3, D-06120 Halle, Germany.	a.pich@mikrobiologie.uni-halle.de						Allen RM, 1999, J BIOL CHEM, V274, P15869, DOI 10.1074/jbc.274.22.15869; Anderson LA, 1997, EUR J BIOCHEM, V246, P119, DOI 10.1111/j.1432-1033.1997.00119.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chambaud I, 1999, TRENDS MICROBIOL, V7, P493, DOI 10.1016/S0966-842X(99)01641-8; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Graentzdoerffer A, 2001, ARCH MICROBIOL, V175, P8, DOI 10.1007/s002030000232; GRAENTZDOERFFER A, 2000, THESIS U HALLE; GRANDERATH K, 1993, THESIS U GOTTINGEN; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hasona A, 1998, FEMS MICROBIOL LETT, V169, P111, DOI 10.1111/j.1574-6968.1998.tb13306.x; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; HERZIG AJ, 1968, ENCY CHEM ELEMENTS, P412; Hochheimer A, 1995, EUR J BIOCHEM, V234, P910, DOI 10.1111/j.1432-1033.1995.910_a.x; Hu YL, 1999, J MOL BIOL, V286, P899, DOI 10.1006/jmbi.1998.2488; Hu YL, 1997, NAT STRUCT BIOL, V4, P703, DOI 10.1038/nsb0997-703; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Imperial J, 1998, BBA-BIOMEMBRANES, V1370, P337, DOI 10.1016/S0005-2736(98)00003-0; Johnson MK, 1996, CHEM REV, V96, P2817, DOI 10.1021/cr950063d; Kletzin A, 1996, FEMS MICROBIOL REV, V18, P5, DOI 10.1016/0168-6445(95)00025-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawson DM, 1998, STRUCTURE, V6, P1529, DOI 10.1016/S0969-2126(98)00151-8; Lawson DM, 1997, J CHEM SOC DALTON, P3981, DOI 10.1039/a704006g; LEONHARDT U, 1977, ARCH MICROBIOL, V115, P277, DOI 10.1007/BF00446453; LJUNGDAHL LG, 1976, TRENDS BIOCHEM SCI, V1, P63, DOI 10.1016/S0968-0004(76)80193-4; LUECKE H, 1990, NATURE, V347, P402, DOI 10.1038/347402a0; Meckenstock RU, 1999, EUR J BIOCHEM, V264, P176, DOI 10.1046/j.1432-1327.1999.00600.x; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; MENENDEZ C, 1995, ARCH MICROBIOL, V164, P142, DOI 10.1007/s002030050246; MEYER M, 1995, EUR J BIOCHEM, V234, P184, DOI 10.1111/j.1432-1033.1995.184_c.x; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; MUKUND S, 1995, J BIOL CHEM, V270, P8389, DOI 10.1074/jbc.270.15.8389; Nikaido H, 1998, METHOD ENZYMOL, V292, P3; Pau RN, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P217; RAUH D, 2000, THESIS U HALLE; Rech S, 1996, J BIOL CHEM, V271, P2557, DOI 10.1074/jbc.271.5.2557; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; ROSENTEL JK, 1995, J BACTERIOL, V177, P4857, DOI 10.1128/jb.177.17.4857-4864.1995; Saier MH, 2000, MICROBIOL-SGM, V146, P1775, DOI 10.1099/00221287-146-8-1775; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; SUTCLIFFE IC, 1995, J BACTERIOL, V177, P1123, DOI 10.1128/jb.177.5.1123-1128.1995; Towbin H, 1992, Biotechnology, V24, P145; Vorholt JA, 1997, MOL MICROBIOL, V23, P1033, DOI 10.1046/j.1365-2958.1997.2931653.x; WAGNER R, 1987, ARCH MICROBIOL, V147, P295, DOI 10.1007/BF00463491; Wagner UG, 2000, STRUCTURE, V8, P1127, DOI 10.1016/S0969-2126(00)00525-6; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wanner C, 1999, GENETICS, V152, P1417; WHITE H, 1992, ARCH MICROBIOL, V158, P81, DOI 10.1007/BF00245209; Williams CEM, 1999, ACTA CRYSTALLOGR D, V55, P1356, DOI 10.1107/S0907444999005375; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826; ZINDEL U, 1988, ARCH MICROBIOL, V150, P254, DOI 10.1007/BF00407789	55	45	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					24557	24564		10.1074/jbc.M101293200	http://dx.doi.org/10.1074/jbc.M101293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11292832	hybrid			2022-12-25	WOS:000169800700020
J	Jullig, M; Eriksson, S				Jullig, M; Eriksson, S			Apoptosis induces efflux of the mitochondrial matrix enzyme deoxyguanosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-DEFICIENT MICE; CELL-FREE-EXTRACTS; CYTOCHROME-C; NUCLEOSIDE ANALOGS; ACTIVATION; INDUCTION; PROGRAM; DATP; DNA	Deoxyguanosine kinase (dGK) initiates the salvage of purine deoxynucleosides in mitochondria and is a key enzyme in mitochondrial DNA precursor synthesis. The active form of the enzyme is a 60-kDa protein normally located in the mitochondrial matrix. Here we describe the subcellular distribution of dGK during apoptosis in human epithelial kidney 293 cells and human lymphoblast Molt-4 cells. Immunological methods were used to monitor dGK as well as other mitochondrial proteins. Surprisingly, dGK was found to relocate to the cytosolic compartment at a similar rate as cytochrome c, a mitochondrial intermembraneous enzyme known to enter the cytosol early in apoptosis. The redistribution of dGK from the mitochondria to the cytosol may be of importance for the activation of apoptotic purine nucleoside cofactors such as dATP and demonstrates that mitochondrial matrix proteins may selectively leak out during apoptosis.	Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Vet Med Chem, S-75123 Uppsala, Sweden	Swedish University of Agricultural Sciences	Jullig, M (corresponding author), Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Vet Med Chem, Box 575, S-75123 Uppsala, Sweden.							ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Arpaia E, 2000, J EXP MED, V191, P2197, DOI 10.1084/jem.191.12.2197; CARSON DA, 1980, P NATL ACAD SCI-BIOL, V77, P6865, DOI 10.1073/pnas.77.11.6865; CASTRO J, 1993, CYTOMETRY, V14, P793, DOI 10.1002/cyto.990140712; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Csapo Z, 2001, BIOCHEM PHARMACOL, V61, P191, DOI 10.1016/S0006-2952(00)00534-7; Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; GOWER WR, 1979, J BIOL CHEM, V254, P2180; HAMADA T, 1994, NEPHRON, V68, P104, DOI 10.1159/000188227; Hamada T, 1996, BIOCHEM BIOPH RES CO, V219, P829, DOI 10.1006/bbrc.1996.0318; Jullig M, 2000, EUR J BIOCHEM, V267, P5466, DOI 10.1046/j.1432-1327.2000.01607.x; Kim CN, 1997, CANCER RES, V57, P3115; Kohler C, 1999, FEBS LETT, V447, P10, DOI 10.1016/S0014-5793(99)00251-3; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; PARK I, 1988, ARCH BIOCHEM BIOPHYS, V266, P51, DOI 10.1016/0003-9861(88)90235-4; Petrakis TG, 1999, J BIOL CHEM, V274, P24726, DOI 10.1074/jbc.274.35.24726; RICHARD K, 1982, J BIOL CHEM, V257, P9300; Shepherd D., 1969, METHODS ENZYMOL, V13, P11, DOI [10.1016/0076-6879(69)13006-2, DOI 10.1016/0076-6879(69)13006-2]; Sjoberg AH, 1998, MOL PHARMACOL, V53, P270, DOI 10.1124/mol.53.2.270; SNYDER FF, 1994, BBA-MOL BASIS DIS, V1227, P33, DOI 10.1016/0925-4439(94)90103-1; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; WANG LY, 1993, J BIOL CHEM, V268, P22847; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Zhu CY, 2000, J BIOL CHEM, V275, P26727; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	29	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24000	24004		10.1074/jbc.M100435200	http://dx.doi.org/10.1074/jbc.M100435200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294860	hybrid			2022-12-25	WOS:000169531100103
J	Tse, WT; Tang, J; Jin, O; Korsgren, C; John, KM; Kung, AL; Gwynn, B; Peters, LL; Lux, SE				Tse, WT; Tang, J; Jin, O; Korsgren, C; John, KM; Kung, AL; Gwynn, B; Peters, LL; Lux, SE			A new spectrin, beta IV, has a major truncated isoform that associates with promyelocytic leukemia protein nuclear bodies and the nuclear matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP-A; PORE COMPLEX PROTEIN; FANCONI-ANEMIA; ERYTHROCYTE-MEMBRANE; PREMATURE SENESCENCE; BINDING PROTEINS; ONCOGENIC RAS; CELL-GROWTH; PML GENE; IN-VITRO	We isolated cDNAs that encode a 77-kDa peptide similar to repeats 10-16 of beta -spectrins, Its gene localizes to human chromosome 19q13.13-q13.2 and mouse chromosome 7, at 7.5 centimorgans, A 289-kDa isoform, similar to full-length beta -spectrins, was partially assembled from sequences in the human genomic DNA data base and completely cloned and sequenced. RNA transcripts are seen predominantly in the brain, and Western analysis shows a major peptide that migrates as a 72-kDa band. This new gene, spectrin beta IV, thus encodes a full-length minor isoform (Sp beta IV Sigma1) and a truncated major isoform (Sp beta IV Sigma5), Immunostaining of cells shows a micropunctate pattern in the cytoplasm and nucleus. In mesenchymal stem cells, the staining concentrates at nuclear dots that stain positively for the promyelocytic leukemia protein (PML). Expression of Sp beta IV Sigma5 fused to green fluorescence protein in cells produces nuclear dots that include all PML bodies, which double in number in transfected cells. Deletion analysis shows that partial repeats 10 and 16 of Sp beta IV Sigma5 are necessary for nuclear dot formation. Immunostaining of whole-mount nuclear matrices reveals diffuse positivity with accentuation at PML bodies, Spectrin beta IV is the first beta -spectrin associated with a subnuclear structure and may be part of a nuclear scaffold to which gene regulatory machinery binds.	Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Jackson Laboratory	Tse, WT (corresponding author), Childrens Hosp, Div Hematol Oncol, 300 Longwood Ave, Boston, MA 02115 USA.	william.tse@tch.harvard.edu	Kung, Andrew L/AEU-0826-2022; Kung, Andrew/AAL-2384-2020	Kung, Andrew L/0000-0002-9091-488X; Peters, Luanne/0000-0002-0784-0534	NCI NIH HHS [CA34196] Funding Source: Medline; NHLBI NIH HHS [HL64885, R01 HL064885, HL33262, HL55321, R01 HL055321] Funding Source: Medline; NICHD NIH HHS [P30-HD18655] Funding Source: Medline; NIDDK NIH HHS [DK34083] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA034196] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033262, R01HL064885, R01HL055321] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034083, R37DK034083] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; AMIN KM, 1993, GENOMICS, V18, P118, DOI 10.1006/geno.1993.1434; BACHS O, 1990, J BIOL CHEM, V265, P18595; BECK KA, 1994, J CELL BIOL, V127, P707, DOI 10.1083/jcb.127.3.707; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; Boddy MN, 1996, ONCOGENE, V13, P971; Brois DW, 1999, CARCINOGENESIS, V20, P1845, DOI 10.1093/carcin/20.9.1845; BURRIDGE K, 1982, J CELL BIOL, V95, P478, DOI 10.1083/jcb.95.2.478; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CONLON RA, 1992, DEVELOPMENT, V116, P357; Corcoran Stacey L., 1997, Biochemical Society Transactions, V25, p483S; Cordes VC, 1997, J CELL BIOL, V136, P515, DOI 10.1083/jcb.136.3.515; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; De Matteis MA, 1998, CURR OPIN CELL BIOL, V10, P542, DOI 10.1016/S0955-0674(98)80071-9; De Matteis MA, 2000, J CELL SCI, V113, P2331; de Ruijter NCA, 2000, CELL BIOL INT, V24, P427, DOI 10.1006/cbir.2000.0508; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Ferbeyre G, 2000, GENE DEV, V14, P2015; GIBB S, 1981, GENET RES, V37, P95, DOI 10.1017/S0016672300020048; GLENNEY JR, 1983, CELL, V34, P503, DOI 10.1016/0092-8674(83)90383-5; Goodman RH, 2000, GENE DEV, V14, P1553; Harborth J, 1999, EMBO J, V18, P1689, DOI 10.1093/emboj/18.6.1689; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Holleran EA, 1996, J CELL BIOL, V135, P1815, DOI 10.1083/jcb.135.6.1815; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; HOZAK P, 1995, J CELL SCI, V108, P635; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jiang WQ, 1996, EXP CELL RES, V229, P289, DOI 10.1006/excr.1996.0374; Kaplan JM, 2000, NAT GENET, V24, P251, DOI 10.1038/73456; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Kumaresan KR, 2000, CARCINOGENESIS, V21, P741, DOI 10.1093/carcin/21.4.741; Lallena MJ, 1998, J CELL SCI, V111, P1963; LAVAU C, 1995, ONCOGENE, V11, P871; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; MALCHIODIALBEDI F, 1993, J CELL SCI, V106, P67; MARCHESI V. T., 1968, SCIENCE, V159, P203, DOI 10.1126/science.159.3811.203; Matera AG, 1999, TRENDS CELL BIOL, V9, P302, DOI 10.1016/S0962-8924(99)01606-2; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattern KA, 1996, J CELL BIOCHEM, V62, P275, DOI 10.1002/(SICI)1097-4644(199608)62:2<275::AID-JCB15>3.0.CO;2-K; Maul GG, 2000, J STRUCT BIOL, V129, P278, DOI 10.1006/jsbi.2000.4239; McMahon LW, 1999, J BIOL CHEM, V274, P32904, DOI 10.1074/jbc.274.46.32904; Michaely P, 1999, J BIOL CHEM, V274, P35908, DOI 10.1074/jbc.274.50.35908; Muresan V, 2001, MOL CELL, V7, P173, DOI 10.1016/S1097-2765(01)00165-4; Nagase T, 2000, DNA RES, V7, P273; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pederson T, 2000, MOL BIOL CELL, V11, P799, DOI 10.1091/mbc.11.3.799; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; REPASKY EA, 1982, CELL, V29, P821, DOI 10.1016/0092-8674(82)90444-5; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SAITO F, 1995, CYTOGENET CELL GENET, V71, P179, DOI 10.1159/000134102; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63; Stabach PR, 2000, J BIOL CHEM, V275, P21385, DOI 10.1074/jbc.C000159200; Stankewich MC, 1998, P NATL ACAD SCI USA, V95, P14158, DOI 10.1073/pnas.95.24.14158; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; STUURMAN N, 1992, J CELL SCI, V101, P773; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TERRIS B, 1995, CANCER RES, V55, P1590; Tse WT, 1999, BRIT J HAEMATOL, V104, P2, DOI 10.1111/j.1365-2141.1999.01130.x; TURNER BM, 1986, FEBS LETT, V197, P41, DOI 10.1016/0014-5793(86)80294-0; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; Ye KQ, 1999, J NEUROSCI, V19, P10747, DOI 10.1523/JNEUROSCI.19-24-10747.1999; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	91	46	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23974	23985		10.1074/jbc.M009307200	http://dx.doi.org/10.1074/jbc.M009307200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294830	hybrid			2022-12-25	WOS:000169531100100
J	Zapata, JM; Pawlowski, K; Haas, E; Ware, CF; Godzik, A; Reed, JC				Zapata, JM; Pawlowski, K; Haas, E; Ware, CF; Godzik, A; Reed, JC			A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; UBIQUITIN-SPECIFIC PROTEASE; POLYCYSTIC KIDNEY-DISEASE; RING FINGER PROTEIN; FACTORS TRAFS; JNK/SAPK ACTIVATION; CYTOPLASMIC DOMAIN; STRUCTURAL BASIS; BINDING-PROTEIN; POZ DOMAIN	We have identified three new tumor necrosis factor-receptor associated factor (TRAF) domain-containing proteins in humans using bioinformatics approaches, including: MUL, the product of the causative gene in Mulibrey Nanism syndrome; USP7 (HAUSP), an ubiquitin protease; and SPOP, a POZ domain-containing protein. Unlike classical TRAF family proteins involved in TNF family receptor (TNFR) signaling, the TRAF domains (TDs) of MUL, USP7, and SPOP are located near the NR, termini or central region of these proteins, rather than carboxyl end. MUL and USP7 are capable of binding in vitro via their TDs to all of the previously identified TRAF family proteins (TRAF1, TRAF2, TRAF3, TRAF4, TRAF5, and TRAF6), whereas the TD of SPOP interacts weakly with TRAF1 and TRAF6 only. The TD of MUL also interacted with itself, whereas the TDs of USP7: and SPOP did not self-associate, Analysis of various MUL and USP7 mutants by transient transfection assays indicated that the TDs of these proteins are necessary and sufficient for suppressing NF-kappaB induction by TRAF2 and TRAF6 as well as certain TRAF-binding TNF family receptors. In contrast, the TIP of SPOP did not inhibit NF-kappaB induction. Immunofluorescence confocal microscopy indicated that MUL localizes to cytosolic bodies, with targeting to these structures mediated by a RBCC tripartite domain within the MUL protein. USP7 localized predominantly to the nucleus, in a TD-dependent manner. Data base searches revealed multiple proteins containing TDs homologous to those found in MUL, USP7, and SPOP throughout eukaryotes, including yeast, protists, plants, invertebrates, and mammals, suggesting that this branch of the TD family arose from an ancient gene. We propose the moniker TEFs (TD-encompassing factors) for this large family of proteins.	Burnham Inst, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Sanford Burnham Prebys Medical Discovery Institute; La Jolla Institute for Immunology	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham-inst.org	Pawlowski, Krzysztof/E-3262-2012; Pawłowski, Krzysztof/C-2949-2013; Godzik, Adam/A-7279-2009; Zapata, Juan M/J-6304-2014; Godzik, Adam/AAW-1467-2020	Pawłowski, Krzysztof/0000-0002-5367-0935; Godzik, Adam/0000-0002-2425-852X; Zapata, Juan M/0000-0002-0110-0009; Godzik, Adam/0000-0002-2425-852X	NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER; NCI NIH HHS [CA-69381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ansieau S, 1996, P NATL ACAD SCI USA, V93, P14053, DOI 10.1073/pnas.93.24.14053; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Avela K, 2000, NAT GENET, V25, P298, DOI 10.1038/77053; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bloch DB, 1999, MOL CELL BIOL, V19, P4423; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Boucher LM, 1997, BIOCHEM BIOPH RES CO, V233, P592, DOI 10.1006/bbrc.1997.6509; Cao TY, 1997, J CELL SCI, V110, P1563; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devergne O, 1996, MOL CELL BIOL, V16, P7098; El-Husseini AE, 1999, J BIOL CHEM, V274, P19771, DOI 10.1074/jbc.274.28.19771; El-Husseini AED, 2000, BIOCHEM BIOPH RES CO, V267, P906, DOI 10.1006/bbrc.1999.2045; ElHodiri HM, 1997, J BIOL CHEM, V272, P20463, DOI 10.1074/jbc.272.33.20463; Eussen BHJ, 2000, J MED GENET, V37, P287, DOI 10.1136/jmg.37.4.287; Everett RD, 1999, TRENDS BIOCHEM SCI, V24, P293, DOI 10.1016/S0968-0004(99)01433-4; Everett RD, 1999, J VIROL, V73, P417, DOI 10.1128/JVI.73.1.417-426.1999; Everett RD, 1997, EMBO J, V16, P566, DOI 10.1093/emboj/16.3.566; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; GALANG CK, 1994, ONCOGENE, V9, P2913; Gedrich RW, 1996, J BIOL CHEM, V271, P12852, DOI 10.1074/jbc.271.22.12852; Gibbons RJ, 1996, MEDICINE, V75, P45, DOI 10.1097/00005792-199603000-00001; HARRIS PC, 1995, J AM SOC NEPHROL, V6, P1125; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Holinski-Feder E, 2000, AM J HUM GENET, V66, P16, DOI 10.1086/302703; Holt BF, 2000, CURR BIOL, V10, pR5, DOI 10.1016/S0960-9822(99)00273-0; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; INITIATIVE TAG, 2000, NATURE, V408, P796, DOI DOI 10.1038/35048692; Jaroszewski L, 1998, PROTEIN SCI, V7, P1431; Jin YS, 1997, CANCER RES, V57, P404; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Krajewska M, 1998, AM J PATHOL, V152, P1549; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Leo E, 1999, EUR J IMMUNOL, V29, P3908, DOI 10.1002/(SICI)1521-4141(199912)29:12<3908::AID-IMMU3908>3.0.CO;2-E; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; McWhirter SM, 1999, P NATL ACAD SCI USA, V96, P8408, DOI 10.1073/pnas.96.15.8408; MIYASHITA T, 1995, CELL, V80, P293; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 1997, FEBS LETT, V418, P23, DOI 10.1016/S0014-5793(97)01340-9; Ni CZ, 2000, P NATL ACAD SCI USA, V97, P10395, DOI 10.1073/pnas.97.19.10395; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Panagopoulos I, 2000, GENE CHROMOSOME CANC, V28, P415, DOI 10.1002/1098-2264(200008)28:4<415::AID-GCC7>3.0.CO;2-I; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Petrij F, 2000, AM J MED GENET, V92, P47, DOI 10.1002/(SICI)1096-8628(20000501)92:1<47::AID-AJMG8>3.0.CO;2-H; PULLEN S, 1998, BIOCHEMISTRY-US, V37, P11330; Pullen SS, 1999, BIOCHEMISTRY-US, V38, P10168, DOI 10.1021/bi9909905; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; REGNIER C, 1985, J BIOL CHEM, V270, P25715; Robinson PA, 1998, CYTOGENET CELL GENET, V83, P100, DOI 10.1159/000015142; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shi CS, 1999, J IMMUNOL, V163, P3279; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Uren AG, 1996, TRENDS BIOCHEM SCI, V21, P244, DOI 10.1016/S0968-0004(96)30022-4; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wallerstein R, 1997, J MED GENET, V34, P203, DOI 10.1136/jmg.34.3.203; Wang ZG, 1998, SCIENCE, V279, P1547; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamamoto H, 1998, J IMMUNOL, V161, P4753; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; Zapata JM, 2000, J BIOL CHEM, V275, P12102, DOI 10.1074/jbc.275.16.12102; Zheng PP, 2000, CANCER GENET CYTOGEN, V122, P18, DOI 10.1016/S0165-4608(00)00265-X	77	169	174	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24242	24252		10.1074/jbc.M100354200	http://dx.doi.org/10.1074/jbc.M100354200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11279055	hybrid			2022-12-25	WOS:000169531100133
J	Nicolas, M; Noe, V; Jensen, KB; Ciudad, CJ				Nicolas, M; Noe, V; Jensen, KB; Ciudad, CJ			Cloning and characterization of the 5 '-flanking region of the human transcription factor Sp1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; FUNCTIONAL-ANALYSIS; ACTIVATION DOMAINS; O-GLYCOSYLATION; CELL-GROWTH; SP-FAMILY; PROMOTER; BINDING; PHOSPHORYLATION; EXPRESSION	The 5 ' -flanking region of the human Sp1 gene was cloned and characterized. Sequence analysis of this region showed the absence of both CAAT and TATA boxes and an initiator element. The proximal promoter of the Sp1 gene is a GC-rich region that contains multiple GC boxes and Ap2 binding sites. The major transcription start site is located 63 base pairs upstream of the translation start site. Transfection experiments demonstrate that all the elements necessary to achieve significant basal transcription activity are located between positions -443 and -20 relative to the translational start. Sp1 and Sp3 proteins bind to the downstream GC box located in the progimal promoter of Sp1. Furthermore, we demonstrate that the Sp1 protein activates Sp1 transcription activity; thus the Sp1 gene is autoregulated.	Univ Barcelona, Fac Farm, Dept Bioquim & Biol Mol, Div 4,Sch Pharm, Barcelona 08028, Spain; Rockefeller Univ, Mol Neurooncol Lab, New York, NY 10021 USA	University of Barcelona; Rockefeller University	Ciudad, CJ (corresponding author), Univ Barcelona, Fac Farm, Dept Bioquim & Biol Mol, Div 4,Sch Pharm, Avda Diagonal 643, Barcelona 08028, Spain.	Cciudad@farmacia.far.ub.es	Noe, Veronique/K-3615-2014; Jensen, Kirk/B-4756-2008; Jensen, Kirk/AAL-5883-2020; Ciudad, Carlos J./D-7917-2014	Noe, Veronique/0000-0001-7937-8038; Jensen, Kirk/0000-0002-2084-1734; Jensen, Kirk/0000-0002-2084-1734; Ciudad, Carlos J./0000-0002-7855-392X				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BERGER I, 1994, DNA CELL BIOL, V13, P249, DOI 10.1089/dna.1994.13.249; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CIUDAD CJ, 1992, J BIOL CHEM, V267, P3650; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GAYNOR RB, 1993, CYTOGENET CELL GENET, V64, P210, DOI 10.1159/000133578; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Marin M, 1997, CELL, V89, P619, DOI 10.1016/S0092-8674(00)80243-3; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MATERA AG, 1993, GENOMICS, V17, P793, DOI 10.1006/geno.1993.1413; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Noe V, 1997, EUR J BIOCHEM, V249, P13, DOI 10.1111/j.1432-1033.1997.00013.x; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; PARK K, 1994, J BIOL CHEM, V269, P6083; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Roder K, 1999, GENE, V234, P61, DOI 10.1016/S0378-1119(99)00180-8; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Strom AC, 1996, NUCLEIC ACIDS RES, V24, P1981, DOI 10.1093/nar/24.11.1981; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Takahara T, 2000, J BIOL CHEM, V275, P38067, DOI 10.1074/jbc.M002010200; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471	54	76	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22126	22132		10.1074/jbc.M010740200	http://dx.doi.org/10.1074/jbc.M010740200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294852	hybrid			2022-12-25	WOS:000169412700022
J	Chishti, MA; Yang, DS; Janus, C; Phinney, AL; Horne, P; Pearson, J; Strome, R; Zuker, N; Loukides, J; French, J; Turner, S; Lozza, G; Grilli, M; Kunicki, S; Morissette, C; Paquette, J; Gervais, F; Bergeron, C; Fraser, PE; Carlson, GA; St George-Hyslop, P; Westaway, D				Chishti, MA; Yang, DS; Janus, C; Phinney, AL; Horne, P; Pearson, J; Strome, R; Zuker, N; Loukides, J; French, J; Turner, S; Lozza, G; Grilli, M; Kunicki, S; Morissette, C; Paquette, J; Gervais, F; Bergeron, C; Fraser, PE; Carlson, GA; St George-Hyslop, P; Westaway, D			Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; A-BETA PEPTIDE; MOUSE MODEL; NEURONAL LOSS; NEUROFIBRILLARY TANGLES; PLAQUES; GENE; PRESENILIN-1; CELLS; BRAIN	We have created early-onset transgenic (Tg) models by exploiting the synergistic effects of familial Alzheimer's disease mutations on amyloid P-peptide (Ap) biogenesis. TgCRND8 mice encode a double mutant form of amyloid precursor protein 695 (KM670/671NL+V717F) under the control of the PrP gene promoter. Thioflavine S-positive AP amyloid deposits are present at 3 months, with dense-cored plaques and neuritic pathology evident from 5 months of age. TgCRND8 mice exhibit 3,200-4,600 pmol of A beta 42 per g brain at age 6 months, with an excess of A beta 42 over A beta 40. High level production of the pathogenic A beta 42 form of A beta peptide was associated with an early impairment in TgCRND8 mice in acquisition and learning reversal in the reference memory version of the Morris water maze, present by 3 months of age. Notably, learning impairment in young mice was offset by immunization against A beta 42 (Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T. J., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St. George-Hyslop, P., and Westaway, D. (2000) Nature 408, 979-982). Amyloid deposition in TgCRND8 mice was enhanced by the expression of presenilin 1 transgenes including familial Alzheimer's disease mutations; for mice also expressing a M146L+L286V presenilin 1 transgene, amyloid deposits were apparent by 1 month of age. The Tg mice described here suggest a potential to investigate aspects of Alzheimer's disease pathogenesis, prophylaxis, and therapy within short time frames.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 3H2, Canada; Univ Toronto, Dept Med, Div Neurol, Toronto, ON M5S 3H2, Canada; Univ Toronto, Univ Hlth Network, Toronto, ON M5S 3H2, Canada; McLaughlin Res Inst, Great Falls, MT 59405 USA; Schering Plough Res Inst, Milan, Italy; Neurochem Inc, Montreal, PQ H4S 2A1, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; McLaughlin Research Institute for Biomedical Sciences, Inc.; Merck & Company	Westaway, D (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, Tanz Neurosci Bldg,6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.		grilli, mariagrazia/ABF-1542-2020; French, Jacqueline/G-6795-2013	grilli, mariagrazia/0000-0001-9165-5827; St George-Hyslop, Peter/0000-0003-0796-7209; French, Jacqueline/0000-0003-2242-8027				Ahlijanian MK, 2000, P NATL ACAD SCI USA, V97, P2910, DOI 10.1073/pnas.040577797; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bartoo GT, 1997, J NEUROPATH EXP NEUR, V56, P531, DOI 10.1097/00005072-199705000-00009; Beach TG, 2000, J NEUROPATH EXP NEUR, V59, P308, DOI 10.1093/jnen/59.4.308; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Capell A, 1997, J NEUROCHEM, V69, P2432; Carlson GA, 1997, HUM MOL GENET, V6, P1951, DOI 10.1093/hmg/6.11.1951; Chapman PF, 1999, NAT NEUROSCI, V2, P271, DOI 10.1038/6374; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; Dewachter I, 2000, J NEUROSCI, V20, P6452, DOI 10.1523/JNEUROSCI.20-17-06452.2000; Dodart JC, 2000, NEUROBIOL DIS, V7, P71, DOI 10.1006/nbdi.1999.0278; Dodart JC, 1999, BEHAV NEUROSCI, V113, P982, DOI 10.1037/0735-7044.113.5.982; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gass P, 1998, LEARN MEMORY, V5, P274; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; HACCOU P, 1995, STAT ANAL BEHAV DATA, P120; Harkany T, 2000, REV NEUROSCIENCE, V11, P329; Holtzman DM, 2000, P NATL ACAD SCI USA, V97, P2892, DOI 10.1073/pnas.050004797; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Hsiao K, 1998, EXP GERONTOL, V33, P883, DOI 10.1016/S0531-5565(98)00045-X; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1995, NEURON, V15, P1203, DOI 10.1016/0896-6273(95)90107-8; Huang XD, 1999, BIOCHEMISTRY-US, V38, P7609, DOI 10.1021/bi990438f; Huang XD, 1999, J BIOL CHEM, V274, P37111, DOI 10.1074/jbc.274.52.37111; Iadecola C, 1999, NAT NEUROSCI, V2, P157, DOI 10.1038/5715; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; Janus C, 2000, NEUROBIOL AGING, V21, P541, DOI 10.1016/S0197-4580(00)00107-X; Janus C, 2000, BBA-MOL BASIS DIS, V1502, P63, DOI 10.1016/S0925-4439(00)00033-8; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; JOHNSTON JA, 1994, FEBS LETT, V354, P274, DOI 10.1016/0014-5793(94)01137-0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; MASLIAH E, 1991, AM J PATHOL, V138, P235; Masliah E, 1996, J NEUROSCI, V16, P5795; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Moechars D, 1999, J BIOL CHEM, V274, P6483, DOI 10.1074/jbc.274.10.6483; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; Storey E, 1999, NEUROPATH APPL NEURO, V25, P81; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Terry RD, 1996, J NEUROPATH EXP NEUR, V55, P1023, DOI 10.1097/00005072-199655100-00001; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wang J, 1999, EXP NEUROL, V158, P328, DOI 10.1006/exnr.1999.7085; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	73	736	782	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21562	21570		10.1074/jbc.M100710200	http://dx.doi.org/10.1074/jbc.M100710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279122	hybrid			2022-12-25	WOS:000169297900102
J	Mahadev, K; Zilbering, A; Zhu, L; Goldstein, BJ				Mahadev, K; Zilbering, A; Zhu, L; Goldstein, BJ			Insulin-stimulated hydrogen peroxide reversibly inhibits protein-tyrosine phosphatase 1B in vivo and enhances the early insulin action cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; ACTIVATION; GENERATION; CATALYSIS; H2O2; DEPHOSPHORYLATION; INACTIVATION; SENSITIVITY; MECHANISM; COMPLEX	The insulin signaling pathway is activated by tyrosine phosphorylation of the insulin receptor and key postreceptor substrate proteins and balanced by the action of specific protein-tyrosine phosphatases (PTPases), PTPase activity, in turn, is highly regulated in vivo by oxidation/reduction reactions involving the cysteine thiol moiety required for catalysis, Here we show that insulin stimulation generates a burst of intracellular H2O2 in insulin-sensitive hepatoma and adipose cells that is associated with reversible oxidative inhibition of up to 62% of overall cellular PTPase activity, as measured by a novel method using strictly anaerobic conditions. The specific activity of immunoprecipitated PTP1B, a PTPase homolog implicated in the regulation of insulin signaling, was also strongly inhibited by up to 88% following insulin stimulation, Catalase pretreatment abolished the insulin-stimulated production of H2O2 as well as the inhibition of cellular PTPases, including PTP1B, and was associated with reduced insulin-stimulated tyrosine phosphorylation of its receptor and high M-r insulin receptor substrate (IRS) proteins. These data provide compelling new evidence for a redox signal that enhances the early insulin-stimulated cascade of tyrosine phosphorylation by oxidative inactivation of PTP1B and possibly other tyrosine phosphatases.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Endocrinol & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	Jefferson University	Goldstein, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Div Endocrinol & Metab Dis, Dorrance H Hamilton Res Labs, Rm 349 Alumni Hall,1020 Locust St, Philadelphia, PA 19107 USA.	Barry.Goldstein@mail.tju.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043396, R01DK053388] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43396, DK53388] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calera MR, 2000, J BIOL CHEM, V275, P6308, DOI 10.1074/jbc.275.9.6308; Cheung A, 1999, J LAB CLIN MED, V134, P115, DOI 10.1016/S0022-2143(99)90115-4; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; CZECH MP, 1974, J BIOL CHEM, V249, P1001; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; ELBERG G, 1995, BBA-MOL CELL RES, V1269, P299, DOI 10.1016/0167-4889(95)00124-8; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Gagnon AM, 1998, OBES RES, V6, P157, DOI 10.1002/j.1550-8528.1998.tb00330.x; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; GOLDSTEIN BJ, 2000, DIABETES MELLITUS FU, P206; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Kennedy BP, 2000, BIOCHEM PHARMACOL, V60, P877, DOI 10.1016/S0006-2952(00)00305-1; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; KOZMA L, 1993, P NATL ACAD SCI USA, V90, P4460, DOI 10.1073/pnas.90.10.4460; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Malamas MS, 2000, J MED CHEM, V43, P995, DOI 10.1021/jm990476x; MEYEROVITCH J, 1992, BIOCHEMISTRY-US, V31, P10338, DOI 10.1021/bi00157a023; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Rao GN, 1996, ONCOGENE, V13, P713; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Venable CL, 2000, J BIOL CHEM, V275, P18318, DOI 10.1074/jbc.M908392199; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHU L, 2001, IN PRESS FASEB J	41	410	424	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21938	21942		10.1074/jbc.C100109200	http://dx.doi.org/10.1074/jbc.C100109200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11297536	hybrid			2022-12-25	WOS:000169297900148
J	Zhu, XL; Hadhazy, M; Groh, ME; Wheeler, MT; Wollmann, R; McNally, EM				Zhu, XL; Hadhazy, M; Groh, ME; Wheeler, MT; Wollmann, R; McNally, EM			Overexpression of gamma-sarcoglycan induces severe muscular dystrophy - Implications for the regulation of sarcoglycan assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; GENE-TRANSFER; MDX MICE; TRANSGENE EXPRESSION; MINIDYSTROPHIN GENE; BETA-SARCOGLYCAN; MUSCLE-FIBERS; DEFICIENCY; PROTEIN; MOUSE	The sarcoglycan complex is found normally at the plasma membrane of muscle. Disruption of the sarcoglycan complex, through primary gene mutations in dystrophin or sarcoglycan subunits, produces membrane instability and muscular dystrophy, Restoration of the sarcoglycan complex at the plasma membrane requires reintroduction of the mutant sarcoglycan subunit in a manner that will permit normal assembly of the entire sarcoglycan complex. To study sarcoglycan gene replacement, we introduced transgenes expressing murine gamma -sarcoglycan into muscle of normal mice. Mice expressing high levels of gamma -sarcoglycan, under the control of the muscle-specific creatine kinase promoter, developed a severe muscular dystrophy with greatly reduced muscle mass and early lethality. Marked gamma -sarcoglycan overexpression produced cytoplasmic aggregates that interfered with normal membrane targeting of gamma -sarcoglycan, Overexpression of gamma -sarcoglycan lead to the up-regulation of alpha- and beta -sarcoglycan. These data suggest that increased gamma -sarcoglycan and/or mislocalization of gamma -sarcoglycan to the cytoplasm is sufficient to induce muscle damage and provides a new model of muscular dystrophy that highlights the importance of this protein in the assembly, function, and downstream signaling of the sarcoglycan complex. Most importantly, gene dosage and promoter strength should be given serious consideration in replacement gene therapy to ensure safety in human clinical trials.	Univ Chicago, Dept Med, Cardiol Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Pathol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	McNally, EM (corresponding author), Univ Chicago, Dept Med, Cardiol Sect, 5841 S Maryland,MC 6088, Chicago, IL 60637 USA.		McNally, Elizabeth/W-4909-2019	Groh, Margaret/0000-0002-7473-597X; Wheeler, Matthew/0000-0001-8721-3022; McNally, Elizabeth/0000-0002-1221-719X	NHLBI NIH HHS [HL10288, HL61322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010288, R01HL061322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Cordier L, 2000, MOL THER, V1, P119, DOI 10.1006/mthe.1999.0019; COX GA, 1993, NATURE, V364, P725, DOI 10.1038/364725a0; Crosbie RH, 2000, HUM MOL GENET, V9, P2019, DOI 10.1093/hmg/9.13.2019; Hack AA, 2000, J CELL SCI, V113, P2535; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; Hack AA, 1999, P NATL ACAD SCI USA, V96, P10723, DOI 10.1073/pnas.96.19.10723; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOGAN B, 1994, MANIPULATING MOUSE E, P115; Holt KH, 1998, MOL CELL, V1, P841, DOI 10.1016/S1097-2765(00)80083-0; Kim S, 1997, J CLIN INVEST, V100, P1006, DOI 10.1172/JCI119611; Larochelle N, 1997, GENE THER, V4, P465, DOI 10.1038/sj.gt.3300414; LEE CC, 1993, HUM GENE THER, V4, P273, DOI 10.1089/hum.1993.4.3-273; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959, DOI 10.1093/jb/118.5.959; MATSUMURA K, 1993, J CLIN INVEST, V92, P866, DOI 10.1172/JCI116661; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; PUNKT K, 1987, ACTA HISTOCHEM, V82, P109, DOI 10.1016/S0065-1281(87)80061-2; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; Stedman Hansell, 2000, Human Gene Therapy, V11, P777; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Thompson TG, 2000, J CELL BIOL, V148, P115, DOI 10.1083/jcb.148.1.115; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; VINCENT N, 1993, NAT GENET, V5, P130, DOI 10.1038/ng1093-130; WEBSTER C, 1988, CELL, V52, P503, DOI 10.1016/0092-8674(88)90463-1; Zatz M, 2000, CURR OPIN NEUROL, V13, P511, DOI 10.1097/00019052-200010000-00002; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	29	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21785	21790		10.1074/jbc.M101877200	http://dx.doi.org/10.1074/jbc.M101877200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287429	hybrid			2022-12-25	WOS:000169297900129
J	Fujishiro, M; Gotoh, Y; Katagiri, H; Sakoda, H; Ogihara, T; Anai, M; Onishi, Y; Ono, H; Funaki, M; Inukai, K; Fukushima, Y; Kikuchi, M; Oka, Y; Asano, T				Fujishiro, M; Gotoh, Y; Katagiri, H; Sakoda, H; Ogihara, T; Anai, M; Onishi, Y; Ono, H; Funaki, M; Inukai, K; Fukushima, Y; Kikuchi, M; Oka, Y; Asano, T			MKK6/3 and p38 MAPK pathway activation is not necessary for insulin-induced glucose uptake but regulates glucose transporter expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; SKELETAL-MUSCLE CELLS; 3T3-L1 ADIPOCYTES; GLUT4 TRANSLOCATION; OSMOTIC SHOCK; RECEPTOR SUBSTRATE-1; GENE-TRANSCRIPTION	p38 mitogen-activated protein kinase (MAPK), which is situated downstream of MAPK kinase (MKK) 6 and MKK3, is activated by mitogenic or stress-inducing stimuli, as well as by insulin. To clarify the role of the MKK6/3-p38 MAPK pathway in the regulation of glucose transport, dominant negative p38 MAPK and MKK6 mutants and constitutively active MKK6 and MKK3 mutants were overexpressed in 3T3-L1 adipocytes and L6 myotubes using an adenovirus-mediated transfection procedure. Constitutively active MKK6/3 mutants up-regulated GLUT1 expression and down-regulated GLUT4 expression, thereby significantly increasing basal glucose transport but diminishing transport induced by insulin. Similar effects were elicited by chronic (24 h) exposure to tumor necrosis factor alpha, interleukin-1 beta, or 200 mM sorbitol, all activate the MKK6/3-p38 MAPK pathway. SB203580, a specific p38 MAPK inhibitor, attenuated these effects, further confirming that both MMK6 and MMK3 act via p38 MAPK,whereas they had no effect on the increase in glucose transport induced by a constitutively active MAPK kinase 1 (MEK1) mutant or by myristoylated Akt, In addition, suppression of p38 MAPK activation by overexpression of a dominant negative p38 MAPK or MKK6 mutant did not diminish insulin-induced glucose uptake by 3T3-L1 adipocytes, It is thus apparent that activation of p38 MAPK is not essential for insulin-induced increases in glucose uptake. Rather, p38 MAPK activation leads to a marked down-regulation of insulin-induced glucose uptake via GLUT4, which may underlie cellular stress-induced insulin resistance caused by tumor necrosis factor alpha and other factors.	Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dept Mol Biol, Bunkyo Ku, Tokyo 1130032, Japan; Asahi Life Fdn, Inst Adult Dis, Shinjuku Ku, Tokyo 1600023, Japan; Yamaguchi Univ, Sch Med, Dept Internal Med 3, Yamaguchi 7550067, Japan	University of Tokyo; University of Tokyo; Asahi Life Foundation; Yamaguchi University	Asano, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med 3, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	asano-tky@umin.ac.jp	Onishi, Yukiko/AAU-9057-2021	Onishi, Yukiko/0000-0003-1180-5982				Anai M, 1998, DIABETES, V47, P13, DOI 10.2337/diabetes.47.1.13; ASANO T, 1992, J BIOL CHEM, V267, P19636; Battelino T, 1999, J LAB CLIN MED, V133, P583, DOI 10.1016/S0022-2143(99)90188-9; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BURANT CF, 1991, RECENT PROG HORM RES, V47, P349; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; Fukuda M, 1997, J BIOL CHEM, V272, P32642, DOI 10.1074/jbc.272.51.32642; GOULD GW, 1994, CELL SIGNAL, V6, P313, DOI 10.1016/0898-6568(94)90036-1; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hansen LL, 1999, J BIOL CHEM, V274, P25078, DOI 10.1074/jbc.274.35.25078; Hansen PA, 1998, J BIOL CHEM, V273, P18173, DOI 10.1074/jbc.273.29.18173; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; KAESTNER KH, 1990, P NATL ACAD SCI USA, V87, P251, DOI 10.1073/pnas.87.1.251; KAHN B B, 1985, Diabetes Metabolism Reviews, V1, P203; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; KONO T, 1983, METHOD ENZYMOL, V98, P431; Long SD, 1996, BIOCHEM J, V319, P179, DOI 10.1042/bj3190179; Martin SS, 1996, J BIOL CHEM, V271, P17605, DOI 10.1074/jbc.271.30.17605; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; OKA Y, 1988, J BIOL CHEM, V263, P13432; OKA Y, 1984, J BIOL CHEM, V259, P8125; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Qi C, 2000, P SOC EXP BIOL MED, V223, P128, DOI 10.1046/j.1525-1373.2000.22318.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RICHARDSON JM, 1993, J BIOL CHEM, V268, P21021; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudich A, 1997, AM J PHYSIOL-ENDOC M, V272, pE935, DOI 10.1152/ajpendo.1997.272.5.E935; Rudich A, 1998, DIABETES, V47, P1562, DOI 10.2337/diabetes.47.10.1562; Sakoda H, 1999, DIABETES, V48, P1365, DOI 10.2337/diabetes.48.7.1365; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; Stephens JM, 1997, J BIOL CHEM, V272, P971, DOI 10.1074/jbc.272.2.971; Storz P, 1999, EUR J BIOCHEM, V266, P17, DOI 10.1046/j.1432-1327.1999.00809.x; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Taha C, 1997, AM J PHYSIOL-ENDOC M, V273, pE68, DOI 10.1152/ajpendo.1997.273.1.E68; Wang CN, 1998, DIABETES, V47, P24, DOI 10.2337/diabetes.47.1.24; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360	62	97	103	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19800	19806		10.1074/jbc.M101087200	http://dx.doi.org/10.1074/jbc.M101087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279172	hybrid			2022-12-25	WOS:000169135100018
J	Wojnar, P; Lechnar, M; Merschak, P; Redl, B				Wojnar, P; Lechnar, M; Merschak, P; Redl, B			Molecular cloning of a novel lipocalin-1 interacting human cell membrane receptor using phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; EBNERS GLAND PROTEIN; CDNA CLONING; ALPHA(1)-ACID GLYCOPROTEIN; GENE; EXPRESSION; FAMILY; MEMBER; SUPERFAMILY; MEGALIN	Human lipocalin-1 (Lcn-1, also called tear lipocalin), a member of the lipocalin structural superfamily, is produced by a number of glands and tissues and is known to bind an unusually large array of hydrophobic ligands, Apart from its specific function in stabilizing the lipid film of human tear fluid, it is suggested to act as a physiological scavenger of potentially harmful lipophilic compounds, in general, To characterize proteins involved in the reception, detoxification, or degradation of these ligands, a cDNA phage-display library from human pituitary gland was constructed and screened for proteins interacting with Lcn-1, Using this method an Lcn-1 interacting phage was isolated that expressed a novel human protein, Molecular cloning and analysis of the entire cDNA indicated that it encodes a 55-kDa protein, lipocalin-1 interacting membrane receptor (LIMR), with nine putative transmembrane domains. The cell membrane location of this protein was confirmed by immunocytochemistry and Western blot analysis of membrane fractions of human NT2 cells. Independent biochemical investigations using a recombinant N-terminal fragment of LIMR also demonstrated a specific interaction with Lcn-1 in vitro, Eased on these data, we suggest LIMR to be a receptor of Lcn-1 ligands, These findings constitute the first report of cloning of a lipocalin interacting plasma membrane-located receptor, in general, In addition, a sequence comparison supports the biological relevance of this novel membrane protein, because genes with significant nucleotide sequence similarity are present in Takifugu rubripes, Drosophila melanogaster, Caenorhabditis elegans, Mus musculus, Bos taurus, and Sus scrofa, According to data derived from the human genome sequencing project, the LIMR-encoding gene has to be mapped on human chromosome 12, and its intron/exon organization could be established. The entire LIMR-encoding gene consists of about 13.7 kilobases in length and contains 16 introns with a length between 91 and 3438 base pairs.	Univ Innsbruck, Sch Med, Dept Microbiol, A-6020 Innsbruck, Austria	University of Innsbruck	Redl, B (corresponding author), Univ Innsbruck, Sch Med, Dept Microbiol, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	bernard.redl@uribk.ac.at						Akerstrom B, 2000, BBA-PROTEIN STRUCT M, V1482, P1, DOI 10.1016/S0167-4838(00)00137-0; Andersen UO, 1996, J MOL RECOGNIT, V9, P364, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<364::AID-JMR266>3.0.CO;2-6; Andersen UO, 1999, ACTA HISTOCHEM, V101, P113, DOI 10.1016/S0065-1281(99)80011-7; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BAVIK CO, 1993, J BIOL CHEM, V268, P20540; BLAKER M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P131, DOI 10.1016/0167-4781(93)90279-M; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Boudjelal M, 1996, BIOCHEM J, V317, P23, DOI 10.1042/bj3170023; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAMERI R, 1993, GENE, V137, P69, DOI 10.1016/0378-1119(93)90253-Y; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P327, DOI 10.1016/S0167-4838(00)00169-2; Flower DR, 1996, BIOCHEM J, V318, P1; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; GLASGOW BJ, 1995, CURR EYE RES, V14, P363, DOI 10.3109/02713689508999934; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Holzfeind P, 1996, FEBS LETT, V395, P95, DOI 10.1016/0014-5793(96)01008-3; KANG AS, 1991, P NATL ACAD SCI USA, V88, P4363, DOI 10.1073/pnas.88.10.4363; KORENBERG JR, 1994, GENOMICS, V22, P88, DOI 10.1006/geno.1994.1348; Lacazette E, 2000, HUM MOL GENET, V9, P289, DOI 10.1093/hmg/9.2.289; LASSAGNE H, 1993, EXP EYE RES, V56, P605, DOI 10.1006/exer.1993.1075; Leheste JR, 1999, AM J PATHOL, V155, P1361, DOI 10.1016/S0002-9440(10)65238-8; LUGDBERG L, 2000, BIOCHIM BIOPHYS ACTA, V1482, P284; Miller RE, 1998, FEBS LETT, V436, P455, DOI 10.1016/S0014-5793(98)01184-3; MITTERDORFER J, 1994, FEBS LETT, V352, P141, DOI 10.1016/0014-5793(94)00938-4; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; NICOLETTI A, 1995, HUM MOL GENET, V4, P641, DOI 10.1093/hmg/4.4.641; NOY N, 1990, BIOCHEMISTRY-US, V29, P3613; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; REDL B, 1992, J BIOL CHEM, V267, P20282; Redl B, 1998, LAB INVEST, V78, P1121; Redl B, 2000, BBA-PROTEIN STRUCT M, V1482, P241, DOI 10.1016/S0167-4838(00)00142-4; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; ROBINSON GW, 1993, MOL CELL BIOL, V13, P2706, DOI 10.1128/MCB.13.5.2706; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; Scalfari F, 1997, COMP BIOCHEM PHYS B, V118, P819, DOI 10.1016/S0305-0491(97)00218-6; SENOO H, 1993, P NATL ACAD SCI USA, V90, P3616, DOI 10.1073/pnas.90.8.3616; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; SMELAND S, 1995, BIOCHEM J, V305, P419, DOI 10.1042/bj3050419; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; vantHof W, 1997, J BIOL CHEM, V272, P1837; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wester L, 1998, SCAND J IMMUNOL, V48, P1; XU S, 2000, BIOCHIM BIOPHYS ACTA, V1482, P289; Yusifov TN, 2000, BIOCHEM J, V347, P815, DOI 10.1042/0264-6021:3470815	46	57	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20206	20212		10.1074/jbc.M101762200	http://dx.doi.org/10.1074/jbc.M101762200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11287427	hybrid			2022-12-25	WOS:000169135100073
J	Ikushiro, H; Hayashi, H; Kagamiyama, H				Ikushiro, H; Hayashi, H; Kagamiyama, H			A water-soluble homodimeric serine palmitoyltransferase from Sphingomonas paucimobilis EY2395(T) strain - Purification, characterization, cloning, and overproduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID SYNTHESIS; BACILLUS-SPHAERICUS; ESCHERICHIA-COLI; BASE SYNTHESIS; ENZYME; LCB1; SACCHAROMYCES; SEQUENCE; GENE; BIOSYNTHESIS	Serine palmitoyltransferase (SPT, EC 2.3.1.50) is a key enzyme in sphingolipid biosynthesis and catalyzes the decarboxylative condensation of L-serine and palmitoylcoenzyme A to 3-ketodihydrosphingosine. We found that the Gram-negative obligatory aerobic bacteria Sphingomonas paucimobilis EY2395(T) have significant SPT activity and purified SPT to homogeneity. This enzyme is a water-soluble homodimeric protein unlike eukaryotic enzymes, known as heterodimers composed of tightly membrane-bound subunits, named LCB1 and LCB2. The purified SPT shows an absorption spectrum characteristic of a pyridoxal 5'-phosphate-dependent enzyme. The substrate specificity of the Sphingomonas SPT is less strict than the SPT complex from Chinese hamster ovary cells. We isolated the SPT gene encoding 420 amino acid residues (M-r 45,041) and succeeded in overproducing the SPT protein in Escherichia coli, in which the product amounted to about 10-20% of the total protein of the cell extract. Sphingomonas SPT shows about 30% homology with the enzymes of the alpha -oxamine synthase family, and amino acid residues supposed to be involved in catalysis are conserved. The recombinant SPT was catalytically and spectrophotometrically indistinguishable from the native enzyme. This is the first successful overproduction of an active enzyme in the sphingolipid biosynthetic pathway. Sphingomonas SPT is a prototype of the eukaryotic enzyme and would be a useful model to elucidate the reaction mechanism of SPT.	Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan	Osaka Medical College	Kagamiyama, H (corresponding author), Osaka Med Coll, Dept Biochem, Osaka 5698686, Japan.							Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AUSUBEL FM, 1994, CURRENT PROTOCOLS S, V27; Batrakov SG, 1999, BBA-MOL CELL BIOL L, V1440, P163, DOI 10.1016/S1388-1981(99)00119-5; BATRAKOV SG, 2000, BIOCHIM BIOPHYS ACTA, V148, P225; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; DROLET M, 1991, MOL GEN GENET, V226, P250, DOI 10.1007/BF00273610; GLOECKLER R, 1990, GENE, V87, P63, DOI 10.1016/0378-1119(90)90496-E; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hanada K, 2000, J BIOL CHEM, V275, P8409, DOI 10.1074/jbc.275.12.8409; Hanada K, 1998, J BIOL CHEM, V273, P33787, DOI 10.1074/jbc.273.50.33787; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Ikushiro H, 2000, BIOCHEMISTRY AND MOLECULAR BIOLOGY OF VITAMIN B6 AND PQQ-DEPENDENT PROTEINS, P251; KALLEN RG, 1985, TRANSAMINASES, P37; KAWASAKI S, 1994, J BACTERIOL, V176, P284, DOI 10.1128/JB.176.2.284-290.1994; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV M, 1981, ARCH BIOCHEM BIOPHYS, V212, P424, DOI 10.1016/0003-9861(81)90384-2; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P1, DOI 10.1016/0005-2760(90)90211-F; MUKHERJEE JJ, 1987, J BIOL CHEM, V262, P14441; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; PINTO WJ, 1992, J BACTERIOL, V174, P2565, DOI 10.1128/jb.174.8.2565-2574.1992; PLOUX O, 1992, BIOCHEM J, V283, P327, DOI 10.1042/bj2830327; Segel I. H., 1975, ENZYME KINETICS BEHA, P505; SNELL EE, 1970, CHEM PHYS LIPIDS, V5, P116, DOI 10.1016/0009-3084(70)90013-7; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; YABUUCHI E, 1979, J GEN APPL MICROBIOL, V25, P95, DOI 10.2323/jgam.25.95; YAMAMOTO A, 1978, J BIOCHEM-TOKYO, V83, P1213, DOI 10.1093/oxfordjournals.jbchem.a132015; YAMAMOTO A, 1982, J OSAKA CITY MED, V31, P201; YANO I, 1982, FEMS MICROBIOL LETT, V15, P303, DOI 10.1111/j.1574-6968.1982.tb00239.x	33	68	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18249	18256		10.1074/jbc.M101550200	http://dx.doi.org/10.1074/jbc.M101550200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279212	hybrid			2022-12-25	WOS:000168866500086
J	Liu, Y; MacDonald, RJ; Swift, GH				Liu, Y; MacDonald, RJ; Swift, GH			DNA binding and transcriptional activation by a PDX1 center dot PBX1b center dot MEIS2b trimer and cooperation with a pancreas-specific basic helix-loop-helix complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELASTASE-I ENHANCER; HOX PROTEINS; HOMEODOMAIN PROTEIN; CELL-LINES; INSULIN PROMOTER; TRANSGENIC MICE; PBX PROTEINS; SOMATOSTATIN PROMOTER; HOMEOBOX FACTOR; FACTOR STF-1	In pancreatic acinar cells, the HOX-like factor PDX1 acts as part of a trimeric complex with two TALE class homeodomain factors, PBX1b and MEIS2b, The complex binds to overlapping half-sites for PDX1 and PBX, The trimeric complex activates transcription in cells to a level about an order of magnitude greater than PDX1 alone. The N-terminal PDX1 activation domain is required for detectable transcriptional activity of the complex, even though PDX1 truncations bearing only the PDX1 C-terminal homeodomain and pentapeptide motifs can still participate in forming the trimeric complex. The conserved N-terminal PBC-B domain of PBX, as well as its homeodomain, is required for both complex formation and transcriptional activity. Only the N-terminal region of MEIS2, including the conserved MEIS domains, is required for formation of a trimer on DNA and transcriptional activity: the MEIS homeodomain is dispensable. The activity of the pancreas-specific ELA1 enhancer requires the cooperation of the trimer-binding element and a nearby element that binds the pancreatic transcription factor PTF1, We show that the PDX1 PBX1b. MEIS2b complex cooperates with the PTF1 basic helix-loop-helix complex to activate an ELA1 minienhancer in HeLa cells and that this cooperation requires all three homeoprotein subunits, including the PDX1 activation domain.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Swift, GH (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		MacDonald, Ray/AAA-1290-2022; Liu, Ying/C-2734-2008		NIDDK NIH HHS [DK-55266] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055266] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; Bromleigh VC, 2000, GENE DEV, V14, P2581, DOI 10.1101/gad.817100; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; BURGLIN TR, 1992, NAT GENET, V1, P319, DOI 10.1038/ng0892-319; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Carty MD, 1997, J BIOL CHEM, V272, P11986, DOI 10.1074/jbc.272.18.11986; Chan SK, 1996, P NATL ACAD SCI USA, V93, P5223, DOI 10.1073/pnas.93.11.5223; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; COCKELL M, 1989, MOL CELL BIOL, V9, P2464, DOI 10.1128/MCB.9.6.2464; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Ferretti E, 2000, DEVELOPMENT, V127, P155; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; GUZ Y, 1995, DEVELOPMENT, V121, P11; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; JESSOP NW, 1980, IN VITRO CELL DEV B, V16, P212; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Krapp A, 1996, EMBO J, V15, P4317, DOI 10.1002/j.1460-2075.1996.tb00806.x; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KRUSE F, 1995, MOL CELL BIOL, V15, P4385; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; Lu M, 1996, ENDOCRINOLOGY, V137, P2959, DOI 10.1210/en.137.7.2959; Lu Q, 1996, P NATL ACAD SCI USA, V93, P470, DOI 10.1073/pnas.93.1.470; Lu Q, 1996, MOL CELL BIOL, V16, P1632; MacDonald RJ, 1998, INT J DEV BIOL, V42, P983; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; ROSE SD, 1994, MOL CELL BIOL, V14, P2048, DOI 10.1128/MCB.14.3.2048; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Sharkey M, 1997, TRENDS GENET, V13, P145, DOI 10.1016/S0168-9525(97)01096-2; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; SWIFT GH, 1989, GENE DEV, V3, P687, DOI 10.1101/gad.3.5.687; SWIFT GH, 1994, J BIOL CHEM, V269, P12809; Swift GH, 1998, MOL CELL BIOL, V18, P5109, DOI 10.1128/MCB.18.9.5109; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478	55	56	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17985	17993		10.1074/jbc.M100678200	http://dx.doi.org/10.1074/jbc.M100678200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279116	hybrid			2022-12-25	WOS:000168866500050
J	Verrecchia, F; Chu, ML; Mauviel, A				Verrecchia, F; Chu, ML; Mauviel, A			Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TRANSCRIPTION FACTOR SP1; HUMAN SKIN FIBROBLASTS; TERMINAL KINASE JNK; COLLAGEN GENE; FUNCTIONAL-CHARACTERIZATION; PROMOTER ACTIVITY; HUMAN ALPHA-1(I); COL7A1 PROMOTER; EXPRESSION	Despite major advances in the understanding of the intimate mechanisms of transforming growth factor-beta (TGF-beta) signaling through the Smad pathway, little progress has been made in the identification of direct target genes. In this report, using cDNA microarrays, we have focussed our attention on the characterization of extracellular matrix-related genes rapidly induced by TGF-beta in human dermal fibroblasts and attempted to identify the ones whose up-regulation by TGF-beta is Smad-mediated. For a gene to qualify as a direct Smad target, we postulated that it had to meet the following criteria: (1) rapid (30 min) and significant (at least S-fold) elevation of steady-state mRNA levels upon TGF-beta stimulation, (2) activation of the promoter by both exogenous TGF-beta and co-transfected Smad3 expression vector, (3) up-regulation of promoter activity by TGF-beta blocked by both dominant-negative Smad3 and inhibitory Smad7 expression vectors, and (4) promoter transactivation by TGF-beta not possible in Smad3(-/-) mouse embryo fibroblasts. Using this stringent approach, we have identified COL1A2, COL3A1, COL6A1, COL6A3, and tissue inhibitor of metalloproteases-1 as definite TGF-beta /Smad3 targets. Extrapolation of this approach to other extracellular matrix-related gene promoters also identified COL1A1 and COL5A2, but not COL6A2, as novel Smad targets. Together, these results represent a significant step toward the identification of novel, early-induced Smad-dependent TGF-beta target genes in fibroblasts.	Hop St Louis, INSERM U532, Inst Rech Peau, F-75475 Paris 10, France; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Jefferson University	Mauviel, A (corresponding author), Hop St Louis, INSERM U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	mauviel@chu-stlouis.fr	MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038912] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38912] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Border WA, 1997, KIDNEY INT, V51, P1388, DOI 10.1038/ki.1997.190; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; COCKAYNE D, 1988, BIOCHEMISTRY-US, V27, P2736, DOI 10.1021/bi00408a013; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HATA RI, 1995, CELL BIOL INT, V19, P735, DOI 10.1006/cbir.1995.1124; HECKMANN M, 1992, FEBS LETT, V310, P79, DOI 10.1016/0014-5793(92)81151-B; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Iozzo RV, 1997, J BIOL CHEM, V272, P5219, DOI 10.1074/jbc.272.8.5219; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; KHALIL N, 1991, CIBA F SYMP, V157, P194; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Letterio JJ, 1997, CLIN IMMUNOL IMMUNOP, V84, P244, DOI 10.1006/clin.1997.4409; LI LY, 1995, GENE, V164, P229, DOI 10.1016/0378-1119(95)00508-4; Martin M, 2000, INT J RADIAT ONCOL, V47, P277, DOI 10.1016/S0360-3016(00)00435-1; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MUDRYJ M, 1988, NUCLEIC ACIDS RES, V16, P7513, DOI 10.1093/nar/16.15.7513; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; SAITTA B, 1995, EUR J BIOCHEM, V234, P542, DOI 10.1111/j.1432-1033.1995.542_b.x; SAITTA B, 1994, EUR J BIOCHEM, V223, P675, DOI 10.1111/j.1432-1033.1994.tb19040.x; SANDMEYER S, 1981, J BIOL CHEM, V256, P5022; Taylor LM, 2000, J BIOL CHEM, V275, P16709, DOI 10.1074/jbc.275.22.16709; TRUTER S, 1992, J BIOL CHEM, V267, P25389; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1997, J BIOL CHEM, V272, P10196; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	50	518	553	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17058	17062		10.1074/jbc.M100754200	http://dx.doi.org/10.1074/jbc.M100754200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279127	hybrid			2022-12-25	WOS:000168730400061
J	Connor, MK; Irrcher, I; Hood, DA				Connor, MK; Irrcher, I; Hood, DA			Contractile activity-induced transcriptional activation of cytochrome c involves Sp1 and is proportional to mitochondrial ATP synthesis in C2C12 muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY GENE-EXPRESSION; RAT SKELETAL-MUSCLE; ELECTRICAL-STIMULATION; DEPENDENT REGULATION; CARDIAC MYOCYTES; MESSENGER-RNAS; NUCLEAR; PROTEINS; CALCIUM; DIFFERENTIATION	Contractile activity induces adaptations in the expression of genes encoding skeletal muscle mitochondrial proteins; however, the putative signals responsible for these adaptations remain unknown. We used electrical stimulation (5 Hz, 65 V) of C2C12 muscle cells in culture to define some of the mechanisms involved in contractile activity-induced changes in cytochrome c gene expression. Chronic contractile activity (4 days, 3 h/day) augmented cytochrome c mRNA by 1.6-fold above control cells. This was likely mediated by increases in transcriptional activation, because cells transfected with full-length (-726 base pairs) or minimal (-66 base pairs) cytochrome c promoter/chloramphenicol acetyltransferase reporter constructs demonstrated contractile activity-induced 1.5-1.7-fold increases in the absence of contractile activity-induced increases in mRNA stability. Transcriptional activation of the -726 promoter was abolished when muscle contraction was inhibited at various subcellular locations by pretreatment with either the Na+ channel blocker tetrodotoxin, the intracellular Ca2+ chelator 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethyl) ester, or the myosin ATPase inhibitor 2,3-butanedione monoxime. It was further reduced in unstimulated cells when mitochondrial ATP synthesis was impaired using the uncoupler 2,4-dinitrophenol. Because the contractile activity-induced response was evident within the minimal promoter, electromobility shift assays performed within the first intron (+75 to +104 base pairs) containing Sp1 sites revealed an elevated DNA binding in response to contractile activity. This was paralleled by increases in Sp1 protein levels. Sp1 overexpression studies also led to increases in cytochrome c transactivation and mRNA levels. These data suggest that variations in the rate of mitochondrial ATP synthesis are important in determining cytochrome c gene expression in muscle cells and that this is mediated, in part, by Sp1-induced increases in cytochrome c transcription.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; York Univ, Dept Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada	York University - Canada; York University - Canada	Hood, DA (corresponding author), York Univ, Dept Biol, 4700 Keele St, N York, ON M3J 1P3, Canada.	dhood@yorku.ca						ABUSHAKRA SR, 1993, MOL BRAIN RES, V18, P216, DOI 10.1016/0169-328X(93)90192-R; ABUSHAKRA SR, 1994, MOL BRAIN RES, V26, P55, DOI 10.1016/0169-328X(94)90073-6; Aronson D, 1997, J BIOL CHEM, V272, P25636, DOI 10.1074/jbc.272.41.25636; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREVET A, 1976, SCIENCE, V193, P1152, DOI 10.1126/science.959833; Byron KL, 1996, AM J PHYSIOL-CELL PH, V271, pC1447, DOI 10.1152/ajpcell.1996.271.5.C01447; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; Connor MK, 1996, ARCH BIOCHEM BIOPHYS, V333, P103, DOI 10.1006/abbi.1996.0369; Eble DM, 1998, AM J PHYSIOL-CELL PH, V274, pC1226, DOI 10.1152/ajpcell.1998.274.5.C1226; Essig D A, 1996, Exerc Sport Sci Rev, V24, P289; EVANS MJ, 1988, MOL CELL BIOL, V8, P35, DOI 10.1128/MCB.8.1.35; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; Fields RD, 1997, J NEUROSCI, V17, P7252; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Freyssenet D, 1999, AM J PHYSIOL-ENDOC M, V277, pE26, DOI 10.1152/ajpendo.1999.277.1.E26; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HOOD DA, 1989, EUR J BIOCHEM, V179, P275, DOI 10.1111/j.1432-1033.1989.tb14551.x; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Huang RP, 1997, J CELL BIOCHEM, V66, P489, DOI 10.1002/(SICI)1097-4644(19970915)66:4<489::AID-JCB8>3.0.CO;2-H; Khayat ZA, 1998, AM J PHYSIOL-CELL PH, V275, pC1487, DOI 10.1152/ajpcell.1998.275.6.C1487; MCDONOUGH PM, 1992, J BIOL CHEM, V267, P11665; MICHEL JB, 1994, J CLIN INVEST, V94, P277, DOI 10.1172/JCI117318; NELSON BD, 1995, BBA-MOL BASIS DIS, V1271, P85, DOI 10.1016/0925-4439(95)00014-U; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Robey RB, 1996, BIOTECHNIQUES, V20, P40; SCHMIDT J, 1995, REV PHYSL BIOCH PHAR, V127, P251; SELLIN LC, 1994, PHARMACOL TOXICOL, V74, P305, DOI 10.1111/j.1600-0773.1994.tb01365.x; Silverman ES, 1997, AM J PHYSIOL-HEART C, V273, pH1415, DOI 10.1152/ajpheart.1997.273.3.H1415; WEHRLE U, 1994, DIFFERENTIATION, V58, P37, DOI 10.1046/j.1432-0436.1994.5810037.x; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; Xia Y, 1998, J BIOL CHEM, V273, P12593, DOI 10.1074/jbc.273.20.12593; Xia Y, 1996, J BIOL CHEM, V271, P12082, DOI 10.1074/jbc.271.20.12082; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; Yan Z, 1996, AM J PHYSIOL-CELL PH, V271, pC1157, DOI 10.1152/ajpcell.1996.271.4.C1157; Zaid A, 1999, J BIOENERG BIOMEMBR, V31, P129, DOI 10.1023/A:1005499727732	38	43	47	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15898	15904		10.1074/jbc.M100272200	http://dx.doi.org/10.1074/jbc.M100272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279044	hybrid			2022-12-25	WOS:000168623100046
J	Keshvara, L; Benhayon, D; Magdaleno, S; Curran, T				Keshvara, L; Benhayon, D; Magdaleno, S; Curran, T			Identification of reelin-induced sites of tyrosyl phosphorylation on disabled 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LAMINAR ORGANIZATION; NEURONAL MIGRATION; CYTOSOLIC ADAPTER; BIPOLAR DISORDER; VLDL RECEPTOR; MUTANT MOUSE; PROTEIN; KINASES; BRAIN	The study of mice with spontaneous and targeted mutations has uncovered a signaling pathway that controls neuronal positioning during mammalian brain development. Mice with disruptions in reelin, dab1, or both vldlr and apoER2 are ataxic, and they exhibit severe lamination defects within several brain structures. Reelin is a secreted extracellular protein that binds to the very low density lipoprotein receptor and the apolipoprotein E receptor 2 on the surface of neurons. Disabled-1 (Dab1), an intracellular adapter protein containing a PTB (phosphotyrosine binding) domain, is tyrosyl-phosphorylated during embryogenesis, but it accumulates in a hypophosphorylated form in mice lacking Reelin or both very low density lipoprotein receptor and apolipoprotein E receptor 2, Dab1 is rapidly phosphorylated when neurons isolated from embryonic brains are stimulated with Reelin, and several tyrosines have been implicated in this response. Mice with phenylalanine substitutions of all five tyrosines (Tyr(185), Tyr(198), Tyr(200), Tyr(220), and Tyr(232)) exhibit a reeler phenotype, implying that tyrosine phosphorylation is critical for Dab1 function. Here we report that, although Src can phosphorylate all five tyrosines in vitro, Tyr(198) and Tyr(220) represent the major sites of Reelin-induced Dab1 phosphorylation in embryonic neurons.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	fos1@aol.com	Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036558] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NINDS NIH HHS [R01-NS36558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHEN WJ, 1990, J BIOL CHEM, V265, P3116; D'Arcangelo G, 1998, BIOESSAYS, V20, P235, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;235::AID-BIES7&gt;3.0.CO;2-Q; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Fatemi SH, 2000, MOL PSYCHIATR, V5, P654, DOI 10.1038/sj.mp.4000783; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Guidotti A, 2000, ARCH GEN PSYCHIAT, V57, P1061, DOI 10.1001/archpsyc.57.11.1061; Hatten ME, 1999, ANNU REV NEUROSCI, V22, P511, DOI 10.1146/annurev.neuro.22.1.511; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Hong SE, 2000, NAT GENET, V26, P93, DOI 10.1038/79246; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Rice DS, 1998, DEVELOPMENT, V125, P3719; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; Yoneshima H, 1997, NEUROSCI RES, V29, P217, DOI 10.1016/S0168-0102(97)00088-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	32	106	115	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16008	16014		10.1074/jbc.M101422200	http://dx.doi.org/10.1074/jbc.M101422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279201	hybrid			2022-12-25	WOS:000168623100060
J	Lim, HW; New, L; Han, JH; Molkentin, JD				Lim, HW; New, L; Han, JH; Molkentin, JD			Calcineurin enhances MAPK phosphatase-1 expression and p38 MAPK inactivation in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED-PROTEIN-KINASE; INDUCED CARDIOMYOCYTE HYPERTROPHY; SIGNAL-REGULATED KINASE; GENE-TRANSCRIPTION; TRANSGENIC MICE; HEART-FAILURE; GROWTH-FACTOR; CELL-GROWTH; IN-VIVO; PATHWAYS	Multiple intracellular signaling pathways have been shown to regulate the hypertrophic growth of cardiac myocytes including mitogen-activated protein kinase (MAPK) and calcineurin-nuclear factor of activated T-cells. However, it is uncertain if individual regulatory pathways operate in isolation or if interconnectivity between unrelated pathways is required for the orchestration of the entire hypertrophic response. To this end, we investigated the interconnectivity between calcineurin-mediated cardiac myocyte hypertrophy and p38 MAPK signaling in vitro and in vivo. We show that calcineurin promotes down-regulation of p38 MAPK activity and enhances expression of the dual specificity phosphatase MAPK phosphatase-1 (MKP-1). Transgenic mice expressing activated calcineurin in the heart were characterized by inactivation of p38 and increased MKP-1 expression during early postnatal development, before the onset of cardiac hypertrophy, In vitro, cultured neonatal cardiomyocytes infected with a calcineurin-expressing adenovirus and stimulated with phenylephrine demonstrated reduced p38 phosphorylation and increased MKP-1 protein levels. Activation of endogenous calcineurin with the calcium ionophore A23187 decreased p38 phosphorylation and increased MKP-1 protein levels. Inhibition of endogenous calcineurin with cyclosporin A decreased MKP-1 protein levels and increased p38 activation in response to agonist stimulation. To further investigate potential cross-talk between calcineurin and p38 through alteration in MKP-1 expression, the MKP-1 promoter was characterized and determined to be calcineurin-responsive. These data suggest that calcineurin enhances MKP-1 expression in cardiac myocytes, which is associated with p38 inactivation.	Univ Cincinnati, Childrens Hosp, Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; Scripps Research Institute	Molkentin, JD (corresponding author), Childrens Hosp, Med Ctr, Dept Pediat, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Han, J/G-4671-2010	Molkentin, Jeffery/0000-0002-3558-6529				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Chajry N, 1996, EUR J BIOCHEM, V235, P97, DOI 10.1111/j.1432-1033.1996.00097.x; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; Durham PL, 2000, MOL ENDOCRINOL, V14, P1570, DOI 10.1210/me.14.10.1570; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; HINES WA, 1999, AM J PHYSIOL, V277, pH311; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; MASADU ES, 1995, MOL CELL BIOL, V15, P267; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Parameswaran N, 2000, EUR J PHARMACOL, V388, P133, DOI 10.1016/S0014-2999(99)00848-1; Sommer A, 2000, FEBS LETT, V474, P146, DOI 10.1016/S0014-5793(00)01566-0; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Sussman MA, 1999, AM J PATHOL, V155, P2101, DOI 10.1016/S0002-9440(10)65528-9; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; van Zwieten PA, 2000, CARDIOVASC RES, V45, P82, DOI 10.1016/S0008-6363(99)00291-6; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	34	74	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15913	15919		10.1074/jbc.M100452200	http://dx.doi.org/10.1074/jbc.M100452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279073	hybrid			2022-12-25	WOS:000168623100048
J	Radaev, S; Motyka, S; Fridman, WH; Sautes-Fridman, C; Sun, PD				Radaev, S; Motyka, S; Fridman, WH; Sautes-Fridman, C; Sun, PD			The structure of a human type III Fc gamma receptor in complex with Fc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT ANTIDANSYL ANTIBODIES; LOW-AFFINITY RECEPTOR; EPSILON-RI-ALPHA; IGG BINDING-SITE; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; MONOCLONAL-ANTIBODY; DOMAIN; FRAGMENT; IDENTIFICATION	Fc gamma receptors mediate antibody-dependent inflammatory responses and cytotoxicity as well as certain autoimmune dysfunctions. Here we report the crystal structure of a human Fc receptor (Fc gamma RIIIB) in complex with an Fc fragment of human IgG1 determined from orthorhombic and hexagonal crystal forms at 3.0- and 3.5-Angstrom resolution, respectively. The refined structures from the two crystal forms are nearly identical with no significant discrepancies between the coordinates. Regions of the C-terminal domain of Fc gamma RIII, including the BC, C'E, FG loops, and the C' beta -strand, bind asymmetrically to the lower hinge region, residues Leu(234)-Pro(238), Of both Fe chains creating a 1:1 receptor-ligand stoichiometry. Minor conformational changes are observed in both the receptor and Fc upon complex formation. Hydrophobic residues, hydrogen bonds, and salt bridges are distributed throughout the receptor le interface. Sequence comparisons of the receptor-ligand interface residues suggest a conserved binding mode common to all members of immunoglobulin-like Fc receptors, Structural comparison between Fc gamma RIII.Fc and Fc epsilon RI.Fc complexes highlights the differences in ligand recognition between the high and low affinity receptors, Although not in direct contact with the receptor, the carbohydrate attached to the conserved glycosylation residue Asn(297) On Fc may stabilize the conformation of the receptor-binding epitope on Fc. An antibody-Fc gamma RIII model suggests two possible ligand-induced receptor aggregations.	NIAID, Struct Biol Sect, Immunogenet Lab, NIH, Rockville, MD 20852 USA; Johns Hopkins Univ, Sch Med, Biochem Cellular & Mol Biol Program, Baltimore, MD 21205 USA; Inst Curie, INSERM, U255, Lab Cellular & Clin Immunol, F-75005 Paris, France	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Sun, PD (corresponding author), NIAID, Struct Biol Sect, Immunogenet Lab, NIH, 12441 Parklawn Dr, Rockville, MD 20852 USA.			fridman, wolf herman/0000-0002-1332-0973; sautes-fridman, catherine/0000-0003-1735-8722	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000853, ZIAAI000853] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOROS P, 1994, J IMMUNOL, V152, P302; Boyington JC, 2000, NATURE, V405, P537, DOI 10.1038/35014520; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Galon J, 1997, EUR J IMMUNOL, V27, P1928, DOI 10.1002/eji.1830270816; Galon J, 1996, J IMMUNOL, V157, P1184; Garman SC, 2000, NATURE, V406, P259, DOI 10.1038/35018500; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; HARRIS LJ, 1992, NATURE, V360, P369, DOI 10.1038/360369a0; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; HIBBS ML, 1994, J IMMUNOL, V152, P4466; HULETT MD, 1995, J BIOL CHEM, V270, P21188, DOI 10.1074/jbc.270.36.21188; HULETT MD, 1994, J BIOL CHEM, V269, P15287; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; Jefferis R, 1998, IMMUNOL REV, V163, P59, DOI 10.1111/j.1600-065X.1998.tb01188.x; JEFFERIS R, 1995, IMMUNOL LETT, V44, P111, DOI 10.1016/0165-2478(94)00201-2; KATO K, 1991, BIOCHEMISTRY-US, V30, P6604, DOI 10.1021/bi00240a033; KATO K, 1991, BIOCHEMISTRY-US, V30, P270, DOI 10.1021/bi00215a037; Kato K, 2000, J MOL BIOL, V295, P213, DOI 10.1006/jmbi.1999.3351; KIMBERLY RP, 1990, J EXP MED, V171, P1239, DOI 10.1084/jem.171.4.1239; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P829, DOI 10.1107/S0907444996001783; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LUND J, 1991, J IMMUNOL, V147, P2657; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Powell MS, 1999, IMMUNOL LETT, V68, P17, DOI 10.1016/S0165-2478(99)00025-5; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Tamm A, 1997, Int Rev Immunol, V16, P57, DOI 10.3109/08830189709045703; Tamm A, 1996, J BIOL CHEM, V271, P3659; Unkeless J C, 1995, Semin Immunol, V7, P37, DOI 10.1016/1044-5323(95)90006-3; ZHAN GY, 2000, IMMUNITY, V13, P387	46	293	378	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16469	16477		10.1074/jbc.M100350200	http://dx.doi.org/10.1074/jbc.M100350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11297532	hybrid			2022-12-25	WOS:000168623100120
J	Yada, T; Sugiura, R; Kita, A; Itoh, Y; Lu, YB; Hong, YJ; Kinoshita, T; Shuntoh, H; Kuno, T				Yada, T; Sugiura, R; Kita, A; Itoh, Y; Lu, YB; Hong, YJ; Kinoshita, T; Shuntoh, H; Kuno, T			Its8, a fission yeast homolog of Mcd4 and Pig-n, is involved in GPI anchor synthesis and shares an essential function with calcineurin in cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; CELL INTEGRITY; CYCLOSPORINE-A; FIRST STEP; GENE; GLYCOSYLPHOSPHATIDYLINOSITOL; BIOSYNTHESIS; EXPRESSION	In fission yeast, calcineurin is required for cytokinesis and ion homeostasis; however, most of its physiological roles remain obscure. To identify genes that share an essential function with calcineurin, we screened for mutations that confer sensitivity to the calcineurin inhibitor FK506 and high temperature and isolated the mutant its8-1. its8(+) encodes a homolog of the budding yeast MCD4 and human Pig-n that are involved in glycosylphosphatidylinositol (GPI) anchor synthesis. Consistently, reduced inositol labeling of proteins suggested impaired GPI anchor synthesis in its8-1 mutants. The temperature upshift induced a further decrease in inositol labeling and caused dramatic increases in the frequency of septation in its8-1 mutants. BE49385A, an inhibitor of MCD4 and Pig-n, also increased the septation index of the wild-type cell. Osmotic stabilization suppressed these morphological defects, indicating that cell wall weakness caused by impaired GPI anchor synthesis resulted in abnormal cytokinesis. Furthermore, calcineurin-deleted cells exhibited hypersensitivity to BE49385A, and FK506 exacerbated the cytokinesis defects of the its8-1 mutant, Thus, calcineurin and Its8 may share an essential function in cytokinesis and cell viability through the regulation of cell wall integrity.	Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, Kobe, Hyogo 6500017, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Immunoregulat, Suita, Osaka 5650871, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Kobe, Hyogo 6540142, Japan	Kobe University; Osaka University; Kobe University	Kuno, T (corresponding author), Kobe Univ, Sch Med, Dept Pharmacol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@kobe-u.ac.jp	Kinoshita, Taroh/C-7353-2009					Arellano M, 1999, J CELL SCI, V112, P3569; BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; Gaynor EC, 1999, MOL BIOL CELL, V10, P627, DOI 10.1091/mbc.10.3.627; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HELM R, 1995, NATURE, V373, P663; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Hong YJ, 1999, J BIOL CHEM, V274, P35099, DOI 10.1074/jbc.274.49.35099; Ishiguro J, 1997, J BACTERIOL, V179, P7653, DOI 10.1128/jb.179.24.7653-7662.1997; LEIDICH SD, 1995, METHOD ENZYMOL, V250, P560; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; LU CF, 1995, J CELL BIOL, V128, P333, DOI 10.1083/jcb.128.3.333; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Mondesert G, 1996, J CELL BIOL, V132, P137, DOI 10.1083/jcb.132.1.137; Mondesert G, 1997, GENETICS, V147, P421; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PLOCHOCKAZULINSKA D, 1995, J BIOL CHEM, V270, P24794, DOI 10.1074/jbc.270.42.24794; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Sutterlin C, 1998, BIOCHEM J, V332, P153; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tiede A, 1999, BIOL CHEM, V380, P503, DOI 10.1515/BC.1999.066; Toda T, 1996, MOL CELL BIOL, V16, P6752; Tujioka H, 1998, BIOCHEM BIOPH RES CO, V251, P737, DOI 10.1006/bbrc.1998.9542; VANDENKAPTEYN JC, 1999, BIOCHIM BIOPHYS ACTA, V1426, P373; Wang YX, 1996, MOL BIOL CELL, V7, P1375, DOI 10.1091/mbc.7.9.1375; YAMAGUCHI H, 1982, J ANTIBIOT, V35, P210, DOI 10.7164/antibiotics.35.210; YOSHIDA T, 1994, J CELL SCI, V107, P1725; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	41	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13579	13586		10.1074/jbc.M009260200	http://dx.doi.org/10.1074/jbc.M009260200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297516	hybrid			2022-12-25	WOS:000168356600012
J	Lepple-Wienhues, A; Wieland, U; Laun, T; Heil, L; Stern, M; Lang, F				Lepple-Wienhues, A; Wieland, U; Laun, T; Heil, L; Stern, M; Lang, F			A src-like kinase activates outwardly rectifying chloride channels in CFTR-defective lymphocytes	FASEB JOURNAL			English	Article						cystic fibrosis; tyrosine kinase; human lymphocytes; cyclic adenosine monophosphate; cell volume	TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS AIRWAY; APICAL-MEMBRANE; EPITHELIAL-CELLS; T-LYMPHOCYTES; CL CHANNEL; RESPIRATORY EPITHELIUM; ION CHANNELS; CAMP; PROTEIN	Defective activation of chloride channels is a hallmark of cystic fibrosis (CF). Recently we have described activation of a volume-sensitive, outwardly rectifying chloride conductance (I-OR) through the src-like tyrosine kinase p56(lck). Here we show that p56(lck) activates I-OR independently of CFTR. In lymphocytes from healthy donors, chloride channels could be opened by either intracellular cAMP, p56(lck) or osmotic swelling. In CF lymphocytes, p56(lck) and cell swelling but not cAMP could activate chloride channels. Regulation of I-OR by p56(lck) thus represents an alternative pathway of stimulating membrane chloride conductance that is left intact in cystic fibrosis.	Univ Tubingen, Inst Physiol, Dept Physiol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Lepple-Wienhues, A (corresponding author), Univ Tubingen, Inst Physiol, Dept Physiol, Gmelinstr 5, D-72076 Tubingen, Germany.	alepplew@uni-tuebingen.de						ALLERT N, 1992, PFLUG ARCH EUR J PHY, V421, P403, DOI 10.1007/BF00374233; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; CHEN JH, 1989, SCIENCE, V243, P657, DOI 10.1126/science.2464852; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; CUNNINGHAM SA, 1992, AM J PHYSIOL, V262, P783; CUTHBERT AW, 1994, BRIT J PHARMACOL, V112, P31, DOI 10.1111/j.1476-5381.1994.tb13024.x; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; Fischer H, 1996, BIOPHYS J, V71, P3073, DOI 10.1016/S0006-3495(96)79501-2; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; Greger R, 1996, J MOL MED-JMM, V74, P527; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KRAUSS RD, 1992, EMBO J, V11, P875, DOI 10.1002/j.1460-2075.1992.tb05125.x; KROUSE ME, 1994, AM J PHYSIOL, V267, pC642, DOI 10.1152/ajpcell.1994.267.2.C642; KUNZELMANN K, 1989, PFLUG ARCH EUR J PHY, V415, P172, DOI 10.1007/BF00370589; KUNZELMANN K, 1995, PFLUG ARCH EUR J PHY, V431, P1, DOI 10.1007/BF00374371; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; MCDONALD TV, 1992, J BIOL CHEM, V267, P3242; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSS PE, 1994, BIOPHYS J, V66, P169, DOI 10.1016/S0006-3495(94)80754-4; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; SOLC CK, 1991, AM J PHYSIOL, V261, pC658, DOI 10.1152/ajpcell.1991.261.4.C658; Sorota S, 1995, PFLUG ARCH EUR J PHY, V431, P178, DOI 10.1007/BF00410189; SOROTA S, 1992, CIRC RES, V70, P679, DOI 10.1161/01.RES.70.4.679; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Voets T, 1998, J PHYSIOL-LONDON, V506, P341, DOI 10.1111/j.1469-7793.1998.341bw.x; WELSH MJ, 1986, SCIENCE, V232, P1648, DOI 10.1126/science.2424085; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1990, FASEB J, V4, P2718, DOI 10.1096/fasebj.4.10.1695593; WELSH MJ, 1989, ANN NY ACAD SCI, V574, P44; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	51	21	23	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					927	931		10.1096/fj.00-0264com	http://dx.doi.org/10.1096/fj.00-0264com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292652				2022-12-25	WOS:000167959300006
J	Yamamoto, H; Hinoi, T; Michiue, T; Fukui, A; Usui, H; Janssens, V; Van Hoof, C; Goris, J; Asashima, M; Kikuchi, A				Yamamoto, H; Hinoi, T; Michiue, T; Fukui, A; Usui, H; Janssens, V; Van Hoof, C; Goris, J; Asashima, M; Kikuchi, A			Inhibition of the Wnt signaling pathway by the PR61 subunit of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; GLYCOGEN-SYNTHASE KINASE-3-BETA; APC TUMOR-SUPPRESSOR; F-BOX PROTEIN; BETA-CATENIN; NEGATIVE REGULATOR; AXIS FORMATION; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; FUNCTIONAL INTERACTION; CATALYTIC SUBUNIT	Axin, a negative regulator of the Wnt signaling pathway, forms a complex with glycogen synthase kinase-3 beta (GSK-3 beta), beta -catenin, adenomatous polyposis coli (APC) gene product, and Dvl, and it regulates GSK-3 beta -dependent phosphorylation in the complex and the stability of beta -catenin. Using yeast two-hybrid screening, we found that regulatory subunits of protein phosphatase 2A, PR61 beta and -gamma, interact with Axin. PR61 beta or -gamma formed a complex with Axin in intact cells, and their interaction was direct. The binding site of PR61 beta on Axin was different from those of GSK-3 beta, beta -catenin, APC, and Dvl. Although PR61 beta did not affect the stability of beta -catenin, it inhibited Dvl- and beta -catenin-dependent T cell factor activation in mammalian cells. Moreover, it suppressed beta -catenin-induced axis formation and expression of siamois, a Wnt target gene, in Xenopus embryos, suggesting that PR61 beta acts either at the level of beta -catenin or downstream of it. Taken together with the previous observations that PR61 interacts with APC and functions upstream of beta -catenin, these results demonstrate that PR61 regulates the Wnt signaling pathway at various steps.	Hiroshima Univ, Fac Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; Univ Tokyo, Dept Life Sci Biol, Meguro Ku, Tokyo 1538902, Japan; Univ Tokyo, Crest Project, Meguro Ku, Tokyo 1538902, Japan; Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	Hiroshima University; University of Tokyo; Japan Science & Technology Agency (JST); University of Tokyo; KU Leuven	Kikuchi, A (corresponding author), Hiroshima Univ, Fac Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp	Janssens, Veerle/I-7059-2016; Fukui, Akimasa/F-5284-2011	Janssens, Veerle/0000-0002-6772-8448; 				Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dale TC, 1998, BIOCHEM J, V329, P209; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 1999, CYTOKINE GROWTH F R, V10, P255, DOI 10.1016/S1359-6101(99)00017-9; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Okazaki M, 1996, CANCER RES, V56, P2387; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SCHARF SR, 1980, DEV BIOL, V79, P181, DOI 10.1016/0012-1606(80)90082-2; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shibamoto S, 1998, GENES CELLS, V3, P659; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tago K, 2000, GENE DEV, V14, P1741; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; USUI H, 1988, J BIOL CHEM, V263, P3752; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	67	54	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					26875	26882		10.1074/jbc.M100443200	http://dx.doi.org/10.1074/jbc.M100443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11297546	hybrid			2022-12-25	WOS:000169966900021
J	Boehr, DD; Thompson, PR; Wright, GD				Boehr, DD; Thompson, PR; Wright, GD			Molecular mechanism of aminoglycoside antibiotic kinase APH(3 ')-IIIa - Roles of conserved active site residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; 16S RIBOSOMAL-RNA; MODIFYING ENZYMES; TRANSITION-STATE; A-SITE; PHOSPHOTRANSFERASE; RESISTANCE; MUTAGENESIS; CATALYSIS; VISCOSITY	The aminoglycoside antibiotic kinases (APHs) constitute a clinically important group of antibiotic resistance enzymes. APHs share structural and functional homology with Ser/Thr and Tyr kinases, yet only five amino acids are invariant between the two groups of enzymes and these residues are all located within the nucleotide binding regions of the proteins. We have performed site-directed mutagenesis on all five conserved residues in the aminoglycoside kinase APH(3 ')-IIIa: Lys(44) and Glu(60) involved in ATP capture, a putative active site base required for deprotonating the incoming aminoglycoside hydroxyl group Asp(190), and the Mg2+ ligands Asn(195) and Glu(208), which coordinate two Mg2+ ions, Mg1 and Mg2. Previous structural and mutagenesis evidence have demonstrated that Lys(44) interacts directly with the phosphate groups of ATP; mutagenesis of invariant Glu(60), which forms a salt bridge with the epsilon -amino group of Lys44, demonstrated that this residue does not play a critical role in ATP recognition or catalysis, Results of mutagenesis of Asp(190) were consistent with a role in proper positioning of the aminoglycoside hydroxyl during phosphoryl transfer but not as a general base. The Mg1 and Mg2 ligand Asp(208) was found to be absolutely required for enzyme activity and the Mg2 ligand Asn(195) is important for Mg ATP recognition. The mutagenesis results together with solvent isotope, solvent viscosity, and divalent cation requirements are consistent with a dissociative mechanism of phosphoryl transfer where initial substrate deprotonation is not essential for phosphate transfer and where Mg2 and Asp(208) likely play a critical role in stabilization of a metaphosphate-like transition state. These results lay the foundation for the synthesis of transition state mimics that could reverse aminoglycoside antibiotic resistance in vivo.	McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University	Wright, GD (corresponding author), McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada.		Wright, G/ABB-7666-2021; Boehr, David/A-2068-2010	Wright, Gerard/0000-0002-9129-7131				Adediran SA, 1996, BIOCHEMISTRY-US, V35, P3604, DOI 10.1021/bi952107i; Admiraal SJ, 1999, BIOCHEMISTRY-US, V38, P4701, DOI 10.1021/bi9827565; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; CLELAND WW, 1987, BIOORG CHEM, V15, P283, DOI 10.1016/0045-2068(87)90026-5; Daigle DM, 1999, CHEM BIOL, V6, P11, DOI 10.1016/S1074-5521(99)80016-7; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fourmy D, 1996, SCIENCE, V274, P1367, DOI 10.1126/science.274.5291.1367; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; Grant BD, 1996, PROTEIN SCI, V5, P1316, DOI 10.1002/pro.5560050710; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; KARSTEN WE, 1995, J AM CHEM SOC, V117, P5914, DOI 10.1021/ja00127a002; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; Kim K, 1998, J AM CHEM SOC, V120, P6851, DOI 10.1021/ja9808393; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEATHERBARROW RJ, 1992, GRAFIT VER 3 0; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P6936, DOI 10.1021/bi00188a024; MCKAY GA, 1994, BIOCHEMISTRY-US, V33, P14115, DOI 10.1021/bi00251a021; McKay GA, 1996, BIOCHEMISTRY-US, V35, P8680, DOI 10.1021/bi9603884; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Northrop DB, 2000, BIOPHYS J, V79, P1621, DOI 10.1016/S0006-3495(00)76412-5; Northrop DB, 1998, J CHEM EDUC, V75, P1153, DOI 10.1021/ed075p1153; QUINN DM, 1991, ENZYME MECH ISOTOPE, P73; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SHAW KJ, 1993, MICROBIOL REV, V57, P138, DOI 10.1128/MMBR.57.1.138-163.1993; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Thompson PR, 1999, J BIOL CHEM, V274, P30697, DOI 10.1074/jbc.274.43.30697; Thompson PR, 1996, BIOCHEMISTRY-US, V35, P8686, DOI 10.1021/bi960389w; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; Wright GD, 1999, CURR OPIN MICROBIOL, V2, P499, DOI 10.1016/S1369-5274(99)00007-7; Wright GD, 1998, ADV EXP MED BIOL, V456, P27; Wright Gerard D., 1999, Frontiers in Bioscience, V4, pD9, DOI 10.2741/Wright; Yoshizawa S, 1998, EMBO J, V17, P6437, DOI 10.1093/emboj/17.22.6437	36	60	65	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23929	23936		10.1074/jbc.M100540200	http://dx.doi.org/10.1074/jbc.M100540200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11279088	hybrid			2022-12-25	WOS:000169531100094
J	Dai, KS; Liew, CC				Dai, KS; Liew, CC			A novel human striated muscle RING zinc finger protein, SMRZ, interacts with SMT3b via its RING domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEINS; HEPATOCELLULAR CARCINOMAS; FREQUENT REARRANGEMENTS; CENTROMERE PROTEIN; CHROMOSOME 1P; GENE; MOTIF; MUTATIONS; PML; EXPRESSION	The RING domain is a conserved zinc finger motif, which serves as a protein-protein interaction interface. Searches of a human heart expressed sequence tag data base for genes encoding the RING domain identified a novel cDNA, named striated muscle RING zinc finger protein (SMRZ). The SMRZ cDNA is 1.9 kilobase pairs in length and encodes a polypeptide of 288 amino acid residues; analysis of the peptide sequence demonstrated an N-terminal RING domain. Fluorescence in situ hybridization localized SMRZ to chromosome 1p33-34. Northern blots demonstrated that SMRZ is expressed exclusively in striated muscle. In the cardiovascular system, SMRZ is more highly expressed in the fetal heart than in the adult heart (slightly higher expression in the ventricle than in the atrium), suggesting that SMRZ is developmentally regulated. SMRZ was found to interact with SMT3b, a ubiquitin-like protein, through the SMRZ-RING domain. This interaction was abolished by mutagenesis of conserved RING domain residues. Transient transfection of SMRZ into C2C12 myoblasts showed localization of SMRZ to the nucleus. These data suggest that SMRZ may play an important role in striated muscle cell embryonic development and perhaps in cell cycle regulation.	Univ Toronto, Inst Med Sci, Toronto, ON M5G 1L5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Toronto; University of Toronto	Liew, CC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Cardiovasc Genome Unit, Sch Med, 75 Francis St,Thorn 1326, Boston, MA 02115 USA.	liewcc@tcgu.med.utoronto.ca						Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Cigudosa JC, 1999, GENE CHROMOSOME CANC, V25, P123, DOI 10.1002/(SICI)1098-2264(199906)25:2<123::AID-GCC8>3.0.CO;2-4; Cohen KJ, 1996, MOL CELL BIOL, V16, P5527; Copps K, 1998, EMBO J, V17, P5409, DOI 10.1093/emboj/17.18.5409; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; Dai KS, 1999, J MOL CELL CARDIOL, V31, P1749, DOI 10.1006/jmcc.1999.1011; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; DING SF, 1992, BRIT J CANCER, V65, P809, DOI 10.1038/bjc.1992.173; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; EVERETT R, 1995, J VIROL, V69, P7339, DOI 10.1128/JVI.69.11.7339-7344.1995; Everett RD, 1999, J CELL SCI, V112, P4581; Ezaki T, 1996, BRIT J CANCER, V73, P424, DOI 10.1038/bjc.1996.76; Farnebo F, 1999, J CLIN ENDOCR METAB, V84, P3775, DOI 10.1210/jc.84.10.3775; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HWANG DM, 1995, GENOMICS, V30, P293, DOI 10.1006/geno.1995.9874; Hwang DM, 1997, CIRCULATION, V96, P4146; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Krause AK, 1997, CANCER GENET CYTOGEN, V94, P138, DOI 10.1016/S0165-4608(96)00223-3; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; LIEW CC, 1994, P NATL ACAD SCI USA, V91, P10645, DOI 10.1073/pnas.91.22.10645; Mannen H, 1996, BIOCHEM BIOPH RES CO, V222, P178, DOI 10.1006/bbrc.1996.0717; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4689, DOI 10.1093/nar/17.12.4689; MEEKSWAGNER D, 1986, CELL, V44, P53, DOI 10.1016/0092-8674(86)90484-8; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Okumoto K, 1998, MOL CELL BIOL, V18, P4324, DOI 10.1128/MCB.18.7.4324; Okura T, 1996, J IMMUNOL, V157, P4277; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; Parada LA, 1998, GENE CHROMOSOME CANC, V23, P26; Prikhodko EA, 1998, J VIROL, V72, P684; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sakakura C, 1999, BRIT J CANCER, V80, P2034, DOI 10.1038/sj.bjc.6690638; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SCHWABE JWR, 1991, TRENDS BIOCHEM SCI, V16, P291, DOI 10.1016/0968-0004(91)90121-B; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Tsukamoto K, 1998, CANCER-AM CANCER SOC, V82, P317, DOI 10.1002/(SICI)1097-0142(19980115)82:2<323::AID-CNCR11>3.3.CO;2-P; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	64	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23992	23999		10.1074/jbc.M011208200	http://dx.doi.org/10.1074/jbc.M011208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11283016	hybrid			2022-12-25	WOS:000169531100102
J	Lin, HH; Stacey, M; Saxby, C; Knott, V; Chaudhry, Y; Evans, D; Gordon, S; McKnight, AJ; Handford, P; Lea, S				Lin, HH; Stacey, M; Saxby, C; Knott, V; Chaudhry, Y; Evans, D; Gordon, S; McKnight, AJ; Handford, P; Lea, S			Molecular analysis of the epidermal growth factor-like short consensus repeat domain-mediated protein-protein interactions - Dissection of the CD97-CD55 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DECAY-ACCELERATING FACTOR; TRANSMEMBRANE RECEPTOR CD97; ACTIVATION ANTIGEN CD97; EPSTEIN-BARR-VIRUS; EGF-LIKE DOMAINS; MARFAN-SYNDROME; LIGAND CD55; FACTOR-IX; BINDING; CALCIUM	Epidermal growth factor-like (EGF) and short consensus repeat (SCR) domains are commonly found in cell sill-face and soluble proteins that mediate specific protein-protein recognition events. Unlike the immunoglobulin (Ig) superfamily, very Little is known about the general properties of intermolecuIar interactions encoded by these common modules, and in particular, how specificity of binding is achieved. We have dissected the binding of CD97 (a member of the EGF-TM7 family) to the complement regulator CD55, two cell surface modular proteins that contain EGF and SCR domains, respectively. We demonstrate that the interaction is mediated solely by these domains and is characterized by a low affinity (86 mum) and rapid off-rate (at least 0.6 s(-1)). The interaction is Ca2+-dependent but is unaffected by glycosylation of the EGF domains. Using biotinylated multimerized peptides in cell binding assays and surface plasmon resonance, we show that a CD97-related EGF-TM7 molecule (termed EMR2), differing by only three amino acids within the EGF domains, binds CD55 with a K-D at least an order of magnitude weaker than that of CD97, These results suggest that low affinity cell-cell interactions may be a general feature of highly expressed cell surface proteins and that specificity of SCR-EGF binding can be finely tuned by a small number of amino acid changes on the EGF module surface.	Univ Oxford, Dept Biochem, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Oxford, Dept Biochem, Div Mol & Cellular Biochem, Oxford OX1 3QU, England; Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Kings Coll London Hosp, Inst Liver Studies, Dept Clin Sci, London WC2R 2LS, England	University of Oxford; University of Oxford; University of Oxford; University of Glasgow; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Lea, S (corresponding author), Univ Oxford, Dept Biochem, Mol Biophys Lab, S Parks Rd, Oxford OX1 3QU, England.	susan@biop.ox.ac.uk	Evans, David/C-7553-2012; LIN, Hsi-Hsien/N-1488-2015; Lea, Susan M/B-7678-2009	Lea, Susan M/0000-0001-9287-8053; Evans, David J./0000-0002-1315-4258				Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; Brown MH, 1995, EUR J IMMUNOL, V25, P3222, DOI 10.1002/eji.1830251204; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; CHARREAU B, 1994, TRANSPLANTATION, V58, P1222, DOI 10.1097/00007890-199412150-00015; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; DYKMAN TR, 1984, J EXP MED, V159, P691, DOI 10.1084/jem.159.3.691; EICHLER W, 1994, SCAND J IMMUNOL, V39, P111, DOI 10.1111/j.1365-3083.1994.tb03348.x; Eichler W, 1997, TISSUE ANTIGENS, V50, P429, DOI 10.1111/j.1399-0039.1997.tb02897.x; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Gray JX, 1996, J IMMUNOL, V157, P5438; Hamann J, 1999, ARTHRITIS RHEUM-US, V42, P650, DOI 10.1002/1529-0131(199904)42:4<650::AID-ANR7>3.0.CO;2-S; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1998, EUR J IMMUNOL, V28, P1701, DOI 10.1002/(SICI)1521-4141(199805)28:05<1701::AID-IMMU1701>3.0.CO;2-2; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; KUTT H, 1989, BIOCHIM BIOPHYS ACTA, V1009, P229, DOI 10.1016/0167-4781(89)90107-3; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; LOWELL CA, 1989, J EXP MED, V170, P1931, DOI 10.1084/jem.170.6.1931; MAYHEW M, 1992, PROTEIN ENG, V5, P489, DOI 10.1093/protein/5.6.489; McGettrick AJ, 2000, HUM MOL GENET, V9, P1987, DOI 10.1093/hmg/9.13.1987; McKnight AJ, 1996, IMMUNOL TODAY, V17, P283, DOI 10.1016/0167-5699(96)80546-9; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MOORE MD, 1991, J VIROL, V65, P3559, DOI 10.1128/JVI.65.7.3559-3565.1991; POST TW, 1990, J IMMUNOL, V144, P740; Powell RM, 1997, J VIROL, V71, P9306, DOI 10.1128/JVI.71.12.9306-9312.1997; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 2000, J BIOL CHEM, V275, P12339, DOI 10.1074/jbc.275.16.12339; Reinhardt DP, 1997, J BIOL CHEM, V272, P1231, DOI 10.1074/jbc.272.2.1231; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; Smallridge RS, 1999, J MOL BIOL, V286, P661, DOI 10.1006/jmbi.1998.2536; SUZUKI K, 1989, J BIOL CHEM, V264, P4872; Werner JM, 2000, J MOL BIOL, V296, P1065, DOI 10.1006/jmbi.1999.3513; Whiteman P, 1998, J BIOL CHEM, V273, P7807, DOI 10.1074/jbc.273.14.7807; WONG WW, 1983, J CLIN INVEST, V72, P685, DOI 10.1172/JCI111018	41	96	98	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24160	24169		10.1074/jbc.M101770200	http://dx.doi.org/10.1074/jbc.M101770200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11297558	hybrid			2022-12-25	WOS:000169531100124
J	Shi, CS; Lee, SB; Sinnarajah, S; Dessauer, CW; Rhee, SG; Kehrl, JH				Shi, CS; Lee, SB; Sinnarajah, S; Dessauer, CW; Rhee, SG; Kehrl, JH			Regulator of G-protein signaling 3 (RGS3) inhibits G beta(1)gamma(2)-induced inositol phosphate production, mitogen-activated protein kinase activation, and Akt activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; HETEROTRIMERIC G-PROTEINS; ALPHA-SUBUNIT; B-LYMPHOCYTES; BINDING; RECEPTORS; PHOSDUCIN; CHEMOTAXIS; PATHWAY; COMPLEX	Regulator of G-protein signaling 3 (RGS3) enhances the intrinsic rate at which G alpha (i) and G alpha (q) hydrolyze GTP to GDP, thereby limiting the duration in which GTP-G alpha (i) and GTP-G alpha (q) can activate effecters. Since GDP-G alpha subunits rapidly combine with free G beta gamma subunits to reform inactive heterotrimeric G-proteins, RGS3 and other RGS proteins may also reduce the amount of G beta gamma subunits available for effector interactions. Although RGS6, RGS7, and RGS11 bind GP, in the absence of a Gy subunit, RGS proteins are not known to directly influence G beta gamma signaling. Here we show that RGS3 binds G beta (1)gamma (2) subunits and limits their ability to trigger the production of inositol phosphates and the activation of Akt and mitogen-activated protein kinase. Go-expression of RGS3 with G beta (1)beta (2) inhibits G beta (1)gamma (2) induced inositol phosphate production and Akt activation in COS-7 cells and mitogen-activated protein kinase activation in HEK 293 cells. The inhibition of G beta (1)gamma (2) signaling does not require an intact RGS domain but depends upon two regions in RGS3 located between acids 313 and 390 and between 391 and 458. Several other RGS proteins do not affect G beta (1)gamma (2) signaling in these assays. Consistent with the in vivo results, RGS3 inhibits G beta gamma -mediated activation of phospholipase C beta in vitro. Thus, RGS3 may limit G beta gamma signaling not only by virtue of its GTPase-activating protein activity for G alpha subunits, but also by directly interfering with the activation of effecters.	NIAID, Immunoregulat Lab, Cell Mol Immunol Sect B, NIH, Bethesda, MD 20892 USA; Univ Texas, Sch Med, Dept Integrat BIol & Pharmacol, Houston, TX 77030 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Texas System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Kehrl, JH (corresponding author), NIAID, Immunoregulat Lab, Cell Mol Immunol Sect B, NIH, Bldg 10,Rm 11B08, Bethesda, MD 20892 USA.		Kehrl, John/AAE-6292-2019; Dessauer, Carmen/N-6933-2018	Dessauer, Carmen/0000-0003-1210-4280; Kehrl, John/0000-0002-6526-159X	NIGMS NIH HHS [R01 GM060419, R01 GM060419-02, GM 60419] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060419] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arai H, 1997, P NATL ACAD SCI USA, V94, P14495, DOI 10.1073/pnas.94.26.14495; Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Bowman EP, 1998, J BIOL CHEM, V273, P28040, DOI 10.1074/jbc.273.43.28040; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHO HS, 2000, CURR T BIOCHEM RES, V2, P161; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Herlitze S, 1997, P NATL ACAD SCI USA, V94, P1512, DOI 10.1073/pnas.94.4.1512; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hirschman JE, 1997, J BIOL CHEM, V272, P240; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; Kasahara S, 2000, P NATL ACAD SCI USA, V97, P412, DOI 10.1073/pnas.97.1.412; Kehrl JH, 1998, IMMUNITY, V8, P1, DOI 10.1016/S1074-7613(00)80453-7; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; LEE SB, 1993, J BIOL CHEM, V268, P25952; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Ma JY, 1997, NEURON, V19, P443, DOI 10.1016/S0896-6273(00)80952-6; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Moratz C, 2000, J IMMUNOL, V164, P1829, DOI 10.4049/jimmunol.164.4.1829; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Neill JD, 1997, ENDOCRINOLOGY, V138, P843, DOI 10.1210/en.138.2.843; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Scheschonka A, 2000, MOL PHARMACOL, V58, P719, DOI 10.1124/mol.58.4.719; Srinivasa SP, 1998, J BIOL CHEM, V273, P1529, DOI 10.1074/jbc.273.3.1529; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; YOSHIDA T, 1994, J BIOL CHEM, V269, P24050	42	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24293	24300		10.1074/jbc.M100089200	http://dx.doi.org/10.1074/jbc.M100089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294858	hybrid			2022-12-25	WOS:000169531100140
J	Haruta, I; Kato, Y; Hashimoto, E; Minjares, C; Kennedy, S; Uto, H; Yamauchi, K; Kobayashi, M; Yusa, S; Muller, U; Hayashi, N; Miyazaki, T				Haruta, I; Kato, Y; Hashimoto, E; Minjares, C; Kennedy, S; Uto, H; Yamauchi, K; Kobayashi, M; Yusa, S; Muller, U; Hayashi, N; Miyazaki, T			Association of AIM, a novel apoptosis inhibitory factor, with hepatitis via supporting macrophage survival and enhancing phagocytotic function of macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CD8(+) T-CELLS; FAS LIGAND; NOD MICE; DEATH; FAMILY; SUSCEPTIBILITY; PATHOGENESIS; REQUIREMENT; THYMOCYTES	A hallmark of many inflammatory diseases is the destruction of tissue cells by infiltrating hematopoietic cells including lymphocytes, neutrophils, and macrophages. The regulation of apoptosis of both target tissue cells and the infiltrating cells is one of the key events that defines the initiation and the progression of inflammation. However, the precise picture of the apoptosis regulation of the cells at the inflammatory sites is still unclear. We recently isolated a novel apoptosis inhibitory factor, termed AIM, which is secreted exclusively by tissue macrophages. In this report, we present unique characteristics of AIM associated with liver inflammation (hepatitis), identified by introducing an experimental hepatitis in both AIM transgenic mice, which overexpress AIM in the body, and normal mice. First, endogenous AIM expression in macrophages is rapidly increased in response to inflammatory stimuli. Second, AIM appears to inhibit the death of macrophages in the inflammatory regions, judging by the remarkably increased number of macrophages observed in the liver from transgenic mice. In addition, we show that AIM also enhances the phagocytosis by macrophages, which emphasizes the multifunctional character of ATM. All these findings strongly provoke an idea that ATM may play an important role in hepatitis pathogenesis in a sequential manner; first AIM expression is up-regulated by inflammatory stimuli, and then in an autocrine fashion, AIM supports the survival of infiltrating macrophages as well as enhances phagocytosis by macrophages, which may result in an efficient clearance of dead cells and infectious or toxic reagents.	Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75235 USA; Tokyo Womens Med Univ, Inst Gastroenterol, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Dept Pathol, Shinjuku Ku, Tokyo 1628666, Japan; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tokyo Women's Medical University; Tokyo Women's Medical University; Fox Chase Cancer Center	Miyazaki, T (corresponding author), Univ Texas, SW Med Ctr, Ctr Immunol, 6000 Harry Hines Blvd,NA7200, Dallas, TX 75235 USA.	toru.miyazaki@UTSouthwestern.edu						Andre I, 1996, P NATL ACAD SCI USA, V93, P2260, DOI 10.1073/pnas.93.6.2260; Benoist C, 1997, CELL, V89, P1, DOI 10.1016/S0092-8674(00)80174-9; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Crispe IN, 2000, IMMUNOL REV, V174, P47, DOI 10.1034/j.1600-0528.2002.017412.x; Grzybowski J, 1999, Postepy Hig Med Dosw, V53, P75; Hahn CS, 2000, VIROLOGY, V276, P127, DOI 10.1006/viro.2000.0541; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jun HS, 1999, DIABETES, V48, P34, DOI 10.2337/diabetes.48.1.34; Jun HS, 1999, J EXP MED, V189, P347, DOI 10.1084/jem.189.2.347; KAWAGUCHI M, 1988, ACTA OTO-LARYNGOL, P108; Kim S, 2000, J IMMUNOL, V164, P2931, DOI 10.4049/jimmunol.164.6.2931; Kim YH, 1999, EUR J IMMUNOL, V29, P455, DOI 10.1002/(SICI)1521-4141(199902)29:02<455::AID-IMMU455>3.0.CO;2-A; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LIU W, 2000, CHUNG HUA KAN TSANG, V8, P269; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Miyazaki T, 1999, J EXP MED, V189, P413, DOI 10.1084/jem.189.2.413; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ogawa S, 2000, J GASTROEN HEPATOL, V15, P69, DOI 10.1046/j.1440-1746.2000.02044.x; Papaccio G, 1998, J CELL BIOCHEM, V71, P479, DOI 10.1002/(SICI)1097-4644(19981215)71:4<479::AID-JCB3>3.0.CO;2-6; POMBO CM, 1994, J BIOL CHEM, V269, P26546; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rosmalen JGM, 2000, LAB INVEST, V80, P23, DOI 10.1038/labinvest.3780004; Rothstein TL, 1996, CURR OPIN IMMUNOL, V8, P362, DOI 10.1016/S0952-7915(96)80126-9; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; TANIDA N, 1992, J BIOCHEM-TOKYO, V112, P616, DOI 10.1093/oxfordjournals.jbchem.a123949; Taya N, 2000, BRIT J HAEMATOL, V110, P89, DOI 10.1046/j.1365-2141.2000.01945.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tsuji H, 1999, J IMMUNOL, V162, P1049; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang B, 1996, EUR J IMMUNOL, V26, P1762, DOI 10.1002/eji.1830260815; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yoon JW, 1999, ARCH PHARM RES, V22, P437, DOI 10.1007/BF02979150; Yusa S, 1999, EUR J IMMUNOL, V29, P1086, DOI 10.1002/(SICI)1521-4141(199904)29:04<1086::AID-IMMU1086>3.3.CO;2-O; 季伟, 1999, [中华肝脏病杂志, Chinese Journal of Hepatology], V7, P77	43	46	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22910	22914		10.1074/jbc.M100324200	http://dx.doi.org/10.1074/jbc.M100324200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294859	hybrid			2022-12-25	WOS:000169412700124
J	Nakamura, K; Miyamoto, H; Suzuma, S; Sakamoto, T; Kawai, G; Yamane, K				Nakamura, K; Miyamoto, H; Suzuma, S; Sakamoto, T; Kawai, G; Yamane, K			Minimal functional structure of Escherichia coli 4.5 S RNA required for binding to elongation factor G	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION-PARTICLE; SMALL CYTOPLASMIC RNA; EF-G; CRYSTAL-STRUCTURE; BACILLUS-SUBTILIS; 23S RNA; SRP RNA; PROTEIN; DOMAIN; COMPLEX	Escherichia coli cells contain abundant amounts of metabolically stable 4.5 S RNA. Consisting of 114 nucleotides, 4.5 S RNA is structurally homologous to mammalian 7 S RNA, and it plays an essential role in targeting proteins containing signal peptide to the secretory apparatus by forming an signal recognition-like particle with Ffh protein. It also binds independently to protein elongation factor G (EF-G) and functions in the translation process. This RNA contains a phylogenetically conserved RNA domain, the predicted secondary structure of which consists of a hairpin motif with two bulges. We examined the binding activity of mutants with systematic deletions to define the minimal functional interaction domain of 4.5 S RNA that interacts with EF-G. This domain consisted of 35-nucleotides extending from 36 to 70 nucleotides of mature 4.5 S RNA and contained two conserved bulges in which mutations of A47, A60, G61, C62, A63, and A67 diminished binding to EF-G, whereas those at A39, C40, C41, A42, G48, and G49 did not affect binding. These data suggested that the 10 nucleotides in 4.5 S RNA, which are conserved between 4.5 S RNA and 23 S rRNA, have a key role for EF-G: binding. Based on the NMR derived structure of mutant A47U, we further verified that substituting U at A47 causes striking structural changes and the loss of the symmetrical bulge. These results indicate the mechanism by which EF-G interacts with 4.5 S RNA and the importance of the bulge structure for EF-G binding.	Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Chiba Inst Technol, Dept Ind Chem, Narashino, Chiba 2750016, Japan	University of Tsukuba; Chiba Institute of Technology	Nakamura, K (corresponding author), Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan.		Sakamoto, Taiichi/V-2389-2019	Sakamoto, Taiichi/0000-0002-1450-9372				Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BOURGAIZE DB, 1990, J BACTERIOL, V172, P1151, DOI 10.1128/jb.172.2.1151-1154.1990; BOURGAIZE DB, 1987, NATURE, V325, P281, DOI 10.1038/325281a0; BROWN S, 1989, J MOL BIOL, V209, P79, DOI 10.1016/0022-2836(89)90171-X; BROWN S, 1984, J MOL BIOL, V178, P533, DOI 10.1016/0022-2836(84)90237-7; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; Conn GL, 1999, SCIENCE, V284, P1171, DOI 10.1126/science.284.5417.1171; ERNST RR, 1987, PRINCIPLES NUCL MAGN, P516; Gowda K, 1997, NUCLEIC ACIDS RES, V25, P2835, DOI 10.1093/nar/25.14.2835; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; Jovine L, 2000, STRUCTURE, V8, P527, DOI 10.1016/S0969-2126(00)00137-4; Larsen N, 1998, NUCLEIC ACIDS RES, V26, P177, DOI 10.1093/nar/26.1.177; Lentzen G, 1996, RNA, V2, P244; Liljas A, 1995, CURR OPIN STRUC BIOL, V5, P721, DOI 10.1016/0959-440X(95)80003-4; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NAKAMURA K, 1992, J BACTERIOL, V174, P2185, DOI 10.1128/JB.174.7.2185-2192.1992; Nakamura K, 1999, EUR J BIOCHEM, V259, P543, DOI 10.1046/j.1432-1327.1999.00077.x; NAKAMURA K, 1995, MICROBIOL-SGM, V141, P2965, DOI 10.1099/13500872-141-11-2965; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; PORITZ MA, 1988, CELL, V55, P4, DOI 10.1016/0092-8674(88)90003-7; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Schmitz U, 1996, RNA, V2, P1213; Schmitz U, 1999, NAT STRUCT BIOL, V6, P634, DOI 10.1038/10683; Schmitz U, 1999, RNA, V5, P1419, DOI 10.1017/S1355838299991458; SELINGER D, 1993, MOL CELL BIOL, V13, P1353, DOI 10.1128/MCB.13.3.1353; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Shibata T, 1996, J BIOL CHEM, V271, P13162, DOI 10.1074/jbc.271.22.13162; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; STRUCK JCR, 1988, NUCLEIC ACIDS RES, V16, P2720, DOI 10.1093/nar/16.6.2720; Suzuma S, 1999, FEMS MICROBIOL LETT, V180, P271, DOI 10.1016/S0378-1097(99)00498-X; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; WOOD H, 1992, NUCLEIC ACIDS RES, V20, P5919, DOI 10.1093/nar/20.22.5919	34	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22844	22849		10.1074/jbc.M101376200	http://dx.doi.org/10.1074/jbc.M101376200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294875	hybrid			2022-12-25	WOS:000169412700115
J	Kridel, SJ; Chen, E; Kotra, LP; Howard, EW; Mobashery, S; Smith, JM				Kridel, SJ; Chen, E; Kotra, LP; Howard, EW; Mobashery, S; Smith, JM			Substrate hydrolysis by matrix metalloproteinase-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; GELATINASE-B; CLEAVAGE SITE; SEQUENCE SPECIFICITIES; PLASMINOGEN-ACTIVATOR; EXTRACELLULAR-MATRIX; CEREBROSPINAL-FLUID; TISSUE INHIBITOR; TERMINAL DOMAIN; IV COLLAGENASES	The catalytic clefts of all matrix metalloproteinases (MMPs) have a similar architecture, raising questions about the redundancy in substrate recognition across the protein family. In the present study, an unbiased phage display strategy was applied to define the substrate recognition profile of MMP-9. Three groups of substrates were identified, each occupying a distinct set of subsites within the catalytic pocket. The most prevalent motif contains the sequence Pro-X-X-Hy-(Ser/Thr) at P-3 through P-2'. This sequence is similar to the MMP cleavage sites within the collagens and is homologous to substrates the have been selected for other MMPs. Despite this similarity, most of the substrates identified here are selective for MMP-9 over MMP-7 and MMP-13. This observation indicates that substrate selectivity is conferred by key subsite interactions at positions other than P-3 and P-1'. This study shows that MMP-9 has a unique preference for Arg at both P-2 and P-1, and a preference for Ser/Thr at P-2'. Substrates containing the consensus MMP-9 recognition motif were used to query the protein data bases. A surprisingly limited List of putative physiologic substrates was identified. The functional implications of these proteins lead to testable hypotheses regarding physiologic substrates for MMP-9.	Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Wayne State Univ, Inst Drug Design, Detroit, MI 48202 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK 73104 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Wayne State University; Wayne State University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Smith, JM (corresponding author), Burnham Inst, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Kotra, Lakshmi P./0000-0002-7071-4637	NCI NIH HHS [CA69036, CA30199] Funding Source: Medline; NIAMS NIH HHS [AR42750, AR08505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042750] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1199; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; CASE DA, 1997, AMBER 5; Conant K, 1999, ANN NEUROL, V46, P391, DOI 10.1002/1531-8249(199909)46:3<391::AID-ANA15>3.0.CO;2-0; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Deng SJ, 2000, J BIOL CHEM, V275, P31422, DOI 10.1074/jbc.M004538200; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Engsig MT, 2000, J CELL BIOL, V151, P879, DOI 10.1083/jcb.151.4.879; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; GIJBELS K, 1993, J NEUROSCI RES, V36, P432, DOI 10.1002/jnr.490360409; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Karas M, 1996, BIOCHEM SOC T, V24, P897, DOI 10.1042/bst0240897; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Leppert D, 1998, BRAIN, V121, P2327, DOI 10.1093/brain/121.12.2327; Lin ECK, 1997, J BIOL CHEM, V272, P23912, DOI 10.1074/jbc.272.38.23912; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; MADISON EL, 1995, J BIOL CHEM, V270, P7558, DOI 10.1074/jbc.270.13.7558; Marinkovich MP, 1996, J INVEST DERMATOL, V106, P734, DOI 10.1111/1523-1747.ep12345782; Massova I, 1997, J MOL MODEL, V3, P17, DOI 10.1007/s008940050021; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MCGEEHAN GM, 1994, J BIOL CHEM, V269, P32814; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; NETZELARNETT S, 1991, J BIOL CHEM, V266, P6747; NETZELARNETT S, 1993, BIOCHEMISTRY-US, V32, P6427, DOI 10.1021/bi00076a016; NGUYEN Q, 1993, BIOCHEM J, V295, P595, DOI 10.1042/bj2950595; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; OCONNELL JP, 1994, J BIOL CHEM, V269, P14967; Olson MW, 2000, J BIOL CHEM, V275, P2661, DOI 10.1074/jbc.275.4.2661; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PROOST P, 1993, BIOCHEM BIOPH RES CO, V192, P1175, DOI 10.1006/bbrc.1993.1540; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELTZER JL, 1990, J BIOL CHEM, V265, P20409; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SMITH GP, 1993, GENE, V128, P1, DOI 10.1016/0378-1119(93)90145-S; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; STOCKER W, 1995, PROTEIN SCI, V4, P823; VORM O, 1994, ANAL CHEM, V66, P3281, DOI 10.1021/ac00091a044; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Xia T, 1996, BBA-PROTEIN STRUCT M, V1293, P259, DOI 10.1016/0167-4838(95)00259-6	58	149	167	3	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20572	20578		10.1074/jbc.M100900200	http://dx.doi.org/10.1074/jbc.M100900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279151	hybrid			2022-12-25	WOS:000169135100121
J	Mohamed, MR; Niles, EG				Mohamed, MR; Niles, EG			The viral RNA polymerase H4L subunit is required for vaccinia virus early gene transcription termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE TRIPHOSPHATE PHOSPHOHYDROLASES; TEMPERATURE-SENSITIVE MUTANTS; MESSENGER-RNA; TERNARY COMPLEXES; CELLULAR PROTEIN; STAGE GENES; NASCENT RNA; IN-VITRO; PURIFICATION; PROMOTER	Vaccinia virus early gene transcription is catalyzed by a multisubunit virion form of RNA polymerase that possesses a unique subunit, H4L. Prior studies from this laboratory showed that the NH2-terminal domain of H4L, containing amino acids 1-195, interacts with the COOH-terminal end of nucleoside triphosphate phosphohydrolase I (NPH I), an ATPase that is employed in early gene transcription termination, Carboxyl-terminal deletion mutations of NPH I lose both the ability to mediate transcription termination and binding to H4L, providing evidence that the interaction between NPN I and H4L is required for termination, In order to test this model further, antibodies raised against segments of H4L mere tested for their ability to inhibit transcription termination in vitro. A bead-bound template was employed. in these studies, which permitted us to separate transcription initiation from elongation and termination. Antibodies raised against H4L amino acids 1-256 inhibited termination in an in vitro assay using virus-infected cell extracts lacking NPH I, but antibodies raised against H4L amino acids 568-795 did not. Preincubation of anti-H4L(1-256) antibodies with H4L fragments 1-256 or 1-195 prevented antibody inhibition of termination, demonstrating that inhibition was mediated by antibody binding to one or more epitopes in the NH2-terminal end of H4L, Antibody inhibition of termination is reduced in wild type virus-infected cell extracts containing NPH I. Furthermore, preincubation of a NPH I minus cell extract with NPH I prior to antibody addition, or readdition of NPH I to isolated ternary complexes prepared in the absence of NPH I, prevented antibody inhibition of transcription termination, These data show that NPH I and the inhibitory antibodies compete for a binding site(s) on H4L, providing further evidence that the H4L subunit of the vaccinia virus RNA polymerase plays a direct, role in transcription termination.	SUNY Buffalo, Sch Med & Biomed Sci, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Sch Med & Biomed Sci, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Niles, EG (corresponding author), SUNY Buffalo, Dept Microbiol & Biochem, 138 Farber Hall, Buffalo, NY 14214 USA.		Mohamed, Mohamed Ragaa/V-9143-2019	Mohamed, Mohamed Ragaa/0000-0002-9269-3128	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043933] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43933] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P3536, DOI 10.1073/pnas.89.8.3536; AHN BY, 1994, J BIOL CHEM, V269, P7552; BROYLES SS, 1988, J BIOL CHEM, V263, P10754; Christen LM, 1998, VIROLOGY, V245, P360, DOI 10.1006/viro.1998.9177; CONDIT RC, 1983, VIROLOGY, V128, P429, DOI 10.1016/0042-6822(83)90268-4; CONDIT RC, 1981, VIROLOGY, V113, P224, DOI 10.1016/0042-6822(81)90150-1; Condit RC, 1996, VIROLOGY, V218, P169, DOI 10.1006/viro.1996.0177; Deng L, 1996, J BIOL CHEM, V271, P29386, DOI 10.1074/jbc.271.46.29386; DENG L, 1994, J BIOL CHEM, V269, P14323; Deng L, 1998, GENE DEV, V12, P538, DOI 10.1101/gad.12.4.538; Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gunasinghe SK, 1998, J BIOL CHEM, V273, P27524, DOI 10.1074/jbc.273.42.27524; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; KANE EM, 1992, J VIROL, V66, P5752, DOI 10.1128/JVI.66.10.5752-5762.1992; KATES JR, 1967, P NATL ACAD SCI USA, V58, P134, DOI 10.1073/pnas.58.1.134; LI J, 1993, J BIOL CHEM, V268, P20016; LI J, 1993, J BIOL CHEM, V268, P2773; Mohamed MR, 2000, J BIOL CHEM, V275, P25798, DOI 10.1074/jbc.M002250200; MOSS B, 1996, VIROLOGY, P2637; MUNYON W, 1967, P NATL ACAD SCI USA, V58, P2280, DOI 10.1073/pnas.58.6.2280; PAOLETTI E, 1974, J BIOL CHEM, V249, P3273; PAOLETTI E, 1974, J BIOL CHEM, V249, P3281; ROHRMANN G, 1986, CELL, V46, P1029, DOI 10.1016/0092-8674(86)90702-6; ROSALES R, 1994, P NATL ACAD SCI USA, V91, P3794, DOI 10.1073/pnas.91.9.3794; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1989, J BIOL CHEM, V264, P21356; SPRINGER T, 1987, CURRENT TOPICS MOL B; WEI CM, 1975, P NATL ACAD SCI USA, V72, P318, DOI 10.1073/pnas.72.1.318; WITTEK R, 1980, CELL, V21, P487, DOI 10.1016/0092-8674(80)90485-7; YUEN L, 1986, J VIROL, V60, P320, DOI 10.1128/JVI.60.1.320-323.1986; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417; Zhu M, 1998, J VIROL, V72, P3893, DOI 10.1128/JVI.72.5.3893-3899.1998	34	12	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20758	20765		10.1074/jbc.M101641200	http://dx.doi.org/10.1074/jbc.M101641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279216	hybrid			2022-12-25	WOS:000169135100144
J	Zhang, PN; McAlinden, A; Li, S; Schumacher, T; Wang, HL; Hu, SS; Sandell, L; Crouch, E				Zhang, PN; McAlinden, A; Li, S; Schumacher, T; Wang, HL; Hu, SS; Sandell, L; Crouch, E			The amino-terminal heptad repeats of the coiled-coil neck domain of pulmonary surfactant protein D are necessary for the assembly of trimeric subunits and dodecamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAIN; I COLLAGEN; OSTEOGENESIS IMPERFECTA; ANTIINFLUENZA ACTIVITY; PRO-ALPHA-1(I) CHAIN; CRYSTAL-STRUCTURE; IIA PROCOLLAGEN; HELIX FORMATION; LECTIN DOMAINS; HOST-DEFENSE	Pulmonary surfactant protein D (SP-D), a lung host defense protein, is assembled as multimers of trimeric subunits. Trimerization of SP-D monomers is required for high affinity saccharide binding, and the oligomerization of trimers is required for many of its functions. A peptide containing the alpha -helical neck region can spontaneously trimerize in vitro. However, it is not known whether this sequence is necessary for the complete cellular assembly of disulfide-cross-linked, trimeric subunits and dodecamers, For the present studies, me synthesized mutant cDNAs with deletions or site-directed substitutions in the neck domain of rat SP-D, and examined the assembly of the newly synthesized proteins after transfection of CHO-K1 cells. The neck domain contains three "classical" heptad repeat motifs with leucine residues at the "d position," and a distinctive C-terminal repeat previously suggested to drive trimeric chain association, Deletion of the highly conserved core of the latter repeat (FSRYLKK) did not interfere with the secretion of dodecamers with lectin activity. Ey contrast, deletion of the entire neck domain or deletion of one or two amino-terminal repeats resulted in defective molecular assembly. The secreted proteins eluted in the position of monomers by gel filtration under nondenaturing conditions, In addition, the neck + carbohydrate recognition domain of SP-D was necessary and sufficient for the trimerization of a heterologous collagen sequence located amino-terminal to the trimeric coiled-coil. These studies provide strong evidence that the amino-terminal heptad repeats of the neck. domain are necessary for the intracellular, trimeric association of SP-D monomers and for the assembly and secretion of functional dodecamers.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Crouch, E (corresponding author), Barnes Jewish Hosp N, Dept Pathol & Immunol, Surg Pathol Mailstop 90-31-649,216 S Kingshighway, St Louis, MO 63110 USA.	crouch@path.wustl.edu		McAlinden, Audrey/0000-0001-8433-4224	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044015, P01HL029594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-29594, HL-44015] Funding Source: Medline; NIAMS NIH HHS [AR-36994] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BrownAugsburger P, 1996, J BIOL CHEM, V271, P13724, DOI 10.1074/jbc.271.23.13724; BrownAugsburger P, 1996, J BIOL CHEM, V271, P18912, DOI 10.1074/jbc.271.31.18912; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; Cai GZ, 1999, AM J PHYSIOL-LUNG C, V276, pL131, DOI 10.1152/ajplung.1999.276.1.L131; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CROUCH E, 1994, J BIOL CHEM, V269, P17311; CROUCH E, 1993, J BIOL CHEM, V268, P2976; CROUCH E, 1994, J BIOL CHEM, V269, P15808; Crouch E C, 2000, Respir Res, V1, P93; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; CURRAN S, 1982, BIOCHEMISTRY-US, V21, P1482, DOI 10.1021/bi00536a003; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOLZ R, 1988, EUR J BIOCHEM, V178, P357, DOI 10.1111/j.1432-1033.1988.tb14458.x; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; FISHER LW, 1987, J BIOL CHEM, V262, P13457; Frank S, 2000, J BIOL CHEM, V275, P11672, DOI 10.1074/jbc.275.16.11672; Frischholz S, 1998, J BIOL CHEM, V273, P4547, DOI 10.1074/jbc.273.8.4547; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753, DOI 10.1152/ajplung.1996.271.5.L753; Hartshorn KL, 1996, BLOOD, V87, P3450, DOI 10.1182/blood.V87.8.3450.bloodjournal8783450; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156, DOI 10.1152/ajplung.1997.273.6.L1156; Hartshorn KL, 2000, AM J PHYSIOL-LUNG C, V278, pL90, DOI 10.1152/ajplung.2000.278.1.L90; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.0.CO;2-W; Holmskov UL, 2000, APMIS, V108, P7; HOPPE HJ, 1994, STRUCTURE, V2, P1129, DOI 10.1016/S0969-2126(94)00115-4; HOPPE HJ, 1994, FEBS LETT, V344, P191, DOI 10.1016/0014-5793(94)00383-1; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Kishore U, 1996, BIOCHEM J, V318, P505, DOI 10.1042/bj3180505; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Mazzorana M, 1996, J BIOL CHEM, V271, P29003, DOI 10.1074/jbc.271.46.29003; Oganesian A, 1997, J HISTOCHEM CYTOCHEM, V45, P1469, DOI 10.1177/002215549704501104; PERSSON A, 1989, BIOCHEMISTRY-US, V28, P6361, DOI 10.1021/bi00441a031; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; SANDELL LJ, 1990, EXTRACELLULAR MATRIX, P1; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; SPISSINGER T, 1991, EUR J BIOCHEM, V199, P65, DOI 10.1111/j.1432-1033.1991.tb16092.x; WANG JY, 1995, FEBS LETT, V376, P6, DOI 10.1016/0014-5793(95)01232-4; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; White MR, 2000, J IMMUNOL, V165, P2108, DOI 10.4049/jimmunol.165.4.2108; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; Zhu Y, 1999, J CELL BIOL, V144, P1069, DOI 10.1083/jcb.144.5.1069	51	43	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19862	19870		10.1074/jbc.M100597200	http://dx.doi.org/10.1074/jbc.M100597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279100	hybrid			2022-12-25	WOS:000169135100026
J	Michell, BJ; Chen, ZP; Tiganis, T; Stapleton, D; Katsis, F; Power, DA; Sim, AT; Kemp, BE				Michell, BJ; Chen, ZP; Tiganis, T; Stapleton, D; Katsis, F; Power, DA; Sim, AT; Kemp, BE			Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; CELLS; DEPHOSPHORYLATION; GROWTH; AKT; IDENTIFICATION; ISOFORMS; PATHWAY; SITES	Endothelial nitric-oxide synthase (eNOS) is an important regulatory enzyme in the cardiovascular system catalyzing the production of NO from arginine. Multiple protein kinases including Akt/PKB, cAMP-dependent protein kinase (PKA), and the AMP-activated protein kinase (AMPK) activate eNOS by phosphorylating Ser-1177 in response to various stimuli. During VEGF signaling in endothelial cells, there is a transient increase in Ser-1177 phosphorylation coupled with a decrease in Thr-495 phosphorylation that reverses over 10 min. PKC signaling in endothelial cells inhibits eNOS activity by phosphorylating Thr-495 and dephosphorylating Ser-1177 whereas PKA signaling acts in reverse by increasing phosphorylation of Ser-1177 and dephosphorylation of Thr-495 to activate eNOS. Both phosphatases PP1 and PP2A are associated with eNOS, PP1 is responsible for dephosphorylation of Thr-495 based on its specificity for this site in both eNOS and the corresponding synthetic phosphopeptide whereas PP2A is responsible for dephosphorylation of Ser-1177. Treatment of endothelial cells with calyculin selectively blocks PKA-mediated dephosphorylation of Thr-495 whereas okadaic acid selectively blocks PKC-mediated dephosphorylation of Ser-1177, These results show that regulation of eNOS activity involves coordinated signaling through Ser-1177 and Thr-495 by multiple protein kinases and phosphatases.	St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia; Austin & Repatriat Med Ctr, Dept Nephrol, Heidelberg, Vic 3084, Australia; Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2308, Australia	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Newcastle	Kemp, BE (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Tiganis, Tony/AAV-3495-2020; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019; Power, David/AAM-6012-2021	Tiganis, Tony/0000-0002-8065-9942; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Power, David/0000-0003-3983-0581				Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; DAVDA RK, 1994, EUR J PHARM-MOLEC PH, V266, P237, DOI 10.1016/0922-4106(94)90132-5; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; HARRIS MB, 2001, J BIOL CHEM; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859; Ludowyke RI, 2000, J BIOL CHEM, V275, P6144, DOI 10.1074/jbc.275.9.6144; MacKenzie S, 1997, BIOCHEM J, V324, P159, DOI 10.1042/bj3240159; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; Ratcliffe MJ, 1999, BIOCHEM J, V338, P471, DOI 10.1042/0264-6021:3380471; Ratcliffe MJ, 1997, J BIOL CHEM, V272, P31894, DOI 10.1074/jbc.272.50.31894; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; Seymour LW, 1996, LAB INVEST, V75, P427; Sim ATR, 1998, NEUROCHEM RES, V23, P487, DOI 10.1023/A:1022422332404; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006	27	450	471	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17625	17628		10.1074/jbc.C100122200	http://dx.doi.org/10.1074/jbc.C100122200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11292821	hybrid			2022-12-25	WOS:000168866500002
J	Qu, ZQ; Hartzell, HC				Qu, ZQ; Hartzell, HC			Functional geometry of the permeation pathway of Ca2+-activated Cl- channels inferred from analysis of voltage-dependent block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; RABBIT VENTRICULAR MYOCYTES; XENOPUS OOCYTES; ANTIARRHYTHMIC APPROACH; ANION MANIPULATION; AIRWAY EPITHELIA; CHLORIDE; CURRENTS; SECRETION; CALCIUM	We examined the voltage-dependent block of Ca2+- activated Cl- channels by anthacene-9-carboxylic acid (A9C), diphenylamine-2-carboxylic acid (DPC), 4,4'-diisothiocyanostilbene-2,2 '-disulfonic acid (DIDS), and niflumic acid (NFA) in excised inside-out and outside-out patches from Xenopus oocytes, The fraction of the voltage field (delta) experienced by the blocking drug was determined from the voltage dependence of block. All the drugs blocked by entering the channel from the outside. delta was 0.6 for A9C, 0.3 for DPC and BIBS, and <0.1 for NFA. Because the voltage dependence of the drugs differed, the order of potency was also voltage-dependent. At +100 mV the order of potency was NFA > A9C > DIDS > DPC (K-i (muM) = 10.1, 18.3, 48, and 11.1, respectively). Because the drugs are hydrophobic, they can cross the bilayer when applied from the inside and block the channel from the outside. The equilibrium geometries of the blockers were determined by molecular modeling and compared with their blocking positions (delta), This analysis suggests that the channel is an elliptical cone with the largest opening facing the extracellular space. The selectivity filter has an apparent size of 0.33 x 0.75 nm, because C(CN)(3)(-), which has these dimensions, permeates. The external opening is at least 0.60 x 0.94 nm, because DPC has these dimensions and penetrates the channel similar to 30%.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Hartzell, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.	criss@cellbio.emory.edu			NIGMS NIH HHS [GM 60448] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060448] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; CURTIS MJ, 1993, J MOL CELL CARDIOL, V25, P417, DOI 10.1006/jmcc.1993.1048; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; Freeman LC, 1997, J CARDIOVASC ELECTR, V8, P872, DOI 10.1111/j.1540-8167.1997.tb00848.x; Frings S, 2000, PROG NEUROBIOL, V60, P247, DOI 10.1016/S0301-0082(99)00027-1; Greger R, 1996, PFLUG ARCH EUR J PHY, V432, P579, DOI 10.1007/s004240050173; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; Han XQ, 1996, J MOL CELL CARDIOL, V28, P2069, DOI 10.1006/jmcc.1996.0200; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; Hehre W. J., 1998, BRIEF GUIDE MOL MECH; Hille B., 1992, ION CHANNELS EXCITAB; HIRAOKA M, 1989, J PHYSIOL-LONDON, V410, P187, DOI 10.1113/jphysiol.1989.sp017528; Hiraoka M, 1998, CARDIOVASC RES, V40, P23, DOI 10.1016/S0008-6363(98)00173-4; JAFFE LA, 1986, ANNU REV PHYSIOL, V48, P191, DOI 10.1146/annurev.ph.48.030186.001203; JANUARY CT, 1988, PHARMACOL REV, V40, P219; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; KAWANO S, 1991, J MOL CELL CARDIOL, V23, P681, DOI 10.1016/0022-2828(91)90978-U; Kuruma A, 2000, J GEN PHYSIOL, V115, P59, DOI 10.1085/jgp.115.1.59; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Linsdell P, 1996, J PHYSIOL-LONDON, V496, P687, DOI 10.1113/jphysiol.1996.sp021719; Machaca K, 1999, J GEN PHYSIOL, V113, P249, DOI 10.1085/jgp.113.2.249; Machaca K, 1998, BIOPHYS J, V74, P1286, DOI 10.1016/S0006-3495(98)77842-7; Machaca K, 1999, J BIOL CHEM, V274, P4824, DOI 10.1074/jbc.274.8.4824; MCCARTY NA, 1993, J GEN PHYSIOL, V102, P1, DOI 10.1085/jgp.102.1.1; PAPP Z, 1995, J PHYSIOL-LONDON, V483, P319, DOI 10.1113/jphysiol.1995.sp020588; Qu ZQ, 2000, J GEN PHYSIOL, V116, P825, DOI 10.1085/jgp.116.6.825; RIDLEY PD, 1992, CIRC RES, V70, P617, DOI 10.1161/01.RES.70.4.617; Schultz BD, 1999, PHYSL REV S, V79, P109; Tanaka H, 1996, J PHARMACOL EXP THER, V278, P854; WHITE MM, 1990, MOL PHARMACOL, V37, P720; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC226, DOI 10.1152/ajpcell.1989.256.2.C226; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687; ZYGMUNT AC, 1994, AM J PHYSIOL-HEART C, V267, pH1984, DOI 10.1152/ajpheart.1994.267.5.H1984; Zygmunt AC, 1998, AM J PHYSIOL-HEART C, V275, pH1979, DOI 10.1152/ajpheart.1998.275.6.H1979; Zygmunt AC, 1997, AM J PHYSIOL-HEART C, V273, pH1096, DOI 10.1152/ajpheart.1997.273.3.H1096	37	55	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18423	18429		10.1074/jbc.M101264200	http://dx.doi.org/10.1074/jbc.M101264200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279188	hybrid			2022-12-25	WOS:000168866500107
J	Angus, LM; Chan, RYY; Jasmin, BJ				Angus, LM; Chan, RYY; Jasmin, BJ			Role of intronic E- and N-box motifs in the transcriptional induction of the acetylcholinesterase gene during myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GA-BINDING-PROTEIN; SKELETAL-MUSCLE FIBERS; DELTA-SUBUNIT GENE; MESSENGER-RNA; NEUROMUSCULAR-JUNCTION; SYNAPTIC EXPRESSION; NEURAL REGULATION; UTROPHIN GENE; RECEPTOR GENE; PROMOTER	In this study, we examined whether an intronic N-box motif is involved in the expression of acetylchollinesterase (AChE) during myogenesis, We determined that AChE transcripts are barely detectable in cultured myoblasts and that their levels increase dramatically in myotubes, Nuclear run-on assays revealed that this increase was accompanied by a parallel induction in the transcriptional activity of the AChE gene, These changes in transcription were also observed in transfection experiments using AChE promoter-reporter gene constructs. Mutation of the intronic N-box at position +755 base pairs (bp) reduced by more than 70% expression of the reporter gene in myotubes, Disruption of an adjacent E-box, at position +767 bp, also reduced expression of the reporter gene following myogenic differentiation. Co-transfection experiments using AChE promoter-reporter gene constructs and a myogenin expression vector showed that expression of this regulatory factor increased expression of the reporter gene in myotubes. Although the AChE promoter contains multiple E-boxes, mutation of this intronic one was sufficient to prevent the myogenin-induced increase in reporter gene expression. Together, these results indicate that changes in AChE gene transcription occur during myogenesis and highlight the contribution of the intronic Nand E-box motifs in the developmental regulation of the AChE gene in skeletal muscle.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Fac Med, Ctr Neuromuscular Dis, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa	Jasmin, BJ (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.							Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; BALDWIN TJ, 1988, J CELL BIOL, V107, P2271, DOI 10.1083/jcb.107.6.2271; Bannert N, 1999, P NATL ACAD SCI USA, V96, P1541, DOI 10.1073/pnas.96.4.1541; BELANGER G, 2000, SOC NEUR ABSTR, V26, P1089; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Boudreau-Lariviere C, 2000, J NEUROCHEM, V74, P2250, DOI 10.1046/j.1471-4159.2000.0742250.x; Buckingham M, 1996, BIOCHEM SOC T, V24, P506, DOI 10.1042/bst0240506; BUONANNO A, 1986, J BIOL CHEM, V261, P1452; Chan RYY, 1998, J BIOL CHEM, V273, P9727, DOI 10.1074/jbc.273.16.9727; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CRESNAR B, 1994, J NEUROSCI RES, V38, P294, DOI 10.1002/jnr.490380307; Culetto E, 1999, J MOL BIOL, V290, P951, DOI 10.1006/jmbi.1999.2937; Curcic D, 1997, J CELL BIOCHEM, V65, P287; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EVANS S, 1987, J BIOL CHEM, V262, P4911; FONTAINE B, 1989, J CELL BIOL, V108, P1025, DOI 10.1083/jcb.108.3.1025; FORSTER E, 1993, NEUROSCI LETT, V155, P216, DOI 10.1016/0304-3940(93)90711-S; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; Gramolini AO, 1999, NUCLEIC ACIDS RES, V27, P3603, DOI 10.1093/nar/27.17.3603; Gramolini AO, 1998, J BIOL CHEM, V273, P736, DOI 10.1074/jbc.273.2.736; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; GRUBIC Z, 1995, NEURON, V14, P317, DOI 10.1016/0896-6273(95)90288-0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; JBILO O, 1994, EUR J BIOCHEM, V225, P115, DOI 10.1111/j.1432-1033.1994.00115.x; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; KLARSFELD A, 1987, BIOCHIMIE, V69, P433, DOI 10.1016/0300-9084(87)90080-0; KOIKE S, 1995, P NATL ACAD SCI USA, V92, P10624, DOI 10.1073/pnas.92.23.10624; Legay C, 2000, MICROSC RES TECHNIQ, V49, P56, DOI 10.1002/(SICI)1097-0029(20000401)49:1<56::AID-JEMT7>3.0.CO;2-R; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; Luo ZD, 1999, MOL PHARMACOL, V56, P886, DOI 10.1124/mol.56.5.886; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MICHEL RN, 1994, J CELL BIOL, V127, P1061, DOI 10.1083/jcb.127.4.1061; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Ou XM, 2000, J BIOL CHEM, V275, P8161, DOI 10.1074/jbc.275.11.8161; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RAY A, 1995, J BIOL CHEM, V270, P25837, DOI 10.1074/jbc.270.43.25837; Rimer M, 1999, BIOCHEM BIOPH RES CO, V260, P251, DOI 10.1006/bbrc.1999.0893; Rossi SG, 2000, J NEUROSCI, V20, P919, DOI 10.1523/JNEUROSCI.20-03-00919.2000; ROSSI SG, 2000, SOC NEUR ABSTR, V26, P1090; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SETH A, 1990, ONCOGENE, V5, P1761; SVEISTRUP H, 1995, AM J PHYSIOL, V269, pC756; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TOUTANT JP, 1987, MAMMALIAN ECTOENZYME, P289; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0	53	40	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17603	17609		10.1074/jbc.M100916200	http://dx.doi.org/10.1074/jbc.M100916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279154	hybrid			2022-12-25	WOS:000168730400134
J	Oyedotun, KS; Lemire, BD				Oyedotun, KS; Lemire, BD			The quinone-binding sites of the Saccharomyces cerevisiae succinate-ubiquinone oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROGENASE FLAVOPROTEIN SUBUNIT; COLI FUMARATE REDUCTASE; MEMBRANE-INTEGRAL DOMAIN; RESPIRATORY COMPLEX-II; ESCHERICHIA-COLI; ELECTRON-TRANSFER; PROTON TRANSLOCATION; CYTOCHROME-B; ENERGY TRANSDUCTION; REACTION CENTERS	The Saccharomyces cerevisiae succinate dehydrogenase (SDH) of the mitochondrial electron transport chain oxidizes succinate and reduces ubiquinone, Using a random mutagenesis approach, we identified functionally important amino acid residues in one of the anchor subunits, Sdh4p, We analyzed three point mutations (F69V, S71A, and H99L) and one nonsense mutation (Y890CH) that truncates the Sdh4p subunit at the third predicted transmembrane segment, The F69V and the S71A mutations result in greatly impaired respiratory growth in vivo and quinone reductase activities in vitro, with negligible effects on enzyme stability. In contrast, the Y89OCH and the H99L mutations elicit large structural perturbations that impair assembly as evidenced by reduced covalent FAD levels, membrane-associated succinate-phenazine methosulfate reductase activities, and thermal stability. We propose that the Phe-69 and the Ser-71 residues are involved in the formation of a quinone-binding site, whereas the His-99 residue is at the interface of the peripheral and the membrane domains. In addition, the properties of the Y890CH mutation are consistent with the interpretation that the third transmembrane segment is not involved in catalysis but rather plays an important structural role. The mutant enzymes are differentially sensitive to a quinone analog inhibitor, providing further evidence for a two-quinone binding model in the yeast SDH.	Univ Alberta, Canadian Inst Hlth Res Grp Mol Biol Membrane Prot, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Lemire, BD (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Mol Biol Membrane Prot, Dept Biochem, Edmonton, AB T6G 2H7, Canada.							ABRAHAM PR, 1994, MOL GEN GENET, V242, P708, DOI 10.1007/BF00283426; Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; ALLEN JP, 1987, P NATL ACAD SCI USA, V84, P5730, DOI 10.1073/pnas.84.16.5730; Allen JP, 1998, FEBS LETT, V438, P5, DOI 10.1016/S0014-5793(98)01245-9; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; Bruel C, 1995, J BIOENERG BIOMEMBR, V27, P527, DOI 10.1007/BF02110192; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; CHAPMAN KB, 1992, GENE, V118, P131, DOI 10.1016/0378-1119(92)90260-V; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; COLSON AM, 1993, J BIOENERG BIOMEMBR, V25, P211, DOI 10.1007/BF00762583; DAIGNANFORNIER B, 1994, J BIOL CHEM, V269, P15469; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; Hederstedt L, 1998, BIOCHEM SOC T, V26, P408, DOI 10.1042/bst0260408; HEDERSTEDT L, 1992, MOL MECHANISMS BIOEN, P163; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; LEE GY, 1995, J BIOL CHEM, V270, P6193, DOI 10.1074/jbc.270.11.6193; LOMBARDO A, 1990, J BIOL CHEM, V265, P10419; LOMBARDO A, 1989, J BIOL CHEM, V264, P18874; MITCHELL P, 1987, ADV MEMBRANE BIOCH B, P25; MIYOSHI H, 1990, BIOCHIM BIOPHYS ACTA, V1016, P99, DOI 10.1016/0005-2728(90)90011-R; Oyedotun KS, 1999, FEBS LETT, V442, P203, DOI 10.1016/S0014-5793(98)01657-3; Oyedotun KS, 1999, BBA-BIOENERGETICS, V1411, P170, DOI 10.1016/S0005-2728(99)00040-7; Oyedotun KS, 1999, J BIOL CHEM, V274, P23956, DOI 10.1074/jbc.274.34.23956; Oyedotun KS, 1997, J BIOL CHEM, V272, P31382, DOI 10.1074/jbc.272.50.31382; PADDOCK ML, 1989, P NATL ACAD SCI USA, V86, P6602, DOI 10.1073/pnas.86.17.6602; RICH PR, 1977, BIOCHIM BIOPHYS ACTA, V462, P501, DOI 10.1016/0005-2728(77)90097-4; RICH PR, 1978, BIOCHIM BIOPHYS ACTA, V504, P345, DOI 10.1016/0005-2728(78)90059-2; Robinson KM, 1995, METHOD ENZYMOL, V260, P34, DOI 10.1016/0076-6879(95)60128-7; ROBINSON KM, 1991, J BIOL CHEM, V266, P21347; ROBINSON KM, 1994, EUR J BIOCHEM, V222, P983, DOI 10.1111/j.1432-1033.1994.tb18949.x; ROBINSON KM, 1992, J BIOL CHEM, V267, P10101; SAITOH I, 1992, EUR J BIOCHEM, V209, P73, DOI 10.1111/j.1432-1033.1992.tb17262.x; Scheffler IE, 1998, PROG NUCLEIC ACID RE, V60, P267, DOI 10.1016/S0079-6603(08)60895-8; SCHULKE N, 1992, P NATL ACAD SCI USA, V89, P8011, DOI 10.1073/pnas.89.17.8011; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; Shenoy SK, 1997, J BIOL CHEM, V272, P17867, DOI 10.1074/jbc.272.28.17867; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; WESTENBERG DJ, 1990, J BIOL CHEM, V265, P19560; WIKSTROM M, 1984, BIOENERGETICS, P49; Wu JW, 1998, BIOCHEM J, V335, P181, DOI 10.1042/bj3350181; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yankovskaya V, 1996, J BIOL CHEM, V271, P21020, DOI 10.1074/jbc.271.35.21020; YU CA, 1980, BIOCHEMISTRY-US, V19, P3579, DOI 10.1021/bi00556a025; YU CA, 1985, BIOCHEMISTRY-US, V24, P3897, DOI 10.1021/bi00336a013; YU L, 1981, BIOCHIM BIOPHYS ACTA, V637, P383, DOI 10.1016/0005-2728(81)90177-8	54	37	38	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16936	16943		10.1074/jbc.M100184200	http://dx.doi.org/10.1074/jbc.M100184200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279023	hybrid			2022-12-25	WOS:000168730400045
J	Siegel, G; Sternfeld, L; Gonzalez, A; Schulz, I; Schmid, A				Siegel, G; Sternfeld, L; Gonzalez, A; Schulz, I; Schmid, A			Arachidonic acid modulates the spatiotemporal characteristics of agonist-evoked Ca2+ waves in mouse pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ACTIVATED PROTEIN-KINASE; EXOCRINE PANCREAS; MAP KINASE; PHAS-I; CHOLECYSTOKININ; PHOSPHORYLATION; RELEASE; OSCILLATIONS; MOBILIZATION	In pancreatic acinar cells analysis of the propagation speed of secretagogue-evoked Ca2+ waves can be used to examine coupling of hormone receptors to intracellular signal cascades that cause activation of protein kinase C or production of arachidonic acid (AA), In the present study we have investigated the role of cytosolic phospholipase A(2) (cPLA(2)) and AA in acetylcholine (ACh)- and bombesin-induced Ca2+ signaling. Inhibition of cPLA(2) caused acceleration of ACh-induced Ca2+ waves, whereas bombesin-evoked Ca2+ waves were unaffected. When enzymatic metabolization of AA was prevented with the cyclooxygenase inhibitor indomethacin or the lipoxygenase inhibitor nordihydroguaiaretic acid, ACh-induced Ca2+ waves were slowed down. Agonist-induced activation of cPLA(2) involves mitogen-activated protein kinase (MAPK) activation. An increase in phosphorylation of p38(MAPK) and p42/44(MAPK) within 10 a after stimulation could be demonstrated for ACh but was absent for bombesin, Rapid phosphorylation of p38(MAPK) and p42/44MAPK could also be observed in the presence of cholecystokinin (CCK), which also causes activation of cPLA(2). ACh-and CCK-induced Ca2+ waves were slowed down when p38MAPK Wag inhibited with SE 203580, whereas inhibition of p42/44MAPK With PD 98059 caused acceleration of ACh- and CCK-induced Ca2+ waves. The spreading of bombesin-evoked Ca2+ waves was affected neither by PD 98059 nor by SE 203580. Our data indicate that in mouse pancreatic acinar cells both ACh and CCK receptors couple to the cPLA(2) pathway. cPLA(2) activation occurs within 1-2 s after hormone application and is promoted by p42/44MAPK and inhibited by p38MAPK. Furthermore, the data demonstrate that secondary (Ca2+-induced) Ca2+ release, which supports Ca2+ wave spreading, is inhibited by AA. itself and not by a metabolite of AA.	Univ Saarland, Dept Physiol 2, D-66421 Homburg, Germany	Saarland University	Schmid, A (corresponding author), Univ Saarland, Dept Physiol 2, D-66421 Homburg, Germany.		Gonzalez, Antonio/C-5428-2018	Gonzalez, Antonio/0000-0001-8380-0270				Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; Blinman TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1993, DOI 10.1152/ajpcell.2000.279.6.C1993; Bragado MJ, 1998, GASTROENTEROLOGY, V115, P733, DOI 10.1016/S0016-5085(98)70153-2; Bragado MJ, 2000, GASTROENTEROLOGY, V119, P1731, DOI 10.1053/gast.2000.20242; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Gonzalez A, 1999, BIOCHEM BIOPH RES CO, V261, P726, DOI 10.1006/bbrc.1999.1106; Gonzalez A, 2000, J BIOL CHEM, V275, P38680, DOI 10.1074/jbc.M005667200; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Lin WW, 1998, BRIT J PHARMACOL, V125, P1601, DOI 10.1038/sj.bjp.0702219; MARUYAMA Y, 1993, J PHYSIOL-LONDON, V463, P729, DOI 10.1113/jphysiol.1993.sp019619; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; Rowles SJ, 1996, BIOCHEM J, V319, P913, DOI 10.1042/bj3190913; Schafer C, 1998, J BIOL CHEM, V273, P24173, DOI 10.1074/jbc.273.37.24173; Schulz I, 1999, BIOL CHEM, V380, P903, DOI 10.1515/BC.1999.111; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; Syrbu SI, 1999, J IMMUNOL, V162, P2334; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TSUNODA Y, 1995, AM J PHYSIOL-GASTR L, V269, pG435, DOI 10.1152/ajpgi.1995.269.3.G435; Wheeler-Jones C, 1997, FEBS LETT, V420, P28, DOI 10.1016/S0014-5793(97)01481-6	24	6	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16986	16991		10.1074/jbc.M101136200	http://dx.doi.org/10.1074/jbc.M101136200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279177	hybrid			2022-12-25	WOS:000168730400051
J	Hirata, K; Ishida, T; Penta, K; Rezaee, M; Yang, E; Wohlgemuth, J; Quertermous, T				Hirata, K; Ishida, T; Penta, K; Rezaee, M; Yang, E; Wohlgemuth, J; Quertermous, T			Cloning of an immunoglobulin family adhesion molecule selectively expressed by endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-JUNCTIONS; SUPERFAMILY; ANGIOGENESIS; RECEPTOR; PROTEIN; MEMBER; MEMBRANE; PECAM-1; SURFACE; CTX	To gain fundamental information regarding the molecular basis of endothelial cell adhesive interactions during vascular formation, we have cloned and characterized a unique cell adhesion molecule. This molecule, named endothelial cell-selective adhesion molecule (ESAM), is a new member of the immunoglobulin superfamily. The conceptual protein encoded by cDNA clones consists of V-type and C2-type immunoglobulin domains as well as a hydrophobic signal sequence, a single transmembrane region, and a cytoplasmic domain. Northern blot analysis showed ESAM to be selectively expressed in cultured human and murine vascular endothelial cells and revealed high level expression in lung and heart and low level expression in kidney and skin. In situ hybridization analysis indicated that ESAM is primarily expressed in the developing vasculature of the embryo in an endothelial cell-restricted pattern. Epitope-tagged ESAM was shown to co-localize with cadherins and catenins in cell-cell junctions. In aggregation assays employing ESAM-expressing Chinese hamster ovary cells, this novel molecule was shown to mediate cell-cell adhesion through homophilic interactions. The endothelial cell-selective expression of this immunoglobulin-like adhesion molecule coupled with its in vitro functional profile strongly suggests a role in cell-cell interactions that is critical for vascular development or function.	Stanford Univ, Sch Med, Div Cardiovasc Med, Falk CVRC, Stanford, CA 94305 USA; Kobe Univ, Sch Med, Dept Internal Med 1, Kobe, Hyogo 6500017, Japan	Stanford University; Kobe University	Quertermous, T (corresponding author), Stanford Univ, Sch Med, Div Cardiovasc Med, Falk CVRC, 300 Pasteur Dr, Stanford, CA 94305 USA.			Quertermous, Thomas/0000-0002-7645-9067				BALDWIN HS, 1994, DEVELOPMENT, V120, P2539; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; Bischoff J, 1997, J CLIN INVEST, V99, P373, DOI 10.1172/JCI119168; Bosenberg MW, 1993, CURR OPIN CELL BIOL, V5, P832, DOI 10.1016/0955-0674(93)90032-L; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chretien I, 1996, EUR J IMMUNOL, V26, P780, DOI 10.1002/eji.1830260409; Chretien I, 1998, EUR J IMMUNOL, V28, P4094; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DeLisser HM, 1997, AM J PATHOL, V151, P671; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Duncan GS, 1999, J IMMUNOL, V162, P3022; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hidai C, 1998, GENE DEV, V12, P21, DOI 10.1101/gad.12.1.21; Hirata K, 1999, J BIOL CHEM, V274, P14170, DOI 10.1074/jbc.274.20.14170; Hogan B., 1994, MANIPULATING MOUSE E, P344; Huang YQ, 1997, J CELL BIOL, V138, P143, DOI 10.1083/jcb.138.1.143; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Katevuo K, 1999, J IMMUNOL, V162, P5685; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Newman PJ, 1997, J CLIN INVEST, V100, pS25; Newman PJ, 1999, J CLIN INVEST, V103, P5, DOI 10.1172/JCI5928; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIMENTA AF, 1995, NEURON, V15, P287, DOI 10.1016/0896-6273(95)90034-9; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robert J, 1997, EXP CELL RES, V235, P227, DOI 10.1006/excr.1997.3672; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; Stromblad S, 1996, CHEM BIOL, V3, P881, DOI 10.1016/S1074-5521(96)90176-3; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Telo P, 1998, J BIOL CHEM, V273, P17565, DOI 10.1074/jbc.273.28.17565; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; VONHEIJNE G, 1987, SEQUENCE ANAL MOL BI, P112; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Zhou Y, 1997, J CLIN INVEST, V99, P2139, DOI 10.1172/JCI119387	45	143	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16223	16231		10.1074/jbc.M100630200	http://dx.doi.org/10.1074/jbc.M100630200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279107	hybrid			2022-12-25	WOS:000168623100088
J	Ishikawa, T; Uematsu, N; Mizukoshi, T; Iwai, S; Iwasaki, H; Masutani, C; Hanaoka, F; Ueda, R; Ohmori, H; Todo, T				Ishikawa, T; Uematsu, N; Mizukoshi, T; Iwai, S; Iwasaki, H; Masutani, C; Hanaoka, F; Ueda, R; Ohmori, H; Todo, T			Mutagenic and nonmutagenic bypass of DNA lesions by Drosophila DNA polymerases dpol eta and dpol iota	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE-THYMINE DIMER; ESCHERICHIA-COLI; CIS-SYN; CYCLOBUTANE DIMER; GENE ENCODES; 6-4 ADDUCT; PHOTOPRODUCT; FIDELITY; PROTEIN; REPAIR	cDNA sequences were identified and isolated that encode Drosophila homologues of human Rad30A and Rad30B called drad30A and drad30B, Here we show that the C-terminal-truncated forms of the drad30A and drad30B gene products, designated dpol eta DeltaC and dpol iota DeltaC, respectively, exhibit DNA polymerase activity, dpol eta DeltaC and dpol iota DeltaC efficiently bypass a cis syn.-cyclobutane thymine-thymine (TT) dimer in a mostly error-free manner. dpol eta DeltaC shows limited ability to bypass a 6-4-photoproduct ((6-4)PP) at thymine-thymine (TT-(6-4)PP) or at thymine-cytosine (TC-(6-4)PP) in an error-prone manner. dpol iota DeltaC scarcely bypasses these lesions. Thus, the fidelity of translesion synthesis depends on the identity of the lesion and on the polymerase. The human XPV gene product, hpol eta, bypasses cis-syn-cyclobutane thymine-thymine dimer efficiently in a mostly error-free manner but does not bypass TT-(6-4)PP, whereas Escherichia coli DNA polymerase V (UmuD'C-2 complex) bypasses both lesions, especially TT-(6-4)PP, in an error prone manner (Tang, M., Pham, P., Shen, X, Taylor, J. S., O'Donnell, M., Woodgate, R., and Goodman, M, F. (2000) Nature 404, 1014-1018); Both dpol eta DeltaC and DNA polymerase V preferentially incorporate GA opposite TT-(6-4)PP. The chemical structure of the lesions and the similarity in the nucleotides incorporated suggest that structural information in the altered bases contribute to nucleotide selection during incorporation opposite these lesions by these polymerases.	Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan; Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University; Osaka University; Osaka University; Kyoto University	Todo, T (corresponding author), Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Yoshidakonoe Cho, Kyoto 6068501, Japan.	todo@house.rbc.kyoto-u.ac.jp	Iwasaki, Hiroshi/Y-7946-2018; Masutani, Chikahide/I-6160-2014	Iwasaki, Hiroshi/0000-0002-0153-6873; Masutani, Chikahide/0000-0002-8600-8227				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Friedberg EC, 1995, DNA REPAIR MUTAGENES, P24; Fujiwara Y, 1997, BIOCHEMISTRY-US, V36, P1544, DOI 10.1021/bi9619942; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; HORSFALL MJ, 1994, J MOL BIOL, V235, P465, DOI 10.1006/jmbi.1994.1006; Horsfall MJ, 1997, J BACTERIOL, V179, P2835, DOI 10.1128/jb.179.9.2835-2839.1997; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KEMMINK J, 1987, NUCLEIC ACIDS RES, V15, P4645, DOI 10.1093/nar/15.11.4645; KIM JK, 1995, PHOTOCHEM PHOTOBIOL, V62, P44, DOI 10.1111/j.1751-1097.1995.tb05236.x; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; LAWRENCE CW, 1990, MOL GEN GENET, V222, P166, DOI 10.1007/BF00283040; LECLERC JE, 1991, P NATL ACAD SCI USA, V88, P9685, DOI 10.1073/pnas.88.21.9685; Lee JH, 1999, P NATL ACAD SCI USA, V96, P6632, DOI 10.1073/pnas.96.12.6632; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; Mizukoshi T, 1998, J AM CHEM SOC, V120, P10634, DOI 10.1021/ja982004y; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, GENE DEV, V14, P1589; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Otoshi E, 2000, CANCER RES, V60, P1729; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; TAYLOR JS, 1990, BIOCHEMISTRY-US, V29, P8858, DOI 10.1021/bi00489a049; Tissier A, 2000, GENE DEV, V14, P1642; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; TODO T, 1993, NATURE, V361, P371, DOI 10.1038/361371a0; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000	46	31	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15155	15163		10.1074/jbc.M009822200	http://dx.doi.org/10.1074/jbc.M009822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11297519	hybrid			2022-12-25	WOS:000168528800084
J	Wang, XY; He, C; Moore, SC; Ausio, J				Wang, XY; He, C; Moore, SC; Ausio, J			Effects of histone acetylation on the solubility and folding of the chromatin fiber	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION IN-VIVO; GENE-EXPRESSION; NUCLEOSOMAL DNA; H1; CELLS; AGGREGATION; BUTYRATE; BINDING; CANCER; YEAST	The folding ability of chromatin fractions containing approximately identical nucleosome numbers and the same linker histone composition, but with different extents of core histone acetylation, were analyzed by analytical ultracentrifugation. It was found that the acetylated fractions consistently exhibited a relatively small but significantly lower extent of compaction than that of their native nonacetylated counterparts. This was regardless of the extent of the size distribution heterogeneity of the fractions analyzed. Furthermore the acetylated chromatin fibers exhibited an enhanced solubility in both NaCl and MgCl2, which is neither the result of a differential binding affinity of the linker histones to chromatin nor of an alteration in the relative amounts of the histone H1 variants.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Ausio, J (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055,Petch Bldg 220, Victoria, BC V8W 3P6, Canada.	jausio@uvic.ca						Albig W, 1998, FEBS LETT, V435, P245, DOI 10.1016/S0014-5793(98)01084-9; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; AUSIO J, 1992, J CELL SCI, V102, P1; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; AUSIO J, 1984, J MOL BIOL, V177, P373, DOI 10.1016/0022-2836(84)90291-2; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1981, DOI 10.1021/bi00356a022; Ausio J, 1998, METHODS, V15, P333, DOI 10.1006/meth.1998.0637; Ausio J, 2000, BIOPHYS CHEM, V86, P141, DOI 10.1016/S0301-4622(00)00144-7; BROWN DT, 1993, J BIOL CHEM, V268, P713; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Conley BA, 1998, CLIN CANCER RES, V4, P629; DANNA JA, 1980, BIOCHEMISTRY-US, V19, P2656, DOI 10.1021/bi00553a019; Davie JR, 2001, PROG NUCLEIC ACID RE, V65, P299; Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265; DIMITROV S, 1986, FEBS LETT, V197, P217, DOI 10.1016/0014-5793(86)80329-5; Dou YL, 2000, MOL CELL, V6, P225, DOI 10.1016/S1097-2765(00)00024-1; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; GUO XW, 1989, J BIOL CHEM, V264, P16873; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Jacobson S, 1999, CURR OPIN GENET DEV, V9, P175, DOI 10.1016/S0959-437X(99)80027-6; JIN YI, 1986, J BIOL CHEM, V261, P3420; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI W, 1993, BIOCHEM J, V296, P737, DOI 10.1042/bj2960737; MCGHEE JD, 1983, NUCLEIC ACIDS RES, V11, P4065, DOI 10.1093/nar/11.12.4065; Misteli T, 2000, NATURE, V408, P877, DOI 10.1038/35048610; Moore SC, 1997, BIOCHEM J, V328, P409; Mutskov V, 1998, MOL CELL BIOL, V18, P6293, DOI 10.1128/MCB.18.11.6293; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PERRY M, 1982, J BIOL CHEM, V257, P7336; PERRY M, 1981, J BIOL CHEM, V256, P3313; PHILLIPS DM, 1963, BIOCHEM J, V87, P258, DOI 10.1042/bj0870258; Rabbani A, 1999, J BIOL CHEM, V274, P18401, DOI 10.1074/jbc.274.26.18401; RIGGS MG, 1977, NATURE, V268, P462, DOI 10.1038/268462a0; SHAW BR, 1981, BIOCHEMISTRY-US, V20, P4971, DOI 10.1021/bi00520a025; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; van Holde K.E., 1988, CHROMATIN; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Wang XY, 2000, J BIOL CHEM, V275, P35013, DOI 10.1074/jbc.M004998200; Waterborg JH, 2000, J BIOL CHEM, V275, P13007, DOI 10.1074/jbc.275.17.13007	45	76	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12764	12768		10.1074/jbc.M100501200	http://dx.doi.org/10.1074/jbc.M100501200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11279082	hybrid			2022-12-25	WOS:000168198600042
J	Mahale, SD; Cavanagh, J; Schmidt, A; MacColl, R; Dias, JA				Mahale, SD; Cavanagh, J; Schmidt, A; MacColl, R; Dias, JA			Autologous biological response modification of the gonadotropin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; HUMAN CHORIONIC-GONADOTROPIN; PROTEIN SECONDARY STRUCTURE; AMINO-ACID-RESIDUES; EXTRACELLULAR DOMAIN; GLYCOPROTEIN HORMONES; CIRCULAR-DICHROISM; LIGAND-BINDING; BETA-SUBUNIT	It is generally held with respect to heterotrimeric guanine nucleotide binding protein-coupled receptors that binding of ligand stabilizes a conformation of receptor that activates adenylyl cyclase, It is not formally appreciated if, in the case of G-protein-coupled receptors with large extracellular domains (ECDs), ECDs directly participate in the activation process. The large ECD of the glycoprotein hormone receptors (GPHRs) is 350 amino acids in length, composed of seven leucine-rich repeat domains, and necessary and sufficient: for high affinity binding of the glycoprotein hormones. Peptide challenge experiments to identify regions in the follicle-stimulating hormone (FSH) receptor (FSHR) ECD that could bind its cognate ligand identified only a single synthetic peptide corresponding to residues 221-252, which replicated a leucine-rich repeat domain of the FSHR ECD and which had intrinsic activity. This peptide inhibited human FSH binding to the human FSHR (hFSHR) and also inhibited human FSH-induced signal transduction in Y-1 cells expressing recombinant hFSHR. The hFSRR-(221-252) domain was not accessible to anti-peptide antibody probes, suggesting that this domain resides at an interface between the hFSHR ECD and transmembrane domains. CD spectroscopy of the peptide in dodecyl phosphocholine micelles showed an increase in the ordered structure of the peptide. CD and NMR spectroscopies of the peptide in trifluoroethanol confirmed that hFSRR-(221-252) has the propensity to form ordered secondary structure. Importantly and consistent with the foregoing results, dodecyl phosphocholine induced a significant increase in the ordered secondary structure of the purified hFSHR ECD as well. These data provide biophysical evidence of the influence of environment on GPHR ECD subdomain secondary structure and identify a specific activation domain that; can autologously modify GPHR activity.	New York State Dept Hlth, David Axelrod Inst Publ Hlth, Wadsworth Ctr, Albany, NY 12208 USA	State University of New York (SUNY) System; Wadsworth Center	Dias, JA (corresponding author), New York State Dept Hlth, David Axelrod Inst Publ Hlth, Wadsworth Ctr, 120 New Scotland Ave, Albany, NY 12208 USA.			Schmidt, Anja/0000-0002-2304-8774; Dias, James A/0000-0002-9792-5469	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018407] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 18407] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AITTOMAKI K, 1995, CELL, V82, P959, DOI 10.1016/0092-8674(95)90275-9; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; DATTATREYAMURTY B, 1992, MOL CELL ENDOCRINOL, V87, P9, DOI 10.1016/0303-7207(92)90228-X; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GRISWOLD MD, 1993, SERTOLI CELL, P494; Hileman MR, 1997, FEBS LETT, V415, P145, DOI 10.1016/S0014-5793(97)01113-7; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Jiang XL, 1995, STRUCTURE, V3, P1341, DOI 10.1016/S0969-2126(01)00272-6; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; KELTON CA, 1992, MOL CELL ENDOCRINOL, V89, P141, DOI 10.1016/0303-7207(92)90220-Z; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; Kumar TR, 1997, NAT GENET, V15, P201, DOI 10.1038/ng0297-201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XB, 1993, J BIOL CHEM, V268, P1513; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; Massi C, 1998, BIOCHEM BIOPH RES CO, V246, P160, DOI 10.1006/bbrc.1998.8580; MATTHEWS CH, 1993, NAT GENET, V5, P83, DOI 10.1038/ng0993-83; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; Means G.E., 1971, CHEM MODIFICATION PR, P214; MINEGISH T, 1991, BIOCHEM BIOPH RES CO, V175, P1125, DOI 10.1016/0006-291X(91)91682-3; MORRIS JC, 1993, J BIOL CHEM, V268, P10900; Moudgal NR, 1997, ENDOCRINOLOGY, V138, P3065, DOI 10.1210/en.138.7.3065; Moudgal NR, 1997, HUM REPROD, V12, P457; MOUDGAL NR, 1992, J REPROD FERTIL, V96, P91; MOYLE WR, 1995, J BIOL CHEM, V270, P20020, DOI 10.1074/jbc.270.34.20020; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Peterson AJ, 2000, MOL CELL ENDOCRINOL, V160, P203, DOI 10.1016/S0303-7207(99)00204-X; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; RANCE M, 1987, J MAGN RESON, V74, P557, DOI 10.1016/0022-2364(87)90277-0; RICHARDS JS, 1980, PHYSIOL REV, V60, P51, DOI 10.1152/physrev.1980.60.1.51; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; ROTH KE, 1995, MOL CELL ENDOCRINOL, V109, P143, DOI 10.1016/0303-7207(95)03494-R; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; Sreerama N, 1999, PROTEIN SCI, V8, P370; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Sreerama N, 1999, PROTEINS, V36, P400, DOI 10.1002/(SICI)1097-0134(19990901)36:4<400::AID-PROT3>3.0.CO;2-B; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Tapanainen JS, 1997, NAT GENET, V15, P205, DOI 10.1038/ng0297-205; TAYLOR JW, 1987, METHOD ENZYMOL, V154, P473; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WATERHOUS DV, 1994, BIOCHEMISTRY-US, V33, P2121, DOI 10.1021/bi00174a019; WEINER RS, 1991, ENDOCRINOLOGY, V128, P1485, DOI 10.1210/endo-128-3-1485; YANAGISHITA M, 1978, ANAL BIOCHEM, V88, P1, DOI 10.1016/0003-2697(78)90393-7	48	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12410	12419		10.1074/jbc.M100115200	http://dx.doi.org/10.1074/jbc.M100115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11279009	hybrid			2022-12-25	WOS:000168081800129
J	Singh, SK; Matsuno, K; LaPorte, DC; Banaszak, LJ				Singh, SK; Matsuno, K; LaPorte, DC; Banaszak, LJ			Crystal structure of Bacillus subtilis isocitrate dehydrogenase at 1.55 angstrom - Insights into the nature of substrate specificity exhibited by Escherichia coli isocitrate dehydrogenase kinase/phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; X-RAY-DIFFRACTION; MOLECULAR-DYNAMICS; ACTIVE-SITE; PHOSPHORYLATION; ENZYME; PHOSPHATASE; REFINEMENT; MECHANISM; MAPS	Isocitrate dehydrogenase from Bacillus subtilis (BsIDH) is a member of a family of metal-dependent decarboxylating dehydrogenases, Its crystal structure was solved to 1.55 Angstrom and detailed comparisons with the homologue from Escherichia coli (EcIDH), the founding member of this family, were made. Although the two IDHs are structurally similar, there are three notable differences between them. First, a mostly nonpolar P-strand and two connecting loops in the small domain of EcIDH are replaced by two polar alpha -helices in BsIDH. Because of a 13-residue insert in this region of BsIDH, these helices protrude over the active site cleft of the opposing monomer, Second, a coil leading into this cleft, the so-called "phosphorylation" loop, is bent inward in the B, subtilis enzyme, narrowing the entrance to the active site from about 12 to 4 Angstrom. Third, although BsIDH is a homodimer, the two unique crystallographic subunits of BsIDH are not structurally identical. The two monomers appear to differ by a domain shift of the large domain relative to the small domain/clasp region, reminiscent of what has been observed in the open/closed conformations of EcIDH. In Escherichia coli, IDH is regulated by reversible phosphorylation by the bifunctional enzyme IDH kinase/phosphatase (IDH-K/P), The site of phosphorylation is Ser(113), which lies deep within the active site crevice. Structural differences between EcIDH and BsIDH may explain disparities in their abilities to act as substrates for IDH-K/P.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA; Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA	University of Minnesota System; University of Minnesota Twin Cities; Tufts University	Banaszak, LJ (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 6-155 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	len_b@dcmir.med.umn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036718] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR VERSION 3 1 SY; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DEAN AM, 1989, J BIOL CHEM, V264, P20482; DEAN AM, 1993, BIOCHEMISTRY-US, V32, P9302, DOI 10.1021/bi00087a007; Duret L, 1996, COMPUT APPL BIOSCI, V12, P507; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HOWARD A, 1978, J APPL CRYSTALLOGR, V20, P383; HUBER R, 1965, ACTA CRYSTALLOGR, V19, P353, DOI 10.1107/S0365110X65003444; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KEMP BE, 1977, J BIOL CHEM, V252, P4888; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KORNBERG HL, 1966, BIOCHEM J, V99, P1; LAPORTE DC, 1984, J BIOL CHEM, V259, P4068; LAPORTE DC, 1985, J BIOL CHEM, V260, P563; LAPORTE DC, 1982, NATURE, V300, P458, DOI 10.1038/300458a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVITT DG, 1993, J APPL CRYSTALLOGR, V26, P736, DOI 10.1107/S0021889893003279; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Matsuno K, 1999, J BACTERIOL, V181, P3382, DOI 10.1128/JB.181.11.3382-3391.1999; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCKEE JS, 1989, BIOCHIMIE, V71, P1059, DOI 10.1016/0300-9084(89)90111-9; Miller SP, 2000, J BIOL CHEM, V275, P833, DOI 10.1074/jbc.275.2.833; NIMMO GA, 1984, EUR J BIOCHEM, V141, P409, DOI 10.1111/j.1432-1033.1984.tb08206.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SRIDHARAN S, 1995, J COMPUT CHEM, V16, P1038, DOI 10.1002/jcc.540160810; STEIGEMANN W, 1974, THESIS TU MUENCHEN; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; Stroud RM, 1991, CURR OPIN STRUC BIOL, V1, P826, DOI 10.1016/0959-440X(91)90186-W; THORSNESS PE, 1987, J BIOL CHEM, V262, P10422; 1996, KALEIDAGRAPH SYNERGY	48	52	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26154	26163		10.1074/jbc.M101191200	http://dx.doi.org/10.1074/jbc.M101191200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11290745	hybrid			2022-12-25	WOS:000169823300070
J	Neudecker, P; Schweimer, K; Nerkamp, J; Scheurer, S; Vieths, S; Sticht, H; Rosch, P				Neudecker, P; Schweimer, K; Nerkamp, J; Scheurer, S; Vieths, S; Sticht, H; Rosch, P			Allergic cross-reactivity made visible - Solution structure of the major cherry allergen Pru av 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIRCH POLLEN ALLERGEN; PATHOGENESIS-RELATED PROTEINS; INTERPROTON DISTANCE DATA; PULSED-FIELD GRADIENTS; 3-DIMENSIONAL STRUCTURES; NMR DATA; BET-V-1; PROGRAM; CLONING; SPECTROSCOPY	Birch pollinosis is often accompanied by hypersensitivity to fruit as a consequence of the cross-reaction of pollen allergen-specific IgE antibodies with homologous food proteins. To provide a basis for examining the cross-reactivity on a structural level, we used heteronuclear multidimensional NMR spectroscopy to determine the high-resolution three dimensional structure of the major cherry allergen, Pru av 1, in solution. Based on a detailed comparison of the virtually identical structures of Pru av 1 and Bet v 1, the major birch pollen allergen, we propose an explanation for a significant aspect of the observed cross-reactivity pattern among the family of allergens under consideration. The large hydrophobic cavity expected to be important for the still unknown physiological function of Bet v 1 is conserved in Pru av 1. Structural homology to a domain of human MLN64 associated with cholesterol transport suggests phytosteroids as putative ligands for Pru av 1, NMR spectroscopy provides experimental evidence that Pru av 1 interacts with phytosteroids, and molecular modeling shows that the hydrophobic cavity is large enough to accommodate two such molecules.	Univ Bayreuth, Lehrstuhl Biopolymere, D-95440 Bayreuth, Germany; Paul Ehrlich Inst, Abt Allergol, D-63225 Langen, Germany	University of Bayreuth; Paul Ehrlich Institute	Rosch, P (corresponding author), Univ Bayreuth, Lehrstuhl Biopolymere, Univ Str 30, D-95447 Bayreuth, Germany.	paul.roesch@uni-bayreuth.de	Neudecker, Philipp/G-5265-2013; Rösch, Paul/I-5445-2014; Neudecker, Philipp/AAP-9005-2020; Scheurer, Stephan/A-6509-2019	Neudecker, Philipp/0000-0002-0557-966X; Rösch, Paul/0000-0003-3330-2446; Neudecker, Philipp/0000-0002-0557-966X; Scheurer, Stephan/0000-0002-2859-562X; Sticht, Heinrich/0000-0001-5644-045X; Schweimer, Kristian/0000-0002-3837-8442				BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Beissinger M, 1998, EMBO J, V17, P27, DOI 10.1093/emboj/17.1.27; Boehm M, 1997, BIOL CHEM, V378, P687, DOI 10.1515/bchm.1997.378.7.687; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1993, SCIENCE, V261, P328, DOI 10.1126/science.8332897; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; Cavanagh J., 1996, PROTEIN NMR SPECTROS, P447; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; Diercks T, 1999, J BIOMOL NMR, V15, P177, DOI 10.1023/A:1008367912535; Faber C, 1996, J BIOL CHEM, V271, P19243, DOI 10.1074/jbc.271.32.19243; Ferreira F, 1998, FASEB J, V12, P231, DOI 10.1096/fasebj.12.2.231; FRENKIEL T, 1990, J MAGN RESON, V90, P420, DOI 10.1016/0022-2364(90)90152-Y; Fujioka S, 1999, BRASSINOSTEROIDS, P21; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GHOSH D, 1995, STRUCTURE, V3, P279, DOI 10.1016/S0969-2126(01)00158-7; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; HOLAK TA, 1989, FEBS LETT, V242, P218, DOI 10.1016/0014-5793(89)80473-9; HOLM J, 2000, ALLERGY, V55, P21; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KARAMLOO F, 2000, IN PRESS J CHROMAT B; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; Kuszewski J, 1996, PROTEIN SCI, V5, P1067; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mirza O, 2000, J IMMUNOL, V165, P331, DOI 10.4049/jimmunol.165.1.331; Neudecker P, 2000, J BIOMOL NMR, V18, P71, DOI 10.1023/A:1008357100592; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; POWELL MJD, 1977, MATH PROGRAM, V12, P241, DOI 10.1007/BF01593790; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; SCHONING B, 1995, J SCI FOOD AGR, V67, P431, DOI 10.1002/jsfa.2740670403; Schweimer K, 1999, APPL MAGN RESON, V17, P449, DOI 10.1007/BF03162177; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; SLUYTERMAN LAA, 1978, J CHROMATOGR, V150, P17, DOI 10.1016/S0021-9673(01)92092-8; Sticht H, 1998, J MOL BIOL, V276, P177, DOI 10.1006/jmbi.1997.1528; SWOBODA I, 1995, PLANT CELL ENVIRON, V18, P865, DOI 10.1111/j.1365-3040.1995.tb00595.x; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vieths S., 1992, Food and Agricultural Immunology, V4, P181, DOI 10.1080/09540109209354767; VIETHS S, 2000, ARBEITEN P EHRLICH I, V93, P159; VIETHS S, 1997, HDB PLANT FUNGAL TOX, P157	56	139	148	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22756	22763		10.1074/jbc.M101657200	http://dx.doi.org/10.1074/jbc.M101657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11287426	hybrid			2022-12-25	WOS:000169412700104
J	Yigzaw, Y; Cartin, L; Pierre, S; Scholich, K; Patel, TB				Yigzaw, Y; Cartin, L; Pierre, S; Scholich, K; Patel, TB			The C terminus of sprouty is important for modulation of cellular migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSDUCTION; DROSOPHILA SPROUTY; FGF; EXPRESSION; ANTAGONIST; INHIBITOR; DELIVERY; HOMOLOG; MOUSE; CELLS	The Drosophila Sprouty (SPRY) protein has been shown to inhibit the actions of epidermal growth factor and fibroblast growth factor. However, the role of mammalian SPRY proteins has not been clearly elucidated. We postulated that human Sprouty2 (hSPRY2) is an inhibitor of cellular migration and proliferation. Indeed, using stably transfected HeLa cells, which expressed hemagglutinin (HA)-tagged hSPRY2 or hSPRY2 tagged at the C terminus with red fluorescent protein, we demonstrated that hSPRY2 inhibits the migration of cells in response to serum, epidermal growth factor, fibroblast growth factor, and platelet-derived growth factor. Additionally, hSPRY2 also inhibited the growth of HeLa cells in response to serum. Previously, two C-terminal domains on hSPRY2, which are necessary for its colocalization with microtubules (residues 123-177) or translocation to membrane ruffles (residues 178-194), have been identified (Lim, J., Wong, E. S., Ong, S. H., Yusoff, P., Low, B. C., and Guy, G. R. (2000) J. Biol. Chem. 275, 32837-32845), Therefore, using TAT-tagged hSPRY2 and its mutants, we determined the role of these two C-terminal domains in the inhibition of cell migration and proliferation. Our data show that the deletion of either of these two regions in hSPRY2 abrogates its ability to modulate cell migration in response to different growth factors and proliferation in response to serum. Therefore, we conclude that hSPRY2 inhibits the actions of a number of growth factors, and its C terminus, which is homologous among various SPRY isoforms, is important in mediating its biological activity.	Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Vasc Biol Ctr Excellence, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Patel, TB (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pharmacol, 874 Union Ave, Memphis, TN 38163 USA.				NHLBI NIH HHS [HL48308, HL07641] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown C, 1999, CIRC RES, V84, P655, DOI 10.1161/01.RES.84.6.655; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Kramer S, 1999, DEVELOPMENT, V126, P2515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lim J, 2000, J BIOL CHEM, V275, P32837, DOI 10.1074/jbc.M002156200; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Minowada G, 1999, DEVELOPMENT, V126, P4465; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Reich A, 1999, DEVELOPMENT, V126, P4139; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Vocero-Akbani A, 2000, METHOD ENZYMOL, V322, P508	15	95	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22742	22747		10.1074/jbc.M100123200	http://dx.doi.org/10.1074/jbc.M100123200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11279012	hybrid			2022-12-25	WOS:000169412700102
J	Arozarena, I; Matallanas, D; Crespo, P				Arozarena, I; Matallanas, D; Crespo, P			Maintenance of Cdc42 GDP-bound state by Rho-GDI inhibits MAP kinase activation by the exchange factor Ras-GRF - Evidence for Ras-GRF function being inhibited by Cdc42-GDP but unaffected by Cdc42-GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS RAC1; DEPENDENT ACTIVATION; TYROSINE KINASE; MOLECULAR-CLONING; IDENTIFICATION; FAMILY; PHOSPHORYLATION; PATHWAY; CDC25; DBL	The function of the Pas guanine nucleotide exchange factor Ras-GRF/cdc25(Mn) is subject to tight regulatory processes. We have recently shown that the activation of the Ras/MAPK pathway by Ras-GRF is controlled by the Rho family GTPase Cdc42 through still unknown mechanisms. Here, we report that retaining Cdc42 in its GDP-bound state by overexpressing Rho-GDI inhibits Ras-GRF-mediated MAPK activation. Conversely, Ras-GRF basal and LPA- or ionomycin-stimulated activities were unaffected by a constitutively active GTP-bound Cdc42, Moreover, the Cdc42 downstream effecters MLK3, ACK1, PAK1, and WASP had no detectable influence on Ras-GRF-mediated MAPK activation. In contrast, promoting GDP release from Cdc42 with the Rho family GEF Dbl or with ionomycin suppressed the restraint exerted by Cdc42 on Ras-GRF activity. We conclude that Cdc42-GDP inhibits Ras-GRF-induced MAPK activation, but neither Cdc42-GTP nor the Cdc42 downstream effecters affect Ras-GRF performance, Interestingly, the loss of the GDP-bound state by Cdc42 abolishes its inhibitory effects on Ras-GRF function. These results suggest that the Cdc42 mechanism of action may not be solely restricted to activation of downstream signaling cascades when GTP-loaded, Furthermore, the GDP-bound form may be acting as an inhibitory molecule down-modulating parallel signaling routes such as the Ras/MAPK pathway.	CSIC, Inst Invest Biomed, E-28029 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Crespo, P (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	pcrespo@iib.uam.es	gomez, david/U-9465-2019; Crespo, Piero/M-3273-2014; Arozarena, Imanol/A-5981-2017	gomez, david/0000-0002-2360-3141; Crespo, Piero/0000-0003-2825-7783; Arozarena, Imanol/0000-0001-6349-2442				Ajenjo N, 2000, J BIOL CHEM, V275, P7189, DOI 10.1074/jbc.275.10.7189; Arozarena I, 2000, J BIOL CHEM, V275, P26441, DOI 10.1074/jbc.M002992200; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHENEY RE, 1994, MOL BIOL CELL, V5; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, J BIOL CHEM, V266, P20840; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kiyono M, 2000, J BIOL CHEM, V275, P5441, DOI 10.1074/jbc.275.8.5441; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Kiyono M, 2000, J BIOL CHEM, V275, P29788, DOI 10.1074/jbc.M001378200; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTTINGLY RR, 1996, NATURE, V382, P268; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MORII N, 1991, J BIOL CHEM, V266, P7646; Nomanbhoy TK, 1999, BIOCHEMISTRY-US, V38, P1744, DOI 10.1021/bi982198u; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; SASAKI T, 1993, J BIOL CHEM, V268, P23959; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; VAN AL, 1997, GENE DEV, V11, P2295; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Zippel R, 1996, ONCOGENE, V12, P2697	44	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21878	21884		10.1074/jbc.M011383200	http://dx.doi.org/10.1074/jbc.M011383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11285260	hybrid			2022-12-25	WOS:000169297900140
J	Levin, MH; Haggie, PM; Vetrivel, L; Verkman, AS				Levin, MH; Haggie, PM; Vetrivel, L; Verkman, AS			Diffusion in the endoplasmic reticulum of an aquaporin-2 mutant causing human nephrogenic diabetes insipidus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; WATER CHANNELS; PHOTOBLEACHING RECOVERY; CHEMICAL CHAPERONES; MEMBRANE; MOBILITY; DISTRIBUTIONS; TRAFFICKING; MUTATIONS; DYNAMICS	Mutations in the aquaporin-2 (AQP2) water channel cause the hereditary renal disease nephrogenic diabetes insipidus (NDI), The missense mutation PIQP2-T126M causes human recessive NDI by retention at the endoplasmic reticulum (ER) of renal epithelial cells, To determine whether the ER retention of AQP2-T126M is due to relative immobilization in the ER, we measured by fluorescence recovery after photobleaching the intramembrane mobility of green fluorescent protein (GFP) chimeras containing human wild-type and mutant AQP2, In transfected LLC-PK1 renal epithelial cells, GFP-labeled AQP2-T126M was localized to the ER, and wild-type AQP2 to endosomes and the plasma membrane; both were localized to the ER after brefeldin A treatment. Photobleaching with image detection indicated that the GFP-AQP2 chimeras were freely mobile throughout the ER, Quantitative spot photobleaching revealed a diffusion-dependent irreversible process whose recovery depended on spot size and was abolished by paraformaldehyde fixation, In addition, a novel slow reversible fluorescence recovery (t(1/2) similar to2 s) was characterized whose recovery was independent of: spot size and not affected by fixation, AQP2 translational diffusion in the ER was not slowed by the T126M mutation; diffusion coefficients were (in cm(2)/s x 10(-10)) 2.6 +/- 0.5 (wild-type) and 3.0 +/- 0.4 (T126M), Much faster diffusion was found for a lipid probe (diOC(4)(3), 2.7 x 10(-8) cm(2)/s) in the ER membrane and for unconjugated GFP in the aqueous ER lumen (6 x 10(-8) cm(2)/s). ER diffusion of GFP-T126M was not significantly affected by up-regulation of molecular chaperones, cAMP activation, or actin filament disruption. ATP depletion by S-deoxyglucose and azide resulted in comparable slowing/immobilization of wild-type and T126M AQP2, These results indicate that the ER retention of AQP2-T126M does not result from restricted or slowed mobility and suggest that the majority of AQP2-T126M is not aggregated or bound to slowly moving membrane proteins.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124, R01DK043840] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Bichet DG, 1998, AM J MED, V105, P431, DOI 10.1016/S0002-9343(98)00301-5; Canfield MC, 1997, HUM MOL GENET, V6, P1865, DOI 10.1093/hmg/6.11.1865; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Gustafson CE, 1998, HISTOCHEM CELL BIOL, V110, P377, DOI 10.1007/s004180050298; Haupts U, 1998, P NATL ACAD SCI USA, V95, P13573, DOI 10.1073/pnas.95.23.13573; KAO HP, 1993, J CELL BIOL, V120, P175, DOI 10.1083/jcb.120.1.175; Kao HP, 1996, BIOPHYS CHEM, V59, P203; Klumperman J, 2000, CURR OPIN CELL BIOL, V12, P445, DOI 10.1016/S0955-0674(00)00115-0; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; LEE GM, 1993, J CELL BIOL, V120, P25, DOI 10.1083/jcb.120.1.25; LEE GM, 1991, P NATL ACAD SCI USA, V88, P6274, DOI 10.1073/pnas.88.14.6274; Mulders SM, 1997, J AM SOC NEPHROL, V8, P242; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Olveczky BP, 1997, BIOPHYS J, V73, P2836, DOI 10.1016/S0006-3495(97)78312-7; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; Periasamy N, 1998, BIOPHYS J, V75, P557, DOI 10.1016/S0006-3495(98)77545-9; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Yang Baoxue, 2000, Journal of the American Society of Nephrology, V11, p23A; Yang BX, 2001, J BIOL CHEM, V276, P2775, DOI 10.1074/jbc.M008216200	29	25	25	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21331	21336		10.1074/jbc.M101901200	http://dx.doi.org/10.1074/jbc.M101901200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11297561	hybrid			2022-12-25	WOS:000169297900072
J	Wu, Y; Dowbenko, D; Pisabarro, MT; Dillard-Telm, L; Koeppen, H; Lasky, LA				Wu, Y; Dowbenko, D; Pisabarro, MT; Dillard-Telm, L; Koeppen, H; Lasky, LA			PTEN 2, a Golgi-associated testis-specific homologue or the PTEN tumor suppressor lipid phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; GLIOBLASTOMA CELLS; 3-KINASE ACTIVITY; GENE; KINASE; PTEN/MMAC1; GROWTH; INACTIVATION	The tumor suppressor PTEN is a phosphatidylinositol phospholipid phosphatase, which indirectly down-regulates the activity of the protein kinase B/Akt survival kinases. Examination of sequence data bases revealed the existence of a highly conserved homologue of PTEN, This homologue, termed PTEN 2, contained an extended amino-terminal domain having four potential transmembrane motifs, a lipid phosphatase domain, and a potential lipid-binding C2 domain. Transcript analysis demonstrated that PTEN 2 is expressed only in testis and specifically in secondary spermatocytes, In contrast to PTEN, PTEN 2 was localized to the Golgi apparatus via the amino-terminal membrane-spanning regions. Molecular modeling suggested that PTEN 2 is a phospholipid phosphatase with potential specificity for the phosphate at the 3 position of inositol phosphates, Enzymatic analysis of PTEN 2 revealed substrate specificity that is similar to PTEN, with a preference for the dephosphorylation of the phosphatidylinositol 3,5-phosphate phospholipid, a known mediator of vesicular trafficking. Together, these data suggest that PTEN 2 is a Golgi-localized, testis-specific phospholipid phosphatase, which may contribute to the terminal stages of spermatocyte differentiation.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Lasky, LA (corresponding author), Genentech Inc, Dept Mol Oncol, 460 Pt San Bruno Blvd, San Francisco, CA 94080 USA.	lal@gene.com	Pisabarro, M. Teresa/D-4270-2012					BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns P, 1997, CANCER RES, V57, P4997; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen HM, 1999, HUM GENET, V105, P399, DOI 10.1007/s004390051122; Cheney IW, 1998, CANCER RES, V58, P2331; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gaullier JM, 1999, BIOCHEM SOC T, V27, P666, DOI 10.1042/bst0270666; Goberdhan DCI, 1999, GENE DEV, V13, P3244, DOI 10.1101/gad.13.24.3244; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; KERR JB, 1995, MICROSC RES TECHNIQ, V32, P364, DOI 10.1002/jemt.1070320503; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Rasheed BKA, 1997, CANCER RES, V57, P4187; Reaves BJ, 1996, J CELL SCI, V109, P749; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tashiro H, 1997, CANCER RES, V57, P3935; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	33	76	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21745	21753		10.1074/jbc.M101480200	http://dx.doi.org/10.1074/jbc.M101480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279206	hybrid			2022-12-25	WOS:000169297900125
J	Yang, Y; Cheng, JZ; Singhal, SS; Saini, M; Pandya, U; Awasthi, S; Awasthi, YC				Yang, Y; Cheng, JZ; Singhal, SS; Saini, M; Pandya, U; Awasthi, S; Awasthi, YC			Role of glutathione S-transferases in protection against lipid peroxidation - Overexpression of hgsta2-2 in k562 cells protects against hydrogen peroxide-induced apoptosis and inhibits JNK and caspase 3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKEMIA-CELLS; OXIDATIVE STRESS; C-JUN; REACTIVE OXYGEN; KINASE PATHWAY; HETEROLOGOUS EXPRESSION; TISSUE DISTRIBUTION; CATALYTIC ACTIVITY; CYTOCHROME-C; HUMAN-PLASMA	The physiological significance of the selenium-independent glutathione peroxidase (GPx) activity of glutathione S-transferases (GSTs), associated with the major Alpha class isoenzymes hGSTA1-1 and hGSTA2-2, is not known. In the present studies we demonstrate that these isoenzymes show high GPx activity toward phospholipid hydroperoxides (PL-OOH) and they can catalyze GSH-dependent reduction of PL-OOH in situ in biological membranes. A major portion of GPx activity of human liver and testis toward phosphatidylcholine hydroperoxide (PC-OOH) is contributed by the Alpha class GSTs. Overexpression of hGSTA2-2 in K562 cells attenuates lipid peroxidation under normal conditions as well as during the oxidative stress and confers about 1.5-fold resistance to these cells from H2O2 cytotoxicity. Treatment with 30 muM H2O2 for 48 h or 40 muM PC-OOH for 8 h causes apoptosis in control cells, whereas hGSTA2-2-overexpressing cells are protected from apoptosis under these conditions. In control cells, H2O2 treatment causes an early (within 2 h), robust, and persistent (at least 24 h) activation of JNK, whereas in hGSTA2-2-overexpressing cells, only a slight activation of JNK activity is observed at 6 h which declines to basal levels within 24 h. Caspase 3-mediated poly(ADP-ribose) polymerase cleavage is also inhibited in cells overexpressing hGSTA2-2. hGSTA2 transfection does not affect the function of antioxidant enzymes including C:Px activity toward H2O2 suggesting that the Alpha class GSTs play an important role in regulation of the intracellular concentrations of the lipid peroxidation products that may be involved in the signaling mechanisms of apoptosis.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Dept Chem & Biochem, Arlington, TX 76019 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Arlington	Awasthi, YC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, 7-138 Med Res Bldg, Galveston, TX 77555 USA.	ycawasth@utmb.edu	Awasthi, Sanjay/R-4904-2019	Awasthi, Sanjay/0000-0002-5214-5717	NCI NIH HHS [CA 77495] Funding Source: Medline; NEI NIH HHS [EY 04396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077495] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R55EY004396, R01EY004396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Awasthi S, 1998, BIOCHEMISTRY-US, V37, P5231, DOI 10.1021/bi972130z; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; AWASTHI YC, 1980, BIOCHEM J, V191, P1; Bao YP, 1997, BIOCHEM SOC T, V25, pS557, DOI 10.1042/bst025s557; BEERS RF, 1952, J BIOL CHEM, V195, P133; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Board PG, 1997, BIOCHEM J, V328, P929; Boekhorst PAW, 1992, CANCER CHEMOTHER PHA, V30, P238; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chau YP, 1998, FREE RADICAL BIO MED, V24, P660, DOI 10.1016/S0891-5849(97)00337-7; Chen SH, 2000, GLIA, V31, P249, DOI 10.1002/1098-1136(200009)31:3<249::AID-GLIA60>3.0.CO;2-L; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; CHU FF, 1993, J BIOL CHEM, V268, P2571; DiPietrantonio AM, 1999, BIOCHEM BIOPH RES CO, V255, P477, DOI 10.1006/bbrc.1999.0208; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; GIROTTI AW, 1985, ARCH BIOCHEM BIOPHYS, V236, P238, DOI 10.1016/0003-9861(85)90623-X; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hijikata M, 1999, FEBS LETT, V457, P405, DOI 10.1016/S0014-5793(99)01077-7; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu SX, 1998, ARCH BIOCHEM BIOPHYS, V352, P306, DOI 10.1006/abbi.1998.0608; Liu W, 2000, J CELL SCI, V113, P635; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; MADDIPATI KR, 1987, ARCH BIOCHEM BIOPHYS, V254, P9, DOI 10.1016/0003-9861(87)90075-0; MAIRORINO M, 1986, ARCH BIOCHEM BIOPHYS, V251, P600; Malecki A, 2000, J NEUROCHEM, V74, P2278, DOI 10.1046/j.1471-4159.2000.0742278.x; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1992, BIOCHEM J, V282, P305, DOI 10.1042/bj2820305; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; MILLS GC, 1957, J BIOL CHEM, V229, P189; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; PROHASKA JR, 1977, BIOCHEM BIOPH RES CO, V76, P437, DOI 10.1016/0006-291X(77)90744-6; Rao AVSK, 2000, FREE RADICAL BIO MED, V29, P1015, DOI 10.1016/S0891-5849(00)00408-1; Rowe JD, 1997, BIOCHEM J, V325, P481, DOI 10.1042/bj3250481; SATO K, 1989, ADV CANCER RES, V52, P205; SEELIG GF, 1984, J BIOL CHEM, V259, P3534; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SINGHAL SS, 1994, ARCH BIOCHEM BIOPHYS, V311, P242, DOI 10.1006/abbi.1994.1233; SINGHAL SS, 1992, ARCH BIOCHEM BIOPHYS, V299, P232, DOI 10.1016/0003-9861(92)90269-3; Singhal SS, 1999, BIOCHEM ARCH, V15, P163; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Soh YJ, 2000, MOL PHARMACOL, V58, P535, DOI 10.1124/mol.58.3.535; STENBERG G, 1992, BIOCHEM J, V284, P313, DOI 10.1042/bj2840313; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; TAKAHASHI K, 1987, ARCH BIOCHEM BIOPHYS, V256, P677, DOI 10.1016/0003-9861(87)90624-2; TAN KH, 1984, BIOCHEM J, V220, P243, DOI 10.1042/bj2200243; THOMAS JP, 1990, J BIOL CHEM, V265, P454; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; URSINI F, 1982, BIOCHIM BIOPHYS ACTA, V710, P197, DOI 10.1016/0005-2760(82)90150-3; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Yin ZM, 2000, CANCER RES, V60, P4053; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277; ZIMNIAK P, 1994, J BIOL CHEM, V269, P992	74	263	274	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19220	19230		10.1074/jbc.M100551200	http://dx.doi.org/10.1074/jbc.M100551200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279091	hybrid			2022-12-25	WOS:000169091000079
J	Xu, YB; Heath, RJ; Li, ZM; Rock, CO; White, SW				Xu, YB; Heath, RJ; Li, ZM; Rock, CO; White, SW			The Fadr DNA complex - Transcriptional control of fatty acid metabolism in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME; CRYSTAL-STRUCTURE; GENE FADR; BINDING; PROTEIN; DEGRADATION; SYSTEM; REGULATOR; ACTIVATOR	In Escherichia coli, the expression of fatty acid metabolic genes is controlled by the transcription factor, FadR, The affinity of FadR for DNA is controlled by long chain acyl-CoA molecules, which bind to the protein and modulate gene expression. The crystal structure of FadR reveals a two domain dimeric molecule where the N-terminal domains bind DNA, and the C-terminal domains bind acyl-CoA. The DNA binding domain has a winged-helix motif, and the C-terminal domain resembles the sensor domain of the Tet repressor, The FadR DNA complex reveals how the protein interacts with DNA and specifically recognizes a palindromic sequence. Structural and functional similarities to the Tet repressor and the BmrR transcription factors suggest how the binding of the acyl-CoA effector molecule to the C-terminal domain may affect the DNA binding affinity of the N-terminal domain. We suggest that the binding of acyl-CoA disrupts a buried network of charged and polar residues in the C-terminal domain, and the resulting conformational change is transmitted to the N-terminal domain via a domain-spanning alpha -helix.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	White, SW (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	stephen.white@stjude.org	White, Stephen W/N-8164-2018	Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETRAND KP, 1988, GENE, V23, P149; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cronan JE, 1998, MOL MICROBIOL, V29, P937, DOI 10.1046/j.1365-2958.1998.00917.x; Cronan JE, 1997, J BACTERIOL, V179, P1819, DOI 10.1128/jb.179.5.1819-1823.1997; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DIRUSSO CC, 1988, NUCLEIC ACIDS RES, V16, P7995, DOI 10.1093/nar/16.16.7995; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DiRusso CC, 1998, MOL MICROBIOL, V27, P1, DOI 10.1046/j.1365-2958.1998.00645.x; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; HAYDON DJ, 1991, FEMS MICROBIOL LETT, V79, P291, DOI 10.1016/0378-1097(91)90101-F; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; Orth P, 2000, NAT STRUCT BIOL, V7, P215; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; OVERATH P, 1967, BIOCHEM BIOPH RES CO, V29, P28, DOI 10.1016/0006-291X(67)90535-9; Raman N, 1997, J BIOL CHEM, V272, P30645, DOI 10.1074/jbc.272.49.30645; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SIMONS RW, 1980, J BACTERIOL, V142, P621, DOI 10.1128/JB.142.2.621-632.1980; SIMONS RW, 1980, J BACTERIOL, V143, P726, DOI 10.1128/JB.143.2.726-730.1980; van Aalten DMF, 2000, EMBO J, V19, P5167, DOI 10.1093/emboj/19.19.5167; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6; [No title captured]	38	96	110	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17373	17379		10.1074/jbc.M100195200	http://dx.doi.org/10.1074/jbc.M100195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279025	hybrid			2022-12-25	WOS:000168730400104
J	Andreadis, ST; Hamoen, KE; Yarmush, ML; Morgan, JR				Andreadis, ST; Hamoen, KE; Yarmush, ML; Morgan, JR			Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system	FASEB JOURNAL			English	Article						KGF; fibroblast growth factor; cell proliferation; rete ridges	HUMAN EPIDERMAL-CELLS; TERMINAL DIFFERENTIATION; FACTOR EXPRESSION; ELECTRICAL CAPACITANCE; DEVELOPMENT SUGGESTS; LAMELLAR ICHTHYOSIS; BARRIER FUNCTION; ATHYMIC MICE; GENE; RECEPTOR	Keratinocyte growth factor (KGF) is a paracrine mediator of epithelial cell growth. To examine the direct effects of KGF on the morphogenesis of the epidermis, we generated skin equivalents in vitro by seeding human keratinocytes on the papillary surface of acellular dermis and raising them up to the air-liquid interface. KGF was either added exogenously or expressed by keratinocytes via a recombinant retrovirus encoding KGF. KGF induced dramatic changes to the 3-dimensional organization of the epidermis including pronounced hyperthickening, crowding, and elongation of the basal cells, flattening of the rete ridges, and a ripple-like pattern in the junction of stratum corneum and granular layers. Quantitative immunostaining for the proliferation antigen, Ki67, revealed that in addition to increasing basal proliferation, KGF extended the proliferative compartment by inducing suprabasal cell proliferation. KGF also induced expression of the integrin alpha5 beta1 and delayed expression of keratin 10 and transglutaminase, However, barrier formation of the epidermis was not disrupted. These results demonstrate for the first time that a single growth factor can alter the 3-dimensional organization and proliferative function of an in vitro epidermis, In addition to new strategies for tissue engineering, such a well-defined system will be useful for analyzing growth factor effects on the complex links between cell proliferation, cell movement and differentiation within a stratified tissue.	Shriners Burn Hosp, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Surg Serv, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Morgan, JR (corresponding author), Shriners Hosp Children, 51 Blossom St, Boston, MA 02114 USA.	jmorgan@sbi.org		Yarmush, Martin/0000-0003-4986-8444; Morgan, Jeffrey/0000-0002-7546-3443	NICHD NIH HHS [HD-28528] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD028528] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; Abrams JR, 1999, J CLIN INVEST, V103, P1243, DOI 10.1172/JCI5857; ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; BOYCE ST, 1993, J INVEST DERMATOL, V101, P180, DOI 10.1111/1523-1747.ep12363678; Boyce ST, 1996, J INVEST DERMATOL, V107, P82, DOI 10.1111/1523-1747.ep12298286; BRAUCHLE M, 1995, J INVEST DERMATOL, V105, P579, DOI 10.1111/1523-1747.ep12323521; Choate KA, 1996, HUM GENE THER, V7, P2247, DOI 10.1089/hum.1996.7.18-2247; Choate KA, 1996, NAT MED, V2, P1263, DOI 10.1038/nm1196-1263; Dellambra E, 1998, HUM GENE THER, V9, P1359, DOI 10.1089/hum.1998.9.9-1359; DISTANTE F, 1995, BIOENGINEERING SKIN, P5; EMING SA, 1995, J INVEST DERMATOL, V105, P756, DOI 10.1111/1523-1747.ep12325550; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Fenjves ES, 1996, J INVEST DERMATOL, V106, P576, DOI 10.1111/1523-1747.ep12344976; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; Finch PW, 1997, AM J PATHOL, V151, P1619; Goretsky Michael J., 1995, Wound Repair and Regeneration, V3, P419, DOI 10.1046/j.1524-475X.1995.30406.x; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HANSBROUGH JF, 1989, JAMA-J AM MED ASSOC, V262, P2125, DOI 10.1001/jama.262.15.2125; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; Medalie DA, 1997, TRANSPLANTATION, V64, P454, DOI 10.1097/00007890-199708150-00015; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MORGAN JR, 1987, SCIENCE, V237, P1476; OHASHI T, 1992, P NATL ACAD SCI USA, V89, P11332, DOI 10.1073/pnas.89.23.11332; Page SM, 1997, J INVEST DERMATOL, V109, P139, DOI 10.1111/1523-1747.ep12319194; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Pilcher BK, 1997, J BIOL CHEM, V272, P18147, DOI 10.1074/jbc.272.29.18147; Ponec M, 1997, J INVEST DERMATOL, V109, P348, DOI 10.1111/1523-1747.ep12336024; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUBIN JS, 1995, CELL BIOL INT, V19, P399, DOI 10.1006/cbir.1995.1085; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TSUBOI R, 1993, J INVEST DERMATOL, V101, P49, DOI 10.1111/1523-1747.ep12358892; WATT FM, 1982, NATURE, V295, P434, DOI 10.1038/295434a0; WERNER S, 1994, J INVEST DERMATOL, V103, P469, DOI 10.1111/1523-1747.ep12395564; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WICKETT RR, 1995, SKIN PHARMACOL, V8, P179; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899	44	114	130	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					898	906		10.1096/fj.00-0324com	http://dx.doi.org/10.1096/fj.00-0324com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292649				2022-12-25	WOS:000167959300003
J	Brockmann, GA; Haley, CS; Wolf, E; Karle, S; Kratzsch, J; Renne, U; Schwerin, M; Hoeflich, A				Brockmann, GA; Haley, CS; Wolf, E; Karle, S; Kratzsch, J; Renne, U; Schwerin, M; Hoeflich, A			Genome-wide search for loci controlling serum IGF binding protein levels of mice	FASEB JOURNAL			English	Article						IGFBP-2; IGFBP-3; IGFBP-4; linkage	GROWTH-FACTOR-I; FOCAL ADHESION KINASE; QUANTITATIVE TRAIT LOCI; BODY-WEIGHT; TRANSGENIC MICE; TYROSINE PHOSPHORYLATION; DIABETES-MELLITUS; GENE-EXPRESSION; INSULIN; RECEPTOR	A segregating F-2 pedigree based on two mouse Lines (DU6i and DBA/2) with extremely different growth characteristics was generated to search for loci affecting serum levels of insulin-like growth factor (IGF) binding proteins (IGFBPs) and to estimate their effects on growth and body composition. DU6i is characterized by high body mass and obesity associated with hyperinsulinemia, hyperleptinemia, and elevated serum IGF-I concentrations. Furthermore, significantly elevated serum levels of IGFBP-2, IGFBP-3, and IGFBP-4 were found in DU6i vs. DBA/2 mice. Linkage analysis identified loci with major effects on the serum level of IGFBP-3 on Chromosome 5 at 58 cM (Igfbp3q1; F = 9.9) and on Chromosome 10 at 46 cM (Igfbp3q2; F = 33.8). A locus significantly influencing serum IGFBP-2 levels in males was found on Chromosome 7. Additional linkage was detected in males and females for IGFBP-2 on Chromosomes 8, 11, 14, 17, and X, and for ICFBP-4 on Chromosome 4. Additional loci affecting IGFBPs acted in a sex-specific manner. The identified loci coincide in part with chromosomal regions controlling growth and obesity. Thus, multiple genes or pleiotropic gene effects may be assumed for these chromosomal regions. The identification of quantitative trait loci for IGFBPs as subcomponents of growth regulation and differentiation will further improve the understanding of complex trait regulation.	Res Inst Biol Farm Anim, Dept Biol Mol, D-18196 Dummerstorf, Germany; Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; Univ Munich, Dept Mol Anim Breeding, D-81377 Munich, Germany; Univ Leipzig, Dept Clin Chem, D-04103 Leipzig, Germany; Univ Leipzig, Dept Pathobiochem, D-04103 Leipzig, Germany	Forschungsinstitut fur Nutztierbiologie (FBN); UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Munich; Leipzig University; Leipzig University	Brockmann, GA (corresponding author), Res Inst Biol Farm Anim, Dept Biol Mol, Wilhelm Stahl Allee 2, D-18196 Dummerstorf, Germany.	Gudrun.Brockmann@fbn-dummerstorf.de	Haley, Chris S/F-3110-2013	Wolf, Eckhard/0000-0002-0430-9510; Haley, Chris/0000-0002-9811-0210; Hoeflich, Andreas/0000-0003-2018-2836				BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BEREKET A, 1995, J CLIN ENDOCR METAB, V80, P3647, DOI 10.1210/jc.80.12.3647; Bohe J, 1998, KIDNEY INT, V54, P1070, DOI 10.1046/j.1523-1755.1998.00096.x; BRADFORD GE, 1984, GENET RES, V44, P293, DOI 10.1017/S0016672300026537; Brockmann GA, 1998, GENETICS, V150, P369; Brockmann GA, 2000, GENOME RES, V10, P1941, DOI 10.1101/gr.GR1499R; BUNGER L, 1990, P 4 WORLD C GEN APPL, V13, P321; CAMACHOHUBNER C, 1991, ENDOCRINOLOGY, V129, P1201, DOI 10.1210/endo-129-3-1201; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHURCHILL GA, 1994, GENETICS, V138, P963; COHEN P, 1993, MOL ENDOCRINOL, V7, P380, DOI 10.1210/me.7.3.380; Coverley JA, 2000, ENDOCRINOLOGY, V141, P564, DOI 10.1210/en.141.2.564; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Das P, 1996, ARCH TIERZUCHT, V39, P185; de Angelis MH, 2000, NAT GENET, V25, P444, DOI 10.1038/78146; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DOMENE HM, 1994, REGUL PEPTIDES, V52, P215, DOI 10.1016/0167-0115(94)90056-6; Erondu NE, 1996, GROWTH REGULAT, V6, P1; GARGOSKY SE, 1994, ENDOCRINOLOGY, V134, P2267, DOI 10.1210/en.134.5.2267; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Grimberg A, 2000, MOL GENET METAB, V70, P85, DOI 10.1006/mgme.2000.3008; HALEY CS, 1994, GENETICS, V136, P1195; Hise MK, 1995, AM J PHYSIOL-RENAL, V269, pF817, DOI 10.1152/ajprenal.1995.269.6.F817; Hoeflich A, 1999, ENDOCRINOLOGY, V140, P5488, DOI 10.1210/en.140.12.5488; Hoeflich A, 1998, GROWTH HORM IGF RES, V8, P113, DOI 10.1016/S1096-6374(98)80101-9; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1987, P NATL ACAD SCI USA, V84, P2363, DOI 10.1073/pnas.84.8.2363; Legare ME, 2000, GENOME RES, V10, P42; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu JL, 1999, ENDOCRINOLOGY, V140, P5178, DOI 10.1210/en.140.11.5178; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Manes S, 1999, MOL CELL BIOL, V19, P3125; Martin JL, 2000, ENDOCRINOLOGY, V141, P2401, DOI 10.1210/en.141.7.2401; MATHEWS LS, 1988, ENDOCRINOLOGY, V123, P2827, DOI 10.1210/endo-123-6-2827; MEDRANO JF, 1991, GENET RES, V58, P67, DOI 10.1017/S0016672300029621; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Mitsui S, 1997, BRIT J DERMATOL, V137, P693; MURPHY LJ, 1995, J MOL ENDOCRINOL, V15, P293, DOI 10.1677/jme.0.0150293; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Richardson RL, 1998, GROWTH DEVELOP AGING, V62, P3; RIESNER D, 1989, ELECTROPHORESIS, V10, P377, DOI 10.1002/elps.1150100516; SCHULER L, 1985, ARCH TIERZUCHT, V28, P357; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; STRASSERVOGEL B, 1995, J CLIN ENDOCR METAB, V80, P1207, DOI 10.1210/jc.80.4.1207; Timtchenko D, 1999, INT J OBESITY, V23, P586, DOI 10.1038/sj.ijo.0800872; Yap OWS, 1997, FERTIL STERIL, V68, P252	52	13	15	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					978	987		10.1096/fj.00-0391com	http://dx.doi.org/10.1096/fj.00-0391com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292658				2022-12-25	WOS:000167959300012
J	Thurnher, M; Zelle-Rieser, C; Ramoner, R; Bartsch, G; Holtl, L				Thurnher, M; Zelle-Rieser, C; Ramoner, R; Bartsch, G; Holtl, L			The disabled dendritic cell	FASEB JOURNAL			English	Article						interleukin-4; phospholipase A2; eicosanoids; platelet-activating factor	COLONY-STIMULATING FACTOR; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE-2; ACTIVATION-INDUCED APOPTOSIS; PERIPHERAL-BLOOD MONOCYTES; T-HELPER-CELL; FACTOR-BETA 1; ARACHIDONIC-ACID; INFLAMMATORY CYTOKINES; IMMUNE-RESPONSES; GENE-EXPRESSION	Dendritic cells are important antigen-presenting cells of the immune system that induce and modulate immune responses. They interact with T and B lymphocytes as well as with natural killer cells to promote activation and differentiation of these cells. Dendritic cells generated in vitro from monocytes by use of the cytokines GM-CSF and IL-4 are increasingly used clinically to enhance antitumor immunity in cancer patients. However, recent studies revealed that the functional repertoire of monocyte-derived dendritic cells may be incomplete. important functions of monocyte-derived dendritic cells such as migration or the ability to induce natural killer cell activation or type 2 T helper cell differentiation appear to be impaired. We propose that ah these deficiencies relate to a single biochemical deficiency of monocyte derived dendritic cells. IL-4, which is used to generate monocyte-derived dendritic cells, suppresses phospholipase A2, the enzyme that liberates arachidonic acid from membrane phospholipids and contributes to the synthesis of platelet-activating factor. Monocyte-derived dendritic cells must therefore fail to generate platelet-activating factor as well as arachidonic acid derivatives such as prostaglandins, leukotrienes, and lipoxins, collectively referred to as eicosanoids, Since eicosanoids and platelet-activating factor are known to play an important role in processes such as leukocyte migration, natural killer cell activation, and type 2 T helper cell differentiation, the deficiency in eicosanoid and platelet-activating factor biosynthesis may be responsible for the observed handicaps of monocyte-derived dendritic cells.	Univ Innsbruck, Dept Urol, A-6020 Innsbruck, Austria	University of Innsbruck	Thurnher, M (corresponding author), Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	martin.thurnher@uibk.ac.at	Thurnher, Martin/AAD-5922-2020	Thurnher, Martin/0000-0001-9940-7326				Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BETZ M, 1991, J IMMUNOL, V146, P108; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; BRAY RA, 1986, J IMMUNOL, V136, P1783; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chavis C, 1996, J EXP MED, V183, P1633, DOI 10.1084/jem.183.4.1633; CIFONE MG, 1993, CELL IMMUNOL, V148, P247, DOI 10.1006/cimm.1993.1109; Coffey MJ, 1999, BLOOD, V94, P3897, DOI 10.1182/blood.V94.11.3897.423k12_3897_3905; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; Corry DB, 1999, CURR OPIN IMMUNOL, V11, P610, DOI 10.1016/S0952-7915(99)00025-4; Demeure CE, 1997, EUR J IMMUNOL, V27, P3526, DOI 10.1002/eji.1830271254; Dhodapkar MV, 1999, J CLIN INVEST, V104, P173, DOI 10.1172/JCI6909; Dubois B, 1997, J EXP MED, V185, P941, DOI 10.1084/jem.185.5.941; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; GAGNON L, 1987, CELL IMMUNOL, V110, P243, DOI 10.1016/0008-8749(87)90120-1; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; HANNIGAN GE, 1991, SCIENCE, V251, P204, DOI 10.1126/science.1898993; Holtl L, 1998, LANCET, V352, P1358, DOI 10.1016/S0140-6736(05)60748-9; Holtl L, 1999, J UROLOGY, V161, P777, DOI 10.1016/S0022-5347(01)61767-1; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kugler A, 2000, NAT MED, V6, P332, DOI 10.1038/73193; Kuroda A, 1997, BIOCHEM BIOPH RES CO, V230, P40, DOI 10.1006/bbrc.1996.5885; Kuroda E, 2000, J IMMUNOL, V164, P2386, DOI 10.4049/jimmunol.164.5.2386; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Mehindate K, 1996, LAB INVEST, V75, P529; Morse MA, 1999, CANCER RES, V59, P56; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; Murphy GP, 1999, PROSTATE, V38, P73; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; OBIRI NI, 1993, J CLIN INVEST, V91, P88, DOI 10.1172/JCI116205; PHIPPS RP, 1991, IMMUNOL TODAY, V12, P349, DOI 10.1016/0167-5699(91)90064-Z; Porter BO, 1999, EUR J IMMUNOL, V29, P2360, DOI 10.1002/(SICI)1521-4141(199907)29:07<2360::AID-IMMU2360>3.0.CO;2-A; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Pouliot M, 1998, FASEB J, V12, P1109, DOI 10.1096/fasebj.12.12.1109; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Rey A, 1998, BBA-LIPID LIPID MET, V1393, P244, DOI 10.1016/S0005-2760(98)00080-0; Rieser C, 1999, UROL INT, V63, P151, DOI 10.1159/000030438; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rocca B, 1999, J CLIN INVEST, V103, P1469, DOI 10.1172/JCI6400; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Schuler T, 1999, J EXP MED, V189, P803, DOI 10.1084/jem.189.5.803; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; Serhan CN, 1999, CLIN CHEM LAB MED, V37, P299, DOI 10.1515/CCLM.1999.052; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; STEINHILBER D, 1993, P NATL ACAD SCI USA, V90, P5984, DOI 10.1073/pnas.90.13.5984; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; THIVIERGE M, 1991, AM REV RESPIR DIS, V144, P272, DOI 10.1164/ajrccm/144.2.272; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; YAMAOKA KA, 1989, J IMMUNOL, V143, P1996	65	44	48	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1054	1061		10.1096/fj.00-0508hyp	http://dx.doi.org/10.1096/fj.00-0508hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292667				2022-12-25	WOS:000167959300021
J	Lundberg, M; Johansson, C; Chandra, J; Enoksson, M; Jacobsson, G; Ljung, J; Johansson, M; Holmgren, A				Lundberg, M; Johansson, C; Chandra, J; Enoksson, M; Jacobsson, G; Ljung, J; Johansson, M; Holmgren, A			Cloning and expression of a novel human glutaredoxin (Grx2) with mitochondrial and nuclear isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI GLUTAREDOXIN; PROTEIN DISULFIDE-ISOMERASE; RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE; GLUTATHIONE-DEPENDENT SYNTHESIS; OXYR TRANSCRIPTION FACTOR; HYDROGEN DONOR SYSTEM; HIGH-LEVEL EXPRESSION; DNA-BINDING ACTIVITY; AMINO-ACID-SEQUENCE; THIOLTRANSFERASE GLUTAREDOXIN	Glutaredoxin (Grx) is a glutathione-dependent hydrogen donor for ribonucleotide reductase, Today glutaredoxins are known as a multifunctional family of GSH-disulfide-oxidoreductases belonging to the thioredoxin fold superfamily, In contrast to Escherichia coli and yeast, a single human glutaredoxin is known. We have identified and cloned a novel 18-kDa human dithiol glutaredoxin, named glutaredoxin-2 (Grx2), which is 34% identical to the previously known cytosolic 12-kDa human Grx1. The human Grx2 sequence contains three characteristic regions of the glutaredoxin family: the dithiol/disulfide active site, CSYC, the GSH binding site, and a hydrophobic surface area. The human Grx2 gene, located at chromosome 1q31.2-31.3, consisted of five exons that were transcribed to a 0.9-kilobase human Grx2 mRNA ubiquitously expressed in several tissues. Two alternatively spliced Grx2 mRNA isoforms that differed in their 5 ' region were identified. These corresponded to alternative proteins with a common 125-residue C-terminal Grx domain but with different N-terminal extensions of 39 and 40 residues, respectively. The 125-residue Grx domain and the two full-length variants were expressed in E. coli and exhibited GSH-dependent hydroxyethyl disulfide and dehydroascorbate reducing activities. Western blot analysis of subcellular fractions from Jurkat cells with a specific anti-Grx2 antibody showed that human Grx2 was predominantly located in the nucleus but also present in the mitochondria, We further showed that one of the mRNA isoforms corresponding to Grx2a encoded a functional N-terminal mitochondrial translocation signal.	Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Hosp, Dept Med, Unit Clin Allergy Res, S-17176 Stockholm, Sweden; Huddinge Univ, Div Clin Virol, S-14186 Huddinge, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Holmgren, A (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.							APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P10, DOI 10.1016/0304-4165(75)90206-8; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Bandyopadhyay S, 1998, J BIOL CHEM, V273, P392, DOI 10.1074/jbc.273.1.392; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fernandez-Checa JC, 1998, BIOFACTORS, V8, P7, DOI 10.1002/biof.5520080102; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOOG JO, 1983, EUR J BIOCHEM, V136, P223, DOI 10.1111/j.1432-1033.1983.tb07730.x; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; Ladner RD, 1997, J BIOL CHEM, V272, P19072, DOI 10.1074/jbc.272.30.19072; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lind C, 1998, BIOCHEM BIOPH RES CO, V247, P481, DOI 10.1006/bbrc.1998.8695; Liu SS, 1999, J BIOENERG BIOMEMBR, V31, P367; LUTHMAN M, 1982, J BIOL CHEM, V257, P6686; LUTHMAN M, 1979, P NATL ACAD SCI USA, V76, P2158, DOI 10.1073/pnas.76.5.2158; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTINEZGALISTEO E, 1995, COMP BIOCHEM PHYS B, V111, P17, DOI 10.1016/0305-0491(94)00235-M; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura T, 1999, FREE RADICAL RES, V31, P357, DOI 10.1080/10715769900300931; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Padilla CA, 1996, FEBS LETT, V378, P69; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Padilla CA, 1996, GENOMICS, V32, P455, DOI 10.1006/geno.1996.0141; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROZELL B, 1993, EUR J CELL BIOL, V62, P314; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; SODANO P, 1991, J MOL BIOL, V221, P1311; Spector D, 2001, J BIOL CHEM, V276, P7011, DOI 10.1074/jbc.M009814200; Sun CH, 1998, J MOL BIOL, V280, P687, DOI 10.1006/jmbi.1998.1913; Takashima Y, 1999, IMMUNOL LETT, V68, P397, DOI 10.1016/S0165-2478(99)00087-5; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WELLS WW, 1990, J BIOL CHEM, V265, P15361; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	65	253	268	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26269	26275		10.1074/jbc.M011605200	http://dx.doi.org/10.1074/jbc.M011605200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11297543	hybrid			2022-12-25	WOS:000169823300084
J	Bahring, R; Dannenberg, J; Peters, HC; Leicher, T; Pongs, O; Isbrandt, D				Bahring, R; Dannenberg, J; Peters, HC; Leicher, T; Pongs, O; Isbrandt, D			Conserved Kv4 N-terminal domain critical for effects of Kv channel-interacting protein 2.2 on channel expression and gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT OUTWARD CURRENT; K+ CHANNEL; POTASSIUM CHANNELS; SUBTHRESHOLD POTENTIALS; ALPHA-SUBUNIT; RAT-HEART; INACTIVATION; NEURONS; CLONING; SIGNAL	Association of Kv channel-interacting proteins (KChIPs) with Kv4 channels leads to modulation of these A-type potassium channels (An, W, F,, Bowlby, M, R, Petty, M., Cao, J,, Ling, RP,, Mendoza, G., Hinson, J, W., Mattsson, R. I., Strassle, B, ni., Trimmer, J, S., and Rhodes, K. J, (2000) Nature 403, 553-556), We cloned a KChIP2 splice variant (KChIP2.2) from human ventricle. In comparison with RChIP2.1, coexpression of KChIP2.2 with human Kv4 channels in mammalian cells slowed the onset of Kv4 current inactivation (23-fold), accelerated the recovery from inactivation (5-7-fold), and shifted Kv4 steady-state inactivation curves by 8-29 mV to more positive potentials. The features of Kv4.2/KChIP2.2 currents closely resemble those of cardiac rapidly inactivating transient outward currents, KChIP2.2 stimulated the Kv4 current density in Chinese hamster ovary cells by similar to 55-fold. This correlated with a redistribution of immunoreactivity hom perinuclear areas to the plasma membrane. Increased Kv4 cell-surface expression and current density were also obtained in the absence of KChIP2.2 when the highly conserved proximal Kv4 N terminus was deleted. The same domain is required for association of RChIP2.2 with Kv4 alpha -subunits. We propose that an efficient transport of Kv4 channels to the cell surface depends on KChIP binding to the Kv4 N-terminal domain. Our data suggest that the binding is necessary, but not sufficient, for the functional activity of KChIPs.	Univ Hamburg, Inst Neurale Signalverarbeitung, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Pongs, O (corresponding author), Univ Hamburg, Inst Neurale Signalverarbeitung, Zentrum Mol Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.		Bähring, Robert/F-7146-2010	Bahring, Robert/0000-0002-0406-5958; Isbrandt, Dirk/0000-0002-4720-1016				An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BARRY DM, 1995, CIRC RES, V77, P361, DOI 10.1161/01.RES.77.2.361; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Hoffman DA, 1997, NATURE, V387, P869, DOI 10.1038/43119; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Isbrandt D, 2000, GENOMICS, V64, P144, DOI 10.1006/geno.2000.6117; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; Petersen KR, 1999, PFLUG ARCH EUR J PHY, V437, P381, DOI 10.1007/s004240050792; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; Roeper J, 1997, J NEUROSCI, V17, P3379; Schoppa NE, 1999, NAT NEUROSCI, V2, P1106, DOI 10.1038/16033; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516, DOI 10.1152/jn.1994.72.4.1516; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174, DOI 10.1152/jn.1996.75.5.2174; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; Yuste R, 1997, NATURE, V387, P851, DOI 10.1038/43063; Zhu XR, 1999, RECEPTOR CHANNEL, V6, P387	23	169	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23888	23894		10.1074/jbc.M101320200	http://dx.doi.org/10.1074/jbc.M101320200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11287421	hybrid			2022-12-25	WOS:000169531100089
J	Takahashi, N; Khoo, KH; Suzuki, N; Johnson, JR; Lee, YC				Takahashi, N; Khoo, KH; Suzuki, N; Johnson, JR; Lee, YC			N-glycan structures from the major glycoproteins of pigeon egg white - Predominance of terminal Gal alpha (1-4)Gal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED SUGAR CHAINS; ESCHERICHIA-COLI; MAPPING TECHNIQUE; CELL-LINE; OLIGOSACCHARIDES; GLYCOPEPTIDES; IDENTIFICATION; SPECIFICITY; SIALYLATION; OVALBUMIN	N-Glycans from major glycoproteins of pigeon egg white (ovotransferrin, ovomucoid, and ovalbumins) were enzymatically released and were reductively aminated with 2-aminopyridine, separated, and structurally characterized by mass spectrometry and a three-dimensional mapping technique using three different columns of high performance liquid chromatography (HPLC) (Takahashi, N., Nakagawa, H., Fujikawa, K., Kawamura, Y., and Tomiya,N. (1995) Anal Biochem. 226, 139-146). Twenty-five major N-glycan structures, all of them hitherto unknown, were identified as pyridylamino derivatives. Of these, 13 were neutral, 10 were monosialyl, and 2 were disialyl oligosaccharides. All N-glycans contain from one to four Gal(YC1,4)GalP(1,4) sequences at the nonreducing terminal positions and are devoid of fucose residues. NAcetylneuraminic acids were alpha (2,6)-linked only to beta -galactose. The HPLC profiles of the N-glycans from four different glycoproteins were qualitatively very similar to each other, but not identical in the peak distributions. Monosialyl glycans were most abundant in all four glycoproteins, followed by neutral glycans, Disialyl glycans were lowest in ovotransferrin, and highest in ovomucoid. Triantennary structures with bisecting GlcNAc were predominant in ovotransferrin, and tetra-antennary (with and without bisecting GlcNAc-containing) structures were predominant in other glycoproteins. Penta-antennary structures (with a sialic acid and without bisecting GlcNAc residue) were also found in small quantities in all four glycoproteins. In contrast to the chicken egg white counterparts, which contain mostly high mannose and hybrid types, all N-glycan structures in the major pigeon egg white glycoproteins are complex type.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Nagoya City Univ, Fac Pharmaceut Sci, Nagoya, Aichi 4678603, Japan; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Univ Minnesota, Dept Med, Minneapolis, MN 55417 USA; Univ Minnesota, Med Ctr, Minneapolis, MN 55417 USA	Johns Hopkins University; Nagoya City University; Academia Sinica - Taiwan; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.		Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	NIDDK NIH HHS [DKO9970, DK-47504] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047504, R01DK009970, R37DK009970] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DELL A, 1994, METHOD ENZYMOL, V230, P108; FRANCOIS C, 1962, J BIOCHEM-TOKYO, V257, P335; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P579, DOI 10.1016/S0338-4535(80)80161-9; JOHNSON JR, 1994, AM J MED SCI, V307, P335, DOI 10.1097/00000441-199405000-00004; JOHNSON JR, 1993, INFECT IMMUN, V61, P4902, DOI 10.1128/IAI.61.11.4902-4905.1993; JOHNSON JR, 1992, INFECT IMMUN, V60, P578, DOI 10.1128/IAI.60.2.578-583.1992; JOZIASSE DH, 1987, J BIOL CHEM, V262, P2025; Lopez M, 1998, J BIOL CHEM, V273, P33644, DOI 10.1074/jbc.273.50.33644; NAKAGAWA H, 1995, ANAL BIOCHEM, V226, P130, DOI 10.1006/abio.1995.1200; SHIMODA N, 1987, J BIOCHEM-TOKYO, V102, P657, DOI 10.1093/oxfordjournals.jbchem.a122101; SHOJI H, 1992, EUR J BIOCHEM, V207, P631, DOI 10.1111/j.1432-1033.1992.tb17090.x; Suzuki N, 2001, J BIOL CHEM, V276, P23221, DOI 10.1074/jbc.M101379200; TAI T, 1975, J BIOL CHEM, V250, P8569; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; TAKAHASHI N, 1995, ANAL BIOCHEM, V226, P139, DOI 10.1006/abio.1995.1201; TAKAHASHI N, 1995, ANAL BIOCHEM, V230, P333, DOI 10.1006/abio.1995.1483; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P209; Tomiya N, 1998, ANAL BIOCHEM, V264, P204, DOI 10.1006/abio.1998.2849; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; WIERUSZESKI JM, 1987, J BIOL CHEM, V262, P6650; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P547, DOI 10.1093/oxfordjournals.jbchem.a122703; YAMASHITA K, 1983, J BIOL CHEM, V258, P3099; YAMASHITA K, 1978, J BIOL CHEM, V253, P3862; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; [No title captured]	25	51	53	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23230	23239		10.1074/jbc.M101380200	http://dx.doi.org/10.1074/jbc.M101380200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11285264	hybrid			2022-12-25	WOS:000169531100004
J	Smith, SK; Farnbach, AR; Harris, FM; Hawes, AC; Jackson, LR; Judd, AM; Vest, RS; Sanchez, S; Bell, JD				Smith, SK; Farnbach, AR; Harris, FM; Hawes, AC; Jackson, LR; Judd, AM; Vest, RS; Sanchez, S; Bell, JD			Mechanisms by which intracellular calcium induces susceptibility to secretory phospholipase A(2) in human erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-CELL DEFORMABILITY; PALMITIC ACID; RED-CELLS; GENERALIZED POLARIZATION; SIGNAL-TRANSDUCTION; FLUORESCENT-PROBE; MEMBRANE; ASYMMETRY; VESICLES; DIPALMITOYLPHOSPHATIDYLCHOLINE	Exposure of human erythrocytes to the calcium ionophore ionomycin rendered them susceptible to the action of secretory phospholipase A(2) (sPLA(2)). Analysis of erythrocyte phospholipid metabolism by thin-layer chromatography revealed significant hydrolysis of both phosphatidylcholine and phosphatidylethanolamine during incubation with ionomycin and sPLA(2). Several possible mechanisms for the effect of ionomycin were considered. Involvement of intracellular phospholipases A, was excluded since inhibitors of these enzymes had no effect. Assessment of membrane oxidation by cis-parinaric acid fluorescence and comparison to the oxidants diamide and phenylhydrazine revealed that oxidation does not participate in the effect of iono- mycin. Incubation with ionomycin caused classical physical changes to the erythrocyte membrane such as morphological alterations (spherocytosis), translocation of aminophospholipids to the outer leaflet of the membrane, and release of microvesicles. Experiments with phenylhydrazine, KCI, quinine, merocyanine 540, the calpain inhibitor E-64d, and the scramblase inhibitor R5421 revealed that neither phospholipid translocation nor vesicle release was required to induce susceptibility. Results from fluorescence spectroscopy and two-photon excitation scanning microscopy using the membrane probe laurdan argued that susceptibility to sPLA(2) is a consequence of increased order of membrane lipids.	Brigham Young Univ, Dept Zool, Provo, UT 84602 USA; Univ Illinois, Lab Flourescence Dynam, Urbana, IL 61801 USA	Brigham Young University; University of Illinois System; University of Illinois Urbana-Champaign	Bell, JD (corresponding author), Brigham Young Univ, Dept Zool, Provo, UT 84602 USA.	john_bell@byu.edu						ALLAN D, 1981, BIOCHEM J, V198, P433, DOI 10.1042/bj1980433; ALLAN D, 1989, BIOCHIM BIOPHYS ACTA, V986, P115, DOI 10.1016/0005-2736(89)90279-4; Allan D, 1987, Folia Haematol Int Mag Klin Morphol Blutforsch, V114, P499; ARDUINI A, 1989, ARCH BIOCHEM BIOPHYS, V273, P112, DOI 10.1016/0003-9861(89)90168-9; ARDUINI A, 1986, BIOCHIM BIOPHYS ACTA, V862, P65, DOI 10.1016/0005-2736(86)90469-4; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARTLETT GR, 1959, J BIOL CHEM, V273, P6830; BASSE F, 1994, BBA-BIOMEMBRANES, V1190, P217, DOI 10.1016/0005-2736(94)90077-9; BELL JD, 1989, J BIOL CHEM, V264, P225; Bell JD, 1996, BIOCHEMISTRY-US, V35, P4945, DOI 10.1021/bi952274i; BELL JD, 1995, BIOCHEMISTRY-US, V34, P11551, DOI 10.1021/bi00036a031; Bell JD, 2001, BIOPHYS J, V80, p46A; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUMENFELD N, 1991, BLOOD, V77, P849; BURACK WR, 1995, BIOCHEMISTRY-US, V34, P14819, DOI 10.1021/bi00045a024; BURACK WR, 1994, CHEM PHYS LIPIDS, V73, P209, DOI 10.1016/0009-3084(94)90182-1; Chukhlovin Alexei B., 1996, Scanning Microscopy, V10, P795; Das Choudhury T, 1999, POL J PHARMACOL, V51, P341; deJong K, 1997, BIOCHEMISTRY-US, V36, P6768, DOI 10.1021/bi962973a; Dekkers DWC, 1998, BLOOD, V91, P2133, DOI 10.1182/blood.V91.6.2133; EATON JW, 1973, NATURE, V246, P105, DOI 10.1038/246105a0; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FRIEDERICHS E, 1994, BIORHEOLOGY, V31, P207; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GRAINGER DW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P365, DOI 10.1016/0005-2736(90)90128-B; HARA S, 1991, J BIOCHEM, V110, P163, DOI 10.1093/oxfordjournals.jbchem.a123550; Harris FM, 2001, J BIOL CHEM, V276, P22722, DOI 10.1074/jbc.M010879200; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Henshaw JB, 1998, BIOCHEMISTRY-US, V37, P10709, DOI 10.1021/bi9728809; HOFFMAN JF, 1987, BLOOD CELLS, V12, P565; Honger T, 1996, BIOCHEMISTRY-US, V35, P9003, DOI 10.1021/bi960866a; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V980, P23, DOI 10.1016/0005-2736(89)90195-8; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; LEW VL, 1985, NATURE, V315, P586, DOI 10.1038/315586a0; MARAGANORE JM, 1984, J BIOL CHEM, V259, P3839; MENASHE M, 1986, J BIOL CHEM, V261, P5328; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORTENSEN AM, 1991, TOXICOL APPL PHARM, V110, P435, DOI 10.1016/0041-008X(91)90045-G; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nielson KH, 2000, BBA-MOL CELL BIOL L, V1484, P163, DOI 10.1016/S1388-1981(00)00004-4; Okafor MC, 1997, AM J PHYSIOL-CELL PH, V272, pC1365, DOI 10.1152/ajpcell.1997.272.4.C1365; PARASASSI T, 1991, BIOPHYS J, V60, P179, DOI 10.1016/S0006-3495(91)82041-0; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; REICHSTEIN E, 1981, J MEMBRANE BIOL, V59, P57, DOI 10.1007/BF01870821; REINHART WH, 1986, BLOOD, V68, P1376; RICHIERI GV, 1995, ANAL BIOCHEM, V229, P256, DOI 10.1006/abio.1995.1410; RUNGEMORRIS MA, 1988, TOXICOL APPL PHARM, V94, P414, DOI 10.1016/0041-008X(88)90282-7; SCHLEGEL RA, 1987, METHOD ENZYMOL, V149, P281; SCHNEIDER GB, 1976, AM J ANAT, V146, P93, DOI 10.1002/aja.1001460105; SHEFFIELD MJ, 1995, BIOCHEMISTRY-US, V34, P7796, DOI 10.1021/bi00024a003; SWEETMAN LL, 1995, ARCH BIOCHEM BIOPHYS, V323, P97, DOI 10.1006/abbi.1995.0014; TSUDA K, 1990, AM J HYPERTENS, V3, P714, DOI 10.1093/ajh/3.9.714; WILLIAMSON P, 1992, BIOCHEMISTRY-US, V31, P6355, DOI 10.1021/bi00142a027; Wilson HA, 1997, BBA-LIPID LIPID MET, V1349, P142, DOI 10.1016/S0005-2760(97)00089-1; Wilson HA, 1999, J BIOL CHEM, V274, P11494, DOI 10.1074/jbc.274.17.11494; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; Yu WM, 1996, BIOPHYS J, V70, P626, DOI 10.1016/S0006-3495(96)79646-7; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121; ZWAAL RFA, 1989, MOL CELL BIOCHEM, V91, P23, DOI 10.1007/BF00228075	64	51	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22732	22741		10.1074/jbc.M010880200	http://dx.doi.org/10.1074/jbc.M010880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294854	hybrid			2022-12-25	WOS:000169412700101
J	Bolhuis, A; Mathers, JE; Thomas, JD; Barrett, CML; Robinson, C				Bolhuis, A; Mathers, JE; Thomas, JD; Barrett, CML; Robinson, C			TatB and TatC form a functional and structural unit of the twin-arginine translocase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEC-INDEPENDENT PROTEIN; EXPORT PATHWAY; PEPTIDE; PURIFICATION; EXPRESSION; MEMBRANE; AFFINITY; COMPLEX; SYSTEM	In Escherichia coli, a subset of periplasmic proteins is exported via the twin-arginine translocation (Tat) pathway. In the present study, we have purified the Tat complex from E. coli, and we show that it contains only TatA, TatB, and TatC, Within the purified complex, TatB and TatC are present in a strict 1:1 ratio, suggesting a functional association. This has been confirmed by expression of a translational fusion between TatB and TatC, This Tat(BC) chimera supports efficient Tat-dependent export, indicating that TatB and TatC act as a unit in both structural and functional terms. The purified Tat complex contains varying levels of TatA, suggesting a gradual loss during isolation and a looser association. The molecular mass of the complex is similar to 600 kDa, demonstrating the presence of multiple copies of TatA, B, and C, Co-immunoprecipitation experiments show that TatC is required for the interaction of TatA with TatB, suggesting that TatA may interact with the complex via binding to TatC.	Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England	University of Warwick	Robinson, C (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.	crobinson@bio.warwick.ac.uk	Bolhuis, Albert/E-9932-2010	Bolhuis, Albert/0000-0001-9307-0515; Smith, Joanna/0000-0003-4234-6686				Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Jack RL, 2001, J BACTERIOL, V183, P1801, DOI 10.1128/JB.183.5.1801-1804.2001; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Sargent F, 1999, J BIOL CHEM, V274, P36073, DOI 10.1074/jbc.274.51.36073; SCHMIDT TGM, 1993, PROTEIN ENG, V6, P109, DOI 10.1093/protein/6.1.109; SILVESTRO A, 1989, BIOCHIM BIOPHYS ACTA, V999, P208, DOI 10.1016/0167-4838(89)90220-3; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wexler M, 2000, J BIOL CHEM, V275, P16717, DOI 10.1074/jbc.M000800200	17	220	228	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20213	20219		10.1074/jbc.M100682200	http://dx.doi.org/10.1074/jbc.M100682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279240	hybrid			2022-12-25	WOS:000169135100074
J	Sung, YH; Shin, J; Chang, HJ; Cho, JM; Lee, W				Sung, YH; Shin, J; Chang, HJ; Cho, JM; Lee, W			Solution structure, backbone dynamics, and stability of a double mutant single-chain monellin - Structural origin of sweetness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; SIMULATED ANNEALING CALCULATIONS; INTERPROTON DISTANCE DATA; AMINO-ACID-SEQUENCE; 3-DIMENSIONAL STRUCTURES; HETERONUCLEAR NMR; PROTEIN MONELLIN; N-15 NMR; SPECTROSCOPY; GEOMETRY	Single-chain monellin (SCM), which is an engineered 94-residue polypeptide, has been characterized as being as sweet as native two-chain monellin, Data from gelfiltration high performance liquid chromatography and NMR has proven that SCM exists as a monomer in aqueous solution. In order to determine the structural origin of the taste of sweetness, we engineered several mutant SCM proteins by mutating Glu(2), Asp(7), and Arg(39) residues, which are responsible for sweetness. In this study, we present the solution structure, backbone dynamics, and stability of mutant SCM proteins using circular dichroism, fluorescence, and NMR spectroscopy. Based on the NMR data, a stable alpha -helix and five-stranded antiparallel beta -sheet were identified for double mutant SCM, Strands beta1 and beta2 are connected by a small bulge, and the disruption of the first beta -strand were observed with SCMDR comprising residues of IIe(38)-Cys(41). The dynamical and folding characteristics from circular dichroism, fluorescence, and backbone dynamics studies revealed that both wild type and mutant proteins showed distinct dynamical as well as stability differences, suggesting the important role of mutated residues in the sweet taste of SCM. Our results will provide an insight into the structural origin of sweet taste as well as the mutational effect in the stability of the engineered sweet protein SCM.	Yonsei Univ, Coll Sci, Dept Biochem, Seodaemoon Gu, Seoul 120740, South Korea; Yonsei Univ, Coll Sci, Prot Network Res Ctr, Seodaemoon Gu, Seoul 120740, South Korea; LG Chem, Biotech Res Inst, Taejon 305380, South Korea	Yonsei University; Yonsei University; LG Chem	Lee, W (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Seodaemoon Gu, Seoul 120740, South Korea.	wlee@biochem.yonsei.ac.kr	LEE, WEON TAE/AAQ-9088-2021					AGASHE VR, 1995, BIOCHEMISTRY-US, V34, P3286, DOI 10.1021/bi00010a019; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BODENHAUSEN G, 1980, CHEM PHYS LETT, V69, P185, DOI 10.1016/0009-2614(80)80041-8; BROUWER JN, 1973, ACTA PHYSIOL SCAND, V89, P550, DOI 10.1111/j.1748-1716.1973.tb05549.x; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DRISCOLL PC, 1989, BIOCHEMISTRY-US, V28, P2188, DOI 10.1021/bi00431a033; FAN P, 1993, BIOCHEMISTRY-US, V32, P1573, DOI 10.1021/bi00057a023; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HELLEKANT G, 1976, ACTA PHYSIOL SCAND, V97, P241, DOI 10.1111/j.1748-1716.1976.tb10257.x; HOUGH CAM, 1978, NATURE, V271, P381, DOI 10.1038/271381a0; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KIM SH, 1989, PROTEIN ENG, V2, P571, DOI 10.1093/protein/2.8.571; KRISHNAGOPAL M, 1985, BIOCHIM BIOPHYS ACTA, V832, P156; KRISHNAMURTHY VV, 1995, J MAGN RESON SER B, V106, P170, DOI 10.1006/jmrb.1995.1028; KURIHARA K, 1968, SCIENCE, V161, P1241, DOI 10.1126/science.161.3847.1241; Lee SY, 1999, BIOCHEMISTRY-US, V38, P2340, DOI 10.1021/bi9822731; LEE W, 1994, EUR J BIOCHEM, V219, P89, DOI 10.1111/j.1432-1033.1994.tb19918.x; LIU XZ, 1993, EUR J BIOCHEM, V211, P281, DOI 10.1111/j.1432-1033.1993.tb19896.x; LOMIZE AL, 1990, BIOORG KHIM+, V16, P179; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MORRIS JA, 1972, BIOCHIM BIOPHYS ACTA, V261, P114, DOI 10.1016/0304-4165(72)90320-0; MORRIS JA, 1976, LLOYDIA, V39, P25; MURZIN AG, 1993, J MOL BIOL, V230, P689, DOI 10.1006/jmbi.1993.1186; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OGATA C, 1987, NATURE, V328, P739, DOI 10.1038/328739a0; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; SURI AK, 1995, J MAGN RESON SER B, V106, P24, DOI 10.1006/jmrb.1995.1004; TOMIC MT, 1992, J BIOMOL NMR, V2, P557, DOI 10.1007/BF02192845; VANDERWEL H, 1972, EUR J BIOCHEM, V31, P221; VANDERWEL H, 1976, BIOCH SENSORY FUNCT, V197, P235; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WOODY RW, 1978, BIOPOLYMERS, V17, P1451, DOI 10.1002/bip.1978.360170606; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMASHITA H, 1990, J BIOL CHEM, V265, P15770	39	30	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19624	19630		10.1074/jbc.M100930200	http://dx.doi.org/10.1074/jbc.M100930200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279156	hybrid			2022-12-25	WOS:000169091000128
J	Li, YH; Lu, WY; Marzolo, MP; Bu, GJ				Li, YH; Lu, WY; Marzolo, MP; Bu, GJ			Differential functions of members of the low density lipoprotein receptor family suggested by their distinct endocytosis rates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; DEPENDENT LIGAND DISSOCIATION; AMYLOID PRECURSOR PROTEIN; LDL-RECEPTOR; CYTOSOLIC ADAPTER; MOLECULAR CHAPERONE; VLDL RECEPTOR; MESSENGER-RNA; GENE FAMILY; IN-VITRO	The low density lipoprotein receptor (LDLR) family is composed of a class of cell surface endocytic receptors that recognize extracellular ligands and internalize them for degradation by lysosomes, In addition to LDLR, mammalian members of this family include the LDLR-related protein (LRP), the very low density lipoprotein receptor (VLDLR), the apolipoprotein E receptor-2 (apoER2), and megalin. Herein we have analyzed the endocytic functions of the cytoplasmic tails of these receptors using LRP minireceptors, its chimeric receptor constructs, and full-length VLDLR and apoER2 stably expressed in LRP-null Chinese hamster ovary cells. We find that the initial endocytosis rates mediated by different cytoplasmic tails are significantly different, with half-times of ligand internalization ranging from less than 30 s to more than 8 min. The tail of LRP mediates the highest rate of endocytosis, whereas those of the VLDLR and apoER2 exhibit least endocytosis function. Compared with the tail of LRP, the tails of the LDLR and megalin display significantly lower levels of endocytosis rates. Ligand degradation analyses strongly support differential endocytosis rates initiated by these receptors. Interestingly apoER2, which has recently been shown to mediate intracellular signal transduction, exhibited the lowest level of ligand degradation efficiency. These results thus suggest that the endocytic functions of members of the LDLR family are distinct and that certain receptors in this family may play their main roles in areas other than receptor-mediated endocytosis.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Chile, Dept Biol, Santiago, Chile; St Louis Childrens Hosp, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Universidad de Chile; St. Louis Children's Hospital; Washington University (WUSTL)	Bu, GJ (corresponding author), Washington Univ, Sch Med, Dept Pediat, CB 8208,660 S Euclid Ave, St Louis, MO 63110 USA.				NHLBI NIH HHS [HL59150] Funding Source: Medline; NIDDK NIH HHS [DK56783] Funding Source: Medline; NINDS NIH HHS [NS37525] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056783] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037525] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BU GJ, 1994, J BIOL CHEM, V269, P29874; BU GJ, 1993, J BIOL CHEM, V268, P13002; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DAVIS CG, 1987, NATURE, V326, P760, DOI 10.1038/326760a0; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERZ J, 1990, EMBO J, V9, P1769, DOI 10.1002/j.1460-2075.1990.tb08301.x; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2000, CURR OPIN LIPIDOL, V11, P161, DOI 10.1097/00041433-200004000-00009; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Hjalm G, 1996, EUR J BIOCHEM, V239, P132, DOI 10.1111/j.1432-1033.1996.0132u.x; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Hussain MM, 1999, ANNU REV NUTR, V19, P141, DOI 10.1146/annurev.nutr.19.1.141; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Li YH, 2001, MOL CELL BIOL, V21, P1185, DOI 10.1128/MCB.21.4.1185-1195.2001; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Mikhailenko I, 1999, J CELL SCI, V112, P3269; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller LM, 1998, J BIOL CHEM, V273, P22374, DOI 10.1074/jbc.273.35.22374; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Savonen R, 1999, J BIOL CHEM, V274, P25877, DOI 10.1074/jbc.274.36.25877; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; VASSILIOU G, 1994, J BIOL CHEM, V269, P15172; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	41	122	127	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18000	18006		10.1074/jbc.M101589200	http://dx.doi.org/10.1074/jbc.M101589200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279214	hybrid			2022-12-25	WOS:000168866500052
J	Orivel, J; Redeker, V; Le Caer, JP; Krier, F; Revol-Junelles, AM; Longeon, A; Chaffotte, A; Dejean, A; Rossier, J				Orivel, J; Redeker, V; Le Caer, JP; Krier, F; Revol-Junelles, AM; Longeon, A; Chaffotte, A; Dejean, A; Rossier, J			Ponericins, new antibacterial and insecticidal peptides from the venom of the ant Pachycondyla goeldii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIMICROBIAL PEPTIDES; METAPLEURAL GLANDS; MYRMECIA-GULOSA; MELITTIN; PROTEIN; CECROPIN; FAMILY; SKIN; HYMENOPTERA; PREDICTION	The antimicrobial, insecticidal, and hemolytic properties of peptides isolated from the venom of the predatory ant Pachycondyla goeldii, a member of the subfamily Ponerinae, were investigated. Fifteen novel peptides, named ponericins, exhibiting antibacterial and insecticidal properties were purified, and their amino acid sequences were characterized. According to their primary structure similarities, they can be classified into three families: ponericin G, W, and L, Ponericins share high sequence similarities with known peptides: ponericins G with cecropin-like peptides, ponericins W with gaegurins and melittin, and ponericins L with dermaseptins, Ten peptides were synthesized for further analysis. Their antimicrobial activities against Gram-positive and Gram-negative bacteria strains were analyzed together with their insecticidal activities against cricket larvae and their hemolytic activities. Interestingly, within each of the three families, several peptides present differences in their biological activities. The comparison of the structural features of ponericins with those of well-studied peptides suggests that the ponericins may adopt an amphipathic alpha -helical structure in polar environments, such as cell membranes. In the venom, the estimated peptide concentrations appear to be compatible with an antibacterial activity in vivo. This suggests that in the ant colony, the peptides exhibit a defensive role against microbial pathogens arising from prey introduction and/or ingestion.	Ecole Super Phys & Chim Ind Ville Paris, Lab Neurobiol & Divers Cellulaire, CNRS, UMR 7637, F-75005 Paris, France; Univ Paris 13, Lab Ethol Expt & Comparee, CNRS, ESA 7025, F-93430 Villetaneuse, France; Inst Natl Polytech Lorraine, Ecole Natl Super Agron & Ind Alimentaires, Lab Fermentat & Bioconvers Ind, F-54505 Vandoeuvre Les Nancy, France; Museum Natl Hist Nat, Lab Chim Subst Nat, CNRS, ESA 8041, F-75005 Paris, France; Inst Pasteur, CNRS, URA 1129, Unite Biochim Cellulaire, F-75015 Paris, France; Univ Toulouse 3, Lab Ecol Terr, CNRS, UMR 5552, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI); Centre National de la Recherche Scientifique (CNRS); Universite Paris 13; Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Redeker, V (corresponding author), Ecole Super Phys & Chim Ind Ville Paris, Lab Neurobiol & Divers Cellulaire, CNRS, UMR 7637, 10 Rue Vauquelin, F-75005 Paris, France.	virginie.redeker@espci.fr	Redeker, Virginie/L-8929-2018; Orivel, Jerome/C-4034-2011; Dejean, Anne/L-5145-2018	Redeker, Virginie/0000-0003-2694-8388; Orivel, Jerome/0000-0002-5636-3228; Dejean, Alain/0000-0002-3561-2248				Amiche M, 1999, FEBS LETT, V456, P352, DOI 10.1016/S0014-5793(99)00964-3; Andreu D, 1998, BIOPOLYMERS, V47, P415, DOI 10.1002/(SICI)1097-0282(1998)47:6<415::AID-BIP2>3.0.CO;2-D; Banks B.E.C., 1986, P329; Blaylock RSM, 2000, TOXICON, V38, P1529, DOI 10.1016/S0041-0101(00)00085-4; Blum M. S., 1978, Arthropod venoms., P801; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BROWN C A, 1979, Journal of the Kansas Entomological Society, V52, P119; CASTEELS P, 1993, J BIOL CHEM, V268, P7044; Deleage G, 1997, BIOCHIMIE, V79, P681, DOI 10.1016/S0300-9084(97)83524-9; EhretSabatier L, 1996, J BIOL CHEM, V271, P29537, DOI 10.1074/jbc.271.47.29537; Ekengren S, 1999, INSECT BIOCHEM MOLEC, V29, P965, DOI 10.1016/S0965-1748(99)00071-5; FERNANDES A, 1996, J VENOM ANIM TOXINS, V3, P287; Finney DJ., 1962, PROBIT ANAL STAT TRE; FUJIWARA S, 1990, J BIOL CHEM, V265, P11333; Giacometti A, 1999, PEPTIDES, V20, P1265, DOI 10.1016/S0196-9781(99)00131-X; Holldobler B., 1990, pi; Houston ME, 1998, J PEPT RES, V52, P81; Hu┬lldobler, 1985, PSYCHE CAMBRIDGE, V91, P201, DOI DOI 10.1155/1984/70141; JOUVENAZ DP, 1972, ANTIMICROB AGENTS CH, V2, P291, DOI 10.1128/AAC.2.4.291; Juvvadi P, 1996, J AM CHEM SOC, V118, P8989, DOI 10.1021/ja9542911; Krishnakumari V, 1997, J PEPT RES, V50, P88; Lowenberger C, 1999, J BIOL CHEM, V274, P20092, DOI 10.1074/jbc.274.29.20092; Mackintosh JA, 1999, AUST J ENTOMOL, V38, P124, DOI 10.1046/j.1440-6055.1999.00092.x; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MASCHWITZ U, 1970, J INSECT PHYSIOL, V16, P387, DOI 10.1016/0022-1910(70)90180-0; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; Oren Z, 1997, BIOCHEMISTRY-US, V36, P1826, DOI 10.1021/bi962507l; Orivel J, 2000, SOCIOBIOLOGY, V35, P131; PARK JM, 1994, BIOCHEM BIOPH RES CO, V205, P948, DOI 10.1006/bbrc.1994.2757; Rosengaus RB, 1998, J CHEM ECOL, V24, P1697, DOI 10.1023/A:1020872729671; Schmidt J.O., 1986, P425; Seon AA, 2000, J BIOL CHEM, V275, P5934, DOI 10.1074/jbc.275.8.5934; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Silvestro L, 1997, BIOCHEMISTRY-US, V36, P11452, DOI 10.1021/bi9630826; Simmaco M, 1998, BIOPOLYMERS, V47, P435, DOI 10.1002/(SICI)1097-0282(1998)47:6<435::AID-BIP3>3.3.CO;2-#; Sun DX, 1998, BIOCHEM BIOPH RES CO, V249, P410, DOI 10.1006/bbrc.1998.9150; Takei J, 1999, FEBS LETT, V442, P11, DOI 10.1016/S0014-5793(98)01617-2; Takei J, 1998, BIOCHEMISTRY-US, V37, P5699, DOI 10.1021/bi9729007; VEAL DA, 1992, J APPL BACTERIOL, V72, P188, DOI 10.1111/j.1365-2672.1992.tb01822.x; Wang CC, 1998, J ELECTROCERAM, V2, P273, DOI 10.1023/A:1009978607621; Yans LZ, 1998, J BIOL CHEM, V273, P2059, DOI 10.1074/jbc.273.4.2059	42	163	195	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17823	17829		10.1074/jbc.M100216200	http://dx.doi.org/10.1074/jbc.M100216200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279030	hybrid			2022-12-25	WOS:000168866500029
J	Feng, ZP; Hamid, J; Doering, C; Bosey, GM; Snutch, TP; Zamponi, GW				Feng, ZP; Hamid, J; Doering, C; Bosey, GM; Snutch, TP; Zamponi, GW			Residue Gly(1326) of the N-type calcium channel alpha(1B) subunit controls reversibility of omega-conotoxin GVIA and MVIIA block	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; GRAMMOTOXIN-SIA; NA+-CHANNELS; SYMPATHETIC NEURONS; SODIUM-CHANNEL; PEPTIDE; MUSCLE; BINDING; RECEPTORS; SUBTYPES	We recently reported that amino acid residues contained within a putative EF hand motif in the domain ill S5-H5 region of the alpha (1B) subunit affected the relative barium:calcium permeability of N-type calcium channels (Feng, Z. P., Hamid, J., Doering, C., Jarvis, S. E., Bosey, G. M., Bourinet, E., Snutch, T. P., and Zamponi, G. W. (2001) J. Biol. Chem. 276, 5726-5730). Since this region partially overlaps with residues previously implicated in block of the channel by omega -conotoxin GVIA, we assessed the effects of mutations in the putative EF hand domain on channel block by omega -conotoxin GVIA and the structurally related omega -conotoxin MVILA. Both of the toxins irreversibly block the activity of wild type alpha (1B) N-type channels. We find that in addition to previously identified amino acid residues, residues in positions 1326 and 1332 are important determinants of omega -conotoxin GVIA blockade. Substitution of residue Glu(1332) to arginine slows the time course of development of block. Point mutations in position Gly(1326) to either arginine, glutamic acid, or proline dramatically decrease the time constant for development of the block. Additionally, in the G1326P mutant channel activity was almost completely recovered following washout. A qualitatively similar result was obtained with omega -conotoxin MVIIA, suggesting that common molecular determinants underlie block by these two toxins. Taken together the data suggest that residue Gly(1326) may form a barrier, which controls the access of peptide toxins to their blocking site within the outer vestibule of the channel pore and also stabilizes the toxin-channel interaction.	Univ Calgary, Dept Physiol & Biophys, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Pharmacol & Therapeut, Neurosci Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of Calgary; University of Calgary; University of British Columbia	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Zamponi, Gerald W./0000-0002-0644-9066				ADAMS ME, 1993, BIOCHEMISTRY-US, V32, P12566, DOI 10.1021/bi00210a003; BECKER S, 1992, BIOCHEMISTRY-US, V31, P8229, DOI 10.1021/bi00150a016; Beedle AM, 2000, BIOPHYS J, V79, P260, DOI 10.1016/S0006-3495(00)76288-6; BOLAND LM, 1993, J NEUROSCI, V13, P516; BOLAND LM, 1994, J NEUROSCI, V14, P5011; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Chahine M, 1998, BIOPHYS J, V75, P236, DOI 10.1016/S0006-3495(98)77510-1; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; ERTEL EA, 1994, BIOCHEMISTRY-US, V33, P5098, DOI 10.1021/bi00183a013; Favreau P, 1999, Acta Physiol Pharmacol Ther Latinoam, V49, P257; Feng ZP, 2001, J BIOL CHEM, V276, P5726, DOI 10.1074/jbc.C000791200; FOX JA, 1995, PFLUG ARCH EUR J PHY, V429, P873, DOI 10.1007/BF00374813; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; Kulak JM, 1997, J NEUROSCI, V17, P5263; LAMPE RA, 1993, MOL PHARMACOL, V44, P451; Li RA, 1997, BIOPHYS J, V73, P1874, DOI 10.1016/S0006-3495(97)78218-3; Li RK, 2000, J BIOL CHEM, V275, P27551; Luo SQ, 1998, J NEUROSCI, V18, P8571; McDonough SI, 1996, J NEUROSCI, V16, P2612; McDonough SI, 1997, BIOPHYS J, V72, P2117, DOI 10.1016/S0006-3495(97)78854-4; McDonough SI, 1997, MOL PHARMACOL, V52, P1095, DOI 10.1124/mol.52.6.1095; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MINTZ IM, 1994, J NEUROSCI, V14, P2844; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOCZYDLOWSKI E, 1986, P NATL ACAD SCI USA, V83, P5321, DOI 10.1073/pnas.83.14.5321; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; PISER TM, 1995, MOL PHARMACOL, V48, P131; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; QUIK M, 1992, MOL NEUROBIOL, V6, P19, DOI 10.1007/BF02935565; Ridgeway B, 2000, PAIN, V85, P287, DOI 10.1016/S0304-3959(99)00255-9; STEA A, 1995, HDB RECEPTORS CHANNE, P113; Tenenholz TC, 2000, REV PHYSIOL BIOCH P, V140, P135, DOI 10.1007/BFb0035552; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WOPPMANN A, 1994, MOL CELL NEUROSCI, V5, P350, DOI 10.1006/mcne.1994.1042	36	73	76	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15728	15735		10.1074/jbc.M100406200	http://dx.doi.org/10.1074/jbc.M100406200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279062	hybrid			2022-12-25	WOS:000168623100022
J	Utkin, YN; Kukhtina, VV; Kryukova, EV; Chiodini, F; Bertrand, D; Methfessel, C; Tsetlin, VI				Utkin, YN; Kukhtina, VV; Kryukova, EV; Chiodini, F; Bertrand, D; Methfessel, C; Tsetlin, VI			"Weak toxin" from Naja kaouthia is a nontoxic antagonist of alpha 7 and muscle-type nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	XIIIth World Congress of the International-Society-on-Toxinology	SEP 18-22, 2000	PARIS, FRANCE	Int Soc Toxinol			SNAKE-VENOM TOXINS; CONOTOXIN IMI; CURAREMIMETIC TOXINS; HOMOMERIC ALPHA-7; LY-6 FAMILY; NEUROTOXINS; BUNGAROTOXIN; IDENTIFICATION; COBRATOXIN; PROTEINS	A novel "weak toxin" (WTX) from Naja kaouthia snake venom competes with [I-125]alpha -bungarotoxin for binding to the membrane-bound Torpedo californica acetylcholine receptor (AChR), with an IC50 of similar to2.2 muM. In this respect, it is similar to 300 times less potent than neurotoxin II from Naja oxiana and alpha -cobratoxin from N. kaouthia, representing short-type and long-type alpha -neurotoxins, respectively. WTX and alpha -cobratoxin displaced [I-125]alpha -bungarotoxin from the Escherichia coli-expressed fusion protein containing the rat alpha7 AChR N-terminal domain 1-208 preceded by glutathione S-transferase with IC50 values of 4.3 and 9.1 muM, respectively, whereas for neurotoxin II the IC50 value was >100 muM. Micromolar concentrations of WTX inhibited acetylcholine-activated currents in Xenopus oocyte-expressed rat muscle AChR and human and rat alpha7 AChRs, inhibiting the latter most efficiently (IC50 of similar to8.3 muM). Thus, a virtually nontoxic "three-fingered" protein WTX, although differing from alpha -neurotoxins by an additional disulfide in the N-terminal loop, can be classified as a weak alpha -neurotoxin. It differs from the short chain alpha -neurotoxins, which potently block the muscle-type but not the alpha7 AChRs, and is closer to the long alpha -neurotoxins, which have comparable potency against the above-mentioned AChR types.	Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Bayer AG, Cent Res Biophys, D-51368 Leverkusen, Germany	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; University of Geneva; Bayer AG	Tsetlin, VI (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, 16-10 Miklukho Maklaya Str,V-437,GSP-7, Moscow 117997, Russia.	vits@ibch.ru	Tsetlin, Victor/X-2491-2018; Utkin, Yuri/L-2952-2019; Utkin, Yuri N./F-1958-2014	Utkin, Yuri/0000-0002-4609-970X; Utkin, Yuri N./0000-0002-4609-970X				Ackermann EJ, 1998, J BIOL CHEM, V273, P10958, DOI 10.1074/jbc.273.18.10958; Aird SD, 1999, TOXICON, V37, P609, DOI 10.1016/S0041-0101(98)00199-8; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Antil-Delbeke S, 2000, J BIOL CHEM, V275, P29594, DOI 10.1074/jbc.M909746199; Ariel S, 1998, ANN NY ACAD SCI, V841, P93, DOI 10.1111/j.1749-6632.1998.tb10912.x; BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BETZEL C, 1991, J BIOL CHEM, V266, P21530; Buisson B, 1998, J PHYSIOL-PARIS, V92, P89, DOI 10.1016/S0928-4257(98)80144-7; CARLSSON FHH, 1975, BIOCHIM BIOPHYS ACTA, V400, P310, DOI 10.1016/0005-2795(75)90186-5; Chang LS, 2000, BBA-PROTEIN STRUCT M, V1480, P293, DOI 10.1016/S0167-4838(00)00082-0; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; Eletskii A V, 2001, Bioorg Khim, V27, P89; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gullick W J, 1994, Methods Mol Biol, V32, P389; GUMLEY TP, 1995, IMMUNOL CELL BIOL, V73, P277, DOI 10.1038/icb.1995.45; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P425, DOI 10.1515/bchm2.1980.361.1.425; JOUBERT FJ, 1975, H-S Z PHYSIOL CHEM, V356, P1901; KIEFFER B, 1994, BIOCHEMISTRY-US, V33, P4471, DOI 10.1021/bi00181a006; KLUKAS O, 1995, BIOORG KHIM+, V21, P152; Kuhn P, 2000, ACTA CRYSTALLOGR D, V56, P1401, DOI 10.1107/S0907444900011501; Kukhtina VV, 2000, BIOORG KHIM+, V26, P803; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; MOORE MA, 1995, BBA-BIOMEMBRANES, V1235, P336, DOI 10.1016/0005-2736(95)80022-8; NIRTHANAN S, 2000, 13 WORLD C INT SOC T, pL108; Osaka H, 2000, J BIOL CHEM, V275, P5478, DOI 10.1074/jbc.275.8.5478; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Quiram PA, 1998, J BIOL CHEM, V273, P11007, DOI 10.1074/jbc.273.18.11007; RICHARDS D, 1988, ELISA OTHER SOLID PH, P345; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; SHAFQAT J, 1991, FEBS LETT, V284, P70, DOI 10.1016/0014-5793(91)80764-T; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; UTKIN Y, 2000, 13 WORLD C INT SOC T, pP162; Utkin YN, 1998, EUR J BIOCHEM, V253, P229, DOI 10.1046/j.1432-1327.1998.2530229.x; Utkin YN, 1999, TOXICON, V37, P1683, DOI 10.1016/S0041-0101(99)00111-7; Utkin YN, 2001, TOXICON, V39, P921, DOI 10.1016/S0041-0101(00)00223-3; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Wonnacott S., 1993, METHODS NEUROSCI, P263	47	101	106	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15810	15815		10.1074/jbc.M100788200	http://dx.doi.org/10.1074/jbc.M100788200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	431GH	11279130	hybrid			2022-12-25	WOS:000168623100033
J	Deb, TB; Su, L; Wong, L; Bonvini, E; Wells, A; David, M; Johnson, GR				Deb, TB; Su, L; Wong, L; Bonvini, E; Wells, A; David, M; Johnson, GR			Epidermal growth factor (EGF) receptor kinase-independent signaling by EGF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; MICE LACKING; EXPRESSION; PHOSPHORYLATION; HETERODIMERIZATION; TRANSDUCTION; REQUIREMENT; SPECIFICITY; MUTATION	The ErbB family of receptors, which includes the epidermal growth factor receptor (EGFR), ErbB2, ErbB3, and ErbB4, mediate signaling by EGF-like polypeptides, To better understand the role of the EGFR tyrosine kinase, we analyzed signaling by a kinase-inactive EGFR (K721M) in ErbB-devoid 32D cells. K721M alone exhibited no detectable signaling capacity, whereas coexpression of K721M with ErbB2, but not ErbB3 or ErbB4, resulted in EGF-dependent mitogen-activated protein kinase (MAPK) activation. The kinase activity, but not tyrosine phosphorylation, of ErbB2 was required for EGF-induced MAPK activation. The presence of tyrosine phosphorylation sites in K721M was not a requisite for signaling, indicating that transphosphorylation of K721M by ErbB2 was not an essential mechanism of receptor activation. Conversely, the mutated kinase domain of K721M (residues 648-973) and tyrosine phosphorylation of at least one of the receptors were necessary. EGF was found to activate the pro-survival protein kinase Akt in stable cell lines expressing K721M and ErbB2 but, unlike cells expressing wild-type EGFR, was incapable of activating signal transducers and activators of transcription (STAT) or driving cell proliferation. These results demonstrate that EGFR-ErbB2 oligomers are potent activators of MAPK and Akt, and this signaling does not require EGFR kinase activity.	US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Bethesda, MD 20892 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA; US FDA, Ctr Biol Evaluat & Res, Div Monoclonal Antibodies, Bethesda, MD 20892 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	US Food & Drug Administration (FDA); University of California System; University of California San Diego; University of California System; University of California San Diego; US Food & Drug Administration (FDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Johnson, GR (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Therapeut Prot, Bldg 29A,Rm 3B-16,8800 Rockville Pike, Bethesda, MD 20892 USA.	Johnsong@cber.fda.gov		Su, Leon/0000-0001-7654-9997; Wells, Alan/0000-0002-1637-8150				Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; ASKEW DS, 1991, ONCOGENE, V6, P1915; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Gamett DC, 1997, J BIOL CHEM, V272, P12052, DOI 10.1074/jbc.272.18.12052; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HACK N, 1993, J BIOL CHEM, V268, P26441; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; Huang GC, 1998, BIOCHEM J, V331, P113, DOI 10.1042/bj3310113; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SELVA E, 1993, J BIOL CHEM, V268, P2250; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; Verveer PJ, 2000, SCIENCE, V290, P1567, DOI 10.1126/science.290.5496.1567; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085	38	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15554	15560		10.1074/jbc.M100928200	http://dx.doi.org/10.1074/jbc.M100928200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279155	hybrid			2022-12-25	WOS:000168528800135
J	Wang, LH; Tsai, AL; Hsu, PY				Wang, LH; Tsai, AL; Hsu, PY			Substrate binding is the rate-limiting step in thromboxane synthase catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDES; LIPID-PEROXIDATION; ARACHIDONIC-ACID; HUMAN-PLATELETS; ENZYME; CYTOCHROME-P-450; MALONDIALDEHYDE; PURIFICATION; MECHANISM; IDENTIFICATION	Thromboxane synthase (TXAS) is "non-classical" cytochrome P450. Without any need for an external electron donor, or for a reductase or molecular oxygen, it uses prostaglandin H-2 (PGrH(2)) to catalyze either an isomerization reaction to form thromboxane A(2) (TXA(2)) or a fragmentation reaction to form 12-L-hydroxy-5,8,10-heptadecatrienoic acid and malondialdehyde (MDA) at a ratio of 1:1:1 (TXA(2):heptadecatrienoic acid:MDA), We report here kinetics of TXAS with heme ligands in binding study and with PGH, in enzymatic study. We determined that 1) binding of U44069, an oxygen-based ligand, is a two-step process; U44069 first binds TXAS, then ligates the heme-iron with a maximal rate constant of 105-130 s(-1); 2) binding of cyanide, a carbon-based ligand, is a one-step process with k(on) of 2.4 M-1 s(-1) and k(off) of 0.112 s(-1); and 3) both imidazole and clotrimazole (nitrogen-based ligands) bind TXAS in a two-step process; an initial binding to the heme-iron with on-rate constants of 8.4 x 10(4) M-1 s(-1) and 1.5 x 10(5) M-1 s(-1) for imidazole and clotrimazole, respectively, followed by a slow conformational change with off-rate constants of 8.8 s(-1) and 0.53 s(-1), respectively. The results of our binding study indicate that the TXAS active site is hydrophobic and spacious. In addition, steady-state kinetic study revealed that; TXAS consumed PGH(2) at a rate of 3,800 min(-1) and that the k(cat)/K-m for PGH(2) consumption was 3 x 10(6) M-1 s(-1). Based on these data, TXAS appears to be a very efficient catalyst. Surprisingly, rapid-scan stopped-flow experiments revealed marginal absorbance changes upon mixing TXAS with PGH(2), indicating minimal accumulation of any heme-derived intermediates, Freeze-quench EPR measurements for the same reaction showed minimal change of heme redox state, Further kinetic analysis using a combination of rapid-mixing chemical quench and computer simulation showed that the kinetic parameters of TXAS-catalyzed reaction are: PGH(2) bound TXAS at a rate of 1.2-2.0 x 10(7) M-1 s(-1): the rate of catalytic conversion of PGH(2) to TXA(2) or MDA was at least 15,000 s(-1) and the lower limit of the rates for products release was 4,000-6,000 s(-1). Given that the cellular PGH(2) concentration is quite low, we concluded that under physiological conditions, the substrate-binding step is the rate-limiting step of the TXAS-catalyzed reaction, in sharp contrast with "classical" P450 enzymes.	Univ Texas, Dept Internal Med, Div Hematol, Houston, TX 77030 USA	University of Texas System	Wang, LH (corresponding author), Univ Texas, Dept Internal Med, Div Hematol, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060625] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056818] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-60625] Funding Source: Medline; NIGMS NIH HHS [GM-56818, GM-44911] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chilton FH, 1996, BBA-LIPID LIPID MET, V1299, P1, DOI 10.1016/0005-2760(95)00169-7; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P345, DOI 10.1073/pnas.71.2.345; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HARA S, 1994, J BIOL CHEM, V269, P19897; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HECKER M, 1987, ARCH BIOCHEM BIOPHYS, V254, P124, DOI 10.1016/0003-9861(87)90088-9; HECKER M, 1987, BIOCHEM PHARMACOL, V36, P851, DOI 10.1016/0006-2952(87)90175-4; HECKER M, 1989, J BIOL CHEM, V264, P141; Hsu PY, 1999, J BIOL CHEM, V274, P762, DOI 10.1074/jbc.274.2.762; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; LEDERGERBER D, 1995, J ENZYM INHIB, V9, P253, DOI 10.3109/14756369509036554; LINDSKOG S, 1984, ANN NY ACAD SCI, V429, P61, DOI 10.1111/j.1749-6632.1984.tb12315.x; Mueller Ernest J., 1995, P83; NAHRI LO, 1986, J BIOL CHEM, V261, P7160; PETERSON JA, 1975, CYTOCHROMES P450 B5, P311; Plastaras JP, 2000, J BIOL CHEM, V275, P11784, DOI 10.1074/jbc.275.16.11784; RUAN KH, 1993, J BIOL CHEM, V268, P19483; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; TRIGGIANI M, 1995, J EXP MED, V182, P1181, DOI 10.1084/jem.182.5.1181; Uchida K, 1999, TRENDS CARDIOVAS MED, V9, P109, DOI 10.1016/S1050-1738(99)00016-X; VANE J, 1987, FASEB J, V1, P89, DOI 10.1096/fasebj.1.2.3111928; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; WATANABE Y, 1992, ENZYMES, V20, P405; WOLF BA, 1991, BIOCHEMISTRY-US, V30, P6372, DOI 10.1021/bi00240a004; WU KK, 1981, J CLIN INVEST, V67, P1801, DOI 10.1172/JCI110221	33	37	37	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14737	14743		10.1074/jbc.M009177200	http://dx.doi.org/10.1074/jbc.M009177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11297515	hybrid			2022-12-25	WOS:000168528800029
J	Han, ZQ; Ni, J; Smits, P; Underhill, CB; Xie, B; Chen, YX; Liu, NF; Tylzanowski, P; Parmelee, D; Feng, P; Ding, I; Gao, F; Gentz, R; Huylebroeck, D; Merregaert, J; Zhang, LR				Han, ZQ; Ni, J; Smits, P; Underhill, CB; Xie, B; Chen, YX; Liu, NF; Tylzanowski, P; Parmelee, D; Feng, P; Ding, I; Gao, F; Gentz, R; Huylebroeck, D; Merregaert, J; Zhang, LR			Extracellular matrix protein 1 (ECM1) has angiogenic properties and is expressed by breast tumor cells	FASEB JOURNAL			English	Article						angiogenesis; breast cancer; ECM1; endothelial cells	DEVELOPMENTAL EXPRESSION; ALPHA-FETOPROTEIN; BINDING; PROLIFERATION; INHIBITOR; ALBUMIN; CLONING; FAMILY; CANCER; MOUSE	Tumor growth and metastasis are critically dependent on the formation of new blood vessels. The present study found that extracelluIar matrix protein 1 (ECM1), a newly described secretory glycoprotein, promotes angiogenesis. This was initially suggested by itt situ hybridization studies of mouse embryos indicating that the ECM1 message was associated with blood vessels and its expression pattern was similar to that of flk-1, a recognized marker for endothelium. More direct evidence for the role of ECM1 in angiogenesis was provided by the fact that highly purified recombinant ECM1 stimulated the proliferation of cultured endothelial cells and promoted blood vessel formation in the chorioallantoic membrane of chicken embryos. Immunohistochemical staining with specific antibodies indicated that ECM1 was expressed by the human breast cancer cell lines MDA-435 and LCC15, both of which are highly tumorigenic. In addition, staining of tissue sections from patients with breast cancer revealed that ECM1 was present in a significant proportion of primary and secondary tumors. Collectively, the results of this study suggest that ECM1 possesses angiogenic properties that may promote tumor progression.	Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA; Human Genome Sci, Rockville, MD 20850 USA; Univ Rochester, Med Ctr, Dept Radiol, Rochester, NY 14642 USA; Xiamen Univ, Dept Biol, Xiamen, Peoples R China; Katholieke Univ Leuven VIB, Mol Biol Lab, Celgen, Louvain, Belgium; Katholieke Univ Leuven VIB, Dept Cell Growth Differentiat & Dev, Louvain, Belgium; Univ Instelling Antwerp, Dept Biochem, Lab Mol Biotechnol, B-2610 Antwerp, Belgium	Georgetown University; GlaxoSmithKline; Human Genome Sciences Inc; University of Rochester; Xiamen University; Flanders Institute for Biotechnology (VIB); KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University of Antwerp	Zhang, LR (corresponding author), Georgetown Univ, Med Ctr, Dept Oncol, 3970 Reservoir Rd NW, Washington, DC 20007 USA.	zhangl@georgetown.edu	Tylzanowski, Przemko/G-8881-2013; Chen, YX/G-3937-2010	Tylzanowski, Przemko/0000-0003-0769-559X; Huylebroeck, Danny/0000-0003-4862-1079	NCI NIH HHS [R29 CA71545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA071545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; BHALERAO J, 1995, J BIOL CHEM, V270, P16385, DOI 10.1074/jbc.270.27.16385; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; DECKERS MML, IN PRESS BONE; DEWULF N, 1995, ENDOCRINOLOGY, V136, P2652, DOI 10.1210/en.136.6.2652; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Hoffmann A, 1996, DEV DYNAM, V207, P332, DOI 10.1002/(SICI)1097-0177(199611)207:3<332::AID-AJA10>3.0.CO;2-6; JACOB F, 1983, CIBA F SYMP, V96, P4; Johnson MR, 1997, MATRIX BIOL, V16, P289, DOI 10.1016/S0945-053X(97)90017-2; KEW M, 1974, GUT, V15, P814, DOI 10.1136/gut.15.10.814; KRAGHHANSEN U, 1990, DAN MED BULL, V37, P57; MATHIEU E, 1994, J BONE MINER RES, V9, P903; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nguyen M, 1997, INVEST NEW DRUG, V15, P29, DOI 10.1023/A:1005766511385; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Ni J, 1997, J BIOL CHEM, V272, P10853; POLVERINI PJ, 1984, LAB INVEST, V51, P635; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; Smits P, 2000, J INVEST DERMATOL, V114, P718, DOI 10.1046/j.1523-1747.2000.00916.x; Sung V, 1998, EXP CELL RES, V241, P273, DOI 10.1006/excr.1998.4029; Thomas KA, 1996, J BIOL CHEM, V271, P603, DOI 10.1074/jbc.271.2.603; YACHNIN S, 1978, ANN CLIN LAB SCI, V8, P84; YANG F, 1985, P NATL ACAD SCI USA, V82, P7994, DOI 10.1073/pnas.82.23.7994	23	107	121	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					988	994		10.1096/fj.99-0934com	http://dx.doi.org/10.1096/fj.99-0934com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292659				2022-12-25	WOS:000167959300013
J	Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G				Tegeder, I; Niederberger, E; Israr, E; Guhring, H; Brune, K; Euchenhofer, C; Grosch, S; Geisslinger, G			Inhibition of NF-KB and AP-1 activation by R- and S-flurbiprofen	FASEB JOURNAL			English	Article									Goethe Univ Frankfurt, Ctr Pharmacol, D-60590 Frankfurt, Germany; Univ Erlangen Nurnberg, Inst Expt Pharmakol & Toxikol, D-91054 Erlangen, Germany	Goethe University Frankfurt; University of Erlangen Nuremberg	Geisslinger, G (corresponding author), Goethe Univ Frankfurt, Ctr Pharmacol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	geisslinger@em.uni-frankfurt.de	Tegeder, Irmgard/AAM-2266-2020; Groesch, Sabine/H-4251-2018; Tegeder, Irmgard/AAM-2246-2020	Tegeder, Irmgard/0000-0001-7524-8025; Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025					0	48	50	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2001	15	3					595	597		10.1096/fasebj.15.3.595	http://dx.doi.org/10.1096/fasebj.15.3.595			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	410BE	11291649				2022-12-25	WOS:000167419500016
J	Garrigue-Antar, L; Barker, C; Kadler, KE				Garrigue-Antar, L; Barker, C; Kadler, KE			Identification of amino acid residues in bone morphogenetic protein-1 important for procollagen C-proteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; ZINC-PEPTIDASES; ASTACIN FAMILY; MEPRIN-A; SPECIFICITY; EXPRESSION; PROTEASE; COLLAGENASES; PURIFICATION; INHIBITORS	Bone morphogenetic protein (BMP)-1, which belongs to the tolloid subgroup of astacin-like zinc metalloproteinases, cleaves the C-propeptides of procollagen at the physiologic site and is, therefore, a procollagen C-proteinase (PCP), Cleavage occurs between a specific alanine or glycine residue (depending on the procollagen chain) and an invariant aspartic acid residue in each of the three chains of procollagen. To learn more about how BMP-1 exhibits PCP activity we mapped the primary structure of BMP-I onto the x-ray crystal structure of astacin and identified residues in the metalloproteinase domain of BMP-1 for subsequent site-directed mutagenesis studies. Recombinant wild-type and mutant BMP-1 were expressed in COS-7 cells and assayed for PCP activity using type I procollagen as the substrate. We showed that substitution of alanine for Glu(94), which occurs in the HEXXH zinc-binding motif of BMP-1, abolishes PCP activity. Furthermore, mutation of residues Lys(87) and Lys(176), Which are located in the S1 ' pocket of the enzyme and are therefore adjacent to the P1 ' residue in the substrate, reduced the proteolytic activity of BMP-1 by similar to 50%. A surprising observation was that mutation of Cys(66) reduced the activity to 20%, suggesting that this residue is crucial for activity, Further experiments showed that Cys(66) and Cys(63) which are located in the tolloid-specific sequence Cys(63)-Gly(64)-Cys(65)-Cys(66) in the active site, most likely form a disulfide bridge.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Chestukhin A, 1997, J BIOL CHEM, V272, P3153, DOI 10.1074/jbc.272.6.3153; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; Grams F, 1996, NAT STRUCT BIOL, V3, P671, DOI 10.1038/nsb0896-671; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Horton R M, 1993, Methods Mol Biol, V15, P251, DOI 10.1385/0-89603-244-2:251; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; LEPAGE T, 1992, DEVELOPMENT, V114, P147; MAENO M, 1993, GENE, V134, P257, DOI 10.1016/0378-1119(93)90103-A; Mullins MC, 1998, TRENDS GENET, V14, P127, DOI 10.1016/S0168-9525(98)01431-0; Ovens A, 2000, J PEPT SCI, V6, P489, DOI 10.1002/1099-1387(200009)6:9<489::AID-PSC282>3.3.CO;2-B; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; REYNOLDS SD, 1992, DEVELOPMENT, V114, P769; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; STOCKER W, 1990, BIOCHEMISTRY-US, V29, P10418; STOCKER W, 1993, EUR J BIOCHEM, V214, P215, DOI 10.1111/j.1432-1033.1993.tb17915.x; STOCKER W, 1995, PROTEIN SCI, V4, P823; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TERLINK T, 1989, CLIN CHIM ACTA, V183, P309; TITANI K, 1987, BIOCHEMISTRY-US, V26, P222, DOI 10.1021/bi00375a029; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; WOLZ RL, 1991, BIOCHEMISTRY-US, V30, P8488, DOI 10.1021/bi00098a029; WOLZ RL, 1995, METHOD ENZYMOL, V248, P325; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yiallouros I, 2000, FEBS LETT, V484, P224, DOI 10.1016/S0014-5793(00)02163-3; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	35	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26237	26242		10.1074/jbc.M010814200	http://dx.doi.org/10.1074/jbc.M010814200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11283002	hybrid			2022-12-25	WOS:000169823300080
J	Ikonomov, OC; Sbrissa, D; Shisheva, A				Ikonomov, OC; Sbrissa, D; Shisheva, A			Mammalian cell morphology and endocytic membrane homeostasis require enzymatically active phosphoinositide 6-kinase PIKfyve	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-PHOSPHATE; MULTIVESICULAR BODY; LYSOSOMAL-ENZYMES; GLUCOSE-TRANSPORT; 3-KINASE ACTIVITY; VACUOLE FUNCTION; FAB1P; KINASE; YEAST; PATHWAY	The dual specificity mammalian enzyme PIKfyve phosphorylates in vitro position D-5 in phosphatidylinositol (PtdIns) and PtdIns 3-P, itself or exogenous protein substrates, Here we have addressed the crucial questions for the identity of the lipid products and the role of PIKfyve enzymatic activity in mammalian cells. CHO, HEK293, and COS cells expressing PIKfyve(WT) at high levels and > 90% efficiencies increased selectively the intracellular PtdIns 3,5-P-2 production by 30-55%. In these cell types PtdIns 5-P was undetectable. A kinase-deficient point mutant, pIKfyve(K1831E), transiently transfected into these or other cells elicited a dramatic dominant phenotype, Subsequent to a dilation of the PIKfyve-containing vesicles, PIKfyve(K1831E)-expressing cells progressively accumulated multiple swollen lucent vacuoles of endosomal origin, first in the perinuclear cytoplasm and then toward the cell periphery. Despite their drastically altered morphology, the PIKfyve(K1831E)-expressing cells were viable and functionally active, evidenced by several criteria. This phenotype was completely reversed by introducing PIKfyveW(T) into the PIKfyve(K1831E)-transfected cells. Disruptions of the localization signal in the PIKfyve kinase-deficient mutant yielded a pIKfyve(K1831E Delta fyve) protein, incompetent to vacuolate cells, implying that an active PIKfyve enzyme at distinct late endocytic membranes is crucial for normal cell morphology, This was further substantiated by examining the vacuolation-induced potency of several pharmacological stimuli in cells expressing high PIKfyve(WT) levels. Together, the results indicate that PIKfyve enzymatic activity, possibly through the generation of PtdIns 3,5-P-2, and/or yet to be identified endogenous phosphoproteins, is critical for cell morphology and endomembrane homeostasis.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.							BROWN WJ, 1986, J CELL BIOL, V103, P1235, DOI 10.1083/jcb.103.4.1235; BROWN WJ, 1995, J CELL BIOL, V130, P781, DOI 10.1083/jcb.130.4.781; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cover TL, 1999, GASTROENTEROLOGY, V117, P257, DOI 10.1016/S0016-5085(99)70575-5; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GROVE RI, 1981, LIPIDS, V16, P691, DOI 10.1007/BF02535065; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henics T, 1999, BIOL CELL, V91, P485, DOI 10.1016/S0248-4900(00)88205-2; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Nave BT, 1996, BIOCHEM J, V318, P203, DOI 10.1042/bj3180203; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Reaves BJ, 1996, J CELL SCI, V109, P749; Reyrat JM, 1999, MOL MICROBIOL, V34, P197, DOI 10.1046/j.1365-2958.1999.01592.x; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2000, BIOCHEMISTRY-US, V39, P15980, DOI 10.1021/bi001897f; SBRISSA D, 2000, DIABETES S1, V49, pA1902; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Stenmark H, 1999, J CELL SCI, V112, P4175; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; Tombola F, 1999, BIOPHYS J, V76, P1401, DOI 10.1016/S0006-3495(99)77301-7; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	36	181	187	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 13	2001	276	28					26141	26147		10.1074/jbc.M101722200	http://dx.doi.org/10.1074/jbc.M101722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451VP	11285266	hybrid			2022-12-25	WOS:000169823300068
J	Hammond, PW; Alpin, J; Rise, CE; Wright, M; Kreider, BL				Hammond, PW; Alpin, J; Rise, CE; Wright, M; Kreider, BL			In vitro selection and characterization of Bcl-X-L-binding proteins from a mix of tissue-specific mRNA display libraries	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTION MAP; BH3 DOMAIN; FAMILY; CHANNEL; YEAST; EXPRESSION; BCL-X(L); CLONING; SYSTEM; GENE	The covalent coupling of an mRNA to the protein that it encodes (mRNA display) provides a powerful tool for analysis of protein function in the post-genomic era. This coupling allows the selective enrichment of individual members from libraries of displayed proteins and the subsequent regeneration of an enriched library using the RNA moiety, Tissue-specific libraries from poly(A)(+) mRNA were prepared by priming first and second strand cDNA synthesis with oligonucleotides containing nine random 3' nucleotides, the fixed regions of which encoded the requisite sequences for formation of mRNA display constructs and a library-specific sequence tag. Starting with a pool of uniquely tagged libraries from different tissues, an iterative selection was performed for binding partners of the anti-apoptotic protein Bcl-X-L. After four rounds of selection, the pool was deconvoluted by polymerase chain reaction amplification with library-specific primers. Subsequent clonal sequence analysis revealed the selection of three members of the Bcl-2 family known to bind to Bcl-X-L. In addition, several proteins not previously demonstrated to interact with Bcl-X-L were identified. The relative binding affinities of individual selected peptides were determined, as was their susceptibility to competition with a BH3 domain peptide. Based on these data, a putative BH3 domain was identified in most peptides.	Phylos Inc, Lexington, MA 02421 USA		Hammond, PW (corresponding author), Phylos Inc, 128 Spring St, Lexington, MA 02421 USA.	phammond@phylos.com						BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Diaz JL, 1997, J BIOL CHEM, V272, P11350; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kawamoto S, 2000, GENOME RES, V10, P1817, DOI 10.1101/gr.151500; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KURZ M, 2000, NUCLEIC ACIDS RES, V28, P83; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; Mayer BJ, 1999, MOL BIOTECHNOL, V13, P201, DOI 10.1385/MB:13:3:201; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Rahmani Z, 1998, EUR J HUM GENET, V6, P337, DOI 10.1038/sj.ejhg.5200198; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scorilas A, 2001, GENOMICS, V72, P217, DOI 10.1006/geno.2000.6455; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Simonen M, 1997, EUR J BIOCHEM, V249, P85, DOI 10.1111/j.1432-1033.1997.t01-1-00085.x; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Wong C, 1997, ANAL BIOCHEM, V252, P33, DOI 10.1006/abio.1997.2284; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; ZHANG HC, 1995, BIOCHEM BIOPH RES CO, V208, P950, DOI 10.1006/bbrc.1995.1426; Zozulya S, 1999, NAT BIOTECHNOL, V17, P1193, DOI 10.1038/70736	26	75	94	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20898	20906		10.1074/jbc.M011641200	http://dx.doi.org/10.1074/jbc.M011641200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283018	hybrid			2022-12-25	WOS:000169297900016
J	Houde, M; Laprise, P; Jean, D; Blais, M; Asselin, C; Rivard, N				Houde, M; Laprise, P; Jean, D; Blais, M; Asselin, C; Rivard, N			Intestinal epithelial cell differentiation involves activation of p38 mitogen-activated protein kinase that regulates the homeobox transcription factor CDX2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE EXPRESSION; GENE-EXPRESSION; POSTNATAL-DEVELOPMENT; 3T3-L1 ADIPOGENESIS; MESSENGER-RNA; CACO-2 CELLS; MAP KINASES; E-CADHERIN; PROMOTER; COMPLEX	The intracellular signaling pathways responsible for cell cycle arrest and differentiation along the crypt-villus axis of the human small intestine remain largely unknown. p38 mitogen-activated protein kinases (MAPKs) have recently emerged as key modulators of various vertebrate cell differentiation processes. In order to elucidate further the mechanism(s) responsible for the loss of proliferative potential once committed intestinal cells begin to differentiate, the role and regulation of p38 MAPK with regard to differentiation were analyzed in both intact epithelium as well as in well established intestinal cell models recapitulating the crypt-villus axis in vitro. Results show that phosphorylated and active forms of p38 were detected primarily in the nuclei of differentiated villus cells. Inhibition of p38 MAPK signaling by 2-20 muM SB203580 did not affect E2F-dependent transcriptional activity in subconfluent Caco-2/15 or HIEC cells. p38 MAPK activity dramatically increased as soon as Caco-2/15 cells reached confluence, whereas addition of SB203580 during differentiation of Caco-2/15 cells strongly attenuated sucrase-isomaltase gene and protein expression as well as protein expression of villin and alkaline phosphatase. The binding of CDX2 to the sucrase-isomaltase promoter and its transcriptional activity were significantly reduced by SB203580. Pull-down glutathione S-transferase and immunoprecipitation experiments demonstrated a direct interaction of CDX3 with p38, Finally, p38-dependent phosphorylation of CDX3 was observed in differentiating Caco-2/15 cells. Taken together, our results indicate that p38 MAPK may be involved in the regulation of CDX2/3 function and intestinal cell differentiation.	Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, CIHR Grp Funct Dev & Physiopathol Digest Tract, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Rivard, N (corresponding author), Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, CIHR Grp Funct Dev & Physiopathol Digest Tract, Sherbrooke, PQ J1H 5N4, Canada.							Aliaga JC, 1999, AM J PHYSIOL-GASTR L, V277, pG631, DOI 10.1152/ajpgi.1999.277.3.G631; [Anonymous], 1920, CONTRIBUTIONS EMBRYO; BABYATSKY MW, 1999, GROWTH DEV GASTROINT, P547; Basora N, 1997, GASTROENTEROLOGY, V113, P1510, DOI 10.1053/gast.1997.v113.pm9352853; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; BEAULIEU JF, 1991, BIOCHEM J, V280, P599, DOI 10.1042/bj2800599; CAIRNIE AB, 1965, EXP CELL RES, V39, P539, DOI 10.1016/0014-4827(65)90056-X; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; Chailler P, 1999, FRONT BIOSCI, V4, P87; CHENG H, 1985, ANAT REC, V211, P420, DOI 10.1002/ar.1092110408; CROSS HS, 1991, AM J PHYSIOL, V261, pC1173; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Deschenes C, 2001, GASTROENTEROLOGY, V120, P423, DOI 10.1053/gast.2001.21199; DOELL RG, 1965, P NATL ACAD SCI USA, V54, P1268, DOI 10.1073/pnas.54.4.1268; EICHHOLZ A, 1967, BIOCHIM BIOPHYS ACTA, V135, P475, DOI 10.1016/0005-2736(67)90037-5; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; Guay J, 1997, J CELL SCI, V110, P357; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; JAMES R, 1994, J BIOL CHEM, V269, P15229; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jin TR, 1997, MOL ENDOCRINOL, V11, P203, DOI 10.1210/me.11.2.203; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Karam Sherif M., 1999, Frontiers in Bioscience, V4, pD286, DOI 10.2741/Karam; Lambert M, 1996, EUR J BIOCHEM, V236, P778, DOI 10.1111/j.1432-1033.1996.00778.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEMISCHKA IR, 1981, J MOL BIOL, V151, P101, DOI 10.1016/0022-2836(81)90223-0; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; MENARD D, 1985, GASTROENTEROLOGY, V88, P691, DOI 10.1016/0016-5085(85)90139-8; Menard D., 1994, MEMBRANE PHYSIOPATHO, P319; MENARD D, 1989, GROWTH PROMOTING FAC, P123; Montgomery RK, 1999, GASTROENTEROLOGY, V116, P702, DOI 10.1016/S0016-5085(99)70193-9; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Pageot LP, 2000, MICROSC RES TECHNIQ, V49, P394; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Perreault N, 1996, EXP CELL RES, V224, P354, DOI 10.1006/excr.1996.0145; Perreault N, 1998, EXP CELL RES, V245, P34, DOI 10.1006/excr.1998.4221; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINTO M, 1983, BIOL CELL, V47, P323; QUARONI A, 1985, DEV BIOL, V111, P280, DOI 10.1016/0012-1606(85)90483-X; QUARONI A, 1985, DEV BIOL, V111, P267, DOI 10.1016/0012-1606(85)90482-8; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RONCARI G, 1969, INT J PROT RES, V1, P45; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taupin D, 1999, GASTROENTEROLOGY, V116, P1072, DOI 10.1016/S0016-5085(99)70010-7; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trinh KY, 1999, J BIOL CHEM, V274, P6011, DOI 10.1074/jbc.274.9.6011; VACHON PH, 1992, GASTROENTEROLOGY, V103, P414, DOI 10.1016/0016-5085(92)90829-N; VACHON PH, 1995, AM J PHYSIOL, V268, P857; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P795; WU GD, 1994, J BIOL CHEM, V269, P17080; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Zavitz KH, 1997, CURR OPIN CELL BIOL, V9, P773, DOI 10.1016/S0955-0674(97)80077-4; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zhou J, 1998, J BIOL CHEM, V273, P33367, DOI 10.1074/jbc.273.50.33367	82	125	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21885	21894		10.1074/jbc.M100236200	http://dx.doi.org/10.1074/jbc.M100236200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283019	hybrid			2022-12-25	WOS:000169297900141
J	Clark, KD; Volkman, BF; Thoetkiattikul, H; King, D; Hayakawa, Y; Strand, MR				Clark, KD; Volkman, BF; Thoetkiattikul, H; King, D; Hayakawa, Y; Strand, MR			Alanine-scanning mutagenesis of plasmatocyte spreading peptide identifies critical residues for biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-BLOCKING PEPTIDE; MOTH PSEUDOPLUSIA-INCLUDENS; PARALYTIC PEPTIDES; MANDUCA-SEXTA; HEMOLYMPH; HEMOCYTES; THROMBIN; PROTEIN; INSECTS	Plasmatocyte spreading peptide (PSP) is a 23-amino acid cytokine that induces a class of insect immune cells called plasmatocytes to spread on foreign surfaces. The structure of PSP consists of a disordered N terminus (residues 1-6) and a well-defined core (residues 7-23) stabilized by a disulfide bridge between Cys(7) and Cys(19), hydrophobic interactions, and a short beta -hairpin, Structural comparisons also indicate that the core region of PSP adopts an epidermal growth factor (EGF)-like fold very similar to the C-terminal subdomain of EGF-like module 5 of thrombomodulin, To identify residues important for plasmatocyte spreading activity, we bioassayed PSP mutants in which amino acids were either replaced with alanine or deleted. Within the well-defined core of PSP, alanine replacement of Cys(7) and Cys(19) (C7.19A) eliminated all activity. Alanine replacement of Arg(13) reduced activity similar to 1000-fold in comparison to wildtype PSP, whereas replacement of the other charged residues (Asp(16), Arg(18), Lys(20)) surrounding Cys(19) diminished activity to a lesser degree. The point mutants Y11A, T14A, T22A, and F23A had activity identical or only slightly reduced to that of wild-type PSP, The mutant PSP-(7-23) lacked the entire unstructured domain of PSP and was found to have no plasmatocyte spreading activity. Surprisingly, E1A and N2A had higher activity than wild-type PSP, but F3A had almost no activity. We thus concluded that the lack of activity for PSP-(7-23) was largely due to the critical importance of Phe(3). To determine whether reductions in activity correlated with alterations in tertiary structure, we compared the C7.19A, R13A, R18A, and F3A mutants to wildtype PSP by NMR spectroscopy. As expected, the simultaneous replacement of Cys(7) and Cys(19) profoundly affected tertiary structure, but the R13A, R18A, and F3A mutants did not differ from wild-type PSP, Collectively, these results indicate that residues in both the unstructured and structured domains of PSP are required for plasmatocyte-spreading activity.	Univ Wisconsin, Dept Entomol, Russell Labs 237, Madison, WI 53706 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Calif Berkeley, Dept Biochem, Berkeley, CA 94702 USA; Hokkaido Univ, Inst Low Temp Sci, Biochem Lab, Sapporo, Hokkaido 0600819, Japan	University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin; University of California System; University of California Berkeley; Hokkaido University	Strand, MR (corresponding author), Univ Wisconsin, Dept Entomol, Russell Labs 237, Madison, WI 53706 USA.		Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020; Clark, Kevin/GQA-9811-2022	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; 	NIAID NIH HHS [AI32917] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032917] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; CUNNINGHAM BC, 1989, SCIENCE, V244, P1801; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Furuya K, 1999, PEPTIDES, V20, P53, DOI 10.1016/S0196-9781(98)00148-X; Gardiner EMM, 1999, J INSECT PHYSIOL, V45, P113, DOI 10.1016/S0022-1910(98)00092-4; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; Hrabal R, 1996, PROTEIN SCI, V5, P195; KING DS, 1990, INT J PEPT PROT RES, V36, P255; LAVINE MD, 2001, IN PRESS J INSECT PH; Loret SM, 1998, EUR J CELL BIOL, V76, P146, DOI 10.1016/S0171-9335(98)80028-9; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P13547, DOI 10.1021/bi00250a006; McInnes C, 1997, BIOPOLYMERS, V43, P339, DOI 10.1002/(SICI)1097-0282(1997)43:5<339::AID-BIP2>3.0.CO;2-W; NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; Seino Atsushi, 1998, Journal of Sericultural Science of Japan, V67, P473; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; SKINNER WS, 1993, COMP BIOCHEM PHYS C, V104, P133, DOI 10.1016/0742-8413(93)90124-4; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Strand MR, 1999, ARCH INSECT BIOCHEM, V42, P213, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;213::AID-ARCH5&gt;3.0.CO;2-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; STRAND MR, 1990, ANN ENTOMOL SOC AM, V83, P538, DOI 10.1093/aesa/83.3.538; Volkman BF, 1999, J BIOL CHEM, V274, P4493, DOI 10.1074/jbc.274.8.4493; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7	26	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18491	18496		10.1074/jbc.M100579200	http://dx.doi.org/10.1074/jbc.M100579200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279096	hybrid			2022-12-25	WOS:000168866500117
J	Akileswaran, L; Taraska, JW; Sayer, JA; Gettemy, JM; Coghlan, VM				Akileswaran, L; Taraska, JW; Sayer, JA; Gettemy, JM; Coghlan, VM			A-kinase-anchoring protein AKAP95 is targeted to the nuclear matrix and associates with p68 RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; POLYMERASE-II; IDENTIFICATION; CLONING; ORGANIZATION; COACTIVATOR; ACTIVATION; SCAFFOLD; SUBUNIT; CAMP	The cell nucleus is structurally and functionally organized by the nuclear matrix. We have examined whether the nuclear cAMP-dependent protein kinase-anchoring protein AKAP95 contains specific signals for targeting to the subnuclear compartment and for interaction with other proteins. AKAP95 was expressed in mammalian cells and found to localize exclusively to the nuclear matrix. Mutational analysis was used to identify determinants for nuclear localization and nuclear matrix targeting of AKAP95, These sites were found to be distinct from previously identified DNA and protein kinase A binding domains. The nuclear matrix-targeting site is unique but conserved among members of the AKAP95 family. Direct binding of AKAP95 to isolated nuclear matrix was demonstrated in situ and found to be dependent on the nuclear matrix-targeting site. Moreover, Far Western blot analysis identified at least three AKAP95-binding proteins in nuclear matrix isolated from rat brain. Yeast two-hybrid cloning identified one binding partner as p68 RNA helicase, The helicase and AKAP95 co-localized in the nuclear matrix of mammalian cells, associated in vitro, and were precipitated as a complex from solubilized cell extracts. The results define novel protein-protein interactions among nuclear matrix proteins and suggest a potential role of AKAP95 as a scaffold for coordinating assembly of hormonally responsive transcription complexes.	Oregon Hlth & Sci Univ, Inst Neurol Sci, Beaverton, OR 97006 USA	Oregon Health & Science University	Coghlan, VM (corresponding author), Oregon Hlth & Sci Univ, Inst Neurol Sci, 505 NW 185th Ave, Beaverton, OR 97006 USA.	coghlanv@ohsu.edu	Taraska, Justin/H-8876-2016	Taraska, Justin/0000-0001-5355-9535	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052491] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52491] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BEREZNEY R, 1974, BIOCHEM BIOPH RES CO, V60, P1410, DOI 10.1016/0006-291X(74)90355-6; BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; Berezney R, 1995, INT REV CYTOL, V162A, P1; Bushmeyer SM, 1998, J CELL BIOCHEM, V68, P484, DOI 10.1002/(SICI)1097-4644(19980315)68:4<484::AID-JCB8>3.3.CO;2-F; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; COGHLAN VM, 1998, GEL ELECTROPHORESIS, P293; Collas P, 1999, J CELL BIOL, V147, P1167, DOI 10.1083/jcb.147.6.1167; Duttweiler HM, 1996, TRENDS GENET, V12, P340, DOI 10.1016/S0168-9525(96)80008-4; DWORETZKY SI, 1992, P NATL ACAD SCI USA, V89, P4178, DOI 10.1073/pnas.89.9.4178; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Endoh H, 1999, MOL CELL BIOL, V19, P5363; ENGELHARDT P, 1982, P NATL ACAD SCI-BIOL, V79, P6937, DOI 10.1073/pnas.79.22.6937; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FEY EG, 1988, P NATL ACAD SCI USA, V85, P121, DOI 10.1073/pnas.85.1.121; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; Grondin B, 1997, J BIOL CHEM, V272, P27877, DOI 10.1074/jbc.272.44.27877; HAKES DJ, 1991, J BIOL CHEM, V266, P11131; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hughes JH, 1999, AM J CLIN PATHOL, V111, P267; JACKSON DA, 1981, NATURE, V292, P552, DOI 10.1038/292552a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lee JY, 1998, DNA CELL BIOL, V17, P849, DOI 10.1089/dna.1998.17.849; LEWIS CD, 1984, J CELL SCI, P103; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nardozza TA, 1996, J CELL BIOCHEM, V61, P467, DOI 10.1002/(SICI)1097-4644(19960601)61:3<467::AID-JCB14>3.3.CO;2-W; NELSON WG, 1986, ANNU REV BIOPHYS BIO, V15, P457, DOI 10.1146/annurev.bb.15.060186.002325; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PETERS KE, 1980, J CELL BIOL, V86, P135, DOI 10.1083/jcb.86.1.135; ReplogleSchwab TS, 1996, CRIT REV EUKAR GENE, V6, P103, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.10; Seki N, 2000, J HUM GENET, V45, P31, DOI 10.1007/s100380070040; VANDRIEL R, 1991, J CELL BIOCHEM, V47, P311, DOI 10.1002/jcb.240470405; Vo NK, 1998, BIOCHEM BIOPH RES CO, V246, P831, DOI 10.1006/bbrc.1998.8722; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746	38	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17448	17454		10.1074/jbc.M101171200	http://dx.doi.org/10.1074/jbc.M101171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279182	hybrid			2022-12-25	WOS:000168730400114
J	Marheineke, K; Hyrien, O				Marheineke, K; Hyrien, O			Aphidicolin triggers a block to replication origin firing in Xenopus egg extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; DNA-REPLICATION; DROSOPHILA-MELANOGASTER; MIDBLASTULA TRANSITION; CHROMOSOME-REPLICATION; CHECKPOINT CONTROL; PROTEIN-KINASE; EARLY EMBRYOS; S-PHASE; INITIATION	DNA replication origins are located at random with respect to DNA sequence in Xenopus early embryos and on DNA replicated in Xenopus egg extracts. We have recently shown that origins fire throughout the S phase in Xenopus egg extracts. To study the temporal regulation of origin firing, we have analyzed origin activation in sperm nuclei treated with the DNA polymerase inhibitor aphidicolin, Sperm chromatin was incubated in Xenopus egg extracts in the presence of aphidicolin and transferred to a fresh extract, and digoxigenin-dUTP and biotin-dUTP were added at various times after aphidicolin release to selectively label early and late replicating DNA. Molecular combing analysis of single DNA fibers showed that only a fraction of potential origins were able to initiate in the presence of aphidicolin, After release from aphidicolin, the remaining origins fired asynchronously throughout the S phase. Therefore, initiation during the S phase depends on the normal progression of replication forks assembled at earlier activated origins. Caffeine, an inhibitor of the checkpoint kinases ATR and ATM, did not relieve the aphidicolin-induced block to origin firing. We conclude that a caffeine-insensitive intra-S phase checkpoint regulates origin activation when DNA synthesis is inhibited in Xenopus egg extracts.	Ecole Normale Super, Genet Mol Lab, F-75230 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Hyrien, O (corresponding author), Ecole Normale Super, Genet Mol Lab, 46 Rue Ulm, F-75230 Paris 05, France.	hyrien@wotan.ens.fr	Hyrien, Olivier/R-5108-2017; Marheineke, Kathrin/C-1797-2008	Hyrien, Olivier/0000-0001-8879-675X; Marheineke, Kathrin/0000-0002-1514-0167				Aparicio OM, 1999, P NATL ACAD SCI USA, V96, P9130, DOI 10.1073/pnas.96.16.9130; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BLOW JJ, 1986, CELL, V47, P577, DOI 10.1016/0092-8674(86)90622-7; Blow JJ, 2001, J CELL BIOL, V152, P15, DOI 10.1083/jcb.152.1.15; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; Costanzo V, 2000, MOL CELL, V6, P649, DOI 10.1016/S1097-2765(00)00063-0; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Dimitrova DS, 1999, MOL CELL, V4, P983, DOI 10.1016/S1097-2765(00)80227-0; Fogarty P, 1997, CURR BIOL, V7, P418, DOI 10.1016/S0960-9822(06)00189-8; Gilbert DM, 1998, CURR OPIN GENET DEV, V8, P194; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Herrick J, 2000, J MOL BIOL, V300, P1133, DOI 10.1006/jmbi.2000.3930; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HYRIEN O, 1995, SCIENCE, V270, P994, DOI 10.1126/science.270.5238.994; HYRIEN O, 1992, NUCLEIC ACIDS RES, V20, P1463, DOI 10.1093/nar/20.7.1463; Jares P, 2000, GENE DEV, V14, P1528; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; KIMELMAN D, 1987, CELL, V48, P399, DOI 10.1016/0092-8674(87)90191-7; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; LASKEY RA, 1985, J EMBRYOL EXP MORPH, V89, P285; Lucas I, 2000, J MOL BIOL, V296, P769, DOI 10.1006/jmbi.2000.3500; MAHBUBANI HM, 1992, NUCLEIC ACIDS RES, V20, P1457, DOI 10.1093/nar/20.7.1457; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; Maric C, 1999, J MOL BIOL, V291, P775, DOI 10.1006/jmbi.1999.3017; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; MILLS AD, 1989, J CELL SCI, V94, P471; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NETHANEL T, 1990, J VIROL, V64, P5912, DOI 10.1128/JVI.64.12.5912-5918.1990; NEWPORT J, 1989, J CELL SCI, P149; NEWPORT J, 1982, CELL, V30, P687, DOI 10.1016/0092-8674(82)90273-2; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Pasero P, 2000, CURR OPIN GENET DEV, V10, P178, DOI 10.1016/S0959-437X(00)00067-8; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; Rhind N, 2000, J CELL SCI, V113, P3889; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Santocanale C, 1999, GENE DEV, V13, P2360, DOI 10.1101/gad.13.18.2360; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sasaki T, 1999, MOL CELL BIOL, V19, P547; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SHINOMIYA T, 1991, NUCLEIC ACIDS RES, V19, P3935, DOI 10.1093/nar/19.14.3935; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Sibon OCM, 1999, CURR BIOL, V9, P302, DOI 10.1016/S0960-9822(99)80138-9; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Tercero JA, 2000, EMBO J, V19, P2082, DOI 10.1093/emboj/19.9.2082; Walter JC, 2000, J BIOL CHEM, V275, P39773, DOI 10.1074/jbc.M008107200; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	51	52	56	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17092	17100		10.1074/jbc.M100271200	http://dx.doi.org/10.1074/jbc.M100271200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279043	hybrid			2022-12-25	WOS:000168730400066
J	Strobeck, M; Kim, S; Zhang, JCL; Clendenin, C; Du, KL; Parmacek, MS				Strobeck, M; Kim, S; Zhang, JCL; Clendenin, C; Du, KL; Parmacek, MS			Binding of serum response factor to CArG box sequences is necessary but not sufficient to restrict gene expression to arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN GENE; FACTOR PLAYS; SM22 ALPHA; PROMOTER; TRANSCRIPTION; ACTIVATION; PATHWAYS; RHOA; SRF; PROLIFERATION	Serum response factor (SRF) plays an important role in regulating smooth muscle cell (SMC) development and differentiation. To understand the molecular mechanisms underlying the activity of SRF in SMCs, the two CArG box-containing elements in the arterial SMC-specific SM22 alpha promoter, SME-1 and SME-4, were functionally and biochemically characterized. Mutations that abolish binding of SRF to the SM22 alpha promoter totally abolish promoter activity in transgenic mice. Moreover, a multimerized copy of either SME-1 or SME-4 subcloned 5' of the minimal SM22 alpha promoter (base pairs -90 to +41) is necessary and sufficient to restrict transgene expression to arterial SMCs in transgenic mice. In contrast, a multimerized copy of the c-fos SRE is totally inactive in arterial SMCs and substitution of the c-fos SRE for the CArG motifs within the SM22 alpha promoter inactivates the 441-base pair SM22 alpha promoter in transgenic mice. Deletion analysis revealed that the SME-4 CArG box alone is insufficient to activate transcription in SMCs and additional 5'-flanking nucleotides are required. Nuclear protein binding assays revealed that SME-4 binds SRF, YY1, and four additional SMC nuclear proteins. Taken together, these data demonstrate that binding of SRF to specific CArG boxes is necessary, but not sufficient, to restrict transgene expression to SMCs in vivo.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	University of Pennsylvania; University of Chicago	Parmacek, MS (corresponding author), Univ Penn, Sch Med, Dept Med, 9123 Founders pavil, Philadelphia, PA 19104 USA.	parmacek@mail.med.upenn.edu		Parmacek, Michael/0000-0003-1449-4665	PHS HHS [R0156915] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Browning CL, 1998, DEV BIOL, V194, P18, DOI 10.1006/dbio.1997.8808; CAMPBELL GR, 1988, ARCH PATHOL LAB MED, V112, P977; CHODOSH LA, 1996, CURRENT PROTOCOLS MO; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; Herring BP, 1997, AM J PHYSIOL-CELL PH, V272, pC1394, DOI 10.1152/ajpcell.1997.272.4.C1394; Herring BP, 1996, AM J PHYSIOL-CELL PH, V270, pC1656, DOI 10.1152/ajpcell.1996.270.6.C1656; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Landerholm TE, 1999, DEVELOPMENT, V126, P2053; LEESMILLER JP, 1987, BIOCHEM J, V244, P705, DOI 10.1042/bj2440705; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1996, J CELL BIOL, V132, P849, DOI 10.1083/jcb.132.5.849; Mack CP, 1999, CIRC RES, V84, P852; Madsen CS, 1998, CIRC RES, V82, P908; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; Moessler H, 1996, DEVELOPMENT, V122, P2415; MOSS JB, 1994, J BIOL CHEM, V269, P12731; MUELLER CGF, 1991, EMBO J, V10, P4219, DOI 10.1002/j.1460-2075.1991.tb05000.x; Newby AC, 1999, CARDIOVASC RES, V41, P345, DOI 10.1016/S0008-6363(98)00286-7; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OSBOURN JK, 1995, GENE, V154, P249, DOI 10.1016/0378-1119(94)00847-L; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; Parmacek MS, 2001, CURR TOP DEV BIOL, V51, P69, DOI 10.1016/S0070-2153(01)51002-9; PARMACEK MS, 1999, HEART DEV, P291; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Qian J, 1996, DEV DYNAM, V207, P135; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; Schwartz SM, 1998, ANNU REV MED, V49, P437; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; SHANAHAN CM, 1997, ARTERIOSCL THROM VAS, V183, P333; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; TREISMAN R, 1995, NATURE, V376, P468, DOI 10.1038/376468a0; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Yang Y, 2000, J CLIN INVEST, V106, P1321, DOI 10.1172/JCI8893; Zhang JCL, 2001, MOL CELL BIOL, V21, P1336, DOI 10.1128/MCB.2001.21.4.1336-1344.2001; [No title captured]	48	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16418	16424		10.1074/jbc.M100631200	http://dx.doi.org/10.1074/jbc.M100631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279108	hybrid			2022-12-25	WOS:000168623100113
J	Lu, CF; Takagi, J; Springer, TA				Lu, CF; Takagi, J; Springer, TA			Association of the membrane proximal regions of the alpha and beta subunit cytoplasmic domains constrains an integrin in the inactive state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; INTERCELLULAR-ADHESION MOLECULE-1; POLYMERASE CHAIN-REACTION; I-DOMAIN; CELL-ADHESION; MAC-1 CD11B/CD18; LIGAND-BINDING; T-CELL; CR3-DEPENDENT ADHESION; MONOCLONAL-ANTIBODY	The adhesiveness of integrins is regulated through a process termed "inside-out" signaling. To understand the molecular mechanism of integrin inside-out signaling, we generated K562 stable cell lines that expressed LFA-1 (alpha (L)beta (2)) Or Mac-1 (alpha (M)beta (2)) with mutations in the cytoplasmic domain. Complete truncation of the beta (2) cytoplasmic domain, but not a truncation that retained the membrane proximal eight residues, resulted in constitutive activation of alpha (L)beta (2) and alpha (M)beta (2) demonstrating the importance of this membrane proximal region in the regulation of integrin adhesive function. Furthermore, replacement of the alpha (L) and beta (2) cytoplasmic domains with acidic and basic peptides that form an alpha -helical coiled coil caused inactivation of alpha (L)beta (2). Association of these artificial cytoplasmic domains was directly demonstrated. By contrast, replacement of the alpha (L) and beta (2) cytoplasmic domains with two basic peptides that do not form an alpha -helical coiled coil activated alpha (L)beta (2). Induction of ligand binding by the activating cytoplasmic domain mutations correlated with the induction of activation epitopes in the extracellular domain. Our data demonstrate that cytoplasmic, membrane proximal association between integrin alpha and beta subunits, constrains an integrin in the inactive conformation.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA031799, R01CA031798, R37CA031798, R37CA031799] Funding Source: NIH RePORTER; NCI NIH HHS [CA31799, CA31798] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DRANSFIELD I, 1989, EMBO J, V8, P3759, DOI 10.1002/j.1460-2075.1989.tb08552.x; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HIBBS ML, 1991, SCIENCE, V251, P1611, DOI 10.1126/science.1672776; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Kashiwagi H, 1997, J CELL BIOL, V137, P1433, DOI 10.1083/jcb.137.6.1433; KEIZER GD, 1988, J IMMUNOL, V140, P1393; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LU C, 2001, IN PRESS J IMMUNOL; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Lub M, 1997, MOL BIOL CELL, V8, P719, DOI 10.1091/mbc.8.4.719; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; ROBINSON MK, 1992, J IMMUNOL, V148, P1080; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Stewart MP, 1996, J IMMUNOL, V156, P1810; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VANKOOYK Y, 1994, J CELL BIOL, V124, P1061, DOI 10.1083/jcb.124.6.1061; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; WEISEL JW, 1992, J BIOL CHEM, V267, P16637	50	137	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14642	14648		10.1074/jbc.M100600200	http://dx.doi.org/10.1074/jbc.M100600200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279101	hybrid			2022-12-25	WOS:000168528800018
J	Tosello-Trampont, AC; Brugnera, E; Ravichandran, KS				Tosello-Trampont, AC; Brugnera, E; Ravichandran, KS			Evidence for a conserved role for CrkII and Rac in engulfment of apoptotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; DENDRITIC CELLS; PROTEIN CED-6; PHAGOCYTOSIS; PHOSPHATIDYLSERINE; RECOGNITION; BINDING; DOCK180; DEATH	Apoptosis or programmed cell death occurs in multicellular organisms throughout life. The removal of apoptotic cells by phagocytes prevents secondary necrosis and inflammation and also plays a key role in tissue remodeling and regulating immune responses. The molecular mechanisms that regulate the engulfment of apoptotic cells are just beginning to be elucidated. Recent genetic studies in the nematode Caenorhabditis elegans have implicated at least six genes in the removal of apoptotic cell corpses. The gene products of ced-2 ced-5, and ced-10 are thought to be part of a pathway that regulates the reorganization of the cytoskeleton during engulfment. The adapter proteins CrkII and Dock180 and the small GTPase Rac represent the mammalian orthologues of the ced-5 ced-5 and ced-10 gene products, respectively. It is not known whether CrkII, Dock180, or Rac proteins have any role during engulfment in mammalian cells. Here we show, using stable cell lines and transient transfections, that overexpression of wild-type CrkII or an activated form of Rad enhances engulfment. Mutants of CrkII failed to mediate this increased engulfment. The higher CrkII-mediated uptake was inhibited by coexpression of a dominant negative form of Rad but not by a dominant a negative Rho protein; this suggested that Rac functions downstream of CrkII in this process, which is consistent with genetic studies in the worm that place ced-10 (rac) downstream of ced-2 (crh) in cell corpse removal, Taken together, these data suggest that CED 2/CrkII and CED-10/Rac are part of an evolutionarily conserved pathway in engulfment of apoptotic cells.	Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Ravichandran, KS (corresponding author), Univ Virginia, Beirne Carter Ctr Immunol Res, MR4,Rm 4012F,HSC, Charlottesville, VA 22908 USA.							Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; da Silva RP, 1999, BIOCHEM J, V338, P687, DOI 10.1042/bj3380687; ELLIS RE, 1991, GENETICS, V129, P79; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 1998, CURR BIOL, V8, pR693, DOI 10.1016/S0960-9822(98)70438-5; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Liu QA, 1999, CURR BIOL, V9, P1347, DOI 10.1016/S0960-9822(00)80061-5; Liu QA, 1998, CELL, V93, P961, DOI 10.1016/S0092-8674(00)81202-7; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schlegel RA, 1999, CELL DEATH DIFFER, V6, P583, DOI 10.1038/sj.cdd.4400529; Smits E, 1999, CURR BIOL, V9, P1351, DOI 10.1016/S0960-9822(00)80062-7; Su HP, 2000, J BIOL CHEM, V275, P9542, DOI 10.1074/jbc.275.13.9542; Wu YC, 1998, NATURE, V392, P501, DOI 10.1038/33163; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5	37	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13797	13802		10.1074/jbc.M011238200	http://dx.doi.org/10.1074/jbc.M011238200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297528	hybrid			2022-12-25	WOS:000168356600042
J	Wu, YJ; Zhang, Y; Cao, L; Chen, LW; Lee, V; Zheng, PS; Kiani, C; Adams, ME; Ang, LC; Paiwand, F; Yang, BB				Wu, YJ; Zhang, Y; Cao, L; Chen, LW; Lee, V; Zheng, PS; Kiani, C; Adams, ME; Ang, LC; Paiwand, F; Yang, BB			Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PG-M; G1 DOMAIN; LINK PROTEIN; TENASCIN-R; ADHESION; CHONDROGENESIS; EXPRESSION; OUTGROWTH; AGGRECAN	This study was designed to investigate the mechanisms by which mutant versican constructs play a dominant-negative effect on astrocytoma cell proliferation. Although a mini-versican or a versican G3 construct promoted growth of U87 astrocytoma cells, a mini-versican lacking epidermal growth factor (EGF) motifs (versican Delta EGF) and a G3 mutant (G3 Delta EGF) exerted a dominant-negative effect on cell proliferation. G3 Delta EGF-transfected cells formed smaller colonies, arrested cell cycle at G(1) phase, inhibited expression of cell cycle proteins cdk4 and cyclin D1, and contained multiple nucleoli, In cell surface binding assays, G3 products expressed in COS-7 cells and bacteria bound to U87 cell surface. G3 Delta EGF products exhibited decreased binding activity, but higher levels of G3 Delta EGF products were able to inhibit the binding of G3 to the cell surface, G3 Delta EGF expression inhibited secretion of endogenous versican in astrocytoma cells and also inhibited the secretion of mini-versican in COS-7 cells co-transfected with the mini-versican and G3 Delta EGF constructs. The effect seems to depend on the expression efficiency of G3 Delta EGF, and it occurred via the carbohydrate recognition domain.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Res Bldg,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P805, DOI 10.1111/j.1460-9568.1995.tb00683.x; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Giese A, 1996, NEUROSURGERY, V39, P235, DOI 10.1097/00006123-199608000-00001; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; NASO MF, 1994, J BIOL CHEM, V269, P32999; NASO MF, 1995, GENOMICS, V29, P297, DOI 10.1006/geno.1995.1251; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; PERIDES G, 1993, ANAT EMBRYOL, V188, P467; SHINOMURA T, 1990, ANAT EMBRYOL, V181, P227; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Tiedemann K, 1997, MATRIX BIOL, V15, P469, DOI 10.1016/S0945-053X(97)90020-2; VONSTRANDMANN EP, 1995, PROTEIN ENG, V8, P732; YAMAGATA M, 1993, ANAT EMBRYOL, V187, P433; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	36	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14178	14186		10.1074/jbc.M100618200	http://dx.doi.org/10.1074/jbc.M100618200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297534	hybrid			2022-12-25	WOS:000168356600090
J	Marsche, G; Levak-Frank, S; Quehenberger, O; Heller, R; Sattler, W; Malle, E				Marsche, G; Levak-Frank, S; Quehenberger, O; Heller, R; Sattler, W; Malle, E			Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high density lipoprotein on human umbilical venous endothelial cells	FASEB JOURNAL			English	Editorial Material									Karl Franzens Univ Graz, Inst Med Biochem, A-8010 Graz, Austria; Univ Calif, Dept Med, La Jolla, CA USA; Friedrich Schiller Univ Jena, Ctr Vasc Biol & Med, Erfurt, Germany	University of Graz; University of California System; University of California San Diego; Friedrich Schiller University of Jena	Malle, E (corresponding author), Karl Franzens Univ Graz, Inst Med Biochem, Harrachgasse 21, A-8010 Graz, Austria.	malle@kfunigraz.ac.at	Malle, Ernst/D-3071-2013	Marsche, Gunther/0000-0002-2422-5381	DFG [HE 2304/1-1]; OENB [8778, 8127]; FWF [P14109, P14186]	DFG(German Research Foundation (DFG)); OENB; FWF(Austrian Science Fund (FWF))	The authors are grateful to Dr. M. Krieger (MIT) providing ldlA[mSR-BI] and ldlA7 cells. The expert technical assistance of B. Hirschmugl is appreciated. This work was supported by the DFG (HE 2304/1-1), OENB (8778 and 8127), and the FWF (P14109 and P14186).		0	60	62	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1095	1097		10.1096/fj.00-0532fje	http://dx.doi.org/10.1096/fj.00-0532fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292679				2022-12-25	WOS:000167959300024
J	Ichihashi, K; Osawa, T; Toyokuni, S; Uchida, K				Ichihashi, K; Osawa, T; Toyokuni, S; Uchida, K			Endogenous formation of protein adducts with carcinogenic aldehydes - Implications for oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; FERRIC NITRILOTRIACETATE; LIPID-PEROXIDATION; CATALYZED OXIDATION; MODEL; INDUCTION; PRODUCT; RATS; CROTONALDEHYDE; NEPHROTOXICITY	In the present study, we characterize the covalent modification of a protein by crotonaldehyde, a representative carcinogenic aldehyde, and describe the endogenous production of this aldehyde in vivo, The crotonaldehyde preferentially reacted with the lysine and histidine residues of bovine serum albumin and generated a protein-linked carbonyl derivative. Upon incubation with the histidine and lysine derivatives, crotonaldehyde predominantly generated beta -substituted butanal adducts of histidine and lysine and N-epsilon-(2,5-dimethyl-3-formyl-3,4-dehydropiperidino)lysine (dimethyl-FDP-lysine) as the putative carbonyl derivatives generated in the crotonaldehyde-modified protein. To verify the endogenous formation of crotonaldehyde in vivo, we raised the monoclonal antibody (mAb82D3) against the crotonaldehyde-modified protein and found that it cross-reacted with the protein-bound 2-alkenals, such as crotonaldehyde, 2-pentenal, and 2-hexenal. The anti-2-alkenal antibody recognized multiple crotonaldehyde-lysine adducts, including dimethyl-FDP-lysine and an unknown product, which showed the greatest immunoreactivity with the antibody. On the basis of the chemical and spectroscopic evidence, the major antigenic product was determined to be a novel Schiff base-derived crotonaldehyde-lysine adduct, N-epsilon- (5-ethyl-2-methylpyridinium)lysine (EMP-lysine), It was found that the lysine residues that had disappeared in the protein treated with crotonaldehyde were partially recovered by EMP-lysine. The presence of immunoreactive materials with mAb82D3 in vivo was demonstrated in the kidney of rats exposed to the renal carcinogen, ferric nitrilotriacetate. In addition, the observations that the metal-catalyzed oxidation of polyunsaturated fatty acids in the presence of proteins resulted in an increase in the antigenicity of the protein indicated that lipid peroxidation represents a potential pathway for the formation of crotonalde-hyde/2-alkenals in vivo, These data suggest that the formation of carcinogenic aldehydes during lipid peroxidation may be causally involved in the pathophysiological effects associated with oxidative stress.	Nagoya Univ, Lab Food & Biodynam, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Kyoto Univ, Grad Sch Med, Dept Pathol & Biol Dis, Sakyo Ku, Kyoto 606, Japan	Nagoya University; Kyoto University	Uchida, K (corresponding author), Nagoya Univ, Lab Food & Biodynam, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan.		Toyokuni, Shinya/ABE-7714-2021; Toyokuni, Shinya/C-1358-2010	Toyokuni, Shinya/0000-0002-5757-1109; Toyokuni, Shinya/0000-0002-5757-1109; Uchida, Koji/0000-0003-3894-5299				ALAIZ M, 1995, CHEM PHYS LIPIDS, V75, P43, DOI 10.1016/0009-3084(94)02399-P; AWAI M, 1979, AM J PATHOL, V95, P663; Baker A, 1998, CHEM RES TOXICOL, V11, P730, DOI 10.1021/tx970167e; Baker AG, 1999, J AM SOC MASS SPECTR, V10, P613, DOI 10.1016/S1044-0305(99)00029-X; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Burcham PC, 1996, BIOCHEM BIOPH RES CO, V220, P996, DOI 10.1006/bbrc.1996.0521; CHUNG FL, 1986, CANCER RES, V46, P1285; Chung FL, 1999, MUTAT RES-FUND MOL M, V424, P71, DOI 10.1016/S0027-5107(99)00009-3; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; EBINA Y, 1986, J NATL CANCER I, V76, P107; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1976, TETRAHEDRON, V32, P285, DOI 10.1016/0040-4020(76)87015-9; GLADSTONE IM, 1994, PEDIATRICS, V93, P764; International Agency for Research on Cancer, 1995, IARC MON EV CARC RIS, V63, P373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LI JL, 1987, CANCER RES, V47, P1867; NADKARNI DV, 1995, CHEM RES TOXICOL, V8, P284, DOI 10.1021/tx00044a014; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TOYOKUNI S, 1990, CANCER RES, V50, P5574; Toyokuni S, 1996, FREE RADICAL BIO MED, V20, P553, DOI 10.1016/0891-5849(95)02111-6; Toyokuni S, 1997, LAB INVEST, V76, P365; TOYOKUNI S, 1994, P NATL ACAD SCI USA, V91, P2616, DOI 10.1073/pnas.91.7.2616; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; UCHIDA K, 1995, ARCH BIOCHEM BIOPHYS, V317, P405, DOI 10.1006/abbi.1995.1181; Uchida K, 1998, J BIOL CHEM, V273, P16058, DOI 10.1074/jbc.273.26.16058; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; WANG MY, 1988, CHEM RES TOXICOL, V1, P28, DOI 10.1021/tx00001a005; Wang MY, 2000, CHEM RES TOXICOL, V13, P1065, DOI 10.1021/tx000095i	38	91	96	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23903	23913		10.1074/jbc.M101947200	http://dx.doi.org/10.1074/jbc.M101947200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11283024	hybrid			2022-12-25	WOS:000169531100091
J	Opitz, B; Schroder, NWJ; Spreitzer, I; Michelsen, KS; Kirschning, CJ; Hallatschek, W; Zahringer, U; Hartung, T; Gobel, UB; Schumann, RR				Opitz, B; Schroder, NWJ; Spreitzer, I; Michelsen, KS; Kirschning, CJ; Hallatschek, W; Zahringer, U; Hartung, T; Gobel, UB; Schumann, RR			Toll-like receptor-2 mediates Treponema glycolipid and lipoteichoic acid-induced NF-kappa B translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL COMPONENTS; BORRELIA-BURGDORFERI LIPOPROTEINS; ACTIVATED PROTEIN-KINASES; HUMAN MONOCYTIC CELLS; INNATE IMMUNE-SYSTEM; CUTTING EDGE; DROSOPHILA TOLL; STAPHYLOCOCCUS-AUREUS; SIGNAL-TRANSDUCTION; PATTERN-RECOGNITION	Recently Toll-like receptors (TLRs) have been found to be involved in cellular activation by microbial products, including lipopolysaccharide, lipoproteins, and peptidoglycan. Although for these ligands the specific transmembrane signal transducers TLR4, TLR-2, or TLR-2 and 6 have now been identified, the molecular basis of recognition of lipoteichoic acids (LTAs) and related glycolipids has not been completely understood. In order to determine the role of TLRs in immune cell activation by these stimuli, experiments involving TLR-2-negative cell lines, TLR-expression plasmids, macrophages from TLR-4-deficient C3H/HeJ-mice, and inhibitory TLR-4/MD-2 antibodies were performed. Glycolipids from Treponema maltophilum and Treponema brennaborense, as well as highly purified LTAs from Staphylococcus aureus and Bacillus subtilis exhibited TLR-2 dependence in nuclear factor KB activation and cytokine induction; however, T. brennaborense additionally appeared to signal via TLR-4. Fractionation of the T. brennaborense glycolipids by hydrophobic interaction chromatography and subsequent cell stimulation experiments revealed two peaks of activity, one exhibiting TLR-2-, and a second TLR-4-dependence. Furthermore, we show involvement of the signaling molecules MyD88 and NIK in cell stimulation by LTAs and glycolipids by dominant negative overexpression experiments. In summary, the results presented here indicate that TLR-2 is the main receptor for Treponema glycolipid and LTA-mediated inflammatory response.	Humboldt Univ, Fak Med, Charite Med Ctr, Inst Mikrobiol & Hyg, D-10117 Berlin, Germany; Univ Konstanz, Dept Biochem Pharmacol, D-78457 Constance, Germany; Tech Univ, Inst Microbiol Immunol & Hyg, D-81657 Munich, Germany; Forschungszentrum Borstel, Dept Immunochem, D-23845 Borstel, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Konstanz; Technical University of Munich; Forschungszentrum Borstel	Schumann, RR (corresponding author), Humboldt Univ, Fak Med, Klinikum Charite, Inst Mikrobiol & Hyg, Dorotheenstr 96, D-10117 Berlin, Germany.			Opitz, Bastian/0000-0003-1276-836X				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BHAKDI S, 1991, INFECT IMMUN, V59, P4614, DOI 10.1128/IAI.59.12.4614-4620.1991; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CHOI BK, 1994, INFECT IMMUN, V62, P1889, DOI 10.1128/IAI.62.5.1889-1895.1994; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FISCHER W, 1980, FEBS LETT, V119, P224, DOI 10.1016/0014-5793(80)80257-2; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Greenberg JW, 1996, INFECT IMMUN, V64, P3318, DOI 10.1128/IAI.64.8.3318-3325.1996; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Hashimoto M, 2000, BIOCHEM BIOPH RES CO, V273, P164, DOI 10.1006/bbrc.2000.2921; Heine H, 1999, J IMMUNOL, V162, P6971; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; IWASAKI H, 1989, J BACTERIOL, V171, P424, DOI 10.1128/jb.171.1.424-429.1989; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; LAMBERT PA, 1977, BIOCHIM BIOPHYS ACTA, V472, P1, DOI 10.1016/0304-4157(77)90012-0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEOPOLD K, 1992, ANAL BIOCHEM, V201, P350, DOI 10.1016/0003-2697(92)90350-G; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Means TK, 1999, J IMMUNOL, V163, P3920; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; MULLER JM, 1993, IMMUNOBIOLOGY, V187, P233; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Polotsky VY, 1996, INFECT IMMUN, V64, P380, DOI 10.1128/IAI.64.1.380-383.1996; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schrank K, 1999, INT J SYST BACTERIOL, V49, P43, DOI 10.1099/00207713-49-1-43; Schroder NWJ, 2000, J IMMUNOL, V165, P2683, DOI 10.4049/jimmunol.165.5.2683; Schultz CP, 1998, J BIOL CHEM, V273, P15661, DOI 10.1074/jbc.273.25.15661; Schumann RR, 1998, GLIA, V22, P295, DOI 10.1002/(SICI)1098-1136(199803)22:3<295::AID-GLIA8>3.0.CO;2-4; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sellati TJ, 1999, J IMMUNOL, V163, P2049; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wyss C, 1996, INT J SYST BACTERIOL, V46, P745, DOI 10.1099/00207713-46-3-745; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yoshimura A, 1999, J IMMUNOL, V163, P1	68	185	192	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22041	22047		10.1074/jbc.M010481200	http://dx.doi.org/10.1074/jbc.M010481200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11285258	hybrid			2022-12-25	WOS:000169412700009
J	Ogura, Y; Yoshida, Y; Yabe, N; Hasunuma, K				Ogura, Y; Yoshida, Y; Yabe, N; Hasunuma, K			A point mutation in nucleoside diphosphate kinase results in a deficient light response for perithecial polarity in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE-COLLAR MUTANTS; X-RAY STRUCTURE; BLUE-LIGHT; SIGNAL-TRANSDUCTION; SCHIZOSACCHAROMYCES-POMBE; TUMOR-METASTASIS; GENETIC-ANALYSIS; HIGHER-PLANTS; IN-VITRO; PROTEIN	In Neurospora crassa, the phosphorylation of nucleoside diphosphate kinase (NDK)-1 is rapidly enhanced after blue light irradiation. We have investigated the function of NDK-1 in the blue light signal transduction pathway. A mutant called psp (phosphorylation of small protein) shows undetectable phosphorylation of NDK-1 and is defective in light-responsive regulation of perithecial polarity. Sequencing analysis of ndk-1 cDNA by reverse transcription-polymerase chain reaction revealed that proline 72 of ndk-1 was replaced with histidine in psp. The mutation ndk-1(P72H) resulted in accumulation of normal levels of mRNA and of about 25% of NDK-1(P72H) protein compared with that of wild type as determined by Western blot analysis. The ectopic expression of cDNA and introduction of genomic DNA of wild type ndk-1 in psp (ndk-1(P72H)) suppressed the reduction in accumulation and phosphorylation of NDK-1 and the light-insensitive phenotype. These findings demonstrated that the phenotype of psp was caused by the ndk-1(P72H) mutation. Biochemical analysis using recombinant NDK-1 and NDK-1P72H indicated that the P72H substitution in NDK-1 was responsible for the decrease in phosphotransfer activities, 5% of autophosphorylation activity, and 2% of V-max for protein kinase activity phosphorylating myelin basic protein, compared with those of wild type NDK-1, respectively.	Yokohama City Univ, Kihara Inst Biol Res, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan	Yokohama City University; Yokohama City University	Hasunuma, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.	kohji@yokohama-cu.ac.jp						Agarwal R P, 1978, Methods Enzymol, V51, P376; Ahmad M, 1998, MOL CELL, V1, P939, DOI 10.1016/S1097-2765(00)80094-5; Arpaia G, 1999, MOL GEN GENET, V262, P314, DOI 10.1007/s004380051089; Ballario P, 1998, MOL MICROBIOL, V29, P719, DOI 10.1046/j.1365-2958.1998.00955.x; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; Batschauer A, 1998, PLANTA, V206, P479, DOI 10.1007/s004250050425; BELOZERSKAYA TA, 1993, EXP MYCOL, V17, P157, DOI 10.1006/emyc.1993.1015; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; Briggs WR, 1999, ANNU REV CELL DEV BI, V15, P33, DOI 10.1146/annurev.cellbio.15.1.33; Choi G, 1999, NATURE, V401, P610, DOI 10.1038/44176; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; DEGLIINNOCENTI F, 1984, J BACTERIOL, V159, P757, DOI 10.1128/JB.159.2.757-761.1984; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; Freije JMP, 1997, J BIOL CHEM, V272, P5525, DOI 10.1074/jbc.272.9.5525; HARDING RW, 1983, PLANT PHYSIOL, V72, P996, DOI 10.1104/pp.72.4.996; HARDING RW, 1981, PLANT PHYSIOL, V68, P745, DOI 10.1104/pp.68.3.745; Horwitz BA, 1997, BOT ACTA, V110, P360, DOI 10.1111/j.1438-8677.1997.tb00651.x; IZUMIYA H, 1995, J BIOL CHEM, V270, P27859, DOI 10.1074/jbc.270.46.27859; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KIMURA N, 1983, J BIOL CHEM, V258, P2278; Lasceve G, 1999, PLANT PHYSIOL, V120, P605, DOI 10.1104/pp.120.2.605; LAUTER FR, 1991, NUCLEIC ACIDS RES, V19, P6883, DOI 10.1093/nar/19.24.6883; Leung SM, 1997, J BIOL CHEM, V272, P2607, DOI 10.1074/jbc.272.5.2607; Linden H, 1997, EMBO J, V16, P98, DOI 10.1093/emboj/16.1.98; MEYEROWITZ EM, 1994, ARABIDOPSIS; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MULLANEY EJ, 1985, MOL GEN GENET, V199, P37, DOI 10.1007/BF00327506; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; Oda K, 1997, MOL GEN GENET, V256, P593, DOI 10.1007/s004380050607; ODA K, 1994, FEBS LETT, V345, P162, DOI 10.1016/0014-5793(94)00436-6; Ogura T, 1999, PHOTOCHEM PHOTOBIOL, V69, P397, DOI 10.1562/0031-8655(1999)069<0397:COPCCN>2.3.CO;2; Ogura Y, 1999, EUR J BIOCHEM, V266, P709, DOI 10.1046/j.1432-1327.1999.00783.x; Otero ADS, 1999, BBA-MOL CELL RES, V1449, P157, DOI 10.1016/S0167-4889(99)00009-9; Pall ML, 1993, FUNGAL GENET NEWSL, V40, P59, DOI DOI 10.4148/1941-4765.1413; PARKS RE, 1973, ENZYMES; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POTAPOVA TV, 1984, ARCH MICROBIOL, V137, P262, DOI 10.1007/BF00414555; Quail PH, 1997, BIOESSAYS, V19, P571, DOI 10.1002/bies.950190708; Sokolovsky V., 1990, FUNGAL GENET NEWSLET, V37, P41; STEEG PS, 1988, CANCER RES, V48, P6550; Talora C, 1999, EMBO J, V18, P4961, DOI 10.1093/emboj/18.18.4961; Tanaka N, 1998, J PHOTOCH PHOTOBIO B, V45, P113, DOI 10.1016/S1011-1344(98)00169-9; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; Whitelam GC, 1998, PLANT PHYSIOL BIOCH, V36, P125, DOI 10.1016/S0981-9428(98)80097-1; Zimmermann S, 1999, J BIOL CHEM, V274, P17017, DOI 10.1074/jbc.274.24.17017	47	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21228	21234		10.1074/jbc.M011381200	http://dx.doi.org/10.1074/jbc.M011381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287415	hybrid			2022-12-25	WOS:000169297900058
J	Camacho, LR; Constant, P; Raynaud, C; Laneelle, MA; Triccas, JA; Gicquel, B; Daffe, M; Guilhot, C				Camacho, LR; Constant, P; Raynaud, C; Laneelle, MA; Triccas, JA; Gicquel, B; Daffe, M; Guilhot, C			Analysis of the phthiocerol dimycocerosate locus of Mycobacterium tuberculosis - Evidence that this lipid is involved in the cell wall permeability barrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOCEROSIC ACID SYNTHASE; GENE-CLUSTER; IDENTIFICATION; VIRULENCE; ATTENUATION; MYCOSIDES; ENVELOPE; FLUIDITY; COMPLEX; ENZYME	Among the few characterized genes that have products involved in the pathogenicity of Mycobacterium tuberculosis, the etiological agent of tuberculosis, are those of the phthiocerol dimycocerosate (DIM) locus. Genes involved in biosynthesis of these compounds are grouped on a 50-kilobase fragment of the chromosome containing 13 genes. Analysis of mRNA produced from this 50-kilobase fragment in the wild type strain showed that this region is subdivided into three transcriptional units. Biochemical characterization of five mutants with transposon insertions in this region demonstrated that (i) the complete DIM molecules are synthesized in the cytoplasm of M. tuberculosis before being translocated into the cell wall; (ii) the genes fadD26 and fadD28 are directly involved in their biosynthesis; and (iii) both the drrC and mmpL7 genes are necessary for the proper localization of DIMs. Insertional mutants unable to synthesize or translocate DIMs exhibit higher cell. wall permeability and are more sensitive to detergent than the wild type strain, indicating for the first time that, in addition to being important virulence factors, extractable lipids of M. tuberculosis play a role in the cell envelope architecture and permeability. This function may represent one of the molecular mechanisms by which DIMs are involved in the virulence of M. tuberculosis.	UPS, Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France; Inst Pasteur, Unite Genet Mycobacterienne, F-75725 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Guilhot, C (corresponding author), UPS, Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	guilhot@ipbs.fr	Triccas, Jamie/AAD-7629-2020	Triccas, James/0000-0003-3730-2339				Asselineau J, 1982, Indian J Chest Dis Allied Sci, V24, P143; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Camacho LR, 1999, MOL MICROBIOL, V34, P257, DOI 10.1046/j.1365-2958.1999.01593.x; CHAMBERS HF, 1995, ANTIMICROB AGENTS CH, V39, P2620, DOI 10.1128/AAC.39.12.2620; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; DAFFE M, 1987, EUR J BIOCHEM, V167, P155, DOI 10.1111/j.1432-1033.1987.tb13317.x; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DAFFE M, 1989, EUR J BIOCHEM, V185, P157, DOI 10.1111/j.1432-1033.1989.tb15097.x; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Draper P, 1998, Front Biosci, V3, pD1253; FERNANDEZMORENO MA, 1991, CELL, V66, P769, DOI 10.1016/0092-8674(91)90120-N; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; GASTAMBIDEODIER M, 1967, B SOC CHIM BIOL, V49, P849; GOREN MB, 1974, INFECT IMMUN, V9, P150, DOI 10.1128/IAI.9.1.150-158.1974; Jackson M, 1999, INFECT IMMUN, V67, P2867, DOI 10.1128/IAI.67.6.2867-2873.1999; Jackson M, 1999, MOL MICROBIOL, V31, P1573, DOI 10.1046/j.1365-2958.1999.01310.x; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; KONDO E, 1976, JPN J MED SCI BIOL, V29, P199, DOI 10.7883/yoken1952.29.199; LEMASSU A, 1994, BIOCHEM J, V297, P351, DOI 10.1042/bj2970351; Liu J, 1996, J BIOL CHEM, V271, P29545, DOI 10.1074/jbc.271.47.29545; LIU J, 1995, P NATL ACAD SCI USA, V92, P11254, DOI 10.1073/pnas.92.24.11254; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MURPHY CK, 1996, ESCHERICHIA COLI SAL, V1, P967; NATHAN CF, 1992, MONONUCLEAR PHAGOCYT; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; OrtaloMagne A, 1996, J BACTERIOL, V178, P456, DOI 10.1128/jb.178.2.456-461.1996; Pelicic V, 1998, MOL MICROBIOL, V28, P413, DOI 10.1046/j.1365-2958.1998.00807.x; Raynaud C, 1998, MICROBIOL-SGM, V144, P577, DOI 10.1099/00221287-144-2-577; Tseng Tsai-Tien, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P107; Yuan Y, 1997, J BIOL CHEM, V272, P10041	35	284	304	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19845	19854		10.1074/jbc.M100662200	http://dx.doi.org/10.1074/jbc.M100662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279114	hybrid, Green Submitted			2022-12-25	WOS:000169135100024
J	Holst, B; Hastrup, H; Raffetseder, U; Martini, L; Schwartz, TW				Holst, B; Hastrup, H; Raffetseder, U; Martini, L; Schwartz, TW			Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG SPLICE VARIANT; AGONIST EFFICACY; BINDING-SITES; SUBSTANCE-P; BETA-GAMMA; G(S); ACTIVATION; G(S)ALPHA; LIGAND; ALPHA	The NK1 neurokinin receptor presents two non-ideal binding phenomena, two-component binding curves for all agonists and significant differences between agonist affinity determined by homologous versus heterologous competition binding. Whole cell binding with fusion proteins constructed between either G alpha (s) or G alpha (q), and the NK1 receptor with a truncated tail, which secured non-promiscuous G-protein interaction, demonstrated monocomponent agonist binding closely corresponding to either of the two affinity states found in the wild-type receptor. High affinity binding of both substance P and neurokinin A was observed in the tail-truncated G alpha (s) fusion construct, whereas the lower affinity component was displayed by the tail-truncated G alpha (q) fusion. The elusive difference between the affinity determined in heterologous versus homologous binding assays for substance P and especially for neurokinin A was eliminated in the G-protein fusions, An NK1 receptor mutant with a single substitution at the extracellular end of TM-III(F111S), which totally uncoupled the receptor from G alpha (s) signaling, showed binding properties that were monocomponent and otherwise very similar to those observed in the tail-truncated G alpha (q) fusion construct. Thus, the heterogenous pharmacological phenotype displayed by the NK1 receptor is a reflection of the occurrence of two active conformations or molecular phenotypes representing complexes with the G alpha (s) and G alpha (q) species, respectively. We propose that these molecular forms do not interchange readily, conceivably because of the occurrence of microdomains or "signal-transductosomes" within the cell membrane.	Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Pharma AS 7TM, DK-2100 Copenhagen, Denmark	University of Copenhagen	Schwartz, TW (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Mol Pharmacol Lab, Bldg 18-6,Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	schwartz@molpharm.dk		Schwartz, Thue W./0000-0002-0261-6904; Holst, Birgitte/0000-0001-7432-097X				Ahuja SK, 1996, J BIOL CHEM, V271, P20545, DOI 10.1074/jbc.271.34.20545; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BERTIN B, 1994, P NATL ACAD SCI USA, V91, P8827, DOI 10.1073/pnas.91.19.8827; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CASCIERI MA, 1992, MOL PHARMACOL, V42, P458; CHABRE O, 1994, J BIOL CHEM, V269, P5730; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, J BIOL CHEM, V268, P7893; Hastrup H, 1996, FEBS LETT, V399, P264, DOI 10.1016/S0014-5793(96)01337-3; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kenakin T, 1999, TRENDS PHARMACOL SCI, V20, P400, DOI 10.1016/S0165-6147(99)01361-9; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; Leff P, 1997, TRENDS PHARMACOL SCI, V18, P355, DOI 10.1016/S0165-6147(97)90664-7; Loisel TP, 1999, J BIOL CHEM, V274, P31014, DOI 10.1074/jbc.274.43.31014; Maggi CA, 1997, TRENDS PHARMACOL SCI, V18, P351, DOI 10.1016/S0165-6147(97)90663-5; MAGGI CA, 1995, GEN PHARMACOL-VASC S, V26, P911, DOI 10.1016/0306-3623(94)00292-U; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; NAKAJIMA Y, 1992, J BIOL CHEM, V267, P2437; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; Onaran HO, 1997, ANN NY ACAD SCI, V812, P98, DOI 10.1111/j.1749-6632.1997.tb48150.x; PRADIER L, 1994, MOL PHARMACOL, V45, P287; REGOLI D, 1994, PHARMACOL REV, V46, P551; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Sagan S, 1999, J BIOL CHEM, V274, P23770, DOI 10.1074/jbc.274.34.23770; Sautel M, 1998, FEBS LETT, V436, P46, DOI 10.1016/S0014-5793(98)01094-1; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Seifert R, 1998, J BIOL CHEM, V273, P5109, DOI 10.1074/jbc.273.9.5109; Seifert R, 1999, TRENDS PHARMACOL SCI, V20, P383, DOI 10.1016/S0165-6147(99)01368-1; Small KM, 2000, BIOCHEMISTRY-US, V39, P2815, DOI 10.1021/bi992497z; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Unson CG, 2000, J BIOL CHEM, V275, P21631, DOI 10.1074/jbc.M002093200; Waldhoer M, 1999, J BIOL CHEM, V274, P30571, DOI 10.1074/jbc.274.43.30571; Wenzel-Seifert K, 2000, MOL PHARMACOL, V58, P954, DOI 10.1124/mol.58.5.954; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; Wenzel-Seifert K, 1998, BIOCHEM J, V334, P519, DOI 10.1042/bj3340519; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8; Wise A, 1997, J BIOL CHEM, V272, P24673, DOI 10.1074/jbc.272.39.24673; Wise A, 1997, FEBS LETT, V419, P141, DOI 10.1016/S0014-5793(97)01431-2; Xiao B, 2000, CURR OPIN NEUROBIOL, V10, P370, DOI 10.1016/S0959-4388(00)00087-8	44	82	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19793	19799		10.1074/jbc.M100621200	http://dx.doi.org/10.1074/jbc.M100621200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279104	hybrid			2022-12-25	WOS:000169135100017
J	Wu, G; Vuletich, JL; Kulmacz, RJ; Osawa, Y; Tsai, AL				Wu, G; Vuletich, JL; Kulmacz, RJ; Osawa, Y; Tsai, AL			Peroxidase self-inactivation in prostaglandin H synthase-1 pretreated with cyclooxygenase inhibitors or substituted with mangano protoporphyrin IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME PROSTHETIC GROUP; VESICULAR GLAND MICROSOMES; HIGHER OXIDATION-STATES; ENDOPEROXIDE SYNTHETASE; TYROSYL RADICALS; FATTY-ACIDS; BIOSYNTHESIS; HYDROPEROXIDASE; MECHANISM; MYOGLOBIN	Self-inactivation imposes an upper limit on bioactive prostanoid synthesis by prostaglandin H synthase (PGHS). Inactivation of PGHS peroxidase activity has been found to begin with Intermediate II, which contains a tyrosyl radical. The structure of this radical is altered by cyclooxygenase inhibitors, such as indomethacin and flurbiprofen, and by replacement of heme by manganese protoporphyrin IX (forming MnPGHS-1). Peroxidase self-inactivation in inhibitor-treated PGHS-1 and MnPGHS-1 was characterized by stopped-flow spectroscopic techniques and by chromatographic and mass spectrometric analysis of the metalloporphyrin. The rate of peroxidase inactivation was about 0.3 s(-1) in inhibitor-treated PGHS-1 and much slower in MnPGHS-1 (0.05 s(-1)); as with PGHS-1 itself, the peroxidase inactivation rates were independent of peroxide concentration and structure, consistent with an inactivation process beginning with Intermediate II. The changes in metalloporphyrin absorbance spectra during inactivation of inhibitor-treated PGHS-1 were similar to those observed with PGHS-1 but were rather distinct in MnPGHS-1; the kinetics of the spectral transition from Intermediate II to the next species were comparable to the inactivation kinetics in each case. In contrast to the situation with PGHS-1 itself, significant amounts of heme degradation occurred during inactivation of inhibitor-treated PGHS-1, producing iron chlorin and heme-protein adduct species. Structural perturbations at the peroxidase site (MnPGHS-1) or at the cyclooxygenase site (inhibitor-treated PGHS-1) thus can influence markedly the kinetics and the chemistry of PGHS-1 peroxidase inactivation.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Texas System; University of Texas Health Science Center Houston; University of Michigan System; University of Michigan	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, POB 20708, Houston, TX 77225 USA.				NCI NIH HHS [CA165954] Funding Source: Medline; NIEHS NIH HHS [ES08365] Funding Source: Medline; NIGMS NIH HHS [GM44911, GM07767, GM52170] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008365] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN YNP, 1987, J BIOL CHEM, V262, P16892; CHEN YNP, 1989, FASEB J, V3, P2294, DOI 10.1096/fasebj.3.11.2506093; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; EGAN RW, 1976, J BIOL CHEM, V251, P7329; GRAFF G, 1990, ANAL BIOCHEM, V188, P38, DOI 10.1016/0003-2697(90)90525-E; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KULMACZ RJ, 1982, BIOCHEM BIOPH RES CO, V104, P758, DOI 10.1016/0006-291X(82)90702-1; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; ODENWALLER R, 1992, J BIOL CHEM, V267, P13863; OGINO N, 1978, J BIOL CHEM, V253, P5061; OHKI S, 1979, J BIOL CHEM, V254, P829; Osawa Y, 1996, FREE RADICAL BIO MED, V21, P35, DOI 10.1016/0891-5849(95)02215-5; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; SAMUELSSON B, 1978, ANNU REV BIOCHEM, V47, P997, DOI 10.1146/annurev.bi.47.070178.005025; Shi WJ, 2000, BIOCHEMISTRY-US, V39, P4112, DOI 10.1021/bi992561c; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; STRIEDER S, 1992, J BIOL CHEM, V267, P13870; Sugiyama K, 1997, P NATL ACAD SCI USA, V94, P796, DOI 10.1073/pnas.94.3.796; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 1997, J BIOL CHEM, V272, P8885; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; Vuletich JL, 1998, ANAL BIOCHEM, V265, P375, DOI 10.1006/abio.1998.2926; Wu G, 1999, J BIOL CHEM, V274, P9231, DOI 10.1074/jbc.274.14.9231	36	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19879	19888		10.1074/jbc.M100628200	http://dx.doi.org/10.1074/jbc.M100628200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279106	hybrid			2022-12-25	WOS:000169135100028
J	Schneider, P; Street, SL; Gaide, O; Hertig, S; Tardivel, A; Tschopp, J; Runkel, L; Alevizopoulos, K; Ferguson, BM; Zonana, J				Schneider, P; Street, SL; Gaide, O; Hertig, S; Tardivel, A; Tschopp, J; Runkel, L; Alevizopoulos, K; Ferguson, BM; Zonana, J			Mutations leading to X-linked hypohidrotic ectodermal dysplasia affect three major functional domains in the tumor necrosis factor family member ectodysplasin-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; CRYSTAL-STRUCTURE; JAPANESE FAMILY; CELL GROWTH; EDA1 GENE; LIGAND; HOMOLOG; PROTEIN; FORM; MORPHOGENESIS	Mutations in the epithelial morphogen ectodysplasin-A (EDA), a member of the tumor necrosis factor (TNF) family, are responsible for the human disorder X-linked hypohidrotic ectodermal dysplasia (XLHED) characterized by impaired development of hair, eccrine sweat glands, and teeth. EDA-A1 and EDA-A2 are two splice variants of EDA, which bind distinct EDA-A1 and X-linked EDA-A2 receptors. We identified a series of novel EDA mutations in families with XLHED, allowing the identification of the following three functionally important regions in EDA: a C-terminal TNF homology domain, a collagen domain, and a furin protease recognition sequence. Mutations in the TNF homology domain impair binding of both splice variants to their receptors, Mutations in the collagen domain can inhibit multimerization of the TNF homology region, whereas those in the consensus furin recognition sequence prevent proteolytic cleavage of EDA. Finally, a mutation affecting an intron splice donor site is predicted to eliminate specifically the EDA-A1 but not the EDA-A2 splice variant. Thus a proteolytically processed, oligomeric form of EDA-A1 is required in vivo for proper morphogenesis.	Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, CH-1066 Epalinges, Switzerland; Oregon Hlth Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; ApoTech, CH-1066 Epalinges, Switzerland; Biogen Inc, Dept Inflammat, Cambridge, MA 02142 USA	University of Lausanne; Oregon Health & Science University; Biogen	Schneider, P (corresponding author), Univ Lausanne, Inst Biochem, BIL Biomed Res Ctr, Ch Boveresses 155, CH-1066 Epalinges, Switzerland.			Schneider, Pascal/0000-0003-0677-9409	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011311] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11311] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aoki N, 2000, J INVEST DERMATOL, V115, P329, DOI 10.1046/j.1523-1747.2000.00065-1.x; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Cassiano Linda, 2000, Scandinavian Journal of Immunology, V51, P22; Chicheportiche Y, 1997, J BIOL CHEM, V272, P32401, DOI 10.1074/jbc.272.51.32401; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Eggleton P, 1998, TRENDS CELL BIOL, V8, P428, DOI 10.1016/S0962-8924(98)01373-7; Ferguson BM, 1998, J MED GENET, V35, P112, DOI 10.1136/jmg.35.2.112; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Hertz JM, 1998, CLIN GENET, V53, P205; Hymowitz SG, 2000, BIOCHEMISTRY-US, V39, P633, DOI 10.1021/bi992242l; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Kishore U, 1999, IMMUNOPHARMACOLOGY, V42, P15, DOI 10.1016/S0162-3109(99)00011-9; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Martinez F, 1999, J INVEST DERMATOL, V113, P285, DOI 10.1046/j.1523-1747.1999.00656.x; Mikkola ML, 1999, MECH DEVELOP, V88, P133, DOI 10.1016/S0925-4773(99)00180-X; Monreal AW, 1998, AM J HUM GENET, V63, P380, DOI 10.1086/301984; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; ORTH U, 1998, AM J HUM GENET, V63, P377; Schneider P, 2000, METHOD ENZYMOL, V322, P325; Schneider P, 1997, J BIOL CHEM, V272, P18827, DOI 10.1074/jbc.272.30.18827; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Tucker AS, 2000, DEVELOPMENT, V127, P4691; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523; Yotsumoto S, 1998, J INVEST DERMATOL, V111, P1246, DOI 10.1046/j.1523-1747.1998.00443.x; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	31	178	197	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18819	18827		10.1074/jbc.M101280200	http://dx.doi.org/10.1074/jbc.M101280200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279189	Green Published, hybrid			2022-12-25	WOS:000169091000024
J	McDonald, ER; Chui, PC; Martelli, PF; Dicker, DT; El-Deiry, WS				McDonald, ER; Chui, PC; Martelli, PF; Dicker, DT; El-Deiry, WS			Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FADD-DEPENDENT APOPTOSIS; TRAIL-INDUCED APOPTOSIS; NF-KAPPA-B; DECOY RECEPTOR; CELL-DEATH; GENE; LIGAND; FAS; CASPASE-8; FAMILY	The Fas/tumor necrosis factor (TNF)/TRAIL receptors signal death through a cytoplasmic death domain (DD) containing six alpha -helices with positively charged helix 2 interacting with negatively charged helix 3 of another DD, DD mutation occurs in head/neck and lung cancer (TRAIL receptor KILLER/DR5) and in Epr mice (Fas). We examined the apoptotic potential of known KILLER DR5 lung tumor-derived mutants (n = 6) and DD mutants (n = 18) generated based on conservation with DR4, Fas, Fas-associated death domain (FADD), and tumor necrosis factor receptor 1 (TNFR1), With the exception of Arg-330 required in Fas or FADD for aggregation or for TNFR1 cytotoxicity, surprisingly major loss-of-function KILLER/DR5 alleles (W325A, L334A (Epr-like), I339A, and W360A) contained hydrophobic residues. Loss-of function of I339A (highly conserved) has not been reported in DDs. Charged residue mutagenesis revealed the following points. 1) E326A, conserved in DR4, is dispensable for death; the homologous residue is positively charged in Fas, TNFR1, and FADD and is critical for DD interactions, 2) K331A, D336A, E338A, K340A, K343A, and D351A have partial loss-of-function suggesting multiple charges stabilize receptor-adapter interactions. Analysis of the tumor-derived KILLER/DR5 mutants revealed the following. 1) L334F has partial loss-of-function versus L334A, whereas E338K has major loss-of-function versus E338A, examples where alanine and tumor-specific substitutions have divergent phenotypes. 2) Unexpectedly, S324F, E326K, K386N, and D407Y have no loss-of-function with tumor-specific or alanine substitutions. Loss-of-function KILLER/DR5 mutants were deficient in recruitment of FADD and caspase 8 to TRAIL death-inducing signaling complexes. The results reveal determinants within KILLER/DR5 for death signaling and drug design.	Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med,Lab Mol Oncol & Cell Cycle Regulat, Howard Hughes Med Inst, 415 Curie Blvd, Philadelphia, PA 19104 USA.	wafik@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA75454, CA75138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075454, P01CA075138] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lee SH, 1999, CANCER RES, V59, P5683; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Ozoren N, 2000, INT J ONCOL, V16, P917; Pai SI, 1998, CANCER RES, V58, P3513; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Screaton GR, 1997, CURR BIOL, V7, P693, DOI 10.1016/S0960-9822(06)00297-1; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang XD, 1999, CANCER RES, V59, P2747	44	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14939	14945		10.1074/jbc.M100399200	http://dx.doi.org/10.1074/jbc.M100399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279061	hybrid			2022-12-25	WOS:000168528800057
J	Mayer, MR; Stone, MJ				Mayer, MR; Stone, MJ			Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine eotaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; MOLECULAR-CLONING; HUMAN EOSINOPHIL; MCP-1 RECEPTOR; CHEMOATTRACTANT; RECRUITMENT; MIP-1-BETA; EXPRESSION; RESIDUES; DYNAMICS	Eotaxin is a CC chemokine that specifically activates the receptor CCR3 causing accumulation of eosinophils in allergic diseases and parasitic infections. Twelve amino acid residues in the N-terminal (residues 1-8) and N-loop (residues 11-20) regions of eotaxin have been individually mutated to alanine, and the ability of the mutants to bind and activate CCR3 has been determined in cell-based assays, The alanine mutants at positions Thr(7), Asn(12), Leu(13), and Leu(20) show near wild type binding affinity and activity. The mutants T8A, N15A, and K17A have near wild type binding affinity for CCR3 but reduced receptor activation. A third class of mutants, S4A, V5A, R16A, and I18A, display significantly perturbed binding affinity for CCR3 while retaining the ability to activate or partially activate the receptor. Finally, the mutant Phe(11) has little detectable activity and 20-fold reduced binding affinity relative to wild type eotaxin, the most dramatic effect observed in both assays but less dramatic than the effect of mutating the corresponding residue in some other chemokines, Taken together, the results indicate that residues contributing to receptor binding affinity and those required for triggering receptor activation are distributed throughout the N-terminal and N-loop regions. This conclusion is in contrast to the separation of binding and activation functions between N-loop and N-terminal regions, respectively, that has been observed previously for some other chemokines.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Stone, MJ (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	mastone@indiana.edu	Stone, Martin/C-2492-2012	Stone, Martin/0000-0002-6468-4427	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055055, R01GM055055] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-55055] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; HE JL, 1995, J VIROL, V69, P4587, DOI 10.1128/JVI.69.7.4587-4592.1995; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Murdoch C, 2000, BLOOD, V95, P3032; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Rankin SM, 2000, MOL MED TODAY, V6, P20, DOI 10.1016/S1357-4310(99)01635-4; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Shinkai A, 1999, J IMMUNOL, V163, P1602; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Stone MJ, 2000, CHEMOKINES IN ALLERGIC DISEASE, P67; Struyf S, 1999, J IMMUNOL, V162, P4903; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; White JR, 1997, J LEUKOCYTE BIOL, V62, P667, DOI 10.1002/jlb.62.5.667; Ye JP, 2000, J BIOL CHEM, V275, P27250; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947	37	33	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13911	13916		10.1074/jbc.M011202200	http://dx.doi.org/10.1074/jbc.M011202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297526	hybrid			2022-12-25	WOS:000168356600057
J	Pellegrini, M; Bremer, AA; Ulfers, AL; Boyd, ND; Mierke, DF				Pellegrini, M; Bremer, AA; Ulfers, AL; Boyd, ND; Mierke, DF			Molecular characterization of the substance P center dot neurokinin-1 receptor complex - Development of an experimentally based model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; NEUROKININ-1 RECEPTOR; NK-1 RECEPTOR; EXTRACELLULAR DOMAIN; ANTAGONIST-BINDING; NK1 RECEPTOR; SITE; RHODOPSIN; PEPTIDE; ANALOG	Molecular models for the interaction of substance P (SP) with its G protein-coupled receptor, the neurokinin-l receptor (NK-1R), have been developed. The ligand receptor complex is based on experimental data from a series of photoaffinity labeling experiments and spectroscopic structural studies of extracellular domains of the NK-1R. Using the ligand/receptor contact points derived from incorporation of photolabile probes (p-benzoylphenylalanine (Bpa)) into SP at positions 3, 4, and 8 and molecular dynamics simulations, the topological arrangement of SP within the NK-1R is explored. The model incorporates the structural features, determined by high resolution NMR studies, of the second extracellular loop (EC2), containing contact points Met(174) and Met(181), providing important experimentally based conformational preferences for the simulations. Extensive molecular dynamics simulations mere carried out to probe the nature of the two contact points identified for the Bpa(3)SP analogue (Bremer, A. A., Leeman, S. E., and Boyd, N. D. (2001) J. Biol. Chem. 276, 22857-22861), examining modes of ligand binding in which the contact points are fulfilled sequentially or simultaneously. The resulting ligand receptor complex has the N terminus of SP projecting toward transmembrane helix (TM) 1 and TM2, exposed to the solvent. The C terminus of SP is located in proximity to TM5 and TM6, deeper into the central core of the receptor. The central portion of the ligand, adopting a helical loop conformation, is found to align with the helices of the central regions EC2 and EC3, forming important interactions with both of these extracellular domains. The model developed here allows for atomic insight into the biochemical data currently available and guides targeting of future experiments to probe specific ligand/receptor interactions and thereby furthers our understanding of the functioning of this important neuropeptide system.	Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; Brown Univ, Dept Mol Pharmacol, Div Biol & Med, Providence, RI 02912 USA	Boston University; Brown University	Boyd, ND (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, L-611,80 E Concord St, Boston, MA 02118 USA.	nboyd@bu.edu; dale_mierke@brown.edu	Pellegrini, Maria/W-6005-2019	Pellegrini, Maria/0000-0003-3817-4412	NIGMS NIH HHS [GM-54082] Funding Source: Medline; NINDS NIH HHS [NS-31346] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054082, R29GM054082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031346] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Auge S, 2000, BIOPOLYMERS, V54, P297, DOI 10.1002/1097-0282(20001015)54:5<297::AID-BIP10>3.0.CO;2-9; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; Bremer AA, 2000, FEBS LETT, V486, P43, DOI 10.1016/S0014-5793(00)02228-6; Bremer AA, 2001, J BIOL CHEM, V276, P22857, DOI 10.1074/jbc.M100824200; Elling CE, 1997, ANN NY ACAD SCI, V814, P142, DOI 10.1111/j.1749-6632.1997.tb46152.x; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; FONG TM, 1994, J BIOL CHEM, V269, P2728; FONG TM, 1995, CAN J PHYSIOL PHARM, V73, P860, DOI 10.1139/y95-118; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1993, NATURE, V362, P350; FONG TM, 1993, REGUL PEPTIDES, V46, P43, DOI 10.1016/0167-0115(93)90010-6; FONG TM, 1992, BIOPHYS J, V62, P59, DOI 10.1016/S0006-3495(92)81778-2; Hastrup H, 1996, FEBS LETT, V399, P264, DOI 10.1016/S0014-5793(96)01337-3; Holst B, 1998, MOL PHARMACOL, V53, P166, DOI 10.1124/mol.53.1.166; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; Huang RRC, 1995, BIOCHEMISTRY-US, V34, P16467, DOI 10.1021/bi00050a030; Kage R, 1996, J BIOL CHEM, V271, P25797, DOI 10.1074/jbc.271.42.25797; KAGE R, 1995, J NEUROCHEM, V64, P316; Li HZ, 2001, J BIOL CHEM, V276, P10589, DOI 10.1074/jbc.M007397200; Macdonald D, 2001, BIOCHEMISTRY-US, V40, P2530, DOI 10.1021/bi001880x; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Paterlini G, 1997, J MED CHEM, V40, P3254; Prado GN, 1998, J BIOL CHEM, V273, P33548, DOI 10.1074/jbc.273.50.33548; RENSDOMIANO S, 1991, J BIOL CHEM, V266, P20094; Rolz C, 1999, BIOCHEMISTRY-US, V38, P6397, DOI 10.1021/bi9829276; Sagan S, 1997, MOL PHARMACOL, V52, P120, DOI 10.1124/mol.52.1.120; Seelig A, 1996, BIOCHEMISTRY-US, V35, P4365, DOI 10.1021/bi952434q; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Takeuchi Y, 1998, J MED CHEM, V41, P3609, DOI 10.1021/jm9700171; TALLON M, 1993, BIOPOLYMERS, V33, P915, DOI 10.1002/bip.360330607; Turcatti G, 1997, J BIOL CHEM, V272, P21167, DOI 10.1074/jbc.272.34.21167; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANBUUREN AR, 1993, J PHYS CHEM-US, V97, P9206, DOI 10.1021/j100138a023; Vedani A, 2000, J MED CHEM, V43, P4416, DOI 10.1021/jm000986n; Whitehead TL, 1998, J MED CHEM, V41, P1497, DOI 10.1021/jm970789x; WINNIK MA, 1981, CHEM REV, V81, P491, DOI 10.1021/cr00045a004; WOOLLEY GA, 1987, BIOPOLYMERS, V26, pS109, DOI 10.1002/bip.360260012	42	38	38	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22862	22867		10.1074/jbc.M101057200	http://dx.doi.org/10.1074/jbc.M101057200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294871	hybrid			2022-12-25	WOS:000169412700118
J	Elholm, M; Dam, I; Jorgensen, C; Krogsdam, AM; Holst, D; Kratchmarova, I; Gottlicher, M; Gustafsson, JA; Berge, R; Flatmark, T; Knudsen, J; Mandrup, S; Kristiansen, K				Elholm, M; Dam, I; Jorgensen, C; Krogsdam, AM; Holst, D; Kratchmarova, I; Gottlicher, M; Gustafsson, JA; Berge, R; Flatmark, T; Knudsen, J; Mandrup, S; Kristiansen, K			Acyl-CoA esters antagonize the effects of ligands on peroxisome proliferator-activated receptor alpha conformation, DNA binding, and interaction with co-factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; RETINOID-X-RECEPTOR; COENZYME-A THIOESTERS; FATTY-ACIDS; CRYSTAL-STRUCTURE; TRANSCRIPTIONAL ACTIVITY; PROGESTERONE-RECEPTOR; HYPOLIPIDEMIC DRUGS; ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS	The peroxisome proliferator-activated receptor alpha (PPAR alpha) is a ligand-activated transcription factor and a key regulator of lipid homeostasis. Numerous fatty acids and eicosanoids serve as ligands and activators for PPAR. Here we demonstrate that S-hexadecyl-CoA, a nonhydrolyzable palmitoyl-CoA analog, antagonizes the effects of agonists on PPAR alpha conformation and function in vitro, In electrophoretic mobility shift assays, S-hexadecyl-CoA prevented agonist-induced binding of the PPAR alpha -retinoid X receptor alpha heterodimer to the acyl-CoA oxidase peroxisome proliferator response element. PPAR alpha bound specifically to immobilized palmitoyl-CoA and Wy14643, but not BRL49653, abolished binding. S-Hexadecyl-CoA increased in a dose-dependent and reversible manner the sensitivity of PPAR alpha to chymotrypsin digestion, and the S-hexadecyl-CoA-induced sensitivity required a functional PPAR alpha ligand-binding pocket. S-Hexadecyl-CoA prevented ligand-induced interaction between the co-activator SRC-1 and PPAR alpha but increased recruitment of the nuclear receptor corepressor NCoR, In cells, the concentration of free acyl-CoA esters is kept in the low nanomolar range due to the buffering effect of high affinity acyl-CoA-binding proteins, especially the acyl-CoA-binding protein. By using PPAR alpha expressed in Sf21 cells for electrophoretic mobility shift assays, we demonstrate that S-hexadecyl-CoA was able to increase the mobility of the PPAR alpha -containing heterodimer even in the presence of a molar excess of acyl-CoA-binding protein, mimicking the conditions found in vivo.	Univ So Denmark, Dept Biochem & Mol Biol, DK-5320 Odense M, Denmark; Univ So Denmark, Ctr Expt Bioinformat, DK-5320 Odense, Denmark; Karolinska Inst, Dept Med Nutr, S-14157 Huddinge, Sweden; Univ Bergen, Inst Clin Biochem, N-5021 Bergen, Norway; Univ Bergen, Dept Biochem & Mol Biol, N-5021 Bergen, Norway	University of Southern Denmark; University of Southern Denmark; Karolinska Institutet; University of Bergen; University of Bergen	Kristiansen, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5320 Odense M, Denmark.		Göttlicher, Martin/M-7342-2014; Kristiansen, Karsten/J-5148-2014; Krogsdam, Anne/AAM-7278-2020; Mandrup, Susanne/B-6693-2008	Göttlicher, Martin/0000-0003-0619-2181; Kristiansen, Karsten/0000-0002-6024-0917; Krogsdam, Anne/0000-0002-5478-0511; Kratchmarova, Irina/0000-0001-6613-7315; Jorgensen, Claus/0000-0002-7841-943X; Mandrup, Susanne/0000-0002-0961-5787				AARSLAND A, 1991, BIOCHEM PHARMACOL, V41, P53, DOI 10.1016/0006-2952(91)90010-3; Auwerx J, 1999, CELL, V97, P161; BERGE RK, 1985, BIOCHIM BIOPHYS ACTA, V837, P141, DOI 10.1016/0005-2760(85)90237-1; BERGE RK, 1989, BIOCHIM BIOPHYS ACTA, V1004, P343; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Braissant O, 1998, ENDOCRINOLOGY, V139, P2748, DOI 10.1210/en.139.6.2748; BRONFMAN M, 1986, BIOCHEM J, V239, P781, DOI 10.1042/bj2390781; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Elholm M, 2000, J LIPID RES, V41, P538; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Glass CK, 2000, GENE DEV, V14, P121; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HERTZ R, 1994, EUR J BIOCHEM, V221, P611, DOI 10.1111/j.1432-1033.1994.tb18773.x; Hertz R, 1996, J BIOL CHEM, V271, P218, DOI 10.1074/jbc.271.1.218; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; HORLEIN AJ, 1995, NATURE, V377, P379; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kussmann-Gerber S, 1999, ANAL BIOCHEM, V271, P102, DOI 10.1006/abio.1999.4117; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094; LYGRE T, 1986, J CHROMATOGR, V38, P95; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Murakami K, 2001, BIOCHEM J, V353, P231, DOI 10.1042/0264-6021:3530231; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; NILSSON A, 1984, LIPIDS, V19, P187, DOI 10.1007/BF02534796; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Nordhoff E, 1999, NAT BIOTECHNOL, V17, P884, DOI 10.1038/12873; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; ONATE SA, 1995, SCIENCE, V270, P1354; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rodriguez JC, 1998, BIOCHEM BIOPH RES CO, V242, P692, DOI 10.1006/bbrc.1997.8032; ROSENDAL J, 1993, BIOCHEM J, V290, P321, DOI 10.1042/bj2900321; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Uppenberg J, 1998, J BIOL CHEM, V273, P31108, DOI 10.1074/jbc.273.47.31108; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu JM, 1996, P NATL ACAD SCI USA, V93, P12195, DOI 10.1073/pnas.93.22.12195; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513	65	38	38	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21410	21416		10.1074/jbc.M101073200	http://dx.doi.org/10.1074/jbc.M101073200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279171	hybrid			2022-12-25	WOS:000169297900083
J	Riedel, C; Levy, O; Carrasco, N				Riedel, C; Levy, O; Carrasco, N			Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID NA+/I SYMPORTER; SODIUM-IODIDE SYMPORTER; GENE-EXPRESSION; FRTL-5 CELLS; PHOSPHORYLATION; TRANSPORTER; VESICLES; CLONING; DOMAIN; CANCER	The Na+/I- symporter (NIS) is a key plasma membrane glycoprotein that mediates active I- transport in the thyroid gland (Dai, G., Levy, O., and Carrasco, N. (1996) Nature 379, 458-460), the first step in thyroid hormone biogenesis, Whereas relatively little is known about the mechanisms by which thyrotropin (TSH), the main hormonal regulator of thyroid function, regulates NIS activity, post-transcriptional events have been suggested to play a role (Kaminsky, S. M., Levy, O., Salvador, C., Dai, G., and Carrasco, N. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 3789-3793), Here we show that TSH induces de novo NIS biosynthesis and modulates the long NIS half-life (similar to5 days). In addition, we demonstrate that TSH is required for NIS targeting to or retention in the plasma membrane. We further show that NIS is a phosphoprotein and that TSH modulates its phosphorylation pattern. These results provide strong evidence of the major role played by post-transcriptional events in the regulation of NIS by TSH. Beyond their inherent interest, it is also of medical significance that these TSH-dependent regulatory mechanisms may be altered in the large proportion of thyroid cancers in which NIS is predominantly expressed in intracellular compartments, instead of being properly targeted to the plasma membrane.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Carrasco, N (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	carrasco@aecom.yu.edu	Carrasco, Nancy/AAH-1053-2019	Carrasco, Nancy/0000-0003-4137-6162; Riedel, Claudia/0000-0001-6168-8601	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041544] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-41544, DK-07218] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arturi F, 2000, EUR J ENDOCRINOL, V143, P623, DOI 10.1530/eje.0.1430623; BAGCHI N, 1973, BIOCHIM BIOPHYS ACTA, V318, P235, DOI 10.1016/0005-2736(73)90117-X; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0; DE la Vieja A, 2000, PHYSIOL REV, V80, P1083, DOI 10.1152/physrev.2000.80.3.1083; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; Glavy JS, 2000, J BIOL CHEM, V275, P1479, DOI 10.1074/jbc.275.2.1479; KAMINSKY SM, 1994, P NATL ACAD SCI USA, V91, P3789, DOI 10.1073/pnas.91.9.3789; Kogai T, 1997, ENDOCRINOLOGY, V138, P2227, DOI 10.1210/en.138.6.2227; Kogai T, 2000, J ENDOCRINOL, V167, P125, DOI 10.1677/joe.0.1670125; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Krantz DE, 2000, J CELL BIOL, V149, P379, DOI 10.1083/jcb.149.2.379; Krantz DE, 1997, J BIOL CHEM, V272, P6752, DOI 10.1074/jbc.272.10.6752; Law RM, 2000, J BIOL CHEM, V275, P23986, DOI 10.1074/jbc.M910283199; Levy O, 1997, P NATL ACAD SCI USA, V94, P5568, DOI 10.1073/pnas.94.11.5568; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MARCOCCI C, 1984, ENDOCRINOLOGY, V115, P2123, DOI 10.1210/endo-115-6-2123; MARTINO E, 2000, THYROID FUNDMENTAL C, P762; MAZAFERRI EL, 2000, THYROID FUNDAMENTAL, P904; Mehrens T, 2000, J AM SOC NEPHROL, V11, P1216, DOI 10.1681/ASN.V1171216; Ohno M, 1999, MOL CELL BIOL, V19, P2051; ORR GA, 1993, J BIOL CHEM, V268, P25054; Paire A, 1997, J BIOL CHEM, V272, P18245, DOI 10.1074/jbc.272.29.18245; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Saito T, 1997, J CLIN ENDOCR METAB, V82, P3331, DOI 10.1210/jc.82.10.3331; Saito T, 1998, J CLIN INVEST, V101, P1296, DOI 10.1172/JCI1259; Schmutzler C, 2000, THYROID, V10, P393, DOI 10.1089/thy.2000.10.393; Smanik PA, 1996, BIOCHEM BIOPH RES CO, V226, P339, DOI 10.1006/bbrc.1996.1358; Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; Venkataraman GM, 1999, J CLIN ENDOCR METAB, V84, P2449, DOI 10.1210/jc.84.7.2449; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1099, DOI 10.1210/endo-114-4-1099; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1108, DOI 10.1210/endo-114-4-1108; WEISS SJ, 1984, ENDOCRINOLOGY, V114, P1090, DOI 10.1210/endo-114-4-1090	39	202	214	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21458	21463		10.1074/jbc.M100561200	http://dx.doi.org/10.1074/jbc.M100561200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290744	hybrid			2022-12-25	WOS:000169297900089
J	Cavelier, LB; Qiu, Y; Bielicki, JK; Afzal, V; Cheng, JF; Rubin, EM				Cavelier, LB; Qiu, Y; Bielicki, JK; Afzal, V; Cheng, JF; Rubin, EM			Regulation and activity of the human ABCA1 gene in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; DENSITY-LIPOPROTEIN CHOLESTEROL; TANGIER-DISEASE PATIENTS; ORPHAN NUCLEAR RECEPTOR; APOLIPOPROTEIN-A-I; CELLULAR CHOLESTEROL; HDL CHOLESTEROL; EFFLUX; TRANSPORTER-1; PHOSPHOLIPIDS	The ABCA1 transporter is one of the limiting steps in cellular cholesterol efflux, To study the expression and activity of the human ABCA1 gene in vivo we have examined mice containing two human BAC transgenes with different 5' ends. Mice containing a 255-kilobase (kb) BAC transgene, including 70 kb upstream of the previously defined exon I, demonstrated a pattern of tissue-specific expression mimicking that of the endogenous mouse gene. Compared with macrophages from control mice, macrophages from these transgenics had increases in apoA-I cholesterol efflux heightened in response to increases in cell cholesterol content. The observed increase in macrophage apoA-I-mediated cholesterol efflux was not accompanied by alterations in plasma high density lipoprotein in the transgenics. Although mice containing a smaller 171-kb human BAC transgene, lacking the previously described exon 1 and ABCA1 promoter, did not express human ABCA1 in macrophages, they did express the human transgene in liver at levels comparable with those of the orthologous mouse gene. Analysis by 5' rapid amplification of cDNA ends of liver mRNA from these animals revealed a new ABCA1 exon 1 (exon 1A) and a previously unrecognized promoter. Analysis of human tissue revealed that exon 1A containing transcripts accounted for a high proportion of the ABCA1 mRNAs present in human liver, This analysis of ABCA1 transgenics showed that the expression of human ABCA1 transgenes can result in increased cholesterol efflux from macrophages, unaccompanied by changes in plasma high density lipoprotein, and identified a new ABCA1 promoter in humans.	Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Cheng, JF (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, 1 Cyclotron Rd,MS-84-171, Berkeley, CA 94720 USA.			Cheng, Jan-Fang/0000-0001-7315-7613	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066728, R01HL059483] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL6398-01, HL66728-01, HL59483-01A2] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; ASSMANN G, 1995, METABOLIC MOL BASES, P2053; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Broccardo C, 1999, BBA-BIOMEMBRANES, V1461, P395, DOI 10.1016/S0005-2736(99)00170-4; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Brousseau ME, 2000, J LIPID RES, V41, P1125; Christiansen-Weber TA, 2000, AM J PATHOL, V157, P1017, DOI 10.1016/S0002-9440(10)64614-7; Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727; Costet P, 2000, J BIOL CHEM, V275, P28240; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GLOMSET JA, 1968, J LIPID RES, V9, P155; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hamon Y, 1997, BLOOD, V90, P2911, DOI 10.1182/blood.V90.8.2911; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Mendez AJ, 1997, J LIPID RES, V38, P1807; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; QIU Y, 2001, IN PRESS GENOMICS; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Schoonjans K, 2000, BBA-MOL CELL BIOL L, V1529, P114, DOI 10.1016/S1388-1981(00)00141-4; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SERFATYLACROSNIERE C, 1994, ATHEROSCLEROSIS, V107, P85, DOI 10.1016/0021-9150(94)90144-9; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; von Eckardstein A, 1998, J LIPID RES, V39, P987; von Eckardstein A, 2000, CURR OPIN LIPIDOL, V11, P627, DOI 10.1097/00041433-200012000-00010	41	76	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18046	18051		10.1074/jbc.M100565200	http://dx.doi.org/10.1074/jbc.M100565200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279093	hybrid, Green Submitted			2022-12-25	WOS:000168866500058
J	Sun, JX; Kamei, CN; Layne, MD; Jain, MK; Liao, JK; Lee, ME; Chin, MT				Sun, JX; Kamei, CN; Layne, MD; Jain, MK; Liao, JK; Lee, ME; Chin, MT			Regulation of myogenic terminal differentiation by the hairy-related transcription factor CHF2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX REPRESSOR; DNA-BINDING; DROSOPHILA HAIRY; GENE-EXPRESSION; BHLH PROTEINS; ENHANCER; SPLIT; DOMAIN; MYOD; SOMITOGENESIS	We have recently cloned a novel basic helix-loop-helix factor, CHF2, that functions as a transcriptional repressor. To address its role in the regulation of myogenic terminal differentiation, we analyzed its expression pattern during C2C12 mouse myotube formation. In undifferentiated myoblasts, CHF2 is expressed at high levels. After induction of myotube formation in low serum, CHF2 expression is barely detectable at 3 days after induction, Myogenin expression, in contrast, peaks at 3 days. In transiently transfected 10T1/2 embryonic fibroblasts, CHF2 inhibited MyoD-dependent activation of the myogenin promoter in a dose-dependent fashion. Electrophoretic mobility shift analysis indicated that CHF2 inhibits the binding of the MyoD.E47 heterodimer to the E-box binding site. CHF2 also inhibited myogenic conversion of 10T1/2 cells by MyoD, as measured by skeletal myosin heavy chain protein expression. Coimmunoprecipitation analysis indicated that CHF2 forms a protein complex with MyoD. Mutational analysis of CHF2 indicated that the repression activity for both transcription and myogenic conversion mapped to a hydrophobic carboxyl-terminal region and did not require either the basic helix-loop-helix or YRPW motifs, Our data indicate that CHF2 functions as a transcriptional repressor of myogenesis by formation of an inactive heterodimeric complex with MyoD and likely plays an important role in muscle development.	Brigham & Womens Hosp, Vasc Med Unit, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chin, MT (corresponding author), Brigham & Womens Hosp, Vasc Med Unit, Div Cardiovasc, 221 Longwood Ave, Boston, MA 02115 USA.			Layne, Matthew/0000-0003-0007-4870	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057664, F32HL010113, P01HL048743] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03745, HL 03747, HL 10113, HL 48743, HL 57664] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Chen CMA, 1996, CELL, V86, P731, DOI 10.1016/S0092-8674(00)80148-8; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; Holley SA, 2000, GENE DEV, V14, P1678; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; Palmeirim I, 1997, CELL, V91, P639, DOI 10.1016/S0092-8674(00)80451-1; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	26	61	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18591	18596		10.1074/jbc.M101163200	http://dx.doi.org/10.1074/jbc.M101163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279181	hybrid			2022-12-25	WOS:000168866500129
J	Sabri, A; Bare, G; Jacques, P; Jabrane, A; Ongena, M; Van Heugen, JC; Devreese, B; Thonart, P				Sabri, A; Bare, G; Jacques, P; Jabrane, A; Ongena, M; Van Heugen, JC; Devreese, B; Thonart, P			Influence of moderate temperatures on myristoyl-CoA metabolism and acyl-CoA thioesterase activity in the psychrophilic antarctic yeast Rhodotorula aurantiaca	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID-SYNTHETASE; PROTEIN N-MYRISTOYLTRANSFERASE; COENZYME-A CARBOXYLASE; SACCHAROMYCES-CEREVISIAE; RAT-LIVER; COLD ADAPTATION; BINDING-PROTEIN; PURIFICATION; HYDROLASE; ESTERS	The inability of psychrophilic microorganisms to grow at moderate temperatures (>20 degreesC) presently represents an unresolved thermodynamic paradox. Here we report for the psychrophilic yeast Rhodotorula aurantiaca A19, isolated from Antarctic ice, that the inability to grow at temperatures close to 20 degreesC is associated with profound alterations in cell morphology and integrity. High performance liquid chromatography analysis of the intracellular acyl-CoA esters revealed an abnormal accumulation of myristoyl-CoA (C14-CoA) in cells cultivated close to the nonpermissive temperature. Its concentration (500 muM) was found to be 28-fold higher than in cells cultivated at 0 degreesC, If one considers its ability to disrupt membrane bilayers and to inhibit many cellular enzymes and functions, intracellular myristoyl-CoA accumulation in the psychrophile R, aurantiaca represents one of the principal causes of growth arrest at moderate temperatures. Intracellular acyl-CoA concentrations are believed to be regulated by thioesterase activity. Thus in an attempt to explore the mechanism by which temperature disrupts myristoyl-CoA metabolism, we isolated and characterized a long chain acyl-CoA thioesterase, The monomeric 80-kDa thioesterase from the psychrophilic yeast shows a very strong specificity for myristoyl-CoA The affinity for substrate and the catalytic efficiency of the thioesterase are optimal below 5 degreesC (temperatures habitually experienced by the strain) and dramatically decrease with increasing temperature. The loss of affinity for substrate is related to the intracellular increase of myristoyl-CoA concentration. Our observations reveal one of the probable mechanisms by which temperature fixes the limit of growth for this psychrophilic yeast.	Univ Liege, Ctr Wallon Biol Ind B40, B-4000 Liege, Belgium; Univ Liege, CHU Sart Tilman, Lab Chim Med B35, B-4000 Liege, Belgium; Lab Eiwitbiochem Eiwitengn, B-9000 Ghent, Belgium	University of Liege; University of Liege	Sabri, A (corresponding author), Univ Liege, Ctr Wallon Biol Ind B40, B40,Sart Tilman, B-4000 Liege, Belgium.		Devreese, Bart/B-2011-2009; Devreese, Bart/K-2841-2019	Devreese, Bart/0000-0002-9764-2581; Devreese, Bart/0000-0002-9764-2581				BERGE RK, 1985, BIOCHIM BIOPHYS ACTA, V837, P141, DOI 10.1016/0005-2760(85)90237-1; BERGE RK, 1979, EUR J BIOCHEM, V96, P393, DOI 10.1111/j.1432-1033.1979.tb13051.x; BERGE RK, 1979, BIOCHIM BIOPHYS ACTA, V574, P321, DOI 10.1016/0005-2760(79)90013-4; BHAKOO M, 1979, ARCH MICROBIOL, V121, P121, DOI 10.1007/BF00689975; BHAKOO M, 1980, ARCH MICROBIOL, V126, P51, DOI 10.1007/BF00421890; BOYLAN JG, 1992, BIOCHEMISTRY-US, V31, P557, DOI 10.1021/bi00117a037; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVAIL S, 1994, J BIOL CHEM, V269, P17448; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; EKENA K, 1995, MOL CELL BIOL, V15, P1671; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; Feller G, 1996, FEMS MICROBIOL REV, V18, P189, DOI 10.1016/0168-6445(96)00011-3; FELLER G, 1992, J BIOL CHEM, V267, P5217; HAMAMOTO T, 1995, FEMS MICROBIOL LETT, V129, P51; HENRY SA, 1971, MOL GEN GENET, V113, P1; Hochachka P.W., 1984, BIOCHEMICAL ADAPTATI, P355; HORI T, 1987, J BIOCHEM-TOKYO, V101, P949, DOI 10.1093/oxfordjournals.jbchem.a121964; INNISS WE, 1975, ANNU REV MICROBIOL, V29, P445, DOI 10.1146/annurev.mi.29.100175.002305; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; Knudsen J, 1999, MOL CELL BIOCHEM, V192, P95, DOI 10.1023/A:1006830606060; KUHN L, 1972, EUR J BIOCHEM, V24, P492, DOI 10.1111/j.1432-1033.1972.tb19711.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MISHINA M, 1980, EUR J BIOCHEM, V111, P79; MORITA RY, 1975, BACTERIOL REV, V39, P144, DOI 10.1128/MMBR.39.2.144-167.1975; NORWOOD DL, 1990, J CHROMATOGR-BIOMED, V527, P289, DOI 10.1016/S0378-4347(00)82113-1; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PRASAD MR, 1987, ANAL BIOCHEM, V162, P202, DOI 10.1016/0003-2697(87)90028-5; ROE CR, 1986, J PEDIATR-US, V108, P13, DOI 10.1016/S0022-3476(86)80762-4; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; RUOHO AE, 1989, J BIOL CHEM, V264, P41168; RUSSELL NJ, 1990, PHILOS T ROY SOC B, V326, P595, DOI 10.1098/rstb.1990.0034; RUSSELL NJ, 1990, FEMS MICROBIOL LETT, V75, P171, DOI 10.1016/0378-1097(90)90530-4; Sabri A, 2000, APPL BIOCHEM BIOTECH, V84-6, P391, DOI 10.1385/ABAB:84-86:1-9:391; SHUG AL, 1975, AM J PHYSIOL, V228, P639; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; SOMERO GN, 1968, BIOCHEM J, V110, P395, DOI 10.1042/bj1100395; SOMERO GN, 1975, J EXP ZOOL, V194, P175, DOI 10.1002/jez.1401940111; SRERE PA, 1959, BIOCHIM BIOPHYS ACTA, V33, P313, DOI 10.1016/0006-3002(59)90118-0; Svensson LT, 1998, BIOCHEM J, V329, P601, DOI 10.1042/bj3290601; Verkruyse LA, 1996, J BIOL CHEM, V271, P15831, DOI 10.1074/jbc.271.26.15831; WAKU K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P101, DOI 10.1016/0005-2760(92)90085-A	45	10	13	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12691	12696		10.1074/jbc.M100155200	http://dx.doi.org/10.1074/jbc.M100155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11279019	hybrid			2022-12-25	WOS:000168198600031
J	Fago, A; Giangiacomo, L; D'Avino, R; Carratore, V; Romano, M; Boffi, A; Chiancone, E				Fago, A; Giangiacomo, L; D'Avino, R; Carratore, V; Romano, M; Boffi, A; Chiancone, E			Hagfish hemoglobins - Structure, function, and oxygen-linked association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYXINE-GLUTINOSA; CRYSTAL-STRUCTURE; LIGAND-BINDING; TRANSPORT; COOPERATIVITY; HAEMOGLOBIN; MYOGLOBIN; PROTEINS	Cyclostomes, hagfishes and lampreys, contain hemoglobins that are monomeric when oxygenated and polymerize to dimers or tetramers when deoxygenated. The three major hemoglobin components (HbI, HbII, and HbIII) from the hagfish Myxine glutinosa have been characterized and compared with lamprey Petromyzon marinus HbV, whose x-ray crystal structure has been solved in the deoxygenated, dimeric state (Heaslet, H. A., and Royer, W. E., Jr. (1999) Structure 7, 517-526). Of these three, HbII bears the highest sequence similarity to P. marinus HbV. In HbI and HbIII the distal histidine is substituted by a glutamine residue and additional substitutions occur in residues located at the deoxy dimer interface of P. marinus HbV. Infrared spectroscopy of the CO derivatives, used to probe the distal pocket fine structure, brings out a correlation between the CO stretching frequencies and the rates of CO combination. Ultracentrifugation studies show that HbI and HbIII are monomeric in both the oxygenated and deoxygenated states under all conditions studied, whereas deoxy HbII forms dimers at acidic pH values, like P. marinus HbV. Accordingly, the oxygen affinities of HbI and HbIII are independent of pH, whereas HbII displays a Bohr effect below pH 7.2. HbII also forms heterodimers with HbIII and heterotetramers with HbI. The functional counterparts of heteropolymer formation are cooperativity in oxygen binding and the oxygen-linked binding of protons and bicarbonate. The observed effects are explained on the basis of the x-ray structure of P. marinus HbV and the association behavior of site-specific mutants.	Univ Roma La Sapienza, CNR, Ctr Mol Biol, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Aarhus, Dept Zoophysiol, DK-8000 Aarhus C, Denmark; CNR, Inst Prot Biochem & Enzymol, I-80125 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; Aarhus University; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Chiancone, E (corresponding author), Univ Roma La Sapienza, CNR, Ctr Mol Biol, Ple Aldo Moro 5, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Fago, Angela/J-5946-2013	Fago, Angela/0000-0001-7315-2628				ACKERS GK, 1976, BIOCHEM BIOPH RES CO, V69, P135, DOI 10.1016/S0006-291X(76)80283-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANTONINI E, 1965, J MOL BIOL, V12, P375, DOI 10.1016/S0022-2836(65)80261-3; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BANNAI S, 1972, J BIOL CHEM, V247, P505; BAUER C, 1975, NATURE, V256, P66, DOI 10.1038/256066a0; BRIEHL RW, 1963, J BIOL CHEM, V238, P2361; BRITTAIN T, 1991, COMP BIOCHEM PHYS B, V99, P731, DOI 10.1016/0305-0491(91)90136-2; CHIANCONE E, 1981, J MOL BIOL, V152, P577, DOI 10.1016/0022-2836(81)90270-9; ELLORY JC, 1987, J EXP BIOL, V129, P377; Fago A, 1999, RESP PHYSIOL, V115, P309, DOI 10.1016/S0034-5687(98)00102-9; FAGO A, 1995, BBA-PROTEIN STRUCT M, V1249, P109, DOI 10.1016/0167-4838(95)00031-O; FANELLI AR, 1958, ARCH BIOCHEM BIOPHYS, V77, P478; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; GOODMAN M, 1981, J MOL EVOL, V17, P114, DOI 10.1007/BF01732683; GROSS E, 1961, J AM CHEM SOC, V83, P1510, DOI 10.1021/ja01467a052; Heaslet HA, 1999, STRUCT FOLD DES, V7, P517, DOI 10.1016/S0969-2126(99)80068-9; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KELLETT GL, 1970, NATURE, V227, P921, DOI 10.1038/227921a0; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Landon, 1977, Methods Enzymol, V47, P145; LI SL, 1972, BIOCHIM BIOPHYS ACTA, V278, P344, DOI 10.1016/0005-2795(72)90239-5; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LILJEQVIST G, 1982, J MOL EVOL, V18, P102, DOI 10.1007/BF01810828; Martini FH, 1998, SCI AM, V279, P70, DOI 10.1038/scientificamerican1098-70; MAXWELL JC, 1976, BIOCHEMISTRY-US, V15, P388, DOI 10.1021/bi00647a023; NIKINMAA M, 1993, VERTEBRATE GAS TRANSPORT CASCADE, P179; OHNO S, 1966, SCIENCE, V154, P1034, DOI 10.1126/science.154.3752.1034; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; PALEUS S, 1971, COMP BIOCHEM PHYSIOL, V39, P551, DOI 10.1016/0305-0491(71)90199-4; PARK KD, 1991, BIOCHEMISTRY-US, V30, P2333, DOI 10.1021/bi00223a007; PERRY SF, 1993, J EXP BIOL, V183, P165; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; Peters T, 1998, BIOLOGY OF HAGFISHES, P307; Qiu Y, 2000, J BIOL CHEM, V275, P13517, DOI 10.1074/jbc.275.18.13517; ROYER WE, 1989, J BIOL CHEM, V264, P21052; RUMEN NM, 1963, ACTA CHEM SCAND, V17, P222, DOI 10.3891/acta.chem.scand.17s-0222; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WELLS RMG, 1986, J EXP BIOL, V123, P43; WELLS RMG, 1989, SOC EXPT BIOL SERIES; [No title captured]	42	20	20	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27415	27423		10.1074/jbc.M100759200	http://dx.doi.org/10.1074/jbc.M100759200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11294865	hybrid			2022-12-25	WOS:000169966900091
J	Nulton-Persson, AC; Szweda, LI				Nulton-Persson, AC; Szweda, LI			Modulation of mitochondrial function by hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOGLUTARATE DEHYDROGENASE; TYROSINE-PHOSPHATASE 1B; FREE-RADICAL GENERATION; SIGNAL-TRANSDUCTION; HEART-MITOCHONDRIA; REVERSIBLE INACTIVATION; CARDIAC REPERFUSION; ALZHEIMERS-DISEASE; PROTEIN OXIDATION; REDOX REGULATION	During normal cellular metabolism, mitochondrial electron transport results in the formation of superox ide anion (O-2) and subsequently hydrogen peroxide (H2O2). Because H2O2 increases in concentration under certain physiologic and pathophysiologic conditions and can oxidatively modify cellular components, it is critical to understand the response of mitochondria to H2O2. In the present study, treatment of isolated rat heart mitochondria with H2O2 resulted in a decline and subsequent recovery of state 3 NADH-linked respiration. Alterations in NADH levels induced by H2O2 closely paralleled changes in the rate of state 3 respiration. Assessment of electron transport chain complexes and Krebs cycle enzymes revealed that alpha -ketoglutarate dehydrogenase (KGDH), succinate dehydrogenase (SDH), and aconitase were susceptible to H2O2 inactivation. Of particular importance, KGDH and SDH activity returned to control levels, concurrent with the recovery of state 3 respiration. Inactivation is not because of direct interaction of H2O2 with KGDH and SDH. In addition, removal of H2O2 alone is not sufficient for reactivation, Enzyme activity does not recover unless mitochondria remain intact. The sensitivity of KGDH and SDH to H2O2-mediated inactivation and the reversible nature of inactivation suggest a potential role for H2O2 in the regulation of KGDH and SDH.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Szweda, LI (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE ON AGING [R01AG016339] Funding Source: NIH RePORTER; NIA NIH HHS [AG-16339] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; BOLLI R, 1988, J CLIN INVEST, V82, P476, DOI 10.1172/JCI113621; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BOVERIS A, 1975, FEBS LETT, V54, P311, DOI 10.1016/0014-5793(75)80928-8; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CADENAS E, 1980, BIOCHEM J, V188, P31, DOI 10.1042/bj1880031; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; EMPTAGE MH, 1983, J BIOL CHEM, V258, P1106; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Janero DR, 1996, AM J PHYSIOL-CELL PH, V270, pC1735, DOI 10.1152/ajpcell.1996.270.6.C1735; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Kish SJ, 1997, ANN NY ACAD SCI, V826, P218, DOI 10.1111/j.1749-6632.1997.tb48473.x; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6; Lucas DT, 1998, P NATL ACAD SCI USA, V95, P510, DOI 10.1073/pnas.95.2.510; Lucas DT, 1999, P NATL ACAD SCI USA, V96, P6689, DOI 10.1073/pnas.96.12.6689; MASTROGIACOMO F, 1993, J NEUROCHEM, V61, P2007, DOI 10.1111/j.1471-4159.1993.tb07436.x; MIZUNO Y, 1995, BBA-MOL BASIS DIS, V1271, P265, DOI 10.1016/0925-4439(95)00038-6; NOHL H, 1978, EUR J BIOCHEM, V90, P385, DOI 10.1111/j.1432-1033.1978.tb12615.x; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; OTANI H, 1984, CIRC RES, V55, P168, DOI 10.1161/01.RES.55.2.168; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; ROKUTAN K, 1987, J BIOCHEM-TOKYO, V101, P415, DOI 10.1093/oxfordjournals.jbchem.a121926; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TONG JJ, 1994, J BIOL CHEM, V269, P24920; TRIMM JL, 1986, J BIOL CHEM, V261, P6092; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; UETA H, 1990, J MOL CELL CARDIOL, V22, P893, DOI 10.1016/0022-2828(90)90120-Q; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168	48	324	338	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23357	23361		10.1074/jbc.M100320200	http://dx.doi.org/10.1074/jbc.M100320200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11283020	hybrid			2022-12-25	WOS:000169531100020
J	Lardinois, OM; de Montellano, PRO				Lardinois, OM; de Montellano, PRO			H2O2-mediated cross-linking between lactoperoxidase and myoglobin - Elucidation of protein-protein radical transfer reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; HYDROGEN-PEROXIDE; COMPOUND-I; HEME; METMYOGLOBIN; REDUCTION; SITE; IDENTIFICATION; DITYROSINE; OXIDATION	The H2O2-dependent reaction of lactoperoxidase (LPO) with sperm whale myoglobin (SwMb) or horse myoglobin (HoMb) produces LPO-Mb cross linked species, in addition to LPO and SwMb homodimers. The HoMb products are a LPO(HoMb) dimer and LPO(HoMb), trimer. Dityrosine cross-links are shown by their fluorescence to be present in the oligomeric products. Addition of H2O2 to myoglobin (Mb), followed by catalase to quench excess H2O2 before the addition of LPO, still yields LPO cross-linked products. LPO oligomerization therefore requires radical transfer from Rib to LPO. In contrast to native LPO, recombinant LPO undergoes little self-dimerization in the absence of Mb but occurs normally in its presence. Simultaneous addition of 3,5-dibromo-4-nitrosobenzenesulfonic acid (DBNBS) and LPO to activated Mb produces a spin-trapped radical electron paramagnetic resonance signal located primarily on LPO, confirming the radical transfer. Mutation of Tyr-103 or Tyr-151 in SwMb decreased cross-linking with LPO, but mutation of Tyr-146, Trp-7, or Trp-14 did not. However, because DBNBS-trapped LPO radicals were observed with all the mutants, DBNBS traps LPO radicals other than those involved in protein oligomerization. The results clearly establish that radical transfer occurs from Mb to LPO and suggest that intermolecularly transferred radicals may reside on residues other than those that are generated by intramolecular reactions.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMADO R, 1984, METHOD ENZYMOL, V107, P377; ANDERSEN SO, 1966, ACTA PHYSL SCAND S, V66, P263; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P44; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CHILDS RE, 1975, BIOCHEM J, V145, P93, DOI 10.1042/bj1450093; COURTIN F, 1984, BIOCHEM BIOPH RES CO, V121, P463, DOI 10.1016/0006-291X(84)90205-5; Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3; DeGray JA, 1997, J BIOL CHEM, V272, P2359; DePillis GD, 1997, J BIOL CHEM, V272, P8857; DUNFORD HB, 1999, HEME PEROXIDASES, P20; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Fancy DA, 1998, BIOCHEM BIOPH RES CO, V247, P420, DOI 10.1006/bbrc.1998.8558; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; Irwin JA, 1999, ARCH BIOCHEM BIOPHYS, V362, P94, DOI 10.1006/abbi.1998.0987; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; KOOSER RG, 1969, J CHEM PHYS, V50, P5243, DOI 10.1063/1.1671041; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; OHLSSON PI, 1983, ACTA CHEM SCAND B, V37, P917, DOI 10.3891/acta.chem.scand.37b-0917; Ostdal H, 1997, FREE RADICAL BIO MED, V23, P754, DOI 10.1016/S0891-5849(97)00023-3; Ostdal H, 1999, ARCH BIOCHEM BIOPHYS, V362, P105, DOI 10.1006/abbi.1998.0988; RAO S, 1998, J BIOL CHEM, V268, P803; RICE RH, 1983, ARCH BIOCHEM BIOPHYS, V221, P417, DOI 10.1016/0003-9861(83)90160-1; SAHLIN M, 1987, BIOCHEMISTRY-US, V26, P5541, DOI 10.1021/bi00391a049; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; SPANGLER BD, 1986, BIOCHIM BIOPHYS ACTA, V872, P155; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; TEW D, 1988, J BIOL CHEM, V263, P17880; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; VOLKER V, 1992, P NATL ACAD SCI USA, V89, P996; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; WILKS A, 1992, J BIOL CHEM, V267, P8827; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; YONETANI T, 1967, J BIOL CHEM, V242, P1974	41	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					23186	23191		10.1074/jbc.M102084200	http://dx.doi.org/10.1074/jbc.M102084200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297563	hybrid			2022-12-25	WOS:000169412700160
J	Li, DL; Randhawa, VK; Patel, N; Hayashi, M; Klip, A				Li, DL; Randhawa, VK; Patel, N; Hayashi, M; Klip, A			Hyperosmolarity reduces GLUT4 endocytosis and increases its exocytosis from a VAMP2-independent pool in L6 muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; RESPONSIVE GLUCOSE-TRANSPORTER; PROTEIN-KINASE-B; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMA-MEMBRANE; OSMOTIC SHOCK; ADIPOSE-CELLS; SUBCELLULAR-DISTRIBUTION; POTASSIUM-DEPLETION	The intracellular traffic of the glucose transporter 4 (GLUT4) in muscle cells remains largely unexplored. Here we make use of L6 myoblasts stably expressing GLUT4 with an exofacially directed Myc-tag (GLUT4myc) to determine the exocytic and endocytic rates of the transporter. Insulin caused a rapid (t(1)/(2) = 4 min) gain, whereas hyperosmolarity (0.45 BI sucrose) caused a slow (t(1)/(2) = 20 min) gain in surface GLUT4myc molecules. With prior insulin stimulation followed by addition of hypertonic sucrose, the increase in surface GLUT4myc was partly additive. Unlike the effect of insulin, the GLUT4myc gain caused by hyperosmolarity was insensitive to wortmannin or to tetanus toxin cleavage of VAMP2 and VAMP3, Disappearance of GLUT4myc from the cell surface was rapid (t(1)/(2) = 1.5 min). Insulin had no effect on the initial rate of GLUT4myc internalization. In contrast, hyperosmolarity almost completely abolished GLUT4myc internalization. Surface GLUT4myc accumulation in response to hyperosmolarity was only partially blocked by inhibition of tyrosine kinases with erbstatin analog (erbstatin A) and genistein. However, neither inhibitor interfered with the ability of hyperosmolarity to block GLUT4myc internalization. We propose that hyperosmolarity increases surface GLUT4myc by preventing GLUT4 endocytosis and stimulating its exocytosis via a pathway independent of phosphatidylinositol 3-kinase activity and of VAMP2 or VAMP3. A tetanus toxin-insensitive v-SNARE such as TI-VAMP detected in these cells, might mediate mem brane fusion of the hyperosmolarity-sensitive pool.	Hosp Sick Children, Program Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Klip, A (corresponding author), Hosp Sick Children, Program Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	amira@sickkids.on.ca						Al-Hasani H, 1998, J BIOL CHEM, V273, P17504, DOI 10.1074/jbc.273.28.17504; Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CZECH MP, 1993, J BIOL CHEM, V268, P9187; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; Fletcher LM, 1999, BIOCHEM SOC T, V27, P677, DOI 10.1042/bst0270677; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Foster LJ, 2000, AM J PHYSIOL-CELL PH, V279, pC877, DOI 10.1152/ajpcell.2000.279.4.C877; Foster LJ, 1999, AM J PHYSIOL-CELL PH, V276, pC1108, DOI 10.1152/ajpcell.1999.276.5.C1108; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; Hresko RC, 2000, J BIOL CHEM, V275, P18114, DOI 10.1074/jbc.M001937200; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Janez A, 2000, J BIOL CHEM, V275, P26870; JHUN BH, 1992, J BIOL CHEM, V267, P17710; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; Khayat ZA, 2000, J CELL SCI, V113, P279; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lee W, 1999, J BIOL CHEM, V274, P37755, DOI 10.1074/jbc.274.53.37755; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; NISHIMURA H, 1993, J BIOL CHEM, V268, P19246; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RAMLAL T, 1988, BIOCHEM BIOPH RES CO, V157, P1329, DOI 10.1016/S0006-291X(88)81020-9; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Rao AW, 1998, J BIOL CHEM, V273, P25450, DOI 10.1074/jbc.273.39.25450; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rice JE, 1996, BIOCHEM SOC T, V24, P540, DOI 10.1042/bst0240540; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SATOH S, 1993, J BIOL CHEM, V268, P17820; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Tonello F, 1996, ADV EXP MED BIOL, V389, P251; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139; Volchuk A, 1998, J BIOL CHEM, V273, P8169, DOI 10.1074/jbc.273.14.8169; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; YANG J, 1993, J BIOL CHEM, V268, P4600	56	82	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22883	22891		10.1074/jbc.M010143200	http://dx.doi.org/10.1074/jbc.M010143200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297538	hybrid			2022-12-25	WOS:000169412700121
J	Schmitz, U; Thommes, K; Beier, I; Wagner, W; Sachinidis, A; Dusing, R; Vetter, H				Schmitz, U; Thommes, K; Beier, I; Wagner, W; Sachinidis, A; Dusing, R; Vetter, H			Angiotensin II-induced stimulation of p21-activated kinase and c-Jun NH2-terminal kinase is mediated by Rac1 and Nck	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; SIGNAL-REGULATED KINASE; ADAPTER PROTEIN; DIFFERENTIAL ACTIVATION; MEMBRANE LOCALIZATION; INDUCED HYPERTROPHY; CARDIAC MYOCYTES; TERMINAL KINASE	p21-activated kinase (PAK) has been shown to be an upstream mediator of JNK in angiotensin II (AngII) signaling. Little is known regarding other signaling molecules involved in activation of PAR and JNK by AngII. Rho family GTPases Pac and Cdc42 have been shown to enhance PAR activity by binding to pal-binding domain of PAR (PAK-PBD), In vascular smooth muscle cells (VSMC) AngII stimulated Rad binding to GST-PAK-PBD fusion protein. Pretreatment of VSMC by genistein inhibited AngII-induced Rad activation, whereas Src inhibitor PP1 had no effect. Inhibition of protein kinase C by phorbol 12,13-dibutyrate pretreatment also decreased AngII-mediated activation of Rac1. The adaptor molecule Nck has been shown previously to mediate PAR activation by facilitating translocation of PAR to the plasma membrane. In VSMC AngII stimulated translocation of Nck and PAK to the membrane fraction. Overexpression of dominant-negative Nck in Chinese hamster ovary (CHO) cells, stably expressing the AngII type I receptor (CHO-AT1), inhibited both PAK and JNK activation by AngII, whereas it did not affect ERK1/2. Finally, dominant-negative Nck inhibited AngII-induced DNA synthesis in CHO-AT1 cells. Our data provide evidence for Rad and Nck as upstream mediators of PAR and JNK in AngII signaling and implicate JNK in AngII-induced growth responses.	Med Univ Poliklin, D-53111 Bonn, Germany	University of Bonn	Schmitz, U (corresponding author), Med Univ Poliklin, Wilhelmstr 35-37, D-53111 Bonn, Germany.		Sachinidis, Agapios/AAD-4178-2020; Sachinidis, Agapios/AAM-7988-2020					BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dimmeler S, 1997, CIRC RES, V81, P970; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Haendeler J, 2000, CIRC RES, V86, P729, DOI 10.1161/01.RES.86.7.729; Heeneman S, 2000, J BIOL CHEM, V275, P15926, DOI 10.1074/jbc.M909616199; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Kim S, 1998, CIRCULATION, V97, P1731, DOI 10.1161/01.CIR.97.17.1731; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Murasawa S, 2000, J BIOL CHEM, V275, P26856; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Pyles JM, 1997, CIRC RES, V81, P904; Sachinidis A, 1999, ARTERIOSCL THROM VAS, V19, P2412, DOI 10.1161/01.ATV.19.10.2412; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; Schmitz U, 1997, TRENDS ENDOCRIN MET, V8, P261, DOI 10.1016/S1043-2760(97)00101-X; Schmitz U, 1998, CIRC RES, V82, P1272, DOI 10.1161/01.RES.82.12.1272; Schmitz U, 1997, CIRC RES, V81, P550, DOI 10.1161/01.RES.81.4.550; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Servant MJ, 1996, J BIOL CHEM, V271, P16047, DOI 10.1074/jbc.271.27.16047; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Viedt C, 2000, ARTERIOSCL THROM VAS, V20, P940, DOI 10.1161/01.ATV.20.4.940; Wen Y, 2000, BIOCHEM J, V349, P481, DOI 10.1042/0264-6021:3490481; Wilkie N, 1996, J BIOL CHEM, V271, P32447, DOI 10.1074/jbc.271.50.32447; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yano P, 1998, CIRC RES, V83, P752, DOI 10.1161/01.RES.83.7.752; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000	55	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22003	22010		10.1074/jbc.M102450200	http://dx.doi.org/10.1074/jbc.M102450200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11279250	hybrid			2022-12-25	WOS:000169412700004
J	Beutner, G; Sharma, VK; Giovannucci, DR; Yule, DI; Sheu, SS				Beutner, G; Sharma, VK; Giovannucci, DR; Yule, DI; Sheu, SS			Identification of a ryanodine receptor in rat heart mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CARDIAC SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE CHANNEL; CA2+ RELEASE; ADENINE-NUCLEOTIDE; SKELETAL; BINDING; MODULATION; DANTROLENE; PHOSPHORYLATION	Recent studies have shown that, in a wide variety of cells, mitochondria respond dynamically to physiological changes in cytosolic Ca2+ concentrations ([Ca2+](c)). Mitochondrial Ca2+ uptake occurs via a ruthenium red-sensitive calcium uniporter and a rapid mode of Ca2+ uptake. Surprisingly, the molecular identity of these Ca2+ transport proteins is still unknown. Using electron microscopy and Western blotting, we identified a ryanodine receptor in the inner mitochondrial membrane with a molecular mass of approximately 600 kDa in mitochondria isolated from the rat heart. [H-3]Ryanodine binds to this mitochondrial ryanodine receptor with high affinity. This binding is modulated by Ca2+ but not caffeine and is inhibited by Mg2+ and ruthenium red in the assay medium. In the presence of ryanodine, Ca2+ uptake into isolated heart mitochondria is suppressed, In addition, ryanodine inhibited mitochondrial swelling induced by Ca2+ overload. This swelling effect was not observed when Ca2+ was applied to the cytosolic fraction containing sarcoplasmic reticulum. These results are the first to identify a mitochondrial Ca2+ transport protein that has characteristics similar to the ryanodine receptor. This mitochondrial ryanodine receptor is likely to play an essential role in the dynamic uptake of Ca2+ into mitochondria during Ca2+ oscillations.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Sheu, SS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.	sheyshing_sheu@urmc.rochester.edu	Giovannucci, David R/A-5657-2018; Sheu, Shey-Shing/Y-4009-2019	Sheu, Shey-Shing/0000-0003-3838-3601	NHLBI NIH HHS [HL-33333] Funding Source: Medline; NIDDK NIH HHS [DK-54568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033333] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054568, R01DK054568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Beal MF, 1996, CURR OPIN NEUROBIOL, V6, P661, DOI 10.1016/S0959-4388(96)80100-0; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Chacon E, 1996, FEBS LETT, V382, P31, DOI 10.1016/0014-5793(96)00138-X; Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Fratea S, 1997, ANESTHESIOLOGY, V86, P205, DOI 10.1097/00000542-199701000-00025; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; Giovannucci DR, 2000, J BIOL CHEM, V275, P33704, DOI 10.1074/jbc.M004278200; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313, DOI 10.1152/ajpcell.1994.267.2.C313; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; HERRERA GA, 1989, ULTRASTRUCT PATHOL, V13, P485, DOI 10.3109/01913128909074532; HOLMBERG SRM, 1990, BIOCHIM BIOPHYS ACTA, V1022, P187, DOI 10.1016/0005-2736(90)90113-3; Huser J, 2000, J BIOENERG BIOMEMBR, V32, P27, DOI 10.1023/A:1005556227425; INUI M, 1987, J BIOL CHEM, V262, P15637; JENSEN KLD, 1992, ULTRASTRUCT PATHOL, V16, P51, DOI 10.3109/01913129209074550; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; LINDSAY ARG, 1991, BIOCHIM BIOPHYS ACTA, V1064, P89, DOI 10.1016/0005-2736(91)90415-5; Liu W, 1998, AM J PHYSIOL-CELL PH, V274, pC120, DOI 10.1152/ajpcell.1998.274.1.C120; MAK DOD, 1994, J BIOL CHEM, V269, P29375; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MCGREW SG, 1989, BIOCHEMISTRY-US, V28, P1686, DOI 10.1021/bi00430a039; Meissner A, 1999, EUR J HEART FAIL, V1, P177, DOI 10.1016/S1388-9842(99)00017-3; MEISSNER G, 1986, BIOCHEMISTRY-US, V25, P236, DOI 10.1021/bi00349a033; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; Munger SD, 2000, J BIOL CHEM, V275, P20450, DOI 10.1074/jbc.M001989200; Nassar A, 2000, J BIOL CHEM, V275, P23661, DOI 10.1074/jbc.M000457200; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; Ogata T, 1997, ANAT REC, V248, P214; OHLENDIECK K, 1986, BIOCHIM BIOPHYS ACTA, V860, P672, DOI 10.1016/0005-2736(86)90567-5; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; PESSAH IN, 1987, MOL PHARMACOL, V31, P232; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Sharma VK, 2000, J BIOENERG BIOMEMBR, V32, P97, DOI 10.1023/A:1005520714221; SHEU SS, 1994, J BIOENERG BIOMEMBR, V26, P487, DOI 10.1007/BF00762733; Simpson PB, 1996, J BIOL CHEM, V271, P33493, DOI 10.1074/jbc.271.52.33493; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 2000, J BIOL CHEM, V275, P15305, DOI 10.1074/jbc.275.20.15305; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Xu L, 1999, J BIOL CHEM, V274, P32680, DOI 10.1074/jbc.274.46.32680; Yamaki H, 1998, J DENT RES, V77, P1807, DOI 10.1177/00220345980770100801; ZIMANYI I, 1991, J PHARMACOL EXP THER, V256, P938	50	191	199	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21482	21488		10.1074/jbc.M101486200	http://dx.doi.org/10.1074/jbc.M101486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11297554	hybrid			2022-12-25	WOS:000169297900092
J	Legaigneur, P; Breton, C; El Battari, A; Guillemot, JC; Auge, C; Malissard, M; Berger, EG; Ronin, C				Legaigneur, P; Breton, C; El Battari, A; Guillemot, JC; Auge, C; Malissard, M; Berger, EG; Ronin, C			Exploring the acceptor substrate recognition of the human beta-galactoside alpha 2,6-sialyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GOLGI LOCALIZATION; HUMAN THYROTROPIN; POLYSIALIC ACID; GLYCOSYLTRANSFERASES; EXPRESSION; GLYCOPROTEIN; ALPHA-2,3-SIALYLTRANSFERASE; SIALYLTRANSFERASES; FAMILY	Human beta1,4-galactoside alpha2,6-sialyltransferase I (ST6GalI) recognition of glycoprotein accepters has been investigated using various soluble forms of the enzyme deleted to a variable extent in the N-terminal half of the polypeptide. Full-length and truncated forms of the enzyme have been investigated with respect to their specificity for a variety of desialylated glycoproteins of known complex glycans as well as related proteins with different carbohydrate chains. Differences in transfer efficiency have been observed between membrane and soluble enzymatic forms, indicating that deletion of the transmembrane fragment induces loss of acceptor preference. No difference in substrate recognition could be observed when soluble enzymes of similar peptide sequence were produced in yeast or mammalian cells, confirming that removal of the membrane anchor and heterologous expression do not alter enzyme folding and activity. When tested on free oligosaccharides, soluble ST6GalI displayed full ability to sialylate free N-glycans as well as various N-acetyllactosaminyl substrates. Progressive truncation of the N terminus demonstrated that the catalytic domain can proceed with sialic acid transfer with increased efficiency until 80 amino acids are deleted. Fusion of the ST6GalI catalytic domain to the N-terminal half of an unrelated transferase (core 2 beta1,6-N-acetylglucosaminyltransferase) further showed that a chimeric form of broad acceptor specificity and high activity could also be engineered in vivo, These findings therefore delineate a peptide region of similar to 50 amino acids within the ST6GalI stem region that governs both the preference for glycoprotein accepters and catalytic activity, thereby suggesting that it may exert a steric control on the catalytic domain.	CNRS, UPR 9024, F-13402 Marseille 20, France; CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 9, France; INSERM, U260, F-13335 Marseille 5, France; Univ Paris 11, UMR 8614, Inst Chim Mol & Organ, F-91405 Orsay, France; Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; University of Zurich	Ronin, C (corresponding author), CNRS, UPR 9024, 31 Chemin Joseph Aiguier, F-13402 Marseille 20, France.	ronin@irlnb.cnrs-mrs.fr						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Burger PC, 1998, GLYCOBIOLOGY, V8, P245, DOI 10.1093/glycob/8.3.245; CANONNE C, 1995, GLYCOBIOLOGY, V5, P473, DOI 10.1093/glycob/5.5.473; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; Datta AK, 1998, J BIOL CHEM, V273, P9608, DOI 10.1074/jbc.273.16.9608; Datta AK, 1997, INDIAN J BIOCHEM BIO, V34, P157; Dupuy F, 1999, J BIOL CHEM, V274, P12257, DOI 10.1074/jbc.274.18.12257; FENOUILLET E, 1986, J BIOL CHEM, V261, P5153; Gagneux P, 1999, GLYCOBIOLOGY, V9, P747, DOI 10.1093/glycob/9.8.747; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; GEREMIA RA, 1997, GLYCOBIOLOGY, V2, pR5; Grossmann M, 1997, ENDOCR REV, V18, P476, DOI 10.1210/er.18.4.476; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; Ikehara Y, 1999, FEBS LETT, V463, P92, DOI 10.1016/S0014-5793(99)01605-1; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; Kiss JZ, 1997, CURR OPIN NEUROBIOL, V7, P640, DOI 10.1016/S0959-4388(97)80083-9; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAZUMEKAWAGUC.S, 1999, GLYCOBIOLOGY, V9, P841; Kojima N, 1996, J BIOL CHEM, V271, P19457, DOI 10.1074/jbc.271.32.19457; KOJIMA N, 1994, BIOCHEMISTRY-US, V33, P5772, DOI 10.1021/bi00185a014; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; Ma JY, 1997, J BIOL CHEM, V272, P672; Malissard M, 2000, BIOCHEM BIOPH RES CO, V267, P169, DOI 10.1006/bbrc.1999.1946; MATTOX S, 1992, ANAL BIOCHEM, V206, P430, DOI 10.1016/0003-2697(92)90389-O; NEMANSKY M, 1995, EUR J BIOCHEM, V227, P880, DOI 10.1111/j.1432-1033.1995.tb20214.x; PAULSON JC, 1977, J BIOL CHEM, V252, P2363; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Ronin C, 1998, CLIN CHEM LAB MED, V36, P373, DOI 10.1515/CCLM.1998.063; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsuji S, 1996, J BIOCHEM-TOKYO, V120, P1; Tsuji S, 1996, GLYCOBIOLOGY, V6, pR5; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; VanDorst JALM, 1996, EUR J BIOCHEM, V242, P674; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Warner TG, 1999, GLYCOBIOLOGY, V9, P841, DOI 10.1093/glycob/9.9.841; WLASICHUK KB, 1993, J BIOL CHEM, V268, P13971; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; Yeh JC, 1997, GLYCOBIOLOGY, V7, P241, DOI 10.1093/glycob/7.2.241; Zerfaoui M, 2000, EUR J BIOCHEM, V267, P53, DOI 10.1046/j.1432-1327.2000.00958.x; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831	50	46	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21608	21617		10.1074/jbc.M100860200	http://dx.doi.org/10.1074/jbc.M100860200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279145	hybrid			2022-12-25	WOS:000169297900108
J	Shih, SF; Wu, YH; Hung, CH; Yang, HY; Lin, JY				Shih, SF; Wu, YH; Hung, CH; Yang, HY; Lin, JY			Abrin triggers cell death by inactivating a thiol-specific antioxidant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PEROXIDE REDUCTASE; INDUCED APOPTOSIS; PHASE-I; CONTINUOUS-INFUSION; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE; A-CHAIN; RICIN; IMMUNOTOXIN; ACTIVATION	Abrin A-chain (ABRA) inhibits protein synthesis by its N-glycosidase activity as well as induces apoptosis, but the molecular mechanism of ABRA-induced cell death has been obscure. Using an ABRA mutant that lacks N-glycosidase activity as bait in a yeast two-hybrid system, a 30-kDa antioxidant protein-1 (AOP-1) was found to be an ABRA(E164Q)-interacting protein. The interaction was further confirmed in vitro by a glutathione S-transferase pull-down assay. The colocalization of endogenous AOP-1 and exogenous ABR proteins in the cell was demonstrated by confocal immunofluorescence, We also demonstrated that ABRA attenuates AOP-1 antioxidant activity in a dose-dependent manner and the intracellular level of reactive oxygen species (ROS) increases in ABR-treated cells. Moreover, ROS scavengers N-acetylcysteine and 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl delayed programmed cell death. This indicates that ROS are important mediators of ABR-induced apoptosis, When ectopically expressed, AOP-1 blocked the release of cytochrome c and prevented apoptosis in ABR-treated cells. These findings suggest that the binding of ABRA to AOP-1 promotes apoptosis by inhibiting the mitochondrial antioxidant protein AOP-1, resulting in the increase of intracellular ROS and the release of cytochrome c from the mitochondria to the cytosol, which activates caspase-9 and caspase-3.	Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10081, Taiwan	National Taiwan University	Lin, JY (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10081, Taiwan.	jylin@ha.mc.ntu.edu.tw	Lin, Jung-Yaw/AGW-9336-2022	Lin, Jung-Yaw/0000-0002-6341-1160				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMLOT PL, 1993, BLOOD, V82, P2624; Araki M, 1999, J BIOL CHEM, V274, P2271, DOI 10.1074/jbc.274.4.2271; BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; Baluna R, 1999, P NATL ACAD SCI USA, V96, P3957, DOI 10.1073/pnas.96.7.3957; Baluna R, 2000, EXP CELL RES, V258, P417, DOI 10.1006/excr.2000.4954; BASS DA, 1983, J IMMUNOL, V130, P1910; Bohler T, 2000, CYTOKINE, V12, P986, DOI 10.1006/cyto.1999.0633; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chen JK, 1997, PROTEIN ENG, V10, P827, DOI 10.1093/protein/10.7.827; Constantini P., 1996, J BIOL CHEM, V271, P6746; COSSARIZZA A, 1995, EXP CELL RES, V220, P232, DOI 10.1006/excr.1995.1311; Geier A, 1996, CANCER INVEST, V14, P435, DOI 10.3109/07357909609018901; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROSSBARD ML, 1993, J CLIN ONCOL, V11, P726, DOI 10.1200/JCO.1993.11.4.726; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; Hughes JN, 1996, HUM EXP TOXICOL, V15, P443, DOI 10.1177/096032719601500513; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Karbowski M, 1999, BBA-MOL CELL RES, V1449, P25, DOI 10.1016/S0167-4889(98)00167-0; Keppler-Hafkemeyer A, 1998, BIOCHEMISTRY-US, V37, P16934, DOI 10.1021/bi980995m; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Komatsu N, 1998, J BIOCHEM-TOKYO, V124, P1038, DOI 10.1093/oxfordjournals.jbchem.a022197; Li PF, 1999, FEBS LETT, V448, P206, DOI 10.1016/S0014-5793(99)00370-1; LIN JY, 1970, NATURE, V227, P292, DOI 10.1038/227292a0; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Miller JH., 1972, EXPT MOL GENETICS; Nett JH, 1998, J BIOL CHEM, V273, P8652, DOI 10.1074/jbc.273.15.8652; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; SAUSVILLE EA, 1995, BLOOD, V85, P3457, DOI 10.1182/blood.V85.12.3457.bloodjournal85123457; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stone MJ, 1996, BLOOD, V88, P1188, DOI 10.1182/blood.V88.4.1188.bloodjournal8841188; Tanudji M, 1999, J BIOL CHEM, V274, P1286, DOI 10.1074/jbc.274.3.1286; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TSUJI K, 1995, BIOCHEM J, V307, P377, DOI 10.1042/bj3070377; VITETTA ES, 1993, IMMUNOL TODAY, V14, P252, DOI 10.1016/0167-5699(93)90041-I; VITETTA ES, 1991, CANCER RES, V51, P4052; Watabe S, 1997, EUR J BIOCHEM, V249, P52, DOI 10.1111/j.1432-1033.1997.t01-1-00052.x; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhuang LH, 1999, J IMMUNOL, V162, P1440; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	77	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21870	21877		10.1074/jbc.M100571200	http://dx.doi.org/10.1074/jbc.M100571200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11285261	hybrid			2022-12-25	WOS:000169297900139
J	Cabral, A; Voskamp, P; Cleton-Jansen, AM; South, A; Nizetic, D; Backendorf, C				Cabral, A; Voskamp, P; Cleton-Jansen, AM; South, A; Nizetic, D; Backendorf, C			Structural organization and regulation of the small proline-rich family of cornified envelope precursors suggest a role in adaptive barrier function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL DIFFERENTIATION COMPLEX; TRANSGLUTAMINASE SUBSTRATE PROPERTIES; CELL-ENVELOPE; EXPRESSION; PROTEINS; GENES; KERATINOCYTE; INVOLUCRIN; EVOLUTION; MARKERS	The protective barrier provided by stratified squamous epithelia relies on the cornified cell envelope (CE), a structure synthesized at late stages of keratinocyte differentiation. It is composed of structural proteins, including involucrin, loricrin, and the small proline-rich (SPRR) proteins, all encoded by genes localized at human chromosome 1q21, The genetic characterization of the SPRR locus reveals that the various members of this multigene family can be classified into two distinct groups with separate evolutionary histories. Whereas group 1 genes have diverged in protein structure and are composed of three different classes (SPRR1 (2x), SPRR3, and SPRR4), an active process of gene conversion has counteracted diversification of the protein sequences of group 2 genes (SPRR2 class, seven genes). Contrasting with this homogenization process, all individual members of the SPRR gene family show specific in vivo and in vitro expression patterns and react selectively to UV irradiation. Apparently, creation of regulatory rather than structural diversity has been the driving force behind the evolution of the SPRR gene family. Differential regulation of highly homologous genes underlines the importance of SPRR protein dosage in providing optimal barrier function to different epithelia, while allowing adaptation to diverse external insults.	Leiden Inst Chem, Dept Mol Genet, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; Univ London, Sch Pharm, Ctr Appl Mol Biol, London WC1N 1AX, England	Leiden University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of London; University College London; University of London School of Pharmacy	Backendorf, C (corresponding author), Gorlaeus Labs, Mol Genet Lab, POB 9502, NL-2300 RA Leiden, Netherlands.	Backendo@chem.leidenuniv.ni	Cabral, Adriana/AAX-3284-2021; Nizetic, Dean/F-9509-2015	Nizetic, Dean/0000-0001-5486-5761				Abraham JM, 1996, CELL GROWTH DIFFER, V7, P855; AN G, 1993, J BIOL CHEM, V268, P10977; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; BELT PBGM, 1989, GENE, V84, P407, DOI 10.1016/0378-1119(89)90515-5; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; Candi E, 1999, J BIOL CHEM, V274, P7226, DOI 10.1074/jbc.274.11.7226; Candi E, 1999, BIOCHEM BIOPH RES CO, V262, P395, DOI 10.1006/bbrc.1999.1215; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; FUJIMOTO W, 1993, J INVEST DERMATOL, V101, P268, DOI 10.1111/1523-1747.ep12365200; GARMYN M, 1992, J INVEST DERMATOL, V99, P743, DOI 10.1111/1523-1747.ep12614470; GIBBS S, 1990, NUCLEIC ACIDS RES, V18, P4401, DOI 10.1093/nar/18.15.4401; GIBBS S, 1993, GENOMICS, V16, P630, DOI 10.1006/geno.1993.1240; Gosden R, 1997, BRIT MED BULL, V53, P644; HOHL D, 1990, DERMATOLOGICA, V180, P201, DOI 10.1159/000248031; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; ISHIDAYAMAMOTO A, 1995, ARCH DERMATOL RES, V287, P705, DOI 10.1007/BF01105793; IVENS AC, 1995, DNA CLONING, V3, P1; Jarnik M, 1996, J CELL SCI, V109, P1381; Jetten AM, 1996, MOL CELL ENDOCRINOL, V123, P7, DOI 10.1016/0303-7207(96)03871-3; Kartasova T, 1996, J INVEST DERMATOL, V106, P294, DOI 10.1111/1523-1747.ep12340741; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2195, DOI 10.1128/MCB.8.5.2195; KARTASOVA T, 1988, MOL CELL BIOL, V8, P2204, DOI 10.1128/MCB.8.5.2204; KARTASOVA T, 1995, J INVEST DERMATOL, V104, P611; Lee CH, 2000, FEBS LETT, V477, P268, DOI 10.1016/S0014-5793(00)01806-8; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Li W. H, 1997, MOL EVOLUTION; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; Marshall D, 2000, J INVEST DERMATOL, V114, P967, DOI 10.1046/j.1523-1747.2000.00955.x; MARTINET N, 1988, J BIOL CHEM, V263, P4236; MATOLTSY AG, 1966, J INVEST DERMATOL, V46, P127, DOI 10.1038/jid.1966.19; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Nemes Z, 1999, P NATL ACAD SCI USA, V96, P8402, DOI 10.1073/pnas.96.15.8402; NIZETIC D, 1994, MAMM GENOME, V5, P801, DOI 10.1007/BF00292017; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; Salamonsen LA, 1999, BEST PRACT RES CL OB, V13, P161, DOI 10.1053/beog.1999.0015; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; SAUNDERS NA, 1993, BIOCHEM BIOPH RES CO, V197, P46, DOI 10.1006/bbrc.1993.2439; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Steinert PM, 1998, J STRUCT BIOL, V122, P76, DOI 10.1006/jsbi.1998.3957; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1997, J BIOL CHEM, V272, P2021, DOI 10.1074/jbc.272.3.2021; Tarcsa E, 1998, J BIOL CHEM, V273, P23297, DOI 10.1074/jbc.273.36.23297; Tesfaigzi J, 1996, EXP CELL RES, V228, P277, DOI 10.1006/excr.1996.0327; VOLZ A, 1993, GENOMICS, V18, P92, DOI 10.1006/geno.1993.1430; Xu XC, 1999, CLIN CANCER RES, V5, P1503; YAAR M, 1995, EXP CELL RES, V217, P217, DOI 10.1006/excr.1995.1081	54	132	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19231	19237		10.1074/jbc.M100336200	http://dx.doi.org/10.1074/jbc.M100336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279051	hybrid			2022-12-25	WOS:000169091000080
J	Tagliarino, C; Pink, JJ; Dubyak, GR; Nieminen, AL; Boothman, DA				Tagliarino, C; Pink, JJ; Dubyak, GR; Nieminen, AL; Boothman, DA			Calcium is a key signaling molecule in beta-lapachone-mediated cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; MITOCHONDRIAL PERMEABILITY TRANSITION; CYTOSOLIC CA-2+ CONCENTRATION; BCL-X-L; DT-DIAPHORASE; INDUCED APOPTOSIS; OXIDATIVE STRESS; LYMPHOMA-CELLS; CYTO-TOXICITY; CYTOCHROME-C	beta -Lapachone (beta -Lap) triggers apoptosis in a number of human breast and prostate cancer cell lines through a unique apoptotic pathway that is dependent upon NQO1, a two-electron reductase. Downstream signaling pathway(s) that initiate apoptosis following treatment with beta -Lap have not been elucidated, Since calpain activation was suspected in beta -Lap-mediated apoptosis, we examined alterations in Ca2+ homeostasis using NQO1-expressing MCF-7 cells. beta -Lap-exposed MCF-7 cells exhibited an early increase in intracellular cytosolic Ca2+, from endoplasmic reticulum Ca2+ stores, comparable to thapsigargin exposures. 1,2-Bis-(2-aminophenoxy) ethane-N,N,N ' ,N ' -tetraacetic acid-acetoxymethyl ester, an intracellular Ca2+ chelator, blocked early increases in Ca2+ levels and inhibited beta -Lap-mediated mitochondrial membrane depolarization, intracellular ATP depletion, specific and unique substrate proteolysis, and apoptosis, The extracellular Ca2+ chelator, EGTA, inhibited later apoptotic end points (observed >8 h, e.g. substrate proteolysis and DNA fragmentation), suggesting that later execution events were triggered by Ca2+ influxes from the extracellular milieu. Collectively, these data suggest a critical, but not sole, role for Ca2+ in the NQO1-dependent cell death pathway initiated by beta -Lap. Use of beta -Lap to trigger an apparently novel, calpain like-mediated apoptotic cell death could be useful for breast and prostate cancer therapy.	Case Western Reserve Univ, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Anat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, 10900 Euclid Ave,BRB-326 E, Cleveland, OH 44106 USA.		Boothman, David/Q-7776-2019	Dubyak, George/0000-0001-9720-4226	NATIONAL CANCER INSTITUTE [R01CA102792, R01CA092250] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102792, R01 CA092250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERMAN KEO, 1978, BIOCHIM BIOPHYS ACTA, V502, P359, DOI 10.1016/0005-2728(78)90056-7; AKMAN SA, 1987, J PHARMACOL EXP THER, V240, P486; Beigi RD, 2000, J IMMUNOL, V165, P7189, DOI 10.4049/jimmunol.165.12.7189; BELLOMO G, 1982, J BIOL CHEM, V257, P1558; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P343, DOI 10.1016/0003-9861(84)90207-8; Distelhorst CW, 1996, CELL CALCIUM, V19, P473, DOI 10.1016/S0143-4160(96)90056-1; Distelhorst CW, 1998, BLOOD, V91, P731, DOI 10.1182/blood.V91.3.731.731_731_734; Eguchi Y, 1999, CANCER RES, V59, P2174; Fang M, 1998, CANCER LETT, V127, P113, DOI 10.1016/S0304-3835(98)00023-8; FREI B, 1986, BIOCHEMISTRY-US, V25, P4438, DOI 10.1021/bi00363a040; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V227, P658, DOI 10.1006/bbrc.1996.1565; GAIDO ML, 1991, J BIOL CHEM, V266, P18580; GERSCHENSON LE, 1992, FASEB J, V6, P2450, DOI 10.1096/fasebj.6.7.1563596; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HOLLANDER PM, 1975, ARCH BIOCHEM BIOPHYS, V169, P560, DOI 10.1016/0003-9861(75)90200-3; HOSODA S, 1974, J BIOL CHEM, V249, P6416; Inai Y, 1997, CELL STRUCT FUNCT, V22, P555, DOI 10.1247/csf.22.555; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; Jackisch C, 2000, CLIN CANCER RES, V6, P2844; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; Kim JE, 1999, J NEUROCHEM, V72, P2456, DOI 10.1046/j.1471-4159.1999.0722456.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kurokawa H, 1999, ONCOL REP, V6, P33; LEVICK V, 1995, BRAIN RES, V676, P325, DOI 10.1016/0006-8993(95)00115-7; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; LI CJ, 1995, CANCER RES, V55, P3712; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YZ, 1999, MOL MED, V5, P232, DOI 10.1007/BF03402120; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; Manna SK, 1999, BIOCHEM PHARMACOL, V57, P763, DOI 10.1016/S0006-2952(98)00354-2; Marin A, 1997, BRIT J CANCER, V76, P923, DOI 10.1038/bjc.1997.485; Marks AR, 1997, AM J PHYSIOL-HEART C, V272, pH597, DOI 10.1152/ajpheart.1997.272.2.H597; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; McColl KS, 1998, MOL CELL ENDOCRINOL, V139, P229, DOI 10.1016/S0303-7207(98)00051-3; McConkey David J., 1996, Scanning Microscopy, V10, P777; MCCONKEY DJ, 1989, J IMMUNOL, V143, P1801; McConkey DJ, 1997, BIOCHEM BIOPH RES CO, V239, P357, DOI 10.1006/bbrc.1997.7409; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MEHENDALE HM, 1985, EUR J BIOCHEM, V149, P201, DOI 10.1111/j.1432-1033.1985.tb08912.x; MIRABELLI F, 1988, ARCH BIOCHEM BIOPHYS, V264, P261, DOI 10.1016/0003-9861(88)90593-0; NICOTERA P, 1988, TOXICOLOGY, V52, P55, DOI 10.1016/0300-483X(88)90196-5; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Petersen A, 2000, BRAIN RES, V857, P20, DOI 10.1016/S0006-8993(99)02320-3; Pink JJ, 2000, J BIOL CHEM, V275, P5416, DOI 10.1074/jbc.275.8.5416; Pink JJ, 2000, EXP CELL RES, V255, P144, DOI 10.1006/excr.1999.4790; PLANCHON SM, 1995, CANCER RES, V55, P3706; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; REDEGELD FAM, 1989, ARCH BIOCHEM BIOPHYS, V273, P215, DOI 10.1016/0003-9861(89)90181-1; REDEGELD FAM, 1990, ARCH BIOCHEM BIOPHYS, V280, P130, DOI 10.1016/0003-9861(90)90527-6; RICHTER C, 1993, FEBS LETT, V325, P104, DOI 10.1016/0014-5793(93)81423-W; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; SAXENA K, 1995, ARCH BIOCHEM BIOPHYS, V317, P79, DOI 10.1006/abbi.1995.1138; SMITH PF, 1987, TOXICOL APPL PHARM, V89, P190, DOI 10.1016/0041-008X(87)90040-8; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Urbano A, 1998, J BIOL CHEM, V273, P34820, DOI 10.1074/jbc.273.52.34820; Waring P, 1996, EXP CELL RES, V227, P264, DOI 10.1006/excr.1996.0276; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Wuerzberger SM, 1998, CANCER RES, V58, P1876; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yao Y, 1997, J GEN PHYSIOL, V109, P703, DOI 10.1085/jgp.109.6.703	70	131	140	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19150	19159		10.1074/jbc.M100730200	http://dx.doi.org/10.1074/jbc.M100730200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279125	hybrid			2022-12-25	WOS:000169091000070
J	Roszmusz, E; Patthy, A; Trexler, M; Patthy, L				Roszmusz, E; Patthy, A; Trexler, M; Patthy, L			Localization of disulfide bonds in the frizzled module of Ror1 receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE ROBINOW-SYNDROME; BRACHYDACTYLY TYPE-B; STRUCTURAL FEATURES; NEURAL NETWORKS; NERVOUS-SYSTEM; CRD DOMAIN; PROTEIN; MUSK; FAMILY; MUTATIONS	The frizzled (FRZ) module is a novel module type that was first identified in G-protein-coupled receptors of the frizzled and smoothened families and has since been shown to be present in several secreted frizzled-related proteins, in some modular proteases, in collagen XVIII, and in various receptor tyrosine kinases of the Bor family, The FRZ modules constitute the extracellular ligand-binding region of frizzled receptors and are known to mediate signals of WNT family members through these receptors, With an eye toward defining the structure of this important module family, we have expressed the FRZ domain of rat Ror1 receptor tyrosine kinase in Pichia pastoris, By proteolytic digestion and amino acid sequencing the disulfide bonds were found to connect the 10 conserved cysteines in a 1-5, 2-4, 3-8, 6-10, and 7-9 pattern. Circular dichroism and differential scanning calorimetry studies on the recombinant protein indicate that the disulfide-bonded FRZ module corresponds to a single, compact, and remarkably stable folding domain possessing both alpha -helices and beta -strands.	Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, H-1518 Budapest, Hungary; Agr Biotechnol Ctr, H-2100 Godollo, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Patthy, L (corresponding author), Hungarian Acad Sci, Inst Enzymol, Biol Res Ctr, POB 7, H-1518 Budapest, Hungary.		Patthy, Laszlo/A-2353-2013; Patthy, Laszlo/Q-6058-2019					Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Forrester WC, 1999, NATURE, V400, P881, DOI 10.1038/23722; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GRINNA LS, 1989, YEAST, V5, P107, DOI 10.1002/yea.320050206; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 1997, J BIOL CHEM, V272, P11916, DOI 10.1074/jbc.272.18.11916; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Rehn M, 1998, TRENDS BIOCHEM SCI, V23, P415, DOI 10.1016/S0968-0004(98)01290-0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROST B, 1995, 3 INT C INT SYST MOL, P314; Saldanha J, 1998, PROTEIN SCI, V7, P1632, DOI 10.1002/pro.5560070718; Steinlein LM, 1998, BIOCHEMISTRY-US, V37, P13696, DOI 10.1021/bi980318s; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P7299, DOI 10.1021/bi9517704; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	30	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18485	18490		10.1074/jbc.M100100200	http://dx.doi.org/10.1074/jbc.M100100200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279007	hybrid			2022-12-25	WOS:000168866500116
J	Rangaraj, P; Ruttimann-Johnson, C; Shah, VK; Ludden, PW				Rangaraj, P; Ruttimann-Johnson, C; Shah, VK; Ludden, PW			Accumulation of Fe-55-labeled precursors of the iron-molybdenum cofactor of nitrogenase on NifH and NifX of Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO BIOSYNTHESIS; ENCODED APODINITROGENASE; NUCLEOTIDE-SEQUENCE; PROTEIN; DINITROGENASE; PURIFICATION; GENE; MATURATION; CLUSTER; EXPRESSION	Iron-molybdenum cofactor (FeMo-co) biosynthesis involves the participation of several proteins. We have used Fe-55-labeled NifB-co, the specific iron and sulfur donor to FeMo-co, to investigate the accumulation of protein-bound precursors of FeMo-co. The Fe-55 label from radiolabeled NifB-co became associated with two major protein bands when the in vitro FeMo-co synthesis reaction was carried out with the extract of an Azotobacter vinelandii mutant lacking apodinitrogenase. One of the bands, termed Fe-55-labeled upper band, was purified and shown to be NifH by immunoblot analysis. The Fe-55-labeled lower band was identified as NifX by N-terminal sequencing, NifX purified from an A. vinelandii nifB strain showed a different electrophoretic mobility on anoxic native gels than did NifX with the FeMo-co precursor bound.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Ctr Study Nitrogen Fixat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Ave, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RM, 1999, J BIOL CHEM, V274, P15869, DOI 10.1074/jbc.274.22.15869; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; BURRIS RH, 1993, ANNU REV NUTR, V13, P317, DOI 10.1146/annurev.nu.13.070193.001533; Chatterjee R, 1996, J BIOL CHEM, V271, P6819, DOI 10.1074/jbc.271.12.6819; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HAUSINGER RP, 1983, J BIOL CHEM, V258, P3486; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1989, BIOCHEMISTRY-US, V28, P2768, DOI 10.1021/bi00433a004; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; JOERGER RD, 1991, J BACTERIOL, V173, P4440, DOI 10.1128/JB.173.14.4440-4446.1991; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KUO CF, 1988, ANAL BIOCHEM, V170, P183, DOI 10.1016/0003-2697(88)90106-6; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rangaraj P, 1999, J BIOL CHEM, V274, P29413, DOI 10.1074/jbc.274.41.29413; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Ruttimann-Johnson C, 1999, J BIOL CHEM, V274, P18087, DOI 10.1074/jbc.274.25.18087; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; STRANDBERG GW, 1968, CAN J MICROBIOL, V14, P14; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WAUGH SI, 1995, J BACTERIOL, V177, P1505, DOI 10.1128/jb.177.6.1505-1510.1995; WOLFINGER ED, 1991, J BACTERIOL, V173, P7565, DOI 10.1128/jb.173.23.7565-7572.1991; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643	40	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15968	15974		10.1074/jbc.M100907200	http://dx.doi.org/10.1074/jbc.M100907200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279153	hybrid			2022-12-25	WOS:000168623100055
J	Jung, H; Kim, T; Chae, HZ; Kim, KT; Ha, H				Jung, H; Kim, T; Chae, HZ; Kim, KT; Ha, H			Regulation of macrophage migration inhibitory factor and thiol-specific antioxidant protein PAG by direct interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROLINE; FACTOR MIF; CRYSTAL-STRUCTURE; PHENYLPYRUVATE TAUTOMERASE; GLUTATHIONE; ACTIVATION; REDUCTASE; MECHANISM; CLONING; CELLS	Macrophage migration inhibitory factor (MIF) is an important mediator that plays a central role in the control of the host immune and inflammatory response. To investigate the molecular mechanism of MIF action, we have used the yeast two-hybrid system and identified PAG, a thiol-specific antioxidant protein, as an interacting partner of MIF. Association of MIF with PAG was found in 293T cells transiently expressing MIF and PAG. The use of PAG mutants (C52S, C71S, and C173S) revealed that this association was significantly affected by C173S, but not C52S and C71S, indicating that a disulfide involving Cys(173) Of PAG is responsible for the formation of MIF.PAG complex. In addition, the interaction was highly dependent on the reducing conditions such as dithiothreitol or beta -mercaptoethanol but not in the presence of H2O2. Analysis of the activities of the interacting proteins showed that the D-dopachrome tautomerase activity of MIF was decreased in a dose-dependent manner by coexpression of wild-type PAG, C52S, and C71S, whereas C173S was almost ineffective, suggesting that the direct interaction may be involved in the control of D-dopachrome tautomerase activity of MIF. Moreover, MIF has been shown to bind to PAG and it also inhibits the antioxidant activity of PAG.	Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Cheongju 361763, South Korea; Chonnam Natl Univ, Coll Sci, Dept Biol, Kwangju 500757, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Chungbuk National University; Chonnam National University; Pohang University of Science & Technology (POSTECH)	Ha, H (corresponding author), Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Cheongju 361763, South Korea.			KIM, KYONG-TAI/0000-0001-7292-2627				BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bernhagen J, 1998, J MOL MED-JMM, V76, P151, DOI 10.1007/s001090050204; Bucala Richard, 1996, Cytokine and Growth Factor Reviews, V7, P19, DOI 10.1016/1359-6101(96)00008-1; Calandra T, 1997, CRIT REV IMMUNOL, V17, P77, DOI 10.1615/CritRevImmunol.v17.i1.30; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CALANDRA T, 1994, J EXP MED, V179, P1985; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAE HZ, 1994, BIOFACTORS, V4, P177; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; Kato Y, 1996, P NATL ACAD SCI USA, V93, P3007, DOI 10.1073/pnas.93.7.3007; KIM KW, 1988, J BIOL CHEM, V263, P4704; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; Kleemann R, 1998, FEBS LETT, V430, P191, DOI 10.1016/S0014-5793(98)00654-1; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; LIU YC, 1994, P NATL ACAD SCI USA, V91, P11227, DOI 10.1073/pnas.91.23.11227; Lubetsky JB, 1999, BIOCHEMISTRY-US, V38, P7346, DOI 10.1021/bi990306m; Metz CN, 1997, ADV IMMUNOL, V66, P197, DOI 10.1016/S0065-2776(08)60598-2; Mischke R, 1997, FEBS LETT, V414, P226, DOI 10.1016/S0014-5793(97)01039-9; Pennock JL, 1998, BIOCHEM J, V331, P905, DOI 10.1042/bj3310905; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; PUIG A, 1994, J BIOL CHEM, V269, P19128; Rosengren E, 1996, MOL MED, V2, P143, DOI 10.1007/BF03402210; Rosengren E, 1997, FEBS LETT, V417, P85, DOI 10.1016/S0014-5793(97)01261-1; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Stamps SL, 1998, BIOCHEMISTRY-US, V37, P10195, DOI 10.1021/bi9806955; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P803, DOI 10.1021/bi951077g; Subramanya HS, 1996, BIOCHEMISTRY-US, V35, P792, DOI 10.1021/bi951732k; Sun HW, 1996, P NATL ACAD SCI USA, V93, P5191, DOI 10.1073/pnas.93.11.5191; Suzuki M, 1996, NAT STRUCT BIOL, V3, P259, DOI 10.1038/nsb0396-259; Swope M, 1998, EMBO J, V17, P3534, DOI 10.1093/emboj/17.13.3534; Swope MD, 1998, J BIOL CHEM, V273, P14877, DOI 10.1074/jbc.273.24.14877; WISTOW GJ, 1993, P NATL ACAD SCI USA, V90, P1272, DOI 10.1073/pnas.90.4.1272; ZHANG M, 1995, FEBS LETT, V373, P203, DOI 10.1016/0014-5793(95)01041-C	38	89	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15504	15510		10.1074/jbc.M009620200	http://dx.doi.org/10.1074/jbc.M009620200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11297517	hybrid			2022-12-25	WOS:000168528800129
J	Thoden, JB; Wohlers, TM; Fridovich-Keil, JL; Holden, HM				Thoden, JB; Wohlers, TM; Fridovich-Keil, JL; Holden, HM			Human UDP-galactose 4-epimerase - Accommodation of UDP-N-acetylglucosamine within the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIMERASE-DEFICIENCY GALACTOSEMIA; ESCHERICHIA-COLI; HUMAN UDP-GALACTOSE-4-EPIMERASE; MACROMOLECULAR STRUCTURES; EXPRESSION; GLUCOSE; MECHANISM; PROGRAM; BINDING	UDP-galactose 4-epimerase catalyzes the interconversion of UDP-galactose and UDP-glucose during normal galactose metabolism. One of the key structural features in the proposed reaction mechanism for the enzyme is the rotation of a 4'-ketopyranose intermediate within the active site pocket. Recently, the three-dimensional structure of the human enzyme with bound NADH and UDP-glucose was determined, Unlike that observed for the protein isolated from Escherichia coli, the human enzyme can also turn over UDP-GlcNAc to UDP-GalNAc and vice versa, Here we describe the three-dimensional structure of human epimerase complexed with NADH and UDP-GlcNAc. To accommodate the additional N-acetyl group at the C2 position of the sugar, the side chain of Asn-207 rotates toward the interior of the protein and interacts with Glu-199, Strikingly, in the human enzyme, the structural equivalent of Tyr-299 in the E, coli protein is replaced with a cysteine residue (Cys-307) and the active site volume for the human protein is calculated to be similar to 15% larger than that observed for the bacterial epimerase, This combination of a larger active site cavity and amino acid residue replacement most likely accounts for the inability of the E, coli enzyme to interconvert UDP-GlcNAc and UDP-GalNAc.	Univ Wisconsin, Dept Biochem, Madison, WI 53705 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA	University of Wisconsin System; University of Wisconsin Madison; Emory University; Emory University	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, 420 Henry Mall, Madison, WI 53705 USA.	hazel_holden@biochem.wisc.edu			NIDDK NIH HHS [DK47814, DK46403] Funding Source: Medline; NIGMS NIH HHS [T32 GM008490, GM08490] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814, R29DK046403, R01DK046403] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alano A., 1997, Journal of Investigative Medicine, V45, p191A; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Duax WL, 1996, CURR OPIN STRUC BIOL, V6, P813, DOI 10.1016/S0959-440X(96)80012-1; ESNOUF R, 1996, ACTA CRYSTALLOGR A, V55, P938; GITZELMANN R, 1977, HELV PAEDIATR ACTA, V31, P441; Holton J. B., 2000, METABOLIC MOL BASES, P1553; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1993, ESF CCP4 NEWSLETTER, V29, P26; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILLER F, 1983, J BIOL CHEM, V258, P774; Quimby BB, 1997, AM J HUM GENET, V61, P590, DOI 10.1086/515517; ROUSSEL A, 1991, SILICON GRPHICS GEOM; Shin YS, 2000, J INHERIT METAB DIS, V23, P383, DOI 10.1023/A:1005699719068; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P10685, DOI 10.1021/bi9704313; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Walter JH, 1999, ARCH DIS CHILD, V80, P374, DOI 10.1136/adc.80.4.374; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263	28	106	110	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15131	15136		10.1074/jbc.M100220200	http://dx.doi.org/10.1074/jbc.M100220200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279032	hybrid			2022-12-25	WOS:000168528800081
J	Cheng, CM; Cohen, M; Wang, J; Bondy, CA				Cheng, CM; Cohen, M; Wang, J; Bondy, CA			Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex	FASEB JOURNAL			English	Article						estradiol; menopause; hormone replacement therapy; Alzheimer's disease; neurodegeneration	GROWTH-FACTOR-I; BLOOD-BRAIN-BARRIER; CENTRAL-NERVOUS-SYSTEM; POSITRON-EMISSION TOMOGRAPHY; GENE-EXPRESSION; ALZHEIMERS-DISEASE; RAT-BRAIN; MESSENGER-RNA; FACTOR RECEPTOR; SPINE DENSITY	Estrogen has many positive effects on neural tissue in experimental model systems, including stimulation of neurite growth and neurotransmitter synthesis and protection against diverse types of neural injury. In humans, estrogen treatment is reputed to protect against Alzheimer's disease. To investigate potential mediators of estrogen's action and determine whether selective estrogen receptor modulators (SERMs) such as tamoxifen have estrogen-like effects in the primate brain, we evaluated the expression of glucose transporters and insulin-like growth factor 1 (IGF1) and its receptor in the frontal cortex of ovariectomized rhesus monkeys. We treated one group for 3 days with vehicle, another with 17 beta estradiol (E2), and a third with tamoxifen. The expression of facilitative glucose transporters (Gluts) 1, 3, and 4 was investigated using in situ hybridization, immunohistochemistry, and immunoblot analysis. Gluts 3 and 4 were concentrated in cortical neurons and Glut1 in capillaries and glial cells. E2 treatment induced two- to fourfold increases in Glut3 and Glut4 mRNA levels and lesser but significant increases in Glut3 and 4 protein levels. E2 treatment induced an similar to 70% increase in parenchymal Glut1 mRNA levels, but did not appreciably affect vascular Glut1 gene expression. IGF1 and IGF1 receptor mRNAs were concentrated in cortical neurons in a distribution similar to Gluts 3 and 4. IGF1 mRNA levels were significantly increased in E2-treated animals but IGF1 receptor mRNA levels were not altered by hormone treatment. Tamoxifen increased cerebral cortical Glut3 and 4 mRNA levels, but did not affect Glut1, IGF1, or IGF1 receptor expression. This study provides novel data showing that Gluts 3 and 4 and IGF1 are coexpressed by primate cerebral cortical neurons, where their expression is enhanced by estrogen. These findings suggest that up-regulation of glucose transporter and IGF1 expression may contribute to estrogen's salutary effects on neural tissue. Tamoxifen, an antiestrogen at the breast, is shown to have estrogen-like effects on higher brain centers in the monkey, suggesting that some SERMs may share estrogen's neuroprotective potential for menopausal women.	NICHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bondy, CA (corresponding author), NICHD, Dev Endocrinol Branch, NIH, Bldg 10-10N262,10 Ctr Dr, Bethesda, MD 20892 USA.	bondyc@exchange.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000628] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000628] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adesanya OO, 1999, P NATL ACAD SCI USA, V96, P3287, DOI 10.1073/pnas.96.6.3287; Adesanya OO, 1996, J CLIN ENDOCR METAB, V81, P1967, DOI 10.1210/jc.81.5.1967; Apelt J, 1999, J NEUROSCI RES, V57, P693, DOI 10.1002/(SICI)1097-4547(19990901)57:5<693::AID-JNR11>3.0.CO;2-X; Azcoitia I, 1999, J NEUROSCI RES, V58, P815, DOI 10.1002/(SICI)1097-4547(19991215)58:6<815::AID-JNR8>3.0.CO;2-R; BARKER KL, 1966, ENDOCRINOLOGY, V79, P1069, DOI 10.1210/endo-79-6-1069; BARTLETT WP, 1991, DEV BIOL, V147, P239, DOI 10.1016/S0012-1606(05)80021-1; BAXTER LR, 1987, PSYCHIAT RES, V21, P237, DOI 10.1016/0165-1781(87)90028-X; Berman KF, 1997, P NATL ACAD SCI USA, V94, P8836, DOI 10.1073/pnas.94.16.8836; Birge SJ, 1997, NEUROLOGY, V48, pS36, DOI 10.1212/WNL.48.5_Suppl_7.36S; BOADO RJ, 1990, BIOCHEM BIOPH RES CO, V166, P174, DOI 10.1016/0006-291X(90)91927-K; BONDY CA, 1991, J NEUROSCI, V11, P3442; BONDY CA, 1993, ANN NY ACAD SCI, V692, P33; BONDY CA, 1992, MOL CELL NEUROSCI, V3, P305, DOI 10.1016/1044-7431(92)90027-Y; Bonnefort AB, 1998, FEBS LETT, V441, P220, DOI 10.1016/S0014-5793(98)01552-X; BOULWARE SD, 1992, AM J PHYSIOL, V262, P130; CASCIERI MA, 1986, BIOCHIM BIOPHYS ACTA, V886, P491, DOI 10.1016/0167-4889(86)90186-2; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Cheng CM, 1998, J NEUROSCI, V18, P5673; CHIN E, 1993, J CLIN INVEST, V91, P1810, DOI 10.1172/JCI116392; Cornford EM, 1998, J NEUROPATH EXP NEUR, V57, P699, DOI 10.1097/00005072-199807000-00007; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; Dore S, 1997, TRENDS NEUROSCI, V20, P326; DUFFY KR, 1987, BRAIN RES, V420, P32, DOI 10.1016/0006-8993(87)90236-8; Fisher B, 2000, EUR J CANCER, V36, P142, DOI 10.1016/S0959-8049(99)00269-5; GERHART DZ, 1992, P NATL ACAD SCI USA, V89, P733, DOI 10.1073/pnas.89.2.733; Gibbs RB, 1998, EXP NEUROL, V151, P289, DOI 10.1006/exnr.1998.6789; Greene RA, 2000, FERTIL STERIL, V73, P143; HARIK SI, 1990, J NEUROSCI, V10, P3862, DOI 10.1523/JNEUROSCI.10-12-03862.1990; Inestrosa NC, 1998, MOL NEUROBIOL, V17, P73, DOI 10.1007/BF02802025; Kobayashi M, 1996, NEUROSCI LETT, V213, P103, DOI 10.1016/0304-3940(96)12845-7; KUMAGAI AK, 1994, BBA-BIOMEMBRANES, V1193, P24, DOI 10.1016/0005-2736(94)90328-X; LEE WH, 1993, ENDOCRINOLOGY, V133, P2540, DOI 10.1210/en.133.6.2540; Leloup C, 1996, MOL BRAIN RES, V38, P45, DOI 10.1016/0169-328X(95)00306-D; Levenson AS, 1999, EUR J CANCER, V35, P1974, DOI 10.1016/S0959-8049(99)00297-X; MacGregor JI, 1998, PHARMACOL REV, V50, P151; MAHER F, 1992, BIOCHEM BIOPH RES CO, V182, P703, DOI 10.1016/0006-291X(92)91789-S; McCall AL, 1996, J CEREBR BLOOD F MET, V16, P69, DOI 10.1097/00004647-199601000-00008; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; Murphy DD, 1998, J NEUROSCI, V18, P2550; MURPHY LJ, 1991, J STEROID BIOCHEM, V40, P223, DOI 10.1016/0960-0760(91)90186-9; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NAMBA H, 1984, BRAIN RES, V291, P391, DOI 10.1016/0006-8993(84)91276-9; NEHLIG A, 1985, J CEREBR BLOOD F MET, V5, P393, DOI 10.1038/jcbfm.1985.54; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Pike CJ, 1999, J NEUROCHEM, V72, P1552, DOI 10.1046/j.1471-4159.1999.721552.x; Pozzo-Miller LD, 1999, J NEUROPHYSIOL, V81, P1404, DOI 10.1152/jn.1999.81.3.1404; Reiman EM, 1996, HUM REPROD, V11, P2799; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; SALDARINI RJ, 1968, ENDOCRINOLOGY, V82, P511, DOI 10.1210/endo-82-3-511; Sawada H, 1998, J NEUROSCI RES, V54, P707, DOI 10.1002/(SICI)1097-4547(19981201)54:5<707::AID-JNR16>3.0.CO;2-T; Shi J, 1997, AM J PHYSIOL-ENDOC M, V272, pE1016, DOI 10.1152/ajpendo.1997.272.6.E1016; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; Simpson IA, 1999, J NEUROCHEM, V72, P238, DOI 10.1046/j.1471-4159.1999.0720238.x; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Vannucci SJ, 1998, BRAIN RES, V797, P1, DOI 10.1016/S0006-8993(98)00103-6; Vedder H, 1999, J NEUROCHEM, V72, P2531, DOI 10.1046/j.1471-4159.1999.0722531.x; Welch RD, 1999, ENDOCRINOLOGY, V140, P3602, DOI 10.1210/en.140.8.3602; WERNER H, 1989, ENDOCRINOLOGY, V125, P314, DOI 10.1210/endo-125-1-314; Woolley CS, 1999, CURR OPIN NEUROBIOL, V9, P349, DOI 10.1016/S0959-4388(99)80051-8; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; YANO H, 1991, BIOCHEM BIOPH RES CO, V174, P470, DOI 10.1016/0006-291X(91)91440-N; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNG WS, 1986, NEUROPEPTIDES, V8, P401; YOUNG WS, 1986, NEUROPEPTIDES, V8, P93, DOI 10.1016/0143-4179(86)90035-1; Yu S, 1998, BRAIN RES, V797, P65, DOI 10.1016/S0006-8993(98)00372-2; ZHOU J, 1993, J CLIN INVEST, V91, P845, DOI 10.1172/JCI116305; ZHOU J, 2000, IN PRESS J INVEST ME	70	91	94	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					907	915		10.1096/fj.00-0398com	http://dx.doi.org/10.1096/fj.00-0398com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292650				2022-12-25	WOS:000167959300004
J	Iljin, K; Karkkainen, MJ; Lawrence, EC; Kimak, MA; Uutela, M; Taipale, J; Pajusola, K; Alhonen, L; Halmekyto, M; Finegold, DN; Ferrell, RE; Alitalo, K				Iljin, K; Karkkainen, MJ; Lawrence, EC; Kimak, MA; Uutela, M; Taipale, J; Pajusola, K; Alhonen, L; Halmekyto, M; Finegold, DN; Ferrell, RE; Alitalo, K			VEGFR3 gene structure, regulatory region, and sequence polymorphisms	FASEB JOURNAL			English	Article						FLT4; receptor tyrosine kinase; promoter; endothelial cell; lymphangiogenesis	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; VASCULAR-PERMEABILITY FACTOR; TRANSGENIC MICE; BINDING-SITES; HUMAN TISSUES; ORF VIRUS; IN-VIVO; EXPRESSION; FLT4	Vascular endothelial growth factor receptor 3 (VEGFR-3) is required for cardiovascular development during embryogenesis. In adults, this receptor is expressed in lymphatic endothelial cells, and mutant VEGFR3 alleles have been implicated in human hereditary lymphedema. To better understand the basis of its specific endothelial lineage-restricted expression, we have characterized the I VEGFR3 gene and its regulatory 5' flanking region. The human gene contains 31 exons, of which exons 30a and 30b are alternatively spliced. The VEGFR3 proximal promoter is TATA-less and contains stretches of sequences homologous with the mouse Vegfr3 promoter region. In transfection experiments of cultured cells, the Vegfr3 promoter was shown to control endothelial cell-specific transcription of downstream reporter genes. This result was further confirmed in vivo; in a subset of transgenic mouse embryos, a 1.6 kb Vegfr3 promoter fragment directed weak lymphatic endothelial expression of the LacZ marker gem. This suggests that endothelial cell-specific elements occur in the proximal promoter, although further enhancer elements are probably located elsewhere. The sequence, organization, and variation in the VEGFR3 gene and its regulatory region provide important tools for the molecular genetic analysis of the lymphatic system and its disorders.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA; Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Eastern Finland	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Kari.Alitalo@Helsinki.FI	Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Iljin, Kristiina/0000-0002-5161-0584; Finegold, David/0000-0001-9901-2578	NHLBI NIH HHS [HL35174, HL54526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL054526, U10HL054526, R01HL035174] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; APRELIKOVA O, 1992, CANCER RES, V52, P746; ARMSTRONG E, 1993, GENE CHROMOSOME CANC, V7, P144, DOI 10.1002/gcc.2870070306; Cowan PJ, 1996, TRANSPLANTATION, V62, P155, DOI 10.1097/00007890-199607270-00002; Cowan PJ, 1998, J BIOL CHEM, V273, P11737, DOI 10.1074/jbc.273.19.11737; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; GALLAND F, 1992, GENOMICS, V13, P475, DOI 10.1016/0888-7543(92)90277-Y; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; Guan JZ, 1999, BLOOD, V94, P3405, DOI 10.1182/blood.V94.10.3405.422k28_3405_3412; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Irrthum A, 2000, AM J HUM GENET, V67, P295, DOI 10.1086/303019; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Kondo K, 1998, GENE, V208, P297, DOI 10.1016/S0378-1119(98)00006-7; KORHONEN J, 1994, ONCOGENE, V9, P395; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; Kukk E, 1996, DEVELOPMENT, V122, P3829; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Nettelbeck DM, 1998, GENE THER, V5, P1656, DOI 10.1038/sj.gt.3300778; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sabin FR, 1912, ANAT REC, V6, P335; Sarao R, 1998, TRANSGENIC RES, V7, P421, DOI 10.1023/A:1008837410485; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1991, ONCOGENE, V6, P1677; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Veikkola T, 2000, CANCER RES, V60, P203; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; WITTE MH, 1997, LYMPHANGIOGENESIS ME, P65; Yin LY, 1998, MAMM GENOME, V9, P408, DOI 10.1007/s003359900783; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X	52	56	66	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					1028	1036		10.1096/fj.00-0383com	http://dx.doi.org/10.1096/fj.00-0383com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292664				2022-12-25	WOS:000167959300018
J	Wu, XY; Li, H; Chen, JD				Wu, XY; Li, H; Chen, JD			The human homologue of the yeast DNA repair and TFIIH regulator MMS19 is an AF-1-specific coactivator of estrogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; SACCHAROMYCES-CEREVISIAE; PAS DOMAIN; ACTIVATION FUNCTION-1; PROTEIN-INTERACTION; STEROID-RECEPTORS; DIOXIN RECEPTOR; AF2 DOMAINS	Steroid/nuclear hormone receptors are ligand-dependent transcriptional regulators that control gene expression in a wide array of biological processes. The transcriptional activity of the receptors is mediated by an N-terminal ligand-independent transcriptional activation function AF-1 and a C-terminal ligand-dependent transcriptional activation function AF-2. The nuclear receptor coactivator RAGS (also known as AIB1/ACTR/ pCIP/TRAM-1/SRC-3) is amplified in breast cancer cells, where it forms a complex with estrogen receptor (ER) and enhances AF-2 activity of the receptor. Here, we identify a putative human homologue of the yeast DNA repair and transcriptional regulator MMS19 as a RAC3-interacting protein. The human MMS19 interacts with the N-terminal PAS-A/B domain of RAC3 in vivo and in vitro through a conserved C-terminal domain, Interestingly, the human MMS19 also interacts with estrogen receptors in a ligand-independent manner but not with retinoic acid receptor or thyroid hormone receptor. Overexpression of the interacting domain of hMMS19 strongly inhibits ER-mediated transcriptional activation, indicating a dominant negative activity. In contrast, over expression of the full-length hMMS19 enhances ER-mediated transcriptional activation. We find that hMMS19 stimulates the AF-1 activity of ER alpha, but not the AF-2 activity, suggesting that hMMS19 may be an AF-1-specific transcriptional coactivator of estrogen receptor.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	Chen, JD (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, 55 Lake Ave N, Worcester, MA 01655 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052888] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK052888-03, R01 DK052888-02, DK52888, R01 DK052888-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alers JC, 2000, LAB INVEST, V80, P931, DOI 10.1038/labinvest.3780096; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Endoh H, 1999, MOL CELL BIOL, V19, P5363; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Lauder S, 1996, MOL CELL BIOL, V16, P6783; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Leo C, 2000, J BIOL CHEM, V275, P5976, DOI 10.1074/jbc.275.8.5976; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; Ma H, 1999, MOL CELL BIOL, V19, P6164; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; MILLER RD, 1982, MOL CELL BIOL, V2, P939, DOI 10.1128/MCB.2.8.939; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1854; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; PRAKASH L, 1977, GENETICS, V86, P33; PRAKASH L, 1979, MOL GEN GENET, V176, P351, DOI 10.1007/BF00333097; Prakash L, 1989, Ann Ist Super Sanita, V25, P99; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Seroz T, 2000, NUCLEIC ACIDS RES, V28, P4506, DOI 10.1093/nar/28.22.4506; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	51	54	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23962	23968		10.1074/jbc.M101041200	http://dx.doi.org/10.1074/jbc.M101041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11279242	hybrid			2022-12-25	WOS:000169531100098
J	Patel, NA; Chalfant, CE; Watson, JE; Wyatt, JR; Dean, NM; Eichler, DC; Cooper, DR				Patel, NA; Chalfant, CE; Watson, JE; Wyatt, JR; Dean, NM; Eichler, DC; Cooper, DR			Insulin regulates alternative splicing of protein kinase C beta II through a phosphatidylinositol 3-kinase-dependent pathway involving the nuclear serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; STIMULATED GLUCOSE-TRANSPORT; RAT ADIPOSE-CELLS; SR PROTEINS; SMOOTH-MUSCLE; SERINE-RICH; TRANSCRIPTION FACTOR; POLYMERASE-II; STAT 5B; PHOSPHORYLATION	Insulin regulates the inclusion of the exon encoding protein kinase C (PKC) PII mRNA In this report, we show that insulin regulates this exon inclusion (alternative splicing) via the phosphatidylinositol 3-kinase (PI 3-kinase) signaling pathway through the phosphorylation state of SRp40, a factor required for insulin-regulated splice site selection for PKC beta II mRNA. By taking advantage of a well known inhibitor of PI S-kinase, LY294002, we demonstrated that pretreatment of L6 myotubes with LY294002 blocked insulin-induced PKC beta II exon inclusion as well as phosphorylation of SRp40. In the absence of LY294002, overexpression of SRp40 in L6 cells mimicked insulin-induced exon inclusion. When antisense oligonucleotides targeted to a putative SRp40-binding sequence in the beta II-betaI intron were transfected into L6 cells, insulin effects on splicing and glucose uptake were blocked. Taken together, these results demonstrate a role for SRp40 in insulin-mediated alternative splicing independent of changes in SRp40 concentration but dependent on serine phosphorylation of SRp40 via a PI 3-kinase signaling pathway. This switch in PKC isozyme expression is important for in creases in the glucose transport effect of insulin. Significantly, insulin regulation of PKCI betaI exon inclusion occurred in the absence of cell growth and differentiation demonstrating that insulin-induced alternative splicing of PKC beta II mRNA in L6 cells occurs in response to a metabolic change.	Univ S Florida, James A Haley Vet Hosp, Coll Med, Dept Biochem & Mol Biol,Res Serv 151, Tampa, FL 33612 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	State University System of Florida; University of South Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; Isis Pharmaceuticals Inc	Cooper, DR (corresponding author), Univ S Florida, James A Haley Vet Hosp, Coll Med, Dept Biochem & Mol Biol,Res Serv 151, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.		Patel, Niketa/A-1392-2012; Cooper, Denise R./A-4740-2012; Eichler, Duane/A-1906-2012	Patel, Niketa A./0000-0003-4811-8596				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BALY DL, 1987, J BIOL CHEM, V262, P21; Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721; Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761; Braiman L, 1999, DIABETES, V48, P1922, DOI 10.2337/diabetes.48.10.1922; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CACERES JF, 1994, SCIENCE, V265, P1707; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Cooper DR, 1999, ARCH BIOCHEM BIOPHYS, V372, P69, DOI 10.1006/abbi.1999.1472; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dirksen WP, 2000, J BIOL CHEM, V275, P29170, DOI 10.1074/jbc.M001126200; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FU XD, 1995, RNA, V1, P663; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GOODE N, 1992, J BIOL CHEM, V267, P16878; Gorman L, 2000, J BIOL CHEM, V275, P35914, DOI 10.1074/jbc.M006259200; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; Henry RR, 1996, DIABETES, V45, P400, DOI 10.2337/diabetes.45.4.400; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JONES TLZ, 1989, J BIOL CHEM, V264, P7874; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MATTHAEI S, 1988, BIOCHEM J, V251, P491, DOI 10.1042/bj2510491; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Nikolakaki E, 1996, J BIOL CHEM, V271, P8365, DOI 10.1074/jbc.271.14.8365; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Okamoto Y, 1998, BIOCHEM BIOPH RES CO, V249, P872, DOI 10.1006/bbrc.1998.9247; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; Patel NA, 1999, FASEB J, V13, P103, DOI 10.1096/fasebj.13.1.103; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Prasad J, 1999, MOL CELL BIOL, V19, P6991; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Sambrook J., 2002, MOL CLONING LAB MANU; Sawka-Verhelle D, 2000, ENDOCRINOLOGY, V141, P1977, DOI 10.1210/en.141.6.1977; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Stark JM, 1998, P NATL ACAD SCI USA, V95, P2163, DOI 10.1073/pnas.95.5.2163; Stark JM, 1999, J BIOL CHEM, V274, P29838, DOI 10.1074/jbc.274.42.29838; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Taylor J K, 1999, Curr Opin Drug Discov Devel, V2, P147; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Thorell A, 1999, AM J PHYSIOL-ENDOC M, V277, pE733, DOI 10.1152/ajpendo.1999.277.4.E733; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8; Withers DJ, 2000, ENDOCRINOLOGY, V141, P1917, DOI 10.1210/en.141.6.1917; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yamamoto M, 1998, EXP CELL RES, V240, P349, DOI 10.1006/excr.1998.3999; Yamamoto M, 1999, INT J CANCER, V83, P98, DOI 10.1002/(SICI)1097-0215(19990924)83:1<98::AID-IJC18>3.0.CO;2-V; Yeakley JM, 1996, P NATL ACAD SCI USA, V93, P7582, DOI 10.1073/pnas.93.15.7582; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	75	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22648	22654		10.1074/jbc.M101260200	http://dx.doi.org/10.1074/jbc.M101260200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11283022	hybrid			2022-12-25	WOS:000169412700091
J	Christophe, T; Karlsson, A; Dugave, C; Rabiet, MJ; Boulay, F; Dahlgren, C				Christophe, T; Karlsson, A; Dugave, C; Rabiet, MJ; Boulay, F; Dahlgren, C			The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A(4) receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; N-FORMYLPEPTIDE RECEPTOR; NADPH-OXIDASE; PHOSPHORYLATION SITES; PHOSPHOINOSITIDE HYDROLYSIS; CELL-LINE; DESENSITIZATION; IDENTIFICATION; 7-TRANSMEMBRANE; INTERNALIZATION	Neutrophils express the G protein-coupled N-formyl peptide receptor (FPR) and its homologue FPRL1, whereas monocytes express FPR, FPRL1, and FPRL2, an orphan receptor sharing 83% amino acid identity with FPRL1, FPRL1 is a promiscuous receptor activated by serum amyloid A and by different synthetic peptides, including the hexapeptide Trp-Lys-Tyr-Met-Val-D-Met-NH2 (WKYMVm), By measuring calcium flux in HL-60 cells transfected with FPR, FPRL1, or FPRL2, we show that WKYMVm activated all three receptors, whereas the L-conformer WKYMVM activated exclusively FPRL1 and FPRL2, The functionality of FPRL2 was further assessed by the ability of HL-60-FPRL2 cells to migrate toward nanomolar concentrations of hexapeptides. The half-maximal effective concentrations of WKYMVM for calcium mobilization in HL-60-FPRL1 and HL-60-FPRL2 cells were 2 and 80 nM, respectively. Those of WKYMVm were 75 pM and 3 nM, The tritiated peptide WK[3,5-H-3(2)]YMVM bound to FPRL1 (K-D similar to 160 nM), but not to FPR, The two conformers similarly inhibited binding of I-125-labeled WKYMVm to FPRL2-expressing cells (IC50 similar to 2.5-3 muM). Metabolic labeling with orthophosphoric acid revealed that FPRL1 was differentially phosphorylated upon addition of the L- or D-conformer, indicating that it induced different conformational changes. In contrast to FPRL1, FPRL2 was already phosphorylated in the absence of agonist and not evenly distributed in the plasma membrane of unstimulated cells. However, both receptors were internalized upon addition of either of the two conformers. Taken together, the results indicate that neutrophils are activated by WKYMVM through FPRL1 and that FPRL2 is a chemotactic receptor transducing signals in myeloid cells.	Univ Grenoble 1, CEA Grenoble, Dept Biol Mol & Struct Biochim & Biophys Syst Int, CNRS,UMR 5092, F-38054 Grenoble 9, France; Univ Gothenburg, Dept Med Microbiol & Immunol, Phagocyte Res Lab, S-40530 Gothenburg, Sweden; CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Gothenburg; CEA; UDICE-French Research Universities; Universite Paris Saclay	Boulay, F (corresponding author), Univ Grenoble 1, CEA Grenoble, Dept Biol Mol & Struct Biochim & Biophys Syst Int, CNRS,UMR 5092, 17 Rue Martyrs, F-38054 Grenoble 9, France.	fboulay@cea.fr	TEST-GU, TEST-GU/B-5469-2010; Karlsson, Anna/A-4130-2012	Karlsson, Anna/0000-0001-6796-1154				Ali H, 1997, MED CLIN N AM, V81, P1, DOI 10.1016/S0025-7125(05)70503-4; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Baek SH, 1996, J BIOL CHEM, V271, P8170, DOI 10.1074/jbc.271.14.8170; BAO L, 1992, Genomics, V13, P437, DOI 10.1016/0888-7543(92)90265-T; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Chiang N, 2000, J EXP MED, V191, P1197, DOI 10.1084/jem.191.7.1197; Christophe T, 2000, J BIOL CHEM, V275, P1656, DOI 10.1074/jbc.275.3.1656; Clark RB, 1999, TRENDS PHARMACOL SCI, V20, P279, DOI 10.1016/S0165-6147(99)01351-6; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Dahlgren C, 2000, BLOOD, V95, P1810, DOI 10.1182/blood.V95.5.1810.005k06_1810_1818; Deng XY, 1999, BLOOD, V94, P1165, DOI 10.1182/blood.V94.4.1165.416k23_1165_1173; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DURSTIN M, 1994, BIOCHEM BIOPH RES CO, V201, P174, DOI 10.1006/bbrc.1994.1685; FEATHERSTONE C, 1995, TRENDS CELL BIOL, V5, P388, DOI 10.1016/S0962-8924(00)89081-9; FIORE S, 1994, J EXP MED, V180, P253, DOI 10.1084/jem.180.1.253; Franci C, 1996, J IMMUNOL, V157, P5606; GAO JL, 1993, J BIOL CHEM, V268, P25395; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Hsu MH, 1997, J BIOL CHEM, V272, P29426, DOI 10.1074/jbc.272.47.29426; JESAITIS AJ, 1993, EUR J HAEMATOL, V51, P288; LANG JC, 1993, EMBO J, V12, P2671, DOI 10.1002/j.1460-2075.1993.tb05928.x; Le YY, 2001, J IMMUNOL, V166, P1448, DOI 10.4049/jimmunol.166.3.1448; Le YY, 1999, J IMMUNOL, V163, P6777; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Liu L, 1998, J IMMUNOL, V160, P2463; Lundqvist H, 1996, FREE RADICAL BIO MED, V20, P785, DOI 10.1016/0891-5849(95)02189-2; LUNQVIST H, 1994, BIOCHIM BIOPHYS ACTA, V1224, P43; MURPHY PM, 1992, J BIOL CHEM, V267, P7637; Naik N, 1997, J CELL SCI, V110, P2381; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rainger GE, 1997, CURR BIOL, V7, P316, DOI 10.1016/S0960-9822(06)00155-2; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; Seo JK, 1997, J IMMUNOL, V158, P1895; Su SB, 1999, J EXP MED, V189, P395, DOI 10.1084/jem.189.2.395; Su SB, 1999, J IMMUNOL, V162, P5924; Tardif M, 1998, J IMMUNOL, V161, P6885; TARDIF M, 1993, J IMMUNOL, V150, P3534; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; Wenzel-Seifert K, 1998, J BIOL CHEM, V273, P24181, DOI 10.1074/jbc.273.37.24181; WENZELSEIFERT K, 1993, J IMMUNOL, V150, P4591; WIENTJES FB, 1995, SEMIN CELL BIOL, V6, P357, DOI 10.1016/S1043-4682(05)80006-6; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Ye R D, 1997, Adv Pharmacol, V39, P221, DOI 10.1016/S1054-3589(08)60073-3; YE RD, 1992, BIOCHEM BIOPH RES CO, V184, P582, DOI 10.1016/0006-291X(92)90629-Y; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	54	158	169	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21585	21593		10.1074/jbc.M007769200	http://dx.doi.org/10.1074/jbc.M007769200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11285256	hybrid			2022-12-25	WOS:000169297900105
J	Yamaoka, T; Yano, M; Kondo, M; Sasaki, H; Hino, S; Katashima, R; Moritani, M; Itakura, M				Yamaoka, T; Yano, M; Kondo, M; Sasaki, H; Hino, S; Katashima, R; Moritani, M; Itakura, M			Feedback inhibition of amidophosphoribosyltransferase regulates the rate of cell growth via purine nucleotide, DNA, and protein syntheses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; LEUKEMIA-CELLS; T-LYMPHOCYTES; PHOSPHORIBOSYLPYROPHOSPHATE; PHOSPHORIBOSYLTRANSFERASE; BIOSYNTHESIS; AMIDOTRANSFERASE; BINDING; DENOVO	To clarify the contributions of amidophosphoribosyltransferase (ATase) and its feedback regulation to the rates of purine de novo synthesis, DNA synthesis, protein synthesis, and cell growth, mutated human ATase (mhATase) resistant to feedback inhibition by purine ribonucleotides was engineered by site-directed mutagenesis and expressed in CHO ade (-)A cells (an ATase-deficient cell line of Chinese hamster ovary fibroblasts) and in transgenic mice (mhATase-Tg mice). In Chinese hamster ovary transfectants with mhATase, the following parameters were examined: ATase activity and its subunit structure, the metabolic rates of de novo and salvage pathways, DNA and protein synthesis rates, and the rate of cell growth. In mhATase-Tg mice, ATase activity in the liver and spleen, the metabolic rate of the de novo pathway in the liver, serum uric acid concentration, urinary excretion of purine derivatives, and T lymphocyte proliferation by phytohemagglutinin were examined. We concluded the following. 1) ATase and its feedback inhibition regulate not only the rate of purine de novo synthesis but also DNA and protein synthesis rates and the rate of cell growth in cultured fibroblasts, 2) Suppression of the de novo pathway by the salvage pathway is mainly due to the feedback inhibition of ATase by purine ribonucleotides produced via the salvage pathway, whereas the suppression of the salvage pathway by the de novo pathway is due to consumption of 5-phosphoribosyl 1-pyrophosphate by the de novo pathway. 3) The feedback inhibition of ATase is more important for the regulation of the de novo pathway than that of 5-phosphoribosyl 1-pyrophosphate synthetase, 4) ATase superactivity leads to hyperuricemia and an increased bromodeoxyuridine incorporation in T lymphocytes stimulated by phytohemagglutinin.	Univ Tokushima, Sch Med, Div Genet Informat, Inst Genome Res, Tokushima 7708503, Japan; Univ Tokushima, Sch Med, Otsuka Dept Clin & Mol Nutr, Tokushima 7708503, Japan	Tokushima University; Tokushima University	Yamaoka, T (corresponding author), Univ Tokushima, Sch Med, Div Genet Informat, Inst Genome Res, Tokushima 7708503, Japan.							ALLISON AC, 1975, LANCET, V2, P1179; BECKER MA, 1995, J CLIN INVEST, V96, P2133, DOI 10.1172/JCI118267; BECKER MA, 1987, J BIOL CHEM, V262, P14531; BOSS GR, 1982, J BIOL CHEM, V257, P4242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSH S, 1976, J CLIN INVEST, V58, P289, DOI 10.1172/JCI108471; FAIRBANKS LD, 1995, J BIOL CHEM, V270, P29682; Fairbanks LD, 1999, BIOCHEM J, V342, P143, DOI 10.1042/0264-6021:3420143; HOLMES EW, 1973, J BIOL CHEM, V248, P6035; ITAKURA M, 1979, J BIOL CHEM, V254, P333; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Kondo M, 2000, J BIOCHEM, V128, P57, DOI 10.1093/oxfordjournals.jbchem.a022730; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pelled D, 1999, J NEUROCHEM, V72, P1139, DOI 10.1046/j.1471-4159.1999.0721139.x; SANT ME, 1992, J BIOL CHEM, V267, P11038; Shi RZ, 1998, INT J BIOCHEM CELL B, V30, P885, DOI 10.1016/S1357-2725(98)00053-3; Yamaoka T, 1998, J CLIN INVEST, V102, P294, DOI 10.1172/JCI2769; Yamaoka T, 1997, J BIOL CHEM, V272, P17719, DOI 10.1074/jbc.272.28.17719; ZHOU GC, 1994, J BIOL CHEM, V269, P6784	19	39	39	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21285	21291		10.1074/jbc.M011103200	http://dx.doi.org/10.1074/jbc.M011103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11290738	hybrid			2022-12-25	WOS:000169297900066
J	Learn, CA; Boger, MS; Li, LW; McCall, CE				Learn, CA; Boger, MS; Li, LW; McCall, CE			The phosphatidylinositol 3-kinase pathway selectively controls sIL-1RA not interleukin-1 beta production in the septic leukocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN-TOLERANT CELLS; MESSENGER-RNA; SEPSIS; EXPRESSION; MACROPHAGES; CYTOKINE; INHIBITION; KINASE; HUMANS; BLOOD	Microbial components such as bacterial endotoxin lipopolysaccharide (LPS) can trigger highly lethal septic shock, The cardinal features of septic leukocytes include the repressed production of inflammatory cytokines, such as interleukin-1 beta (IL-1 beta), and elevated production of anti-inflammatory cytokines, such as secretory interleukin-1 receptor antagonist (sIL-1RA), Pro- and anti-inflammatory cytokine gene transcriptions are equally repressed in septic leukocytes due to disruption of the LPS signaling pathway at the level of interleukin-1 receptor-associated kinase, The selective elevation of sIL-1RA protein in septic blood is caused by efficient translation of residual sIL-1RA message. In this study, we report that the LPS-inducible phosphatidylinositol 3-kinase (PI3-kinase)-dependent signaling pathway contributes to the elevated translation of sIL-1RA in septic/LPS-adapted leukocytes, We also observe that this pathway is gene specific and does not affect the production of proinflammatory IL-1 beta protein.	Wake Forest Univ, Sch Med, Dept Med, Infect Dis Sect, Winston Salem, NC 27157 USA	Wake Forest University	Li, LW (corresponding author), Wake Forest Univ, Sch Med, Dept Med, Infect Dis Sect, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Li, Liwu/0000-0001-8870-5299	NCI NIH HHS [CA-09422] Funding Source: Medline; NCRR NIH HHS [MM01 RR07122-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bone RC, 1997, CHEST, V112, P235, DOI 10.1378/chest.112.1.235; Bone RC, 1996, JAMA-J AM MED ASSOC, V276, P565, DOI 10.1001/jama.276.7.565; Bowling WM, 1996, J SURG RES, V63, P287, DOI 10.1006/jsre.1996.0262; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; CROSS A, 1995, J CLIN INVEST, V96, P676, DOI 10.1172/JCI118110; Diaz-Guerra MJM, 1999, J IMMUNOL, V162, P6184; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; LARUE KEA, 1994, J EXP MED, V180, P2269, DOI 10.1084/jem.180.6.2269; Learn CA, 2000, J BIOL CHEM, V275, P12185, DOI 10.1074/jbc.275.16.12185; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; MCCALL CE, 1993, J CLIN INVEST, V91, P853, DOI 10.1172/JCI116306; Medvedev AE, 2000, J IMMUNOL, V164, P5564, DOI 10.4049/jimmunol.164.11.5564; Medzhitov R, 1998, SEMIN IMMUNOL, V10, P351, DOI 10.1006/smim.1998.0136; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; STONE R, 1994, SCIENCE, V264, P365, DOI 10.1126/science.8153620; vanderPoll T, 1996, J INFECT DIS, V174, P1356, DOI 10.1093/infdis/174.6.1356; Weinstein SL, 2000, J LEUKOCYTE BIOL, V67, P405, DOI 10.1002/jlb.67.3.405; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Yoza BK, 2000, SHOCK, V13, P236, DOI 10.1097/00024382-200003000-00011	21	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20234	20239		10.1074/jbc.M100316200	http://dx.doi.org/10.1074/jbc.M100316200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279236	hybrid			2022-12-25	WOS:000169135100077
J	Cheltsov, AV; Barber, MJ; Ferreira, GC				Cheltsov, AV; Barber, MJ; Ferreira, GC			Circular permutation of 5-aminolevulinate synthase - Mapping the polypeptide chain to its function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; IN-VIVO; ESCHERICHIA-COLI; 8-AMINO-7-OXONONANOATE SYNTHASE; DIHYDROFOLATE-REDUCTASE; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; SWISS-MODEL; PROTEIN; SUBSTRATE	5-Aminolevulinate synthase is the first enzyme of the heme biosynthetic pathway in non-plant eukaryotes and some prokaryotes, The enzyme functions as a homodimer and requires pyridoxal 5'-phosphate as a cofactor, Although the roles of defined amino acids in the active site and catalytic mechanism have been recently explored using site-directed mutagenesis, much less is known about the role of the ii-aminolevulinate synthase polypeptide chain arrangement in folding, structure, and ultimately, function. To assess the importance of the continuity of the polypeptide chain, circularly permuted 5-aminolevulinate synthase variants were constructed through either rational design or screening of an engineered random library. One percent of the random library clones were active, and a total of 21 active variants had sequences different from that of the wild type 5-aminolevulinate synthase. Out of these 21 variants, 9 displayed unique circular permutations of the 5-aminolevulinate synthase polypeptide chain. The new termini of the active variants disrupted secondary structure elements and loop regions and fell in 100 amino acid regions from each terminus. This indicates that the natural continuity of the 5-aminolevulinate synthase polypeptide chain and the sequential arrangement of the secondary structure elements are not requirements for proper folding, binding of the cofactor, or assembly of the two subunits, Furthermore, the order of two identified functional elements (i.e. the catalytic and the glycine-binding domains) is apparently irrelevant for proper functioning of the enzyme. Although the wild type B-aminolevulinate synthase and the circularly permuted variants appear to have similar, predicted overall tertiary structures, they exhibit differences in the arrangement of the secondary structure elements and in the cofactor-binding site environment, Taken together, the data lead us to propose that the 5-aminolevulinate synthase overall structure can be reached through multiple or alternative folding pathways.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Inst Biomol Sci, Tampa, FL 33612 USA; Univ S Florida, H Lee Canc Ctr & Res Inst, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Ferreira, GC (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	gferreir@hsc.usf.edu	Ferreira, Gloria C/A-4709-2012	Ferreira, Gloria C/0000-0001-9279-2217	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063191, R01DK052053] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK063191, DK52053] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BOTTOMLEY SS, 1995, J BIOENERG BIOMEMBR, V27, P161, DOI 10.1007/BF02110031; BOTTOMLEY SS, 1999, WINTROBES CLIN HEMAT, P1022; BUCHWALDER A, 1992, BIOCHEMISTRY-US, V31, P1621, DOI 10.1021/bi00121a006; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; Cotter PD, 1999, BLOOD, V93, P1757, DOI 10.1182/blood.V93.5.1757.405a12_1757_1769; COTTER PD, 1992, GENOMICS, V13, P211, DOI 10.1016/0888-7543(92)90223-F; FANICAGA.M, 1973, EUR J BIOCHEM, V40, P19, DOI 10.1111/j.1432-1033.1973.tb03164.x; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FERREIRA GC, 1995, J BIOENERG BIOMEMBR, V27, P151, DOI 10.1007/BF02110030; FERREIRA GC, 1993, J BIOL CHEM, V268, P584; Ferreira GC, 2000, BIOCHEMISTRY AND MOLECULAR BIOLOGY OF VITAMIN B6 AND PQQ-DEPENDENT PROTEINS, P257; FERREIRA GC, 1995, PROTEIN SCI, V4, P1001; Ferreira GC., 1999, IRON METABOLISM, P15, DOI [10.1002/9783527613700.CH02., DOI 10.1002/9783527613700.CH02]; FLORES TP, 1994, PROTEIN ENG, V7, P31, DOI 10.1093/protein/7.1.31; GABRIEL D, 1971, METHOD ENZYMOL, V22, P568; Garnier J, 1996, METHOD ENZYMOL, V266, P540; GOLDENBERG DP, 1983, J MOL BIOL, V165, P407, DOI 10.1016/S0022-2836(83)80265-4; Gong J, 1998, BIOCHEMISTRY-US, V37, P3509, DOI 10.1021/bi9719298; Graf R, 1996, P NATL ACAD SCI USA, V93, P11591, DOI 10.1073/pnas.93.21.11591; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gutknecht R, 1998, J BIOL CHEM, V273, P25745, DOI 10.1074/jbc.273.40.25745; HAHN M, 1994, P NATL ACAD SCI USA, V91, P10417, DOI 10.1073/pnas.91.22.10417; Harigae H, 1999, BRIT J HAEMATOL, V106, P175, DOI 10.1046/j.1365-2141.1999.01479.x; Hennecke J, 1999, J MOL BIOL, V286, P1197, DOI 10.1006/jmbi.1998.2531; Hennecke J, 1998, BIOCHEMISTRY-US, V37, P17590, DOI 10.1021/bi981888v; HUALA E, 1991, J BACTERIOL, V173, P382, DOI 10.1128/jb.173.1.382-390.1991; HUNTER GA, 1995, ANAL BIOCHEM, V226, P221, DOI 10.1006/abio.1995.1217; Hunter GA, 1999, BIOCHEMISTRY-US, V38, P3711, DOI 10.1021/bi982390w; Hunter GA, 1999, J BIOL CHEM, V274, P12222, DOI 10.1074/jbc.274.18.12222; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JM, 1989, J BACTERIOL, V171, P2547, DOI 10.1128/jb.171.5.2547-2552.1989; MUNAKATA H, 1993, J BIOCHEM, V114, P103, DOI 10.1093/oxfordjournals.jbchem.a124123; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; Nakamura T, 1999, J BIOL CHEM, V274, P19041, DOI 10.1074/jbc.274.27.19041; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; ROTE KV, 1989, J BIOL CHEM, V264, P1156; Sadlon TJ, 1999, INT J BIOCHEM CELL B, V31, P1153, DOI 10.1016/S1357-2725(99)00073-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STERNBERG MJE, 1977, J MOL BIOL, V110, P269, DOI 10.1016/S0022-2836(77)80072-7; Tan DW, 1996, BIOCHEMISTRY-US, V35, P8934, DOI 10.1021/bi952918m; Tan DW, 1998, PROTEIN SCI, V7, P1208, DOI 10.1002/pro.5560070516; Tan DW, 1998, BIOCHEMISTRY-US, V37, P1478, DOI 10.1021/bi971928f; Uversky VN, 1996, PROTEIN SCI, V5, P1844, DOI 10.1002/pro.5560050910; VIGUERA AR, 1995, J MOL BIOL, V247, P670, DOI 10.1016/S0022-2836(05)80146-9; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j; Zhang PH, 1996, PROTEIN SCI, V5, P1290, DOI 10.1002/pro.5560050708; ZHANG T, 1993, BIOCHEMISTRY-US, V32, P12311, DOI 10.1021/bi00097a006	52	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19141	19149		10.1074/jbc.M100329200	http://dx.doi.org/10.1074/jbc.M100329200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279050	hybrid, Green Accepted			2022-12-25	WOS:000169091000069
J	Yamaguchi, Y; Katoh, H; Yasui, H; Mori, K; Negishi, M				Yamaguchi, Y; Katoh, H; Yasui, H; Mori, K; Negishi, M			RhoA inhibits the nerve growth factor-induced Rac1 activation through Rho-associated kinase-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; NEURITE OUTGROWTH; FAMILY GTPASES; SIGNALING PATHWAYS; AXONAL OUTGROWTH; MAP KINASE; RAS; PROTEIN; DIFFERENTIATION; BINDING	The Rho family of small GTPases has been shown to be involved in the regulation of neuronal morphology, and Rac and Rho exert antagonistic actions in neurite formation. In this study, we have examined the cross-talk between Rac and Rho in relation to the nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. NGF induced a rapid activation of Pac 1 and suppression of RhoA activity. Constitutively active RhoA, RhoA(V14) or constitutively active G alpha (12)-induced endogenous RhoA activation inhibited the NGF-induced Rad activation without any effect on the NGF-induced extracellular signal-regulated kinase activation. Moreover, Y-27632, an inhibitor of Rho-associated kinase, completely abolished the RhoA-induced down-regulation of the NGF-induced Rad activation. We also revealed that NGF induced a rapid recruitment of Rad to the cell surface protrusion sites and formed filamentous actin-rich protrusions. Activation of RhoA and Rho-associated kinase formed a thick ringlike structure of cortical actin filaments at the cell periphery and then inhibited the NGF-induced recruitment of Rad to protrusions. These results indicate that RhoA down-regulates the NGF-induced Rad activation through Rho-associated kinase, inhibiting the neurite formation.	Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Grad Sch Biostudies, Mol Neurobiol Lab, Sakyo Ku, Kyoto 6068502, Japan.	mnegishi@pharm.kyoto-u.ac.jp	Yamaguchi, Yoshiaki/K-9418-2013	Yamaguchi, Yoshiaki/0000-0003-4126-542X				Albertinazzi C, 1998, J CELL BIOL, V142, P815, DOI 10.1083/jcb.142.3.815; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bilderback TR, 1999, J BIOL CHEM, V274, P257, DOI 10.1074/jbc.274.1.257; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Burridge K, 1999, SCIENCE, V283, P2028, DOI 10.1126/science.283.5410.2028; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lamoureux P, 1997, J CELL SCI, V110, P635; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Ory S, 2000, J CELL SCI, V113, P1177; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Sebok A, 1999, J NEUROCHEM, V73, P949, DOI 10.1046/j.1471-4159.1999.0730949.x; SPERO DA, 1985, DEV BRAIN RES, V23, P155, DOI 10.1016/0165-3806(85)90016-1; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; van Leeuwen FN, 1999, NAT CELL BIOL, V1, P242, DOI 10.1038/12068; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Yamaguchi Y, 2000, J NEUROCHEM, V75, P708, DOI 10.1046/j.1471-4159.2000.0750708.x; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	50	156	160	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18977	18983		10.1074/jbc.M100254200	http://dx.doi.org/10.1074/jbc.M100254200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279039	hybrid			2022-12-25	WOS:000169091000045
J	Espinosa, E; Belmant, C; Pont, F; Luciani, B; Poupot, R; Romagne, F; Brailly, H; Bonneville, M; Fournie, JJ				Espinosa, E; Belmant, C; Pont, F; Luciani, B; Poupot, R; Romagne, F; Brailly, H; Bonneville, M; Fournie, JJ			Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONPEPTIDE ANTIGENS; RECOGNITION; LIGANDS; RECEPTORS; IMMUNITY; DAUDI	Small phosphorylated metabolites from mycobacteria stimulate human gamma delta T lymphocytes. Although such phosphoantigens could prove useful in the composition of vaccines involving gamma delta T cell-mediated immunity, their very low abundance in natural sources limits such applications. Here, we describe the chemical production, purification, and bioactivity of a phosphorylated bromohydrin (BrHPP) analogue that mimics the biological properties of natural phosphoantigens, This compound can be obtained in gram amounts, is easy to detect, and is of high stability in aqueous solutions. Whereas unspecific binding of BrHPP to a wide panel of cell surface receptors is not detected even at micromolar concentrations, nanomolar concentrations specifically trigger effector responses of human gamma delta T lymphocytes, Thus, BrHPP is a novel molecule enabling potent immunostimulation of human gamma delta T lymphocytes.	CHU Purpan, INSERM, U395, F-31024 Toulouse, France; Inst Biol, INSERM, U463, F-44035 Nantes, France; Immeuble Grand Pre, Innate Pharma, F-13006 Marseille, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Fournie, JJ (corresponding author), CHU Purpan, INSERM, U395, BP3028, F-31024 Toulouse, France.		PONT, Frédéric/G-6289-2011; Fournie, Jean-Jacques/J-7805-2013; espinosa, eric/E-4872-2013	PONT, Frédéric/0000-0002-5493-527X; Fournie, Jean-Jacques/0000-0001-6542-6908; espinosa, eric/0000-0002-3512-0921				Belman C, 1999, J BIOL CHEM, V274, P32079, DOI 10.1074/jbc.274.45.32079; Belmant C, 2000, FASEB J, V14, P1669, DOI 10.1096/fj.99-0909fje; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Bukowski JF, 1998, J IMMUNOL, V161, P286; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; DAVISSON VJ, 1986, J ORG CHEM, V51, P4768, DOI 10.1021/jo00375a005; DAVODEAU F, 1993, J IMMUNOL, V151, P1214; Fisch P, 2000, IMMUNOL TODAY, V21, P187, DOI 10.1016/S0167-5699(99)01576-5; Fournie JJ, 1996, RES IMMUNOL, V147, P338, DOI 10.1016/0923-2494(96)89648-9; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; NAG B, 1992, J IMMUNOL, V148, P2040; Poccia F, 1998, IMMUNOL TODAY, V19, P253, DOI 10.1016/S0167-5699(98)01266-3; Poquet Y, 1996, EUR J IMMUNOL, V26, P2344, DOI 10.1002/eji.1830261011; Poquet Y, 1996, ANAL BIOCHEM, V243, P119, DOI 10.1006/abio.1996.0489; Rabinowitz JD, 1996, IMMUNITY, V5, P125, DOI 10.1016/S1074-7613(00)80489-6; Sicard H, 2000, INFECT IMMUN, V68, P4375, DOI 10.1128/IAI.68.8.4375-4377.2000; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TANAKA Y, 1994, P NATL ACAD SCI USA, V91, P8175, DOI 10.1073/pnas.91.17.8175	20	134	137	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18337	18344		10.1074/jbc.M100495200	http://dx.doi.org/10.1074/jbc.M100495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279081	hybrid			2022-12-25	WOS:000168866500097
J	Mitoma, M; Oho, T; Shimazaki, Y; Koga, T				Mitoma, M; Oho, T; Shimazaki, Y; Koga, T			Inhibitory effect of bovine milk lactoferrin on the interaction between a streptococcal surface protein antigen and human salivary agglutinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROTOXIGENIC ESCHERICHIA-COLI; BIOSPECIFIC INTERACTION ANALYSIS; MUTANS SEROTYPE-C; PLASMON RESONANCE; 3-DIMENSIONAL STRUCTURE; COATED HYDROXYAPATITE; DENTAL-CARIES; BINDING-SITE; ADHERENCE; GLUCOSYLTRANSFERASE	Human whole saliva induces aggregation of Streptococcus mutans cells via an interaction between a surface protein antigen (PAc) of the organism and salivary agglutinin, Bovine milk inhibits the saliva-induced aggregation of S, mutans, In this study, the milk component that possesses inhibitory activity against this aggregation was isolated and found to be lactoferrin, Surface plasmon resonance analysis indicated that bovine lactoferrin binds more strongly to salivary agglutinin, especially to high molecular mass glycoprotein, which is a component of the agglutinin, than to recombinant PAc. The binding of bovine lactoferrin to salivary agglutinin was thermostable, and the optimal pH for binding was 4.0, To identify the saliva-binding region of bovine lactoferrin, 11 truncated bovine lactoferrin fragments were constructed. A fragment corresponding to the C-terminal half of the lactoferrin molecule had a strong inhibitory effect on the saliva-induced aggregation of S. mutans, whereas a fragment corresponding to the N-terminal half had a weak inhibitory effect. Seven shorter fragments corresponding to lactoferrin residues 473-538 also showed a high ability to inhibit the aggregation of S. mutans. These results suggest that residues 473-538 of bovine lactoferrin are important in the inhibition of saliva-induced aggregation of S. mutans.	Kyushu Univ, Fac Dent Sci, Dept Prevent Dent, Fukuoka 8128582, Japan	Kyushu University	Oho, T (corresponding author), Kyushu Univ, Fac Dent Sci, Dept Prevent Dent, Fukuoka 8128582, Japan.	oho@dent.kyushu-u.ac.jp	Abrams, William R/A-5782-2008					Baker EN, 1998, ADV EXP MED BIOL, V443, P1; Baker HM, 2000, INT CONGR SER, V1195, P3; BELLAMY W, 1992, BIOCHIM BIOPHYS ACTA, V1121, P130, DOI 10.1016/0167-4838(92)90346-F; BOWEN WH, 1991, INFECT IMMUN, V59, P4606, DOI 10.1128/IAI.59.12.4606-4609.1991; Brock JH, 1997, EXP BIOL M, V28, P3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARLEN A, 1995, J DENT RES, V74, P1040, DOI 10.1177/00220345950740040301; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; EBINA T, 1992, J MED VIROL, V38, P117, DOI 10.1002/jmv.1890380209; Freedman DJ, 1998, J INFECT DIS, V177, P662, DOI 10.1086/514227; GIBBONS RJ, 1989, J DENT RES, V68, P750, DOI 10.1177/00220345890680050101; GIBBONS RJ, 1988, INFECT IMMUN, V56, P439, DOI 10.1128/IAI.56.2.439-445.1988; Gong K, 2000, J BIOL CHEM, V275, P8970, DOI 10.1074/jbc.275.12.8970; ISHIDA A, 1992, J NUTR, V122, P1875, DOI 10.1093/jn/122.9.1875; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kawasaki Y, 2000, BIOSCI BIOTECH BIOCH, V64, P348, DOI 10.1271/bbb.64.348; KOGA T, 1990, INFECT IMMUN, V58, P289, DOI 10.1128/IAI.58.2.289-296.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laloi P, 1996, INFECT IMMUN, V64, P28, DOI 10.1128/IAI.64.1.28-36.1996; LASSITER MO, 1987, J DENT RES, V66, P480, DOI 10.1177/00220345870660021601; LEE SF, 1989, INFECT IMMUN, V57, P3306, DOI 10.1128/IAI.57.11.3306-3313.1989; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHESHWARI P, 1997, BIOCHEM J, V323, P815; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Mulvihill DM, 1997, ADV EXP MED BIOL, V415, P77; MUROSAKI S, 1991, J NUTR, V121, P1860, DOI 10.1093/jn/121.11.1860; Oho T, 1998, INFECT IMMUN, V66, P115, DOI 10.1128/IAI.66.1.115-121.1998; Oho T, 1999, J NUTR, V129, P1836, DOI 10.1093/jn/129.10.1836; PAYNE JB, 1991, ORAL MICROBIOL IMMUN, V6, P169, DOI 10.1111/j.1399-302X.1991.tb00472.x; RAJ PA, 1992, J BIOL CHEM, V267, P5968; ROGER V, 1994, CARIES RES, V28, P421, DOI 10.1159/000262015; Russell M W, 1992, Curr Opin Dent, V2, P72; RUSSELL RRB, 1994, CARIES RES, V28, P69, DOI 10.1159/000261625; SAITO H, 1994, ADV EXP MED BIOL, V357, P219; SANCHEZ L, 1992, ARCH DIS CHILD, V67, P657, DOI 10.1136/adc.67.5.657; Senpuku H, 1996, FEMS MICROBIOL LETT, V139, P195, DOI 10.1016/0378-1097(96)00141-3; SHIMAZAKI K, 1993, INT J BIOCHEM, V25, P1653, DOI 10.1016/0020-711X(93)90524-I; SHIMAZAKI K, 1991, COMP BIOCHEM PHYS B, V98, P417, DOI 10.1016/0305-0491(91)90199-N; Shimazaki K, 2000, INT CONGR SER, V1195, P37; SOUKKA T, 1993, ARCH ORAL BIOL, V38, P227, DOI 10.1016/0003-9969(93)90032-H; SOUKKA T, 1994, MICROB ECOL HEALTH D, V7, P139, DOI 10.3109/08910609409141343; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Tsukioka Y, 1997, J BACTERIOL, V179, P4411, DOI 10.1128/jb.179.13.4411-4414.1997; VACCASMITH AM, 1995, CARIES RES, V29, P498, DOI 10.1159/000262121; VACCASMITH AM, 1994, ARCH ORAL BIOL, V39, P1063, DOI 10.1016/0003-9969(94)90059-0; WINGFIELD PT, 1995, CURRENT PROTOCOLS PR, V1; YAMAUCHI K, 1993, INFECT IMMUN, V61, P719, DOI 10.1128/IAI.61.2.719-728.1993	48	40	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18060	18065		10.1074/jbc.M101459200	http://dx.doi.org/10.1074/jbc.M101459200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279204	hybrid			2022-12-25	WOS:000168866500060
J	Gaburjakova, M; Gaburjakova, J; Reiken, S; Huang, F; Marx, SO; Rosemblit, N; Marks, AR				Gaburjakova, M; Gaburjakova, J; Reiken, S; Huang, F; Marx, SO; Rosemblit, N; Marks, AR			FKBP12 binding modulates ryanodine receptor channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; FK506; RAPAMYCIN; PROTEIN; COMPLEX	The ryanodine receptor (RyR1)/calcium release channel on the sarcoplasmic reticulum of skeletal muscle is comprised of four 565,000-dalton RyR1s, each of which binds one FK506 binding protein (FKBP12), RyR1 is required for excitation-contraction coupling in skeletal muscle. FKBP12, a cis-trans peptidyl-prolyl isomerase, is required for the normal gating of the RyR1 channel. In the absence of FKBP12, RyR1 channels Exhibit increased gating frequency, suggesting that FKBP12 "stabilizes" the channel in the open and closed states. We now show that substitution of a Gly, Glu, or Ile for Val(2461) in RyR1 prevents FKBP12 binding to RyR1, resulting in channels with increased gating frequency. In the case of the V2461I mutant RyR1, normal channel function can be restored by adding FKBP12.6, an isoform of FKBP12. These data identify Val(2461) ag a critical residue required for FKBP12 binding to RyR1 and demonstrate the functional role for FKBP12 in the RyR1 channel complex.	Columbia Univ, Coll Phys & Surg, Ctr Mol Cardiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University	Marks, AR (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Mol Cardiol, Rm 9-401,630 W 168th St, New York, NY 10032 USA.	arm42@columbia.edu	Gaburjakova, Jana/HGA-3661-2022; Gaburjakova, Marta/AAV-6066-2021	Gaburjakova, Jana/0000-0001-9540-7169; Gaburjakova, Marta/0000-0002-9300-0688	FIC NIH HHS [R03 TW00949] Funding Source: Medline; NHLBI NIH HHS [R01 HL61503, R01 HL56180] Funding Source: Medline; NIAID NIH HHS [R01 AI39794] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW000949] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061503, R01HL056180] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039794] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHERN GP, 1994, FEBS LETT, V352, P369, DOI 10.1016/0014-5793(94)01001-3; Ahern GP, 1997, BIOPHYS J, V72, P146, DOI 10.1016/S0006-3495(97)78654-5; ALBERS MW, 1990, J ORG CHEM, V55, P4984, DOI 10.1021/jo00304a003; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CHEN SRW, 1994, P NATL ACAD SCI USA, V91, P11953, DOI 10.1073/pnas.91.25.11953; Huse M, 1999, CELL, V96, P425, DOI 10.1016/S0092-8674(00)80555-3; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kaftan E, 1996, CIRC RES, V78, P990, DOI 10.1161/01.RES.78.6.990; Marks AR, 2000, CIRC RES, V87, P8, DOI 10.1161/01.RES.87.1.8; Marks AR, 1996, PHYSIOL REV, V76, P631, DOI 10.1152/physrev.1996.76.3.631; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Ondrias K, 1996, SOC GEN PHY, V51, P29; ROSEN MK, 1990, SCIENCE, V248, P863, DOI 10.1126/science.1693013; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; Shou WN, 1998, NATURE, V391, P489, DOI 10.1038/35146; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; Xin HB, 2001, BIOPHYS J, V80, p579A	21	139	147	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16931	16935		10.1074/jbc.M100856200	http://dx.doi.org/10.1074/jbc.M100856200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279144	hybrid			2022-12-25	WOS:000168730400044
J	Klatt, AR; Nitsche, DP; Kobbe, B; Macht, M; Paulsson, M; Wagener, R				Klatt, AR; Nitsche, DP; Kobbe, B; Macht, M; Paulsson, M; Wagener, R			Molecular structure, processing, and tissue distribution of matrilin-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE MATRIX PROTEIN; HELICAL COILED-COIL; C-TERMINAL DOMAIN; SKELETAL DEVELOPMENT; FILAMENTOUS NETWORK; FORMS; ORGANIZATION; PURIFICATION; EXPRESSION; ASSEMBLES	Matrilin-4 is the most recently identified member of the matrilin family of von Willebrand factor A-like domain containing extracellular matrix adapter proteins. Full-length matrilin-4 was expressed in 293-EBNA cells, purified using affinity tags, and subjected to biochemical characterization. The largest oligomeric form of recombinantly expressed full-length matrilin-1 is a trimer as shown by electron microscopy, SDS-polyacrylamide gel electrophoresis, and mass spectrometry, Proteolytically processed matrilin-4 species were also detected, The cleavage occurs in the short linker region between the second von Willebrand factor A-like domain and the coiled-coil domain leading to the release of large fragments and the formation of dimers and monomers of intact subunits still containing a trimeric coiled-coil. In immunoblots of calvaria extracts similar degradation products could be detected, indicating that a related proteolytic processing occurs in vivo. Matrilin-4 was first observed at day 7.5 post-coitum in mouse embryos. Affinity-purified antibodies detect a broad expression in dense and loose connective tissue, bone, cartilage, central and peripheral nervous systems and in association with basement membranes. In the matrix formed by cultured primary embryonic fibroblasts, matrilin-4 is found in a filamentous network connecting individual cells.	Univ Cologne, Fac Med, Inst Biochem 2, D-50931 Cologne, Germany; Univ Cologne, Fac Med, Cologne Serv Lab, Ctr Mol Med, D-50931 Cologne, Germany	University of Cologne; University of Cologne	Wagener, R (corresponding author), Univ Cologne, Fac Med, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.							Aszodi A, 1999, MOL CELL BIOL, V19, P7841; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; DEBLOCK M, 1993, ANAL BIOCHEM, V215, P86, DOI 10.1006/abio.1993.1558; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; Gibson TJ, 2000, BIOCHEM SOC T, V28, P259, DOI 10.1042/bst0280259; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Huang XM, 1999, DEV DYNAM, V216, P434, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<434::AID-DVDY11>3.3.CO;2-O; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PAULSSON M, 1981, BIOCHEM J, V197, P367, DOI 10.1042/bj1970367; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; Segat D, 2000, MATRIX BIOL, V19, P649, DOI 10.1016/S0945-053X(00)00112-8; Smyth N, 2000, METH MOL B, V139, P49; Wagener R, 1998, FEBS LETT, V438, P165, DOI 10.1016/S0014-5793(98)01293-9; Wagener R, 1998, FEBS LETT, V436, P123, DOI 10.1016/S0014-5793(98)01111-9; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; WUTTKE M, 2001, THESIS U COLOGNE GER; Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200	26	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17267	17275		10.1074/jbc.M100587200	http://dx.doi.org/10.1074/jbc.M100587200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279097	hybrid			2022-12-25	WOS:000168730400089
J	Mitsuzawa, H; Seino, H; Yamao, F; Ishihama, A				Mitsuzawa, H; Seino, H; Yamao, F; Ishihama, A			Two WD repeat-containing TATA-binding protein-associated factors in fission yeast that suppress defects in the anaphase-promoting complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION IN-VIVO; TBP-ASSOCIATED FACTORS; HISTONE-LIKE TAFS; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; NUCLEOSOME ACETYLATION; MOLECULAR-CLONING; SAGA COMPLEXES; TFIID COMPLEX	The general transcription factor IID consists of the TATA-binding protein (TBP) and multiple TBP-associated factors (TAFs). Here we report the isolation of two related TAF genes from the fission yeast Schizosaccha romyces pombe as multicopy suppressors of a temperature-sensitive mutation in the ubiquitin-conjugating enzyme gene ubcP4(+). The ubcP4(ts) mutation causes cell cycle arrest in mitosis, probably due to defects in ubiquitination mediated by the anaphase-promoting complex/cyclosome. One multicopy suppressor is the previously reported gene taf72(+), whereas the other is a previously unidentified gene named taf73(+). We show that the taf73(+) gene, like taf72(+), is essential for cell viability. The taf72(+) and taf73(+) genes encode proteins homologous to WD repeat-containing TAFs such as human TAF100, Drosophila TAF80/85, and Saccharomyces cerevisiae TAF90, We demonstrate that TAF72 and TAF73 proteins are present in the same complex with TBP and other TAFs and that TAF72, but not TAF73, is associated with the putative histone acetylase Gcn5, We also show that overexpression of TAF72 or TAF73 suppresses the cell cycle arrest in mitosis caused by a mutation in the anaphase-promoting complex/cyclosome subunit gene cut9(+), These results suggest that TAF72 and TAF73 may regulate the expression of genes involved in ubiquitin-dependent proteolysis during mitosis. Our study thus provides evidence for a possible role of WD repeat-containing TAFs in the expression of genes involved in progression through the M phase of the cell cycle.	Natl Inst Genet, Dept Mol Genet, Div Mol Genet, Mishima, Shizuoka 4118540, Japan; Natl Inst Genet, Dept Mol Genet, Div Mutagenesis, Mishima, Shizuoka 4118540, Japan	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Mitsuzawa, H (corresponding author), Natl Inst Genet, Dept Mol Genet, Div Mol Genet, Mishima, Shizuoka 4118540, Japan.	hmitsuza@lab.nig.ac.jp						Alfa C., 1993, EXPT FISSION YEAST; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bell B, 1999, EXP CELL RES, V246, P11, DOI 10.1006/excr.1998.4294; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Dubrovskaya V, 1996, EMBO J, V15, P3702, DOI 10.1002/j.1460-2075.1996.tb00740.x; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Green MR, 2000, TRENDS BIOCHEM SCI, V25, P59, DOI 10.1016/S0968-0004(99)01527-3; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KOKUBO T, 1993, MOL CELL BIOL, V13, P7859, DOI 10.1128/MCB.13.12.7859; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; Lee TI, 2000, NATURE, V405, P701, DOI 10.1038/35015104; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Osaka F, 1997, MOL CELL BIOL, V17, P3388, DOI 10.1128/MCB.17.6.3388; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Shibuya T, 1999, GENETICS, V152, P869; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tao Y, 1997, J BIOL CHEM, V272, P6714, DOI 10.1074/jbc.272.10.6714; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; WINSTON F, 1983, METHOD ENZYMOL, V101, P211; Yamada H, 1997, J CELL SCI, V110, P1793; Yamamoto T, 1997, GENES CELLS, V2, P245, DOI 10.1046/j.1365-2443.1997.1180316.x; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	50	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17117	17124		10.1074/jbc.M100248200	http://dx.doi.org/10.1074/jbc.M100248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279037	hybrid			2022-12-25	WOS:000168730400070
J	Kain, KH; Klemke, RL				Kain, KH; Klemke, RL			Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; GROWTH-FACTOR RECEPTOR; C-ABL; PHILADELPHIA-CHROMOSOME; DNA-DAMAGE; PROTEIN; BINDING; ACTIN; PHOSPHORYLATION; ACTIVATION	c-Abl and the Abl-related gene product (Arg) are nonreceptor tyrosine kinases that regulate the actin cytoskeleton of cells by direct association with F-actin and localization to focal contacts. However, the biological significance of this interaction is not known. We show here that transfection of COS-7 cells with a kinase-inactive form of c-Abl (Abl) promotes c-Crk II/p130(CAS) (Crk-CAS) coupling, enhancing cell migration. Moreover, embryonic fibroblast cells isolated from mice devoid of endogenous Abl and Arg (abl-/- arg-/-) demonstrate increased Crk-CAS coupling and motility. Conversely, expression of a kinase-active form of Abl or reconstitution of abl-/- arg-/- cells with wild-type Abl prevents Crk-CAS coupling and inhibits cell migration. Thus, Abl and Arg kinases play a critical role in preventing cell migration through regulation of Crk and CAS adaptor protein complexes, which are necessary for cell movement.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Klemke, RL (corresponding author), Scripps Res Inst, Dept Immunol, CAL-9,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Agami R, 1999, NATURE, V399, P809; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Bhatia R, 1998, BLOOD, V91, P3414, DOI 10.1182/blood.V91.9.3414.3414_3414_3422; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; Buchdunger E, 1996, CANCER RES, V56, P100; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Hashimoto Y, 1998, J BIOL CHEM, V273, P17186, DOI 10.1074/jbc.273.27.17186; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kaufmann N, 1998, DEVELOPMENT, V125, P453; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Lanier LM, 2000, CURR OPIN NEUROBIOL, V10, P80, DOI 10.1016/S0959-4388(99)00058-6; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MATSUDA M, 1993, J BIOL CHEM, V268, P4441; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; Nakashima N, 1999, J BIOL CHEM, V274, P3001, DOI 10.1074/jbc.274.5.3001; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Renshaw MW, 2000, ONCOGENE, V19, P3216, DOI 10.1038/sj.onc.1203667; Salgia R, 1999, BLOOD, V94, P4233; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SIRARD C, 1994, BLOOD, V83, P1575; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang BL, 1996, ONCOGENE, V13, P1379; Wills Z, 1999, NEURON, V22, P291, DOI 10.1016/S0896-6273(00)81090-9; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yano H, 2000, J NEUROSCI RES, V59, P356, DOI 10.1002/(SICI)1097-4547(20000201)59:3<356::AID-JNR9>3.0.CO;2-G; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437	54	121	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16185	16192		10.1074/jbc.M100095200	http://dx.doi.org/10.1074/jbc.M100095200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279004	hybrid			2022-12-25	WOS:000168623100083
J	Hofmann, WE; Liu, XT; Bearden, CM; Harper, ME; Kozak, LP				Hofmann, WE; Liu, XT; Bearden, CM; Harper, ME; Kozak, LP			Effects of genetic background on thermoregulation and fatty acid-induced uncoupling of mitochondria in UCP1-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; INDUCED THERMOGENESIS; NONSHIVERING THERMOGENESIS; MESSENGER-RNA; BLOOD-FLOW; PROTEIN; RAT; PROBE; UCP1; NORADRENALINE	An interaction between free fatty acids and UCP1 (uncoupling protein-1) leading to de-energization of mitochondria was assumed to be a key event for triggering heat production in brown fat. Recently, Matthias ef al;, finding indistinguishable de-energization of isolated brown fat mitochondria by fatty acids in UCP1-deficient mice and control mice, challenged this assumption (Matthias, A., Jacobsson, A., Cannon, B,, and Nedergaard, J, (1999) J, Biol. Chem, 274, 28150-28160). Since their results were obtained using UCP1-deficient and control mice on an undefined genetic background, we wanted to determine unambiguously the phenotype of UCP1 deficiency with the targeted Ucp1 allele on congenic C57BL/6J and 129/SvImJ backgrounds. UCP1-deficient congenic mice have a very pronounced cold-sensitive phenotype; however, deficient mice on the F1 hybrid background were resistant to cold. We propose that heterosis provides a mechanism to compensate for UCP1 deficiency. contrary to the results of Matthias st al,, we found a significant loss of fatty acid-induced de-energization, as reflected by membrane potential and oxygen consumption, in brown fat mitochondria from UCP1-deficient mice. Unlike cold sensitivity, fatty acid-induced uncoupling of mitochondria was independent of the genetic background of UCP1-deficient mice. We propose that intracellular free fatty acids directly regulate uncoupling activity of UCP1 in a manner consistent with models described in the literature.	Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Ottawa, Fac Med, Dept Biochem, Ottawa, ON K1H 8M5, Canada	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of Ottawa	Kozak, LP (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	KozakLP@pbrc.edu		Harper, Mary-Ellen/0000-0003-3864-5886				BARBATO GF, 1992, BEHAV GENET, V22, P381, DOI 10.1007/BF01066669; Cannon B, 1979, Methods Enzymol, V55, P65; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Comings DE, 2000, MOL GENET METAB, V71, P19, DOI 10.1006/mgme.2000.3015; DAVIS TRA, 1954, AM J PHYSIOL, V177, P222; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; FOSTER DO, 1978, CAN J PHYSIOL PHARM, V56, P110, DOI 10.1139/y78-015; GARDNER RS, 1974, ANAL BIOCHEM, V59, P272, DOI 10.1016/0003-2697(74)90033-5; GonzalezBarroso MM, 1996, EUR J BIOCHEM, V239, P445, DOI 10.1111/j.1432-1033.1996.0445u.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; JEZEK P, 1990, J LIPID MEDIATOR, V2, P85; Koza RA, 2000, J BIOL CHEM, V275, P34486, DOI 10.1074/jbc.M002136200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Matthias A, 2000, J BIOL CHEM, V275, P25073, DOI 10.1074/jbc.M000547200; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Monemdjou S, 1999, AM J PHYSIOL-ENDOC M, V276, pE1073, DOI 10.1152/ajpendo.1999.276.6.E1073; NEDERGAARD J, 1983, EUR J BIOCHEM, V133, P185, DOI 10.1111/j.1432-1033.1983.tb07446.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; PRUSINER SB, 1968, EUR J BIOCHEM, V7, P51, DOI 10.1111/j.1432-1033.1968.tb19572.x; RICHIERI GV, 1993, BIOCHEMISTRY-US, V32, P7574, DOI 10.1021/bi00080a032; RICQUIER D, 1984, FEBS LETT, V178, P240, DOI 10.1016/0014-5793(84)80608-0; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SMITH RE, 1969, PHYSIOL REV, V49, P330, DOI 10.1152/physrev.1969.49.2.330; SUSULIC VS, 1995, J BIOL CHEM, V270, P29483, DOI 10.1074/jbc.270.49.29483; Thomas SA, 1997, NATURE, V387, P94, DOI 10.1038/387094a0; TRAYHURN P, 1977, NATURE, V266, P60, DOI 10.1038/266060a0; WINKLER E, 1994, J BIOL CHEM, V269, P2508; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002	35	97	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12460	12465		10.1074/jbc.M100466200	http://dx.doi.org/10.1074/jbc.M100466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11279075	hybrid			2022-12-25	WOS:000168081800136
J	Gilbertson, DG; Duff, ME; West, JW; Kelly, JD; Sheppard, PO; Hofstrand, PD; Gao, ZR; Shoemaker, K; Bukowski, TR; Moore, M; Feldhaus, AL; Humes, JM; Palmer, TE; Hart, CE				Gilbertson, DG; Duff, ME; West, JW; Kelly, JD; Sheppard, PO; Hofstrand, PD; Gao, ZR; Shoemaker, K; Bukowski, TR; Moore, M; Feldhaus, AL; Humes, JM; Palmer, TE; Hart, CE			Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; DIFFERENT ISOFORMS; TYROSINE KINASES; NERVOUS-SYSTEM; FACTOR FGF; TGF-BETA; A-CHAINS; NEUROPILIN; EXPRESSION; FAMILY	We have characterized platelet-derived growth factor (PDGF) C, a novel growth factor belonging to the PDGF family. PDGF-C is a multidomain protein with the N-terminal region homologous-to the extracellular CUB domain of neuropilin-1, and the C-terminal region consists of a growth factor domain (GFD) with homology to vascular endothelial growth factor (25%) and PDGF A-chain (23%). A serum-sensitive cleavage site between the two domains allows release of the GFD from the CUE domain. Competition binding and immunoprecipitation studies on cells bearing both PDGF alpha and beta receptors reveal a high affinity binding of recombinant GFD (PDGF-CC) to PDGF receptor-alpha homodimers and PDGF receptor-alpha/beta heterodimers, PDGF-CC exhibits greater mitogenic potency than PDGF-AA and comparable or greater mitogenic activity than PDGF-AB and PDGF-BB on several mesenchymal cell types. Analysis of PDGF-CC in vivo in a diabetic mouse model of delayed wound healing showed that PDGF-CC significantly enhanced repair of a full-thickness skin excision. Together, these studies describe a third member of the PDGF family (PDGF-C) as a potent mitogen for cells of mesenchymal origin in in vitro and in vivo systems with a binding pattern similar to PDGF-AB.	ZymoGenet Inst, Seattle, WA 98102 USA	Zymogenet Inc.	Gilbertson, DG (corresponding author), 1201 Eastlake Ave E, Seattle, WA 98102 USA.	gilbertd@zgi.com						ABBOUD HE, 1994, J CELL PHYSIOL, V158, P140, DOI 10.1002/jcp.1041580118; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; ANSEL JC, 1993, J CLIN INVEST, V92, P671, DOI 10.1172/JCI116636; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Clark DA, 1998, INT J BIOCHEM CELL B, V30, P293, DOI 10.1016/S1357-2725(97)00128-3; COLLINS T, 1987, NATURE, V328, P621, DOI 10.1038/328621a0; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; FOSTER DC, 1994, Patent No. 5641655; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; GREENWEL P, 1993, LAB INVEST, V69, P210; HART CE, 1987, J BIOL CHEM, V262, P10780; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HELDIN CH, 1993, GROWTH FACTORS, V8, P245, DOI 10.3109/08977199308991570; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Joukov V, 1996, EMBO J, V15, P290; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOYAMA N, 1994, CIRC RES, V75, P682, DOI 10.1161/01.RES.75.4.682; Lepisto J, 1996, CELL TISSUE RES, V286, P449, DOI 10.1007/s004410050714; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Malinda KM, 1999, FASEB J, V13, P53, DOI 10.1096/fasebj.13.1.53; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; NICOSIA RF, 1990, IN VITRO CELL DEV B, V26, P119; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; RAINES W, 1993, CYTOKINES, V5, P74; Raymond CK, 1999, BIOTECHNIQUES, V26, P134, DOI 10.2144/99261rr02; Rosenkranz S, 1999, GROWTH FACTORS, V16, P201, DOI 10.3109/08977199909002130; RUPP E, 1994, EUR J BIOCHEM, V225, P29, DOI 10.1111/j.1432-1033.1994.00029.x; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; SPRUGEL KH, 1991, PROG CLIN BIOL RES, V365, P327; STROOBANT P, 1984, EMBO J, V3, P2963, DOI 10.1002/j.1460-2075.1984.tb02241.x; Szebenyi G, 1999, INT REV CYTOL, V185, P45; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TIESMAN J, 1993, J BIOL CHEM, V268, P9621; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TONG BD, 1987, NATURE, V328, P619, DOI 10.1038/328619a0	46	213	245	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 20	2001	276	29					27406	27414		10.1074/jbc.M101056200	http://dx.doi.org/10.1074/jbc.M101056200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	454HJ	11297552	hybrid			2022-12-25	WOS:000169966900090
J	Linnell, J; Groeger, G; Hassan, AB				Linnell, J; Groeger, G; Hassan, AB			Real time kinetics of insulin-like growth factor II (IGF-II) interaction with the IGF-II/mannose 6-phosphate receptor - The effects of domain 13 and pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; MANNOSE 6-PHOSPHATE; BINDING-SITE; MANNOSE-6-PHOSPHATE RECEPTOR; PERINATAL LETHALITY; LYSOSOMAL-ENZYMES; LIGAND-BINDING; ORGAN SIZE; G-PROTEINS; EXPRESSION	The interaction of soluble forms of the human cation-independent insulin-like growth factor-II/mannose 6-phosphate receptor (IGF-IIR) with IGFs and mannosylated ligands was analyzed in real time. IGF-IIR proteins containing domains 1-15, 10-13, 11-13, or 11-12 were combined with rat CD4 domains 3 and 4. Following transient expression in 293T cells, secreted protein was immobilized onto biosensor chips. beta -Glucuronidase and latent transforming growth factor-beta1 bound only to domains 1-15. IGF-II bound to all constructs except a control, which contained a point mutation in domain 11. The affinity of domains 1-15, 10-13, 11-13, and 11-12 to IGF-II were 14, 120, 100, and 450 nM, respectively. Our data suggest. that domain 13 acts as an enhancer of IGF-II affinity by slowing the rate of dissociation, but additional enhancement by domains other than 10-13 also occurs. As the receptor functions to transport ligands from either the trans-Golgi network or extracellular space to the endosomes, the interaction of IGF-IIR extracellular domains with IGF-II was analyzed over a pH range of 5.0-7.4, The constructs behaved differently in response to pH and in recovery after low pH exposure, suggesting that pH stability of the extracellular domains depends on domains other than 10-13.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Hassan, AB (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.			Hassan, Andrew/0000-0002-2517-6681				AlShamkhani A, 1997, J BIOL CHEM, V272, P5275, DOI 10.1074/jbc.272.8.5275; Blanchard F, 1999, J BIOL CHEM, V274, P24685, DOI 10.1074/jbc.274.35.24685; BRADY RL, 1993, BIOCHEM SOC T, V21, P958, DOI 10.1042/bst0210958; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; CHISHOLM V, 1995, DNA CLONING PRACTICA; Chorney K M, 1998, J Biocommun, V25, P25; DAHMS NM, 1993, ENDOCRINOLOGY, V133, P440, DOI 10.1210/en.133.2.440; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; FISCHER HD, 1980, J BIOL CHEM, V255, P5069; GALLAHER BW, 1994, EUR J ENDOCRINOL, V131, P398, DOI 10.1530/eje.0.1310398; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GELATO MC, 1988, J CLIN ENDOCR METAB, V67, P669, DOI 10.1210/jcem-67-4-669; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Hassan AB, 2000, CANCER RES, V60, P1070; HOFLACK B, 1987, J BIOL CHEM, V262, P123; IKEZU T, 1995, J BIOL CHEM, V270, P29224, DOI 10.1074/jbc.270.49.29224; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kang JX, 1997, P NATL ACAD SCI USA, V94, P13671, DOI 10.1073/pnas.94.25.13671; Killian JK, 2000, MOL CELL, V5, P707, DOI 10.1016/S1097-2765(00)80249-X; KORNER C, 1995, J BIOL CHEM, V270, P287, DOI 10.1074/jbc.270.1.287; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LI M, 1991, Glycobiology, V1, P511, DOI 10.1093/glycob/1.5.511; LOBEL P, 1988, J BIOL CHEM, V263, P2563; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Gorman DB, 1999, CANCER RES, V59, P5692; Ouyang H, 1997, CANCER RES, V57, P1851; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; ROHRER J, 1995, J CELL BIOL, V130, P1297, DOI 10.1083/jcb.130.6.1297; SAHAGIAN GG, 1983, J BIOL CHEM, V258, P7121; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; TONG PY, 1988, J BIOL CHEM, V263, P2585; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Valenzano KJ, 1997, J BIOL CHEM, V272, P4804, DOI 10.1074/jbc.272.8.4804; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Yamada T, 1997, P NATL ACAD SCI USA, V94, P10351, DOI 10.1073/pnas.94.19.10351; York SJ, 1999, J BIOL CHEM, V274, P1164, DOI 10.1074/jbc.274.2.1164; Zaina S, 1998, J BIOL CHEM, V273, P28610, DOI 10.1074/jbc.273.44.28610; Zaina S, 1998, ENDOCRINOLOGY, V139, P3886, DOI 10.1210/en.139.9.3886	54	53	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23986	23991		10.1074/jbc.M100700200	http://dx.doi.org/10.1074/jbc.M100700200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11297550	hybrid			2022-12-25	WOS:000169531100101
J	Borisov, VB; Sedelnikova, SE; Poole, RK; Konstantinov, AA				Borisov, VB; Sedelnikova, SE; Poole, RK; Konstantinov, AA			Interaction of cytochrome bd with carbon monoxide at low and room temperatures - Evidence that only a small fraction of heme b(595) reacts with CO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AEROBIC RESPIRATORY-CHAIN; TERMINAL OXIDASE COMPLEX; ESCHERICHIA-COLI; QUINOL OXIDASE; UBIQUINOL OXIDASE; AZOTOBACTER-VINELANDII; OXYGEN; BINDING; PURIFICATION; COMPONENT	Azotobacter vinelandii is an obligately aerobic bacterium in which aerotolerant dinitrogen fixation requires cytochrome bd, This oxidase comprises two polypeptide subunits and three hemes, but no copper, and has been studied extensively. However, there remain apparently conflicting reports on the reactivity of the high spin heme b(595) with ligands. Using purified cytochrome bd, we show that absorption changes induced by CO photodissociation from the fully reduced cytochrome bd at low temperatures demonstrate binding of the ligand with heme b(595). However, the magnitude of these changes corresponds to the reaction with CO of only about 5% of the heme. CO binding with a minor fraction of heme b(595) is also revealed at room temperature by time-resolved studies of CO recombination, The data resolve the apparent discrepancies between conclusions drawn from room and low temperature spectroscopic studies of the CO reaction with cytochrome bd, The results are consistent with the proposal that hemes b(595) and d form a diheme oxygen-reducing center with a binding capacity for a single exogenous ligand molecule that partitions between the hemes d and b(595) in accordance with their intrinsic affinities for the ligand, In this model, the affinity of heme b(595) for CO is about 20-fold lower than that of heme d.	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Univ Sheffield, Krebs Inst Biomolec Res, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Lomonosov Moscow State University; University of Sheffield	Borisov, VB (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia.	r.poole@sheffield.ac.uk	Borisov, Vitaliy B/C-9504-2012	Borisov, Vitaliy B/0000-0002-3400-9068				ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; Azarkina N, 1999, J BIOL CHEM, V274, P32810, DOI 10.1074/jbc.274.46.32810; Azarkina N, 1997, FEBS LETT, V416, P171, DOI 10.1016/S0014-5793(97)01196-4; Bertsova YV, 1997, FEBS LETT, V414, P369, DOI 10.1016/S0014-5793(97)01047-8; Borisov V, 1999, BIOCHEMISTRY-US, V38, P740, DOI 10.1021/bi981908t; BORISOV VB, 1995, BIOCHEMISTRY-MOSCOW+, V60, P231; CHANCE B, 1975, ANAL BIOCHEM, V67, P552, DOI 10.1016/0003-2697(75)90331-0; DMELLO R, 1994, FEMS MICROBIOL LETT, V121, P115, DOI 10.1111/j.1574-6968.1994.tb07084.x; Dmello R, 1996, MICROBIOL-UK, V142, P755, DOI 10.1099/00221287-142-4-755; DUEWEKE TJ, 1991, BIOCHEMISTRY-US, V30, P3401, DOI 10.1021/bi00228a007; GREEN GN, 1986, BIOCHEMISTRY-US, V25, P2309, DOI 10.1021/bi00357a002; HATATANAKA A, 1987, BIOCHIM BIOPHYS ACTA, V893, P289, DOI 10.1016/0005-2728(87)90050-8; HILL JJ, 1993, P NATL ACAD SCI USA, V90, P5863, DOI 10.1073/pnas.90.12.5863; JUNEMANN S, 1995, J BIOL CHEM, V270, P16213, DOI 10.1074/jbc.270.27.16213; JUNEMANN S, 1995, BIOCHEM SOC T, V23, pS157; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; Kalnenieks U, 1998, FEMS MICROBIOL LETT, V168, P91; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KELLY MJS, 1990, J BACTERIOL, V172, P6010, DOI 10.1128/jb.172.10.6010-6019.1990; KITA K, 1984, J BIOL CHEM, V259, P3375; Kobayashi K, 1999, BIOCHEMISTRY-US, V38, P5913, DOI 10.1021/bi982088n; KOLAND JG, 1984, BIOCHEMISTRY-US, V23, P445, DOI 10.1021/bi00298a008; KRASNOSELSKAYA I, 1993, FEBS LETT, V327, P279, DOI 10.1016/0014-5793(93)81004-J; LORENCE RM, 1986, BIOCHEMISTRY-US, V25, P2314, DOI 10.1021/bi00357a003; MILLER MJ, 1985, J BIOL CHEM, V260, P4003; MILLER MJ, 1986, METHOD ENZYMOL, V126, P87; Osborne JP, 1999, BBA-BIOENERGETICS, V1410, P32, DOI 10.1016/S0005-2728(98)00171-6; POOLE RK, 1987, FEBS LETT, V217, P49, DOI 10.1016/0014-5793(87)81240-1; POOLE RK, 1982, FEBS LETT, V141, P237, DOI 10.1016/0014-5793(82)80056-2; POOLE RK, 1981, J GEN MICROBIOL, V125, P431; POOLE RK, 1983, J GEN MICROBIOL, V129, P1345; POOLE RK, 1994, MICROBIOL-SGM, V140, P1027, DOI 10.1099/13500872-140-5-1027; POOLE RK, 1994, ANTON LEEUW INT J G, V65, P289, DOI 10.1007/BF00872215; Poole RK., 1988, BACTERIAL ENERGY TRA, P231; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; ROTHERY RA, 1987, J GEN MICROBIOL, V133, P3247; Sakamoto J, 1999, BBA-BIOENERGETICS, V1411, P147, DOI 10.1016/S0005-2728(99)00012-2; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; TSUBAKI M, 1995, J BIOL CHEM, V270, P28565, DOI 10.1074/jbc.270.48.28565; VINCENT JC, 1982, ANAL BIOCHEM, V126, P86, DOI 10.1016/0003-2697(82)90112-9; Vos MH, 2000, P NATL ACAD SCI USA, V97, P1554, DOI 10.1073/pnas.030528197; WILSON DF, 1967, ARCH BIOCHEM BIOPHYS, V121, P757, DOI 10.1016/0003-9861(67)90065-3; WOOD PM, 1984, BIOCHIM BIOPHYS ACTA, V768, P293, DOI 10.1016/0304-4173(84)90020-X	43	44	51	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22095	22099		10.1074/jbc.M011542200	http://dx.doi.org/10.1074/jbc.M011542200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11283005	hybrid			2022-12-25	WOS:000169412700017
J	Sweeney, C; Fambrough, D; Huard, C; Diamonti, AJ; Lander, ES; Cantley, LC; Carraway, KL				Sweeney, C; Fambrough, D; Huard, C; Diamonti, AJ; Lander, ES; Cantley, LC; Carraway, KL			Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; DIFFERENTIATION FACTOR; TYROSINE KINASES; BREAST-CANCER; NEURONAL DIFFERENTIATION; NEUREGULIN RECEPTOR; CARDIAC DEVELOPMENT; PC12 CELLS; LIGAND; NETWORK	The mechanisms by which receptor tyrosine kinases (RTKs) utilize intracellular signaling pathways to direct gene expression and cellular response remain unclear. A current question is whether different RTKs within a single cell target similar or different sets of genes. In this study we have used the ErbB receptor network to explore the relationship between RTK activation and gene expression, We profiled growth factor-stimulated signaling pathway usage and broad gene expression patterns in two human mammary tumor cell lines expressing different complements of ErbB receptors. Although the growth factors epidermal growth factor (EGF) and neuregulin (NRG) 1 similarly stimulated Erk1/2 in MDA-MB-361 cells, EGF acting through an EGF receptor/ ErbB2 heterodimer preferentially stimulated protein kinase C, and NRG1 beta acting through an ErbB2/ErbB3 heterodimer preferentially stimulated Akt, The two growth factors regulated partially overlapping yet distinct sets of genes in these cells. In MDA-MB-453 cells, NRG1 beta acting through an ErbB2/ErbB3 heterodimer stimulated prolonged signaling of all pathways examined relative to NRG2 beta acting through the same heterodimeric receptor species, Surprisingly, NRG1 beta and NRG2 beta also regulated partially overlapping but distinct sets of genes in these cells. These results demonstrate that the activation of different RTKs, or activation of the same RTKs with different Iigands, can lead to distinct profiles of gene regulation within a single cell type. Our observations also suggest that the identity and kinetics of signaling pathway usage by RTKs may play a role in the selection of regulated genes.	Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA; Whitehead Inst Biomed Res, Nine Cambridge Ctr, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Sweeney, C (corresponding author), Univ Calif Davis, Ctr Canc, Res Bldg 3,Rm 1400,4645 2nd Ave, Sacramento, CA 95817 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NCI NIH HHS [CA71702] Funding Source: Medline; NIGMS NIH HHS [GM41890, R01 GM041890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adlkofer K, 2000, GLIA, V29, P104, DOI 10.1002/(SICI)1098-1136(20000115)29:2<104::AID-GLIA2>3.0.CO;2-2; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.0.CO;2-B; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Cohen BD, 1996, J BIOL CHEM, V271, P30897, DOI 10.1074/jbc.271.48.30897; Crovello CS, 1998, J BIOL CHEM, V273, P26954, DOI 10.1074/jbc.273.41.26954; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Daly JM, 1997, CANCER RES, V57, P3804; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Flores GV, 2000, CELL, V103, P75, DOI 10.1016/S0092-8674(00)00106-9; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lin WC, 2000, P NATL ACAD SCI USA, V97, P1299, DOI 10.1073/pnas.97.3.1299; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pawson T, 1999, CELL, V97, P675, DOI 10.1016/S0092-8674(00)80779-5; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Shak S, 1999, SEMIN ONCOL, V26, P71; Simon MA, 2000, CELL, V103, P13, DOI 10.1016/S0092-8674(00)00100-8; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; WOODGETT JR, 1989, BRIT MED BULL, V45, P529, DOI 10.1093/oxfordjournals.bmb.a072340; Xu CY, 2000, CELL, V103, P87, DOI 10.1016/S0092-8674(00)00107-0; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215	57	98	101	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22685	22698		10.1074/jbc.M100602200	http://dx.doi.org/10.1074/jbc.M100602200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297548	hybrid			2022-12-25	WOS:000169412700096
J	Aoki, K; Ishida, N; Kawakita, M				Aoki, K; Ishida, N; Kawakita, M			Substrate recognition by UDP-galactose and CMP-sialic acid transporters - Different sets of transmembrane helices are utilized for the specific recognition of UDP-galactose and CMP-sialic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINE TRANSPORTER; NUCLEOTIDE-SUGAR TRANSPORTERS; GOLGI VESICLE MEMBRANES; OVARY CELL MUTANT; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; VRG4 GENE; DEFICIENT	Human UDP-galactose transporter (hUGT1) and CMP-sialic acid transporter (hCST) are related Golgi membrane proteins with 10 transmembrane helices. We have constructed chimeras between these proteins in order to identify submolecular regions responsible for the determination of substrate specificity. To assess the UGT and CST activities, chimeric cDNAs were transiently expressed in either UGT-deficient mutant Lec8 cells or CST-deficient mutant Lec2 cells, and the binding of plant lectins, GS-II or PNA, respectively, to these cells was examined. During the course of analysis of various chimeric transporters, we found that chimeras whose submolecular regions contained helices 1, 8, 9, and 10, and helices 2, 3, and 7 derived from hUGT1 and hCST sequences, respectively, exhibited both UGT and CST activities. The dual substrate specificity for UDP-galactose and CMP-sialic acid of one such representative chimera was directly confirmed by in vitro measurement of the nucleotide sugar transport activity casing a heterologous expression system in the yeast Saccharomyces cerevisiae, These findings indicated that the regions which are critical for determining the substrate specificity of UGT and CST resided in different submolecular sites in the two transporters, and that these different determinants could be present within one protein without interfering with each other's function.	Tokyo Metropolitan Inst Med Sci, Dept Physiol Chem, Bunkyo Ku, Tokyo 1138613, Japan	Tokyo Metropolitan Institute of Medical Science	Kawakita, M (corresponding author), Kogakuin Univ, Dept Appl Chem, Shinjuku Ku, 1-24-2 Nishi Shinjuku, Tokyo 1638677, Japan.	bt13004@ns.kogakuin.ac.jp						Abeijon C, 1996, P NATL ACAD SCI USA, V93, P5963, DOI 10.1073/pnas.93.12.5963; Aoki K, 1999, J BIOCHEM, V126, P940, DOI 10.1093/oxfordjournals.jbchem.a022538; BOSSUYT X, 1994, BIOCHEM J, V302, P261, DOI 10.1042/bj3020261; BRILES EB, 1977, J BIOL CHEM, V252, P1107; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; Eckhardt M, 1999, J BIOL CHEM, V274, P8779, DOI 10.1074/jbc.274.13.8779; Eckhardt M, 1997, EUR J BIOCHEM, V248, P187, DOI 10.1111/j.1432-1033.1997.00187.x; Eckhardt M, 1996, P NATL ACAD SCI USA, V93, P7572, DOI 10.1073/pnas.93.15.7572; Guillen E, 1998, P NATL ACAD SCI USA, V95, P7888, DOI 10.1073/pnas.95.14.7888; HARA T, 1989, J BIOCHEM-TOKYO, V106, P236, DOI 10.1093/oxfordjournals.jbchem.a122838; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Ishida N, 1996, J BIOCHEM, V120, P1074; Ishida N, 1999, J BIOCHEM, V126, P1107, DOI 10.1093/oxfordjournals.jbchem.a022556; Ishida N, 1998, J BIOCHEM, V124, P171, DOI 10.1093/oxfordjournals.jbchem.a022076; Ishida N, 1999, J BIOCHEM, V126, P68, DOI 10.1093/oxfordjournals.jbchem.a022437; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kawakita M, 1998, J BIOCHEM, V123, P777; Lubke T, 1999, J BIOL CHEM, V274, P25986, DOI 10.1074/jbc.274.37.25986; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Poster JB, 1996, J BIOL CHEM, V271, P3837; Segawa H, 1999, FEBS LETT, V451, P295, DOI 10.1016/S0014-5793(99)00596-7; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; Sun-Wada GH, 1998, J BIOCHEM, V123, P912; TAKI T, 1991, CANCER RES, V51, P1701; Wang J, 1997, J BIOL CHEM, V272, P28845, DOI 10.1074/jbc.272.46.28845; Yoshioka S, 1997, J BIOCHEM, V122, P691	30	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21555	21561		10.1074/jbc.M101462200	http://dx.doi.org/10.1074/jbc.M101462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279205	hybrid			2022-12-25	WOS:000169297900101
J	Chattopadhyay, MK; Murakami, Y; Matsufuji, S				Chattopadhyay, MK; Murakami, Y; Matsufuji, S			Antizyme regulates the degradation of ornithine decarboxylase in fission yeast Schizosaccharomyces pombe - Study in the spe2 knockout strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; SACCHAROMYCES-CEREVISIAE; POLYAMINE SYNTHESIS; MAMMALIAN ANTIZYME; NEUROSPORA-CRASSA; 26S PROTEASOME; BUDDING YEAST; PROTEIN; CELLS; EXPRESSION	The mechanism of the regulatory degradation of ornithine decarboxylase (ODC) by polyamines was studied in fission yeast, Schizosaccharomyces pombe. To regulate cellular spermidine experimentally, we cloned and disrupted S-adenosylmethionine decarboxylase gene (spe2) in S. pombe. The null mutant of spe2 was devoid of spermidine and spermine, accumulated putrescine, and contained a high level of ODC. Addition of spermidine to the culture medium resulted in rapid decrease in the ODC activity caused by the acceleration of ODC degradation, which was dependent on de novo protein synthesis. A fraction of ODC forming an inactive complex concomitantly increased. The accelerated ODC degradation was prevented either by knockout of antizyme gene or by selective inhibitors of proteasome. Thus, unlike budding yeast, mammalian type antizyme-mediated ODC degradation by proteasome is operating in S. pombe.	Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, Tokyo 1058461, Japan	Jikei University	Matsufuji, S (corresponding author), Jikei Univ, Sch Med, Dept Biochem 2, Minato Ku, 3-25-8 Nishi Shinbashi, Tokyo 1058461, Japan.	senya@jikei.ac.jp						Bagni N., 1989, PHYSL POLYAMINES, P107; BALASUNDARAM D, 1993, P NATL ACAD SCI USA, V90, P4693, DOI 10.1073/pnas.90.10.4693; BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; BARNETT GR, 1988, J BIOL CHEM, V263, P10005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Da'Dara AA, 1998, BIOCHEM J, V336, P545, DOI 10.1042/bj3360545; ELIAS S, 1995, EUR J BIOCHEM, V229, P276, DOI 10.1111/j.1432-1033.1995.0276l.x; FONZI WA, 1989, J BIOL CHEM, V264, P18110; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; Hayashi S, 1996, TRENDS BIOCHEM SCI, V21, P27, DOI 10.1016/0968-0004(96)80882-6; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; HELLER JS, 1976, P NATL ACAD SCI USA, V73, P1858, DOI 10.1073/pnas.73.6.1858; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; Ivanov IP, 2000, NUCLEIC ACIDS RES, V28, P3185, DOI 10.1093/nar/28.17.3185; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Ivanov IP, 1998, RNA, V4, P1230, DOI 10.1017/S1355838298980864; KASHIWAGI K, 1990, J BIOL CHEM, V265, P22321; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1985, BIOCHEM J, V225, P689, DOI 10.1042/bj2250689; MURAKAMI Y, 1989, EUR J BIOCHEM, V180, P181, DOI 10.1111/j.1432-1033.1989.tb14630.x; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; MURAKAMI Y, 1988, BIOCHEM J, V254, P367, DOI 10.1042/bj2540367; Pegg AE, 1998, BIOCHEM SOC T, V26, P580, DOI 10.1042/bst0260580; PITKIN J, 1990, ARCH BIOCHEM BIOPHYS, V278, P386, DOI 10.1016/0003-9861(90)90275-4; ROM E, 1994, P NATL ACAD SCI USA, V91, P3959, DOI 10.1073/pnas.91.9.3959; Ruan HJ, 1996, J BIOL CHEM, V271, P29576, DOI 10.1074/jbc.271.47.29576; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; Saito T, 2000, BIOCHEM J, V345, P99, DOI 10.1042/0264-6021:3450099; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; Sakata K, 1997, BIOCHEM BIOPH RES CO, V238, P415, DOI 10.1006/bbrc.1997.7266; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Toth C, 1999, J BIOL CHEM, V274, P25921, DOI 10.1074/jbc.274.36.25921; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; Zhu C, 2000, BIOINFORMATICS, V16, P478, DOI 10.1093/bioinformatics/16.5.478	45	20	22	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21235	21241		10.1074/jbc.M010643200	http://dx.doi.org/10.1074/jbc.M010643200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283013	hybrid			2022-12-25	WOS:000169297900059
J	Mertani, HC; Zhu, T; Goh, ELK; Lee, KO; Morel, G; Lobie, PE				Mertani, HC; Zhu, T; Goh, ELK; Lee, KO; Morel, G; Lobie, PE			Autocrine human growth hormone (hGH) regulation of human mammary carcinoma cell gene expression - Identification of chop as a mediator of hGH-stimulated human mammary carcinoma cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR CHOP; RECEPTOR MESSENGER-RNA; AMINO-ACID LIMITATION; BINDING-PROTEIN; BETA-CATENIN; FACTOR-I; BREAST-CANCER; SKI ONCOGENE; GADD153 GENE; GLAND FACTOR	By use of cDNA array technology we have screened 588 genes to determine the effect of autocrine production of human growth hormone (hGH) on gene expression in human mammary carcinoma cells. We have used a previously described cellular model to study autocrine hGH function in which the hGH gene or a translation-deficient hGH gene was stably transfected into MCF-7 cells. Fifty two of the screened genes were regulated, either positively (24) or negatively (28), by autocrine production of hGH, We have now characterized the role of one of the up-regulated genes, chop (gadd153), in the effect of autocrine production of hGH on mammary carcinoma cell number. The effect of autocrine production of hGH on the level of CHOP mRNA was exerted at the transcriptional level as autocrine hGH increased chloramphenicol acetyltransferase production from a reporter plasmid containing a l-kilobase pair fragment of the chop promoter. The autocrine hGH-stimulated increase in CHOP mRNA also resulted in an increase in CHOP protein. As a consequence, autocrine hGH stimulation of CHOP-mediated transcriptional activation was increased. Stable transfection of human CHOP cDNA into mammary carcinoma cells demonstrated that CHOP functioned not as a mediator of hGH-stimulated mitogenesis but rather enhanced the protection from apoptosis afforded by hGH in a p38 MAPK-dependent manner. Thus transcriptional up-regulation of chop is one mechanism by which hGH regulates mammary carcinoma cell number.	Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Dept Med, Singapore 119074, Singapore; Univ Lyon 1, CNRS, UMR 5578, F-69622 Villeurbanne, France	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Lobie, PE (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbpel@imcb.nus.edu.sg	MERTANI, Hichem-Claude/AAR-6415-2020; Lee, Kok-Onn/E-9874-2011; Goh, Eyleen/A-8006-2013	Lee, Kok-Onn/0000-0002-3040-1185; Goh, Eyleen/0000-0002-8244-6959				Abcouwer SF, 1999, J BIOL CHEM, V274, P28645, DOI 10.1074/jbc.274.40.28645; Adelmant G, 1998, J BIOL CHEM, V273, P15574, DOI 10.1074/jbc.273.25.15574; Arnal M, 1999, INT J MOL MED, V4, P545; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bergad PL, 2000, J BIOL CHEM, V275, P8114, DOI 10.1074/jbc.275.11.8114; Brenner B, 1997, J BIOL CHEM, V272, P22173, DOI 10.1074/jbc.272.35.22173; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; CHEN Q, 1992, J BIOL CHEM, V267, P8207; Cianfarani S, 1998, EUR J CLIN INVEST, V28, P41; Coutts M, 1999, BLOOD, V93, P3369, DOI 10.1182/blood.V93.10.3369.410k11_3369_3378; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; Cui KY, 2000, J BIOL CHEM, V275, P7591, DOI 10.1074/jbc.275.11.7591; Del Bino G, 1999, CELL PROLIFERAT, V32, P25, DOI 10.1046/j.1365-2184.1999.00130.x; ENGERT JC, 1995, NUCLEIC ACIDS RES, V23, P2988, DOI 10.1093/nar/23.15.2988; Fawcett TW, 1997, CELL STRESS CHAPERON, V2, P104, DOI 10.1379/1466-1268(1997)002<0104:POHSIH>2.3.CO;2; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FELDMAN M, 1993, ENDOCRINOLOGY, V133, P1602, DOI 10.1210/en.133.4.1602; Friedman AD, 1996, CANCER RES, V56, P3250; GIARRE M, 1998, ANN NY ACAD SCI, V23, P43; GLIMM DR, 1990, J ENDOCRINOL, V126, pR5, DOI 10.1677/joe.0.126R005; Goh ELK, 1998, ENDOCRINOLOGY, V139, P4364, DOI 10.1210/en.139.10.4364; Goh ELK, 1997, ENDOCRINOLOGY, V138, P3207, DOI 10.1210/en.138.8.3207; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; Haeffner A, 1999, EUR J IMMUNOL, V29, P334, DOI 10.1002/(SICI)1521-4141(199901)29:01<334::AID-IMMU334>3.0.CO;2-S; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUGUET EL, 1994, CANCER RES, V54, P2615; ILKBAHAR YN, 1995, ENDOCRINOLOGY, V136, P386, DOI 10.1210/en.136.2.386; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JAMMES H, 1991, MOL CELL ENDOCRINOL, V75, P27, DOI 10.1016/0303-7207(91)90242-K; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; Kim R, 1999, ANTICANCER RES, V19, P1779; Kim R, 1999, ANTICANCER RES, V19, P5399; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lantinga-van Leeuwen IS, 1999, MOL CELL ENDOCRINOL, V150, P121, DOI 10.1016/S0303-7207(99)00010-6; Li H, 1998, ENDOCRINOLOGY, V139, P3855, DOI 10.1210/en.139.9.3855; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; LINCOLN DT, 1990, ACTA HISTOCHEM, P47; MARTEN NW, 1994, FASEB J, V8, P538, DOI 10.1096/fasebj.8.8.8181673; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Mertani HC, 1998, INT J CANCER, V79, P202; MERTANI HC, 1995, ENDOCRINE, V3, P135, DOI 10.1007/BF02990065; MOL JA, 1995, J CLIN ENDOCR METAB, V80, P3094, DOI 10.1210/jc.80.10.3094; MOL JA, 1995, J CLIN INVEST, V95, P2028, DOI 10.1172/JCI117888; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MOSER AR, 1993, P NATL ACAD SCI USA, V90, P8977, DOI 10.1073/pnas.90.19.8977; Nam S Y, 2000, Obes Rev, V1, P73, DOI 10.1046/j.1467-789x.2000.00015.x; Nicol R, 1998, J BIOL CHEM, V273, P3588, DOI 10.1074/jbc.273.6.3588; Nicol R, 1999, CELL GROWTH DIFFER, V10, P243; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Orme SM, 1998, J CLIN ENDOCR METAB, V83, P2730, DOI 10.1210/jc.83.8.2730; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLAUT K, 1993, ENDOCRINOLOGY, V133, P1843, DOI 10.1210/en.133.4.1843; PRICE BD, 1992, CANCER RES, V52, P3814; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUDICK VL, 1993, J CELL SCI, V104, P509; Schlosshauer PW, 2000, CARCINOGENESIS, V21, P1453, DOI 10.1093/carcin/21.7.1453; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shen J, 2000, EXP CELL RES, V259, P274, DOI 10.1006/excr.2000.4963; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; SOBRIER ML, 1993, FEBS LETT, V319, P16, DOI 10.1016/0014-5793(93)80028-S; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	87	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21464	21475		10.1074/jbc.M100437200	http://dx.doi.org/10.1074/jbc.M100437200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11297545	hybrid			2022-12-25	WOS:000169297900090
J	Tang, A; Curthoys, NP				Tang, A; Curthoys, NP			Identification of zeta-crystallin/NADPH : quinone reductase as a renal glutaminase mRNA pH response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; PHOSPHATE-DEPENDENT GLUTAMINASE; GUINEA-PIG; METABOLIC-ACIDOSIS; GENE-EXPRESSION; RAT-KIDNEY; LENS; TIAR; RECRUITMENT; STABILITY	Increased renal ammoniagenesis and bicarbonate synthesis from glutamine during chronic metabolic acidosis facilitate the excretion of acids and partially restore normal acid-base balance. This adaptation is sustained, in part, by a cell-specific stabilization of the glutaminase mRNA that leads to an increased synthesis of the mitochondrial glutaminase, A direct repeat of an 8-base AU sequence within the 3'-nontranslated region of the glutaminase mRNA binds a unique protein with high affinity and specificity. Expression of various chimeric mRNAs in LLC-PK1-FBPase(+) cells demonstrated that a single 8-base AU sequence is both necessary and sufficient to function as a pH response element (pH RE). A biotinylated oligoribonucleotide containing the direct repeat was used as an affinity ligand to purify the pH RE-binding protein from a cytosolic extract of rat renal cortex. The purified binding activity retained the same specific binding properties as observed with crude extracts and correlated with the elution of a 36-kDa protein. Microsequencing by mass spectroscopy and Western blot analysis were used to identify this protein as zeta -crystallin/NADPH:quinone reductase, The purified protein contained eight tryptic peptides that were identical to sequences found in mouse zeta -crystallin and three peptides that differed by only a single amino acid. The observed differences may represent substitutions found in the rat homolog. A second protein purified by this protocol was identified as T-cell-restricted intracellular antigen-related protein (TIAR), However, the purified TIAR neither bound nor affected the binding of zeta -crystallin/NADPH:quinone reductase to the pH RE. Further; more, specific antibodies to zeta -crystallin, but not TIAR, blocked the formation of the complex between the pH RE and either the crude cytosolic extract or the purified protein. Thus, zeta -crystallin/NADPH:quinone reductase is a pH response element-binding protein.	Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA	Colorado State University	Curthoys, NP (corresponding author), Colorado State Univ, Dept Biochem & Mol Biol, Ft Collins, CO 80523 USA.				NIDDK NIH HHS [DK-37124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERTA JA, 1994, J BIOL CHEM, V269, P4532; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brosnan JT, 1988, PH HOMEOSTASIS MECHA, P281; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; CURTHOYS NP, 1976, ARCH BIOCHEM BIOPHYS, V172, P162, DOI 10.1016/0003-9861(76)90062-X; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; Gagna CE, 1998, CELL BIOL INT, V22, P217, DOI 10.1006/cbir.1998.0243; GARLAND D, 1991, ARCH BIOCHEM BIOPHYS, V285, P134, DOI 10.1016/0003-9861(91)90339-K; GONZALEZ P, 1994, GENOMICS, V21, P317, DOI 10.1006/geno.1994.1272; GONZALEZ P, 1995, MOL BIOL EVOL, V12, P773; GONZALEZ P, 1994, MOL BIOL EVOL, V11, P305; GSTRAUNTHALER G, 1987, AM J PHYSIOL, V252, pC232, DOI 10.1152/ajpcell.1987.252.2.C232; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hansen WR, 1996, AM J PHYSIOL-RENAL, V271, pF126, DOI 10.1152/ajprenal.1996.271.1.F126; HWANG JJ, 1991, J BIOL CHEM, V266, P9392; HWANG JJ, 1991, BIOCHEMISTRY-US, V30, P7522, DOI 10.1021/bi00244a022; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; Laterza OF, 2000, J AM SOC NEPHROL, V11, P1583, DOI 10.1681/ASN.V1191583; Laterza OF, 1997, J BIOL CHEM, V272, P22481, DOI 10.1074/jbc.272.36.22481; Laterza OF, 2000, AM J PHYSIOL-RENAL, V278, pF970, DOI 10.1152/ajprenal.2000.278.6.F970; LEE DC, 1994, J MOL BIOL, V236, P669, DOI 10.1006/jmbi.1994.1178; RAO PV, 1992, BIOCHIM BIOPHYS ACTA, V1117, P315; RAO PV, 1992, J BIOL CHEM, V267, P96; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; SQUIRES EJ, 1976, BIOCHEM J, V160, P125, DOI 10.1042/bj1600125; TANNEN RL, 1992, HDB PHYSL 8, V1, P1017; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; TONG J, 1987, BIOCHEMISTRY-US, V26, P2773, DOI 10.1021/bi00384a018; TONG J, 1986, BIOCHEM J, V233, P139, DOI 10.1042/bj2330139; Wang ZR, 2000, MOL CELL BIOL, V20, P6334, DOI 10.1128/MCB.20.17.6334-6341.2000; WELBOURNE TC, 1986, AM J PHYSIOL, V250, pF457; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF961, DOI 10.1152/ajprenal.1990.259.6.F961	39	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21375	21380		10.1074/jbc.M101941200	http://dx.doi.org/10.1074/jbc.M101941200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11294877	hybrid			2022-12-25	WOS:000169297900078
J	Stacey, M; Lin, HH; Hilyard, KL; Gordon, S; McKnight, AJ				Stacey, M; Lin, HH; Hilyard, KL; Gordon, S; McKnight, AJ			Human epidermal growth factor (EGF) module-containing mucin-like hormone receptor 3 is a new member of the EGF-TM7 family that recognizes a ligand on human macrophages and activated neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALPHA-LATROTOXIN RECEPTOR; MOLECULAR-CLONING; POINT MUTATIONS; MARFAN-SYNDROME; MOUSE CD97; RAT CD2; SURFACE; 7-TRANSMEMBRANE; CD48	The epidermal growth factor (EGF)-TM7 subgroup of G-protein-coupled receptors is composed predominantly of leukocyte-restricted glycoproteins defined by their unique hybrid structure, in which extracellular EGF-like domains are coupled to a seven-span transmembrane moiety via a mucin-like stalk. The EGF-TM7 group comprises mouse F4/80, human EGF module-containing mucin-like hormone receptor (EMR) 1, human EMR2, and human and mouse CD97, the genes for which map to human chromosome 19p13 and the syntenic regions of the mouse genome. In this study we describe the cloning and characterization of EMR3, a novel human EGF-TM7 molecule, and show the existence of its cellular ligand. The EMR3 gene maps closely to the existing members of the EGF-TM7 family on human chromosome 19p13.1 and, in common with other EGF-TM7 genes, is capable of generating different protein isoforms through alternative splicing. Two alternative splice forms have been isolated: one encoding a 652-amino acid cell surface protein consisting of two EGF-like domains, a mucin stalk, and a putative G-protein-coupled receptor domain and the other encoding a truncated soluble form containing only two EGF-like domains. As with other members of the EGF-TM7 family, EMR3 mRNA displays a predominantly leukocyte-restricted expression pattern, with highest levels in neutrophils, monocytes, and macrophages, Through the use of soluble EMR3 multivalent probes we have shown the presence of a ligand at the surface of monocyte-derived macrophages and activated human neutrophils. These interactions suggest a potential role for EMR3 in myeloid-myeloid interactions during immune and inflammatory responses.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Roche Discovery Welwyn, Welwyn Garden City AL7 3AY, Herts, England; Kings Coll London Hosp, Dept Clin Sci, Inst Liver Studies, London SE5 9PJ, England	University of Oxford; Roche Holding; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Stacey, M (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	mstacey@molbiol.ox.ac.uk	LIN, Hsi-Hsien/N-1488-2015					BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brown MH, 1995, EUR J IMMUNOL, V25, P3222, DOI 10.1002/eji.1830251204; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Carver EA, 1999, MAMM GENOME, V10, P1039, DOI 10.1007/s003359901157; Chomczynski P, 1997, BIOTECHNIQUES, V22, P550, DOI 10.2144/97223pf01; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; Gray JX, 1996, J IMMUNOL, V157, P5438; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hobbs Helen H., 1992, Human Mutation, V1, P445, DOI 10.1002/humu.1380010602; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Lin HH, 1997, GENOMICS, V41, P301, DOI 10.1006/geno.1997.4674; Lin HH, 2000, GENOMICS, V67, P188, DOI 10.1006/geno.2000.6238; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; McKnight AJ, 1998, J LEUKOCYTE BIOL, V63, P271, DOI 10.1002/jlb.63.3.271; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Qian YM, 1999, IMMUNOLOGY, V98, P303; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Sugita S, 1998, J BIOL CHEM, V273, P32715, DOI 10.1074/jbc.273.49.32715; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x	28	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					18863	18870		10.1074/jbc.M101147200	http://dx.doi.org/10.1074/jbc.M101147200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279179	hybrid			2022-12-25	WOS:000169091000030
J	Tuominen, EKJ; Zhu, K; Wallace, CJA; Clark-Lewis, I; Craig, DB; Rytomaa, M; Kinnunen, PKJ				Tuominen, EKJ; Zhu, K; Wallace, CJA; Clark-Lewis, I; Craig, DB; Rytomaa, M; Kinnunen, PKJ			ATP induces a conformational change in lipid-bound cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITE; PHOSPHOLIPID-VESICLES; CIRCULAR-DICHROISM; FERRICYTOCHROME-C; EMISSION-SPECTRA; LIPOSOMES; OXIDASE; MEMBRANES; MITOCHONDRIA; RESONANCE	Resonance energy transfer studies using a pyrene-labeled phospholipid derivative 1-palmitoyl-2-[10(pyren-1-yl)decanoyl]-sn-glycero-3-phosphoglycerol (donor) and the heme (acceptor) of cytochrome c (cyt c) have indicated that ATP causes changes in the conformation of the lipid-bound protein (Rytomaa, M., Mustonen, P., and Kinnunen, P. K. J. (1992) J. Biol. Chem. 267, 22243-22248). Accordingly, after binding cyt c via its so called C-site to neat phosphatidylglycerol liposomes (mole fraction of PG = 1.0) has commenced, further quenching of donor fluorescence is caused by ATP, saturating at 2 mM nucleotide. ATP-induced conformational changes in liposome-associated cyt c could be directly demonstrated by CD in the Soret band region (380-460 nm). The latter data were further supported by time-resolved spectroscopy using the fluorescent cyt c analog with a Zn2+-substituted heme moiety. A high affinity ATP-binding site has been demonstrated in cyt c (Craig, D. B., and Wallace, C. J. A. (1993) Protein Sci. 2, 966-976) that is compromised by replacing the invariant Arg(91) to norleucine. Although no major effects on conformation and function of cyt c were concluded due to the modification, a significantly reduced effect by ATP on the lipid-bound [Nle(91)]cyt c was evident, implying that this modulation is mediated via the Arg(91)-containing binding site.	Univ Helsinki, Inst Biomed, Dept Med Chem, Helsinki Biophys & Biomembrane Grp, FIN-00014 Helsinki, Finland; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1W5, Canada; Dalhousie Univ, Dept Biochem, Halifax, NS B3H 4H7, Canada	University of Helsinki; University of British Columbia; Dalhousie University	Kinnunen, PKJ (corresponding author), Univ Helsinki, Inst Biomed, Dept Med Chem, Helsinki Biophys & Biomembrane Grp, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.							ANNI H, 1995, BIOCHEMISTRY-US, V34, P5744, DOI 10.1021/bi00017a006; ANTALIK M, 1995, GEN PHYSIOL BIOPHYS, V14, P19; BLAUER G, 1993, BIOCHEMISTRY-US, V32, P6674, DOI 10.1021/bi00077a021; Cortese JD, 1998, BIOCHEMISTRY-US, V37, P6402, DOI 10.1021/bi9730543; CORTHESY BE, 1988, BIOCHEM J, V252, P349, DOI 10.1042/bj2520349; CORTHESY BE, 1986, BIOCHEM J, V236, P359, DOI 10.1042/bj2360359; CRAIG DB, 1995, BIOCHEMISTRY-US, V34, P2686, DOI 10.1021/bi00008a036; CRAIG DB, 1991, BIOCHEM J, V279, P781, DOI 10.1042/bj2790781; CRAIG DB, 1993, PROTEIN SCI, V2, P966, DOI 10.1002/pro.5560020610; DEJONGH HHJ, 1992, BIOCHEMISTRY-US, V31, P1636, DOI 10.1021/bi00121a008; DEJONGH HHJ, 1995, FEBS LETT, V360, P255, DOI 10.1016/0014-5793(95)00115-P; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V602, P477, DOI 10.1016/0005-2736(80)90327-2; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GRATTON E, 1984, ANNU REV BIOPHYS BIO, V13, P105; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HILDEBRANDT P, 1990, EUR BIOPHYS J, V18, P193, DOI 10.1007/BF02427378; Jameson D. M., 1991, BIOPHYSICAL BIOCH AS, P105; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; Kinnunen PKJ, 1996, CHEM PHYS LIPIDS, V81, P151, DOI 10.1016/0009-3084(96)02579-0; KINNUNEN PKJ, 1994, CHEM PHYS LIPIDS, V73, P181, DOI 10.1016/0009-3084(94)90181-3; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN J, 1995, BIOCHEMISTRY-US, V34, P2678, DOI 10.1021/bi00008a035; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; McIntosh DB, 1996, J BIOL CHEM, V271, P18379, DOI 10.1074/jbc.271.31.18379; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; MUSTONEN P, 1993, J BIOL CHEM, V268, P1074; MYER YP, 1968, J BIOL CHEM, V243, P2115; Pinheiro TJT, 1997, BIOCHEMISTRY-US, V36, P13122, DOI 10.1021/bi971235z; Rosell FI, 1998, J AM CHEM SOC, V120, P11234, DOI 10.1021/ja971756+; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Salamon Z, 1996, BIOPHYS J, V71, P848, DOI 10.1016/S0006-3495(96)79286-X; Santucci R, 1997, J INORG BIOCHEM, V68, P211, DOI 10.1016/S0162-0134(97)00100-1; SKOOG L, 1974, J BIOL CHEM, V249, P6434; SMITH L, 1980, BIOCHEMISTRY-US, V19, P1613, DOI 10.1021/bi00549a013; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SPOONER J, 1992, BIOCHEMISTRY-US, V30, P3880; SPOONER J, 1992, BIOCHEMISTRY-US, V30, P3871; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Subramanian M, 1998, BIOCHEMISTRY-US, V37, P1394, DOI 10.1021/bi9716581; TAANMAN JW, 1994, BIOCHEMISTRY-US, V33, P11833, DOI 10.1021/bi00205a020; Tuominen EKJ, 1997, BIOCHEM BIOPH RES CO, V238, P140, DOI 10.1006/bbrc.1997.7257; VANDERKOOI JM, 1975, EUR J BIOCHEM, V60, P199, DOI 10.1111/j.1432-1033.1975.tb20992.x; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WALLACE CJA, 1984, BIOCHEM J, V217, P601, DOI 10.1042/bj2170601; WALLACE CJA, 1983, BIOCHEM J, V215, P651, DOI 10.1042/bj2150651; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	56	46	46	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19356	19362		10.1074/jbc.M100853200	http://dx.doi.org/10.1074/jbc.M100853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279142	hybrid			2022-12-25	WOS:000169091000096
J	Hackam, DJ; Botelho, RJ; Sjolin, C; Rotstein, OD; Robinson, JM; Schreiber, AD; Grinstein, S				Hackam, DJ; Botelho, RJ; Sjolin, C; Rotstein, OD; Robinson, JM; Schreiber, AD; Grinstein, S			Indirect role for COPI in the completion of Fc gamma receptor-mediated phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SYK TYROSINE KINASE; PLASMA-MEMBRANE; EPSILON-COP; TRANSFERRIN RECEPTOR; GOLGI MEMBRANES; CELL MUTANT; BREFELDIN-A; CHO CELLS; MACROPHAGES	Recent evidence suggests that extension of pseudopods during phagocytosis requires localized insertion of endomembrane vesicles. The nature of these vesicles and the processes mediating their release and insertion are unknown. COPI plays an essential role in the budding and traffic of membrane vesicles in intracellular compartments. We therefore assessed whether COPI is also involved in phagosome formation. We used IdlF cells, a mutant line derived from Chinese hamster ovary cells that express a temperature-sensitive form of epsilon COP, To confer phagocytic ability to IdlF cells, they were stably transfected with Fc receptors type IIA (Fc gamma RIIA), In the presence of functional COPI, Fc gamma RIIA-transfected IdlF cells effectively internalized opsonized particles. In contrast, phagocytosis was virtually eliminated after incubation at the restrictive temperature. Similar results were obtained impairing COPI function in macrophages using brefeldin A. Notably, loss of COPI function preceded complete inhibition of phagocytosis, suggesting that COPI is indirectly required for phagocytosis, Despite their inability to internalize particles, COPI-deficient cells nevertheless expressed normal levels of Fc gamma RIIA, and signal transduction appeared unimpeded, The opsonized particles adhered normally to COPI-deficient cells and were often found on actin-rich pedestals, but they were not internalized due to the inability of the cells to extend pseudopods. The failure to extend pseudopods was attributed to the inability of COPI-deficient cells to mobilize endomembrane vesicles, including a VAMP3-containing compartment, in response to the phagocytic stimulus.	Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 2C4, Canada; Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University System of Ohio; Ohio State University; University of Pennsylvania	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Botelho, Roberto J/B-9145-2013	Botelho, Roberto J/0000-0002-7820-0999; Hackam, David/0000-0001-5195-8807				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; BERON W, 1995, TRENDS CELL BIOL, V5, P100, DOI 10.1016/S0962-8924(00)88958-8; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Botelho RJ, 2000, J BIOL CHEM, V275, P15717, DOI 10.1074/jbc.M910068199; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Cox D, 1996, J BIOL CHEM, V271, P16597, DOI 10.1074/jbc.271.28.16597; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GONZALEZROTHI RJ, 1991, EXP LUNG RES, V17, P687, DOI 10.3109/01902149109062873; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; Hackam DJ, 1997, J EXP MED, V186, P955, DOI 10.1084/jem.186.6.955; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Holevinsky KO, 1998, BIOPHYS J, V75, P2577, DOI 10.1016/S0006-3495(98)77703-3; Jun CD, 1996, CELL IMMUNOL, V174, P25, DOI 10.1006/cimm.1996.0290; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennartz MR, 1997, J CELL SCI, V110, P2041; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PARK JG, 1993, J CLIN INVEST, V92, P1967, DOI 10.1172/JCI116790; Prekeris R, 1999, J NEUROSCI, V19, P10324; ROBINSON JM, 1986, J CELL BIOL, V102, P1615, DOI 10.1083/jcb.102.5.1615; ROSALES C, 1991, J IMMUNOL, V146, P3937; ROSALES C, 1992, J BIOL CHEM, V267, P5265; Scales SJ, 2000, INT REV CYTOL, V195, P67; Schnitzler N, 1999, NAT MED, V5, P231, DOI 10.1038/5597; SCHONHORN JE, 1994, MOL CELL BIOCHEM, V135, P159, DOI 10.1007/BF00926519; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; WERB Z, 1972, J BIOL CHEM, V247, P2439; Wieland F, 1999, CURR OPIN CELL BIOL, V11, P440, DOI 10.1016/S0955-0674(99)80063-5; Zhang Q, 1998, J BIOL CHEM, V273, P19977, DOI 10.1074/jbc.273.32.19977; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	42	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18200	18208		10.1074/jbc.M102009200	http://dx.doi.org/10.1074/jbc.M102009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279223	hybrid			2022-12-25	WOS:000168866500079
J	Zyryanov, AB; Pohjanjoki, P; Kasho, VN; Shestakov, AS; Goldman, A; Lahti, R; Baykov, AA				Zyryanov, AB; Pohjanjoki, P; Kasho, VN; Shestakov, AS; Goldman, A; Lahti, R; Baykov, AA			The electrophilic and leaving group phosphates in the catalytic mechanism of yeast pyrophosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI INORGANIC PYROPHOSPHATASE; DIVALENT METAL-ION; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; REACTION PATHWAY; OXYGEN-EXCHANGE; MAGNESIUM-ION; 2 PATHWAYS; BINDING	Binding of pyrophosphate or two phosphate molecules to the pyrophosphatase (PPase) active site occurs at two subsites, P1 and P2. Mutations at P2 subsite residues (Y93F and K56R) caused a much greater decrease in phosphate binding affinity of yeast PPase in the presence of Mn2+ or Co2+ than mutations at P1 subsite residues (R78K and K193R). Phosphate binding was estimated in these experiments from the inhibition of ATP hydrolysis at a sub-K-m concentration of ATP. Tight phosphate binding required four Mn2+ ions/active site. These data identify P2 as the high affinity subsite and pi as the low affinity subsite, the difference in the affinities being at least 250-fold. The time course of five "isotopomers" of phosphate that have from zero to four O-18 during [O-18]P-i-[O-16]H2O oxygen exchange indicated that the phosphate containing added water is released after the leaving group phosphate during pyrophosphate hydrolysis, These findings provide support for the structure-based mechanism in which pyrophosphate hydrolysis involves water attack on the phosphorus atom located at the P2 subsite of PPase.	Univ Turku, Dept Biochem, FIN-20500 Turku, Finland; Moscow MV Lomonosov State Univ, Sch Chem, Moscow 119899, Russia; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia; Univ Calif Los Angeles, Dept Med, Ctr Ulcer Res & Educ, Los Angeles, CA 90073 USA; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	Finland National Institute for Health & Welfare; University of Turku; Lomonosov Moscow State University; Lomonosov Moscow State University; University of California System; University of California Los Angeles; University of Helsinki	Lahti, R (corresponding author), Univ Turku, Dept Biochem, FIN-20500 Turku, Finland.		Baykov, Alexander A/C-7981-2012; Shestakov, Alexander/A-3216-2019; Baykov, Alexander/AAH-5301-2021	Sestakov, Aleksandr/0000-0002-0426-4789; Baykov, Alexander/0000-0002-2495-8200				Avaeva S, 1997, FEBS LETT, V410, P502, DOI 10.1016/S0014-5793(97)00650-9; Baykov A A, 1999, Prog Mol Subcell Biol, V23, P127; BAYKOV AA, 1992, EUR J BIOCHEM, V206, P463, DOI 10.1111/j.1432-1033.1992.tb16947.x; Baykov AA, 2000, BIOCHEMISTRY-US, V39, P11939, DOI 10.1021/bi000627u; Baykov AA, 1996, BIOCHEMISTRY-US, V35, P4655, DOI 10.1021/bi952635u; BAYKOV AA, 1989, BIOKHIMIYA, V54, P796; Belogurov GA, 2000, BIOCHEMISTRY-US, V39, P13931, DOI 10.1021/bi000895s; BERGER L, 1956, BIOCHIM BIOPHYS ACTA, V20, P23, DOI 10.1016/0006-3002(56)90257-8; CHUKHLANTSEV VG, 1961, IZV VYSSH UCHCBN ZAV, V5, P707; COHEN SA, 1978, J BIOL CHEM, V253, P889; COHN M, 1958, J BIOL CHEM, V230, P369; COOPERMAN BS, 1992, TRENDS BIOCHEM SCI, V17, P262, DOI 10.1016/0968-0004(92)90406-Y; COOPERMAN BS, 1981, BIOCHEMISTRY-US, V20, P6051, DOI 10.1021/bi00524a021; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DIXON M, 1979, ENZYMES, P144; Fabrichniy IP, 1997, BIOCHEMISTRY-US, V36, P7746, DOI 10.1021/bi9629844; GOLOSHCHAPOV MV, 1966, INORG CHEM, V11, P935; GONZALEZ MA, 1984, BIOCHEMISTRY-US, V23, P797, DOI 10.1021/bi00300a002; Hackney D D, 1980, Methods Enzymol, V64, P60; HACKNEY DD, 1980, J BIOL CHEM, V255, P5320; Harutyunyan EH, 1997, BIOCHEMISTRY-US, V36, P7754, DOI 10.1021/bi962637u; Harutyunyan EH, 1996, EUR J BIOCHEM, V239, P220, DOI 10.1111/j.1432-1033.1996.0220u.x; Heikinheimo P, 1996, STRUCTURE, V4, P1491, DOI 10.1016/S0969-2126(96)00155-4; Heikinheimo P, 1996, EUR J BIOCHEM, V239, P138, DOI 10.1111/j.1432-1033.1996.0138u.x; Heikinheimo P, 2001, P NATL ACAD SCI USA, V98, P3121, DOI 10.1073/pnas.061612498; JANSON CA, 1979, J BIOL CHEM, V254, P3743; KASHO VN, 1989, BIOCHEM BIOPH RES CO, V161, P475, DOI 10.1016/0006-291X(89)92623-5; KNIGHT WB, 1984, J BIOL CHEM, V259, P2886; Kornberg A., 1962, HORIZONS BIOCH, P251; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; ROWATT E, 1989, BIOCHEM J, V259, P295, DOI 10.1042/bj2590295; SCHLESINGER MJ, 1960, BIOCHIM BIOPHYS ACTA, V41, P30, DOI 10.1016/0006-3002(60)90365-6; SMIRNOVA IN, 1989, EUR J BIOCHEM, V182, P451, DOI 10.1111/j.1432-1033.1989.tb14852.x; SPRINGS B, 1981, BIOCHEMISTRY-US, V20, P6384, DOI 10.1021/bi00525a016; TEPLYAKOV A, 1994, PROTEIN SCI, V3, P1098, DOI 10.1002/pro.5560030713; Tuominen V, 1998, J MOL BIOL, V284, P1565, DOI 10.1006/jmbi.1998.2266; VANNI A, 1986, ANN CHIM-ROME, V76, P375; WELSH KM, 1983, BIOCHEMISTRY-US, V22, P2243, DOI 10.1021/bi00278a029	38	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17629	17634		10.1074/jbc.M100343200	http://dx.doi.org/10.1074/jbc.M100343200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279052	hybrid			2022-12-25	WOS:000168866500003
J	Fujimaki, W; Iwashima, M; Yagi, J; Zhang, H; Yagi, H; Seo, K; Imai, Y; Imanishi, K; Uchiyama, T				Fujimaki, W; Iwashima, M; Yagi, J; Zhang, H; Yagi, H; Seo, K; Imai, Y; Imanishi, K; Uchiyama, T			Functional uncoupling of T-cell receptor engagement and Lck activation in anergic human thymic CD4(+) T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PROTEIN-KINASE; SHOCK-SYNDROME TOXIN-1; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; INDUCTION; CD45; SUPERANTIGEN; MATURATION; PATHWAYS; CALCIUM	Human thymic CD1a(-)CD4(+) T cells in the final stage of thymic maturation are susceptible to anergy induced by a superantigen, toxic shock syndrome toxin-1 (TSST-1). Thymic CD4(+) T-cell blasts, established by stimulating human thymic CD1a(-)CD4(+) T cells with TSST-1 in vitro, produce a low level of interleukin-2 after restimulation with TSST-1, whereas TSST-1-induced adult peripheral blood (APB) CD4(+) T-cell blasts produce high levels of interleukin-2. The extent of tyrosine phosphorylation of the T-cell receptor zeta chain induced after restimulation with TSST-1 was 2-4-fold higher in APE CD4(+) T-cell blasts than in thymic CD4(+) T-cell blasts. The tyrosine kinase activity of Lck was low in both thymic and APE CD4(+) T-cell blasts before restimulation with TSST-1, After restimulation, the Lck kinase activity increased in APE CD4(+) T-cell blasts but not in thymic CD4(+) T-cell blasts. Surprisingly, Lck was highly tyrosine-phosphorylated in both thymic and APE CD4(+) T-cell blasts before restimulation with TSST-1, After restimulation, it was markedly dephosphorylated in APE CD4(+) T-cell blasts but not in thymic CD4(+) T-cell blasts. Lck fi om APE CD4(+) T-cell blasts bound the peptide containing the phosphotyrosine at the negative regulatory site of Lck-505 indicating that the site of dephosphorylation in TSST-1-activated T-cell blasts is Tyr-505, Confocal microscopy demonstrated that colocalization of Lck and CD45 was induced after restimulation with TSST-1 in APE CD4(+) T-cell blasts but not in thymic CD4(+) T-cell blasts. Further, remarkable accumulation of Lck in the membrane raft was observed in restimulated APE CD4(+) T-cell blasts but not in thymic CD4(+) T-cell blasts. These data indicate that interaction between Lck and CD45 is suppressed physically in thymic CD4(+) T-cell blasts and plays a critical role in sustaining an anergic state.	Tokyo Womens Med Univ, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Heart Inst Japan, Dept Pediat Cardiovasc Surg, Shinjuku Ku, Tokyo 1628666, Japan; Med Coll Georgia, Inst Mol Med & Genet, Program Mol Immunol, Augusta, GA 30912 USA	Tokyo Women's Medical University; Tokyo Women's Medical University; University System of Georgia; Augusta University	Fujimaki, W (corresponding author), Tokyo Womens Med Univ, Dept Microbiol & Immunol, Shinjuku Ku, 8-1 Kawadacho, Tokyo 1628666, Japan.							AKATSUKA H, 1994, CLIN EXP IMMUNOL, V96, P422; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOI YW, 1989, P NATL ACAD SCI USA, V86, P8941, DOI 10.1073/pnas.86.22.8941; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; Fields PE, 1996, SCIENCE, V271, P1276, DOI 10.1126/science.271.5253.1276; GAJEWSKI TF, 1995, EUR J IMMUNOL, V25, P1836, DOI 10.1002/eji.1830250707; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Imanishi K, 1998, J IMMUNOL, V160, P112; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KATO H, 1994, J TOKYO WOM MED COLL, V64, P985; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Leitenberg D, 1999, IMMUNITY, V10, P701, DOI 10.1016/S1074-7613(00)80069-2; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MIGITA K, 1995, J IMMUNOL, V155, P5083; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MUELLER DL, 1989, J IMMUNOL, V142, P2617; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; Res P, 1997, J EXP MED, V185, P141, DOI 10.1084/jem.185.1.141; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKAHASHI N, 1995, J IMMUNOL, V155, P5213; UCHIYAMA T, 1987, CLIN EXP IMMUNOL, V68, P638; VEILLETTE A, 1990, ONCOGENE, V5, P1455; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8	32	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17455	17460		10.1074/jbc.M101072200	http://dx.doi.org/10.1074/jbc.M101072200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279170	hybrid			2022-12-25	WOS:000168730400115
J	Chen, Z; Cobb, MH				Chen, Z; Cobb, MH			Regulation of stress-responsive mitogen-activated protein (MAP) kinase pathways by TAO2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; STE20-LIKE KINASE; KAPPA-B; IDENTIFICATION; FAMILY; P38; MYOGENESIS; SCAFFOLD; MEMBER	Previous studies demonstrated that in vitro the protein kinase TAO2 activates MAP/ERK kinases (MEKs) 3, 4, and 6 toward their substrates p38 MAP kinase and c-dun N-terminal kinase/stress-activated protein kinase (JNK/SAPK). In this study, we examined the ability of TAO2 to activate stress-sensitive MAP kinase pathways in cells and the relationship between activation of TAO2 and potential downstream pathways. Over-expression of TAO2 activated endogenous JNK/SAPK and p38 but not ERK1/2. Cotransfection experiments suggested that TAO2 selectively activates MEK3 and MEK6 but not MEKs 1, 4, or 7. Coimmunoprecipitation demonstrated that endogenous TAO2 specifically associates with MEK3 and MEK6 providing one mechanism for preferential recognition of MEKs upstream of p38. Sorbitol, and to a lesser extent, sodium chloride, Taxol, and nocodazole increased TAO2 activity toward itself and kinase-dead MEKs 3 and 6, Activation of endogenous TAO2 during differentiation of C2C12 myoblasts paralleled activation of p38 but not JNK/SAPK, consistent with the idea that TAO2 is a physiological regulator of p38 under certain circumstances.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIGMS NIH HHS [GM53032] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEARSON G, 2001, IN PRESS ENDOCRINE R; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Swantek JL, 1999, J BIOL CHEM, V274, P11667, DOI 10.1074/jbc.274.17.11667; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yustein JT, 2000, ONCOGENE, V19, P710, DOI 10.1038/sj.onc.1203342	29	47	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16070	16075		10.1074/jbc.M100681200	http://dx.doi.org/10.1074/jbc.M100681200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279118	hybrid			2022-12-25	WOS:000168623100069
J	Kawar, Z; Karaveg, K; Moremen, KW; Jarvis, DL				Kawar, Z; Karaveg, K; Moremen, KW; Jarvis, DL			Insect cells encode a class II alpha-mannosidase with unique properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; BROAD-SPECIFICITY ALPHA-1->2; RAT-LIVER; EXPRESSION; CDNA; PURIFICATION; ALPHA-1,2-MANNOSIDASE; BIOSYNTHESIS; PROTEINS; PATHWAY	Previously, we cloned and characterized an insect (Sf9) cell cDNA encoding a class II alpha -mannosidase with amino acid sequence and biochemical similarities to mammalian Golgi alpha -mannosidase II. Since then, it has been demonstrated that other mammalian class II alpha -mannosidases can participate in N-glycan processing. Thus, the present study was performed to evaluate the catalytic properties of the Sf9 class II alpha -mannosidase and to more clearly determine its relationship to mammalian Golgi alpha -mannosidase II. The results showed that the Sf9 enzyme is cobalt-dependent and can hydrolyze Man(5)GlcNAc(2) to Man(3)GlcNAc(2), but it cannot hydrolyze GlcNAcMan(5)GlcNAc(2). These data establish that the Sf9 enzyme is distinct from Golgi alpha -mannosidase II. This enzyme is not a lysosomal alpha -mannosidase because it is not active at acidic pH and it is localized in the Golgi apparatus. In fact, its sensitivity to swainsonine distinguishes the Sf9 enzyme from all other known mammalian class II alpha -mannosidases that can hydrolyze Man(5)GlcNAc(2). Based on these properties, we designated this enzyme Sf9 alpha -mannosidase III and concluded that it probably provides an alternate N-glycan processing pathway in Sf9 cells.	Univ Wyoming, Dept Mol Biol, Laramie, WY 82071 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University of Wyoming; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Jarvis, DL (corresponding author), Univ Wyoming, Dept Mol Biol, POB 3944, Laramie, WY 82071 USA.		Moremen, Kelley/AAD-4661-2019	Jarvis, Donald/0000-0002-8104-7155	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049734, R01GM047533] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05351, P41 RR005351] Funding Source: Medline; NIGMS NIH HHS [R01 GM049734, GM47533, GM49734, R01 GM047533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN F, 1993, GLYCOBIOLOGY, V3, P619, DOI 10.1093/glycob/3.6.619; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; Chui D, 1997, CELL, V90, P157, DOI 10.1016/S0092-8674(00)80322-0; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; FODDY L, 1986, BIOCHEM J, V233, P697, DOI 10.1042/bj2330697; Gonzalez DS, 1999, J BIOL CHEM, V274, P21375, DOI 10.1074/jbc.274.30.21375; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; Grard T, 1996, BIOCHEM J, V316, P787, DOI 10.1042/bj3160787; HUGHES RC, 1986, EUR J BIOCHEM, V158, P227, DOI 10.1111/j.1432-1033.1986.tb09742.x; Jarvis DL, 1996, PROTEIN EXPRES PURIF, V8, P191, DOI 10.1006/prep.1996.0092; Jarvis DL, 1998, CURR OPIN BIOTECH, V9, P528, DOI 10.1016/S0958-1669(98)80041-4; Jarvis DL, 1997, GLYCOBIOLOGY, V7, P113, DOI 10.1093/glycob/7.1.113; Kawar Z, 2000, GLYCOBIOLOGY, V10, P347, DOI 10.1093/glycob/10.4.347; Kawar Z, 1997, GLYCOBIOLOGY, V7, P433, DOI 10.1093/glycob/7.3.433; Kawar Z, 2001, INSECT BIOCHEM MOLEC, V31, P289, DOI 10.1016/S0965-1748(00)00121-1; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARZ L, 1995, GLYCOPROTEINS A, V29, P543; MISAGO M, 1995, P NATL ACAD SCI USA, V92, P11766, DOI 10.1073/pnas.92.25.11766; MONIS E, 1987, EUR J BIOCHEM, V168, P287, DOI 10.1111/j.1432-1033.1987.tb13419.x; Moremen K., 2000, OLIGOSACCHARIDES CHE, VII, P81; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; MURHAMMER DW, 1988, BIO-TECHNOL, V6, P1411, DOI 10.1038/nbt1288-1411; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; Ren JX, 1997, BIOCHEM J, V324, P951, DOI 10.1042/bj3240951; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; Weng SA, 1996, ARCH BIOCHEM BIOPHYS, V325, P113, DOI 10.1006/abbi.1996.0014; Yamashiro K, 1997, J BIOCHEM-TOKYO, V122, P1174, DOI 10.1093/oxfordjournals.jbchem.a021878	35	38	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16335	16340		10.1074/jbc.M100119200	http://dx.doi.org/10.1074/jbc.M100119200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279010	Green Accepted, hybrid			2022-12-25	WOS:000168623100102
J	Cerutti, ML; Centeno, JM; Goldbaum, FA; de Prat-Gay, G				Cerutti, ML; Centeno, JM; Goldbaum, FA; de Prat-Gay, G			Generation of sequence-specific, high affinity anti-DNA antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIABLE GENES; BINDING DOMAIN; MOUSE; RECOGNITION; PROTEINS	By taking advantage of the extreme stability of a protein-DNA complex, we have obtained two highly specific monoclonal antibodies against a predetermined palindromic DNA sequence corresponding to the binding site of the E2 transcriptional regulator of the human papillomavirus (HPV-16), The purified univalent antibody fragments bind to a double-stranded DNA oligonucleotide corresponding to the E2 binding site in solution with dissociation constants in the low and subnanomolar range. This affinity matches that of the natural DNA binding domain and is severalfold higher than the affinity of a homologous bovine E2 C-terminal domain (BPV-1) for the same DNA. These antibodies discriminate effectively among a number of double- and single-stranded synthetic DNAs with factors ranging from 125- to 20,000-fold the dissociation constant of the specific DNA sequence used in the immunogenic protein-DNA complex. Moreover, they are capable of fine specificity tuning, since they both bind less tightly to another HPV-16 E2 binding site, differing in only 1 base pair in a noncontact flexible region. Beyond the relevance of obtaining a specific anti-DNA response, these results provide a first glance at how DNA as an antigen is recognized specifically by an antibody. The accuracy of the spectroscopic method used for the binding analysis suggests that a detailed mechanistic analysis is attainable.	Fdn Campomar, Inst Invest Bioquim, RA-1405 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Ciencias Exactas & Nat, RA-1405 Buenos Aires, DF, Argentina	Leloir Institute; University of Buenos Aires	de Prat-Gay, G (corresponding author), Fdn Campomar, Inst Invest Bioquim, Av Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.			Prat Gay, Gonzalo/0000-0001-5748-6863; Goldbaum, Fernando/0000-0001-6235-3002				BARBAS SM, 1994, J AM CHEM SOC, V116, P2161, DOI 10.1021/ja00084a073; Blackburn G.M, 1996, NUCL ACIDS CHEM BIOL; BRANDEN C, 1999, INTRO PROTEIN STRUCT, P299; Dattamajumdar AK, 1996, IMMUNOGENETICS, V43, P141, DOI 10.1007/BF00176675; DEPRATGAY G, 1994, BIOCHEMISTRY-US, V33, P1957; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; Ferreiro DU, 2000, BIOCHEMISTRY-US, V39, P14692, DOI 10.1021/bi001694r; FRIGUET B, 1997, PROTEIN STRUCTURE; Galfre G, 1981, Methods Enzymol, V73, P3; Goldbaum FA, 1999, J IMMUNOL, V162, P6040; GREISMAN HA, 1997, SCIENCE, V275, P357; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HEINRICH G, 1984, J EXP MED, V159, P417, DOI 10.1084/jem.159.2.417; Krishnan MR, 1996, J IMMUNOL, V157, P2430; LeBlanc JF, 1998, BIOCHEMISTRY-US, V37, P6015, DOI 10.1021/bi9730792; Mauricio L, 1997, J BIOL CHEM, V272, P19295, DOI 10.1074/jbc.272.31.19295; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Mok YK, 1996, NAT STRUCT BIOL, V3, P711, DOI 10.1038/nsb0896-711; Oehler S, 1999, ANAL BIOCHEM, V268, P330, DOI 10.1006/abio.1998.3056; Payelle-Brogard B, 1998, HYBRIDOMA, V17, P289, DOI 10.1089/hyb.1998.17.289; RADIC MZ, 1994, ANNU REV IMMUNOL, V12, P487, DOI 10.1146/annurev.iy.12.040194.002415; Rondon IJ, 1997, ANNU REV MICROBIOL, V51, P257, DOI 10.1146/annurev.micro.51.1.257; STOLLAR BD, 1986, CRC CR REV BIOCH MOL, V20, P1, DOI 10.3109/10409238609115899; STOLLAR BD, 1994, FASEB J, V8, P337, DOI 10.1096/fasebj.8.3.7511550; Thiebe R, 1999, EUR J IMMUNOL, V29, P2072, DOI 10.1002/(SICI)1521-4141(199907)29:07&lt;2072::AID-IMMU2072&gt;3.0.CO;2-E; TRAVERS A, 1993, DNA PROTEIN INTERACT, P375	26	23	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12769	12773		10.1074/jbc.M100260200	http://dx.doi.org/10.1074/jbc.M100260200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11279040	Green Published, hybrid			2022-12-25	WOS:000168198600043
J	Gounni, AS; Lamkhioued, B; Koussih, L; Ra, C; Renzi, PM; Hamid, Q				Gounni, AS; Lamkhioued, B; Koussih, L; Ra, C; Renzi, PM; Hamid, Q			Human neutrophils express the high-affinity receptor for immunoglobulin E (Fc epsilon RI): role in asthma	FASEB JOURNAL			English	Article						allergic diseases; IgE receptors; interleukin 8	COLONY-STIMULATING FACTOR; MAST-CELLS; POLYMORPHONUCLEAR NEUTROPHILS; BRONCHOALVEOLAR LAVAGE; CHEMOTACTIC FACTOR; HUMAN PLATELETS; T-LYMPHOCYTES; BETA-SUBUNIT; IN-VITRO; IGE	Polymorphonuclear neutrophils (PMNs) are important effector cells in host defense and the inflammatory response to antigen. The involvement of PMNs in inflammation is mediated mainly by the Fc receptor family, including IgE receptors. Recently, PMNs were shown to express two IgE receptors (CD23/Fc epsilon RII and galectin-3). In allergic diseases, the dominant role of IgE has been mainly ascribed to its high-affinity receptor, Fc epsilon RI. We have examined the expression of Fc epsilon RI by PMNs. mRNA and cell surface expression of Fc epsilon RI alpha chain was identified on PMNs from asthmatic subjects. Furthermore, preincubation with human IgE Fc fragment blocks completely the binding of anti-Fc epsilon RI alpha chain (mAb15-1) to human PMNs. Conversely, preincubation of PMNs with mAb15-1 inhibits significantly the binding of IgE Fc fragment to PMNs, indicating that IgE bound to the cell surface of PMNs mainly via the Fc epsilon RI. Peripheral blood and bronchoalveolar lavage (BAL) PMNs from asthmatic subjects also express intracellular Fc epsilon RI alpha and beta chain immunoreactivity. Engagement of Fc epsilon RI induces the release of IL-8 by PMNs. Collectively, these observations provide new evidence that PMNs express the Fc epsilon RI and suggest that these cells may play a role in allergic inflammation through an IgE-dependent activation mechanism.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Montreal, Notre Dame Hosp, Res Ctr, CHUM, Montreal, PQ H2L 4M1, Canada; Juntendo Univ, Sch Med, Tokyo 113, Japan	McGill University; Universite de Montreal; Juntendo University	Gounni, AS (corresponding author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	Abdel@meakins.lan.mcgill.ca	Gounni, Abdelilah Soussi/AAH-3456-2020; LAMKHIOUED, Bouchaib/AAL-4201-2021	Soussi Gounni, Abdelilah/0000-0002-7282-0388; Gounni, Abdelilah/0000-0003-1265-6560				[Anonymous], 1987, AM REV RESPIR DIS, V136, P225; BOSHETTO P, 1989, EUR RESPIR J, V6, P456; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209, DOI 10.1152/jappl.1990.69.6.2209; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; Carulli G, 1997, HAEMATOLOGICA, V82, P606; Dale DC, 1998, AM J HEMATOL, V57, P7, DOI 10.1002/(SICI)1096-8652(199801)57:1<7::AID-AJH2>3.0.CO;2-0; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DRIVER AG, 1991, AM REV RESPIR DIS, V143, P1002, DOI 10.1164/ajrccm/143.5_Pt_1.1002; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36, DOI 10.1164/ajrccm/136.1.36; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FISCHKOFF SA, 1988, LEUKEMIA RES, V12, P679, DOI 10.1016/0145-2126(88)90103-8; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689, DOI 10.1164/ajrccm/141.3.689; Girard D, 1997, BIOCHEM J, V325, P147, DOI 10.1042/bj3250147; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GOSSELIN EJ, 1993, J IMMUNOL, V151, P1482; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; GOUNNI AS, 1998, INT IMMUNOL, V10, P395; HALLAHAN AR, 1990, EUR RESPIR J, V3, P554; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hasegawa S, 1999, BLOOD, V93, P2543, DOI 10.1182/blood.V93.8.2543.408k14_2543_2551; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; KAY AB, 1987, ALLERGY INFLAMMATION, P203; Kraft S, 1998, J IMMUNOL, V161, P1000; KUROSAKI T, 1992, J EXP MED, V175, P447, DOI 10.1084/jem.175.2.447; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; LEHRER RI, 1988, ANN INTERN MED, V109, P127, DOI 10.7326/0003-4819-109-2-127; LLYOLD AR, 1992, IMMUNOL TODAY, V13, P169; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1993, INT IMMUNOL, V5, P47, DOI 10.1093/intimm/5.1.47; RA C, 1989, J BIOL CHEM, V264, P15323; RAVETCH JV, 1994, NAT GENET, V7, P117, DOI 10.1038/ng0694-117; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHEN L, 1987, J IMMUNOL, V139, P534; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SMITH HR, 1992, J ALLERGY CLIN IMMUN, V89, P1076, DOI 10.1016/0091-6749(92)90291-9; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; TRUONG MJ, 1993, J EXP MED, V177, P243, DOI 10.1084/jem.177.1.243; VARINBLANK N, 1990, J BIOL CHEM, V265, P15685; VENGE P, 1990, J ALLERGY CLIN IMMUN, V85, P498, DOI 10.1016/0091-6749(90)90161-V; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WANG B, 1992, J EXP MED, V175, P1353, DOI 10.1084/jem.175.5.1353; WUYTS A, 1998, CYTOKINE HDB, P185; Yamamoto F, 1996, NUCL MED BIOL, V23, P479, DOI 10.1016/0969-8051(96)00025-X; Ying S, 1998, IMMUNOLOGY, V93, P281, DOI 10.1046/j.1365-2567.1998.00418.x	54	99	106	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					940	949		10.1096/fj.00-0378com	http://dx.doi.org/10.1096/fj.00-0378com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292654				2022-12-25	WOS:000167959300008
J	Dorlet, P; Xiong, L; Sayre, RT; Un, S				Dorlet, P; Xiong, L; Sayre, RT; Un, S			High field EPR study of the pheophytin anion radical in wild type and D1-E130 mutants of photosystem II in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-ACCEPTOR; REACTION CENTERS; RESONANCE	The intermediate electron acceptor in photosystem II is a pheophytin molecule. The radical anion of this molecule was studied using high field electron paramagnetic resonance in a series of Chlamydomonas reinhardtii mutants. Glutamic acid 130 of the D1 polypeptide is thought to hydrogen bond the ring V carbonyl group of this radical. Mutations at this site, designed to weaken or remove this hydrogen bond, strongly affected the g tenser of the radical. The upward shift of the g,component followed the decreasing hydro gen bonding capacity of the amino acid introduced. This behavior is similar to that of tyrosyl and semiquinone radicals. It is also consistent with the optical spectra of the pheophytin in similar mutants. Density functional calculations were used to calculate the g tensors and rationalize the observed trend in the variation of the g, value for pheophytin and bacteriopheophytin radical. The theoretical results support the experimental observations and demonstrate the sensitivity of g values to the electrostatic protein environment for these types of radicals.	CEA Saclay, CNRS URA2096, Sect Bioenerget, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France; Ohio State Univ, Dept Plant Biol, Columbus, OH 43210 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; University System of Ohio; Ohio State University	Un, S (corresponding author), CEA Saclay, CNRS URA2096, Sect Bioenerget, Dept Biol Cellulaire & Mol, F-91191 Gif Sur Yvette, France.			Dorlet, Pierre/0000-0001-7394-3374; Sayre, Richard/0000-0002-3153-7084				Baerends E. J., 1992, J COMPUT PHYS, V99, P84, DOI DOI 10.1016/0021-9991(92)90277-6; BURGHAUS O, 1993, J PHYS CHEM-US, V97, P7639, DOI 10.1021/j100131a037; Dorlet P, 2000, BIOCHEMISTRY-US, V39, P7826, DOI 10.1021/bi000175l; FASANELL.EL, 1969, P NATL ACAD SCI USA, V62, P299, DOI 10.1073/pnas.62.2.299; Giorgi LB, 1996, J BIOL CHEM, V271, P2093, DOI 10.1074/jbc.271.4.2093; Guerra CF, 1998, THEOR CHEM ACC, V99, P391, DOI 10.1007/s002140050021; Knupling M, 1997, CHEM PHYS, V219, P291, DOI 10.1016/S0301-0104(97)00104-3; LUBITZ W, 1989, BIOCHIM BIOPHYS ACTA, V977, P227, DOI 10.1016/S0005-2728(89)80076-3; MOENNELOCCOZ P, 1989, BIOCHEMISTRY-US, V28, P3641, DOI 10.1021/bi00435a003; NABEDRYK E, 1990, BIOCHIM BIOPHYS ACTA, V1016, P49, DOI 10.1016/0005-2728(90)90005-O; O'Malley PJ, 2000, J PHYS CHEM B, V104, P2176, DOI 10.1021/jp993907w; PIMENTEL GC, 1960, HYDROGEN BOND, P157; Schlegel HB., 2009, GAUSSIAN 09 REVISION; STONE AJ, 1963, MOL PHYS, V6, P509, DOI 10.1080/00268976300100571; STONE AJ, 1963, PROC R SOC LON SER-A, V271, P424, DOI 10.1098/rspa.1963.0027; STONE AJ, 1964, MOL PHYS, V7, P311, DOI 10.1080/00268976300101081; SVENSSON B, 1990, EMBO J, V9, P2051, DOI 10.1002/j.1460-2075.1990.tb07372.x; Un S, 1996, BIOCHEMISTRY-US, V35, P679, DOI 10.1021/bi9523769; UN S, 1995, J AM CHEM SOC, V117, P10713, DOI 10.1021/ja00148a013; Un S, 2001, J AM CHEM SOC, V123, P3048, DOI 10.1021/ja003650b; vanLenthe E, 1996, J CHEM PHYS, V105, P6505, DOI 10.1063/1.472460; VERSLUIS L, 1988, J CHEM PHYS, V88, P322, DOI 10.1063/1.454603; *VRIJ U, 1999, AMST DENS FUNCT PROG; Xiong J, 1998, PHOTOSYNTH RES, V56, P229, DOI 10.1023/A:1006061918025; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	26	30	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22313	22316		10.1074/jbc.M102475200	http://dx.doi.org/10.1074/jbc.M102475200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294881	hybrid			2022-12-25	WOS:000169412700047
J	Loewen, CJR; Moritz, OL; Molday, RS				Loewen, CJR; Moritz, OL; Molday, RS			Molecular characterization of peripherin-2 and Rom-1 mutants responsible for digenic retinitis pigmentosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGENERATION SLOW RDS; RETINAL DEGENERATION; PHOTORECEPTOR PERIPHERIN/RDS; MEMBRANE-PROTEIN; DISK MEMBRANE; ROD PHOTORECEPTORS; COILED-COIL; GENE; MUTATIONS; LOCALIZATION	Peripherin-2 and Rom-l are homologous tetraspanning membrane proteins that assemble into noncovalent tetramers and higher order disulfide-linked oligomers implicated in photoreceptor disc morphogenesis. Individuals who coinherit a L185P peripherin-2 mutation and a null or G113E rom I mutation are afflicted with retinitis pigmentosa, whereas individuals who inherit only one defective gene are normal. We examined the expression, subunit assembly, and disulfide-mediated oligomerization of L185P and L185A peripherin-2 and L188P Rom-l by velocity sedimentation, co-immunoprecipitation, and cross-linking. These mutants formed noncovalent dimers under disulfide-reducing conditions but failed to assemble into core tetramers. Under nonreducing conditions, L185P dimers formed disulfide linked tetramers but not higher order oligomers. L185P coassembled with wild-type peripherin-2 and Rom-l to form tetramers and higher order disulfide-linked oligomers characteristic of the wild-type proteins. The G113E Rom-l mutant expressed 20-fold lower than wildtype Rom-l, indicating that it behaves mechanistically as a null allele. We conclude that Leu(185) of peripherin-2 (Leu(188) of Rom-l) is critical for tetramer but not dimer formation and that the core tetramer has a-fold symmetry. Peripherin-2-containing tetramers are required for higher order disulfide-linked oligomer formation, The level of these oligomers is critical for stable photoreceptor disc formation and the digenic retinitis pigmentosa disease phenotype.	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Ophthalmol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Molday, RS (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	molday@interchange.ubc.ca		Moritz, Orson L/0000-0002-6183-6499	NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 2422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARIKAWA K, 1992, J CELL BIOL, V116, P659, DOI 10.1083/jcb.116.3.659; BASCOM RA, 1992, NEURON, V8, P1171, DOI 10.1016/0896-6273(92)90137-3; Boesze-Battaglia K, 1998, BIOCHEMISTRY-US, V37, P9477, DOI 10.1021/bi980173p; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; Clarke G, 2000, NAT GENET, V25, P67, DOI 10.1038/75621; CLARKE S, 1989, METHOD ENZYMOL, V172, P696; CONNELL G, 1991, P NATL ACAD SCI USA, V88, P723, DOI 10.1073/pnas.88.3.723; CONNELL GJ, 1990, BIOCHEMISTRY-US, V29, P4691, DOI 10.1021/bi00471a025; Dryja TP, 1997, INVEST OPHTH VIS SCI, V38, P1972; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FASMAN GD, 1975, HDB BIOCH MOL BIOL, pL10; Goldberg AFX, 1998, BIOCHEMISTRY-US, V37, P680, DOI 10.1021/bi972036i; Goldberg AFX, 1996, BIOCHEMISTRY-US, V35, P6144, DOI 10.1021/bi960259n; GOLDBERG AFX, 1995, BIOCHEMISTRY-US, V34, P14213, DOI 10.1021/bi00043a028; Goldberg AFX, 1996, P NATL ACAD SCI USA, V93, P13726, DOI 10.1073/pnas.93.24.13726; HAWKINS RK, 1985, EXP EYE RES, V41, P701, DOI 10.1016/0014-4835(85)90179-4; KAJIWARA K, 1994, SCIENCE, V264, P1604, DOI 10.1126/science.8202715; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Kedzierski W, 1999, J BIOL CHEM, V274, P29181, DOI 10.1074/jbc.274.41.29181; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Loewen CJR, 2000, J BIOL CHEM, V275, P5370, DOI 10.1074/jbc.275.8.5370; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Moritz OL, 1996, INVEST OPHTH VIS SCI, V37, P352; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; SAGA M, 1993, HUM GENET, V92, P519, DOI 10.1007/BF00216463; SANYAL S, 1981, NEUROSCI LETT, V21, P23, DOI 10.1016/0304-3940(81)90051-3; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; TRAVIS GH, 1989, NATURE, V338, P70, DOI 10.1038/338070a0; TRAVIS GH, 1991, NEURON, V6, P61, DOI 10.1016/0896-6273(91)90122-G; WELEBER RG, 1993, ARCH OPHTHALMOL-CHIC, V111, P1531, DOI 10.1001/archopht.1993.01090110097033; WELLS J, 1993, NAT GENET, V3, P213, DOI 10.1038/ng0393-213; *WORTH BIOCH CORP, 1996, WORTH ENZ MAN, P36; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Wrigley JDJ, 2000, J BIOL CHEM, V275, P13191, DOI 10.1074/jbc.C900853199	39	55	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22388	22396		10.1074/jbc.M011710200	http://dx.doi.org/10.1074/jbc.M011710200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297544	hybrid			2022-12-25	WOS:000169412700057
J	Morinaga, N; Kaihou, Y; Vitale, N; Moss, J; Noda, M				Morinaga, N; Kaihou, Y; Vitale, N; Moss, J; Noda, M			Involvement of ADP-ribosylation factor 1 in cholera toxin induced morphological changes of Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR TRAFFICKING; PHOSPHOLIPASE-D; GOLGI; MEMBRANE; SUBUNIT; TRANSPORT; KDEL	ADP-ribosylation factor 1 (ARF1) was originally found as a cofactor in CT-catalyzed ADP-ribosylation of Ga, but is now known to participate in vesicle trafficking. We asked whether ARF1 function in vesicular trafficking is necessary for CT induced morphological changes in Chinese hamster ovary (CHO) cells, which result from increased intracellular cAMCP. Brefeldin A treatment of cells suppressed CT action, confirming a requirement for Golgi integrity. Overexpression of a GFP-ARF1 fusion protein did not affect the morphological changes induced by CT, but changes were reduced in cells over expressing guanine nucleotide exchange-defective ARF1(T31N) or GTP hydrolysis-deficient ARF1(Q71L) mutants. In cells expressing these mutants, 8-bromo-cAMP induced changes similar to those seen in cells transfected with ARF1 or vector. Inhibition of CT action was specific for mutants of ARF1 and not reproduced by analogous mutants of ARF5 or ARF6. ARF1(Q71L) was mostly colocalized with beta COP, but ARF5(Q71L) less so. ARF6(Q67L) did not colocalize with beta COP and was partially associated with the plasma membrane. These data are consistent with the conclusion that ARF1 influenced CT action in cells by its specific function in the vesicular transport pathway used by CT to travel from plasma membrane to Golgi to ER.	Chiba Univ, Sch Med, Dept Microbiol 2, Chuo Ku, Chiba 2608670, Japan; INSERM U338, Ctr Neurochim, F-67084 Strasbourg, France; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	Chiba University; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Morinaga, N (corresponding author), Chiba Univ, Sch Med, Dept Microbiol 2, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL000659, ZIAHL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACT T, 1998, EMBO J, V16, P7305; Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; Claude A, 1999, J CELL BIOL, V146, P71, DOI 10.1083/jcb.146.1.71; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASHER C, 1994, J BIOL CHEM, V269, P1437; FENSOME A, 1994, FEBS LETT, V349, P34, DOI 10.1016/0014-5793(94)00634-2; GILL DM, 1975, J BIOL CHEM, V250, P6424; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KASSIS S, 1982, J BIOL CHEM, V257, P12141; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; Majoul I, 1997, FEBS LETT, V401, P104, DOI 10.1016/S0014-5793(96)01447-0; Majoul IV, 1996, J CELL BIOL, V133, P777, DOI 10.1083/jcb.133.4.777; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5855; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MOSS J, 1977, J BIOL CHEM, V252, P2455; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; NANBIAR MP, 1993, J CELL PHYSL, V154, P222; ORLANDI PA, 1993, J BIOL CHEM, V268, P12010; Orlandi PA, 1997, J BIOL CHEM, V272, P4591; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; Shin OH, 1999, J BIOL CHEM, V274, P36609, DOI 10.1074/jbc.274.51.36609; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	33	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22838	22843		10.1074/jbc.M101184200	http://dx.doi.org/10.1074/jbc.M101184200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11279243	hybrid			2022-12-25	WOS:000169412700114
J	Mohapatra, S; Agrawal, D; Pledger, WJ				Mohapatra, S; Agrawal, D; Pledger, WJ			P27(Kip1) regulates T cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; HUMAN LYMPHOCYTES-T; GROWTH-FACTOR; INHIBITOR P27(KIP1); MICE LACKING; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; RESTRICTION POINT; GENE-EXPRESSION; CDK INHIBITORS	Our studies addressed the mechanism by which serum acts in conjunction with T cell receptor (TCR) agonists to promote the proliferation of primary splenic T cells. When added to resting splenocytes, TCR agonists initiated G(0)/G(1) traverse and activated cyclin D3-cdk6 complexes in a serum-independent manner. On the other hand, both TCR agonists and 10% serum were required for the activation of cyclin E-cdk2 and cyclin A-cdk2 complexes and the entry of cells into S phase. Serum facilitated cdk2 activation by maximizing the extent and extending the duration of the TCR-initiated down-regulation of the cdk2 inhibitor, p27(Kip1). Although p27(Kip1) levels were reduced (albeit submaximally) in cells stimulated in serum-deficient medium, nearly all of the cdk2 complexes in these cells contained p27(Kip1). I, contrast, in cells receiving TCR agonist and 10% serum, little if any p27(Kip1) was present in cyclin-cdk2 complexes. Unlike wild-type splenocytes, p27(Kip1)-null splenocytes did not require serum for cdk2 activation or S phase entry whereas loss of the related cdk2 inhibitor, p21(Cip1), did not override the serum dependence of these responses. We also found that cdk2 activation was both necessary and sufficient for maximal expression of cdk2 protein. These studies provide a mechanistic basis for the serum dependence of T cell mitogenesis.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Mohapatra, Subhra/A-1381-2012		NATIONAL CANCER INSTITUTE [R01CA072694, R01CA067360] Funding Source: NIH RePORTER; NCI NIH HHS [CA67360, CA72694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; Balomenos D, 2000, NAT MED, V6, P171, DOI 10.1038/72272; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HERZBERG VL, 1987, J IMMUNOL, V139, P998; Karnitz LM, 1996, ADV IMMUNOL, V61, P147, DOI 10.1016/S0065-2776(08)60867-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kwon TK, 1997, J IMMUNOL, V158, P5642; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEUER SC, 1984, P NATL ACAD SCI-BIOL, V81, P1509, DOI 10.1073/pnas.81.5.1509; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MODIANO JF, 1994, J BIOL CHEM, V269, P32972; Modiano JF, 1995, ANN NY ACAD SCI, V766, P134, DOI 10.1111/j.1749-6632.1995.tb26657.x; Mohapatra S, 2001, J BIOL CHEM, V276, P21984, DOI 10.1074/jbc.M100037200; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS ME, 1990, J IMMUNOL, V144, P1208; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	46	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21976	21983		10.1074/jbc.M009788200	http://dx.doi.org/10.1074/jbc.M009788200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11297537	hybrid			2022-12-25	WOS:000169297900153
J	Kupke, T; Hernandez-Acosta, P; Steinbacher, S; Culianez-Macia, FA				Kupke, T; Hernandez-Acosta, P; Steinbacher, S; Culianez-Macia, FA			Arabidopsis thaliana flavoprotein AtHAL3a catalyzes the decarboxylation of 4 '-phosphopantothenoylcysteine to 4 '-phosphopantetheine, a key step in coenzyme A biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE DECARBOXYLATION; SALT TOLERANCE; PRECURSOR PEPTIDE; A BIOSYNTHESIS; PURIFICATION; SUBSTRATE; EPIDERMIN; TRANSPORT; PROTEINS; SUBUNIT	Arabidopsis thaliana flavoprotein AtHAL3a is related to plant growth and salt and osmotic tolerance. AtHAL3a shows sequence homology to the bacterial flavoproteins EpiD and Dfp. EpiD, Dfp, and AtHAL3a are members of the homo-oligomeric flavin-containing Cys decarboxylase (HFCD) protein family. We demonstrate that AtHAL3a catalyzes the decarboxylation of (R)-4 ' -phospho-N-pantothenoylcysteine to 4 ' -phosphopantetheine. This key step in coenzyme A biosynthesis is catalyzed in bacteria by the Dfp proteins. Exchange of His-90 of AtHAL3a for Asn led to complete inactivation of the enzyme. Dfp and AtHAL3a are characterized by a shortened substrate binding clamp compared with EpiD. Exchange of the cysteine residue of the conserved ACGD motif of this binding clamp resulted in loss of (R)-4 ' -phospho-N-pantothenoylcysteine decarboxylase activity. Based on the crystal structures of EpiD H67N with bound substrate peptide and of AtHAL3a, we present a model for the binding of (R)-4 ' -phospho-N-pantothenoylcysteine to AtHAL3a.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany; Univ Politecn Valencia, Inst Mol & Celular Plantas, CSIC, Valencia 46022, Spain; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Planegg Martinsried, Germany	Eberhard Karls University of Tubingen; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; Max Planck Society	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15, D-72076 Tubingen, Germany.	Thomas.Kupke@t-online.de	Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Abiko Y., 1975, Metabolism of sulphur compounds., P1; Albert A, 2000, STRUCTURE, V8, P961, DOI 10.1016/S0969-2126(00)00187-8; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; Blumwald E, 2000, CURR OPIN CELL BIOL, V12, P431, DOI 10.1016/S0955-0674(00)00112-5; Clotet J, 1999, MOL CELL BIOL, V19, P2408; de Nadal E, 1998, P NATL ACAD SCI USA, V95, P7357, DOI 10.1073/pnas.95.13.7357; DICOMO CJ, 1995, GENETICS, V139, P95; DUPRE S, 1975, ITAL J BIOCHEM, V24, P369; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; GRAHAM JE, 1992, J BACTERIOL, V174, P2711, DOI 10.1128/jb.174.8.2711-2716.1992; Ichimura K, 2000, PLANT J, V24, P655, DOI 10.1046/j.1365-313x.2000.00913.x; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kempter C, 1996, ANGEW CHEM INT EDIT, V35, P2104, DOI 10.1002/anie.199621041; Kupke T, 1997, J BIOL CHEM, V272, P4759, DOI 10.1074/jbc.272.8.4759; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; KUPKE T, 1992, J BACTERIOL, V174, P5354, DOI 10.1128/JB.174.16.5354-5361.1992; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 1997, FEMS MICROBIOL LETT, V153, P25, DOI 10.1016/S0378-1097(97)00216-4; KUPKE T, 1995, J BIOL CHEM, V270, P11282, DOI 10.1074/jbc.270.19.11282; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNELL N, 1988, NATURE, V333, P276, DOI 10.1038/333276a0; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURK D, 1992, THESIS TU MUNCHEN; YANG HC, 1987, BIOCHEMISTRY-US, V26, P4076, DOI 10.1021/bi00387a050; Zhu JK, 2000, PLANT PHYSIOL, V124, P941, DOI 10.1104/pp.124.3.941	29	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19190	19196		10.1074/jbc.M100776200	http://dx.doi.org/10.1074/jbc.M100776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279129	hybrid			2022-12-25	WOS:000169091000075
J	Numata, M; Orlowski, J				Numata, M; Orlowski, J			Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; NA+/H+ EXCHANGER; HEART-MITOCHONDRIA; BREFELDIN-A; RETROGRADE TRANSPORT; CYTOPLASMIC DOMAIN; PLASMA-MEMBRANE; K+/H+ ANTIPORT; LIVING CELLS; PH	The luminal pH of organelles along the secretory and endocytic pathways of mammalian cells is acidic and tightly regulated, with the [H+] varying up to 100-fold between compartments. Steady-state organellar pH is thought to reflect a balance between the rates of H+ pumping by the vacuolar-type H+-ATPase and H+ efflux through ill-defined pathways. Here, we describe the cloning of a novel gene (NHE7) in humans that is homologous to Na+/H+ exchangers, is ubiquitously expressed, and localizes predominantly to the trans-Golgi network. Significantly, NHE7 mediates the influx of Na+ or K+ in exchange for H+. The activity of NHE7 was also found to be relatively insensitive to inhibition by amiloride but could be antagonized by the analogue benzamil and the unrelated compound quinine. Thus, NHE7 displays unique functional and pharmacological properties and may play an important role in maintaining cation homeostasis of this important organelle.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Orlowski, J (corresponding author), McGill Univ, Dept Physiol, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.			Orlowski, John/0000-0001-7371-175X				ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; Apse MP, 1999, SCIENCE, V285, P1256, DOI 10.1126/science.285.5431.1256; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Biemesderfer D, 1998, J BIOL CHEM, V273, P12391, DOI 10.1074/jbc.273.20.12391; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BRIERLEY GP, 1984, J BIOL CHEM, V259, P4672; BRIERLEY GP, 1994, J BIOENERG BIOMEMBR, V26, P519, DOI 10.1007/BF00762736; BRIERLEY GP, 1989, BIOCHEMISTRY-US, V28, P4337; COUNILLON L, 1993, BIOCHIM BIOPHYS ACTA, V1172, P343, DOI 10.1016/0167-4781(93)90228-6; COUNILLON L, 1994, BIOCHEMISTRY-US, V33, P10463, DOI 10.1021/bi00200a030; D'Souza S, 1998, J BIOL CHEM, V273, P2035, DOI 10.1074/jbc.273.4.2035; Demaurex N, 1998, J BIOL CHEM, V273, P2044, DOI 10.1074/jbc.273.4.2044; DIRESTA DJ, 1986, AM J PHYSIOL, V251, pR787, DOI 10.1152/ajpregu.1986.251.4.R787; FAFOURNOUX P, 1994, J BIOL CHEM, V269, P2589; Farinas J, 1999, J BIOL CHEM, V274, P7603, DOI 10.1074/jbc.274.12.7603; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1991, J BIOL CHEM, V266, P6518; GARLID KD, 1978, BIOCHEM BIOPH RES CO, V83, P1450, DOI 10.1016/0006-291X(78)91383-9; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; GLUCK S, 1992, J EXP BIOL, V172, P29; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JUNG DW, 1992, AM J PHYSIOL, V262, pC1047, DOI 10.1152/ajpcell.1992.262.4.C1047; KAPUS A, 1988, BIOCHIM BIOPHYS ACTA, V944, P383, DOI 10.1016/0005-2736(88)90509-3; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; MARTIN WH, 1984, J BIOL CHEM, V259, P2062; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Nath S., 1988, INTEGRATION MITOCHON, P357; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; Rybak SL, 1997, BIOPHYS J, V73, P674, DOI 10.1016/S0006-3495(97)78102-5; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SASTRASINH M, 1995, AM J PHYSIOL-CELL PH, V268, pC1227, DOI 10.1152/ajpcell.1995.268.5.C1227; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schapiro FB, 2000, J BIOL CHEM, V275, P21025, DOI 10.1074/jbc.M002386200; Shrode LD, 1998, AM J PHYSIOL-CELL PH, V275, pC431, DOI 10.1152/ajpcell.1998.275.2.C431; TSE CM, 1994, BIOCHEMISTRY-US, V33, P12954, DOI 10.1021/bi00248a003; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Wakabayashi S, 2000, J BIOL CHEM, V275, P7942, DOI 10.1074/jbc.275.11.7942; WONG SH, 1993, J BIOL CHEM, V268, P22853; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	63	198	205	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17387	17394		10.1074/jbc.M101319200	http://dx.doi.org/10.1074/jbc.M101319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279194	hybrid			2022-12-25	WOS:000168730400106
J	Jeong, HS; Jeong, KC; Choi, HK; Park, KJ; Lee, KH; Rhee, JH; Choi, SH				Jeong, HS; Jeong, KC; Choi, HK; Park, KJ; Lee, KH; Rhee, JH; Choi, SH			Differential expression of Vibrio vulnificus elastase gene in a growth phase-dependent manner by two different types of promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; STATIONARY-PHASE; CYCLIC-AMP; VIRULENCE DETERMINANTS; ELASTOLYTIC PROTEASE; SUICIDE VECTOR; SIGMA-FACTOR; RPOS GENE; CONSTRUCTION; CHOLERAE	Elastase activity of Vibrio vulnificus was highly dependent on growth phase, reached a maximum during the stationary phase, and was regulated at the level of transcription. The stationary phase production of elastase in crp or rpoS mutants, which were constructed by allelic exchanges, decreased about 3- and 10-fold, respectively. However, the promoter activity of vvpE encoding elastase was unaffected by those mutations in the log phase when analyzed using a vvpE-lux fusion, A primer extension analysis revealed that the transcription of vvpE begins at two different sites, consisting of putative promoter L (PL) and promoter S (PS), The PL activity was constitutive through the log and stationary phases, lower than the PS activity, and unaffected by the crp or rpoS mutations. The transcription of PS, induced only in the stationary phase, was dependent on RpoS. The mutation in crp reduced the activity of PS; however, the additional inactivation of crp did not influence the PS activity in the rpoS mutant, indicating that CRP exerted its effects through PS requiring RpoS, These results demonstrate that vvpE expression is differentially directed by PL and PS depending on the growth phase and elevated by RpoS and CRP in the stationary phase.	Chonnam Natl Univ, Inst Biotechnol, Dept Food Sci & Technol, Kwangju 500757, South Korea; Chonnam Natl Univ, Inst Biotechnol, Dept Mol Biotechnol, Kwangju 500757, South Korea; Hankuk Univ Foreign Studies, Dept Environm Sci, Yongin 449791, Kyunggi Do, South Korea; Chonnam Natl Univ, Sch Med, Dept Microbiol, Kwangju 500190, South Korea	Chonnam National University; Chonnam National University; Hankuk University Foreign Studies; Chonnam National University	Choi, SH (corresponding author), Chonnam Natl Univ, Inst Biotechnol, Dept Food Sci & Technol, Kwangju 500757, South Korea.			Choi, Sang Ho/0000-0003-3865-1039				BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; CHEN CY, 1995, J BACTERIOL, V177, P5303, DOI 10.1128/jb.177.18.5303-5309.1995; Choi SH, 2000, APPL ENVIRON MICROB, V66, P3911, DOI 10.1128/AEM.66.9.3911-3916.2000; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; HASE CC, 1993, MICROBIOL REV, V57, P823; Hengge-Aronis R., 1996, ESCHERICHIA COLI SAL, V5, P1497; IRIARTE M, 1995, INFECT IMMUN, V63, P1840, DOI 10.1128/IAI.63.5.1840-1847.1995; Jeong KC, 2000, INFECT IMMUN, V68, P5096, DOI 10.1128/IAI.68.9.5096-5106.2000; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.micro.47.1.855; KOTHARY MH, 1987, J GEN MICROBIOL, V133, P1783; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; Linkous DA, 1999, FEMS MICROBIOL LETT, V174, P207, DOI 10.1111/j.1574-6968.1999.tb13570.x; Loewen PC, 1998, CAN J MICROBIOL, V44, P707, DOI 10.1139/cjm-44-8-707; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; MIYOSHI S, 1988, MICROBIOL IMMUNOL, V32, P1025, DOI 10.1111/j.1348-0421.1988.tb01467.x; Miyoshi S, 1998, INFECT IMMUN, V66, P4851, DOI 10.1128/IAI.66.10.4851-4855.1998; Nagai S, 1998, VET MICROBIOL, V60, P227, DOI 10.1016/S0378-1135(98)00144-8; OBYRNE CP, 1994, J BACTERIOL, V176, P905, DOI 10.1128/jb.176.3.905-912.1994; OKA A, 1981, J MOL BIOL, V147, P217, DOI 10.1016/0022-2836(81)90438-1; Sambrook J., 2002, MOL CLONING LAB MANU; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; Shao CP, 2000, INFECT IMMUN, V68, P3569, DOI 10.1128/IAI.68.6.3569-3573.2000; Skorupski K, 1997, P NATL ACAD SCI USA, V94, P265, DOI 10.1073/pnas.94.1.265; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Yildiz FH, 1998, J BACTERIOL, V180, P773, DOI 10.1128/JB.180.4.773-784.1998	28	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					13875	13880		10.1074/jbc.M010567200	http://dx.doi.org/10.1074/jbc.M010567200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297524	hybrid			2022-12-25	WOS:000168356600053
J	Ranganathan, AC; Nelson, KK; Rodriguez, AM; Kim, KH; Tower, GB; Rutter, JL; Brinckerhoff, CE; Huang, TT; Epstein, CJ; Jeffrey, JJ; Melendez, JA				Ranganathan, AC; Nelson, KK; Rodriguez, AM; Kim, KH; Tower, GB; Rutter, JL; Brinckerhoff, CE; Huang, TT; Epstein, CJ; Jeffrey, JJ; Melendez, JA			Manganese superoxide dismutase signals matrix metalloproteinase expression via H2O2-dependent ERK1/2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 MESSENGER-RNA; SMOOTH-MUSCLE CELLS; GASTRIC-CANCER; INTERSTITIAL COLLAGENASE; HYDROGEN-PEROXIDE; GENE-EXPRESSION; OVEREXPRESSION; FIBROBLASTS; TISSUE	Manganese-superoxide dismutase (Sod2) removes mitochondrially derived superoxide (O-2(radical anion)) at near-diffusion limiting rates and is the only antioxidant enzyme whose expression is regulated by numerous stimuli. Here it is shown that Sod2 also serves as a source of the intracellular signaling molecule H2O2. Sod2-dependent increases in the steady-state levels of H2O2 led to ERK1/2 activation and subsequent downstream transcriptional increases in matrix metalloproteinase-1 (MMP-1) expression, which were reversed by expression of the H2O2-detoxifying enzyme, catalase. In addition, a single nucleotide polymorphism has recently been identified (1G/2G) at base pair -1607 that creates an Ets site adjacent to an AP-1 site at base pair -1602 and has been shown to dramatically enhance transcription of the MMP-1 promoter. Luciferase promoter constructs containing either the 1G or 2G variation were 25- or 1000-fold more active when transiently transfected into Sod2-overexpressing cell lines, respectively. The levels of MMP-2, -3, and -7 were also increased in the Sod2-overexpressing cell lines, suggesting that Sod2 may function as a "global" redox regulator of MMP expression. In addition, Sod2(-/+) mouse embryonic fibroblasts failed to respond to the cytokine-mediated induction of the murine functional analog of MMP-1, MMP-13. This study provides evidence that the modulation of Sod2 activity by a wide array of pathogenic and inflammatory stimuli may be utilized by the cell as a primary signaling mechanism leading to matrix metalloproteinase expression.	Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Dartmouth Coll, Sch Med, Hanover, NH 03755 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Albany Medical College; Albany Medical College; Dartmouth College; University of California System; University of California San Francisco	Melendez, JA (corresponding author), Albany Med Coll, Ctr Immunol & Microbial Dis, MC151,47 New Scotland Ave, Albany, NY 12208 USA.			Rutter, Joni/0000-0002-6502-2361; Melendez, Juan/0000-0001-8021-3097				Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; Birkenkamp KU, 2000, BRIT J PHARMACOL, V131, P99, DOI 10.1038/sj.bjp.0703534; Brenneisen P, 1997, FREE RADICAL BIO MED, V22, P515, DOI 10.1016/S0891-5849(96)00404-2; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Day BJ, 1999, FREE RADICAL BIO MED, V27, pS59; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dumin J, 1998, J BIOL CHEM, V273, P25488, DOI 10.1074/jbc.273.39.25488; FINI ME, 1998, MATRIX METALLOPROTEI; Fisher GJ, 1996, NATURE, V379, P335, DOI 10.1038/379335a0; Fisher GJ, 1997, NEW ENGL J MED, V337, P1419, DOI 10.1056/NEJM199711133372003; FRUCHART JC, 1994, FREE RADICAL DAMAGE; FUJII J, 1991, J BIOL CHEM, V266, P23142; GOROSPE M, 1993, J BIOL CHEM, V268, P6214; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Huang TT, 1997, ARCH BIOCHEM BIOPHYS, V344, P424, DOI 10.1006/abbi.1997.0237; Inoue T, 1999, INT J MOL MED, V4, P73; Janssen AML, 2000, CLIN CANCER RES, V6, P3183; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KUMAR S, 1992, P NATL ACAD SCI USA, V89, P4683, DOI 10.1073/pnas.89.10.4683; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Manzano VM, 1999, J PHARMACOL EXP THER, V289, P123; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Melendez JA, 1996, J BIOL CHEM, V271, P18898, DOI 10.1074/jbc.271.31.18898; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Poswig A, 1999, J INVEST DERMATOL, V112, P13, DOI 10.1046/j.1523-1747.1999.00465.x; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; Rutter JL, 1998, CANCER RES, V58, P5321; Sasaki H, 1997, PHOTOCHEM PHOTOBIOL, V65, P707, DOI 10.1111/j.1751-1097.1997.tb01914.x; SATOMI A, 1995, J GASTROENTEROL, V30, P177, DOI 10.1007/BF02348662; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Toh Y, 2000, INT J ONCOL, V17, P107; TOWER GB, 2000, 91 ANN M AM ASS CANC; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WEBER GF, 1994, MED HYPOTHESES, V43, P223, DOI 10.1016/0306-9877(94)90070-1; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; WESTMAYS JA, 1995, P NATL ACAD SCI USA, V92, P6768, DOI 10.1073/pnas.92.15.6768; WILCOX BD, 1994, J BIOL CHEM, V269, P29658; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; ZYAD A, 1994, CANCER RES, V54, P825	45	130	139	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 27	2001	276	17					14264	14270		10.1074/jbc.M100199200	http://dx.doi.org/10.1074/jbc.M100199200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	426PB	11297530	hybrid			2022-12-25	WOS:000168356600100
J	Baudry, K; Swain, E; Rahier, A; Germann, M; Batta, A; Rondet, S; Mandala, S; Henry, K; Tint, GS; Edlind, T; Kurtz, M; Nickels, JT				Baudry, K; Swain, E; Rahier, A; Germann, M; Batta, A; Rondet, S; Mandala, S; Henry, K; Tint, GS; Edlind, T; Kurtz, M; Nickels, JT			The effect of the erg26-1 mutation on the regulation of lipid metabolism in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT STEROL BIOSYNTHESIS; PHOSPHOLIPID BIOSYNTHESIS; PHOSPHATIDATE PHOSPHATASE; PHOSPHATIDYLINOSITOL SYNTHASE; PARTIAL-PURIFICATION; YEAST; GENE; REDUCTASE; ACID; IDENTIFICATION	A temperature-sensitive Saccharomyces cerevisiae mutant harboring a lesion in the ERG26 gene has been isolated. ERG26 encodes 4 alpha -carboxysterol-C3 dehydrogenase, one of three enzymatic activities required for the conversion of 4,4-dimethylzymosterol to zymosterol. Gas chromatography/mass spectrometry analyses of sterols in this mutant, designated erg26-1, revealed the aberrant accumulation of a 4-methyl-4-carboxy zymosterol intermediate, as well as a novel 4-carboxysterol. Neutral lipid radiolabeling studies showed that erg26-1 cells also harbored defects in the rate of biosynthesis and steady-state levels of mono-, di-, and triglycerides. Phospholipid radiolabeling studies showed defects in the rate of biosynthesis of both phosphatidic acid and phosphatidylinositol. Biochemical studies revealed that microsomes isolated from erg26-1 cells contained greatly reduced 4 alpha -carboxysterol-C3 dehydrogenase activity when compared with microsomes from wild type cells. Previous studies have shown that loss of function mutations in either of the fatty acid elongase genes SUR4/EL03 or FEN1/GNS1/ELO2 can "by-pass" the essentiality of certain ERG genes (Ladeveze, V., Marcireau, C., Delourme, D., and Karat, F. (1993) Lipids 28, 907-912; Silve, S., Leplatois, P., Josse, A., Dupuy, P. H., Lanau, C., Kaghad, M., Dhers, C., Picard, C., Rahier, A, Taton, M., Le Fur, G., Caput, D., Ferrara, P., and Loison, G. (1996) Mol Cell. Biol. 16, 2719-2727). Studies presented here have shown that this sphingolipid-dependent "bypass" mechanism did not suppress the essential requirement for zymosterol biosynthesis. However, studies aimed at understanding the underlying physiology behind the temperature-sensitive growth defect of erg26-1 cells showed that the addition of several antifungal compounds to the growth media of erg26-1 cells could suppress the temperature-sensitive growth defect. Fluorescence microscopic analysis showed that GFP-Erg26p and GFP-Erg27p fusion proteins were localized to the endoplasmic reticulum. Two-hybrid analysis indicated that Erg25p, Erg26p, and Erg27p, which are required for the biosynthesis of zymosterol, form a complex within the cell.	Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Med Coll Penn & Hahnemann Univ, Dept Immunol & Microbiol, Philadelphia, PA 19129 USA; Inst Bot, Dept Enzymol Cellulaire & Mol, Strasbourg, France; Univ Med & Dent New Jersey, Dept Vet Affairs, E Orange, NJ 07018 USA; Merck Res Labs, Dept Biochem, Rahway, NJ 07065 USA	Drexel University; Drexel University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company	Nickels, JT (corresponding author), 245 N 15th St, Philadelphia, PA 19102 USA.	Joseph.Nickels@drexel.edu						AOYAMA Y, 1987, J BIOL CHEM, V262, P1239; ASHMAN WH, 1991, LIPIDS, V26, P628, DOI 10.1007/BF02536427; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bammert GF, 2000, ANTIMICROB AGENTS CH, V44, P1255, DOI 10.1128/AAC.44.5.1255-1265.2000; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BAUDRY K, UNPUB; BERRY DJ, 1982, BIOCHEMISTRY-US, V21, P573, DOI 10.1021/bi00532a025; BILLHEIMER JT, 1981, ARCH BIOCHEM BIOPHYS, V211, P430, DOI 10.1016/0003-9861(81)90474-4; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BOTTEMA CK, 1978, BIOCHIM BIOPHYS ACTA, V531, P301, DOI 10.1016/0005-2760(78)90212-6; BOUROT S, 1995, GENE, V165, P97, DOI 10.1016/0378-1119(95)00478-O; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; D'Hondt K, 2000, ANNU REV GENET, V34, P255, DOI 10.1146/annurev.genet.34.1.255; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Farese RV, 1998, TRENDS GENET, V14, P115, DOI 10.1016/S0168-9525(97)01377-2; FAUST JR, 1988, BIOL CHOLESTEROL, P19; FINE JB, 1982, J LIPID RES, V23, P660; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FOREMAN PK, 1994, GENE, V144, P63, DOI 10.1016/0378-1119(94)90204-6; FUKUSHIMA H, 1981, J BIOL CHEM, V256, P4822; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Illingworth R, 2000, MED CLIN N AM, V84, P23, DOI 10.1016/S0025-7125(05)70205-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; Kelly SL, 1997, J BIOL CHEM, V272, P9986, DOI 10.1074/jbc.272.15.9986; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; LADEVEZE V, 1993, LIPIDS, V28, P907, DOI 10.1007/BF02537499; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; Lees N., 1997, BIOCH FUNCTION STERO, P85; LEIDICH SD, 1995, METHOD ENZYMOL, V250, P560; Li LT, 1996, J BIOL CHEM, V271, P16927, DOI 10.1074/jbc.271.28.16927; LIN YP, 1989, J BIOL CHEM, V264, P8641; LORENZ RT, 1986, J BACTERIOL, V167, P981, DOI 10.1128/jb.167.3.981-985.1986; MANDALA S, COMMUNICATION; MOLZAHN SW, 1972, J GEN MICROBIOL, V72, P339, DOI 10.1099/00221287-72-2-339; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; OSUMI T, 1979, J BIOCHEM-TOKYO, V85, P819; PARKS LW, 1995, LIPIDS, V30, P227, DOI 10.1007/BF02537825; PASCAL S, 1993, J BIOL CHEM, V268, P11639; PASCAL S, 1994, ARCH BIOCHEM BIOPHYS, V312, P260, DOI 10.1006/abbi.1994.1308; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PLEMENITAS A, 1990, J BIOL CHEM, V265, P17012; RAHIMTULA AD, 1972, J BIOL CHEM, V247, P9; Rondet S, 1999, ARCH BIOCHEM BIOPHYS, V366, P249, DOI 10.1006/abbi.1999.1218; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SHERMAN F, 1982, METHODS YEAST GENETI, P170; SIKORSKI RS, 1989, GENETICS, V122, P19; Silve S, 1996, MOL CELL BIOL, V16, P2719; Szkopinska A, 2000, BIOCHEM BIOPH RES CO, V267, P473, DOI 10.1006/bbrc.1999.1981; WELIHINDA AA, 1994, BBA-BIOMEMBRANES, V1193, P107, DOI 10.1016/0005-2736(94)90339-5; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; WU WI, 1993, J BIOL CHEM, V268, P13830; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353	63	48	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					12702	12711		10.1074/jbc.M100274200	http://dx.doi.org/10.1074/jbc.M100274200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11279045	hybrid			2022-12-25	WOS:000168198600033
J	Kress, M; Fickenscher, H				Kress, M; Fickenscher, H			Infection by human varicella-zoster virus confers norepinephrine sensitivity to sensory neurons from rat dorsal root ganglia	FASEB JOURNAL			English	Article						DRG cells; norepinephrine; postherpetic neuralgia; sensory neurons	HERPES-ZOSTER; ADULT-RAT; ACCUMULATION; ATTENUATION; LATENCY; STRAIN; CELLS; MODEL; PAIN; DNA	Varicella-zoster virus (VZV) is a widespread human herpes virus causing chicken pox on primary infection and persisting in sensory neurons. Reactivation causes shingles, which are characterized by severe pain and often lead to postherpetic neuralgia, To elucidate the mechanisms of VZV-associated hyperalgesia, we elaborated an in vitro model for the VZV infection of sensory neurons from rat dorsal root ganglia. Between 35 and 50% of the neurons showed strong expression of the immediate-early virus antigens IE62 and IE63 and the late glycoprotein gE. When the intracellular calcium concentration was monitored microfluorometrically for individual cells after infection, the sensitivity to GABA or capsaicin was similar in controls and in VZV-infected neurons. However, the baseline calcium concentration was increased. Neurons became de novo sensitive to adrenergic stimulation after VZV infection, Norepinephrine-responsive neurons were more frequent and calcium responses to norepinephrine were significantly higher after infection with wild-type isolates than with the attenuated vaccine strain OKA. The adrenergic agonists phenylephrine and isoproterenol had similar efficacy. We suggest that the infection with wild-type VZV isolates confers norepinephrine sensitivity to sensory neurons by using alpha (1)-and/or beta (1)-adrenergic receptors providing a model for the pathophysiology of the severe pain associated with the acute reactivation of VZV.	Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Klin & Mol Virol, D-91054 Erlangen, Germany	University of Erlangen Nuremberg; University of Erlangen Nuremberg	Kress, M (corresponding author), Univ Erlangen Nurnberg, Inst Physiol & Expt Pathophysiol, Univ Str 17, D-91054 Erlangen, Germany.	kress@physiologie1.uni-erlangen.de	Fickenscher, Helmut/J-9655-2019; Fickenscher, Helmut/A-3004-2010	Fickenscher, Helmut/0000-0003-0043-1153; Kress, Michaela/0000-0002-8921-7470				Abdulla FA, 1997, J NEUROSCI, V17, P1633; ALEXANDER SPH, 1999, TRENDS PHARMACOL SCI, V20, P11; Ali Z, 1999, J NEUROPHYSIOL, V81, P455, DOI 10.1152/jn.1999.81.2.455; Annunziato P, 1998, J INFECT DIS, V178, pS48, DOI 10.1086/514261; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Arvin AM, 1996, ANNU REV MICROBIOL, V50, P59, DOI 10.1146/annurev.micro.50.1.59; Choi B, 1997, PAIN, V69, P55, DOI 10.1016/S0304-3959(96)03245-9; CROEN KD, 1988, P NATL ACAD SCI USA, V85, P9773, DOI 10.1073/pnas.85.24.9773; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; Dittert I, 1998, J NEUROSCI METH, V82, P195, DOI 10.1016/S0165-0270(98)00051-X; Dong SJ, 1999, ADV BIOSENS, V4, P1; Fleetwood-Walker SM, 1999, J GEN VIROL, V80, P2433, DOI 10.1099/0022-1317-80-9-2433; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HENKEN DB, 1991, J NEUROL SCI, V105, P29, DOI 10.1016/0022-510X(91)90114-M; Kennedy PGE, 1998, P NATL ACAD SCI USA, V95, P4658, DOI 10.1073/pnas.95.8.4658; KINCHINGTON PR, 1990, J VIROL, V64, P4540, DOI 10.1128/JVI.64.9.4540-4548.1990; KRAUSE PR, 1995, J PEDIATR-US, V127, P518, DOI 10.1016/S0022-3476(95)70106-0; Kress M, 1999, J NEUROPHYSIOL, V81, P2612, DOI 10.1152/jn.1999.81.6.2612; LaGuardia JJ, 1999, J VIROL, V73, P8571, DOI 10.1128/JVI.73.10.8571-8577.1999; Martinez E, 1998, CLIN INFECT DIS, V27, P1510, DOI 10.1086/515019; MAYER ML, 1986, J NEUROSCI, V6, P391; MCLACHLAN EM, 1993, NATURE, V363, P543, DOI 10.1038/363543a0; MERVILLELOUIS MP, 1989, J VIROL, V63, P3155, DOI 10.1128/JVI.63.7.3155-3160.1989; Moffat JF, 1998, J VIROL, V72, P965, DOI 10.1128/JVI.72.2.965-974.1998; MYERS MG, 1991, J INFECT DIS, V163, P746, DOI 10.1093/infdis/163.4.746; OLIVIER M, 1992, J IMMUNOL, V148, P1188; Petersen M, 1996, PAIN, V67, P391, DOI 10.1016/0304-3959(96)03146-6; SADZOTDELVAUX C, 1995, J GEN VIROL, V76, P2875, DOI 10.1099/0022-1317-76-11-2875; SADZOTDELVAUX C, 1990, J NEUROSCI RES, V26, P83, DOI 10.1002/jnr.490260110; SadzotDelvaux C, 1995, NEUROLOGY, V45, pS18, DOI 10.1212/WNL.45.12_Suppl_8.S18; SATO J, 1991, SCIENCE, V251, P1608, DOI 10.1126/science.2011742; STEFANINI M, 1967, NATURE, V216, P173, DOI 10.1038/216173a0; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108; WELLER TH, 1992, J INFECT DIS, V166, pS1; WOOD JN, 1988, J NEUROSCI, V8, P3208; Wu CL, 2000, PAIN, V87, P121, DOI 10.1016/S0304-3959(00)00230-X; Zeilhofer HU, 1996, J NEUROPHYSIOL, V76, P2834, DOI 10.1152/jn.1996.76.5.2834	37	23	25	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2001	15	6					1037	1043		10.1096/fj.00-0440com	http://dx.doi.org/10.1096/fj.00-0440com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292665				2022-12-25	WOS:000167959300019
J	Jackson, MW; Lindstrom, MS; Berberich, SJ				Jackson, MW; Lindstrom, MS; Berberich, SJ			MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; NUCLEOLAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; P53-BINDING PROTEIN; ONCOPROTEIN MDM2; CELL-GROWTH; GENE; P19(ARF); AMPLIFICATION; IDENTIFICATION	Regulation of p53 involves a complex network of protein interactions. The primary regulator of p53 protein stability is the Mdm2 protein. ARF and MdmX are two proteins that have recently been shown to inhibit Mdm2-mediated degradation of p53 via distinct associations with Mdm2, We demonstrate here that ARF is capable of interacting with MdmX and in a manner similar to its association with Mdm2, sequestering MdmX within the nucleolus. The sequestration of MdmX by ARF results in an increase in p53 transactivation, In addition, the redistribution of MdmX by ARF requires that a nucleolar localization signal be present on MdmX Although expression of either MdmX or ARF leads to Mdm2 stabilization, coexpression of both MdmX and ARF results in a decrease in Mdm2 protein levels. Similarly, increasing ARF protein levels in the presence of constant MdmX and Mdm2 leads to a dose-dependent decrease in Mdm2 levels. Under these conditions, ARF can synergistically reverse the ability of Mdm2 and MdmX to inhibit p53-dependent transactivation. Finally, the association and redistribution of MdmX by ARF has no effect on the protein stability of either ARF or MdmX, Taken together, these results demonstrate that the interaction between MdmX and ARF represents a novel pathway for regulating Mdm2 protein levels. Additionally, both MdmX and Mdm2, either individually or together, are capable of antagonizing the effects of the ARF tumor suppressor on p53 activity.	Wright State Univ, Dept Biochem & Mol Biol, Dayton, OH 45435 USA; Karolinska Hosp & Inst, Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden	University System of Ohio; Wright State University Dayton; Karolinska Institutet; Karolinska University Hospital	Berberich, SJ (corresponding author), Wright State Univ, Dept Biochem & Mol Biol, 3640 Colonel Glenn Hwy, Dayton, OH 45435 USA.		Lindström, Mikael S/AAA-1451-2019	Lindström, Mikael S/0000-0003-1148-8497	NATIONAL CANCER INSTITUTE [R29CA064430, R01CA064430] Funding Source: NIH RePORTER; NCI NIH HHS [CA64430, R01 CA064430-08, R01 CA064430] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berberich SJ, 1999, DIFFERENTIATION, V64, P205, DOI 10.1046/j.1432-0436.1999.6440205.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HARPER JW, 1993, CELL, V75, P805; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Ko JL, 1996, GENE DEV, V10, P1054; Liggett WH, 1996, CANCER RES, V56, P4119; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Stad R, 2000, J BIOL CHEM, V275, P28039; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	33	57	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25336	25341		10.1074/jbc.M010685200	http://dx.doi.org/10.1074/jbc.M010685200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11297540	hybrid			2022-12-25	WOS:000169800700120
J	Noji, H; Bald, D; Yasuda, R; Itoh, H; Yoshida, M; Kinosita, K				Noji, H; Bald, D; Yasuda, R; Itoh, H; Yoshida, M; Kinosita, K			Purine but not pyrimidine nucleotides support rotation of F-1-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA(3)BETA(3)GAMMA COMPLEX; ESCHERICHIA-COLI; CATALYTIC SITE; BETA-SUBUNITS; F1-ATPASE; BINDING	The binding change model for the F-1-ATPase predicts that its rotation is intimately correlated with the changes in the affinities of the three catalytic sites for nucleotides. If so, subtle differences in the nucleotide structure may have pronounced effects on rotation. Here we show by single-molecule imaging that purine nucleotides ATP, GTP, and ITP support rotation but pyrimidine nucleotides UTP and CTP do not, suggesting that the extra ring in purine is indispensable for proper operation of this molecular motor. Although the three purine nucleotides were bound to the enzyme at different rates, all showed similar rotational characteristics: counterclockwise rotation, 120 degrees steps each driven by hydrolysis of one nucleotide molecule, occasional back steps, rotary torque of similar to 40 piconewtons (pN)(.)nm, and mechanical work done in a step of similar to 80 pN(.)nm. These latter characteristics are likely to be determined by the rotational mechanism built in the protein structure, which purine nucleotides can energize. With ATP and GTP, rotation was observed even when the free energy of hydrolysis was -80 pN(.)nm/molecule, indicating similar to 100% efficiency. Reconstituted F0F1-ATPase actively translocated protons by hydrolyzing ATP, GTP, and ITP, but CTP and UTP were not even hydrolyzed. Isolated F-1 very slowly hydrolyzed UTP (but not CTP), suggesting possible uncoupling from rotation.	Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, CREST,Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Tokyo Inst Technol, Chem Resources Lab, PRESTO, Yokohama, Kanagawa 2268503, Japan; Hamamatsu Photon KK, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan; Keio Univ, Fac Sci & Technol, Yokohama, Kanagawa 2238522, Japan	Japan Science & Technology Agency (JST); Teikyo University; Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Hamamatsu Photonics; Keio University	Kinosita, K (corresponding author), Teikyo Univ, Biotechnol Res Ctr 3F, Genet Programming Team 13, CREST,Miyamae Ku, Nogawa 907, Kawasaki, Kanagawa 2160001, Japan.		Yasuda, Ryohei/E-7726-2011	Yasuda, Ryohei/0000-0001-6263-9297				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Adachi K, 2000, P NATL ACAD SCI USA, V97, P7243, DOI 10.1073/pnas.120174297; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Bald D, 1998, J BIOL CHEM, V273, P865, DOI 10.1074/jbc.273.2.865; Boyer PD, 2000, BBA-BIOENERGETICS, V1458, P252, DOI 10.1016/S0005-2728(00)00077-3; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oosawa F, 1986, Adv Biophys, V22, P151, DOI 10.1016/0065-227X(86)90005-5; Papageorgiou S, 1998, J BIOENERG BIOMEMBR, V30, P533, DOI 10.1023/A:1020528432609; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SORGATO MC, 1982, BIOCHIM BIOPHYS ACTA, V681, P319, DOI 10.1016/0005-2728(82)90038-X; STRYER L, 1995, BIOCHEMISTRY-US, P443; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837	19	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 6	2001	276	27					25480	25486		10.1074/jbc.M102200200	http://dx.doi.org/10.1074/jbc.M102200200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	451KF	11279248	hybrid, Green Published			2022-12-25	WOS:000169800700138
J	Batchu, RB; Shammas, MA; Wang, JY; Munshi, NC				Batchu, RB; Shammas, MA; Wang, JY; Munshi, NC			Dual level inhibition of E2F-1 activity by adeno-associated virus Rep78	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; TRANSCRIPTION FACTOR; SUPPRESSOR PROTEIN; IN-VITRO; DNA; BINDING; TRANSFORMATION; ACTIVATION; AAV	E2F-1, a major cellular transcription factor, plays a pivotal role in regulating the cell cycle. The activity of E2F-1 is negatively regulated by its interaction with retinoblastoma protein (pRB), and disruption of the pRB-E2F-1 complex, a hallmark of cellular transformation by DNA tumor viruses, leads to cell proliferation, Adeno-associated virus-2 (AAV) is known to have oncosuppressive properties against DNA tumor viruses. Here we provide, for the first time, the molecular basis for antioncogenic activity of AAV. Rep78, a major regulatory protein of AAV, interacts at the protein level with E2F-1 and stabilizes the pRB-E2F-1 complex. At the DNA level, Rep78 binds to a putative site on the E2F-1 promoter and down-regulates the adenovirus-induced E2F-1 transcription. This dual level of Rep78 activity leads to decreased cellular levels of free E2F-1, leading to its once-suppressive properties.	Univ Arkansas Med Sci, Cent Arkansas Vet Hlth Care Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences	Munshi, NC (corresponding author), Univ Arkansas Med Sci, Cent Arkansas Vet Hlth Care Syst, 4301 W Markham,Slot 776, Little Rock, AR 72205 USA.		Munshi, Nikhil/ABE-2338-2021		NATIONAL CANCER INSTITUTE [P01CA055819] Funding Source: NIH RePORTER; NCI NIH HHS [CA55819] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1989, P NATL ACAD SCI USA, V86, P4352, DOI 10.1073/pnas.86.12.4352; Batchu RB, 1999, CANCER RES, V59, P3592; BATCHU RB, 1994, CANCER LETT, V86, P23, DOI 10.1016/0304-3835(94)90176-7; BATCHU RB, 1995, FEBS LETT, V367, P267, DOI 10.1016/0014-5793(95)00584-V; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BERNS KI, 1987, ADV VIRUS RES, V32, P243, DOI 10.1016/S0065-3527(08)60479-0; CASTO BC, 1972, P SOC EXP BIOL MED, V140, P72; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHIORINI JA, 1994, J VIROL, V68, P7448, DOI 10.1128/JVI.68.11.7448-7457.1994; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; GILDEN RV, 1968, NATURE, V220, P1139, DOI 10.1038/2201139b0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HEILBRONN R, 1990, J VIROL, V64, P3012, DOI 10.1128/JVI.64.6.3012-3018.1990; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hermanns J, 1997, J VIROL, V71, P6020, DOI 10.1128/JVI.71.8.6020-6027.1997; HERMONAT PL, 1989, VIROLOGY, V172, P253, DOI 10.1016/0042-6822(89)90127-X; Hermonat PL, 1997, GYNECOL ONCOL, V66, P487, DOI 10.1006/gyno.1997.4789; Hermonat PL, 1996, CANCER RES, V56, P5299; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KHLEIF SN, 1991, VIROLOGY, V181, P738, DOI 10.1016/0042-6822(91)90909-U; KYOSTIO SRM, 1995, J VIROL, V69, P6787; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; MAYOR HD, 1977, CANCER BIOCHEM BIOPH, V2, P25; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1992, SCIENCE, V258, P424; OSTROVE JM, 1981, VIROLOGY, V113, P521, DOI 10.1016/0042-6822(81)90180-X; PAGANO M, 1992, ONCOGENE, V7, P1681; RAYCHAUDHURI P, 1990, J VIROL, V64, P2702, DOI 10.1128/JVI.64.6.2702-2710.1990; SAMULSKI RJ, 1991, EMBO J, V10, P3941, DOI 10.1002/j.1460-2075.1991.tb04964.x; SCHLEHOFER JR, 1994, MUTAT RES, V305, P303, DOI 10.1016/0027-5107(94)90250-X; TYAGI RK, 1993, ELECTROPHORESIS, V14, P826, DOI 10.1002/elps.11501401130; Walz CM, 1998, VIROLOGY, V247, P97, DOI 10.1006/viro.1998.9226; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEITZMAN MD, 1994, P NATL ACAD SCI USA, V91, P5808, DOI 10.1073/pnas.91.13.5808; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; YANG QC, 1992, J VIROL, V66, P6058, DOI 10.1128/JVI.66.10.6058-6069.1992; YANG QC, 1995, VIROLOGY, V207, P246, DOI 10.1006/viro.1995.1072; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	45	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24315	24322		10.1074/jbc.M008154200	http://dx.doi.org/10.1074/jbc.M008154200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294829	hybrid			2022-12-25	WOS:000169531100143
J	Evanko, DS; Thiyagarajan, MM; Siderovski, DP; Wedegaertner, PB				Evanko, DS; Thiyagarajan, MM; Siderovski, DP; Wedegaertner, PB			G beta gamma isoforms selectively rescue plasma membrane localization and palmitoylation of mutant G alpha(s) and G alpha(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; DIFFERENTIAL DISTRIBUTION; ALPHA-SUBUNITS; RAT-BRAIN; RECEPTOR; ACTIVATION; ASSOCIATION; SPECIFICITY; PALMITATE; CHANNELS	Mutation of G alpha (q) or G alpha (s) N-terminal contact sites for G beta gamma resulted in alpha subunits that failed to localize at the plasma membrane or undergo palmitoylation when expressed in HEK293 cells. We now show that overexpression of specific py subunits can recover plasma membrane localization and palmitoylation of the beta gamma -binding-deficient mutants of alpha (s) or alpha (q). Thus, the beta gamma -binding-defective alpha is completely dependent on co-expression of exogenous beta gamma for proper membrane localization. In this report, we examined the ability of beta (1-5) in combination with gamma (2) or gamma (3) to promote proper localization and palmitoylation of mutant alpha (s) or alpha (q). Immunofluorescence localization, cellular fractionation, and palmitate labeling revealed distinct subtype-specific differences in beta gamma interactions with alpha subunits. These studies demonstrate that 1) alpha and beta gamma reciprocally promote the plasma membrane targeting of the other subunit; 2) beta (5), when coexpressed with gamma (2) or gamma (3), fails to localize to the plasma membrane or promote plasma membrane localization of mutant alpha (s) or alpha (q); 3) beta (3) is deficient in promoting plasma membrane localization of mutant alpha (s) and alpha (q), whereas beta (4) is deficient in promoting plasma membrane localization of mutant alpha (q); 4) both palmitoylation and interactions with beta gamma are required for plasma membrane localization of alpha.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA	Jefferson University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wedegaertner, PB (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Kimmel Canc Inst, 233 S 10th St,839 BLSB, Philadelphia, PA 19107 USA.		Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210	NIGMS NIH HHS [GM56444] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056444, R56GM056444, R55GM056444] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASANO T, 1995, J NEUROCHEM, V64, P1267; ASANO T, 1993, J BIOL CHEM, V268, P20512; Asano T, 1999, J BIOL CHEM, V274, P21425, DOI 10.1074/jbc.274.30.21425; Bayewitch ML, 1998, J BIOL CHEM, V273, P2273, DOI 10.1074/jbc.273.4.2273; Betty M, 1998, NEUROSCIENCE, V85, P475, DOI 10.1016/S0306-4522(97)00623-4; Brunk I, 1999, EUR J CELL BIOL, V78, P311, DOI 10.1016/S0171-9335(99)80065-X; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Denker SP, 1996, J CELL BIOL, V133, P1027, DOI 10.1083/jcb.133.5.1027; Diverse-Pierluissi M, 2000, J BIOL CHEM, V275, P28380, DOI 10.1074/jbc.M003571200; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Fishburn CS, 2000, P NATL ACAD SCI USA, V97, P1085, DOI 10.1073/pnas.97.3.1085; Fishburn CS, 1999, J BIOL CHEM, V274, P18793, DOI 10.1074/jbc.274.26.18793; Fletcher JE, 1998, J BIOL CHEM, V273, P636, DOI 10.1074/jbc.273.1.636; Gudermann T, 1997, ADV SEC MESS PHOSPH, V31, P253; HANSEN CA, 1994, J CELL BIOL, V126, P811, DOI 10.1083/jcb.126.3.811; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kalkbrenner F, 1996, BBA-MOL CELL RES, V1314, P125, DOI 10.1016/S0167-4889(96)00072-9; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lei QB, 2000, P NATL ACAD SCI USA, V97, P9771, DOI 10.1073/pnas.97.17.9771; Liang JJ, 1998, J NEUROCHEM, V71, P345; Lindorfer MA, 1998, J BIOL CHEM, V273, P34429, DOI 10.1074/jbc.273.51.34429; Maier U, 2000, J BIOL CHEM, V275, P13746, DOI 10.1074/jbc.275.18.13746; Morishita R, 1997, J NEUROCHEM, V68, P820; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Richardson M, 1999, J BIOL CHEM, V274, P13525, DOI 10.1074/jbc.274.19.13525; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Q, 1999, J BIOL CHEM, V274, P17365, DOI 10.1074/jbc.274.24.17365; Wang YR, 1999, J BIOL CHEM, V274, P37435, DOI 10.1074/jbc.274.52.37435; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILCOX MD, 1995, J BIOL CHEM, V270, P4189, DOI 10.1074/jbc.270.9.4189; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575; Zhou JY, 2000, J NEUROSCI, V20, P7143	50	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23945	23953		10.1074/jbc.M101154200	http://dx.doi.org/10.1074/jbc.M101154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294873	hybrid			2022-12-25	WOS:000169531100096
J	Felizmenio-Quimio, ME; Daly, NL; Craik, DJ				Felizmenio-Quimio, ME; Daly, NL; Craik, DJ			Circular proteins in plants - Solution structure of a novel macrocyclic trypsin inhibitor from Momordica cochinchinensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE KALATA B1; NMR STRUCTURE CALCULATION; TORSION ANGLE DYNAMICS; BOVINE BETA-TRYPSIN; CYSTINE KNOT MOTIF; 3-DIMENSIONAL STRUCTURE; CHASSALIA-PARVIFOLIA; MOLECULAR-DYNAMICS; DISTANCE GEOMETRY; CRYSTAL-STRUCTURE	Much interest has been generated by recent reports on the discovery of circular (i.e. head-to-tail cyclized) proteins in plants. Here we report the three-dimensional structure of one of the newest such circular proteins, MCoTI-II, a novel trypsin inhibitor from Momordica cochinchinensis, a member of the Cucurbitaceae plant family. The structure consists of a small beta -sheet, several turns, and a cystine knot arrangement of the three disulfide bonds. Interestingly, the molecular topology is similar to that of the plant cyclotides (Craik, D. J., Daly, N. L., Bond, T., and Waine, C. (1999) J. Mol. Biol, 294, 1327-1336), which derive from the Rubiaceae and Violaceae plant families, have antimicrobial activities, and exemplify the cyclic cystine knot structural motif as part of their circular backbone. The sequence, biological activity, and plant family of MCoTI-II are all different from known cyclotides. However, given the structural similarity, cyclic backbone, and plant origin of MCoTI-II, we propose that MCoTI-II can be classified as a new member of the cyclotide class of proteins. The expansion of the cyclotides to include trypsin inhibitory activity and a new plant family highlights the importance and functional variability of circular proteins and the fact that they are more common than has previously been believed, Insights into the possible roles of backbone cyclization have been gained by a comparison of the structure of MCoTI-II with the homologous acyclic trypsin inhibitors CMTI-I and EETI-II from the Cucurbitaceae plant family.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Craik, DJ (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Daly, Norelle L/D-4302-2013; Craik, David/B-1695-2010	Daly, Norelle L/0000-0002-4697-6602; Craik, David/0000-0003-0007-6796				BODE W, 1989, FEBS LETT, V242, P285, DOI 10.1016/0014-5793(89)80486-7; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1996, X PLOR MANUAL VERSIO; CLORE GM, 1986, J MOL BIOL, V191, P523, DOI 10.1016/0022-2836(86)90146-4; Craik DJ, 1999, J MOL BIOL, V294, P1327, DOI 10.1006/jmbi.1999.3383; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Daly NL, 2000, J BIOL CHEM, V275, P19068, DOI 10.1074/jbc.M000450200; Daly NL, 1999, BIOCHEMISTRY-US, V38, P10606, DOI 10.1021/bi990605b; Daly NL, 1999, J MOL BIOL, V285, P333, DOI 10.1006/jmbi.1998.2276; DiMarco S, 1997, STRUCTURE, V5, P1465; ECCLES C, 1991, Journal of Biomolecular NMR, V1, P111, DOI 10.1007/BF01877224; Evans TC, 1999, J BIOL CHEM, V274, P18359, DOI 10.1074/jbc.274.26.18359; Goransson U, 1999, J NAT PROD, V62, P283, DOI 10.1021/np9803878; Gran L, 2000, J ETHNOPHARMACOL, V70, P197, DOI 10.1016/S0378-8741(99)00175-0; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUSTAFSON KR, 1994, J AM CHEM SOC, V116, P9337, DOI 10.1021/ja00099a064; Gustafson KR, 2000, J NAT PROD, V63, P176, DOI 10.1021/np990432r; Hallock YF, 2000, J ORG CHEM, V65, P124, DOI 10.1021/jo990952r; HEITZ A, 1989, BIOCHEMISTRY-US, V28, P2392, DOI 10.1021/bi00432a009; Helland R, 1999, ACTA CRYSTALLOGR D, V55, P139, DOI 10.1107/S090744499801052X; Hernandez JF, 2000, BIOCHEMISTRY-US, V39, P5722, DOI 10.1021/bi9929756; HOLAK TA, 1989, J MOL BIOL, V210, P635, DOI 10.1016/0022-2836(89)90137-X; HUANG QC, 1993, J MOL BIOL, V229, P1022, DOI 10.1006/jmbi.1993.1102; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; Iwai H, 1999, FEBS LETT, V459, P166, DOI 10.1016/S0014-5793(99)01220-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LING MH, 1993, J BIOL CHEM, V268, P810; Luckett S, 1999, J MOL BIOL, V290, P525, DOI 10.1006/jmbi.1999.2891; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; SAETHER O, 1995, BIOCHEMISTRY-US, V34, P4147, DOI 10.1021/bi00013a002; Schoepke T., 1993, SCI PHARM, V61, P145; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Tam JP, 1999, P NATL ACAD SCI USA, V96, P8913, DOI 10.1073/pnas.96.16.8913; U QUEENSLAND, 2000, Patent No. 0015654; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WITHERUP KM, 1994, J NAT PRODUCTS, V57, P1619, DOI 10.1021/np50114a002; Wuthrich K, 1986, NMR PROTEINS NUCL AC	43	199	201	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22875	22882		10.1074/jbc.M101666200	http://dx.doi.org/10.1074/jbc.M101666200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292835	hybrid			2022-12-25	WOS:000169412700120
J	Mouton, J; Feltz, A; Maulet, Y				Mouton, J; Feltz, A; Maulet, Y			Interactions of calmodulin with two peptides derived from the C-terminal cytoplasmic domain of the Ca(v)1.2 Ca2+ channel provide evidence for a molecular switch involved in Ca2+-induced inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; CALCIUM CHANNELS; CA2+-SENSITIVE INACTIVATION; ALPHA(1C) SUBUNIT; CA2+-DEPENDENT INACTIVATION; MOTIF; BINDING; DETERMINANTS; FACILITATION; VOLTAGE	When opened by depolarization, L-type calcium channels are rapidly inactivated by the elevation of Ca2+ concentration on the cytoplasmic side, Recent studies have shown that the interaction of calmodulin with the proximal part of the cytoplasmic C-terminal tail of the channel plays a prominent role in this modulation, Two motifs interacting with calmodulin in a Ca2+-dependent manner have been described: the IQ sequence and more recently the neighboring CB sequence. Here, using synthetic peptides and fusion proteins derived from the Ca(v)1.2 channel combined with biochemical techniques, we show that these two peptides are the only motifs of the cytoplasmic tail susceptible to interact with calmodulin, We determined the K-d of the CB interaction with calmodulin to be 12 nM, i.e, below the K-d of IQ-calmodulin, thereby precluding a competitive displacement of CB by IQ in the presence of Ca2+. In place, we demonstrated that a ternary complex is formed at high Ca2+ concentration, provided that calmodulin and the peptides are initially allowed to interact at a low Ca2+ concentration. These results provide evidence that CB and IQ motifs interacting together with calmodulin constitute a minimal molecular switch leading to Ca2+-induced inactivation. In addition, we suggest that they could also be the tethering site of calmodulin.	CNRS, Lab Neurobiol Cellulaire, FRE 2180, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maulet, Y (corresponding author), CNRS, Lab Neurobiol Cellulaire, FRE 2180, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.		Maulet, Yves/AAC-3207-2019	Maulet, Yves/0000-0002-3162-0435; mouton, jerome/0000-0002-7984-3996				CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; Cens T, 1999, FEBS LETT, V450, P17, DOI 10.1016/S0014-5793(99)00463-9; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HADLEY RW, 1991, J PHYSIOL-LONDON, V444, P257, DOI 10.1113/jphysiol.1991.sp018876; Hall DR, 1996, ANAL BIOCHEM, V235, P175, DOI 10.1006/abio.1996.0109; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; KLOCKNER U, 1995, J BIOL CHEM, V270, P17306, DOI 10.1074/jbc.270.29.17306; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LANG DG, 1987, PFLUG ARCH EUR J PHY, V410, P614, DOI 10.1007/BF00581321; MARTIN SR, 1996, BIOCHEMISTRY-US, V35, P3506; MAULET Y, 1983, BIOCHEMISTRY-US, V22, P5680, DOI 10.1021/bi00293a035; MORAD M, 1988, SCIENCE, V241, P842, DOI 10.1126/science.2457253; OLWIN BB, 1985, BIOCHEMISTRY-US, V24, P8081, DOI 10.1021/bi00348a037; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PLANT TD, 1983, J PHYSIOL-LONDON, V334, P189, DOI 10.1113/jphysiol.1983.sp014489; Qin N, 1999, P NATL ACAD SCI USA, V96, P2435, DOI 10.1073/pnas.96.5.2435; Restituito S, 2000, J NEUROSCI, V20, P9046; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Schneggenburger R, 2000, NATURE, V406, P889, DOI 10.1038/35022702; Schuhmann K, 1997, J GEN PHYSIOL, V110, P503, DOI 10.1085/jgp.110.5.503; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; Soldatov NM, 1998, J BIOL CHEM, V273, P957, DOI 10.1074/jbc.273.2.957; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; YAZAWA M, 1987, J BIOL CHEM, V262, P10951; YAZAWA M, 1992, BIOCHEMISTRY-US, V31, P3171, DOI 10.1021/bi00127a018; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 2000, J BIOL CHEM, V275, P21121, DOI 10.1074/jbc.M002986200; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200; ZYGMUNT AC, 1990, J PHYSIOL-LONDON, V428, P653, DOI 10.1113/jphysiol.1990.sp018233	36	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22359	22367		10.1074/jbc.M100755200	http://dx.doi.org/10.1074/jbc.M100755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294864	hybrid			2022-12-25	WOS:000169412700053
J	Salmeron, A; Janzen, J; Soneji, Y; Bump, N; Kamens, J; Allen, H; Ley, SC				Salmeron, A; Janzen, J; Soneji, Y; Bump, N; Kamens, J; Allen, H; Ley, SC			Direct phosphorylation of NF-kappa B1 p105 by the I kappa B kinase complex on serine 927 is essential for signal-induced p105 proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SUBUNIT; UBIQUITIN LIGASE; IMMUNE-RESPONSE; DIFFERENTIAL REGULATION; TERMINAL SEQUENCES; ALPHA PROTEOLYSIS; INNATE IMMUNITY; PRECURSOR P105; REL PROTEINS; MICE LACKING	The p105 precursor protein of NF-kappa B1 acts as an NF-KB inhibitory protein, retaining associated Rel subunits in the cytoplasm of unstimulated cells. Tumor necrosis factor alpha (TNF alpha) and interleukin-1 alpha (IL-1 alpha) stimulate p105 degradation, releasing associated Rel subunits to translocate into the nucleus. By using knockout embryonic fibroblasts, it was first established that the I kappaB kinase (IKK) complex is essential for these pro-inflammatory cytokines to trigger efficiently p105 degradation. The p105 PEST domain contains a motif (Asp-Ser(927) Gly-Val Glu-Thr), related to the IKK target sequence in I kappaB alpha, which is conserved between human, mouse, rat, and chicken p105. Analysis of a panel of human p105 mutants in which serine/threonine residues within and adjacent to this motif were individually changed to alanine established that only serine 927 is essential for p105 proteolysis triggered by IKK2 overexpression. This residue is also required for TNF alpha and IL-1 alpha to stimulate p105 degradation. By using a specific anti-phosphopeptide antibody, it was confirmed that IKK2 overexpression induces serine 927 phosphorylation of co transfected p105 and that endogenous p105 is also rapidly phosphorylated on this residue after TNF alpha or IL-1 alpha stimulation. lie vitro kinase assays with purified proteins demonstrated that both IKK1 and IKK2 can directly phosphorylate p105 on serine 927. Together these experiments indicate that the IKK complex regulates the signal-induced proteolysis of NF-kappa B1 p105 by direct phosphorylation of serine 927 in its PEST domain.	Natl Inst Med Res, Div Cellular Immunol, London NW7 1AA, England; Abbott Biores Ctr, Worcester, MA 01605 USA	MRC National Institute for Medical Research	Ley, SC (corresponding author), Natl Inst Med Res, Div Cellular Immunol, The Ridgeway,Mill Hill, London NW7 1AA, England.			Soneji, Yasmina/0000-0001-9189-6348; Kamens, Joanne/0000-0002-7000-1477				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DADAMIO L, 1992, J IMMUNOL, V149, P3550; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rudolph D, 2000, GENE DEV, V14, P854; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2000, GENE DEV, V14, P2461, DOI 10.1101/gad.817800; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stoven S, 2000, EMBO REP, V1, P347, DOI 10.1093/embo-reports/kvd072; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	59	111	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22215	22222		10.1074/jbc.M101754200	http://dx.doi.org/10.1074/jbc.M101754200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297557	hybrid			2022-12-25	WOS:000169412700034
J	Suvorova, ES; Kurten, RC; Lupashin, VV				Suvorova, ES; Kurten, RC; Lupashin, VV			Identification of a human orthologue of Sec34p as a component of the cis-Golgi vesicle tethering machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIPHERAL MEMBRANE-PROTEIN; GTP-BINDING PROTEINS; RAB5 EFFECTOR EEA1; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; COPII VESICLES; SNARE COMPLEX; ER; YEAST; LOCALIZATION	The roles of the components of the Sec34p protein complex in intracellular membrane trafficking, first identified in the yeast Saccharomyces cerevisiae, have yet to be characterized in higher eukaryotes. We cloned a human cDNA whose predicted amino acid sequence showed 41% similarity to yeast Sec34p with homology throughout the entire coding region. Affinity-purified antibodies raised against the human SEC34 protein (hSec34p) recognized a cellular protein of 94 kDa in both soluble and membrane fractions. Like yeast Sec34p, cytosolic hSec34p migrated with an apparent molecular mass of 300 kDa on a glycerol velocity gradient, suggesting that it is part of a protein complex. Immunofluorescence microscopy localized hSec34p to the Golgi compartment in cells of all species examined, where it co-localized well with the cis/medial Golgi marker membrin and partially co-localized with cis-Golgi network marker p115 and trans-Golgi marker TGN38. The co localization with membrin was maintained at 15 degreesC and after microtubule depolymerization with nocodazole. During transport of the tsO45 vesicular stomatitis virus G protein through the Golgi, there was significant overlap with the hSec34p compartment. Green fluorescent protein-hSec34 expressed in HeLa cells was restricted to Golgi cisternae, and its membrane association was sensitive to brefeldin A treatment. Taken together, our findings indicate that hSec34p is part of a peripheral membrane protein complex localized on cis/medial Golgi cisternae where it may participate in tethering intra-Golgi transport vesicles.	Univ Arkansas Med Sci, Dept Physiol & Biophys, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Lupashin, VV (corresponding author), Univ Arkansas Med Sci, Dept Physiol & Biophys, 4301 W Markham,Slot 750, Little Rock, AR 72205 USA.	lupashinvladimirv@uams.edu	Lupashin, Vladimir/AAB-4312-2020; Lupashin, Vladimir/E-3013-2013	Lupashin, Vladimir/0000-0002-2350-1962; Lupashin, Vladimir/0000-0002-2350-1962				Allan BB, 2000, SCIENCE, V289, P444, DOI 10.1126/science.289.5478.444; Alvarez C, 1999, J CELL BIOL, V147, P1205, DOI 10.1083/jcb.147.6.1205; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; Cao H, 2000, J CELL SCI, V113, P1993; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; Fleischer B, 1974, Methods Enzymol, V31, P180; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Kim DW, 1999, MOL BIOL CELL, V10, P3317, DOI 10.1091/mbc.10.10.3317; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1995, BIOCHEM SOC T, V23, P544, DOI 10.1042/bst0230544; Lupashin VV, 1996, J CELL BIOL, V132, P277, DOI 10.1083/jcb.132.3.277; Lupashin VV, 1997, MOL BIOL CELL, V8, P2659, DOI 10.1091/mbc.8.12.2659; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Morinaga N, 1999, J BIOL CHEM, V274, P17417, DOI 10.1074/jbc.274.25.17417; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nelson DS, 1998, J CELL BIOL, V143, P319, DOI 10.1083/jcb.143.2.319; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SHAYWITZ DA, 1995, J CELL BIOL, V128, P769, DOI 10.1083/jcb.128.5.769; Shugrue CA, 1999, J CELL SCI, V112, P4547; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spelbrink RG, 1999, MOL BIOL CELL, V10, P4263, DOI 10.1091/mbc.10.12.4263; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Waters MG, 1999, CURR OPIN CELL BIOL, V11, P453, DOI 10.1016/S0955-0674(99)80065-9; Wuestehube LJ, 1996, GENETICS, V142, P393	43	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22810	22818		10.1074/jbc.M011624200	http://dx.doi.org/10.1074/jbc.M011624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292827	hybrid			2022-12-25	WOS:000169412700111
J	Wicksteed, B; Herbert, TP; Alarcon, C; Lingohr, MK; Moss, LG; Rhodes, CJ				Wicksteed, B; Herbert, TP; Alarcon, C; Lingohr, MK; Moss, LG; Rhodes, CJ			Cooperativity between the preproinsulin mRNA untranslated regions is necessary for glucose-stimulated translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PROINSULIN BIOSYNTHESIS; INSULIN; ISLETS; PC3; CONVERSION; MECHANISM; PROTEINS	Glucose regulates proinsulin biosynthesis via stimulation of the translation of the preproinsulin mRNA in pancreatic beta -cells, However, the mechanism by which this occurs has remained unclear. Using recombinant adenoviruses that express the preproinsulin mRNA with defined alterations, the untranslated regions (UTRs) of the preproinsulin mRNA were examined for elements that specifically control translation of the mRNA in rat pancreatic islets. These studies revealed that the preproinsulin 5 ' -UTR was necessary for glucose stimulation of preproinsulin mRNA translation, whereas the 3 ' -UTR appeared to suppress translation. However, together the 5 '- and 3 ' -UTRs acted cooperatively to markedly increase glucose-induced proinsulin biosynthesis. In primary hepatocytes the presence of the preproinsulin 3 ' -UTR led to reduced mRNA levels compared with the presence of the SV40 3 ' -UTR, consistent with the presence of mRNA stability determinants in the 3 ' -UTR that stabilize the preproinsulin mRNA in a pancreatic beta -cell-specific manner. Translation of these mRNAs in primary hepatocytes was not stimulated by glucose, indicating that regulated translation of the preproinsulin mRNA occurs in a pancreatic beta -cell-specific manner. Thus, the untranslated regions of the preproinsulin mRNA play crucial roles in regulating insulin production and therefore glucose homeostasis by regulating the translation and the stability of the preproinsulin mRNA.	Pacific NW Res Fdn, Inst Res, Seattle, WA 98122 USA; Tufts Univ New England Med Ctr, Dept Med, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Dept Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts Medical Center; Tufts University	Rhodes, CJ (corresponding author), Pacific NW Res Fdn, Inst Res, 720 Broadway, Seattle, WA 98122 USA.	cjr@pnri.org		Herbert, Terence/0000-0001-5402-0814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050610, R56DK050610] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50610] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALARCON C, 1993, J BIOL CHEM, V268, P4276; ALARCON C, 1995, J CLIN INVEST, V95, P1032, DOI 10.1172/JCI117748; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; Dodson G, 1998, CURR OPIN STRUC BIOL, V8, P189, DOI 10.1016/S0959-440X(98)80037-7; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; HERBERT TP, 1998, MOL B INT U, V2, P105; HSU CJ, 1992, AM J PHYSIOL, V263, pE1106; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; KNIGHT SW, 1992, J MOL ENDOCRINOL, V8, P225, DOI 10.1677/jme.0.0080225; KOZAK M, 1991, GENE EXPRESSION, V1, P117; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; MARTIN SK, 1994, FEBS LETT, V356, P279, DOI 10.1016/0014-5793(94)01284-9; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Rhodes CJ., 2000, DIABETES MELLITUS FU, P20; ROUAULT TA, 1999, TRANSLATIONAL CONTRO, P655; SACHS A, 1999, TRANSLATIONAL CONTRO, P447; SCHPPIN GT, 1995, BIOCHEM J, V313, P259; SEGLEN PO, 1984, IN VITRO BIOL SYSTEM, P231; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; WELSH N, 1991, BIOCHEM J, V275, P23, DOI 10.1042/bj2750023; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485	28	77	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22553	22558		10.1074/jbc.M011214200	http://dx.doi.org/10.1074/jbc.M011214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297542	hybrid, Green Accepted			2022-12-25	WOS:000169412700078
J	Iwata, H; Tomita, T; Maruyama, K; Iwatsubo, T				Iwata, H; Tomita, T; Maruyama, K; Iwatsubo, T			Subcellular compartment and molecular subdomain of beta-amyloid precursor protein relevant to the A beta 42-promoting effects of Alzheimer mutant presenilin 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE INHIBITORS; ENDOPLASMIC-RETICULUM; PATHOGENIC MUTATION; DISEASE INCREASE; DISTINCT SITES; APP GENE; CLEAVAGE; PEPTIDES; CELLS; GENERATION	Increased production of amyloid beta peptides ending at position 42 (A beta 42) is one of the pathogenic phenotypes caused by mutant forms of presenilins (PS) linked to familial Alzheimer's disease. To identify the subcellular compartment(s) in which familial Alzheimer's disease mutant PS2 (mt PS2) affects the gamma -cleavage of beta APP to increase A beta 42, we co-expressed the C-terminal 99-amino acid fragment of beta APP (C100) tagged with sorting signals to the endoplasmic reticulum (C100/ER) or to the trans-Golgi network (C100/TGN) together with mt PS2 in N2a cells. C100/TGN co-transfected with mt PS2 increased levels or ratios of intracellular as well as secreted A beta 42 at similar levels to those with C100 without signals (C100/WT), whereas C100/ER yielded a negligible level of A beta, which was not affected by co-transfection of mt PS2, To identify the molecular subdomain of beta APP required for the effects of mt PS2, we next co-expressed C100 variously truncated at the C-terminal cytoplasmic domain together with mt PS2, All types of C-terminally truncated C100 variants including that lacking the entire cytoplasmic domain yielded the secreted form of A beta at levels comparable with those from C100/WT, and cotransfection of mt PS2 increased the secretion of A beta 42, These results suggest that (i) late intracellular compartments including TGN are the major sites in which A beta 42 is produced and up-regulated by mt PS2 and that (ii) the anterior half of C100 lacking the entire cytoplasmic domain is sufficient for the overproduction of A beta 42 caused by mt PS2.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Saitama Med Sch, Dept Pharmacol, Moroyama, Saitama 3500495, Japan	University of Tokyo; Saitama Medical University	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943				Ancolio K, 1999, P NATL ACAD SCI USA, V96, P4119, DOI 10.1073/pnas.96.7.4119; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Eckman CB, 1997, HUM MOL GENET, V6, P2087, DOI 10.1093/hmg/6.12.2087; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kwok JBJ, 2000, ANN NEUROL, V47, P249, DOI 10.1002/1531-8249(200002)47:2<249::AID-ANA18>3.3.CO;2-#; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; MARUYAMA K, 1990, NATURE, V347, P566, DOI 10.1038/347566a0; Maruyama K, 1996, BIOCHEM BIOPH RES CO, V227, P730, DOI 10.1006/bbrc.1996.1577; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Peraus GC, 1997, J NEUROSCI, V17, P7714; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Sudoh S, 1998, J NEUROCHEM, V71, P1535; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Tomita T, 1998, NEUROREPORT, V9, P911, DOI 10.1097/00001756-199803300-00027; USAMI M, 1993, J NEUROCHEM, V61, P239, DOI 10.1111/j.1471-4159.1993.tb03560.x; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Yamazaki T, 2001, J BIOL CHEM, V276, P4454, DOI 10.1074/jbc.M009598200	62	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21678	21685		10.1074/jbc.M007989200	http://dx.doi.org/10.1074/jbc.M007989200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283011	hybrid			2022-12-25	WOS:000169297900117
J	Dart, C; Leyland, ML				Dart, C; Leyland, ML			Targeting of an a kinase-anchoring protein, AKAP79, to an inwardly rectifying potassium channel, Kir2.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNELS; PHOSPHORYLATION; EXPRESSION; RECEPTORS; COMPLEX; RII; CYTOSKELETON; CONDUCTANCE; ASSOCIATION; INHIBITION	Protein kinase A (PKA) is targeted to discrete subcellular locations close to its intended substrates through interaction with A kinase-anchoring proteins (AKAPs), Ion channels represent a diverse and important group of kinase substrates, and it has been shown that membrane targeting of PKA through association with AKAPs facilitates PKA-mediated phosphorylation and regulation of several classes of ion channel. Here, we investigate the effect of AKAP79, a membrane associated multivalent-anchoring protein, upon the function and modulation of the strong inwardly rectifying potassium channel, Kir2.1. Functionally, the presence of AKAP79 enhanced the response of Kir2.1 to elevated intracellular cAMP, suggesting a requirement for a pool of PKA anchored close to the channel. Antibodies directed against a hemagglutinin epitope tag on Kir2.1 coimmunoprecipitated AKAP79, indicating that the two proteins exist together in a complex within intact cells. In support of this, glutathione S-transferase fusion proteins of both the intracellular N and C domains of Kir2.1 isolated AKAP79 from cell lysates, while glutathione S-transferase alone failed to interact with AKAP79. Together, these findings suggest that AKAP79 associates directly with the Kir2.1 ion channel and may serve to anchor kinase enzymes in close proximity to key channel phosphorylation sites.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Dart, C (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138, Leicester LE1 9HN, Leics, England.			Dart, Caroline/0000-0002-3509-8349				Ali S, 1998, P NATL ACAD SCI USA, V95, P10274, DOI 10.1073/pnas.95.17.10274; CARR DW, 1991, J BIOL CHEM, V266, P14188; CASSOLA AC, 1993, AM J PHYSIOL, V264, pF502, DOI 10.1152/ajprenal.1993.264.3.F502; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dart C, 1998, J PHYSIOL-LONDON, V511, P15, DOI 10.1111/j.1469-7793.1998.015bi.x; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; Fraser IDC, 2000, CURR BIOL, V10, P409, DOI 10.1016/S0960-9822(00)00419-X; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; GLANTZ SB, 1993, J BIOL CHEM, V268, P12796; Gray PC, 1998, NEURON, V20, P1017, DOI 10.1016/S0896-6273(00)80482-1; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; Henry P, 1996, J PHYSIOL-LONDON, V495, P681, DOI 10.1113/jphysiol.1996.sp021625; Hille B, 1992, IONIC CHANNELS EXCIT, P127; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Karschin A, 1999, NEWS PHYSIOL SCI, V14, P215; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Leyland ML, 1999, PFLUG ARCH EUR J PHY, V438, P778, DOI 10.1007/s004240051106; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; Ruppersberg JP, 2000, PFLUG ARCH EUR J PHY, V441, P1, DOI 10.1007/s004240000380; WANG WH, 1994, AM J PHYSIOL-RENAL, V267, pF599, DOI 10.1152/ajprenal.1994.267.4.F599; Wang ZW, 1996, AM J PHYSIOL-LUNG C, V271, pL100, DOI 10.1152/ajplung.1996.271.1.L100; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93; Wischmeyer E, 1996, P NATL ACAD SCI USA, V93, P5819, DOI 10.1073/pnas.93.12.5819	38	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20499	20505		10.1074/jbc.M101425200	http://dx.doi.org/10.1074/jbc.M101425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11287423	hybrid			2022-12-25	WOS:000169135100111
J	Simon, M; Jonca, N; Guerrin, M; Haftek, M; Bernard, D; Caubet, C; Egelrud, T; Schmidt, R; Serre, G				Simon, M; Jonca, N; Guerrin, M; Haftek, M; Bernard, D; Caubet, C; Egelrud, T; Schmidt, R; Serre, G			Refined characterization of corneodesmosin proteolysis during terminal differentiation of human epidermis and its relationship to desquamation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRATUM-CORNEUM; S GENE; IN-VITRO; EXPRESSION; HLA; DESMOSOMES; IDENTIFICATION; CLONING; PURIFICATION; ASSOCIATION	Corneodesmosin is a putative adhesion glycoprotein located in the extracellular part of the desmosomes in the upper layers of the epidermis. Synthesized by granular keratinocytes as a 52-56-kDa protein, corneodesmosin is progressively proteolysed during corneocyte maturation. This processing is a prerequisite for desquamation. Two glycine- and serine-rich domains of the protein might take on the conformation of adhesive secondary structures similar to glycine loops. Corneodesmosin proteolysis was further characterized. Deglycosylation experiments and reactivity with lectins demonstrated that the corneodesmosin carbohydrate moiety does not prevent the proteolysis. Immunoblotting, immunohistochemistry, and immunoelectron microscopy experiments using affinity-purified antipeptide antibodies raised to four of the five structural domains of corneodesmosin and a monoclonal antibody against its fifth central domain showed that the first step in corneodesmosin processing is the cleavage of its extremities and probably occurs before its incorporation into desmosomes. Then the glycine loop-related domains are cleaved, first the N-terminal and then part of the C-terminal domain. At the epidermis surface, the multistep proteolytic cleavage leaves intact only the central domain, which was detected on exfoliated corneocytes and probably lacks adhesive properties. Importantly, corneodesmosin was demonstrated to be a preferred substrate of two serine proteases involved in desquamation, the stratum corneum tryptic and chymotryptic enzymes.	Univ Toulouse 3, Sch Med, Dept Biol & Pathol Cell, INSERM,Contrat Jeune Format 9602, Toulouse, France; LOreal, Life Sci Res, Ctr Charles Zviak, F-92583 Clichy, France; Univ Umea Hosp, Dept Dermatol, S-90185 Umea, Sweden; CNRS, INSERM, U346, F-69437 Lyon, France; Univ Toulouse 3, Sch Med, Dept Biol & Patholl Cell, INSERM,Contrat Jeune Format 9602, F-31059 Toulouse, France; Univ Toulouse 3, Ctr Hosp, Inst Fed Rech 30, INSERM,CNRS, F-31073 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; L'Oreal Group; Umea University; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Serre, G (corresponding author), Univ Toulouse 3, Sch Med, Dept Biol & Patholl Cell, INSERM,Contrat Jeune Format 9602, Pl Dr Baylac, F-31059 Toulouse, France.	serre.g@chu-toulouse.fr	Jonca, Nathalie/AAX-3870-2020; Simon, Michel/B-7308-2011	Jonca, Nathalie/0000-0003-3602-0102; Simon, Michel/0000-0003-3655-6329				Ahnini RT, 1999, HUM MOL GENET, V8, P1135, DOI 10.1093/hmg/8.6.1135; Allen MH, 1999, LANCET, V353, P1589, DOI 10.1016/S0140-6736(99)01618-9; ALLEN TD, 1975, J ULTRA MOL STRUCT R, V51, P94, DOI 10.1016/S0022-5320(75)80011-6; ARNEMANN J, 1993, J CELL SCI, V104, P741; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; CHAPMAN SJ, 1990, ARCH DERMATOL RES, V282, P304, DOI 10.1007/BF00375724; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Egelrud T, 2000, CRC DERMAT, P109; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Enerback C, 2000, J INVEST DERMATOL, V114, P1158, DOI 10.1046/j.1523-1747.2000.00002.x; GHADIALLY R, 1992, J INVEST DERMATOL, V99, P755, DOI 10.1111/1523-1747.ep12614489; Guerrin M, 1998, J BIOL CHEM, V273, P22640, DOI 10.1074/jbc.273.35.22640; Guerrin M, 2001, TISSUE ANTIGENS, V57, P32, DOI 10.1034/j.1399-0039.2001.057001032.x; HAFTEK M, 1994, J INVEST DERMATOL, V103, P656, DOI 10.1111/1523-1747.ep12398417; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531, DOI 10.1177/39.11.1717544; Haftek M, 1997, BRIT J DERMATOL, V137, P864, DOI 10.1046/j.1365-2133.1997.19792087.x; HANSSON L, 1994, J BIOL CHEM, V269, P19420; HOLBROOK K, 1994, KERATINOCYTE HDB, P275; Jenisch S, 1999, TISSUE ANTIGENS, V54, P439, DOI 10.1034/j.1399-0039.1999.540501.x; Kowalczyk AP, 1999, INT REV CYTOL, V185, P237; Long S, 1996, J INVEST DERMATOL, V106, P397; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; LUNDSTROM A, 1990, J INVEST DERMATOL, V94, P216, DOI 10.1111/1523-1747.ep12874531; MENTON DN, 1971, J ULTRA MOL STRUCT R, V35, P247, DOI 10.1016/S0022-5320(71)80155-7; MOMMAAS AM, 1992, HUM IMMUNOL, V34, P99, DOI 10.1016/0198-8859(92)90035-L; ROOP D, 1995, SCIENCE, V267, P474, DOI 10.1126/science.7529942; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Simon M, 2001, J INVEST DERMATOL, V116, P23, DOI 10.1046/j.1523-1747.2001.00208.x; Simon M, 1997, J BIOL CHEM, V272, P31770, DOI 10.1074/jbc.272.50.31770; SKERROW CJ, 1989, J CELL SCI, V92, P667; SKYTT A, 1995, BIOCHEM BIOPH RES CO, V211, P586, DOI 10.1006/bbrc.1995.1853; STEINERT PM, 1991, INT J BIOL MACROMOL, V13, P130, DOI 10.1016/0141-8130(91)90037-U; SUZUKI Y, 1994, ARCH DERMATOL RES, V286, P249, DOI 10.1007/BF00387596; Vicanova J, 1996, CELL TISSUE RES, V286, P115, DOI 10.1007/s004410050680; ZHOU YQ, 1993, P NATL ACAD SCI USA, V90, P9470, DOI 10.1073/pnas.90.20.9470	35	135	141	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20292	20299		10.1074/jbc.M100201200	http://dx.doi.org/10.1074/jbc.M100201200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279026	hybrid			2022-12-25	WOS:000169135100085
J	Vinson, M; Strijbos, PJLM; Rowles, A; Facci, L; Moore, SE; Simmons, DL; Walsh, FS				Vinson, M; Strijbos, PJLM; Rowles, A; Facci, L; Moore, SE; Simmons, DL; Walsh, FS			Myelin-associated glycoprotein interacts with ganglioside GT1b - A mechanism for neurite outgrowth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING LECTIN; MONOCLONAL-ANTIBODY; CELL-ADHESION; HUMAN-MELANOMA; RAT-BRAIN; ONE SET; SIALOADHESIN; PROTEIN; SITE; SPECIFICITY	Myelin-associated glycoprotein (MAG) is expressed on myelinating glia and inhibits neurite outgrowth from post-natal neurons. MAG has a sialic acid binding site in its N-terminal domain and binds to specific sialylated glycans and gangliosides present on the surface of neurons, but the significance of these interactions in the effect of MAG on neurite outgrowth is unclear. Here we present evidence to suggest that recognition of sialylated glycans is essential for inhibition of neurite outgrowth by MAG. Arginine 118 on MAG is known to make a key contact with sialic acid. me show that mutation of this residue reduces the potency of MAG inhibitory activity hut that residual activity is also a result of carbohydrate recognition. me then go on to investigate gangliosides GT1b and GD1a as candidate MAG receptors. me show that MAG specifically binds both gangliosides and that both are expressed on the surface of MAG-responsive neurons. Furthermore, antibody cross-linking of cell surface GT1b, but not GD1a, mimics the effect of MAG, in that neurite outgrowth is inhibited through activation of Rho kinase, These data strongly suggest that interaction with GT1b on the neuronal cell surface is a potential mechanism for inhibition of neurite outgrowth by MAG.	GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Vinson, M (corresponding author), GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, New Frontiers Sci Pk N,3rd Ave, Harlow CM19 5AW, Essex, England.	Mary_Vinson-1@sbphrd.com						Angata T, 2000, GLYCOBIOLOGY, V10, P431, DOI 10.1093/glycob/10.4.431; Barnes YC, 1999, BLOOD, V93, P1245, DOI 10.1182/blood.V93.4.1245.404k09_1245_1252; Brinkman-Van der Linden ECM, 2000, J BIOL CHEM, V275, P8625, DOI 10.1074/jbc.275.12.8625; Buffo A, 2000, J NEUROSCI, V20, P2275; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CHAKRABORTY M, 1993, BRAIN RES, V625, P197, DOI 10.1016/0006-8993(93)91059-2; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; Collins BE, 1999, J BIOL CHEM, V274, P37637, DOI 10.1074/jbc.274.53.37637; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; Cornish AL, 1998, BLOOD, V92, P2123, DOI 10.1182/blood.V92.6.2123.418k20_2123_2132; Crocker PR, 1999, BIOCHEM J, V341, P355, DOI 10.1042/0264-6021:3410355; De Bellard M, 1999, J NEUROSCI RES, V56, P213, DOI 10.1002/(SICI)1097-4547(19990415)56:2<213::AID-JNR11>3.3.CO;2-L; DeBellard ME, 1996, MOL CELL NEUROSCI, V7, P89, DOI 10.1006/mcne.1996.0007; DOHI T, 1988, CANCER RES, V48, P5680; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; Floyd H, 2000, J BIOL CHEM, V275, P861, DOI 10.1074/jbc.275.2.861; FREDMAN P, 1984, ARCH BIOCHEM BIOPHYS, V233, P661, DOI 10.1016/0003-9861(84)90492-2; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; JOHNSON AR, 1993, BIOESSAYS, V15, P807, DOI 10.1002/bies.950151206; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kasahara K, 2000, J BIOL CHEM, V275, P34701, DOI 10.1074/jbc.M003163200; Kelm S, 1998, EUR J BIOCHEM, V255, P663, DOI 10.1046/j.1432-1327.1998.2550663.x; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KOTANI M, 1992, BIOCHIM BIOPHYS ACTA, V1117, P97, DOI 10.1016/0304-4165(92)90168-T; Kotani M, 2000, J BIOCHEM-TOKYO, V127, P13, DOI 10.1093/oxfordjournals.jbchem.a022574; Lassmann H, 1997, GLIA, V19, P104, DOI 10.1002/(SICI)1098-1136(199702)19:2<104::AID-GLIA2>3.3.CO;2-R; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Li C, 1998, J NEUROSCI RES, V51, P210, DOI 10.1002/(SICI)1097-4547(19980115)51:2<210::AID-JNR9>3.0.CO;2-G; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; Lunn MPT, 2000, J NEUROCHEM, V75, P404, DOI 10.1046/j.1471-4159.2000.0750404.x; Masserini M, 1999, J NEUROCHEM, V73, P1, DOI 10.1046/j.1471-4159.1999.0730001.x; May AP, 1998, MOL CELL, V1, P719, DOI 10.1016/S1097-2765(00)80071-4; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; Nicoll G, 1999, J BIOL CHEM, V274, P34089, DOI 10.1074/jbc.274.48.34089; OZAWA H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P184, DOI 10.1016/0005-2760(92)90110-H; Palestini P, 1999, BIOSCIENCE REP, V19, P385, DOI 10.1023/A:1020208121454; Patel N, 1999, J BIOL CHEM, V274, P22729, DOI 10.1074/jbc.274.32.22729; Pitto M, 1998, FEBS LETT, V439, P93, DOI 10.1016/S0014-5793(98)01344-1; Prinetti A, 2000, J BIOL CHEM, V275, P11658, DOI 10.1074/jbc.275.16.11658; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Probstmeier R, 1999, EUR J NEUROSCI, V11, P2474, DOI 10.1046/j.1460-9568.1999.00670.x; Probstmeier R, 1999, GLYCOBIOLOGY, V9, P101, DOI 10.1093/glycob/9.2.101; Razi N, 1998, P NATL ACAD SCI USA, V95, P7469, DOI 10.1073/pnas.95.13.7469; SBASCHNIGAGLER M, 1988, J NEUROCHEM, V51, P212, DOI 10.1111/j.1471-4159.1988.tb04858.x; Sheikh KA, 1999, P NATL ACAD SCI USA, V96, P7532, DOI 10.1073/pnas.96.13.7532; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; Strenge K, 1999, FEBS LETT, V444, P59, DOI 10.1016/S0014-5793(99)00029-0; Strenge K, 1998, EUR J BIOCHEM, V258, P677, DOI 10.1046/j.1432-1327.1998.2580677.x; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Taylor VC, 1999, J BIOL CHEM, V274, P11505, DOI 10.1074/jbc.274.17.11505; TETTAMANTI G, 1993, ADV LIPID RES, V25, P235; vanderMerwe PA, 1996, J BIOL CHEM, V271, P9273, DOI 10.1074/jbc.271.16.9273; Vinson M, 1996, J BIOL CHEM, V271, P9267, DOI 10.1074/jbc.271.16.9267; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814	69	152	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20280	20285		10.1074/jbc.M100345200	http://dx.doi.org/10.1074/jbc.M100345200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279053	hybrid			2022-12-25	WOS:000169135100083
J	Bacolla, A; Jaworski, A; Connors, TD; Wells, RD				Bacolla, A; Jaworski, A; Connors, TD; Wells, RD			PKD1 unusual DNA conformations are recognized by nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							POLYCYSTIC KIDNEY-DISEASE; LEFT-HANDED DNA; CENTER-DOT-CAG; NONSENSE MUTATION; TRIPLET REPEATS; STRUCTURAL TRANSITIONS; INTRAMOLECULAR TRIPLEX; MOLECULAR-GENETICS; CRYSTAL-STRUCTURE; REPEATED PART	The 2.5-kilobase pair poly(purine pyrimidine) (poly(R.Y)) tract present in intron 21 of the polycystic kidney disease 1 (PKD1) gene has been proposed to contribute to the high mutation frequency of the gene. To evaluate this hypothesis, we investigated the growth rates of II Escherichia coli strains, with mutations in the nucleotide excision repair, SOS, and topoisomerase I and/or gyrase genes, harboring plasmids containing the full-length tract, six 5'-truncations of the tract, and a control plasmid (pSPL3), The full-length poly(R.Y) tract induced dramatic losses of cell viability during the first few hours of growth and lengthened the doubling times of the populations in strains with an inducible SOS response. The extent of cell loss was correlated with the length of the poly(R.Y) tract and the levels of negative supercoiling as modulated by the genotype of the strains or drugs that specifically inhibited DNA gyrase or bound to DNA directly, thereby affecting conformations at specific loci. We conclude that the unusual DNA conformations formed by the PKD1 poly(R.Y) tract under the influence of negative supercoiling induced the SOS response pathway, and they were recognized as lesions by the nucleotide excision repair system and were cleaved, causing delays in cell division and loss of the plasmid, These data support a role for this sequence in the mutation of the PKD1 gene by stimulating repair and/or recombination functions.	Texas A&M Univ, Hlth Sci Ctr, Texas Med Ctr, Inst Biosci & Technol,Ctr Genome Res, Houston, TX 77030 USA; Genzyme Corp, Framingham, MA 01701 USA	Baylor College of Medicine; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston; Sanofi-Aventis; Genzyme Corporation	Wells, RD (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Texas Med Ctr, Inst Biosci & Technol,Ctr Genome Res, 2121 Holcombe Blvd, Houston, TX 77030 USA.	rwells@ibt.tamu.edu	Bacolla, Albino/N-3877-2013; Bacolla, Albino/AAP-1727-2020	Bacolla, Albino/0000-0003-0206-8423; Bacolla, Albino/0000-0003-0206-8423	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 52982] Funding Source: Medline; NINDS NIH HHS [NS 37554] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Afzal AR, 1999, HUM GENET, V105, P648, DOI 10.1007/s004390051157; Bacolla A, 1997, J BIOL CHEM, V272, P16783, DOI 10.1074/jbc.272.27.16783; BACOLLA A, 1995, J BIOL CHEM, V270, P24556, DOI 10.1074/jbc.270.41.24556; Badenas C, 1999, KIDNEY INT, V55, P1225, DOI 10.1046/j.1523-1755.1999.00368.x; Bailly Christian, 1992, Journal of Molecular Recognition, V5, P155, DOI 10.1002/jmr.300050406; Barre FX, 2000, P NATL ACAD SCI USA, V97, P3084, DOI 10.1073/pnas.050368997; Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573; Bierne H, 1997, MOL MICROBIOL, V26, P557, DOI 10.1046/j.1365-2958.1997.6011973.x; Blaszak RT, 1999, NUCLEIC ACIDS RES, V27, P2610, DOI 10.1093/nar/27.13.2610; Bowater RP, 2001, PROG NUCLEIC ACID RE, V66, P159; Bowater RP, 1996, J MOL BIOL, V264, P82, DOI 10.1006/jmbi.1996.0625; Brasier JL, 1997, J CLIN INVEST, V99, P194, DOI 10.1172/JCI119147; Budavari S., 1989, MERCK INDEX; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; Calvet JP, 1998, J NEPHROL, V11, P24; Chen DR, 1999, J MOL BIOL, V285, P443, DOI 10.1006/jmbi.1998.2358; CHEN FM, 1991, BIOCHEMISTRY-US, V30, P4472, DOI 10.1021/bi00232a014; COLL M, 1989, BIOCHEMISTRY-US, V28, P310, DOI 10.1021/bi00427a042; Courcelle J, 1999, MOL GEN GENET, V262, P543, DOI 10.1007/s004380051116; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; Daniells C, 1998, HUM GENET, V102, P216, DOI 10.1007/s004390050681; Duong TH, 1997, J BIOMOL STRUCT DYN, V14, P691, DOI 10.1080/07391102.1997.10508172; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; Gilbert DE, 1999, CURR OPIN STRUC BIOL, V9, P305, DOI 10.1016/S0959-440X(99)80041-4; GLUCKSMANNKUIS MA, 1995, CELL, V81, P289; Grunfeld JP, 1999, J NEPHROL, V12, pS42; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; Herbert A, 1999, GENETICA, V106, P37, DOI 10.1023/A:1003768526018; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; JAWORSKI A, 1989, J MOL BIOL, V207, P513, DOI 10.1016/0022-2836(89)90461-0; KAMITORI S, 1992, J MOL BIOL, V225, P445, DOI 10.1016/0022-2836(92)90931-9; KLYSIK J, 1982, J BIOL CHEM, V257, P152; KLYSIK J, 1981, NATURE, V290, P672, DOI 10.1038/290672a0; KOCH WH, 1998, DNA DAMAGE REPAIR, V1, P107; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; Koptides M, 1998, HUM GENET, V103, P709, DOI 10.1007/s004390050896; Lewis RJ, 1996, EMBO J, V15, P1412, DOI 10.1002/j.1460-2075.1996.tb00483.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIRAU PA, 1983, NUCLEIC ACIDS RES, V11, P1931, DOI 10.1093/nar/11.6.1931; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; Moolenaar GF, 1998, J BIOL CHEM, V273, P34896, DOI 10.1074/jbc.273.52.34896; Moolenaar GF, 2000, J BACTERIOL, V182, P5706, DOI 10.1128/JB.182.20.5706-5714.2000; Murcia NS, 1998, PEDIATR NEPHROL, V12, P721, DOI 10.1007/s004670050534; Neophytou P, 1996, HUM GENET, V98, P437, DOI 10.1007/s004390050235; Opperman T, 1999, P NATL ACAD SCI USA, V96, P9218, DOI 10.1073/pnas.96.16.9218; OSSANNA N, 1989, J BACTERIOL, V171, P303, DOI 10.1128/jb.171.1.303-307.1989; PARK YW, 1992, P NATL ACAD SCI USA, V89, P6653, DOI 10.1073/pnas.89.14.6653; Parniewski P, 1999, NUCLEIC ACIDS RES, V27, P616, DOI 10.1093/nar/27.2.616; Peral B, 1996, HUM MOL GENET, V5, P539, DOI 10.1093/hmg/5.4.539; Peral B, 1996, AM J HUM GENET, V58, P86; Peral B, 1997, AM J HUM GENET, V60, P1399, DOI 10.1086/515467; PERAL B, 1995, HUM MOL GENET, V4, P569, DOI 10.1093/hmg/4.4.569; Perrichot RA, 1999, HUM GENET, V105, P231, DOI 10.1007/s004390051094; Podtelezhnikov AA, 1999, P NATL ACAD SCI USA, V96, P12974, DOI 10.1073/pnas.96.23.12974; Qian F, 1996, CELL, V87, P979, DOI 10.1016/S0092-8674(00)81793-6; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; RAHMOUNI AR, 1992, J MOL BIOL, V223, P131, DOI 10.1016/0022-2836(92)90721-U; Roelfsema JH, 1997, AM J HUM GENET, V61, P1044, DOI 10.1086/301600; ROSCHE WA, 1995, J BACTERIOL, V177, P4385, DOI 10.1128/jb.177.15.4385-4391.1995; Rossetti S, 1996, AM J MED GENET, V65, P155, DOI 10.1002/(SICI)1096-8628(19961016)65:2<155::AID-AJMG15>3.0.CO;2-P; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; Shimizu M, 1996, J MOL BIOL, V258, P614, DOI 10.1006/jmbi.1996.0273; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; Sinden RR, 1998, ADV GENOM B, V5, P1; Smith BT, 1998, GENETICS, V148, P1599; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; Soyfer V.N., 1996, TRIPLE HELICAL NUCL; STORL K, 1993, FEBS LETT, V334, P49, DOI 10.1016/0014-5793(93)81678-S; Thomas R, 1999, AM J HUM GENET, V65, P39, DOI 10.1086/302460; Thongnoppakhun A, 2000, Hum Mutat, V15, P115, DOI 10.1002/(SICI)1098-1004(200001)15:1<115::AID-HUMU22>3.0.CO;2-Z; Torra R, 1998, HUM MUTAT, pS117; TRINH TQ, 1993, GENETICS, V134, P409; Tsai FTF, 1997, PROTEINS, V28, P41; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Turco AE, 1997, HUM MUTAT, V10, P164, DOI 10.1002/(SICI)1098-1004(1997)10:2<164::AID-HUMU9>3.3.CO;2-8; TURCO AE, 1995, HUM MOL GENET, V4, P1331, DOI 10.1093/hmg/4.8.1331; van Adelsberg JS, 1999, PEDIATR NEPHROL, V13, P454, DOI 10.1007/s004670050639; Van Raay T J, 1996, Microb Comp Genomics, V1, P317; VOLOGODSKII AV, 1994, ANNU REV BIOPH BIOM, V23, P609, DOI 10.1146/annurev.bb.23.060194.003141; WALKER GT, 1985, BIOCHEMISTRY-US, V24, P7471, DOI 10.1021/bi00346a066; Wang G, 1996, SCIENCE, V271, P802, DOI 10.1126/science.271.5250.802; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WARD CJ, 1994, CELL, V77, P881; WARTELL RM, 1974, J BIOL CHEM, V249, P6719; Watnick T, 1999, AM J HUM GENET, V65, P1561, DOI 10.1086/302657; Watnick TJ, 1997, HUM MOL GENET, V6, P1473, DOI 10.1093/hmg/6.9.1473; Watnick TJ, 1998, HUM MOL GENET, V7, P1239, DOI 10.1093/hmg/7.8.1239; Wells R.D., 1988, UNUSUAL DNA STRUCTUR; WELLS RD, 1970, J MOL BIOL, V49, P319, DOI 10.1016/0022-2836(70)90248-2; White PJ, 1999, MOL CELL BIOL, V19, P5675; Wilson W. D., 1994, Journal of Molecular Recognition, V7, P89, DOI 10.1002/jmr.300070206; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103; Zimmer C, 1975, Prog Nucleic Acid Res Mol Biol, V15, P285, DOI 10.1016/S0079-6603(08)60122-1	105	52	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18597	18604		10.1074/jbc.M100845200	http://dx.doi.org/10.1074/jbc.M100845200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279140	hybrid			2022-12-25	WOS:000168866500130
J	Wolters, PJ; Pham, CTN; Muilenburg, DJ; Ley, TJ; Caughey, GH				Wolters, PJ; Pham, CTN; Muilenburg, DJ; Ley, TJ; Caughey, GH			Dipeptidyl peptidase I is essential for activation of mast cell chymases, but not tryptases, in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAPILLON-LEFEVRE-SYNDROME; CATHEPSIN-C GENE; NEUTROPHIL ELASTASE; SECRETORY GRANULES; SERINE PROTEASES; GRANZYME-A; MOUSE; EXPRESSION; HEPARIN; IDENTIFICATION	Dipeptidyl peptidase I (DPPI) is the sole activator in vivo of several granule-associated serine proteases of cytotoxic lymphocytes. In vitro, DPPI also activates mast cell chymases and tryptases, To determine whether DPPI is essential for their activation in vivo, we used enzyme histochemical and immunohistochemical approaches and solution-based activity assays to study these enzymes in tissues and bone marrow-derived mast cells (BMMCs) from DPPI +/+ and DPPI -/- mice. We find that DPPI -/- mast cells contain normal amounts of immunoreactive chymases but no chymase activity, indicating that DPPI is essential for chymase activation and suggesting that DPPI -/- mice are functional chymase knockouts. The absence of DPPI and chymase activity does not affect the growth, granularity, or staining characteristics of BMMCs and, despite prior predictions, does not alter IgE-mediated exocytosis of histamine. In contrast, the level of active tryptase (mMCP-6) in DPPI -/- BMMCs is 25% that of DPPI +/- BMMCs. These findings indicate that DPPI is not essential for mMCP-6 activation but does influence the total amount of active mMCP-6 in mast cells and therefore may be an important, but not exclusive mechanism for tryptase activation.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Wolters, PJ (corresponding author), Univ Calif San Francisco, Dept Med, Box 0911, San Francisco, CA 94143 USA.		Wolters, Paul/A-7181-2009		NHLBI NIH HHS [HL-04055, HL-24136, HL-03774, K08 HL004055] Funding Source: Medline; NIDDK NIH HHS [DK-49786] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004055, P01HL024136] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Caughey GH, 2000, J IMMUNOL, V164, P6566, DOI 10.4049/jimmunol.164.12.6566; CAUGHEY GH, 1994, AM J RESP CRIT CARE, V150, P138; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; Fang KC, 1996, J CLIN INVEST, V97, P1589, DOI 10.1172/JCI118583; HANEKE E, 1979, HUM GENET, V51, P1, DOI 10.1007/BF00278288; Hart TC, 1999, J MED GENET, V36, P881; He SH, 1999, J PHARMACOL EXP THER, V291, P517; Hunt JE, 1996, J BIOL CHEM, V271, P2851, DOI 10.1074/jbc.271.5.2851; Hunt JE, 1997, J BIOL CHEM, V272, P29158, DOI 10.1074/jbc.272.46.29158; Khiav BE, 1998, BRIT J PHARMACOL, V123, P1267; KIDO H, 1985, BIOCHEM INT, V10, P863; Kummer JA, 1996, J BIOL CHEM, V271, P9281, DOI 10.1074/jbc.271.16.9281; LEDER L-D, 1979, American Journal of Dermatopathology, V1, P39; McEuen AR, 1998, EUR J BIOCHEM, V253, P300, DOI 10.1046/j.1432-1327.1998.2530300.x; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; McQueney MS, 1997, J BIOL CHEM, V272, P13955, DOI 10.1074/jbc.272.21.13955; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; MURAKAMI M, 1995, J BIOL CHEM, V270, P2218, DOI 10.1074/jbc.270.5.2218; Pallaoro M, 1999, J BIOL CHEM, V274, P3355, DOI 10.1074/jbc.274.6.3355; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; RAZIN E, 1984, J IMMUNOL, V132, P1479; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHICK B, 1984, J IMMUNOL, V132, P2571; SCHWARTZ LB, 1981, J IMMUNOL, V126, P1290; Scudamore CL, 1997, AM J PATHOL, V150, P1661; SERAFIN WE, 1991, P NATL ACAD SCI USA, V88, P5984, DOI 10.1073/pnas.88.14.5984; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; Springman E. B, 1995, MAST CELL PROTEASES, P169; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Toomes C, 1999, NAT GENET, V23, P421, DOI 10.1038/70525; Valchanov KP, 1999, J HISTOCHEM CYTOCHEM, V47, P617, DOI 10.1177/002215549904700504; Wolters PJ, 1998, J BIOL CHEM, V273, P15514, DOI 10.1074/jbc.273.25.15514; Wong UW, 1999, J BIOL CHEM, V274, P30784, DOI 10.1074/jbc.274.43.30784	39	153	160	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18551	18556		10.1074/jbc.M100223200	http://dx.doi.org/10.1074/jbc.M100223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279033	hybrid			2022-12-25	WOS:000168866500124
J	de Beer, MC; Durbin, DM; Cai, L; Mirocha, N; Jonas, A; Webb, NR; de Beer, FC; van der Westhuyzen, R				de Beer, MC; Durbin, DM; Cai, L; Mirocha, N; Jonas, A; Webb, NR; de Beer, FC; van der Westhuyzen, R			Apolipoprotein A-II modulates the binding and selective lipid uptake of reconstituted high density lipoprotein by scavenger receptor BI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B TYPE-I; ESTER TRANSFER PROTEIN; CELLULAR CHOLESTEROL EFFLUX; SR-BI; HDL RECEPTOR; LPA-I; TARGETED MUTATION; TRANSGENIC MICE; PARTICLES; AII	High density lipoprotein (HDL) represents a mixture of particles containing either apoA-I and apoA-II (LpA-I/A-II) or apoA-I without apoA-II (LpA-I). Differences in the function and metabolism of LpA-I and LpA-I/A-II have been reported, and studies in transgenic mice have suggested that apoA-II is pro-atherogenic in contrast to anti-atherogenic apoA-I. The molecular basis for these observations is unclear. The scavenger receptor BI (SR-BI) is an HDL receptor that plays a key role in HDL metabolism. In this study we investigated the abilities of apoA-I and apoA-II to mediate SR-BI-specific binding and selective uptake of cholesterol ester using reconstituted HDLs (rHDLs) that were homogeneous in size and apolipoprotein content. Particles were labeled in the protein (with I-125) and in the lipid (with [H-3]cholesterol ether) components and SR-BI-specific events were analyzed in SR-BI-transfected Chinese hamster ovary cells. At 1 mug/ml apolipoprotein, SR-BI-mediated cell association of palmitoyloleoylphosphatidylcholine-containing AI-rHDL was significantly greater (3-fold) than that of AI/AII-rHDL, with a lower K-d and a higher B-max for AI-rHDL as compared with AI/AII-rHDL. Unexpectedly, selective cholesterol ester uptake from AI/AII-rHDL was not compromised compared with AI-rHDL, despite decreased binding. The efficiency of selective cholesterol ester uptake in terms of SR-BI-associated rHDL was 4-5-fold greater for AI/AII-rHDL than AI-rHDL. These results are consistent with a two-step mechanism in which SR-BI binds ligand and then mediates selective cholesterol ester uptake with an efficiency dependent on the composition of the ligand, ApoA-II decreases binding but increases selective uptake. These findings show that apoA-II can exert a significant influence on selective cholesterol ester uptake by SR-BI and may consequently influence the metabolism and function of HDL, as well as the pathway of reverse cholesterol transport.	Univ Kentucky, Med Ctr, Dept Internal Med, Lexington, KY 40536 USA; Dept Vet Affair Med Ctr, Lexington, KY 40511 USA; Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA	University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Illinois System; University of Illinois Urbana-Champaign	van der Westhuyzen, R (corresponding author), Univ Kentucky, Med Ctr, Dept Internal Med, MN520,800 Rose St, Lexington, KY 40536 USA.	dvwest1@pop.uky.edu	Webb, Nancy/AAL-7030-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059376, R01HL016059, R01HL063763] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-16059, HL-59376, HL-63763] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BLANCHE PJ, 1988, BIOCHIM BIOPHYS ACTA, V958, P143, DOI 10.1016/0005-2760(88)90171-3; BU XD, 1994, HUM GENET, V93, P639, DOI 10.1007/BF00201563; Calvo D, 1998, J LIPID RES, V39, P777; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; de Beer FC, 2000, J LIPID RES, V41, P1849; de Beer MC, 2001, J LIPID RES, V42, P309; Durbin DM, 1997, J BIOL CHEM, V272, P31333, DOI 10.1074/jbc.272.50.31333; FIELDING CJ, 1995, J LIPID RES, V36, P211; FRANCONE OL, 1995, J CLIN INVEST, V96, P1440, DOI 10.1172/JCI118180; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; LAGROST L, 1994, J BIOL CHEM, V269, P3189; LAGROST L, 1995, J BIOL CHEM, V270, P13004, DOI 10.1074/jbc.270.22.13004; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; OIKAWA S, 1993, BIOCHIM BIOPHYS ACTA, V1165, P327, DOI 10.1016/0005-2760(93)90144-X; PIETERS MN, 1993, BIOCHEM J, V292, P819, DOI 10.1042/bj2920819; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; POWNALL HJ, 1986, METHOD ENZYMOL, V128, P515; RADER DJ, 1991, J LIPID RES, V32, P1849; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; STEIN O, 1995, BBA-LIPID LIPID MET, V1257, P174, DOI 10.1016/0005-2760(95)00069-O; Tailleux A, 2000, ARTERIOSCL THROM VAS, V20, P2453, DOI 10.1161/01.ATV.20.11.2453; Tall AR, 1998, EUR HEART J, V19, pA31; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Weigel P H, 1993, Subcell Biochem, V19, P125; Weng W, 1996, P NATL ACAD SCI USA, V93, P14788, DOI 10.1073/pnas.93.25.14788; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Xu SZ, 1997, J LIPID RES, V38, P1289; ZHONG SB, 1994, J CLIN INVEST, V94, P2457, DOI 10.1172/JCI117614	50	58	58	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15832	15839		10.1074/jbc.M100228200	http://dx.doi.org/10.1074/jbc.M100228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279034	hybrid			2022-12-25	WOS:000168623100036
J	Kasparkova, J; Pospisilova, S; Brabec, V				Kasparkova, J; Pospisilova, S; Brabec, V			Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERSTRAND CROSS-LINKS; SUPERCOILED DNA; MAJOR ADDUCT; PLATINUM; BINDING; DRUG; DUPLEX; SITE; CIS-DIAMMINEDICHLOROPLATINUM(II); SPECIFICITY	The p53 gene encodes a nuclear phosphoprotein that is biologically activated in response to genotoxic stresses including treatment with anticancer platinum drugs. The DNA binding activity of p53 protein is crucial for its tumor suppressor function. DNA interactions of active wild-type human p53 protein with DNA fragments and oligodeoxyribonucleotide duplexes modified by antitumor cisplatin and its clinically ineffective trans isomer (transplatin) were investigated by using a gel mobility shift assay. It was found that DNA adducts of cisplatin reduced binding affinity of the consensus DNA sequence to p53, whereas transplatin adducts did not. This result was interpreted to mean that the precise steric fit required for the formation and stability of the tetrameric complex of p53 with the consensus sequence cannot be attained, as a consequence of severe conformational perturbations induced in DNA by cisplatin adducts. The results also demonstrate an increase of the binding affinity of p53 to DNA lacking the consensus sequence and modified by cisplatin but not by transplatin. In addition, only major 1,2-GG intrastrand crosslinks of cisplatin are responsible for this enhanced binding affinity of p53. The data base on structures of various DNA adducts of cisplatin and transplatin reveals distinctive structural features of 1,2-intrastrand cross-links of cisplatin, suggesting a unique role for this adduct in the binding of p53 to DNA lacking the consensus sequence. The results support the hypothesis that the mechanism of antitumor activity of cisplatin may also be associated with its efficiency to affect the binding affinity of platinated DNA to active p53 protein.	Acad Sci Czech Republ, Inst Biophys, CZ-61265 Brno, Czech Republic; Masaryk Mem Canc Inst, CZ-65653 Brno, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences; Masaryk Memorial Cancer Institute	Brabec, V (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.	brabec@ibp.cz	Brabec, Viktor/H-1946-2014; Pospisilova, Sarka/D-7200-2012	Brabec, Viktor/0000-0002-8233-1393; Pospisilova, Sarka/0000-0001-7136-2680				Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BRABEC V, 1990, BIOPHYS CHEM, V35, P129, DOI 10.1016/0301-4622(90)80003-P; BRABEC V, 1993, P NATL ACAD SCI USA, V90, P5345, DOI 10.1073/pnas.90.11.5345; BRABEC V, 1993, BIOCHEMISTRY-US, V32, P11676, DOI 10.1021/bi00094a025; Brabec V, 2000, CANC DRUG DISC DEV, V7, P37; Brabec V, 2000, J BIOL INORG CHEM, V5, P364, DOI 10.1007/PL00010665; BRABEC V, 1992, BIOCHEMISTRY-US, V31, P12397, DOI 10.1021/bi00164a014; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI [DOI 10.1002/9783906390420.CH4, 10.1002/9783906390420.ch4]; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; KASPARKOVA J, 1995, BIOCHEMISTRY-US, V34, P12379, DOI 10.1021/bi00038a035; Kasparkova J, 2000, J BIOL CHEM, V275, P15789, DOI 10.1074/jbc.M000777200; KECK MV, 1992, J AM CHEM SOC, V114, P3386, DOI 10.1021/ja00035a033; KIM SD, 1990, ANAL LETT, V23, P1505, DOI 10.1080/00032719008052504; LEMAIRE MA, 1991, P NATL ACAD SCI USA, V88, P1982, DOI 10.1073/pnas.88.5.1982; Leng M, 2000, MOL PHARMACOL, V58, P1525, DOI 10.1124/mol.58.6.1525; Leng M, 2000, CANC DRUG DISC DEV, V7, P63; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Mazur SJ, 1999, J MOL BIOL, V292, P241, DOI 10.1006/jmbi.1999.3064; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; O'Dwyer P. J., 1999, CISPLATIN CHEM BIOCH, P31; OConnor PM, 1997, CANCER RES, V57, P4285; Rosenberg B., 1999, CISPLATIN CHEM BIOCH, P1, DOI DOI 10.1002/9783906390420; Teuben JM, 1999, BIOCHEMISTRY-US, V38, P12305, DOI 10.1021/bi9904757; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Wetzel CC, 1998, ONCOL RES, V10, P151; Wong E, 1999, CHEM REV, V99, P2451, DOI 10.1021/cr980420v; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; ZAMBLE DB, 1999, CISPLATIN CHEM BIOCH, P73	37	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16064	16069		10.1074/jbc.M101224200	http://dx.doi.org/10.1074/jbc.M101224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279186	hybrid			2022-12-25	WOS:000168623100068
J	Horiuchi, M; Baron, GS; Xiong, LW; Caughey, B				Horiuchi, M; Baron, GS; Xiong, LW; Caughey, B			Inhibition of interactions and interconversions of prion protein isoforms by peptide fragments from the C-terminal folded domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE CONVERSION; IN-VITRO FORMATION; SECONDARY STRUCTURE; RESISTANT PRP; SCRAPIE; MICE; TRANSMISSION; REPLICATION; DISEASE; BARRIER	The formation of protease-resistant prion protein (PrP-res or PrPSc) involves selective interactions between PrP-res and its normal protease-sensitive counterpart, PrP-sen or PrPC. Previous studies have shown that synthetic peptide fragments of the PrP sequence corresponding to residues 119-136 of hamster PrP (Ha119-136) can selectively block PrP-res formation in cell-free systems and scrapie-infected tissue culture cells. Here we show that two other peptides corresponding to residues 166-179 (Ha166-179) and 200-223 (Ha200-223) also potently inhibit the PrP-res induced cell-free conversion of PrP-sen to the protease-resistant state. In contrast, Ha121-141, Ha180-199, and Ha218-232 were much less effective as inhibitors. Mechanistic analyses indicated that Ha166-179, Ha200-223, and peptides containing residues 119-136 inhibit primarily by binding to PrP-sen and blocking its binding to PrP-res, Circular dichroism analyses indicated that Ha117-141 and Ha200-223, but not non-inhibitory peptides, readily formed high beta -sheet structures when placed under the conditions of the conversion reaction, We conclude that these inhibitory peptides may mimic contact surfaces between PrP-res and PrP-sen and thereby serve as models of potential therapeutic agents for transmissible spongiform encephalopathies.	NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Obihiro Univ Agr & Vet Med, Dept Vet Publ Hlth, Obihiro, Hokkaido 0808555, Japan; Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 0808555, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Obihiro University of Agriculture & Veterinary Medicine; Obihiro University of Agriculture & Veterinary Medicine	Caughey, B (corresponding author), NIAID, Persistent Viral Dis Lab, Rocky Mt Labs, NIH, 903 S 4th St, Hamilton, MT 59840 USA.	bcaughey@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000580, ZIAAI000580] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bossers A, 1996, J GEN VIROL, V77, P2669, DOI 10.1099/0022-1317-77-10-2669; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Caughey B, 1999, MOL BIOTECHNOL, V13, P45, DOI 10.1385/MB:13:1:45; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 1995, CHEM BIOL, V2, P807, DOI 10.1016/1074-5521(95)90087-X; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Caughey WS, 1998, P NATL ACAD SCI USA, V95, P12117, DOI 10.1073/pnas.95.21.12117; Chabry J, 1998, J BIOL CHEM, V273, P13203, DOI 10.1074/jbc.273.21.13203; Chabry J, 1999, J VIROL, V73, P6245, DOI 10.1128/JVI.73.8.6245-6250.1999; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Demaimay R, 2000, ARCH VIROL, P277; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; GIACCONE G, 1992, P NATL ACAD SCI USA, V89, P9349, DOI 10.1073/pnas.89.19.9349; GOLDFARB LG, 1993, P NATL ACAD SCI USA, V90, P4451, DOI 10.1073/pnas.90.10.4451; Holscher C, 1998, J VIROL, V72, P1153; Horiuchi M, 2000, P NATL ACAD SCI USA, V97, P5836, DOI 10.1073/pnas.110523897; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Kaneko K, 1997, J MOL BIOL, V270, P574, DOI 10.1006/jmbi.1997.1135; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KANEKO K, 1995, P NATL ACAD SCI USA, V92, P11160, DOI 10.1073/pnas.92.24.11160; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KITAMOTO T, 1993, BIOCHEM BIOPH RES CO, V192, P525, DOI 10.1006/bbrc.1993.1447; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; MURAMOTO T, 1993, J VIROL, V67, P6808, DOI 10.1128/JVI.67.11.6808-6810.1993; Muramoto T, 1996, P NATL ACAD SCI USA, V93, P15457, DOI 10.1073/pnas.93.26.15457; Perrier V, 2000, P NATL ACAD SCI USA, V97, P6073, DOI 10.1073/pnas.97.11.6073; PRIOLA SA, 1994, J VIROL, V68, P4873, DOI 10.1128/JVI.68.8.4873-4878.1994; Priola SA, 2000, SCIENCE, V287, P1503, DOI 10.1126/science.287.5457.1503; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Soto C, 2000, LANCET, V355, P192, DOI 10.1016/S0140-6736(99)11419-3; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 1999, CELL, V96, P869, DOI 10.1016/S0092-8674(00)80596-6; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395	42	63	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15489	15497		10.1074/jbc.M100288200	http://dx.doi.org/10.1074/jbc.M100288200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279046	hybrid			2022-12-25	WOS:000168528800127
J	Mizuguchi, G; Vassilev, A; Tsukiyama, T; Nakatani, Y; Wu, C				Mizuguchi, G; Vassilev, A; Tsukiyama, T; Nakatani, Y; Wu, C			ATP-dependent nucleosome remodeling and histone hyperacetylation synergistically facilitate transcription of chromatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							RNA-POLYMERASE-II; SOLUBLE NUCLEAR FRACTION; SWI-SNF COMPLEX; ACETYLTRANSFERASE COMPLEXES; IN-VITRO; YEAST GCN5P; FACTOR NURF; ACETYLATION; ACTIVATION; ISWI	Drosophila nucleosome remodeling factor (NURF) is an ISWI-containing protein complex that facilitates nucleosome mobility and transcriptional activation in an ATP-dependent manner. Numerous studies have implicated histone acetylation in transcriptional activation. We investigated the relative contributions of these two chromatin modifications to transcription in vitro of a chromatinized adenovirus E4 minimal promoter that contains binding sites for the GAL4-VP16 activator. We found that NURF could remodel chromatin and stimulate transcription irrespective of the acetylation status of histones, In contrast, hyperacetylation of histones in the absence of NURF was unable to stimulate transcription, suggesting that NURF-dependent chromatin remodeling is an obligatory step in E4 promoter activation. When chromatin templates were first hyperacetylated and then incubated with NURF, significantly greater transcription stimulation was observed. The results suggest that changes in chromatin induced by acetylation of histones and the mobilization of nucleosomes by NURF combine synergistically to facilitate transcription. Experiments using single and multiple rounds of transcription indicate that these chromatin modifications stimulate transcription preinitiation as well as reinitiation.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan; NICHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Fred Hutchinson Cancer Center; Harvard University; Dana-Farber Cancer Institute	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	carlwu@helix.nih.gov						Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; BAKER CC, 1981, J MOL BIOL, V149, P189, DOI 10.1016/0022-2836(81)90298-9; BECKER PB, 1991, P NATL ACAD SCI USA, V88, P4109, DOI 10.1073/pnas.88.10.4109; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Biggar SR, 1999, EMBO J, V18, P2254, DOI 10.1093/emboj/18.8.2254; Bochar DA, 2000, P NATL ACAD SCI USA, V97, P1038, DOI 10.1073/pnas.97.3.1038; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Bustin M, 1999, MOL CELL BIOL, V19, P5237; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; CONAWAY RC, 1990, J BIOL CHEM, V265, P7559; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Deuring R, 2000, MOL CELL, V5, P355, DOI 10.1016/S1097-2765(00)80430-X; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; EVANS RM, 1977, CELL, V12, P733, DOI 10.1016/0092-8674(77)90273-2; Fletcher TM, 1996, CRIT REV EUKAR GENE, V6, P149, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.40; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUO HL, 1993, J BIOL CHEM, V268, P18762; Guschin D, 1999, CURR BIOL, V9, pR742, DOI 10.1016/S0960-9822(99)80473-4; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Howe L, 1999, CRIT REV EUKAR GENE, V9, P231, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.80; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Ito T, 2000, GENE DEV, V14, P1899; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kal AJ, 2000, GENE DEV, V14, P1058; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KAMAKAKA RT, 1994, METHOD CELL BIOL, V44, P225, DOI 10.1016/S0091-679X(08)60916-4; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Krajewski WA, 1998, P NATL ACAD SCI USA, V95, P1540, DOI 10.1073/pnas.95.4.1540; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Kundu TK, 2000, MOL CELL, V6, P551, DOI 10.1016/S1097-2765(00)00054-X; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; Mizuguchi G, 1999, METH MOL B, V119, P333; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Reines D, 1997, METHODS, V12, P192, DOI 10.1006/meth.1997.0471; Roberts SM, 1997, GENETICS, V147, P451; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Sheridan PL, 1997, GENE DEV, V11, P3327, DOI 10.1101/gad.11.24.3327; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; VANHOLDE K, 1995, CHROMATIN STRUCTURE, P1; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wallberg AE, 1999, MOL CELL BIOL, V19, P5952; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZHENG XM, 1987, CELL, V50, P361, DOI 10.1016/0092-8674(87)90490-9	104	51	51	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14773	14783		10.1074/jbc.M100125200	http://dx.doi.org/10.1074/jbc.M100125200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279013	hybrid			2022-12-25	WOS:000168528800034
J	Rosenthal, R; Thieme, H; Strauss, O				Rosenthal, R; Thieme, H; Strauss, O			Fibroblast growth factor receptor 2 (FGFR2) in brain neurons and retinal pigment epithelial cells act via stimulation of neuroendocrine L-type channels (Ca(v)1,3)	FASEB JOURNAL			English	Article						RPE; bek; flg; Ca2+ channels; bFGF	SENSITIVE CALCIUM CHANNELS; PROTEIN-KINASE-C; POTASSIUM CURRENTS; GENE-EXPRESSION; CULTURED RAT; CREB PHOSPHORYLATION; TYROSINE KINASE; PHOTORECEPTORS; ACTIVATION; RELEASE	In contrast to the fibroblast growth factor receptor 1 (FGFR1), little is known about intracellular signaling of FGFR2, The signaling cascade of FGFR2 was studied using the perforated patch configuration of the patch-clamp technique in cultured rat retinal pigment epithelial (RPE) cells that express both FGFR1 and FGFR2, Interaction of signaling proteins was studied using immunoprecipitation techniques with membrane proteins from RPE cells and freshly isolated rat brain, When Ba2+ currents through L-type channels were studied, extracellular application of bFGF (10 ng/ml) led to a shift of the steady-state activation to more negative values. In 50% of cells, an additional increase in maximal current amplitude was observed, This effect was blocked by the tyrosine kinase inhibitor lavendustin A (10(-5) M) but was not influenced by the FGFR1 blocker SU5402 (2x10(-5) M) or by the blocker for src-kinase herbimycin A (10(-5) M). Immunoprecipitation of FGFR2 led to coprecipitation of alpha 1D Ca2+ channel subunits and precipitation of alpha 1D subunits led to coprecipitation of FGFR2, Immunoprecipitation of FGFR1 did not result in the coprecipitation with alpha 1D Ca2+ channel subunits, The coprecipitation results were comparable when using brain tissue and RPE cells. The alpha 1D subunit-specific band were stained with antiphosphotyrosine antibodies, We conclude that FGFR2 acts via a different signaling cascade than FGFR1, This cascade involves an src-kinase-independent, close functional interaction of FGFR2 and the alpha subunit of neuroendocrine L-type channels.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Strauss, O (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Physiol, Hindenburgdamm 30, D-12200 Berlin, Germany.	strauss@ukbf.fu-berlin.de	Strauss, Olaf/AAA-6485-2019	Strauss, Olaf/0000-0002-6272-8596				AHLIJANIAN MK, 1990, NEURON, V4, P819, DOI 10.1016/0896-6273(90)90135-3; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BOST LM, 1992, EXP EYE RES, V55, P727, DOI 10.1016/0014-4835(92)90177-T; CAMPOCHIARO PA, 1994, J CELL SCI, V107, P2459; Catterall WA, 1998, CELL CALCIUM, V24, P307, DOI 10.1016/S0143-4160(98)90055-0; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; EDWARDS RB, 1977, IN VITRO CELL DEV B, V13, P301; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542; HUGHES BA, 1990, J PHYSIOL-LONDON, V428, P273, DOI 10.1113/jphysiol.1990.sp018212; ISHIGOOKA H, 1993, INVEST OPHTH VIS SCI, V34, P2813; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; KOIKE H, 1993, NEUROSCI LETT, V150, P57, DOI 10.1016/0304-3940(93)90107-V; KURIYAMA S, 1991, INVEST OPHTH VIS SCI, V32, P2882; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; Liu XP, 1998, OPHTHALMIC RES, V30, P302, DOI 10.1159/000055489; Mergler S, 1998, FASEB J, V12, P1125, DOI 10.1096/fasebj.12.12.1125; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; PURO DG, 1991, J NEUROSCI, V11, P1873; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; STRAUSS O, 1993, BIOCHEM BIOPH RES CO, V191, P775, DOI 10.1006/bbrc.1993.1284; Strauss O, 1997, FASEB J, V11, P859, DOI 10.1096/fasebj.11.11.9285484; STRAUSS O, 1994, J CELL PHYSIOL, V160, P89, DOI 10.1002/jcp.1041600111; STRAUSS O, 1994, COMP BIOCHEM PHYS A, V109, P975, DOI 10.1016/0300-9629(94)90246-1; Tanihara H, 1997, PROG RETIN EYE RES, V16, P271, DOI 10.1016/S1350-9462(96)00028-6; TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413; TAO Q, 1994, J MEMBRANE BIOL, V141, P123; UEDA Y, 1995, INVEST OPHTH VIS SCI, V36, P373; UEDA Y, 1993, INVEST OPHTH VIS SCI, V34, P3408; WEN R, 1993, J PHYSIOL-LONDON, V465, P121, DOI 10.1113/jphysiol.1993.sp019669; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WILLIAMS EJ, 1994, DEVELOPMENT, V120, P1685; YOSHIDA M, 1992, BIOCHEM BIOPH RES CO, V189, P66, DOI 10.1016/0006-291X(92)91526-V; ZHU DL, 1994, J CARDIOVASC PHARM, V23, P395, DOI 10.1097/00005344-199423030-00006	38	36	38	1	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					970	977		10.1096/fj.00-0188com	http://dx.doi.org/10.1096/fj.00-0188com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292657				2022-12-25	WOS:000167959300011
J	Blader, IJ; Manger, ID; Boothroyd, JC				Blader, IJ; Manger, ID; Boothroyd, JC			Microarray analysis reveals previously unknown changes in Toxoplasma gondii-infected human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MEDIATED-IMMUNITY; HUMAN FIBROBLASTS; REGULATED GENES; KAPPA-B; IDENTIFICATION; TACHYZOITES; MAINTENANCE; INTERFERON; RESISTANCE	Cells infected with the intracellular protozoan parasite Toxoplasma gondii undergo up-regulation of proinflammatory cytokines, organelle redistribution, and protection from apoptosis, To examine the molecular basis of these and other changes, gene expression pro files of human foreskin fibroblasts infected with Toxoplasma were studied using human cDNA microarrays consisting of similar to 22,000 known genes and uncharacterized expressed sequence tags. Early during infection (1-2 h), <1% of all genes show a significant change in the abundance of their transcripts. Of the 63 known genes in this group, 27 encode proteins associated with the immune response. These genes are also up-regulated by secreted, soluble factors from extracellular parasites indicating that the early response does not require parasite invasion. Later during infection, genes involved in numerous host cell processes, including glucose and mevalonate metabolism, are modulated. Many of these late genes are dependent on the direct presence of the parasite; i.e. secreted products from either the parasite or infected cells are insufficient to induce these changes. These results reveal several previously unknown effects on the host cell and lay the foundation for detailed analysis of their role in the host-pathogen interaction.	Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Stanford University	Boothroyd, JC (corresponding author), Stanford Univ, Dept Microbiol & Immunol, 299 Campus Dr, Stanford, CA 94305 USA.	john.boothroyd@Stanford.edu		Boothroyd, John C./0000-0001-9719-745X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI010478] Funding Source: NIH RePORTER; NIAID NIH HHS [1F32AI10478-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander J, 1997, PHILOS T ROY SOC B, V352, P1355, DOI 10.1098/rstb.1997.0120; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; ANSARI AA, 1981, BIOCHEM BIOPH RES CO, V102, P93, DOI 10.1016/0006-291X(81)91493-5; Boothroyd JC, 1997, PHILOS T ROY SOC B, V352, P1347, DOI 10.1098/rstb.1997.0119; Brenier-Pinchart MP, 2000, MOL CELL BIOCHEM, V209, P79, DOI 10.1023/A:1007075701551; Caamano J, 1999, J IMMUNOL, V163, P4453; Caamano J, 2000, J IMMUNOL, V165, P5720, DOI 10.4049/jimmunol.165.10.5720; Carruthers VB, 1999, MOL MICROBIOL, V31, P421, DOI 10.1046/j.1365-2958.1999.01174.x; Channon JY, 1999, INFECT IMMUN, V67, P2547, DOI 10.1128/IAI.67.5.2547-2551.1999; Cohen P, 2000, J BIOL CHEM, V275, P11181, DOI 10.1074/jbc.275.15.11181; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; DARCY F, 1988, PARASITE IMMUNOL, V10, P553, DOI 10.1111/j.1365-3024.1988.tb00242.x; DENKERS EY, 1994, J EXP MED, V180, P985, DOI 10.1084/jem.180.3.985; Denney CF, 1999, INFECT IMMUN, V67, P1547; Denton H, 1996, FEMS MICROBIOL LETT, V137, P103, DOI 10.1111/j.1574-6968.1996.tb08090.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Geiss GK, 2000, VIROLOGY, V266, P8, DOI 10.1006/viro.1999.0044; HUNTER CA, 1994, INFECT IMMUN, V62, P2818, DOI 10.1128/IAI.62.7.2818-2824.1994; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KHAN IA, 1991, J IMMUNOL, V147, P3501; LI ZY, 1994, INFECT IMMUN, V62, P3434, DOI 10.1128/IAI.62.8.3434-3440.1994; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; LUFT BJ, 1991, EUR J CLIN MICROBIOL, V10, P178, DOI 10.1007/BF01964455; Manger ID, 2000, CURR OPIN IMMUNOL, V12, P215, DOI 10.1016/S0952-7915(99)00077-1; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Rosenberger CM, 2000, J IMMUNOL, V164, P5894, DOI 10.4049/jimmunol.164.11.5894; SCHMITZ JL, 1989, INFECT IMMUN, V57, P3254, DOI 10.1128/IAI.57.10.3254-3256.1989; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; Sher A, 1995, CIBA F SYMP, V195, P95; Sinai AP, 1997, J CELL SCI, V110, P2117; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Taylor LA, 2000, CIRC RES, V87, P328, DOI 10.1161/01.RES.87.4.328; vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069; Yap G, 2000, J IMMUNOL, V165, P628, DOI 10.4049/jimmunol.165.2.628; Yap GS, 1999, IMMUNOBIOLOGY, V201, P240, DOI 10.1016/S0171-2985(99)80064-3; Zhu H, 1998, P NATL ACAD SCI USA, V95, P14470, DOI 10.1073/pnas.95.24.14470	41	206	222	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24223	24231		10.1074/jbc.M100951200	http://dx.doi.org/10.1074/jbc.M100951200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294868	hybrid			2022-12-25	WOS:000169531100131
J	Giulivi, C; Davies, KJA				Giulivi, C; Davies, KJA			Mechanism of the formation and proteolytic release of H2O2-induced dityrosine and tyrosine oxidation products in hemoglobin and red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC QUANTIFICATION; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; ACTIVATED METMYOGLOBIN; SELECTIVE PROTEOLYSIS; MODIFIED PROTEINS; VITAMIN-E; TROLOX-C; MYOGLOBIN; FERRYLMYOGLOBIN	Oxyhemoglobin exposed to a continuous flux of H2O2 underwent oxidative modifications, including limited release of fluorescent fragmentation products. The main fragments formed were identified as oxidation products of tyrosine, including dopamine, dopamine quinone, and dihydroxyindol. Further release of these oxidation products plus dityrosine was only seen after proteolytic degradation of the oxidatively modified hemoprotein. A possible mechanism is proposed to explain the formation of these oxidation products that includes cyclization, decarboxylation, and further oxidation of the intermediates. Release of dityrosine is proposed as a useful technique for evaluating selective proteolysis after an oxidative stress, because dityrosine is metabolically stable, and it is only released after enzymatic hydrolysis of the oxidatively modified protein. The measurement can be accomplished by high performance liquid chromatography with fluorescence detection or by high efficiency thin layer chromatography. Comparable results, in terms of dityrosine release, were obtained using red blood cells of different sources after exposing them to a flux of H2O2. Furthermore, dityrosine has been reported to occur in a wide variety of oxidatively modified proteins. These observations suggest that dityrosine formation and release can be used as a highly specific marker for protein oxidation and selective proteolysis.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA; Univ Minnesota, Dept Chem, Duluth, MN 55812 USA; Univ So Calif, Div Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Minnesota System; University of Minnesota Duluth; University of Southern California	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave,Rm 306, Los Angeles, CA 90089 USA.	Kelvin@usc.edu	Giulivi, Cecilia/AAV-6774-2021; Giulivi, Cecilia/ABB-7809-2020	Giulivi, Cecilia/0000-0003-1033-7435; Davies, Kelvin/0000-0001-7790-3003				ALLENTOFF AJ, 1992, J AM CHEM SOC, V114, P9744, DOI 10.1021/ja00051a003; BOVERIS A, 1977, ANAL BIOCHEM, V80, P145, DOI 10.1016/0003-2697(77)90634-0; BRUCKDORFER KR, 1990, BIOCHEM SOC T, V18, P1061, DOI 10.1042/bst0181061; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANG JY, 1972, ARCH BIOCHEM BIOPHYS, V148, P505, DOI 10.1016/0003-9861(72)90169-5; COUGHEY WS, 1985, HDB METHODS OXYGEN R, P95; CUDINA I, 1987, RADIAT RES, V109, P206, DOI 10.2307/3576947; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; Di Iorio E E, 1981, Methods Enzymol, V76, P57; DIEM K, 1974, SCI TABLES, P574; GALARIS D, 1989, ARCH BIOCHEM BIOPHYS, V273, P497, DOI 10.1016/0003-9861(89)90509-2; GALARIS D, 1988, ARCH BIOCHEM BIOPHYS, V262, P221, DOI 10.1016/0003-9861(88)90184-1; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GIULIVI C, 1992, ARCH BIOCHEM BIOPHYS, V299, P302, DOI 10.1016/0003-9861(92)90279-6; GIULIVI C, 1994, METHOD ENZYMOL, V233, P363; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GIULIVI C, 1994, FREE RADICAL BIO MED, V16, P123, DOI 10.1016/0891-5849(94)90249-6; GIULIVI C, 1990, J BIOL CHEM, V265, P19453; GIULIVI C, 1993, ARCH BIOCHEM BIOPHYS, V303, P152, DOI 10.1006/abbi.1993.1266; GIULIVI C, 1993, FEBS LETT, V332, P287, DOI 10.1016/0014-5793(93)80651-A; Giulivi C, 1998, FREE RADICAL BIO MED, V24, P269, DOI 10.1016/S0891-5849(97)00226-8; Giulivi C, 1998, FREE RADICAL BIO MED, V25, P175, DOI 10.1016/S0891-5849(98)00027-6; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GROSS AJ, 1959, J BIOL CHEM, V234, P1611; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HARADA K, 1987, J BIOCHEM, V101, P283, DOI 10.1093/oxfordjournals.jbchem.a121903; Heinecke JW, 1999, FASEB J, V13, P1113, DOI 10.1096/fasebj.13.10.1113; HUNTER EPL, 1989, FREE RADICAL BIO MED, V6, P581, DOI 10.1016/0891-5849(89)90064-6; KANNER J, 1985, LIPIDS, V20, P625, DOI 10.1007/BF02534290; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Malencik DA, 1996, ANAL BIOCHEM, V242, P202, DOI 10.1006/abio.1996.0454; MALENCIK DA, 1987, BIOCHEMISTRY-US, V26, P695, DOI 10.1021/bi00377a006; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; NICHOLLS P, 1962, BIOCHIM BIOPHYS ACTA, V59, P414, DOI 10.1016/0006-3002(62)90191-9; PRUTZ WA, 1983, INT J RADIAT BIOL, V44, P183, DOI 10.1080/09553008314550981; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SEGURAAGUILAR J, 1989, CHEM-BIOL INTERACT, V72, P309, DOI 10.1016/0009-2797(89)90006-9; SHIGA T, 1985, ARCH BIOCHEM BIOPHYS, V167, P469; SOUPART P, 1962, AMINO ACID POOLS, P263; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STRYER L, 1981, BIOCHEMISTRY-US, P59; TEPHLY TR, 1961, J PHARMACOL EXP THER, V134, P77; TEW D, 1988, J BIOL CHEM, V263, P17880; TINOCO JI, 1978, PHYSICAL CHEM PRINCI, P282; YONETANI T, 1967, J BIOL CHEM, V242, P1974	54	79	81	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24129	24136		10.1074/jbc.M010697200	http://dx.doi.org/10.1074/jbc.M010697200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294851	hybrid			2022-12-25	WOS:000169531100120
J	Suzuki, N; Khoo, KH; Chen, HC; Johnson, JR; Lee, YC				Suzuki, N; Khoo, KH; Chen, HC; Johnson, JR; Lee, YC			Isolation and characterization of major glycoproteins of pigeon egg white - Ubiquitous presence of unique N-glycans containing Gal alpha 1-4Gal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; LINKED SUGAR CHAINS; SIALOSYL GALACTOSYL GLOBOSIDE; PREFERRED BINDING-RECEPTOR; AMINO-ACID-SEQUENCE; STREPTOCOCCUS-SUIS; HEN OVALBUMIN; STRUCTURAL CHARACTERIZATION; LIQUID-CHROMATOGRAPHY; BIOSYNTHETIC-PATHWAY	Ovotransferrin (POT), two ovalbumins (POA(hi) and POA(lo)), and ovomucoid (POM) were isolated from pigeon egg white (PEW). Unlike their chicken egg white counterparts, PEW glycoproteins contain terminal Gal alpha1-4Gal, as evidenced by GS-I lectin (specific for terminal alpha -Gal), anti-P-1 (Gal alpha1-4Gal beta1- 4GlcNAc beta1-3Gal beta1-4Glc beta1-1Cer) monoclonal antibody, and P fimbriae on uropathogenic Escherichia coli (specific for Gal alpha1-4Gal). Gal alpha1-4Gal on PEW glycoproteins were found in N-glycans releasable by treatment with glycoamidase F. The respective contents of N-glycans in each glycoprotein were 3.5%, POT; 17%, POA(hi); and 31-37%, POM. POA(hi) has four N-glycosylation sites, in contrast to chicken ovalbumin, which has only one. High performance liquid chromatography analysis showed that N-glycans on POA(hi) were highly heterogeneous. Mass spectrometric analysis revealed that the major N-glycans were monosialylated tri-, tetra-, and penta-antennary oligosaccharides containing terminal Gal alpha1-4Gal with or without bisecting N-acetylglucosamine, Oligo saccharide chains terminating in Gal alpha1-4Gal are rare among N-glycans from the mammals and avians that have been studied, and our finding is the first predominant presence of (Gal alpha1-4Gal)-terminated N-glycans.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55417 USA; Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA	Johns Hopkins University; Academia Sinica - Taiwan; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Lee, YC (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.		Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970, R01DK047504] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; Awade AC, 1996, Z LEBENSM UNTERS FOR, V202, P1, DOI 10.1007/BF01229676; BEELEY JG, 1976, BIOCHEM J, V159, P335, DOI 10.1042/bj1590335; BEELEY JG, 1971, BIOCHEM J, V123, P399, DOI 10.1042/bj1230399; BOCK K, 1985, J BIOL CHEM, V260, P8545; BROCTEUR J, 1975, Haematologia, V9, P43; CHATTERJEE S, 1995, GLYCOBIOLOGY, V5, P327, DOI 10.1093/glycob/5.3.327; CHEN LM, 1988, FASEB J, V2, P2819, DOI 10.1096/fasebj.2.12.3410198; COSSEY A, 1979, EUR J BIOCHEM, V98, P53, DOI 10.1111/j.1432-1033.1979.tb13159.x; CRACRAFT J, 1986, PALEOBIOLOGY, V12, P383, DOI 10.1017/S0094837300003122; DASILVA MLC, 1995, ARCH BIOCHEM BIOPHYS, V318, P465, DOI 10.1006/abbi.1995.1255; DELL A, 1994, METHOD ENZYMOL, V230, P108; DORLAND L, 1984, BIOCHEM BIOPH RES CO, V122, P859, DOI 10.1016/S0006-291X(84)80113-8; DORLAND L, 1979, EUR J BIOCHEM, V100, P569, DOI 10.1111/j.1432-1033.1979.tb04203.x; FAN JQ, 1994, ANAL BIOCHEM, V219, P375, DOI 10.1006/abio.1994.1280; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P95, DOI 10.1016/S0338-4535(80)80050-X; FRANCOISGERARD C, 1979, BIOCHEM J, V177, P679, DOI 10.1042/bj1770679; FRANCOISGERARD C, 1980, VOX SANG, V39, P141, DOI 10.1111/j.1423-0410.1980.tb01849.x; FRANCOISGERARD C, 1980, REV FR TRANSFUS IMMU, V23, P579, DOI 10.1016/S0338-4535(80)80161-9; FUJIWARA S, 1988, BIOCHEM J, V252, P453, DOI 10.1042/bj2520453; GAHMBERG CG, 1975, J BIOL CHEM, V250, P2438; Galili U, 1998, TRANSPLANTATION, V65, P1129, DOI 10.1097/00007890-199804270-00020; GILBOAGARBER N, 1994, GLYCOCONJUGATE J, V11, P414, DOI 10.1007/BF00731276; HAATAJA S, 1993, J BIOL CHEM, V268, P4311; HASE S, 1986, J BIOCHEM-TOKYO, V99, P1725, DOI 10.1093/oxfordjournals.jbchem.a135649; HASE S, 1982, J BIOCHEM-TOKYO, V91, P735, DOI 10.1093/oxfordjournals.jbchem.a133748; JOHNSON JR, 1993, INFECT IMMUN, V61, P4902, DOI 10.1128/IAI.61.11.4902-4905.1993; JOHNSON JR, 1992, INFECT IMMUN, V60, P578, DOI 10.1128/IAI.60.2.578-583.1992; KATO I, 1987, BIOCHEMISTRY-US, V26, P193, DOI 10.1021/bi00375a027; Khoo KH, 1997, MOL BIOCHEM PARASIT, V86, P237, DOI 10.1016/S0166-6851(97)00036-4; KORHONEN TK, 1982, INFECT IMMUN, V37, P286, DOI 10.1128/IAI.37.1.286-291.1982; KOTANI M, 1994, ARCH BIOCHEM BIOPHYS, V310, P89, DOI 10.1006/abbi.1994.1144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YC, 1962, ARCH BIOCHEM BIOPHYS, V97, P9, DOI 10.1016/0003-9861(62)90037-1; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; LYERLA T, 1986, J CELL PHYSIOL, V129, P390, DOI 10.1002/jcp.1041290318; Mindell David P., 1997, P213, DOI 10.1016/B978-012498315-1/50014-5; Miyake M, 2000, ANAL BIOCHEM, V281, P202, DOI 10.1006/abio.2000.4559; NAKAGAWA H, 1995, ANAL BIOCHEM, V226, P130, DOI 10.1006/abio.1995.1200; NAKAMURA K, 1984, J BIOCHEM-TOKYO, V95, P1137, DOI 10.1093/oxfordjournals.jbchem.a134702; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; RUSSI S, 1974, J IMMUNOL, V112, P1061; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SPIK G, 1979, CR ACAD SCI D NAT, V288, P967; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; Stapleton AE, 1998, INFECT IMMUN, V66, P3856, DOI 10.1128/IAI.66.8.3856-3861.1998; Stroud MR, 1998, BIOCHEMISTRY-US, V37, P17420, DOI 10.1021/bi9814639; TAKAHASHI N, 1993, GLYCOCONJUGATE J, V10, P425, DOI 10.1007/BF00737962; Takahashi N, 2001, J BIOL CHEM, V276, P23230, DOI 10.1074/jbc.M101380200; Tikkanen K, 1996, INFECT IMMUN, V64, P3659, DOI 10.1128/IAI.64.9.3659-3665.1996; TIKKANEN K, 1995, J BIOL CHEM, V270, P28874, DOI 10.1074/jbc.270.48.28874; Tomiya N, 1998, ANAL BIOCHEM, V264, P204, DOI 10.1006/abio.1998.2849; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; WIERUSZESKI JM, 1987, J BIOL CHEM, V262, P6650; WILLIAMS J, 1968, BIOCHEM J, V108, P57, DOI 10.1042/bj1080057; YAMASHITA K, 1983, J BIOL CHEM, V258, P3099; YAMASHITA K, 1984, CARBOHYD RES, V130, P271, DOI 10.1016/0008-6215(84)85285-4; YAMASHITA K, 1978, J BIOL CHEM, V253, P3862; YAMASHITA K, 1982, J BIOL CHEM, V257, P2809; YANG ZT, 1994, J BIOL CHEM, V269, P14620; [No title captured]; [No title captured]	63	50	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					23221	23229		10.1074/jbc.M101379200	http://dx.doi.org/10.1074/jbc.M101379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11287422	hybrid			2022-12-25	WOS:000169531100003
J	Brandes, C; Kahr, L; Stockinger, W; Hiesberger, T; Schneider, WJ; Nimpf, J				Brandes, C; Kahr, L; Stockinger, W; Hiesberger, T; Schneider, WJ; Nimpf, J			Alternative splicing in the ligand binding domain of mouse ApoE receptor-2 produces receptor variants binding reelin but not alpha(2)-macroglobulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E RECEPTOR-2; CHICKEN OOCYTE RECEPTOR; TYROSINE PHOSPHORYLATION; NEURONAL MIGRATION; CYTOSOLIC ADAPTER; BRAIN-DEVELOPMENT; VLDL RECEPTOR; GENE FAMILY; PROTEIN	LR7/8B and ApoER2 are recently discovered members of the low density lipoprotein (LDL) receptor family, Although structurally different, these two proteins are derived from homologous genes in chicken and man by alternative splicing and contain 7 or 8 LDL receptor ligand binding repeats. Here we present the cDNA for ApoER2 cloned from mouse brain and describe splice variants in the ligand binding domain of this protein, which are distinct from those present in man and chicken, The cloned cDNA is coding for a receptor with only five LDL receptor ligand-binding repeats, i.e. comprising repeats 1-3, 7, and 8. Reverse transcriptase-polymerase chain reaction analysis of mRNA from murine brain revealed the existence of two additional transcripts. One is lacking repeat 8, and in the other repeat 8 is substituted for by a 13-amino acid insertion with a consensus site for furin cleavage arising from an additional small exon present in the murine gene. None of the transcripts in the mouse, however, contain repeats 4-6. In murine placenta only the form containing repeats 1-3 and 7 and the furin cleavage site is detectable. Analysis of the corresponding region of the murine gene showed the existence of 6 exons coding for a total of 8 ligand binding repeats, with one exon encoding repeats 4-6. Exon trapping experiments demonstrated that this exon is constitutively spliced out in all murine transcripts, Thus, the murine ApoER2 gene codes for receptor variants harboring either 4 or 5 binding repeats only. Recombinant expression of the 5-repeat and 4-repeat variants showed that repeats 1-3, 7, and 8 are sufficient for binding of beta -very low density lipoprotein and reelin, but not for recognition of alpha (2)-macroglobulin, which binds to the avian homologue of ApoER2 harboring 8 ligand binding repeats.	Bioctr, Dept Mol Genet, Inst Med Biochem, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nimpf, J (corresponding author), Bioctr, Dept Mol Genet, Inst Med Biochem, Dr Bohrgasse 9-2, A-1030 Vienna, Austria.			Nimpf, Johannes/0000-0002-9273-3492				Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; Cooper JA, 1999, CELL, V97, P671, DOI 10.1016/S0092-8674(00)80778-3; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Dulabon L, 2000, NEURON, V27, P33, DOI 10.1016/S0896-6273(00)00007-6; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HEIJNE GV, 1983, EUR J BIOCHEM, V133, P17; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1999, MOL CELL BIOL, V19, P5179; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; Kim DH, 1997, J BIOL CHEM, V272, P8498, DOI 10.1074/jbc.272.13.8498; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kim HJ, 1998, J BIOCHEM-TOKYO, V124, P451, DOI 10.1093/oxfordjournals.jbchem.a022134; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1396, DOI 10.1073/pnas.78.3.1396; LEUVEN FV, 1981, J BIOL CHEM, V256, P9016; MACLACHLAN I, 1993, J BIOL CHEM, V268, P23222; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; SCHNEIDER WJ, 1980, J BIOL CHEM, V255, P1442; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; SENAPATHY P, 1990, MOL EVOLUTION COMPUT, P183; Senzaki K, 1999, CELL, V99, P635, DOI 10.1016/S0092-8674(00)81552-4; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Stockinger W, 1998, J BIOL CHEM, V273, P32213, DOI 10.1074/jbc.273.48.32213; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556	35	63	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22160	22169		10.1074/jbc.M102662200	http://dx.doi.org/10.1074/jbc.M102662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294845	hybrid			2022-12-25	WOS:000169412700027
J	Chetyrkin, SV; Belyaeva, OV; Gough, MH; Kedishvili, NY				Chetyrkin, SV; Belyaeva, OV; Gough, MH; Kedishvili, NY			Characterization of a novel type of human microsomal 3 alpha-hydroxysteroid dehydrogenase - Unique tissue distribution and catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							11-CIS RETINOL DEHYDROGENASE; CDNA CLONING; 17BETA-HYDROXY-5ALPHA-ANDROSTAN-3-ONE 5ALPHA-DIHYDROTESTOSTERONE; HYDROXYSTEROID DEHYDROGENASES; GENE STRUCTURE; RAT; EXPRESSION; 5ALPHA-ANDROSTANE-3ALPHA,17BETA-DIOL; DIHYDROTESTOSTERONE; OXIDOREDUCTASES	We report characterization of a novel member of the short chain dehydrogenase/reductase superfamily. The 1513-base pair cDNA encodes a 319-amino acid protein. The corresponding gene spans over 26 kilobase pairs on chromosome 2 and contains five exons, The recombinant protein produced using the baculovirus system is localized in the microsomal fraction of Sf9 cells and is an integral membrane protein with cytosolic orientation of its catalytic domain. The enzyme exhibits an oxidoreductase activity toward hydroxysteroids with NAD(+) and NADH as the preferred cofactors, The enzyme is most efficient as a 3 alpha -hydroxysteroid dehydrogenase, converting 3 alpha -tetrahydroprogesterone (allopregnanolone) to dihydroprogesterone and 3 alpha -androstanediol to dihydrotes- tosterone with similar catalytic efficiency (V-max values of 13-14 nmol/min/mg microsomal protein and K-m values of 5-7 muM). Despite similar to 44-47% sequence identity with retinol/ 3 alpha -hydroxysterol dehydrogenases, the enzyme is not active toward retinols, The corresponding message is abundant in human trachea and is present at lower levels in the spinal cord, bone marrow, brain, heart, colon, testis, placenta, lung, and lymph node, Thus, the new short chain dehydrogenase represents a novel type of microsomal NAD(+)-dependent 3 alpha -hydroxysteroid dehydrogenase with unique catalytic properties and tissue distribution.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Missouri System; University of Missouri Kansas City	Kedishvili, NY (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, 5007 Rockhill Rd,103 BSB, Kansas City, MO 64110 USA.	kedishvilin@umkc.edu		Kedishvili, Natalia/0000-0001-6917-4891; Beliaeva, Olga/0000-0003-2512-925X	NIAAA NIH HHS [R01 AA012153-02, AA00221, R01 AA012153, AA12153] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012153] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Biswas MG, 1997, J BIOL CHEM, V272, P15959, DOI 10.1074/jbc.272.25.15959; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chetyrkin SV, 2001, ARCH BIOCHEM BIOPHYS, V386, P1, DOI 10.1006/abbi.2000.2203; Dombroski RA, 1997, J STEROID BIOCHEM, V63, P155, DOI 10.1016/S0960-0760(97)00058-7; Gamble MV, 1999, J LIPID RES, V40, P2279; Ge RS, 1999, BIOL REPROD, V60, P855, DOI 10.1095/biolreprod60.4.855; Gough WH, 1998, J BIOL CHEM, V273, P19778, DOI 10.1074/jbc.273.31.19778; Huang XF, 2000, J BIOL CHEM, V275, P29452, DOI 10.1074/jbc.M000562200; Jurukovski V, 1999, MOL GENET METAB, V67, P62, DOI 10.1006/mgme.1999.2840; Kedishvili NY, 2001, CHEM-BIOL INTERACT, V130, P457, DOI 10.1016/S0009-2797(00)00291-X; KHANNA M, 1995, J BIOL CHEM, V270, P20162, DOI 10.1074/jbc.270.34.20162; KRAUSE JE, 1980, J BIOL CHEM, V255, P1807; Labrie F, 1997, STEROIDS, V62, P148, DOI 10.1016/S0039-128X(96)00174-2; Li XD, 1997, J STEROID BIOCHEM, V60, P311, DOI 10.1016/S0960-0760(96)00195-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Odermatt A, 1999, J BIOL CHEM, V274, P28762, DOI 10.1074/jbc.274.40.28762; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; Penning TM, 1996, STEROIDS, V61, P508, DOI 10.1016/S0039-128X(96)00093-1; PIROG EC, 1994, STEROIDS, V59, P259, DOI 10.1016/0039-128X(94)90110-4; Pirog EC, 1999, J CLIN ENDOCR METAB, V84, P3217, DOI 10.1210/jc.84.9.3217; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Simon A, 1996, GENOMICS, V36, P424, DOI 10.1006/geno.1996.0487; Simon A, 1999, J CELL SCI, V112, P549; Span PN, 1996, J STEROID BIOCHEM, V58, P319, DOI 10.1016/0960-0760(96)00036-2; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; TANNIN GM, 1991, J BIOL CHEM, V266, P16653; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VERHOEVEN G, 1976, EUR J BIOCHEM, V65, P565; VERHOEVEN G, 1977, J STEROID BIOCHEM, V8, P731, DOI 10.1016/0022-4731(77)90004-8; Wang J, 1999, BIOCHEM J, V338, P23, DOI 10.1042/0264-6021:3380023; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707	33	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22278	22286		10.1074/jbc.M102076200	http://dx.doi.org/10.1074/jbc.M102076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294878	hybrid			2022-12-25	WOS:000169412700043
J	Togayachi, A; Akashima, T; Ookubo, R; Kudo, T; Nishihara, S; Iwasaki, H; Natsume, A; Mio, H; Inokuchi, J; Irimura, T; Sasaki, K; Narimatsu, H				Togayachi, A; Akashima, T; Ookubo, R; Kudo, T; Nishihara, S; Iwasaki, H; Natsume, A; Mio, H; Inokuchi, J; Irimura, T; Sasaki, K; Narimatsu, H			Molecular cloning and characterization of UDP-GlcNAc : Lactosylceramide beta 1,3-N-acetylglucosaminyltransferase (beta 3Gn-T5), an essential enzyme for the expression of HNK-1 and Lewis X epitopes on glycolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLONIC ADENOCARCINOMA; BIOSYNTHESIS IN-VITRO; SULFOGLUCURONYL GLYCOLIPIDS; DEVELOPMENTAL EXPRESSION; BINDING-PROTEIN; CEREBRAL-CORTEX; NERVOUS-SYSTEM; UP-REGULATION; CD15 EPITOPE; CARBOHYDRATE	A new member of the UDP-N-acetylglucosamine:beta -galactose beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T) family having the beta 3Gn-T motifs was cloned from rat and human cDNA libraries and named beta 3Gn-T5 based on its position in a phylogenetic tree. We concluded that beta 3Gn-T5 is the most feasible candidate for lactotriaosylceramide (Lc,Cer) synthase, an important enzyme which plays a key role in the synthesis of lacto- or neolacto-series carbohydrate chains on glycolipids. beta 3Gn-T5 exhibited strong activity to transfer GlcNAc to glycolipid substrates, such as lactosylceramide (LacCer) and neolactotetraosylceramide (nLc(4)Cer; paragloboside), resulting in the synthesis of Lc(3)Cer and neolactopentaosylceramide (nLc(5)Cer), respectively. A marked decrease in LacCer and increase in nLc(4)Cer was detected in Namalwa cells stably expressing beta 3Gn-T5. This indicated that beta 3Gn-T5 exerted activity to synthesize Lc(3)Cer and decrease LacCer, followed by conversion to nLc(4)Cer via endogenous galactosylation. The following four findings further supported that beta 3Gn-T5 is Lc(3)Cer synthase. 1) The beta 3Gn-T5 transcript levels in various cells were consistent with the activity levels of Lc(3)Cer synthase in those cells. 2) The beta 3Gn-T5 transcript was presented in various tissues and cultured cells. 3) The beta 3Gn-T5 expression was up-regulated by stimulation with retinoic acid and down-regulated with 12-O-tetradecanoylphorbol-13-acetate in HL-60 cells. 4) The changes in beta 3Gn-T5 transcript levels during the rat brain development were determined. Points 2, 3, and 4 were consistent with the Lc,Cer synthase activity reported previously.	AIST, Natl Inst Adv Ind Sci & Technol, IMCB, Lab Gene Funct Anal, Tsukuba, Ibaraki 3058568, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Hachioji, Tokyo 1928577, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Canc Biol & Mol Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Agr, Fac Bioind, Lab Anim Resources, Abashiri, Hokkaido 0992422, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Biomembrane & Biofunct Chem, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948582, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Soka University; University of Tokyo; Tokyo University of Agriculture; Hokkaido University; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), AIST, Natl Inst Adv Ind Sci & Technol, IMCB, Lab Gene Funct Anal, Cent 2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.	h.narimatsu@aist.go.jp	Togayachi, Akira/M-4144-2018; Narimatsu, Hisashi/M-4757-2018; Natsume, Atsushi/I-7364-2014; Inokuchi, Jin-ichi/AAW-9964-2020	Togayachi, Akira/0000-0003-3600-9149; Narimatsu, Hisashi/0000-0002-8402-133X; Natsume, Atsushi/0000-0002-9113-0470; Inokuchi, Jin-ichi/0000-0002-0703-5746; Nishihara, Shoko/0000-0002-1668-2603				Allendoerfer KL, 1999, DEV BIOL, V211, P208, DOI 10.1006/dbio.1999.9308; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Ashwell KWS, 1997, INT J DEV NEUROSCI, V15, P883, DOI 10.1016/S0736-5748(97)00036-1; Ashwell KWS, 1997, CELL TISSUE RES, V289, P17, DOI 10.1007/s004410050848; BASU M, 1991, CARBOHYD RES, V209, P261, DOI 10.1016/0008-6215(91)80162-G; BASU M, 1984, J BIOL CHEM, V259, P2557; Chou DKH, 1996, GLYCOCONJUGATE J, V13, P295, DOI 10.1007/BF00731504; Chou DKH, 1996, J BIOL CHEM, V271, P28868, DOI 10.1074/jbc.271.46.28868; CHOU DKH, 1993, J BIOL CHEM, V268, P21727; Chou DKH, 1998, J BIOL CHEM, V273, P8508, DOI 10.1074/jbc.273.14.8508; CHOU DKH, 1994, J NEUROCHEM, V62, P307; CHOU DKH, 1991, J BIOL CHEM, V266, P17941; CHOU DKH, 1988, J NEUROCHEM, V50, P1655, DOI 10.1111/j.1471-4159.1988.tb03056.x; CHOU DKH, 1990, J NEUROCHEM, V54, P1589, DOI 10.1111/j.1471-4159.1990.tb01209.x; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; Dasgupta S, 1996, GLYCOCONJUGATE J, V13, P367, DOI 10.1007/BF00731469; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gocht A, 1996, HISTOL HISTOPATHOL, V11, P1007; Gotz M, 1996, NEURON, V16, P551, DOI 10.1016/S0896-6273(00)80074-4; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1988, ARCH BIOCHEM BIOPHYS, V260, P461, DOI 10.1016/0003-9861(88)90470-5; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; Kudo T, 1998, J BIOL CHEM, V273, P26729, DOI 10.1074/jbc.273.41.26729; Kudo T, 1998, LAB INVEST, V78, P797; Mai JK, 1999, NEUROSCIENCE, V88, P847, DOI 10.1016/S0306-4522(98)00266-8; Mai JK, 1999, J COMP NEUROL, V404, P197; Nair SM, 1998, NEUROSCIENCE, V85, P759, DOI 10.1016/S0306-4522(97)00666-0; Nair SM, 1997, J NEUROCHEM, V68, P1286; NAIR SM, 1993, J COMP NEUROL, V332, P282, DOI 10.1002/cne.903320303; NAKAMURA M, 1992, J BIOL CHEM, V267, P23507; Nishihara S, 1999, FEBS LETT, V462, P289, DOI 10.1016/S0014-5793(99)01549-5; Oka S, 1998, YAKUGAKU ZASSHI, V118, P431, DOI 10.1248/yakushi1947.118.10_431; PILLER F, 1983, J BIOL CHEM, V258, P2293; PRASADARAO N, 1990, J NEUROCHEM, V55, P2024, DOI 10.1111/j.1471-4159.1990.tb05791.x; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sajdel-Sulkowska EM, 1998, ACTA BIOCHIM POL, V45, P781, DOI 10.18388/abp.1998_4272; SASAKI K, 1994, J BIOL CHEM, V269, P15950; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SASAKI K, 1994, Patent No. 0612759; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Streit A, 1996, J NEUROCHEM, V66, P834; STULTS CLM, 1993, ARCH BIOCHEM BIOPHYS, V303, P125, DOI 10.1006/abbi.1993.1263; TAGA S, 1995, BBA-LIPID LIPID MET, V1254, P56, DOI 10.1016/0005-2760(94)00167-W; Togayachi A, 1999, INT J CANCER, V83, P70, DOI 10.1002/(SICI)1097-0215(19990924)83:1<70::AID-IJC14>3.0.CO;2-K; Yoshida-Noro C, 1999, GLYCOBIOLOGY, V9, P1323, DOI 10.1093/glycob/9.12.1323; YOUNG WW, 1981, J BIOL CHEM, V256, P967; Zhou DP, 2000, P NATL ACAD SCI USA, V97, P11673; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	54	94	99	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22032	22040		10.1074/jbc.M011369200	http://dx.doi.org/10.1074/jbc.M011369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11283017	hybrid			2022-12-25	WOS:000169412700008
J	Berwin, B; Reed, RC; Nicchitta, CV				Berwin, B; Reed, RC; Nicchitta, CV			Virally induced lytic cell death elicits the release of immunogenic GRP94/gp96	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DENDRITIC CELLS; T-CELLS; ENDOPLASMIC-RETICULUM; IN-VIVO; INDUCED APOPTOSIS; CTL RESPONSES; CHAPERONE; CALRETICULIN; PEPTIDES	Necrotic cell death yields the release of cellular components that can function in the initiation of cellular immune responses. Given the established capacity of the endoplasmic reticulum chaperone GRP94 (gp96) to elicit CD8(+) T cell activation, we have investigated the cellular fate and antigenicity of GRP94 in differing scenarios of cell death. Virally induced cell death or mechanical cell death, elicited by freeze/thaw treatment of cell suspensions, yielded GRP94 release into the extracellular space; apoptotic cell death occurring in response to serum deprivation did not elicit GRP94 release. To assess the antigenicity of GRP94 released following virally induced cell death (lethal infection of cells with rVV ES-OVA(Met258-265), a recombinant, ovalbumin epitope-expressing vaccinia virus) or mechanical cell death (freeze/thaw of ovalbumin-expressing cells), tissue culture supernatant fractions were pulsed onto antigen-presenting cells, and antigen re-presentation was assayed as activation of an ovalbumin-specific T cell hybridoma, For both cell death scenarios, released GRP94 elicited a dose-dependent, ovalbumin-specific, hybridoma activation. In contrast, calreticulin derived from rVV ES-OVA(Met258-265)-infected cell extracts did not stimulate B3Z activity. These data identify GRP94 as an antigenic component released upon pathological, but not apoptotic, cell death and provide an assay system far the identification of cellular components of related activity.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Duke University	Nicchitta, CV (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.			Berwin, Brent/0000-0001-9196-3256	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053058] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53058] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD D, 1995, J EXP MED, V182, P885, DOI 10.1084/jem.182.3.885; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Baixeras E, 1998, VIRUS RES, V58, P107, DOI 10.1016/S0168-1702(98)00105-1; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Basu S, 1999, J EXP MED, V189, P797, DOI 10.1084/jem.189.5.797; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; Engelmayer J, 1999, J IMMUNOL, V163, P6762; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gillet G, 1996, TRENDS MICROBIOL, V4, P312, DOI 10.1016/0966-842X(96)10047-0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; McConkey DJ, 1998, TOXICOL LETT, V99, P157, DOI 10.1016/S0378-4274(98)00155-6; Melcher A, 1999, J MOL MED-JMM, V77, P824, DOI 10.1007/s001099900066; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Nair S, 1999, J IMMUNOL, V162, P6426; Nicchitta CV, 1998, CURR OPIN IMMUNOL, V10, P103, DOI 10.1016/S0952-7915(98)80039-3; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; RESTIFO NP, 1995, J IMMUNOL, V154, P4414; Rodenburg RJT, 2000, BIOESSAYS, V22, P627, DOI 10.1002/1521-1878(200007)22:7<627::AID-BIES5>3.0.CO;2-K; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SHASTRI N, 1993, J IMMUNOL, V150, P2724; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Spiro RG, 1996, J BIOL CHEM, V271, P11588, DOI 10.1074/jbc.271.19.11588; Srivastava PK, 1998, IMMUNITY, V8, P657, DOI 10.1016/S1074-7613(00)80570-1; Steinhoff U, 1999, IMMUNITY, V11, P349, DOI 10.1016/S1074-7613(00)80110-7; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tamura Y, 1997, SCIENCE, V278, P117, DOI 10.1126/science.278.5335.117; Todryk S, 1999, J IMMUNOL, V163, P1398; Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077; UDONO H, 1994, J IMMUNOL, V152, P5398; Vassilakos A, 1998, BIOCHEMISTRY-US, V37, P3480, DOI 10.1021/bi972465g; Wassenberg JJ, 1999, J CELL SCI, V112, P2167; Wearsch PA, 1996, PROTEIN EXPRES PURIF, V7, P114, DOI 10.1006/prep.1996.0015	38	74	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21083	21088		10.1074/jbc.M101836200	http://dx.doi.org/10.1074/jbc.M101836200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279246	hybrid			2022-12-25	WOS:000169297900040
J	Chughtai, ZS; Rassadi, R; Matusiewicz, N; Stochaj, U				Chughtai, ZS; Rassadi, R; Matusiewicz, N; Stochaj, U			Starvation promotes nuclear accumulation of the hsp70 Ssa4p in yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; LOCALIZATION; EXPORT; TRANSPORT; PROTEIN; SEQUENCES; ENVELOPE; IMPORT	Nuclear import of proteins that are too large to passively enter the nucleus requires soluble factors, energy, and a nuclear localization signal (NLS). Nuclear protein transport can be regulated, and different forms of stress affect nucleocytoplasmic trafficking. As such, import of proteins containing a classical NLS is inhibited in starving yeast cells. In contrast, the hsp70 Ssa4p concentrates in nuclei upon starvation. Nuclear concentration of Ssa4p in starving cells is reversible, and transfer of stationary phase cells to fresh medium induces Ssa4p nuclear export. This export reaction represents an active process that is sensitive to oxidative stress. In starving cells, the N-terminal domain of Ssa4p mediates Ssa4p nuclear accumulation, and a short hydrophobic sequence, termed Star (for starvation), is sufficient to localize the reporter proteins green fluorescent protein or beta -galactosidase to nuclei. To determine whether nuclear accumulation of Star-beta -galactosidase depends on a specific nuclear carrier, we have analyzed its distribution in mutant yeast strains that carry a deletion of a single beta -importin gene. With this assay we have identified Nmd5p as a beta -importin required to concentrate Star-beta -galactosidase in nuclei when cells enter stationary phase.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Stochaj, U (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	stochaj@med.mcgill.ca	stochaj, ursula/AAC-1865-2021					Albertini M, 1998, J CELL BIOL, V143, P1447, DOI 10.1083/jcb.143.6.1447; Barth W, 1999, BIOCHEM CELL BIOL, V77, P355, DOI 10.1139/bcb-77-4-355; Barth W, 1996, BIOCHEM CELL BIOL, V74, P363, DOI 10.1139/o96-039; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DeVit MJ, 1999, CURR BIOL, V9, P1231, DOI 10.1016/S0960-9822(99)80503-X; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Griffioen G, 2000, J BIOL CHEM, V275, P1449, DOI 10.1074/jbc.275.2.1449; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Shulga N, 1999, J BIOL CHEM, V274, P16501, DOI 10.1074/jbc.274.23.16501; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stochaj U, 1999, BIOESSAYS, V21, P579, DOI 10.1002/(SICI)1521-1878(199907)21:7<579::AID-BIES6>3.0.CO;2-E; STOCHAJ U, 2000, FASEB J         0908; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; [No title captured]	21	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20261	20266		10.1074/jbc.M100364200	http://dx.doi.org/10.1074/jbc.M100364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279056	hybrid			2022-12-25	WOS:000169135100081
J	Parks, WT; Frank, DB; Huff, C; Haft, CR; Martino, J; Meng, XW; de Caestecker, MP; McNally, JG; Reddi, A; Taylor, SI; Roberts, AB; Wang, TW; Lechleider, RJ				Parks, WT; Frank, DB; Huff, C; Haft, CR; Martino, J; Meng, XW; de Caestecker, MP; McNally, JG; Reddi, A; Taylor, SI; Roberts, AB; Wang, TW; Lechleider, RJ			Sorting nexin 6, a novel SNX, interacts with the transforming growth factor-beta family of receptor serine-threonine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I RECEPTORS; SMAD PROTEINS; ACTIVIN; COMPLEX; ACTIVATION; MEMBRANE; CLONING; IDENTIFICATION; BIOSYNTHESIS; RESPONSES	Sorting nexins (SNX) comprise a family of proteins with homology to several yeast proteins, including Vps5p and Mvp1p, that are required for the sorting of proteins to the yeast vacuole. Human SNX1, -2, and -4 have been proposed to play a role in receptor trafficking and have been shown to bind to several receptor tyrosine kinases, including receptors for epidermal growth factor, platelet-derived growth factor, and insulin as well as the long form of the leptin receptor, a glycoprotein 130-associated receptor. We now describe a novel member of this family, SNX6, which interacts with mem bers of the transforming growth factor-p family of receptor serine-threonine kinases. These receptors belong to two classes: type II receptors that bind ligand, and type I receptors that are subsequently recruited to transduce the signal. Of the type II receptors, SNX6 was found to interact strongly with ActRIIB and more moderately with wild type and kinase-defective mutants of T beta RII. Of the type I receptors, SNX6 was found to interact only with inactivated T beta RI. SNXs 1-4 also interacted with the transforming growth factor-p receptor family, showing different receptor preferences. Conversely, SNX6 behaved similarly to the other SNX proteins in its interactions with receptor tyrosine kinases. Strong heteromeric interactions were also seen among SNX1, -2, -4, and -6, suggesting the formation in vivo of oligomeric complexes. These findings are the first evidence for the association of the SNX family of molecules with receptor serine-threonine kinases.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Genet,Dept Surg, Boston, MA 02114 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Harvard University; Harvard Medical School; Massachusetts General Hospital	Roberts, AB (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.			Parks, W. Tony/0000-0001-7341-3277				Attisano L, 1996, MOL CELL BIOL, V16, P1066; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; EKENA K, 1995, MOL CELL BIOL, V15, P1671; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Kim RH, 2000, GENE DEV, V14, P1605; Koli KM, 1997, J BIOL CHEM, V272, P6423, DOI 10.1074/jbc.272.10.6423; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; MASSAGUE J, 1985, J CELL BIOL, V100, P1508, DOI 10.1083/jcb.100.5.1508; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Otsuki T, 1999, BIOCHEM BIOPH RES CO, V265, P630, DOI 10.1006/bbrc.1999.1731; Padgett Richard W., 1997, Cytokine and Growth Factor Reviews, V8, P1, DOI 10.1016/S1359-6101(96)00050-0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; Padgett RW, 1998, BIOESSAYS, V20, P382, DOI 10.1002/(SICI)1521-1878(199805)20:5&lt;382::AID-BIES5&gt;3.0.CO;2-Q; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Seaman MNJ, 1997, J CELL BIOL, V137, P79, DOI 10.1083/jcb.137.1.79; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; Wells RG, 1997, J BIOL CHEM, V272, P11444; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; ZHAO J, 1995, CANCER RES, V55, P6181	36	108	115	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19332	19339		10.1074/jbc.M100606200	http://dx.doi.org/10.1074/jbc.M100606200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279102	hybrid			2022-12-25	WOS:000169091000093
J	Reusch, HP; Schaefer, M; Plum, C; Schultz, G; Paul, M				Reusch, HP; Schaefer, M; Plum, C; Schultz, G; Paul, M			G beta gamma mediate differentiation of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL-GROWTH-FACTOR; HEAVY-CHAIN ISOFORMS; FACTOR RECEPTOR; COUPLED RECEPTORS; ARGININE-VASOPRESSIN; ANGIOTENSIN-II; ALPHA-ACTIN; TRANSCRIPTIONAL REGULATION; DEPENDENT ACTIVATION	Proliferation and subsequent dedifferentiation of vascular smooth muscle (VSM) cells contribute to the pathogenesis of atherosclerosis and postangioplastic restenosis, The dedifferentiation of VSRI cells in vivo or in cell culture is characterized by a loss of contractile proteins such as smooth muscle-specific Lu-actin and myosin heavy chain (SM-MHC). Serum increased the expression of contractile proteins in neonatal rat VSM cells, indicating a redifferentiation process. RNase protection assays defined thrombin as a serum component that increases the abundance of SRI-MHC transcripts. Additionally, serum and thrombin transiently elevated cytosolic Ca2+ concentrations, led to a biphasic extracellular signal-regulated kinase (ERK) phosphorylation, up-regulated a transfected SRI-MHC promoter construct, and induced expression of the contractile proteins SM-MHc and ol-actin, Pertussis toxin, N17-Ras/Raf, and PD98059 prevented both the serum- and thrombin-induced second phase ERK phosphorylation and SM-MHc promoter activation. Constitutively active G alpha (q), G alphai, G alpha (12), and G alpha (13) failed to up-regulate SRI-MHC transcription, whereas G beta gamma concentration-dependently increased the SM-MHC promoter activity. Furthermore, the G beta gamma scavenger beta -adrenergic receptor kinase 1 C-terminal peptide abolished the serum-mediated differentiation. We conclude that receptor-mediated differentiation of VSM cells requires G beta gamma and an intact Ras/Raf/MEK/ERK signaling.	Free Univ Berlin, Inst Klin Pharmakol & Toxikol, Benjamin Franklin Med Ctr, D-14195 Berlin, Germany; Free Univ Berlin, Inst Pharmacol, Benjamin Franklin Med Ctr, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Reusch, HP (corresponding author), Free Univ Berlin, Inst Klin Pharmakol & Toxikol, Benjamin Franklin Med Ctr, Garystr 5, D-14195 Berlin, Germany.		Paul, Martin/K-5425-2015					AIKAWA M, 1995, ANN NY ACAD SCI, V748, P578; Aikawa M, 1997, CIRCULATION, V96, P82; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Crompton T, 1996, CELL, V86, P243, DOI 10.1016/S0092-8674(00)80096-3; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; GEISTERFER AAT, 1989, HYPERTENSION, V14, P413, DOI 10.1161/01.HYP.14.4.413; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; Gohla A, 2000, CIRC RES, V87, P221, DOI 10.1161/01.RES.87.3.221; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HEDIN U, 1988, J CELL BIOL, V107, P307, DOI 10.1083/jcb.107.1.307; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IVES HE, 1978, J EXP MED, V148, P1400, DOI 10.1084/jem.148.5.1400; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Mack CP, 2001, J BIOL CHEM, V276, P341, DOI 10.1074/jbc.M005505200; Madsen CS, 1997, J BIOL CHEM, V272, P29842, DOI 10.1074/jbc.272.47.29842; Madsen CS, 1997, J BIOL CHEM, V272, P6332, DOI 10.1074/jbc.272.10.6332; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; NAGAI R, 1989, J BIOL CHEM, V264, P9734; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; OWENS GK, 1995, PHYSIOL REV, V75, P487; Piiper A, 2000, MOL PHARMACOL, V58, P608, DOI 10.1124/mol.58.3.608; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Reusch P, 1996, CIRC RES, V79, P1046, DOI 10.1161/01.RES.79.5.1046; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shanahan CM, 1998, ARTERIOSCL THROM VAS, V18, P333, DOI 10.1161/01.ATV.18.3.333; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WILSON E, 1993, J CELL BIOL, V123, P741, DOI 10.1083/jcb.123.3.741; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zeidan A, 2000, CIRC RES, V87, P228, DOI 10.1161/01.RES.87.3.228; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	53	30	30	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 1	2001	276	22					19540	19547		10.1074/jbc.M101963200	http://dx.doi.org/10.1074/jbc.M101963200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439BM	11279222	hybrid			2022-12-25	WOS:000169091000117
J	Schild-Poulter, C; Pope, L; Giffin, W; Kochan, JC; Ngsee, JK; Traykova-Andonova, M; Hache, RJG				Schild-Poulter, C; Pope, L; Giffin, W; Kochan, JC; Ngsee, JK; Traykova-Andonova, M; Hache, RJG			The binding of Ku antigen to homeodomain proteins promotes their phosphorylation by DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; V(D)J RECOMBINATION; GLUCOCORTICOID RECEPTOR; CATALYTIC SUBUNIT; GENE-PRODUCT; C-ABL; DOMAIN; ACTIVATION; REPAIR; OCT-1	The Ku antigen (70- and 80-kDa subunits) is a regulatory subunit of DNA-dependent protein kinase (DNA-PK) that promotes the recruitment of the catalytic subunit of DNA-PK (DNA-PKcs) to DNA ends and to specific DNA sequences from which the kinase is activated. Ku and DNA-PKcs plays essential roles in double-stranded DNA break repair and V(D)J recombination and have been implicated in the regulation of specific gene transcription. In a yeast two-hybrid screen of a Jurkat T cell cDNA library, we have identified a specific interaction between the 70-kDa subunit of Ku heterodimer and the homeodomain of HOXC4, a homeodomain protein expressed in the hematopoietic system. Unexpectedly, a similar interaction with Ku was observed for several additional homeodomain proteins including octamer transcription factors 1 and 2 and D1x2, suggesting that specific binding to Ku may be a property shared by many homeodomain proteins. Ku-homeodomain binding was mediated through the extreme C terminus of Ku70 and was abrogated by amino acid substitutions at Lys(595)/lys(596). Ku binding allowed the recruitment of the homeodomain to DNA ends and dramatically enhanced the phosphorylation of homeodomain-containing proteins by DNA-PK. These results suggest that Ku functions as a substrate docking protein for signaling by DNA-PK to homeodomain proteins from DNA ends.	Ottawa Hosp, Loeb Hlth Res Inst, Dept Med, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Loeb Hlth Res Inst, Dept Cellular & Mol Med, Ottawa Hosp, Ottawa, ON K1Y 4K9, Canada; Univ Ottawa, Loeb Hlth Res Inst, Dept Biochem Microbiol & Immunol, Ottawa Hosp, Ottawa, ON K1Y 4K9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Ottawa Hosp, Loeb Hlth Res Inst, Dept Med, 725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.		Hoff, Paulo M. PH/M-7662-2017; Schild-Poulter, Caroline/K-4476-2013	Hoff, Paulo M. PH/0000-0002-0065-2194; 				AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P395; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Chariot A, 1999, BIOCHEM PHARMACOL, V58, P1851, DOI 10.1016/S0006-2952(99)00234-8; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; EDELMAN GM, 1993, J BIOL CHEM, V268, P20683; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Giffin W, 1999, MOL CELL BIOL, V19, P4065; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Grande MA, 1997, J CELL SCI, V110, P1781; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HINKLEY CS, 1992, MOL CELL BIOL, V12, P638, DOI 10.1128/MCB.12.2.638; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Imai S, 1997, MOL BIOL CELL, V8, P2407, DOI 10.1091/mbc.8.12.2407; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jin SF, 1997, J BIOL CHEM, V272, P24763, DOI 10.1074/jbc.272.40.24763; Jin SF, 1997, CANCER SURV, V29, P221; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kim MK, 1996, MOL CELL BIOL, V16, P4366; KORNBERG TB, 1993, J BIOL CHEM, V268, P26813; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; Leber R, 1998, J BIOL CHEM, V273, P1794, DOI 10.1074/jbc.273.3.1794; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; MANAK JR, 1994, DEVELOPMENT, P61; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Phelan ML, 1997, J BIOL CHEM, V272, P8635, DOI 10.1074/jbc.272.13.8635; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Romero F, 1996, MOL CELL BIOL, V16, P37; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sartorius CA, 2000, J MOL ENDOCRINOL, V24, P165, DOI 10.1677/jme.0.0240165; Scott MP, 1999, NATURE, V397, P649, DOI 10.1038/17685; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Vershon AK, 1996, CURR OPIN BIOTECH, V7, P392, DOI 10.1016/S0958-1669(96)80113-3; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Wang JM, 1999, MOL CELL BIOL, V19, P7106; Weaver DT, 1998, CURR BIOL, V8, pR492, DOI 10.1016/S0960-9822(98)70315-X; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhao HC, 2000, CANCER RES, V60, P6276; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	64	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					16848	16856		10.1074/jbc.M100768200	http://dx.doi.org/10.1074/jbc.M100768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279128	hybrid			2022-12-25	WOS:000168730400035
J	Provost, P; Doucet, J; Hammarberg, T; Gerisch, G; Samuelsson, B; Radmark, O				Provost, P; Doucet, J; Hammarberg, T; Gerisch, G; Samuelsson, B; Radmark, O			5-Lipoxygenase interacts with coactosin-like protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN POLYMERIZATION DEPOLYMERIZATION; POLYMORPHONUCLEAR LEUKOCYTES; BINDING MOTIF; IN-VITRO; LEUKOTRIENES; CALCIUM; DOMAIN; TRIGGERS; LIGANDS; NUCLEUS	We have recently identified coactosin-like protein (CLP) in a yeast two-hybrid screen using 5-lipoxygenase (5LO) as a bait. In this report, we demonstrate a direct interaction between 5LO and CLP, 5LO associated with CLP, which was expressed as a glutathione S-transferase fusion protein, in a dose-dependent manner. Coimmunoprecipitation experiments using epitope-tagged 5LO and CLP proteins transiently expressed in human embryonic kidney 293 cells revealed the presence of CLP in 5LO immunoprecipitates, In reciprocal experiments, 5LO was detected in CLP immunoprecipitates. Non-denaturing polyacrylamide gel electrophoresis and cross-linking experiments showed that 5LO binds CLP in a 1:1 molar stoichiometry in a Ca2+-independent manner. Site-directed mutagenesis suggested an important role for lysine 131 of CLP in mediating 5LO binding. In view of the ability of CLP to bind 5LO and filamentous actin (F-actin), we determined whether CLP could physically link 5LO to actin filaments. However, no F-actin-CLP.5LO ternary complex was observed. In contrast, 5LO appeared to compete with F-actin for the binding of CLP. Moreover, 5LO was found to interfere with actin polymerization. Our results indicate that the 5LO-CLP and CLP-F-actin interactions are mutually exclusive and suggest a modulatory role for 5LO in actin dynamics.	Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Karolinska Institutet; Max Planck Society	Radmark, O (corresponding author), Karolinska Inst, Div Physiol Chem 2, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.	olof.radmark@mbb.ki.se	Provost, Patrick/G-2786-2010	Provost, Patrick/0000-0002-6099-6562				Alberts B., 1994, MOL BIOL CELL; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; Chen KS, 1997, NAT GENET, V17, P154, DOI 10.1038/ng1097-154; DEHOSTOS EL, 1993, CELL MOTIL CYTOSKEL, V26, P181, DOI 10.1002/cm.970260302; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; HAMMARBERG T, 1995, EUR J BIOCHEM, V230, P401; Hammarberg T, 2000, J BIOL CHEM, V275, P38787, DOI 10.1074/jbc.M006136200; HAURAND M, 1989, BIOCHEM PHARMACOL, V38, P2129, DOI 10.1016/0006-2952(89)90067-1; Howard T H, 1994, Curr Opin Hematol, V1, P61; James P, 1996, GENETICS, V144, P1425; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; Kang LT, 1998, J LIPID RES, V39, P1476; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lodish H., 1995, MOL CELL BIOL; MARRIOTT G, 1988, BIOCHEMISTRY-US, V27, P6214, DOI 10.1021/bi00417a004; Massoumi R, 1998, EUR J CELL BIOL, V76, P185, DOI 10.1016/S0171-9335(98)80033-2; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; OMANN GM, 1989, J BIOL CHEM, V264, P16355; OMANN GM, 1995, J IMMUNOL, V155, P5375; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Reddy KV, 2000, BIOCHEMISTRY-US, V39, P1840, DOI 10.1021/bi9919246; REES MK, 1967, J BIOL CHEM, V242, P4449; ROHRIG U, 1995, FEBS LETT, V374, P284, DOI 10.1016/0014-5793(95)01130-7; SAFER D, 1989, ANAL BIOCHEM, V178, P32, DOI 10.1016/0003-2697(89)90351-5; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Turchin A, 1999, BIOTECHNIQUES, V26, P672, DOI 10.2144/99264st02; Wang JHC, 2000, CELL MOTIL CYTOSKEL, V46, P137, DOI 10.1002/1097-0169(200006)46:2<137::AID-CM6>3.0.CO;2-8; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; WOODS JW, 1995, J CLIN INVEST, V95, P2035, DOI 10.1172/JCI117889; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485; Zigmond SH, 1989, CURR OPIN CELL BIOL, V1, P80, DOI 10.1016/S0955-0674(89)80041-9	39	82	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					16520	16527		10.1074/jbc.M011205200	http://dx.doi.org/10.1074/jbc.M011205200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11297527	hybrid			2022-12-25	WOS:000168623100126
J	Hahn-Dantona, E; Ruiz, JF; Bornstein, P; Strickland, DK				Hahn-Dantona, E; Ruiz, JF; Bornstein, P; Strickland, DK			The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; ACTIVATOR INHIBITOR TYPE-1; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; ALPHA(2)-MACROGLOBULIN RECEPTOR; DECREASED EXPRESSION; MOLECULAR CHAPERONE; DEGRADATION; CELLS	Members of the matrix metalloproteinase (MMP) family of enzymes participate in matrix remodeling and share a number of structural and functional features. The activity of this family of proteinases is carefully regulated at the level of zymogen activation and by a family of specific inhibitors termed tissue inhibitors of metalloproteinases (TIMP). It is now becoming clear that levels of certain MMPs are modulated by their association with cellular receptors that mediate their rapid internalization and degradation. In the current investigation we report that the amount of MMP-9 in conditioned cell culture medium is significantly increased when mouse embryonic fibroblasts are grown in the presence of the 39-kDa receptor-associated protein (RAP), an antagonist of ligand binding to low density lipoprotein receptor-related protein (LRP). In vitro assays reveal that the MMP-9-TIMP-1 complex binds to LRP with high affinity and that the binding determinant for LRP appears to reside on MMP-9. Cell lines expressing LRP mediate the internalization of I-125-labeled MMP-9.TIMP-1 complexes, whereas cell lines genetically deficient in LRP show a diminished capacity to mediate the cellular catabolism of MMP-9.TIMP-1 complexes. The results demonstrate that LRP is a functional receptor for MMP-9 and suggest a major role for LRP in modulating remodeling of the extracellular matrix by regulating extracellular proteinase activity.	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Inst Biomed Sci, Washington, DC 20037 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	American Red Cross; George Washington University; George Washington University; University of Washington; University of Washington Seattle	Strickland, DK (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [HL50784, HL54710] Funding Source: Medline; NIAMS NIH HHS [AR 45418] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045418] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERNHARD EJ, 1995, INT J CANCER, V60, P718, DOI 10.1002/ijc.2910600525; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CHEN K, 1996, P NATL ACAD SCI USA, V271, P15993; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; deVries TJ, 1996, CANCER RES, V56, P1432; Ducharme A, 2000, J CLIN INVEST, V106, P55, DOI 10.1172/JCI8768; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Hahn-Dantona EA, 2000, J BIOL CHEM, V275, P40827, DOI 10.1074/jbc.M006234200; HEMBROUGH TA, 2001, IN PRESS J BIOL CHEM; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; KANCHA RK, 1994, ONCOL RES, V6, P365; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P21162; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; Liu Z, 1998, J EXP MED, V188, P475, DOI 10.1084/jem.188.3.475; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5678; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J CELL SCI, V107, P719; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; Yang ZT, 2000, MOL BIOL CELL, V11, P3353, DOI 10.1091/mbc.11.10.3353; Yu Q, 2000, GENE DEV, V14, P163; Zhang JC, 1998, J BIOL CHEM, V273, P32273, DOI 10.1074/jbc.273.48.32273	44	182	189	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					15498	15503		10.1074/jbc.M100121200	http://dx.doi.org/10.1074/jbc.M100121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11279011	hybrid			2022-12-25	WOS:000168528800128
J	Huang, CS; Ding, M; Li, JX; Leonard, SS; Rojanasakul, Y; Castranova, V; Vallyathan, V; Ju, G; Shi, XL				Huang, CS; Ding, M; Li, JX; Leonard, SS; Rojanasakul, Y; Castranova, V; Vallyathan, V; Ju, G; Shi, XL			Vanadium-induced nuclear factor of activated T cells activation through hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CYCLOSPORINE-A; TRANSCRIPTION FACTORS; AP-1 TRANSACTIVATION; PROTEIN-1 ACTIVATION; PLASMA-MEMBRANE; FAMILY; CALCINEURIN; EXPRESSION; TRANSFORMATION	The present study investigated the role of reactive oxygen species (ROS) in activation of nuclear factor of activated T cells (NFAT), a pivotal transcription factor responsible for regulation of cytokines, by vanadium in mouse embryo fibroblast PW cells or mouse epidermal Cl 41 cells. Exposure of cells to vanadium led to the transactivation of NFAT in a time- and dose-dependent manner. Scavenging of vanadium-induced H2O2 with Nacety-L-cyteine (a general antioxidant) or catalase (a specific H2O2 inhibitor) or the chelation of vanadate with deferoxamine, resulted in inhibition of NFAT activation. In contrast, an increase in H2O2 generation by the addition of superoxide dismutase or NADPH enhanced vanadium-induced NEAT activation. This vanadate-mediated H2O2 generation was verified by both electron spin resonance and fluorescence staining assay. These results demonstrate that H2O2 plays an important role in vanadium-induced NFAT transactivation in two different cell types. Furthermore, pretreatment of cells with nifedipine, a calcium channel blocker, inhibited vanadium-induced NFAT activation, whereas A23187 and ionomycin, two calcium ionophores, had synergistic effects with vanadium for NFAT induction, Incubation of cells with cyclosporin A (CsA), a pharmacological inhibitor of the phosphatase calcineurin, blocked vanadium-induced NFAT activation. Ah data show that vanadium induces NFAT activation not only through a calcium-dependent and CsA-sensitive pathway but also involved H2O2 generation, suggesting that H2O2 may be involved in activation of calcium-calcineurin pathways for NFAT activation caused by vanadium exposure.	NIOSH, Hlth Effects Lab Div, NIH, Morgantown, WV 26505 USA; NYU, Sch Med, Nelson Inst Environm Med, New York, NY 10016 USA; Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China; W Virginia Univ, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; New York University; Air Force Military Medical University; West Virginia University	Shi, XL (corresponding author), NIOSH, Hlth Effects Lab Div, NIH, Morgantown, WV 26505 USA.	xas0@cdc.gov	Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096; Rojanasakul, Yon/0000-0002-8839-6462				Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL GW, 1995, BLOOD, V86, P2689; COHEN MD, 1992, MUTAT RES, V269, P141, DOI 10.1016/0027-5107(92)90169-3; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; Dong W, 1998, TOXICOL APPL PHARM, V146, P180; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Dye JA, 1999, AM J PHYSIOL-LUNG C, V277, pL498, DOI 10.1152/ajplung.1999.277.3.L498; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HO AM, 1994, J BIOL CHEM, V269, P28181; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hoyal CR, 1996, J BIOL CHEM, V271, P29205, DOI 10.1074/jbc.271.46.29205; Huang CS, 1998, CANCER RES, V58, P4102; Huang CS, 1998, INT J ONCOL, V13, P711; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; Huang CS, 2000, J BIOL CHEM, V275, P32516, DOI 10.1074/jbc.M005366200; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1997, P NATL ACAD SCI USA, V94, P11957, DOI 10.1073/pnas.94.22.11957; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 2000, J BIOL CHEM, V275, P9143, DOI 10.1074/jbc.275.13.9143; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JIANG H, 1993, CARCINOGENESIS, V14, P67, DOI 10.1093/carcin/14.1.67; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Luo C, 1996, MOL CELL BIOL, V16, P3955; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Masuda ES, 1998, CELL SIGNAL, V10, P599, DOI 10.1016/S0898-6568(98)00019-9; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Park JC, 1996, J BIOL CHEM, V271, P20914, DOI 10.1074/jbc.271.34.20914; Pierce LM, 1996, TOXICOL APPL PHARM, V138, P1, DOI 10.1006/taap.1996.9999; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rincon M, 1997, MOL CELL BIOL, V17, P1522, DOI 10.1128/MCB.17.3.1522; Rincon M, 1996, MOL CELL BIOL, V16, P1074; SABBIONI E, 1992, J RADIOAN NUCL CH AR, V160, P493, DOI 10.1007/BF02037125; Saccani S, 1999, EUR J IMMUNOL, V29, P1194, DOI 10.1002/(SICI)1521-4141(199904)29:04&lt;1194::AID-IMMU1194&gt;3.0.CO;2-0; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SERTLING E, 1995, BIOCHIM BIOPHYS ACTA, V1263, P181; SERTLING E, 1989, EMBO J, V8, P465; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHEU CW, 1992, FOOD CHEM TOXICOL, V30, P307, DOI 10.1016/0278-6915(92)90008-9; SHI XL, 1992, FREE RADICAL RES COM, V17, P369, DOI 10.3109/10715769209083141; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SINGH RK, 1995, CANCER RES, V55, P3669; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tsatsanis C, 1998, ONCOGENE, V17, P2609, DOI 10.1038/sj.onc.1202460; Weiss DL, 1996, MOL CELL BIOL, V16, P228; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056	62	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22397	22403		10.1074/jbc.M010828200	http://dx.doi.org/10.1074/jbc.M010828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11292823	hybrid			2022-12-25	WOS:000169412700058
J	Yarmola, EG; Edison, AS; Lenox, RH; Bubb, MR				Yarmola, EG; Edison, AS; Lenox, RH; Bubb, MR			Actin filament cross-linking by MARCKS - Characterization of two actin-binding sites within the phosphorylation site domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ACANTHAMOEBA ACTOBINDIN; DENDRITIC SPINES; F-ACTIN; SELF-ASSOCIATION; DYNAMICS; BRAIN; MODEL; MACROMOLECULES; IDENTIFICATION	We recently identified conformational changes that occur upon phosphorylation of myristoylated alanine-rich protein kinase C substrate (MARCKS) that preclude efficient cross-linking of actin filaments (Bubb, M. R,, Lenox, R, H., and Edison, A. S, (1999) J; Biol. Chem. 274, 36472-36478), These results implied that the phosphorylation site domain of MARCKS has two actin-binding sites. We now present evidence for the existence of two actin-binding sites that not only mutually compete but also specifically compete with the actin-binding proteins thymosin P, and actobindin to bind to actin. The effects of substitution of alanine for phenylalanine within a repeated hexapeptide segment suggest that the noncharged region of the domain contributes to binding affinity, but the binding affinity of peptides corresponding to each binding site has a steep dependence on salt concentration consistent with presumed electrostatic interactions between these polycationic peptides and the polyanionic N terminus of actin, Phosphorylation decreases the site-specific affinity by no more than 0.7 kcal/mol, which is less than the effect of alanine substitution. However, phosphorylation has a much greater effect than alanine substitution on the loss of actin filament cross-linking activity. These results are consistent with the hypothesis that the compact structure resulting from conformational changes due to phosphorylation, in addition to modest decreases in site-specific affinity, explains the loss of cross-linking activity in phosphorylated MARCKS.	Univ Florida, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Malcom Randall Dept Vet Affairs Med Ctr, Res Serv, Gainesville, FL 32608 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Bubb, MR (corresponding author), Univ Florida, Dept Med, Box 100277, Gainesville, FL 32610 USA.	bubb@medicine.ufl.edu		Edison, Arthur/0000-0002-5686-2350				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; Angenstein F, 1999, HIPPOCAMPUS, V9, P173, DOI 10.1002/(SICI)1098-1063(1999)9:2<173::AID-HIPO8>3.0.CO;2-K; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BUBB MR, 1991, J BIOL CHEM, V266, P3820; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; BUBB MR, 1991, METHOD ENZYMOL, V196, P119; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CHATELIER RC, 1987, BIOPHYS CHEM, V28, P121, DOI 10.1016/0301-4622(87)80081-9; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; GRIFFITH LM, 1982, J BIOL CHEM, V257, P9135; Halpain S, 2000, TRENDS NEUROSCI, V23, P141, DOI 10.1016/S0166-2236(00)01576-9; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HO MF, 1991, J BIOL CHEM, V266, P5600; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; KIRSCHNER MW, 1971, BIOCHEMISTRY-US, V10, P1900, DOI 10.1021/bi00786a027; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krucker T, 2000, P NATL ACAD SCI USA, V97, P6856, DOI 10.1073/pnas.100139797; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; LEWIS MS, 1994, MODERN ANAL ULTRACEN, P94; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Lu D, 1998, J CELL BIOL, V142, P217, DOI 10.1083/jcb.142.1.217; Matus A, 2000, HIPPOCAMPUS, V10, P555, DOI 10.1002/1098-1063(2000)10:5<555::AID-HIPO5>3.0.CO;2-Z; McNamara RK, 1998, J COMP NEUROL, V397, P337; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; MINTON AP, 1981, MOL PHARMACOL, V19, P1; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Ohmori S, 2000, J BIOL CHEM, V275, P26449, DOI 10.1074/jbc.M003588200; Rao A, 2000, HIPPOCAMPUS, V10, P527, DOI 10.1002/1098-1063(2000)10:5<527::AID-HIPO3>3.0.CO;2-B; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SCHOLZ WK, 1991, J NEUROSCI, V11, P2422; Schutt CE, 1997, NAT STRUCT BIOL, V4, P169, DOI 10.1038/nsb0397-169; SELDEN SC, 1986, ANN NY ACAD SCI, V466, P803, DOI 10.1111/j.1749-6632.1986.tb38464.x; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; TORGERSON PM, 1979, BIOCHEMISTRY-US, V18, P3079, DOI 10.1021/bi00581a026; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE J, 1990, J BIOL CHEM, V265, P12801; Wohnsland F, 2000, J BIOL CHEM, V275, P20873, DOI 10.1074/jbc.M910298199; WOODY RW, 1983, BIOCHEMISTRY-US, V22, P2186, DOI 10.1021/bi00278a020; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yarmola EG, 2000, J BIOL CHEM, V275, P28120	47	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22351	22358		10.1074/jbc.M101457200	http://dx.doi.org/10.1074/jbc.M101457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294839	hybrid			2022-12-25	WOS:000169412700052
J	Eichhorn, K; Jackson, SP				Eichhorn, K; Jackson, SP			A role for TAF3B2 in the repression of human RNA polymerase III transcription in nonproliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEIC-ACID POLYMERASE; TATA-BINDING PROTEIN; RETINOBLASTOMA PROTEIN; ACCURATE TRANSCRIPTION; MULTIPLE FORMS; FACTOR TFIIIB; GENE; PROMOTER; P53; SEQUENCE	RNA polymerase III (Pol III) synthesizes various small RNA species, including the tRNAs and the 5 S ribosomal RNA,which are involved in protein synthesis. Here, we describe the regulation of human Pol III transcription in response to sustained cell cycle arrest. The experimental system used is a cell line in which cell cycle arrest is induced by the regulated expression of the tumor suppressor protein p53. We show that the capacity of cells to carry out Pol III transcription from various promoter types, when tested in vitro, is severely reduced in response to sustained p53-mediated cell cycle arrest. Furthermore, this effect does not appear to be due to direct inhibition by p53. By using complementation assays, we demonstrate that a subcomponent of the Pol III transcription factor IIIB, which contains the proteins TATA-binding protein and TAF3B2, is the target of repression. Moreover, we reveal that TAF3B2 levels are markedly reduced in extracts from cell cycle-arrested cells because of a decrease in TAF3B2 protein stability. These findings provide a novel mechanism of Pol III regulation and yield insights into how cellular biosynthetic capacity and growth status can be coordinated.	Wellcome Trust & Canc Res Campaign, Inst Canc & Dev Biol, Cambridge CB2 1QR, England; Univ Cambridge, Dept Zool, Cambridge CB2 1QR, England	University of Cambridge	Jackson, SP (corresponding author), Wellcome Trust & Canc Res Campaign, Inst Canc & Dev Biol, Tennis Court Rd, Cambridge CB2 1QR, England.		Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; 				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Coligan J.E., 1997, CURRENT PROTOCOLS PR; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; GALLI G, 1981, NATURE, V294, P626, DOI 10.1038/294626a0; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GODDARD JP, 1983, NUCLEIC ACIDS RES, V11, P2551, DOI 10.1093/nar/11.9.2551; HARLOW E, 1988, ANTIBODIES LABORATOR, P421; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KEDINGER C, 1970, BIOCHEM BIOPH RES CO, V38, P165, DOI 10.1016/0006-291X(70)91099-5; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Larminie CGC, 1998, J MOL MED, V76, P94, DOI 10.1007/s001090050196; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCLAREN A, 1986, NUCLEIC ACIDS RES, V14, P5938, DOI 10.1093/nar/14.14.5938; Mital R, 1996, MOL CELL BIOL, V16, P7031; MOOREFIELD B, 1994, J BIOL CHEM, V269, P20857; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; ROEDER RG, 1974, J BIOL CHEM, V249, P241; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROHAN RM, 1987, J BIOL CHEM, V262, P8500; Rosenwald IB, 1996, BIOESSAYS, V18, P243, DOI 10.1002/bies.950180312; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5889; SEGALL J, 1980, J BIOL CHEM, V255, P1986; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SORENSEN PD, 1990, NUCLEIC ACIDS RES, V18, P3060, DOI 10.1093/nar/18.10.3060; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; Teichmann M, 2000, P NATL ACAD SCI USA, V97, P14200, DOI 10.1073/pnas.97.26.14200; Wang ZX, 1998, MOL CELL, V1, P749, DOI 10.1016/S1097-2765(00)80074-X; WANG ZX, 1995, P NATL ACAD SCI USA, V92, P7026, DOI 10.1073/pnas.92.15.7026; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; White RJ, 1998, INT J ONCOL, V12, P741; WHITE RJ, 1998, GENE THER MOL BIOL, V1, P613; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; YOON JB, 1995, MOL CELL BIOL, V15, P2019; YOSHINAGA SK, 1987, P NATL ACAD SCI USA, V84, P3585, DOI 10.1073/pnas.84.11.3585	47	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21158	21165		10.1074/jbc.M102295200	http://dx.doi.org/10.1074/jbc.M102295200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11283026	hybrid			2022-12-25	WOS:000169297900050
J	Kneidinger, B; Graninger, M; Puchberger, M; Kosma, P; Messner, P				Kneidinger, B; Graninger, M; Puchberger, M; Kosma, P; Messner, P			Biosynthesis of nucleotide-activated D-glycero-D-manno-heptose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; D-MANNOHEPTOSE 6-EPIMERASE; SALMONELLA-TYPHIMURIUM; BACILLUS-THERMOAEROPHILUS; PHOSPHOHEPTOSE ISOMERASE; CAMPYLOBACTER-JEJUNI; SHIGELLA-SONNEI; CORE REGION; RFAD GENE; LIPOPOLYSACCHARIDE	The glycan chain repeats of the S-layer glycoprotein of Aneurinibacillus thermoaerophilus DSM 10155 contain D-glycero-D-manno-heptose, which has also been described as constituent of lipopolysaccharide cores of Gram-negative bacteria The four genes required for biosynthesis of the nucleotide-activated form GDP-D-glycero-D-manno-heptose were cloned, sequenced, and overexpressed in Escherichia coli, and the corresponding enzymes GmhA, GmhB, GmhC, and GmhD were purified to homogeneity, The isomerase GmhA catalyzed the conversion of D-sedoheptulose 7-phosphate to D-glycero-D-manno-heptose 7-phosphate, and the phosphokinase GmhB added a phosphate group to form D-glycero-D-manno-heptose 1,7-bisphosphate, The phosphatase GmhC removed the phosphate in the C-7 position, and the intermediate D-glycero-cu-D-manno-heptose :L-phosphate was eventually activated with GTP by the pyrophosphorylase GmhD to yield the final product GDP-D-glycero-alpha -D-manno-heptose. The intermediate and end products were analyzed by high performance liquid chromatography. Nuclear magnetic resonance spectroscopy was used to confirm the structure of these substances. This is the first report of the biosynthesis of GDP-D-glycero-alpha -D-manno-heptose in Gram-positive organisms. In addition, we propose a pathway for biosynthesis of the nucleotide-activated form of L-glycero-D-manno-heptose.	Agr Univ Vienna, Zentrum Ultrastrukturforsch, A-1180 Vienna, Austria; Agr Univ Vienna, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Agr Univ Vienna, Inst Chem, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Messner, P (corresponding author), Agr Univ Vienna, Zentrum Ultrastrukturforsch, Gregor Mendel Str 33, A-1180 Vienna, Austria.		Kosma, Paul/Y-7443-2019; Messner, Paul/Q-5345-2017	Kosma, Paul/0000-0001-5342-7161; Messner, Paul/0000-0002-3246-5801				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooke JS, 1996, J BIOL CHEM, V271, P3608; CARLOMAGNO MS, 1988, J MOL BIOL, V203, P585, DOI 10.1016/0022-2836(88)90194-5; Clark MA, 1998, CURR MICROBIOL, V37, P356, DOI 10.1007/s002849900392; COLEMAN WG, 1983, J BIOL CHEM, V258, P1985; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CURTISS R, 1968, BACTERIOL REV, V32, P320, DOI 10.1128/MMBR.32.4_Pt_1.320-348.1968; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; DING L, 1994, J BIOL CHEM, V269, P24384; EIDELS L, 1971, P NATL ACAD SCI USA, V68, P1673, DOI 10.1073/pnas.68.8.1673; EIDELS L, 1974, J BIOL CHEM, V249, P5642; GINSBURG V, 1962, J BIOL CHEM, V237, P497; Giraud MF, 2000, CURR OPIN STRUC BIOL, V10, P687, DOI 10.1016/S0959-440X(00)00145-7; Grzeszczyk BG, 1998, CARBOHYD RES, V307, P55, DOI 10.1016/S0008-6215(98)00037-8; HAVEKES LM, 1976, MOL GEN GENET, V146, P43, DOI 10.1007/BF00267981; Heinrichs DE, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P305; Heyndrickx M, 1997, INT J SYST BACTERIOL, V47, P808, DOI 10.1099/00207713-47-3-808; Kneidinger B, 2001, BIOTECHNIQUES, V30, P248, DOI 10.2144/01302bm01; Kneidinger B, 2001, J BIOL CHEM, V276, P5577, DOI 10.1074/jbc.M010027200; Knirel YA, 1999, EUR J BIOCHEM, V266, P123, DOI 10.1046/j.1432-1327.1999.00831.x; KOCSIS B, 1984, J BIOL CHEM, V259, P1858; KONTROHR T, 1981, J BIOL CHEM, V256, P7715; Kosma P, 1995, GLYCOBIOLOGY, V5, P791, DOI 10.1093/glycob/5.8.791; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARUMO K, 1992, EUR J BIOCHEM, V204, P539, DOI 10.1111/j.1432-1033.1992.tb16665.x; MELAUGH W, 1992, J BIOL CHEM, V267, P13434; Messner P, 2000, GLYCOMICROBIOLOGY, P93; NAESS V, 1984, J GEN MICROBIOL, V130, P2783; PALMIERI MJ, 1991, ANAL BIOCHEM, V194, P388, DOI 10.1016/0003-2697(91)90246-P; PAULSEN H, 1994, LIEBIGS ANN CHEM, P389; RADZIEJEWSKALEBRECHT J, 1994, EUR J BIOCHEM, V221, P343, DOI 10.1111/j.1432-1033.1994.tb18746.x; RADZIEJEWSKALEBRECHT J, 1989, EUR J BIOCHEM, V183, P573, DOI 10.1111/j.1432-1033.1989.tb21086.x; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; REEVES PR, 1994, NEW COMPR BIOCH, V27, P271; Sambrook J., 2002, MOL CLONING LAB MANU; Sara M, 2000, J BACTERIOL, V182, P859, DOI 10.1128/JB.182.4.859-868.2000; Schaffer C, 1996, MICROB DRUG RESIST, V2, P17, DOI 10.1089/mdr.1996.2.17; SIRISENA DM, 1994, J BACTERIOL, V176, P2379, DOI 10.1128/JB.176.8.2379-2385.1994; SUMMERS MF, 1986, J AM CHEM SOC, V108, P4285, DOI 10.1021/ja00275a008; Susskind M, 1998, J BIOL CHEM, V273, P7006, DOI 10.1074/jbc.273.12.7006; Szymanski CM, 1999, MOL MICROBIOL, V32, P1022, DOI 10.1046/j.1365-2958.1999.01415.x; TAMAKI S, 1971, J BACTERIOL, V105, P968, DOI 10.1128/JB.105.3.968-975.1971; Valvano MA, 2000, J BACTERIOL, V182, P488, DOI 10.1128/JB.182.2.488-497.2000; WILKINSON SG, 1983, REV INFECT DIS S5, V5, P941; Zamyatina A, 2000, ANGEW CHEM INT EDIT, V39, P4150, DOI 10.1002/1521-3773(20001117)39:22<4150::AID-ANIE4150>3.0.CO;2-A; ZWAHLEN A, 1985, J INFECT DIS, V152, P485, DOI 10.1093/infdis/152.3.485	49	75	83	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					20935	20944		10.1074/jbc.M100378200	http://dx.doi.org/10.1074/jbc.M100378200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279237	hybrid			2022-12-25	WOS:000169297900020
J	Liang, CC; Chen, HC				Liang, CC; Chen, HC			Sustained activation of extracellular signal-regulated kinase stimulated by hepatocyte growth factor leads to integrin alpha(2) expression that is involved in cell scattering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-TYROSINE-PHOSPHATASE; CANINE KIDNEY-CELLS; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MDCK CELLS; MET PROTOONCOGENE; EPITHELIAL-CELLS; RAS; RECEPTOR	We have previously shown that hepatocyte growth factor (HGF) selectively increases the expression of integrin alpha (2) in Madin-Darby canine kidney (MDCK) cells. In this study, we have further investigated the signal transduction pathways responsible for the event and its role in HGF-induced cell scattering. We found that the level of integrin alpha (2)beta (1) expression induced by HGF correlated with the extent of cell scattering and that a functional blocking antibody against integrin alpha (2) at the concentration of 25 mug/ml partially (40%) inhibited the HGF-induced cell scattering, However, in the presence of the specific phosphatidylinositol 3-kinase inhibitor LY294002 or the selective Src family kinase inhibitor PP1, although cells retained their response to HGF for increasing integrin alpha (2) expression, they failed to scatter, indicating that increased expression of integrin alpha (2) alone is not sufficient for cell scattering. Moreover, epidermal growth factor, which induced a transient (1 h) activation of extracellular signal-regulated kinase (ERK) in MDCK cells, only slightly increased integrin alpha (2) expression and failed to trigger cell scattering. Conversely, HGF induced a sustained (at least 12 h) activation of ERK in the cells, Expression of constitutively active ERK kinase (MEK) in MDCK cells led to increased expression of integrin alpha (2) even in the absence of HGF stimulation. In contrast, expression of ERK phosphatase or dominant negative MEK inhibited HGF-induced integrin alpha (2) expression. Taken together, our results suggest that the increased expression of integrin alpha (2)beta (1) by HGF is at least partially required for cell scattering and that the duration of MEK/ERK activation is likely to be a crucial determinant for cells to activate integrin alpha (2) expression and cell scattering.	Natl Chung Hsing Univ, Coll Life Sci, Dept Zool, Taichung 40227, Taiwan	National Chung Hsing University	Chen, HC (corresponding author), Natl Chung Hsing Univ, Coll Life Sci, Dept Zool, Taichung 40227, Taiwan.		Liang, Chun-Chi/D-7986-2016; Liang, Richard Chun-Chi/C-6989-2013	Liang, Chun-Chi/0000-0002-8345-8564; 				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; CHIN R, 1988, CELL, V54, P541; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; GUAN KL, 1995, J BIOL CHEM, V270, P7191; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Herrera R, 1998, J CELL SCI, V111, P1039; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Muda M, 1996, J BIOL CHEM, V271, P4319; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; Nissinen L, 1998, EXP CELL RES, V243, P1, DOI 10.1006/excr.1998.4128; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rosfjord EC, 1999, EXP CELL RES, V248, P260, DOI 10.1006/excr.1998.4390; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SAELMAN EUM, 1995, J CELL SCI, V108, P3531; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCHOENENBERGER CA, 1994, J CELL SCI, V107, P527; Schramek H, 1997, J BIOL CHEM, V272, P11426; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; Takeda H, 1999, EMBO J, V18, P386, DOI 10.1093/emboj/18.2.386; Terauchi R, 2000, EXP CELL RES, V256, P411, DOI 10.1006/excr.2000.4850; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689; ZUTTER MM, 1994, J BIOL CHEM, V269, P463; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	41	50	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21146	21152		10.1074/jbc.M010669200	http://dx.doi.org/10.1074/jbc.M010669200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287413	hybrid			2022-12-25	WOS:000169297900048
J	Martel, V; Racaud-Sultan, C; Dupe, S; Marie, C; Paulhe, F; Galmiche, A; Block, MR; Albiges-Rizo, C				Martel, V; Racaud-Sultan, C; Dupe, S; Marie, C; Paulhe, F; Galmiche, A; Block, MR; Albiges-Rizo, C			Conformation, localization, and integrin binding of talin depend on its interaction with phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PLECKSTRIN HOMOLOGY DOMAINS; CYTOSKELETAL PROTEIN TALIN; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIN-BINDING; PLASMA-MEMBRANE; ALPHA-ACTININ; INTRAMOLECULAR ASSOCIATION; ALPHA-5-BETA-1 INTEGRIN; SIGNAL-TRANSDUCTION	Talin is a structural component of focal adhesion sites and is thought to be engaged in multiple protein interactions at the cytoplasmic face of cell/matrix contacts. Talin is a major link between integrin and the actin cytoskeleton and was shown to play an important role in focal adhesion assembly. Consistent with the view that talin must be activated at these sites, we found that phosphatidylinositol 4-monophosphate and phosphatidylinositol 4,5-bisphosphate (PI4,5P(2)) bound to talin in cells in suspension or at early stages of adhesion, respectively. When phosphoinositides were associated with phospholipid bilayer, talin/phosphoinositide association was restricted to PI4,5P(2). This association led to a conformational change of the protein. Moreover, the interaction between integrin and talin was greatly enhanced by PI4,5P(2)-induced talin activation. Finally, sequestration of PI4,5P(2) by a specific pleckstrin homology domain confirms that PI4,5P(2) is necessary for proper membrane localization of talin and that this localization is essential for the maintenance of focal adhesions. Our results support a model in which PI4,5P(2) exposes the integrin-binding site on talin, We propose that PI4,5P(2)-dependent signaling modulates assembly of focal adhesions by regulating integrin-talin complexes. These results demonstrate that activation of the integrin-binding activity of talin requires not only integrin engagement to the extracellular matrix but also the binding of PI4,5P(2) to talin, suggesting a possible role of lipid metabolism in organizing the sequential assembly of focal adhesion components.	Fac Med Grenoble, Inst Albert Bonniot, LEDAC,UJF, CNRS,UMR 5538, F-38706 La Tronche, France; Hop Purpan, Inst Federatif Rech Claude de Preval, INSERM, U326, F-31059 Toulouse, France; Fac Med Nice, INSERM, U452, F-06107 Nice, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Martel, V (corresponding author), Fac Med Grenoble, Inst Albert Bonniot, LEDAC,UJF, CNRS,UMR 5538, F-38706 La Tronche, France.		Frachet, Véronique/B-8418-2018; Martel-Frachet, Veronique/B-8657-2014; Albiges-Rizo, Corinne/M-2568-2013	Frachet, Véronique/0000-0001-6739-7901; ALBIGES-RIZO, Corinne/0000-0002-6333-4150; Racaud-Sultan, Claire/0000-0002-6549-1088				ALBIGESRIZO C, 1995, J CELL SCI, V108, P3317; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; Borowsky ML, 1998, J CELL BIOL, V143, P429, DOI 10.1083/jcb.143.2.429; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Chockalingam PS, 1999, BIOCHEMISTRY-US, V38, P5596, DOI 10.1021/bi982564+; DEPASQUALE JA, 1987, J CELL BIOL, V105, P2803, DOI 10.1083/jcb.105.6.2803; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; EVANS E, 1982, BIOCHEMISTRY-US, V21, P4874, DOI 10.1021/bi00263a007; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Gironcel D, 1996, FEBS LETT, V389, P253, DOI 10.1016/0014-5793(96)00595-9; GOLDMANN WH, 1994, J STRUCT BIOL, V112, P3, DOI 10.1006/jsbi.1994.1002; GOLDMANN WH, 1992, BIOCHEMISTRY-US, V31, P7665, DOI 10.1021/bi00148a030; GROUX H, 1989, NATURE, V339, P152, DOI 10.1038/339152a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HEISE H, 1991, BIOCHIM BIOPHYS ACTA, V1061, P121, DOI 10.1016/0005-2736(91)90276-E; Hemmings L, 1996, J CELL SCI, V109, P2715; Heraud JM, 1998, J BIOL CHEM, V273, P17817, DOI 10.1074/jbc.273.28.17817; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; Irvine R, 1998, CURR BIOL, V8, pR557, DOI 10.1016/S0960-9822(07)00360-0; Isenberg G, 1996, FEBS LETT, V397, P316, DOI 10.1016/S0014-5793(96)01203-3; Isenberg G., 1995, CYTOSKELETON, V1, P169; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Knezevic I, 1996, J BIOL CHEM, V271, P16416, DOI 10.1074/jbc.271.27.16416; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Loyet KM, 1998, J BIOL CHEM, V273, P8337, DOI 10.1074/jbc.273.14.8337; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MUGURUMA M, 1990, BIOCHEM BIOPH RES CO, V171, P1217, DOI 10.1016/0006-291X(90)90815-5; Nakamura F, 1999, MOL BIOL CELL, V10, P2669, DOI 10.1091/mbc.10.8.2669; NIGGLI V, 1994, EUR J BIOCHEM, V224, P951, DOI 10.1111/j.1432-1033.1994.00951.x; NUCKOLLS GH, 1992, J CELL SCI, V102, P753; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; Patil S, 1999, J BIOL CHEM, V274, P28575, DOI 10.1074/jbc.274.40.28575; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; RAGHUNATHAN V, 1992, FEBS LETT, V297, P46, DOI 10.1016/0014-5793(92)80324-A; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Steimle PA, 1999, J BIOL CHEM, V274, P18414, DOI 10.1074/jbc.274.26.18414; Takenawa T, 1999, CHEM PHYS LIPIDS, V98, P13, DOI 10.1016/S0009-3084(99)00014-6; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; TURNER CE, 1989, EUR J CELL BIOL, V49, P202; Udagawa T, 1996, J BIOL CHEM, V271, P12542, DOI 10.1074/jbc.271.21.12542; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Vignoud L, 1997, J CELL SCI, V110, P1421; Weekes J, 1996, BIOCHEM J, V314, P827, DOI 10.1042/bj3140827; WENNSTROM S, 1994, ONCOGENE, V9, P651; YU FX, 1992, J BIOL CHEM, V267, P14616	74	252	258	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21217	21227		10.1074/jbc.M102373200	http://dx.doi.org/10.1074/jbc.M102373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11279249	hybrid			2022-12-25	WOS:000169297900057
J	Sauna, ZE; Smith, MM; Muller, M; Ambudkar, SV				Sauna, ZE; Smith, MM; Muller, M; Ambudkar, SV			Functionally similar vanadate-induced 8-azidoadenosine 5 '-[alpha-P-32]diphosphate-trapped transition state intermediates of human P-glycoprotein are generated in the absence and presence of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; REPAIR PROTEIN MUTS; HAMSTER OVARY CELLS; MULTIDRUG TRANSPORTER; CRYSTAL-STRUCTURE; CATALYTIC SITES; RESISTANCE PUMP; ABC TRANSPORTER; WALKER-A; SUBUNIT	P-glycoprotein (Pgp) is an ATP-dependent drug efflux pump whose overexpression confers multidrug resistance to cancer cells. Pgp exhibits a robust drug substrate-stimulable ATPase activity, and vanadate (Vi) blocks this activity effectively by trapping Pgp nucleotide in a noncovalent stable transition state conformation. In this study we compare Vi-induced [alpha-P-32]8-azido-ADP trapping into Pgp in the presence of [alpha-P-32]8-azido-ATP (with ATP hydrolysis) or [alpha-P-32]8-azido-ADP (without ATP hydrolysis), Vi mimics Pi to trap the nucleotide tenaciously in the Pgp . [alpha-P-32]8-azido-ADP.Vi conformation in either condition. Thus, by using [alpha-P-32]8-azido-ADP we show that the Vi-induced transition state of Pgp can be generated even in the absence of ATP hydrolysis. Furthermore, half-maximal trapping of nucleotide into Pgp in the]presence of Vi occurs at similar concentrations of [(alpha-P-32]8-azido-ATP or [alpha-P-32]8-azido-ADP. The trapped [(alpha-P-32]8-azido-ADP is almost equally distributed between the N- and the C-terminal ATP sites of Pgp in both conditions. Additionally, point mutations in the Walker B domain of either the N- (D555N) or C (D1200N)-terminal ATP sites that arrest ATP hydrolysis and Vi-induced trapping also show abrogation of [alpha-P-32]8-azido-ADP trapping into Pgp in the absence of hydrolysis, These data suggest that both ATP sites are dependent on each other for function and that each site exhibits similar affinity for 8-azido-ATP (ATP) or 8-azido-ADP (ADP), Similarly, Pgp in the transition state conformation generated with either ADP or ATP exhibits drastically reduced affinity for the binding of analogues of drug substrate ([I-125]iodoarylazidoprazosin) as well as nucleotide (2'(3')-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate). Analyses of Arrhenius plots show that trapping of Pgp with [alpha-P-32]8-azido-ADP tin the, absence of hydrolysis) displays an similar to2.5-fold higher energy of activation (152 kJ/mol) compared with that observed when the transition state intermediate is generated through hydrolysis of [alpha-P-32]8-azido-ATP (62 kJ/mol), In aggregate, these results demonstrate that the Pgp [alpha-P-32]8-azido-ADP (or ADP) Vi transition state complexes generated either in the absence of or accompanying [alpha-P-32]8-azido-ATP hydrolysis are functionally indistinguishable.	NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 1B-22,37 convent Dr, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Sauna, Zuben E./AAA-7149-2019; Ambudkar, Suresh V/B-5964-2008; Ambudkar, Suresh V/L-1317-2016					Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hrycyna CA, 1998, METHOD ENZYMOL, V292, P456; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Lamers MH, 2000, NATURE, V407, P711, DOI 10.1038/35037523; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Liu RH, 1997, BIOCHEMISTRY-US, V36, P2836, DOI 10.1021/bi9627119; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Obmolova G, 2000, NATURE, V407, P703, DOI 10.1038/35037509; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Romsicki Y, 1998, EUR J BIOCHEM, V256, P170, DOI 10.1046/j.1432-1327.1998.2560170.x; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2000, BIOCHEM BIOPH RES CO, V276, P1314, DOI 10.1006/bbrc.2000.3576; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Weinreich F, 1999, J GEN PHYSIOL, V114, P55, DOI 10.1085/jgp.114.1.55; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	44	35	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21199	21208		10.1074/jbc.M100886200	http://dx.doi.org/10.1074/jbc.M100886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11287418	hybrid			2022-12-25	WOS:000169297900055
J	Bain, DL; Berton, N; Ortega, M; Baran, J; Yang, Q; Catalano, CE				Bain, DL; Berton, N; Ortega, M; Baran, J; Yang, Q; Catalano, CE			Biophysical characterization of the DNA binding domain of gpNu1, a viral DNA packaging protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-LAMBDA TERMINASE; GENE-PRODUCT-A; PHAGE-LAMBDA; KINETIC CHARACTERIZATION; LARGE SUBUNIT; ENDONUCLEASE ACTIVITY; DEFINED SYSTEM; ENZYME; PURIFICATION; HOLOENZYME	Terminase enzymes are common to double-stranded DNA viruses. These enzymes "package" the viral genome into a pre-formed capsid, Terminase from bacteriophage lambda is composed of gpA (72.4 kDa) and gpNu1 (20.4 kDa) subunits. We have described the expression and biochemical characterization of gpNu1 Delta K100, a construct comprising the N-terminal 100 amino acids of gpNu1 (Yang, Q., de Beer, T., Woods, L., Meyer, J., Manning, M., Overduin, M., and Catalano, C. E. (1999) Biochemistry 38, 465-477), Here we present a biophysical characterization of this construct. Thermally induced loss of secondary and tertiary structures is fully reversible. Surprisingly, although loss of tertiary structure is cooperative, loss of secondary structure is non-cooperative. NMR and limited proteolysis data suggest that approximate to 30 amino acids of gpNu1 Delta K100 are solvent-exposed and highly flexible. We therefore constructed gpNu1 Delta E68, a protein consisting of the N-terminal 68 residues of gpNu1. gpNu1 Delta E68 is a dimer with no evidence of dissociation or further aggregation, Thermally induced unfolding of gpNu1 Delta E68 is reversible, with concomitant loss of both secondary and tertiary structure, The melting temperature increases with increasing protein concentration, suggesting that dimerization and folding are, at least in part, coupled. The data suggest that gpNu1 Delta E68 represents the minimal DNA binding domain of gpNu1. We further suggest that the C-terminal approximate to 30 residues in gpNu1 Delta K100 adopt a pseudo-stable alpha -helix that extends from the folded core of the protein. A model describing the role of this helix in the assembly of the packaging apparatus is discussed.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Catalano, CE (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Campus Box C238, Denver, CO 80262 USA.	carlos.catalano@uchsc.edu		Catalano, Carlos E./0000-0003-2349-5758				BECKER A, 1990, J BACTERIOL, V172, P2819, DOI 10.1128/jb.172.6.2819-2824.1990; BLACK LW, 1989, ANNU REV MICROBIOL, V43, P267, DOI 10.1146/annurev.micro.43.1.267; Cai ZH, 1997, J BACTERIOL, V179, P2479, DOI 10.1128/jb.179.8.2479-2485.1997; Catalano CE, 2000, CELL MOL LIFE SCI, V57, P128, DOI 10.1007/s000180050503; CATALANO CE, 1995, MOL MICROBIOL, V16, P1075, DOI 10.1111/j.1365-2958.1995.tb02333.x; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Cohn E. J., 1943, PROTEINS AMINO ACIDS; CUE D, 1992, J MOL BIOL, V228, P72, DOI 10.1016/0022-2836(92)90492-3; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; Droge A, 2000, J MOL BIOL, V296, P103, DOI 10.1006/jmbi.1999.3449; FEISS M, 1986, TRENDS GENET, V2, P100, DOI 10.1016/0168-9525(86)90193-9; FEISS M, 1982, GENE, V17, P123, DOI 10.1016/0378-1119(82)90064-6; Fujisawa H, 1997, GENES CELLS, V2, P537, DOI 10.1046/j.1365-2443.1997.1450343.x; Fujita N, 2000, BIOCHEMISTRY-US, V39, P6243, DOI 10.1021/bi000020d; Furth M., 1983, LAMBDA 2, P145; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GILL SC, 1990, ANAL BIOCHEM, V189, P283; GOLD M, 1983, J BIOL CHEM, V258, P4619; GUO PX, 1986, P NATL ACAD SCI USA, V83, P3505, DOI 10.1073/pnas.83.10.3505; Hanagan A, 1998, INT J BIOL MACROMOL, V23, P37, DOI 10.1016/S0141-8130(98)00010-5; Hang Q, 1999, J BIOL CHEM, V274, P15305, DOI 10.1074/jbc.274.22.15305; Hwang Y, 1996, BIOCHEMISTRY-US, V35, P2796, DOI 10.1021/bi952322z; HWANG Y, 1995, VIROLOGY, V211, P367, DOI 10.1006/viro.1995.1419; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KYPR J, 1986, J MOL BIOL, V191, P139, DOI 10.1016/0022-2836(86)90430-4; Meyer JD, 1998, INT J BIOL MACROMOL, V23, P27, DOI 10.1016/S0141-8130(98)00009-9; MURIALDO H, 1991, ANNU REV BIOCHEM, V60, P125; PARRIS W, 1988, J BIOL CHEM, V263, P8413; PARRIS W, 1994, J BIOL CHEM, V269, P13564; RAO VB, 1988, J MOL BIOL, V200, P475, DOI 10.1016/0022-2836(88)90537-2; ROIZMAN B, 1996, FIELDS VIROLOGY, V2, P2231; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13586; RUBINCHIK S, 1995, J BIOL CHEM, V270, P20059, DOI 10.1074/jbc.270.34.20059; RUBINCHIK S, 1994, J BIOL CHEM, V269, P13575; SKALKA AM, 1977, CURR TOP MICROBIOL, P201; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; TOMKA MA, 1993, BIOCHEMISTRY-US, V32, P11992, DOI 10.1021/bi00096a008; TOMKA MA, 1993, J BIOL CHEM, V268, P3056; Woods L, 1997, BIOCHEMISTRY-US, V36, P5777, DOI 10.1021/bi963044m; Woods L, 1999, BIOCHEMISTRY-US, V38, P14624, DOI 10.1021/bi990866l; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; Yang Q, 1997, BIOCHEMISTRY-US, V36, P10638, DOI 10.1021/bi970689t; Yang Q, 1999, BIOCHEMISTRY-US, V38, P465, DOI 10.1021/bi981271d; Yang Q, 1999, BIOCHEMISTRY-US, V38, P14238, DOI 10.1021/bi991408f; Yang Q, 1997, BIOCHEMISTRY-US, V36, P2744, DOI 10.1021/bi9622682; [No title captured]	47	13	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20175	20181		10.1074/jbc.M100517200	http://dx.doi.org/10.1074/jbc.M100517200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279084	hybrid			2022-12-25	WOS:000169135100068
J	Lutz, W; Lingle, WL; McCormick, D; Greenwood, TM; Salisbury, JL				Lutz, W; Lingle, WL; McCormick, D; Greenwood, TM; Salisbury, JL			Phosphorylation of centrin during the cell cycle and its role in centriole separation preceding centrosome duplication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE POLE BODY; PROTEIN-KINASE-A; EF-HAND PROTEIN; SACCHAROMYCES-CEREVISIAE; MITOTIC CENTROSOMES; CONTRACTILE FIBERS; MAMMALIAN-CELLS; DIVISION CYCLE; GOLGI-COMPLEX; ANIMAL-CELLS	Once during each cell cycle, mitotic spindle poles arise by separation of newly duplicated centrosomes. Ne report here the involvement of phosphorylation of the centrosomal protein centrin in this process. We show that centrin is phosphorylated at serine residue 170 during the G(2)/M phase of the cell cycle. Indirect immunofluorescence staining of HeLa cells using a phosphocentrin-specific antibody reveals intense labeling of mitotic spindle poles during prophase and metaphase of the cell division cycle, with diminished staining of anaphase and no staining of telophase and interphase centrosomes. Cultured cells undergo a dramatic increase in centrin phosphorylation following the experimental elevation of PKA activity, suggesting that this kinase can phosphorylate centrin tn vivo. Surprisingly, elevated PKA activity also resulted intense phosphocentrin antibody labeling of interphase centrosomes and in the concurrent movement of individual centrioles apart from one another, Taken together, these results suggest that centrin phosphorylation signals the separation of centrosomes at prophase and implicates centrin phosphorylation in centriole separation that normally precedes centrosome duplication.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic	Salisbury, JL (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Tumor Biol Program, Rochester, MN 55905 USA.	salisbury@mayo.edu		Salisbury, Jeffrey/0000-0001-9257-4578	NCI NIH HHS [CA72836] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072836] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams IR, 2000, TRENDS CELL BIOL, V10, P329, DOI 10.1016/S0962-8924(00)01798-0; ALBADER AA, 1976, EXP CELL RES, V103, P47, DOI 10.1016/0014-4827(76)90239-1; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Balczon R, 1996, INT REV CYTOL, V169, P25, DOI 10.1016/S0074-7696(08)61984-1; BARON AT, 1995, METHOD CELL BIOL, V47, P341, DOI 10.1016/S0091-679X(08)60828-6; BAUM P, 1988, MOL CELL BIOL, V8, P5386, DOI 10.1128/MCB.8.12.5386; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; BURGER MM, 1972, NATURE-NEW BIOL, V239, P161, DOI 10.1038/newbio239161a0; CENTONZE VE, 1990, J CELL SCI, V95, P405; DECAMILLI P, 1986, J CELL BIOL, V103, P189, DOI 10.1083/jcb.103.1.189; Diviani D, 2000, CURR BIOL, V10, P417, DOI 10.1016/S0960-9822(00)00422-X; ERRABOLU R, 1994, J CELL SCI, V107, P9; FANTES P, 1993, CELL CYCLE; Fry AM, 2000, CURR TOP DEV BIOL, V49, P291; Goepfert TM, 2000, CURR TOP DEV BIOL, V49, P331; Hardie G., 1995, PROTEIN KINASE FACTS, P418; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; HOHMANN P, 1993, CELL PROLIFERAT, V26, P195, DOI 10.1111/j.1365-2184.1993.tb00019.x; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; Keryer G, 1999, EXP CELL RES, V249, P131, DOI 10.1006/excr.1999.4447; KURIYAMA R, 1989, CELL MOTIL CYTOSKEL, V12, P90, DOI 10.1002/cm.970120204; Kurokawa K, 1998, CELL STRUCT FUNCT, V23, P357, DOI 10.1247/csf.23.357; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; MARTINDALE VE, 1990, J CELL SCI, V96, P395; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; MCFADDEN GI, 1987, J CELL BIOL, V105, P903, DOI 10.1083/jcb.105.2.903; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Middendorp S, 1997, P NATL ACAD SCI USA, V94, P9141, DOI 10.1073/pnas.94.17.9141; MORBECK DE, 1993, MOL CELL ENDOCRINOL, V97, P173, DOI 10.1016/0303-7207(93)90225-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; NIGG EA, 1985, CELL, V41, P1039, DOI 10.1016/S0092-8674(85)80084-2; Oh WJ, 1996, BIOCHEM MOL BIOL INT, V39, P991; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Paoletti A, 1996, J CELL SCI, V109, P3089; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERICH JW, 1992, INT J PEPT PROT RES, V40, P134; Piel M, 2000, J CELL BIOL, V149, P317, DOI 10.1083/jcb.149.2.317; RAO PN, 1989, J CELL SCI, V93, P63; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SALISBURY JL, 1978, SCIENCE, V202, P975, DOI 10.1126/science.202.4371.975; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; Stearns T, 1997, CELL, V91, P303, DOI 10.1016/S0092-8674(00)80414-6; Sullivan DS, 1998, J CELL BIOL, V143, P751, DOI 10.1083/jcb.143.3.751; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vandre DD, 2000, MICROSC RES TECHNIQ, V49, P458; VOROBJEV IA, 1982, J CELL BIOL, V93, P938, DOI 10.1083/jcb.93.3.938; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858; ZEILIG CE, 1976, J CELL BIOL, V71, P515, DOI 10.1083/jcb.71.2.515	59	90	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20774	20780		10.1074/jbc.M101324200	http://dx.doi.org/10.1074/jbc.M101324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279195	hybrid			2022-12-25	WOS:000169135100146
J	Thoden, JB; Wohlers, TM; Fridovich-Keil, JL; Holden, HM				Thoden, JB; Wohlers, TM; Fridovich-Keil, JL; Holden, HM			Molecular basis for severe epimerase deficiency galactosemia - X-ray structure of the human V94M-substituted UDP-galactose 4-epimerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAM	Galactosemia is an inherited disorder characterized by an inability to metabolize galactose. Although classical galactosemia results from impairment of the second enzyme of the Leloir pathway, namely galactose-1-phosphate uridylyltransferase, alternate forms of the disorder can occur due to either galactokinase or UDP-galactose 4-epimerase deficiencies. One of the more severe cases of epimerase deficiency galactosemia arises from an amino acid substitution at position 94. It has been previously demonstrated that the V94M protein is impaired relative to the wild-type enzyme predominantly at the level of V-max rather than K-m. To address the molecular consequences the mutation imparts on the three-dimensional architecture of the enzyme, we have solved the structures of the V94M-substituted human epimerase complexed with NADH and UDP-glucose, UDP-galactose, UDP-GlcNAc, or UDP-GalNAc. In the wild-type enzyme, the hydrophobic side chain of Val(94) packs near the aromatic group of the catalytic Tyr(157) and serves as a molecular "fence" to limit the rotation of the glycosyl portions of the UDP-sugar substrates within the active site. The net effect of the V94M substitution is an opening up of the Ala(93) to Glu(96) surface loop, which allows free rotation of the sugars into nonproductive binding modes.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Emory Univ, Sch Med, Grad Program Genet & Mol Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Genet, Atlanta, GA 30322 USA	University of Wisconsin System; University of Wisconsin Madison; Emory University; Emory University	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK047814, R29DK046403, R01DK046403, R01DK047814] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814, DK46403] Funding Source: Medline; NIGMS NIH HHS [GM08490, T32 GM008490] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANO A, 1997, J INVEST MED, V45, P191; ESNOUF R, 1991, J APPL CRYSTALLOGR, V24, P946; FREY PA, 1987, PYRIDINE NUCLEOTID B, P461; GITZELMANN R, 1972, HELV PAEDIATR ACTA, V27, P125; GITZELMANN R, 1977, HELV PAEDIATR ACTA, V31, P441; GITZELMANN R, 1973, HELV PAEDIATR ACTA, V28, P497; Holton J. B., 2000, METABOLIC MOL BASES, P1553; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MALEY F, 1959, BIOCHIM BIOPHYS ACTA, V31, P577, DOI 10.1016/0006-3002(59)90047-2; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PILLER F, 1983, J BIOL CHEM, V258, P774; ROUSSEL A, 1991, SILICON GRAPHICS GEO; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Wohlers TM, 2000, J INHERIT METAB DIS, V23, P713, DOI 10.1023/A:1005682913784; Wohlers TM, 1999, AM J HUM GENET, V64, P462, DOI 10.1086/302263	20	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					20617	20623		10.1074/jbc.M101304200	http://dx.doi.org/10.1074/jbc.M101304200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279193	hybrid			2022-12-25	WOS:000169135100127
J	Jones, I; Lindberg, C; Jakobsson, S; Hellqvist, A; Hellman, U; Borg, B; Olsson, PE				Jones, I; Lindberg, C; Jakobsson, S; Hellqvist, A; Hellman, U; Borg, B; Olsson, PE			Molecular cloning and characterization of spiggin - An androgen-regulated extraorganismal adhesive with structural similarities to von Willebrand Factor-related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALE 3-SPINED STICKLEBACK; GASTEROSTEUS-ACULEATUS; VONWILLEBRAND-FACTOR; NEW-GENERATION; SEQUENCE; IDENTIFICATION; KIDNEY; THIOREDOXIN; PREDICTION; CLEAVAGE	One of the most definitive examples of a vertebrate extraorganismal structural protein can be found in three-spined sticklebacks (Gasterosteus aculeatus), In the breeding male the kidney hypertrophies and synthesizes an adhesive protein called "spiggin,'" which is secreted into the urinary bladder from where it is employed as a structural thread for nest building. This paper describes the first molecular characterization of spiggin and demonstrates that this adhesive is a protein complex assembled from a potential of three distinct subunits (alpha, beta, and gamma). These subunits arise by alternative splicing, and 11-ketoandrogens induce their expression in stickleback kidneys. Analysis of the predicted amino acid sequence of each subunit reveals a modular organization whose structural elements display a similarity to the multimerization domains found within von Willebrand Factor-related proteins. These results implicate that spiggin utilizes a conserved multimerization mechanism for the formation of a viscous agglutinate from its constituent subunits in the urinary bladders of male sticklebacks, This novel extraorganismal structural protein is therefore ideally suited to its function as an adhesive thread.	Umea Univ, Dept Cell & Mol Biol, Unit Physiol, SE-90187 Umea, Sweden; Stockholm Univ, Dept Zool, SE-10691 Stockholm, Sweden; Uppsala Biomed Ctr, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Umea University; Stockholm University; Ludwig Institute for Cancer Research	Olsson, PE (corresponding author), Umea Univ, Dept Cell & Mol Biol, Unit Physiol, SE-90187 Umea, Sweden.			Olsson, Per-Erik/0000-0001-7336-6335				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BORG B, 1994, COMP BIOCHEM PHYS C, V109, P219, DOI 10.1016/0742-8413(94)00063-G; BORG B, 1993, CAN J ZOOL, V71, P2327, DOI 10.1139/z93-326; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEVORE DP, 1984, COMP BIOCHEM PHYS B, V77, P529, DOI 10.1016/0305-0491(84)90270-0; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; Gosline JM, 1999, J EXP BIOL, V202, P3295; GUM JR, 1994, J BIOL CHEM, V269, P2440; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Harada N, 1997, J BIOL CHEM, V272, P15232, DOI 10.1074/jbc.272.24.15232; HARDY DM, 1995, J BIOL CHEM, V270, P26025, DOI 10.1074/jbc.270.44.26025; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HYELLMAN U, 2000, PROTEOMICS FUNCTIONA; HYLLNER SJ, 1995, MOL REPROD DEV, V41, P339, DOI 10.1002/mrd.1080410309; Jakobsson S, 1999, FISH PHYSIOL BIOCHEM, V20, P79, DOI 10.1023/A:1007776016610; Joba W, 1997, J BIOL CHEM, V272, P1805, DOI 10.1074/jbc.272.3.1805; JONGENS TA, 1988, EMBO J, V7, P2559, DOI 10.1002/j.1460-2075.1988.tb03105.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MAYADAS TN, 1992, P NATL ACAD SCI USA, V89, P3531, DOI 10.1073/pnas.89.8.3531; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; MAYER I, 1990, GEN COMP ENDOCR, V79, P23, DOI 10.1016/0016-6480(90)90084-Y; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Perez-Vilar J, 1998, J BIOL CHEM, V273, P34527, DOI 10.1074/jbc.273.51.34527; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; ROUX KH, 1995, PCR METH APPL, V4, P185; Sambrook J., 2002, MOL CLONING LAB MANU; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOOLE JJ, 1979, CELL, V17, P441, DOI 10.1016/0092-8674(79)90170-3; TSUDA M, 1979, P NATL ACAD SCI USA, V76, P4872, DOI 10.1073/pnas.76.10.4872; Urich K., 1994, COMP ANIMAL BIOCH, P376; WAGNER DD, 1990, ANNU REV CELL BIOL, V6, P217, DOI 10.1146/annurev.cellbio.6.1.217	35	50	55	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					17857	17863		10.1074/jbc.M101142200	http://dx.doi.org/10.1074/jbc.M101142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279178	hybrid			2022-12-25	WOS:000168866500034
J	Node, K; Ruan, XL; Dai, JW; Yang, SX; Graham, L; Zeldin, DC; Liao, JK				Node, K; Ruan, XL; Dai, JW; Yang, SX; Graham, L; Zeldin, DC; Liao, JK			Activation of G alpha(s) mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL SMOOTH-MUSCLE; ARACHIDONIC-ACID; ENDOTHELIAL-CELLS; RELAXING FACTOR; CYCLIC-AMP; 11,12-EPOXYEICOSATRIENOIC ACID; HYPERPOLARIZING FACTORS; CORONARY-ARTERIES; MOLECULAR-CLONING; ADP-RIBOSYLATION	The epoxyeicosatrienoic acids (EETs) are products of cytochrome P450 (CYP) epoxygenases that have vasodilatory and anti-inflammatory properties. Here we report that EETs have additional fibrinolytic properties. In vascular endothelial cells, physiological concentrations of EETs, particularly 11,12-EET, or overexpression of the endothelial epoxygenase, CYP2J2, increased tissue plasminogen activator (t-PA) expression by 2.5-fold without affecting plasminogen activator inhibitor-1 expression. This increase in t-PA expression correlated with a 4-fold induction in t-PA gene transcription and a 3-fold increase in t-PA fibrinolytic activity and was blocked by the CYP inhibitor, SKF525A, but not by the calcium-activated potassium channel blocker, charybdotoxin, indicating a mechanism that does not involve endothelial cell hyperpolarization. The t-PA promoter is cAMP-responsive, and induction of t-PA gene transcription by EETs correlated with increases in intracellular cAMP levels and, functionally, with cAMP-driven promoter activity. To determine whether increases in intracellular cAMP levels were due to modulation of guanine nucleotide-binding proteins, we assessed the effects of EETs on G alpha (s) and G alpha (i2). Treatment with EETs increased G alpha (s), but not G alpha (i2), GTP-binding activity by 3.5-fold. These findings indicate that EETs possess fibrinolytic properties through the induction of t-PA and suggest that endothelial CYP2J2 may play an important role in regulating vascular hemostasis.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Osaka 5650871, Japan; NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liao, JK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 221 Longwood Ave,LMRC-322, Boston, MA 02115 USA.	jliao@rics.bwh.harvard.edu	Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048743, R01HL052233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050106, Z01ES025044, Z01ES025043, Z01ES025041, Z01ES025034] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-52233, HL-48743] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; DEGEN SJF, 1986, J BIOL CHEM, V261, P6972; FALCK JR, 1990, METHOD ENZYMOL, V187, P357; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Imig JD, 1999, HYPERTENSION, V33, P408, DOI 10.1161/01.HYP.33.1.408; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; Leffler CW, 1997, AM J PHYSIOL-HEART C, V273, pH333, DOI 10.1152/ajpheart.1997.273.1.H333; Li PL, 1999, CIRC RES, V85, P349, DOI 10.1161/01.RES.85.4.349; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; LIAO JK, 1993, J BIOL CHEM, V268, P19528; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; Miyamoto A, 1999, J BIOL CHEM, V274, P12055, DOI 10.1074/jbc.274.17.12055; NAGAMINE Y, 1985, P NATL ACAD SCI USA, V82, P4606, DOI 10.1073/pnas.82.14.4606; NAGY LE, 1992, BIOCHEM J, V286, P681, DOI 10.1042/bj2860681; NAKAGAWA J, 1988, J BIOL CHEM, V263, P2460; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Oltman CL, 1998, CIRC RES, V83, P932; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SANTELL L, 1988, J BIOL CHEM, V263, P16802; SEKI K, 1992, BIOCHEM J, V281, P185, DOI 10.1042/bj2810185; Soeda S, 1997, BIOL PHARM BULL, V20, P15; Sumpio BE, 1997, AM J PHYSIOL-CELL PH, V273, pC1441, DOI 10.1152/ajpcell.1997.273.5.C1441; Uno S, 1998, J BIOCHEM, V123, P806; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; Wong PYK, 1997, J LIPID MEDIAT CELL, V16, P155, DOI 10.1016/S0929-7855(97)00005-9; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551	35	199	216	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 11	2001	276	19					15983	15989		10.1074/jbc.M100439200	http://dx.doi.org/10.1074/jbc.M100439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	431GH	11279071	hybrid			2022-12-25	WOS:000168623100057
J	Akakura, S; Yoshida, M; Yoneda, Y; Horinouchi, S				Akakura, S; Yoshida, M; Yoneda, Y; Horinouchi, S			A role for Hsc70 in regulating nucleocytoplasmic transport of a temperature-sensitive p53 (p53(Val-135))	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; NUCLEAR EXPORT SIGNAL; RING-FINGER DOMAIN; HEAT-SHOCK COGNATE; MUTANT P53; LEPTOMYCIN-B; IN-VIVO; CYTOPLASMIC SEQUESTRATION; SUBCELLULAR-LOCALIZATION	Mouse temperature-sensitive p53(Val-135) accumulates in the nucleus and acts as a "wild-type" at 32 degreesC while it is sequestered in the cytoplasm at 37 degreesC. The cytoplasmic p53(Val-135) relocalized into the nucleus upon inhibition of the nuclear export at 37 degreesC, whereas a mutation in a major bipartite nuclear localization signal (NLS) caused constitutive cytoplasmic localization, indicating that it shuttled between the cytoplasm and the nucleus by its own nuclear export signal and NLS rather than tethered to cytoplasmic structures. Although the full-length p53(Val-135) did not bind the import receptor at 37 degreesC, a C-terminally truncated p53(Val-135) lacking residues 326-390 did bind it. Molecular chaperones such as Hsc70 were associated with p53(Val-135) at 37 degreesC but not at 32 degreesC. When the nuclear export was blocked by leptomycin B, only a fraction lacking Hsc70 was specifically accumulated in the nucleus. Immunodepletion of Hsc70 from the reticulocyte lysate caused p53(Val-135) to bind the import receptor. This binding was blocked by supplying the cell extract containing Hsc70 but not by the addition of recombinant Hsc70 alone. We suggest that the association with the Hsc70-containing complex prevents the NLS from the access of the import receptor through the C-terminal region of p53(Val-135) at 37 degreesC, whereas its dissociation at 32 degreesC allows rapid nuclear import.	Univ Tokyo, Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 565, Japan; Japan Sci & Technol Corp, CREST Res Project, Saitama 3320012, Japan	University of Tokyo; Osaka University; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Univ Tokyo, Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				ALI IU, 1994, CANCER RES, V54, P1; Angelidis CE, 1999, EUR J BIOCHEM, V259, P505, DOI 10.1046/j.1432-1327.1999.00078.x; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; BOSARI S, 1995, AM J PATHOL, V147, P790; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; CORVI R, 1995, ONCOGENE, V10, P1081; ELKIND NB, 1995, ONCOGENE, V11, P841; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GAITONDESV, 2000, ONCOGENE, V19, P4042; GANNON JV, 1991, NATURE, V349, P802; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; IMAMOTO N, 1992, J CELL BIOL, V119, P1047, DOI 10.1083/jcb.119.5.1047; IMAMOTO N, 1995, FEBS LETT, V368, P415; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699; Liang SH, 1998, J BIOL CHEM, V273, P19817, DOI 10.1074/jbc.273.31.19817; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; LUNA RMD, 1995, NATURE, V378, P203; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Merrick BA, 1996, BBA-PROTEIN STRUCT M, V1297, P57; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Middeler G, 1997, ONCOGENE, V14, P1407, DOI 10.1038/sj.onc.1200949; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; PORTER PL, 1992, AM J PATHOL, V140, P145; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; ROTTER V, 1983, EMBO J, V2, P1041, DOI 10.1002/j.1460-2075.1983.tb01543.x; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Sepehrnia B, 1996, J BIOL CHEM, V271, P15084, DOI 10.1074/jbc.271.25.15084; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; TAKAHASHI K, 1994, ONCOGENE, V9, P183; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; YEHIELY F, 1992, CELL GROWTH DIFFER, V3, P803; ZERRAHN J, 1992, ONCOGENE, V7, P1371	60	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 4	2001	276	18					14649	14657		10.1074/jbc.M100200200	http://dx.doi.org/10.1074/jbc.M100200200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	429QQ	11297531	hybrid			2022-12-25	WOS:000168528800019
J	Friedrich, CL; Rozek, A; Patrzykat, A; Hancock, REW				Friedrich, CL; Rozek, A; Patrzykat, A; Hancock, REW			Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC ANTIMICROBIAL PEPTIDES; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; CYTOPLASMIC MEMBRANE; NEUTROPHIL DEFENSIN; CIRCULAR-DICHROISM; DISTANCE GEOMETRY; NMR-SPECTROSCOPY; HELICAL PEPTIDES	Indolicidin, an antimicrobial peptide with a unique amino acid sequence (ILPWKWPWWPWRR-NH2) is found in bovine neutrophils, A derivative of indolicidin, CP10A, has alanine residues substituted for proline residues and has improved activity against Gram-positive organisms. Transmission electron microscopy of Staphylococcus aureus and Staphylococcus epidermidis treated with CP10A showed mesosome-like structures in the cytoplasm, The peptide at a-fold the minimal inhibitory concentration did not show significant killing of S, aureus ISP67 (a histidine, uridine, and thymidine auxotroph) but did show an early effect on histidine and uridine incorporation and, later, an effect on thymidine incorporation. Upon interaction with liposomes, detergents, and lipoteichoic acid, CP10A was shown by circular dichroism spectroscopy to undergo a change in secondary structure. Fluorescence spectroscopy indicated that the tryptophan residues were located at the hydrophobic/hydrophilic interface of liposomes and detergent micelles and were inaccessible to the aqueous quencher KI. The three-dimensional structure of CP10A in the Lipid mimetic dodecylphosphocholine was determined using two-dimensional NMR methods and was characterized as a short, amphipathic helical structure, whereas indolicidin was previously shown to have an extended structure. These studies have introduced a cationic peptide with a unique structure and an ability to interact with membranes and to affect intracellular synthesis of proteins, RNA, and DNA.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Hancock, REW (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 300-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	bob@cmdr.ubc.ca	Hancock, Robert E. W./E-1145-2013	Hancock, Robert E. W./0000-0001-5989-8503				Amsterdam D, 1996, ANTIBIOTICS LAB MED, V4, P52; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEVERIDGE TJ, 1989, BACTERIA NATURE, V3, P1; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHAKRABARTTY A, 1994, PROTEIN SCI, V3, P843; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; FIOCCO MM, 1994, J MOL BIOL, V235, P709; Friedrich C, 1999, ANTIMICROB AGENTS CH, V43, P1542, DOI 10.1128/AAC.43.7.1542; Friedrich CL, 2000, ANTIMICROB AGENTS CH, V44, P2086, DOI 10.1128/AAC.44.8.2086-2092.2000; Hancock RE, 1995, ADV MICROB PHYSL, V37, P136; HOLZWARTH G, 1965, J AM CHEM SOC, V87, P218, DOI 10.1021/ja01080a015; Huo SH, 1999, PROTEINS, V36, P249; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; JURETIC D, 1989, FEBS LETT, V249, P219, DOI 10.1016/0014-5793(89)80627-1; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; MILLHAUSER GL, 1995, BIOCHEMISTRY-US, V34, P3873, DOI 10.1021/bi00012a001; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILGES M, 1991, COMPUTATIONAL ASPECT; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; PETERSON AA, 1987, ANTIMICROB AGENTS CH, V31, P230, DOI 10.1128/AAC.31.2.230; PIERS KL, 1994, MOL MICROBIOL, V12, P951, DOI 10.1111/j.1365-2958.1994.tb01083.x; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Rozek A, 2000, BIOCHEMISTRY-US, V39, P15765, DOI 10.1021/bi000714m; SAWYER JG, 1988, INFECT IMMUN, V56, P693, DOI 10.1128/IAI.56.3.693-698.1988; Scott MG, 1999, INFECT IMMUN, V67, P6445; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SHIMODA M, 1995, INFECT IMMUN, V63, P2886, DOI 10.1128/IAI.63.8.2886-2891.1995; SIMS PJ, 1974, BIOCHEMISTRY-US, V13, P3315, DOI 10.1021/bi00713a022; SKLENAR V, 1993, J MAGN RESON SER A, V102, P241, DOI 10.1006/jmra.1993.1098; Subbalakshmi C, 1996, FEBS LETT, V395, P48, DOI 10.1016/0014-5793(96)00996-9; WALLACE BA, 1984, ANAL BIOCHEM, V142, P317, DOI 10.1016/0003-2697(84)90471-8; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; WOODY RW, 1994, EUR BIOPHYS J BIOPHY, V23, P253, DOI 10.1007/BF00213575; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; WUTHERICH K, 1986, NMR PROTEINS NUCL AC; Xiong YQ, 1999, ANTIMICROB AGENTS CH, V43, P1111, DOI 10.1128/AAC.43.5.1111; Yeaman MR, 1998, J CLIN INVEST, V101, P178, DOI 10.1172/JCI562; Zhang LJ, 1999, BIOCHEMISTRY-US, V38, P8102, DOI 10.1021/bi9904104	45	177	194	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 29	2001	276	26					24015	24022		10.1074/jbc.M009691200	http://dx.doi.org/10.1074/jbc.M009691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	446TW	11294848	hybrid			2022-12-25	WOS:000169531100105
J	Han, YP; Tuan, TL; Hughes, M; Wu, HY; Garner, WL				Han, YP; Tuan, TL; Hughes, M; Wu, HY; Garner, WL			Transforming growth factor-beta- and tumor necrosis factor-alpha-mediated induction and proteolytic activation of MMP-9 in human skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE GELATINASE; GENE-EXPRESSION; MATRIX METALLOPROTEINASE-9; HYPERTROPHIC SCAR; VII COLLAGEN; CELL-LINES; MESSENGER-RNA; WOUND FLUID; CANCER; GROWTH-FACTOR-BETA-1	Both cytokines and matrix metalloproteinases (MMPs) are active during physiologic and pathologic processes such as cancer metastasis and wound repair. We have systematically studied cytokine-mediated MMP regulation. Cytokine-mediated proteinase induction and activation were initially investigated in organ-cultured human skin followed by determination of underlying cellular and molecular mechanisms using isolated skin cells. In this report we demonstrate that tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) synergistically induce pro-MMP-9 in human skin as well as isolated dermal fibroblasts and epidermal keratinocytes. Furthermore, TNF-alpha promotes proteolytic activation of pro-MMP-9 by conversion of the 92-kDa pro-MMP-9 to the 82-kDa active enzyme. This activation occurred only in skin organ culture and not by either isolated fibroblasts or keratinocyte, although the pro-MMP-9 activation could be measured in a cell-free system derived from TNF-alpha -activated skin. The cytokine-mediated induction of pro-MMP-9 in dermal fibroblasts was evident by increased mRNA At the transcription level, we examined the cytokine-mediated transactivation of the 5'-region promoter of the human MMP 9 in dermal fibroblasts. The results demonstrated that TNF-alpha and TGF-beta could independently stimulate the 5'-flanking 670-base pair promoter. A TGF-beta -response element (-474) and an NF-kappaB-binding site (-601) were identified to be the cis-elements for TGF-P or TNF-alpha activation, respectively. Taken together, these findings suggest a specific mechanism whereby multiple cytokines can regulate MMP-9 expression/activation in the cells of human skin. These results imply roles for these cytokines in the regulation of MMP-9 in physiologic and pathologic tissue remodeling.	Univ So Calif, Sch Med, Div Plast & Reconstruct Surg, Los Angeles, CA 90033 USA; Univ So Calif, Childrens Hosp, Sch Med, Dept Surg, Los Angeles, CA 90027 USA	University of Southern California; Children's Hospital Los Angeles; University of Southern California	Garner, WL (corresponding author), Univ So Calif, Sch Med, Div Plast & Reconstruct Surg, 1450 San Pablo St,Ste 2000, Los Angeles, CA 90033 USA.	wgarner@surgery.usc.edu		Hughes, Michael W./0000-0002-8899-9773	NIGMS NIH HHS [R01 GM050967-07, GM55081, GM 50967, R01 GM050967-08] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050967, R01GM050967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENTO EP, 1991, CIBA F SYMP, V157, P115; Beck LS, 1990, GROWTH FACTORS, V3, P267, DOI 10.3109/08977199009003669; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Cooney R, 1997, J TRAUMA, V42, P415, DOI 10.1097/00005373-199703000-00008; FAJARDO LF, 1992, AM J PATHOL, V140, P539; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; FRIDMAN R, 1995, CANCER RES, V55, P2548; GARNER WL, 1993, J INVEST DERMATOL, V101, P875, DOI 10.1111/1523-1747.ep12371710; GHAHARY A, 1993, J LAB CLIN MED, V122, P465; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Han YP, 2001, J CELL SCI, V114, P131; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Iocono JA, 2000, WOUND REPAIR REGEN, V8, P216, DOI 10.1046/j.1524-475x.2000.00216.x; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Karelina TV, 2000, J INVEST DERMATOL, V114, P371, DOI 10.1046/j.1523-1747.2000.00886.x; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; Kitzis V, 1999, J SURG RES, V87, P134, DOI 10.1006/jsre.1999.5747; Kon A, 1999, ONCOGENE, V18, P1837, DOI 10.1038/sj.onc.1202495; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Lijnen HR, 1998, BLOOD, V91, P2045, DOI 10.1182/blood.V91.6.2045.2045_2045_2053; LYONS JG, 1993, J BIOL CHEM, V268, P19143; Malik S T, 1992, Semin Cancer Biol, V3, P27; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MIYAGI E, 1995, CLIN EXP METASTAS, V13, P89, DOI 10.1007/BF00133613; Moses MA, 1996, J CELL BIOCHEM, V60, P379, DOI 10.1002/(SICI)1097-4644(19960301)60:3<379::AID-JCB9>3.0.CO;2-T; MURPHY G, 1989, BIOCHEM J, V258, P463, DOI 10.1042/bj2580463; Neely AN, 1999, WOUND REPAIR REGEN, V7, P166, DOI 10.1046/j.1524-475X.1999.00166.x; OGATA Y, 1995, J BIOL CHEM, V270, P18506, DOI 10.1074/jbc.270.31.18506; OKADA Y, 1990, BIOCHEM BIOPH RES CO, V171, P610, DOI 10.1016/0006-291X(90)91190-4; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Parks WC, 1999, WOUND REPAIR REGEN, V7, P423, DOI 10.1046/j.1524-475X.1999.00423.x; PERUCCIO D, 1994, BURNS, V20, P118, DOI 10.1016/S0305-4179(06)80007-0; PLATZER C, 1995, CYTOKINES PRACTICAL, P57; POLVERINI PJ, 1977, NATURE, V269, P804, DOI 10.1038/269804a0; Rha SY, 1997, BREAST CANCER RES TR, V43, P175; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; ROBERTS AB, 1988, BRIT J CANCER, V57, P594, DOI 10.1038/bjc.1988.135; SALO T, 1994, LAB INVEST, V70, P176; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Sehgal I, 1996, CANCER RES, V56, P3359; SELTZER JL, 1989, J BIOL CHEM, V264, P3822; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; SPORN MB, 1993, J CLIN INVEST, V92, P2565, DOI 10.1172/JCI116868; Tarlton JF, 1999, WOUND REPAIR REGEN, V7, P347, DOI 10.1046/j.1524-475X.1999.00347.x; Tarlton JF, 1997, BRIT J DERMATOL, V137, P506, DOI 10.1111/j.1365-2133.1997.tb03779.x; VU TH, 1995, MATRIX METALLOPROTEA, P115; WAHL SM, 1993, P NATL ACAD SCI USA, V90, P4577, DOI 10.1073/pnas.90.10.4577; WYSOCKI AB, 1993, J INVEST DERMATOL, V101, P64, DOI 10.1111/1523-1747.ep12359590; Wysocki AB, 1999, WOUND REPAIR REGEN, V7, P154, DOI 10.1046/j.1524-475X.1999.00154.x; YOUNG PK, 1994, J INVEST DERMATOL, V103, P660, DOI 10.1111/1523-1747.ep12398424; Zeng ZS, 1998, BRIT J CANCER, V78, P349, DOI 10.1038/bjc.1998.497; ZHANG K, 1995, J INVEST DERMATOL, V104, P750, DOI 10.1111/1523-1747.ep12606979	54	137	146	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22341	22350		10.1074/jbc.M010839200	http://dx.doi.org/10.1074/jbc.M010839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11297541	Green Accepted, hybrid			2022-12-25	WOS:000169412700051
J	Meyer, TN; Schwesinger, C; Ye, JM; Denker, BM; Nigam, SK				Meyer, TN; Schwesinger, C; Ye, JM; Denker, BM; Nigam, SK			Reassembly of the tight junction after oxidative stress depends on tyrosine kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBULAR EPITHELIAL-CELLS; EPIDERMAL GROWTH-FACTOR; ATP DEPLETION; HYDROGEN-PEROXIDE; INTRACELLULAR CALCIUM; BARRIER FUNCTION; LLC-PK1 CELLS; ADENOSINE-TRIPHOSPHATE; ACTIN CYTOSKELETON; OXIDANT INJURY	Oxidative stress compromises the tight junction, but the mechanisms underlying its recovery remain unclear. We developed a model in which oxidative stress reversibly disrupts the tight junction. Exposure of Madin-Darby canine kidney cells to hydrogen peroxide markedly reduced transepithelial resistance and disrupted the staining patterns of the tight junction proteins ZO-1 and occludin. These changes were reversed by catalase. The short-term reassembly of tight junctions was not dependent on new protein synthesis, suggesting that recovery occurs through re-utilization of existing proteins. Although ATP levels were reduced, the reduction was insufficient to explain the observed changes, since a comparable reduction of ATP levels (with a-deoxy-D-glucose) did not induce these changes. The intracellular hydrogen peroxide scavenger pyruvate protected Madin-Darby canine kidney cells front loss of transepithelial resistance as did the heavy metal scavenger N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine. Of a wide variety of agents examined, only tyrosine kinase inhibitors and protein kinase C inhibitors markedly inhibited tight junction reassembly. During reassembly, tyrosine phosphorylation in or near the lateral membrane, was detected by immunofluorescence. The tyrosine kinase inhibitors genistein and PP-2 inhibited the recovery of transepithelial resistance and perturbed the relocalization of ZO-1 and occludin to the tight junction, indicating that tyrosine kinases, possibly members of the Src family, are critical for reassembly after oxidative stress.	Univ Calif San Diego, Dept Pediat & Med, Div Nephrol & Hypertens, La Jolla, CA 92093 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA	University of California System; University of California San Diego; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Nigam, SK (corresponding author), Univ Calif San Diego, Dept Pediat, Div Nephrol & Hypertens, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055223, R29GM055223] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53507] Funding Source: Medline; NIGMS NIH HHS [GM55223] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aito H, 1999, AM J PHYSIOL-CELL PH, V277, pC878, DOI 10.1152/ajpcell.1999.277.5.C878; ANDREOLI SP, 1990, KIDNEY INT, V38, P785, DOI 10.1038/ki.1990.272; ANDREOLI SP, 1993, AM J PHYSIOL, V265, pF377, DOI 10.1152/ajprenal.1993.265.3.F377; BACALLAO R, 1994, J CELL SCI, V107, P3301; BAKER RD, 1995, DIGEST DIS SCI, V40, P510, DOI 10.1007/BF02064358; BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; CANFIELD PE, 1991, AM J PHYSIOL, V261, pF1038, DOI 10.1152/ajprenal.1991.261.6.F1038; Caselli A, 1998, J BIOL CHEM, V273, P32554, DOI 10.1074/jbc.273.49.32554; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Collares-Buzato CB, 1998, EUR J CELL BIOL, V76, P85, DOI 10.1016/S0171-9335(98)80020-4; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DOCTOR RB, 1994, AM J PHYSIOL, V266, pC1803, DOI 10.1152/ajpcell.1994.266.6.C1803; Filipovic DM, 1999, AM J PHYSIOL-RENAL, V277, pF428, DOI 10.1152/ajprenal.1999.277.3.F428; GOLIGORSKY MS, 1993, ARCH BIOCHEM BIOPHYS, V301, P119, DOI 10.1006/abbi.1993.1123; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HINSHAW DB, 1989, J SURG RES, V46, P339, DOI 10.1016/0022-4804(89)90199-6; Hirase T, 2001, J BIOL CHEM, V276, P10423, DOI 10.1074/jbc.M007136200; Hopkins AM, 2000, ADV DRUG DELIVER REV, V41, P329, DOI 10.1016/S0169-409X(00)00050-8; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; KAUFMAN DS, 1993, ARCH BIOCHEM BIOPHYS, V302, P245, DOI 10.1006/abbi.1993.1206; Kevil CG, 2000, AM J PHYSIOL-CELL PH, V279, pC21, DOI 10.1152/ajpcell.2000.279.1.C21; KROSHIAN VM, 1994, AM J PHYSIOL, V266, pF21, DOI 10.1152/ajprenal.1994.266.1.F21; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; MANDEL LJ, 1994, J CELL SCI, V107, P3315; Meng XM, 2000, AM J PHYSIOL-RENAL, V278, pF83, DOI 10.1152/ajprenal.2000.278.1.F83; Molitoris BA, 1997, PEDIATR NEPHROL, V11, P761, DOI 10.1007/s004670050385; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; Rao R, 1999, BIOCHEM PHARMACOL, V57, P685, DOI 10.1016/S0006-2952(98)00333-5; Rao RK, 1997, AM J PHYSIOL-GASTR L, V273, pG812, DOI 10.1152/ajpgi.1997.273.4.G812; Rao RK, 2000, AM J PHYSIOL-GASTR L, V279, pG332, DOI 10.1152/ajpgi.2000.279.2.G332; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; SALAHUDEEN AK, 1991, J CLIN INVEST, V88, P1886, DOI 10.1172/JCI115511; SHASBY DM, 1985, BLOOD, V65, P605; SHASBY DM, 1988, AM J PHYSIOL, V255, pC781, DOI 10.1152/ajpcell.1988.255.6.C781; STADDON JM, 1995, J CELL SCI, V108, P609; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; Takeda M, 1999, NEPHRON, V81, P234, DOI 10.1159/000045282; Tsukamoto T, 1999, AM J PHYSIOL-RENAL, V276, pF737, DOI 10.1152/ajprenal.1999.276.5.F737; Tsukamoto T, 1997, J BIOL CHEM, V272, P16133, DOI 10.1074/jbc.272.26.16133; UEDA N, 1992, AM J PHYSIOL, V263, pF214, DOI 10.1152/ajprenal.1992.263.2.F214; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; VANITALLIE CM, 1995, J CELL SCI, V108, P1735; WELSH MJ, 1985, J CLIN INVEST, V76, P1155, DOI 10.1172/JCI112071; WILSON J, 1990, BLOOD, V76, P2578; WINTER M, 1990, AM J RESP CELL MOL, V2, P355, DOI 10.1165/ajrcmb/2.4.355; YAMAYA M, 1995, AM J PHYSIOL-LUNG C, V268, pL284, DOI 10.1152/ajplung.1995.268.2.L284; Ye JM, 1999, AM J PHYSIOL-RENAL, V277, pF524, DOI 10.1152/ajprenal.1999.277.4.F524; Zager RA, 1996, J AM SOC NEPHROL, V7, P2327	51	104	107	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 22	2001	276	25					22048	22055		10.1074/jbc.M011477200	http://dx.doi.org/10.1074/jbc.M011477200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	444RE	11294856	hybrid			2022-12-25	WOS:000169412700010
J	Zhou, ZH; Liao, WC; Cheng, RH; Lawson, JE; McCarthy, DB; Reed, LJ; Stoops, JK				Zhou, ZH; Liao, WC; Cheng, RH; Lawson, JE; McCarthy, DB; Reed, LJ; Stoops, JK			Direct evidence for the size and conformational variability of the pyruvate dehydrogenase complex revealed by three-dimensional electron microscopy - The "breathing" core and its functional relationship to protein dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLAMINE TUNGSTATE STAIN; X-RAY CRYSTALLOGRAPHY; BUTVAR SUPPORT FILM; CRYOELECTRON MICROSCOPY; STRUCTURAL-ANALYSIS; BINDING PROTEIN; CUBIC CORE; RECONSTRUCTION; CRYSTALLIZATION; MACROMOLECULES	Structural studies by three-dimensional electron microscopy of the Saccharomyces cerevisiae truncated dihydrolipoamide acetyltransferase (tE(2)) component of the pyruvate dehydrogenase complex reveal an extraordinary example of protein dynamics. The tE(2) forms a 60-subunit core with the morphology of a pentagonal dodecahedron and consists of 20 cone-shaped trimers interconnected by 30 bridges. Frozen-hydrated and stained molecules of tE(2) in the same field vary in size similar to 20%, Analyses of the data show that the size distribution is bell-shaped, and there is an approximately 40-Angstrom difference in the diameter of the smallest and largest structures that corresponds to similar to 14 Angstrom of variation in the length of the bridge between interconnected trimers, Companion studies of mature E-2 show that the complex of the intact subunit exhibits a similar size variation, The x-ray structure of Bacillus stearothermophilus tE(2) shows that there is an similar to 10-Angstrom gap between adjacent trimers and that the trimers are interconnected by the potentially flexible C-terminal ends of two adjacent subunits. We propose that this springlike feature is involved in a thermally driven expansion and contraction of the core and, since it appears to be a common feature in the phylogeny of pyruvate dehydrogenase complexes, protein dynamics is an integral component of the function of these multienzyme complexes.	Univ Texas, Houston Med Sch, Dept Pathol & Lab Med, Houston, TX 77030 USA; Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Health Science Center Houston; Karolinska Institutet; University of Texas System; University of Texas Austin	Stoops, JK (corresponding author), Univ Texas, Houston Med Sch, Dept Pathol & Lab Med, Houston, TX 77030 USA.	James.K.Stoops@uth.tmc.edu	Cheng, Holland/A-8973-2008; Zhou, Z Hong/HDN-0747-2022		NIAID NIH HHS [AI46420] Funding Source: Medline; NIGMS NIH HHS [GM06590] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDROUBI A, 1992, ULTRAMICROSCOPY, V46, P175, DOI 10.1016/0304-3991(92)90013-A; Baker TS, 1996, J STRUCT BIOL, V116, P120, DOI 10.1006/jsbi.1996.0020; Balabin IA, 2000, SCIENCE, V290, P114, DOI 10.1126/science.290.5489.114; BOSMA HJ, 1984, EUR J BIOCHEM, V142, P541, DOI 10.1111/j.1432-1033.1984.tb08320.x; Bothner B, 1998, J BIOL CHEM, V273, P673, DOI 10.1074/jbc.273.2.673; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHENG RH, 1995, CELL, V80, P621; CROWTHER RA, 1970, PROC R SOC LON SER-A, V317, P319, DOI 10.1098/rspa.1970.0119; CROWTHER RA, 1971, PHILOS T R SOC B, V261, P221, DOI 10.1098/rstb.1971.0054; DEROSIER DJ, 1971, P NATL ACAD SCI USA, V68, P1135, DOI 10.1073/pnas.68.6.1135; DOUGHERTY MT, 1998, MICROSC MICROANAL, P452; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FULLER CC, 1979, BIOCHEM BIOPH RES CO, V90, P431, DOI 10.1016/0006-291X(79)91253-1; Fuller SD, 1996, J STRUCT BIOL, V116, P48, DOI 10.1006/jsbi.1996.0009; GUEST JR, 1989, ANN N Y ACAD SCI, V573, P76; HACKERT ML, 1989, BIOCHEMISTRY-US, V28, P6816, DOI 10.1021/bi00443a006; Hall C. E., 1966, INTRO ELECT MICROSCO, V2nd; Izard T, 1999, P NATL ACAD SCI USA, V96, P1240, DOI 10.1073/pnas.96.4.1240; Johnson O, 1997, FOURTH INTERNATIONAL CONFERENCE ON HIGH-PERFORMANCE COMPUTING, PROCEEDINGS, P517, DOI 10.1109/HIPC.1997.634540; Jones M, 2000, J BIOL CHEM, V275, P21349, DOI 10.1074/jbc.M001564200; Knapp JE, 1998, J MOL BIOL, V280, P655, DOI 10.1006/jmbi.1998.1924; Knapp JE, 2000, PROTEIN SCI, V9, P37; Kolodziej SJ, 1997, J STRUCT BIOL, V120, P158, DOI 10.1006/jsbi.1997.3911; Lata R, 2000, CELL, V100, P253, DOI 10.1016/S0092-8674(00)81563-9; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; Lu GY, 1998, J VIROL, V72, P8541, DOI 10.1128/JVI.72.11.8541-8549.1998; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Maeng CY, 1996, BIOCHEMISTRY-US, V35, P5879, DOI 10.1021/bi9600254; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; OLSON NH, 1992, J STRUCT BIOL, V108, P168, DOI 10.1016/1047-8477(92)90016-4; Orlova EV, 1996, NAT STRUCT BIOL, V3, P547, DOI 10.1038/nsb0696-547; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; REED LJ, 1990, J BIOL CHEM, V265, P8971; Schulten K, 2000, SCIENCE, V290, P61, DOI 10.1126/science.290.5489.61; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; Stoops James K., 1998, Microscopy and Microanalysis, V4, P954, DOI 10.1017/S1431927600024892; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilson EK, 2000, CHEM ENG NEWS, V78, P42, DOI 10.1021/cen-v078n029.p042; Zaccai G, 2000, SCIENCE, V288, P1604, DOI 10.1126/science.288.5471.1604; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999; Zhou ZH, 1998, BIOPHYS J, V74, P576, DOI 10.1016/S0006-3495(98)77816-6; Zhou ZH, 1996, J STRUCT BIOL, V116, P216, DOI 10.1006/jsbi.1996.0033; ZHOU ZH, 1995, THESIS BAYLOR COLL M	50	48	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	2001	276	24					21704	21713		10.1074/jbc.M101765200	http://dx.doi.org/10.1074/jbc.M101765200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442RC	11285267	hybrid			2022-12-25	WOS:000169297900121
J	Kypreos, KE; van Dijk, KW; van der Zee, A; Havekes, LM; Zannis, VI				Kypreos, KE; van Dijk, KW; van der Zee, A; Havekes, LM; Zannis, VI			Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo - Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BINDING DOMAIN; E-DEFICIENT MICE; TRANSGENIC MICE; APO-E; ATHEROSCLEROSIS; DIET; HYPERLIPOPROTEINEMIA; HYPERCHOLESTEROLEMIA; EXPRESSION; VARIANT	Apolipoprotein (apo)E has been implicated in cholesterol. and triglyceride homeostasis in humans. At physiological concentration apoE promotes efficient clearance of apoE-containing lipoprotein remnants. However, high apoE plasma levels correlate with high plasma triglyceride levels. We have used adenovirus-mediated gene transfer in apoE-deficient mice (E-/-) to define the domains of apoE required for cholesterol and triglyceride homeostasis in, vivo. A dose of 2 x 10(9) plaque-forming units of apoE4-expressing adenovirus reduced slightly the cholesterol levels of E-/- mice and resulted in severe hypertriglyceridemia, due to accumulation of cholesterol and triglyceride-rich very low density Lipoprotein particles in plasma, In contrast, the truncated form apoE4-202 resulted in a 90% reduction in the plasma cholesterol levels but did not alter plasma triglyceride levels in the E-/- mice. ApoE secretion by cell cultures, as well as the steady-state hepatic mRNA levels in individual mice expressing apoE4 or apoE4-202, were similar. In contrast, very low density lipoprotein-triglyceride secretion in mice expressing apoE4, but not, apoE4-202, was increased 10-fold, as compared with mice infected with a control adenovirus, The findings suggest that the amino-terminal 1-202 region of apoE4 contains the domains required for the in vivo clearance of Lipoprotein remnants. Furthermore, the carboxyl-terminal 203-299 residues of apoE promote hepatic very low density lipoprotein-triglyceride secretion and contribute to apoE-induced hypertriglyceridemia.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Leiden Univ, Med Ctr, Dept Human & Clin Genet, NL-2333 AL Leiden, Netherlands; TNO PG Prevent & Hlth, Gaubius Lab, NL-2333 CK Leiden, Netherlands; Univ Crete, Dept Biochem, Iraklion 71110, Crete, Greece; Univ Crete, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece	Boston University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Organization Applied Science Research; University of Crete; University of Crete	Zannis, VI (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst, 715 Albany St,W509, Boston, MA 02118 USA.	vzannis@bu.edu	van Dijk, Ko Willems/A-1798-2008; Kypreos, Kyriakos/AAG-1745-2020; van Dijk, Ko Willems/AAT-4681-2021; KYPREOS, KYRIAKOS/AAN-4485-2020	van Dijk, Ko Willems/0000-0002-2172-7394; Kypreos, Kyriakos/0000-0001-6784-2710; van Dijk, Ko Willems/0000-0002-2172-7394; 	NATIONAL INSTITUTE ON AGING [R01AG012717] Funding Source: NIH RePORTER; NIA NIH HHS [AG12717] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; CARDIN AD, 1986, BIOCHEM BIOPH RES CO, V134, P783, DOI 10.1016/S0006-291X(86)80489-2; CHAIT A, 1978, METABOLISM, V27, P1055, DOI 10.1016/0026-0495(78)90151-8; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; Cohn JS, 1996, ARTERIOSCL THROM VAS, V16, P149, DOI 10.1161/01.ATV.16.1.149; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; DONG LM, 1994, J BIOL CHEM, V269, P22358; EHNHOLM C, 1984, P NATL ACAD SCI-BIOL, V81, P5566, DOI 10.1073/pnas.81.17.5566; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Fan JL, 1998, J CLIN INVEST, V101, P2151, DOI 10.1172/JCI1599; FAZIO S, 1994, ARTERIOSCLER THROMB, V14, P1873, DOI 10.1161/01.ATV.14.11.1873; FAZIO S, 1994, J LIPID RES, V35, P408; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; GHISELLI G, 1981, SCIENCE, V214, P1239, DOI 10.1126/science.6795720; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Huang YD, 1999, ARTERIOSCL THROM VAS, V19, P2952, DOI 10.1161/01.ATV.19.12.2952; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; Huang YD, 1997, ARTERIOSCL THROM VAS, V17, P2010, DOI 10.1161/01.ATV.17.10.2010; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; INNERARITY TL, 1983, J BIOL CHEM, V258, P2341; JI SS, 1994, J BIOL CHEM, V289, P2784; JI ZS, 1994, J BIOL CHEM, V269, P13421; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1995, J LIPID RES, V36, P583; Jong MC, 1997, BIOCHEM J, V328, P745; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KULPERS F, 1997, J CLIN INVEST, V100, P2915; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley RW, 1999, CURR OPIN LIPIDOL, V10, P207, DOI 10.1097/00041433-199906000-00003; MANN WA, 1989, BIOCHIM BIOPHYS ACTA, V1005, P239, DOI 10.1016/0005-2760(89)90043-X; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rensen PCN, 1996, J BIOL CHEM, V271, P14791, DOI 10.1074/jbc.271.25.14791; Salah D, 1997, J LIPID RES, V38, P904; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMIT M, 1990, J LIPID RES, V31, P45; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; VANDENMAAGDENBERG AMJM, 1989, BIOCHEM BIOPH RES CO, V165, P851, DOI 10.1016/S0006-291X(89)80044-0; VANDENMAAGDENBERG AMJM, 1993, J BIOL CHEM, V268, P10540; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; WEISGRABER KH, 1986, J BIOL CHEM, V261, P2068; WEISGRABER KH, 1983, J BIOL CHEM, V258, P2348; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WOLF BB, 1992, AM J PATHOL, V141, P37; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	61	57	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19778	19786		10.1074/jbc.M100418200	http://dx.doi.org/10.1074/jbc.M100418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279066	hybrid			2022-12-25	WOS:000169135100015
J	Roeffen, WFG; Raats, JMH; Teelen, K; Hoet, RMA; Eling, WM; van Venrooij, WJ; Sauerwein, RW				Roeffen, WFG; Raats, JMH; Teelen, K; Hoet, RMA; Eling, WM; van Venrooij, WJ; Sauerwein, RW			Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSION-BLOCKING IMMUNITY; TARGET ANTIGENS; LIBRARIES; REACTIVITY; PHAGE; ASSAY	We report the first construction of two combinatorial human phage display libraries derived from malaria-immune patients. Specific single-chain Fv fragments (scFv) against Pfs48/45, a gamete surface protein of the sexual stages of Plasmodium falciparum, were selected and analyzed extensively. The selected scFv reacted with the surface of extracellular sexual forms of the parasite and showed Pfs48/45 reactivity on immunoblot. The scFv inhibit binding of human malaria sera to native Pfs48/45 from gametocytes. Moreover, the scFv bind to target epitopes of Pfs48/45 exposed in natural infections. Sequence analysis of eight scFv clones specific for epitope III of Pfs48/45 revealed that these clones could be divided into one V-H family-derived germ-line gene (V(H)1) and two V-L family segments (V(L)2 and VKI).	Univ Med Ctr St Radboud, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Dyax BV, NL-6202 AZ Maastricht, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Roeffen, WFG (corresponding author), Univ Med Ctr St Radboud, Dept Med Microbiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Roeffen, W.F.G./L-4607-2015; Sauerwein, Robert/C-8519-2013					BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CARTER R, 1990, PARASITE IMMUNOL, V12, P587, DOI 10.1111/j.1365-3024.1990.tb00990.x; Hoet RMA, 1998, MOL IMMUNOL, V35, P1045, DOI 10.1016/S0161-5890(98)00093-5; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUMAR N, 1984, MOL BIOCHEM PARASIT, V13, P333, DOI 10.1016/0166-6851(84)90124-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MEULEMANS EV, 1994, J MOL BIOL, V244, P353, DOI 10.1006/jmbi.1994.1735; Nakane M. B., 1978, IMMUNOFLUORESCENCE R, P215; PONNUDURAI T, 1982, T ROY SOC TROP MED H, V76, P812, DOI 10.1016/0035-9203(82)90116-X; RENER J, 1983, J EXP MED, V158, P976, DOI 10.1084/jem.158.3.976; Roeffen W, 1996, PARASITE IMMUNOL, V18, P103, DOI 10.1046/j.1365-3024.1996.d01-54.x; ROEFFEN W, 1995, AM J TROP MED HYG, V52, P60, DOI 10.4269/ajtmh.1995.52.60; ROEFFEN W, 1995, EXP PARASITOL, V80, P15, DOI 10.1006/expr.1995.1003; Roeffen W, 2001, EXP PARASITOL, V97, P45, DOI 10.1006/expr.2000.4586; TARGETT GAT, 1990, IMMUNOL LETT, V25, P77, DOI 10.1016/0165-2478(90)90095-8; Tomlinson I, 1996, 5 BASE SEQUENCE DIRE; VERMEULEN AN, 1985, J EXP MED, V162, P1460, DOI 10.1084/jem.162.5.1460	18	28	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 8	2001	276	23					19807	19811		10.1074/jbc.M100562200	http://dx.doi.org/10.1074/jbc.M100562200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	439UC	11279092	Green Published, hybrid			2022-12-25	WOS:000169135100019
J	Keller, SH; Lindstrom, J; Ellisman, M; Taylor, P				Keller, SH; Lindstrom, J; Ellisman, M; Taylor, P			Adjacent basic amino acid residues recognized by the COPI complex and ubiquitination govern endoplasmic reticulum to cell surface trafficking of the nicotinic acetylcholine receptor alpha-subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTEIN TRAFFICKING; PLASMA-MEMBRANE; SECRETORY PATHWAY; POTASSIUM CHANNEL; BINDING-SITE; ENDOCYTOSIS; RETRIEVAL; CALNEXIN; SIGNAL; GAMMA	The nicotinic acetylcholine receptor in muscle is a ligand-gated ion channel with an ordered subunit arrangement of alpha-gamma-alpha-delta-beta. The subunits are sequestered in the endoplasmic reticulum (ER) and assembled into the pentameric arrangement prior to their exit to the cell surface. Mutating the Arg(313)-Lys(314) sequence in the large cytoplasmic loop of the alpha -subunit to K314Q promotes the trafficking of the mutant unassembled alpha -subunit from the ER to the Golgi in transfected HEK cells, identifying an important determinant that modulates the ER to Golgi trafficking of the subunit, The association of the K314Q alpha -subunit with gamma -COP, a component of COP I coats implicated in Golgi to ER anterograde transport, is diminished to a level comparable to that observed for wild-type alpha -subunits when co-expressed with the beta-, delta-, and gamma -subunits. This suggests that the Arg(313)-Lys(314) sequence is masked when the subunits assemble, thereby enabling ER to Golgi trafficking of the alpha -subunit, Although unassembled K314Q alpha -subunits accumulate in the Golgi, they are not detected at the cell surface, suggesting that a second post-Golgi level of capture exists, Expressing the K314Q alpha -subunit in the absence of the other subunits in ubiquitinating deficient cells (ts20) results in detecting this subunit at the cell surface, indicating that ubiquitination functions as a post-Golgi modulator of trafficking. Taken together, our findings support the hypothesis that subunit assembly sterically occludes the trafficking signals and ubiquitination at specific sites. Following the masking of these signals, the assembled ion channel expresses at the cell surface.	Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	University of Pennsylvania; University of California System; University of California San Diego; University of Pennsylvania; University of California System; University of California San Diego	Keller, SH (corresponding author), Univ Penn, Dept Neurosci, Philadelphia, PA 19104 USA.	shkeller@ucsd.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS011323] Funding Source: NIH RePORTER; NCRR NIH HHS [RR P41-04050] Funding Source: Medline; NIGMS NIH HHS [GM18360] Funding Source: Medline; NINDS NIH HHS [NS11323] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BOULTER J, 1985, J NEUROSCI, V5, P2545; Chang W, 1997, J BIOL CHEM, V272, P28925, DOI 10.1074/jbc.272.46.28925; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; DAS MK, 1991, BIOCHEMISTRY-US, V30, P2470, DOI 10.1021/bi00223a025; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; Harter C, 1998, P NATL ACAD SCI USA, V95, P11649, DOI 10.1073/pnas.95.20.11649; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Keller SH, 1998, J BIOL CHEM, V273, P17064, DOI 10.1074/jbc.273.27.17064; KELLER SH, 1995, J BIOL CHEM, V270, P4165, DOI 10.1074/jbc.270.8.4165; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lindstrom J, 1996, Ion Channels, V4, P377; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; RIORDAN JR, 1989, SCIENCE, V245, P1066; Schwappach B, 2000, NEURON, V26, P155, DOI 10.1016/S0896-6273(00)81146-0; SMITH MM, 1987, J BIOL CHEM, V262, P4367; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Strous GJ, 1997, J BIOL CHEM, V272, P40; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; Sugiyama N, 1996, J BIOL CHEM, V271, P26575, DOI 10.1074/jbc.271.43.26575; Vincent MJ, 1998, J BIOL CHEM, V273, P950, DOI 10.1074/jbc.273.2.950; WELSH MJ, 1993, J CELL SCI, P235; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123	37	67	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	2001	276	21					18384	18391		10.1074/jbc.M100691200	http://dx.doi.org/10.1074/jbc.M100691200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	435FJ	11279119	hybrid			2022-12-25	WOS:000168866500102
J	Burgess, BR; Richardson, JP				Burgess, BR; Richardson, JP			Transcription factor Rho does not require a free end to act as an RNA-DNA helicase on an RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; CRO MESSENGER-RNA; SINGLE-STRANDED-DNA; PROTEIN HEXAMER; KINETICS; BINDING; COMPLEX; ACID; ATP	Escherichia coli Rho factor is a ring-shaped, homohexameric protein that terminates synthesis of RNA through interactions with the nascent RNA transcript, Because its mechanism of action may involve translocation of the RNA transcript through the hole in its ring structure, its action could depend on the availability of a free 5' terminus. To determine whether Rho's activity is 5'-end-dependent, its ability to bind to and function on a circular derivative of A cro mRNA was investigated. The circular derivative was made in vitro by action of RNA ligase on a derivative of A cro RNA containing an extra 10-nucleotide sequence near the 5'-end that was complementary to a sequence located near the 3'-end. Rho bound nearly as tightly to the circular derivative RNA as to the standard cro transcript, Rho was also able to readily dissociate a DNA oligonucleotide from its helical complex with the circular RNA in an ATP-dependent reaction. Thus, the action of Rho on a transcript does not depend on the availability of a free 5' terminus.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	richardj@indiana.edu			NIGMS NIH HHS [GM 56095] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUDRY D, 1995, NUCLEIC ACIDS RES, V23, P3064; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Burgess BR, 2001, J BIOL CHEM, V276, P4182, DOI 10.1074/jbc.M007066200; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GOGOL EP, 1991, J MOL BIOL, V221, P1127, DOI 10.1016/0022-2836(91)80116-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; ODA T, 1972, J MOL BIOL, V71, P799; RICHARDSON JP, 1991, CELL, V64, P1047, DOI 10.1016/0092-8674(91)90257-Y; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1996, ESCHERICHIA COLI SAL, P882; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7993, DOI 10.1021/bi963180r; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7980, DOI 10.1021/bi963179s; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	21	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17106	17110		10.1074/jbc.M101856200	http://dx.doi.org/10.1074/jbc.M101856200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279220	hybrid			2022-12-25	WOS:000168730400068
J	Smith, AJ; Surviladze, Z; Gaudet, EA; Backer, JM; Mitchell, CA; Wilson, BS				Smith, AJ; Surviladze, Z; Gaudet, EA; Backer, JM; Mitchell, CA; Wilson, BS			P110 beta and p110 delta phosphatidylinositol 3-kinases up-regulate Fc epsilon RI-activated Ca2+ influx by enhancing inositol 1,4,5-trisphosphate production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; RBL-2H3 MAST-CELLS; PHOSPHOLIPASE C-GAMMA-1; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; PHOSPHATASE SHIP; CALCIUM-RELEASE; RECEPTOR; WORTMANNIN	Fc is an element of RI-induced Ca2+ signaling in mast cells is initiated by activation of cytosolic tyrosine kinases, Here, in vitro phospholipase assays establish that the phosphatidylinositol S-kinase (PI 3-kinase) lipid product, phosphatidylinositol 3,4,5-triphosphate, further stimulates phospholipase Cy2 that has been activated by conformational changes associated with tyrosine phosphorylation or low pH, A microinjection approach is used to directly assess the consequences of inhibiting class IA PI 3-kinases on Ca2+ responses after Fc is an element of RI cross-linking in RBL-2H3 cells. Injection of antibodies to the p110 beta or p110 delta catalytic isoforms of PI 3-kinase, but not antibodies to p110 alpha, lengthens the lag time to release of Ca2+ stores and blunts the sustained phase of the calcium response. Ca2+ responses are also inhibited in cells microinjected with recombinant inositol polyphosphate B-phosphatase I, which degrades inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3), or heparin, a competitive inhibitor of the Ins(1,4,5)P-3 receptor. This indicates a requirement for Ins(1,4,5)P-3 to initiate and sustain Ca2+ responses even when PI 3-kinase is fully active. Antigen-induced cell ruffling, a calcium-independent event, is blocked by injection of p110 beta and p110 delta antibodies, but not by injection of B-phosphatase I, heparin, or anti-p110 alpha antibodies. These results suggest that the p110 beta and p110 delta isoforms of PI 3-kinase support Fc is an element of RI-induced calcium signaling by modulating Ins(1,4,5)P-3 production, not by directly regulating the Ca2+ influx channel.	Univ New Mexico, Sch Med, Cancc Res & Treatment Ctr, Albuquerque, NM 87107 USA; Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87107 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	University of New Mexico; University of New Mexico; Yeshiva University; Albert Einstein College of Medicine; Monash University	Wilson, BS (corresponding author), Univ New Mexico, Canc Res Facil, Rm 205, Albuquerque, NM 87131 USA.			Smith, Alex/0000-0002-3034-9137; Mitchell, Christina A/0000-0001-9372-3192				Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; Barker SA, 1999, J LEUKOCYTE BIOL, V65, P321, DOI 10.1002/jlb.65.3.321; BARKER SA, 1995, MOL BIOL CELL, V6, P1145, DOI 10.1091/mbc.6.9.1145; Barker SA, 1998, MOL BIOL CELL, V9, P483, DOI 10.1091/mbc.9.2.483; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Choi OH, 1996, NATURE, V380, P634; DeSmedt F, 1997, J BIOL CHEM, V272, P17367, DOI 10.1074/jbc.272.28.17367; Downing GJ, 1996, BIOCHEMISTRY-US, V35, P3587, DOI 10.1021/bi9517493; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; Fierro L, 2000, J PHYSIOL-LONDON, V522, P247, DOI 10.1111/j.1469-7793.2000.t01-1-00247.x; Fluckiger AC, 1998, EMBO J, V17, P1973, DOI 10.1093/emboj/17.7.1973; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Glitsch MD, 2000, J PHYSIOL-LONDON, V523, P283, DOI 10.1111/j.1469-7793.2000.t01-2-00283.x; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; HILL TD, 1987, BIOCHEM BIOPH RES CO, V149, P897, DOI 10.1016/0006-291X(87)90492-X; Hofmann T, 2000, J MOL MED, V78, P14, DOI 10.1007/s001090050378; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hsu AL, 2000, J BIOL CHEM, V275, P16242, DOI 10.1074/jbc.M002077200; Huber M, 1998, P NATL ACAD SCI USA, V95, P11330, DOI 10.1073/pnas.95.19.11330; Johanson SO, 1999, EXP CELL RES, V248, P223, DOI 10.1006/excr.1999.4405; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; LEE RJ, 1995, MOL BIOL CELL, V6, P825, DOI 10.1091/mbc.6.7.825; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; Malbec O, 1998, J IMMUNOL, V160, P1647; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PARK DJ, 1991, J BIOL CHEM, V266, P24237; Pasquet JM, 2000, EMBO J, V19, P2793, DOI 10.1093/emboj/19.12.2793; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; Rosado JA, 2000, BIOCHEM J, V350, P631, DOI 10.1042/0264-6021:3500631; Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647; SIRAGANIAN RP, 1975, J IMMUNOL, V115, P1599; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; WAHL MI, 1992, J BIOL CHEM, V267, P10447; Wilson BS, 1998, MOL BIOL CELL, V9, P1465, DOI 10.1091/mbc.9.6.1465; YANO H, 1993, J BIOL CHEM, V268, P25846; ZHANG L, 1995, J PHYSIOL-LONDON, V483, P59, DOI 10.1113/jphysiol.1995.sp020567; Zhou C, 1999, J BIOL CHEM, V274, P2786, DOI 10.1074/jbc.274.5.2786	45	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 18	2001	276	20					17213	17220		10.1074/jbc.M100417200	http://dx.doi.org/10.1074/jbc.M100417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	432ZG	11279065	hybrid			2022-12-25	WOS:000168730400082
J	Blum, AM; Metwali, A; Crawford, C; Li, J; Qadir, K; Elliott, DE; Weinstock, JV				Blum, AM; Metwali, A; Crawford, C; Li, J; Qadir, K; Elliott, DE; Weinstock, JV			Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine schistosomiasis mansoni	FASEB JOURNAL			English	Article						schistosomiasis; substance P; substance P receptor; IL-12; schistosome egg antigen	IFN-GAMMA PRODUCTION; NK-1 RECEPTOR; NEUROKININ-1 RECEPTOR; MACROPHAGES; ANTAGONIST; GRANULOMAS; MICE; SOMATOSTATIN; LOCALIZATION; LYMPHOCYTES	Substance P (SP) regulates interferon-gamma (IFN-gamma) production through interaction with the SP receptor NK1 (SPr) on T cells at sites of inflammation. Using murine schistosomiasis, we evaluated whether SPr expression was subject to immunoregulation. Splenocytes from schistosome-infected mice cultured for less than or equal to 18 h did not express SPr, as determined by quantitative polymerase chain reaction assay. However, exposure to schistosome egg antigen (SEA) for less than or equal to4 h induced strong receptor expression. Experiments using splenocytes fractionated with antibody-coupled, paramagnetic beads showed that induction localized exclusively to T cells. Receptor protein expression was confirmed with Western blot. Interleukin 12 (IL-12) also induced strong T-cell SPr expression. Both SEA and IL-12 remained strong inducers of T-cell SPr in lymphocytes from the IL-12 (p40) and IFN-gammaR doublel-knockout mouse, which suggested that SEA did not require IL-12 to induce SPr and that both worked independently of IFN-gamma. Splenocytes from wild-type mice cultured with SEA and neutralizing anti-IL-12 monoclonal antibody (mAb) also showed SPr induction. However, anti-Ia mAb inhibited SEA. induction of SPr. Thus, SPr is inducible on T cells. SEA induces SPr through interaction with T-cell receptor (TCR), independently of IL-12 and IFN-gamma. IL-12 induces SPr independently of TCR activation and IFN-gamma expression. SP and its receptor, which regulate IFN-gamma production, are probably part of the IL-12-Th1 circuit.	Univ Iowa, Dept Internal Med, Div Gastroenterol Hepatol, Iowa City, IA 52242 USA	University of Iowa	Weinstock, JV (corresponding author), Univ Iowa Hosp & Clin, Div Gastroenterol, 4607 JCP,200 Hawkins Dr, Iowa City, IA 52242 USA.	joelweinstock@uiowa.edu		Elliott, David/0000-0002-5359-7125	NIDDK NIH HHS [DK25295, DK38327] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R01DK038327] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahluwalia AA, 1998, BRIT J PHARMACOL, V124, P1013, DOI 10.1038/sj.bjp.0701978; BAI TR, 1995, AM J PHYSIOL, V269, P309; Blum A, 1996, J NEUROIMMUNOL, V66, P1, DOI 10.1016/0165-5728(95)00163-8; Blum AM, 1999, J IMMUNOL, V162, P6080; BLUM AM, 1993, J IMMUNOL, V151, P225; BLUM AM, 1993, J IMMUNOL, V151, P6994; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; Castagliuolo I, 1998, J CLIN INVEST, V101, P1547, DOI 10.1172/JCI2039; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOK GA, 1994, J IMMUNOL, V152, P1830; Elliott David E., 1996, Methods (Orlando), V9, P255, DOI 10.1006/meth.1996.0032; Goode T, 1998, J IMMUNOL, V161, P2232; GREENO EW, 1993, J EXP MED, V177, P1269, DOI 10.1084/jem.177.5.1269; Ho WZ, 1997, J IMMUNOL, V159, P5654; Kennedy PGE, 1997, P NATL ACAD SCI USA, V94, P4167, DOI 10.1073/pnas.94.8.4167; KincyCain T, 1996, J IMMUNOL, V157, P255; Maggi CA, 1997, REGUL PEPTIDES, V70, P75, DOI 10.1016/S0167-0115(97)00029-3; MANTYH CR, 1995, GASTROENTEROLOGY, V109, P850, DOI 10.1016/0016-5085(95)90394-1; Marriott I, 1998, CELL IMMUNOL, V183, P113, DOI 10.1006/cimm.1998.1248; Marriott I, 2000, J IMMUNOL, V165, P182, DOI 10.4049/jimmunol.165.1.182; McCormack RJ, 1996, NEUROIMMUNOMODULAT, V3, P35, DOI 10.1159/000097225; OHKUBO H, 1991, ANN NY ACAD SCI, V632, P53, DOI 10.1111/j.1749-6632.1991.tb33094.x; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Rakasz E, 1998, J IMMUNOL, V160, P4994; Trinchieri G, 1999, CURR TOP MICROBIOL, V238, P57; WEINSTOCK JV, 1988, J IMMUNOL, V141, P961; Weinstock JV, 1998, ANN NY ACAD SCI, V840, P532, DOI 10.1111/j.1749-6632.1998.tb09592.x	27	23	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2001	15	6					950	957		10.1096/fj.00-0379	http://dx.doi.org/10.1096/fj.00-0379			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	419QC	11292655				2022-12-25	WOS:000167959300009
J	Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R				Ullrich, O; Diestel, A; Bechmann, I; Homberg, M; Grune, T; Hass, R; Nitsch, R			Turnover of oxidatively damaged nuclear proteins in BV-2 microglial cells is linked to their activation state by poly(ADP-ribose)polymerase	FASEB JOURNAL			English	Article						oxidative stress; proteasome; protein degradation; tumor necrosis factor-alpha; antioxidative protection	ADHESION MOLECULE EXPRESSION; ADP-RIBOSE-POLYMERASE; OXIDIZED PROTEINS; INTERFERON-GAMMA; ASTROCYTES; PROTEASOME; 20S; DIFFERENTIATION; DEGRADATION; MODULATION	During neuroinflammation, activated microglial cells migrate to the sites of neuronal injury, phagocytose neighboring cells, and produce large amounts of oxygen free radicals, which might contribute to severe cell damage and death. It is interesting that microglial cells have withstood this cytotoxic action of free radicals, which indicates that there is an intracellular mechanism that apparently enables microglial cells to cope with such oxidative challenges. In this study, we investigated the capability of BV-2 murine microglial cells to cope with oxidatively damaged proteins by the proteasomal proteolytic system. To induce a highly activated state, we used the proinflammatory cytokine tumor necrosis factor-alpha, which acts as a priming signal for microglial superoxide radical production. We showed that activation of the nuclear enzyme poly(ADPribose)polymerase (PARP) enabled activated microglial cells to resist oxidative damage by an up-regulation of the nuclear proteasome. Activated microglial cells revealed an efficient recognition and degradation of oxidatively damaged proteins during an enhanced endogenous protein turnover. The impairment of PARP function by inhibitor or antisense experiments resulted in an accumulation of damaged proteins and subsequently cell death. In contrast, this was not the case in resting microglial cells. These findings demonstrate the crucial role of the PARP in microglial cell survival during activation and renders it a potential anti-inflammatory target.	Humboldt Univ, Fac Med Charite, Dept Cell & Neurobiol, Inst Anat, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10098 Berlin, Germany; Hannover Med Sch, Oststadtkrankenhaus, Clin Obstet & Gynecol OE 6410, Dept Biochem & Tumor Biol, D-30659 Hannover, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Hannover Medical School	Ullrich, O (corresponding author), Humboldt Univ, Fac Med Charite, Inst Anat, Dept Cell & Neurobiol, Philippstr 12, D-10115 Berlin, Germany.	oliver.ullrich@charite.de	Nitsch, Robert/AAI-9129-2021; Hass, Ralf/F-3197-2012	Hass, Ralf/0000-0002-2481-7547; Gimsa, Ulrike/0000-0003-2248-5793; Grune, Tilman/0000-0003-4775-9973				AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Bechmann I, 1997, GLIA, V20, P145, DOI 10.1002/(SICI)1098-1136(199706)20:2<145::AID-GLIA6>3.0.CO;2-8; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; CANTONI O, 1989, BIOCHIM BIOPHYS ACTA, V1014, P1, DOI 10.1016/0167-4889(89)90234-6; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; GRADWOHL G, 1990, P NATL ACAD SCI USA, V87, P2990, DOI 10.1073/pnas.87.8.2990; Grune T, 1997, BIOFACTORS, V6, P165, DOI 10.1002/biof.5520060210; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hailer NP, 1997, HIPPOCAMPUS, V7, P341, DOI 10.1002/(SICI)1098-1063(1997)7:3<341::AID-HIPO8>3.0.CO;2-N; Heppner FL, 1998, GLIA, V22, P180, DOI 10.1002/(SICI)1098-1136(199802)22:2<180::AID-GLIA9>3.0.CO;2-B; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HU SX, 1995, GLIA, V13, P45, DOI 10.1002/glia.440130106; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KIRSTEN E, 1991, EXP CELL RES, V194, P1, DOI 10.1016/0014-4827(91)90122-B; Kleczkowska HE, 1996, MUTAT RES-FUND MOL M, V358, P215, DOI 10.1016/S0027-5107(96)00123-6; KREUTZBERG GW, 1995, ARZNEIMITTEL-FORSCH, V45-1, P357; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LEE SC, 1993, J IMMUNOL, V150, P594; Leist P, 1996, FREE RADICAL BIO MED, V21, P297, DOI 10.1016/0891-5849(96)00045-7; Lindenau J, 1998, GLIA, V24, P252, DOI 10.1002/(SICI)1098-1136(199810)24:2<252::AID-GLIA10>3.0.CO;2-Z; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Mayer-Kuckuk P, 1999, BIOCHEM BIOPH RES CO, V259, P576, DOI 10.1006/bbrc.1999.0824; MAZEN A, 1989, NUCLEIC ACIDS RES, V17, P4589; MESSMER UK, 1995, MOL PHARMACOL, V47, P757; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; NITSCH R, 1993, HIPPOCAMPUS, V3, P247; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; Paris D, 2000, NEUROSCI LETT, V278, P5, DOI 10.1016/S0304-3940(99)00901-5; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V377, P65, DOI 10.1006/abbi.2000.1717; REZNICK AZ, 1994, METHOD ENZYMOL, V233, P357; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schubert P, 1998, ALZ DIS ASSOC DIS, V12, pS21; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.0.CO;2-4; Sugaya K, 1997, NEUROREPORT, V8, P2241, DOI 10.1097/00001756-199707070-00030; Takahashi K, 1999, BRAIN RES, V829, P46, DOI 10.1016/S0006-8993(99)01335-9; TOMODA T, 1992, BIOCHIM BIOPHYS ACTA, V1135, P79, DOI 10.1016/0167-4889(92)90169-C; Ullrich O, 2000, FREE RADICAL BIO MED, V29, P995, DOI 10.1016/S0891-5849(00)00399-3; Ullrich O, 1999, ARCH BIOCHEM BIOPHYS, V362, P211, DOI 10.1006/abbi.1998.1031; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIELASEK J, 1993, NEUROSCI LETT, V153, P136, DOI 10.1016/0304-3940(93)90306-6; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	51	102	103	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR 27	2001	15	6					1460	+		10.1096/fj.00-0540fje	http://dx.doi.org/10.1096/fj.00-0540fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	519BV	11292676				2022-12-25	WOS:000173705800009
